PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Min, J; Kim, YK; Cipriani, PG; Kang, M; Khersonsky, SM; Walsh, DP; Lee, JY; Niessen, S; Yates, JR; Gunsalus, K; Piano, F; Chang, YT				Min, Jaeki; Kim, Yun Kyung; Cipriani, Patricia G.; Kang, Mira; Khersonsky, Sonya M.; Walsh, Daniel P.; Lee, Ji-Young; Niessen, Sherry; Yates, John R., III; Gunsalus, Kristin; Piano, Fabio; Chang, Young-Tae			Forward chemical genetic approach identifies new role for GAPDH in insulin signaling	NATURE CHEMICAL BIOLOGY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CAENORHABDITIS-ELEGANS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOINOSITIDE PHOSPHATASES; TRIAZINE LIBRARY; RESISTANCE; LONGEVITY; DISCOVERY; PROTEINS; COMPLEX	Insulin and insulin-like growth factor have an essential role in growth, development and the maintenance of metabolic homeostasis, including glucose uptake from the bloodstream. Researchers have identified mutations in insulin receptors that cause severe insulin resistance(1), and a temperature-sensitive daf-2 (a gene encoding an insulin receptor-like protein) mutant in Caenorhabditis elegans has served as an insulin resistance model(2). Here we report a forward chemical genetic approach with a tagged library that we used to identify a small molecule, GAPDH segregator (GAPDS), that suppresses the dauer formation induced by the daf-2 mutant. Like insulin, GAPDS increased both glucose uptake and the concentration of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P-3) in mammalian preadipocytes. Using affinity matrices and RNA interference, we identified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a GAPDS target. We discovered that GAPDH stimulates phosphatase activity against not only PtdIns(3,4,5)P-3 but also PtdIns(4,5)P-2. These results suggest that GAPDH is both an active regulator in the phosphoinositide-mediated signaling pathway and a potential new target for insulin resistance treatment.	NYU, Dept Chem, New York, NY 10003 USA; NYU, Dept Biol, New York, NY 10003 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	New York University; New York University; Scripps Research Institute	Min, J (corresponding author), NYU, Dept Chem, New York, NY 10003 USA.		Chang, Young-Tae/B-2780-2010	Chang, Young-Tae/0000-0002-1927-3688; Min, Jaeki/0000-0002-0083-3198	NCI NIH HHS [R01-CA096912] Funding Source: Medline; NCRR NIH HHS [P41RR11823-10, C06 RR-16572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096912] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823, C06RR016572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; Carlile GW, 2000, MOL PHARMACOL, V57, P2; Carroll PM, 2003, PHARMACOL THERAPEUT, V99, P183, DOI 10.1016/S0163-7258(03)00059-7; Cheeseman IM, 2001, J CELL BIOL, V155, P1137, DOI 10.1083/jcb.200109063; Chen GL, 2004, J BIOL CHEM, V279, P39705, DOI 10.1074/jbc.C400171200; Choy RKM, 1999, MOL CELL, V4, P143, DOI 10.1016/S1097-2765(00)80362-7; CONSTANTINIDES SM, 1969, J BIOL CHEM, V244, P5695; Gems D, 1998, GENETICS, V150, P129; Glaser PE, 2002, P NATL ACAD SCI USA, V99, P14104, DOI 10.1073/pnas.222542999; Grigorieva JA, 1999, ARCH BIOCHEM BIOPHYS, V369, P252, DOI 10.1006/abbi.1999.1341; Hanover JA, 2005, P NATL ACAD SCI USA, V102, P11266, DOI 10.1073/pnas.0408771102; Hayes JP, 2002, TOXICOL LETT, V128, P197, DOI 10.1016/S0378-4274(02)00013-9; Itoh Y, 2004, J CEREBR BLOOD F MET, V24, P993, DOI 10.1097/01.WCB.0000127661.07591.DE; Khersonsky SM, 2003, J AM CHEM SOC, V125, P11804, DOI 10.1021/ja035334d; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Nagashima H, 2002, J ENVIRON SCI HEAL B, V37, P1, DOI 10.1081/PFC-120002893; Niswender KD, 2003, J HISTOCHEM CYTOCHEM, V51, P275, DOI 10.1177/002215540305100302; Pagliarini DJ, 2004, J BIOL CHEM, V279, P38590, DOI 10.1074/jbc.M404959200; Patterson RL, 2005, P NATL ACAD SCI USA, V102, P1357, DOI 10.1073/pnas.0409657102; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Strawbridge AB, 2005, DIABETES, V54, P1698, DOI 10.2337/diabetes.54.6.1698; Taylor GS, 2001, ANAL BIOCHEM, V295, P122, DOI 10.1006/abio.2001.5179; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; Uttamchandani M, 2004, J COMB CHEM, V6, P862, DOI 10.1021/cc049900s; Williams D, 2004, CHEM BIOL, V11, P1251, DOI 10.1016/j.chembiol.2004.06.013	27	61	81	4	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2007	3	1					55	59		10.1038/nchembio833	http://dx.doi.org/10.1038/nchembio833			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	118QE	17115034				2022-12-25	WOS:000242956000015
J	Brooks, DG; Trifilo, MJ; Edelmann, KH; Teyton, L; McGavern, DB; Oldstone, MBA				Brooks, David G.; Trifilo, Matthew J.; Edelmann, Kurt H.; Teyton, Luc; McGavern, Dorian B.; Oldstone, Michael B. A.			Interleukin-10 determines viral clearance or persistence in vivo	NATURE MEDICINE			English	Article							HEPATITIS-C VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL RESPONSES; ACTIVE ANTIRETROVIRAL THERAPY; DENDRITIC CELLS; IL-10 PRODUCTION; IMMUNE-RESPONSES; INTERFERON-ALPHA; DISEASE PROGRESSION	Persistent viral infections are a major health concern. One obstacle inhibiting the clearance of persistent infections is functional inactivation of antiviral T cells. Although such immunosuppression occurs rapidly after infection, the mechanisms that induce the loss of T-cell activity and promote viral persistence are unknown. Herein we document that persistent viral infection in mice results in a significant upregulation of interleukin (IL)-10 by antigen-presenting cells, leading to impaired T-cell responses. Genetic removal of II10 resulted in the maintenance of robust effector T-cell responses, the rapid elimination of virus and the development of antiviral memory T-cell responses. Therapeutic administration of an antibody that blocks the IL-10 receptor restored T-cell function and eliminated viral infection. Thus, we identify a single molecule that directly induces immunosuppression leading to viral persistence and demonstrate that a therapy to neutralize IL-10 results in T-cell recovery and the prevention of viral persistence.	Scripps Res Inst, Viral Immunobiol Lab, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Harold L Dorris Neurol Res Inst, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Infectol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Brooks, DG (corresponding author), Scripps Res Inst, Viral Immunobiol Lab, Mol & Integrat Neurosci Dept, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dbrooks@scripps.edu	McGavern, Dorian/HCH-3601-2022	McGavern, Dorian/0000-0001-9568-545X; Brooks, David/0000-0001-7763-8764	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI009484, T32AI007244, R01AI045927, R21AI062718, R37AI009484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS048866] Funding Source: NIH RePORTER; NIAID NIH HHS [AI45927, R01 AI045927, R01 AI009484, T32 AI007244, AI09484, R01 AI009484-36, R01 AI045927-07, AI062718-01, AI07244-22, R21 AI062718] Funding Source: Medline; NINDS NIH HHS [NS048866-01, R21 NS048866] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Accapezzato D, 2004, J CLIN INVEST, V113, P963, DOI [10.1172/JCI200420415, 10.1172/JCI200420515]; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; BATTEGAY M, 1994, J VIROL, V68, P4700, DOI 10.1128/JVI.68.7.4700-4704.1994; BORROW P, 1995, J VIROL, V69, P1059, DOI 10.1128/JVI.69.2.1059-1070.1995; Borrow Persephone, 1997, P593; Brady MT, 2003, EUR J IMMUNOL, V33, P3448, DOI 10.1002/eji.200324251; Brooks DG, 2006, J CLIN INVEST, V116, P1675, DOI 10.1172/JCI26856; Brooks DG, 2005, J VIROL, V79, P10514, DOI 10.1128/JVI.79.16.10514-10527.2005; Cacciarelli TV, 1996, HEPATOLOGY, V24, P6, DOI 10.1053/jhep.1996.v24.pm0008707283; Carbonneil C, 2004, J IMMUNOL, V172, P7832, DOI 10.4049/jimmunol.172.12.7832; Clerici M, 1996, BLOOD, V88, P574, DOI 10.1182/blood.V88.2.574.bloodjournal882574; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Dolganiuc A, 2003, J IMMUNOL, V170, P5615, DOI 10.4049/jimmunol.170.11.5615; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Fuller MJ, 2004, J IMMUNOL, V172, P4204, DOI 10.4049/jimmunol.172.7.4204; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Granelli-Piperno A, 2004, P NATL ACAD SCI USA, V101, P7669, DOI 10.1073/pnas.0402431101; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; Homann D, 2001, NAT MED, V7, P913, DOI 10.1038/90950; Ji JX, 2005, INT IMMUNOL, V17, P729, DOI 10.1093/intimm/dxh252; Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069; Klenerman P, 2005, NAT IMMUNOL, V6, P873, DOI 10.1038/ni1241; Landay AL, 1996, J INFECT DIS, V173, P1085, DOI 10.1093/infdis/173.5.1085; Lechmann M, 1999, J HEPATOL, V31, P971, DOI 10.1016/S0168-8278(99)80307-9; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Lin MT, 1998, VIROLOGY, V245, P270, DOI 10.1006/viro.1998.9170; Marin-Serrano E, 2006, J VIRAL HEPATITIS, V13, P230, DOI 10.1111/j.1365-2893.2005.00679.x; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Orsilles MA, 2006, APMIS, V114, P55, DOI 10.1111/j.1600-0463.2006.apm_108.x; Ostrowski MA, 2001, J INFECT DIS, V184, P1268, DOI 10.1086/324005; Ou R, 2001, J VIROL, V75, P8407, DOI 10.1128/JVI.75.18.8407-8423.2001; Rico MA, 2001, HEPATOLOGY, V33, P295, DOI 10.1053/jhep.2001.21147; Rigopoulou EI, 2005, CLIN IMMUNOL, V117, P57, DOI 10.1016/j.clim.2005.06.003; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; SALVATO M, 1991, J VIROL, V65, P1863, DOI 10.1128/JVI.65.4.1863-1869.1991; Sevilla N, 2000, J EXP MED, V192, P1249, DOI 10.1084/jem.192.9.1249; Strestik BD, 2001, J GEN VIROL, V82, P1349, DOI 10.1099/0022-1317-82-6-1349; Thimme R, 2001, J EXP MED, V194, P1395, DOI 10.1084/jem.194.10.1395; TISHON A, 1995, VIROLOGY, V212, P244, DOI 10.1006/viro.1995.1477; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Tsai SL, 1997, HEPATOLOGY, V25, P449; van der Most RG, 1998, VIROLOGY, V240, P158, DOI 10.1006/viro.1997.8934; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zuniga EI, 2004, NAT IMMUNOL, V5, P1227, DOI 10.1038/ni1136	48	710	744	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1301	1309		10.1038/nm1492	http://dx.doi.org/10.1038/nm1492			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17041596	Green Accepted			2022-12-25	WOS:000241844900028
J	Melkus, MW; Estes, JD; Padgett-Thomas, A; Gatlin, J; Denton, PW; Othieno, FA; Wege, AK; Haase, AT; Garcia, JV				Melkus, Michael W.; Estes, Jacob D.; Padgett-Thomas, Angela; Gatlin, Joel; Denton, Paul W.; Othieno, Florence A.; Wege, Anja K.; Haase, Ashley T.; Garcia, J. Victor			Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1	NATURE MEDICINE			English	Article							HUMAN CD34(+) CELLS; SCID-HU MOUSE; SHOCK-SYNDROME TOXIN-1; EPSTEIN-BARR-VIRUS; NOD/SCID MICE; T-CELLS; ENGRAFTMENT; INFECTION; BLOOD; MODEL	Here we show that transplantation of autologous human hematopoietic fetal liver CD34(+) cells into NOD/ SCID mice previously implanted with human fetal thymic and liver tissues results in long-term, systemic human T-cell homeostasis. In addition, these mice show systemic repopulation with human B cells, monocytes and macrophages, and dendritic cells (DCs). T cells in these mice generate human major histocompatibility complex class I- and class II-restricted adaptive immune responses to Epstein-Barr virus (EBV) infection and are activated by human DCs to mount a potent T-cell immune response to superantigens. Administration of the superantigen toxic shock syndrome toxin 1 (TSST-1) results in the specific systemic expansion of human V beta 2(+) T cells, release of human proinflammatory cytokines and localized, specific activation and maturation of human CD11c(+) dendritic cells. This represents the first demonstration of long-term systemic human T-cell reconstitution in vivo allowing for the manifestation of the differential response by human DCs to TSST-1.	Univ Texas, SW Med Ctr, Div Infect Dis, Dept Internal Med, Dallas, TX 75390 USA; Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Arena Pharmaceut Inc, San Diego, CA 92121 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Minnesota System; University of Minnesota Twin Cities	Melkus, MW (corresponding author), Univ Texas, SW Med Ctr, Div Infect Dis, Dept Internal Med, Dallas, TX 75390 USA.			Denton, Paul/0000-0003-2458-8147	NCI NIH HHS [CA82055] Funding Source: Medline; NIAID NIH HHS [5T32 AI005284, R37 AI028246, AI39416, T32 AI07421] Funding Source: Medline; NICHD NIH HHS [HD011149] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD011149] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD011149] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA082055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI005284, R37AI028246, T32AI007421, R01AI039416] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKKINA RK, 1994, BLOOD, V84, P1393; ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; An DS, 1997, J VIROL, V71, P1397, DOI 10.1128/JVI.71.2.1397-1404.1997; Bente DA, 2005, J VIROL, V79, P13797, DOI 10.1128/JVI.79.21.13797-13799.2005; Cravens PD, 2005, STEM CELLS, V23, P264, DOI 10.1634/stemcells.2004-0116; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Estes JD, 2006, J INFECT DIS, V193, P703, DOI 10.1086/500368; Gatlin J, 2001, HUM GENE THER, V12, P1079, DOI 10.1089/104303401750214294; Gatlin J, 2001, J VIROL, V75, P9995, DOI 10.1128/JVI.75.20.9995-9999.2001; Gimeno R, 2004, BLOOD, V104, P3886, DOI 10.1182/blood-2004-02-0656; Greiner DL, 1998, STEM CELLS, V16, P166, DOI 10.1002/stem.160166; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Islas-Ohlmayer M, 2004, J VIROL, V78, P13891, DOI 10.1128/JVI.78.24.13891-13900.2004; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; KARP DR, 1990, NATURE, V346, P474, DOI 10.1038/346474a0; Kum WWS, 2001, INFECT IMMUN, V69, P7544, DOI 10.1128/IAI.69.12.7544-7549.2001; Makida R, 1996, MOL IMMUNOL, V33, P891, DOI 10.1016/0161-5890(96)84615-3; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; Palucka AK, 2003, BLOOD, V102, P3302, DOI 10.1182/blood-2003-02-0384; Roos MTL, 2000, J INFECT DIS, V182, P451, DOI 10.1086/315737; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Traggiai E, 2004, SCIENCE, V304, P104, DOI 10.1126/science.1093933; VANDEKERCKHOVE BAE, 1991, J IMMUNOL, V146, P4173; Yahata T, 2002, J IMMUNOL, V169, P204, DOI 10.4049/jimmunol.169.1.204	25	472	477	1	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1316	1322		10.1038/nm1431	http://dx.doi.org/10.1038/nm1431			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17057712				2022-12-25	WOS:000241844900030
J	Niu, QW; Lin, SS; Reyes, JL; Chen, KC; Wu, HW; Yeh, SD; Chua, NH				Niu, Qi-Wen; Lin, Shih-Shun; Reyes, Jose Luis; Chen, Kuan-Chun; Wu, Hui-Wen; Yeh, Shyi-Dong; Chua, Nam-Hai			Expression of artificial microRNAs in transgenic Arabidopsis thaliana confers virus resistance	NATURE BIOTECHNOLOGY			English	Article							YELLOW-MOSAIC-VIRUS; SILENCING-MEDIATED DEFENSE; RNA INTERFERENCE; GENE; PLANTS; PROTEIN; TARGETS; RECOMBINATION; REPLICATION; SUPPRESSOR	Plant microRNAs ( miRNAs) regulate the abundance of target mRNAs by guiding their cleavage at the sequence complementary region. We have modified an Arabidopsis thaliana miR159 precursor to express artificial miRNAs ( amiRNAs) targeting viral mRNA sequences encoding two gene silencing suppressors, P69 of turnip yellow mosaic virus ( TYMV) and HC- Pro of turnip mosaic virus ( TuMV). Production of these amiRNAs requires A. thaliana DICER- like protein 1. Transgenic A. thaliana plants expressing amiR- P69(159) and amiR- HC- Pro(159) are specifically resistant to TYMV and TuMV, respectively. Expression of amiR-TuCP(159) targeting TuMV coat protein sequences also confers specific TuMV resistance. However, transgenic plants that express both amiR- P69(159) and amiR- HC- Pro(159) from a dimeric pre- amiR- P69(159)/ amiR- HC- Pro(159) transgene are resistant to both viruses. The virus resistance trait is displayed at the cell level and is hereditable. More important, the resistance trait is maintained at 15 degrees C, a temperature that compromises small interfering RNA - mediated gene silencing. The amiRNA- mediated approach should have broad applicability for engineering multiple virus resistance in crop plants.	Rockefeller Univ, Plant Mol Biol Lab, New York, NY 10021 USA; Natl Chung Hsing Univ, Dept Plant Pathol, Taichung 402, Taiwan	Rockefeller University; National Chung Hsing University	Chua, NH (corresponding author), Rockefeller Univ, Plant Mol Biol Lab, 1230 York Ave, New York, NY 10021 USA.	chua@mail.rockefeller.edu	Lin, Shih-Shun/HCH-9241-2022; Reyes, Jose/D-7331-2013	Reyes, Jose L./0000-0001-5129-9741; LIN, SHIH-SHUN/0000-0002-7295-5004				Aaziz R, 1999, J GEN VIROL, V80, P1339, DOI 10.1099/0022-1317-80-6-1339; ABEL PP, 1986, SCIENCE, V232, P738, DOI 10.1126/science.3457472; Alvarez JP, 2006, PLANT CELL, V18, P1134, DOI 10.1105/tpc.105.040725; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baulcombe DC, 1996, PLANT CELL, V8, P1833, DOI 10.1105/tpc.8.10.1833; Boden D, 2004, NUCLEIC ACIDS RES, V32, P1154, DOI 10.1093/nar/gkh278; Carrington JC, 2001, VIROLOGY, V281, P1, DOI 10.1006/viro.2000.0812; Chen CC, 2003, PLANT DIS, V87, P901, DOI 10.1094/PDIS.2003.87.8.901; Chen J, 2004, PLANT CELL, V16, P1302, DOI 10.1105/tpc.018986; Chung MH, 2000, TRANSGENIC RES, V9, P471, DOI 10.1023/A:1026522104478; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; FALK BW, 1994, SCIENCE, V263, P1395, DOI 10.1126/science.8179685; Fortier E, 2000, GENESIS, V26, P240, DOI 10.1002/(SICI)1526-968X(200004)26:4<240::AID-GENE40>3.0.CO;2-P; Gazzani S, 2004, SCIENCE, V306, P1046, DOI 10.1126/science.1101092; Hammond J, 1999, ADV VIRUS RES, V54, P189, DOI 10.1016/S0065-3527(08)60368-1; Helliwell CA, 2005, METHOD ENZYMOL, V392, P24, DOI 10.1016/S0076-6879(04)92002-2; Jones-Rhoades MW, 2006, ANNU REV PLANT BIOL, V57, P19, DOI 10.1146/annurev.arplant.57.032905.105218; Kameda T, 2004, BIOCHEM BIOPH RES CO, V315, P599, DOI 10.1016/j.bbrc.2004.01.097; Kang BC, 2005, ANNU REV PHYTOPATHOL, V43, P581, DOI 10.1146/annurev.phyto.43.011205.141140; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; LIN SS, IN PRESS PHYTOPATHOL; Llave C, 2000, P NATL ACAD SCI USA, V97, P13401, DOI 10.1073/pnas.230334397; Mitchell EJ, 2005, ARCH VIROL, V150, P2347, DOI 10.1007/s00705-005-0593-y; MORCH MD, 1988, NUCLEIC ACIDS RES, V16, P6157, DOI 10.1093/nar/16.13.6157; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Overhoff M, 2005, J MOL BIOL, V348, P871, DOI 10.1016/j.jmb.2005.03.012; Palukaitis P, 1997, ADV VIRUS RES, V48, P349, DOI 10.1016/S0065-3527(08)60292-4; Prod'homme D, 2003, J VIROL, V77, P9124, DOI 10.1128/JVI.77.17.9124-9135.2003; RIECHMANN JL, 1992, J GEN VIROL, V73, P1, DOI 10.1099/0022-1317-73-1-1; Rubio T, 1999, MOL PLANT MICROBE IN, V12, P87, DOI 10.1094/MPMI.1999.12.2.87; Sanchez F, 1998, VIRUS RES, V55, P207, DOI 10.1016/S0168-1702(98)00049-5; SANFORD JC, 1985, J THEOR BIOL, V113, P395, DOI 10.1016/S0022-5193(85)80234-4; Schwab R, 2006, PLANT CELL, V18, P1121, DOI 10.1105/tpc.105.039834; Simon-Mateo C, 2006, J VIROL, V80, P2429, DOI 10.1128/JVI.80.5.2429-2436.2006; SKOTNICKI ML, 1992, ARCH VIROL, V127, P25, DOI 10.1007/BF01309572; SMITH HA, 1994, PLANT CELL, V6, P1441, DOI 10.1105/tpc.6.10.1441; Souret FF, 2004, MOL CELL, V15, P173, DOI 10.1016/j.molcel.2004.06.006; Stegmeier F, 2005, P NATL ACAD SCI USA, V102, P13212, DOI 10.1073/pnas.0506306102; Sun DQ, 2006, BIOTECHNIQUES, V41, P59, DOI 10.2144/000112203; Szittya G, 2003, EMBO J, V22, P633, DOI 10.1093/emboj/cdg74; Tepfer M, 2002, ANNU REV PHYTOPATHOL, V40, P467, DOI 10.1146/annurev.phyto.40.120301.093728; Tomimura K, 2003, MOL ECOL, V12, P2099, DOI 10.1046/j.1365-294X.2003.01881.x; Vaucheret H, 2004, GENE DEV, V18, P1187, DOI 10.1101/gad.1201404; Voinnet O, 2000, CELL, V103, P157, DOI 10.1016/S0092-8674(00)00095-7; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhang XR, 2005, GENE DEV, V19, P1532, DOI 10.1101/gad.1318705	49	367	457	1	76	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2006	24	11					1420	1428		10.1038/nbt1255	http://dx.doi.org/10.1038/nbt1255			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	106TP	17057702				2022-12-25	WOS:000242124700039
J	Trautmann, L; Janbazian, L; Chomont, N; Said, EA; Gimmig, S; Bessette, B; Boulassel, MR; Delwart, E; Sepulveda, H; Balderas, RS; Routy, JP; Haddad, EK; Sekaly, RP				Trautmann, Lydie; Janbazian, Loury; Chomont, Nicolas; Said, Elias A.; Gimmig, Sylvain; Bessette, Benoit; Boulassel, Mohamed-Rachid; Delwart, Eric; Sepulveda, Homero; Balderas, Robert S.; Routy, Jean-Pierre; Haddad, Elias K.; Sekaly, Rafick-Pierre			Upregulation of PD-1 expression on HIV-specific CD8(+) T cells leads to reversible immune dysfunction	NATURE MEDICINE			English	Article							CHRONIC VIRAL-INFECTION; ANTIRETROVIRAL THERAPY; LYMPHOCYTES; ACTIVATION; PERFORIN; RECEPTOR; ANTIGEN; ESCAPE; PROLIFERATION; PERSISTENCE	The engagement of programmed death 1 (PD-1) to its ligands, PD-L1 and PD-L2(1-4), inhibits proliferation and cytokine production mediated by antibodies to CD3 (refs. 5-7). Blocking the PD-1 - PD-L1 pathway in mice chronically infected with lymphocytic choriomeningitis virus restores the capacity of exhausted CD8(+) T cells to undergo proliferation, cytokine production and cytotoxic activity and, consequently, results in reduced viral load(8). During chronic HIV infection, HIV-specific CD8(+) T cells are functionally impaired(9-11), showing a reduced capacity to produce cytokines and effector molecules as well as an impaired capacity to proliferate(12-15). Here, we found that PD-1 was upregulated on HIV-specific CD8(+) T cells; PD-1 expression levels were significantly correlated both with viral load and with the reduced capacity for cytokine production and proliferation of HIV-specific CD8(+) T cells. Notably, cytomegalovirus (CMV)-specific CD8(+) T cells from the same donors did not upregulate PD-1 and maintained the production of high levels of cytokines. Blocking PD-1 engagement to its ligand (PD-L1) enhanced the capacity of HIV-specific CD8(+) T cells to survive and proliferate and led to an increased production of cytokines and cytotoxic molecules in response to cognate antigen. The accumulation of HIV-specific dysfunctional CD8(+) T cells in the infected host could prevent the renewal of a functionally competent HIV-specific CD8(+) repertoire.	CR CHUM St Luc, Lab Immunol, Montreal, PQ H3X 1P1, Canada; Univ Montreal, Lab Immunol, Dept Microbiol & Immunol, Montreal, PQ, Canada; Univ Montreal, CR CHUM, INSERM, U743, Montreal, PQ H2X 1P1, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Royal Victoria Hosp, Immunodeficiency Serv, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Div Haematol, Ctr Hlth, Montreal, PQ H3A 1A1, Canada; Blood Syst Res Inst, San Francisco, CA 94118 USA; BD Biosci, San Diego, CA 92121 USA	Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montreal; McGill University; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Vitalant; Vitalant Research Institute	Sekaly, RP (corresponding author), CR CHUM St Luc, Lab Immunol, 264 Rene Levesque Est, Montreal, PQ H3X 1P1, Canada.	rafick-pierre.sekaly@umontreal.ca	Chomont, Nicolas/ABG-2545-2020; Said, Elias/AAY-5557-2020	Chomont, Nicolas/0000-0001-9747-5018; Said, Elias/0000-0003-4224-6351; Delwart, Eric/0000-0002-6296-4484; Trautmann, Lydie/0000-0002-3012-0009				Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Almanzar G, 2005, J VIROL, V79, P3675, DOI 10.1128/JVI.79.6.3675-3683.2005; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Champagne P, 2001, NATURE, V410, P106, DOI 10.1038/35065118; Chemnitz JM, 2004, J IMMUNOL, V173, P945, DOI 10.4049/jimmunol.173.2.945; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Douek DC, 2002, J IMMUNOL, V168, P3099, DOI 10.4049/jimmunol.168.6.3099; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Geels MJ, 2003, J VIROL, V77, P12430, DOI 10.1128/JVI.77.23.12430-12440.2003; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Price DA, 2004, IMMUNITY, V21, P793, DOI 10.1016/j.immuni.2004.10.010; Shanker P, 2000, BLOOD, V96, P3094, DOI 10.1182/blood.V96.9.3094.h8003094_3094_3101; Wherry EJ, 2004, P NATL ACAD SCI USA, V101, P16004, DOI 10.1073/pnas.0407192101; Wherry EJ, 2005, J VIROL, V79, P8960, DOI 10.1128/JVI.79.14.8960-8968.2005; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Yang OO, 2005, VIROLOGY, V332, P16, DOI 10.1016/j.virol.2004.11.028; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598; Zajac AJ, 1998, J EXP MED, V188, P2205, DOI 10.1084/jem.188.12.2205; Zhang D, 2003, BLOOD, V101, P226, DOI 10.1182/blood-2002-03-0791; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	29	1154	1226	0	66	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1198	1202		10.1038/nm1482	http://dx.doi.org/10.1038/nm1482			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16917489				2022-12-25	WOS:000241102200038
J	Yang, WH; Kim, JE; Nam, HW; Ju, JW; Kim, HS; Kim, YS; Cho, JW				Yang, Won Ho; Kim, Ji Eun; Nam, Hyung Wook; Ju, Jung Won; Kim, Hoe Suk; Kim, Yu Sam; Cho, Jin Won			Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability	NATURE CELL BIOLOGY			English	Article							ESTROGEN-RECEPTOR-BETA; TUMOR-SUPPRESSOR P53; GLYCOSYLATION/O-PHOSPHORYLATION; POSTTRANSLATIONAL MODIFICATIONS; SIGNAL-TRANSDUCTION; COP9 SIGNALOSOME; MDM2 BINDING; CELL-DEATH; IN-VIVO; GLCNAC	Post-translational addition of O-linked N-acetylglucosamine (O-GlcNAc) to p53 is known to occur, but the site of O-GlcNAcylation and its effects on p53 are not understood. Here, we show that Ser 149 of p53 is O-GlcNAcylated and that this modification is associated with decreased phosphorylation of p53 at Thr 155, which is a site that is targeted by the COP9 signalosome, resulting in decreased p53 ubiquitination. Accordingly, O-GlcNAcylation at Ser 149 stabilizes p53 by blocking ubiquitin-dependent proteolysis. Our results indicate that the dynamic interplay between O-GlcNAc and O-phosphate modifications coordinately regulate p53 stability and activity.	Yonsei Univ, Dept Biol, Seoul 120749, South Korea; Yonsei Univ, Prot Network Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; ProteomeTech, Seoul 120749, South Korea	Yonsei University; Yonsei University; Yonsei University	Cho, JW (corresponding author), Yonsei Univ, Dept Biol, 134 Shinchon Dong, Seoul 120749, South Korea.	chojw311@yonsei.ac.kr		Ju, Jung-Won/0000-0001-5248-6995				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Canadillas JMP, 2006, P NATL ACAD SCI USA, V103, P2109, DOI 10.1073/pnas.0510941103; Chalkley RJ, 2003, MOL CELL PROTEOMICS, V2, P182, DOI 10.1074/mcp.M300027-MCP200; Chehab NH, 2000, GENE DEV, V14, P278; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fiordaliso F, 2001, DIABETES, V50, P2363, DOI 10.2337/diabetes.50.10.2363; Fuchs Serge Y, 2002, Cell, V110, P531, DOI 10.1016/S0092-8674(02)00902-9; Gao Y, 2000, ARCH BIOCHEM BIOPHYS, V383, P296, DOI 10.1006/abbi.2000.2094; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haltiwanger RS, 1998, J BIOL CHEM, V273, P3611, DOI 10.1074/jbc.273.6.3611; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hsu CH, 1999, BRIT J CANCER, V80, P1080, DOI 10.1038/sj.bjc.6690467; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kang HT, 2003, J BIOL CHEM, V278, P51223, DOI 10.1074/jbc.M307332200; Kawaguchi T, 2005, ONCOGENE, V24, P6976, DOI 10.1038/sj.onc.1208839; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Konrad RJ, 2001, BIOCHEM J, V356, P31, DOI 10.1042/0264-6021:3560031; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Licitra L, 2004, J CLIN ONCOL, V22, P4901, DOI 10.1200/JCO.2004.05.071; Liu K, 2004, J NEUROCHEM, V89, P1044, DOI 10.1111/j.1471-4159.2004.02389.x; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Morgan SE, 2000, ONCOGENE, V19, P5010, DOI 10.1038/sj.onc.1203865; Prives C, 1999, J PATHOL, V187, P112; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Ryu J, 2004, MOL CELLS, V17, P353; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Shaw P, 1996, ONCOGENE, V12, P921; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Toleman C, 2006, BIOCHEM BIOPH RES CO, V340, P526, DOI 10.1016/j.bbrc.2005.12.041; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wells L, 2002, MOL CELL PROTEOMICS, V1, P791, DOI 10.1074/mcp.M200048-MCP200; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	49	322	351	3	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1074	U53		10.1038/ncb1470	http://dx.doi.org/10.1038/ncb1470			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16964247				2022-12-25	WOS:000241395300011
J	Murphy, GJ; Mostoslavsky, G; Kotton, DN; Mulligan, RC				Murphy, George J.; Mostoslavsky, Gustavo; Kotton, Darrell N.; Mulligan, Richard C.			Exogenous control of mammalian gene expression via modulation of translational termination	NATURE MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; IN-VIVO; NONSENSE MUTATION; ESCHERICHIA-COLI; STOP CODON; AMINOGLYCOSIDE; SUPPRESSION; EFFICIENCY; RECEPTOR; VECTORS	Here, we describe a system for the exogenous control of gene expression in mammalian cells that relies on the control of translational termination. To achieve gene regulation, we modified protein-coding sequences by introduction of a translational termination codon just downstream from the initiator AUG codon. Translation of the resulting mRNA leads to potent reduction in expression of the desired gene product. Expression of the gene product can be controlled by treating cells that express the mRNA with either aminoglycoside antibiotics or several nonantibiotic compounds. We show that the extent of regulation of gene expression can be substantial (60-fold) and that regulation can be achieved in the case of a variety of different genes, in different cultured cell lines and in primary cells in vivo. This gene regulation strategy offers significant advantages over existing methods for controlling gene expression and should have both immediate experimental application and possible clinical application.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Childrens Hosp, Div Mol Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Mulligan, RC (corresponding author), Harvard Univ, Sch Med, Dept Genet, 300 Longwood Ave, Boston, MA 02115 USA.	mulligan@receptor.med.harvard.edu		Kotton, Darrell/0000-0002-9604-8476; Mostoslavsky, Gustavo/0000-0002-0784-2169	NHLBI NIH HHS [5P0-HL54785] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ainsworth C, 2005, NATURE, V438, P726, DOI 10.1038/438726a; Barton-Davis ER, 1999, J CLIN INVEST, V104, P375, DOI 10.1172/JCI7866; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P6339, DOI 10.1093/nar/18.21.6339; BURKE JF, 1985, NUCLEIC ACIDS RES, V13, P6265, DOI 10.1093/nar/13.17.6265; Contag CH, 2002, ANNU REV BIOMED ENG, V4, P235, DOI 10.1146/annurev.bioeng.4.111901.093336; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Howard MT, 2000, ANN NEUROL, V48, P164, DOI 10.1002/1531-8249(200008)48:2<164::AID-ANA5>3.3.CO;2-2; KAHLMETER G, 1984, J ANTIMICROB CHEMOTH, V13, P9, DOI 10.1093/jac/13.suppl_A.9; Lai CH, 2004, P NATL ACAD SCI USA, V101, P15676, DOI 10.1073/pnas.0405155101; LOEBENBERG D, 1975, ANTIMICROB AGENTS CH, V7, P811, DOI 10.1128/AAC.7.6.811; MARTIN R, 1989, MOL GEN GENET, V217, P411, DOI 10.1007/BF02464911; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mostoslavsky G, 2005, MOL THER, V11, P932, DOI 10.1016/j.ymthe.2005.01.005; Nilsson M, 2003, BBA-GENE STRUCT EXPR, V1627, P1, DOI 10.1016/S0167-4781(03)00050-2; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; PARROTT CL, 1992, J LIPID RES, V33, P361; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; Rivera VM, 2005, BLOOD, V105, P1424, DOI 10.1182/blood-2004-06-2501; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sangkuhl K, 2004, HUM MOL GENET, V13, P893, DOI 10.1093/hmg/ddh105; Suhr ST, 1998, P NATL ACAD SCI USA, V95, P7999, DOI 10.1073/pnas.95.14.7999; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Wilschanski M, 2003, NEW ENGL J MED, V349, P1433, DOI 10.1056/NEJMoa022170; Yen L, 2004, NATURE, V431, P471, DOI 10.1038/nature02844; Zufferey R, 1999, J VIROL, V73, P2886, DOI 10.1128/JVI.73.4.2886-2892.1999; 2004009533	30	45	48	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1093	1099		10.1038/nm1376	http://dx.doi.org/10.1038/nm1376			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16892063				2022-12-25	WOS:000240373900035
J	Fallon, L; Belanger, CML; Corera, AT; Kontogiannea, M; Regan-Klapisz, E; Moreau, F; Voortman, J; Haber, M; Rouleau, G; Thorarinsdottir, T; Brice, A; Henegouwen, PMPVBE; Fon, EA				Fallon, Lara; Belanger, Catherine M. L.; Corera, Amadou T.; Kontogiannea, Maria; Regan-Klapisz, Elsa; Moreau, France; Voortman, Jarno; Haber, Michael; Rouleau, Genevieve; Thorarinsdottir, Thorhildur; Brice, Alexis; Henegouwen, Paul M. P. van Bergen en; Fon, Edward A.			A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3) K-Akt signalling	NATURE CELL BIOLOGY			English	Article							GROWTH-FACTOR RECEPTOR; RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-BINDING PROTEINS; ENDOCYTIC PATHWAY; GENE; DISEASE; MOTIF; MONOUBIQUITINATION; ACTIVATION; MUTATIONS	Mutations in the parkin gene are responsible for a common familial form of Parkinson's disease(1,2). As parkin encodes an E3 ubiquitin ligase(3), defects in proteasome-mediated protein degradation are believed to have a central role in the pathogenesis of Parkinson's disease(4). Here, we report a novel role for parkin in a proteasome-independent ubiquitination pathway. We have identified a regulated interaction between parkin and Eps15, an adaptor protein that is involved in epidermal growth factor ( EGF) receptor ( EGFR) endocytosis and trafficking(5). Treatment of cells with EGF stimulates parkin binding to both Eps15 and the EGFR and promotes parkin-mediated ubiquitination of Eps15. Binding of the parkin ubiquitin-like ( Ubl) domain to the Eps15 ubiquitin-interacting motifs ( UIMs) is required for parkin-mediated Eps15 ubiquitination. Furthermore, EGFR endocytosis and degradation are accelerated in parkin-deficient cells, and EGFR signalling via the phosphoinositide 3-kinase ( PI( 3) K)Akt pathway is reduced in parkin knockout mouse brain. We propose that by ubiquitinating Eps15, parkin interferes with the ability of the Eps15 UIMs to bind ubiquitinated EGFR(6-8), thereby delaying EGFR internalization and degradation, and promoting PI( 3)K-Akt signalling. Considering the role of Akt in neuronal survival(9), our results have broad new implications for understanding the pathogenesis of Parkinson's disease.	McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ Utrecht, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; INSERM, U679, F-75651 Paris 13, France; Grp Hosp Pitie Salpetriere, Dept Genet Cytogenet & Embryol, F-75651 Paris 13, France	McGill University; McGill University; Utrecht University; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Fon, EA (corresponding author), McGill Univ, Montreal Neurol Inst, Ctr Neuronal Survival, Montreal, PQ H3A 2B4, Canada.	ted.fon@mcgill.ca	brice, alexis/AAE-8275-2019; Brice, Alexis/A-2170-2009; van Bergen en Henegouwen, Paul/B-8870-2011	brice, alexis/0000-0002-0941-3990; van Bergen en Henegouwen, Paul/0000-0001-6050-9042				Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; de Melker AA, 2004, J CELL SCI, V117, P5001, DOI 10.1242/jcs.01354; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; FAUNDEZ V, 1992, J BIOL CHEM, V267, P20363; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Goldberg MS, 2003, J BIOL CHEM, V278, P43628, DOI 10.1074/jbc.M308947200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hicks AA, 2002, ANN NEUROL, V52, P549, DOI 10.1002/ana.10324; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Huang FT, 2004, J BIOL CHEM, V279, P16657, DOI 10.1074/jbc.C400046200; Iwakura Y, 2005, J NEUROCHEM, V93, P974, DOI 10.1111/j.1471-4159.2005.03073.x; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Ko HS, 2005, J NEUROSCI, V25, P7968, DOI 10.1523/JNEUROSCI.2172-05.2005; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Pawlyk AC, 2003, J BIOL CHEM, V278, P48120, DOI 10.1074/jbc.M306889200; Periquet M, 2005, J NEUROCHEM, V95, P1259, DOI 10.1111/j.1471-4159.2005.03442.x; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; vanDelft S, 1997, J BIOL CHEM, V272, P14013, DOI 10.1074/jbc.272.22.14013; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Yang YF, 2005, P NATL ACAD SCI USA, V102, P13670, DOI 10.1073/pnas.0504610102; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	35	297	302	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					834	U87		10.1038/ncb1441	http://dx.doi.org/10.1038/ncb1441			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16862145				2022-12-25	WOS:000239423000013
J	Ohta, Y; Hartwig, JH; Stossel, TP				Ohta, Yasutaka; Hartwig, John H.; Stossel, Thomas P.			FilGAP, a Rho- and ROCK-regulated GAP for Rac binds filamin A to control actin remodelling	NATURE CELL BIOLOGY			English	Article							GTPASE-ACTIVATING PROTEIN; FOCAL ADHESIONS; TARGETS FILAMIN; EXCHANGE FACTOR; CELL; KINASE; CDC42; ALPHA; PHOSPHORYLATION; MIGRATION	FilGAP is a newly recognized filamin A ( FLNa)-binding RhoGTPase-activating protein. The GTPase-activating protein ( GAP) activity of FilGAP is specific for Rac and FLNa binding targets FilGAP to sites of membrane protrusion, where it antagonizes Rac in vivo. Dominant-negative FilGAP constructs lacking GAP activity or knockdown of endogenous FilGAP by small interference RNA ( siRNA) induce spontaneous lamellae formation and stimulate cell spreading on fibronectin. Knockdown of endogenous FilGAP abrogates ROCK-dependent suppression of lamellae. Conversely, forced expression of FilGAP induces numerous blebs around the cell periphery and a ROCK-specific inhibitor suppresses bleb formation. ROCK phosphorylates FilGAP, and this phosphorylation stimulates its RacGAP activity and is a requirement for FilGAP-mediated bleb formation. FilGAP is, therefore, a mediator of the well-established antagonism of Rac by RhoA that suppresses leading edge protrusion and promotes cell retraction to achieve cellular polarity.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Hematol Div, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ohta, Y (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Hematol Div, Boston, MA 02115 USA.	yohta@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL19429] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aitsebaomo J, 2004, J BIOL CHEM, V279, P17963, DOI 10.1074/jbc.M311721200; Alberts AS, 2005, J BIOL CHEM, V280, P12152, DOI 10.1074/jbc.M405073200; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Bellanger JM, 2000, NAT CELL BIOL, V2, P888, DOI 10.1038/35046533; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Caron E, 2003, NAT CELL BIOL, V5, P185, DOI 10.1038/ncb0303-185; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Feng YY, 2004, NAT CELL BIOL, V6, P1034, DOI 10.1038/ncb1104-1034; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Katoh M, 2004, INT J MOL MED, V14, P333; Lavelin I, 2005, J BIOL CHEM, V280, P7178, DOI 10.1074/jbc.M411990200; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; Nakamura F, 2002, J BIOL CHEM, V277, P9148, DOI 10.1074/jbc.M111297200; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; Nimnual AS, 2003, NAT CELL BIOL, V5, P236, DOI 10.1038/ncb938; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Pi M, 2002, ENDOCRINOLOGY, V143, P3830, DOI 10.1210/en.2002-220240; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Puls A, 1999, J CELL SCI, V112, P2983; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Roovers K, 2003, MOL CELL BIOL, V23, P4283, DOI 10.1128/MCB.23.12.4283-4294.2003; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schwartz MA, 1998, ONCOGENE, V17, P625, DOI 10.1038/sj.onc.1201977; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shinohara M, 2002, NATURE, V416, P759, DOI 10.1038/416759a; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Su ZJ, 2004, P NATL ACAD SCI USA, V101, P12212, DOI 10.1073/pnas.0404631101; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Ueda K, 2003, BIOCHEM BIOPH RES CO, V301, P886, DOI 10.1016/S0006-291X(03)00048-2; Vadlamudi RK, 2002, NAT CELL BIOL, V4, P681, DOI 10.1038/ncb838; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; VIDALI L, IN PRESS MOL BIOL CE; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867	50	280	289	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					803	U35		10.1038/ncb1437	http://dx.doi.org/10.1038/ncb1437			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16862148				2022-12-25	WOS:000239423000010
J	Cupers, P; Sautter, J; Vanvossel, A				Cupers, Philippe; Sautter, Jurgen; Vanvossel, Alain			European Union research policy and funding for Alzheimer disease	NATURE MEDICINE			English	Editorial Material							DEMENTIA; BRAIN; COST		Commiss European Communities, Res Directorate Gen, Off CDMA 02 005, BE-1049 Brussels, Belgium		Cupers, P (corresponding author), Commiss European Communities, Res Directorate Gen, Off CDMA 02 005, BE-1049 Brussels, Belgium.	philippe.cupers@ec.europa.eu						Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Berr C, 2005, EUR NEUROPSYCHOPHARM, V15, P463, DOI 10.1016/j.euroneuro.2005.04.003; Fratiglioni L, 2000, NEUROLOGY, V54, pS10; Jonsson L, 2005, EUR J NEUROL, V12, P50, DOI 10.1111/j.1468-1331.2005.01190.x; Lobo A, 2000, NEUROLOGY, V54, pS4; Olesen J, 2003, EUR J NEUROL, V10, P471, DOI 10.1046/j.1468-1331.2003.00682.x	6	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					774	775		10.1038/nm0706-774	http://dx.doi.org/10.1038/nm0706-774			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829944				2022-12-25	WOS:000238862800057
J	Paolini, GV; Shapland, RHB; van Hoorn, WP; Mason, JS; Hopkins, AL				Paolini, Gaia V.; Shapland, Richard H. B.; van Hoorn, Willem P.; Mason, Jonathan S.; Hopkins, Andrew L.			Global mapping of pharmacological space	NATURE BIOTECHNOLOGY			English	Article							DRUG-LIKE PROPERTIES; MARKETED ORAL-DRUGS; MOLECULAR-PROPERTIES; SELECTION CRITERIA; KINASE INHIBITORS; DISCOVERY; LIKENESS; PERMEABILITY; SOLUBILITY; PREDICTION	We present the global mapping of pharmacological space by the integration of several vast sources of medicinal chemistry structure-activity relationships (SAR) data. Our comprehensive mapping of pharmacological space enables us to identify confidently the human targets for which chemical tools and drugs have been discovered to date. The integration of SAR data from diverse sources by unique canonical chemical structure, protein sequence and disease indication enables the construction of a ligand-target matrix to explore the global relationships between chemical structure and biological targets. Using the data matrix, we are able to catalog the links between proteins in chemical space as a polypharmacology interaction network. We demonstrate that probabilistic models can be used to predict pharmacology from a large knowledge base. The relationships between proteins, chemical structures and drug-like properties provide a framework for developing a probabilistic approach to drug discovery that can be exploited to increase research productivity.	Pfizer Global Res & Dev, Dept Knowledge Discovery, Sandwich CT13 9NJ, Kent, England; Pfizer Global Res & Dev, Dept Computat Chem, Sandwich CT13 9NJ, Kent, England; Pfizer Global Res & Dev, Dept Med Informat Struct & Design, Sandwich CT13 9NJ, Kent, England; Pfizer Global Res & Dev, Dept Res Informat, Sandwich CT13 9NJ, Kent, England; Servefile Software Ltd, Bristol BS48 4SG, North Somerset, England; Lundbeck Res, DK-2500 Copenhagen, Denmark	Pfizer; Pfizer; Pfizer; Pfizer; Lundbeck Corporation	Hopkins, AL (corresponding author), Pfizer Global Res & Dev, Dept Knowledge Discovery, Sandwich CT13 9NJ, Kent, England.	andrew.hopkins@pfizer.com	; Hopkins, Andrew/H-5138-2011	van Hoorn, Willem Paul/0000-0002-5325-4261; Hopkins, Andrew/0000-0003-1977-018X				Ajay, 1998, J MED CHEM, V41, P3314, DOI 10.1021/jm970666c; ANDREWS PR, 1984, J MED CHEM, V27, P1648, DOI 10.1021/jm00378a021; Austin CP, 2004, SCIENCE, V306, P1138, DOI 10.1126/science.1105511; Blake JF, 2003, BIOTECHNIQUES, P16; CONNOLLY T, 2002, DATABASE SYSTEMS PRA; Drews J, 1997, NAT BIOTECHNOL, V15, P1318, DOI 10.1038/nbt1297-1318; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; Egan WJ, 2002, CURR OPIN DRUG DISC, V5, P540; Feldman HJ, 2005, FEBS LETT, V579, P4685, DOI 10.1016/j.febslet.2005.07.039; Frantz S, 2005, NATURE, V437, P942, DOI 10.1038/437942a; FRYS SV, 1999, CHEM BIOL, V6, pR3; Golden JB, 2003, CURR OPIN DRUG DISC, V6, P310; Hopkins AL, 2004, DRUG DISCOV TODAY, V9, P430, DOI 10.1016/S1359-6446(04)03069-7; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Horvath D, 2003, J CHEM INF COMP SCI, V43, P680, DOI 10.1021/ci025634z; Jacoby E., 2004, DRUG DISCOV TODAY BI, V2, P190, DOI DOI 10.1016/S1741-8364(04)02408-4; Klosgen Willi., 2002, HDB DATA MINING KNOW; Krejsa CM, 2003, CURR OPIN DRUG DISC, V6, P470; Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997; Lajiness MS, 2004, CURR OPIN DRUG DISC, V7, P470; Lipinski C, 2004, NATURE, V432, P855, DOI 10.1038/nature03193; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6; McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r; Muegge I, 2003, MED RES REV, V23, P302, DOI 10.1002/med.10041; Muegge I, 2001, J MED CHEM, V44, P1841, DOI 10.1021/jm015507e; PIATETSKISHAPIR.G, 1992, KNOWLEDGE DISCOVERY; Podlogar B L, 2001, Curr Opin Drug Discov Devel, V4, P102; Proudfoot JR, 2002, BIOORG MED CHEM LETT, V12, P1647, DOI 10.1016/S0960-894X(02)00244-5; *R COR DEV TEAM, 2005, LANG ENV STAT COMP; Rogers D, 2005, J BIOMOL SCREEN, V10, P682, DOI 10.1177/1087057105281365; Root DE, 2003, CHEM BIOL, V10, P881, DOI 10.1016/j.chembiol.2003.08.009; Roth BL, 2000, NEUROSCIENTIST, V6, P252, DOI 10.1177/107385840000600408; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; Schuffenhauer A, 2002, J CHEM INF COMP SCI, V42, P947, DOI 10.1021/ci010385k; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sneader W., 1996, DRUG PROTOTYPES THEI; Stockwell BR, 2000, NAT REV GENET, V1, P116, DOI 10.1038/35038557; Strausberg RL, 2003, SCIENCE, V300, P294, DOI 10.1126/science.1083395; VANGESTEL G, 1986, DRUG DEVELOP RES, V8, P1; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Vieth M, 2004, J MED CHEM, V47, P224, DOI 10.1021/jm030267j; Vieth M, 2005, DRUG DISCOV TODAY, V10, P839, DOI 10.1016/S1359-6446(05)03477-X; Vieth M, 2004, BBA-PROTEINS PROTEOM, V1697, P243, DOI 10.1016/j.bbapap.2003.11.028; Wallqvist Anders, 2003, Prog Cell Cycle Res, V5, P173; Walters WP, 2002, ADV DRUG DELIVER REV, V54, P255, DOI 10.1016/S0169-409X(02)00003-0; Walters WP, 1999, CURR OPIN CHEM BIOL, V3, P384, DOI 10.1016/S1367-5931(99)80058-1; Wang J, 1999, J COMB CHEM, V1, P524, DOI 10.1021/cc990032m; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wenlock MC, 2003, J MED CHEM, V46, P1250, DOI 10.1021/jm021053p; Wermuth CG, 2004, J MED CHEM, V47, P1303, DOI 10.1021/jm030480f; Xia XY, 2004, J MED CHEM, V47, P4463, DOI 10.1021/jm0303195	52	621	642	1	84	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					805	815		10.1038/nbt1228	http://dx.doi.org/10.1038/nbt1228			11	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16841068	Bronze			2022-12-25	WOS:000239025100030
J	Holden, MA; Jayasinghe, L; Daltrop, O; Mason, A; Bayley, H				Holden, Matthew A.; Jayasinghe, Lakmal; Daltrop, Oliver; Mason, Amy; Bayley, Hagan			Direct transfer of membrane proteins from bacteria to planar bilayers for rapid screening by single-channel recording	NATURE CHEMICAL BIOLOGY			English	Article							BICOMPONENT TOXIN; CRYSTAL-STRUCTURE; PORE; COMPONENT; FORMS	Although the examination of membrane proteins in planar bilayers is a powerful methodology for evaluating their pharmacology and physiological roles, introducing membrane proteins into bilayers is often a difficult process(1). Here, we use a mechanical probe to transfer membrane proteins directly from Escherichia coli expression colonies to artificial lipid bilayers. In this way, single-channel electrical recordings can be made from both of the major classes of membrane proteins, alpha-helix bundles and beta barrels, which are represented respectively by a K+ channel and a bacterial pore-forming toxin. Further, we examined the bicomponent toxin leukocidin (Luk), which is composed of LukF and LukS subunits. We mixed separate LukF- and LukS-expressing colonies and transferred the mixture to a planar bilayer, which generated functional Luk pores. By this means, we rapidly screened binary combinations of mutant Luk subunits for a specific function: the ability to bind a molecular adaptor. We suggest that direct transfer from cells to bilayers will be useful in several aspects of membrane proteomics and in the construction of sensor arrays.	Univ Oxford, Dept Chem, Chem Res Lab, Oxford OX1 3TA, England	University of Oxford	Holden, MA (corresponding author), Univ Oxford, Dept Chem, Chem Res Lab, Mansfield Rd, Oxford OX1 3TA, England.	matthew.holden@chem.ox.ac.uk		Bayley, Hagan/0000-0003-2499-6116				Bayley H, 2001, NATURE, V413, P226, DOI 10.1038/35093038; Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5; Cheley S, 1997, PROTEIN ENG, V10, P1433, DOI 10.1093/protein/10.12.1433; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Gu LQ, 1999, NATURE, V398, P686, DOI 10.1038/19491; Gu LQ, 2001, J GEN PHYSIOL, V118, P481, DOI 10.1085/jgp.118.5.481; Gu LQ, 2001, SCIENCE, V291, P636, DOI 10.1126/science.291.5504.636; Guillet V, 2004, J BIOL CHEM, V279, P41028, DOI 10.1074/jbc.M406904200; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Holden MA, 2005, J AM CHEM SOC, V127, P6502, DOI 10.1021/ja042470p; Howorka S, 1998, BIOTECHNIQUES, V25, P764, DOI 10.2144/98255bm03; Irizarry SN, 2002, BIOCHEMISTRY-US, V41, P13653, DOI 10.1021/bi026393r; Jayasinghe L, 2005, PROTEIN SCI, V14, P2550, DOI 10.1110/ps.051648505; Kaneko J, 2004, BIOSCI BIOTECH BIOCH, V68, P981, DOI 10.1271/bbb.68.981; Kang XF, 2005, ANGEW CHEM INT EDIT, V44, P1495, DOI 10.1002/anie.200461885; Miles G, 2002, PROTEIN SCI, V11, P894, DOI 10.1110/ps.4360102; Miles G, 2001, BIOCHEMISTRY-US, V40, P8514, DOI 10.1021/bi010454o; Miller C., 1986, ION CHANNEL RECONSTI; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; Olson R, 1999, NAT STRUCT BIOL, V6, P134; Pedelacq JD, 1999, STRUCTURE, V7, P277, DOI 10.1016/S0969-2126(99)80038-0; Prevost G, 2001, CURR TOP MICROBIOL, V257, P53	23	47	72	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2006	2	6					314	318		10.1038/nchembio793	http://dx.doi.org/10.1038/nchembio793			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	045OH	16680158				2022-12-25	WOS:000237750900012
J	Siller, KH; Cabernard, C; Doe, CQ				Siller, Karsten H.; Cabernard, Clemens; Doe, Chris Q.			The NuMA-related Mud protein binds Pins and regulates spindle orientation in Drosophila neuroblasts	NATURE CELL BIOLOGY			English	Article							ASYMMETRIC CELL-DIVISION; MUSHROOM-BODY-DEFECT; C-ELEGANS; CORTICAL POLARITY; ALPHA-I; COMPLEX; PARTNER; GENE; DIFFERENTIATION; PROLIFERATION	Asymmetric cell division generates cell diversity during development(1,2) and regulates stem-cell self-renewal in Drosophila and mammals(3,4). In Drosophila, neuroblasts align their spindle with a cortical Partner of Inscuteable (Pins)-Gai crescent to divide asymmetrically, but the link between cortical polarity and the mitotic spindle is poorly understood. Here, we show that Pins directly binds, and coimmunoprecipitates with, the NuMA-related Mushroom body defect (Mud) protein. Pins recruits Mud to the neuroblast apical cortex, and Mud is also strongly localized to centrosome/spindle poles, in a similar way to NuMA. In mud mutants, cortical polarity is normal, but the metaphase spindle frequently fails to align with the cortical polarity axis. When spindle orientation is orthogonal to cell polarity, symmetric division occurs. We propose that Mud is a functional orthologue of mammalian NuMA and Caenorhabditis elegans Lin-5, and that Mud coordinates spindle orientation with cortical polarity to promote asymmetric cell division.	Univ Oregon, Howard Hughes Med Inst, Inst Neurosci, Inst Mol Biol, Eugene, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon	Doe, CQ (corresponding author), Univ Oregon, Howard Hughes Med Inst, Inst Neurosci, Inst Mol Biol, Eugene, OR 97403 USA.	cdoe@uoregon.edu	Cabernard, Clemens/A-9033-2010	Cabernard, Clemens/0000-0003-3706-6401				Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Du QS, 2002, CURR BIOL, V12, P1928, DOI 10.1016/S0960-9822(02)01298-8; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; Guan ZH, 2000, P NATL ACAD SCI USA, V97, P8122, DOI 10.1073/pnas.97.14.8122; Haren L, 2002, J CELL SCI, V115, P1815; HEUER JG, 1995, DEVELOPMENT, V121, P3861; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Lorson MA, 2000, J CELL BIOL, V148, P73, DOI 10.1083/jcb.148.1.73; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Peterson FC, 2004, MOL CELL, V13, P665, DOI 10.1016/S1097-2765(04)00086-3; PROKOP A, 1994, DEV BIOL, V161, P321, DOI 10.1006/dbio.1994.1034; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Siegrist SE, 2005, CELL, V123, P1323, DOI 10.1016/j.cell.2005.09.043; Siegrist SE, 2006, DEVELOPMENT, V133, P529, DOI 10.1242/dev.02211; Siller KH, 2005, MOL BIOL CELL, V16, P5127, DOI 10.1091/mbc.E05-04-0338; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Yu FW, 2005, GENE DEV, V19, P1341, DOI 10.1101/gad.1295505; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174; YU JX, GENETICS	29	243	248	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					594	600		10.1038/ncb1412	http://dx.doi.org/10.1038/ncb1412			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16648843				2022-12-25	WOS:000238029000012
J	Service, S; DeYoung, J; Karayiorgou, M; Roos, JL; Pretorious, H; Bedoya, G; Ospina, J; Ruiz-Linares, A; Macedo, A; Palha, JA; Heutink, P; Aulchenko, Y; Oostra, B; van Duijn, C; Jarvelin, MR; Varilo, T; Peddle, L; Rahman, P; Piras, G; Monne, M; Murray, S; Galver, L; Peltonen, L; Sabatti, C; Collins, A; Freimer, N				Service, S; DeYoung, J; Karayiorgou, M; Roos, JL; Pretorious, H; Bedoya, G; Ospina, J; Ruiz-Linares, A; Macedo, A; Palha, JA; Heutink, P; Aulchenko, Y; Oostra, B; van Duijn, C; Jarvelin, MR; Varilo, T; Peddle, L; Rahman, P; Piras, G; Monne, M; Murray, S; Galver, L; Peltonen, L; Sabatti, C; Collins, A; Freimer, N			Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies	NATURE GENETICS			English	Article							ALLELIC ASSOCIATION; AFRIKANERS; MAP; CHROMOSOMES; DEMOGRAPHY; DISEASE	The genome-wide distribution of linkage disequilibrium (LD) determines the strategy for selecting markers for association studies, but it varies between populations. We assayed LD in large samples (200 individuals) from each of 11 well-described population isolates and an outbred European-derived sample, using SNP markers spaced across chromosome 22. Most isolates show substantially higher levels of LD than the outbred sample and many fewer regions of very low LD (termed 'holes'). Young isolates known to have had relatively few founders show particularly extensive LD with very few holes; these populations offer substantial advantages for genome-wide association mapping.	Univ Calif Los Angeles, Ctr Neurobehav Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, So Calif Genotyping Consortium, Los Angeles, CA 90095 USA; Rockefeller Univ, New York, NY 10021 USA; Univ Pretoria, Dept Psychiat, ZA-0001 Pretoria, South Africa; Weskoppies Hosp, ZA-0001 Pretoria, South Africa; Univ Antioquia, Mol Genet Lab, Medellin, Colombia; Univ Antioquia, Dept Psychiat, Medellin, Colombia; UCL, Galton Lab, Dept Biol, London NW1 2HE, England; Univ Coimbra, Fac Med, Inst Med Psychol, P-3000033 Coimbra, Portugal; Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4704553 Braga, Portugal; Vrije Univ Amsterdam, Dept Human Genet, Sect Med Genom, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Ctr Neurogenom & Cognit Res, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, NL-1081 BT Amsterdam, Netherlands; Erasmus MC, Genet Epidemiol Unit, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Oulu, Dept Publ Hlth Sci & Gen Practice, SF-90220 Oulu, Finland; Imperial Coll London, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Univ Helsinki, Dept Med Genet, FIN-00290 Helsinki, Finland; Biomedicum, Natl Publ Hlth Inst, Dept Mol Med, Helsinki 00290, Finland; Newfound Genom, St John, NF A1C 2H5, Canada; Mem Univ Newfoundland, St John, NF A1C 5S7, Canada; San Francesco Hosp, Div Haematol, Nuoro, Italy; Illumina Inc, San Diego, CA 92121 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Stat, Los Angeles, CA 90095 USA; Univ Southampton, Southampton Gen Hosp, Human Genet Res Div, Southampton SO16 6YA, Hants, England; Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Rockefeller University; University of Pretoria; Universidad de Antioquia; Universidad de Antioquia; University of London; University College London; Universidade de Coimbra; Universidade do Minho; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Oulu; Imperial College London; University of Helsinki; Finland National Institute for Health & Welfare; University of Helsinki; Memorial University Newfoundland; Illumina; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of Southampton; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Freimer, N (corresponding author), Univ Calif Los Angeles, Ctr Neurobehav Genet, Los Angeles, CA 90095 USA.	nfreimer@mednet.ucla.edu	Collins, Andrew/S-2196-2019; Collins, Andrew/A-6595-2010; macedo, antónio/AFQ-1570-2022; Ruiz-Linares, Andres/AAR-1104-2021; Palha, Joana Almeida/C-2745-2009; macedo santos, antónio/M-5737-2013; macedo, antónio/AFQ-1571-2022; Aulchenko, Yurii/M-8270-2013	Collins, Andrew/0000-0001-7108-0771; Collins, Andrew/0000-0001-7108-0771; macedo, antónio/0000-0003-2180-2718; Ruiz-Linares, Andres/0000-0001-8372-1011; Palha, Joana Almeida/0000-0002-8866-368X; macedo santos, antónio/0000-0003-2180-2718; macedo, antónio/0000-0003-2180-2718; Aulchenko, Yurii/0000-0002-7899-1575; Van Duijn, Cornelia/0000-0002-2374-9204; Roos, Johannes/0000-0002-0572-1072; MONNE, MARIA/0000-0003-4978-4427; Varilo, Teppo/0000-0002-5839-8854; Jarvelin, Marjo-Riitta/0000-0002-2149-0630; Piras, Giovanna/0000-0003-4550-6606; Heutink, Peter/0000-0001-5218-1737	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Aulchenko YS, 2004, EUR J HUM GENET, V12, P527, DOI 10.1038/sj.ejhg.5201188; Carvajal-Carmona LG, 2003, HUM GENET, V112, P534, DOI 10.1007/s00439-002-0899-8; Collins A, 1998, P NATL ACAD SCI USA, V95, P1741, DOI 10.1073/pnas.95.4.1741; Dawson E, 2002, NATURE, V418, P544, DOI 10.1038/nature00864; De la Vega FM, 2005, GENOME RES, V15, P454, DOI 10.1101/gr.3241705; Efron B., 1994, INTRO BOOTSTRAP; Fan JB, 2003, COLD SPRING HARB SYM, V68, P69, DOI 10.1101/sqb.2003.68.69; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Gordon D, 2000, GENOMICS, V66, P87, DOI 10.1006/geno.2000.6190; Groenewald JZ, 1998, AM J HUM GENET, V62, P1254, DOI 10.1086/301833; Hall D, 2002, GENOME RES, V12, P956, DOI 10.1101/gr.136202; Ke XY, 2004, HUM MOL GENET, V13, P577, DOI 10.1093/hmg/ddh060; Kong X, 2004, AM J HUM GENET, V75, P1143, DOI 10.1086/426405; Maniatis N, 2004, AM J HUM GENET, V74, P846, DOI 10.1086/383589; Maniatis N, 2002, P NATL ACAD SCI USA, V99, P2228, DOI 10.1073/pnas.042680999; Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Morton NE, 2001, P NATL ACAD SCI USA, V98, P5217, DOI 10.1073/pnas.091062198; NEI M, 1972, AM NAT, V106, P283, DOI 10.1086/282771; Peltonen L, 2000, NAT REV GENET, V1, P182, DOI 10.1038/35042049; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Service SK, 2001, HUM MOL GENET, V10, P545, DOI 10.1093/hmg/10.5.545; Stumpf MPH, 2003, CURR BIOL, V13, P1, DOI 10.1016/S0960-9822(02)01404-5; Tapper WJ, 2003, ANN HUM GENET, V67, P487, DOI 10.1046/j.1469-1809.2003.00050.x; Teare MD, 2002, ANN HUM GENET, V66, P223, DOI 10.1017/S0003480002001082; Tenesa A, 2004, HUM MOL GENET, V13, P25, DOI 10.1093/hmg/ddh001; Thomas DC, 2005, AM J HUM GENET, V77, P337, DOI 10.1086/432962; Varilo T, 2003, HUM MOL GENET, V12, P51, DOI 10.1093/hmg/ddg005; Wright AF, 1999, NAT GENET, V23, P397, DOI 10.1038/70501	30	190	193	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2006	38	5					556	560		10.1038/ng1770	http://dx.doi.org/10.1038/ng1770			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16582909				2022-12-25	WOS:000237147500017
J	Bohn, G; Allroth, A; Brandes, G; Thiel, J; Glocker, E; Schaffer, AA; Rathinam, C; Taub, N; Teis, D; Zeidler, C; Dewey, RA; Geffers, R; Buer, J; Huber, LA; Welte, K; Grimbacher, B; Klein, C				Bohn, Georg; Allroth, Anna; Brandes, Gudrun; Thiel, Jens; Glocker, Erik; Schaffer, Alejandro A.; Rathinam, Chozhavendan; Taub, Nicole; Teis, David; Zeidler, Cornelia; Dewey, Ricardo A.; Geffers, Robert; Buer, Jan; Huber, Lukas A.; Welte, Karl; Grimbacher, Bodo; Klein, Christoph			A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14	NATURE MEDICINE			English	Article							CHEDIAK-HIGASHI-SYNDROME; SEVERE CONGENITAL NEUTROPENIA; HERMANSKY-PUDLAK-SYNDROME; COLONY-STIMULATING FACTOR; GRANULE EXOCYTOSIS; GRISCELLI-SYNDROME; HUMAN-NEUTROPHILS; PROGENITOR CELLS; LINKAGE ANALYSIS; MYELOID CELLS	Lysosome-related organelles have versatile functions, including protein and lipid degradation, signal transduction and protein secretion. The molecular elucidation of rare congenital diseases affecting endosomal-lysosomal biogenesis has given insights into physiological functions of the innate and adaptive immune system. Here, we describe a previously unknown human primary immunodeficiency disorder and provide evidence that the endosomal adaptor protein p14, previously characterized as confining mitogen-activated protein kinase (MAPK) signaling to late endosomes, is crucial for the function of neutrophils, B cells, cytotoxic T cells and melanocytes. Combining genetic linkage studies and transcriptional profiling analysis, we identified a homozygous point mutation in the 3' untranslated region (UTR) of p14 (also known as MAPBPIP), resulting in decreased protein expression. In p14-deficient cells, the distribution of late endosomes was severely perturbed, suggesting a previously unknown role for p14 in endosomal biogenesis. These findings have implications for understanding endosomal membrane dynamics, compartmentalization of cell signal cascades, and their role in immunity.	Hannover Med Sch, Dept Pediat Hematol Oncol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Cell Biol, D-30625 Hannover, Germany; Univ Hosp Freiburg, Div Clin Immunol & Rheumatol, D-79106 Freiburg, Germany; Natl Inst Hlth, Natl Ctr Biotechnol Informat, Dept Hlth & Human Serv, Bethesda, MD 20894 USA; Med Univ Innsbruck, Div Cell Biol, A-6020 Innsbruck, Austria; Helmholtz Ctr Infect Res, HCI, Array Facil & Mucosal Immun, D-38124 Braunschweig, Germany	Hannover Medical School; Hannover Medical School; University of Freiburg; National Institutes of Health (NIH) - USA; Medical University of Innsbruck; Helmholtz Association; Helmholtz-Center for Infection Research	Klein, C (corresponding author), Hannover Med Sch, Dept Pediat Hematol Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	klein.christoph@mh-hannover.de	Schaffer, Alejandro/N-1222-2019; Huber, Lukas Alfons/AAM-3499-2021; Saborowski, Anna/GQH-4609-2022; Schaffer, Alejandro A/F-2902-2012	Saborowski, Anna/0000-0003-4857-4276; Buer, Jan/0000-0002-7602-1698; Teis, David/0000-0002-8181-0253; Dewey, Ricardo/0000-0003-1677-2745; Huber, Lukas Alfons/0000-0003-1116-2120; Schider, Nicole/0000-0002-3579-3667	NATIONAL LIBRARY OF MEDICINE [Z01LM000097, ZIALM000097] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aarts LHJ, 2004, BLOOD, V103, P571, DOI 10.1182/blood-2003-07-2250; BAETZ K, 1995, J IMMUNOL, V154, P6122; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Carlsson G, 2004, BLOOD, V103, P3355, DOI 10.1182/blood-2003-04-1011; Chen JM, 2006, HUM GENET, V120, P1, DOI 10.1007/s00439-006-0180-7; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Fischer A, 2004, NAT IMMUNOL, V5, P23, DOI 10.1038/ni1023; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Gruenberg J, 2004, NAT REV MOL CELL BIO, V5, P317, DOI 10.1038/nrm1360; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HAMERS MN, 1984, BLOOD, V64, P635, DOI 10.1182/blood.V64.3.635.635; Hino M, 2000, BRIT J HAEMATOL, V109, P314, DOI 10.1046/j.1365-2141.2000.02054.x; Huynh C, 2004, P NATL ACAD SCI USA, V101, P16795, DOI 10.1073/pnas.0405905101; Janvier K, 2005, MOL BIOL CELL, V16, P4231, DOI 10.1091/mbc.E05-03-0213; Jung J, 2006, BLOOD, V108, P362, DOI 10.1182/blood-2005-11-4377; KLEIN C, 1994, J PEDIATR-US, V125, P886, DOI 10.1016/S0022-3476(05)82003-7; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084/jem.191.10.1699; KLEIN C, IN PRESS NAT GENET; Kollner I, 2006, BLOOD, V108, P493, DOI 10.1182/blood-2005-11-4689; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kurzbauer R, 2004, P NATL ACAD SCI USA, V101, P10984, DOI 10.1073/pnas.0403435101; LATHROP GM, 1984, AM J HUM GENET, V36, P460; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Mor A, 2006, ANNU REV IMMUNOL, V24, P771, DOI 10.1146/annurev.immunol.24.021605.090723; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Price TH, 1996, BLOOD, V88, P335; Russell JH, 2002, ANNU REV IMMUNOL, V20, P323, DOI 10.1146/annurev.immunol.20.100201.131730; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; Stinchcombe J, 2004, SCIENCE, V305, P55, DOI 10.1126/science.1095291; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; TEIS D, IN PRESS J CELL BIOL; Trambas CM, 2003, NAT IMMUNOL, V4, P399, DOI 10.1038/ni0503-399; Wunderlich W, 2001, J CELL BIOL, V152, P765, DOI 10.1083/jcb.152.4.765; Zhuang DZ, 2006, J BIOL CHEM, V281, P10745, DOI 10.1074/jbc.M510924200	42	140	144	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2007	13	1					38	45		10.1038/nm1528	http://dx.doi.org/10.1038/nm1528			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17195838				2022-12-25	WOS:000243301800034
J	Katz, ML; Mueller, LV; Polyakov, M; Weinstock, SF				Katz, Martin L.; Mueller, Lisa V.; Polyakov, Mark; Weinstock, Steven F.			Where have all the antibiotic patents gone?	NATURE BIOTECHNOLOGY			English	Editorial Material									Wood Phillips, Chicago, IL 60661 USA		Katz, ML (corresponding author), Wood Phillips, 500 W Madison St,Suite 3800, Chicago, IL 60661 USA.	mlkatz@woodphillips.com						Fermini B, 2003, NAT REV DRUG DISCOV, V2, P439, DOI 10.1038/nrd1108; HARRIS G, 2006, NY TIMES        0719; Infectious Diseases Society of America, 2004, BAD BUGS NO DRUGS; US Patent and Trademark Office, 2001, FED REGISTER, V66, P1092; 2006, DENVER BUSINESS 1023	5	65	68	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1529	1531		10.1038/nbt1206-1529	http://dx.doi.org/10.1038/nbt1206-1529			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17160057				2022-12-25	WOS:000242795800030
J	Ingraham, CR; Kinoshita, A; Kondo, S; Yang, BL; Sajan, S; Trout, KJ; Malik, MI; Dunnwald, M; Goudy, SL; Lovett, M; Murray, JC; Schutte, BC				Ingraham, Christopher R.; Kinoshita, Akira; Kondo, Shinji; Yang, Baoli; Sajan, Samin; Trout, Kurt J.; Malik, Margaret I.; Dunnwald, Martine; Goudy, Stephen L.; Lovett, Michael; Murray, Jeffrey C.; Schutte, Brian C.			Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6)	NATURE GENETICS			English	Article							DER-WOUDE-SYNDROME; INTERFERON-REGULATORY FACTOR-6; NONSYNDROMIC CLEFT-LIP; GENE INDUCTION; TRANSCRIPTION FACTORS; PALATE; VAN; IDENTIFICATION; POPULATION; MUTATIONS	Transcription factor paralogs may share a common role in staged or overlapping expression in specific tissues, as in the Hox family. In other cases, family members have distinct roles in a range of embryologic, differentiation or response pathways (as in the Tbx and Pax families). For the interferon regulatory factor (IRF) family of transcription factors, mice deficient in Irf1, Irf2, Irf3, Irf4, Irf5, Irf7, Irf8 or Irf9 have defects in the immune response but show no embryologic abnormalities(1-7). Mice deficient for Irf6 have not been reported, but in humans, mutations in IRF6 cause two mendelian orofacial clefting syndromes(8-10), and genetic variation in IRF6 confers risk for isolated cleft lip and palate(11-15). Here we report that mice deficient for Irf6 have abnormal skin, limb and craniofacial development. Histological and gene expression analyses indicate that the primary defect is in keratinocyte differentiation and proliferation. This study describes a new role for an IRF family member in epidermal development.	Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Nagasaki Univ, Div Funct Genom, Ctr Frontier Life Sci, Nagasaki 852, Japan; Univ Iowa, Dept Obstet & Gynecol, Iowa City, IA 52242 USA; Univ Iowa, Dept Dermatol, Iowa City, IA 52242 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Vanderbilt Univ, Dept Otolaryngol, Nashville, TN 37232 USA	University of Iowa; Nagasaki University; University of Iowa; University of Iowa; Washington University (WUSTL); Vanderbilt University	Schutte, BC (corresponding author), Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA.	brian-schutte@uiowa.edu			NIDCR NIH HHS [P50 DE016215-01, DE08559, DE13513, P50 DE016215, R01 DE008559-10, R01 DE013513, R01 DE008559, DE16215, R37 DE008559] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE008559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016215, R01DE008559, R01DE013513] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bailey CM, 2005, J BIOL CHEM, V280, P34210, DOI 10.1074/jbc.M503523200; Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Blanton SH, 2005, AM J MED GENET A, V137A, P259, DOI 10.1002/ajmg.a.30887; Dornan D, 2004, MOL CELL BIOL, V24, P10083, DOI 10.1128/MCB.24.22.10083-10098.2004; FISHER C, 1987, J CELL BIOL, V105, P1807, DOI 10.1083/jcb.105.4.1807; Ghassibe M, 2005, EUR J HUM GENET, V13, P1239, DOI 10.1038/sj.ejhg.5201486; Herron BJ, 2005, NAT GENET, V37, P1210, DOI 10.1038/ng1652; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kayano S, 2003, J HUM GENET, V48, P622, DOI 10.1007/s10038-003-0089-0; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; Knight AS, 2006, DEV DYNAM, V235, P1441, DOI 10.1002/dvdy.20598; Kondo S, 2002, NAT GENET, V32, P285, DOI 10.1038/ng985; Li QT, 2005, P NATL ACAD SCI USA, V102, P15977, DOI 10.1073/pnas.0508310102; MacPartlin M, 2005, J BIOL CHEM, V280, P30604, DOI 10.1074/jbc.M503352200; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Qin BY, 2005, STRUCTURE, V13, P1269, DOI 10.1016/j.str.2005.06.011; Richardson RJ, 2006, NAT GENET, V38, P1329, DOI 10.1038/ng1894; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Scapoli L, 2005, AM J HUM GENET, V76, P180, DOI 10.1086/427344; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Srichomthong C, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.032235; Sugihara TM, 2001, J BIOL CHEM, V276, P33036, DOI 10.1074/jbc.M103000200; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Wang XF, 2003, HUM GENET, V113, P382, DOI 10.1007/s00439-003-0989-2; Yang HM, 2003, J BIOL CHEM, V278, P15495, DOI 10.1074/jbc.M212940200; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zucchero TM, 2004, NEW ENGL J MED, V351, P769, DOI 10.1056/NEJMoa032909	30	245	251	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1335	1340		10.1038/ng1903	http://dx.doi.org/10.1038/ng1903			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17041601	Green Accepted			2022-12-25	WOS:000241592700024
J	Roy, NS; Cleren, C; Singh, SK; Yang, L; Beal, MF; Goldman, SA				Roy, Neeta S.; Cleren, Carine; Singh, Shashi K.; Yang, Lichuan; Beal, M. Flint; Goldman, Steven A.			Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes	NATURE MEDICINE			English	Article							EMBRYONIC STEM-CELLS; PARKINSONS-DISEASE; IN-VITRO; PROTEOMIC ANALYSIS; NEURAL PRECURSORS; TYPE-1 ASTROCYTES; HUMAN BLASTOCYSTS; SUBSTANTIA-NIGRA; SPINAL-CORD; RAT MODELS	To direct human embryonic stem (HES) cells to a dopaminergic neuronal fate, we cocultured HES cells that were exposed to both sonic hedgehog and fibroblast growth factor 8 with telomerase-immortalized human fetal midbrain astrocytes. These astrocytes substantially potentiated dopaminergic neurogenesis by both WA09 and WA01 HES cells, biasing them to the A9 nigrostriatal phenotype. When transplanted into the neostriata of 6-hydroxydopamine-lesioned parkinsonian rats, the dopaminergic implants yielded a significant, substantial and long-lasting restitution of motor function. However, although rich in donor-derived tyrosine hydroxylase-expressing neurons, the grafts exhibited expanding cores of undifferentiated mitotic neuroepithelial cells, which can be tumorigenic. These results show the utility of recreating the cellular environment of the developing human midbrain while driving dopaminergic neurogenesis from HES cells, and they demonstrate the potential of the resultant cells to mediate substantial functional recovery in a model of Parkinson disease. Yet these data also mandate caution in the clinical application of HES cell-derived grafts, given their potential for phenotypic instability and undifferentiated expansion.	Cornell Univ, Weill Med Coll, Dept Neurol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurosci, New York, NY 10021 USA; Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Neurosurg & Pediat, Rochester, NY 14642 USA	Cornell University; Cornell University; University of Rochester; University of Rochester	Roy, NS (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol, New York, NY 10021 USA.	ner2004@med.cornell.edu; steven_goldman@urmc.rochester.edu		Goldman, Steven/0000-0002-5498-4303; Cleren, Carine/0000-0002-2451-8387				Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Buytaert-Hoefen KA, 2004, STEM CELLS, V22, P669, DOI 10.1634/stemcells.22-5-669; CARMAN LS, 1991, BRAIN RES, V553, P275, DOI 10.1016/0006-8993(91)90835-J; Chang JW, 1999, NEUROSCIENCE, V88, P617, DOI 10.1016/S0306-4522(98)00217-6; Chung S, 2006, J NEUROCHEM, V97, P1467, DOI 10.1111/j.1471-4159.2006.03841.x; Egnaczyk GF, 2003, PROTEOMICS, V3, P689, DOI 10.1002/pmic.200300407; HUDSON JL, 1993, BRAIN RES, V626, P167, DOI 10.1016/0006-8993(93)90576-9; Iancu R, 2005, BEHAV BRAIN RES, V162, P1, DOI 10.1016/j.bbr.2005.02.023; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Lafon-Cazal M, 2003, J BIOL CHEM, V278, P24438, DOI 10.1074/jbc.M211980200; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; McRitchie DA, 1996, J COMP NEUROL, V364, P121, DOI 10.1002/(SICI)1096-9861(19960101)364:1<121::AID-CNE11>3.0.CO;2-1; Mendez I, 2005, BRAIN, V128, P1498, DOI 10.1093/brain/awh510; Morga E, 1998, J NEUROIMMUNOL, V87, P179, DOI 10.1016/S0165-5728(98)00099-X; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; OLSSON M, 1995, J NEUROSCI, V15, P3863; Onofre GR, 2001, BRAZ J MED BIOL RES, V34, P251, DOI 10.1590/S0100-879X2001000200014; Perrier AL, 2004, P NATL ACAD SCI USA, V101, P12543, DOI 10.1073/pnas.0404700101; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Reuss B, 2000, MOL CELL NEUROSCI, V16, P42, DOI 10.1006/mcne.2000.0857; Roy NS, 2004, NAT BIOTECHNOL, V22, P297, DOI 10.1038/nbt944; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Schwarting RKW, 1996, PROG NEUROBIOL, V50, P275, DOI 10.1016/S0301-0082(96)00040-8; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137; TAKESHIMA T, 1994, J NEUROSCI, V14, P4769; Thompson L, 2005, J NEUROSCI, V25, P6467, DOI 10.1523/JNEUROSCI.1676-05.2005; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Yan YP, 2005, STEM CELLS, V23, P781, DOI 10.1634/stemcells.2004-0365; Yang LC, 2004, NEUROBIOL DIS, V17, P250, DOI 10.1016/j.nbd.2004.07.021; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Yoshida M, 2001, J NEUROSCI RES, V63, P284, DOI 10.1002/1097-4547(20010201)63:3<284::AID-JNR1022>3.0.CO;2-6; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129	35	618	669	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2006	12	11					1259	1268		10.1038/nm1495	http://dx.doi.org/10.1038/nm1495			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17057709				2022-12-25	WOS:000241844900023
J	Tavano, R; Contento, RL; Baranda, SJ; Soligo, M; Tuosto, L; Manes, S; Viola, A				Tavano, Regina; Contento, Rita Lucia; Jimenez Baranda, Sonia; Soligo, Marzia; Tuosto, Loretta; Manes, Santos; Viola, Antonella			CD28 interaction with filamin-A controls lipid raft accumulation at the T-cell immunological synapse	NATURE CELL BIOLOGY			English	Article							ACTIVATION; MEMBRANE; REORGANIZATION; COSTIMULATION; RECRUITMENT; ENGAGEMENT; VAV; LCK	During physiological T-cell stimulation by antigen presenting cells (APCs), a major T-cell membrane rearrangement is known to occur leading to the organization of 'supramolecular activation clusters' at the immunological synapse(1,2). A possible role for the synapse is the generation of membrane compartments where signalling may be organized and propagated(2). Thus, engagement of the costimulatory molecule CD28 at the immunological synapse promotes the organization of a signalling compartment by inducing cytoskeletal changes and lipid raft accumulation(3-5). We identified the actin-binding protein Filamin-A (FLNa) as a novel molecular partner of CD28. We found that, after physiological stimulation, CD28 associated with and recruited FLNa into the immunological synapse, where FLNa organized CD28 signalling. FLNa knockdown by short interfering RNA (siRNA) inhibited CD28-mediated raft accumulation at the immunological synapse and T-cell costimulation. Together, our data indicate that CD28 binding to FLNa is required to induce the T-cell cytoskeletal rearrangements leading to recruitment of lipid microdomains and signalling mediators into the immunological synapse.	Univ Padua, Dept Biomed Sci, Venetian Inst Mol Med, I-35100 Padua, Italy; Ctr Nacl Biotecnol, Dept Immunol & Oncol, Madrid, Spain; Ist Clin Humanitas, I-20089 Rozzano, MI, Italy; Univ Roma La Sapienza, Dept Cellular & Dev Biol, I-00185 Rome, Italy	University of Padua; Veneto Institute Molecular Medicine; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); IRCCS Humanitas Research Hospital; Sapienza University Rome	Viola, A (corresponding author), Univ Padua, Dept Biomed Sci, Venetian Inst Mol Med, I-35100 Padua, Italy.	antonella.viola@unipd.it	Manes, Santos/E-4725-2011; Tuosto, Loretta/F-7017-2011; Soligo, Marzia/AAC-1543-2019; Agatea, Lisa/L-8267-2016; Viola, Antonella/A-4321-2015	Tuosto, Loretta/0000-0001-9056-4077; Manes, Santos/0000-0001-8023-957X; Soligo, Marzia/0000-0002-1420-0914; TAVANO, REGINA/0000-0002-0699-1859; Viola, Antonella/0000-0002-0125-9271				Dupre L, 2002, IMMUNITY, V17, P157, DOI 10.1016/S1074-7613(02)00360-6; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Gaus K, 2005, J CELL BIOL, V171, P121, DOI 10.1083/jcb.200505047; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hayashi K, 2006, J IMMUNOL, V177, P1721, DOI 10.4049/jimmunol.177.3.1721; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; KARR RW, 1991, J IMMUNOL, V146, P4242; Manes S, 2006, MOL MEMBR BIOL, V23, P59, DOI 10.1080/09687860500430069; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Pizzo P, 2004, IMMUNOL LETT, V91, P3, DOI 10.1016/j.imlet.2003.09.008; Pizzo P, 2002, EUR J IMMUNOL, V32, P3082, DOI 10.1002/1521-4141(200211)32:11<3082::AID-IMMU3082>3.0.CO;2-2; Ponsioen B, 2004, EMBO REP, V5, P1176, DOI 10.1038/sj.embor.7400290; Rodgers W, 2005, TRENDS IMMUNOL, V26, P97, DOI 10.1016/j.it.2004.11.016; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Rouquette-Jazdanian AK, 2006, CELL SIGNAL, V18, P105, DOI 10.1016/j.cellsig.2005.03.024; Salazar-Fontana LI, 2003, J IMMUNOL, V171, P2225, DOI 10.4049/jimmunol.171.5.2225; Sechi AS, 2004, TRENDS IMMUNOL, V25, P257, DOI 10.1016/j.it.2004.03.003; Sharma CP, 2004, CELL BIOL INT, V28, P935, DOI 10.1016/j.cellbi.2004.09.006; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Tavano R, 2004, J IMMUNOL, V173, P5392, DOI 10.4049/jimmunol.173.9.5392; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Viola A, 2001, TRENDS IMMUNOL, V22, P322, DOI 10.1016/S1471-4906(01)01938-X; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329; Zhang M, 2005, J IMMUNOL, V174, P1479, DOI 10.4049/jimmunol.174.3.1479	32	117	122	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1270	U46		10.1038/ncb1492	http://dx.doi.org/10.1038/ncb1492			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17060905				2022-12-25	WOS:000241732400016
J	Cho, E; Feng, Y; Rauskolb, C; Maitra, S; Fehon, R; Irvine, KD				Cho, Eunjoo; Feng, Yongqiang; Rauskolb, Cordelia; Maitra, Sushmita; Fehon, Rick; Irvine, Kenneth D.			Delineation of a Fat tumor suppressor pathway	NATURE GENETICS			English	Article							PLANAR CELL POLARITY; PROMOTES APOPTOSIS; DROSOPHILA-MELANOGASTER; PROLIFERATION CONTROL; CUBITUS INTERRUPTUS; EXPANDED FUNCTION; PROTEIN-KINASE; DOUBLE-TIME; CYCLE EXIT; GROWTH	Recent studies in Drosophila melanogaster of the protocadherins Dachsous and Fat suggest that they act as ligand and receptor, respectively, for an intercellular signaling pathway that influences tissue polarity, growth and gene expression, but the basis for signaling downstream of Fat has remained unclear. Here, we characterize functional relationships among D. melanogaster tumor suppressors and identify the kinases Discs overgrown and Warts as components of a Fat signaling pathway. fat, discs overgrown and warts regulate a common set of downstream genes in multiple tissues. Genetic experiments position the action of discs overgrown upstream of the Fat pathway component dachs, whereas warts acts downstream of dachs. Warts protein coprecipitates with Dachs, and Warts protein levels are influenced by fat, dachs and discs overgrown in vivo, consistent with its placement as a downstream component of the pathway. The tumor suppressors Merlin, expanded, hippo, salvador and mob as tumor suppressor also share multiple Fat pathway phenotypes but regulate Warts activity independently. Our results functionally link what had been four disparate groups of D. melanogaster tumor suppressors, establish a basic framework for Fat signaling from receptor to transcription factor and implicate Warts as an integrator of multiple growth control signals.	Rutgers State Univ, Howard Hughes Med Inst, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of Chicago	Irvine, KD (corresponding author), Rutgers State Univ, Howard Hughes Med Inst, Waksman Inst, Piscataway, NJ 08854 USA.	irvine@waksman.rutgers.edu	Feng, Yongqiang/AAR-7719-2021; Feng, Yongqiang/N-2731-2018	Feng, Yongqiang/0000-0002-2320-5063; Feng, Yongqiang/0000-0002-2320-5063	Howard Hughes Medical Institute Funding Source: Medline; NIGMS NIH HHS [GM63057] Funding Source: Medline; NINDS NIH HHS [NS034783] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS034783, R01NS034783] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Blaumueller CM, 2000, MECH DEVELOP, V92, P251, DOI 10.1016/S0925-4773(00)00246-X; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; BRYANT PJ, 1988, DEV BIOL, V129, P541, DOI 10.1016/0012-1606(88)90399-5; Buckles GR, 2001, DEVELOPMENT, V128, P3533; Casal J, 2002, CURR BIOL, V12, P1189, DOI 10.1016/S0960-9822(02)00974-0; Cho E, 2004, DEVELOPMENT, V131, P4489, DOI 10.1242/dev.01315; CLARK HF, 1995, GENE DEV, V9, P1530, DOI 10.1101/gad.9.12.1530; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Edwards KM, 2004, ONCOGENE, V23, P5263, DOI 10.1038/sj.onc.1207686; Fanto M, 2003, DEVELOPMENT, V130, P763, DOI 10.1242/dev.00304; Garoia F, 2005, MECH DEVELOP, V122, P175, DOI 10.1016/j.mod.2004.10.007; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jaiswal M, 2006, DEVELOPMENT, V133, P925, DOI 10.1242/dev.02243; Jia JH, 2005, DEV CELL, V9, P819, DOI 10.1016/j.devcel.2005.10.006; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Klein TJ, 2006, CURR BIOL, V16, P1337, DOI 10.1016/j.cub.2006.06.030; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Ma D, 2003, NATURE, V421, P543, DOI 10.1038/nature01366; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Maitra S, 2006, CURR BIOL, V16, P702, DOI 10.1016/j.cub.2006.02.063; Mao YP, 2006, DEVELOPMENT, V133, P2539, DOI 10.1242/dev.02427; Matakatsu H, 2004, DEVELOPMENT, V131, P3785, DOI 10.1242/dev.01254; Matakatsu H, 2006, DEVELOPMENT, V133, P2315, DOI 10.1242/dev.02401; McCartney BM, 2000, DEVELOPMENT, V127, P1315; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Rauskolb C, 1999, DEV BIOL, V210, P339, DOI 10.1006/dbio.1999.9273; Simon MA, 2004, DEVELOPMENT, V131, P6175, DOI 10.1242/dev.01550; Strutt H, 2004, DEVELOPMENT, V131, P881, DOI 10.1242/dev.00996; Strutt H, 2002, DEV CELL, V3, P851, DOI 10.1016/S1534-5807(02)00363-5; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; WATSON KL, 1994, J CELL SCI, P19; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; XU TA, 1995, DEVELOPMENT, V121, P1053; Yang CH, 2002, CELL, V108, P675, DOI 10.1016/S0092-8674(02)00658-X; Zeidler MP, 2000, DEV BIOL, V228, P181, DOI 10.1006/dbio.2000.9940; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zilian O, 1999, DEVELOPMENT, V126, P5409	49	347	354	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1142	1150		10.1038/ng1887	http://dx.doi.org/10.1038/ng1887			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16980976				2022-12-25	WOS:000241251100013
J	Strom, E; Sathe, S; Komarov, PG; Chernova, OB; Pavlovska, I; Shyshynova, I; Bosykh, DA; Burdelya, LG; Macklis, RM; Skaliter, R; Komarova, EA; Gudkov, AV				Strom, Evguenia; Sathe, Swati; Komarov, Pavel G.; Chernova, Olga B.; Pavlovska, Ivanda; Shyshynova, Inna; Bosykh, Dmitry A.; Burdelya, Lyudmila G.; Macklis, Roger M.; Skaliter, Rami; Komarova, Elena A.; Gudkov, Andrei V.			Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation	NATURE CHEMICAL BIOLOGY			English	Article							SENSITIVITY IN-VIVO; INDUCED APOPTOSIS; CELL-DEATH; TRANSCRIPTION; ACTIVATION; THERAPY; TARGET	p53-dependent apoptosis contributes to the side effects of cancer treatment, and genetic or pharmacological inhibition of p53 function can increase normal tissue resistance to genotoxic stress(1-6). It has recently been shown that p53 can induce apoptosis through a mechanism that does not depend on transactivation but instead involves translocation of p53 to mitochondria(7-13). To determine the impact of this p53 activity on normal tissue radiosensitivity, we isolated a small molecule named pifithrin-mu (PFT mu, 1) that inhibits p53 binding to mitochondria by reducing its affinity to antiapoptotic proteins Bcl-xL and Bcl-2 but has no effect on p53-dependent transactivation. PFT mu has a high specificity for p53 and does not protect cells from apoptosis induced by overexpression of proapoptotic protein Bax or by treatment with dexamethasone (2). PFT mu rescues primary mouse thymocytes from p53-mediated apoptosis caused by radiation and protects mice from doses of radiation that cause lethal hematopoietic syndrome. These results indicate that selective inhibition of the mitochondrial branch of the p53 pathway is sufficient for radioprotection in vivo.	Cleveland Clin, Dept Mol Genet, Lerner Res Inst, Cleveland, OH 44195 USA; Quark Biotech Inc, Fremont, CA 94555 USA; Cleveland BioLabs Inc, Cleveland, OH 44106 USA; Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Gudkov, AV (corresponding author), Cleveland Clin, Dept Mol Genet, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	gudkov@ccf.org		Strom, Evguenia/0000-0003-1237-2138; Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R43CA103283, R01CA075179] Funding Source: NIH RePORTER; NCI NIH HHS [CA75179, CA103283] Funding Source: Medline; PHS HHS [HHSN261200422015C] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; Botchkarev VA, 2000, CANCER RES, V60, P5002; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chow BM, 2000, CELL DEATH DIFFER, V7, P712, DOI 10.1038/sj.cdd.4400704; Cui Y. F., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P159; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fang BL, 2003, CANCER BIOL THER, V2, pS115; Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Komarova EA, 2005, FASEB J, V19, P1030, DOI 10.1096/fj.04-3213fje; Komarova EA, 2001, BIOCHEM PHARMACOL, V62, P657, DOI 10.1016/S0006-2952(01)00733-X; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Pfeifer A, 2002, P NATL ACAD SCI USA, V99, P2140, DOI 10.1073/pnas.251682798; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Song SY, 1999, AM J PATHOL, V155, P1121, DOI 10.1016/S0002-9440(10)65215-7; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Willis A. C., 2002, Current Molecular Medicine (Hilversum), V2, P329, DOI 10.2174/1566524023362474	30	279	299	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2006	2	9					474	479		10.1038/nchembio809	http://dx.doi.org/10.1038/nchembio809			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	075XO	16862141				2022-12-25	WOS:000239920900010
J	Topczewska, JM; Postovit, LM; Margaryan, NV; Sam, A; Hess, AR; Wheaton, WW; Nickoloff, BJ; Topczewski, J; Hendrix, MJC				Topczewska, Jolanta M.; Postovit, Lynne-Marie; Margaryan, Naira V.; Sam, Anthony; Hess, Angela R.; Wheaton, William W.; Nickoloff, Brian J.; Topczewski, Jacek; Hendrix, Mary J. C.			Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness	NATURE MEDICINE			English	Article							VASCULOGENIC MIMICRY; STEM-CELLS; MALIGNANT-MELANOMA; TUMOR-CELLS; IN-VIVO; EXPRESSION; ZEBRAFISH; GROWTH; GENE; MICROENVIRONMENT	Bidirectional cellular communication is integral to both cancer progression and embryological development. In addition, aggressive tumor cells are phenotypically plastic, sharing many properties with embryonic cells. Owing to the similarities between these two types of cells, the developing zebrafish can be used as a biosensor for tumor-derived signals. Using this system, we show that aggressive melanoma cells secrete Nodal (a potent embryonic morphogen) and consequently can induce ectopic formation of the embryonic axis. We further show that Nodal is present in human metastatic tumors, but not in normal skin, and thus may be involved in melanoma pathogenesis. Inhibition of Nodal signaling reduces melanoma cell invasiveness, colony formation and tumorigenicity. Nodal inhibition also promotes the reversion of melanoma cells toward a melanocytic phenotype. These data suggest that Nodal signaling has a key role in melanoma cell plasticity and tumorigenicity, thereby providing a previously unknown molecular target for regulating tumor progression.	Northwestern Univ, Feinberg Sch Med, Childens Mem Res Ctr, Program Dev Biol, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Childens Mem Res Ctr, Program Canc Biol & Epigenom, Chicago, IL 60614 USA; Loyola Univ, Med Ctr, Dept Pathol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Loyola University Chicago	Hendrix, MJC (corresponding author), Northwestern Univ, Feinberg Sch Med, Childens Mem Res Ctr, Program Dev Biol, 2300 Childrens Pl,Box 222, Chicago, IL 60614 USA.	mjchendrix@childrensmemorial.org	Topczewski, Jacek/D-5895-2016	Topczewski, Jacek/0000-0001-6023-9556; Postovit, Lynne-Marie/0000-0002-8088-4197; Topczewska, Jolanta M/0000-0003-1876-5039	NATIONAL CANCER INSTITUTE [P01CA027502, R01CA059702, R37CA059702, P01CA059327, R01CA080318] Funding Source: NIH RePORTER; NCI NIH HHS [CA59327, CA27502, CA80318, CA59702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Branford WW, 2004, CURR BIOL, V14, pR341, DOI 10.1016/j.cub.2004.04.020; Chen CH, 2004, CURR BIOL, V14, P618, DOI 10.1016/j.cub.2004.02.042; Chen Y, 2001, NATURE, V411, P607, DOI 10.1038/35079121; Cheng SK, 2004, PLOS BIOL, V2, P215, DOI 10.1371/journal.pbio.0020030; Chu YW, 1996, AM J PATHOL, V148, P63; De Robertis EM, 2000, NAT REV GENET, V1, P171, DOI 10.1038/35042039; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; GERSCHENSON M, 1986, P NATL ACAD SCI USA, V83, P7307, DOI 10.1073/pnas.83.19.7307; Gritsman K, 2000, DEVELOPMENT, V127, P921; Halpern ME, 1997, DEV BIOL, V187, P154, DOI 10.1006/dbio.1997.8605; Hatta K, 1996, DEV DYNAM, V205, P183, DOI 10.1002/(SICI)1097-0177(199602)205:2<183::AID-AJA9>3.0.CO;2-E; Hendrix MJC, 2003, ANN NY ACAD SCI, V995, P151, DOI 10.1111/j.1749-6632.2003.tb03218.x; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447; Hendrix MJC, 2002, CANCER RES, V62, P665; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2001, CANCER RES, V61, P3250; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; Javelaud D, 2005, ONCOGENE, V24, P7624, DOI 10.1038/sj.onc.1208900; JUHASZ I, 1993, AM J PATHOL, V143, P528; Kim DS, 2004, INT J BIOCHEM CELL B, V36, P1482, DOI 10.1016/j.biocel.2003.10.023; Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Martinez-Esparza M, 1999, CELL MOL BIOL, V45, P991; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Niehrs C, 2004, NAT REV GENET, V5, P425, DOI 10.1038/nrg1347; PIERCE GB, 1982, CANCER RES, V42, P1082; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Seftor EA, 2005, CANCER RES, V65, P10164, DOI 10.1158/0008-5472.CAN-05-2497; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; SMITH JC, 1995, CURR OPIN CELL BIOL, V7, P856, DOI 10.1016/0955-0674(95)80070-0; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; Takeuchi H, 2003, CANCER RES, V63, P441; THISSE C, 1993, DEVELOPMENT, V119, P1203; Topczewska JM, 2001, GENE DEV, V15, P2483, DOI 10.1101/gad.907401; TOYAMA R, 1995, DEVELOPMENT, V121, P383; Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031; Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; Whitman M, 2001, DEV CELL, V1, P605, DOI 10.1016/S1534-5807(01)00076-4; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	50	343	366	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2006	12	8					925	932		10.1038/nm1448	http://dx.doi.org/10.1038/nm1448			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16892036				2022-12-25	WOS:000239626200023
J	Hodes, RJ				Hodes, Richard J.			Public funding for Alzheimer disease research in the United States	NATURE MEDICINE			English	Editorial Material									NIA, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Hodes, RJ (corresponding author), NIA, NIH, Room 5C35,31 Ctr Dr, Bethesda, MD 20892 USA.	hodesr@nia.nih.gov						Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; HOYERT DC, 2003, DEATHS FINAL DATA	2	14	16	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					770	773		10.1038/nm0706-770	http://dx.doi.org/10.1038/nm0706-770			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829943				2022-12-25	WOS:000238862800056
J	Balasubramanian, S; Sureshkumar, S; Agrawal, M; Michael, TP; Wessinger, C; Maloof, JN; Clark, R; Warthmann, N; Chory, J; Weigel, D				Balasubramanian, Sureshkumar; Sureshkumar, Sridevi; Agrawal, Mitesh; Michael, Todd P.; Wessinger, Carrie; Maloof, Julin N.; Clark, Richard; Warthmann, Norman; Chory, Joanne; Weigel, Detlef			The PHYTOCHROME C photoreceptor gene mediates natural variation in flowering and growth responses of Arabidopsis thaliana	NATURE GENETICS			English	Article							REGULATORY ACTIVITY; LATITUDINAL CLINE; TERMINAL-DOMAIN; TIME; LIGHT; TRAIT; FRIGIDA; LOCI; REVEALS; RECOMBINANT	Light has an important role in modulating seedling growth and flowering time. We show that allelic variation at the PHYTOCHROME C ( PHYC) photoreceptor locus affects both traits in natural populations of A. thaliana. Two functionally distinct PHYC haplotype groups are distributed in a latitudinal cline dependent on FRIGIDA, a locus that together with FLOWERING LOCUS C explains a large portion of the variation in A. thaliana flowering time(1). In a genome-wide scan for association of 65 loci with latitude, there was an excess of significant P values, indicative of population structure. Nevertheless, PHYC was the most strongly associated locus across 163 strains, suggesting that PHYC alleles are under diversifying selection in A. thaliana. Our work, together with previous findings(2-5), suggests that photoreceptor genes are major agents of natural variation in plant flowering and growth response.	Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany; Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA	Max Planck Society; Salk Institute; Howard Hughes Medical Institute; Salk Institute; University of California System; University of California Davis	Weigel, D (corresponding author), Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany.	weigel@weigelworld.org	Warthmann, Norman/E-1069-2011; Weigel, Detlef/GSJ-0799-2022; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008; Balasubramanian, Sureshkumar/AAS-6919-2020	Warthmann, Norman/0000-0002-1178-8409; Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Balasubramanian, Sureshkumar/0000-0002-1057-2606; Maloof, Julin/0000-0002-9623-2599; Michael, Todd/0000-0001-6272-2875	NIGMS NIH HHS [R01 GM062932, GM62932] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062932] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso-Blanco C, 1998, GENETICS, V149, P749; Aukerman MJ, 1997, PLANT CELL, V9, P1317, DOI 10.1105/tpc.9.8.1317; Borevitz JO, 2002, GENETICS, V160, P683; Caicedo AL, 2004, P NATL ACAD SCI USA, V101, P15670, DOI 10.1073/pnas.0406232101; Devos KM, 2005, PLANT MOL BIOL, V58, P625, DOI 10.1007/s11103-005-6801-z; El-Assal SED, 2001, NAT GENET, V29, P435, DOI 10.1038/ng767; El-Lithy ME, 2004, PLANT PHYSIOL, V135, P444, DOI 10.1104/pp.103.036822; Franklin KA, 2003, PLANT CELL, V15, P1981, DOI 10.1105/tpc.015164; Halliday KJ, 1997, PLANT J, V12, P1079, DOI 10.1046/j.1365-313X.1997.12051079.x; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; Lempe J, 2005, PLOS GENET, V1, P109, DOI 10.1371/journal.pgen.0010006; Loudet O, 2002, THEOR APPL GENET, V104, P1173, DOI 10.1007/s00122-001-0825-9; Maloof JN, 2001, NAT GENET, V29, P441, DOI 10.1038/ng777; Mathews S, 1999, SCIENCE, V286, P947, DOI 10.1126/science.286.5441.947; Monte E, 2003, PLANT CELL, V15, P1962, DOI 10.1105/tpc.012971; Olsen KM, 2004, GENETICS, V167, P1361, DOI 10.1534/genetics.103.024950; Qin MM, 1997, PLANT J, V12, P1163, DOI 10.1046/j.1365-313X.1997.12051163.x; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Schmid K, 2006, THEOR APPL GENET, V112, P1104, DOI 10.1007/s00122-006-0212-7; Shindo C, 2005, PLANT PHYSIOL, V138, P1163, DOI 10.1104/pp.105.061309; Stinchcombe JR, 2004, P NATL ACAD SCI USA, V101, P4712, DOI 10.1073/pnas.0306401101; Takano M, 2005, PLANT CELL, V17, P3311, DOI 10.1105/tpc.105.035899; WAGNER D, 1995, P NATL ACAD SCI USA, V92, P8596, DOI 10.1073/pnas.92.19.8596; Wang XS, 2004, GENOME RES, V14, P1767, DOI 10.1101/gr.2668204; Weinig C, 2002, GENETICS, V162, P1875; Werner JD, 2005, GENETICS, V170, P1197, DOI 10.1534/genetics.104.036533; Werner JD, 2005, P NATL ACAD SCI USA, V102, P2460, DOI 10.1073/pnas.0409474102; White GM, 2004, MOL BIOL EVOL, V21, P716, DOI 10.1093/molbev/msh067; Wolyn DJ, 2004, GENETICS, V167, P907, DOI 10.1534/genetics.103.024810; XU Y, 1995, PLANT CELL, V7, P1433, DOI 10.1105/tpc.7.9.1433	30	166	171	2	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2006	38	6					711	715		10.1038/ng1818	http://dx.doi.org/10.1038/ng1818			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16732287	Green Accepted			2022-12-25	WOS:000237954800028
J	Colby, DW; Cassady, JP; Lin, GC; Ingram, VM; Wittrup, KD				Colby, David W.; Cassady, John P.; Lin, Grace C.; Ingram, Vernon M.; Wittrup, K. Dane			Stochastic kinetics of intracellular huntingtin aggregate formation	NATURE CHEMICAL BIOLOGY			English	Article							NEURODEGENERATION IN-VIVO; AGE-OF-ONSET; POLYGLUTAMINE AGGREGATION; SICKLE HEMOGLOBIN; INTRANUCLEAR INCLUSIONS; MUTANT HUNTINGTIN; DISEASE; PROTEIN; NUCLEATION; DEATH	Neurodegeneration in Huntington disease is described by neuronal loss in which the probability of cell death remains constant with time(1). However, the quantitative connection between the kinetics of cell death and the molecular mechanism initiating neurodegeneration remains unclear. One hypothesis is that nucleation of protein aggregates containing exon I fragments of the mutant huntingtin protein (mhttex1), which contains an expanded polyglutamine region in patients with the disease, is the explanation for the infrequent but steady occurrence of neuronal death, resulting in adult onset of the disease(2). Recent in vitro evidence suggests that sufficiently long polyglutamine peptides undergo a unimolecular conformational change to form a nucleus that seeds aggregation(3). Here we use this nucleation mechanism as the basis to derive a stochastic mathematical model describing the probability of aggregate formation in cells as a function of time and mhttex1 protein concentration, and validate the model experimentally. These findings suggest that therapeutic strategies for Huntington disease predicated on reducing the rate of mhttex1 aggregation need only make modest reductions in huntingtin expression level to substantially increase the delay time until aggregate formation.	MIT, Dept Chem Engn, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Wittrup, KD (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	wittrup@mit.edu	colby, david/E-5821-2011	Colby, David/0000-0002-4856-6295				Arrasate M, 2005, P NATL ACAD SCI USA, V102, P3840, DOI 10.1073/pnas.0409777102; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bhattacharyya AM, 2005, P NATL ACAD SCI USA, V102, P15400, DOI 10.1073/pnas.0501651102; Cao ZQ, 1997, BIOPHYS J, V72, P343, DOI 10.1016/S0006-3495(97)78673-9; Cattaneo E, 1998, J NEUROSCI RES, V53, P223, DOI 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Colby DW, 2004, P NATL ACAD SCI USA, V101, P17616, DOI 10.1073/pnas.0408134101; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Garcia M, 2004, NEUROSCIENCE, V127, P859, DOI 10.1016/j.neuroscience.2004.05.054; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; Gu XF, 2005, NEURON, V46, P433, DOI 10.1016/j.neuron.2005.03.025; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Harper SQ, 2005, P NATL ACAD SCI USA, V102, P5820, DOI 10.1073/pnas.0501507102; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; HOFRICHTER J, 1974, P NATL ACAD SCI USA, V71, P4864, DOI 10.1073/pnas.71.12.4864; Ivanova M, 2000, BIOPHYS J, V79, P1016, DOI 10.1016/S0006-3495(00)76355-7; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Larson H., 1982, INTRO PROBABILITY TH; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Nance MA, 2001, MENT RETARD DEV D R, V7, P153, DOI 10.1002/mrdd.1022; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Renshaw E., 1991, MODELLING BIOL POPUL, DOI 10.1017/CBO9780511624094; Rose N, 2000, THEOR CRIMINOL, V4, P5, DOI 10.1177/1362480600004001001; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shtilerman MD, 2002, BIOCHEMISTRY-US, V41, P3855, DOI 10.1021/bi0120906; Slow EJ, 2005, P NATL ACAD SCI USA, V102, P11402, DOI 10.1073/pnas.0503634102; Squitieri F, 2003, BRAIN, V126, P946, DOI 10.1093/brain/awg077; SZABO A, 1988, J MOL BIOL, V199, P539, DOI 10.1016/0022-2836(88)90624-9; Wexler NS, 2004, P NATL ACAD SCI USA, V101, P3498, DOI 10.1073/pnas.0308479101; Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102	38	51	51	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2006	2	6					319	323		10.1038/nchembio792	http://dx.doi.org/10.1038/nchembio792			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	045OH	16699519				2022-12-25	WOS:000237750900013
J	Ogi, T; Lehmann, AR				Ogi, Tomoo; Lehmann, Alan R.			The Y-family DNA polymerase kappa (pol kappa) functions in mammalian nucleotide-excision repair	NATURE CELL BIOLOGY			English	Article							CELLS; RECOMBINATION; REPLICATION; EPSILON; DAMAGE; DELTA; PCNA; ETA	DNA polymerase. (pol kappa) is a member of the Y-family of DNA polymerases that are thought to function in translesion synthesis (TLS) past different types of DNA damage. Here, we show that pol kappa-deficient mouse cells have substantially reduced (but not absent) levels of nucleotide excision repair (NER) of UV damage, as measured by several methods. Our results provide evidence for an unexpected role for pol. in mammalian NER.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	University of Sussex	Lehmann, AR (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	a.r.lehmann@sussex.ac.uk		Ogi, Tomoo/0000-0002-5492-9072	Medical Research Council [G0001132] Funding Source: Medline; Medical Research Council [G0300662B] Funding Source: researchfish; MRC [G0001132] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Avkin S, 2004, J BIOL CHEM, V279, P53298, DOI 10.1074/jbc.M409155200; Bi XH, 2005, J BIOL CHEM, V280, P22343, DOI 10.1074/jbc.M501562200; DRESLER SL, 1984, J BIOL CHEM, V259, P3947; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Godoy VG, 2006, EMBO J, V25, P868, DOI 10.1038/sj.emboj.7600986; Haracska L, 2002, P NATL ACAD SCI USA, V99, P16000, DOI 10.1073/pnas.252524999; Kawamoto T, 2005, MOL CELL, V20, P793, DOI 10.1016/j.molcel.2005.10.016; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Ogi T, 2005, J CELL SCI, V118, P129, DOI 10.1242/jcs.01603; Ogi T, 2002, P NATL ACAD SCI USA, V99, P15548, DOI 10.1073/pnas.222377899; Ohashi E, 2000, GENE DEV, V14, P1589; Okada T, 2002, J BIOL CHEM, V277, P48690, DOI 10.1074/jbc.M207957200; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664	15	171	174	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					640	642		10.1038/ncb1417	http://dx.doi.org/10.1038/ncb1417			3	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16738703				2022-12-25	WOS:000238029000018
J	Sung, SB; He, YH; Eshoo, TW; Tamada, Y; Johnson, L; Nakahigashi, K; Goto, K; Jacobsen, SE; Amasino, RM				Sung, Sibum; He, Yuehui; Eshoo, Tifani W.; Tamada, Yosuke; Johnson, Lianna; Nakahigashi, Kenji; Goto, Koji; Jacobsen, Steve E.; Amasino, Richard M.			Epigenetic maintenance of the vernalized state in Arabidopsis thaliana requires LIKE HETEROCHROMATIN PROTEIN 1	NATURE GENETICS			English	Article							HISTONE H3 METHYLATION; FLOWERING-LOCUS-C; POLYCOMB-GROUP PROTEINS; WINTER-ANNUAL HABIT; GENE; CHROMATIN; HOMOLOG; HP1; REPRESSOR; LYSINE-9	Vernalization is the process by which sensing a prolonged exposure to winter cold leads to competence to flower in the spring. In winter annual Arabidopsis thaliana accessions, flowering is suppressed in the fall by expression of the potent floral repressor FLOWERING LOCUS C (FLC) 1. Vernalization promotes flowering via epigenetic repression of FLC2. Repression is accompanied by a series of histone modifications of FLC chromatin that include dimethylation of histone H3 at Lys9 (H3K9) and Lys27 (H3K27) 3,4. Here, we report that A. thaliana LIKE HETEROCHROMATIN PROTEIN 1 (LHP1) is necessary to maintain the epigenetically repressed state of FLC upon return to warm conditions typical of spring. LHP1 is enriched at FLC chromatin after prolonged exposure to cold, and LHP1 activity is needed to maintain the increased levels of H3K9 dimethylation at FLC chromatin that are characteristic of the vernalized state.	Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Res Inst Biol Sci, Okayama 7161241, Japan	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Amasino, RM (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53705 USA.	amasino@biochem.wisc.edu	HE, Yuehui/H-9795-2012; Sung, Sibum/AAM-6500-2020; Tamada, Yosuke/A-4144-2010; HE, Yuehui/Y-8792-2018	HE, Yuehui/0000-0003-3304-4555; HE, Yuehui/0000-0003-3304-4555; ANTON, TIFANI/0000-0002-9297-4042; Tamada, Yosuke/0000-0002-4845-4867	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060398, R37GM060398] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM060398] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bastow R, 2004, NATURE, V427, P164, DOI 10.1038/nature02269; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Dejardin J, 2005, NATURE, V434, P533, DOI 10.1038/nature03386; Gaudin V, 2001, DEVELOPMENT, V128, P4847; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; He YH, 2004, GENE DEV, V18, P2774, DOI 10.1101/gad.1244504; Huang T, 2005, SCIENCE, V309, P1694, DOI 10.1126/science.1117768; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Kim SY, 2005, PLANT CELL, V17, P3301, DOI 10.1105/tpc.105.034645; Kotake T, 2003, PLANT CELL PHYSIOL, V44, P555, DOI 10.1093/pcp/pcg091; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; LEE I, 1995, PLANT PHYSIOL, V108, P157, DOI 10.1104/pp.108.1.157; Libault M, 2005, PLANTA, V222, P910, DOI 10.1007/s00425-005-0129-4; Lindroth AM, 2004, EMBO J, V23, P4146, DOI 10.1038/sj.emboj.7600430; Liu LP, 2005, NAT GENET, V37, P1361, DOI 10.1038/ng1662; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Michaels SD, 2000, PLANT CELL ENVIRON, V23, P1145, DOI 10.1046/j.1365-3040.2000.00643.x; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Mylne JS, 2006, P NATL ACAD SCI USA, V103, P5012, DOI 10.1073/pnas.0507427103; Nakahigashi K, 2005, PLANT CELL PHYSIOL, V46, P1747, DOI 10.1093/pcp/pci195; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Schubert D, 2005, CURR OPIN PLANT BIOL, V8, P553, DOI 10.1016/j.pbi.2005.07.005; Sheldon CC, 2002, PLANT CELL, V14, P2527, DOI 10.1105/tpc.004564; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; Sung S, 2005, ANNU REV PLANT BIOL, V56, P491, DOI 10.1146/annurev.arplant.56.032604.144307; Sung SB, 2004, NATURE, V427, P159, DOI 10.1038/nature02195; Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761; Zemach A, 2006, PLANT CELL, V18, P133, DOI 10.1105/tpc.105.036855	30	234	253	1	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					706	710		10.1038/ng1795	http://dx.doi.org/10.1038/ng1795			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16682972				2022-12-25	WOS:000237954800027
J	Vodovar, N; Vallenet, D; Cruveiller, S; Rouy, Z; Barbe, V; Acosta, C; Cattolico, L; Jubin, C; Lajus, A; Segurens, B; Vacherie, B; Wincker, P; Weissenbach, J; Lemaitre, B; Medigue, C; Boccard, F				Vodovar, Nicolas; Vallenet, David; Cruveiller, Stephane; Rouy, Zoe; Barbe, Valerie; Acosta, Carlos; Cattolico, Laurence; Jubin, Claire; Lajus, Aurelie; Segurens, Beatrice; Vacherie, Benoit; Wincker, Patrick; Weissenbach, Jean; Lemaitre, Bruno; Medigue, Claudine; Boccard, Frederic			Complete genome sequence of the entomopathogenic and metabolically versatile soil bacterium Pseudomonas entomophila	NATURE BIOTECHNOLOGY			English	Article							CAENORHABDITIS-ELEGANS; YERSINIA-PESTIS; AERUGINOSA PAO1; GENES; PHOTORHABDUS; ANNOTATION; CLONING; IDENTIFICATION; DIVERGENCE; EXPRESSION	Pseudomonas entomophila is an entomopathogenic bacterium that, upon ingestion, kills Drosophila melanogaster as well as insects from different orders. The complete sequence of the 5.9-Mb genome was determined and compared to the sequenced genomes of four Pseudomonas species. P. entomophila possesses most of the catabolic genes of the closely related strain P. putida KT2440, revealing its metabolically versatile properties and its soil lifestyle. Several features that probably contribute to its entomopathogenic properties were disclosed. Unexpectedly for an animal pathogen, P. entomophila is devoid of a type III secretion system and associated toxins but rather relies on a number of potential virulence factors such as insecticidal toxins, proteases, putative hemolysins, hydrogen cyanide and novel secondary metabolites to infect and kill insects. Genome-wide random mutagenesis revealed the major role of the two-component system GacS/GacA that regulates most of the potential virulence factors identified.	CNRS, Ctr Mol Genet, F-91198 Gif Sur Yvette, France; Genoscope, Ctr Natl Sequencage, F-91057 Evry, France; CNRS, UMR 8030, F-91057 Evry, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA	Boccard, F (corresponding author), CNRS, Ctr Mol Genet, F-91198 Gif Sur Yvette, France.	boccard@cgm.cnrs-gif.fr	Vodovar, Nicolas/S-2947-2019; Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667; Vacherie, Benoit/0000-0002-1564-0575; Vodovar, Nicolas/0000-0001-8087-387X; Acosta-Muniz, Carlos/0000-0001-6329-3507; Vallenet, David/0000-0001-6648-0332; Boccard, Frederic/0000-0002-1866-2489				Aranda-Olmedo I, 2002, NUCLEIC ACIDS RES, V30, P1826, DOI 10.1093/nar/30.8.1826; Basset A, 2003, EMBO REP, V4, P205, DOI 10.1038/sj.embor.embor730; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bocs S, 2003, NUCLEIC ACIDS RES, V31, P3723, DOI 10.1093/nar/gkg590; Bowen D, 1998, SCIENCE, V280, P2129, DOI 10.1126/science.280.5372.2129; Buell CR, 2003, P NATL ACAD SCI USA, V100, P10181, DOI 10.1073/pnas.1731982100; Burger M, 2000, MICROBIOL-SGM, V146, P3149, DOI 10.1099/00221287-146-12-3149; Chattopadhyay A, 2004, CRIT REV MICROBIOL, V30, P33, DOI 10.1080/10408410490270712; Claudel-Renard C, 2003, NUCLEIC ACIDS RES, V31, P6633, DOI 10.1093/nar/gkg847; Darby C, 2005, INFECT IMMUN, V73, P7236, DOI 10.1128/IAI.73.11.7236-7242.2005; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; Eisen JA, 2000, GENOME BIOL, V1; Feil H, 2005, P NATL ACAD SCI USA, V102, P11064, DOI 10.1073/pnas.0504930102; Gallagher LA, 2001, J BACTERIOL, V183, P6207, DOI 10.1128/JB.183.21.6207-6214.2001; Ha EM, 2005, DEV CELL, V8, P125, DOI 10.1016/j.devcel.2004.11.007; Haas D, 2005, NAT REV MICROBIOL, V3, P307, DOI 10.1038/nrmicro1129; Hinnebusch BJ, 2002, SCIENCE, V296, P733, DOI 10.1126/science.1069972; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Hultmark D., 1996, Experientia Supplementum (Basel), V75, P87; Hurst MRH, 2004, J BACTERIOL, V186, P5116, DOI 10.1128/jb.186.15.5116-5128.2004; Jimenez JI, 2002, ENVIRON MICROBIOL, V4, P824, DOI 10.1046/j.1462-2920.2002.00370.x; Joardar V, 2005, J BACTERIOL, V187, P6488, DOI 10.1128/JB.187.18.6488-6498.2005; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lee PJ, 2004, BIOCHEM BIOPH RES CO, V319, P1110, DOI 10.1016/j.bbrc.2004.04.203; LIEHL P, IN PRESS PLOS PATHOG; Liu DQ, 2005, MICROBIOL RES, V160, P53, DOI 10.1016/j.micres.2004.09.003; Lizewski SE, 2004, J BACTERIOL, V186, P5672, DOI 10.1128/JB.186.17.5672-5684.2004; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Mercado-Blanco J, 2001, J BACTERIOL, V183, P1909, DOI 10.1128/JB.183.6.1909-1920.2001; Meyer JM, 2000, ARCH MICROBIOL, V174, P135, DOI 10.1007/s002030000188; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Miyoshi S, 2000, MICROBES INFECT, V2, P91, DOI 10.1016/S1286-4579(00)00280-X; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; Paulsen IT, 2005, NAT BIOTECHNOL, V23, P873, DOI 10.1038/nbt1110; Prieto MA, 1996, J BACTERIOL, V178, P111, DOI 10.1128/jb.178.1.111-120.1996; Ravel J, 2003, TRENDS MICROBIOL, V11, P195, DOI 10.1016/S0966-842X(03)00076-3; Regel R, 1998, INSECT BIOCHEM MOLEC, V28, P309, DOI 10.1016/S0965-1748(97)00108-2; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Thotsaporn K, 2004, BBA-GENE STRUCT EXPR, V1680, P60, DOI 10.1016/j.bbaexp.2004.08.003; Vallenet D, 2006, NUCLEIC ACIDS RES, V34, P53, DOI 10.1093/nar/gkj406; Vodovar N, 2005, P NATL ACAD SCI USA, V102, P11414, DOI 10.1073/pnas.0502240102; Waterfield N, 2005, CELL MICROBIOL, V7, P373, DOI 10.1111/j.1462-5822.2004.00467.x; Waterfield NR, 2004, NAT REV MICROBIOL, V2, P833, DOI 10.1038/nrmicro1008; Waterfield NR, 2001, TRENDS MICROBIOL, V9, P185, DOI 10.1016/S0966-842X(01)01978-3; Weinel C, 2002, ENVIRON MICROBIOL, V4, P809, DOI 10.1046/j.1462-2920.2002.00331.x; Whitchurch CB, 2002, J BACTERIOL, V184, P4544, DOI 10.1128/JB.184.16.4544-4554.2002; WILSON MR, 2002, BACTERIAL DIS MECH	47	185	698	1	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2006	24	6					673	679		10.1038/nbt1212	http://dx.doi.org/10.1038/nbt1212			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	051UQ	16699499	hybrid, Green Published			2022-12-25	WOS:000238187300029
J	Yu, Y; Fan, JJ; Chen, XS; Wang, DR; Klein-Szanto, AJ; Campbell, RL; FitzGerald, GA; Funk, CD				Yu, Ying; Fan, Jinjin; Chen, Xin-Sheng; Wang, Dairong; Klein-Szanto, Andres J.; Campbell, Robert L.; FitzGerald, Garret A.; Funk, Colin D.			Genetic model of selective COX2 inhibition reveals novel heterodimer signaling	NATURE MEDICINE			English	Article							DUCTUS-ARTERIOSUS; CYCLOOXYGENASE-2; MICE; SYNTHASE-1; EXPRESSION; AGENTS; MOUSE; TRIAL	Selective inhibitors of cyclooxygenase-2 ( COX2) have attracted widespread media attention because of evidence of an elevated risk of cardiovascular complications in placebo-controlled trials, resulting in the market withdrawal of some members of this class(1-5). These drugs block the cyclooxygenase activity of prostaglandin H synthase-2 ( PGHS2), but do not affect the associated peroxidase function. They were developed with the rationale of conserving the anti-inflammatory and analgesic actions of traditional nonsteroidal anti-inflammatory drugs ( tNSAIDs) while sparing the ability of PGHS1-derived prostaglandins to afford gastric cytoprotection(1,2,6). PGHS1 and PGHS2 coexist in the vasculature and in macrophages, and are upregulated together in inflammatory tissues such as rheumatoid synovia(7) and atherosclerotic plaque(8). They are each believed to function as homodimers(6). Here, we developed a new genetic mouse model of selective COX2 inhibition using a gene-targeted point mutation, resulting in a Y385F substitution. Structural modeling and biochemical assays showed the ability of PGHS1 and PGHS2 to heterodimerize and form prostaglandins. The heterodimerization of PGHS1-PGHS2 may explain how the ductus arteriosus closes normally at birth in mice expressing PGHS2 Y385F, but not in PGHS2-null mice(9,10).	Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada	University of Pennsylvania; Pennsylvania Medicine; Fox Chase Cancer Center; Queens University - Canada; Queens University - Canada	Funk, CD (corresponding author), Univ Penn, Inst Translat Med & Therapeut, 421 Curie Blvd,BRB 2-3, Philadelphia, PA 19104 USA.	funkc@post.queensu.ca	FitzGerald, Garret A/A-4222-2010; Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233; yu, ying/0000-0002-6476-1752; Campbell, Robert/0000-0002-5473-5876				Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Campean V, 2003, AM J PHYSIOL-RENAL, V285, pF19, DOI 10.1152/ajprenal.00443.2002; Chen W, 1999, J BIOL CHEM, V274, P20301, DOI 10.1074/jbc.274.29.20301; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Loftin CD, 2002, J CLIN INVEST, V110, P549, DOI 10.1172/JCI200214924; Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; Nussmeier NA, 2005, NEW ENGL J MED, V352, P1081, DOI 10.1056/NEJMoa050330; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; Selinsky BS, 2001, BIOCHEMISTRY-US, V40, P5172, DOI 10.1021/bi010045s; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; Smith GCS, 1998, PHARMACOL REV, V50, P35; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Szewczuk LM, 2004, J BIOL CHEM, V279, P22727, DOI 10.1074/jbc.M314302200; Trifan OC, 1999, J BIOL CHEM, V274, P34141, DOI 10.1074/jbc.274.48.34141; Yu Y, 2005, J CLIN INVEST, V115, P986, DOI 10.1172/JCI23683; Yuan C, 2006, P NATL ACAD SCI USA, V103, P6142, DOI 10.1073/pnas.0601805103; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	30	57	58	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					699	704		10.1038/nm1412	http://dx.doi.org/10.1038/nm1412			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16732282				2022-12-25	WOS:000238149200034
J	Dadke, S; Cotteret, S; Yip, SC; Jaffer, ZM; Haj, F; Ivanov, A; Rauscher, F; Shuai, K; Ng, T; Neel, BG; Chernoff, J				Dadke, Shrikrishna; Cotteret, Sophie; Yip, Shu-Chin; Jaffer, Zahara M.; Haj, Fawaz; Ivanov, Alexey; Rauscher, Frank, III; Shuai, Ke; Ng, Tony; Neel, Benjamin G.; Chernoff, Jonathan			Regulation of protein tyrosine phosphatase 1B by sumoylation	NATURE CELL BIOLOGY			English	Article							E3 LIGASE; SUMO; KINASE; INSULIN; SUBSTRATE; COMPLEX; RANBP2	Protein-tyrosine phosphatase 1B (PTP1B) is an ubiquitously expressed enzyme that negatively regulates growth-factor signalling and cell proliferation by binding to and dephosphorylating key receptor tyrosine kinases, such as the insulin receptor(1). It is unclear how the activity of PTP1B is regulated. Using a yeast two-hybrid assay, a protein inhibitor of activated STAT1 (PIAS1)(2) was isolated as a PTP1B-interacting protein. Here, we show that PIAS1, which functions as a small ubiquitin-like modifier (SUMO) E3 ligase, associates with PTP1B in mammalian fibroblasts and catalyses sumoylation of PTP1B. Sumoylation of PTP1B reduces its catalytic activity and inhibits the negative effect of PTP1B on insulin receptor signalling and on transformation by the oncogene v-crk. Insulin-stimulated sumoylation of endogenous PTP1B results in a transient downregulation of the enzyme; this event does not occur when the endogenous enzyme is replaced with a sumoylation-resistant mutant of PTP1B. These results suggest that sumoylation, which has been implicated primarily in processes in the nucleus and nuclear pore, also modulates a key enzyme-substrate signalling complex that regulates metabolism and cell proliferation.	Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02115 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA 90095 USA; Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England	Fox Chase Cancer Center; Harvard University; Beth Israel Deaconess Medical Center; The Wistar Institute; University of California System; University of California Los Angeles; University of London; King's College London	Chernoff, J (corresponding author), Fox Chase Canc Ctr, 333 Cottman Ave, Philadelphia, PA 19111 USA.	J_Chernoff@fccc.edu	Chernoff, Jonathan/I-7631-2014; Ivanov, Alexey/I-9445-2012	Chernoff, Jonathan/0000-0002-4803-7836; Ivanov, Alexey/0000-0002-8617-4604; Ng, Tony/0000-0003-3894-5619	Medical Research Council [G0100152] Funding Source: Medline; MRC [G0100152] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bourdeau A, 2005, CURR OPIN CELL BIOL, V17, P203, DOI 10.1016/j.ceb.2005.02.001; Bylebyl GR, 2003, J BIOL CHEM, V278, P44113, DOI 10.1074/jbc.M308357200; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Dadke S, 2003, J BIOL CHEM, V278, P40607, DOI 10.1074/jbc.M306772200; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Ganesan S, 2006, P NATL ACAD SCI USA, V103, P4089, DOI 10.1073/pnas.0509922103; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; GOLEMIS EA, 1994, INTERACTION TRAP 2 H; Haj FG, 2003, J BIOL CHEM, V278, P739, DOI 10.1074/jbc.M210194200; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kim YH, 2005, FEBS LETT, V579, P6272, DOI 10.1016/j.febslet.2005.10.010; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Peter M, 2005, BIOPHYS J, V88, P1224, DOI 10.1529/biophysj.104.050153; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh N, 2006, EXP CELL RES, V312, P1418, DOI 10.1016/j.yexcr.2006.01.013; Takino T, 2003, J CELL SCI, V116, P3145, DOI 10.1242/jcs.00632; Uchimura Y, 2004, ANAL BIOCHEM, V331, P204, DOI 10.1016/j.ab.2004.04.034; Wiesmann C, 2004, NAT STRUCT MOL BIOL, V11, P730, DOI 10.1038/nsmb803; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; Zhao YM, 2004, J BIOL CHEM, V279, P20999, DOI 10.1074/jbc.M401541200	29	90	98	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					80	U102		10.1038/ncb1522	http://dx.doi.org/10.1038/ncb1522			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17159996				2022-12-25	WOS:000243255100015
J	Gao, Q; Mezei, G; Nie, YZ; Rao, Y; Choi, CS; Bechmann, I; Leranth, C; Toran-Allerand, D; Priest, CA; Roberts, JL; Gao, XB; Mobbs, C; Shulman, GI; Diano, S; Horvath, TL				Gao, Qian; Mezei, Gabor; Nie, Yongzhan; Rao, Yan; Choi, Cheol Soo; Bechmann, Ingo; Leranth, Csaba; Toran-Allerand, Dominique; Priest, Catherine A.; Roberts, James L.; Gao, Xiao-Bing; Mobbs, Charles; Shulman, Gerald I.; Diano, Sabrina; Horvath, Tamas L.			Anorectic estrogen mimics leptin's effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals	NATURE MEDICINE			English	Article							RECEPTOR-CONTAINING NEURONS; ARCUATE NUCLEUS; RAT HYPOTHALAMUS; WEIGHT-GAIN; BODY-WEIGHT; FOOD-INTAKE; DISRUPTION; MUTATION; CYCLE; RNA	Metabolic hormones, such as leptin, alter the input organization of hypothalamic circuits(1-3), resulting in increased proopiomelanocortin (POMC) tone, followed by decreased food intake and adiposity. The gonadal steroid estradiol can also reduce appetite and adiposity(4,5), and it influences synaptic plasticity(6). Here we report that estradiol (E2) triggers a robust increase in the number of excitatory inputs to POMC neurons in the arcuate nucleus of wild-type rats and mice. This rearrangement of synapses in the arcuate nucleus is leptin independent because it also occurred in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice, and was paralleled by decreased food intake and body weight gain as well as increased energy expenditure. However, estrogen-induced decrease in body weight was dependent on Stat3 activation in the brain. These observations support the notion that synaptic plasticity of arcuate nucleus feeding circuits is an inherent element in body weight regulation and offer alternative approaches to reducing adiposity under conditions of failed leptin receptor signaling.	Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med & Cellular & Mol Physiol, New Haven, CT 06520 USA; Goethe Univ Frankfurt, Inst Clin Neuroanat, D-60596 Frankfurt, Germany; Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10027 USA; Columbia Univ Coll Phys & Surg, Dept Pathol & Cell Biol, New York, NY 10027 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10027 USA; Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; Mt Sinai Sch Med, Neurobiol Aging Labs, New York, NY 10029 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Comparat Med, New Haven, CT 06520 USA	Yale University; Yale University; Goethe University Frankfurt; Columbia University; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Health San Antonio; Yale University; Yale University	Horvath, TL (corresponding author), Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA.	qian.gao@yale.edu; tamas.horvath@yale.edu	Gao, Xiao-Bing/C-3121-2011; Shulman, Gerald I./P-7176-2019; Roberts, James/AAI-3283-2020	Gao, Xiao-Bing/0000-0002-2035-4936; Shulman, Gerald I./0000-0003-1529-5668; Roberts, James/0000-0002-2671-3207; Mobbs, Charles/0000-0002-5815-8711	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U2CDK059635, K01DK061478, R01DK040936, R01DK074386, U24DK059635, R01DK070723, R01DK070039, R01DK061619, R01DK060711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-060711, DK061619, DK061478, DK-070723, DK-059635, DK-070039, DK-074386, R01 DK040936] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; BROWN TJ, 1992, BRAIN RES, V578, P129, DOI 10.1016/0006-8993(92)90239-6; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; COUSE JF, 1995, MOL ENDOCRINOL, V9, P1441, DOI 10.1210/me.9.11.1441; Diano S, 1998, BRAIN RES, V812, P256, DOI 10.1016/S0006-8993(98)00936-6; Diano S, 1997, ENDOCRINOLOGY, V138, P778, DOI 10.1210/en.138.2.778; DUBUC PU, 1985, P SOC EXP BIOL MED, V180, P468; Ehrlich I, 2004, J NEUROSCI, V24, P916, DOI 10.1523/JNEUROSCI.4733-03.2004; Flanagan-Cato LM, 2001, PHYSIOL BEHAV, V72, P549, DOI 10.1016/S0031-9384(01)00411-5; Friedman JM, 2002, NUTR REV, V60, pS1, DOI 10.1301/002966402320634878; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Geary N, 2001, ENDOCRINOLOGY, V142, P4751, DOI 10.1210/en.142.11.4751; Horvath TL, 2005, CELL METAB, V1, P279, DOI 10.1016/j.cmet.2005.03.003; HUMMEL KP, 1966, SCIENCE, V153, P1127, DOI 10.1126/science.153.3740.1127; INGALLS AM, 1950, J HERED, V41, P317, DOI 10.1093/oxfordjournals.jhered.a106073; LEY CJ, 1992, AM J CLIN NUTR, V55, P950, DOI 10.1093/ajcn/55.5.950; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Meli R, 2004, ENDOCRINOLOGY, V145, P3115, DOI 10.1210/en.2004-0129; Naftolin F, 1996, ENDOCRINOLOGY, V137, P5576, DOI 10.1210/en.137.12.5576; Osterlund M, 1998, MOL BRAIN RES, V54, P175, DOI 10.1016/S0169-328X(97)00351-3; Parker GC, 2001, PHYSIOL BEHAV, V74, P399, DOI 10.1016/S0031-9384(01)00599-6; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Polidori C, 2002, PEPTIDES, V23, P1697, DOI 10.1016/S0196-9781(02)00112-2; Qiu J, 2006, J NEUROSCI, V26, P5649, DOI 10.1523/JNEUROSCI.0327-06.2006; Roesch DM, 2006, PHYSIOL BEHAV, V87, P39, DOI 10.1016/j.physbeh.2005.08.035; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Sternson SM, 2005, NAT NEUROSCI, V8, P1356, DOI 10.1038/nn1550; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; WADE GN, 1985, INT J OBESITY, V9, P83	30	321	327	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					89	94		10.1038/nm1525	http://dx.doi.org/10.1038/nm1525			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17195839				2022-12-25	WOS:000243301800041
J	Handa, Y; Suzuki, M; Ohya, K; Iwai, H; Ishijima, N; Koleske, AJ; Fukui, Y; Sasakawa, C				Handa, Yutaka; Suzuki, Masato; Ohya, Kenji; Iwai, Hiroki; Ishijima, Nozomi; Koleske, Anthony J.; Fukui, Yoshinori; Sasakawa, Chihiro			Shigella IpgB1 promotes bacterial entry through the ELMO-Dock180 machinery	NATURE CELL BIOLOGY			English	Article							TYROSINE KINASES; EPITHELIAL-CELLS; EFFECTOR PROTEIN; INVASION; RAC1; ACTIVATION; PHAGOCYTOSIS; COOPERATE; CORTACTIN; FLEXNERI	Shigella use a special mechanism to invade epithelial cells called 'the trigger mechanism of entry'(1-3), which allows epithelial cells to trap several bacteria simultaneously. On contact, Shigella deliver effectors into epithelial cells through the type III secretion system(4-6). Here, we show that one of the effectors, IpgB1, has a pivotal role in producing membrane ruffles by exploiting the RhoG-ELMO-Dock180 pathway to stimulate Rac1 activity. Using pulldown assays, we identified engulfment and cell motility (ELMO) protein as the IpgB1 binding partner. IpgB1 colocalized with ELMO and Dock180 in membrane ruffles induced by Shigella. Shigella invasiveness and IpgB1-induced ruffles were less in ELMO- and Dock180-knockdown cells compared with wild-type cells. Membrane association of ELMO-Dock180 with ruffles were promoted when cells expressed an IpgB1-ELMO chimera, establishing that IpgB1 mimics the role of RhoG in producing membrane ruffles. Taken together, our findings show that IpgB1 mimicry is the key to invasion by Shigella.	Inst Med Sci, Dept Microbiol & Immunol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Minato Ku, Tokyo 1088639, Japan; Int Res Ctr Infect Dis, Dept Infectious Control, Minato Ku, Tokyo 1088639, Japan; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, Dept Neurobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Interdept Neurosci Program, New Haven, CT 06520 USA; Kyushu Univ, Dept Immunobiol & Neurosci, Med Inst Bioregulat, Div Immunogenet, Fukuoka 8128582, Japan; CREST, Japan Sci & Technol Agcy, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; Yale University; Yale University; Kyushu University; Japan Science & Technology Agency (JST)	Sasakawa, C (corresponding author), Inst Med Sci, Dept Microbiol & Immunol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sasakawa@ims.u-tokyo.ac.jp	Suzuki, Masato/B-7568-2013	Suzuki, Masato/0000-0001-8975-2193; Fukui, Yoshinori/0000-0003-2335-8745; Ohya, Kenji/0000-0002-8867-3618	NINDS NIH HHS [R01 NS039475] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039475] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alto NM, 2006, CELL, V124, P133, DOI 10.1016/j.cell.2005.10.031; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Bougneres L, 2004, J CELL BIOL, V166, P225, DOI 10.1083/jcb.200402073; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; DeBakker CD, 2004, CURR BIOL, V14, P2208, DOI 10.1016/j.cub.2004.12.029; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Gumienny TL, 2001, CELL, V107, P27, DOI 10.1016/S0092-8674(01)00520-7; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Katoh H, 2003, NATURE, V424, P461, DOI 10.1038/nature01817; Katoh H, 2006, J CELL SCI, V119, P56, DOI 10.1242/jcs.02720; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lu MJ, 2004, NAT STRUCT MOL BIOL, V11, P756, DOI 10.1038/nsmb800; Mounier J, 1999, J CELL SCI, V112, P2069; Ogawa M, 2006, CELL MICROBIOL, V8, P177, DOI 10.1111/j.1462-5822.2005.00652.x; Ohya K, 2005, J BIOL CHEM, V280, P24022, DOI 10.1074/jbc.M502509200; Okuda J, 2005, BIOCHEM BIOPH RES CO, V333, P531, DOI 10.1016/j.bbrc.2005.05.145; Parsot C, 2005, FEMS MICROBIOL LETT, V252, P11, DOI 10.1016/j.femsle.2005.08.046; Patel JC, 2005, CURR OPIN MICROBIOL, V8, P10, DOI 10.1016/j.mib.2004.09.001; Sorensen M, 2003, FEBS LETT, V552, P110, DOI 10.1016/S0014-5793(03)00856-1; Suzuki M, 2005, J EXP MED, V202, P1235, DOI 10.1084/jem.20051027; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; Van Nhieu GT, 2005, CURR OPIN MICROBIOL, V8, P16, DOI 10.1016/j.mib.2004.12.006; Yin JH, 2004, ARCH BIOCHEM BIOPHYS, V429, P23, DOI 10.1016/j.abb.2004.05.014; Yoshida S, 2002, EMBO J, V21, P2923, DOI 10.1093/emboj/cdf319	30	119	122	0	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					121	U165		10.1038/ncb1526	http://dx.doi.org/10.1038/ncb1526			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17173036				2022-12-25	WOS:000243255100021
J	Yang, JS; Zhang, LL; Lee, SY; Gad, H; Luini, A; Hsu, VW				Yang, Jia-Shu; Zhang, Leiliang; Lee, Stella Y.; Gad, Helge; Luini, Alberto; Hsu, Victor W.			Key components of the fission machinery are interchangeable	NATURE CELL BIOLOGY			English	Article							VESICLE FORMATION; LYSOPHOSPHATIDIC ACID; GOLGI STRUCTURE; TRANSPORT; MEMBRANE; PROTEINS; COAT; CURVATURE; PROMOTES; COMPLEX	Brefeldin- A ADP- ribosylated substrate (BARS) and dynamin function in membrane fission in distinct intracellular transport pathways(1), but whether their functions are mechanistically similar is unclear. Here, we show that ARFGAP1, a GTPase-activating protein (GAP) for ADP- ribosylation factor 1 (ARF1)(2), couples to either BARS or endophilin B for vesicle formation by the coat protein I (COPI) complex- a finding that reveals an unanticipated mechanistic flexibility in mammalian COPI transport. Because dynamin is coupled to endophilin A in vesicle formation by the clathrin- coat complex(3-5), our finding also predicts that dynamin and ARF GAPs are likely to be functional counterparts in membrane fission among different transport pathways that connect intracellular membrane compartments.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Italy	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Consorzio Mario Negri Sud	Hsu, VW (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.	vhsu@rics.bwh.harvard.edu	Gad, Helge/J-2238-2014	Gad, Helge/0000-0001-6530-1443	Telethon [GGP04235] Funding Source: Medline	Telethon(Fondazione Telethon)		Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Bonazzi M, 2005, NAT CELL BIOL, V7, P570, DOI 10.1038/ncb1260; Coleman R Edward, 1998, Clin Positron Imaging, V1, P15, DOI 10.1016/S1095-0397(97)00004-6; Corda D, 2006, TRENDS CELL BIOL, V16, P167, DOI 10.1016/j.tcb.2006.01.007; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Dai J, 2004, DEV CELL, V7, P771, DOI 10.1016/j.devcel.2004.10.002; Emery G, 2000, J CELL SCI, V113, P2507; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Girod A, 1999, NAT CELL BIOL, V1, P423, DOI 10.1038/15658; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; Lee SY, 2005, J CELL BIOL, V168, P281, DOI 10.1083/jcb.200404008; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Reinhard C, 2003, P NATL ACAD SCI USA, V100, P8253, DOI 10.1073/pnas.1432391100; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; Yang JS, 2005, EMBO J, V24, P4133, DOI 10.1038/sj.emboj.7600873; Yang JS, 2002, J CELL BIOL, V159, P69, DOI 10.1083/jcb.200206015	24	47	51	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1376	U34		10.1038/ncb1503	http://dx.doi.org/10.1038/ncb1503			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17086176				2022-12-25	WOS:000242419800013
J	Aranda, V; Haire, T; Nolan, ME; Calarco, JP; Rosenberg, AZ; Fawcett, JP; Pawson, T; Muthuswamy, SK				Aranda, Victoria; Haire, Teresa; Nolan, Marissa E.; Calarco, Joseph P.; Rosenberg, Avi Z.; Fawcett, James P.; Pawson, Tony; Muthuswamy, Senthil K.			Par6-aPKC uncouples ErbB2 induced disruption of polarized epithelial organization from proliferation control	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-C; CELL POLARITY; TIGHT JUNCTIONS; MAMMARY TUMORIGENESIS; SIGNALING PATHWAYS; CANCER-THERAPY; E-CADHERIN; APKC; RECEPTORS; ONCOGENE	The polarized glandular organization of epithelial cells is frequently lost during development of carcinoma. However, the specific oncogene targets responsible for polarity disruption have not been identified. Here, we demonstrate that activation of ErbB2 disrupts apical-basal polarity by associating with Par6-aPKC, components of the Par polarity complex. Inhibition of interaction between Par6 and aPKC blocked the ability of ErbB2 to disrupt the acinar organization of breast epithelia and to protect cells from apoptosis but was not required for cell proliferation. Therefore, oncogenes target polarity proteins to disrupt glandular organization and protect cells from apoptotic death during development of carcinoma.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Grad Program Genet, Stony Brook, NY 11794 USA; Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; Univ Toronto, Program Mol Biol & Canc, Samuel Lunenfeld Res Inst, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Muthuswamy, SK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	muthuswa@cshl.edu	Pawson, Tony J/E-4578-2013; Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634; Rosenberg, Avi/0000-0003-2356-950X; Fawcett, Jim/0000-0003-0043-2164	NATIONAL CANCER INSTITUTE [R01CA098830, R56CA098830] Funding Source: NIH RePORTER; NCI NIH HHS [CA098830] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Howley P M, 1989, Princess Takamatsu Symp, V20, P199; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Loden M, 2003, ANTICANCER RES, V23, P2053; Macara AG, 2004, CURR BIOL, V14, pR160, DOI 10.1016/j.cub.2004.01.048; Margolis B, 2005, J CELL SCI, V118, P5157, DOI 10.1242/jcs.02597; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Noda Y, 2003, J BIOL CHEM, V278, P43516, DOI 10.1074/jbc.M306330200; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Polosukhin VV, 2001, ULTRASTRUCT PATHOL, V25, P119; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; RAGAZ J, 2004, DIS BREAST, P619; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; SCHNITT SJ, 2004, DIS BREAST, P77; SCHOENENBERGER CA, 1991, J CELL BIOL, V112, P873, DOI 10.1083/jcb.112.5.873; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Stoll M, 2004, NAT GENET, V36, P476, DOI 10.1038/ng1345; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Yamanaka T, 2001, GENES CELLS, V6, P721, DOI 10.1046/j.1365-2443.2001.00453.x; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zegers MMP, 2003, TRENDS CELL BIOL, V13, P169, DOI 10.1016/S0962-8924(03)00036-9	49	195	201	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1235	U20		10.1038/ncb1485	http://dx.doi.org/10.1038/ncb1485			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17060907				2022-12-25	WOS:000241732400012
J	Mruk, DD; Wong, CH; Silvestrini, B; Cheng, CY				Mruk, Dolores D.; Wong, Ching-Hang; Silvestrini, Bruno; Cheng, C. Yan			A male contraceptive targeting germ cell adhesion	NATURE MEDICINE			English	Article							FOLLICLE-STIMULATING-HORMONE; FREE ALPHA-SUBUNIT; N-TERMINAL SERINE; SEMINIFEROUS EPITHELIUM; PERIODATE-OXIDATION; JUNCTION DYNAMICS; ECTOPLASMIC SPECIALIZATION; CARBOHYDRATE RESIDUES; SIGNAL-TRANSDUCTION; RECEPTOR-BINDING	Throughout spermatogenesis, developing germ cells remain attached to Sertoli cells via testis- specific anchoring junctions. If adhesion between these cell types is compromised, germ cells detach from the seminiferous epithelium and infertility often results. Previously, we reported that Adjudin is capable of inducing germ cell loss from the epithelium. In a small subset of animals, however, oral administration of Adjudin (50 mg per kg body weight (b. w.) for 29 d) resulted in adverse effects such as liver inflammation and muscle atrophy. Here, we report a novel approach in which Adjudin is specifically targeted to the testis by conjugating Adjudin to a recombinant follicle-stimulating hormone (FSH) mutant, which serves as its 'carrier'. Using this approach, infertility was induced in adult rats when 0.5 mu g Adjudin per kg b. w. was administered intraperitoneally, which was similar to results when 50 mg per kg b. w. was given orally. This represents a substantial increase in Adjudin's selectivity and efficacy as a male contraceptive.	Ctr Biomed Res, Populat Council, New York, NY 10021 USA; Univ Roma La Sapienza, I-00185 Rome, Italy	Population Council; Sapienza University Rome	Mruk, DD (corresponding author), Ctr Biomed Res, Populat Council, 1230 York Ave, New York, NY 10021 USA.	d-mruk@popcbr.rockefeller.edu; y-cheng@popcbr.rockefeller.edu		Cheng, C Yan/0000-0003-3117-3791	NICHD NIH HHS [U01 HD045908, U54 HD029990] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD029990] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD045908] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beardsley A, 2003, BIOL REPROD, V68, P1299, DOI 10.1095/biolreprod.102.009811; BISHOP LA, 1995, ENDOCRINOLOGY, V136, P2635, DOI 10.1210/en.136.6.2635; BISHOP LA, 1994, MOL ENDOCRINOL, V8, P722, DOI 10.1210/me.8.6.722; BLITHE DL, 1995, ENDOCRINOLOGY, V136, P903, DOI 10.1210/en.136.3.903; Braghiroli L, 1998, BIOL REPROD, V59, P111, DOI 10.1095/biolreprod59.1.111; Cheng CY, 2005, CONTRACEPTION, V72, P251, DOI 10.1016/j.contraception.2005.03.008; Cheng CY, 2002, PHYSIOL REV, V82, P825, DOI 10.1152/physrev.00009.2002; Cheng CY, 2001, BIOL REPROD, V65, P449, DOI 10.1095/biolreprod65.2.449; CLAMP JR, 1965, BIOCHEM J, V94, P17, DOI 10.1042/bj0940017; FLACK MR, 1994, J BIOL CHEM, V269, P14015; Gaertner HF, 1996, BIOCONJUGATE CHEM, V7, P38, DOI 10.1021/bc950074d; GEOGHEGAN KF, 1992, BIOCONJUGATE CHEM, V3, P138, DOI 10.1021/bc00014a008; GEOGHEGAN KF, 1993, BIOCONJUGATE CHEM, V4, P537, DOI 10.1021/bc00024a017; Grima J, 2001, BIOL REPROD, V64, P1500, DOI 10.1095/biolreprod64.5.1500; GRISWOLD MD, 1995, J STEROID BIOCHEM, V53, P215, DOI 10.1016/0960-0760(95)00049-6; Lee NPY, 2004, J ANDROL, V25, P200; Lui WY, 2003, BIOL REPROD, V68, P2189, DOI 10.1095/biolreprod.102.011379; Mruk DD, 2004, ENDOCR REV, V25, P747, DOI 10.1210/er.2003-0022; Mruk DD, 2004, TRENDS ENDOCRIN MET, V15, P439, DOI 10.1016/j.tem.2004.09.009; O'Donnell L, 2000, BIOL REPROD, V63, P99, DOI 10.1095/biolreprod63.1.99; Rosenthal CS, 2000, WOMEN POLIT, V21, P21, DOI 10.1300/J014v21n02_02; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Siu MKY, 2003, ENDOCRINOLOGY, V144, P2141, DOI 10.1210/en.2002-221035; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; THOTAKURA NR, 1995, GLYCOBIOLOGY, V5, P3, DOI 10.1093/glycob/5.1.3; Toyama Yoshiro, 2003, Anatomical Science International, V78, P1, DOI 10.1046/j.0022-7722.2003.00034.x; VALOVE FM, 1994, ENDOCRINOLOGY, V135, P2657, DOI 10.1210/en.135.6.2657; Walker WH, 2005, REPRODUCTION, V130, P15, DOI 10.1530/rep.1.00358; Wong CH, 2005, ENDOCRINOLOGY, V146, P1192, DOI 10.1210/en.2004-1275; Zhang JY, 2005, J CELL PHYSIOL, V204, P470, DOI 10.1002/jcp.20303	30	83	92	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1323	1328		10.1038/nm1420	http://dx.doi.org/10.1038/nm1420			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17072312				2022-12-25	WOS:000241844900031
J	Parma, P; Radi, O; Vidal, V; Chaboissier, MC; Dellambra, E; Valentini, S; Guerra, L; Schedl, A; Camerino, G				Parma, Pietro; Radi, Orietta; Vidal, Valerie; Chaboissier, Marie Christine; Dellambra, Elena; Valentini, Stella; Guerra, Liliana; Schedl, Andreas; Camerino, Giovanna			R-spondin1 is essential in sex determination, skin differentiation and malignancy	NATURE GENETICS			English	Article							SQUAMOUS-CELL CARCINOMA; PALMOPLANTAR KERATODERMA; HURIEZ-SYNDROME; R-SPONDIN; SOX9; MICE; ASSOCIATION; ACTIVATION; PROTEINS; REVERSAL	R-spondins are a recently characterized small family of growth factors. Here we show that human R-spondin1 (RSPO1) is the gene disrupted in a recessive syndrome characterized by XX sex reversal, palmoplantar hyperkeratosis and predisposition to squamous cell carcinoma of the skin. Our data show, for the first time, that disruption of a single gene can lead to complete female-to-male sex reversal in the absence of the testis-determining gene, SRY.	Univ Pavia, Dipartimento Patol Umana & Ereditaria, Sez Biol Gen & Genet Med, I-27100 Pavia, Italy; Fac Sci, Ctr Biochim, INSERM, U636, F-06108 Nice, France; IRCCS, Ist Dermopat Immacolata, Lab Ingn Tessuti & Fisiopatol Cutanea, I-00167 Rome, Italy	University of Pavia; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Camerino, G (corresponding author), Univ Pavia, Dipartimento Patol Umana & Ereditaria, Sez Biol Gen & Genet Med, Via Forianini 14, I-27100 Pavia, Italy.	camerino@unipv.it	Schedl, Andreas/F-8823-2015; vidal, valerie/S-2597-2019; CHABOISSIER, Marie-Christine/AAZ-5905-2021; CHABOISSIER, Marie-Christine/F-6166-2019; Schedl, Andreas/GOP-3427-2022; Vidal, Valerie/M-1477-2018; Dellambra, Elena/A-4005-2014; Guerra, Liliana/G-8849-2016	Schedl, Andreas/0000-0001-9380-7396; CHABOISSIER, Marie-Christine/0000-0003-0934-8217; CHABOISSIER, Marie-Christine/0000-0003-0934-8217; Dellambra, Elena/0000-0002-4329-3312; Parma, Pietro/0000-0003-1544-6673; Guerra, Liliana/0000-0001-6274-6607	Telethon [GGP06252] Funding Source: Medline	Telethon(Fondazione Telethon)		Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Bernerd F, 2001, P NATL ACAD SCI USA, V98, P7817, DOI 10.1073/pnas.141221998; Bishop CE, 2000, NAT GENET, V26, P490, DOI 10.1038/82652; Brennan J, 2004, NAT REV GENET, V5, P509, DOI 10.1038/nrg1381; Christiano AM, 1997, TRENDS GENET, V13, P227, DOI 10.1016/S0168-9525(97)01104-9; Guerra L, 2003, ARCH DERMATOL, V139, P1303, DOI 10.1001/archderm.139.10.1303; HOGAN B, 1996, MANIPULATING MOUSE E; Kamata T, 2004, BBA-GENE STRUCT EXPR, V1676, P51, DOI 10.1016/j.bbaexp.2003.10.009; Kazanskaya O, 2004, DEV CELL, V7, P525, DOI 10.1016/j.devcel.2004.07.019; Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Kim Y, 2006, PLOS BIOL, V4, P1000, DOI 10.1371/journal.pbio.0040187; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Micali G, 2005, J AM ACAD DERMATOL, V53, pS234, DOI 10.1016/j.jaad.2005.02.033; Nam JS, 2006, J BIOL CHEM, V281, P13247, DOI 10.1074/jbc.M508324200; Qin YJ, 2004, HUM MOL GENET, V13, P1213, DOI 10.1093/hmg/ddh141; Radi O, 2005, AM J MED GENET A, V138A, P241, DOI 10.1002/ajmg.a.30935; Riggio E, 2005, PLAST RECONSTR SURG, V116, P689, DOI 10.1097/01.prs.0000175966.01538.73; Ross AJ, 2005, TRENDS ENDOCRIN MET, V16, P19, DOI 10.1016/j.tem.2004.11.004; TERWILLIGER JD, 1994, HDB HUMAN GENETIC LI; Vernole P, 2000, CLIN GENET, V57, P61, DOI 10.1034/j.1399-0004.2000.570109.x; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; Viegas-Pequignot E., 1992, PRACTICAL APPROACHES, P137; Wilhelm D, 2006, NAT REV GENET, V7, P620, DOI 10.1038/nrg1903; Yao HHC, 2005, MOL CELL ENDOCRINOL, V230, P87, DOI 10.1016/j.mce.2004.11.003; [No title captured]	26	442	470	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2006	38	11					1304	1309		10.1038/ng1907	http://dx.doi.org/10.1038/ng1907			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17041600				2022-12-25	WOS:000241592700019
J	Goldstein, JL				Goldstein, Joseph L.			Venture science: climbing the ladder to telomerase, cognitive therapy and in situ hybridization	NATURE MEDICINE			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1129	1132		10.1038/nm1006-1129	http://dx.doi.org/10.1038/nm1006-1129			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17024207				2022-12-25	WOS:000241102200026
J	Shiva, S; Wang, X; Ringwood, LA; Xu, XY; Yuditskaya, S; Annavajjhala, V; Miyajima, H; Hogg, N; Harris, ZL; Gladwin, MT				Shiva, Sruti; Wang, Xunde; Ringwood, Lorna A.; Xu, Xueying; Yuditskaya, Susan; Annavajjhala, Vidhya; Miyajima, Hiroaki; Hogg, Neil; Harris, Zena Leah; Gladwin, Mark T.			Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis	NATURE CHEMICAL BIOLOGY			English	Article							IN-VIVO; LIPID-PEROXIDATION; NITROSOTHIOL FORMATION; ISCHEMIA-REPERFUSION; SERUM CERULOPLASMIN; VASCULAR CONTROL; GENE-EXPRESSION; S-NITROSOTHIOLS; FATTY-ACIDS; ACERULOPLASMINEMIA	Nitrite represents a bioactive reservoir of nitric oxide ( NO) that may modulate vasodilation, respiration and cytoprotection after ischemia-reperfusion injury. Although nitrite formation is thought to occur via reaction of NO with oxygen, this third-order reaction cannot compete kinetically with the reaction of NO with hemoglobin to form nitrate. Indeed, the formation of nitrite from NO in the blood is limited when plasma is substituted with physiological buffers, which suggests that plasma contains metal-based enzymatic pathways for nitrite synthesis. We therefore hypothesized that the multicopper oxidase, ceruloplasmin, could oxidize NO to NO+, with subsequent hydration to nitrite. Accordingly, plasma NO oxidase activity was decreased after ceruloplasmin immunodepletion, in ceruloplasmin knockout mice and in people with congenital aceruloplasminemia. Compared to controls, plasma nitrite concentrations were substantially reduced in ceruloplasmin knockout mice, which were more susceptible to liver infarction after ischemia and reperfusion. The extent of hepatocellular infarction normalized after nitrite repletion. These data suggest new functions for the multicopper oxidases in endocrine NO homeostasis and nitrite synthesis, and they support the hypothesis that physiological concentrations of nitrite contribute to hypoxic signaling and cytoprotection.	NHLBI, Vasc Med Branch, NIH, Bethesda, MD 20892 USA; NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA; Johns Hopkins Univ Hosp, Dept Anaesthesia & Crit Care Med, Baltimore, MD 21287 USA; Sch Med, Baltimore, MD 21287 USA; Hamamatsu Univ Sch Med, Dept Med 1, Hamamatsu, Shizuoka 4313192, Japan; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Rad Res Ctr, Milwaukee, WI 53226 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Johns Hopkins University; Johns Hopkins Medicine; Hamamatsu University School of Medicine; Medical College of Wisconsin; Medical College of Wisconsin	Gladwin, MT (corresponding author), NHLBI, Vasc Med Branch, NIH, Bethesda, MD 20892 USA.	mgladwin@nih.gov		Harris, Zena Leah/0000-0003-0110-8438	CLINICAL CENTER [Z01CL008050] Funding Source: NIH RePORTER	CLINICAL CENTER		Bryan NS, 2005, NAT CHEM BIOL, V1, P290, DOI 10.1038/nchembio734; Bryan NS, 2004, P NATL ACAD SCI USA, V101, P4308, DOI 10.1073/pnas.0306706101; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; Dejam A, 2005, BLOOD, V106, P734, DOI 10.1182/blood-2005-02-0567; Duranski MR, 2005, J CLIN INVEST, V115, P1232, DOI 10.1172/JCI200522493; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; Fox PL, 2000, FREE RADICAL BIO MED, V28, P1735, DOI 10.1016/S0891-5849(00)00231-8; FOX PL, 1995, LIFE SCI, V56, P1749, DOI 10.1016/0024-3205(95)00146-W; GITLIN JD, 1988, J BIOL CHEM, V263, P6281; Gladwin MT, 2005, NAT CHEM BIOL, V1, P308, DOI 10.1038/nchembio1105-308; Harada H, 2001, J APPL PHYSIOL, V91, P2816, DOI 10.1152/jappl.2001.91.6.2816; Harris ZL, 2003, J NEUROL SCI, V207, P108, DOI 10.1016/S0022-510X(02)00434-3; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hazen SL, 1999, CIRC RES, V85, P950; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Huang KT, 2005, J BIOL CHEM, V280, P31126, DOI 10.1074/jbc.M501496200; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Hughes MN, 1999, BBA-BIOENERGETICS, V1411, P263, DOI 10.1016/S0005-2728(99)00019-5; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Kim-Shapiro DB, 2006, ARTERIOSCL THROM VAS, V26, P697, DOI 10.1161/01.ATV.0000204350.44226.9a; Kleinbongard P, 2003, FREE RADICAL BIO MED, V35, P790, DOI 10.1016/S0891-5849(03)00406-4; Lauer T, 2003, BASIC RES CARDIOL, V98, P84, DOI 10.1007/s003950300000; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Lim MD, 2005, METHOD ENZYMOL, V396, P3, DOI 10.1016/S0076-6879(05)96001-1; Lundberg JO, 2005, ARTERIOSCL THROM VAS, V25, P915, DOI 10.1161/01.ATV.0000161048.72004.c2; Martin F, 2005, BLOOD, V105, P4613, DOI 10.1182/blood-2004-10-3980; Meyer LA, 2001, J BIOL CHEM, V276, P36857, DOI 10.1074/jbc.M105361200; Miyajima H, 2001, QJM-INT J MED, V94, P417, DOI 10.1093/qjmed/94.8.417; Miyajima H, 1996, FREE RADICAL BIO MED, V20, P757, DOI 10.1016/0891-5849(95)02178-7; Miyajima H, 2003, NEUROPATHOLOGY, V23, P345, DOI 10.1046/j.1440-1789.2003.00521.x; Miyajima H, 1998, NEUROLOGY, V50, P130, DOI 10.1212/WNL.50.1.130; Modin A, 2001, ACTA PHYSIOL SCAND, V171, P9, DOI 10.1046/j.1365-201x.2001.171001009.x; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Musci G, 1999, ADV EXP MED BIOL, V448, P175; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; O'Donnell VB, 1999, CHEM RES TOXICOL, V12, P83, DOI 10.1021/tx980207u; OSAKI S, 1966, J BIOL CHEM, V241, P2746; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; Sarkar J, 2003, J BIOL CHEM, V278, P44018, DOI 10.1074/jbc.M304926200; SINGH TKA, 1992, ACTA CARDIOL, V47, P321; SUNDERMAN FW, 1970, CLIN CHEM, V16, P903; Torres J, 1999, BBA-BIOENERGETICS, V1411, P310, DOI 10.1016/S0005-2728(99)00022-5; Torres J, 2000, FEBS LETT, V475, P263, DOI 10.1016/S0014-5793(00)01682-3; Wang XD, 2004, P NATL ACAD SCI USA, V101, P11477, DOI 10.1073/pnas.0402201101; Webb A, 2004, P NATL ACAD SCI USA, V101, P13683, DOI 10.1073/pnas.0402927101; Xu XY, 2004, ANN NY ACAD SCI, V1012, P299, DOI 10.1196/annals.1306.024; Yang BK, 2003, FREE RADICAL RES, V37, P1, DOI 10.1080/1071576021000033112; Yoshida K, 2000, J NEUROL SCI, V175, P91, DOI 10.1016/S0022-510X(00)00295-1; Zhang Y, 2002, FREE RADICAL BIO MED, V32, P1212, DOI 10.1016/S0891-5849(02)00829-8; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	52	280	294	2	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2006	2	9					486	493		10.1038/nchembio813	http://dx.doi.org/10.1038/nchembio813			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	075XO	16906150				2022-12-25	WOS:000239920900012
J	Vilcheze, C; Wang, F; Arai, M; Hazbon, MH; Colangeli, R; Kremer, L; Weisbrod, TR; Alland, D; Sacchettini, JC; Jacobs, WR				Vilcheze, Catherine; Wang, Feng; Arai, Masayoshi; Hazbon, Manzour Hernando; Colangeli, Roberto; Kremer, Laurent; Weisbrod, Torin R.; Alland, David; Sacchettini, James C.; Jacobs, William R., Jr.			Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid	NATURE MEDICINE			English	Article							BOVIS BCG; ETHIONAMIDE; RESISTANCE; GENE; REDUCTASE; SYNTHASE	Isoniazid is one of the most effective antituberculosis drugs, yet its precise mechanism of action is still controversial. Using specialized linkage transduction, a single point mutation allele (S94A) within the putative target gene inhA was transferred in Mycobacterium tuberculosis. The inhA(S94A) allele was sufficient to confer clinically relevant levels of resistance to isoniazid killing and inhibition of mycolic acid biosynthesis. This resistance correlated with the decreased binding of the INH-NAD inhibitor to InhA, as shown by enzymatic and X-ray crystallographic analyses, and establishes InhA as the primary target of isoniazid action in M. tuberculosis.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10461 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Infect Dis, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Ruy V Lourenco Ctr Study Emerging & Reemerging Pa, Newark, NJ 07103 USA; Univ Montpellier 2, CNRS, Lab Dynam Mol Interact Membranaires, UMR 5539, F-34095 Montpellier 05, France	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Texas A&M University System; Texas A&M University College Station; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Jacobs, WR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	jacobsw@hhmi.org	Kremer, Laurent/M-4935-2017	Kremer, Laurent/0000-0002-6604-4458; Hazbon, Manzour Hernando/0000-0001-6967-815X; Wang, Feng/0000-0003-2980-4646; ROBERTO, COLANGELI/0000-0003-3263-7404; Jacobs, William/0000-0003-3321-3080	NIAID NIH HHS [AI46669, AI43268] Funding Source: Medline; NIGMS NIH HHS [1P50GM6241] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043268, R21AI043268, R01AI046669] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Argyrou A, 2006, NAT STRUCT MOL BIOL, V13, P408, DOI 10.1038/nsmb1089; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007; BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Ramaswamy SV, 2003, ANTIMICROB AGENTS CH, V47, P1241, DOI 10.1128/AAC.47.4.1241-1250.2003; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000; Vilcheze C, 2005, ANTIMICROB AGENTS CH, V49, P708, DOI 10.1128/AAC.49.2.708-720.2005; Wilming M, 1999, ANGEW CHEM INT EDIT, V38, P2588, DOI 10.1002/(SICI)1521-3773(19990903)38:17<2588::AID-ANIE2588>3.0.CO;2-8; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	15	230	248	2	19	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1027	1029		10.1038/nm1466	http://dx.doi.org/10.1038/nm1466			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16906155				2022-12-25	WOS:000240373900026
J	Celli, GB; Denchi, EL; de Lange, T				Celli, Giulia B.; Denchi, Eros Lazzerini; de Lange, Titia			Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination	NATURE CELL BIOLOGY			English	Article							DOUBLE-STRAND BREAKS; MAMMALIAN-CELLS; IN-VITRO; DNA; REPAIR; DEFICIENT; LENGTH; YEAST; TRF2; KU86	Ku70-Ku80 heterodimers promote the non-homologous endjoining ( NHEJ) of DNA breaks and, as shown here, the fusion of dysfunctional telomeres. Paradoxically, this heterodimer is also located at functional mammalian telomeres and interacts with components of shelterin, the protein complex that protects telomeres(1-6). To determine whether Ku contributes to telomere protection, we analysed Ku70(-/-) mouse cells(7). Telomeres of Ku70(-/-) cells had a normal DNA structure and did not activate a DNA damage signal. However, Ku70 repressed exchanges between sister telomeres - a form of homologous recombination implicated in the alternative lengthening of telomeres ( ALT) pathway(8). Sister telomere exchanges occurred at approximately 15% of the chromosome ends when Ku70 and the telomeric protein TRF2 were absent. Combined deficiency of TRF2 and another NHEJ factor, DNA ligase IV, did not elicit this phenotype. Sister telomere exchanges were not elevated at telomeres with functional TRF2, indicating that TRF2 and Ku70 act in parallel to repress recombination. We conclude that mammalian chromosome ends are highly susceptible to homologous recombination, which can endanger cell viability if an unequal exchange generates a critically shortened telomere. Therefore, Ku- and TRF2-mediated repression of homologous recombination is an important aspect of telomere protection.	Rockefeller Univ, Lab Cell Biol & Genet, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, Lab Cell Biol & Genet, 1230 York Ave, New York, NY 10021 USA.	delange@mail.rockefeller.edu	lazzerini denchi, eros/F-7913-2010; de Lange, Titia/B-8263-2011; Denchi, Eros Lazzerini/AAD-8208-2020	lazzerini denchi, eros/0000-0001-5378-4644; de Lange, Titia/0000-0002-9267-367X; 	NIGMS NIH HHS [GM49046] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049046, R37GM049046] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi N, 2001, P NATL ACAD SCI USA, V98, P12109, DOI 10.1073/pnas.201271098; Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Baumann P, 2000, MOL BIOL CELL, V11, P3265, DOI 10.1091/mbc.11.10.3265; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bertuch AA, 2003, GENE DEV, V17, P2347, DOI 10.1101/gad.1146603; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; d'Adda di Fagagna F, 2003, NATURE, V426, P194, DOI [10.1038/nature02118, DOI 10.1038/NATURE02118]; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; DuBois ML, 2002, GENETICS, V161, P995; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Espejel S, 2002, EMBO J, V21, P2207, DOI 10.1093/emboj/21.9.2207; Gilley D, 2001, P NATL ACAD SCI USA, V98, P15084, DOI 10.1073/pnas.261574698; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Laud PR, 2005, GENE DEV, V19, P2560, DOI 10.1101/gad.1321305; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; Ma JL, 2003, MOL CELL BIOL, V23, P8820, DOI 10.1128/MCB.23.23.8820-8828.2003; O'Connor MS, 2004, J BIOL CHEM, V279, P28585, DOI 10.1074/jbc.M312913200; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Polotnianka RM, 1998, CURR BIOL, V8, P831, DOI 10.1016/S0960-9822(98)70325-2; Riha K, 2002, EMBO J, V21, P2819, DOI 10.1093/emboj/21.11.2819; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Stansel RM, 2001, EMBO J, V20, P5532; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Wang YS, 2005, P NATL ACAD SCI USA, V102, P10256, DOI 10.1073/pnas.0504635102; Weinstock DM, 2006, MOL CELL BIOL, V26, P131, DOI 10.1128/MCB.26.1.131-139.2006	35	208	214	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					885	U162		10.1038/ncb1444	http://dx.doi.org/10.1038/ncb1444			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16845382				2022-12-25	WOS:000239423000020
J	To, MD; Perez-Losada, J; Mao, JH; Hsu, J; Jacks, T; Balmain, A				To, Minh D.; Perez-Losada, Jesus; Mao, Jian-Hua; Hsu, Jeff; Jacks, Tyler; Balmain, Allan			A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2(LA2) mice	NATURE GENETICS			English	Article							K-RAS; TUMOR SUSCEPTIBILITY; MODIFIER LOCI; MOUSE; CARCINOGENESIS; MUTATION; SKIN; PROTOONCOGENE; PROGRESSION; ACTIVATION	Pulmonary adenoma susceptibility 1 (Pas1) is the major mouse lung cancer susceptibility locus on chromosome 6 (ref. 1). Kras2 is a common target of somatic mutation in chemically induced mouse lung tumors(2,3) and is a candidate Pas1 gene(4). M. spretus mice (SPRET/Ei) carry a Pas1 resistance haplotype for chemically induced lung tumors(5). We demonstrate that the SPRET/Ei Pas1 allele is switched from resistance to susceptibility by fixation of the parental origin of the mutant Kras2 allele. This switch correlates with low expression of endogenous Kras2 in SPRET/Ei. We propose that the Pas1 modifier effect is due to Kras2, and that a sensitive balance between the expression levels of wild-type and mutant alleles determines lung tumor susceptibility. These data demonstrate that cancer predisposition should also be considered in the context of somatic events and could have major implications for the design of human association studies to identify cancer susceptibility genes.	Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Ctr Canc Res, Howard Hughes Med Inst, Cambridge, MA 02139 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Balmain, A (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA.	abalmain@cc.ucsf.edu	Pérez-Losada, Jesús/A-5883-2019; Mao, Jian-Hua/EIZ-8595-2022	Pérez-Losada, Jesús/0000-0003-2400-624X; Mao, Jian-Hua/0000-0001-9320-6021	NCI NIH HHS [U01CA84306, U01 CA084244, R01 CA111834-04, R01 CA111834-02, R01 CA111834-03, R01 CA111834, R01 CA111834-01A2, U01 CA084306, U01CA84244, U01 CA141455] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA141455, U01CA084244, U01CA084306, R01CA111834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; Bystrykh L, 2005, NAT GENET, V37, P225, DOI 10.1038/ng1497; Czarnomska A, 2003, CANCER RES, V63, P4533; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; Diaz R, 2005, INT J CANCER, V113, P241, DOI 10.1002/ijc.20563; Dragani TA, 2000, CANCER RES, V60, P5017; Dragani TA, 2003, CANCER RES, V63, P3011; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Li J, 2003, ONCOGENE, V22, P1243, DOI 10.1038/sj.onc.1206192; Manenti G, 2004, ONCOGENE, V23, P4495, DOI 10.1038/sj.onc.1207584; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Manenti G, 1997, CANCER RES, V57, P4164; Maria DA, 2003, ONCOGENE, V22, P426, DOI 10.1038/sj.onc.1206157; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RYAN J, 1987, J NATL CANCER I, V79, P1351; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Wang M, 2003, CANCER RES, V63, P3317; Wang M, 2005, ONCOGENE, V24, P1958, DOI 10.1038/sj.onc.1208295; Wang Y, 2001, EXP LUNG RES, V27, P255, DOI 10.1080/019021401300054028; Yanagitani N, 2002, CARCINOGENESIS, V23, P1177, DOI 10.1093/carcin/23.7.1177; YOU M, 1992, CARCINOGENESIS, V13, P1583, DOI 10.1093/carcin/13.9.1583; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	30	60	60	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2006	38	8					926	930		10.1038/ng1836	http://dx.doi.org/10.1038/ng1836			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16823377	Green Accepted			2022-12-25	WOS:000239325700023
J	Yao, XJ; Parnot, C; Deupi, X; Ratnala, VRP; Swaminath, G; Farrens, D; Kobilka, B				Yao, Xiaojie; Parnot, Charles; Deupi, Xavier; Ratnala, Venkata R. P.; Swaminath, Gayathri; Farrens, David; Kobilka, Brian			Coupling ligand structure to specific conformational switches in the beta(2)-adrenoceptor	NATURE CHEMICAL BIOLOGY			English	Article							G-PROTEIN; RECEPTOR ACTIVATION; AGONISTS; BINDING; DISRUPTION; RHODOPSIN; REVEALS; DOMAIN	G protein-coupled receptors (GPCRs) regulate a wide variety of physiological functions in response to structurally diverse ligands ranging from cations and small organic molecules to peptides and glycoproteins. For many GPCRs, structurally related ligands can have diverse efficacy profiles. To investigate the process of ligand binding and activation, we used fluorescence spectroscopy to study the ability of ligands having different efficacies to induce a specific conformational change in the human beta(2)-adrenoceptor (beta(2)-AR). The 'ionic lock' is a molecular switch found in rhodopsin-family GPCRs that has been proposed to link the cytoplasmic ends of transmembrane domains 3 and 6 in the inactive state(1-3). We found that most partial agonists were as effective as full agonists in disrupting the ionic lock. Our results show that disruption of this important molecular switch is necessary, but not sufficient, for full activation of the beta(2)-AR.	Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Oregon Hlth & Sci Univ, Dept Biochem, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Mol Biol, Portland, OR 97201 USA	Stanford University; Oregon Health & Science University; Oregon Health & Science University	Kobilka, B (corresponding author), Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, 279 Campus Dr, Stanford, CA 94305 USA.	kobilka@stanford.edu	Deupi, Xavier/B-2424-2009	Deupi, Xavier/0000-0003-4572-9316; Kobilka, Brian/0000-0001-5958-3990	NIDA NIH HHS [R01 DA14896] Funding Source: Medline; NINDS NIH HHS [5 R01 NS28471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Greasley PJ, 2002, MOL PHARMACOL, V61, P1025, DOI 10.1124/mol.61.5.1025; GREEN SA, 1993, J BIOL CHEM, V268, P23116; Hoffmann C, 2005, NAT METHODS, V2, P171, DOI 10.1038/NMETH742; Jongejan A, 2005, NAT CHEM BIOL, V1, P98, DOI 10.1038/nchembio714; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Mansoor SE, 2002, BIOCHEMISTRY-US, V41, P2475, DOI 10.1021/bi011198i; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Ruprecht JJ, 2004, EMBO J, V23, P3609, DOI 10.1038/sj.emboj.7600374; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Swaminath G, 2004, J BIOL CHEM, V279, P686, DOI 10.1074/jbc.M310888200; Swaminath G, 2005, J BIOL CHEM, V280, P22165, DOI 10.1074/jbc.M502352200; Vilardaga JP, 2005, NAT CHEM BIOL, V1, P25, DOI 10.1038/nchembio705; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035	22	285	296	1	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2006	2	8					417	422		10.1038/nchembio801	http://dx.doi.org/10.1038/nchembio801			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065GD	16799554				2022-12-25	WOS:000239146800010
J	Liu, Y; Gray, NS				Liu, Y; Gray, NS			Rational design of inhibitors that bind to inactive kinase conformations	NATURE CHEMICAL BIOLOGY			English	Article							P38 MAP KINASE; CYCLIN-DEPENDENT KINASE; TYROSINE KINASE; STRUCTURAL BASIS; POTENT; RECEPTOR; STI-571; SELECTIVITY; MECHANISM; DISCOVERY	The majority of kinase inhibitors that have been developed so far-known as type I inhibitors-target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated. Recently, crystal structures of inhibitors such as imatinib (STI571), BIRB796 and sorafenib (BAY43-9006)-known as type II inhibitors - have revealed a new binding mode that exploits an additional binding site immediately adjacent to the region occupied by ATP. This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation. Here, we present a structural analysis of binding modes of known human type II inhibitors and demonstrate that they conform to a pharmacophore model that is currently being used to design a new generation of kinase inhibitors.	Novartis Res Fdn, Dept Biol Chem, Genom Inst, San Diego, CA 92121 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Novartis; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Liu, Y (corresponding author), Novartis Res Fdn, Dept Biol Chem, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.	yliu@gnf.org; nathanael_gray@dfci.harvard.edu						ADAMS JL, 2003, Patent No. 2003029209; Atwell S, 2004, J BIOL CHEM, V279, P55827, DOI 10.1074/jbc.M409792200; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Cumming JG, 2004, BIOORG MED CHEM LETT, V14, P5389, DOI 10.1016/j.bmcl.2004.08.007; Dai YJ, 2005, J MED CHEM, V48, P6066, DOI 10.1021/jm050458h; Ding Q., 2005, [No title captured], Patent No. [2005034869, WO2005034869]; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Gill AL, 2005, J MED CHEM, V48, P414, DOI 10.1021/jm049575n; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Heron NM, 2006, BIOORG MED CHEM LETT, V16, P1320, DOI 10.1016/j.bmcl.2005.11.053; HOELZEMANN G, 2005, Patent No. 2005019192; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hunter T, 1998, Harvey Lect, V94, P81; Jung FH, 2006, J MED CHEM, V49, P955, DOI 10.1021/jm050786h; Klebl BM, 2005, EXPERT OPIN THER TAR, V9, P975, DOI 10.1517/14728222.9.5.975; Kubo K, 2005, J MED CHEM, V48, P1359, DOI 10.1021/jm030427r; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Lowinger TB, 2002, CURR PHARM DESIGN, V8, P2269, DOI 10.2174/1381612023393125; Manley PW, 2004, BBA-PROTEINS PROTEOM, V1697, P17, DOI 10.1016/j.bbapap.2003.11.010; Manley PW, 2002, EUR J CANCER, V38, pS19, DOI 10.1016/S0959-8049(02)80599-8; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Mol CD, 2004, CURR OPIN DRUG DISC, V7, P639; Nagar B, 2002, CANCER RES, V62, P4236; Noble M, 2005, BBA-PROTEINS PROTEOM, V1754, P58, DOI 10.1016/j.bbapap.2005.08.019; Pargellis C, 2002, NAT STRUCT BIOL, V9, P268, DOI 10.1038/nsb770; Pratt DJ, 2004, CURR OPIN DRUG DISC, V7, P428; Regan J, 2002, J MED CHEM, V45, P2994, DOI 10.1021/jm020057r; REN P, 2006, Patent No. 2006002367; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shewchuk L, 2000, J MED CHEM, V43, P133, DOI 10.1021/jm990401t; Sim T., 2005, WO Patent, Patent No. [2005/011597, 2005011597]; Traxler P, 1999, PHARMACOL THERAPEUT, V82, P195, DOI 10.1016/S0163-7258(98)00044-8; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168	36	861	898	5	125	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2006	2	7					358	364		10.1038/nchembio799	http://dx.doi.org/10.1038/nchembio799			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	054KV	16783341				2022-12-25	WOS:000238376400008
J	Peng, L; Liu, RW; Marik, J; Wang, XB; Takada, Y; Lam, KS				Peng, Li; Liu, Ruiwu; Marik, Jan; Wang, Xiaobing; Takada, Yoshikazu; Lam, Kit S.			Combinatorial chemistry identifies high-affinity peptidomimetics against alpha(4)beta(1) integrin for in vivo tumor imaging	NATURE CHEMICAL BIOLOGY			English	Article							AMINO-ACID-RESIDUES; LIGAND-BINDING; ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; PEPTIDE LIBRARY; ALPHA-4-BETA-1; FIBRONECTIN; RADIOIMMUNOTHERAPY; ANTAGONISTS; EXPRESSION	Small peptide-based agents have attracted wide interest as cancer-targeting agents for diagnostic imaging and targeted therapy. There is a need to develop new high-affinity and high-specificity peptidomimetic or small-molecule ligands against cancer cell surface receptors. Here we report on the identification of a high-affinity peptidomimetic ligand (LLP2A; IC50 = 2 pM) against alpha(4)beta(1) integrin using both diverse and highly focused one-bead-one-compound combinatorial peptidomimetic libraries in conjunction with high-stringency screening. We further demonstrate that LLP2A can be used to image alpha(4)beta(1)-expressing lymphomas with high sensitivity and specificity when conjugated to a near infrared fluorescent dye in a mouse xenograft model. Thus, LLP2A provides an important tool for noninvasive monitoring of alpha(4)beta(1) expression and activity during tumor progression, and it shows great potential as an imaging and therapeutic agent for alpha(4)beta(1)-positive tumors.	Univ Calif Davis, Ctr Canc, Dept Internal Med, Sacramento, CA 95817 USA; Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis	Lam, KS (corresponding author), Univ Calif Davis, Ctr Canc, Dept Internal Med, 4501 X St, Sacramento, CA 95817 USA.	Kit.Lam@ucdmc.ucdavis.edu		takada, yoshikazu/0000-0001-5481-9589	NATIONAL CANCER INSTITUTE [U19CA113298, R33CA099136, R33CA086364] Funding Source: NIH RePORTER; NCI NIH HHS [R33CA-99136, U19CA113298, R33CA-86364] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Affleck RL, 2001, CURR OPIN CHEM BIOL, V5, P257, DOI 10.1016/S1367-5931(00)00200-3; Aina OH, 2002, BIOPOLYMERS, V66, P184, DOI 10.1002/bip.10257; Becker A, 2001, NAT BIOTECHNOL, V19, P327, DOI 10.1038/86707; BOEMAN OC, 2003, J NUCL MED, V44, P400; Chen XY, 2004, MOL IMAGING, V3, P96, DOI 10.1162/1535350041464892; Coiffier B, 1998, BLOOD, V92, P1927; Copeland GT, 2001, J AM CHEM SOC, V123, P6496, DOI 10.1021/ja0108584; Damiano JS, 2000, LEUKEMIA LYMPHOMA, V38, P71, DOI 10.3109/10428190009060320; de la Fuente MT, 1999, LEUKEMIA, V13, P266, DOI 10.1038/sj.leu.2401275; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; FALCIONI R, 1994, EXP CELL RES, V210, P113, DOI 10.1006/excr.1994.1017; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Garmy-Susini B, 2005, J CLIN INVEST, V115, P1542, DOI 10.1172/JCI23445; Holzmann B, 1998, CURR TOP MICROBIOL, V231, P125; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; KAISER E, 1970, ANAL BIOCHEM, V34, P595, DOI 10.1016/0003-2697(70)90146-6; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; Lam KS, 1997, CHEM REV, V97, P411, DOI 10.1021/cr9600114; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; Lin KC, 1998, CURR OPIN CHEM BIOL, V2, P453, DOI 10.1016/S1367-5931(98)80120-8; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Liu RW, 2002, J AM CHEM SOC, V124, P7678, DOI 10.1021/ja026421t; Lowman HB, 1997, ANNU REV BIOPH BIOM, V26, P401, DOI 10.1146/annurev.biophys.26.1.401; Marco RAW, 2003, J CELL BIOCHEM, V88, P1038, DOI 10.1002/jcb.10465; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; McIntyre JO, 2004, BIOCHEM J, V377, P617, DOI 10.1042/BJ20030582; MELDAL M, 1994, P NATL ACAD SCI USA, V91, P3314, DOI 10.1073/pnas.91.8.3314; Okarvi SM, 2004, MED RES REV, V24, P357, DOI 10.1002/med.20002; Olson DL, 2005, MOL CANCER THER, V4, P91; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; Park SI, 2001, LETT PEPT SCI, V8, P171, DOI 10.1007/BF02446514; Rivera-Nieves J, 2005, J IMMUNOL, V174, P2343, DOI 10.4049/jimmunol.174.4.2343; Rosebrough S F, 1996, Q J Nucl Med, V40, P234; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Singh J, 2002, J MED CHEM, V45, P2988, DOI 10.1021/jm020054e; Song AM, 2003, J AM CHEM SOC, V125, P6180, DOI 10.1021/ja034539j; Spies SM, 2004, SEMIN NUCL MED, V34, P10, DOI 10.1053/j.semnuclmed.2003.11.004; Spring DR, 2002, J AM CHEM SOC, V124, P1354, DOI 10.1021/ja017248o; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Venditto VJ, 2005, MOL PHARMACEUT, V2, P302, DOI 10.1021/mp050019e; Vincent AM, 1996, BLOOD, V87, P4780, DOI 10.1182/blood.V87.11.4780.bloodjournal87114780; Weiner RE, 2002, APPL RADIAT ISOTOPES, V57, P749, DOI 10.1016/S0969-8043(02)00192-6; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Wilbur DS, 2004, BIOCONJUGATE CHEM, V15, P1454, DOI 10.1021/bc049869n; Wiseman GA, 2002, BLOOD, V99, P4336, DOI 10.1182/blood.V99.12.4336; YANG JT, 1995, DEVELOPMENT, V121, P549; Yusuf-Makagiansar H, 2002, MED RES REV, V22, P146, DOI 10.1002/med.10001	50	210	218	3	71	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2006	2	7					381	389		10.1038/nchembio798	http://dx.doi.org/10.1038/nchembio798			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	054KV	16767086				2022-12-25	WOS:000238376400013
J	Tran, MH; Pearson, MS; Jeffrey, MB; Smyth, DJ; Jones, MK; Duke, M; Don, TA; McManus, DP; Correa-Oliveira, R; Loukas, A				Tran, Mai H.; Pearson, Mark S.; Jeffrey, M. Bethony; Smyth, Danielle J.; Jones, Malcolm K.; Duke, Mary; Don, Tegan A.; McManus, Donald P.; Correa-Oliveira, Rodrigo; Loukas, Alex			Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis	NATURE MEDICINE			English	Article							RURAL AREA; ENDEMIC AREA; IRRADIATED CERCARIAE; INTERFERON-GAMMA; IMMUNE-RESPONSE; INFECTION; ANTIBODY; BRAZIL; INDIVIDUALS; EXPOSURE	Schistosomes are blood-dwelling flukes that infect 200 million people worldwide and are responsible for hundreds of thousands of deaths annually(1). Using a signal sequence trap, we cloned from Schistosoma mansoni two cDNAs, Sm-tsp-1 and Sm-tsp-2, encoding the tetraspanin (TSP) integral membrane proteins TSP-1 and TSP-2. We raised antibodies to recombinant TSP fusion proteins and showed that both proteins are exposed on the surface of S. mansoni. Recombinant TSP-2, but not TSP-1, is strongly recognized by IgG1 and IgG3 ( but not IgE) from naturally resistant individuals but is not recognized by IgG from chronically infected or unexposed individuals. Vaccination of mice with the recombinant proteins followed by challenge infection with S. mansoni resulted in reductions of 57% and 64% (TSP-2) and 34% and 52% (TSP-1) for mean adult worm burdens and liver egg burdens, respectively, over two independent trials. Fecal egg counts were reduced by 65-69% in both test groups. TSP-2 in particular provided protection in excess of the 40% benchmark set by the World Health Organization for progression of schistosome vaccine antigens into clinical trials. When coupled with its selective recognition by naturally resistant people, TSP-2 seems to be an effective vaccine antigen against S. mansoni.	Queensland Inst Med Res, Helminth Biol Lab, Div Infect Dis & Immunol, Brisbane, Qld 4006, Australia; George Washington Univ, Dept Microbiol Trop Med & Immunol, Washington, DC 20037 USA; Fiocruz MS, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil	QIMR Berghofer Medical Research Institute; George Washington University; Fundacao Oswaldo Cruz	Loukas, A (corresponding author), Queensland Inst Med Res, Helminth Biol Lab, Div Infect Dis & Immunol, 300 Herston Rd, Brisbane, Qld 4006, Australia.	alex.loukas@qimr.edu.au	McManus, Donald P./G-2678-2013; Pearson, Mark S/O-5636-2014; Jones, Malcolm K/A-1097-2009; Loukas, Alex/B-7355-2014; McManus, Don/AAC-5394-2020	Jones, Malcolm K/0000-0002-0035-6141; Loukas, Alex/0000-0002-0896-8441; McManus, Don/0000-0001-6443-1449; Smyth, Danielle/0000-0001-6080-2679; Pearson, Mark/0000-0002-0002-1544	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Sherbiny M, 2003, ACTA TROP, V88, P117, DOI 10.1016/S0001-706X(03)00195-5; Bergquist NR, 2005, TRENDS PARASITOL, V21, P112, DOI 10.1016/j.pt.2005.01.001; Bergquist NR, 1998, PARASITOL TODAY, V14, P99, DOI 10.1016/S0169-4758(97)01207-6; Bethony J, 2004, TROP MED INT HEALTH, V9, P381, DOI 10.1111/j.1365-3156.2004.01203.x; Bethony J, 2002, AM J TROP MED HYG, V67, P336, DOI 10.4269/ajtmh.2002.67.336; Bethony J, 1999, J INFECT DIS, V180, P1665, DOI 10.1086/315069; Bethony J, 2001, TROP MED INT HEALTH, V6, P136, DOI 10.1046/j.1365-3156.2001.00685.x; Braschi S, 2005, MOL CELL PROTEOMICS; Brito CFA, 2000, SCAND J IMMUNOL, V51, P595; Correa-Oliveira R, 2000, PARASITOL TODAY, V16, P397, DOI 10.1016/S0169-4758(00)01740-3; CORREAOLIVEIRA R, 1989, T ROY SOC TROP MED H, V83, P798, DOI 10.1016/0035-9203(89)90334-9; de Jesus AR, 2000, INFECT IMMUN, V68, P2797, DOI 10.1128/IAI.68.5.2797-2803.2000; El-Sayed NMA, 2004, TRENDS PARASITOL, V20, P154, DOI 10.1016/j.pt.2004.02.002; Gazzinelli A, 2001, TROP MED INT HEALTH, V6, P126, DOI 10.1046/j.1365-3156.2001.00684.x; HARN DA, 1984, J EXP MED, V159, P1371, DOI 10.1084/jem.159.5.1371; HARN DA, 1985, J IMMUNOL, V135, P2115; Hoffmann KF, 2002, ADV PARASIT, V52, P265, DOI 10.1016/S0065-308X(02)52014-5; JAMES SL, 1983, PARASITE IMMUNOL, V5, P567, DOI 10.1111/j.1365-3024.1983.tb00773.x; JAMES SL, 1981, CELL IMMUNOL, V65, P75, DOI 10.1016/0008-8749(81)90053-8; Jones MK, 2004, BIOESSAYS, V26, P752, DOI 10.1002/bies.20058; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Kloos H, 2006, ACTA TROP, V97, P31, DOI 10.1016/j.actatropica.2005.08.006; Kloos H, 2004, MEM I OSWALDO CRUZ, V99, P673, DOI 10.1590/S0074-02762004000700002; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; LEWIS FA, 1981, INFECT IMMUN, V32, P260, DOI 10.1128/IAI.32.1.260-267.1981; Loukas A, 2001, INFECT IMMUN, V69, P3646, DOI 10.1128/IAI.69.6.3646-3651.2001; MINARD P, 1978, AM J TROP MED HYG, V27, P76, DOI 10.4269/ajtmh.1978.27.76; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; SHER A, 1978, J EXP MED, V148, P46, DOI 10.1084/jem.148.1.46; SILVA EE, 1993, J IMMUNOL, V151, P7057; Smyth D, 2003, INFECT IMMUN, V71, P2548, DOI 10.1128/IAI.71.5.2548-2554.2003; STEK M, 1981, SCIENCE, V212, P1518, DOI 10.1126/science.7233238; van Balkom BWM, 2005, J PROTEOME RES, V4, P958, DOI 10.1021/pr050036w; Verjovski-Almeida S, 2003, NAT GENET, V35, P148, DOI 10.1038/ng1237; VIANA IRC, 1994, T ROY SOC TROP MED H, V88, P466, DOI 10.1016/0035-9203(94)90436-7; VIANA IRC, 1995, PARASITE IMMUNOL, V17, P297, DOI 10.1111/j.1365-3024.1995.tb00895.x; Williams GM, 2002, ACTA TROP, V82, P253, DOI 10.1016/S0001-706X(02)00017-7; World Health Organization, 2002, PREV CONTR SCHIST SO	38	292	312	0	51	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					835	840		10.1038/nm1430	http://dx.doi.org/10.1038/nm1430			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16783371				2022-12-25	WOS:000238862800072
J	Carroll, DK; Carroll, JS; Leong, CO; Cheng, F; Brown, M; Mills, AA; Brugge, JS; Ellisen, LW				Carroll, Danielle K.; Carroll, Jason S.; Leong, Chee-Onn; Cheng, Fang; Brown, Myles; Mills, Alea. A.; Brugge, Joan S.; Ellisen, Leif W.			p63 regulates an adhesion programme and cell survival in epithelial cells	NATURE CELL BIOLOGY			English	Article							STEM-CELLS; P53 HOMOLOG; EPIDERMAL MORPHOGENESIS; EXPRESSION; APOPTOSIS; DELTA-NP63-ALPHA; INTEGRIN; MATRIX; NICHE; SKIN	p63 is critical for epithelial development yet little is known about the transcriptional programmes it regulates. By characterising transcriptional changes and cellular effects following modulation of p63 expression, we have defined a vital role for p63 in cellular adhesion. Knockdown of p63 expression caused downregulation of cell adhesion-associated genes, cell detachment and anoikis in mammary epithelial cells and keratinocytes. Conversely, overexpression of the TAp63 gamma or Delta Np63 alpha isoforms of p63 upregulated cell adhesion molecules, increased cellular adhesion and conferred resistance to anoikis. Apoptosis induced by loss of p63 was rescued by signalling downstream of beta 4 integrin. Our results implicate p63 as a key regulator of cellular adhesion and survival in basal cells of the mammary gland and other stratified epithelial tissues.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; NYU, Courant Inst Math Sci, Bioinformat Grp, New York, NY 10003 USA; NYU, Dept Biol, New York, NY 10003 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; New York University; New York University; Cold Spring Harbor Laboratory	Brugge, JS (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	joan_brugge@hms.harvard.edu	Leong, Chee-Onn/C-9779-2013; Brown, Myles/AAX-5332-2021; Ellisen, Leif W/AAA-6572-2022; Brown, Myles/B-6906-2008	Leong, Chee-Onn/0000-0002-6353-9703; Brown, Myles/0000-0002-8213-1658; Ellisen, Leif W/0000-0003-0444-7910; Carroll, Jason/0000-0003-3643-0080	NCI NIH HHS [CA080111] Funding Source: Medline; NIAMS NIH HHS [AR47898] Funding Source: Medline; NIDCR NIH HHS [DE15945-01, R01 DE015945] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA080111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR047898] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015945] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dellavalle RP, 2001, J DERMATOL SCI, V27, P82, DOI 10.1016/S0923-1811(01)00105-0; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; King KE, 2003, ONCOGENE, V22, P3635, DOI 10.1038/sj.onc.1206536; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Kurata S, 2004, J BIOL CHEM, V279, P50069, DOI 10.1074/jbc.M406322200; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Li N, 2006, ONCOGENE, V25, P2349, DOI 10.1038/sj.onc.1209270; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mills AA, 2002, GENESIS, V32, P138, DOI 10.1002/gene.10067; Nanba D, 2001, DEV GROWTH DIFFER, V43, P535, DOI 10.1046/j.1440-169X.2001.00596.x; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Shimada A, 1999, CANCER RES, V59, P2781; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	42	332	339	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					551	561		10.1038/ncb1420	http://dx.doi.org/10.1038/ncb1420			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16715076				2022-12-25	WOS:000238029000007
J	Tappe, A; Klugmann, M; Luo, C; Hirlinger, D; Agarwal, N; Benrath, J; Ehrengruber, MU; During, MJ; Kuner, R				Tappe, Anke; Klugmann, Matthias; Luo, Ceng; Hirlinger, David; Agarwal, Nitin; Benrath, Justus; Ehrengruber, Markus U.; During, Matthew J.; Kuner, Rohini			Synaptic scaffolding protein Homer1a protects against chronic inflammatory pain	NATURE MEDICINE			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; IP3 RECEPTORS; NEURONS; ACTIVATION; EXPRESSION; PLASTICITY; CHANNELS; COMPLEX; FAMILY; BINDS	Glutamatergic signaling and intracellular calcium mobilization in the spinal cord are crucial for the development of nociceptive plasticity, which is associated with chronic pathological pain(1,2). Long-form Homer proteins anchor glutamatergic receptors to sources of calcium influx and release at synapses(3-5), which is antagonized by the short, activity-dependent splice variant Homer1a. We show here that Homer1a operates in a negative feedback loop to regulate the excitability of the pain pathway in an activity-dependent manner. Homer1a is rapidly and selectively upregulated in spinal cord neurons after peripheral inflammation in an NMDA receptor-dependent manner. Homer1a strongly attenuates calcium mobilization as well as MAP kinase activation induced by glutamate receptors and reduces synaptic contacts on spinal cord neurons that process pain inputs. Preventing activity-induced upregulation of Homer1a using shRNAs in mice in vivo exacerbates inflammatory pain. Thus, activity-dependent uncoupling of glutamate receptors from intracellular signaling mediators is a novel, endogenous physiological mechanism for counteracting sensitization at the first, crucial synapse in the pain pathway. Furthermore, we observed that targeted gene transfer of Homer1a to specific spinal segments in vivo reduces inflammatory hyperalgesia. Thus, Homer1 function is crucially involved in pain plasticity and constitutes a promising therapeutic target for the treatment of chronic inflammatory pain.	Univ Heidelberg, Inst Pharmacol, D-69120 Heidelberg, Germany; Univ Auckland, Dept Mol Med & Pathol, Auckland 1, New Zealand; Med Univ Vienna, Dept Anesthesiol & Gen Intens Care, A-1090 Vienna, Austria; Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland	Ruprecht Karls University Heidelberg; University of Auckland; Medical University of Vienna; University of Zurich	Kuner, R (corresponding author), Univ Heidelberg, Inst Pharmacol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.	rohini.kuner@pharma.uni-heidelberg.de	During, Matthew/AAC-1388-2020; Kuner, Rohini/AGU-0204-2022					Ango F, 2001, NATURE, V411, P962, DOI 10.1038/35082096; Bottai D, 2002, J NEUROSCI, V22, P167, DOI 10.1523/JNEUROSCI.22-01-00167.2002; During Matthew J, 2003, Methods Mol Med, V76, P221; Ehrengruber MU, 2004, MOL NEUROBIOL, V29, P213, DOI 10.1385/MN:29:3:213; Fagni L, 2000, TRENDS NEUROSCI, V23, P80, DOI 10.1016/S0166-2236(99)01492-7; Feng W, 2002, J BIOL CHEM, V277, P44722, DOI 10.1074/jbc.M207675200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hartmann B, 2004, NEURON, V44, P637, DOI 10.1016/j.neuron.2004.10.029; Hennou S, 2003, EUR J NEUROSCI, V18, P811, DOI 10.1046/j.1460-9568.2003.02812.x; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; Klugmann M, 2005, MOL CELL NEUROSCI, V28, P347, DOI 10.1016/j.mcn.2004.10.002; Sandkuhler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304-3959(00)00424-3; TJOLSEN A, 1992, PAIN, V51, P5, DOI 10.1016/0304-3959(92)90003-T; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8; Yang L, 2004, J NEUROSCI, V24, P10846, DOI 10.1523/JNEUROSCI.2496-04.2004; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5	20	102	107	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					677	681		10.1038/nm1406	http://dx.doi.org/10.1038/nm1406			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715092				2022-12-25	WOS:000238149200030
J	Aerts, S; Lambrechts, D; Maity, S; Van Loo, P; Coessens, B; De Smet, F; Tranchevent, LC; De Moor, B; Marynen, P; Hassan, B; Carmeliet, P; Moreau, Y				Aerts, S; Lambrechts, D; Maity, S; Van Loo, P; Coessens, B; De Smet, F; Tranchevent, LC; De Moor, B; Marynen, P; Hassan, B; Carmeliet, P; Moreau, Y			Gene prioritization through genomic data fusion	NATURE BIOTECHNOLOGY			English	Article							CIS-REGULATORY-MODULES; DE-LANGE-SYNDROME; DIGEORGE-SYNDROME; MISSENSE MUTATIONS; DISEASE; TBX1; IDENTIFICATION; DEFECTS; ASSOCIATION; DIFFERENTIATION	The identification of genes involved in health and disease remains a challenge. We describe a bioinformatics approach, together with a freely accessible, interactive and flexible software termed Endeavour, to prioritize candidate genes underlying biological processes or diseases, based on their similarity to known genes involved in these phenomena. Unlike previous approaches, ours generates distinct prioritizations for multiple heterogeneous data sources, which are then integrated, or fused, into a global ranking using order statistics. In addition, it offers the flexibility of including additional data sources. Validation of our approach revealed it was able to efficiently prioritize 627 genes in disease data sets and 76 genes in biological pathway sets, identify candidates of 16 mono- or polygenic diseases, and discover regulatory genes of myeloid differentiation. Furthermore, the approach identified a novel gene involved in craniofacial development from a 2-Mb chromosomal region, deleted in some patients with DiGeorge-like birth defects. The approach described here offers an alternative integrative method for gene discovery.	Univ Leuven VIB, Neurogenet Lab, Dept Human Genet, B-3000 Louvain, Belgium; Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Univ Leuven VIB, Human Genome Lab, Dept Human Genet, B-3000 Louvain, Belgium; Univ Leuven, ESAT SCD, Bioinformat Grp, Dept Elect Engn, Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven	Aerts, S (corresponding author), Univ Leuven VIB, Neurogenet Lab, Dept Human Genet, Herestr 49,Bus 602, B-3000 Louvain, Belgium.	stein.aerts@med.kuleuven.be	Hassan, Bassem A/D-5221-2012; Carmeliet, Peter/AAQ-5140-2020; Verdrengh, Evelien/H-4571-2012; De Smet, Frederik/Q-7808-2016; Aerts, Stein/A-1100-2009; Van Loo, Peter/A-3287-2012; Lambrechts, Diether/AAJ-3167-2020	Hassan, Bassem A/0000-0001-9533-4908; Carmeliet, Peter/0000-0001-7961-1821; De Smet, Frederik/0000-0002-6669-3335; Aerts, Stein/0000-0002-8006-0315; Lambrechts, Diether/0000-0002-3429-302X; Van Loo, Peter/0000-0003-0292-1949; Tranchevent, Leon-Charles/0000-0002-1257-4824; Moreau, Yves/0000-0002-4647-6560; Maity, Sunit/0000-0001-6667-3249				Adie EA, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-55; Aerts S, 2005, NUCLEIC ACIDS RES, V33, pW393, DOI 10.1093/nar/gki354; Aerts S, 2004, BIOINFORMATICS, V20, P1974, DOI 10.1093/bioinformatics/bth179; Aerts S, 2003, BIOINFORMATICS, V19, pII5, DOI 10.1093/bioinformatics/btg1052; Aharon-Peretz J, 2004, NEW ENGL J MED, V351, P1972, DOI 10.1056/NEJMoa033277; Altermann E, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-60; Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Baldini A, 2005, CURR OPIN GENET DEV, V15, P279, DOI 10.1016/j.gde.2005.03.001; Ball CA, 2004, NAT BIOTECHNOL, V22, P1179, DOI 10.1038/nbt0904-1179; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; Bertram L, 2005, NEW ENGL J MED, V352, P884, DOI 10.1056/NEJMoa042765; Bienengraeber M, 2004, NAT GENET, V36, P382, DOI 10.1038/ng1329; Brown NJ, 2004, J IMMUNOL, V173, P7584, DOI 10.4049/jimmunol.173.12.7584; Freudenberg J, 2002, BIOINFORMATICS, V18, pS110, DOI 10.1093/bioinformatics/18.suppl_2.S110; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Glenisson P, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r43; Graham A, 2001, J ANAT, V199, P133, DOI 10.1017/S0021878201008159; Hayashi T, 2004, BIOCHEM BIOPH RES CO, V313, P178, DOI 10.1016/j.bbrc.2003.11.101; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Jerome LA, 2001, NAT GENET, V27, P286, DOI 10.1038/85845; Kanehisa M, 2003, NAT GENET, V33, P305, DOI 10.1038/ng1109; Kent WJ, 2005, GENOME RES, V15, P737, DOI 10.1101/gr.3694705; Kimmel CB, 1998, DEV BIOL, V203, P245, DOI 10.1006/dbio.1998.9016; Krantz ID, 2001, AM J MED GENET, V101, P120, DOI 10.1002/1096-8628(20010615)101:2<120::AID-AJMG1319>3.3.CO;2-7; Lindsay EA, 2001, NATURE, V410, P97, DOI 10.1038/35065105; Lopez-Bigas N, 2004, NUCLEIC ACIDS RES, V32, P3108, DOI 10.1093/nar/gkh605; Merscher S, 2001, CELL, V104, P619, DOI 10.1016/S0092-8674(01)00247-1; Munch C, 2004, NEUROLOGY, V63, P724, DOI 10.1212/01.WNL.0000134608.83927.B1; Peltekova VD, 2004, NAT GENET, V36, P471, DOI 10.1038/ng1339; Perez-Iratxeta C, 2002, NAT GENET, V31, P316, DOI 10.1038/ng895; Piotrowski T, 2003, DEVELOPMENT, V130, P5043, DOI 10.1242/dev.00704; Pixley FJ, 2005, J CELL SCI, V118, P1873, DOI 10.1242/jcs.02314; Quackenbush J, 2003, SCIENCE, V302, P240, DOI 10.1126/science.1090887; Rauch A, 1999, AM J HUM GENET, V64, P659, DOI 10.1086/302235; Robinson SW, 2003, AM J HUM GENET, V72, P1047, DOI 10.1086/374319; Scambler PJ, 2000, HUM MOL GENET, V9, P2421, DOI 10.1093/hmg/9.16.2421; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; Stalmans I, 2003, NAT MED, V9, P173, DOI 10.1038/nm819; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tian XL, 2004, NATURE, V427, P640, DOI 10.1038/nature02320; Tiffin N, 2005, NUCLEIC ACIDS RES, V33, P1544, DOI 10.1093/nar/gki296; Tonkin ET, 2004, NAT GENET, V36, P636, DOI 10.1038/ng1363; Turner FS, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-11-r75; Wang XS, 2005, NAT GENET, V37, P365, DOI 10.1038/ng1524; Westerfield M, 1994, ZEBRAFISH BOOK GUIDE; Windpassinger C, 2004, NAT GENET, V36, P271, DOI 10.1038/ng1313; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005; Zuchner S, 2005, NAT GENET, V37, P289, DOI 10.1038/ng1514	50	657	671	3	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2006	24	5					537	544		10.1038/nbt1203	http://dx.doi.org/10.1038/nbt1203			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	039TX	16680138				2022-12-25	WOS:000237331300028
J	Rahmouni, S; Cerignoli, F; Alonso, A; Tsutji, T; Henkens, R; Zhu, CJ; Louis-Dit-Sully, C; Moutschen, M; Jiang, W; Mustelin, T				Rahmouni, S; Cerignoli, F; Alonso, A; Tsutji, T; Henkens, R; Zhu, CJ; Louis-Dit-Sully, C; Moutschen, M; Jiang, W; Mustelin, T			Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence	NATURE CELL BIOLOGY			English	Article							PROTEIN-TYROSINE PHOSPHATASES; SIGNAL-REGULATED KINASE; N-TERMINAL-KINASE; MAP KINASE; ACTIVATION; GENE; ERK; RECEPTOR; JNK1; P53	Protein tyrosine phosphatases regulate important processes in eukaryotic cells and have critical functions in many human diseases including diabetes to cancer(1-3). Here, we report that the human Vaccinia H1-related (VHR) dual-specific protein tyrosine phosphatase regulates cell-cycle progression and is itself modulated during the cell cycle. Using RNA interference (RNAi), we demonstrate that cells lacking VHR arrest at the G1-S and G2-M transitions of the cell cycle and show the initial signs of senescence, such as flattening, spreading, appearance of autophagosomes, beta-galactosidase staining and decreased telomerase activity. In agreement with this notion, cells lacking VHR were found to upregulate p21(Cip-Waf1), whereas they downregulated the expression of genes for cell-cycle regulators, DNA replication, transcription and mRNA processing. Loss of VHR also caused a several-fold increase in serum-induced activation of its substrates, the mitogen-activated protein ( MAP) kinases Jnk and Erk. VHR-induced cell-cycle arrest was dependent on this hyperactivation of Jnk and Erk, and was reversed by Jnk and Erk inhibition or knock-down. We conclude that VHR is required for cell-cycle progression as it modulates MAP kinase activation in a cell-cycle phase-dependent manner.	Burnham Inst Med Res, La Jolla, CA 92037 USA; Univ Liege, B-4000 Liege 1, Belgium; Inst Biol & Genet Med, Valladolid 47003, Spain	Sanford Burnham Prebys Medical Discovery Institute; University of Liege	Mustelin, T (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnham-inst.org	Alonso, Andrés/L-7523-2014	Alonso, Andrés/0000-0001-8674-9378; Moutschen, Michel/0000-0002-6405-1785; Mustelin, Tomas/0000-0001-5912-8840; Jiang, Wei/0000-0002-2309-9571	NIAID NIH HHS [AI35603] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035603] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Alonso A, 2004, J BIOL CHEM, V279, P35768, DOI 10.1074/jbc.M403412200; Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Andersen JN, 2004, FASEB J, V18, P8, DOI 10.1096/fj.02-1212rev; Chau ASS, 1999, J BIOL CHEM, V274, P32085, DOI 10.1074/jbc.274.45.32085; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dorfman K, 1996, ONCOGENE, V13, P925; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Grosch S, 2003, FASEB J, V17, P1316, DOI 10.1096/fj.02-0919fje; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Huynh H, 2004, NAT CELL BIOL, V6, P831, DOI 10.1038/ncb1164; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jiang W, 1998, MOL CELL, V2, P877, DOI 10.1016/S1097-2765(00)80302-0; Kang MK, 2003, EXP CELL RES, V287, P272, DOI 10.1016/S0014-4827(03)00061-2; Lahlou H, 2003, J BIOL CHEM, V278, P39356, DOI 10.1074/jbc.M304524200; Mustelin T, 2005, NAT REV IMMUNOL, V5, P43, DOI 10.1038/nri1530; Park JI, 2003, MOL CELL BIOL, V23, P543, DOI 10.1128/MCB.23.2.543-554.2003; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tchou WW, 1999, ONCOGENE, V18, P6974, DOI 10.1038/sj.onc.1203195; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Xue Y, 2003, MOL CARCINOGEN, V36, P38, DOI 10.1002/mc.10096	29	101	105	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					524	U178		10.1038/ncb1398	http://dx.doi.org/10.1038/ncb1398			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16604064				2022-12-25	WOS:000237299400017
J	Rai, P; Padala, C; Poon, V; Saraph, A; Basha, S; Kate, S; Tao, K; Mogridge, J; Kane, RS				Rai, P; Padala, C; Poon, V; Saraph, A; Basha, S; Kate, S; Tao, K; Mogridge, J; Kane, RS			Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins	NATURE BIOTECHNOLOGY			English	Article							HEAT-LABILE ENTEROTOXIN; PROTECTIVE ANTIGEN; INFLUENZA-VIRUS; BINDING-SITES; LETHAL FACTOR; MEMBRANES; GANGLIOSIDE; LIPOSOMES; FLUORESCENCE; RECOGNITION	Numerous biological processes involve the recognition of a specific pattern of binding sites on a target protein or surface. Although ligands displayed by disordered scaffolds form stochastic rather than specific patterns, theoretical models predict that recognition will occur between patterns that are characterized by similar or "matched'' statistics(1-4). Endowing synthetic biomimetic structures with statistical pattern matching capabilities may improve the specificity of sensors and resolution of separation processes(5). We demonstrate that statistical pattern matching enhances the potency of polyvalent therapeutics. We functionalized liposomes with an inhibitory peptide at different densities and observed a transition in potency at an interpeptide separation that matches the distance between ligand-binding sites on the heptameric component of anthrax toxin. Pattern-matched polyvalent liposomes inhibited anthrax toxin in vitro at concentrations four orders of magnitude lower than the corresponding monovalent peptide, and neutralized this toxin in vivo. Statistical pattern matching also enhanced the potency of polyvalent inhibitors of cholera toxin. This facile strategy should be broadly applicable to the detection and neutralization of toxins and pathogens.	Rensselaer Polytech Inst, Howard P Isermann Dept Chem & Biol Engn, Troy, NY 12180 USA; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	Rensselaer Polytechnic Institute; University of Toronto	Kane, RS (corresponding author), Rensselaer Polytech Inst, Howard P Isermann Dept Chem & Biol Engn, Ricketts 131,110 8th St, Troy, NY 12180 USA.	jeremy.mogridge@utoronto.ca; kaner@rpi.edu			NIAID NIH HHS [U01 AI056546] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI056546] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrami L, 2004, J CELL BIOL, V166, P645, DOI 10.1083/jcb.200312072; [Anonymous], 1992, INTERMOLECULAR SURFA; CHAN PY, 1991, J CELL BIOL, V115, P245, DOI 10.1083/jcb.115.1.245; Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655; Cunningham K, 2002, P NATL ACAD SCI USA, V99, P7049, DOI 10.1073/pnas.062160399; Fan EK, 2000, CURR OPIN STRUC BIOL, V10, P680, DOI 10.1016/S0959-440X(00)00152-4; Golumbfskie AJ, 1999, P NATL ACAD SCI USA, V96, P11707, DOI 10.1073/pnas.96.21.11707; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gujraty K, 2005, MOL PHARMACEUT, V2, P367, DOI 10.1021/mp050040f; HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jayaraman A, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.078103; Johnson RD, 1996, J PHYS CHEM-US, V100, P5134, DOI 10.1021/jp9523682; KINGERYWOOD JE, 1992, J AM CHEM SOC, V114, P7303, DOI 10.1021/ja00044a057; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; MALLIK S, 1994, NEW J CHEM, V18, P299; Maynard JA, 2002, NAT BIOTECHNOL, V20, P597, DOI 10.1038/nbt0602-597; MERRITT EA, 1994, PROTEIN SCI, V3, P166; Minke WE, 1999, BIOCHEMISTRY-US, V38, P5684, DOI 10.1021/bi982649a; Mourez M, 2001, NAT BIOTECHNOL, V19, P958, DOI 10.1038/nbt1001-958; Rainey GJA, 2004, NAT REV MICROBIOL, V2, P721, DOI 10.1038/nrmicro977; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SOUMPASIS DM, 1983, BIOPHYS J, V41, P95, DOI 10.1016/S0006-3495(83)84410-5; SPEVAK W, 1993, J AM CHEM SOC, V115, P1146, DOI 10.1021/ja00056a047; Srebnik S, 1996, PHYS REV LETT, V77, P3157, DOI 10.1103/PhysRevLett.77.3157; Sun WJ, 1996, BIOPHYS J, V71, P885, DOI 10.1016/S0006-3495(96)79290-1; SVENNERHOLM AM, 1978, CURR MICROBIOL, V1, P19, DOI 10.1007/BF02601701; TOCANNE JF, 1994, PROG LIPID RES, V33, P203, DOI 10.1016/0163-7827(94)90027-2; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Tristram-Nagle S, 1998, BIOPHYS J, V75, P917, DOI 10.1016/S0006-3495(98)77580-0	30	71	71	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2006	24	5					582	586		10.1038/nbt1204	http://dx.doi.org/10.1038/nbt1204			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	039TX	16633350				2022-12-25	WOS:000237331300035
J	Watt, MJ; Dzamko, N; Thomas, WG; Rose-John, S; Ernst, M; Carling, D; Kemp, BE; Febbraio, MA; Steinberg, GR				Watt, Matthew J.; Dzamko, Nicolas; Thomas, Walter G.; Rose-John, Stefan; Ernst, Matthias; Carling, David; Kemp, Bruce E.; Febbraio, Mark A.; Steinberg, Gregory R.			CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK	NATURE MEDICINE			English	Article							CILIARY NEUROTROPHIC FACTOR; FATTY-ACID OXIDATION; LEPTIN SENSITIVITY; PROTEIN-KINASE; RECEPTOR; EXPRESSION; WEIGHT; MICE; IDENTIFICATION; LOCALIZATION	Ciliary neurotrophic factor (CNTF) induces weight loss and improves glucose tolerance in humans and rodents. CNTF is thought to act centrally by inducing hypothalamic neurogenesis to modulate food intake and peripherally by altering hepatic gene expression, in a manner similar to that of leptin. Here, we show that CNTF signals through the CNTFR alpha-IL-6R-gp130 beta receptor complex to increase fatty-acid oxidation and reduce insulin resistance in skeletal muscle by activating AMP-activated protein kinase (AMPK), independent of signaling through the brain. Thus, our findings further show that the antiobesogenic effects of CNTF in the periphery result from direct effects on skeletal muscle, and that these peripheral effects are not suppressed by diet-induced or genetic models of obesity, an essential requirement for the therapeutic treatment of obesity-related diseases.	RMIT Univ, Sch Med Sci, Cellulalr & Mol Metab Lab, Bundoora, Vic 3083, Australia; Univ Melbourne, St Vincents Inst, Fitzroy, Vic 3065, Australia; Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia; Baker Heart Res Inst, Mol Endocrinol Lab, Melbourne, Vic 3008, Australia; Univ Kiel, Dept Biochem, D-24098 Kiel, Germany; Royal Melbourne Hosp, Ludwig Inst Canc Res, Colon Mol & Cell Biol Lab, Melbourne, Vic 3050, Australia; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Cellular Stress Grp, Med Res Council Clin Sci Ctr, London W12 0NN, England; Commonwealth Sci & Ind Res Org Hlth Sci & Nutr, Parkville, Vic 3052, Australia	Royal Melbourne Institute of Technology (RMIT); St. Vincent's Institute of Medical Research; University of Melbourne; University of Melbourne; Baker Heart and Diabetes Institute; University of Kiel; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Imperial College London; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Febbraio, MA (corresponding author), RMIT Univ, Sch Med Sci, Cellulalr & Mol Metab Lab, POB 71, Bundoora, Vic 3083, Australia.	mark.febbraio@rmit.edu.au	Watt, Matthew J/B-2089-2014; Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014; Febbraio, Mark/AAE-9632-2019; Dzamko, Nicolas/AAD-6922-2019; Thomas, Walter/I-2208-2015; Carling, David/F-1943-2014; Ernst, Matthias/D-5111-2012; Rose-John, Stefan/A-7998-2010	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Thomas, Walter/0000-0003-0685-2952; Carling, David/0000-0002-2316-1830; Ernst, Matthias/0000-0002-6399-1177; Rose-John, Stefan/0000-0002-7519-3279; Steinberg, Gregory/0000-0001-5425-8275; Febbraio, Mark/0000-0002-9296-4418; Dzamko, Nicolas/0000-0002-9121-0294	Medical Research Council [MC_U120027537] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V5, P1967; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; Bluher S, 2004, DIABETES, V53, P2787, DOI 10.2337/diabetes.53.11.2787; Bonen A, 2004, FASEB J, V18, P1144, DOI 10.1096/fj.03-1065fje; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; Chen ZP, 2000, AM J PHYSIOL-ENDOC M, V279, pE1202, DOI 10.1152/ajpendo.2000.279.5.E1202; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; Ernst M, 2001, J EXP MED, V194, P189, DOI 10.1084/jem.194.2.189; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Howard JK, 2004, NAT MED, V10, P734, DOI 10.1038/nm1072; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Kallen KJ, 1999, J BIOL CHEM, V274, P11859, DOI 10.1074/jbc.274.17.11859; Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Lee MY, 1997, NEUROSCIENCE, V77, P233, DOI 10.1016/S0306-4522(96)00476-9; MacLennan AJ, 1996, J NEUROSCI, V16, P621; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Petersen EW, 2005, AM J PHYSIOL-ENDOC M, V288, pE155, DOI 10.1152/ajpendo.00257.2004; PREISS J, 1986, J BIOL CHEM, V261, P8597; Schuster B, 2003, J BIOL CHEM, V278, P9528, DOI 10.1074/jbc.M210044200; Shibata R, 2003, HUM GENE THER, V14, P601, DOI 10.1089/104303403321618128; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Sinha S, 2004, J BIOL CHEM, V279, P41294, DOI 10.1074/jbc.M406514200; Sleeman MW, 2003, P NATL ACAD SCI USA, V100, P14297, DOI 10.1073/pnas.2335926100; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Steinberg GR, 2002, J BIOL CHEM, V277, P8854, DOI 10.1074/jbc.M107683200; Steinberg GR, 2004, AM J PHYSIOL-ENDOC M, V286, pE57, DOI 10.1152/ajpendo.00302.2003; Steinberg GR, 2002, AM J PHYSIOL-ENDOC M, V282, pE593, DOI 10.1152/ajpendo.00303.2001; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Watt MJ, 2004, FASEB J, V18, P1445, DOI 10.1096/fj.03-1067fje; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Ziotopoulou M, 2000, DIABETES, V49, P1890, DOI 10.2337/diabetes.49.11.1890; ZURLO F, 1990, J CLIN INVEST, V86, P1423, DOI 10.1172/JCI114857	49	235	241	3	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					541	548		10.1038/nm1383	http://dx.doi.org/10.1038/nm1383			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604088				2022-12-25	WOS:000238149100038
J	Mallick, P; Schirle, M; Chen, SS; Flory, MR; Lee, H; Martin, D; Raught, B; Schmitt, R; Werner, T; Kuster, B; Aebersold, R				Mallick, Parag; Schirle, Markus; Chen, Sharon S.; Flory, Mark R.; Lee, Hookeun; Martin, Daniel; Raught, Brian; Schmitt, Robert; Werner, Thilo; Kuster, Bernhard; Aebersold, Ruedi			eComputational prediction of proteotypic peptides for quantitative proteomics	NATURE BIOTECHNOLOGY			English	Article							MASS-SPECTROMETRY; ABSOLUTE QUANTIFICATION; PROTEIN; IDENTIFICATION; CLEAVAGE; STRATEGY; DATABASE	Mass spectrometry-based quantitative proteomics has become an important component of biological and clinical research. Although such analyses typically assume that a protein's peptide fragments are observed with equal likelihood, only a few so-called 'proteotypic' peptides are repeatedly and consistently identified for any given protein present in a mixture. Using 4600,000 peptide identifications generated by four proteomic platforms, we empirically identified > 16,000 proteotypic peptides for 4,030 distinct yeast proteins. Characteristic physicochemical properties of these peptides were used to develop a computational tool that can predict proteotypic peptides for any protein from any organism, for a given platform, with > 85% cumulative accuracy. Possible applications of proteotypic peptides include validation of protein identifications, absolute quantification of proteins, annotation of coding sequences in genomes, and characterization of the physical principles governing key elements of mass spectrometric workflows (e.g., digestion, chromatography, ionization and fragmentation).	Inst Syst biol, Seattle, WA 98103 USA; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Los Angeles, CA 90095 USA; Cellzome AG, D-69117 Heidelberg, Germany; Univ Zurich, Inst Mol Syst Biol, ETH, CH-8006 Zurich, Switzerland; Univ Zurich, Fac Sci, CH-8006 Zurich, Switzerland	Institute for Systems Biology (ISB); Cedars Sinai Medical Center; University of California System; University of California Los Angeles; GlaxoSmithKline; Cellzome GmbH; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Zurich	Kuster, B (corresponding author), Inst Syst biol, 1441 N 34th St, Seattle, WA 98103 USA.	Bernhard.kuester@cellzome.com	Raught, Brian/A-5619-2008; Kuster, Bernhard/Q-6031-2016	Kuster, Bernhard/0000-0002-9094-1677; Lee, Hookeun/0000-0002-0696-8421	DIVISION OF HEART AND VASCULAR DISEASES [N01HV028179] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HV-28179] Funding Source: Medline	DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Breci LA, 2003, ANAL CHEM, V75, P1963, DOI 10.1021/ac026359i; Craig R, 2004, J PROTEOME RES, V3, P1234, DOI 10.1021/pr049882h; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Desiere F, 2005, GENOME BIOL, V6; Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993; Eisenberg D, 2000, NATURE, V405, P823, DOI 10.1038/35015694; Flory MR, 2002, TRENDS BIOTECHNOL, V20, pS23, DOI 10.1016/S1471-1931(02)00203-3; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Jones P, 2006, NUCLEIC ACIDS RES, V34, pD659, DOI 10.1093/nar/gkj138; Kawashima S, 2000, NUCLEIC ACIDS RES, V28, P374, DOI 10.1093/nar/28.1.374; Keller Andrew, 2002, OMICS A Journal of Integrative Biology, V6, P207, DOI 10.1089/153623102760092805; Kirkpatrick DS, 2005, METHODS, V35, P265, DOI 10.1016/j.ymeth.2004.08.018; KUSTER B, 2005, NAT REV MOL CELL BIO; Marko-Varga G, 2005, J PROTEOME RES, V4, P1200, DOI 10.1021/pr050122w; Marques JT, 2006, NAT BIOTECHNOL, V24, P559, DOI 10.1038/nbt1205; Marzolf B, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-286; Old WM, 2005, MOL CELL PROTEOMICS, V4, P1487, DOI 10.1074/mcp.M500084-MCP200; Ong SE, 2003, METHODS, V29, P124, DOI 10.1016/S1046-2023(02)00303-1; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Ranish JA, 2003, NAT GENET, V33, P349, DOI 10.1038/ng1101; ROTZSCHKE O, 1991, EUR J IMMUNOL, V21, P2891, DOI 10.1002/eji.1830211136; SCHIRLE M, 2004, P 52 ASMS C MASS SPE; Schwartz D, 2005, NAT BIOTECHNOL, V23, P1391, DOI 10.1038/nbt1146; Tabb DL, 2004, ANAL CHEM, V76, P1243, DOI 10.1021/ac0351163; Wright ME, 2004, GENOME BIOL, V5; Xing Y, 2006, NAT REV GENET, V7, P499, DOI 10.1038/nrg1896	30	536	560	3	46	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2007	25	1					125	131		10.1038/nbt1275	http://dx.doi.org/10.1038/nbt1275			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126CY	17195840				2022-12-25	WOS:000243491000038
J	Nakamura, T; Arai, Y; Umehara, H; Masuhara, M; Kimura, T; Taniguchi, H; Sekimoto, T; Ikawa, M; Yoneda, Y; Okabe, M; Tanaka, S; Shiota, K; Nakano, T				Nakamura, Toshinobu; Arai, Yoshikazu; Umehara, Hiroki; Masuhara, Masaaki; Kimura, Tohru; Taniguchi, Hisaaki; Sekimoto, Toshihiro; Ikawa, Masahito; Yoneda, Yoshihiro; Okabe, Masaru; Tanaka, Satoshi; Shiota, Kunio; Nakano, Toru			PGC7/Stella protects against DNA demethylation in early embryogenesis	NATURE CELL BIOLOGY			English	Article							CYTOSINE METHYLATION; BINDING; GENOME	DNA methylation is an important means of epigenetic gene regulation(1,2) and must be carefully controlled as a prerequisite for normal early embryogenesis. Although global demethylation occurs soon after fertilization, it is not evenly distributed throughout the genome. Genomic imprinting and epigenetic asymmetry between parental genomes, that is, delayed demethylation of the maternal genome after fertilization(3-6), are clear examples of the functional importance of DNA methylation. Here, we show that PGC7/Stella, a maternal factor essential for early development, protects the DNA methylation state of several imprinted loci and epigenetic asymmetry. After determining that PGC7/Stella binds to Ran binding protein 5 (RanBP5; a nuclear transport shuttle protein), mutant versions of the two proteins were used to examine exactly when and where PGC7/Stella functions within the cell. It is likely that PGC7/Stella protects the maternal genome from demethylation only after localizing to the nucleus, where it maintains the methylation of several imprinted genes. These results demonstrate that PGC7/Stella is indispensable for the maintenance of methylation involved in epigenetic reprogramming after fertilization.	Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Pathol, Suita, Osaka 5650871, Japan; Univ Tokyo, Dept Anim Resources Sci Vet Med Sci, Tokyo 1138657, Japan; Meikai Univ, Sch Dent, Dept Oral Anat, Kawagoe, Saitama 3500283, Japan; Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Res Inst Microbial Dis, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka 5650871, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan	Osaka University; University of Tokyo; Meikai University; Tokushima University; Osaka University; Osaka University; Osaka University; Osaka University	Nakano, T (corresponding author), Osaka Univ, Grad Sch Med & Frontier Biosci, Dept Pathol, Suita, Osaka 5650871, Japan.	tnakano@patho.med.osaka-u.ac.jp	Nakamura, Toshinobu/ABD-5906-2020; Taniguchi, Hisaaki/I-9171-2012; ikawa, masahito/A-5315-2009; Okabe, Masaru/B-6917-2015	ikawa, masahito/0000-0001-9859-6217; Nakamura, Toshinobu/0000-0003-3881-3368; Okabe, Masaru/0000-0002-0803-9044; Kimura, Tohru/0000-0001-9227-0996; Tanaka, Satoshi/0000-0002-4745-550X				Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bortvin Alex, 2004, BMC Developmental Biology, V4; Dean W, 2003, SEMIN CELL DEV BIOL, V14, P93, DOI 10.1016/S1084-9521(02)00141-6; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; Gurdon JB, 2003, P NATL ACAD SCI USA, V100, P11819, DOI 10.1073/pnas.1834207100; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Kikuchi M, 2004, J BIOL CHEM, V279, P421, DOI 10.1074/jbc.M305623200; Lane N, 2003, GENESIS, V35, P88, DOI 10.1002/gene.10168; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mayer W, 2000, J CELL BIOL, V148, P629, DOI 10.1083/jcb.148.4.629; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Payer B, 2003, CURR BIOL, V13, P2110, DOI 10.1016/j.cub.2003.11.026; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Santos F, 2003, CURR BIOL, V13, P1116, DOI 10.1016/S0960-9822(03)00419-6; Santos F, 2005, DEV BIOL, V280, P225, DOI 10.1016/j.ydbio.2005.01.025; Santos F, 2004, REPRODUCTION, V127, P643, DOI 10.1530/rep.1.00221; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Sato M, 2002, MECH DEVELOP, V113, P91, DOI 10.1016/S0925-4773(02)00002-3; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; YE Q, 1994, J BIOL CHEM, V269, P11306	28	419	442	2	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					64	U81		10.1038/ncb1519	http://dx.doi.org/10.1038/ncb1519			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17143267				2022-12-25	WOS:000243255100013
J	Scheckhuber, CQ; Erjavec, N; Tinazli, A; Hamann, A; Nystrom, T; Osiewacz, HD				Scheckhuber, C. Q.; Erjavec, N.; Tinazli, A.; Hamann, A.; Nystrom, T.; Osiewacz, H. D.			Reducing mitochondrial fission results in increased life span and fitness of two fungal ageing models	NATURE CELL BIOLOGY			English	Article							DYNAMIN-RELATED GTPASE; PODOSPORA-ANSERINA; FUSION; DNA; EXPRESSION; MORPHOLOGY; PLASMID; GENES; DEATH; YEAST	Ageing of biological systems is accompanied by alterations in mitochondrial morphology, including a transformation from networks and filaments to punctuate units(1). The significance of these alterations with regard to ageing is not known. Here, we demonstrate that the dynamin-related protein 1 (Dnm1p), a mitochondrial fission protein conserved from yeast to humans(2), affects ageing in the two model systems we studied, Podospora anserina and Saccharomyces cerevisiae. Deletion of the Dnm1 gene delays the transformation of filamentous to punctuate mitochondria and retards ageing without impairing fitness and fertility typically observed in long-lived mutants. Our data further suggest that reduced mitochondrial fission extends life span by increasing cellular resistance to the induction of apoptosis and links mitochondrial dynamics, apoptosis and life-span control.	Goethe Univ Frankfurt, Inst Mol Biosci, D-90438 Frankfurt, Germany; Gothenburg Univ, Dept Cell & Mol Biol, S-41390 Gothenburg, Sweden	Goethe University Frankfurt; University of Gothenburg	Osiewacz, HD (corresponding author), Goethe Univ Frankfurt, Inst Mol Biosci, Max von Laue Str 9, D-90438 Frankfurt, Germany.	osiewacz@bio.uni-frankfurt.de	Osiewacz, Heinz D./D-3454-2011; Scheckhuber, Christian Q./A-6462-2012	Scheckhuber, Christian Q./0000-0002-2924-7547; Hamann, Andrea/0000-0001-9821-7491				BELCOUR L, 1981, CURR GENET, V3, P13, DOI 10.1007/BF00419575; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Borghouts C, 2000, CURR GENET, V37, P268, DOI 10.1007/s002940050528; Borghouts C, 2002, INT J BIOCHEM CELL B, V34, P1355, DOI 10.1016/S1357-2725(02)00078-X; Borghouts C, 2002, BIOGERONTOLOGY, V3, P143, DOI 10.1023/A:1015696404723; Borghouts C, 2001, MOL CELL BIOL, V21, P390, DOI 10.1128/MCB.21.2.390-399.2001; Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015; Chaveroche MK, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e97; Esser K., 1974, BACTERIA BACTERIOPHA, P531; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gredilla R, 2006, EXP GERONTOL, V41, P439, DOI 10.1016/j.exger.2006.01.010; Hamann A, 2005, CURR GENET, V48, P270, DOI 10.1007/s00294-005-0018-1; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; KUCK U, 1981, CURR GENET, V3, P151, DOI 10.1007/BF00365719; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Munkres KD., 1990, FUNG GENET NEWSLETT, V37, P24, DOI DOI 10.4148/1941-4765.1477; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; OSIEWACZ HD, 1984, CURR GENET, V8, P299, DOI 10.1007/BF00419728; Osiewacz HD, 2002, MYCOLOGY S, V15, P87; OSIEWACZ HD, 2002, AGEING RES REV, V28, P1; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; PRILLINGER H, 1977, MOL GEN GENET, V156, P333, DOI 10.1007/BF00267190; Rapaport D, 1998, J BIOL CHEM, V273, P20150, DOI 10.1074/jbc.273.32.20150; Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026	29	256	265	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					99	U129		10.1038/ncb1524	http://dx.doi.org/10.1038/ncb1524			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17173038				2022-12-25	WOS:000243255100018
J	Stransky, N; Vallot, C; Reyal, F; Bernard-Pierrot, I; de Medina, SGD; Segraves, R; de Rycke, Y; Elvin, P; Cassidy, A; Spraggon, C; Graham, A; Southgate, J; Asselain, B; Allory, Y; Abbou, CC; Albertson, DG; Thiery, JP; Chopin, DK; Pinkel, D; Radvanyi, F				Stransky, Nicolas; Vallot, Celine; Reyal, Fabien; Bernard-Pierrot, Isabelle; de Medina, Sixtina Gil Diez; Segraves, Rick; de Rycke, Yann; Elvin, Paul; Cassidy, Andrew; Spraggon, Carolyn; Graham, Alexander; Southgate, Jennifer; Asselain, Bernard; Allory, Yves; Abbou, Claude C.; Albertson, Donna G.; Thiery, Jean Paul; Chopin, Dominique K.; Pinkel, Daniel; Radvanyi, Francois			Regional copy number-independent deregulation of transcription in cancer	NATURE GENETICS			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; GENE-EXPRESSION; CHROMOSOMAL REGIONS; DNA; METHYLATION; INDUCTION; CHROMATIN; PATTERNS; REVEALS; DOMAINS	Genetic and epigenetic alterations have been identified that lead to transcriptional deregulation in cancers. Genetic mechanisms may affect single genes or regions containing several neighboring genes, as has been shown for DNA copy number changes. It was recently reported that epigenetic suppression of gene expression can also extend to a whole region; this is known as long-range epigenetic silencing. Various techniques are available for identifying regional genetic alterations, but no large-scale analysis has yet been carried out to obtain an overview of regional epigenetic alterations. We carried out an exhaustive search for regions susceptible to such mechanisms using a combination of transcriptome correlation map analysis and array CGH data for a series of bladder carcinomas. We validated one candidate region experimentally, demonstrating histone methylation leading to the loss of expression of neighboring genes without DNA methylation.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; Hop Henri Mondor, INSERM, EMI 0337, F-94010 Creteil, France; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Inst Curie, Dept Biostat, F-75248 Paris 05, France; AstraZeneca, Canc & Infect Res Area, Macclesfield SK10 4TG, Cheshire, England; Univ York, Dept Biol, Jack Birch Unit Mol Carcinogenesis, York YO10 5DD, N Yorkshire, England; Hop Henri Mondor, Dept Pathol, F-94010 Creteil, France; Hop Henri Mondor, Dept Urol, F-94010 Creteil, France; Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA; Inst Curie, Dept Translat Res, F-75248 Paris, France; Inst Mol & Cell Biol, Singapore 138673, Singapore	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; AstraZeneca; University of York - UK; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; University of California System; University of California San Francisco; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Radvanyi, F (corresponding author), Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France.	Francois.Radvanyi@curie.fr	Southgate, Jennifer/AAJ-9089-2021; Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Southgate, Jennifer/0000-0002-0135-480X; Thiery, Jean Paul/0000-0003-0478-5020; Radvanyi, Francois/0000-0002-5696-6424				Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; COOMBS LM, 1990, ANAL BIOCHEM, V188, P338, DOI 10.1016/0003-2697(90)90617-I; Crawley JJ, 2002, GENOME BIOL, V3; Daigo Y, 1999, CANCER RES, V59, P1966; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; Fujii T, 2002, CANCER RES, V62, P3340; Furge KA, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-67; Gialitakis M, 2006, NUCLEIC ACIDS RES, V34, P765, DOI 10.1093/nar/gkj462; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Huebert DJ, 2005, CURR OPIN GENET DEV, V15, P476, DOI 10.1016/j.gde.2005.08.001; Hughes TR, 2000, NAT GENET, V25, P333, DOI 10.1038/77116; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Hyman E, 2002, CANCER RES, V62, P6240; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kano M, 2003, PHYSIOL GENOMICS, V13, P31, DOI 10.1152/physiolgenomics.00116.2002; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Masayesva BG, 2004, P NATL ACAD SCI USA, V101, P8715, DOI 10.1073/pnas.0400027101; Midorikawa Y, 2004, CANCER RES, V64, P7263, DOI 10.1158/0008-5472.CAN-04-1275; Nakamura Y, 2003, EMBO J, V22, P2981, DOI 10.1093/emboj/cdg302; Neuvial P, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-264; Nguyen CT, 2002, CANCER RES, V62, P6456; O'Neill LP, 2003, METHODS, V31, P76, DOI 10.1016/S1046-2023(03)00090-2; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; R Development Core Team, 2006, R LANG ENV STAT COMP; Reyal F, 2005, CANCER RES, V65, P1376, DOI 10.1158/0008-5472.CAN-04-2706; Snijders AM, 2003, ONCOGENE, V22, P4281, DOI 10.1038/sj.onc.1206621; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Driel R, 2003, J CELL SCI, V116, P4067, DOI 10.1242/jcs.00779; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yang XMJ, 2005, CANCER RES, V65, P5628, DOI 10.1158/0008-5472.CAN-05-0533; Yi YJ, 2005, GENOMICS, V85, P401, DOI 10.1016/j.ygeno.2004.11.011; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007; Zhou Y, 2003, CANCER RES, V63, P5781	45	167	170	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2006	38	12					1386	1396		10.1038/ng1923	http://dx.doi.org/10.1038/ng1923			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17099711				2022-12-25	WOS:000242404200015
J	Leen, AM; Myers, GD; Sili, U; Huls, MH; Weiss, H; Leung, KS; Carrum, G; Krance, RA; Chang, CC; Molldrem, JJ; Gee, AP; Brenner, MK; Heslop, HE; Rooney, CM; Bollard, CM				Leen, Ann M.; Myers, G. Doug; Sili, Uluhan; Huls, M. Helen; Weiss, Heidi; Leung, Kathryn S.; Carrum, George; Krance, Robert A.; Chang, Chung-Che; Molldrem, Jeffrey J.; Gee, Adrian P.; Brenner, Malcolm K.; Heslop, Helen E.; Rooney, Cliona M.; Bollard, Catherine M.			Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals	NATURE MEDICINE			English	Article							ALLOGENEIC BONE-MARROW; STEM-CELL TRANSPLANTATION; EXTENSIVE CROSS-REACTIVITY; LYMPHOPROLIFERATIVE DISEASE; ADOPTIVE TRANSFER; CYTOMEGALOVIRUS-INFECTION; ADENOVIRUS; GENE; RECIPIENTS; THERAPY	Immunocompromised individuals are at high risk for life-threatening diseases, especially those caused by cytomegalovirus (CMV), Epstein-Barr virus (EBV) and adenovirus. Conventional therapeutics are primarily active only against CMV, and resistance is frequent. Adoptive transfer of polyclonal cytotoxic T lymphocytes (CTLs) specific for CMV or EBV seems promising, but it is unclear whether this strategy can be extended to adenovirus, which comprises many serotypes. In addition, the preparation of a specific CTL line for each virus in every eligible individual would be impractical. Here we describe genetic modification of antigen-presenting cell lines to facilitate the production of CD4(+) and CD8(+) T lymphocytes specific for CMV, EBV and several serotypes of adenovirus from a single cell culture. When administered to immunocompromised individuals, the single T lymphocyte line expands into multiple discrete virus-specific populations that supply clinically measurable antiviral activity. Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host.	Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Methodist Hosp, Dept Virol, Houston, TX 77030 USA; Texas Childrens Hosp, Houston, TX 77030 USA; Cornell Univ, TMHRI, Methodist Hosp, Dept Pathol,Weill Med Coll, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; Cornell University; The Methodist Hospital System; The Methodist Hospital - Houston; University of Texas System; UTMD Anderson Cancer Center	Bollard, CM (corresponding author), Baylor Coll Med, Methodist Hosp, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.	cmbollar@txccc.org	Wilson, Matthew H/K-3193-2013; Heslop, Helen/AAC-9500-2020; Brenner, Malcolm/Y-2509-2019; Rooney, Cliona/ABD-5475-2021; Sili, Uluhan/AAE-4280-2020	Sili, Uluhan/0000-0002-9939-9298	NCI NIH HHS [P01 CA094237] Funding Source: Medline; NCRR NIH HHS [U42 RR16578, RR00188] Funding Source: Medline; NHLBI NIH HHS [N01HB37163-C001] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA094237] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U42RR016578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bollard CM, 2004, J EXP MED, V200, P1623, DOI 10.1084/jem.20040890; Bollard CM, 2004, BIOL BLOOD MARROW TR, V10, P143, DOI 10.1016/j.bbmt.2003.09.017; Bunde T, 2005, J EXP MED, V201, P1031, DOI 10.1084/jem.20042384; BUSSON P, 1995, J GEN VIROL, V76, P139, DOI 10.1099/0022-1317-76-1-139; Chakrabarti S, 2002, BLOOD, V100, P1619, DOI 10.1182/blood-2002-02-0377; Chakrabarti S, 2002, BLOOD, V99, P4357, DOI 10.1182/blood.V99.12.4357; Cobbold M, 2005, J EXP MED, V202, P379, DOI 10.1084/jem.20040613; Einsele H, 2002, BLOOD, V99, P3916, DOI 10.1182/blood.V99.11.3916; Gottschalk S, 2001, BLOOD, V97, P835, DOI 10.1182/blood.V97.4.835; Gustafsson A, 2000, BLOOD, V95, P807, DOI 10.1182/blood.V95.3.807.003k24_807_814; Heemskerk B, 2003, J VIROL, V77, P6562, DOI 10.1128/JVI.77.11.6562-6566.2003; Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382; HESLOP HE, 1994, NEW ENGL J MED, V331, P679; Heslop HE, 1996, NAT MED, V2, P551, DOI 10.1038/nm0596-551; Khanna R, 2000, ANNU REV MICROBIOL, V54, P19, DOI 10.1146/annurev.micro.54.1.19; Leen AM, 2004, BLOOD, V104, P2432, DOI 10.1182/blood-2004-02-0646; Leen AM, 2004, BLOOD, V103, P1011, DOI 10.1182/blood-2003-07-2449; Lion T, 2003, BLOOD, V102, P1114, DOI 10.1182/blood-2002-07-2152; Myers GD, 2005, BONE MARROW TRANSPL, V36, P1001, DOI 10.1038/sj.bmt.1705164; PAPADOPOULOS EB, 1994, NEW ENGL J MED, V330, P1185, DOI 10.1056/NEJM199404283301703; Peggs KS, 2003, LANCET, V362, P1375, DOI 10.1016/S0140-6736(03)14634-X; RIDDELL SR, 1992, SCIENCE, V257, P238; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; Sili U, 2003, J IMMUNOTHER, V26, P241, DOI 10.1097/00002371-200305000-00008; Smith CA, 1998, HUM GENE THER, V9, P1419, DOI 10.1089/hum.1998.9.10-1419; Wadell G, 1980, Ann N Y Acad Sci, V354, P16, DOI 10.1111/j.1749-6632.1980.tb27955.x; Wagner HJ, 2004, BLOOD, V103, P3979, DOI 10.1182/blood-2003-12-4287; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wang Q, 2001, J EXP MED, V194, P1721, DOI 10.1084/jem.194.12.1721; Wherry EJ, 2002, ADV EXP MED BIOL, V512, P165; Yotnda P, 2001, GENE THER, V8, P930, DOI 10.1038/sj.gt.3301488	32	427	444	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1160	1166		10.1038/nm1475	http://dx.doi.org/10.1038/nm1475			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16998485				2022-12-25	WOS:000241102200032
J	Ramirez, A; Heimbach, A; Gruendemann, J; Stiller, B; Hampshire, D; Cid, LP; Goebel, I; Mubaidin, AF; Wriekat, AL; Roeper, J; Al-Din, A; Hillmer, AM; Karsak, M; Liss, B; Woods, CG; Behrens, MI; Kubisch, C				Ramirez, Alfredo; Heimbach, Andre; Gruendemann, Jan; Stiller, Barbara; Hampshire, Dan; Cid, L. Pablo; Goebel, Ingrid; Mubaidin, Ammar F.; Wriekat, Abdul-Latif; Roeper, Jochen; Al-Din, Amir; Hillmer, Axel M.; Karsak, Meliha; Liss, Birgit; Woods, C. Geoffrey; Behrens, Maria I.; Kubisch, Christian			Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase	NATURE GENETICS			English	Article							PALLIDO-PYRAMIDAL DEGENERATION; SUPRANUCLEAR UPGAZE PARESIS; ALPHA-SYNUCLEIN; DISEASE; DEGRADATION; GENE; ALZHEIMERS; UBIQUITIN; NEURONS; BIOLOGY	Neurodegenerative disorders such as Parkinson and Alzheimer disease cause motor and cognitive dysfunction and belong to a heterogeneous group of common and disabling disorders(1). Although the complex molecular pathophysiology of neurodegeneration is largely unknown, major advances have been achieved by elucidating the genetic defects underlying mendelian forms of these diseases(2). This has led to the discovery of common pathophysiological pathways such as enhanced oxidative stress, protein misfolding and aggregation and dysfunction of the ubiquitin-proteasome system(3-6). Here, we describe loss-of-function mutations in a previously uncharacterized, predominantly neuronal P-type ATPase gene, ATP13A2, underlying an autosomal recessive form of early-on-set parkinsonism with pyramidal degeneration and dementia (PARK9, Kufor-Rakeb syndrome(7,8)). Whereas the wild-type protein was located in the lysosome of transiently transfected cells, the unstable truncated mutants were retained in the endoplasmic reticulum and degraded by the proteasome. Our findings link a class of proteins with unknown function and substrate specificity(9) to the protein networks implicated in neurodegeneration and parkinsonism.	Univ Cologne, Inst Human Genet, D-50931 Cologne, Germany; Univ Cologne, Inst Genet, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50931 Cologne, Germany; Univ Bonn, Inst Human Genet, D-53111 Bonn, Germany; Univ Marburg, Inst Physiol, D-35037 Marburg, Germany; Univ Leeds, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England; Ctr Estudios Cient, Valdivia 5099100, Chile; King Hussein Med Ctr, Dept Neurol, Amman 11947, Jordan; Pinderfields Gen Hosp, Dept Neurol, Wakefield WF1 4DG, England; Univ Bonn, Life & Brain Ctr, Dept Genom, D-53127 Bonn, Germany; Univ Bonn, Life & Brain Ctr, Dept Mol Psychiat, D-53127 Bonn, Germany; Cambridge Inst Med Res, Cambridge CB2 2QQ, England; Univ Chile, Dept Neurol & Neurosurg, Santiago 8207257, Chile	University of Cologne; University of Cologne; University of Cologne; University of Bonn; Philipps University Marburg; University of Leeds; Pinderfields Hospital; University of Bonn; University of Bonn; University of Cambridge; Universidad de Chile	Kubisch, C (corresponding author), Univ Cologne, Inst Human Genet, D-50931 Cologne, Germany.	christian.kubisch@uk-koeln.de	woods, christopher g/A-1361-2010; Kubisch, Christian/F-1893-2011; Hillmer, Axel M/N-2927-2014; Hillmer, Axel M/B-7485-2015; Ramirez, Alfredo/S-5126-2019; Behrens, Maria I I/I-1083-2013	Kubisch, Christian/0000-0003-4220-0978; Hillmer, Axel M/0000-0002-3381-7266; Hillmer, Axel M/0000-0002-3381-7266; Ramirez, Alfredo/0000-0003-4991-763X; Behrens, Maria I I/0000-0003-0964-426X; Grundemann, Jan/0000-0002-3149-0001; liss, Birgit/0000-0002-6733-9207; Roeper, Jochen/0000-0003-2145-8742; Karsak, Meliha/0000-0001-6612-6317; Cid, Pablo/0000-0003-0394-0498	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aharon-Peretz J, 2004, NEW ENGL J MED, V351, P1972, DOI 10.1056/NEJMoa033277; ALDIN ASN, 1994, ACTA NEUROL SCAND, V89, P347; Auer H, 2003, NAT GENET, V35, P292, DOI 10.1038/ng1203-292; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bonifati V, 2003, NEUROL SCI, V24, P159, DOI 10.1007/s10072-003-0108-0; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Goker-Alpan O, 2004, J MED GENET, V41, P937, DOI 10.1136/jmg.2004.024455; Hampshire DJ, 2001, J MED GENET, V38, P680, DOI 10.1136/jmg.38.10.680; Hoyt MA, 2004, CELL MOL LIFE SCI, V61, P1596, DOI 10.1007/s00018-004-4133-9; Imbeaud S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni054; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kuhlbrandt W, 2004, NAT REV MOL CELL BIO, V5, P282, DOI 10.1038/nrm1354; Kwasnicka-Crawford DA, 2005, GENOMICS, V86, P182, DOI 10.1016/j.ygeno.2005.04.002; Lee HJ, 2004, J NEUROSCI, V24, P1888, DOI 10.1523/JNEUROSCI.3809-03.2004; Liss B, 1999, J NEUROSCI, V19, P8839, DOI 10.1523/JNEUROSCI.19-20-08839.1999; Liss B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf088; Liss B, 2001, EMBO J, V20, P5715, DOI 10.1093/emboj/20.20.5715; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Schultheis PJ, 2004, BIOCHEM BIOPH RES CO, V323, P731, DOI 10.1016/j.bbrc.2004.08.156; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Williams DR, 2005, MOVEMENT DISORD, V20, P1264, DOI 10.1002/mds.20511	30	831	867	4	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1184	1191		10.1038/ng1884	http://dx.doi.org/10.1038/ng1884			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16964263				2022-12-25	WOS:000241251100019
J	Skokowa, J; Cario, G; Uenalan, M; Schambach, A; Germeshausen, M; Battmer, K; Zeidler, C; Lehmann, U; Eder, M; Baum, C; Grosschedl, R; Stanulla, M; Scherr, M; Welte, K				Skokowa, Julia; Cario, Gunnar; Uenalan, Murat; Schambach, Axel; Germeshausen, Manuela; Battmer, Karin; Zeidler, Cornelia; Lehmann, Ulrich; Eder, Matthias; Baum, Christopher; Grosschedl, Rudolf; Stanulla, Martin; Scherr, Michaela; Welte, Karl			LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia	NATURE MEDICINE			English	Article							COLONY-STIMULATING-FACTOR; BINDING PROTEIN-ALPHA; ACUTE MYELOID-LEUKEMIA; C/EBP-ALPHA; PROGENITOR CELLS; COLORECTAL-CANCER; GENE-EXPRESSION; BETA-CATENIN; C-MYC; MUTATIONS	We demonstrate here that lymphoid enhancer-binding factor 1 (LEF-1) mediates the proliferation, survival and differentiation of granulocyte progenitor cells. We initially documented the importance of this transcription factor in the bone marrow of individuals with severe congenital neutropenia (CN) with a 'differentiation block' at the promyelocytic stage of myelopoiesis(1). LEF-1 expression was greatly reduced or even absent in CN arrested promyelocytes, resulting in defective expression of the LEF-1 target genes CCND1, MYC and BIRC5, encoding cyclin D1 (ref. 2), c-Myc(3) and survivin(4), respectively. In contrast, healthy individuals showed highest LEF-1 expression in promyelocytes. Reconstitution of LEF-1 in early hematopoietic progenitors of two individuals with CN corrected the defective myelopoiesis and resulted in the differentiation of these progenitors into mature granulocytes. Repression of endogenous LEF-1 by specific short hairpin RNA inhibited proliferation and induced apoptosis of CD34(+) progenitors from healthy individuals and of cells from two myeloid lines (HL-60 and K562). C/EBP alpha, a key transcription factor in granulopoiesis(5,6), was directly regulated by LEF-1. These observations indicate that LEF-1 is an instructive factor regulating neutrophilic granulopoiesis whose absence plays a critical role in the defective maturation program of myeloid progenitors in individuals with CN.	Hannover Med Sch, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Hematol Hemostaseol & Oncol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Pathol, D-30625 Hannover, Germany; Max Planck Inst Immunobiol, Dept Cellular & Mol Immunol, D-79108 Freiburg, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School; Max Planck Society	Welte, K (corresponding author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	skokowa.julia@mh-hannover.de; Welte.Karl.H@mh-hannover.de	Schambach, Axel/C-5491-2011; Skokowa, Julia/AAU-3622-2021; Stanulla, Martin/N-4674-2017; Stanulla, Martin/D-2528-2010; Cario, Gunnar/D-2535-2010	Skokowa, Julia/0000-0002-4399-2324; Stanulla, Martin/0000-0002-3834-0727; 				Cammenga J, 2003, BLOOD, V101, P2206, DOI 10.1182/blood-2002-05-1546; Cario G, 2005, BRIT J HAEMATOL, V129, P275, DOI 10.1111/j.1365-2141.2005.05428.x; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; Devriendt K, 2001, NAT GENET, V27, P313, DOI 10.1038/85886; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Harris TE, 2001, J BIOL CHEM, V276, P29200, DOI 10.1074/jbc.M011587200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4; Konishi N, 1999, BLOOD, V94, P4077, DOI 10.1182/blood.V94.12.4077.424k04_4077_4083; Liu F, 2005, DEVELOPMENT, V132, P5375, DOI 10.1242/dev.02152; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Nawshad A, 2003, J CELL BIOL, V163, P1291, DOI 10.1083/jcb.200306024; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Person RE, 2003, NAT GENET, V34, P308, DOI 10.1038/ng1170; Radomska HS, 2006, J EXP MED, V203, P371, DOI 10.1084/jem.20052242; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Rosenberg PS, 2006, BLOOD, V107, P4628, DOI 10.1182/blood-2005-11-4370; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Scherr M, 2003, CELL CYCLE, V2, P251, DOI 10.4161/cc.2.3.376; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Suh HC, 2006, BLOOD, V107, P4308, DOI 10.1182/blood-2005-06-2216; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Waterman ML, 2004, CANCER METAST REV, V23, P41, DOI 10.1023/A:1025858928620; WELTE K, 1990, BLOOD, V75, P1056; Welte K, 2006, SEMIN HEMATOL, V43, P189, DOI 10.1053/j.seminhematol.2006.04.004; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 2002, BLOOD, V99, P4406, DOI 10.1182/blood.V99.12.4406	36	152	156	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1191	1197		10.1038/nm1484	http://dx.doi.org/10.1038/nm1484			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17063141				2022-12-25	WOS:000241102200037
J	Contoli, M; Message, SD; Laza-Stanca, V; Edwards, MR; Wark, PAB; Bartlett, NW; Kebadze, T; Mallia, P; Stanciu, LA; Parker, HL; Slater, L; Lewis-Antes, A; Kon, OM; Holgate, ST; Davies, DE; Kotenko, SV; Papi, A; Johnston, SL				Contoli, Marco; Message, Simon D.; Laza-Stanca, Vasile; Edwards, Michael R.; Wark, Peter A. B.; Bartlett, Nathan W.; Kebadze, Tatiana; Mallia, Patrick; Stanciu, Luminita A.; Parker, Hayley L.; Slater, Louise; Lewis-Antes, Anita; Kon, Onn M.; Holgate, Stephen T.; Davies, Donna E.; Kotenko, Sergei V.; Papi, Alberto; Johnston, Sebastian L.			Role of deficient type III interferon-lambda production in asthma exacerbations	NATURE MEDICINE			English	Article							BRONCHIAL EPITHELIAL-CELLS; IFN-LAMBDA; RHINOVIRUS; INFECTIONS; INDUCTION; COHORT; VIRUS	Rhinoviruses are the major cause of asthma exacerbations, and asthmatics have increased susceptibility to rhinovirus and risk of invasive bacterial infections. Here we show deficient induction of interferon-lambda s by rhinovirus in asthmatic primary bronchial epithelial cells and alveolar macrophages, which was highly correlated with severity of rhinovirus-induced asthma exacerbation and virus load in experimentally infected human volunteers. Induction by lipopolysaccharide in asthmatic macrophages was also deficient and correlated with exacerbation severity. These results identify previously unknown mechanisms of susceptibility to infection in asthma and suggest new approaches to prevention and/or treatment of asthma exacerbations.	Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, Wright Fleming Inst Infect & Immun, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, MRC & Asthma UK Ctr Allerg Mechan Asthma, London W2 1PG, England; Univ Ferrara, Res Ctr Asthma, Dept Clin & Expt Med, I-44100 Ferrara, Italy; Univ Ferrara, COPD, Dept Clin & Expt Med, I-44100 Ferrara, Italy; Univ Southampton, Southampton Gen Hosp, Brooke Labs, Sch Med, Southampton SO16 6YD, Hants, England; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; St Marys NHS Trust, London W2 1NY, England	Imperial College London; Imperial College London; University of Ferrara; University of Ferrara; University of Southampton; Rutgers State University New Brunswick; Rutgers State University Medical Center	Johnston, SL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, Wright Fleming Inst Infect & Immun, Norfolk Pl, London W2 1PG, England.	s.johnston@imperial.ac.uk	Davies, Donna E/H-2993-2012; Stanciu, Luminita A/B-8384-2012; Papi, alberto/AAC-1888-2019; Johnston, Sebastian Lennox/I-2423-2012; Contoli, Marco/K-3947-2018; Wark, Peter/G-7037-2013	Johnston, Sebastian Lennox/0000-0003-3009-9200; Contoli, Marco/0000-0002-2731-5809; Wark, Peter/0000-0001-5676-6126; Edwards, Michael Robert/0000-0001-6837-0532; PAPI, ALBERTO/0000-0002-6924-4500; Kon, Onn Min/0000-0003-2647-4688; Davies, Donna/0000-0002-5117-2991; Bartlett, Nathan/0000-0002-2715-5163	Medical Research Council [G19/34, G0800766] Funding Source: Medline; NIAID NIH HHS [AI051139, R01 AI057468, AI057468, R01 AI051139] Funding Source: Medline; MRC [G19/34] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051139, R01AI057468] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Carr DJJ, 2005, J VIROL, V79, P9341, DOI 10.1128/JVI.79.14.9341-9345.2005; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Illi S, 2001, BMJ-BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Spann KM, 2004, J VIROL, V78, P4363, DOI 10.1128/JVI.78.8.4363-4369.2004; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Yang K, 2005, IMMUNITY, V23, P465, DOI 10.1016/j.immuni.2005.09.016; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	14	775	820	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1023	1026		10.1038/nm1462	http://dx.doi.org/10.1038/nm1462			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16906156				2022-12-25	WOS:000240373900025
J	Feng, QY; Baird, D; Peng, X; Wang, JB; Ly, T; Guan, JL; Cerione, RA				Feng, Qiyu; Baird, Dan; Peng, Xu; Wang, Jianbin; Ly, Thi; Guan, Jun-Lin; Cerione, Richard A.			Cool-1 functions as an essential regulatory node for EGF receptor-and Src-mediated cell growth	NATURE CELL BIOLOGY			English	Article							TYROSINE KINASE; C-CBL; P21-ACTIVATED KINASES; BINDING PARTNERS; DOWN-REGULATION; FOCAL ADHESION; RING FINGER; DBL FAMILY; BETA-PIX; PROTEIN	Cool-1 (cloned-out of library 1) has a key role in regulating epidermal growth factor receptor (EGFR) degradation. Here, we show that Cool-1 performs this function by functioning as both an upstream activator and downstream target for Cdc42. EGF-dependent phosphorylation of Cool-1 enables it to act as a nucleotide exchange factor for Cdc42 and to form a complex with the E3 ligase Cbl, thus regulating Cbl-catalysed EGFR degradation. The EGF-dependent phosphorylation is normally transient; however, Cool-1 phosphorylation is sustained in cells expressing v-Src and is essential for cellular transformation, as well as for v-Src-induced tumour formation in mice. These findings demonstrate that the regulated phosphorylation of Cool-1 is necessary to maintain the balance between normal signalling by EGFR and Src versus aberrant growth and transformation.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Dept Chem & Chem Biol, Ithaca, NY 14853 USA	Cornell University; Cornell University	Cerione, RA (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	rac1@cornell.edu						Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Baird D, 2005, CURR BIOL, V15, P1, DOI 10.1016/j.cub.2004.12.040; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Feng QY, 2002, J BIOL CHEM, V277, P5644, DOI 10.1074/jbc.M107704200; Flanders JA, 2003, FEBS LETT, V550, P119, DOI 10.1016/S0014-5793(03)00853-6; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Jiang XJ, 2003, TRAFFIC, V4, P529, DOI 10.1034/j.1600-0854.2003.t01-1-00109.x; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON PL, 1983, MOL CELL BIOL, V5, P1073; Jozic D, 2005, NAT STRUCT MOL BIOL, V12, P972, DOI 10.1038/nsmb1000; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Melkoumian ZK, 2005, CANCER RES, V65, P6676, DOI 10.1158/0008-5472.CAN-04-4142; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Park HS, 2004, MOL CELL BIOL, V24, P4384, DOI 10.1128/MCB.24.10.4384-4394.2004; PAVELIC K, 1993, ANTICANCER RES, V13, P1133; Schmidt MHH, 2006, ONCOGENE, V25, P3071, DOI 10.1038/sj.onc.1209329; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WHITEHEAD IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, pR1; WILSON LK, 1990, ONCOGENE, V5, P1471; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3	29	86	88	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					945	U55		10.1038/ncb1453	http://dx.doi.org/10.1038/ncb1453			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16892055				2022-12-25	WOS:000240241700010
J	Varga, V; Helenius, J; Tanaka, K; Hyman, AA; Tanaka, TU; Howard, J				Varga, Vladimir; Helenius, Jonne; Tanaka, Kozo; Hyman, Anthony A.; Tanaka, Tomoyuki U.; Howard, Jonathon			Yeast kinesin-8 depolymerizes microtubules in a length-dependent manner	NATURE CELL BIOLOGY			English	Article							PLUS-END; PROTEINS; DYNAMICS; MITOSIS; MECHANISMS; MEIOSIS; ROLES	The microtubule cytoskeleton and the mitotic spindle are highly dynamic structures(1), yet their sizes are remarkably constant, thus indicating that the growth and shrinkage of their constituent microtubules are finely balanced(2,3). This balance is achieved, in part, through kinesin-8 proteins (such as Kip3p in budding yeast and KLP67A in Drosophila) that destabilize microtubules(3.-8). Here, we directly demonstrate that Kip3p destabilizes microtubules by depolymerizing them - accounting for the effects of kinesin-8 perturbations on microtubule and spindle length observed in fungi and metazoan cells. Furthermore, using single- molecule microscopy assays(9), we show that Kip3p has several properties that distinguish it from other depolymerizing kinesins, such as the kinesin-13 MCAK(10,11). First, Kip3p disassembles microtubules exclusively at the plus end and second, remarkably, Kip3p depolymerizes longer microtubules faster than shorter ones. These properties are consequences of Kip3p being a highly processive, plus-end-directed motor(12), both in vitro and in vivo. Length- dependent depolymerization provides a new mechanism for controlling the lengths of subcellular structures(13).	Max Planck Inst Cell Biol & Genet, D-01307 Dresden, Germany; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	Max Planck Society; University of Dundee	Howard, J (corresponding author), Max Planck Inst Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	howard@mpi-cbg.de	Howard, Jonathon/J-7492-2016; Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011; Tanaka, Tomoyuki U/A-4775-2008; Howard, Jonathon/D-4229-2011; Tanaka, Kozo/Y-6566-2018	Howard, Jonathon/0000-0003-0086-1196; Hyman, Anthony A/0000-0003-3664-154X; Howard, Jonathon/0000-0003-0086-1196; Varga, Vladimir/0000-0002-0384-1281; Tanaka, Tomoyuki/0000-0002-9886-5947; Tanaka, Kozo/0000-0001-6086-2858	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001; Bressan DA, 2004, J CELL BIOL, V164, P361, DOI 10.1083/jcb.200311063; Bringmann H, 2004, SCIENCE, V303, P1519, DOI 10.1126/science.1094838; Cottingham FR, 1997, J CELL BIOL, V138, P1041, DOI 10.1083/jcb.138.5.1041; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; Goshima G, 2005, CURR BIOL, V15, P1979, DOI 10.1016/j.cub.2005.09.054; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Helenius J, 2006, NATURE, V441, P115, DOI 10.1038/nature04736; Hildebrandt ER, 2000, BBA-MOL CELL RES, V1496, P99, DOI 10.1016/S0167-4889(00)00012-4; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; HOWARD J, 2001, MECH MOTOR PROTEINS, V367; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Kalaidzidis YL, 1997, PROGRAM COMPUT SOFT+, V23, P206; Lawrence CJ, 2002, J MOL EVOL, V54, P42, DOI 10.1007/s00239-001-0016-y; Maekawa H, 2003, EMBO J, V22, P438, DOI 10.1093/emboj/cdg063; Maney T, 2001, J BIOL CHEM, V276, P34753, DOI 10.1074/jbc.M106626200; Marshall WF, 2004, ANNU REV CELL DEV BI, V20, P677, DOI 10.1146/annurev.cellbio.20.012103.094437; Miller RK, 1998, MOL BIOL CELL, V9, P2051, DOI 10.1091/mbc.9.8.2051; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; Rischitor PE, 2004, EUKARYOT CELL, V3, P632, DOI 10.1128/EC.3.3.632-645.2004; Sakamoto T, 2000, BIOCHEM BIOPH RES CO, V272, P586, DOI 10.1006/bbrc.2000.2819; Savoian MS, 2004, J CELL SCI, V117, P3669, DOI 10.1242/jcs.01213; Sproul LR, 2005, CURR BIOL, V15, P1420, DOI 10.1016/j.cub.2005.06.066; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Tanaka K, 2005, NATURE, V434, P987, DOI 10.1038/nature03483; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; West RR, 2001, MOL BIOL CELL, V12, P3919, DOI 10.1091/mbc.12.12.3919	31	323	325	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					957	U60		10.1038/ncb1462	http://dx.doi.org/10.1038/ncb1462			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16906145				2022-12-25	WOS:000240241700011
J	Friesen, TL; Stukenbrock, EH; Liu, ZH; Meinhardt, S; Ling, H; Faris, JD; Rasmussen, JB; Solomon, PS; McDonald, BA; Oliver, RP				Friesen, Timothy L.; Stukenbrock, Eva H.; Liu, Zhaohui; Meinhardt, Steven; Ling, Hua; Faris, Justin D.; Rasmussen, Jack B.; Solomon, Peter S.; McDonald, Bruce A.; Oliver, Richard P.			Emergence of a new disease as a result of interspecific virulence gene transfer	NATURE GENETICS			English	Article							PYRENOPHORA-TRITICI-REPENTIS; QUANTITATIVE TRAIT LOCI; STAGONOSPORA-NODORUM; TAN SPOT; FILAMENTOUS FUNGI; CAUSAL AGENT; WHEAT; EVOLUTION; TOXIN; SENSITIVITY	New diseases of humans, animals and plants emerge regularly. Enhanced virulence on a new host can be facilitated by the acquisition of novel virulence factors. Interspecific gene transfer is known to be a source of such virulence factors in bacterial pathogens (often manifested as pathogenicity islands in the recipient organism(1)) and it has been speculated that interspecific transfer of virulence factors may occur in fungal pathogens(2). Until now, no direct support has been available for this hypothesis. Here we present evidence that a gene encoding a critical virulence factor was transferred from one species of fungal pathogen to another. This gene transfer probably occurred just before 1941, creating a pathogen population with significantly enhanced virulence and leading to the emergence of a new damaging disease of wheat.	Murdoch Univ, Div Hlth Sci, Australian Ctr Necrotroph Fungal Pathogens, Western Australian State Agr Biotechnol Ctr, Murdoch, WA 6150, Australia; USDA ARS, Cereal Crops Res Unit, Red Valley Agr Res Ctr, No Crop Sci Lab, Fargo, ND 58105 USA; ETH, Inst Integrat Biol, CH-8092 Zurich, Switzerland; N Dakota State Univ, Dept Plant Pathol, Fargo, ND 58105 USA; N Dakota State Univ, Dept Chem, Fargo, ND 58105 USA	Murdoch University; United States Department of Agriculture (USDA); Swiss Federal Institutes of Technology Domain; ETH Zurich; North Dakota State University Fargo; North Dakota State University Fargo	Oliver, RP (corresponding author), Murdoch Univ, Div Hlth Sci, Australian Ctr Necrotroph Fungal Pathogens, Western Australian State Agr Biotechnol Ctr, Murdoch, WA 6150, Australia.	roliver@murdoch.edu.au	Solomon, Peter/C-9301-2009; Oliver, Richard P/D-1166-2009; Holtgrewe Stukenbrock, Eva/I-4333-2016; McDonald, Bruce A/A-2748-2008	Solomon, Peter/0000-0002-5130-7307; Holtgrewe Stukenbrock, Eva/0000-0001-8590-3345; McDonald, Bruce A/0000-0002-5332-2172; Faris, Justin/0000-0002-9653-3287				Barrus M. F., 1942, PLANT DIS REPORTER, V26, P246; Bearchell SJ, 2005, P NATL ACAD SCI USA, V102, P5438, DOI 10.1073/pnas.0501596102; Ciuffetti LM, 1997, PLANT CELL, V9, P135, DOI 10.1105/tpc.9.2.135; DUFF A. D. S., 1954, East African Agricultural Journal, V19, P225; Faris JD, 1996, PHYTOPATHOLOGY, V86, P459, DOI 10.1094/Phyto-86-459; Friesen TL, 2005, PHYTOPATHOLOGY, V95, P1144, DOI 10.1094/PHYTO-95-1144; Friesen TL, 2004, THEOR APPL GENET, V109, P464, DOI 10.1007/s00122-004-1678-9; Hacker J, 1997, MOL MICROBIOL, V23, P1089, DOI 10.1046/j.1365-2958.1997.3101672.x; Hosford RM., 1982, TAN SPOT WHEAT RELAT, P1; Johnson A. G., 1942, PLANT DIS REPORTER, V26, P246; Kempken F, 1998, BIOESSAYS, V20, P652, DOI 10.1002/(SICI)1521-1878(199808)20:8&lt;652::AID-BIES8&gt;3.0.CO;2-K; Lamari L, 1998, CAN J PLANT PATHOL, V20, P396, DOI 10.1080/07060669809500410; Lichter A, 2002, FUNGAL GENET BIOL, V37, P180, DOI 10.1016/S1087-1845(02)00500-5; Liu ZH, 2005, THEOR APPL GENET, V111, P782, DOI 10.1007/s00122-005-2064-y; Liu ZH, 2004, PHYTOPATHOLOGY, V94, P1061, DOI 10.1094/PHYTO.2004.94.10.1061; Liu ZH, 2004, PHYTOPATHOLOGY, V94, P1056, DOI 10.1094/PHYTO.2004.94.10.1056; MEEHAN F, 1947, SCIENCE, V106, P270, DOI 10.1126/science.106.2751.270-a; Nei M., 1987, MOL EVOLUTIONARY GEN; Panaccione DG, 2001, P NATL ACAD SCI USA, V98, P12820, DOI 10.1073/pnas.221198698; Roca MG, 2005, FEMS MICROBIOL LETT, V249, P191, DOI 10.1016/j.femsle.2005.06.048; Rosewich UL, 2000, ANNU REV PHYTOPATHOL, V38, P325, DOI 10.1146/annurev.phyto.38.1.325; Schurch S, 2004, MOL PLANT MICROBE IN, V17, P1114, DOI 10.1094/MPMI.2004.17.10.1114; Shaukat A., 2002, Plant Protection Science, V38, P302; Solomon PS, 2006, MOL PLANT PATHOL, V7, P147, DOI [10.1111/j.1364-3703.2006.00326.x, 10.1111/J.1364-3703.2006.00326.X]; Solomon PS, 2003, PHYSIOL MOL PLANT P, V63, P191, DOI 10.1016/j.pmpp.2003.12.003; TATUM LA, 1971, SCIENCE, V171, P1113, DOI 10.1126/science.171.3976.1113; Terauchi R, 2000, MOL GEN GENET, V263, P554, DOI 10.1007/s004380051201; TOMAS A, 1990, MOL PLANT MICROBE IN, V3, P221, DOI 10.1094/MPMI-3-221; VALDER P. G., 1953, PROC LINN SOC N S WALES, V77, P323; Walton JD, 2000, FUNGAL GENET BIOL, V30, P167, DOI 10.1006/fgbi.2000.1224	30	502	520	2	86	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2006	38	8					953	956		10.1038/ng1839	http://dx.doi.org/10.1038/ng1839			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16832356				2022-12-25	WOS:000239325700028
J	Ross, JL; Wallace, K; Shuman, H; Goldman, YE; Holzbaur, ELF				Ross, Jennifer L.; Wallace, Karen; Shuman, Henry; Goldman, Yale E.; Holzbaur, Erika L. F.			Processive bidirectional motion of dynein-dynactin complexes in vitro	NATURE CELL BIOLOGY			English	Article							ACTIN-RELATED PROTEIN; MOTOR-NEURON DISEASE; CYTOPLASMIC DYNEIN; AXONAL-TRANSPORT; MOLECULAR MOTORS; ATP HYDROLYSIS; MICROTUBULES; KINESIN; INCREASES; BINDING	Cytoplasmic dynein is the primary molecular motor responsible for transport of vesicles, organelles, proteins and RNA cargoes from the periphery of the cell towards the nucleus along the microtubule cytoskeleton of eukaryotic cells. Dynactin, a large multi-subunit activator of dynein, docks cargo to the motor and may enhance dynein processivity. Here, we show that individual fluorescently labelled dynein-dynactin complexes exhibit bidirectional and processive motility towards both the plus and minus ends of microtubules. The dependence of this activity on substrate ATP concentration, nucleotide analogues and inhibitors suggests that bidirectional motility is an active energy-transduction property of dynein-dynactin motor mechano-chemistry. The unique motility characteristics observed may reflect the flexibility of the dynein structure that leads to an enhanced ability to navigate around obstacles in the cell.	Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA; Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Holzbaur, ELF (corresponding author), Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA.	holzbaur@mail.med.upenn.edu	Ross, Jennifer L/D-7208-2012	Ross, Jennifer L/0000-0002-4838-3798	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR051174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM075754] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01-AR-051174] Funding Source: Medline; NIGMS NIH HHS [1F32GM075754-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bingham JB, 1998, METHOD ENZYMOL, V298, P171, DOI 10.1016/S0076-6879(98)98017-X; Burgess SA, 2003, NATURE, V421, P715, DOI 10.1038/nature01377; Culver-Hanlon TL, 2006, NAT CELL BIOL, V8, P264, DOI 10.1038/ncb1370; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; EUTENEUER U, 1988, NATURE, V332, P176, DOI 10.1038/332176a0; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; Gross SP, 2002, J CELL BIOL, V156, P855, DOI 10.1083/jcb.200105055; He Y, 2005, J CELL BIOL, V168, P697, DOI 10.1083/jcb.200407191; HOLZBAUR ELF, 1989, BIOCHEMISTRY-US, V28, P7010, DOI 10.1021/bi00443a034; Ishii Y, 2004, CURR PROTEIN PEPT SC, V5, P81, DOI 10.2174/1389203043486838; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Kon T, 2005, NAT STRUCT MOL BIOL, V12, P513, DOI 10.1038/nsmb930; Kon T, 2004, BIOCHEMISTRY-US, V43, P11266, DOI 10.1021/bi048985a; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; LASEK RJ, 1985, NATURE, V316, P645, DOI 10.1038/316645a0; Levy JR, 2006, J CELL BIOL, V172, P733, DOI 10.1083/jcb.200511068; Ling SC, 2004, P NATL ACAD SCI USA, V101, P17428, DOI 10.1073/pnas.0408114101; Mallik R, 2005, CURR BIOL, V15, P2075, DOI 10.1016/j.cub.2005.10.039; Mallik R, 2004, NATURE, V427, P649, DOI 10.1038/nature02293; Mancini EJ, 2004, CELL, V118, P743, DOI 10.1016/j.cell.2004.09.007; Murray JW, 2000, MOL BIOL CELL, V11, P419, DOI 10.1091/mbc.11.2.419; Nan XL, 2005, J PHYS CHEM B, V109, P24220, DOI 10.1021/jp056360w; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; Schroer TA, 2004, ANNU REV CELL DEV BI, V20, P759, DOI 10.1146/annurev.cellbio.20.012103.094623; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P1575, DOI 10.1021/bi00005a013; Takahashi Y, 2004, P NATL ACAD SCI USA, V101, P12865, DOI 10.1073/pnas.0403429101; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Wang ZH, 2000, BIOPHYS J, V78, P1955, DOI 10.1016/S0006-3495(00)76743-9; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; Wang ZH, 1999, CELL STRUCT FUNCT, V24, P373, DOI 10.1247/csf.24.373; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180	40	227	231	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					562	570		10.1038/ncb1421	http://dx.doi.org/10.1038/ncb1421			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16715075				2022-12-25	WOS:000238029000008
J	Clark, RM; Wagler, TN; Quijada, P; Doebley, J				Clark, RM; Wagler, TN; Quijada, P; Doebley, J			A distant upstream enhancer at the maize domestication gene tb1 has pleiotropic effects on plant and inflorescent architecture	NATURE GENETICS			English	Article							MORPHOLOGICAL DIFFERENCES; QUANTITATIVE TRAITS; GENOME EVOLUTION; FLOWERING PLANTS; FRUIT SIZE; TEOSINTE; ORIGIN; MECHANISMS; EXPRESSION; DOMINANCE	Although quantitative trait locus (QTL) mapping has been successful in describing the genetic architecture of complex traits(1-4), the molecular basis of quantitative variation is less well understood, especially in plants such as maize that have large genome sizes. Regulatory changes at the teosinte branched1 (tb1) gene have been proposed to underlie QTLs of large effect for morphological differences that distinguish maize (Zea mays ssp. mays) from its wild ancestors, the teosintes (Z. mays ssp. parviglumis and mexicana)(1,5-7). We used a fine mapping approach to show that intergenic sequences similar to 58-69 kb 5' to the tb1 cDNA confer pleiotropic effects on Z. mays morphology. Moreover, using an allele-specific expression assay, we found that sequences > 41 kb upstream of tb1 act in cis to alter tb1 transcription. Our findings show that the large stretches of noncoding DNA that comprise the majority of many plant genomes can be a source of variation affecting gene expression and quantitative phenotypes.	Univ Wisconsin, Genet Lab, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Doebley, J (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.	jdoebley@wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM065008, R01GM058816] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-58816, F32 GM-65008] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso-Blanco C, 2005, INT J DEV BIOL, V49, P717, DOI 10.1387/ijdb.051994ca; Bennetzen JL, 2005, ANN BOT-LONDON, V95, P127, DOI 10.1093/aob/mci008; Clark RM, 2004, P NATL ACAD SCI USA, V101, P700, DOI 10.1073/pnas.2237049100; DOEBLEY J, 1990, P NATL ACAD SCI USA, V87, P9888, DOI 10.1073/pnas.87.24.9888; Doebley J, 2004, ANNU REV GENET, V38, P37, DOI 10.1146/annurev.genet.38.072902.092425; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; DOEBLEY J, 1993, GENETICS, V134, P559; DOEBLEY J, 1991, GENETICS, V129, P285; DOEBLEY J, 1995, GENETICS, V141, P333; Frary A, 2000, SCIENCE, V289, P85, DOI 10.1126/science.289.5476.85; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Koornneef M, 2004, ANNU REV PLANT BIOL, V55, P141, DOI 10.1146/annurev.arplant.55.031903.141605; Lukens LN, 1999, GENET RES, V74, P291, DOI 10.1017/S0016672399004073; Mackay TFC, 2001, ANNU REV GENET, V35, P303, DOI 10.1146/annurev.genet.35.102401.090633; Mackay TFC, 2004, CURR OPIN GENET DEV, V14, P253, DOI 10.1016/j.gde.2004.04.003; Meagher TR, 2005, NEW PHYTOL, V168, P71, DOI 10.1111/j.1469-8137.2005.01527.x; Rostoks N, 2002, FUNCT INTEGR GENOMIC, V2, P51, DOI 10.1007/s10142-002-0055-5; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Sheehan MJ, 2004, GENETICS, V167, P1395, DOI 10.1534/genetics.103.026096; Simons KJ, 2006, GENETICS, V172, P547, DOI 10.1534/genetics.105.044727; Stam M, 2002, GENETICS, V162, P917; Tanksley SD, 2004, PLANT CELL, V16, pS181, DOI 10.1105/tpc.018119; Thornsberry JM, 2001, NAT GENET, V28, P286, DOI 10.1038/90135; Wang H, 2005, NATURE, V436, P714, DOI 10.1038/nature03863; Wang RL, 1999, NATURE, V398, P236, DOI 10.1038/18435; Wendel JF, 2002, GENETICA, V115, P37, DOI 10.1023/A:1016020030189; Wicker T, 2005, PLANT J, V41, P184, DOI 10.1111/j.1365-313X.2004.02285.x; Wicker T, 2001, PLANT J, V26, P307, DOI 10.1046/j.1365-313X.2001.01028.x	29	282	307	1	79	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					594	597		10.1038/ng1784	http://dx.doi.org/10.1038/ng1784			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16642024				2022-12-25	WOS:000237147500024
J	Reis, A; Chang, HY; Levasseur, M; Jones, KT				Reis, A; Chang, HY; Levasseur, M; Jones, KT			APC(cdh1) activity in mouse oocytes prevents entry into the first meiotic division	NATURE CELL BIOLOGY			English	Article							DEGRADATION; MATURATION; ARREST; EGGS	Fully grown mammalian oocytes maintain a prophase I germinal-vesicle stage arrest in the ovary for extended periods before a luteinizing hormone surge induces entry into the first meiotic division. Cdh1 is an activator of the anaphase-promoting complex (APC) and APC(cdh1) is normally restricted to late M to early G1 phases of the cell cycle. Here, we find that APC(cdh1) is active in mouse oocytes and is necessary to maintain prophase arrest.	Univ Newcastle Upon Tyne, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Jones, KT (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	k.t.jones@newcastle.ac.uk	Jones, Keith/C-9821-2013; Jones, Keith/AAA-3479-2021	Jones, Keith/0000-0002-0294-0851; Jones, Keith/0000-0002-0294-0851	Wellcome Trust [075744, 065354] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Chang HY, 2004, J CELL SCI, V117, P6289, DOI 10.1242/jcs.01567; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Han SJ, 2005, CURR BIOL, V15, P1670, DOI 10.1016/j.cub.2005.07.056; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Madgwick S, 2004, DEV BIOL, V275, P68, DOI 10.1016/j.ydbio.2004.07.024; Mehlmann LM, 2004, SCIENCE, V306, P1947, DOI 10.1126/science.1103974; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Tsafriri A, 1996, DEV BIOL, V178, P393, DOI 10.1006/dbio.1996.0226; ZernickaGoetz M, 1997, DEVELOPMENT, V124, P1133; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	11	123	124	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					539	540		10.1038/ncb1406	http://dx.doi.org/10.1038/ncb1406			2	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16715549	Green Accepted			2022-12-25	WOS:000237299400019
J	Blount, KF; Wang, JX; Lim, J; Sudarsan, N; Breaker, RR				Blount, Kenneth F.; Wang, Joy Xin; Lim, Jinsoo; Sudarsan, Narasimhan; Breaker, Ronald R.			Antibacterial lysine analogs that target lysine riboswitches	NATURE CHEMICAL BIOLOGY			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; GENE-EXPRESSION; RNA; BIOSYNTHESIS; BACTERIA; BINDING; TRANSPORT; KINETICS	Lysine riboswitches are bacterial RNA structures that sense the concentration of lysine and regulate the expression of lysine biosynthesis and transport genes. Members of this riboswitch class are found in the 5' untranslated region of messenger RNAs, where they form highly selective receptors for lysine. Lysine binding to the receptor stabilizes an mRNA tertiary structure that, in most cases, causes transcription termination before the adjacent open reading frame can be expressed. A lysine riboswitch conceivably could be targeted for antibacterial therapy by designing new compounds that bind the riboswitch and suppress lysine biosynthesis and transport genes. As a test of this strategy, we have identified several lysine analogs that bind to riboswitches in vitro and inhibit Bacillus subtilis growth, probably through a mechanism of riboswitch-mediated repression of lysine biosynthesis. These results indicate that riboswitches could serve as new classes of antibacterial drug targets.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University; Yale University	Breaker, RR (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, 266 Whitney Ave,KBT 506, New Haven, CT 06520 USA.	ronald.breaker@yale.edu	Breaker, Ronald/E-9679-2010; Wang, Joy Xin/D-2482-2010	Breaker, Ronald/0000-0002-2165-536X				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; BLOUNT KF, IN PRESS NAT BIOTECH; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; *CLIN LAB STAND I, 2006, M7A7 NAT COMM CLIN L; D'Costa VM, 2006, SCIENCE, V311, P374, DOI 10.1126/science.1120800; Grundy FJ, 2003, P NATL ACAD SCI USA, V100, P12057, DOI 10.1073/pnas.2133705100; HIGGINS CF, 1986, METHOD ENZYMOL, V125, P365; Hutton CA, 2003, MINI-REV MED CHEM, V3, P115, DOI 10.2174/1389557033405359; KAWASAKI T, 1969, J BIOCHEM-TOKYO, V65, P417, DOI 10.1093/oxfordjournals.jbchem.a129029; Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214; Landick R, 1996, METHOD ENZYMOL, V274, P334; Lazazzera BA, 1997, CELL, V89, P917, DOI 10.1016/S0092-8674(00)80277-9; LU Y, 1991, J GEN MICROBIOL, V137, P1135, DOI 10.1099/00221287-137-5-1135; MATSUMOTO N, 1984, Journal of the Medical Society of Toho University, V31, P249; Patte JC, 1998, FEMS MICROBIOL LETT, V169, P165, DOI 10.1016/S0378-1097(98)00479-0; Rodionov DA, 2003, NUCLEIC ACIDS RES, V31, P6748, DOI 10.1093/nar/gkg900; SHOTA T, 1958, ARCH BIOCHEM BIOPHYS, V77, P372; Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891; Sudarsan N, 2003, GENE DEV, V17, P2688, DOI 10.1101/gad.1140003; Sudarsan N, 2005, CHEM BIOL, V12, P1325, DOI 10.1016/j.chembiol.2005.10.007; Wickiser JK, 2005, MOL CELL, V18, P49, DOI 10.1016/j.molcel.2005.02.032; Wickiser JK, 2005, BIOCHEMISTRY-US, V44, P13404, DOI 10.1021/bi051008u; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Winkler WC, 2005, ANNU REV MICROBIOL, V59, P487, DOI 10.1146/annurev.micro.59.030804.121336; Wolfson W, 2006, CHEM BIOL, V13, P1, DOI 10.1016/j.chembiol.2006.01.001; Woolley DW, 1943, J EXP MED, V78, P489, DOI 10.1084/jem.78.6.489; ZHANG JJ, 1990, J BACTERIOL, V172, P701, DOI 10.1128/jb.172.2.701-708.1990; Zhang R, 2004, NUCLEIC ACIDS RES, V32, pD271, DOI 10.1093/nar/gkh024	28	175	189	1	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2007	3	1					44	49		10.1038/nchembio842	http://dx.doi.org/10.1038/nchembio842			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	118QE	17143270				2022-12-25	WOS:000242956000013
J	Mu, JB; Awadalla, P; Duan, JH; McGee, KM; Keebler, J; Seydel, K; McVean, GAT; Su, XZ				Mu, Jianbing; Awadalla, Philip; Duan, Junhui; McGee, Kate M.; Keebler, Jon; Seydel, Karl; McVean, Gilean A. T.; Su, Xin-zhuan			Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome	NATURE GENETICS			English	Article							DIVERSIFYING SELECTION; GENETIC DIVERSITY; MALARIA; RECOMBINATION; POLYMORPHISMS; ERYTHROCYTES; RESISTANCE; PROTEINS; LOCUS; ASSAY	One goal in sequencing the Plasmodium falciparum genome, the agent of the most lethal form of malaria, is to discover vaccine and drug targets(1). However, identifying those targets in a genome in which similar to 60% of genes have unknown functions is an enormous challenge. Because the majority of known malaria antigens and drug-resistant genes are highly polymorphic and under various selective pressures(2-6), genome-wide analysis for signatures of selection may lead to discovery of new vaccine and drug candidates. Here we surveyed 3,539 P. falciparum genes (similar to 65% of the predicted genes) for polymorphisms and identified various highly polymorphic loci and genes, some of which encode new antigens that we confirmed using human immune sera. Our collections of genome-wide SNPs (similar to 65% nonsynonymous) and polymorphic microsatellites and indels provide a high-resolution map (one marker per similar to 4 kb) for mapping parasite traits and studying parasite populations. In addition, we report new antigens, providing urgently needed vaccine candidates for disease control.	NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA; Univ Oxford, Dept Stat, Oxford OX1 3TG, England	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of North Carolina; North Carolina State University; University of Oxford	Awadalla, P (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	pawadalla@ncsu.edu; xsu@niaid.nih.gov	Awadalla, Philip/AAC-4896-2021	Su, Xinzhuan/0000-0003-3246-3248	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000892, Z01AI000892] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Baum J, 2003, GENETICS, V163, P1327; Charlesworth D, 2006, PLOS GENET, V2, P379, DOI 10.1371/journal.pgen.0020064; Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Hardenbol P, 2005, GENOME RES, V15, P269, DOI 10.1101/gr.3185605; Hey J, 1999, CURR BIOL, V9, pR565, DOI 10.1016/S0960-9822(99)80356-X; HUDSON RR, 1988, GENETICS, V120, P831; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Kissinger JC, 2002, NATURE, V419, P490, DOI 10.1038/419490a; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Mu JB, 2005, PLOS BIOL, V3, P1734, DOI 10.1371/journal.pbio.0030335; Mu JB, 2002, NATURE, V418, P323, DOI 10.1038/nature00836; Myers SR, 2003, GENETICS, V163, P375; Nordborg M, 1996, P ROY SOC B-BIOL SCI, V263, P1033, DOI 10.1098/rspb.1996.0152; Polley SD, 2001, GENETICS, V158, P1505; Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876; Sato S, 2005, CURR TOP MICROBIOL, V295, P251; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Su XZ, 1999, SCIENCE, V286, P1351, DOI 10.1126/science.286.5443.1351; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Su XZ, 1997, CELL, V91, P593, DOI 10.1016/S0092-8674(00)80447-X; Trimnell AR, 2006, MOL BIOCHEM PARASIT, V148, P169, DOI 10.1016/j.molbiopara.2006.03.012; VAIDYA AB, 1995, MOL BIOCHEM PARASIT, V69, P65, DOI 10.1016/0166-6851(94)00199-W; Volkman SK, 2002, SCIENCE, V298, P216, DOI 10.1126/science.1075642; Wang P, 1997, MOL MICROBIOL, V23, P979, DOI 10.1046/j.1365-2958.1997.2821646.x; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; Wootton JC, 2002, NATURE, V418, P320, DOI 10.1038/nature00813	29	164	165	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2007	39	1					126	130		10.1038/ng1924	http://dx.doi.org/10.1038/ng1924			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17159981	Bronze			2022-12-25	WOS:000243136500028
J	Obeid, M; Tesniere, A; Ghiringhelli, F; Fimia, GM; Apetoh, L; Perfettini, JL; Castedo, M; Mignot, G; Panaretakis, T; Casares, N; Metivier, D; Larochette, N; van Endert, P; Ciccosanti, F; Piacentini, M; Zitvogel, L; Kroemer, G				Obeid, Michel; Tesniere, Antoine; Ghiringhelli, Francois; Fimia, Gian Maria; Apetoh, Lionel; Perfettini, Jean-Luc; Castedo, Maria; Mignot, Gregoire; Panaretakis, Theoharis; Casares, Noelia; Metivier, Didier; Larochette, Nathanael; van Endert, Peter; Ciccosanti, Fabiola; Piacentini, Mauro; Zitvogel, Laurence; Kroemer, Guido			Calreticulin exposure dictates the immunogenicity of cancer cell death	NATURE MEDICINE			English	Article							DENDRITIC CELLS; APOPTOTIC CELLS; ENDOPLASMIC-RETICULUM; SURFACE CALRETICULIN; DYING CELLS; TUMOR; CLEARANCE; ANTIGEN; CHAPERONE; BINDING	Anthracyclin-treated tumor cells are particularly effective in eliciting an anticancer immune response, whereas other DNA-damaging agents such as etoposide and mitomycin C do not induce immunogenic cell death. Here we show that anthracyclins induce the rapid, preapoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knockdown of CRT suppressed the phagocytosis of anthracyclin-treated tumor cells by dendritic cells and abolished their immunogenicity in mice. The anthracyclin-induced CRT translocation was mimicked by inhibition of the protein phosphatase 1/GADD34 complex. Administration of recombinant CRT or inhibitors of protein phosphatase 1/GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify CRT as a key feature determining anticancer immune responses and delineate a possible strategy for immunogenic chemotherapy.	INSERM, U848, F-94805 Villejuif, France; Inst Gustave Roussy, F-94805 Villejuif, France; Univ Paris 11, Fac Paris Sud, F-94805 Villejuif, France; INSERM, U805, F-94805 Villejuif, France; Natl Inst Infect Dis Lazzaro Spallanzani, I-00149 Rome, Italy; Hop Necker Enfants Malad, INSERM, U580, F-75015 Paris, France; Univ Paris 05, F-75015 Paris, France; Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); IRCCS Lazzaro Spallanzani; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; University of Rome Tor Vergata	Obeid, M (corresponding author), INSERM, U848, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Casares, Noelia/AAA-5568-2019; Mignot, Grégoire/R-4976-2017; Ciccosanti, Fabiola/B-5284-2017; Kroemer, Guido/AAY-9859-2020; OBEID, Michel/HCI-9145-2022; Apetoh, Lionel/G-3310-2014; PERFETTINI, Jean-Luc/N-4699-2017; van Endert, Peter/R-4606-2017; KROEMER, Guido/B-4263-2013; LAROCHETTE, Nathanael/R-4298-2017; Fimia, Gian Maria/K-3232-2016	Casares, Noelia/0000-0003-3817-6434; Mignot, Grégoire/0000-0002-0682-0152; Ciccosanti, Fabiola/0000-0003-0481-6878; Apetoh, Lionel/0000-0002-2774-438X; PERFETTINI, Jean-Luc/0000-0002-2427-2604; van Endert, Peter/0000-0003-3782-0750; KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Fimia, Gian Maria/0000-0003-4438-3325; ZITVOGEL, laurence/0000-0003-1596-0998; ghiringhelli, francois/0000-0002-5465-8305; Panaretakis, Theocharis/0000-0001-5754-6950				Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Bedard K, 2005, INT REV CYTOL, V245, P91, DOI 10.1016/S0074-7696(05)45004-4; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; Blacher NE, 2005, PLOS BIOL, V3, P1070, DOI 10.1371/journal.pbio.0030185; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Cheng WF, 2006, CANCER GENE THER, V13, P873, DOI 10.1038/sj.cgt.7700956; Culina S, 2004, J BIOL CHEM, V279, P54210, DOI 10.1074/jbc.M410841200; Gaipl US, 2006, CURR TOP MICROBIOL, V305, P161, DOI 10.1007/3-540-29714-6_8; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Gelebart P, 2005, INT J BIOCHEM CELL B, V37, P260, DOI 10.1016/j.biocel.2004.02.030; Gupta V, 1997, J MED CHEM, V40, P3199, DOI 10.1021/jm960873x; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Henson PM, 2006, TRENDS IMMUNOL, V27, P244, DOI 10.1016/j.it.2006.03.005; Hsieh CJ, 2004, VACCINE, V22, P3993, DOI 10.1016/j.vaccine.2004.03.057; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kim SJ, 2006, BIOCHEM BIOPH RES CO, V339, P463, DOI 10.1016/j.bbrc.2005.11.040; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Lake RA, 2006, NEW ENGL J MED, V354, P2503, DOI 10.1056/NEJMcibr061443; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Steinman RM, 2004, SCIENCE, V305, P197, DOI 10.1126/science.1099688; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Williams DB, 2006, J CELL SCI, V119, P615, DOI 10.1242/jcs.02856; Yoshida H, 2005, NATURE, V437, P754, DOI 10.1038/nature03964; ZAMZAMI N, 2003, METH MOL B, V282, P103; Zhang KZ, 2004, J BIOL CHEM, V279, P25935, DOI 10.1074/jbc.R400008200; Zitvogel L, 2004, ADV IMMUNOL, V84, P131, DOI 10.1016/S0065-2776(04)84004-5; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	35	2070	2197	25	335	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					54	61		10.1038/nm1523	http://dx.doi.org/10.1038/nm1523			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17187072				2022-12-25	WOS:000243301800036
J	Carroll, JS; Meyer, CA; Song, J; Li, W; Geistlinger, TR; Eeckhoute, J; Brodsky, AS; Keeton, EK; Fertuck, KC; Hall, GF; Wang, QB; Bekiranov, S; Sementchenko, V; Fox, EA; Silver, PA; Gingeras, TR; Liu, XS; Brown, M				Carroll, Jason S.; Meyer, Clifford A.; Song, Jun; Li, Wei; Geistlinger, Timothy R.; Eeckhoute, Jerome; Brodsky, Alexander S.; Keeton, Erika Krasnickas; Fertuck, Kirsten C.; Hall, Giles F.; Wang, Qianben; Bekiranov, Stefan; Sementchenko, Victor; Fox, Edward A.; Silver, Pamela A.; Gingeras, Thomas R.; Liu, X. Shirley; Brown, Myles			Genome-wide analysis of estrogen receptor binding sites	NATURE GENETICS			English	Article							BREAST-CANCER CELLS; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; ACTIVATION; REVEALS; PROGRESSION; RECRUITMENT; PROMOTERS; CHROMATIN; NETWORKS	The estrogen receptor is the master transcriptional regulator of breast cancer phenotype and the archetype of a molecular therapeutic target. We mapped all estrogen receptor and RNA polymerase II binding sites on a genome-wide scale, identifying the authentic cis binding sites and target genes, in breast cancer cells. Combining this unique resource with gene expression data demonstrates distinct temporal mechanisms of estrogen-mediated gene regulation, particularly in the case of estrogen-suppressed genes. Furthermore, this resource has allowed the identification of cis-regulatory sites in previously unexplored regions of the genome and the cooperating transcription factors underlying estrogen signaling in breast cancer.	Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biostat & Computat Biol, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Brown Univ, Labs Mol Med, Ctr Genom & Proteom, Providence, RI 02903 USA; Harvard Univ, Sch Med, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA; Affymetrix, Santa Clara, CA 95051 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Brown University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Affymetrix; Harvard University; Harvard Medical School	Liu, XS (corresponding author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	xsliu@jimmy.harvard.edu; myles_brown@dfci.harvard.edu	Brown, Myles/B-6906-2008; Li, Wei/A-8544-2009; Wang, Qianben/E-4267-2011; Pillay, Nischalan/F-9536-2012; Brown, Myles/AAX-5332-2021; Song, Jun S/E-2526-2016; Eeckhoute, Jerome/AAN-8219-2021	Brown, Myles/0000-0002-8213-1658; Song, Jun S/0000-0002-0422-2175; Eeckhoute, Jerome/0000-0002-7222-9264; Li, Wei/0000-0001-9931-5990; Liu, Xiaole/0000-0003-4736-7339; Carroll, Jason/0000-0003-3643-0080; Gingeras, Thomas/0000-0001-9106-3573	NCI NIH HHS [CA089393] Funding Source: Medline; NHGRI NIH HHS [R01 HG004069-01, R01 HG004069] Funding Source: Medline; NIDDK NIH HHS [DK074967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA089393] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK074967, R01DK074967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; Brodsky AS, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r64; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen ZP, 2004, ASIA PAC J OPER RES, V21, P393, DOI 10.1142/S0217595904000308; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Cicatiello L, 2004, MOL CELL BIOL, V24, P7260, DOI 10.1128/MCB.24.16.7260-7274.2004; Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8; Cirillo LA, 1998, EMBO J, V17, P244, DOI 10.1093/emboj/17.1.244; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; DARROCH JN, 1980, ANN STAT, V8, P522, DOI 10.1214/aos/1176345006; DUBIK D, 1992, ONCOGENE, V7, P1587; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Ghosh MG, 2000, CANCER RES, V60, P6367; Hoch RV, 1999, INT J CANCER, V84, P122; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; JOHNSON WE, 2006, IN PRESS P NATL ACAD; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lazennec G, 1995, GENE, V166, P243, DOI 10.1016/0378-1119(95)00601-X; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Liu XS, 2002, NAT BIOTECHNOL, V20, P835, DOI 10.1038/nbt717; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Nishidate T, 2004, INT J ONCOL, V25, P797; O'Lone R, 2004, MOL ENDOCRINOL, V18, P1859, DOI 10.1210/me.2003-0044; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prefontaine GG, 1999, J BIOL CHEM, V274, P26713, DOI 10.1074/jbc.274.38.26713; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; SONG JG, UNPUB; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Teyssier C, 2003, MOL ENDOCRINOL, V17, P287, DOI 10.1210/me.2002-0324; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van Steensel B, 2005, NAT GENET, V37, pS18, DOI 10.1038/ng1559; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672	49	1036	1066	0	69	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1289	1297		10.1038/ng1901	http://dx.doi.org/10.1038/ng1901			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17013392				2022-12-25	WOS:000241592700017
J	Peters, U; Cherian, J; Kim, JH; Kwok, BH; Kapoor, TM				Peters, Ulf; Cherian, Joseph; Kim, Jeffrey H.; Kwok, Benjamin H.; Kapoor, Tarun M.			Probing cell-division phenotype space and Polo-like kinase function using small molecules	NATURE CHEMICAL BIOLOGY			English	Article							METAPHASE CHROMOSOME ALIGNMENT; CHEMICAL GENETICS; FORCE GENERATION; AURORA-B; INHIBITORS; PROTEIN; MITOSIS; MECHANISMS; CHECKPOINT; CANCER	Cell-permeable small molecules that inhibit their targets on fast timescales are powerful probes of cell-division mechanisms. Such inhibitors have been identified using phenotype-based screens with chemical libraries. However, the characteristics of compound libraries needed to effectively span cell-division phenotype space, to find probes that target different mechanisms, are not known. Here we show that a small collection of 100 diaminopyrimidines (DAPs) yields a range of cell-division phenotypes, including changes in spindle geometry, chromosome positioning and mitotic index. Monopolar mitotic spindles are induced by four inhibitors, including one that targets Polo-like kinases (Plks), evolutionarily conserved serine/threonine kinases. Using chemical inhibitors and high-resolution live-cell microscopy, we found that Plk activity is needed for the assembly and maintenance of bipolar mitotic spindles. Plk inhibition destabilizes kinetochore microtubules while stabilizing other spindle microtubules, leading to monopolar spindles. Further testing of compounds based on 'privileged scaffolds', such as the DAP scaffold, could lead to new cell-division probes and antimitotic agents.	Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA	Rockefeller University	Kapoor, TM (corresponding author), Rockefeller Univ, Lab Chem & Cell Biol, 1230 York Ave, New York, NY 10021 USA.	kapoor@rockefeller.edu	Cherian, Joseph/Q-2522-2016	Peters, Ulf/0000-0003-4664-8198; Cherian, Joseph/0000-0003-2663-7192	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM071772] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM71772] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Aronov AM, 2004, J MED CHEM, V47, P5616, DOI 10.1021/jm049793g; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Breault GA, 2003, BIOORG MED CHEM LETT, V13, P2961, DOI 10.1016/S0960-894X(03)00203-8; Burdine L, 2004, CHEM BIOL, V11, P593, DOI 10.1016/j.chembiol.2004.05.001; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; DAVISWARD D, 2004, Patent No. 2004074244; De Corte BL, 2005, J MED CHEM, V48, P1689, DOI 10.1021/jm040127p; Dogterom M, 2005, CURR OPIN CELL BIOL, V17, P67, DOI 10.1016/j.ceb.2004.12.011; EVANS BE, 1988, J MED CHEM, V31, P2235, DOI 10.1021/jm00120a002; Feng BY, 2005, NAT CHEM BIOL, V1, P146, DOI 10.1038/nchembio718; Fitzgerald K, 2005, CURR OPIN DRUG DISC, V8, P557; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gruber J, 2002, J CELL SCI, V115, P4053, DOI 10.1242/jcs.00088; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Holt SV, 2005, J CELL SCI, V118, P4889, DOI 10.1242/jcs.02614; Hotha S, 2003, ANGEW CHEM INT EDIT, V42, P2379, DOI 10.1002/anie.200351173; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; Kittler R, 2005, CELL CYCLE, V4, P564; Knight ZA, 2005, CHEM BIOL, V12, P621, DOI 10.1016/j.chembiol.2005.04.011; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lampson MA, 2006, NAT CHEM BIOL, V2, P19, DOI 10.1038/nchembio757; Legendre P., 1998, NUMERICAL ECOLOGY, V24; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lipinski C, 2004, NATURE, V432, P855, DOI 10.1038/nature03193; McEwen BF, 1997, J CELL BIOL, V137, P1567, DOI 10.1083/jcb.137.7.1567; McInnes C, 2005, CURR TOP MED CHEM, V5, P181, DOI 10.2174/1568026053507660; MCINNES C, 2004, Patent No. 2004067000; Mitchison TJ, 2001, NAT CELL BIOL, V3, pE17, DOI 10.1038/35050656; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Niiya F, 2005, J BIOL CHEM, V280, P36502, DOI 10.1074/jbc.M508007200; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sorbera LA, 2004, DRUG FUTURE, V29, P455, DOI 10.1358/dof.2004.029.05.807945; Specht KM, 2002, CURR OPIN CELL BIOL, V14, P155, DOI 10.1016/S0955-0674(02)00317-4; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tan DS, 2005, NAT CHEM BIOL, V1, P74, DOI 10.1038/nchembio0705-74; Tanaka M, 2005, PLOS BIOL, V3, P764, DOI 10.1371/journal.pbio.0030128; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Waters JC, 1996, MOL BIOL CELL, V7, P1547, DOI 10.1091/mbc.7.10.1547; Zhu CJ, 2005, MOL BIOL CELL, V16, P3187, DOI 10.1091/mbc.E05-02-0167	51	98	100	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2006	2	11					618	626		10.1038/nchembio826	http://dx.doi.org/10.1038/nchembio826			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	098BC	17028580				2022-12-25	WOS:000241494000014
J	Tegeder, I; Costigan, M; Griffin, RS; Abele, A; Belfer, I; Schmidt, H; Ehnert, C; Nejim, J; Marian, C; Scholz, J; Wu, TX; Allchorne, A; Diatchenko, L; Binshtok, AM; Goldman, D; Adolph, J; Sama, S; Atlas, SJ; Carlezon, WA; Parsegian, A; Lotsch, J; Fillingim, RB; Maixner, W; Geisslinger, G; Max, MB; Woolf, CJ				Tegeder, Irmgard; Costigan, Michael; Griffin, Robert S.; Abele, Andrea; Belfer, Inna; Schmidt, Helmut; Ehnert, Corina; Nejim, Jemiel; Marian, Claudiu; Scholz, Joachim; Wu, Tianxia; Allchorne, Andrew; Diatchenko, Luda; Binshtok, Alexander M.; Goldman, David; Adolph, Jan; Sama, Swetha; Atlas, Steven J.; Carlezon, William A.; Parsegian, Aram; Loetsch, Joern; Fillingim, Roger B.; Maixner, William; Geisslinger, Gerd; Max, Mitchell B.; Woolf, Clifford J.			GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence	NATURE MEDICINE			English	Article							PERIPHERAL-NERVE INJURY; MAINE LUMBAR SPINE; NITRIC-OXIDE; DORSAL-HORN; I GENE; LAPAROSCOPIC CHOLECYSTECTOMY; NONSURGICAL MANAGEMENT; GABAERGIC INHIBITION; NEUROPATHIC PAIN; PROTEIN	We report that GTP cyclohydrolase (GCH1), the rate-limiting enzyme for tetrahydrobiopterin (BH4) synthesis, is a key modulator of peripheral neuropathic and inflammatory pain. BH4 is an essential cofactor for catecholamine, serotonin and nitric oxide production. After axonal injury, concentrations of BH4 rose in primary sensory neurons, owing to upregulation of GCH1. After peripheral inflammation, BH4 also increased in dorsal root ganglia (DRGs), owing to enhanced GCH1 enzyme activity. Inhibiting this de novo BH4 synthesis in rats attenuated neuropathic and inflammatory pain and prevented nerve injury-evoked excess nitric oxide production in the DRG, whereas administering BH4 intrathecally exacerbated pain. In humans, a haplotype of the GCH1 gene (population frequency 15.4%) was significantly associated with less pain following diskectomy for persistent radicular low back pain. Healthy individuals homozygous for this haplotype exhibited reduced experimental pain sensitivity, and forskolinstimulated immortalized leukocytes from haplotype carriers upregulated GCH1 less than did controls. BH4 is therefore an intrinsic regulator of pain sensitivity and chronicity, and the GTP cyclohydrolase haplotype is a marker for these traits.	Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Frankfurt, Pharmazentrum, Inst Klin Pharmakol, Zentrum Arzneimittelforsch Entwicklung & Sicherhe, D-60590 Frankfurt, Germany; NIAAA, Neurogenet Lab, Dept Hlth & Human Serv, NIH, Rockville, MD 20852 USA; Natl Inst Dent & Craniofacial Res, Dept Hlth & Human Serv, NIH, Bethesda, MD 20892 USA; Univ N Carolina, Ctr Neurosensory Disorders, Sch Dent, Chapel Hill, NC 27599 USA; Univ Florida, Coll Dent, Gainesville, FL 32608 USA; Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Clin Epidemiol Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Psychiat, McLean Hosp, Belmont, MA 02478 USA; Howard Hughes Med Inst, Natl Inst Hlth Res Scholars Program, Bethesda, MD 20892 USA	Harvard University; Massachusetts General Hospital; Harvard University; Goethe University Frankfurt; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Carolina; University of North Carolina Chapel Hill; State University System of Florida; University of Florida; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; McLean Hospital; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA	Woolf, CJ (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Neural Plast Res Grp, 149 13th St,Room 4309, Charlestown, MA 02129 USA.	cwoolf@partners.org	Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020; Fillingim, Roger/K-3569-2019; Woolf, Clifford/A-9784-2010; Tegeder, Irmgard/AAM-2266-2020; Tegeder, Irmgard/AAM-2246-2020	Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405; Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025; Binshtok, Alexander/0000-0002-3620-8116; /0000-0002-4162-3947; Fillingim, Roger/0000-0002-7699-8183; Lotsch, Jorn/0000-0002-5818-6958	NIAAA NIH HHS [Z01 AA000301] Funding Source: Medline; NIDCR NIH HHS [DE07509, Z01 DE00366, DE16558] Funding Source: Medline; NINDS NIH HHS [NS045685, NS038253, NS052623, NS039518] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016558, P01DE007509, Z01DE000366, P50DE007509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038253, R01NS039518, R03NS052623, R37NS039518, P01NS045685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000281, Z01AA000301, Z01AA000303, Z01AA000302] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Atlas SJ, 1996, SPINE, V21, P1777, DOI 10.1097/00007632-199608010-00011; Atlas SJ, 2005, SPINE, V30, P927, DOI 10.1097/01.brs.0000158954.68522.2a; Baba H, 2003, MOL CELL NEUROSCI, V24, P818, DOI 10.1016/S1044-7431(03)00236-7; Bauer M, 2002, J NEUROCHEM, V82, P1300, DOI 10.1046/j.1471-4159.2002.01074.x; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Bisgaard T, 2005, SCAND J GASTROENTERO, V40, P1358, DOI 10.1080/00365520510023675; Bonafe L, 2001, AM J HUM GENET, V69, P269, DOI 10.1086/321970; Choi HJ, 2000, MOL PHARMACOL, V58, P633, DOI 10.1124/mol.58.3.633; Costigan M, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-16; Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016/S0304-3959(00)00276-1; Diatchenko L, 2005, HUM MOL GENET, V14, P135, DOI 10.1093/hmg/ddi013; Frank S, 1998, J INVEST DERMATOL, V111, P1058, DOI 10.1046/j.1523-1747.1998.00434.x; Hagenah J, 2005, NEUROLOGY, V64, P908, DOI 10.1212/01.WNL.0000152839.50258.A2; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hastie BA, 2005, PAIN, V116, P227, DOI 10.1016/j.pain.2005.04.016; Hesslinger C, 1998, J BIOL CHEM, V273, P21616, DOI 10.1074/jbc.273.34.21616; Hirayama K, 2001, J NEUROCHEM, V79, P576, DOI 10.1046/j.1471-4159.2001.00583.x; Huang CC, 2003, MOL PHARMACOL, V64, P521, DOI 10.1124/mol.64.2.521; ICHINOSE H, 1994, NAT GENET, V8, P236, DOI 10.1038/ng1194-236; Kapatos G, 2000, J BIOL CHEM, V275, P5947, DOI 10.1074/jbc.275.8.5947; Kolinsky MA, 2004, J BIOL CHEM, V279, P40677, DOI 10.1074/jbc.M405370200; KOSHIMURA K, 1994, J NEUROCHEM, V63, P649; Lewin MR, 1999, NAT NEUROSCI, V2, P18, DOI 10.1038/4520; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MacGregor AJ, 2004, ARTHRIT RHEUM-ARTHR, V51, P160, DOI 10.1002/art.20236; Mague SD, 2003, J PHARMACOL EXP THER, V305, P323, DOI 10.1124/jpet.102.046433; Maita N, 2002, P NATL ACAD SCI USA, V99, P1212, DOI 10.1073/pnas.022646999; Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700; MILSTIEN S, 1983, BIOCHEM BIOPH RES CO, V115, P888, DOI 10.1016/S0006-291X(83)80018-7; Mogil JS, 1999, PAIN, V80, P67, DOI 10.1016/S0304-3959(98)00197-3; Mogil JS, 2003, P NATL ACAD SCI USA, V100, P4867, DOI 10.1073/pnas.0730053100; Moore KA, 2002, J NEUROSCI, V22, P6724, DOI 10.1523/jneurosci.22-15-06724.2002; Pan ZH, 1996, P NATL ACAD SCI USA, V93, P15423, DOI 10.1073/pnas.93.26.15423; Porreca F, 2002, TRENDS NEUROSCI, V25, P319, DOI 10.1016/S0166-2236(02)02157-4; Rebelo J, 2003, J MOL BIOL, V326, P503, DOI 10.1016/S0022-2836(02)01303-7; Scholz J, 2005, J NEUROSCI, V25, P7317, DOI 10.1523/JNEUROSCI.1526-05.2005; Shiraki T, 1996, BIOCHEM BIOPH RES CO, V221, P181, DOI 10.1006/bbrc.1996.0566; Tegeder I, 2004, P NATL ACAD SCI USA, V101, P3253, DOI 10.1073/pnas.0304076101; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; Willis WD, 2001, ANN NY ACAD SCI, V933, P142; Wood JN, 2004, J NEUROBIOL, V61, P55, DOI 10.1002/neu.20094; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Woolf CJ, 1999, P NATL ACAD SCI USA, V96, P7723, DOI 10.1073/pnas.96.14.7723; Xie LJ, 1998, J BIOL CHEM, V273, P21091, DOI 10.1074/jbc.273.33.21091; Yu XM, 1999, P NATL ACAD SCI USA, V96, P7697, DOI 10.1073/pnas.96.14.7697; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546	49	410	434	2	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1269	1277		10.1038/nm1490	http://dx.doi.org/10.1038/nm1490			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17057711				2022-12-25	WOS:000241844900024
J	Yoshida, T; Inoue, R; Morii, T; Takahashi, N; Yamamoto, S; Hara, Y; Tominaga, M; Shimizu, S; Sato, Y; Mori, Y				Yoshida, Takashi; Inoue, Ryuji; Morii, Takashi; Takahashi, Nobuaki; Yamamoto, Shinichiro; Hara, Yuji; Tominaga, Makoto; Shimizu, Shunichi; Sato, Yoji; Mori, Yasuo			Nitric oxide activates TRP channels by cysteine S-nitrosylation	NATURE CHEMICAL BIOLOGY			English	Article							VASCULAR ENDOTHELIAL-CELLS; CAPACITATIVE CA2+ ENTRY; RECEPTOR POTENTIAL CHANNELS; UNION-OF-PHARMACOLOGY; ION-CHANNEL; CALCIUM STORES; RELEASE; FAMILY; SIGNAL; DEATH	Transient receptor potential (TRP) proteins form plasma-membrane cation channels that act as sensors for diverse cellular stimuli. Here, we report a novel activation mechanism mediated by cysteine S-nitrosylation in TRP channels. Recombinant TRPC1, TRPC4, TRPC5, TRPV1, TRPV3 and TRPV4 of the TRPC and TRPV families, which are commonly classified as receptor-activated channels and thermosensor channels, induce entry of Ca2+ into cells in response to nitric oxide (NO). Labeling and functional assays using cysteine mutants, together with membrane sidedness in activating reactive disulfides, show that cytoplasmically accessible Cys553 and nearby Cys558 are nitrosylation sites mediating NO sensitivity in TRPC5. The responsive TRP proteins have conserved cysteines on the same N-terminal side of the pore region. Notably, nitrosylation of native TRPC5 upon G protein-coupled ATP receptor stimulation elicits entry of Ca2+ into endothelial cells. These findings reveal the structural motif for the NO-sensitive activation gate in TRP channels and indicate that NO sensors are a new functional category of cellular receptors extending over different TRP families.	Kyoto Univ, Dept Synthet Chem & Biol Chem, Grad Sch Engn, Kyoto 6158510, Japan; Natl Inst Physiol Sci, Ctr Integrat Biosci, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Aichi 4448585, Japan; Fukuoka Univ, Dept Physiol, Fukuoka 8140180, Japan; Kyoto Univ, Inst Adv Energy, Kyoto 6110011, Japan; Showa Univ, Dept Pathophysiol, Sch Pharmaceut Sci, Tokyo 1428555, Japan; Natl Inst Hlth Sci, Div Cellular & Gene Therapy Prod, Tokyo 1588510, Japan	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; Fukuoka University; Kyoto University; Showa University; National Institute of Health Sciences - Japan	Mori, Y (corresponding author), Kyoto Univ, Dept Synthet Chem & Biol Chem, Grad Sch Engn, Kyoto 6158510, Japan.	mori@sbchem.kyoto-u.ac.jp	Takahashi, Nobuaki/AAG-9411-2019; Morii, Takashi/AAL-1392-2020	Takahashi, Nobuaki/0000-0002-0606-3921; Morii, Takashi/0000-0003-3663-3267				Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chang AS, 1997, FEBS LETT, V415, P335, DOI 10.1016/S0014-5793(97)01155-1; Chen J, 2000, J BIOL CHEM, V275, P28739, DOI 10.1074/jbc.M000910200; Choi YB, 2000, NAT NEUROSCI, V3, P15, DOI 10.1038/71090; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2005, PHARMACOL REV, V57, P427, DOI 10.1124/pr.57.4.6; Dedkova EN, 2002, J PHYSIOL-LONDON, V539, P77, DOI 10.1113/jphysiol.2001.013258; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hutcheson IR, 1997, BRIT J PHARMACOL, V122, P117, DOI 10.1038/sj.bjp.0701340; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; Jin YJ, 2004, NEUROSCI LETT, V369, P250, DOI 10.1016/j.neulet.2004.07.059; Khan SA, 2003, CURR OPIN DRUG DI DE, V6, P658; Koliwad SK, 1996, J PHYSIOL-LONDON, V491, P1; Koyama T, 2002, LIFE SCI, V72, P511, DOI 10.1016/S0024-3205(02)02246-4; Kwan HY, 2000, J BIOL CHEM, V275, P6758, DOI 10.1074/jbc.275.10.6758; Lantoine F, 1998, BIOCHEM J, V330, P695, DOI 10.1042/bj3300695; Li NZ, 2003, J NEUROSCI, V23, P10302; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; Moncada S, 1997, PHARMACOL REV, V49, P137; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Mungrue IN, 2004, J CELL SCI, V117, P2627, DOI 10.1242/jcs.01187; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Patapoutian A, 2003, NAT REV NEUROSCI, V4, P529, DOI 10.1038/nrn1141; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Tang XD, 2003, NATURE, V425, P531, DOI 10.1038/nature02003; Thyagarajan B, 2001, J BIOL CHEM, V276, P48149, DOI 10.1074/jbc.M103977200; Tousova K, 2004, NEUROPHARMACOLOGY, V47, P273, DOI 10.1016/j.neuropharm.2004.04.001; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Vazquez G, 2004, BBA-MOL CELL RES, V1742, P21, DOI 10.1016/j.bbamcr.2004.08.015; Venema VJ, 1998, BIOCHEM BIOPH RES CO, V246, P70, DOI 10.1006/bbrc.1998.8574; Voets T, 2005, NAT CHEM BIOL, V1, P85, DOI 10.1038/nchembio0705-85; Volk T, 1997, J CELL PHYSIOL, V172, P296, DOI 10.1002/(SICI)1097-4652(199709)172:3<296::AID-JCP3>3.0.CO;2-J; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Xu SZ, 2005, NAT BIOTECHNOL, V23, P1289, DOI 10.1038/nbt1148; Yamada H, 2000, NEUROSCI LETT, V285, P111, DOI 10.1016/S0304-3940(00)01033-8; Yao XQ, 2005, CIRC RES, V97, P853, DOI 10.1161/01.RES.0000187473.85419.3e; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; ZAIDI NF, 1989, J BIOL CHEM, V264, P21725; Zeng FN, 2004, J PHYSIOL-LONDON, V559, P739, DOI 10.1113/jphysiol.2004.065391; Zeng XH, 2003, NAT STRUCT BIOL, V10, P448, DOI 10.1038/nsb932; Zhang N, 2005, J NEUROSCI, V25, P2761, DOI 10.1523/JNEUROSCI.3195-04.2005; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	50	425	447	3	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2006	2	11					596	607		10.1038/nchembio821	http://dx.doi.org/10.1038/nchembio821			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	098BC	16998480				2022-12-25	WOS:000241494000012
J	Janssens, H; Hou, SL; Jaeger, J; Kim, AR; Myasnikova, E; Sharp, D; Reinitz, J				Janssens, Hilde; Hou, Shuling; Jaeger, Johannes; Kim, Ah-Ram; Myasnikova, Ekaterina; Sharp, David; Reinitz, John			Quantitative and predictive model of transcriptional control of the Drosophila melanogaster even skipped gene	NATURE GENETICS			English	Article							SEGMENTATION GENES; EXPRESSION; STRIPE; DNA; ENHANCERS; PATTERNS; PROTEIN; REQUIREMENT; GRADIENTS; ELEMENTS	Here we present a quantitative and predictive model of the transcriptional readout of the proximal 1.7 kb of the control region of the Drosophila melanogaster gene even skipped ( eve). The model is based on the positions and sequence of individual binding sites on the DNA and quantitative, time-resolved expression data at cellular resolution. These data demonstrated new expression features, first reported here. The model correctly predicts the expression patterns of mutations in trans, as well as point mutations, insertions and deletions in cis. It also shows that the nonclassical expression of stripe 7 driven by this fragment is activated by the protein Caudal (Cad), and repressed by the proteins Tailless (TII) and Giant (Gt).	SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA; St Petersburg State Polytech Univ, Ctr Adv Studies, Dept Computat Biol, St Petersburg 195251, Russia; Los Alamos Natl Lab, Chief Sci Off, Los Alamos, NM 87545 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; United States Department of Energy (DOE); Los Alamos National Laboratory; Peter the Great St. Petersburg Polytechnic University; United States Department of Energy (DOE); Los Alamos National Laboratory	Reinitz, J (corresponding author), SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.	reinitz@odd.bio.sunysb.edu	Myasnikova, Ekaterina/I-2711-2017	Jaeger, Johannes/0000-0002-2568-2103; Kim, Ah-Ram/0000-0002-7860-9137	NCRR NIH HHS [2 R01 RR07801, R01 RR007801] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007801] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arnosti DN, 1996, DEVELOPMENT, V122, P205; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; Berman BP, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r61; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; CAPOVILLA M, 1992, DEVELOPMENT, V114, P99; Clyde DE, 2003, NATURE, V426, P849, DOI 10.1038/nature02189; EISNER J, 1996, SINGULAR SPECTRUM AN; Fujioka M, 1995, DEVELOPMENT, V121, P4371; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; Hughes SC, 1999, METH MOL B, V122, P93; Jaeger J, 2004, GENETICS, V167, P1721, DOI 10.1534/genetics.104.027334; Janssens H, 2005, DEV GENES EVOL, V215, P374, DOI 10.1007/s00427-005-0484-y; Kosman D, 1998, DEV GENES EVOL, V208, P290, DOI 10.1007/s004270050184; Lam J, 1988, 8816 YAL EL ENG DEP; Lam J, 1988, 8817 YAL EL ENG DEP; Ludwig MZ, 2005, PLOS BIOL, V3, P588, DOI 10.1371/journal.pbio.0030093; Myasnikova E, 2005, DEV GENES EVOL, V215, P320, DOI 10.1007/s00427-005-0472-2; Myasnikova E, 2001, BIOINFORMATICS, V17, P3, DOI 10.1093/bioinformatics/17.1.3; Nagaso H, 2001, J HISTOCHEM CYTOCHEM, V49, P1177, DOI 10.1177/002215540104900911; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; Rajewsky N, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-30; REINITZ J, 1995, MECH DEVELOP, V49, P133, DOI 10.1016/0925-4773(94)00310-J; Reinitz John, 2003, ComPlexUs, V1, P54, DOI 10.1159/000070462; ROTHE M, 1994, MECH DEVELOP, V46, P169, DOI 10.1016/0925-4773(94)90069-8; Schroeder MD, 2004, PLOS BIOL, V2, P1396, DOI 10.1371/journal.pbio.0020271; SMALL S, 1993, DEVELOPMENT, V119, P767; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Small S, 1996, DEV BIOL, V175, P314, DOI 10.1006/dbio.1996.0117; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; Wu XL, 2001, DEV BIOL, V237, P79, DOI 10.1006/dbio.2001.0355; Yuh CH, 2001, DEVELOPMENT, V128, P617	38	152	156	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1159	1165		10.1038/ng1886	http://dx.doi.org/10.1038/ng1886			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16980977				2022-12-25	WOS:000241251100015
J	Lippard, SJ				Lippard, Stephen J.			The inorganic side of chemical biology	NATURE CHEMICAL BIOLOGY			English	Editorial Material							CHEMISTRY; MECHANISM	Bioinorganic chemistry remains a vibrant discipline at the interface of chemistry and the biological sciences. Metal ions function in numerous metalloenzymes, are incorporated into pharmaceuticals and imaging agents, and inspire the synthesis of catalysts used to achieve many chemical transformations.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave,Room 18-498, Cambridge, MA 02139 USA.	lippard@mit.edu						Benini S, 1999, STRUCTURE, V7, P205, DOI 10.1016/S0969-2126(99)80026-4; Burdette SC, 2003, P NATL ACAD SCI USA, V100, P3605, DOI 10.1073/pnas.0637711100; Caravan P., 2005, MED INORGANIC CHEM, P166; Crichton R.R., 2006, METAL BASED NEURODEG; Dempsey JL, 2005, INORG CHEM, V44, P6879, DOI 10.1021/ic0509276; HAZES B, 1993, PROTEIN SCI, V2, P597; Holm RH, 2004, CHEM REV, V104, P347, DOI 10.1021/cr0206364; KITAJIMA N, 1989, J AM CHEM SOC, V111, P8975, DOI 10.1021/ja00206a062; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Morrison KL, 2006, NAT CHEM BIOL, V2, P3, DOI 10.1038/nchembio0106-3; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; Thompson KH, 2003, SCIENCE, V300, P936, DOI 10.1126/science.1083004; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	15	63	64	6	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2006	2	10					504	507		10.1038/nchembio1006-504	http://dx.doi.org/10.1038/nchembio1006-504			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	095IX	16983380				2022-12-25	WOS:000241302500002
J	Kang, TH; Kim, KT				Kang, Tae-Hong; Kim, Kyong-Tai			Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase	NATURE CELL BIOLOGY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; VACCINIA-RELATED KINASE-1; MAP KINASE; CATALYTIC ACTIVATION; NEURITE OUTGROWTH; GENE FAMILY; IN-VIVO; PHOSPHORYLATION; BINDING; JNK	Extracellular signal regulated kinases ( ERKs) represent a signalling hub in many physiological responses and have pivotal functions in cell proliferation, differentiation, development and death, as well as in synaptic plasticity(1,2). Mitogen-activated protein kinase phosphatases ( MKPs) selectively inactivate ERKs by dephosphorylating critical phosphothreonine and phosphotyrosine residues(3,4). Transcriptional induction of MKP expression(5,6) and posttranscriptional stabilization of MKP mRNA7 are well-documented as negative-feedback mechanisms for ERK signalling. Vaccinia-related kinase 3 ( VRK3) is a member of the novel VRK family(8,9), but its function has not been defined. Here, we show that VRK3 suppresses ERK activity through direct binding to one of the MKPs, vaccinia H1-related ( VHR)(10), which specifically dephosphorylates and inactivates ERK in the nucleus(11). Notably, VRK3 enhances the phosphatase activity of VHR by a mechanism independent of its kinase activity. VRK3 is therefore a member of a new class of phosphatase-activating kinases that regulate the activity of ERK. Our findings show that direct interaction of VHR with VRK3 posttranslationally regulates ERK signalling.	Pohang Univ Sci & Technol, Dept Life Sci, Biotechnol Res Ctr, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH)	Kim, KT (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Biotechnol Res Ctr, Div Mol & Life Sci, San 31,Hyoja Dong, Pohang 790784, South Korea.	ktk@postech.ac.kr	Kang, Tae-Hong/Y-8294-2019	Kang, Tae-Hong/0000-0002-6013-900X; KIM, KYONG-TAI/0000-0001-7292-2627				Alonso A, 2003, NAT IMMUNOL, V4, P44, DOI 10.1038/ni856; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Brondello JM, 1999, SCIENCE, V286, P2514, DOI 10.1126/science.286.5449.2514; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Castelli M, 2004, J BIOL CHEM, V279, P44731, DOI 10.1074/jbc.M407669200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Farooq A, 2001, MOL CELL, V7, P387, DOI 10.1016/S1097-2765(01)00186-1; Gwag BJ, 1998, MOL BRAIN RES, V63, P53, DOI 10.1016/S0169-328X(98)00251-4; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Marchetti S, 2005, MOL CELL BIOL, V25, P854, DOI 10.1128/MCB.25.2.854-864.2005; Masuda K, 2003, J BIOL CHEM, V278, P32448, DOI 10.1074/jbc.M213254200; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Olsson AK, 2001, EXP CELL RES, V265, P21, DOI 10.1006/excr.2001.5163; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Sevilla A, 2004, ONCOGENE, V23, P8950, DOI 10.1038/sj.onc.1208015; Sevilla A, 2004, J BIOL CHEM, V279, P27458, DOI 10.1074/jbc.M401009200; Sugiura R, 2003, NATURE, V424, P961, DOI 10.1038/nature01907; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vega FM, 2004, MOL CELL BIOL, V24, P10366, DOI 10.1128/MCB.24.23.10366-10380.2004; Vega FM, 2003, FEBS LETT, V544, P176, DOI 10.1016/S0014-5793(03)00501-5; Volmat V, 2001, J CELL SCI, V114, P3433; Watanabe H, 2004, J BIOL CHEM, V279, P37870, DOI 10.1074/jbc.M402610200; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328	30	64	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					863	U126		10.1038/ncb1447	http://dx.doi.org/10.1038/ncb1447			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16845380				2022-12-25	WOS:000239423000017
J	Banci, L; Bertini, I; Cantini, F; Felli, IC; Gonnelli, L; Hadjiliadis, N; Pierattelli, R; Rosato, A; Voulgaris, P				Banci, Lucia; Bertini, Ivano; Cantini, Francesca; Felli, Isabella C.; Gonnelli, Leonardo; Hadjiliadis, Nick; Pierattelli, Roberta; Rosato, Antonio; Voulgaris, Petros			The Atx1-Ccc2 complex is a metal-mediated protein-protein interaction	NATURE CHEMICAL BIOLOGY			English	Article							COPPER CHAPERONE; MENKES PROTEIN; DISEASE PROTEINS; METALLOCHAPERONE; DOMAIN; INTERPLAY; ATPASE; ATOX1; ATP7A; ATX1	Cellular systems allow transition-metal ions to reach or leave the cell or intracellular locations through metal transfer between proteins. By coupling mutagenesis and advanced NMR experiments, we structurally characterized the adduct between the copper chaperone Atx1 and the first copper(I)-binding domain of the Ccc2 ATPase. Copper was required for the interaction. This study provides an understanding of metal-mediated protein-protein interactions in which the metal ion is essential for the weak, reversible interaction between the partners.	Univ Florence, Magnet Resonance Ctr, CERM, I-50019 Sesto Fiorentino, Italy; Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy; Univ Ioannina, Dept Chem, Sect Inorgan & Analyt Chem, GR-45110 Ioannina, Greece	University of Florence; University of Florence; University of Ioannina	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr, CERM, Via L Sacconi 6, I-50019 Sesto Fiorentino, Italy.	ivanobertini@cerm.unifi.it	Cantini, Francesca/O-1220-2015; Rosato, Antonio/M-3250-2019; Rosato, Antonio/D-8548-2011; Pierattelli, Roberta/F-9439-2012; Hadjikakou, Sotiris K./I-2909-2019; Felli, Isabella C./O-1751-2015	Cantini, Francesca/0000-0003-0526-6732; Rosato, Antonio/0000-0001-6172-0368; Rosato, Antonio/0000-0001-6172-0368; Pierattelli, Roberta/0000-0001-7755-0885; Hadjikakou, Sotiris K./0000-0001-9556-6266; Felli, Isabella C./0000-0002-6018-9090; BANCI, LUCIA/0000-0003-0562-5774				Achila D, 2006, P NATL ACAD SCI USA, V103, P5729, DOI 10.1073/pnas.0504472103; Arnesano F, 2001, J BIOL CHEM, V276, P41365, DOI 10.1074/jbc.M104807200; Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Banci L, 2005, J BIOL CHEM, V280, P38259, DOI 10.1074/jbc.M506219200; Banci L, 2005, J MOL BIOL, V352, P409, DOI 10.1016/j.jmb.2005.07.034; Banci L, 2005, FEBS J, V272, P865, DOI 10.1111/j.1742-4658.2004.04526.x; Banci L, 2003, BIOCHEMISTRY-US, V42, P1939, DOI 10.1021/bi027096p; Banci L, 2001, J BIOL CHEM, V276, P8415, DOI 10.1074/jbc.M008389200; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Strausak D, 2003, J BIOL CHEM, V278, P20821, DOI 10.1074/jbc.M212437200; Tanchou V, 2004, BIOCHEM BIOPH RES CO, V325, P388, DOI 10.1016/j.bbrc.2004.10.048; van Dongen EMWM, 2004, BIOCHEM BIOPH RES CO, V323, P789, DOI 10.1016/j.bbrc.2004.08.160; Walker JM, 2004, J BIOL CHEM, V279, P15376, DOI 10.1074/jbc.M400053200; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766	14	179	182	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2006	2	7					367	368		10.1038/nchembio797	http://dx.doi.org/10.1038/nchembio797			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	054KV	16732294				2022-12-25	WOS:000238376400010
J	Guccione, E; Martinato, F; Finocchiaro, G; Luzi, L; Tizzoni, L; Dall'Olio, V; Zardo, G; Nervi, C; Bernard, L; Amati, B				Guccione, Ernesto; Martinato, Francesca; Finocchiaro, Giacomo; Luzi, Lucilla; Tizzoni, Laura; Dall'Olio, Valentina; Zardo, Giuseppe; Nervi, Clara; Bernard, Loris; Amati, Bruno			Myc-binding-site recognition in the human genome is determined by chromatin context	NATURE CELL BIOLOGY			English	Article							HISTONE MODIFICATIONS; C-MYC; ACTIVE GENES; METHYLATION; ACETYLATION; H3; PATTERNS; PROMOTER; NETWORK; PROTEIN	Large-scale chromatin immunoprecipitation ( ChIP) studies have been effective in unravelling the distribution of DNA-binding transcription factors along eukaryotic genomes(1), but specificity determinants remain elusive. Gene-regulatory regions display distinct histone variants and modifications ( or marks)(2-15). An attractive hypothesis is that these marks modulate protein recognition(16-18), but whether or not this applies to transcription factors remains unknown. Based on large-scale datasets(2,19-21) and quantitative ChIP, we dissect the correlations between 35 histone marks and genomic binding by the transcription factor Myc. Our data reveal a relatively simple combinatorial organization of histone marks in human cells, with a few main groups of marks clustering on distinct promoter populations. A stretch of chromatin bearing high H3 K4/K79 methylation and H3 acetylation ( or 'euchromatic island'), which is generally associated with a pre-engaged basal transcription machinery(12,13), is a strict prerequisite for recognition of any target site by Myc ( whether the consensus CACGTG or an alternative sequence)(22). These data imply that tethering of a transcription factor to restricted chromatin domains is rate-limiting for sequence-specific DNA binding in vivo.	European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy; IFOM, FIRC, Inst Mol Oncol, I-20139 Milan, Italy; Real Time PCR Facil, I-20139 Milan, Italy; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, I-00128 Rome, Italy; San Raffaele BioMed Pk Fdn, I-00128 Rome, Italy; Univ Roma La Sapienza, Dept Histol & Med Embryol, Rome, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; Sapienza University Rome; Sapienza University Rome	Amati, B (corresponding author), European Inst Oncol, Dept Expt Oncol, IFOM-IEO Campus, I-20139 Milan, Italy.	bruno.amati@ifom-ieo-campus.it	Luzi, Lucilla/K-4350-2018; guccione, ernesto/G-9874-2011; Amati, Bruno/AAM-3418-2020	Luzi, Lucilla/0000-0002-8746-4179; Amati, Bruno/0000-0002-2958-1799; NERVI, Clara/0000-0001-9341-0188				Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Blais A, 2005, GENE DEV, V19, P1499, DOI 10.1101/gad.1325605; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kouskouti A, 2005, EMBO J, V24, P347, DOI 10.1038/sj.emboj.7600516; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; McKinney K, 2004, MOL CELL, V16, P413, DOI 10.1016/j.molcel.2004.09.032; Perini G, 2005, P NATL ACAD SCI USA, V102, P12117, DOI 10.1073/pnas.0409097102; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Schreiber SL, 2002, CELL, V111, P771, DOI 10.1016/S0092-8674(02)01196-0; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Szutorisz H, 2005, MOL CELL BIOL, V25, P1804, DOI 10.1128/MCB.25.5.1804-1820.2005; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wirbelauer C, 2005, GENE DEV, V19, P1761, DOI 10.1101/gad.347705	31	295	298	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					764	U225		10.1038/ncb1434	http://dx.doi.org/10.1038/ncb1434			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16767079				2022-12-25	WOS:000238837800020
J	Jung, CR; Hwang, KS; Yoo, J; Cho, WK; Kim, JM; Kim, WH; Im, DS				Jung, Cho-Rok; Hwang, Kyung-Sun; Yoo, Jinsang; Cho, Won-Kyung; Kim, Jin-Man; Kim, Woo Ho; Im, Dong-Soo			E2-EPF UCP targets pVHL for degradation and associates with tumor growth and metastasis	NATURE MEDICINE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; UBIQUITIN CARRIER PROTEIN; HIPPEL-LINDAU PROTEIN; SUPPRESSOR PROTEIN; SOLID TUMOR; MOLECULAR-BASIS; CELL-GROWTH; IN-VIVO; VHL; COMPLEX	The von Hippel-Lindau tumor suppressor, pVHL, forms part of an E3 ubiquitin ligase complex that targets specific substrates for degradation, including hypoxia-inducible factor-1 alpha (HIF-1 alpha), which is involved in tumor progression and angiogenesis. It remains unclear, however, how pVHL is destabilized. Here we show that E2-EPF ubiquitin carrier protein (UCP) associates with and targets pVHL for ubiquitin-mediated proteolysis in cells, thereby stabilizing HIF-1 alpha. UCP is detected coincidently with HIF-1 alpha in human primary liver, colon and breast tumors, and metastatic cholangiocarcinoma and colon cancer cells. UCP level correlates inversely with pVHL level in most tumor cell lines. In vitro and in vivo, forced expression of UCP boosts tumor-cell proliferation, invasion and metastasis through effects on the pVHL-HIF pathway. Our results suggest that UCP helps stabilize HIF-1 alpha and may be a new molecular target for therapeutic intervention in human cancers.	Korea Res Inst Biosci & Biotechnol, Gene Therapy Res Unit, Taejon 305333, South Korea; Chung Nam Natl Univ, Dept Pathol, Sch Med, Taejon 301721, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 110799, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; Seoul National University (SNU)	Im, DS (corresponding author), Korea Res Inst Biosci & Biotechnol, Gene Therapy Res Unit, Taejon 305333, South Korea.	imdongsu@kribb.re.kr	Kim, Wooho/G-3703-2011	, cho-rok/0000-0002-4474-6563; KIM, JIN MAN/0000-0003-0905-9730				Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003; Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Bilton RL, 2003, EUR J BIOCHEM, V270, P791, DOI 10.1046/j.1432-1033.2003.03446.x; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cho WK, 2004, MOL THER, V10, P938, DOI 10.1016/j.ymthe.2004.07.023; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jung CR, 2006, HEPATOLOGY, V43, P1042, DOI 10.1002/hep.21137; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 2002, J BIOL CHEM, V277, P30388, DOI 10.1074/jbc.M203344200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lee DH, 2003, CANCER RES, V63, P4648; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Liu Z, 1996, J BIOL CHEM, V271, P2817, DOI 10.1074/jbc.271.5.2817; LIU Z, 1992, J BIOL CHEM, V267, P15829; Los M, 1996, LAB INVEST, V75, P231; Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rho J, 2001, J VIROL, V75, P8031, DOI 10.1128/JVI.75.17.8031-8044.2001; Rho J, 2001, J BIOL CHEM, V276, P11393, DOI 10.1074/jbc.M008660200; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sakyo T, 2002, BBA-BIOMEMBRANES, V1567, P165, DOI 10.1016/S0005-2736(02)00613-2; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schwartz AL, 1999, ANNU REV MED, V50, P57; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu PY, 2003, EMBO J, V22, P5241, DOI 10.1093/emboj/cdg501; Zhong H, 2002, CANCER LETT, V181, P233, DOI 10.1016/S0304-3835(02)00053-8; Zhong H, 1999, CANCER RES, V59, P5830	49	98	105	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					809	816		10.1038/nm1440	http://dx.doi.org/10.1038/nm1440			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16819549				2022-12-25	WOS:000238862800068
J	Keurentjes, JJB; Fu, JY; de Vos, CHR; Lommen, A; Hall, RD; Bino, RJ; van der Plas, LHW; Jansen, RC; Vreugdenhil, D; Koornneef, M				Keurentjes, Joost J. B.; Fu, Jingyuan; Ric de Vos, C. H.; Lommen, Arjen; Hall, Robert D.; Bino, Raoul J.; van der Plas, Linus H. W.; Jansen, Ritsert C.; Vreugdenhil, Dick; Koornneef, Maarten			The genetics of plant metabolism	NATURE GENETICS			English	Article							QUANTITATIVE TRAIT LOCI; INTEGRATIVE GENOMICS APPROACH; ARABIDOPSIS-THALIANA; SECONDARY METABOLISM; SHOOT DEVELOPMENT; EXPRESSION; DIVERSIFICATION; CONSTRUCTION; METABOLOMICS; ASSOCIATIONS	Variation for metabolite composition and content is often observed in plants. However, it is poorly understood to what extent this variation has a genetic basis. Here, we describe the genetic analysis of natural variation in the metabolite composition in Arabidopsis thaliana. Instead of focusing on specific metabolites, we have applied empirical untargeted metabolomics using liquid chromatography-time of flight mass spectrometry (LC-QTOF MS). This uncovered many qualitative and quantitative differences in metabolite accumulation between A. thaliana accessions. Only 13.4% of the mass peaks were detected in all 14 accessions analyzed. Quantitative trait locus (QTL) analysis of more than 2,000 mass peaks, detected in a recombinant inbred line (RIL) population derived from the two most divergent accessions, enabled the identification of QTLs for about 75% of the mass signals. More than one-third of the signals were not detected in either parent, indicating the large potential for modification of metabolic composition through classical breeding.	Univ Wageningen & Res Ctr, Genet Lab, NL-6703 BD Wageningen, Netherlands; Univ Wageningen & Res Ctr, Lab Plant Physiol, NL-6703 BD Wageningen, Netherlands; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Groningen Bioinformat Ctr, NL-9751 NN Haren, Netherlands; Plant Res Int, NL-6708 PB Wageningen, Netherlands; Ctr Biosyst Genom, NL-6708 PB Wageningen, Netherlands; RIKILT, Inst Food Safety, NL-6700 AE Wageningen, Netherlands; Max Planck Inst Plant Breeding Res, D-50829 Cologne, Germany	Wageningen University & Research; Wageningen University & Research; University of Groningen; Centre for BioSystems Genomics; Wageningen University & Research; Max Planck Society	Koornneef, M (corresponding author), Univ Wageningen & Res Ctr, Genet Lab, Arboretumlaan 4, NL-6703 BD Wageningen, Netherlands.	maarten.koornneef@wur.nl	Jansen, Ritsert C/C-1160-2013; Fu, JY/GRR-6179-2022; HALL, ROBERT D/B-8707-2015; De Vos, Ric/F-5012-2017; Fu, Jingyuan/E-8980-2012; Fu, Jingyuan/ABE-6868-2020	Jansen, Ritsert C/0000-0003-2977-9110; HALL, ROBERT D/0000-0002-5786-768X; Fu, Jingyuan/0000-0001-5578-1236; Keurentjes, Joost/0000-0001-8918-0711; Koornneef, Maarten/0000-0002-7759-4869				Alba R, 2005, PLANT CELL, V17, P2954, DOI 10.1105/tpc.105.036053; Alonso-Blanco C, 1998, PLANT J, V14, P259, DOI 10.1046/j.1365-313X.1998.00115.x; Bentsink L, 2000, PLANT PHYSIOL, V124, P1595, DOI 10.1104/pp.124.4.1595; Bing N, 2005, GENETICS, V170, P533, DOI 10.1534/genetics.105.041103; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Broman KW, 2003, GENETICS, V163, P1169; D'Auria JC, 2005, CURR OPIN PLANT BIOL, V8, P308, DOI 10.1016/j.pbi.2005.03.012; de Koning DJ, 2005, TRENDS GENET, V21, P377, DOI 10.1016/j.tig.2005.05.004; de la Fuente A, 2004, BIOINFORMATICS, V20, P3565, DOI 10.1093/bioinformatics/bth445; DeCook R, 2006, GENETICS, V172, P1155, DOI 10.1534/genetics.105.042275; Dixon RA, 2005, CURR OPIN PLANT BIOL, V8, P329, DOI 10.1016/j.pbi.2005.03.008; Hobbs DH, 2004, PLANT PHYSIOL, V136, P3341, DOI 10.1104/pp.104.049486; JANSEN RC, 1993, GENETICS, V135, P205; Jansen RC, 2003, NAT REV GENET, V4, P145, DOI 10.1038/nrg996; Jansen RC, 2001, TRENDS GENET, V17, P388, DOI 10.1016/S0168-9525(01)02310-1; Kliebenstein DJ, 2001, GENETICS, V159, P359; Kliebenstein DJ, 2001, PLANT CELL, V13, P681, DOI 10.1105/tpc.13.3.681; Kliebenstein DJ, 2001, PLANT PHYSIOL, V126, P811, DOI 10.1104/pp.126.2.811; Koornneef M, 2004, ANNU REV PLANT BIOL, V55, P141, DOI 10.1146/annurev.arplant.55.031903.141605; Kroymann J, 2001, PLANT PHYSIOL, V127, P1077, DOI 10.1104/pp.010416; Lall S, 2004, GENETICS, V167, P1883, DOI 10.1534/genetics.103.025213; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 2004, BIOTECHNOL BIOENG, V87, P623, DOI 10.1002/bit.20154; Loudet O, 2003, PLANT PHYSIOL, V131, P345, DOI 10.1104/pp.102.010785; Lumba S, 2005, CURR OPIN PLANT BIOL, V8, P501, DOI 10.1016/j.pbi.2005.07.015; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; Mita S, 1997, PLANT J, V11, P841, DOI 10.1046/j.1365-313X.1997.11040841.x; Mitchell-Olds T, 1998, GENETICS, V149, P739; Oksman-Caldentey KM, 2005, CURR OPIN BIOTECH, V16, P174, DOI 10.1016/j.copbio.2005.02.007; Reichelt M, 2002, PHYTOCHEMISTRY, V59, P663, DOI 10.1016/S0031-9422(02)00014-6; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; STAM P, 1993, PLANT J, V3, P739, DOI 10.1111/j.1365-313X.1993.00739.x; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tikunov Y, 2005, PLANT PHYSIOL, V139, P1125, DOI 10.1104/pp.105.068130; Vorst O, 2005, METABOLOMICS, V1, P169, DOI 10.1007/s11306-005-4432-7; Windsor AJ, 2005, PHYTOCHEMISTRY, V66, P1321, DOI 10.1016/j.phytochem.2005.04.016; WINK M, 1988, THEOR APPL GENET, V75, P225, DOI 10.1007/BF00303957; Zhu J, 2004, CYTOGENET GENOME RES, V105, P363, DOI 10.1159/000078209	39	358	381	1	124	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					842	849		10.1038/ng1815	http://dx.doi.org/10.1038/ng1815			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16751770	Green Published			2022-12-25	WOS:000238669300023
J	Schubert, C				Schubert, Charlotte			Can biofuels finally take center stage?	NATURE BIOTECHNOLOGY			English	Article								Today, ethanol and biodiesel are predominantly produced from corn kernels, sugarcane or soybean oil. But researchers and investors are increasingly upbeat about another biofuel feedstock, lignocellulose - the most abundant biological material on earth.										Farrell AE, 2006, SCIENCE, V311, P506, DOI 10.1126/science.1121416; Talukder K, 2006, NAT BIOTECHNOL, V24, P395, DOI 10.1038/nbt0406-395; Tilman D, 2006, NATURE, V441, P629, DOI 10.1038/nature04742	3	255	271	2	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					777	784		10.1038/nbt0706-777	http://dx.doi.org/10.1038/nbt0706-777			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16841058				2022-12-25	WOS:000239025100022
J	Shinin, V; Gayraud-Morel, B; Gomes, D; Tajbakhsh, S				Shinin, Vasily; Gayraud-Morel, Barbara; Gomes, Danielle; Tajbakhsh, Shahragim			Asymmetric division and cosegregation of template DNA strands in adult muscle satellite cells	NATURE CELL BIOLOGY			English	Article							STEM-CELLS; SKELETAL-MUSCLE; NEUROEPITHELIAL CELLS; PROGENITOR CELLS; BONE-MARROW; NUMB; DROSOPHILA; SEGREGATION; FATE; SPECIFICATION	Satellite cells assure postnatal skeletal muscle growth and repair. Despite extensive studies, their stem cell character remains largely undefined. Using pulse-chase labelling with BrdU to mark the putative stem cell niche, we identify a subpopulation of label-retaining satellite cells during growth and after injury. Strikingly, some of these cells display selective template-DNA strand segregation during mitosis in the muscle fibre in vivo, as well as in culture independent of their niche, indicating that genomic DNA strands are nonequivalent. Furthermore, we demonstrate that the asymmetric cell-fate determinant Numb segregates selectively to one daughter cell during mitosis and before differentiation, suggesting that Numb is associated with self-renewal. Finally, we show that template DNA cosegregates with Numb in label-retaining cells that express the self-renewal marker Pax7. The cosegregation of 'immortal' template DNA strands and their link with the asymmetry apparatus has important implications for stem cell biology and cancer.	Inst Pasteur, Dept Dev Biol, CNRS, URA 2578, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Tajbakhsh, S (corresponding author), Inst Pasteur, Dept Dev Biol, CNRS, URA 2578, 25 Rue Dr Roux, F-75724 Paris 15, France.	shaht@pasteur.fr		Shinin, Vasily/0000-0002-4285-6515				Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Bhalerao S, 2005, CURR BIOL, V15, P1583, DOI 10.1016/j.cub.2005.07.061; BISCHOFF R, 1970, J CELL BIOL, V44, P134, DOI 10.1083/jcb.44.1.134; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cairns J, 2002, P NATL ACAD SCI USA, V99, P10567, DOI 10.1073/pnas.162369899; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Carmena A, 1998, GENE DEV, V12, P304, DOI 10.1101/gad.12.3.304; Cayouette M, 2002, NAT NEUROSCI, V5, P1265, DOI 10.1038/nn1202-1265; Chang P, 2000, NAT CELL BIOL, V2, P30, DOI 10.1038/71350; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gomez MR, 1997, DEVELOPMENT, V124, P4857; Hutterer A, 2005, EMBO REP, V6, P836, DOI 10.1038/sj.embor.7400500; Karpowicz P, 2005, J CELL BIOL, V170, P721, DOI 10.1083/jcb.200502073; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Kassar-Duchossoy L, 2004, NATURE, V431, P466, DOI 10.1038/nature02876; KUROKI T, 1989, JPN J CANCER RES, V80, P637, DOI 10.1111/j.1349-7006.1989.tb01690.x; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Merok JR, 2002, CANCER RES, V62, P6791; Mikkers H, 2005, EMBO J, V24, P2715, DOI 10.1038/sj.emboj.7600749; Morris RJ, 1999, J INVEST DERMATOL, V112, P470, DOI 10.1046/j.1523-1747.1999.00537.x; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Ogino H, 2002, J BIOCHEM, V132, P953, DOI 10.1093/oxfordjournals.jbchem.a003309; Petersen PH, 2006, DEV NEUROSCI-BASEL, V28, P156, DOI 10.1159/000090761; Petersen PH, 2002, NATURE, V419, P929, DOI 10.1038/nature01124; Potten CS, 2002, J CELL SCI, V115, P2381; POTTEN CS, 1978, CELL, V15, P899, DOI 10.1016/0092-8674(78)90274-X; Rambhatla L., 2001, J BIOMED BIOTECHNOL, V1, P28, DOI DOI 10.1155/S1110724301000079; Reugels AM, 2006, DEV DYNAM, V235, P934, DOI 10.1002/dvdy.20699; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Roegiers F, 2004, CURR OPIN CELL BIOL, V16, P195, DOI 10.1016/j.ceb.2004.02.010; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Smith GH, 2005, DEVELOPMENT, V132, P681, DOI 10.1242/dev.01609; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; Tajbakhsh S, 2005, EXP CELL RES, V306, P364, DOI 10.1016/j.yexcr.2005.03.033; Tajbakhsh S, 1996, NATURE, V384, P266, DOI 10.1038/384266a0; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; Verdi JM, 1999, P NATL ACAD SCI USA, V96, P10472, DOI 10.1073/pnas.96.18.10472; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Zammit PS, 2001, DIFFERENTIATION, V68, P193, DOI 10.1046/j.1432-0436.2001.680407.x; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2; Zhong WM, 2003, NEURON, V37, P11, DOI 10.1016/S0896-6273(02)01178-9	51	358	376	0	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					677	U69		10.1038/ncb1425	http://dx.doi.org/10.1038/ncb1425			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16799552				2022-12-25	WOS:000238837800010
J	Henderson, IR; Zhang, XY; Lu, C; Johnson, L; Meyers, BC; Green, PJ; Jacobsen, SE				Henderson, Ian R.; Zhang, Xiaoyu; Lu, Cheng; Johnson, Lianna; Meyers, Blake C.; Green, Pamela J.; Jacobsen, Steven E.			Dissecting Arabidopsis thaliana DICER function in small RNA processing, gene silencing and DNA methylation patterning	NATURE GENETICS			English	Article							TRANS-ACTING SIRNAS; INTERFERING RNA; DE-NOVO; BIOGENESIS; GENOME; METHYLTRANSFERASE; DICER-LIKE-4; MAINTENANCE; COMPONENT	Small RNAs have several important biological functions(1). MicroRNAs (miRNAs) and trans-acting small interfering RNAs (tasiRNAs) regulate mRNA stability and translation, and siRNAs cause post-transcriptional gene silencing of transposons, viruses and transgenes and are important in both the establishment and maintenance of cytosine DNA methylation(2). Here, we study the role of the four Arabidopsis thaliana DICER-LIKE genes (DCL1-DCL4) in these processes. Sequencing of small RNAs from a dcl2 dcl3 dcl4 triple mutant showed markedly reduced tasiRNA and siRNA production and indicated that DCL1, in addition to its role as the major enzyme for processing miRNAs, has a previously unknown role in the production of small RNAs from endogenous inverted repeats. DCL2, DCL3 and DCL4 showed functional redundancy in siRNA and tasiRNA production and in the establishment and maintenance of DNA methylation. Our studies also suggest that asymmetric DNA methylation can be maintained by pathways that do not require siRNAs.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Delaware Biotechnol Inst, Newark, DE 19714 USA; Univ Delaware, Dept Plant & Soil Sci, Newark, DE 19714 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of Delaware; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Jacobsen, SE (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.	jacobsen@ucla.edu	Zhang, xiaoyu/GXA-3206-2022; Henderson, Ian/A-2174-2012; Meyers, Blake/B-6535-2012	Meyers, Blake/0000-0003-3436-6097; Henderson, Ian/0000-0001-5066-1489	NIGMS NIH HHS [GM60398] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM060398, R01GM060398] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen E, 2005, CELL, V121, P207, DOI 10.1016/j.cell.2005.04.004; Allen E, 2004, NAT GENET, V36, P1282, DOI 10.1038/ng1478; Cam HP, 2005, NAT GENET, V37, P809, DOI 10.1038/ng1602; Cao XF, 2002, CURR BIOL, V12, P1138, DOI 10.1016/S0960-9822(02)00925-9; Chan SWL, 2005, NAT REV GENET, V6, P351, DOI 10.1038/nrg1601; Chan SWL, 2004, SCIENCE, V303, P1336, DOI 10.1126/science.1095989; Dunoyer P, 2005, NAT GENET, V37, P1356, DOI 10.1038/ng1675; Gasciolli V, 2005, CURR BIOL, V15, P1494, DOI 10.1016/j.cub.2005.07.024; Hamilton A, 2002, EMBO J, V21, P4671, DOI 10.1093/emboj/cdf464; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jacobsen SE, 2000, CURR BIOL, V10, P179, DOI 10.1016/S0960-9822(00)00324-9; Li JJ, 2005, CURR BIOL, V15, P1501, DOI 10.1016/j.cub.2005.07.029; Liu B, 2005, PLANT PHYSIOL, V139, P296, DOI 10.1104/pp.105.063420; Lu C, 2005, SCIENCE, V309, P1567, DOI 10.1126/science.1114112; Malagnac F, 2002, EMBO J, V21, P6842, DOI 10.1093/emboj/cdf687; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Qi Y, 2005, MOL CELL, V19, P421, DOI 10.1016/j.molcel.2005.06.014; SCHANK RC, 1991, J LEARN SCI, V1, P7; Shen BZ, 2004, SCIENCE, V306, P997, DOI 10.1126/science.1103521; Soppe WJJ, 2000, MOL CELL, V6, P791, DOI 10.1016/S1097-2765(05)00090-0; Valoczi A, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh171; Xie ZX, 2005, P NATL ACAD SCI USA, V102, P12984, DOI 10.1073/pnas.0506426102; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Yoder JA, 1997, J MOL BIOL, V270, P385, DOI 10.1006/jmbi.1997.1125; Yoshikawa M, 2005, GENE DEV, V19, P2164, DOI 10.1101/gad.1352605; Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130; Zilberman D, 2004, CURR BIOL, V14, P1214, DOI 10.1016/j.cub.2004.06.055	29	438	456	4	63	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2006	38	6					721	725		10.1038/ng1804	http://dx.doi.org/10.1038/ng1804			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16699516				2022-12-25	WOS:000237954800030
J	Netea, MG; Joosten, LAB; Lewis, E; Jensen, DR; Voshol, PJ; Kullberg, BJ; Tack, CJ; van Krieken, H; Kim, SH; Stalenhoef, AF; Van de Loo, FA; Verschueren, I; Pulawa, L; Akira, S; Eckel, RH; Dinarello, CA; Van den Berg, W; Van der Meer, JWM				Netea, MG; Joosten, LAB; Lewis, E; Jensen, DR; Voshol, PJ; Kullberg, BJ; Tack, CJ; van Krieken, H; Kim, SH; Stalenhoef, AF; Van de Loo, FA; Verschueren, I; Pulawa, L; Akira, S; Eckel, RH; Dinarello, CA; Van den Berg, W; Van der Meer, JWM			Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance	NATURE MEDICINE			English	Article							IFN-GAMMA PRODUCTION; CYTOKINE; IL-18; INHIBITION; TRANSDUCER; DISRUPTION; ACTIVATOR; STRESS; STAT3; SERUM	Here we report the presence of hyperphagia, obesity and insulin resistance in knockout mice deficient in IL-18 or IL-18 receptor, and in mice transgenic for expression of IL-18 binding protein. Obesity of II18(-/-) mice resulted from accumulation of fat tissue based on increased food intake. II18(-/-) mice also had hyperinsulinemia, consistent with insulin resistance and hyperglycemia. Insulin resistance was secondary to obesity induced by increased food intake and occurred at the liver level as well as at the muscle and fat-tissue level. The molecular mechanisms responsible for the hepatic insulin resistance in the II18(-/-) mice involved an enhanced expression of genes associated with gluconeogenesis in the liver of II18(-/-) mice, resulting from defective phosphorylation of STAT3. Recombinant IL-18 ( rIL-18) administered intracerebrally inhibited food intake. In addition, rIL-18 reversed hyperglycemia in II18(-/-) mice through activation of STAT3 phosphorylation. These findings indicate a new role of IL-18 in the homeostasis of energy intake and insulin sensitivity.	Dept Internal Med, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Ctr Infect Dis, NL-6500 HB Nijmegen, Netherlands; Univ Colorado, Hlth Sci Ctr, Div Infect Dis, Denver, CO 80262 USA; Radboud Univ, Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Rheumatol Res & Adv Therapeut, NL-6500 HB Nijmegen, Netherlands; Radboud Univ, Nijmegen Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan; Univ Colorado, Hlth Sci Ctr, Div Endocrinol, Aurora, CO 80045 USA; Leiden Univ, Med Ctr, Dept Endocrinol, NL-2333 ZA Leiden, Netherlands	Radboud University Nijmegen; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Radboud University Nijmegen; Radboud University Nijmegen; Osaka University; University of Colorado System; University of Colorado Anschutz Medical Campus; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Netea, MG (corresponding author), Dept Internal Med, Geert Grootepl 8, NL-6500 HB Nijmegen, Netherlands.	m.netea@aig.umcn.nl	LEWIS, ELI C/F-1552-2012; Kullberg, BJ/C-8520-2013; van Krieken, Joannes H J M/D-4138-2009; van de Loo, Fons AJ/A-3425-2014; Akira, Shizuo/C-3134-2009; Netea, Mihai/N-5155-2014; Joosten, Leo AB/H-3138-2015; Dinarello, Charles/C-8524-2013; Stalenhoef, A.F.H./H-8094-2014; van den Berg, W.B./H-8010-2014; Tack, Cees J/A-2368-2014; van der Meer, Jos W.M./C-8521-2013	LEWIS, ELI C/0000-0002-4189-2207; Kullberg, BJ/0000-0002-6813-8167; van Krieken, Joannes H J M/0000-0001-6544-1040; van de Loo, Fons AJ/0000-0002-5851-099X; Joosten, Leo AB/0000-0001-6166-9830; van der Meer, Jos W.M./0000-0001-5120-3690				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Blaskovich MA, 2003, CANCER RES, V63, P1270; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Escobar-Morreale HF, 2004, J CLIN ENDOCR METAB, V89, P806, DOI 10.1210/jc.2003-031365; Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gorogawa S, 2004, BIOCHEM BIOPH RES CO, V319, P1159, DOI 10.1016/j.bbrc.2004.05.095; Inoue H, 2004, NAT MED, V10, P168, DOI 10.1038/nm980; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; Joosten LAB, 2000, J IMMUNOL, V165, P6553, DOI 10.4049/jimmunol.165.11.6553; Kalina U, 2000, J IMMUNOL, V165, P1307, DOI 10.4049/jimmunol.165.3.1307; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Moriwaki Y, 2003, METABOLISM, V52, P605, DOI 10.1053/meta.2003.50096; Netea MG, 2000, J IMMUNOL, V164, P2644, DOI 10.4049/jimmunol.164.5.2644; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Pocai A, 2005, DIABETES, V54, P3182, DOI 10.2337/diabetes.54.11.3182; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Takeda K, 1998, IMMUNITY, V8, P383, DOI 10.1016/S1074-7613(00)80543-9; Ueki K, 2004, P NATL ACAD SCI USA, V101, P10422, DOI 10.1073/pnas.0402511101; Voshol PJ, 2001, DIABETES, V50, P2585, DOI 10.2337/diabetes.50.11.2585; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	25	323	329	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2006	12	6					650	656		10.1038/nm1415	http://dx.doi.org/10.1038/nm1415			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16732281				2022-12-25	WOS:000238149200026
J	Valente, EM; Silhavy, JL; Brancati, F; Barrano, G; Krishnaswami, SR; Castori, M; Lancaster, MA; Boltshauser, E; Boccone, L; Al-Gazali, L; Fazzi, E; Signorini, S; Louie, CM; Bellacchio, E; Bertini, E; Dallapiccola, B; Gleeson, JG				Valente, Enza Maria; Silhavy, Jennifer L.; Brancati, Francesco; Barrano, Giuseppe; Krishnaswami, Suguna Rani; Castori, Marco; Lancaster, Madeline A.; Boltshauser, Eugen; Boccone, Loredana; Al-Gazali, Lihadh; Fazzi, Elisa; Signorini, Sabrina; Louie, Carrie M.; Bellacchio, Emanuele; Bertini, Enrico; Dallapiccola, Bruno; Gleeson, Joseph G.		JSRD Study Grp	Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome	NATURE GENETICS			English	Article							ABNORMAL EYE-MOVEMENTS; EPISODIC HYPERPNEA; CEREBELLAR VERMIS; RETARDATION; DISORDERS; DISEASE; ATAXIA	Joubert syndrome-related disorders (JSRD) are a group of syndromes sharing the neuroradiological features of cerebellar vermis hypoplasia and a peculiar brainstem malformation known as the 'molar tooth sign'. We identified mutations in the CEP290 gene in five families with variable neurological, retinal and renal manifestations. CEP290 expression was detected mostly in proliferating cerebellar granule neuron populations and showed centrosome and ciliary localization, linking JSRDs to other human ciliopathies.	Mendel Inst Med Genet & Twin Res, Ist Ricovero & Cura Carattere Sci, I-00198 Rome, Italy; Univ Calif San Diego, Dept Neurosci, Lab Neurogenet, La Jolla, CA 92093 USA; G Annunzio Univ, Dept Biomed Sci, I-66013 Chieti, Italy; G DAnnunzio Univ Fdn, Aging Res Ctr, I-66013 Chieti, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00187 Rome, Italy; Childrens Univ Hosp, Dept Neurol, CH-8032 Zurich, Switzerland; Osped Microcitemico, I-09120 Cagliari, Italy; United Emirates Univ, Fac Med & Hlth Sci, Dept Pediat, Al Ain, U Arab Emirates; Univ Pavia, IRCCS C Mondino Fdn, Dept Child Neurol & Psychiat, I-27100 Pavia, Italy; IRCCS, Bambino Gesu Hosp, Dept Lab Med, Mol Med Unit, I-00165 Rome, Italy	University of California System; University of California San Diego; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; Sapienza University Rome; University Children's Hospital Zurich; United Arab Emirates University; IRCCS Fondazione Casimiro Mondino; University of Pavia; IRCCS Bambino Gesu	Valente, EM (corresponding author), Mendel Inst Med Genet & Twin Res, Ist Ricovero & Cura Carattere Sci, Viale Regina Margherita 261, I-00198 Rome, Italy.	e.valente@css-mendel.it; jogleeson@ucsd.edu	Bertini, Enrico/A-2284-2014; Valente, Enza Maria/G-2942-2017; Fazzi, Elisa/J-6076-2016; Brancati, Francesco/AAC-3778-2022; Bertini, Enrico/ABG-1278-2020; Castori, Marco/K-1099-2016; Bellacchio, Emanuele/AAH-9255-2019; Romano, Corrado/B-9695-2008; Signorini, Sabrina Giovanna/AAA-8467-2019; Dallapiccola, Bruno/K-8692-2016	Bertini, Enrico/0000-0001-9276-4590; Valente, Enza Maria/0000-0002-0600-6820; Fazzi, Elisa/0000-0003-4805-7906; Brancati, Francesco/0000-0003-3624-2354; Castori, Marco/0000-0002-6069-0993; Romano, Corrado/0000-0003-1049-0683; Bellacchio, Emanuele/0000-0002-2757-849X; Lancaster, Madeline/0000-0003-2324-8853; Dallapiccola, Bruno/0000-0002-5031-1013; Boccone, Loredana/0000-0002-0168-0322	NINDS NIH HHS [R01 NS048453] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048453] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Badano JL, 2005, NAT REV GENET, V6, P194, DOI 10.1038/nrg1557; BOLTSHAUSER E, 1977, NEUROPADIATRIE, V8, P57, DOI 10.1055/s-0028-1091505; Chen DH, 2001, BIOCHEM BIOPH RES CO, V280, P99, DOI 10.1006/bbrc.2000.4087; Dixon-Salazar T, 2004, AM J HUM GENET, V75, P979, DOI 10.1086/425985; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Ferland RJ, 2004, NAT GENET, V36, P1008, DOI 10.1038/ng1419; Gleeson JG, 2004, AM J MED GENET A, V125A, P125, DOI 10.1002/ajmg.a.20437; Hildebrandt F, 2005, NAT REV GENET, V6, P928, DOI 10.1038/nrg1727; JOUBERT M, 1969, NEUROLOGY, V19, P813, DOI 10.1212/WNL.19.9.813; Katsanis N, 2006, NAT GENET, V38, P135, DOI 10.1038/ng0206-135; Louie CM, 2005, HUM MOL GENET, V14, pR235, DOI 10.1093/hmg/ddi264; Maria BL, 1997, J CHILD NEUROL, V12, P423, DOI 10.1177/088307389701200703; Valente EM, 2005, ANN NEUROL, V57, P513, DOI 10.1002/ana.20422	14	288	300	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					623	625		10.1038/ng1805	http://dx.doi.org/10.1038/ng1805			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16682970				2022-12-25	WOS:000237954800014
J	Spinazzola, A; Viscomi, C; Fernandez-Vizarra, E; Carrara, F; D'Adamo, P; Calvo, S; Marsano, RM; Donnini, C; Weiher, H; Strisciuglio, P; Parini, R; Sarzi, E; Chan, A; DiMauro, S; Rotig, A; Gasparini, P; Ferrero, I; Mootha, VK; Tiranti, V; Zeviani, M				Spinazzola, A; Viscomi, C; Fernandez-Vizarra, E; Carrara, F; D'Adamo, P; Calvo, S; Marsano, RM; Donnini, C; Weiher, H; Strisciuglio, P; Parini, R; Sarzi, E; Chan, A; DiMauro, S; Rotig, A; Gasparini, P; Ferrero, I; Mootha, VK; Tiranti, V; Zeviani, M			MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; KIDNEY-DISEASE; GENE MPV17; MUTATIONS; IMPORT; DEFICIENCY; KINASE; CHAIN	The mitochondrial (mt) DNA depletion syndromes (MDDS) are genetic disorders characterized by a severe, tissue-specific decrease of mtDNA copy number, leading to organ failure. There are two main clinical presentations: myopathic (OMIM 609560) and hepatocerebral(1) (OMIM 251880). Known mutant genes, including TK2 (ref. 2), SUCLA2 (ref. 3), DGUOK (ref. 4) and POLG(5,6), account for only a fraction of MDDS cases(7). We found a new locus for hepatocerebral MDDS on chromosome 2p21-23 and prioritized the genes on this locus using a new integrative genomics strategy. One of the top-scoring candidates was the human ortholog of the mouse kidney disease gene Mpv17 (ref. 8). We found disease-segregating mutations in three families with hepatocerebral MDDS and demonstrated that, contrary to the alleged peroxisomal localization of the MPV17 gene product(9), MPV17 is a mitochondrial inner membrane protein, and its absence or malfunction causes oxidative phosphorylation (OXPHOS) failure and mtDNA depletion, not only in affected individuals but also in Mpv17(-/-) mice.	Natl Neurol Inst C Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, I-20126 Milan, Italy; Telethon Inst Genet Med TIGEM, Linkage Unit & Serv, I-80131 Naples, Italy; Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Syst Biol, Cambridge, MA 02138 USA; MIT, Broad Inst, Cambridge, MA 02446 USA; Harvard Univ, Cambridge, MA 02446 USA; Univ Parma, Dept Genet Anthropol Evolut, I-43100 Parma, Italy; Univ Appl Sci Bonn Rhein Sieg, D-53359 Bonn, Germany; Univ Catanzaro Magna Graecia, Dept Clin & Expt Med, I-88100 Catanzaro, Italy; Milano Bicocca State Univ, Univ Hosp, Pediat Unit, Pierfranco & Luisa Mariani Ctr Study Childrens Me, I-20052 Monza, Italy; Hop Necker Enfants Malad, Dept Genet, F-75015 Paris, France; Hop Necker Enfants Malad, INSERM Unit U393, F-75015 Paris, France; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2H7, Canada; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Univ Trieste, Dept Med Genet, I-34137 Trieste, Italy	IRCCS Istituto Neurologico Besta; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; University of Parma; Hochschule Bonn Rhein Sieg; Magna Graecia University of Catanzaro; University of Milano-Bicocca; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Alberta; Columbia University; University of Trieste	Zeviani, M (corresponding author), Natl Neurol Inst C Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, I-20126 Milan, Italy.	zeviani@istituto-besta.it	Donnini, Claudia/B-5548-2015; Zeviani, Massimo/K-2891-2014; Fernandez-Vizarra, Erika/AAE-5600-2020; Marsano, René Massimiliano/B-9640-2012; Tiranti, Valeria/AFN-5783-2022; Spinazzola, Antonella/P-5791-2019; viscomi, Carlo/R-1940-2016; Spinazzola, Antonella/P-5298-2017; d'Adamo, Adamo Pio/G-4064-2011; Gasparini, Paolo/B-6173-2014; Tiranti, Valeria/J-8233-2016; Rötig, Agnès/G-9592-2017; Zeviani, Massimo/AAU-2632-2021; Parini, Rossella/J-9202-2018	Donnini, Claudia/0000-0002-4901-2358; Marsano, René Massimiliano/0000-0001-8450-1010; Tiranti, Valeria/0000-0002-3584-7338; Spinazzola, Antonella/0000-0003-4242-8091; Spinazzola, Antonella/0000-0003-4242-8091; d'Adamo, Adamo Pio/0000-0001-9367-4909; Tiranti, Valeria/0000-0002-3584-7338; Rötig, Agnès/0000-0003-0589-0703; Zeviani, Massimo/0000-0002-9067-5508; Parini, Rossella/0000-0003-4505-1306; Gasparini, Paolo/0000-0002-0859-0856; Viscomi, Carlo/0000-0001-6050-0566; Fernandez-Vizarra, Erika/0000-0002-2469-142X; Sarzi, Emmanuelle/0000-0002-7623-6699	Telethon [TGM03P12, GGP030039, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006; Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776; Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843; Fernandez-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8; Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410; Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; Gallet PF, 1999, BBA-BIOMEMBRANES, V1418, P61, DOI 10.1016/S0005-2736(99)00022-X; GOTTESBERGE AMM, 1996, EUR ARCH OTO-RHINO-L, V253, P470; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Koehler CM, 2004, ANNU REV CELL DEV BI, V20, P309, DOI 10.1146/annurev.cellbio.20.010403.105057; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; MOUNOLOU JC, 1966, BIOCHEM BIOPH RES CO, V24, P218, DOI 10.1016/0006-291X(66)90723-6; Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70; OHBA M, 1987, EMBO J, V6, P2117, DOI 10.1002/j.1460-2075.1987.tb02478.x; OTSUKA M, 1988, NUCLEIC ACIDS RES, V16, P10916, DOI 10.1093/nar/16.22.10916; Petruzzella V, 1998, GENOMICS, V54, P494, DOI 10.1006/geno.1998.5580; Rehling P, 2003, J MOL BIOL, V326, P639, DOI 10.1016/S0022-2836(02)01440-7; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284; Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025; Tiranti V, 1999, HUM MOL GENET, V8, P2533, DOI 10.1093/hmg/8.13.2533; Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653; Trott A, 2004, EUKARYOT CELL, V3, P620, DOI 10.1128/EC.3.3.620-631.2004; WEIHER H, 1990, CELL, V62, P425, DOI 10.1016/0092-8674(90)90008-3; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A; ZWACKA RM, 1994, EMBO J, V13, P5129, DOI 10.1002/j.1460-2075.1994.tb06842.x	30	310	317	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					570	575		10.1038/ng1765	http://dx.doi.org/10.1038/ng1765			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16582910	Green Published			2022-12-25	WOS:000237147500020
J	Baltus, AE; Menke, DB; Hu, YC; Goodheart, ML; Carpenter, AE; de Rooij, DG; Page, DC				Baltus, Andrew E.; Menke, Douglas B.; Hu, Yueh-Chiang; Goodheart, Mary L.; Carpenter, Anne E.; de Rooij, Dirk G.; Page, David C.			In germ cells of mouse embryonic ovaries, the decision to enter meiosis precedes premeiotic DNA replication	NATURE GENETICS			English	Article							CHROMOSOME SYNAPSIS; PROTEIN; OOGENESIS; TESTIS; GENE	The transition from mitosis to meiosis is a defining juncture in the life cycle of sexually reproducing organisms. In yeast, the decision to enter meiosis is made before the single round of DNA replication that precedes the two meiotic divisions(1). We present genetic evidence of an analogous decision point in the germ line of a multicellular organism. The mouse Stra8 gene is expressed in germ cells of embryonic ovaries, where meiosis is initiated, but not in those of embryonic testes, where meiosis does not begin until after birth(2). Here we report that in female embryos lacking Stra8 gene function, the early, mitotic development of germ cells is normal, but these cells then fail to undergo premeiotic DNA replication, meiotic chromosome condensation, cohesion, synapsis and recombination. Combined with previous findings, these genetic data suggest that active differentiation of ovarian germ cells commences at a regulatory point upstream of premeiotic DNA replication.	MIT, Howard Hughes Med Inst, Cambridge, MA 02142 USA; MIT, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Univ Utrecht, Fac Biol, Dept Endocrinol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Cell Biol, NL-3584 CH Utrecht, Netherlands	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Utrecht University; Utrecht University	Page, DC (corresponding author), MIT, Howard Hughes Med Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	page_admin@wi.mit.edu	Hu, Yueh-Chiang/AAX-2370-2020; Carpenter, Anne/C-4982-2008; Holt, Janet E/B-2415-2013; de Rooij, D.G./AAW-1195-2021	Carpenter, Anne/0000-0003-1555-8261; de Rooij, Dirk/0000-0003-3932-4419; Hu, Yueh-Chiang/0000-0002-7992-0525; Menke, Douglas/0000-0002-7109-1451				Adams IR, 2002, DEVELOPMENT, V129, P1155; Albrecht KH, 2001, DEV BIOL, V240, P92, DOI 10.1006/dbio.2001.0438; Bannister LA, 2004, GENESIS, V40, P184, DOI 10.1002/gene.20085; Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; BORUM K, 1961, EXP CELL RES, V24, P495, DOI 10.1016/0014-4827(61)90449-9; Bowles J, 2006, SCIENCE, V312, P596, DOI 10.1126/science.1125691; Brennan J, 2004, NAT REV GENET, V5, P509, DOI 10.1038/nrg1381; Bullejos M, 2004, MOL REPROD DEV, V68, P422, DOI 10.1002/mrd.20105; CRONE M, 1965, EXP CELL RES, V39, P678, DOI 10.1016/0014-4827(65)90071-6; DEVICTOR M, 1979, J GENET HUM, V27, P21; Eijpe M, 2003, J CELL BIOL, V160, P657, DOI 10.1083/jcb.200212080; Fujiwara S, 2003, ZOOL SCI, V20, P809, DOI 10.2108/zsj.20.809; HARTUNG M, 1977, CYTOGENET CELL GENET, V18, P309, DOI 10.1159/000130777; Koubova J, 2006, P NATL ACAD SCI USA, V103, P2474, DOI 10.1073/pnas.0510813103; Lee J, 2003, J CELL SCI, V116, P2781, DOI 10.1242/jcs.00495; Marston AL, 2004, NAT REV MOL CELL BIO, V5, P983, DOI 10.1038/nrm1526; McLaren A, 1997, DEV BIOL, V187, P107, DOI 10.1006/dbio.1997.8584; Menke DB, 2003, DEV BIOL, V262, P303, DOI 10.1016/S0012-1606(03)00391-9; MOENS PB, 1995, CHROMOSOMA, V104, P175, DOI 10.1007/BF00352182; OuladAbdelghani M, 1996, J CELL BIOL, V135, P469, DOI 10.1083/jcb.135.2.469; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Prieto I, 2004, CHROMOSOME RES, V12, P197, DOI 10.1023/B:CHRO.0000021945.83198.0e; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; SPEED RM, 1982, CHROMOSOMA, V85, P427, DOI 10.1007/BF00330366; Toyooka Y, 2000, MECH DEVELOP, V93, P139, DOI 10.1016/S0925-4773(00)00283-5; Xu HL, 2005, DEV CELL, V8, P949, DOI 10.1016/j.devcel.2005.03.018; Yao HHC, 2003, DEVELOPMENT, V130, P5895, DOI 10.1242/dev.00836; YOSHIDA N, 1998, REC RES DEV FERMEN 1, V1, P1; Yuan L, 2000, MOL CELL, V5, P73, DOI 10.1016/S1097-2765(00)80404-9	30	366	389	1	39	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2006	38	12					1430	1434		10.1038/ng1919	http://dx.doi.org/10.1038/ng1919			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17115059				2022-12-25	WOS:000242404200021
J	Boyadjiev, SA; Fromme, JC; Ben, J; Chong, SS; Nauta, C; Hur, DJ; Zhang, G; Hamamoto, S; Schekman, R; Ravazzola, M; Orci, L; Eyaid, W				Boyadjiev, Simeon A.; Fromme, J. Christopher; Ben, Jin; Chong, Samuel S.; Nauta, Christopher; Hur, David J.; Zhang, George; Hamamoto, Susan; Schekman, Randy; Ravazzola, Mariella; Orci, Lelio; Eyaid, Wafaa			Cranio-lenticulo-sutural dysplasia is caused by a SEC23A mutation leading to abnormal endoplasmic-reticulumto-Golgi trafficking	NATURE GENETICS			English	Article							MEMBRANE-PROTEINS; CARGO SELECTION; COPII VESICLES; ER; TRANSPORT; COAT; COMPLEX; EXPORT; YEAST; DISORDERS	Cranio-lenticulo-sutural dysplasia (CLSD) is an autosomal recessive syndrome characterized by late-closing fontanels, sutural cataracts, facial dysmorphisms and skeletal defects mapped to chromosome 14q13-q21 (ref. 1). Here we show, using a positional cloning approach, that an F382L amino acid substitution in SEC23A segregates with this syndrome. SEC23A is an essential component of the COPII-coated vesicles that transport secretory proteins from the endoplasmic reticulum to the Golgi complex. Electron microscopy and immunofluorescence show that there is gross dilatation of the endoplasmic reticulum in fibroblasts from individuals affected with CLSD. These cells also exhibit cytoplasmic mislocalization of SEC31. Cell-free vesicle budding assays show that the F382L substitution results in loss of SEC23A function. A phenotype reminiscent of CLSD is observed in zebrafish embryos injected with sec23a-blocking morpholinos. Our observations suggest that disrupted endoplasmic reticulum export of the secretory proteins required for normal morphogenesis accounts for CLSD.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Univ Calif Davis, Dept Pediat, Genet Sect, Sacramento, CA 95817 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA; Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pediat, Singapore 119074, Singapore; Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; King Fahad Cent Hosp, Dept Pediat, Riyadh 11426, Saudi Arabia	Johns Hopkins University; University of California System; University of California Davis; Howard Hughes Medical Institute; University of California System; University of California Berkeley; National University of Singapore; University of Geneva	Boyadjiev, SA (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA.	simeon.boyd@ucdmc.ucdavis.edu	Hur, David J./AAV-8648-2020; Chong, Samuel S./D-8098-2015	Hur, David J./0000-0002-5604-3670; Chong, Samuel S./0000-0002-1872-5937; Fromme, J. Christopher/0000-0002-8837-0473	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE016342] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE00462, DE16342] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Antonny B, 2001, NAT CELL BIOL, V3, P531, DOI 10.1038/35078500; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Ben J, 2005, GENE EXPR PATTERNS, V5, P629, DOI 10.1016/j.modgep.2005.03.002; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Bottomley MJ, 2001, CURR BIOL, V11, P1114, DOI 10.1016/S0960-9822(01)00317-7; Boyadjiev SA, 2003, HUM GENET, V113, P1, DOI 10.1007/s00439-003-0932-6; Fisher L. W., 1989, CONNECT TISSUE RES, V21, P43; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; Kim J, 2005, J BIOL CHEM, V280, P7758, DOI 10.1074/jbc.M411091200; Matsuoka K, 2000, METHODS, V20, P417, DOI 10.1006/meth.2000.0955; Miller E, 2002, EMBO J, V21, P6105, DOI 10.1093/emboj/cdf605; Miller EA, 2003, CELL, V114, P497, DOI 10.1016/S0092-8674(03)00609-3; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; NOVICK P, 1983, J CELL BIOL, V96, P541, DOI 10.1083/jcb.96.2.541; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pagano A, 1999, J BIOL CHEM, V274, P7833, DOI 10.1074/jbc.274.12.7833; Roberts B, 2003, MOL BIOL CELL, V14, P4414, DOI 10.1091/mbc.E03-03-0162; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Tiller GE, 2001, AM J HUM GENET, V68, P1398, DOI 10.1086/320594; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Zhang B, 2003, NAT GENET, V34, P220, DOI 10.1038/ng1153	27	218	223	2	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2006	38	10					1192	1197		10.1038/ng1876	http://dx.doi.org/10.1038/ng1876			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16980979				2022-12-25	WOS:000241251100020
J	Chan, TL; Yuen, ST; Kong, CK; Chan, YW; Chan, ASY; Ng, WF; Tsui, WY; Lo, MWS; Tam, WY; Li, VSW; Leung, SY				Chan, Tsun Leung; Yuen, Siu Tsan; Kong, Chi Kwan; Chan, Yee Wai; Chan, Annie S. Y.; Ng, Wai Fu; Tsui, Wai Yin; Lo, Michelle W. S.; Tam, Wing Yip; Li, Vivian S. W.; Leung, Suet Yi			Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer	NATURE GENETICS			English	Article							MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; METHYLATION; HMLH1; MLH1; EXPRESSION; MUTATIONS; GENE	Epimutations in the germline, such as methylation of the MLH1 gene, may contribute to hereditary cancer syndrome in human, but their transmission to offspring has never been documented. Here we report a family with inheritance, in three successive generations, of germline allele-specific and mosaic hypermethylation of the MSH2 gene, without evidence of DNA mismatch repair gene mutation. Three siblings carrying the germline methylation developed early-onset colorectal or endometrial cancers, all with microsatellite instability and MSH2 protein loss. Clonal bisulfite sequencing and pyrosequencing showed different methylation levels in different somatic tissues, with the highest level recorded in rectal mucosa and colon cancer tissue, and the lowest in blood leukocytes. This mosaic state of germline methylation with different tissue distribution could act as the first hit and provide a mechanism for genetic disease inheritance that may deviate from the mendelian pattern and be overlooked in conventional leukocyte-based genetic diagnosis strategy.	Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hereditary Gastrointestinal Canc Genet Diag Lab, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Hereditary Gastrointestinal Canc Registry, Hong Kong, Hong Kong, Peoples R China; St Pauls Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Pathol, Tsuen Wah, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Surg, Tsuen Wah, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Hong Kong St. Paul's Hospital	Yuen, ST (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hereditary Gastrointestinal Canc Genet Diag Lab, Hong Kong, Hong Kong, Peoples R China.	styuen@hkucc.hku.hk; suetyi@hkucc.hku.hk	Yuen, Siu/K-6311-2014; Leung, Suet Yi/C-4340-2009; Khoo, Ui Soon/C-4293-2009; Leung, Suet Yi/T-9620-2019	Khoo, Ui Soon/0000-0003-2200-7505; Leung, Suet Yi/0000-0001-8614-4619; Tam, Terence/0000-0001-9714-5879; Li, Vivian/0000-0003-2041-0085				Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799; Chan TL, 2003, CANCER RES, V63, P4878; Chan TL, 1999, JNCI-J NATL CANCER I, V91, P1221, DOI 10.1093/jnci/91.14.1221; Chan TL, 2004, AM J HUM GENET, V74, P1035, DOI 10.1086/383591; Chong SY, 2004, CURR OPIN GENET DEV, V14, P692, DOI 10.1016/j.gde.2004.09.001; Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01; Cubas P, 1999, NATURE, V401, P157, DOI 10.1038/43657; Gazzoli I, 2002, CANCER RES, V62, P3925; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hitchins M, 2005, GASTROENTEROLOGY, V129, P1392, DOI 10.1053/j.gastro.2005.09.003; Kane MF, 1997, CANCER RES, V57, P808; Leung SY, 1999, CANCER RES, V59, P159; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Miyakura Y, 2004, CLIN GASTROENTEROL H, V2, P147, DOI 10.1016/S1542-3565(03)00314-8; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Rijcken FEM, 2002, GUT, V50, P382, DOI 10.1136/gut.50.3.382; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342; Tost J, 2003, BIOTECHNIQUES, V35, P152, DOI 10.2144/03351md02; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968	20	232	245	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1178	1183		10.1038/ng1866	http://dx.doi.org/10.1038/ng1866			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16951683	Green Published			2022-12-25	WOS:000241251100018
J	de Bakker, PIW; McVean, G; Sabeti, PC; Miretti, MM; Green, T; Marchini, J; Ke, XY; Monsuur, AJ; Whittaker, P; Delgado, M; Morrison, J; Richardson, A; Walsh, EC; Gao, XJ; Galver, L; Hart, J; Hafler, DA; Pericak-Vance, M; Todd, JA; Daly, MJ; Trowsdale, J; Wijmenga, C; Vyse, TJ; Beck, S; Murray, SS; Carrington, M; Gregory, S; Deloukas, P; Rioux, JD				de Bakker, Paul I. W.; McVean, Gil; Sabeti, Pardis C.; Miretti, Marcos M.; Green, Todd; Marchini, Jonathan; Ke, Xiayi; Monsuur, Alienke J.; Whittaker, Pamela; Delgado, Marcos; Morrison, Jonathan; Richardson, Angela; Walsh, Emily C.; Gao, Xiaojiang; Galver, Luana; Hart, John; Hafler, David A.; Pericak-Vance, Margaret; Todd, John A.; Daly, Mark J.; Trowsdale, John; Wijmenga, Cisca; Vyse, Tim J.; Beck, Stephan; Murray, Sarah Shaw; Carrington, Mary; Gregory, Simon; Deloukas, Panos; Rioux, John D.			A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC	NATURE GENETICS			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; NONCODING SEQUENCE POLYMORPHISMS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; HUMAN GENOME; LINKAGE-DISEQUILIBRIUM; CELIAC-DISEASE; REGION; RISK	The proteins encoded by the classical HLA class I and class II genes in the major histocompatibility complex (MHC) are highly polymorphic and are essential in self versus non-self immune recognition. HLA variation is a crucial determinant of transplant rejection and susceptibility to a large number of infectious and autoimmune diseases(1). Yet identification of causal variants is problematic owing to linkage disequilibrium that extends across multiple HLA and non-HLA genes in the MHC2,3. We therefore set out to characterize the linkage disequilibrium patterns between the highly polymorphic HLA genes and background variation by typing the classical HLA genes and > 7,500 common SNPs and deletion-insertion polymorphisms across four population samples. The analysis provides informative tag SNPs that capture much of the common variation in the MHC region and that could be used in disease association studies, and it provides new insight into the evolutionary dynamics and ancestral origins of the HLA loci and their haplotypes.	Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA; MIT, Cambridge Ctr 7, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Ctr Human Genet, Boston, MA 02114 USA; Univ Oxford, Dept Stat, Oxford OX1 2JD, England; Wellcome Trust Sanger Inst, Hinxton, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; Univ Utrecht, Med Ctr, Dept Med Genet, Complex Genet Sect, NL-3508 TC Utrecht, Netherlands; SAIC Frederick Inc, Lab Genom Divers, Frederick, MD USA; NCI, Frederick, MD 21701 USA; Illumina Inc, San Diego, CA USA; Duke Univ, Med Ctr, Ctr Human Genet, Durham, NC 27706 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Cambridge, Inst Med Res, Wellcome Trust Diabet & Inflammat Lab, Juventil Diabet Res Fdn, Cambridge CB2 1TN, England; Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge, England; Imperial Coll Sch Med, London, England; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; University of Oxford; Wellcome Trust Sanger Institute; University of Oxford; Wellcome Centre for Human Genetics; Utrecht University; Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Illumina; Duke University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Imperial College London; Universite de Montreal; Universite de Montreal	Rioux, JD (corresponding author), Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.	rioux@broad.mit.edu	Daly, Mark J/B-2453-2017; Ke, Xiayi/C-7674-2009; Sabeti, Pardis/GQH-8610-2022; Richardson, Angela/AAN-8731-2020; Marchini, Jonathan/ABE-9024-2020; Todd, John A/A-3542-2010; Wijmenga, Cisca/D-2173-2009; de Bakker, Paul IW/B-8730-2009; Miretti, Marcos M./AAY-5895-2020; Deloukas, Panos/B-2922-2013; Wijmenga, Cisca/AAE-7719-2019; Rioux, John D/A-9599-2015	Daly, Mark J/0000-0002-0949-8752; Richardson, Angela/0000-0003-2656-7438; Marchini, Jonathan/0000-0003-0610-8322; Todd, John A/0000-0003-2740-8148; de Bakker, Paul IW/0000-0001-7735-7858; Miretti, Marcos M./0000-0001-8179-1606; Deloukas, Panos/0000-0001-9251-070X; Wijmenga, Cisca/0000-0002-5635-1614; Rioux, John D/0000-0001-7560-8326; Gregory, Simon/0000-0002-7805-1743	Intramural NIH HHS Funding Source: Medline; Medical Research Council [G9800943] Funding Source: Medline; NCI NIH HHS [N01CO12400, N01-CO-12400] Funding Source: Medline; NIAID NIH HHS [U19 AI050864] Funding Source: Medline; Wellcome Trust [077011] Funding Source: Medline; MRC [G9800943] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI050864] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allcock RJN, 2002, TISSUE ANTIGENS, V59, P520, DOI 10.1034/j.1399-0039.2002.590609.x; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Chadha S, 2006, EUR J HUM GENET, V14, P69, DOI 10.1038/sj.ejhg.5201527; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; DUPONT B, 1977, TRANSPLANT P, V9, P1271; Froeschke G, 2005, MOL BIOL EVOL, V22, P1254, DOI 10.1093/molbev/msi112; FRY B, 2005, COMPUTATIONAL INFORM; Gonzalez-Neira A, 2006, GENOME RES, V16, P323, DOI 10.1101/gr.4138406; Graham RR, 2002, AM J HUM GENET, V71, P543, DOI 10.1086/342290; HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622; Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489; KLEIN J, 1987, HUM IMMUNOL, V19, P155, DOI 10.1016/0198-8859(87)90066-8; LIMM TM, 1993, HUM IMMUNOL, V38, P57, DOI 10.1016/0198-8859(93)90520-B; Malkki M, 2005, TISSUE ANTIGENS, V66, P114, DOI 10.1111/j.1399-0039.2005.00453.x; Marsh SGE, 2005, TISSUE ANTIGENS, V66, P338, DOI 10.1111/j.1399-0039.2005.00479.x; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Miretti MM, 2005, AM J HUM GENET, V76, P634, DOI 10.1086/429393; Monsuur AJ, 2005, NAT GENET, V37, P1341, DOI 10.1038/ng1680; Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196; Nei M., 1987, MOL EVOLUTIONARY GEN; Raymond CK, 2005, GENOME RES, V15, P1250, DOI 10.1101/gr.3554305; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; SIMONS MJ, 1993, HUM IMMUNOL, V38, P69, DOI 10.1016/0198-8859(93)90521-2; Stenzel A, 2004, HUM GENET, V114, P377, DOI 10.1007/s00439-003-1075-5; Stewart CA, 2004, GENOME RES, V14, P1176, DOI 10.1101/gr.2188104; Traherne JA, 2006, PLOS GENET, V2, P81, DOI 10.1371/journal.pgen.0020009; Vader W, 2003, P NATL ACAD SCI USA, V100, P12390, DOI 10.1073/pnas.2135229100; Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072; Walsh EC, 2003, AM J HUM GENET, V73, P580, DOI 10.1086/378101	29	574	602	1	45	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1166	1172		10.1038/ng1885	http://dx.doi.org/10.1038/ng1885			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16998491	Green Accepted			2022-12-25	WOS:000241251100016
J	van der Horst, A; de Vries-Smits, AMM; Brenkman, AB; van Triest, MH; van den Broek, N; Colland, F; Maurice, MM; Burgering, BMT				van der Horst, Armando; de Vries-Smits, Alida M. M.; Brenkman, Arjan B.; van Triest, Miranda H.; van den Broek, Niels; Colland, Frederic; Maurice, Madelon M.; Burgering, Boudewijn M. T.			FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-B; PROMOTES CELL-SURVIVAL; OXIDATIVE STRESS; FACTOR AFX; PROTEASOMAL DEGRADATION; CAENORHABDITIS-ELEGANS; TUMOR SUPPRESSION; LIFE-SPAN; FORKHEAD; PATHWAY	FOXO (Forkhead box O) transcription factors are important regulators of cellular metabolism, cell-cycle progression and cell death. FOXO activity is regulated by multiple post-translational modifications, including phosphorylation, acetylation and polyubiquitination. Here, we show that FOXO becomes monoubiquitinated in response to increased cellular oxidative stress, resulting in its re-localization to the nucleus and an increase in its transcriptional activity. Deubiquitination of FOXO requires the deubiquitinating enzyme USP7/HAUSP (herpesvirus-associated ubiquitin-specific protease), which interacts with and deubiquitinates FOXO in response to oxidative stress. Oxidative stress-induced ubiquitination and deubiquitination by USP7 do not influence FOXO protein half-life. However, USP7 does negatively regulate FOXO transcriptional activity towards endogenous promoters. Our results demonstrate a novel mechanism of FOXO regulation and indicate that USP7 has an important role in regulating FOXO-mediated stress responses.	Univ Utrecht, Med Ctr, Dept Physiol Chem, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Hybrigen SA, F-75014 Paris, France; Univ Utrecht, Dept Cell Biol, Med Ctr, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University	Burgering, BMT (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands.	B.M.T.Burgering@med.uu.nl		Maurice, Madelon/0000-0001-6885-5361				Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burgering BMT, 2002, TRENDS BIOCHEM SCI, V27, P352, DOI 10.1016/S0968-0004(02)02113-8; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cao C, 2005, ONCOGENE, V24, P2433, DOI 10.1038/sj.onc.1208454; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Dikic I, 2003, BIOCHEM SOC T, V31, P1178; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; Fukuoka M, 2003, INT J MOL MED, V12, P503; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Katoh M, 2004, INT J ONCOL, V25, P1495; Kobayashi Y, 2005, INT J MOL MED, V16, P237; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mahmud DL, 2002, ONCOGENE, V21, P1556, DOI 10.1038/sj.onc.1205230; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nanji M, 2005, AGING CELL, V4, P235, DOI 10.1111/j.1474-9726.2005.00166.x; Oh SW, 2005, P NATL ACAD SCI USA, V102, P4494, DOI 10.1073/pnas.0500749102; Onishi Y, 2005, BIOCHEM BIOPH RES CO, V336, P799, DOI 10.1016/j.bbrc.2005.08.175; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; van der Knaap JA, 2005, MOL CELL, V17, P695, DOI 10.1016/j.molcel.2005.02.013; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; Yin LM, 2000, BIOCHEMISTRY-US, V39, P10001, DOI 10.1021/bi0007019	47	371	397	3	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1064	U40		10.1038/ncb1469	http://dx.doi.org/10.1038/ncb1469			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16964248				2022-12-25	WOS:000241395300010
J	Zara, F; Biancheri, R; Bruno, C; Bordo, L; Assereto, S; Gazzerro, E; Sotgia, F; Wang, XB; Gianotti, S; Stringara, S; Pedemonte, M; Uziel, G; Rossi, A; Schenone, A; Tortori-Donati, P; van der Knaap, MS; Lisanti, MP; Minetti, C				Zara, Federico; Biancheri, Roberta; Bruno, Claudio; Bordo, Laura; Assereto, Stefania; Gazzerro, Elisabetta; Sotgia, Federica; Wang, Xiao Bo; Gianotti, Stefania; Stringara, Silvia; Pedemonte, Marina; Uziel, Graziella; Rossi, Andrea; Schenone, Angelo; Tortori-Donati, Paolo; van der Knaap, Marjo S.; Lisanti, Michael P.; Minetti, Carlo			Deficiency of hyccin, a newly identified membrane protein, causes hypomyelination and congenital cataract	NATURE GENETICS			English	Article							MUTATIONS; GENE; DIFFERENTIATION; DISEASE; CATENIN	We describe a new autosomal recessive white matter disorder ('hypomyelination and congenital cataract') characterized by hypomyelination of the central and peripheral nervous system, progressive neurological impairment and congenital cataract. We identified mutations in five affected families, resulting in a deficiency of hyccin, a newly identified 521 - amino acid membrane protein. Our study highlights the essential role of hyccin in central and peripheral myelination.	G Gaslini Inst Children, Muscular & Neurodegenerat Dis Unit, Genoa, Italy; Univ Genoa, I-16126 Genoa, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Canc Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA; C Besta Inst, Div Child Neuropsychiat, Milan, Italy; G Gaslini Inst Children, Dept Pediat Neuroradiol, Genoa, Italy; Univ Genoa, Dept Neurosci Ophthalmol & Genet, Genoa, Italy; Vrije Univ Amsterdam, Med Ctr, Dept Child Neurol, Amsterdam, Netherlands	University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; Jefferson University; Jefferson University; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; Vrije Universiteit Amsterdam	Zara, F (corresponding author), G Gaslini Inst Children, Muscular & Neurodegenerat Dis Unit, Genoa, Italy.	federicozara@ospedale-gaslini.ge.it; minettic@unige.it	Minetti, Carlo/K-4666-2018; schenone, angelo/I-3194-2012; Lisanti, Michael P/C-6866-2013; Rossi, Andrea/A-4146-2011; Lisanti, Michael/B-6131-2018; Bruno, Claudio/A-3148-2015; Zara, Federico/U-3477-2017	Minetti, Carlo/0000-0002-0640-1804; schenone, angelo/0000-0002-2604-7830; Rossi, Andrea/0000-0001-8575-700X; Lisanti, Michael/0000-0003-2034-1382; Bruno, Claudio/0000-0002-3426-2901; Zara, Federico/0000-0001-9744-5222; Pedemonte, Marina/0000-0001-8410-6918; Sotgia, Federica/0000-0003-2826-4529	Telethon [GTF04002] Funding Source: Medline	Telethon(Fondazione Telethon)		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Kasai M, 2005, GENES CELLS, V10, P777, DOI 10.1111/j.1365-2443.2005.00876.x; Kawasoe T, 2000, CANCER RES, V60, P3354; Lyu J, 2004, DEVELOPMENT, V131, P1813, DOI 10.1242/dev.01060; Mackay D, 1999, AM J HUM GENET, V64, P1357, DOI 10.1086/302383; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Schiffmann R, 2004, CURR OPIN NEUROL, V17, P187, DOI 10.1097/00019052-200404000-00017; Shiels A, 1998, AM J HUM GENET, V62, P526, DOI 10.1086/301762; Shimizu T, 2005, DEV BIOL, V282, P397, DOI 10.1016/j.ydbio.2005.03.020; Stump RJW, 2003, DEV BIOL, V259, P48, DOI 10.1016/S0012-1606(03)00179-9; Uhlenberg B, 2004, AM J HUM GENET, V75, P251, DOI 10.1086/422763; van der Knaap MS, 2002, AM J NEURORADIOL, V23, P1466; van der Knaap MS, 1999, RADIOLOGY, V213, P121, DOI 10.1148/radiology.213.1.r99se01121	13	69	71	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2006	38	10					1111	1113		10.1038/ng1870	http://dx.doi.org/10.1038/ng1870			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16951682	Green Published			2022-12-25	WOS:000241251100009
J	Qi, Y; Rolfe, A; MacIsaac, KD; Gerber, GK; Pokholok, D; Zeitlinger, J; Danford, T; Dowell, RD; Fraenkel, E; Jaakkola, TS; Young, RA; Gifford, DK				Qi, Yuan; Rolfe, Alex; MacIsaac, Kenzie D.; Gerber, Georg K.; Pokholok, Dmitry; Zeitlinger, Julia; Danford, Timothy; Dowell, Robin D.; Fraenkel, Ernest; Jaakkola, Tommi S.; Young, Richard A.; Gifford, David K.			High-resolution computational models of genome binding events	NATURE BIOTECHNOLOGY			English	Article							WIDE LOCATION; SITES; MAPS; IDENTIFICATION; ACETYLATION; METHYLATION; CIRCUITRY	Direct physical information that describes where transcription factors, nucleosomes, modified histones, RNA polymerase II and other key proteins interact with the genome provides an invaluable mechanistic foundation for understanding complex programs of gene regulation. We present a method, joint binding deconvolution (JBD), which uses additional easily obtainable experimental data about chromatin immunoprecipitation (ChIP) to improve the spatial resolution of the transcription factor binding locations inferred from ChIP followed by DNA microarray hybridization (ChIP-Chip) data. Based on this probabilistic model of binding data, we further pursue improved spatial resolution by using sequence information. We produce positional priors that link ChIP-Chip data to sequence data by guiding motif discovery to inferred protein-DNA binding sites. We present results on the yeast transcription factors Gcn4 and Mig2 to demonstrate JBD's spatial resolution capabilities and show that positional priors allow computational discovery of the Mig2 motif when a standard approach fails.	MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Gifford, DK (corresponding author), MIT, Comp Sci & Artificial Intelligence Lab, 32 Vassar St, Cambridge, MA 02139 USA.	gifford@mit.edu	Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Fraenkel, Ernest/0000-0001-9249-8181; DOWELL, ROBIN/0000-0001-7665-9985	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069676] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 069676] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY TL, 1995, P 3 INT C INT SYST M, P21; Bar-Joseph Z, 2003, NAT BIOTECHNOL, V21, P1337, DOI 10.1038/nbt890; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brooks SP, 1998, J ROY STAT SOC D-STA, V47, P69, DOI 10.1111/1467-9884.00117; Buck MJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r97; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Gerton JL, 2000, P NATL ACAD SCI USA, V97, P11383, DOI 10.1073/pnas.97.21.11383; Gordon DB, 2005, BIOINFORMATICS, V21, P3164, DOI 10.1093/bioinformatics/bti481; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Hartemink Alexander J, 2002, Pac Symp Biocomput, P437; Horak CE, 2002, P NATL ACAD SCI USA, V99, P2924, DOI 10.1073/pnas.052706999; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; KELES S, 2004, BERKELEY ELECT P JUN; Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Li XM, 2005, P NATL ACAD SCI USA, V102, P9481, DOI 10.1073/pnas.0501620102; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Luscombe NM, 2004, NATURE, V431, P308, DOI 10.1038/nature02782; Lutfiyya LL, 1996, MOL CELL BIOL, V16, P4790; Marion RM, 2004, P NATL ACAD SCI USA, V101, P14315, DOI 10.1073/pnas.0405353101; Minka T. P., 2001, PROC 17 C UNCERTAINT, P362; Nagy PL, 2003, P NATL ACAD SCI USA, V100, P6364, DOI 10.1073/pnas.1131966100; Neal R. M., 1993, PROBABILISTIC INFERE; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; QI Y, 2004, THESIS MIT; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Wyrick JJ, 2001, SCIENCE, V294, P2357, DOI 10.1126/science.1066101; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178	40	63	68	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2006	24	8					963	970		10.1038/nbt1233	http://dx.doi.org/10.1038/nbt1233			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	072VY	16900145				2022-12-25	WOS:000239702300037
J	Sanna, MG; Wang, SK; Gonzalez-Cabrera, PJ; Don, A; Marsolais, D; Matheu, MP; Wei, SH; Parker, I; Jo, EJ; Cheng, WC; Cahalan, MD; Wong, CH; Rosen, H				Sanna, M. Germana; Wang, Sheng-Kai; Gonzalez-Cabrera, Pedro J.; Don, Anthony; Marsolais, David; Matheu, Melanie P.; Wei, Sindy H.; Parker, Ian; Jo, Euijung; Cheng, Wei-Chieh; Cahalan, Michael D.; Wong, Chi-Huey; Rosen, Hugh			Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P(1) antagonist in vivo	NATURE CHEMICAL BIOLOGY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR; RENAL-TRANSPLANT PATIENTS; BARRIER INTEGRITY; IMMUNOSUPPRESSANT FTY720; THYMOCYTE EMIGRATION; G-PROTEIN; T-CELLS; SPHINGOSINE-1-PHOSPHATE; AGONISTS; CD69	Sphingosine 1-phosphate (S1P, 1) regulates vascular barrier and lymphoid development, as well as lymphocyte egress from lymphoid organs, by activating high-affinity S1P1 receptors. We used reversible chemical probes (i) to gain mechanistic insights into S1P systems organization not accessible through genetic manipulations and (ii) to investigate their potential for therapeutic modulation. Vascular (but not airway) administration of the preferred R enantiomer of an in vivo-active chiral S1P1 receptor antagonist induced loss of capillary integrity in mouse skin and lung. In contrast, the antagonist did not affect the number of constitutive blood lymphocytes. Instead, alteration of lymphocyte trafficking and phenotype required supraphysiological elevation of S1P1 tone and was reversed by the antagonist. In vivo two-photon imaging of lymph nodes confirmed requirements for obligate agonism, and the data were consistent with the presence of a stromal barrier mechanism for gating lymphocyte egress. Thus, chemical modulation reveals differences in S1P-S1P(1) 'set points' among tissues and highlights both mechanistic advantages (lymphocyte sequestration) and risks (pulmonary edema) of therapeutic intervention.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Mol Screening Ctr, La Jolla, CA 92037 USA; Novartis Fdn, Genom Inst, San Diego, CA 92121 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Immunol, Irvine, CA 92697 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Novartis; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Rosen, H (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wong@scripps.edu; hrosen@scripps.edu	Don, Anthony Simon/AAE-9687-2021	Don, Anthony Simon/0000-0003-1655-1184; Jo, Euijung/0000-0003-1131-2723; Wang, Sheng-Kai/0000-0002-3827-7983	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI055509] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048071, R01GM041514, R37GM048071] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-055509] Funding Source: Medline; NIGMS NIH HHS [GM-48071, GM-41514] Funding Source: Medline; PHS HHS [NIMH-074404] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alfonso C, 2006, EUR J IMMUNOL, V36, P149, DOI 10.1002/eji.200535127; Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Awad AS, 2006, AM J PHYSIOL-RENAL, V290, pF1516, DOI 10.1152/ajprenal.00311.2005; Budde K, 2003, AM J TRANSPLANT, V3, P846, DOI 10.1034/j.1600-6143.2003.00130.x; Budde K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341073; Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200; Feng CG, 2002, INT IMMUNOL, V14, P535, DOI 10.1093/intimm/dxf020; Forrest M, 2004, J PHARMACOL EXP THER, V309, P758, DOI 10.1124/jpet.103.062828; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Goetzl EJ, 2004, J CLIN INVEST, V114, P1531, DOI 10.1172/JCI200423704; Gon Y, 2005, P NATL ACAD SCI USA, V102, P9270, DOI 10.1073/pnas.0501997102; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Hale JJ, 2004, BIOORG MED CHEM LETT, V14, P3351, DOI 10.1016/j.bmcl.2004.02.106; Ho JWY, 2005, MOL CANCER THER, V4, P1430, DOI 10.1158/1535-7163.MCT-05-0021; Jo EJ, 2005, CHEM BIOL, V12, P703, DOI 10.1016/j.chembiol.2005.04.019; LaMontagne K, 2006, CANCER RES, V66, P221, DOI 10.1158/0008-5472.CAN-05-2001; Ley K, 2005, NAT IMMUNOL, V6, P1215, DOI 10.1038/ni1205-1215; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Mahrus S, 2005, CHEM BIOL, V12, P567, DOI 10.1016/j.chembiol.2005.03.006; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; McVerry BJ, 2004, AM J RESP CRIT CARE, V170, P987, DOI 10.1164/rccm.200405-684oc; McVerry BJ, 2005, CELL SIGNAL, V17, P131, DOI 10.1016/j.cellsig.2004.08.006; McVerry BJ, 2004, J CELL BIOCHEM, V92, P1075, DOI 10.1002/jcb.20088; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; Miller MJ, 2003, P NATL ACAD SCI USA, V100, P2604, DOI 10.1073/pnas.2628040100; Nakayama T, 2002, J IMMUNOL, V168, P87, DOI 10.4049/jimmunol.168.1.87; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Rosen H, 2003, P NATL ACAD SCI USA, V100, P10907, DOI 10.1073/pnas.1832725100; Rosen H, 2003, IMMUNOL REV, V195, P160, DOI 10.1034/j.1600-065X.2003.00068.x; Rosen H, 2003, CURR OPIN CHEM BIOL, V7, P461, DOI 10.1016/S1367-5931(03)00085-1; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Singer II, 2005, J IMMUNOL, V175, P7151, DOI 10.4049/jimmunol.175.11.7151; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Wei SH, 2005, NAT IMMUNOL, V6, P1228, DOI 10.1038/ni1269; Yagi H, 2000, EUR J IMMUNOL, V30, P1435, DOI 10.1002/(SICI)1521-4141(200005)30:5<1435::AID-IMMU1435>3.0.CO;2-O	39	322	353	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2006	2	8					434	441		10.1038/nchembio804	http://dx.doi.org/10.1038/nchembio804			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065GD	16829954	Green Submitted			2022-12-25	WOS:000239146800013
J	Dafa'alla, TH; Condon, GC; Condon, KC; Phillips, CE; Morrison, NI; Jin, L; Epton, MJ; Fu, GL; Alphey, L				Dafa'alla, Tarig H.; Condon, George C.; Condon, Kirsty C.; Phillips, Caroline E.; Morrison, Neil I.; Jin, Li; Epton, Matthew J.; Fu, Guoliang; Alphey, Luke			Transposon-free insertions for insect genetic engineering	NATURE BIOTECHNOLOGY			English	Article							TRANSFORMATION; VECTOR	Methods involving the release of transgenic insects in the field hold great promise for controlling vector-borne diseases and agricultural pests. Insect transformation depends on nonautonomous transposable elements as gene vectors. The resulting insertions are stable in the absence of suitable transposase, however, such absence cannot always be guaranteed. We describe a method for post-integration elimination of all transposon sequences in the pest insect Medfly, Ceratitis capitata. The resulting insertions lack transposon sequences and are therefore impervious to transposase activity.	Oxitec Ltd, Oxford OX14 4RX, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Alphey, L (corresponding author), Oxitec Ltd, 71 Milton Pk, Oxford OX14 4RX, England.	luke.alphey@zoo.ox.ac.uk		Alphey, Luke/0000-0002-2916-3802	Biotechnology and Biological Sciences Research Council [BBS/B/14213] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alphey L, 2002, SCIENCE, V298, P119, DOI 10.1126/science.1078278; Alphey L, 2002, INSECT BIOCHEM MOLEC, V32, P1243, DOI 10.1016/S0965-1748(02)00087-5; Atkinson PW, 2001, ANNU REV ENTOMOL, V46, P317, DOI 10.1146/annurev.ento.46.1.317; BERG CA, 1991, GENETICS, V127, P515; Handler AM, 2004, NAT BIOTECHNOL, V22, P1150, DOI 10.1038/nbt1002; Handler AM, 2004, INSECT BIOCHEM MOLEC, V34, P121, DOI 10.1016/j.ibmb.2003.08.005; Horn C, 2005, P NATL ACAD SCI USA, V102, P12483, DOI 10.1073/pnas.0504305102; Hoy MA, 2000, INSECT TRANSGENESIS, P335; Li X, 2005, INSECT MOL BIOL, V14, P17, DOI 10.1111/j.1365-2583.2004.00525.x; Li X, 2001, MOL GENET GENOMICS, V266, P190, DOI 10.1007/s004380100525; Nimmo DD, 2006, INSECT MOL BIOL, V15, P129, DOI 10.1111/j.1365-2583.2006.00615.x; Oberstein A, 2005, NAT METHODS, V2, P583, DOI 10.1038/NMETH775; OLSON KE, 2006, BRIDGING LAB FIELD R, V11, P210; Shagin DA, 2004, MOL BIOL EVOL, V21, P841, DOI 10.1093/molbev/msh079; Wimmer EA, 2003, NAT REV GENET, V4, P225, DOI 10.1038/nrg1021	15	46	57	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					820	821		10.1038/nbt1221	http://dx.doi.org/10.1038/nbt1221			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16823373				2022-12-25	WOS:000239025100032
J	Gao, MG; Kaiser, CA				Gao, Minggeng; Kaiser, Chris A.			A conserved GTPase-containing complex is required for intracellular sorting of the general amino-acid permease in yeast	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; PREVACUOLAR COMPARTMENT; LATE-GOLGI; ACTIN CYTOSKELETON; SECRETORY PATHWAY; PROTEIN COMPLEXES; BINDING PROTEINS; CONTROLS ENTRY; ENDOSOME; VACUOLAR	The Saccharomyces cerevisiae general amino-acid permease, Gap1p, is a model for membrane proteins that are regulated by intracellular sorting according to physiological cues set by the availability of amino acids. Here, we report the identification of a conserved sorting complex for Gap1p, named the GTPase-containing complex for Gap1p sorting in the endosomes ( GSE complex), which is required for proper sorting of Gap1p from the late endosome for eventual delivery to the plasma membrane. The complex contains two small GTPases ( Gtr1p and Gtr2p) and three other proteins ( Ybr077c, Ykr007w and Ltv1p) that are located in the late endosomal membrane. Importantly, Gtr2p interacts with the carboxy ( C)-terminal cytosolic domain of Gap1p and a tyrosine-containing motif in this domain is necessary both to bind Gtr2p and to direct sorting of Gap1p to the plasma membrane. Together, these studies provide evidence that the GSE complex has a key role in trafficking Gap1p out of the endosome and may serve as coat proteins in this process.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Kaiser, CA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ckaiser@mit.edu			NIGMS NIH HHS [GM56933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM PR, 1992, YEAST, V8, P227, DOI 10.1002/yea.320080309; Arighi CN, 2004, J CELL BIOL, V165, P123, DOI 10.1083/jcb.200312055; Ashrafi K, 1998, J BIOL CHEM, V273, P25864, DOI 10.1074/jbc.273.40.25864; Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bowers K, 2005, BBA-MOL CELL RES, V1744, P438, DOI 10.1016/j.bbamcr.2005.04.004; Bugnicourt A, 2004, MOL BIOL CELL, V15, P4203, DOI 10.1091/mbc.E04-05-0420; Chen EJ, 2002, P NATL ACAD SCI USA, V99, P14837, DOI 10.1073/pnas.232591899; Conibear E, 2000, MOL BIOL CELL, V11, P305, DOI 10.1091/mbc.11.1.305; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; Dubouloz F, 2005, MOL CELL, V19, P15, DOI 10.1016/j.molcel.2005.05.020; Gao XD, 2005, FEBS J, V272, P2497, DOI 10.1111/j.1742-4658.2005.04670.x; Gerrard SR, 2000, MOL BIOL CELL, V11, P613, DOI 10.1091/mbc.11.2.613; Gerrard SR, 2000, TRAFFIC, V1, P259, DOI 10.1034/j.1600-0854.2000.010308.x; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kaiser CA, 2002, METHOD ENZYMOL, V351, P325; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Malkus P, 2002, J CELL BIOL, V159, P915, DOI 10.1083/jcb.200208074; Nakashima N, 1999, GENETICS, V152, P853; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Ram RJ, 2002, MOL BIOL CELL, V13, P1484, DOI 10.1091/mbc.01-10-0495; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Redding K, 1996, MOL CELL BIOL, V16, P6208; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; Roberg KJ, 1997, J CELL BIOL, V137, P1469, DOI 10.1083/jcb.137.7.1469; Ross-Macdonald P, 1999, NATURE, V402, P413, DOI 10.1038/46558; SCHURMANN A, 1995, J BIOL CHEM, V270, P28982, DOI 10.1074/jbc.270.48.28982; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Seaman MNJ, 2004, J CELL BIOL, V165, P111, DOI 10.1083/jcb.200312034; Sekiguchi T, 2001, J BIOL CHEM, V276, P7246, DOI 10.1074/jbc.M004389200; SIKORSKI RS, 1989, GENETICS, V122, P19; Siniossoglou S, 2001, EMBO J, V20, P5991, DOI 10.1093/emboj/20.21.5991; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wiederkehr A, 2000, J CELL BIOL, V149, P397, DOI 10.1083/jcb.149.2.397	48	142	149	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					657	U14		10.1038/ncb1419	http://dx.doi.org/10.1038/ncb1419			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16732272				2022-12-25	WOS:000238837800008
J	Hahn, CG; Wang, HY; Cho, DS; Talbot, K; Gur, RE; Berrettini, WH; Bakshi, K; Kamins, J; Borgmann-Winter, KE; Siegel, SJ; Gallop, RJ; Arnold, SE				Hahn, Chang-Gyu; Wang, Hoau-Yan; Cho, Dan-Sung; Talbot, Konrad; Gur, Raquel E.; Berrettini, Wade H.; Bakshi, Kalindi; Kamins, Joshua; Borgmann-Winter, Karin E.; Siegel, Steven J.; Gallop, Robert J.; Arnold, Steven E.			Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia	NATURE MEDICINE			English	Article							PREFRONTAL CORTEX; SUSCEPTIBILITY; EXPRESSION; PROTEINS; ERBB4; GENES	Recent molecular genetics studies implicate neuregulin 1 (NRG1) and its receptor erbB in the pathophysiology of schizophrenia(1-3). Among NRG1 receptors, erbB4 is of particular interest because of its crucial roles in neurodevelopment and in the modulation of N-methyl-D-aspartate ( NMDA) receptor signaling(4-6). Here, using a new postmortem tissue-stimulation approach, we show a marked increase in NRG1-induced activation of erbB4 in the prefrontal cortex in schizophrenia. Levels of NRG1 and erbB4, however, did not differ between schizophrenia and control groups. To evaluate possible causes for this hyperactivation of erbB4 signaling, we examined the association of erbB4 with PSD-95 (postsynaptic density protein of 95 kDa), as this association has been shown to facilitate activation of erbB4. Schizophrenia subjects showed substantial increases in erbB4-PSD-95 interactions. We found that NRG1 stimulation suppresses NMDA receptor activation in the human prefrontal cortex, as previously reported in the rodent cortex. NRG1-induced suppression of NMDA receptor activation was more pronounced in schizophrenia subjects than in controls, consistent with enhanced NRG1-erbB4 signaling seen in this illness. Therefore, these findings suggest that enhanced NRG1 signaling may contribute to NMDA hypofunction in schizophrenia.	Univ Penn, Dept Psychiat, Cellular & Mol Neuropathol Program, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA; CUNY, Sch Med, Dept Physiol & Pharmacol, New York, NY 10031 USA; W Chester Univ, Dept Math, Appl Stat Program, W Chester, PA 19380 USA	University of Pennsylvania; Pennsylvania Medicine; City University of New York (CUNY) System; Pennsylvania State System of Higher Education (PASSHE); West Chester University of Pennsylvania	Hahn, CG (corresponding author), Univ Penn, Dept Psychiat, Cellular & Mol Neuropathol Program, Ctr Neurobiol & Behav, Philadelphia, PA 19104 USA.	hahnc@mail.med.upenn.edu	Arnold, Steven E/J-7546-2012; Gur, Ruben/K-1999-2019	Gur, Ruben/0000-0002-9657-1996; Siegel, Steven/0000-0001-8058-9713	NIMH NIH HHS [MH63946, MH64045] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K23MH063946, P50MH064045] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Anton ES, 2004, NAT NEUROSCI, V7, P1319, DOI 10.1038/nn1345; Arnold SE, 2005, PROG BRAIN RES, V147, P319, DOI 10.1016/S0079-6123(04)47023-X; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Clinton SM, 2004, NEUROPSYCHOPHARMACOL, V29, P1353, DOI 10.1038/sj.npp.1300451; Corvin AP, 2004, MOL PSYCHIATR, V9, P208, DOI 10.1038/sj.mp.4001412; Coyle JT, 2003, ANN NY ACAD SCI, V1003, P318, DOI 10.1196/annals.1300.020; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Frenzel KE, 2001, J NEUROCHEM, V77, P1; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Gu ZL, 2005, J NEUROSCI, V25, P4974, DOI 10.1523/JNEUROSCI.1086-05.2005; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; Harrison PJ, 2003, LANCET, V361, P417, DOI 10.1016/S0140-6736(03)12379-3; Hashimoto R, 2004, MOL PSYCHIATR, V9, P299, DOI 10.1038/sj.mp.4001434; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Kwon OB, 2005, J NEUROSCI, V25, P9378, DOI 10.1523/JNEUROSCI.2100-05.2005; Lemke G, 2001, ANNU REV NEUROSCI, V24, P87, DOI 10.1146/annurev.neuro.24.1.87; Moghaddam B, 2003, NEURON, V40, P881, DOI 10.1016/S0896-6273(03)00757-8; Okada M, 2004, HIPPOCAMPUS, V14, P337, DOI 10.1002/hipo.10185; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; Rieff HI, 1999, J NEUROSCI, V19, P10757, DOI 10.1523/JNEUROSCI.19-24-10757.1999; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; Stefansson H, 2004, ANN MED, V36, P62, DOI 10.1080/07853890310017585; Stefansson H, 2002, AM J HUM GENET, V71, P877, DOI 10.1086/342734; Toyooka K, 2002, J NEUROCHEM, V83, P797, DOI 10.1046/j.1471-4159.2002.01181.x; Wang HY, 1996, BIOL PSYCHIAT, V40, P568, DOI 10.1016/0006-3223(95)00611-7; WANG HY, 1994, NEUROSCI LETT, V173, P37, DOI 10.1016/0304-3940(94)90144-9; Williams NM, 2003, MOL PSYCHIATR, V8, P485, DOI 10.1038/sj.mp.4001348	27	438	464	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					824	828		10.1038/nm1418	http://dx.doi.org/10.1038/nm1418			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16767099				2022-12-25	WOS:000238862800070
J	Chromek, M; Slamova, Z; Bergman, P; Kovacs, L; Podracka, L; Ehren, I; Hokfelt, T; Gudmundsson, GH; Gallo, RL; Agerberth, B; Brauner, A				Chromek, Milan; Slamova, Zuzana; Bergman, Peter; Kovacs, Laszlo; Podracka, L'udmila; Ehren, Ingrid; Hokfelt, Tomas; Gudmundsson, Gudmundur H.; Gallo, Richard L.; Agerberth, Birgitta; Brauner, Annelie			The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection	NATURE MEDICINE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; INNATE IMMUNITY; DEFENSE PEPTIDES; LL-37; EXPRESSION; BETA-DEFENSIN-1; BLADDER; HCAP-18; MICE; DIFFERENTIATION	The urinary tract functions in close proximity to the outside environment, yet must remain free of microbial colonization to avoid disease. The mechanisms for establishing an antimicrobial barrier in this area are not completely understood. Here, we describe the production and function of the cathelicidin antimicrobial peptides LL-37, its precursor hCAP-18 and its ortholog CRAMP in epithelial cells of human and mouse urinary tract, respectively. Bacterial contact with epithelial cells resulted in rapid production and secretion of the respective peptides, and in humans LL-37/hCAP-18 was released into urine. Epithelium-derived cathelicidin substantially contributed to the protection of the urinary tract against infection, as shown using CRAMP-deficient and neutrophil-depleted mice. In addition, clinical E. coli strains that were more resistant to LL-37 caused more severe urinary tract infections than did susceptible strains. Thus, cathelicidin seems to be a key factor in mucosal immunity of the urinary tract.	Karolinska Univ Hosp, Dept Clin Microbiol, Microbiol & Tumorbiol Ctr, SE-17176 Stockholm, Sweden; Karolinska Inst, SE-17176 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden; Karolinska Univ Hosp, Dept Urol, SE-17176 Stockholm, Sweden; Comenius Univ, Sch Med, Dept Pediat, Bratislava, Slovakia; Safarik Univ, Sch Med, Dept Pediat, Kosice 04066, Slovakia; Univ Iceland, Inst Biol, IS-101 Reykjavik, Iceland; Univ Calif San Diego, Div Dermatol, San Diego, CA 92161 USA	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Comenius University Bratislava; University of Pavol Jozef Safarik Kosice; University of Iceland; University of California System; University of California San Diego	Brauner, A (corresponding author), Karolinska Univ Hosp, Dept Clin Microbiol, Microbiol & Tumorbiol Ctr, SE-17176 Stockholm, Sweden.	Annelie.Brauner@ki.se	Gallo, Richard L/A-8931-2009; Chromek, Milan/AAD-9116-2022; Gudmundsson, Gudmundur H/K-9178-2015; Chromek, Milan/ABE-7455-2020	Gallo, Richard L/0000-0002-1401-7861; Chromek, Milan/0000-0002-8941-057X; Gudmundsson, Gudmundur H/0000-0001-5793-0565; Ehren, Ingrid/0000-0001-7995-1252; Podracka, Ludmila/0000-0002-6633-0251; Bergman, Peter/0000-0003-3306-3713				Abrink M, 2000, KIDNEY INT, V57, P2004, DOI 10.1046/j.1523-1755.2000.00050.x; Agerberth B, 1999, AM J RESP CRIT CARE, V160, P283, DOI 10.1164/ajrccm.160.1.9807041; Bates JM, 2004, KIDNEY INT, V65, P791, DOI 10.1111/j.1523-1755.2004.00452.x; Bergman P, 2005, CELL MICROBIOL, V7, P1009, DOI 10.1111/j.1462-5822.2005.00530.x; Black CA, 1998, INFECT IMMUN, V66, P1273, DOI 10.1128/IAI.66.3.1273-1275.1998; Bowdish DME, 2005, CURR PROTEIN PEPT SC, V6, P35, DOI 10.2174/1389203053027494; Braff MH, 2005, INFECT IMMUN, V73, P6771, DOI 10.1128/IAI.73.10.6771-6781.2005; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Chromek M, 2003, PEDIATR RES, V53, P698, DOI 10.1203/01.PDR.0000057575.86337.CB; COX CE, 1961, J UROLOGY, V86, P739, DOI 10.1016/S0022-5347(17)65257-1; Dorschner RA, 2006, FASEB J, V20, P35, DOI 10.1096/fj.05-4406com; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; FLIEDNER M, 1986, J PEDIATR-US, V109, P416, DOI 10.1016/S0022-3476(86)80110-X; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; GORDON DM, 1992, MOL MICROBIOL, V6, P555, DOI 10.1111/j.1365-2958.1992.tb01500.x; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Hase K, 2002, INFECT IMMUN, V70, P953, DOI 10.1128/IAI.70.2.953-963.2002; Islam D, 2001, NAT MED, V7, P180, DOI 10.1038/84627; Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718; Justice SS, 2004, P NATL ACAD SCI USA, V101, P1333, DOI 10.1073/pnas.0308125100; Khalil A, 1997, J UROLOGY, V158, P1576, DOI 10.1016/S0022-5347(01)64282-4; Malm J, 2000, INFECT IMMUN, V68, P4297, DOI 10.1128/IAI.68.7.4297-4302.2000; Morrison G, 2002, INFECT IMMUN, V70, P3053, DOI 10.1128/IAI.70.6.3053-3060.2002; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; NORDEN CW, 1968, J CLIN INVEST, V47, P2689, DOI 10.1172/JCI105952; Pestonjamasp VK, 2001, PEPTIDES, V22, P1643, DOI 10.1016/S0196-9781(01)00499-5; Rossi MR, 2001, ENVIRON HEALTH PERSP, V109, P801, DOI 10.1289/ehp.01109801; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Sorensen O, 1997, BLOOD, V90, P2796; Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951; TODD JH, 1996, HUMAN CELL CULTURE P, P431; Tollin M, 2003, PEPTIDES, V24, P523, DOI 10.1016/S0196-9781(03)00114-1; Turner J, 1998, ANTIMICROB AGENTS CH, V42, P2206, DOI 10.1128/AAC.42.9.2206; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Yan H, 2001, ANTIMICROB AGENTS CH, V45, P1558, DOI 10.1128/AAC.45.5.1558-1560.2001; Yang D, 2002, TRENDS IMMUNOL, V23, P291, DOI 10.1016/S1471-4906(02)02246-9; Yoshio H, 2003, PEDIATR RES, V53, P211, DOI 10.1203/01.PDR.0000047471.47777.B0; Zaiou M, 2003, J INVEST DERMATOL, V120, P810, DOI 10.1046/j.1523-1747.2003.12132.x; Zaiou M, 2002, J MOL MED, V80, P549, DOI 10.1007/s00109-002-0350-6; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zucht H D, 1998, Eur J Med Res, V3, P315	45	455	477	2	69	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					636	641		10.1038/nm1407	http://dx.doi.org/10.1038/nm1407			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16751768				2022-12-25	WOS:000238149200024
J	Bender, A; Krishnan, KJ; Morris, CM; Taylor, GA; Reeve, AK; Perry, RH; Jaros, E; Hersheson, JS; Betts, J; Klopstock, T; Taylor, RW; Turnbull, DM				Bender, A; Krishnan, KJ; Morris, CM; Taylor, GA; Reeve, AK; Perry, RH; Jaros, E; Hersheson, JS; Betts, J; Klopstock, T; Taylor, RW; Turnbull, DM			High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease	NATURE GENETICS			English	Article							CYTOCHROME-C-OXIDASE; MUTATIONS; CELLS; POLYMERASE; AGE	Here we show that in substantia nigra neurons from both aged controls and individuals with Parkinson disease, there is a high level of deleted mitochondrial DNA (mtDNA) (controls, 43.3% +/- 9.3%; individuals with Parkinson disease, 52.3% +/- 9.3%). These mtDNA mutations are somatic, with different clonally expanded deletions in individual cells, and high levels of these mutations are associated with respiratory chain deficiency. Our studies suggest that somatic mtDNA deletions are important in the selective neuronal loss observed in brain aging and in Parkinson disease.	Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Newcastle Gen Hosp, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Gen Hosp, Dept Neuropathol, Inst Hlth Elderly, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Munich, Klinikum Grosshadern, Dept Neurol, D-81377 Munich, Germany	Newcastle University - UK; Newcastle General Hospital; Newcastle University - UK; Newcastle General Hospital; Newcastle University - UK; University of Munich	Turnbull, DM (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	d.m.turnbull@ncl.ac.uk	Bender, Andreas/A-7401-2012	Reeve, Amy/0000-0002-4474-2204; Bender, Andreas/0000-0002-6328-7104; Morris, Christopher/0000-0002-3749-0993	Medical Research Council [G0700718] Funding Source: Medline; Wellcome Trust [074454] Funding Source: Medline; Alzheimers Research UK [ART-PG2003-3] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK))		CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927; Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7; FEARNLEY JM, 1991, BRAIN, V114, P2283, DOI 10.1093/brain/114.5.2283; Greene JG, 2005, NEUROBIOL DIS, V18, P19, DOI 10.1016/j.nbd.2004.10.003; He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067; Itoh K, 1996, NEUROBIOL AGING, V17, P843, DOI 10.1016/S0197-4580(96)00168-6; JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9; KRAYTSBERG Y, 2006, NAT GENET; Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13; Smeyne RJ, 2005, MOL BRAIN RES, V134, P57, DOI 10.1016/j.molbrainres.2004.09.017; Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517	15	1086	1128	3	83	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					515	517		10.1038/ng1769	http://dx.doi.org/10.1038/ng1769			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16604074				2022-12-25	WOS:000237147500009
J	Hashimoto, N; Kido, Y; Uchida, T; Asahara, SI; Shigeyama, Y; Matsuda, T; Takeda, A; Tsuchihashi, D; Nishizawa, A; Ogawa, W; Fujimoto, Y; Okamura, H; Arden, KC; Herrera, PL; Noda, T; Kasuga, M				Hashimoto, N; Kido, Y; Uchida, T; Asahara, SI; Shigeyama, Y; Matsuda, T; Takeda, A; Tsuchihashi, D; Nishizawa, A; Ogawa, W; Fujimoto, Y; Okamura, H; Arden, KC; Herrera, PL; Noda, T; Kasuga, M			Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass	NATURE GENETICS			English	Article							FORKHEAD TRANSCRIPTION FACTOR; INSULIN-RECEPTOR SUBSTRATE-2; PROTEIN-KINASE; MICE LACKING; FACTOR FOXO1; SIZE; DISRUPTION; RESISTANCE; GROWTH; TISSUE	The total mass of islets of Langerhans is reduced in individuals with type 2 diabetes(1), possibly contributing to the pathogenesis of this condition. Although the regulation of islet mass is complex, recent studies have suggested the importance of a signaling pathway that includes the insulin or insulin-like growth factor-1 receptors, insulin receptor substrate and phosphatidylinositol ( PI) 3-kinase(2-4). 3-Phosphoinositide dependent protein kinase 1 (PDK1) is a serine-threonine kinase that mediates signaling downstream of PI 3-kinase. Here we show that mice that lack PDK1 specifically in pancreatic beta cells (beta Pdk1(-/-) mice) develop progressive hyperglycemia as a result of a loss of islet mass. The mice show reductions in islet density as well as in the number and size of beta cells. Haploinsufficiency of the gene for the transcription factor Foxo1 resulted in a marked increase in the number, but not the size, of beta cells and resulted in the restoration of glucose homeostasis in beta bPdk1(-/-) mice. These results suggest that PDK1 is important in maintenance of pancreatic beta cell mass and glucose homeostasis.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Brain Sci, Div Mol Brain Sci, Kobe, Hyogo 6500017, Japan; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Geneva, Sch Med, Dept Genet Med & Dev, CH-1211 Geneva 4, Switzerland; Inst Canc Res, Dept Cell Biol, Tokyo 1358550, Japan	Kobe University; Kobe University; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of Geneva; Japanese Foundation for Cancer Research	Kasuga, M (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis, Kobe, Hyogo 6500017, Japan.	kasuga@med.kobe-u.ac.jp	OGAWA, Wataru/AAQ-9586-2020; Noda, Tetsuo/B-1667-2016	Herrera Merino, Pedro Luis/0000-0003-0771-9504				Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler AE, 2003, DIABETES, V52, P102, DOI 10.2337/diabetes.52.1.102; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005; Garofalo RS, 2003, J CLIN INVEST, V112, P197, DOI 10.1172/JCI200316885; Hashimoto N, 2005, J CLIN INVEST, V115, P138, DOI 10.1172/JCI200522232; Herrera PL, 2000, DEVELOPMENT, V127, P2317; INOUE H, IN PRESS CELL METAB; Ishihara H, 2004, HUM MOL GENET, V13, P1159, DOI 10.1093/hmg/ddh125; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Kubota N, 2004, J CLIN INVEST, V114, P917, DOI 10.1172/JCI200421484; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Lin XY, 2004, J CLIN INVEST, V114, P908, DOI [10.1172/JCI22217, 10.1172/JCI200422217]; Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Uchida T, 2005, NAT MED, V11, P175, DOI 10.1038/nm1187; UEKI K, 2006, NAT GENET; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116	28	174	184	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					589	593		10.1038/ng1774	http://dx.doi.org/10.1038/ng1774			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16642023				2022-12-25	WOS:000237147500023
J	Binne, UK; Classon, MK; Dick, FA; Wei, W; Rape, M; Kaelin, WG; Naar, AM; Dyson, NJ				Binne, Ulrich K.; Classon, Marie K.; Dick, Frederick A.; Wei, Wenyi; Rape, Michael; Kaelin, William G., Jr.; Naar, Anders M.; Dyson, Nicholas J.			Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit	NATURE CELL BIOLOGY			English	Article							UBIQUITIN LIGASE; DEGRADATION; BINDING; SKP2; PRB; DOMAIN; DIFFERENTIATION; TRANSCRIPTION; INHIBITOR; P27(KIP1)	The retinoblastoma protein (pRB) negatively regulates the progression from G1 to S phase of the cell cycle, in part, by repressing E2F-dependent transcription(1). pRB also possesses E2F-independent functions that contribute to cell-cycle control - for example, during pRB-mediated cell-cycle arrest pRB associates with Skp2, the F-box protein of the Skp1-Cullin-F-box protein (SCF) E3 ubiquitin ligase complex, and promotes the stability of the cyclin-dependent kinase-inhibitor p27(Kip1) through an unknown mechanism(2,3). Degradation of p27(Kip1) is mediated by ubiquitin-dependent targeting of p27(Kip1) by SCF-Skp2 (ref. 4). Here, we report a novel interaction between pRB and the anaphase-promoting complex/cyclosome (APC/C) that controls p27(Kip1) stability by targeting Skp2 for ubiquitin-mediated degradation. Cdh1, an activator of APC/C, not only interacts with pRB but is also required for a pRB-induced cell-cycle arrest. The results reveal an unexpected physical convergence between the pRB tumour-suppressor protein and E3 ligase complexes, and raise the possibility that pRB may direct APC/C to additional targets during pRB-mediated cell-cycle exit.	Massachusetts Gen Hosp, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Schulich Sch Med, Dept Biochem, London, ON N6A 4L6, Canada; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute	Dyson, NJ (corresponding author), Massachusetts Gen Hosp, Charlestown, MA 02129 USA.	Naar@helix.mgh.harvard.edu; Dyson@helix.mgh.harvard.edu		Rape, Michael/0000-0003-4849-6343	NCI NIH HHS [CA64402] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; ANG XL, 2004, SCI STKE E, V31; ANG XL, 2004, SCI STKE, pE31; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Castro A, 2005, ONCOGENE, V24, P314, DOI 10.1038/sj.onc.1207973; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Dick FA, 2000, MOL CELL BIOL, V20, P3715, DOI 10.1128/MCB.20.10.3715-3727.2000; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dick FA, 2002, J VIROL, V76, P6224, DOI 10.1128/JVI.76.12.6224-6234.2002; Dickins RA, 2005, NAT GENET, V37, P1289, DOI 10.1038/ng1651; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; Imaki H, 2003, CANCER RES, V63, P4607; Isaac CE, 2006, MOL CELL BIOL, V26, P3659, DOI 10.1128/MCB.26.9.3659-3671.2006; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Stroschein SL, 2001, GENE DEV, V15, P2822; Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; van Roessel P, 2004, CELL, V119, P707, DOI 10.1016/j.cell.2004.11.028; Vernell R, 2003, J BIOL CHEM, V278, P46124, DOI 10.1074/jbc.M304930200; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6	33	131	133	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2007	9	2					225	U140		10.1038/ncb1532	http://dx.doi.org/10.1038/ncb1532			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	131WR	17187060				2022-12-25	WOS:000243903000016
J	Varma, H; Voisine, C; DeMarco, CT; Cattaneo, E; Lo, DC; Hart, AC; Stockwell, BR				Varma, Hemant; Voisine, Cindy; DeMarco, C. Todd; Cattaneo, Elena; Lo, Donald C.; Hart, Anne C.; Stockwell, Brent R.			Selective inhibitors of death in mutant huntingtin cells	NATURE CHEMICAL BIOLOGY			English	Article							MOUSE MODEL; DISEASE; CASPASE-1	Huntington disease (HD) is an inherited neurodegenerative disorder with unclear pathophysiology. We developed a high-throughput assay in a neuronal cell culture model of HD, screened 43,685 compounds and identified 29 novel selective inhibitors of cell death in mutant huntingtin - expressing cells. Four compounds were active in diverse HD models, which suggests a role for cell death in HD; these compounds are mechanistic probes and potential drug leads for HD.	Columbia Univ, Dept Biol Sci, Fairchild Ctr, New York, NY 10027 USA; Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Pathol, Charlestown, MA 02129 USA; Duke Univ, Med Ctr, Ctr Drug Discovery, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27704 USA; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University; Harvard University; Massachusetts General Hospital; Harvard University; Duke University; Duke University; University of Milan; Columbia University	Stockwell, BR (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild Ctr, MC 2406,1212 Amsterdam Ave, New York, NY 10027 USA.	stockwell@biology.columbia.edu	Stockwell, Brent R/AAE-7200-2019; Voisine, Cindy/AAG-9045-2019	Stockwell, Brent R/0000-0002-3532-3868; CATTANEO, ELENA/0000-0002-0755-4917; Voisine, Cindy/0000-0001-7165-9636	Telethon [GGP06250] Funding Source: Medline	Telethon(Fondazione Telethon)		Aiken CT, 2004, NEUROBIOL DIS, V16, P546, DOI 10.1016/j.nbd.2004.04.001; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Di Prospero NA, 2005, NAT REV GENET, V6, P756, DOI 10.1038/nrg1690; Duennwald ML, 2006, P NATL ACAD SCI USA, V103, P11045, DOI 10.1073/pnas.0604547103; Faber PW, 2002, P NATL ACAD SCI USA, V99, P17131, DOI 10.1073/pnas.262544899; Graham RK, 2006, CELL, V125, P1179, DOI 10.1016/j.cell.2006.04.026; Mejia ROS, 2001, NEUROSCIENTIST, V7, P480, DOI 10.1177/107385840100700604; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Tobin AJ, 2000, TRENDS CELL BIOL, V10, P531, DOI 10.1016/S0962-8924(00)01853-5	11	36	41	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2007	3	2					99	100		10.1038/nchembio852	http://dx.doi.org/10.1038/nchembio852			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	128UZ	17195849				2022-12-25	WOS:000243685800012
J	Kametani, Y; Takeichi, M				Kametani, Yoshiko; Takeichi, Masatoshi			Basal-to-apical cadherin flow at cell junctions	NATURE CELL BIOLOGY			English	Article							RETROGRADE ACTIN FLOW; ADHERENS JUNCTIONS; ALPHA-CATENIN; GROWTH CONE; F-ACTIN; ADHESION; DYNAMICS; MORPHOGENESIS; PROTRUSION; MOTILITY	Stable cell-cell adhesion is essential for maintaining tissue integrity, but cells are also able to relocate, implying the existence of mechanisms for coordinating cell adhesion and movement. Here, we show that, in some transformed lines, cadherin adhesion molecules exhibit a flow-like movement in a basal-apical direction at the cell junction and that this flow is associated with reorganizing actin filaments. Such flow also occurs in normal epithelial sheets, but solely at the junctions formed by moving cells. We propose that cadherin flow may provide a mechanism for facilitating the sliding of the two contacting cell membranes in morphogenetically active cell sheets.	Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; RIKEN, Ctr Dev Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan	Kyoto University; RIKEN	Takeichi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan.	takeichi@cdb.riken.jp	Takeichi, Masatoshi/G-5903-2012	Takeichi, Masatoshi/0000-0002-9931-3378				Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Kobielak A, 2004, NAT REV MOL CELL BIO, V5, P614, DOI 10.1038/nrm1433; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Nicholson-Dykstra S, 2005, CURR BIOL, V15, pR346, DOI 10.1016/j.cub.2005.04.029; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; Nishimura K, 2003, J CELL BIOL, V163, P1077, DOI 10.1083/jcb.200303060; Park C, 2002, NAT GENET, V31, P279, DOI 10.1038/ng908; Ponti A, 2004, SCIENCE, V305, P1782, DOI 10.1126/science.1100533; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; SAITOH M, 1987, J BIOL CHEM, V262, P7796; Small JV, 2005, CURR OPIN CELL BIOL, V17, P517, DOI 10.1016/j.ceb.2005.08.004; Totsukawa G, 2004, J CELL BIOL, V164, P427, DOI 10.1083/jcb.200306172; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watanabe N, 2002, SCIENCE, V295, P1083, DOI 10.1126/science.1067470; Waterman-Storer CM, 2000, MOL BIOL CELL, V11, P2471, DOI 10.1091/mbc.11.7.2471; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Zhang XF, 2003, NEURON, V40, P931, DOI 10.1016/S0896-6273(03)00754-2	23	165	168	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					92	U118		10.1038/ncb1520	http://dx.doi.org/10.1038/ncb1520			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17159998				2022-12-25	WOS:000243255100017
J	Fox, JL				Fox, Jeffrey L.			The business of developing antibacterials	NATURE BIOTECHNOLOGY			English	Article																		Moore A, 2003, EMBO REP, V4, P114, DOI 10.1038/sj.embor.embor748; Mygind PH, 2005, NATURE, V437, P975, DOI 10.1038/nature04051	2	47	48	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1521	1528		10.1038/nbt1206-1521	http://dx.doi.org/10.1038/nbt1206-1521			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17160056				2022-12-25	WOS:000242795800029
J	Liu, CC; Schultz, PG				Liu, Chang C.; Schultz, Peter G.			Recombinant expression of selectively sulfated proteins in Escherichia coli	NATURE BIOTECHNOLOGY			English	Article							TIGHT-BINDING INHIBITORS; TYROSINE SULFATION; MASS-SPECTROMETRY; AMINO-TERMINUS; GENETIC-CODE; HIV-1 ENTRY; O-SULFATION; HIRUDIN; THROMBIN; IDENTIFICATION	Although tyrosine sulfation is a post- translational modification widespread across multicellular eukaryotes(1), its biological functions remain largely unknown. This is in part due to the difficulties of synthesizing selectively sulfated proteins. Here we report the selective incorporation of sulfotyrosine into proteins in bacteria by genetically encoding the modified amino acid in response to the amber nonsense codon TAG. Moreover, we show that this strategy enables direct expression in Escherichia coli of sulfo- hirudin, previously inaccessible through recombinant methods. The affinity of sulfo- hirudin toward human thrombin is enhanced more than tenfold over that of desulfo- hirudin, suggesting that sulfo- hirudin may offer clinical advantages for use as an anticoagulant(2). This general approach to the biosynthesis of sulfated proteins should facilitate further study and application of tyrosine sulfation.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA	Scripps Research Institute; Scripps Research Institute; Novartis	Liu, CC (corresponding author), Scripps Res Inst, Dept Chem, 1550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	ccliu@scripps.edu; schultz@scripps.edu		Liu, Chang/0000-0002-3290-2880	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062159] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62159] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagdy D, 1976, Methods Enzymol, V45, P669; Bose M, 2006, J AM CHEM SOC, V128, P388, DOI 10.1021/ja055467u; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CHA S, 1976, BIOCHEM PHARMACOL, V25, P2695, DOI 10.1016/0006-2952(76)90259-8; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; Di Nisio M, 2005, NEW ENGL J MED, V353, P1028, DOI 10.1056/NEJMra044440; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; KIRANO Y, 1987, J CHEM SOC CHEM COMM, P323; KOMATSU Y, 1993, BIOCHEM BIOPH RES CO, V196, P773, DOI 10.1006/bbrc.1993.2316; Markwardt F, 2002, SEMIN THROMB HEMOST, V28, P405, DOI 10.1055/s-2002-35292; Moore KL, 2003, J BIOL CHEM, V278, P24243, DOI 10.1074/jbc.R300008200; MURAMATSU R, 1994, EUR J BIOCHEM, V223, P243, DOI 10.1111/j.1432-1033.1994.tb18988.x; Nemeth-Cawley JF, 2001, J MASS SPECTROM, V36, P1301, DOI 10.1002/jms.235; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Ryu YH, 2006, NAT METHODS, V3, P263, DOI 10.1038/NMETH864; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SZEDLACSEK SE, 1995, METHOD ENZYMOL, V249, P144; Velan T, 2003, PATHOPHYSIOL HAEMO T, V33, P144, DOI 10.1159/000077823; Veldkamp CT, 2006, J MOL BIOL, V359, P1400, DOI 10.1016/j.jmb.2006.04.052; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wolfender JL, 1999, J MASS SPECTROM, V34, P447, DOI 10.1002/(SICI)1096-9888(199904)34:4<447::AID-JMS801>3.3.CO;2-T; Xiang SH, 2005, J VIROL, V79, P6068, DOI 10.1128/JVI.79.10.6068-6077.2005; Young T, 2002, ANGEW CHEM INT EDIT, V41, P3449, DOI 10.1002/1521-3773(20020916)41:18<3449::AID-ANIE3449>3.0.CO;2-U; Zhang ZW, 2004, P NATL ACAD SCI USA, V101, P8882, DOI 10.1073/pnas.0307029101	30	107	116	3	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2006	24	11					1436	1440		10.1038/nbt1254	http://dx.doi.org/10.1038/nbt1254			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	106TP	17072302				2022-12-25	WOS:000242124700041
J	Wu, SQ; Schalk, M; Clark, A; Miles, RB; Coates, R; Chappell, J				Wu, Shuiqin; Schalk, Michel; Clark, Anthony; Miles, R. Brandon; Coates, Robert; Chappell, Joe			Redirection of cytosolic or plastidic isoprenoid precursors elevates terpene production in plants	NATURE BIOTECHNOLOGY			English	Article							ESCHERICHIA-COLI; BIOSYNTHESIS; SYNTHASE; PATHWAY; ARABIDOPSIS; METABOLISM; MONOTERPENE; DIPHOSPHATE; MEVALONATE; EXPRESSION	Terpenes constitute a distinct class of natural products(1) that attract insects(2), defend against phytopathogenic microbes(3) and combat human diseases(4). However, like most natural products, they are usually made by plants and microbes in small amounts and as complex mixtures. Chemical synthesis is often costly and inefficient, and may not yield enantiomerically pure terpenes, whereas large- scale microbial production requires expensive feedstocks. We engineered high-level terpene production in tobacco plants by diverting carbon flow from cytosolic or plastidic isopentenyl diphosphate through overexpression in either compartment of an avian farnesyl diphosphate synthase and an appropriate terpene synthase. Isotopic labeling studies suggest little, if any, metabolite exchange between these two subcellular compartments. The strategy increased synthesis of the sesquiterpenes patchoulol and amorpha- 4,11- diene more than 1,000- fold, as well as the monoterpene limonene 10 - 30 fold, and seems equally suited to generating higher levels of other terpenes for research, industrial production or therapeutic applications.	Univ Kentucky, Dept Plant & Soil Sci, Lexington, KY 40546 USA; Firmenich Co, Corp R&D Div, CH-1211 Geneva, Switzerland; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Kentucky; Firmenich; University of Illinois System; University of Illinois Urbana-Champaign	Chappell, J (corresponding author), Univ Kentucky, Dept Plant & Soil Sci, Lexington, KY 40546 USA.	chappell@uky.edu			NIGMS NIH HHS [GM 13956] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam KP, 1998, ARCH BIOCHEM BIOPHYS, V354, P181, DOI 10.1006/abbi.1998.0666; Aharoni A, 2004, PLANT CELL, V16, P3110, DOI 10.1105/tpc.104.023895; Aharoni A, 2003, PLANT CELL, V15, P2866, DOI 10.1105/tpc.016253; Arantes SF, 1999, PHYTOCHEMISTRY, V52, P635; Bauer K., 2008, COMMON FRAGRANCE FLA; Besumbes O, 2004, BIOTECHNOL BIOENG, V88, P168, DOI 10.1002/bit.20237; Brodelius M, 2002, EUR J BIOCHEM, V269, P3570, DOI 10.1046/j.1432-1033.2002.03044.x; BUCKINGHAM J, 2003, DICT NATURAL PRODUCT; Burke C, 2002, J BIOL CHEM, V277, P3141, DOI 10.1074/jbc.M105900200; Carter OA, 2003, PHYTOCHEMISTRY, V64, P425, DOI 10.1016/S0031-9422(03)00204-8; CHAPPELL J, 1995, PLANT PHYSIOL, V109, P1337, DOI 10.1104/pp.109.4.1337; Dewick, 2002, MED NATURAL PRODUCTS; Dinkins RD, 2003, PLANT SCI, V165, P751, DOI 10.1016/S0168-9452(03)00236-X; DUGUERRY F, IN PRESS ARCH BIOCH; Gardner RG, 1999, J BIOL CHEM, V274, P31671, DOI 10.1074/jbc.274.44.31671; Hemmerlin A, 2003, J BIOL CHEM, V278, P26666, DOI 10.1074/jbc.M302526200; Jackson BE, 2003, ORG LETT, V5, P1629, DOI 10.1021/ol034231x; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kang MJ, 2005, BIOTECHNOL BIOENG, V91, P636, DOI 10.1002/bit.20539; Kappers IF, 2005, SCIENCE, V309, P2070, DOI 10.1126/science.1116232; Mahmoud SS, 2001, P NATL ACAD SCI USA, V98, P8915, DOI 10.1073/pnas.141237298; Martin VJJ, 2003, NAT BIOTECHNOL, V21, P796, DOI 10.1038/nbt833; NESZMELYI A, 1981, J CHEM SOC CHEM COMM, P999, DOI 10.1039/c39810000999; Reiling KK, 2004, BIOTECHNOL BIOENG, V87, P200, DOI 10.1002/bit.20128; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; STOESSL A, 1976, PHYTOCHEMISTRY, V15, P855, DOI 10.1016/S0031-9422(00)84361-7; TAKAHASHI S, IN PRESS BIOTECHNOL; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; Wallaart TE, 2001, PLANTA, V212, P460, DOI 10.1007/s004250000428; Wang EM, 2003, PLANTA, V216, P686, DOI 10.1007/s00425-002-0904-4; Zook M, 1996, PLANT PHYSIOL, V112, P311, DOI 10.1104/pp.112.1.311	31	251	297	4	91	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2006	24	11					1441	1447		10.1038/nbt1251	http://dx.doi.org/10.1038/nbt1251			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	106TP	17057703				2022-12-25	WOS:000242124700042
J	Martin, AC; Welch, MD; Drubin, DG				Martin, Adam C.; Welch, Matthew D.; Drubin, David G.			Arp2/3 ATP hydrolysis-catalysed branch dissociation is critical for endocytic force generation	NATURE CELL BIOLOGY			English	Article							ACTIN-BASED MOTILITY; SACCHAROMYCES-CEREVISIAE; MEDIATED ENDOCYTOSIS; BUDDING YEAST; IN-VIVO; COMPLEX; PROTEIN; FILAMENT; MECHANISM; INTERNALIZATION	The Arp2/3 complex, which is crucial for actin-based motility, nucleates actin filaments and organizes them into y-branched networks. The Arp2 subunit has been shown to hydrolyse ATP, but the functional importance of Arp2/3 ATP hydrolysis is not known. Here, we analysed an Arp2 mutant in Saccharomyces cerevisiae that is defective in ATP hydrolysis. Arp2 ATP hydrolysis and Arp2/3-dependent actin nucleation occur almost simultaneously. However, ATP hydrolysis is not required for nucleation. In addition, Arp2 ATP hydrolysis is not required for the release of a WASP-like activator from y-branches. ATP hydrolysis by Arp2, and possibly Arp3, is essential for efficient y-branch dissociation in vitro. In living cells, both Arp2 and Arp3 ATP-hydrolysis mutants exhibit defects in endocytic internalization and actin-network disassembly. Our results suggest a critical feature of dendritic nucleation in which debranching and subsequent actin-filament remodelling and/or depolymerization are important for endocytic vesicle morphogenesis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Drubin, DG (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 16 Barker Hall, Berkeley, CA 94720 USA.	drubin@socrates.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042759, R01GM059609, R01GM042759, R01GM050399] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59609, R01 GM059609-07, GM50399, GM42759, R01 GM059609] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanchoin L, 2000, CURR BIOL, V10, P1273, DOI 10.1016/S0960-9822(00)00749-1; Blanchoin L, 1999, J BIOL CHEM, V274, P15538, DOI 10.1074/jbc.274.22.15538; Dayel MJ, 2004, PLOS BIOL, V2, P476, DOI 10.1371/journal.pbio.0020091; Dayel MJ, 2001, P NATL ACAD SCI USA, V98, P14871, DOI 10.1073/pnas.261419298; Duncan MC, 2001, NAT CELL BIOL, V3, P687, DOI 10.1038/35083087; Egile C, 2005, PLOS BIOL, V3, P1902, DOI 10.1371/journal.pbio.0030383; Goley ED, 2004, MOL CELL, V16, P269, DOI 10.1016/j.molcel.2004.09.018; Huckaba TM, 2004, J CELL BIOL, V167, P519, DOI 10.1083/jcb.200404173; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kaksonen M, 2005, CELL, V123, P305, DOI 10.1016/j.cell.2005.09.024; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Le Clainche C, 2003, P NATL ACAD SCI USA, V100, P6337, DOI 10.1073/pnas.1130513100; Le Clainche C, 2001, J BIOL CHEM, V276, P46689, DOI 10.1074/jbc.C100476200; Martin AC, 2005, J CELL BIOL, V168, P315, DOI 10.1083/jcb.200408177; Moreau V, 1996, J CELL BIOL, V134, P117, DOI 10.1083/jcb.134.1.117; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Newpher TM, 2005, DEV CELL, V9, P87, DOI 10.1016/j.devcel.2005.04.014; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pantaloni D, 2000, NAT CELL BIOL, V2, P385, DOI 10.1038/35017011; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Rodal AA, 1999, J CELL BIOL, V145, P1251, DOI 10.1083/jcb.145.6.1251; Rodal AA, 2003, CURR BIOL, V13, P1000, DOI 10.1016/S0960-9822(03)00383-X; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; Toshima J, 2005, NAT CELL BIOL, V7, P246, DOI 10.1038/ncb1229; Toshima JY, 2006, P NATL ACAD SCI USA, V103, P5793, DOI 10.1073/pnas.0601042103; Volkmann N, 2001, SCIENCE, V293, P2456, DOI 10.1126/science.1063025; Vorobiev S, 2003, P NATL ACAD SCI USA, V100, P5760, DOI 10.1073/pnas.0832273100; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Welch MD, 1997, NATURE, V385, P265, DOI 10.1038/385265a0; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5	30	63	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					826	U71		10.1038/ncb1443	http://dx.doi.org/10.1038/ncb1443			18	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16862144				2022-12-25	WOS:000239423000012
J	Delmaghani, S; del Castillo, FJ; Michel, V; Leibovici, M; Aghaie, A; Ron, U; Van Laer, L; Ben-Tal, N; Van Camp, G; Weil, D; Langa, F; Lathrop, M; Avan, P; Petit, C				Delmaghani, Sedigheh; del Castillo, Francisco J.; Michel, Vincent; Leibovici, Michel; Aghaie, Asadollah; Ron, Uri; Van Laer, Lut; Ben-Tal, Nir; Van Camp, Guy; Weil, Dominique; Langa, Francina; Lathrop, Mark; Avan, Paul; Petit, Christine			Mutations in the gene encoding pejvakin, a newly identified protein of the afferent auditory pathway, cause DFNB59 auditory neuropathy	NATURE GENETICS			English	Article							HEARING IMPAIRMENT; OTOFERLIN; SYSTEM; INNER; MICE; OTOF	Auditory neuropathy is a particular type of hearing impairment in which neural transmission of the auditory signal is impaired, while cochlear outer hair cells remain functional. Here we report on DFNB59, a newly identified gene on chromosome 2q31.1-q31.3 mutated in four families segregating autosomal recessive auditory neuropathy. DFNB59 encodes pejvakin, a 352-residue protein. Pejvakin is a paralog of DFNA5, a protein of unknown function also involved in deafness. By immunohistofluorescence, pejvakin is detected in the cell bodies of neurons of the afferent auditory pathway. Furthermore, Dfnb59 knock-in mice, homozygous for the R183W variant identified in one DFNB59 family, show abnormal auditory brainstem responses indicative of neuronal dysfunction along the auditory pathway. Unlike previously described sensorineural deafness genes, all of which underlie cochlear cell pathologies, DFNB59 is the first human gene implicated in nonsyndromic deafness due to a neuronal defect.	Inst Pasteur, INSERM, Unite Genet Deficits Sensoriels, U587, F-75724 Paris 15, France; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; Univ Antwerp, Dept Med Genet, B-2020 Antwerp, Belgium; Inst Pasteur, Ctr Ingn Genet Murine, Paris, France; Ctr Natl Genotypage, Evry, France; Univ Auvergne, Lab Biophys Sensorielle, Fac Med, Clermont Ferrand, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Tel Aviv University; University of Antwerp; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; CEA; UDICE-French Research Universities; Universite Paris Saclay; Universite Clermont Auvergne (UCA)	Petit, C (corresponding author), Inst Pasteur, INSERM, Unite Genet Deficits Sensoriels, U587, 25,Rue Dr Roux, F-75724 Paris 15, France.	cpetit@pasteur.fr	Van Camp, Guy/F-3386-2013; AVAN, Paul/J-6878-2015; Leibovici, Michel/ABB-6745-2020; del Castillo, Francisco J./A-6467-2013	Van Camp, Guy/0000-0001-5105-9000; AVAN, Paul/0000-0003-1054-1479; del Castillo, Francisco J./0000-0003-0467-4320; Petit, Christine/0000-0002-9069-002X; Ben-Tal, Nir/0000-0001-6901-832X; Delmaghani, Sedigheh/0000-0003-2092-5097; Aghaie, Asadollah Alain/0000-0002-3247-7087; Vincent, Michel/0000-0002-7025-4343				Adato A, 2005, HUM MOL GENET, V14, P347, DOI 10.1093/hmg/ddi031; Berezin C, 2004, BIOINFORMATICS, V20, P1322, DOI 10.1093/bioinformatics/bth070; Cohen-Salmon M, 1997, P NATL ACAD SCI USA, V94, P14450, DOI 10.1073/pnas.94.26.14450; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Cone-Wesson Barbara, 2000, CURR OPIN OTOLARYNGO, V8, P421; Dirks DD, 2000, EAR: COMPREHENSIVE OTOLOGY, P231; Durrant JD, 1998, J ACOUST SOC AM, V104, P370, DOI 10.1121/1.423293; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Katoh M, 2004, INT J ONCOL, V25, P765; Kemp DT, 2002, BRIT MED BULL, V63, P223, DOI 10.1093/bmb/63.1.223; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Kress C, 1998, MAMM GENOME, V9, P998, DOI 10.1007/s003359900914; Kussel-Andermann P, 2000, EMBO J, V19, P6020, DOI 10.1093/emboj/19.22.6020; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; LIBERMAN MC, 1982, SCIENCE, V216, P1239, DOI 10.1126/science.7079757; Liu PT, 2003, GENOME RES, V13, P476, DOI 10.1101/gr.749203; Lunny DP, 2005, J INVEST DERMATOL, V124, P615, DOI 10.1111/j.0022-202X.2005.23623.x; MATISE MP, 1999, GENE TARGETING PRACT, P101; Oertel D, 1999, ANNU REV PHYSIOL, V61, P497, DOI 10.1146/annurev.physiol.61.1.497; Pulleyn LJ, 2000, EUR J HUM GENET, V8, P991, DOI 10.1038/sj.ejhg.5200567; Rance Gary, 2005, Trends Amplif, V9, P1, DOI 10.1177/108471380500900102; Rapin I, 2003, INT J PEDIATR OTORHI, V67, P707, DOI 10.1016/S0165-5876(03)00103-4; Rodriguez-Ballesteros M, 2003, HUM MUTAT, V22, P451, DOI 10.1002/humu.10274; Romand R, 1997, PROG NEUROBIOL, V51, P1, DOI 10.1016/S0301-0082(96)00043-3; Rouiller EM, 1997, CENTRAL AUDITORY SYS, P3; Rubel EW, 2002, ANNU REV NEUROSCI, V25, P51, DOI 10.1146/annurev.neuro.25.112701.142849; Runkel F, 2004, GENOMICS, V84, P824, DOI 10.1016/j.ygeno.2004.07.003; Schaffer AA, 1996, HUM HERED, V46, P226, DOI 10.1159/000154358; Sininger Yvonne S., 2002, Seminars in Hearing, V23, P193, DOI 10.1055/s-2002-34456; Starr A., 2000, Journal of Basic and Clinical Physiology and Pharmacology, V11, P215; Starr A, 1996, BRAIN, V119, P741, DOI 10.1093/brain/119.3.741; STEEL KP, 1996, WHATS WRONG MY MOUSE, P26; Van Laer L, 2005, NEUROBIOL DIS, V19, P386, DOI 10.1016/j.nbd.2005.01.019; Van Laer L, 1998, NAT GENET, V20, P194; Varga R, 2003, J MED GENET, V40, P45, DOI 10.1136/jmg.40.1.45; Yasunaga S, 1999, NAT GENET, V21, P363, DOI 10.1038/7693; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9	40	191	232	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					770	778		10.1038/ng1829	http://dx.doi.org/10.1038/ng1829			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16804542				2022-12-25	WOS:000238669300012
J	Bar-Even, A; Paulsson, J; Maheshri, N; Carmi, M; O'Shea, E; Pilpel, Y; Barkai, N				Bar-Even, Arren; Paulsson, Johan; Maheshri, Narendra; Carmi, Miri; O'Shea, Erin; Pilpel, Yitzhak; Barkai, Naama			Noise in protein expression scales with natural protein abundance	NATURE GENETICS			English	Article							STOCHASTIC GENE-EXPRESSION; ESCHERICHIA-COLI; SINGLE-CELL; GLOBAL ANALYSIS; NETWORKS; YEAST; FLUCTUATIONS; POPULATION; MECHANISMS; MODEL	Noise in gene expression is generated at multiple levels, such as transcription and translation, chromatin remodeling and pathway-specific regulation. Studies of individual promoters have suggested different dominating noise sources, raising the question of whether a general trend exists across a large number of genes and conditions. We examined the variation in the expression levels of 43 Saccharomyces cerevisiae proteins, in cells grown under 11 experimental conditions. For all classes of genes and under all conditions, the expression variance was approximately proportional to the mean; the same scaling was observed at steady state and during the transient responses to the perturbations. Theoretical analysis suggests that this scaling behavior reflects variability in mRNA copy number, resulting from random 'birth and death' of mRNA molecules or from promoter fluctuations. Deviation of coexpressed genes from this general trend, including high noise in stress-related genes and low noise in proteasomal genes, may indicate fluctuations in pathway-specific regulators or a differential activation pattern of the underlying gene promoters.	Harvard Univ, Dept Syst Biol, Boston, MA 02115 USA; Univ Cambridge, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England; Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Weizmann Inst Sci, Phys Complex Syst, IL-76100 Rehovot, Israel	Harvard University; University of Cambridge; Harvard University; Howard Hughes Medical Institute; Weizmann Institute of Science	Pilpel, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	pilpel@weizmann.ac.il; naama.barkai@weizmann.ac.il		Bar-Even, Arren/0000-0002-1039-4328				Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Becskei A, 2005, NAT GENET, V37, P937, DOI 10.1038/ng1616; Berg OG, 2000, BIOPHYS J, V79, P1228, DOI 10.1016/S0006-3495(00)76377-6; BERG OG, 1978, J THEOR BIOL, V71, P587, DOI 10.1016/0022-5193(78)90326-0; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Colman-Lerner A, 2005, NATURE, V437, P699, DOI 10.1038/nature03998; de Menezes MA, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.068701; de Menezes MA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.028701; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Fraser HB, 2004, PLOS BIOL, V2, P834, DOI 10.1371/journal.pbio.0020137; Garcia-Martinez J, 2004, MOL CELL, V15, P303, DOI 10.1016/j.molcel.2004.06.004; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; Kussell E, 2005, SCIENCE, V309, P2075, DOI 10.1126/science.1114383; Lobner-Olesen A, 1999, EMBO J, V18, P1712, DOI 10.1093/emboj/18.6.1712; MALONEY PC, 1973, J MOL BIOL, V73, P77, DOI 10.1016/0022-2836(73)90160-5; McAdams HH, 1999, TRENDS GENET, V15, P65, DOI 10.1016/S0168-9525(98)01659-X; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; NEWMAN JRS, IN PRESS NATURE; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257; Paulsson J, 2005, PHYS LIFE REV, V2, P157, DOI 10.1016/j.plrev.2005.03.003; PECCOUD J, 1995, THEOR POPUL BIOL, V48, P222, DOI 10.1006/tpbi.1995.1027; Pedraza JM, 2005, SCIENCE, V307, P1965, DOI 10.1126/science.1109090; Rao CV, 2002, NATURE, V420, P231, DOI 10.1038/nature01258; Raser JM, 2005, SCIENCE, V309, P2010, DOI 10.1126/science.1105891; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; RIGNEY DR, 1977, J THEOR BIOL, V69, P761, DOI 10.1016/0022-5193(77)90381-2; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; SPUDICH JL, 1976, NATURE, V262, P467, DOI 10.1038/262467a0; Swain PS, 2002, P NATL ACAD SCI USA, V99, P12795, DOI 10.1073/pnas.162041399; Thattai M, 2001, P NATL ACAD SCI USA, V98, P8614, DOI 10.1073/pnas.151588598; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; VOLFSON D, 2005, NATURE; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799	40	588	590	3	83	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2006	38	6					636	643		10.1038/ng1807	http://dx.doi.org/10.1038/ng1807			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16715097				2022-12-25	WOS:000237954800016
J	Barrett, JC; Cardon, LR				Barrett, Jeffrey C.; Cardon, Lon R.			Evaluating coverage of genome-wide association studies	NATURE GENETICS			English	Article							LINKAGE DISEQUILIBRIUM; COMPLEX DISEASE; POLYMORPHISM; FUTURE; POWER	Genome-wide association studies involving hundreds of thousands of SNPs in thousands of cases and controls are now underway. The first of many analytical challenges in these studies involves the choice of SNPs to genotype. It is not practical to construct a different panel of tag SNPs for each study, so the first generation of genome-wide scans will use predefined, commercially available marker panels, which will in part dictate their success or failure. We compare different approaches in use today, and show that although many of them provide substantial coverage of common variation in non-African populations, the precise extent is strongly dependent on the frequencies of alleles of interest and on specific considerations of study design. Overall, despite substantial differences in genotyping technologies, marker selection strategies and number of markers assayed, the first-generation high-throughput platforms all offer similar levels of genome coverage.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	University of Oxford; Wellcome Centre for Human Genetics	Cardon, LR (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	lon.cardon@well.ox.ac.uk		Barrett, Jeffrey/0000-0002-1152-370X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Clayton DG, 2005, NAT GENET, V37, P1243, DOI 10.1038/ng1653; DALY M, 2006, NAT GENET       0521; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Dong SL, 2001, GENOME RES, V11, P1418, DOI 10.1101/gr.171101; Hardenbol P, 2005, GENOME RES, V15, P269, DOI 10.1101/gr.3185605; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Jorgenson E, 2006, AM J HUM GENET, V78, P884, DOI 10.1086/503751; Ke XY, 2005, HUM MOL GENET, V14, P2757, DOI 10.1093/hmg/ddi309; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Neale BM, 2004, AM J HUM GENET, V75, P353, DOI 10.1086/423901; Palmer LJ, 2005, LANCET, V366, P1223, DOI 10.1016/S0140-6736(05)67485-5; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Rieder MJ, 2005, NEW ENGL J MED, V352, P2285, DOI 10.1056/NEJMoa044503; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522	19	308	338	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					659	662		10.1038/ng1801	http://dx.doi.org/10.1038/ng1801			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16715099				2022-12-25	WOS:000237954800019
J	Venkatesha, S; Toporsian, M; Lam, C; Hanai, J; Mammoto, T; Kim, YM; Bdolah, Y; Lim, KH; Yuan, HT; Libermann, TA; Stillman, IE; Roberts, D; D'Amore, PA; Epstein, FH; Sellke, FW; Romero, R; Sukhatme, VP; Letarte, M; Karumanchi, SA				Venkatesha, Shivalingappa; Toporsian, Mourad; Lam, Chun; Hanai, Jun-ichi; Mammoto, Tadanori; Kim, Yeon M.; Bdolah, Yuval; Lim, Kee-Hak; Yuan, Hai-Tao; Libermann, Towia A.; Stillman, Isaac E.; Roberts, Drucilla; D'Amore, Patricia A.; Epstein, Franklin H.; Sellke, Frank W.; Romero, Roberto; Sukhatme, Vikas P.; Letarte, Michelle; Karumanchi, S. Ananth			Soluble endoglin contributes to the pathogenesis of preeclampsia	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; ELEVATED LIVER-ENZYMES; BETA BINDING-PROTEIN; HUMAN CYTOTROPHOBLASTS; PLASMA; PATHOPHYSIOLOGY; ANGIOGENESIS; HYPERTENSION; PROSTACYCLIN	Preeclampsia is a pregnancy-specific hypertensive syndrome that causes substantial maternal and fetal morbidity and mortality. Maternal endothelial dysfunction mediated by excess placenta-derived soluble VEGF receptor 1 ( sVEGFR1 or sFlt1) is emerging as a prominent component in disease pathogenesis. We report a novel placenta-derived soluble TGF-beta coreceptor, endoglin ( sEng), which is elevated in the sera of preeclamptic individuals, correlates with disease severity and falls after delivery. sEng inhibits formation of capillary tubes in vitro and induces vascular permeability and hypertension in vivo. Its effects in pregnant rats are amplified by coadministration of sFlt1, leading to severe preeclampsia including the HELLP ( hemolysis, elevated liver enzymes, low platelets) syndrome and restriction of fetal growth. sEng impairs binding of TGF-beta 1 to its receptors and downstream signaling including effects on activation of eNOS and vasodilation, suggesting that sEng leads to dysregulated TGF-beta signaling in the vasculature. Our results suggest that sEng may act in concert with sFlt1 to induce severe preeclampsia.	Beth Israel Deaconess Med Ctr, Dept Med, Ctr Vasc Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Ctr Vasc Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Ctr Vasc Biol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Ctr Vasc Biol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Heart & Stroke Fdn, Richard Lewar Ctr Excellence, Toronto, ON M5G 1X8, Canada; NICHHD, Perinatol Res Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Wayne State Univ, Sch Med, Detroit, MI 48201 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Schepens Eye Res Inst, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Wayne State University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Schepens Eye Research Institute	Karumanchi, SA (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Ctr Vasc Biol, Boston, MA 02215 USA.	sananth@bidmc.harvard.edu	Karumanchi, Subbian Ananth/AAI-1694-2021; Stillman, Isaac E/ABC-7278-2020; Sukhatme, Vikas/W-2776-2019; D'Amore, Patricia A/G-5660-2017; Libermann, Towia/F-9866-2010; Roberts, Drucilla/AAB-6379-2022; Romero, Roberto/A-5268-2019	D'Amore, Patricia A/0000-0001-9652-8974; Toporsian, Mourad/0000-0002-8430-2094; Libermann, Towia/0000-0002-4006-8179; Romero, Roberto/0000-0002-4448-5121	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD002400] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK064255] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL079594] Funding Source: Medline; NIDDK NIH HHS [DK064255] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACOG, 2002, OBSTET GYNECOL, V99, P869; Ahmad S, 2004, CIRC RES, V95, P884, DOI 10.1161/01.RES.0000147365.86159.f5; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bdolah Y, 2004, SEMIN NEPHROL, V24, P548, DOI 10.1016/S0270-9295(04)00125-1; Benian A, 2002, OBSTET GYNECOL, V100, P327, DOI 10.1016/S0029-7844(02)02077-X; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; BROWN MA, 1989, CLIN SCI, V77, P599, DOI 10.1042/cs0770599; Caniggia I, 1997, ENDOCRINOLOGY, V138, P4977, DOI 10.1210/en.138.11.4977; Chaiworapongsa T, 2004, AM J OBSTET GYNECOL, V190, P1541, DOI 10.1016/j.ajog.2004.03.043; Chaiworapongsa T, 2005, J MATERN-FETAL NEO M, V17, P3, DOI 10.1080/14767050400028816; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fonsatti E, 2003, CURR DRUG TARGETS, V4, P291, DOI 10.2174/1389450033491073; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GOUGOS A, 1992, INT IMMUNOL, V4, P83, DOI 10.1093/intimm/4.1.83; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hennessy A, 2002, CLIN EXP PHARMACOL P, V29, P968, DOI 10.1046/j.1440-1681.2002.03763.x; Hertig A, 2004, CLIN CHEM, V50, P1702, DOI 10.1373/clinchem.2004.036715; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; INOUE N, 1995, ARTERIOSCL THROM VAS, V15, P1255, DOI 10.1161/01.ATV.15.8.1255; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Li CG, 2000, INT J CANCER, V89, P122, DOI 10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lowe DT, 2000, NITRIC OXIDE-BIOL CH, V4, P441, DOI 10.1006/niox.2000.0296; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Mills JL, 1999, JAMA-J AM MED ASSOC, V282, P356, DOI 10.1001/jama.282.4.356; Muy-Rivera M, 2004, AM J HYPERTENS, V17, P334, DOI 10.1016/j.amjhyper.2003.12.010; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Predescu D, 2005, AM J PHYSIOL-LUNG C, V289, pL371, DOI 10.1152/ajplung.00175.2004; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; RISTIMAKI A, 1990, ARTERIOSCLEROSIS, V10, P653, DOI 10.1161/01.ATV.10.4.653; ROBERTS JM, 1989, AM J OBSTET GYNECOL, V161, P1200, DOI 10.1016/0002-9378(89)90665-0; ROMERO R, 1989, AM J PERINAT, V6, P32, DOI 10.1055/s-2007-999540; Saura M, 2002, CIRC RES, V91, P806, DOI 10.1161/01.RES.0000040397.23817.E5; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)71003-5; STJACQUES S, 1994, BIOL REPROD, V51, P405, DOI 10.1095/biolreprod51.3.405; Tatsumi M, 2000, THROMB RES, V98, P451, DOI 10.1016/S0049-3848(00)00190-0; Taylor RN, 2003, AM J OBSTET GYNECOL, V188, P177, DOI 10.1067/mob.2003.111; Toporsian M, 2005, CIRC RES, V96, P684, DOI 10.1161/01.res.0000159936.38601.22; Velasco-Loyden G, 2004, J BIOL CHEM, V279, P7721, DOI 10.1074/jbc.M306499200; WEINSTEIN L, 1982, AM J OBSTET GYNECOL, V142, P159, DOI 10.1016/S0002-9378(16)32330-4; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; Zhou Y, 1997, J CLIN INVEST, V99, P2152, DOI 10.1172/JCI119388; Zhou Y, 2002, AM J PATHOL, V160, P1405, DOI 10.1016/S0002-9440(10)62567-9	50	1334	1392	1	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					642	649		10.1038/nm1429	http://dx.doi.org/10.1038/nm1429			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16751767				2022-12-25	WOS:000238149200025
J	Yamada, T; Kawano, H; Koshizuka, Y; Fukuda, T; Yoshimura, K; Kamekura, S; Saito, T; Ikeda, T; Kawasaki, Y; Azuma, Y; Ikegawa, S; Hoshi, K; Chung, UI; Nakamura, K; Kato, S; Kawaguchi, H				Yamada, Takashi; Kawano, Hirotaka; Koshizuka, Yu; Fukuda, Toru; Yoshimura, Kimihiro; Kamekura, Satoru; Saito, Taku; Ikeda, Toshiyuki; Kawasaki, Yosuke; Azuma, Yoshiaki; Ikegawa, Shiro; Hoshi, Kazuto; Chung, Ung-il; Nakamura, Kozo; Kato, Shigeaki; Kawaguchi, Hiroshi			Carminerin contributes to chondrocyte calcification during endochondral ossification	NATURE MEDICINE			English	Article							DIFFERENTIATION; EXPRESSION; PROTEIN; PC-1; CARTILAGE; PATHWAYS; ROLES; STEPS	Endochondral ossification is an essential process not only for physiological skeletal development and growth, but also for pathological disorders. We recently identified a novel cartilage-specific molecule, carminerin ( also known as cystatin 10 and encoded by Cst10), which is upregulated in synchrony with cartilage maturation and stimulates the later differentiation of cultured chondrocytes(1). Although carminerin-deficient ( Cst10(-/-)) mice developed and grew normally, they had a microscopic decrease in the calcification of hypertrophic chondrocytes at the growth plate. When we created experimental models of pathological endochondral ossification, we observed suppression of chondrocyte calcification during formation of osteoarthritic osteophytes, age-related ectopic ossification and healing of bone fractures in Cst10(-/-) mice. Cultured Cst10(-/-) chondrocytes showed a reduction in calcification with activation of an SRY site in the promoter of the gene encoding nucleotide pyrophosphatase phosphodiesterase 1 ( NPP1, encoded by Enpp1). Functional NPP1 is required for carminerin deficiency to suppress the pathological endochondral ossifications listed above. Carminerin is the first cartilage-specific protein that contributes to chondrocyte calcification during endochondral ossification under physiological and pathological conditions through the transcriptional inhibition of NPP1.	Univ Tokyo, Fac Med, Dept Sensory & Motor Syst Med, Tokyo 1138655, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; RIKEN, Inst Phys & Chem Res, Tokyo 1068639, Japan; Teijin Inst Biomed Res, Hino, Tokyo 1918512, Japan	University of Tokyo; University of Tokyo; RIKEN	Kawaguchi, H (corresponding author), Univ Tokyo, Fac Med, Dept Sensory & Motor Syst Med, Hongo 7-3-1, Tokyo 1138655, Japan.	kawaguchi-ort@h.u-tokyo.ac.jp	Ikeda, Toshiyuki/GVS-5588-2022; Saito, Takashi/C-9684-2009; Ikegawa, Shiro/N-6895-2015	Saito, Takashi/0000-0001-9495-3547; Ikegawa, Shiro/0000-0003-0316-2147				Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Chikuda H, 2004, GENE DEV, V18, P2418, DOI 10.1101/gad.1224204; de Crombrugghe B, 2001, CURR OPIN CELL BIOL, V13, P721, DOI 10.1016/S0955-0674(00)00276-3; Goldfine ID, 1999, ANN NY ACAD SCI, V892, P204, DOI 10.1111/j.1749-6632.1999.tb07797.x; Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10; Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004; Koshizuka Y, 2003, J BIOL CHEM, V278, P48259, DOI 10.1074/jbc.M211639200; Laroche M, 2001, JOINT BONE SPINE, V68, P211, DOI 10.1016/S1297-319X(01)00274-3; LOTZ M, 1995, P NATL ACAD SCI USA, V92, P10364, DOI 10.1073/pnas.92.22.10364; MANKIN HJ, 1981, J BONE JOINT SURG AM, V63, P131, DOI 10.2106/00004623-198163010-00017; Nakamichi Y, 2003, MOL CELL BIOL, V23, P636, DOI 10.1128/MCB.23.2.636-644.2003; Okawa A, 1998, NAT GENET, V19, P271, DOI 10.1038/956; OYAJOBI BO, 1994, J BONE MINER RES, V9, P99; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Ryan LM, 2001, ARTHRITIS RES, V3, P77, DOI 10.1186/ar143; Shimoaka T, 2004, J BIOL CHEM, V279, P15314, DOI 10.1074/jbc.M312525200; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Solan JL, 1996, J BONE MINER RES, V11, P183; Terkeltaub RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1; WOLBACH SB, 1947, J BONE JOINT SURG, V29, P171	22	47	49	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					665	670		10.1038/nm1409	http://dx.doi.org/10.1038/nm1409			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16680148				2022-12-25	WOS:000238149200028
J	Toydemir, RM; Rutherford, A; Whitby, FG; Jorde, LB; Carey, JC; Bamshad, MJ				Toydemir, RM; Rutherford, A; Whitby, FG; Jorde, LB; Carey, JC; Bamshad, MJ			Mutations in embryonic myosin heavy chain (MYH3) cause Freeman- Sheldon syndrome and Sheldon-Hall syndrome	NATURE GENETICS			English	Article							MUSCLE ALPHA-ACTIN; DISTAL ARTHROGRYPOSES; MISSENSE MUTATION; MYOPATHY; GENE; CARDIOMYOPATHY; COMPLEX; VARIANT; ERRORS; LOCUS	The genetic basis of most conditions characterized by congenital contractures is largely unknown. Here we show that mutations in the embryonic myosin heavy chain (MYH3) gene cause Freeman-Sheldon syndrome (FSS), one of the most severe multiple congenital contracture (that is, arthrogryposis) syndromes, and nearly one-third of all cases of Sheldon-Hall syndrome (SHS), the most common distal arthrogryposis. FSS and SHS mutations affect different myosin residues, demonstrating that MYH3 genotype is predictive of phenotype. A structure-function analysis shows that nearly all of the MYH3 mutations are predicted to interfere with myosin's catalytic activity. These results add to the growing body of evidence showing that congenital contractures are a shared outcome of prenatal defects in myofiber force production. Elucidation of the genetic basis of these syndromes redefines congenital contractures as unique defects of the sarcomere and provides insights about what has heretofore been a poorly understood group of disorders.	Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Utah, Dept Human Genet, Salt Lake City, UT USA; Univ Utah, Dept Pediat, Salt Lake City, UT USA; Univ Utah, Dept Biochem, Salt Lake City, UT USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Bamshad, MJ (corresponding author), Univ Washington, Dept Pediat, Seattle, WA 98195 USA.	mbamshad@u.washington.edu	Toydemir, Reha/U-9739-2019	Toydemir, Reha M./0000-0002-0797-1999				Agrawal PB, 2004, ANN NEUROL, V56, P86, DOI 10.1002/ana.20157; Allingham JS, 2005, NAT STRUCT MOL BIOL, V12, P378, DOI 10.1038/nsmb908; Bamshad M, 1996, AM J MED GENET, V65, P277, DOI 10.1002/(SICI)1096-8628(19961111)65:4<277::AID-AJMG6>3.0.CO;2-M; Bamshad M, 1996, AM J MED GENET, V65, P282, DOI 10.1002/(SICI)1096-8628(19961111)65:4<282::AID-AJMG7>3.0.CO;2-R; BURIAN F, 1963, Br J Plast Surg, V16, P140, DOI 10.1016/S0007-1226(63)80095-8; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; ELLER M, 1989, FEBS LETT, V256, P21, DOI 10.1016/0014-5793(89)81710-7; Freeman E A, 1938, Arch Dis Child, V13, P277; Hall J, 1992, PRINCIPLES PRACTICE, P989; HALL JG, 1982, AM J MED GENET, V11, P185, DOI 10.1002/ajmg.1320110208; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARSCHMIZRACHI I, 1989, NUCLEIC ACIDS RES, V17, P6167, DOI 10.1093/nar/17.15.6167; Krakowiak PA, 1997, AM J HUM GENET, V60, P426; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; Martinsson T, 2000, P NATL ACAD SCI USA, V97, P14614, DOI 10.1073/pnas.250289597; Meredith C, 2004, AM J HUM GENET, V75, P703, DOI 10.1086/424760; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Richard P, 2003, CIRCULATION, V107, P2227, DOI 10.1161/01.CIR.0000066323.15244.54; Seidman JG, 2001, CELL, V104, P557, DOI 10.1016/S0092-8674(01)00242-2; Stevenson DA, 2006, PEDIATRICS, V117, P754, DOI 10.1542/peds.2005-1219; Sung SS, 2003, AM J HUM GENET, V73, P212, DOI 10.1086/376418; Sung SS, 2003, AM J HUM GENET, V72, P681, DOI 10.1086/368294; Swank DM, 2001, J BIOL CHEM, V276, P15117, DOI 10.1074/jbc.M008379200; Tajsharghi H, 2003, ANN NEUROL, V54, P494, DOI 10.1002/ana.10693; Veugelers M, 2004, NEW ENGL J MED, V351, P460, DOI 10.1056/NEJMoa040584; Wallgren-Pettersson C, 2004, NEUROMUSCULAR DISORD, V14, P461, DOI 10.1016/j.nmd.2004.03.006; Wells L, 1996, EMBO J, V15, P4454, DOI 10.1002/j.1460-2075.1996.tb00822.x	29	168	174	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					561	565		10.1038/ng1775	http://dx.doi.org/10.1038/ng1775			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16642020				2022-12-25	WOS:000237147500018
J	Valentine, MT; Fordyce, PM; Krzysiak, TC; Gilbert, SP; Block, SM				Valentine, MT; Fordyce, PM; Krzysiak, TC; Gilbert, SP; Block, SM			Individual dimers of the mitotic kinesin motor Eg5 step processively and support substantial loads in vitro	NATURE CELL BIOLOGY			English	Article							OPTICAL FORCE CLAMP; STATISTICAL KINETICS; MICROTUBULE MOTOR; SINGLE MOLECULES; CROSS-LINKS; MOVEMENT; SPINDLES; VELOCITY; ATP; NCD	Eg5, a member of the kinesin superfamily of microtubule-based motors, is essential for bipolar spindle assembly and maintenance during mitosis, yet little is known about the mechanisms by which it accomplishes these tasks. Here, we used an automated optical trapping apparatus in conjunction with a novel motility assay that employed chemically modified surfaces to probe the mechanochemistry of Eg5. Individual dimers, formed by a recombinant human construct Eg5 513-5His, stepped processively along microtubules in 8-nm increments, with short run lengths averaging approximately eight steps. By varying the applied load ( with a force clamp) and the ATP concentration, we found that the velocity of Eg5 was slower and less sensitive to external load than that of conventional kinesin, possibly reflecting the distinct demands of spindle assembly as compared with vesicle transport. The Eg5-513-5His velocity data were described by a minimal, three-state model where a force-dependent transition follows nucleotide binding.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Stanford University; Stanford University; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Block, SM (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	sblock@stanford.edu	Fordyce, Polly/AAY-6365-2020	Fordyce, Polly/0000-0002-9505-0638; Valentine, Megan/0000-0003-4781-8478	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051453] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Block SM, 2003, P NATL ACAD SCI USA, V100, P2351, DOI 10.1073/pnas.0436709100; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169; Crevel IMTC, 1997, J MOL BIOL, V273, P160, DOI 10.1006/jmbi.1997.1319; Crevel IMTC, 2004, CURR BIOL, V14, pR411, DOI 10.1016/j.cub.2004.05.030; deCastro MJ, 2000, NAT CELL BIOL, V2, P724, DOI 10.1038/35036357; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; Kamei T, 2005, BIOPHYS J, V88, P2068, DOI 10.1529/biophysj.104.049759; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kapoor TM, 2001, J CELL BIOL, V154, P1125, DOI 10.1083/jcb.200106011; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Kwok BH, 2004, CURR BIOL, V14, P1783, DOI 10.1016/j.cub.2004.09.052; Lang MJ, 2004, NAT METHODS, V1, P133, DOI 10.1038/NMETH714; Lang MJ, 2002, BIOPHYS J, V83, P491, DOI 10.1016/S0006-3495(02)75185-0; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Miyamoto DT, 2004, J CELL BIOL, V167, P813, DOI 10.1083/jcb.200407126; Neuman KC, 2004, REV SCI INSTRUM, V75, P2787, DOI 10.1063/1.1785844; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rosenfeld SS, 2005, J BIOL CHEM, V280, P35684, DOI 10.1074/jbc.M506561200; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Shaevitz JW, 2005, BIOPHYS J, V89, P2277, DOI 10.1529/biophysj.105.064295; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Thorn KS, 2000, J CELL BIOL, V151, P1093, DOI 10.1083/jcb.151.5.1093; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146	34	192	197	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					470	U89		10.1038/ncb1394	http://dx.doi.org/10.1038/ncb1394			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16604065	Green Accepted			2022-12-25	WOS:000237299400010
J	Driskell, OJ; Mironov, A; Allan, VJ; Woodman, PG				Driskell, Owen J.; Mironov, Aleksandr; Allan, Victoria J.; Woodman, Philip G.			Dynein is required for receptor sorting and the morphogenesis of early endosomes	NATURE CELL BIOLOGY			English	Article							CARCINOMA A431 CELLS; RECYCLING PATHWAY; DISTINCT POPULATIONS; EGF RECEPTOR; IN-VITRO; DYNACTIN; MEMBRANE; TRANSFERRIN; TRANSPORT; MOTILITY	The early endosome is organised into domains to ensure the separation of cargo(1,2). Activated mitogenic receptors, such as epidermal growth factor (EGF) receptor, are concentrated into vacuoles enriched for the small GTPase Rab5(3,4), which progressively exclude nutrient receptors, such as transferrin receptor, into neighbouring tubules(4-7). These vacuoles become enlarged, increase their content of intralumenal vesicles as EGF receptor is sorted from the limiting membrane, and eventually mature to late endosomes(8). Maturation is governed by the loss of Rab5 and is accompanied by the movement of endosomes along microtubules towards the cell centre(9). Here, we show that EGF relocates to the cell centre in a dynein-dependent fashion, concomitant with the sorting away of transferrin receptor, although it remains in Rab5-positive early endosomes. When dynein function is acutely disrupted, efficient recycling of transferrin from EGF-containing endosomes is retarded, loss of Rab5 is slowed and endosome enlargement is reduced.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Allan, VJ (corresponding author), Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England.	philip.woodman@manchester.ac.uk		Mironov, Aleksandr/0000-0002-1497-328X; Allan, Victoria/0000-0003-4583-0836	Biotechnology and Biological Sciences Research Council [BB/C512929/1] Funding Source: Medline; Medical Research Council [G0501725, G0001128, G9722026] Funding Source: Medline; MRC [G0501725, G9722026, G0001128] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Allan VJ, 1999, CURR OPIN CELL BIOL, V11, P476, DOI 10.1016/S0955-0674(99)80068-4; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; Bananis E, 2000, J CELL BIOL, V151, P179, DOI 10.1083/jcb.151.1.179; Bananis E, 2003, J CELL SCI, V116, P2749, DOI 10.1242/jcs.00478; Blangy A, 1997, J BIOL CHEM, V272, P19418, DOI 10.1074/jbc.272.31.19418; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Futter CE, 1996, J CELL BIOL, V132, P1011, DOI 10.1083/jcb.132.6.1011; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Hoepfner S, 2005, CELL, V121, P437, DOI 10.1016/j.cell.2005.02.017; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Jordens I, 2001, CURR BIOL, V11, P1680, DOI 10.1016/S0960-9822(01)00531-0; King SJ, 2003, MOL BIOL CELL, V14, P5089, DOI 10.1091/mbc.E03-01-0025; Lakadamyali M, 2006, CELL, V124, P997, DOI 10.1016/j.cell.2005.12.038; Lebrand C, 2002, EMBO J, V21, P1289, DOI 10.1093/emboj/21.6.1289; Mayhew TM, 2002, J MICROSC-OXFORD, V205, P153, DOI 10.1046/j.0022-2720.2001.00977.x; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MILLER K, 1986, J CELL BIOL, V102, P500, DOI 10.1083/jcb.102.2.500; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STOORVOGEL W, 1991, CELL, V65, P417, DOI 10.1016/0092-8674(91)90459-C; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	35	137	138	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					113	U152		10.1038/ncb1525	http://dx.doi.org/10.1038/ncb1525			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17173037				2022-12-25	WOS:000243255100020
J	Vilimas, T; Mascarenhas, J; Palomero, T; Mandal, M; Buonamici, S; Meng, FY; Thompson, B; Spaulding, C; Macaroun, S; Alegre, ML; Kee, BL; Ferrando, A; Miele, L; Aifantis, I				Vilimas, Tomas; Mascarenhas, Joaquina; Palomero, Teresa; Mandal, Malay; Buonamici, Silvia; Meng, Fanyong; Thompson, Benjamin; Spaulding, Christina; Macaroun, Sami; Alegre, Maria-Luisa; Kee, Barbara L.; Ferrando, Adolfo; Miele, Lucio; Aifantis, Iannis			Targeting the NF-kappa B signaling pathway in Notch1-induced T-cell leukemia	NATURE MEDICINE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSGENIC MICE; LYMPHOCYTE DEVELOPMENT; CANCER DEVELOPMENT; NOTCH; ACTIVATION; LEUKEMIA/LYMPHOMA; LINEAGE; GENE; EXPRESSION	T-cell acute lymphoblastic leukemia (T-ALL), unlike other ALL types, is only infrequently associated with chromosomal aberrations, but it was recently shown that most individuals with T-ALL carry activating mutations in the NOTCH1 gene. However, the signaling pathways and target genes responsible for Notch1-induced neoplastic transformation remain undefined. We report here that constitutively active Notch1 activates the NF-kappa B pathway transcriptionally and via the I kappa B kinase (IKK) complex, thereby causing increased expression of several well characterized target genes of NF-kappa B in bone marrow hematopoietic stem cells and progenitors. Our observations demonstrate that the NF-kappa B pathway is highly active in established human T-ALL and that inhibition of the pathway can efficiently restrict tumor growth both in vitro and in vivo. These findings identify NF-kappa B as one of the major mediators of Notch1-induced transformation and suggest that the NF-kappa B pathway is a potential target of future therapies of T-ALL.	Univ Chicago, Dept Med, Rheumatol Sect, Chicago, IL 60637 USA; Loyola Univ, Med Ctr, Inst Oncol, Maywood, IL 60153 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; Loyola University Chicago; Columbia University; New York University; University of Chicago	Aifantis, I (corresponding author), Univ Chicago, Dept Med, Rheumatol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.	iannis.aifantis@med.nyu.edu	Ferrando, Adolfo A/Q-7026-2016	Miele, Lucio/0000-0002-5853-7287	NATIONAL CANCER INSTITUTE [R01CA105129, R01CA084065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG025531] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA105129, R01CA84065] Funding Source: Medline; NIA NIH HHS [P01AG025531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aifantis I, 2001, NAT IMMUNOL, V2, P403, DOI 10.1038/87704; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Allman D, 2001, J EXP MED, V194, P99, DOI 10.1084/jem.194.1.99; Aster JC, 2005, INT J HEMATOL, V82, P295, DOI 10.1532/IJH97.05096; Bellavia D, 2000, EMBO J, V19, P3337, DOI 10.1093/emboj/19.13.3337; Beverly LJ, 2003, CANCER CELL, V3, P551, DOI 10.1016/S1535-6108(03)00137-5; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Borowski C, 2004, J EXP MED, V199, P607, DOI 10.1084/jem.20031973; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Campese AF, 2006, BLOOD, V108, P305, DOI 10.1182/blood-2006-01-0143; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chauhan D, 2005, MOL CANCER THER, V4, P686, DOI 10.1158/1535-7163.MCT-04-0338; El Abdaloussi E, 2006, NAT IMMUNOL, V7, P418, DOI 10.1038/ni1313; Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02-07-0404; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Maillard I, 2004, BLOOD, V104, P1696, DOI 10.1182/blood-2004-02-0514; Mandal M, 2005, J EXP MED, V201, P603, DOI 10.1084/jem.20041924; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; Oakley F, 2003, J BIOL CHEM, V278, P24359, DOI 10.1074/jbc.M211051200; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Palomero T, 2006, LEUKEMIA, V20, P1279, DOI 10.1038/sj.leu.2404258; Palomero T, 2006, BLOOD, V108, P986, DOI 10.1182/blood-2005-08-3482; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 2005, EMBO REP, V6, P1120, DOI 10.1038/sj.embor.7400585; Reizis B, 2002, GENE DEV, V16, P295, DOI 10.1101/gad.960702; Schmitt TM, 2004, J EXP MED, V200, P469, DOI 10.1084/jem.20040394; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; Spano JP, 2005, B CANCER, V92, P945; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang JH, 2001, J IMMUNOL, V167, P289, DOI 10.4049/jimmunol.167.1.289; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035	45	255	268	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					70	77		10.1038/nm1524	http://dx.doi.org/10.1038/nm1524			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17173050				2022-12-25	WOS:000243301800038
J	Fischetti, VA; Nelson, D; Schuch, R				Fischetti, Vincent A.; Nelson, Daniel; Schuch, Raymond			Reinventing phage therapy: are the parts greater than the sum?	NATURE BIOTECHNOLOGY			English	Editorial Material							LYTIC ENZYME; STREPTOCOCCUS-PNEUMONIAE; BACTERIOPHAGE THERAPY; ANTIBACTERIAL AGENTS; LACTOCOCCUS-LACTIS; BACILLUS-ANTHRACIS; ESCHERICHIA-COLI; EXPRESSION; VIRUSES; LYSIS		Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA	Rockefeller University	Fischetti, VA (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA.	vaf@rockefeller.edu	Nelson, Daniel C./I-2198-2012	Nelson, Daniel C./0000-0003-3248-4831				Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Bernhardt TG, 2001, SCIENCE, V292, P2326, DOI 10.1126/science.1058289; Bugg Timothy D. H., 2006, Infectious Disorders - Drug Targets, V6, P85, DOI 10.2174/187152606784112128; Bull JJ, 2006, P R SOC B, V273, P2703, DOI 10.1098/rspb.2006.3640; Cheng Q, 2005, ANTIMICROB AGENTS CH, V49, P111, DOI 10.1128/AAC.49.1.111-117.2005; Clark JR, 2004, FEMS IMMUNOL MED MIC, V40, P21, DOI 10.1016/S0928-8244(03)00344-4; Clark JR, 2006, TRENDS BIOTECHNOL, V24, P212, DOI 10.1016/j.tibtech.2006.03.003; Dabrowska K, 2005, J APPL MICROBIOL, V98, P7, DOI 10.1111/j.1365-2672.2004.02422.x; deRuyter PGGA, 1997, NAT BIOTECHNOL, V15, P976, DOI 10.1038/nbt1097-976; Doyle MP, 2006, POULTRY SCI, V85, P960, DOI 10.1093/ps/85.6.960; Entenza JM, 2005, ANTIMICROB AGENTS CH, V49, P4789, DOI 10.1128/AAC.49.11.4789-4792.2005; Gaeng S, 2000, APPL ENVIRON MICROB, V66, P2951, DOI 10.1128/AEM.66.7.2951-2958.2000; Goodridge LD, 2004, TRENDS BIOTECHNOL, V22, P384, DOI 10.1016/j.tibtech.2004.05.007; Hendrix RW, 2002, THEOR POPUL BIOL, V61, P471, DOI 10.1006/tpbi.2002.1590; Heuer H, 2002, APPL ENVIRON MICROB, V68, P1325, DOI 10.1128/AEM.68.3.1325-1335.2002; Irving MB, 2001, CURR OPIN CHEM BIOL, V5, P314, DOI 10.1016/S1367-5931(00)00208-8; Kerr DE, 2001, NAT BIOTECHNOL, V19, P66, DOI 10.1038/83540; Kim WS, 2004, MICROBIOL-SGM, V150, P2707, DOI 10.1099/mic.0.27224-0; Liu J, 2004, NAT BIOTECHNOL, V22, P185, DOI 10.1038/nbt932; Loeffler JM, 2001, SCIENCE, V294, P2170, DOI 10.1126/science.1066869; Loeffler JM, 2003, ANTIMICROB AGENTS CH, V47, P375, DOI 10.1128/AAC.47.1.375-377.2003; Loeffler JM, 2003, INFECT IMMUN, V71, P6199, DOI 10.1128/IAI.71.11.6199-6204.2003; Loessner MJ, 2002, MOL MICROBIOL, V44, P335, DOI 10.1046/j.1365-2958.2002.02889.x; Lopez R, 1997, MICROB DRUG RESIST, V3, P199, DOI 10.1089/mdr.1997.3.199; Matsuda T, 2005, SURGERY, V137, P639, DOI 10.1016/j.surg.2005.02.012; Merril CR, 1996, P NATL ACAD SCI USA, V93, P3188, DOI 10.1073/pnas.93.8.3188; Nakai T, 2002, RES MICROBIOL, V153, P13, DOI 10.1016/S0923-2508(01)01280-3; Nelson D, 2001, P NATL ACAD SCI USA, V98, P4107, DOI 10.1073/pnas.061038398; Nelson D, 2006, P NATL ACAD SCI USA, V103, P10765, DOI 10.1073/pnas.0604521103; Park SC, 2000, APPL ENVIRON MICROB, V66, P1416, DOI 10.1128/AEM.66.4.1416-1422.2000; Pennazio S, 2006, RIV BIOL-BIOL FORUM, V99, P103; Projan S, 2004, NAT BIOTECHNOL, V22, P167, DOI 10.1038/nbt0204-167; Schuch R, 2002, NATURE, V418, P884, DOI 10.1038/nature01026; Sheng HQ, 2006, APPL ENVIRON MICROB, V72, P5359, DOI 10.1128/AEM.00099-06; Sulakvelidze A, 2001, ANTIMICROB AGENTS CH, V45, P649, DOI 10.1128/AAC.45.3.649-659.2001; Suttle CA, 2005, NATURE, V437, P356, DOI 10.1038/nature04160; Thiel K, 2004, NAT BIOTECHNOL, V22, P31, DOI 10.1038/nbt0104-31; Weinbauer MG, 2004, ENVIRON MICROBIOL, V6, P1, DOI 10.1046/j.1462-2920.2003.00539.x; Westwater C, 2003, ANTIMICROB AGENTS CH, V47, P1301, DOI 10.1128/AAC.47.4.1301-1307.2003; Withey S, 2005, SCI TOTAL ENVIRON, V339, P1, DOI 10.1016/j.scitotenv.2004.09.021; Yacoby I, 2006, ANTIMICROB AGENTS CH, V50, P2087, DOI 10.1128/AAC.00169-06; Yoong P, 2006, J BACTERIOL, V188, P2711, DOI 10.1128/JB.188.7.2711-2714.2006; Yoong P, 2004, J BACTERIOL, V186, P4808, DOI 10.1128/JB.186.14.4808-4812.2004	43	113	125	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1508	1511		10.1038/nbt1206-1508	http://dx.doi.org/10.1038/nbt1206-1508			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17160051				2022-12-25	WOS:000242795800025
J	Simonis, M; Klous, P; Splinter, E; Moshkin, Y; Willemsen, R; de Wit, E; van Steensel, B; de Laat, W				Simonis, Marieke; Klous, Petra; Splinter, Erik; Moshkin, Yuri; Willemsen, Rob; de Wit, Elzo; van Steensel, Bas; de Laat, Wouter			Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C)	NATURE GENETICS			English	Article							SPATIAL PROXIMITY; GENES; TRANSCRIPTION; LOCI	The spatial organization of DNA in the cell nucleus is an emerging key contributor to genomic function(1-12). We developed 4C technology (chromosome conformation capture (3C)-on-chip), which allows for an unbiased genome-wide search for DNA loci that contact a given locus in the nuclear space. We demonstrate here that active and inactive genes are engaged in many long-range intrachromosomal interactions and can also form interchromosomal contacts. The active beta-globin locus in fetal liver preferentially contacts transcribed, but not necessarily tissue-specific, loci elsewhere on chromosome 7, whereas the inactive locus in fetal brain contacts different transcriptionally silent loci. A housekeeping gene in a gene-dense region on chromosome 8 forms long-range contacts predominantly with other active gene clusters, both in cis and in trans, and many of these intra- and interchromosomal interactions are conserved between the tissues analyzed. Our data demonstrate that chromosomes fold into areas of active chromatin and areas of inactive chromatin and establish 4C technology as a powerful tool to study nuclear architecture.	Erasmus MC, Dept Cell Biol & Genet, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Biochem, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands; Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Netherlands Cancer Institute	de Laat, W (corresponding author), Erasmus MC, Dept Cell Biol & Genet, NL-3000 CA Rotterdam, Netherlands.	w.delaat@erasmusmc.nl	Moshkin, Yuri M./M-3093-2016; Moshkin, Yuri/ABA-3435-2021	Moshkin, Yuri M./0000-0003-2964-8823; Moshkin, Yuri/0000-0003-2964-8823; de Laat, Wouter/0000-0002-6393-595X; de Wit, Elzo/0000-0003-2883-1415				Branco MR, 2006, PLOS BIOL, V4, P780, DOI 10.1371/journal.pbio.0040138; Brown JM, 2006, J CELL BIOL, V172, P177, DOI 10.1083/jcb.200507073; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Chakalova L, 2005, NAT REV GENET, V6, P669, DOI 10.1038/nrg1673; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979; Lemaitre JM, 2005, CELL, V123, P787, DOI 10.1016/j.cell.2005.08.045; Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191; Lomvardas S, 2006, CELL, V126, P403, DOI 10.1016/j.cell.2006.06.035; Misteli T, 2005, BIOESSAYS, V27, P477, DOI 10.1002/bies.20226; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Sokal R. R., 2012, BIOMETRY; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688; Volpi EV, 2000, J CELL SCI, V113, P1565; Wurtele H, 2006, CHROMOSOME RES, V14, P477, DOI 10.1007/s10577-006-1075-0; Zhang Z, 2000, J COMPUT BIOL, V7, P203, DOI 10.1089/10665270050081478	22	919	993	4	103	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1348	1354		10.1038/ng1896	http://dx.doi.org/10.1038/ng1896			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17033623				2022-12-25	WOS:000241592700026
J	Steidl, U; Rosenbauer, F; Verhaak, RGW; Gu, XS; Ebralidze, A; Otu, HH; Klippel, S; Steidl, C; Bruns, I; Costa, DB; Wagner, K; Aivado, M; Kobbe, G; Valk, PJM; Passegue, E; Libermann, TA; Delwel, R; Tenen, DG				Steidl, Ulrich; Rosenbauer, Frank; Verhaak, Roel G. W.; Gu, Xuesong; Ebralidze, Alexander; Otu, Hasan H.; Klippel, Steffen; Steidl, Christian; Bruns, Ingmar; Costa, Daniel B.; Wagner, Katharina; Aivado, Manuel; Kobbe, Guido; Valk, Peter J. M.; Passegue, Emmanuelle; Libermann, Towia A.; Delwel, Ruud; Tenen, Daniel G.			Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells	NATURE GENETICS			English	Article							CD34(+) HEMATOPOIETIC STEM; GENE-EXPRESSION; SELF-RENEWAL; PROGENITOR CELLS; CANCER; DIFFERENTIATION; PROLIFERATION; INTEGRATION; DISRUPTION; MUTATIONS	Knockdown of the transcription factor PU.1 (encoded by Sfpi1) leads to acute myeloid leukemia (AML) in mice. We examined the transcriptome of preleukemic hematopoietic stem cells (HSCs) in which PU.1 was knocked down (referred to as `PU.1-knockdown HSCs') to identify transcriptional changes preceding malignant transformation. Transcription factors c-Jun and JunB were among the top-downregulated targets. Restoration of c-Jun expression in preleukemic cells rescued the PU.1 knockdown initiated myelomonocytic differentiation block. Lentiviral restoration of JunB at the leukemic stage led to loss of leukemic self-renewal capacity and prevented leukemia in NOD-SCID mice into which leukemic PU.1-knockdown cells were transplanted. Examination of human individuals with AML confirmed the correlation between PU.1 and JunB downregulation. These results delineate a transcriptional pattern that precedes leukemic transformation in PU.1- knockdown HSCs and demonstrate that decreased levels of c-Jun and JunB contribute to the development of PU.1 knockdown-induced AML by blocking differentiation and increasing self-renewal. Therefore, examination of disturbed gene expression in HSCs can identify genes whose dysregulation is essential for leukemic stem cell function and that are targets for therapeutic interventions.	Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA; Harvard Univ, Harvard Stem Cell Inst, Boston, MA 02115 USA; Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Erasmus Univ, Med Ctr, Dept Hematol, NL-3015 GE Rotterdam, Netherlands; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Yeditepe Univ, Dept Genet & Bioengn, TR-34755 Istanbul, Turkey; Univ Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany; Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, D-40225 Dusseldorf, Germany; Univ Calif San Francisco, Dev & Stem Cell Biol Program, San Francisco, CA 94314 USA	Harvard University; Harvard Medical School; Harvard University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Erasmus University Rotterdam; Erasmus MC; Harvard University; Beth Israel Deaconess Medical Center; Yeditepe University; University of Gottingen; Heinrich Heine University Dusseldorf; University of California System; University of California San Francisco	Tenen, DG (corresponding author), Harvard Univ, Sch Med, Harvard Inst Med, Boston, MA 02115 USA.	dtenen@bidmc.harvard.edu	Valk, Peter/AAX-2823-2020; Verhaak, Roel/ABE-7058-2020; Kobbe, Guido/ABG-9472-2021	Bruns, Ingmar/0000-0001-6316-8378; Libermann, Towia/0000-0002-4006-8179; Rosenbauer, Frank/0000-0001-7977-9421; Passegue, Emmanuelle/0000-0002-3516-297X; Otu, Hasan/0000-0002-9253-8152; Tenen, Daniel/0000-0002-6423-3888; Costa, Daniel/0000-0002-0689-395X	NCI NIH HHS [CA41456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Behre G, 1999, J BIOL CHEM, V274, P4939, DOI 10.1074/jbc.274.8.4939; Bellon T, 1997, BLOOD, V90, P1828, DOI 10.1182/blood.V90.5.1828; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bjerregaard MD, 2003, BLOOD, V101, P4322, DOI 10.1182/blood-2002-03-0835; BORRAS FE, 1995, J BIOL CHEM, V270, P24385, DOI 10.1074/jbc.270.41.24385; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; Donninger H, 2004, ONCOGENE, V23, P8065, DOI 10.1038/sj.onc.1207959; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; Gilliland DG, 2002, CANCER CELL, V1, P417, DOI 10.1016/S1535-6108(02)00081-8; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Landgrebe J, 2002, GENOME BIOL, V3; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; Mueller BU, 2002, BLOOD, V100, P998, DOI 10.1182/blood.V100.3.998; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Phinney DG, 1996, ONCOGENE, V13, P1875; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rosenbauer F, 2005, BLOOD, V106, P1519, DOI 10.1182/blood-2005-02-0717; Rosenbauer F, 2006, NAT GENET, V38, P27, DOI 10.1038/ng1679; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Steidl U, 2002, BLOOD, V99, P2037, DOI 10.1182/blood.V99.6.2037; Steidl U, 2004, BLOOD, V104, P81, DOI 10.1182/blood-2004-01-0373; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wang Q, 2005, J CELL PHYSIOL, V204, P962, DOI 10.1002/jcp.20355	50	143	146	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1269	1277		10.1038/ng1898	http://dx.doi.org/10.1038/ng1898			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17041602				2022-12-25	WOS:000241592700015
J	Oshimori, N; Ohsugi, M; Yamamoto, T				Oshimori, Naoki; Ohsugi, Miho; Yamamoto, Tadashi			The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity	NATURE CELL BIOLOGY			English	Article							POLO-LIKE KINASE; CELL-DIVISION; CHROMOKINESIN KID; TUBULIN; PHOSPHORYLATION; CENTRIOLES; COMPLEX; MITOSIS; ORGANIZATION; CHROMOSOMES	Formation of a bipolar spindle is essential for faithful chromosome segregation at mitosis. Because centrosomes define spindle poles, defects in centrosome number and structural organization can lead to a loss of bipolarity(1). In addition, microtubule-mediated pulling and pushing forces acting on centrosomes and chromosomes are also important for bipolar spindle formation(2). Polo-like kinase 1 (Plk1) is a highly conserved Ser/Thr kinase that has essential roles in the formation of a bipolar spindle with focused poles(3-5). However, the mechanism by which Plk1 regulates spindle-pole formation is poorly understood. Here, we identify a novel centrosomal substrate of Plk1, Kizuna (Kiz), depletion of which causes fragmentation and dissociation of the pericentriolar material from centrioles at prometaphase, resulting in multipolar spindles. We demonstrate that Kiz is critical for establishing a robust mitotic centrosome architecture that can endure the forces that converge on the centrosomes during spindle formation, and suggest that Plk1 maintains the integrity of the spindle poles by phosphorylating Kiz.	Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp	Ohsugi, Miho/AAY-9339-2020	Ohsugi, Miho/0000-0003-0288-3428				Abal M, 2005, BIOL CELL, V97, P425, DOI 10.1042/BC20040112; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Chang P, 2003, NAT CELL BIOL, V5, P71, DOI 10.1038/ncb900; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Fry AM, 2000, CURR TOP DEV BIOL, V49, P291; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Garrett S, 2002, CURR BIOL, V12, P2055, DOI 10.1016/S0960-9822(02)01277-0; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; Ishikawa H, 2005, NAT CELL BIOL, V7, P517, DOI 10.1038/ncb1251; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Levesque AA, 2001, J CELL BIOL, V154, P1135, DOI 10.1083/jcb.200106093; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Mogensen MM, 2000, J CELL SCI, V113, P3013; Murphy SM, 1998, J CELL BIOL, V141, P663, DOI 10.1083/jcb.141.3.663; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Ohsugi M, 2003, EMBO J, V22, P2091, DOI 10.1093/emboj/cdg208; Palazzo RE, 2000, CURR TOP DEV BIOL, V49, P449; Paoletti A, 1996, J CELL SCI, V109, P3089; Saunders W, 2005, SEMIN CANCER BIOL, V15, P25, DOI 10.1016/j.semcancer.2004.09.003; Scholey JM, 2003, NATURE, V422, P746, DOI 10.1038/nature01599; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Tachibana KEK, 2005, EMBO REP, V6, P1052, DOI 10.1038/sj.embor.7400527; Takahashi M, 2002, MOL BIOL CELL, V13, P3235, DOI 10.1091/mbc.E02-02-0112; Tokai-Nishizumi N, 2005, MOL BIOL CELL, V16, P5455, DOI 10.1091/mbc.E05-03-0244; van Vugt MATM, 2004, J BIOL CHEM, V279, P36841, DOI 10.1074/jbc.M313681200; Zimmerman WC, 2004, MOL BIOL CELL, V15, P3642, DOI 10.1091/mbc.E03-11-0796	34	112	121	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1095	U86		10.1038/ncb1474	http://dx.doi.org/10.1038/ncb1474			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16980960				2022-12-25	WOS:000241395300013
J	Roeder, I; Horn, M; Glauche, I; Hochhaus, A; Mueller, MC; Loeffler, M				Roeder, Ingo; Horn, Matthias; Glauche, Ingmar; Hochhaus, Andreas; Mueller, Martin C.; Loeffler, Markus			Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications	NATURE MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; STEM-CELL ORGANIZATION; ABL TYROSINE KINASE; POSITIVE CELLS; RESISTANCE; INTERFERON; INHIBITOR; THERAPY; STI571; PROGENITORS	Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitor imatinib represents a successful application of molecularly targeted cancer therapy. A rapid hematologic and cytogenetic response can be induced in the majority of people, even in advanced disease. However, complete eradication of malignant cells, which are characterized by the expression of the BCR-ABL1 fusion protein, is rare. Reasons for the persistence of the malignant clone are currently not known and provide a substantial challenge for clinicians and biologists. Based on a mathematical modeling approach that quantitatively explains a broad range of phenomena, we show for two independent datasets that clinically observed BCR-ABL1 transcript dynamics during imatinib treatment of CML can consistently be explained by a selective functional effect of imatinib on proliferative leukemia stem cells. Our results suggest the general potential of imatinib to induce a complete elimination of the malignant clone. Moreover, we predict that the therapeutic benefit of imatinib can, under certain circumstances, be accelerated by combination with proliferation-stimulating treatment strategies.	Univ Leipzig, Inst Med Informat Stat & Epidemiol, D-04107 Leipzig, Germany; Heidelberg Univ, Med Klin 3, Fak Klin Med Mannheim, D-68305 Mannheim, Germany	Leipzig University	Roeder, I (corresponding author), Univ Leipzig, Inst Med Informat Stat & Epidemiol, Haertelstr 16-18, D-04107 Leipzig, Germany.	ingo.roeder@imise.uni-leipzig.de		Hochhaus, Andreas/0000-0003-0626-0834				Catlin SN, 2005, BLOOD, V106, P2688, DOI 10.1182/blood-2005-03-1240; Cortes J, 2005, CLIN CANCER RES, V11, P3425, DOI 10.1158/1078-0432.CCR-04-2139; Deininger MWN, 2004, CANCER CELL, V6, P108, DOI 10.1016/j.ccr.2004.08.006; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; EAVES C, 1993, LEUKEMIA LYMPHOMA, V11, P245, DOI 10.3109/10428199309047894; Emig M, 1999, LEUKEMIA, V13, P1825, DOI 10.1038/sj.leu.2401566; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Hehlmann R, 2000, ANN HEMATOL, V79, P345, DOI 10.1007/s002770000167; Hochhaus A, 2004, LEUKEMIA, V18, P1321, DOI 10.1038/sj.leu.2403426; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; ICHIMARU M, 1991, J RADIAT RES, V32, P14, DOI 10.1269/jrr.32.SUPPLEMENT2_14; Jorgensen HG, 2005, CANCER, V103, P210, DOI 10.1002/cncr.20742; Komarova NL, 2005, P NATL ACAD SCI USA, V102, P9714, DOI 10.1073/pnas.0501870102; Lahaye T, 2005, CANCER-AM CANCER SOC, V103, P1659, DOI 10.1002/cncr.20922; Loeffler M, 2002, CELLS TISSUES ORGANS, V171, P8, DOI 10.1159/000057688; Marley SB, 2000, EXP HEMATOL, V28, P551, DOI 10.1016/S0301-472X(00)00142-9; Mauro MJ, 2001, CURR OPIN ONCOL, V13, P3, DOI 10.1097/00001622-200101000-00002; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; Muller MC, 2003, LEUKEMIA, V17, P2392, DOI 10.1038/sj.leu.2403157; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Oetzel C, 2000, CLIN CANCER RES, V6, P1958; Roeder I, 2005, BLOOD, V105, P609, DOI 10.1182/blood-2004-01-0282; Roeder I, 2002, EXP HEMATOL, V30, P853, DOI 10.1016/S0301-472X(02)00832-9; Topaly J, 2002, BRIT J CANCER, V86, P1487, DOI 10.1038/sj.bjc.6600242; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683	26	252	261	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1181	1184		10.1038/nm1487	http://dx.doi.org/10.1038/nm1487			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17013383				2022-12-25	WOS:000241102200035
J	Gaetz, J; Gueroui, Z; Libchaber, A; Kapoor, TM				Gaetz, Jedidiah; Gueroui, Zoher; Libchaber, Albert; Kapoor, Tarun M.			Examining how the spatial organization of chromatin signals influences metaphase spindle assembly	NATURE CELL BIOLOGY			English	Article							XENOPUS EGG EXTRACTS; SMALL-MOLECULE INHIBITOR; GTP-BOUND RAN; MITOTIC SPINDLE; SELF-ORGANIZATION; CYTOPLASMIC DYNEIN; MICROTUBULE STABILIZATION; MOTOR PROTEINS; CELL-CYCLE; IN-VITRO	During cell division, the proper assembly of a microtubule-based bipolar spindle depends on signals from chromatin. However, it is unknown how the spatial organization of chromatin signals affects spindle morphology. Here, we use paramagnetic chromatin beads, and magnetic fields for their alignment in cell-free extracts, to examine the spatial components of signals that regulate spindle assembly. We find that for linear chromatin-bead arrays that vary by eightfold in length, metaphase spindle size and shape are constant. Our findings indicate that, although chromatin provides cues for microtubule formation, metaphase spindle organization, which is controlled by microtubule-based motors, is robust to changes in the shape of chromatin signals.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Libchaber, A (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	libchbr@rockefeller.edu; kapoor@rockefeller.edu		Gaetz, Jedidiah/0000-0002-7103-6241	NIGMS NIH HHS [GM 65933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Bonaccorsi S, 1998, J CELL BIOL, V142, P751, DOI 10.1083/jcb.142.3.751; Carazo-Salas RE, 2003, CURR BIOL, V13, P1728, DOI 10.1016/j.cub.2003.09.006; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Caudron M, 2005, SCIENCE, V309, P1373, DOI 10.1126/science.1115964; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; Desai A, 1999, METHOD CELL BIOL, V61, P385; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; Durand D, 2003, TRENDS GENET, V19, P2, DOI 10.1016/S0168-9525(02)00008-2; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Ems-McClung SC, 2004, MOL BIOL CELL, V15, P46, DOI 10.1091/mbc.E03-07-0454; Gadde S, 2004, CURR BIOL, V14, pR797, DOI 10.1016/j.cub.2004.09.021; Gaetz J, 2004, J CELL BIOL, V166, P465, DOI 10.1083/jcb.200404015; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Heald R, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P326; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Houchmandzadeh B, 1997, J CELL BIOL, V139, P1, DOI 10.1083/jcb.139.1.1; Houchmandzadeh B, 1999, J CELL BIOL, V145, P215, DOI 10.1083/jcb.145.2.215; HYMAN AA, 1991, J CELL SCI, P125; Kalab P, 2006, NATURE, V440, P697, DOI 10.1038/nature04589; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kapoor TM, 2006, SCIENCE, V311, P388, DOI 10.1126/science.1122142; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Khodjakov A, 2003, J CELL BIOL, V160, P671, DOI 10.1083/jcb.200208143; Mallik R, 2004, NATURE, V427, P649, DOI 10.1038/nature02293; Marshall WF, 2001, CURR BIOL, V11, P569, DOI 10.1016/S0960-9822(01)00180-4; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Megraw TL, 2001, CURR BIOL, V11, P116, DOI 10.1016/S0960-9822(01)00017-3; Mitchison TJ, 2005, MOL BIOL CELL, V16, P3064, DOI 10.1091/mbc.E05-02-0174; Nedelec F, 2003, CURR OPIN CELL BIOL, V15, P118, DOI 10.1016/S0955-0674(02)00014-5; NICKLAS RB, 1965, J CELL BIOL, V25, P119, DOI 10.1083/jcb.25.1.119; Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Pitaevskii L.P., 1986, THEORY ELASTICITY; Poirier MG, 2002, MOL BIOL CELL, V13, P2170, DOI 10.1091/mbc.01-08-0401; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Reinsch S, 1997, CURR BIOL, V7, P211, DOI 10.1016/S0960-9822(97)70092-7; Rusan NM, 2002, J CELL BIOL, V158, P997, DOI 10.1083/jcb.200204109; Sampath SC, 2004, CELL, V118, P187, DOI 10.1016/j.cell.2004.06.026; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tirnauer JS, 2004, MOL BIOL CELL, V15, P1776, DOI 10.1091/mbc.E03-11-0824; Tirnauer JS, 2002, MOL BIOL CELL, V13, P3614, DOI 10.1091/mbc.E02-04-0210; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Valentine MT, 2006, NAT CELL BIOL, V8, P470, DOI 10.1038/ncb1394; Wadsworth P, 2004, TRENDS CELL BIOL, V14, P413, DOI 10.1016/j.tcb.2004.07.004; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Wilde A, 2001, NAT CELL BIOL, V3, P221, DOI 10.1038/35060000; Wittmann T, 1999, METHOD CELL BIOL, V61, P137	58	30	30	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					924	U41		10.1038/ncb1455	http://dx.doi.org/10.1038/ncb1455			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16892054				2022-12-25	WOS:000240241700008
J	Rossi, AG; Sawatzky, DA; Walker, A; Ward, C; Sheldrake, TA; Riley, NA; Caldicott, A; Martinez-Losa, M; Walker, TR; Duffin, R; Gray, M; Crescenzi, E; Martin, MC; Brady, HJ; Savill, JS; Dransfield, I; Haslett, C				Rossi, Adriano G.; Sawatzky, Deborah A.; Walker, Annemieke; Ward, Carol; Sheldrake, Tara A.; Riley, Nicola A.; Caldicott, Alison; Martinez-Losa, Magdalena; Walker, Trevor R.; Duffin, Rodger; Gray, Mohini; Crescenzi, Elvira; Martin, Morag C.; Brady, Hugh J.; Savill, John S.; Dransfield, Ian; Haslett, Christopher			Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis	NATURE MEDICINE			English	Article							NF-KAPPA-B; HUMAN NEUTROPHILS; IN-VIVO; DOWN-REGULATION; R-ROSCOVITINE; BACTERIAL LIPOPOLYSACCHARIDE; INDUCIBLE CYCLOOXYGENASE; SELICICLIB CYC202; AGING NEUTROPHILS; MULTIPLE-MYELOMA	Apoptosis is essential for clearance of potentially injurious inflammatory cells and subsequent efficient resolution of inflammation. Here we report that human neutrophils contain functionally active cyclin-dependent kinases (CDKs), and that structurally diverse CDK inhibitors induce caspase-dependent apoptosis and override powerful anti-apoptosis signals from survival factors such as granulocyte - macrophage colony-stimulating factor (GM-CSF). We show that the CDK inhibitor R-roscovitine (Seliciclib or CYC202) markedly enhances resolution of established neutrophil-dependent inflammation in carrageenan-elicited acute pleurisy, bleomycininduced lung injury, and passively induced arthritis in mice. In the pleurisy model, the caspase inhibitor zVAD-fmk prevents R-roscovitine - enhanced resolution of inflammation, indicating that this CDK inhibitor augments inflammatory cell apoptosis. We also provide evidence that R-roscovitine promotes apoptosis by reducing concentrations of the anti-apoptotic protein Mcl-1. Thus, CDK inhibitors enhance the resolution of established inflammation by promoting apoptosis of inflammatory cells, thereby demonstrating a hitherto unrecognized potential for the treatment of inflammatory disorders.	Univ Edinburgh, Queens Med Res Inst, MRC, Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland; UCL, Great Ormond St Hosp Children NHS Trust, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England	University of Edinburgh; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Rossi, AG (corresponding author), Univ Edinburgh, Queens Med Res Inst, MRC, Ctr Inflammat Res, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland.	a.g.rossi@ed.ac.uk		Martin, Morag/0000-0002-8667-6057; CRESCENZI, ELVIRA/0000-0002-9258-8053; Duffin, Rodger/0000-0002-3425-9745; Dransfield, Ian/0000-0001-5848-7059; Brady, Hugh/0000-0002-3152-067X	Medical Research Council [G0601481] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Azambuja E, 2005, PULM PHARMACOL THER, V18, P363, DOI 10.1016/j.pupt.2005.01.007; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Cailhier JFO, 2006, AM J RESP CRIT CARE, V173, P540, DOI 10.1164/rccm.200504-538OC; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; De Paepe ME, 2004, AM J PHYSIOL-LUNG C, V287, pL730, DOI 10.1152/ajplung.00120.2004; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Gilroy DW, 2003, FASEB J, V17, P2269, DOI 10.1096/fj.02-1162fje; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; HASLETT C, 1985, AM J PATHOL, V119, P101; Jonsson H, 2005, NAT MED, V11, P666, DOI 10.1038/nm1248; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Klausen P, 2004, J LEUKOCYTE BIOL, V75, P569, DOI 10.1189/jlb.1003474; Kobayashi SD, 2005, J LEUKOCYTE BIOL, V78, P1408, DOI 10.1189/jlb.0605289; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200; McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Monaco EA, 2003, CURR MED CHEM, V10, P367, DOI 10.2174/0929867033368277; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Nagase T, 2002, NAT MED, V8, P480, DOI 10.1038/nm0502-480; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Pinho V, 2005, J LEUKOCYTE BIOL, V77, P800, DOI 10.1189/jlb.0704386; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Riley Nicola A., 2006, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V5, P3, DOI 10.2174/187152306775537319; Rosales JL, 2004, J BIOL CHEM, V279, P53932, DOI 10.1074/jbc.M408467200; Sabroe I, 2003, J IMMUNOL, V170, P5268, DOI 10.4049/jimmunol.170.10.5268; Sabroe I, 2002, J IMMUNOL, V168, P4701, DOI 10.4049/jimmunol.168.9.4701; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Sawatzky DA, 2006, AM J PATHOL, V168, P33, DOI 10.2353/ajpath.2006.050058; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Serhan CN, 2006, J IMMUNOL, V176, P1848, DOI 10.4049/jimmunol.176.3.1848; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Subrahmanyam YVBK, 2001, BLOOD, V97, P2457, DOI 10.1182/blood.V97.8.2457; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Tsukahara Y, 2003, J CELL BIOCHEM, V89, P848, DOI 10.1002/jcb.10526; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Ward C, 2005, EUR J IMMUNOL, V35, P2728, DOI 10.1002/eji.200425561; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Williams O, 2000, EUR J IMMUNOL, V30, P709; Zhang XQ, 2004, J LEUKOCYTE BIOL, V75, P358, DOI 10.1189/jlb.0903412	50	400	420	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1056	1064		10.1038/nm1468	http://dx.doi.org/10.1038/nm1468			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16951685				2022-12-25	WOS:000240373900030
J	Larrivee, M; Wellinger, RJ				Larrivee, Michel; Wellinger, Raymund J.			Telomerase- and capping-independent yeast survivors with alternate telomere states	NATURE CELL BIOLOGY			English	Article							DNA; RECOMBINATION; MAINTENANCE; REPLICATION; CHROMOSOMES; ADAPTATION; ELONGATION; GENERATION; PROTEINS; PATHWAY	Maintaining telomeric DNA at chromosome ends is essential for genome stability(1,2). In virtually all organisms the telomerase enzyme provides this function; however, telomerase-independent mechanisms also exist(3,4). These latter mechanisms rely on recombination pathways to replenish telomeric DNA(4,5) and extrachromosomal DNA may also be implicated(6). Here, we report that in Saccharomyces cerevisiae cells, extrachromosomal circular DNA occurs for both subtypes of telomerase- independent telomere-maintenance mechanisms. This DNA consists of circular molecules of full-length subtelomeric repeat elements in type I cells, and very heterogeneously sized circles of telomeric repeat DNA in type II cells that are at least partially single stranded. Surprisingly, both type I and type II cells can adapt to a loss of the normally essential telomere-capping protein Cdc13p by inducing an alternate and reversible state of chromosome ends. Chromosome capping, therefore, is not strictly dependent on canonical capping proteins, such as Cdc13p, but can be achieved by alternate mechanisms.	Univ Sherbrooke, Fac Med, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Wellinger, RJ (corresponding author), Univ Sherbrooke, Fac Med, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1H 5N4, Canada.	Raymund.Wellinger@Usherbrooke.ca	Wellinger, Raymund/K-3207-2019	Wellinger, Raymund/0000-0001-6670-2759				BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; Chakhparonian M, 2003, TRENDS GENET, V19, P439, DOI 10.1016/S0168-9525(03)00135-5; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ferreira MG, 2004, MOL CELL, V13, P7, DOI 10.1016/S1097-2765(03)00531-8; Ferreira MG, 2001, MOL CELL, V7, P55, DOI 10.1016/S1097-2765(01)00154-X; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; Groff-Vindman C, 2005, MOL CELL BIOL, V25, P4406, DOI 10.1128/MCB.25.11.4406-4412.2005; HOROWITZ H, 1985, MOL CELL BIOL, V5, P2369, DOI 10.1128/MCB.5.9.2369; Larrivee M, 2004, GENE DEV, V18, P1391, DOI 10.1101/gad.1199404; Le S, 1999, GENETICS, V152, P143; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lundblad V, 2003, NATURE, V423, P926, DOI 10.1038/423926a; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Michelson RJ, 2005, GENE DEV, V19, P2546, DOI 10.1101/gad.1293805; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Tomaska L, 2004, FEBS LETT, V567, P142, DOI 10.1016/j.febslet.2004.04.058; Vega LR, 2003, NAT REV MOL CELL BIO, V4, P948, DOI 10.1038/nrm1256; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V	30	58	58	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					741	U187		10.1038/ncb1429	http://dx.doi.org/10.1038/ncb1429			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16767083				2022-12-25	WOS:000238837800017
J	Ayele, S; Chataway, J; Wield, D				Ayele, Seife; Chataway, Joanna; Wield, David			Partnerships in African crop biotech	NATURE BIOTECHNOLOGY			English	Editorial Material									Open Univ, Technol Fac, UK Econ & Social Res Council, Innogen Ctr, Milton Keynes MK7 6AA, Bucks, England	Innogenetics NV; Open University - UK	Ayele, S (corresponding author), Open Univ, Technol Fac, UK Econ & Social Res Council, Innogen Ctr, Milton Keynes MK7 6AA, Bucks, England.	s.ayele@open.ac.uk		wield, david/0000-0003-3838-3724	Economic and Social Research Council [RES-145-28-1004] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))		Acharya T, 2003, NAT BIOTECHNOL, V21, P1434, DOI 10.1038/nbt1203-1434; ANNAN K, 2004, IMPLEMENTATION UN MI; [Anonymous], 2005, INV DEV PRACT PLAN A; Ayele S., 2005, Journal of International Development, V17, P631, DOI 10.1002/jid.1228; Chataway J., 2005, Journal of International Development, V17, P597, DOI 10.1002/jid.1226; Cohen JI, 2005, NAT BIOTECHNOL, V23, P27, DOI 10.1038/nbt0105-27; *EARTH I COL U, 2005, HALV HUNG CAN BE DON; *EARTHSC, 2005, INN APPL KNOWL DEV; *FAO, 2004, SUMM FOOD AGR STAT 2; *FAO, 2004, STAT FOOD AGR AGR BI; Hall A., 2005, J INT DEV, V17, P611, DOI DOI 10.1002/JID.1227; *UN U I NEW TECHN, 2004, TECHN POL BRIEFS, V3; WAMBUGU F, 2001, ISAAA BRIEFS; 2002, IRMA INS RES MAIZ AF	14	13	14	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2006	24	6					619	621		10.1038/nbt0606-619	http://dx.doi.org/10.1038/nbt0606-619			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	051UQ	16763585				2022-12-25	WOS:000238187300016
J	Ochi, H; Abraham, M; Ishikawa, H; Frenkel, D; Yang, KY; Basso, AS; Wu, H; Chen, ML; Gandhi, R; Miller, A; Maron, R; Weiner, HL				Ochi, Hirofumi; Abraham, Michal; Ishikawa, Hiroki; Frenkel, Dan; Yang, Kaiyong; Basso, Alexandre S.; Wu, Henry; Chen, Mei-Ling; Gandhi, Roopali; Miller, Ariel; Maron, Ruth; Weiner, Howard L.			Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4(+) CD25(-)LAP(+) T cells	NATURE MEDICINE			English	Article							ANTI-CD3 MONOCLONAL-ANTIBODY; MYELIN BASIC-PROTEIN; GROWTH-FACTOR-BETA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NONOBESE DIABETIC MICE; NOD MICE; MULTIPLE-SCLEROSIS; IMMUNE-RESPONSES; SELF-TOLERANCE; ACTIVATION	A major goal of immunotherapy for autoimmune diseases and transplantation is induction of regulatory T cells that mediate immunologic tolerance. The mucosal immune system is unique, as tolerance is preferentially induced after exposure to antigen, and induction of regulatory T cells is a primary mechanism of oral tolerance. Parenteral administration of CD3-specific monoclonal antibody is an approved therapy for transplantation in humans and is effective in autoimmune diabetes. We found that orally administered CD3-specific antibody is biologically active in the gut and suppresses autoimmune encephalomyelitis both before induction of disease and at the height of disease. Orally administered CD3-specific antibody induces CD4(+)CD25(-)LAP(+) regulatory T cells that contain latency-associated peptide ( LAP) on their surface and that function in vitro and in vivo through a TGF-beta-dependent mechanism. These findings identify a new immunologic approach that is widely applicable for the treatment of human autoimmune conditions.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Carmel Hosp, Dept Neurol, Neuroimmunol Unit, IL-34362 Haifa, Israel	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Clalit Health Services; Carmel Medical Center	Weiner, HL (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	hweiner@rics.bwh.harvard.edu	Basso, Alexandre S/K-2281-2012	Basso, Alexandre S/0000-0002-3302-4792; Miller, Ariel/0000-0001-5843-6841				Belghith M, 2003, NAT MED, V9, P1202, DOI 10.1038/nm924; Bisikirska B, 2005, J CLIN INVEST, V115, P2904, DOI 10.1172/JCI23961; CHATENOUD L, 1986, J IMMUNOL, V137, P830; Chatenoud L, 1997, J IMMUNOL, V158, P2947; CHATENOUD L, 1994, P NATL ACAD SCI USA, V91, P123, DOI 10.1073/pnas.91.1.123; CHATENOUD L, 1982, EUR J IMMUNOL, V12, P979, DOI 10.1002/eji.1830121116; Chatenoud L, 2003, NAT REV IMMUNOL, V3, P123, DOI 10.1038/nri1000; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Frenkel D, 2003, J IMMUNOL, V171, P6549, DOI 10.4049/jimmunol.171.12.6549; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; HAFLER DA, 1988, J IMMUNOL, V141, P131; Herold KC, 2005, DIABETES, V54, P1763, DOI 10.2337/diabetes.54.6.1763; Herold KC, 2003, J CLIN INVEST, V111, P409, DOI 10.1172/JCI200316090; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; HEROLD KC, 1992, DIABETES, V41, P385, DOI 10.2337/diabetes.41.3.385; Inobe J, 1998, EUR J IMMUNOL, V28, P2780, DOI 10.1002/(SICI)1521-4141(199809)28:09<2780::AID-IMMU2780>3.0.CO;2-J; Jorritsma PJ, 2003, J IMMUNOL, V170, P2427, DOI 10.4049/jimmunol.170.5.2427; Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; Kohm AP, 2005, J IMMUNOL, V174, P4525, DOI 10.4049/jimmunol.174.8.4525; Leitenberg D, 1999, SEMIN IMMUNOL, V11, P283, DOI 10.1006/smim.1999.0184; LIDER O, 1989, J IMMUNOL, V142, P748; Maron R, 2002, CIRCULATION, V106, P1708, DOI 10.1161/01.CIR.0000029750.99462.30; Maron R, 1999, J AUTOIMMUN, V12, P251, DOI 10.1006/jaut.1999.0278; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MILLER A, 1993, J IMMUNOL, V151, P7307; Mottram PL, 2002, TRANSPL IMMUNOL, V10, P63, DOI 10.1016/S0966-3274(02)00050-3; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Oida T, 2003, J IMMUNOL, V170, P2516, DOI 10.4049/jimmunol.170.5.2516; SAYEGH MH, 1992, P NATL ACAD SCI USA, V89, P7762, DOI 10.1073/pnas.89.16.7762; Slavin AJ, 2001, INT IMMUNOL, V13, P825, DOI 10.1093/intimm/13.6.825; Tran GT, 2001, INT IMMUNOL, V13, P1109, DOI 10.1093/intimm/13.9.1109; Utset TO, 2002, J RHEUMATOL, V29, P1907; von Herrath MG, 2002, J IMMUNOL, V168, P933, DOI 10.4049/jimmunol.168.2.933; WEINSHENKER BG, 1991, NEUROLOGY, V41, P1047, DOI 10.1212/WNL.41.7.1047; WESSELBORG S, 1993, J IMMUNOL, V150, P4338; Zhang XM, 2006, INT IMMUNOL, V18, P495, DOI 10.1093/intimm/dxh390; Zhang XM, 2001, J IMMUNOL, V167, P4245, DOI 10.4049/jimmunol.167.8.4245; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252	42	196	212	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					627	635		10.1038/nm1408	http://dx.doi.org/10.1038/nm1408			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715091				2022-12-25	WOS:000238149200023
J	Spudich, G; Chibalina, MV; Au, JSY; Arden, SD; Buss, F; Kendrick-Jones, J				Spudich, Giulietta; Chibalina, Margarita V.; Au, Josephine Sui-Yan; Arden, Susan D.; Buss, Folma; Kendrick-Jones, John			Myosin VI targeting to clathrin-coated structures and dimerization is mediated by binding to disabled-2 and PtdIns(4,5)P-2	NATURE CELL BIOLOGY			English	Article							PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PROTEIN INTERACTIONS; GOLGI-COMPLEX; ORGANIZATION; ENDOCYTOSIS; FIBROBLASTS; RECRUITMENT; TRANSPORT; VESICLES; KINESIN	Vesicle transport is essential for the movement of proteins, lipids and other molecules between membrane compartments within the cell. The role of the class VI myosins in vesicular transport is particularly intriguing because they are the only class that has been shown to move 'backwards' towards the minus end of actin filaments(1). Myosin VI is found in distinct intracellular locations and implicated in processes such as endocytosis(2,3), exocytosis, maintenance of Golgi morphology(4,5) and cell movement(6). We have shown that the carboxy-terminal tail is the key targeting region and have identified three binding sites: a WWY motif for Disabled-2 (Dab2) binding, a RRL motif for glucose-transporter binding protein (GIPC) and optineurin binding and a site that binds specifically and with high affinity (K-d = 0.3 mu M) to PtdIns(4,5)P-2-containing liposomes. This is the first demonstration that myosin VI binds lipid membranes. Lipid binding induces a large structural change in the myosin VI tail (31% increase in helicity) and when associated with lipid vesicles, it can dimerize. In vivo targeting and recruitment of myosin VI to clathrin-coated structures (CCSs) at the plasma membrane is mediated by Dab2 and PtdIns(4,5) P-2 binding.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England	MRC Laboratory Molecular Biology; University of Cambridge	Kendrick-Jones, J (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	jkj@mrc-lmb.cam.ac.uk		Buss, Folma/0000-0003-4457-3479	Wellcome Trust [071162] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aschenbrenner L, 2003, MOL BIOL CELL, V14, P2728, DOI 10.1091/mbc.E02-11-0767; Brett TJ, 2002, STRUCTURE, V10, P797, DOI 10.1016/S0969-2126(02)00784-0; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Buss F, 2001, EMBO J, V20, P3676, DOI 10.1093/emboj/20.14.3676; Buss F, 1998, J CELL BIOL, V143, P1535, DOI 10.1083/jcb.143.6.1535; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Cremona O, 2001, J CELL SCI, V114, P1041; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Dance AL, 2004, TRAFFIC, V5, P798, DOI 10.1111/j.1600-0854.2004.00224.x; Dell'Angelica EC, 2001, TRENDS CELL BIOL, V11, P315, DOI 10.1016/S0962-8924(01)02043-8; Evans PR, 2002, CURR OPIN STRUC BIOL, V12, P814, DOI 10.1016/S0959-440X(02)00395-0; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; Itoh T, 2004, CURR TOP MICROBIOL, V282, P31; Iwaki M, 2006, BIOPHYS J, V90, P3643, DOI 10.1529/biophysj.105.075721; Janmey PA, 1999, CHEM PHYS LIPIDS, V101, P93, DOI 10.1016/S0009-3084(99)00058-4; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; Klopfenstein DR, 2004, MOL BIOL CELL, V15, P3729, DOI 10.1091/mbc.E04-04-0326; Klopfenstein DR, 2002, CELL, V109, P347, DOI 10.1016/S0092-8674(02)00708-0; Lister I, 2004, EMBO J, V23, P1729, DOI 10.1038/sj.emboj.7600180; Lou XJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134918; Mishra SK, 2002, EMBO J, V21, P4915, DOI 10.1093/emboj/cdf487; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Park H, 2006, MOL CELL, V21, P331, DOI 10.1016/j.molcel.2005.12.015; Pashkova N, 2006, EMBO J, V25, P693, DOI 10.1038/sj.emboj.7600965; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Sahlender DA, 2005, J CELL BIOL, V169, P285, DOI 10.1083/jcb.200501162; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Warner CL, 2003, EMBO J, V22, P569, DOI 10.1093/emboj/cdg055; Weisman LS, 2006, NAT REV MOL CELL BIO, V7, P243, DOI 10.1038/nrm1892; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835	32	157	159	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2007	9	2					176	U67		10.1038/ncb1531	http://dx.doi.org/10.1038/ncb1531			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	131WR	17187061	Green Accepted			2022-12-25	WOS:000243903000010
J	Lu, P; Vogel, C; Wang, R; Yao, X; Marcotte, EM				Lu, Peng; Vogel, Christine; Wang, Rong; Yao, Xin; Marcotte, Edward M.			Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation	NATURE BIOTECHNOLOGY			English	Article							TANDEM MASS-SPECTROMETRY; SACCHAROMYCES-CEREVISIAE; YEAST PROTEOME; MESSENGER-RNA; ESCHERICHIA-COLI; GENE-EXPRESSION; SCALE ANALYSIS; GENOMIC SCALE; ABUNDANCE; PEPTIDE	We report a method for large-scale absolute protein expression measurements (APEX) and apply it to estimate the relative contributions of transcriptional-and translational-level gene regulation in the yeast and Escherichia coli proteomes. APEX relies upon correcting each protein's mass spectrometry sampling depth (observed peptide count) by learned probabilities for identifying the peptides. APEX abundances agree with measurements from controls, western blotting, flow cytometry and two-dimensional gels, as well as known correlations with mRNA abundances and codon bias, providing absolute protein concentrations across approximately three to four orders of magnitude. Using APEX, we demonstrate that 73% of the variance in yeast protein abundance (47% in E. coli) is explained by mRNA abundance, with the number of proteins per mRNA log-normally distributed about similar to 5,600 (similar to 540 in E. coli) protein molecules/ mRNA. Therefore, levels of both eukaryotic and prokaryotic proteins are set per mRNA molecule and independently of overall protein concentration, with > 70% of yeast gene expression regulation occurring through mRNA-directed mechanisms.	Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, Ctr Syst & Synth Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Marcotte, EM (corresponding author), Univ Texas, Inst Cellular & Mol Biol, Dept Chem & Biochem, Ctr Syst & Synth Biol, 2500 Speedway, Austin, TX 78712 USA.	marcotte@icmb.utexas.edu		Marcotte, Edward/0000-0001-8808-180X				Allemeersch J, 2005, PLANT PHYSIOL, V137, P588, DOI 10.1104/pp.104.051300; Allen TE, 2003, J BACTERIOL, V185, P6392, DOI 10.1128/JB.185.21.6392-6399.2003; Arava Y, 2003, P NATL ACAD SCI USA, V100, P3889, DOI 10.1073/pnas.0635171100; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Belle A, 2006, P NATL ACAD SCI USA, V103, P13004, DOI 10.1073/pnas.0605420103; Beyer A, 2004, MOL CELL PROTEOMICS, V3, P1083, DOI 10.1074/mcp.M400099-MCP200; Corbin RW, 2003, P NATL ACAD SCI USA, V100, P9232, DOI 10.1073/pnas.1533294100; Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Craig R, 2005, RAPID COMMUN MASS SP, V19, P1844, DOI 10.1002/rcm.1992; Fievet J, 2004, PROTEOMICS, V4, P1939, DOI 10.1002/pmic.200300731; Futcher B, 1999, MOL CELL BIOL, V19, P7357; Gao J, 2005, J AM SOC MASS SPECTR, V16, P1231, DOI 10.1016/j.jasms.2004.12.002; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Greenbaum D, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-117; Griffin TJ, 2002, MOL CELL PROTEOMICS, V1, P323, DOI 10.1074/mcp.M200001-MCP200; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HOLMBERG S, 1988, CURR GENET, V13, P207, DOI 10.1007/BF00387766; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; Ishihama Y, 2005, MOL CELL PROTEOMICS, V4, P1265, DOI 10.1074/mcp.M500061-MCP200; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; Kuster B, 2005, NAT REV MOL CELL BIO, V6, P577, DOI 10.1038/nrm1683; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LITSKE JG, 1986, NUCLEIC ACIDS RES, V14, P9631, DOI 10.1093/nar/14.24.9631; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Lopez-Campistrous A, 2005, MOL CELL PROTEOMICS, V4, P1205, DOI 10.1074/mcp.D500006-MCP200; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Neidhardt F.C., 1996, ESCHERICHIA COLI SAL, Vvol. 1; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Newman J., 2006, NATURE; Oda Y, 1999, P NATL ACAD SCI USA, V96, P6591, DOI 10.1073/pnas.96.12.6591; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Prince JT, 2004, NAT BIOTECHNOL, V22, P471, DOI 10.1038/nbt0404-471; Rappsilber J, 2002, GENOME RES, V12, P1231, DOI 10.1101/gr.473902; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Silva JC, 2006, MOL CELL PROTEOMICS, V5, P144, DOI 10.1074/mcp.M500230-MCP200; Sloan JS, 1999, J BIOL CHEM, V274, P37575, DOI 10.1074/jbc.274.53.37575; States DJ, 2006, NAT BIOTECHNOL, V24, P333, DOI 10.1038/nbt1183; Steen H, 2002, TRENDS BIOTECHNOL, V20, P361, DOI 10.1016/S0167-7799(02)02009-7; Tang HX, 2006, BIOINFORMATICS, V22, pE481, DOI 10.1093/bioinformatics/btl237; THIELE D, 1985, J BIOL CHEM, V260, P3084; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wang YL, 2002, P NATL ACAD SCI USA, V99, P5860, DOI 10.1073/pnas.092538799; Washburn MP, 2003, P NATL ACAD SCI USA, V100, P3107, DOI 10.1073/pnas.0634629100; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; Yi EC, 2002, ELECTROPHORESIS, V23, P3205, DOI 10.1002/1522-2683(200209)23:18<3205::AID-ELPS3205>3.0.CO;2-Y	50	869	888	2	123	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2007	25	1					117	124		10.1038/nbt1270	http://dx.doi.org/10.1038/nbt1270			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126CY	17187058				2022-12-25	WOS:000243491000037
J	Park, BK; Zhang, HL; Zeng, QH; Dai, JL; Keller, ET; Giordano, T; Gu, KN; Shah, V; Pei, L; Zarbo, RJ; McCauley, L; Shi, ST; Chen, SQ; Wang, CY				Park, Bae Keun; Zhang, Honglai; Zeng, Qinghua; Dai, Jinlu; Keller, Evan T.; Giordano, Thomas; Gu, Keni; Shah, Veena; Pei, Lei; Zarbo, Richard J.; McCauley, Laurie; Shi, Songtao; Chen, Shaoqiong; Wang, Cun-Yu			NF-kappa B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; MARROW CULTURES; TUMOR-GROWTH; IN-VIVO; INFLAMMATION; INHIBITION; PATHOGENESIS; ACTIVATION; EXPRESSION; THERAPY	Advanced breast cancers frequently metastasize to bone, resulting in osteolytic lesions, yet the underlying mechanisms are poorly understood. Here we report that nuclear factor-kappa B (NF-kappa B) plays a crucial role in the osteolytic bone metastasis of breast cancer by stimulating osteoclastogenesis. Using an in vivo bone metastasis model, we found that constitutive NF-kappa B activity in breast cancer cells is crucial for the bone resorption characteristic of osteolytic bone metastasis. We identified the gene encoding granulocyte macrophage-colony stimulating factor (GM-CSF) as a key target of NF-kappa B and found that it mediates osteolytic bone metastasis of breast cancer by stimulating osteoclast development. Moreover, we observed that the expression of GM-CSF correlated with NF-kappa B activation in bone-metastatic tumor tissues from individuals with breast cancer. These results uncover a new and specific role of NF-kappa B in osteolytic bone metastasis through GM-CSF induction, suggesting that NF-kappa B is a potential target for the treatment of breast cancer and the prevention of skeletal metastasis.	Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Henry Ford Hlth Syst, Dept Pathol, Detroit, MI 48202 USA; Univ Michigan, Sch Med & Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Henry Ford Health System; Henry Ford Hospital; University of Michigan System; University of Michigan; University of Southern California	Wang, CY (corresponding author), Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	cunywang@umich.edu	Dai, Jin/GVT-2414-2022; McCauley, Laurie/G-4041-2012; Keller, Evan T/M-1446-2016	Dai, Jin/0000-0003-3063-746X; Keller, Evan T/0000-0002-7592-7535; Giordano, Thomas/0000-0003-0641-8873	NCI NIH HHS [CA100849, CA093900, P01 CA093900] Funding Source: Medline; NIDCR NIH HHS [DE015618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA093900, R01CA100849] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baxter A, 2004, BIOORG MED CHEM LETT, V14, P2817, DOI 10.1016/j.bmcl.2004.03.058; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Hamilton JA, 2002, TRENDS IMMUNOL, V23, P403, DOI 10.1016/S1471-4906(02)02260-3; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hodge JM, 2004, J BONE MINER RES, V19, P190, DOI 10.1359/JBMR.0301232; Horak CE, 2005, CANCER CELL, V8, P93, DOI 10.1016/j.ccr.2005.07.013; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Javed A, 2005, P NATL ACAD SCI USA, V102, P1454, DOI 10.1073/pnas.0409121102; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911-005-5399-8; Li FH, 2005, J BONE MINER RES, V20, P1161, DOI 10.1359/JBMR.050207; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; Martin T. J., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P243; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Menaa C, 1999, J CLIN INVEST, V103, P1605, DOI 10.1172/JCI6374; Morgan H, 2004, INT J CANCER, V109, P653, DOI 10.1002/ijc.20056; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Myint YY, 1999, AM J PATHOL, V154, P553, DOI 10.1016/S0002-9440(10)65301-1; Queen MM, 2005, CANCER RES, V65, P8896, DOI 10.1158/0008-5472.CAN-05-1734; Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831; Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yoneda T, 2005, BIOCHEM BIOPH RES CO, V328, P679, DOI 10.1016/j.bbrc.2004.11.070; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685	46	264	281	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					62	69		10.1038/nm1519	http://dx.doi.org/10.1038/nm1519			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17159986				2022-12-25	WOS:000243301800037
J	Richt, JA; Kasinathan, P; Hamir, AN; Castilla, J; Sathiyaseelan, T; Vargas, F; Sathiyaseelan, J; Wu, H; Matsushita, H; Koster, J; Kato, S; Ishida, I; Soto, C; Robl, JM; Kuroiwa, Y				Richt, Jurgen A.; Kasinathan, Poothappillai; Hamir, Amir N.; Castilla, Joaquin; Sathiyaseelan, Thillai; Vargas, Francisco; Sathiyaseelan, Janaki; Wu, Hua; Matsushita, Hiroaki; Koster, Julie; Kato, Shinichiro; Ishida, Isao; Soto, Claudio; Robl, James M.; Kuroiwa, Yoshimi			Production of cattle lacking prion protein	NATURE BIOTECHNOLOGY			English	Article							SPONGIFORM ENCEPHALOPATHY; CELLULAR-FORM; MICE; PRP; RESISTANT; SCRAPIE; ATAXIA; GENE; IDENTIFICATION; TRANSMISSION	Prion diseases are caused by propagation of misfolded forms of the normal cellular prion protein PrPC, such as PrPBSE in bovine spongiform encephalopathy (BSE) in cattle and PrPCJD in Creutzfeldt-Jakob disease (CJD) in humans(1). Disruption of PrPC expression in mice, a species that does not naturally contract prion diseases, results in no apparent developmental abnormalities(2-5). However, the impact of ablating PrPC function in natural host species of prion diseases is unknown. Here we report the generation and characterization of PrPC-deficient cattle produced by a sequential gene-targeting system(6). At over 20 months of age, the cattle are clinically, physiologically, histopathologically, immunologically and reproductively normal. Brain tissue homogenates are resistant to prion propagation in vitro as assessed by protein misfolding cyclic amplification(7). PrPC-deficient cattle may be a useful model for prion research and could provide industrial bovine products free of prion proteins.	Kirin Brewery Co Ltd, Div Pharmaceut, Shibuya Ku, Tokyo, Japan; USDA ARS, Natl Anim Dis Ctr, Ames, IA 50010 USA; Hematech Inc, Sioux Falls, SD 57106 USA; Univ Texas, Dept Neurol, Med Branch, Galveston, TX USA; Gemini Sci Inc, La Jolla, CA 92109 USA	Kirin Brewery Company Limited; United States Department of Agriculture (USDA); University of Texas System; University of Texas Medical Branch Galveston	Richt, JA (corresponding author), Kirin Brewery Co Ltd, Div Pharmaceut, Shibuya Ku, 26-1 Jinguamae 6-Chome, Tokyo, Japan.	jricht@nadc.ars.usda.gov	Castilla, Joaquin/D-5261-2011; Richt, Juergen/AAL-3632-2020; Castilla, Joaquín/J-8414-2019	Castilla, Joaquin/0000-0002-2216-1361; Castilla, Joaquín/0000-0002-2216-1361	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049173, R01NS050349] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS050349, R01 NS049173-03, R01 NS049173, NS050349, NS049173] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguzzi A, 2000, HAEMATOLOGICA, V85, P3; Bainbridge J, 2005, IMMUNOL LETT, V96, P147, DOI 10.1016/j.imlet.2004.08.006; BERTHEIN BC, 2002, 6 INT WORKSH DIAGN S; Biacabe AG, 2004, EMBO REP, V5, P110, DOI 10.1038/sj.embor.7400054; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Casalone C, 2004, P NATL ACAD SCI USA, V101, P3065, DOI 10.1073/pnas.0305777101; Castilla J, 2005, CELL, V121, P195, DOI 10.1016/j.cell.2005.02.011; Castilla J, 2005, NAT MED, V11, P982, DOI 10.1038/nm1286; CASTILLA J, 2004, METHODS TOOLS BIOSCI, P198; Chesebro B, 1999, NEURON, V24, P503, DOI 10.1016/S0896-6273(00)81105-8; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; Criado JR, 2005, NEUROBIOL DIS, V19, P255, DOI 10.1016/j.nbd.2005.01.001; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Kuroiwa Y, 2004, NAT GENET, V36, P775, DOI 10.1038/ng1373; Li AM, 2000, CELL MOL NEUROBIOL, V20, P553, DOI 10.1023/A:1007059827541; Lledo PM, 1996, P NATL ACAD SCI USA, V93, P2403, DOI 10.1073/pnas.93.6.2403; Mabbott NA, 1997, IMMUNOLOGY, V92, P161, DOI 10.1046/j.1365-2567.1997.00331.x; Mabbott N, 2005, HAEMATOLOGICA, V90, P542; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 2004, SCI AM, V291, P86, DOI 10.1038/scientificamerican0704-86; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rossi D, 2001, EMBO J, V20, P694, DOI 10.1093/emboj/20.4.694; Saa Paula, 2004, V299, P53; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Seabury CM, 2004, P NATL ACAD SCI USA, V101, P15142, DOI 10.1073/pnas.0406403101; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Silverman GL, 2000, J BIOL CHEM, V275, P26834; Tobler I, 1996, NATURE, V380, P639, DOI 10.1038/380639a0; Tobler I, 1997, J NEUROSCI, V17, P1869; Vargas F, 2006, J VET INTERN MED, V20, P187, DOI 10.1892/0891-6640(2006)20[187:DACEOS]2.0.CO;2; Weissmann C, 2002, P NATL ACAD SCI USA, V99, P16378, DOI 10.1073/pnas.172403799; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Yamakawa Y, 2003, JPN J INFECT DIS, V56, P221	38	212	242	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2007	25	1					132	138		10.1038/nbt1271	http://dx.doi.org/10.1038/nbt1271			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126CY	17195841	Green Accepted			2022-12-25	WOS:000243491000039
J	Choi, JH; Kim, HS; Kim, SH; Yang, YR; Bae, YS; Chang, JS; Kwon, HM; Ryu, SH; Suh, PG				Choi, Jang Hyun; Kim, Hyeon Soo; Kim, Sun-Hee; Yang, Yong Ryoul; Bae, Yun Soo; Chang, Jong-Soo; Kwon, H. Moo; Ryu, Sung Ho; Suh, Pann-Ghill			Phospholipase C gamma 1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B	NATURE CELL BIOLOGY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; FACTOR-RECEPTOR; INSULIN SENSITIVITY; C-FOS; MICE; 1B; KINASE; ENDOCYTOSIS; ACTIVATION; FAILURE	Growth hormone binds to its membrane receptor (GHR), whereby it regulates many cellular functions, including proliferation, differentiation and chemotaxis. However, although the activation of growth hormone-mediated signalling is well understood, the precise mechanism responsible for its regulation has not been elucidated. Here, we demonstrate that phospholipase C gamma 1 (PLC gamma 1) modulates the action of growth hormone-mediated signalling by interacting with tyrosine kinase Jak2 (janus kinase 2) in a growth hormone-dependent manner. In the absence of PLC gamma 1 (PLC gamma 1(-/-)), growth hormone-induced JAK2 and STAT5 phosphorylation significantly increased in mouse embryonic fibroblasts (MEFs). Furthermore, the re-expression of PLC gamma 1 reduced growth hormone-induced Jak2 activation. Growth hormone-induced Jak2 phosphorylation was enhanced by siRNA-specific knockdown of PLC gamma 1. Interestingly, PLC gamma 1 physically linked Jak2 and protein tyrosine phosphatase-1B (PTP-1B) by binding to both using different domains, and this process was implicated in the modulation of cytokine signalling through Jak2. In addition, in PLC gamma 1(-/-) MEFs, growth hormone-dependent c-Fos activation was upregulated and growth hormone-induced proliferation was potentiated. These results suggest that PLC gamma 1 has a key function in the regulation of growth hormone-mediated signalling by negatively regulating Jak2 activation.	Pohang Univ Sci & Technol, Dept Life Sci, Natl Res Lab Signaling Network, Pohang 790784, Kyungbuk, South Korea; Ewha Womans Univ, Div Mol Life Sci, Ctr Cell Signalling Res, Seoul 120750, South Korea; Daejin Univ, Coll Nat Sci, Dept Life Sci, Kyonggi Do 487711, South Korea; Univ Maryland, Div Nephrol, Baltimore, MD 21201 USA	Pohang University of Science & Technology (POSTECH); Ewha Womans University; Daejin University; University System of Maryland; University of Maryland Baltimore	Suh, PG (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Natl Res Lab Signaling Network, Pohang 790784, Kyungbuk, South Korea.	pgs@postech.ac.kr	Suh, Pann-Ghill/F-3610-2010; Choi, Jang Hyun/B-3055-2012; Lee-Kwon, Whaseon/D-6021-2011	Ryu, Sung Ho/0000-0003-0913-3048				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Choi JH, 2004, J CELL SCI, V117, P3785, DOI 10.1242/jcs.01220; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; FAIN JN, 1990, BIOCHIM BIOPHYS ACTA, V1053, P81, DOI 10.1016/0167-4889(90)90029-D; Gu F, 2003, MOL CELL BIOL, V23, P3753, DOI 10.1128/MCB.23.11.3753-3762.2003; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Herrington J, 2001, TRENDS ENDOCRIN MET, V12, P252, DOI 10.1016/S1043-2760(01)00423-4; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Irvin BJ, 2000, MOL CELL BIOL, V20, P9149, DOI 10.1128/MCB.20.24.9149-9161.2000; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Kofoed EM, 2003, NEW ENGL J MED, V349, P1139, DOI 10.1056/NEJMoa022926; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Lupu F, 2001, DEV BIOL, V229, P141, DOI 10.1006/dbio.2000.9975; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Patterson RL, 2002, CELL, V111, P529, DOI 10.1016/S0092-8674(02)01045-0; Peng B, 2002, MOL ENDOCRINOL, V16, P2019, DOI 10.1210/me.2002-0108; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; ROGERS SA, 1989, P NATL ACAD SCI USA, V86, P6363, DOI 10.1073/pnas.86.16.6363; Sangwan V, 2006, J BIOL CHEM, V281, P221, DOI 10.1074/jbc.M507858200; Sjoholm A, 2000, J BIOL CHEM, V275, P21033, DOI 10.1074/jbc.M001212200; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; Waters MJ, 2006, J MOL ENDOCRINOL, V36, P1, DOI 10.1677/jme.1.01933; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a	30	27	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1389	U53		10.1038/ncb1509	http://dx.doi.org/10.1038/ncb1509			23	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17128263				2022-12-25	WOS:000242419800015
J	Mena, MA; Treynor, TP; Mayo, SL; Daugherty, PS				Mena, Marco A.; Treynor, Thomas P.; Mayo, Stephen L.; Daugherty, Patrick S.			Blue fluorescent proteins with enhanced brightness and photostability from a structurally targeted library	NATURE BIOTECHNOLOGY			English	Article							CONSTRUCTION; EVOLUTION; VARIANTS; DESIGN	The utility of blue fluorescent protein ( BFP) has been limited by its low quantum yield and rapid photobleaching. A library targeting residues neighboring the chromophore yielded a variant with enhanced quantum yield ( 0.55 versus 0.34), reduced pH sensitivity and a 40-fold increase in photobleaching half-life. This BFP, named Azurite, is well expressed in bacterial and mammalian cells and extends the palette of fluorescent proteins that can be used for imaging.	Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Collaborat Biotechnol, Santa Barbara, CA 93106 USA; CALTECH, Div Biol, Div Chem & Chem Engn, Pasadena, CA 91125 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; California Institute of Technology	Daugherty, PS (corresponding author), Univ Calif Santa Barbara, Dept Chem Engn, Santa Barbara, CA 93106 USA.	psd@engineering.ucsb.edu			NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000205] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB-000205] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Bessette Paul H, 2003, Methods Mol Biol, V231, P29; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Ellenberg J, 1999, TRENDS CELL BIOL, V9, P52, DOI 10.1016/S0962-8924(98)01420-2; Ellenberg J, 1998, BIOTECHNIQUES, V25, P838, DOI 10.2144/98255bt01; Hayes RJ, 2002, P NATL ACAD SCI USA, V99, P15926, DOI 10.1073/pnas.212627499; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Kummer AD, 2002, CHEMBIOCHEM, V3, P659, DOI 10.1002/1439-7633(20020703)3:7<659::AID-CBIC659>3.0.CO;2-U; Lippincott-Schwartz J, 2003, SCIENCE, V300, P87, DOI 10.1126/science.1082520; Mauring K, 2005, J PHYS CHEM B, V109, P12976, DOI 10.1021/jp0448595; Neylon C, 2004, NUCLEIC ACIDS RES, V32, P1448, DOI 10.1093/nar/gkh315; Park S, 2004, CURR OPIN STRUC BIOL, V14, P487, DOI 10.1016/j.sbi.2004.06.002; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; TREYNOR TP, IN PRESS P NATL ACAD; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Voigt CA, 2001, P NATL ACAD SCI USA, V98, P3778, DOI 10.1073/pnas.051614498; Wachter RM, 1997, BIOCHEMISTRY-US, V36, P9759, DOI 10.1021/bi970563w	19	97	104	4	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1569	1571		10.1038/nbt1264	http://dx.doi.org/10.1038/nbt1264			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17115054				2022-12-25	WOS:000242795800036
J	Blackburn, EH; Greider, CW; Szostak, JW				Blackburn, Elizabeth H.; Greider, Carol W.; Szostak, Jack W.			Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging	NATURE MEDICINE			English	Editorial Material							DOMINANT DYSKERATOSIS-CONGENITA; RIBOSOMAL-RNA GENES; REVERSE-TRANSCRIPTASE; TERMINAL TRANSFERASE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SEGREGATION; MOLECULAR-STRUCTURE; DNA-SEQUENCES; EST GENES; IN-VITRO		Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Harvard Univ, Sch Med, Dept Mol Biol, Boston, MA 02114 USA; Simches Res Ctr, Ctr Computat & Integrat Biol, Boston, MA 02114 USA	University of California System; University of California San Francisco; Johns Hopkins University; Harvard University; Harvard Medical School	Blackburn, EH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 600 16th St,MC 2200, San Francisco, CA 94158 USA.	elizabeth.blackburn@ucsf.edu; cgreider@jhmi.edu; szostak@molbio.mgh.harvard.edu	daehun, lee/H-2435-2013	Greider, Carol/0000-0002-5494-8126				ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; Armanios M, 2005, P NATL ACAD SCI USA, V102, P15960, DOI 10.1073/pnas.0508124102; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1982, COLD SPRING HARB SYM, V47, P1195, DOI 10.1101/SQB.1983.047.01.135; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BOSWELL RE, 1982, P NATL ACAD SCI-BIOL, V79, P3255, DOI 10.1073/pnas.79.10.3255; Chen JL, 2004, TRENDS BIOCHEM SCI, V29, P183, DOI 10.1016/j.tibs.2004.02.003; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COOKE HJ, 1985, NATURE, V317, P687, DOI 10.1038/317687a0; DAWSON DS, 1986, SCIENCE, V234, P713, DOI 10.1126/science.3535068; de Lange T, 1999, CELL, V98, P273, DOI 10.1016/S0092-8674(00)81955-8; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; EMERY HS, 1981, CELL, V26, P411, DOI 10.1016/0092-8674(81)90210-5; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hao LY, 2005, CELL, V123, P1121, DOI 10.1016/j.cell.2005.11.020; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; JOHNSON EM, 1980, CELL, V22, P875, DOI 10.1016/0092-8674(80)90564-4; KATZEN AL, 1981, CELL, V24, P313, DOI 10.1016/0092-8674(81)90321-4; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; Kornberg Arthur, 1974, DNA SYNTHESIS; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1997, P NATL ACAD SCI USA, V94, P11190, DOI 10.1073/pnas.94.21.11190; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; McCLINTOCK B., 1931, MISSOURI AGRIC EXP STA RES BULL, V163, P1; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Muller H, 1938, COLLECTING NET, V13, P181; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; MURRAY AW, 1986, CELL, V45, P529, DOI 10.1016/0092-8674(86)90284-9; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PAN WC, 1981, CELL, V23, P459, DOI 10.1016/0092-8674(81)90141-0; Prescott J, 1997, GENE DEV, V11, P528, DOI 10.1101/gad.11.4.528; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Vulliamy T, 2004, NAT GENET, V36, P447, DOI 10.1038/ng1346; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WU R, 1971, J MOL BIOL, V57, P491, DOI 10.1016/0022-2836(71)90105-7; Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980; YAO MC, 1979, COLD SPRING HARB SYM, V43, P1293, DOI 10.1101/SQB.1979.043.01.147; YAO MC, 1981, J CELL BIOL, V90, P515, DOI 10.1083/jcb.90.2.515; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	58	620	643	8	190	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1133	1138		10.1038/nm1006-1133	http://dx.doi.org/10.1038/nm1006-1133			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17024208				2022-12-25	WOS:000241102200027
J	Derti, A; Roth, FP; Church, GM; Wu, CT				Derti, Adnan; Roth, Frederick P.; Church, George M.; Wu, C-ting			Mammalian ultraconserved elements are strongly depleted among segmental duplications and copy number variants	NATURE GENETICS			English	Article							STRUCTURAL VARIATION; VERTEBRATE; GENE; SEQUENCES; TRANSVECTION; POLYMORPHISM; ENHANCER; GENOMES; REGIONS; MOUSE	An earlier search in the human, mouse and rat genomes for sequences that are 100% conserved in orthologous segments and >= 200 bp in length identified 481 distinct sequences(1). These human-mouse-rat sequences, which represent ultraconserved elements (UCEs), are believed to be important for functions involving DNA binding, RNA processing and the regulation of transcription and development. In vivo and additional computational studies of UCEs and other highly conserved sequences are consistent with these functional associations, with some observations indicating enhancer-like activity for these elements(1-9). Here, we show that UCEs are significantly depleted among segmental duplications and copy number variants. Notably, of the UCEs that are found in segmental duplications or copy number variants, the majority overlap exons, indicating, along with other findings presented, that UCEs overlapping exons represent a distinct subset.	Harvard Univ, Sch Med, Div Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Mol Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Lipper Ctr Computat Genet, Boston, MA 02115 USA; Boston Univ, Bioinformat Program, Boston, MA 02215 USA; Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Boston University; Harvard University; Dana-Farber Cancer Institute	Wu, CT (corresponding author), Harvard Univ, Sch Med, Div Genet, Boston, MA 02115 USA.	twu@genetics.med.harvard.edu	Roth, Frederick P/H-6308-2011	Roth, Frederick/0000-0002-6628-649X; church, george/0000-0001-6232-9969	NHGRI NIH HHS [HG003224, HG0017115] Funding Source: Medline; NIGMS NIH HHS [GM61936] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061936] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bailey JA, 2003, AM J HUM GENET, V73, P823, DOI 10.1086/378594; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Bejerano G, 2006, NATURE, V441, P87, DOI 10.1038/nature04696; Bejerano G, 2004, SCIENCE, V304, P1321, DOI 10.1126/science.1098119; Boffelli D, 2003, SCIENCE, V299, P1391, DOI 10.1126/science.1081331; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-8-r47; Cheung J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r25; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; de la Calle-Mustienes E, 2005, GENOME RES, V15, P1061, DOI 10.1101/gr.4004805; Dermitzakis ET, 2004, GENOME RES, V14, P852, DOI 10.1101/gr.1934904; Duncan IW, 2002, ANNU REV GENET, V36, P521, DOI 10.1146/annurev.genet.36.060402.100441; Eichler EE, 2006, NAT GENET, V38, P9, DOI 10.1038/ng0106-9; Feuk L, 2006, NAT REV GENET, V7, P85, DOI 10.1038/nrg1767; Goode DK, 2005, GENOMICS, V86, P172, DOI 10.1016/j.ygeno.2005.04.006; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; Hinds DA, 2006, NAT GENET, V38, P82, DOI 10.1038/ng1695; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Kennison JA, 2002, ADV GENET, V46, P399; McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Poulin F, 2005, GENOMICS, V85, P774, DOI 10.1016/j.ygeno.2005.03.003; Sandelin A, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-99; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Sharp AJ, 2005, AM J HUM GENET, V77, P78, DOI 10.1086/431652; She XW, 2004, NATURE, V431, P927, DOI 10.1038/nature03062; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562; Woolfe A, 2005, PLOS BIOL, V3, P116, DOI 10.1371/journal.pbio.0030007	28	84	87	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1216	1220		10.1038/ng1888	http://dx.doi.org/10.1038/ng1888			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16998490				2022-12-25	WOS:000241251100024
J	Wang, CG; Chen, LH; Hou, XH; Li, ZY; Kabra, N; Ma, YH; Nemoto, S; Finkel, T; Gu, W; Cress, WD; Chen, JD				Wang, Chuangui; Chen, Lihong; Hou, Xinghua; Li, Zhenyu; Kabra, Neha; Ma, Yihong; Nemoto, Shino; Finkel, Toren; Gu, Wei; Cress, W. Douglas; Chen, Jiandong			Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage	NATURE CELL BIOLOGY			English	Article							LIFE-SPAN EXTENSION; CELL-SURVIVAL; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; P53; TRANSCRIPTION; DEACETYLASE; EXPRESSION; INDUCTION; CYCLE	The nicotinamide adenine dinucleotide (NAD)-dependent deacetylase Sir2 (silent information regulator 2) regulates gene silencing in yeast and promotes lifespan extension during caloric restriction. The mammalian homologue of Sir2 (SirT1) regulates p53, NF-kappa B and Forkhead transcription factors, and is implicated in stress response. This report shows that the cell-cycle and apoptosis regulator E2F1 induces SirT1 expression at the transcriptional level. Furthermore, SirT1 binds to E2F1 and inhibits E2F1 activities, forming a negative feedback loop. Knockdown of SirT1 by small interference RNA (siRNA) increases E2F1 transcriptional and apoptotic functions. DNA damage by etoposide causes E2F1-dependent induction of SirT1 expression and knockdown of SirT1 increases sensitivity to etoposide. These results reveal a mutual regulation between E2F1 and SirT1 that affects cellular sensitivity to DNA damage.	H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Columbia Univ, Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; NHLBI, Cardiovasc Branch, Bethesda, MD 20892 USA	Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Chen, JD (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jchen@moffitt.usf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL005012, Z01HL005012] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chu F, 2005, CANCER RES, V65, P10183, DOI 10.1158/0008-5472.CAN-05-2002; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Guarante LP, 2005, ANN NY ACAD SCI, V1055, P222; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin WC, 2001, GENE DEV, V15, P1833; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma YH, 2004, CANCER BIOL THER, V3, P1262, DOI 10.4161/cbt.3.12.1239; Ma YH, 2003, J BIOL CHEM, V278, P16770, DOI 10.1074/jbc.M212702200; Ma YH, 2003, MOL CANCER THER, V2, P73; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Pruschy M, 1999, CELL GROWTH DIFFER, V10, P141; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2005, J BIOL CHEM, V280, P12339, DOI 10.1074/jbc.C400536200; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	30	343	368	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					1025	U109		10.1038/ncb1468	http://dx.doi.org/10.1038/ncb1468			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16892051				2022-12-25	WOS:000240241700020
J	Tang, J; Qu, LK; Zhang, J; Wang, W; Michaelson, JS; Degenhardt, YY; El-Deiry, WS; Yang, XO				Tang, Jun; Qu, Li-Ke; Zhang, Jianke; Wang, Wenge; Michaelson, Jennifer S.; Degenhardt, Yan Y.; El-Deiry, Wafik S.; Yang, Xiaolu			Critical role for Daxx in regulating Mdm2	NATURE CELL BIOLOGY			English	Article							UBIQUITIN LIGASE; P53; PROTEIN; APOPTOSIS; DOMAIN; HAUSP; DEUBIQUITINATION; DEGRADATION; ACTIVATION; PATHWAY	The tumour suppressor p53 induces apoptosis or cell-cycle arrest in response to genotoxic and other stresses(1,2). In unstressed cells, the anti-proliferative effects of p53 are restrained by mouse double minute 2 ( Mdm2), a ubiquitin ligase ( E3) that promotes p53 ubiquitination and degradation(3). Mdm2 also mediates its own degradation through auto-ubiquitination. It is unclear how the cis- and trans-E3 activities of Mdm2, which have opposing effects on cell fate, are differentially regulated. Here, we show that death domain-associated protein ( Daxx) 4 is required for Mdm2 stability. Downregulation of Daxx decreases Mdm2 levels, whereas overexpression of Daxx strongly stabilizes Mdm2. Daxx simultaneously binds to Mdm2 and the deubiquitinase Hausp, and it mediates the stabilizing effect of Hausp on Mdm2. In addition, Daxx enhances the intrinsic E3 activity of Mdm2 towards p53. On DNA damage, Daxx dissociates from Mdm2, which correlates with Mdm2 self-degradation. These findings reveal that Daxx modulates the function of Mdm2 at multiple levels and suggest that the disruption of the Mdm2-Daxx interaction may be important for p53 activation in response to DNA damage.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet & Pharmacol, Philadelphia, PA 19104 USA; Biogen Idec Inc, Dept Exploratory Sci, Cambridge, MA 02142 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Jefferson University; University of Pennsylvania; University of Pennsylvania; Biogen	Yang, XO (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	xyang@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Zhang, Jianke/0000-0002-5822-2226; Wang, Edward/0000-0001-9509-6735	NATIONAL CANCER INSTITUTE [T32CA009140, R01CA088868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060911] Funding Source: NIH RePORTER; NCI NIH HHS [CA88868, T32CA09140] Funding Source: Medline; NIGMS NIH HHS [GM60911] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Gostissa M, 2004, J BIOL CHEM, V279, P48013, DOI 10.1074/jbc.M310801200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Tang J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhao LY, 2004, J BIOL CHEM, V279, P50566, DOI 10.1074/jbc.M406743200; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	29	176	188	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					855	U115		10.1038/ncb1442	http://dx.doi.org/10.1038/ncb1442			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16845383				2022-12-25	WOS:000239423000016
J	Weisenberger, DJ; D Siegmund, K; Campan, M; Young, J; Long, TI; Faasse, MA; Kang, GH; Widschwendter, M; Weener, D; Buchanan, D; Koh, H; Simms, L; Barker, M; Leggett, B; Levine, J; Kim, M; French, AJ; Thibodeau, SN; Jass, J; Haile, R; Laird, PW				Weisenberger, Daniel J.; D Siegmund, Kimberly; Campan, Mihaela; Young, Joanne; Long, Tiffany I.; Faasse, Mark A.; Kang, Gyeong Hoon; Widschwendter, Martin; Weener, Deborah; Buchanan, Daniel; Koh, Hoey; Simms, Lisa; Barker, Melissa; Leggett, Barbara; Levine, Joan; Kim, Myungjin; French, Amy J.; Thibodeau, Stephen N.; Jass, Jeremy; Haile, Robert; Laird, Peter W.			CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer	NATURE GENETICS			English	Article							DNA METHYLATION; TRANSFORMATION; PROFILES	Aberrant DNA methylation of CpG islands has been widely observed in human colorectal tumors and is associated with gene silencing when it occurs in promoter areas. A subset of colorectal tumors has an exceptionally high frequency of methylation of some CpG islands, leading to the suggestion of a distinct trait referred to as 'CpG island methylator phenotype', or 'CIMP'(1,2). However, the existence of CIMP has been challenged(3,4). To resolve this continuing controversy, we conducted a systematic, stepwise screen of 195 CpG island methylation markers using MethyLight technology, involving 295 primary human colorectal tumors and 16,785 separate quantitative analyses. We found that CIMP-positive (CIMP+) tumors convincingly represent a distinct subset, encompassing almost all cases of tumors with BRAF mutation (odds ratio = 203). Sporadic cases of mismatch repair deficiency occur almost exclusively as a consequence of CIMP-associated methylation of MLH1. We propose a robust new marker panel to classify CIMP+ tumors.	Univ So Calif, Dept Surg, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA; Queensland Inst Med Res, Mol Canc Epidemiol Lab, Herston, Qld 4006, Australia; Seoul Natl Univ Hosp, Dept Pathol, Seoul 110744, South Korea; UCL, Dept Gynaecol Oncol, Inst Womens Hlth, London WC1E 6DH, England; Royal Brisbane & Womens Hosp Res Fdn, Conjoint Gastroenterol Lab, Clin Res Ctr, Herston, Qld 4006, Australia; McGill Univ, Dept Pathol, Montreal, PQ H3A 2B4, Canada; Mayo Clin & Mayo Fdn, Dept Lab Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pathol, Rochester, MN 55905 USA	University of Southern California; University of Southern California; University of Southern California; QIMR Berghofer Medical Research Institute; Seoul National University (SNU); Seoul National University Hospital; University of London; University College London; Royal Brisbane & Women's Hospital; McGill University; Mayo Clinic; Mayo Clinic	Laird, PW (corresponding author), Univ So Calif, Dept Surg, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.	plaird@usc.edu	Young, Joanne P/B-9981-2011; Young, Joanne P/H-7774-2014; Kang, Gyeong Hoon/F-1051-2010; Faasse, Mark/AAD-4049-2019; Weisenberger, Daniel/AAA-8314-2020; Leggett, Barbara A/D-3579-2011; Laird, Peter W/G-8683-2012	Kang, Gyeong Hoon/0000-0003-2380-6675; Weisenberger, Daniel/0000-0001-8303-2603; Laird, Peter W/0000-0001-9117-3641; Simms, Lisa/0000-0002-5387-7397; Young, Joanne/0000-0002-1514-1522; Buchanan, Daniel/0000-0003-2225-6675; Leggett, Barbara/0000-0003-2062-7380; Widschwendter, Martin/0000-0002-7778-8380; Faasse, Mark/0000-0002-1524-7239	NCI NIH HHS [R01 CA075090, U01 CA074794, U01 CA097735, U01 CA074783, U01 CA074800] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA074794, R01CA075090, U01CA097735, U01CA074783, U01CA074800] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anacleto C, 2005, NEOPLASIA, V7, P331, DOI 10.1593/neo.04502; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BREIMAN L., 1984, CRC PRESS; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Hastie T, 2001, GENOME BIOL, V2; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kaufman L., 1990, FINDING GROUPS DATA, DOI 10.1002/9780470316801; Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113; MCLACHLAN G, 2000, WILEY SER PROB STAT, P1; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Whitehall VLJ, 2002, CANCER RES, V62, P6011; Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852; Yamashita K, 2003, CANCER CELL, V4, P121, DOI 10.1016/S1535-6108(03)00190-9; Young J, 2001, AM J PATHOL, V159, P2107, DOI 10.1016/S0002-9440(10)63062-3; Young J, 2005, CLIN GASTROENTEROL H, V3, P254, DOI 10.1016/S1542-3565(04)00673-1	24	1429	1483	2	108	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					787	793		10.1038/ng1834	http://dx.doi.org/10.1038/ng1834			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16804544				2022-12-25	WOS:000238669300014
J	Natarajan, M; Lin, KM; Hsueh, RC; Sternweis, PC; Ranganathan, R				Natarajan, Madhusudan; Lin, Keng-Mean; Hsueh, Robert C.; Sternweis, Paul C.; Ranganathan, Rama			A global analysis of cross-talk in a mammalian cellular signalling network	NATURE CELL BIOLOGY			English	Article							TOLL-LIKE RECEPTOR; SOCS PROTEINS; CUTTING EDGE; TNF-ALPHA; LIPOPOLYSACCHARIDE; CYTOKINE; MACROPHAGES; INTERFERON; TLR; ACTIVATION	Cellular information processing requires the coordinated activity of a large network of intracellular signalling pathways. Crosstalk between pathways provides for complex non-linear responses to combinations of stimuli, but little is known about the density of these interactions in any specific cell. Here, we have analysed a large-scale survey of pathway interactions carried out by the Alliance for Cellular Signalling (AfCS) in RAW 264.7 macrophages. Twenty-two receptor-specific ligands were studied, both alone and in all pairwise combinations, for Ca2+ mobilization, cAMP synthesis, phosphorylation of many signalling proteins and for cytokine production. A large number of non-additive interactions are evident that are consistent with known mechanisms of cross-talk between pathways, but many novel interactions are also revealed. A global analysis of cross-talk suggests that many external stimuli converge on a relatively small number of interaction mechanisms to provide for context-dependent signalling.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Alliance Cellular Signalling, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Ranganathan, R (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	rama.ranganathan@utsouthwestern.edu		Natarajan, Madhusudan/0000-0003-1607-2917	NIGMS NIH HHS [U54 GM062114] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062114] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADERKA D, 1989, J IMMUNOL, V143, P3517; Akaogi J, 2004, J LEUKOCYTE BIOL, V76, P227, DOI 10.1189/jlb.1203627; Akira S, 2003, BIOCHEM SOC T, V31, P637, DOI 10.1042/BST0310637; Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200; Chen LW, 2005, J BIOMED SCI, V12, P311, DOI 10.1007/s11373-005-1704-1; CHEN ZP, 1995, J NEUROENDOCRINOL, V7, P83, DOI 10.1111/j.1365-2826.1995.tb00671.x; Dalpke AH, 2003, J ENDOTOXIN RES, V9, P51, DOI 10.1179/096805103125001342; Durbin J, 2003, J ENDOTOXIN RES, V9, P313, DOI 10.1179/096805103225002575; Farmer P, 2000, AM J PHYSIOL-LUNG C, V279, pL675, DOI 10.1152/ajplung.2000.279.4.L675; GESSANI S, 1989, J VIROL, V63, P2785, DOI 10.1128/JVI.63.6.2785-2789.1989; Gilman AG, 2002, NATURE, V420, P703, DOI 10.1038/nature01304; Harada K, 2006, J CLIN PATHOL, V59, P184, DOI 10.1136/jcp.2004.023507; Hareng L, 2003, EUR J IMMUNOL, V33, P2287, DOI 10.1002/eji.200323923; Hausler KG, 2002, EUR J NEUROSCI, V16, P2113, DOI 10.1046/j.1460-9568.2002.02287.x; Heeg K, 2003, VACCINE, V21, pS61, DOI 10.1016/S0264-410X(03)00202-0; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hertzog PJ, 2003, TRENDS IMMUNOL, V24, P534, DOI 10.1016/j.it.2003.08.006; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Lukashev D, 2004, J IMMUNOL, V173, P21, DOI 10.4049/jimmunol.173.1.21; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; MOJENA R, 1977, COMPUT J, V20, P359, DOI 10.1093/comjnl/20.4.359; Nansen A, 2001, J IMMUNOL, V166, P982, DOI 10.4049/jimmunol.166.2.982; Niemand C, 2003, J IMMUNOL, V170, P3263, DOI 10.4049/jimmunol.170.6.3263; O'Donnell PM, 2002, J INTERF CYTOK RES, V22, P539, DOI 10.1089/10799900252982016; Rozen S, 2000, Methods Mol Biol, V132, P365; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Tilg H, 2004, EXPERT OPIN BIOL TH, V4, P469, DOI 10.1517/eobt.4.4.469.29791; VanDeusen JB, 2006, EUR J IMMUNOL, V36, P623, DOI 10.1002/eji.200535241; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Zhang HB, 1999, AM J RESP CRIT CARE, V160, P1703, DOI 10.1164/ajrccm.160.5.9903068; Zhao J, 2006, J BIOL CHEM, V281, P10073, DOI 10.1074/jbc.M507788200	31	180	186	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					571	580		10.1038/ncb1418	http://dx.doi.org/10.1038/ncb1418			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16699502				2022-12-25	WOS:000238029000009
J	Shaunak, S; Godwin, A; Choi, JW; Balan, S; Pedone, E; Vijayarangam, D; Heidelberger, S; Teo, I; Zloh, M; Brocchini, S				Shaunak, Sunil; Godwin, Antony; Choi, Ji-Won; Balan, Sibu; Pedone, Elisa; Vijayarangam, Damotharan; Heidelberger, Sibylle; Teo, Ian; Zloh, Mire; Brocchini, Steve			Site-specific PEGylation of native disulfide bonds in therapeutic proteins	NATURE CHEMICAL BIOLOGY			English	Article								Native disulfide bonds in therapeutic proteins are crucial for tertiary structure and biological activity and are therefore considered unsuitable for chemical modification(1,2). We show that native disulfides in human interferon alpha-2b and in a fragment of an antibody to CD4(+) can be modified by site-specific bisalkylation of the two cysteine sulfur atoms to form a three-carbon PEGylated bridge. The yield of PEGylated protein is high, and tertiary structure and biological activity are retained.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, London W12 0NN, England; Univ London, Sch Pharm, Dept Pharmaceut, London WC1N 1AX, England; Univ London, Sch Pharm, Dept Pharmaceut & Biol Chem, London WC1N 1AX, England	Imperial College London; University of London; University College London; University of London School of Pharmacy; University of London; University College London; University of London School of Pharmacy	Brocchini, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Ducane Rd, London W12 0NN, England.	steve.brocchini@pharmacy.ac.uk	Zloh, Mire/M-5597-2018; Zloh, Mire/A-8124-2008; D, Vijayarangam/Z-3360-2019	Zloh, Mire/0000-0002-4848-2737; 	Wellcome Trust [068309] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALAN S, P 33 CONTR REL SOC M; BIALON P, 2001, BIOCONJUG CHEM, V2, P195; BROCCHINI SJ, 1988, J AM CHEM SOC, V110, P5211, DOI 10.1021/ja00223a061; GODWIN A, IN PRESS THEORETICAL; Grace M, 2001, J INTERF CYTOK RES, V21, P1103, DOI 10.1089/107999001317205240; Grace MJ, 2005, J BIOL CHEM, V280, P6327, DOI 10.1074/jbc.M412134200; Guo ZY, 2004, BIOL CHEM, V385, P1171, DOI 10.1515/BC.2004.151; Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; Liberatore FA, 1990, BIOCONJUGATE CHEM, V1, P36, DOI 10.1021/bc00001a005; Reddy KR, 2002, ADV DRUG DELIVER REV, V54, P571, DOI 10.1016/S0169-409X(02)00028-5; Wedemeyer WJ, 2000, BIOCHEMISTRY-US, V39, P4207, DOI 10.1021/bi992922o	12	211	239	0	75	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2006	2	6					312	313		10.1038/nchembio786	http://dx.doi.org/10.1038/nchembio786			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	045OH	16633351				2022-12-25	WOS:000237750900011
J	Robbins, MA; Li, MJ; Leung, I; Li, HT; Boyer, DV; Song, Y; Behlke, MA; Rossi, JJ				Robbins, MA; Li, MJ; Leung, I; Li, HT; Boyer, DV; Song, Y; Behlke, MA; Rossi, JJ			Stable expression of shRNAs in human CD34(+) progenitor cells can avoid induction of interferon responses to siRNAs in vitro	NATURE BIOTECHNOLOGY			English	Article							PLASMACYTOID DENDRITIC CELLS; STRANDED RNA; RECOGNITION; INNATE; INFECTION; GENES; ALPHA	RNA interference occurs when cytoplasmic small interfering RNAs (siRNAs) enter the RNA-induced silencing complex and one strand guides cleavage of the target RNA by the Argonaute 2 protein(1-3). A significant concern when applying siRNAs or expressing small hairpin RNAs (shRNAs) in human cells is activation of the interferon (IFN) response(4-10). Synthetic siRNAs harboring certain motifs can induce an immune response when delivered to mouse and human immune cells such as peripheral blood mononuclear cells, monocytes, plasmacytoid dendritic cells (pDCs) and nonplasmacytoid dendritic cells (mDCs)(11-13). In the present study we have tested the immunostimulatory effects of lipid-delivered siRNAs versus Pol III promoter-expressed shRNAs in primary CD34(+) progenitor-derived hematopoietic cells. We show that in this system, lipid-delivered siRNAs are potent inducers of IFN alpha and type I IFN gene expression, whereas the same sequences when expressed endogenously are nonimmunostimulatory.	City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Grad Sch Biol Sci, Duarte, CA 91010 USA; Beckman Coulter Inc, Biomed Res Div, Fullerton, CA 92834 USA; Integrated DNA Technol, Coralville, IA 52241 USA	City of Hope; Beckman Research Institute of City of Hope; Beckman Coulter Inc.	Rossi, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Grad Sch Biol Sci, 1500 E Duarte Rd, Duarte, CA 91010 USA.	jrossi@coh.org		Behlke, Mark/0000-0002-4218-857X; Robbins, Marjorie/0000-0002-4123-7106	NHLBI NIH HHS [HL07470] Funding Source: Medline; NIAID NIH HHS [AI42552, AI29329, AI061389] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029329, R37AI029329] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Giron-Michel J, 2002, LEUKEMIA, V16, P1135, DOI 10.1038/sj.leu.2402492; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Kariko K, 2004, CELLS TISSUES ORGANS, V177, P132, DOI 10.1159/000079987; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Kim S, 2003, ENDOCRINOLOGY, V144, P5203, DOI 10.1210/en.2003-0665; Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500; Li MJ, 2005, MOL THER, V12, P900, DOI 10.1016/j.ymthe.2005.07.524; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; MacQuillan GC, 2003, J MED VIROL, V70, P219, DOI 10.1002/jmv.10381; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Parker JS, 2005, NATURE, V434, P663, DOI 10.1038/nature03462; Pebernard S, 2004, DIFFERENTIATION, V72, P103, DOI 10.1111/j.1432-0436.2004.07202001.x; Sioud M, 2005, J MOL BIOL, V348, P1079, DOI 10.1016/j.jmb.2005.03.013; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang LL, 2002, J CLIN INVEST, V110, P1175, DOI 10.1172/JCI200215536; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	22	75	143	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2006	24	5					566	571		10.1038/nbt1206	http://dx.doi.org/10.1038/nbt1206			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	039TX	16648841				2022-12-25	WOS:000237331300032
J	Shore, EM; Xu, MQ; Feldman, GJ; Fenstermacher, DA; Brown, MA; Kaplan, FS				Shore, EM; Xu, MQ; Feldman, GJ; Fenstermacher, DA; Brown, MA; Kaplan, FS		FOP Int Res Consortium	A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva	NATURE GENETICS			English	Article							DISORDER; INHIBITOR	Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of skeletal malformations and progressive extraskeletal ossification. We mapped FOP to chromosome 2q23-24 by linkage analysis and identified an identical heterozygous mutation (617G -> A; R206H) in the glycine-serine (GS) activation domain of ACVR1, a BMP type I receptor, in all affected individuals examined. Protein modeling predicts destabilization of the GS domain, consistent with constitutive activation of ACVR1 as the underlying cause of the ectopic chondrogenesis, osteogenesis and joint fusions seen in FOP.	Univ Penn, Sch Med, Ctr Res FOP & Related Disorders, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Biomed Informat Facil, Philadelphia, PA 19104 USA; Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Immunol & Metab Med, Brisbane, Qld 4102, Australia; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Queensland; University of Pennsylvania	Kaplan, FS (corresponding author), Univ Penn, Sch Med, Ctr Res FOP & Related Disorders, Philadelphia, PA 19104 USA.	Frederick.Kaplan@uphs.upenn.edu	Brown, Matthew A/E-5749-2010; Shore, Eileen/D-2593-2009	Brown, Matthew A/0000-0003-0538-8211; 	NIAMS NIH HHS [R01 AR041916, R01-AR41916] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041916] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahn J, 2003, J BONE JOINT SURG AM, V85A, P667, DOI 10.2106/00004623-200304000-00013; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; de la Pena LS, 2005, J BONE MINER RES, V20, P1168, DOI 10.1359/JBMR.050305; Feldman G, 2000, AM J HUM GENET, V66, P128, DOI 10.1086/302724; Fiori JL, 2006, J BONE MINER RES, V21, P902, DOI 10.1359/JBMR.060215; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Kaplan F.S., 2002, CONNECTIVE TISSUE IT, P827; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Payne TL, 2001, MECH DEVELOP, V100, P275, DOI 10.1016/S0925-4773(00)00541-4; Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804; Shore EM, 2005, CLIN REV BONE MINER, V3, P201, DOI 10.1385/BMM:3:3-4:201; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Xu MQ, 2000, CLIN GENET, V58, P291, DOI 10.1034/j.1399-0004.2000.580407.x; Xu MQ, 2002, AM J MED GENET, V109, P161, DOI 10.1002/ajmg.10288; Zhang DH, 2003, J BONE MINER RES, V18, P1593, DOI 10.1359/jbmr.2003.18.9.1593	15	807	860	2	70	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					525	527		10.1038/ng1783	http://dx.doi.org/10.1038/ng1783			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16642017				2022-12-25	WOS:000237147500012
J	Schwartz, EC; Saez, L; Young, MW; Muir, TW				Schwartz, Edmund C.; Saez, Lino; Young, Michael W.; Muir, Tom W.			Post-translational enzyme activation in an animal via optimized conditional protein splicing	NATURE CHEMICAL BIOLOGY			English	Article							CEREVISIAE VMA INTEIN; SMALL-MOLECULE; MAMMALIAN-CELLS; GENE-EXPRESSION; IN-VITRO; DROSOPHILA; LUCIFERASE; SYSTEM; VIVO	Control over the timing, location and level of protein activity in vivo is crucial to understanding biological function(1). Living systems are able to respond to external and internal stimuli rapidly and in a graded fashion by maintaining a pool of proteins whose activities are altered through post-translational modifications(2). Here we show that the process of protein trans-splicing(3) can be used to modulate enzymatic activity both in cultured cells and in Drosophila melanogaster. We used an optimized conditional protein splicing(4) system to rapidly trigger the in vivo ligation of two inactive fragments of firefly luciferase in a tunable manner. This technique provides a means of controlling enzymatic function with greater speed and precision than with standard genetic techniques and is a useful tool for probing biological processes.	Rockefeller Univ, Lab Synthet Prot Chem, New York, NY 10021 USA; Rockefeller Univ, Genet Lab, New York, NY 10021 USA	Rockefeller University; Rockefeller University	Muir, TW (corresponding author), Rockefeller Univ, Lab Synthet Prot Chem, 1230 York Ave, New York, NY 10021 USA.	muirt@rockefeller.edu	Muir, Tom/AHD-0860-2022; , 机智的马小跳和机智的羊不愁/ABC-5169-2020	Muir, Tom/0000-0001-9635-0344; 	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM072015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS053087] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB001991] Funding Source: Medline; NIGMS NIH HHS [GM072015] Funding Source: Medline; NINDS NIH HHS [NS053087] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam E, 2002, J MOL MICROB BIOTECH, V4, P479; Bieschke ET, 1998, MOL GEN GENET, V258, P571, DOI 10.1007/s004380050770; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brandes C, 1996, NEURON, V16, P687, DOI 10.1016/S0896-6273(00)80088-4; Buskirk AR, 2004, P NATL ACAD SCI USA, V101, P10505, DOI 10.1073/pnas.0402762101; Caspi J, 2003, MOL MICROBIOL, V50, P1569, DOI 10.1046/j.1365-2958.2003.03825.x; Choi JJ, 2006, J MOL BIOL, V356, P1093, DOI 10.1016/j.jmb.2005.12.036; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; Chong SR, 1997, J BIOL CHEM, V272, P15587, DOI 10.1074/jbc.272.25.15587; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Iwai H, 2006, FEBS LETT, V580, P1853, DOI 10.1016/j.febslet.2006.02.045; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; Kohler JJ, 2003, CHEM BIOL, V10, P1303, DOI 10.1016/j.chembiol.2003.11.018; Mootz HD, 2004, ANGEW CHEM INT EDIT, V43, P5189, DOI 10.1002/anie.200460941; Mootz HD, 2003, J AM CHEM SOC, V125, P10561, DOI 10.1021/ja0362813; Mootz HD, 2002, J AM CHEM SOC, V124, P9044, DOI 10.1021/ja026769o; Ozawa T, 2001, ANAL CHEM, V73, P2516, DOI 10.1021/ac0013296; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Shi JX, 2005, J AM CHEM SOC, V127, P6198, DOI 10.1021/ja042287w; Shogren-Knaak MA, 2001, ANNU REV CELL DEV BI, V17, P405, DOI 10.1146/annurev.cellbio.17.1.405; Skretas G, 2005, PROTEIN SCI, V14, P523, DOI 10.1110/ps.04996905; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Stebbins MJ, 2001, GENE, V270, P103, DOI 10.1016/S0378-1119(01)00447-4; Stempfl T, 2002, GENETICS, V160, P571; Walsh CT, 2005, ANGEW CHEM INT EDIT, V44, P7342, DOI 10.1002/anie.200501023; Welsh DK, 2005, CURR OPIN BIOTECH, V16, P73, DOI 10.1016/j.copbio.2004.12.006; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; Ye XH, 1999, SCIENCE, V283, P88, DOI 10.1126/science.283.5398.88; Yuen CM, 2006, J AM CHEM SOC, V128, P8939, DOI 10.1021/ja062980e; Zeidler MP, 2004, NAT BIOTECHNOL, V22, P871, DOI 10.1038/nbt979	30	66	76	0	25	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2007	3	1					50	54		10.1038/nchembio832	http://dx.doi.org/10.1038/nchembio832			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	118QE	17128262				2022-12-25	WOS:000242956000014
J	Conrad, DF; Jakobsson, M; Coop, G; Wen, XQ; Wall, JD; Rosenberg, NA; Pritchard, JK				Conrad, Donald F.; Jakobsson, Mattias; Coop, Graham; Wen, Xiaoquan; Wall, Jeffrey D.; Rosenberg, Noah A.; Pritchard, Jonathan K.			A worldwide survey of haplotype variation and linkage disequilibrium in the human genome	NATURE GENETICS			English	Article							HUMAN-POPULATIONS; HIGH-RESOLUTION; POLYMORPHISM DATA; WIDE ASSOCIATION; WHOLE-GENOME; DIVERSITY; PATTERNS; MAP; PORTABILITY; CHIMPANZEES	Recent genomic surveys have produced high-resolution haplotype information, but only in a small number of human populations. We report haplotype structure across 12 Mb of DNA sequence in 927 individuals representing 52 populations. The geographic distribution of haplotypes reflects human history, with a loss of haplotype diversity as distance increases from Africa. Although the extent of linkage disequilibrium (LD) varies markedly across populations, considerable sharing of haplotype structure exists, and inferred recombination hotspot locations generally match across groups. The four samples in the International HapMap Project contain the majority of common haplotypes found in most populations: averaging across populations, 83% of common 20-kb haplotypes in a population are also common in the most similar HapMap sample. Consequently, although the portability of tag SNPs based on the HapMap is reduced in low-LD Africans, the HapMap will be helpful for the design of genome-wide association mapping studies in nearly all human populations.	Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	University of Michigan System; University of Michigan; University of Southern California; University of Chicago	Rosenberg, NA (corresponding author), Univ Michigan, Dept Human Genet, 100 Washtenaw Ave, Ann Arbor, MI 48109 USA.	rnoah@umich.edu	Jakobsson, Mattias/A-6116-2011	Jakobsson, Mattias/0000-0001-7840-7853; Wen, Xiaoquan/0000-0001-8990-2737; Coop, Graham/0000-0001-8431-0302; Rosenberg, Noah/0000-0002-1829-8664				Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Barrett JC, 2006, NAT GENET, V38, P659, DOI 10.1038/ng1801; Bonnen PE, 2006, NAT GENET, V38, P214, DOI 10.1038/ng1712; BOWCOCK AM, 1994, NATURE, V368, P455, DOI 10.1038/368455a0; Cann HM, 2002, SCIENCE, V296, P261; Cavalli-Sforza LL, 2005, NAT REV GENET, V6, P333, DOI 10.1038/nrg1579; DEBAKKER PI, 2006, PAC S BIOCOMPUT, V11, P478; Fearnhead P, 2005, AM J HUM GENET, V77, P781, DOI 10.1086/497579; Gonzalez-Neira A, 2006, GENOME RES, V16, P323, DOI 10.1101/gr.4138406; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Huang W, 2006, P NATL ACAD SCI USA, V103, P1418, DOI 10.1073/pnas.0510360103; HURLBERT SH, 1971, ECOLOGY, V52, P577, DOI 10.2307/1934145; Kalinowski ST, 2004, CONSERV GENET, V5, P539, DOI 10.1023/B:COGE.0000041021.91777.1a; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Montpetit A, 2006, PLOS GENET, V2, P282, DOI 10.1371/journal.pgen.0020027; MOUNTAIN JL, 1994, P NATL ACAD SCI USA, V91, P6515, DOI 10.1073/pnas.91.14.6515; Nielsen R, 2004, GENETICS, V168, P2373, DOI 10.1534/genetics.104.031039; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; Plagnol V, 2006, PLOS GENET, V2, P972, DOI 10.1371/journal.pgen.0020105; Pritchard JK, 2000, GENETICS, V155, P945; Ptak SE, 2005, NAT GENET, V37, P429, DOI 10.1038/ng1529; Ramachandran S, 2005, P NATL ACAD SCI USA, V102, P15942, DOI 10.1073/pnas.0507611102; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Rogers AR, 1996, AM J HUM GENET, V58, P1033; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Sawyer SL, 2005, EUR J HUM GENET, V13, P677, DOI 10.1038/sj.ejhg.5201368; Service S, 2006, NAT GENET, V38, P556, DOI 10.1038/ng1770; Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380; Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072; Willer CJ, 2006, GENET EPIDEMIOL, V30, P180, DOI 10.1002/gepi.20131; Winckler W, 2005, SCIENCE, V308, P107, DOI 10.1126/science.1105322; Yoo YK, 2006, GENETICS, V174, P491, DOI 10.1534/genetics.105.052225; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270	35	350	362	1	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1251	1260		10.1038/ng1911	http://dx.doi.org/10.1038/ng1911			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17057719				2022-12-25	WOS:000241592700013
J	Moreno-Loshuertos, R; Acin-Perez, R; Fernandez-Silva, P; Movilla, N; Perez-Martos, A; de Cordoba, SR; Gallardo, ME; Enriquez, JA				Moreno-Loshuertos, Raquel; Acin-Perez, Rebeca; Fernandez-Silva, Patricio; Movilla, Nieves; Perez-Martos, Acisclo; de Cordoba, Santiago Rodriguez; Gallardo, M. Esther; Enriquez, Jose Antonio			Differences in reactive oxygen species production explain the phenotypes associated with common mouse mitochondrial DNA variants	NATURE GENETICS			English	Article							OXIDATIVE STRESS; RESPIRATORY-FUNCTION; NADH DEHYDROGENASE; MTDNA HAPLOGROUPS; MAMMALIAN-CELLS; MUTATION; GENE; SELECTION; RNA; FIBROBLASTS	Common mitochondrial DNA (mtDNA) haplotypes in humans and mice have been associated with various phenotypes, including learning performance and disease penetrance. Notably, no influence of mtDNA haplotype in cell respiration has been demonstrated. Here, using cell lines carrying four different common mouse mtDNA haplotypes in an identical nuclear background, we show that the similar level of respiration among the cell lines is only apparent and is a consequence of compensatory mechanisms triggered by different production of reactive oxygen species. We observe that the respiration capacity per molecule of mtDNA in cells with the NIH3T3 or NZB mtDNA is lower than in those with the C57BL/6J, CBA/J or BALB/cJ mtDNA. In addition, we have determined the genetic element underlying these differences. Our data provide insight into the molecular basis of the complex phenotypes associated with common mtDNA variants and anticipate a relevant contribution of mtDNA single nucleotide polymorphisms to phenotypic variability in humans.	Univ Zaragoza, Dept Bioquim & Biol Mol & Celular, E-50013 Zaragoza, Spain; CSIC, Ctr Invest Biol, Dept Inmunol, E-28040 Madrid, Spain	University of Zaragoza; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Enriquez, JA (corresponding author), Univ Zaragoza, Dept Bioquim & Biol Mol & Celular, Miguel Servet 177, E-50013 Zaragoza, Spain.	enriquez@unizar.es	Silva, Patricio Fernandez/U-2256-2017; Enríquez, J.A./M-8468-2016; de Cordoba, Santiago Rodriguez/K-6727-2014; Acin-Perez, Rebeca/AAU-4913-2020; Acin-Perez, Rebeca/H-6160-2015; Gallardo, M. Esther/AFK-7298-2022; Moreno-Loshuertos, Raquel/H-4545-2015	Silva, Patricio Fernandez/0000-0001-8971-7355; Enríquez, J.A./0000-0002-3671-2961; de Cordoba, Santiago Rodriguez/0000-0001-6401-1874; Acin-Perez, Rebeca/0000-0001-9553-8337; Acin-Perez, Rebeca/0000-0001-9553-8337; Gallardo, M. Esther/0000-0002-8699-8734; Moreno Loshuertos, Raquel/0000-0002-6600-1618				Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; Acin-Perez R, 2003, HUM MOL GENET, V12, P329, DOI 10.1093/hmg/ddg021; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848; Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469; Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, P5349, DOI 10.1093/nar/gkg739; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8; Carelli V, 2002, BBA-MOL BASIS DIS, V1588, P7, DOI 10.1016/S0925-4439(02)00097-2; CHOMYN A, 1994, AM J HUM GENET, V54, P966; De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532; DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Enriquez JA, 1996, EUR J BIOCHEM, V237, P601, DOI 10.1111/j.1432-1033.1996.0601p.x; ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47; Fernandez-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Gallardo ME, 2006, HUM MUTAT, V27, P575, DOI 10.1002/humu.20338; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; Geromel V, 2001, HUM MOL GENET, V10, P1221, DOI 10.1093/hmg/10.11.1221; Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868; Herrnstadt C, 2004, MITOCHONDRION, V4, P791, DOI 10.1016/j.mito.2004.07.041; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; Howell N, 2003, AM J MED GENET A, V119A, P147, DOI 10.1002/ajmg.a.20135; Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93; Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lee HC, 2002, J BIOMED SCI, V9, P517, DOI 10.1007/BF02254978; Lee HC, 2005, INT J BIOCHEM CELL B, V37, P822, DOI 10.1016/j.biocel.2004.09.010; Liu CS, 2003, FREE RADICAL RES, V37, P1307, DOI 10.1080/10715760310001621342; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; Montiel-Sosa F, 2006, GENE, V368, P21, DOI 10.1016/j.gene.2005.09.015; Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y; Noben-Trauth K, 2003, NAT GENET, V35, P21, DOI 10.1038/ng1226; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311; Roubertoux PL, 2003, NAT GENET, V35, P65, DOI 10.1038/ng1230; Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434; Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040; Staden R, 2000, Methods Mol Biol, V132, P115; Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8; Tretter L, 2000, J NEUROSCI, V20, P8972; Wallace DC, 2003, COLD SPRING HARB SYM, V68, P479; Wang H, 1999, FREE RADICAL BIO MED, V27, P612, DOI 10.1016/S0891-5849(99)00107-0; Zhao H, 2004, AM J HUM GENET, V74, P139, DOI 10.1086/381133	48	254	262	0	29	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1261	1268		10.1038/ng1897	http://dx.doi.org/10.1038/ng1897			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17013393				2022-12-25	WOS:000241592700014
J	Daga, RR; Lee, KG; Bratman, S; Salas-Pino, S; Chang, F				Daga, Rafael R.; Lee, Kyeng-Gea; Bratman, Scott; Salas-Pino, Silvia; Chang, Fred			Self-organization of microtubule bundles in anucleate fission yeast cells	NATURE CELL BIOLOGY			English	Article							ORGANIZING CENTERS; NUCLEAR; DIVISION; COMPLEX; INTERPHASE; PROTEINS; POLARITY; ROLES	Self-organization of cellular structures is an emerging principle underlying cellular architecture. Properties of dynamic microtubules and microtubule-binding proteins contribute to the self-assembly of structures such as microtubule asters(1,2). In the fission yeast Schizosaccharomyces pombe, longitudinal arrays of cytoplasmic microtubule bundles regulate cell polarity and nuclear positioning(3-5). These bundles are thought to be organized from the nucleus at multiple interphase microtubule organizing centres (iMTOCs)(3). Here, we find that microtubule bundles assemble even in cells that lack a nucleus. These bundles have normal organization, dynamics and orientation, and exhibit anti-parallel overlaps in the middle of the cell. The mechanisms that are responsible for formation of these microtubule bundles include cytoplasmic microtubule nucleation, microtubule release from the equatorial MTOC (eMTOC), and the dynamic fusion and splitting of microtubule bundles. Bundle formation and organization are dependent on mto1p (gamma-TUC associated protein), ase1p (PRC1), klp2p (kinesin-14) and tip1p (CLIP-170). Positioning of nuclear fragments and polarity factors by these microtubules illustrates how self- organization of these bundles contributes to establishing global spatial order.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Columbia University	Chang, F (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 168th St, New York, NY 10032 USA.	fc99@columbia.edu	salas-pino, silvia/T-7800-2017; Daga, Rafael/P-8340-2014	salas-pino, silvia/0000-0003-2713-0123; Daga, Rafael/0000-0001-5726-761X; Bratman, Scott/0000-0001-8610-4908	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069670] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM069670, R01 GM069670] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behrens R, 2002, J CELL BIOL, V157, P783, DOI 10.1083/jcb.200112027; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Carazo-Salas RE, 2005, SCIENCE, V309, P297, DOI 10.1126/science.1113465; Daga RR, 2006, CURR BIOL, V16, P1544, DOI 10.1016/j.cub.2006.06.026; Daga RR, 2005, P NATL ACAD SCI USA, V102, P8228, DOI 10.1073/pnas.0409021102; Ding DQ, 1998, J CELL SCI, V111, P701; Dogterom M, 2005, CURR OPIN CELL BIOL, V17, P67, DOI 10.1016/j.ceb.2004.12.011; Feierbach B, 2004, J CELL BIOL, V165, P697, DOI 10.1083/jcb.200403090; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; Hagan IM, 2000, PRACT APPROACH SER, V218, P179; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; Heitz MJ, 2001, J CELL SCI, V114, P4521; Janson ME, 2005, J CELL BIOL, V169, P297, DOI 10.1083/jcb.200410119; Loiodice I, 2005, MOL BIOL CELL, V16, P1756, DOI 10.1091/mbc.E04-10-0899; Martin SG, 2005, CELL CYCLE, V4, P1046, DOI 10.4161/cc.4.8.1853; Mata J, 1997, CELL, V89, P939, DOI 10.1016/S0092-8674(00)80279-2; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; Sacconi L, 2005, APPL OPTICS, V44, P2001, DOI 10.1364/AO.44.002001; Sawin KE, 2004, CURR BIOL, V14, P763, DOI 10.1016/j.cub.2004.03.042; Tolic-Norrelykke IM, 2005, CURR BIOL, V15, P1212, DOI 10.1016/j.cub.2005.05.052; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Venkatram S, 2004, MOL BIOL CELL, V15, P2287, DOI 10.1091/mbc.E03-10-0728; West RR, 1998, MOL BIOL CELL, V9, P2839, DOI 10.1091/mbc.9.10.2839; Yamashita A, 2005, MOL BIOL CELL, V16, P1378, DOI 10.1091/mbc.e04-10-0859; Zimmerman S, 2005, MOL BIOL CELL, V16, P2719, DOI 10.1091/mbc.E04-08-0676; Zimmerman S, 2004, DEV CELL, V6, P497, DOI 10.1016/S1534-5807(04)00096-6	26	50	50	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1108	U98		10.1038/ncb1480	http://dx.doi.org/10.1038/ncb1480			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16998476				2022-12-25	WOS:000241395300015
J	Herman, D; Jenssen, K; Burnett, R; Soragni, E; Perlman, SL; Gottesfeld, JM				Herman, David; Jenssen, Kai; Burnett, Ryan; Soragni, Elisabetta; Perlman, Susan L.; Gottesfeld, Joel M.			Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia	NATURE CHEMICAL BIOLOGY			English	Article							TRIPLET-REPEAT EXPANSION; DOT-TTC REPEATS; FRATAXIN EXPRESSION; CHROMATIN-STRUCTURE; RNA-POLYMERASE; TRANSCRIPTION; ACETYLATION; DNA; HETEROCHROMATIN; PROMOTER	Expansion of GAA - TTC triplets within an intron in FXN (the gene encoding frataxin) leads to transcription silencing, forming the molecular basis for the neurodegenerative disease Friedreich's ataxia. Gene silencing at expanded FXN alleles is accompanied by hypoacetylation of histones H3 and H4 and trimethylation of histone H3 at Lys9, observations that are consistent with a heterochromatin-mediated repression mechanism. We describe the synthesis and characterization of a class of histone deacetylase (HDAC) inhibitors that reverse FXN silencing in primary lymphocytes from individuals with Friedreich's ataxia. We show that these molecules directly affect the histones associated with FXN, increasing acetylation at particular lysine residues on histones H3 and H4 (H3K14, H4K5 and H4K12). This class of HDAC inhibitors may yield therapeutics for Friedreich's ataxia.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA	Scripps Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gottesfeld, JM (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	joelg@scripps.edu		Gottesfeld, Joel/0000-0002-4643-5777	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS048989] Funding Source: NIH RePORTER; NINDS NIH HHS [R21 NS048989] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agalioti T, 2002, CELL, V111, P381, DOI 10.1016/S0092-8674(02)01077-2; ANNUNZIATO AT, 1988, CHROMOSOMA, V96, P132, DOI 10.1007/BF00331045; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Aron JL, 2003, BLOOD, V102, P652, DOI 10.1182/blood-2002-12-3794; Astrand C, 2004, EUR J BIOCHEM, V271, P1153, DOI 10.1111/j.1432-1033.2004.04019.x; Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Burnett R, 2006, P NATL ACAD SCI USA, V103, P11497, DOI 10.1073/pnas.0604939103; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Chuma M, 2003, HEPATOLOGY, V37, P198, DOI 10.1053/jhep.2003.50022; Di Prospero NA, 2005, NAT REV GENET, V6, P756, DOI 10.1038/nrg1690; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Elgin SCR, 2003, CURR BIOL, V13, pR895, DOI 10.1016/j.cub.2003.11.006; Ghazizadeh Mohammad, 2003, Journal of Nippon Medical School, V70, P367; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P2815, DOI 10.1093/nar/28.14.2815; Grabczyk E, 2000, NUCLEIC ACIDS RES, V28, P4930, DOI 10.1093/nar/28.24.4930; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hart PE, 2005, ARCH NEUROL-CHICAGO, V62, P621, DOI 10.1001/archneur.62.4.621; Langley B, 2005, CNS NEUROL DISORD-DR, V4, P41, DOI 10.2174/1568007053005091; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Napierala M, 2004, J BIOL CHEM, V279, P6444, DOI 10.1074/jbc.M309596200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Pandolfo Massimo, 2003, Semin Pediatr Neurol, V10, P163, DOI 10.1016/S1071-9091(03)00025-1; Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011; Peart MJ, 2005, P NATL ACAD SCI USA, V102, P3697, DOI 10.1073/pnas.0500369102; Pohler JRG, 1997, BIOCHEM SOC T, V25, pS647; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sarsero JP, 2003, J GENE MED, V5, P72, DOI 10.1002/jgm.320; Saveliev A, 2003, NATURE, V422, P909, DOI 10.1038/nature01596; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shestakova E, 2001, J VIROL, V75, P3444, DOI 10.1128/JVI.75.7.3444-3452.2001; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sturm B, 2005, EUR J CLIN INVEST, V35, P711, DOI 10.1111/j.1365-2362.2005.01568.x; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Sumner CJ, 2003, ANN NEUROL, V54, P647, DOI 10.1002/ana.10743; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Turano M, 2003, NEUROSCI LETT, V350, P184, DOI 10.1016/S0304-3940(03)00906-6; Wong JC, 2003, J AM CHEM SOC, V125, P5586, DOI 10.1021/ja0341440; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	43	334	359	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2006	2	10					551	558		10.1038/nchembio815	http://dx.doi.org/10.1038/nchembio815			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	095IX	16921367				2022-12-25	WOS:000241302500013
J	Lalioti, MD; Zhang, JH; Volkman, HM; Kahle, KT; Hoffmann, KE; Toka, HR; Nelson-Williams, C; Ellison, DH; Flavell, R; Booth, CJ; Lu, Y; Geller, DS; Lifton, RP				Lalioti, Maria D.; Zhang, Junhui; Volkman, Heather M.; Kahle, Kristopher T.; Hoffmann, Kristin E.; Toka, Hakan R.; Nelson-Williams, Carol; Ellison, David H.; Flavell, Richard; Booth, Carmen J.; Lu, Yin; Geller, David S.; Lifton, Richard P.			Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule	NATURE GENETICS			English	Article							NA-CL COTRANSPORTER; TRANSPORT PATHWAYS; CALCIUM-METABOLISM; HUMAN HYPERTENSION; MUTANT WNK4; HYPERKALEMIA; SODIUM; MICE; REABSORPTION; MUTATIONS	The mechanisms that govern homeostasis of complex systems have been elusive but can be illuminated by mutations that disrupt system behavior. Mutations in the gene encoding the kinase WNK4 cause pseudohypoaldosteronism type II (PHAII), a syndrome featuring hypertension and hyperkalemia. We show that physiology in mice transgenic for genomic segments harboring wild-type (TgWnk4(WT)) or PHAII mutant (TgWnk4(PHAII)) Wnk4 is changed in opposite directions: TgWnk4(PHAII) mice have higher blood pressure, hyperkalemia, hypercalciuria and marked hyperplasia of the distal convoluted tubule (DCT), whereas the opposite is true in TgWnk4(WT) mice. Genetic deficiency for the Na-Cl cotransporter of the DCT (NCC) reverses phenotypes seen in TgWnk4PHAII mice, demonstrating that the effects of the PHAII mutation are due to altered NCC activity. These findings establish that Wnk4 is a molecular switch that regulates the balance between NaCl reabsorption and K+ secretion by altering the mass and function of the DCT through its effect on NCC.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06520 USA; Oregon Hlth Sci Univ, Div Nephrol & Hypertens, Portland, OR 97239 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Oregon Health & Science University; Howard Hughes Medical Institute; Yale University; Yale University	Lifton, RP (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, New Haven, CT 06520 USA.	richard.lifton@yale.edu	Toka, Hakan/AAQ-2162-2021; , David/X-5730-2019	Ellison, David/0000-0003-2915-265X				Brooks HL, 2002, HYPERTENSION, V39, P470, DOI 10.1161/hy02t2.102959; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chrast R, 1999, TRANSGENIC RES, V8, P147, DOI 10.1023/A:1008858014473; GORDON RD, 1986, AUST NZ J MED, V16, P183, DOI 10.1111/j.1445-5994.1986.tb01145.x; Hansen PB, 2004, ACTA PHYSIOL SCAND, V181, P431, DOI 10.1111/j.1365-201X.2004.01315.x; Kahle KT, 2005, TRENDS ENDOCRIN MET, V16, P98, DOI 10.1016/j.tem.2005.02.012; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P14877, DOI 10.1073/pnas.0406172101; Kahle KT, 2004, P NATL ACAD SCI USA, V101, P2064, DOI 10.1073/pnas.0308434100; Kahle KT, 2003, NAT GENET, V35, P372, DOI 10.1038/ng1271; KAISSLING B, 1985, AM J PHYSIOL, V248, P374; Kim GH, 1998, P NATL ACAD SCI USA, V95, P14552, DOI 10.1073/pnas.95.24.14552; Lalioti MD, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e14; Levy D, 2000, HYPERTENSION, V36, P477, DOI 10.1161/01.HYP.36.4.477; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LIND L, 1993, J HUM HYPERTENS, V7, P53; Loffing J, 2004, J AM SOC NEPHROL, V15, P2276, DOI 10.1097/01.ASN.0000138234.18569.63; Loffing J, 2001, AM J PHYSIOL-RENAL, V281, pF1021, DOI 10.1152/ajprenal.0085.2001; Mayan H, 2004, J CLIN ENDOCR METAB, V89, P4025, DOI 10.1210/jc.2004-0037; MUJAIS SK, 1986, J CLIN INVEST, V77, P315, DOI 10.1172/JCI112293; Nijenhuis T, 2005, J CLIN INVEST, V115, P1651, DOI 10.1172/JCI24134; PAVER WK, 1964, MED J AUSTRALIA, V35, P305; Reilly RF, 2000, PHYSIOL REV, V80, P277, DOI 10.1152/physrev.2000.80.1.277; Rubera I, 2003, J CLIN INVEST, V112, P554, DOI 10.1172/JCI200316956; SCHAMBELAN M, 1981, KIDNEY INT, V19, P716, DOI 10.1038/ki.1981.72; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Wang T, 1996, AM J PHYSIOL-RENAL, V271, pF143, DOI 10.1152/ajprenal.1996.271.1.F143; Weinstein AM, 2005, AM J PHYSIOL-RENAL, V289, pF699, DOI 10.1152/ajprenal.00043.2005; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Wilson FH, 2003, P NATL ACAD SCI USA, V100, P680, DOI 10.1073/pnas.242735399; YAMAKAWA H, 1992, HYPERTENSION, V19, P528, DOI 10.1161/01.HYP.19.6.528; Yamauchi K, 2004, P NATL ACAD SCI USA, V101, P4690, DOI 10.1073/pnas.0306924101; Yang CL, 2003, J CLIN INVEST, V111, P1039, DOI 10.1172/JCI200317443	33	285	289	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2006	38	10					1124	1132		10.1038/ng1877	http://dx.doi.org/10.1038/ng1877			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16964266				2022-12-25	WOS:000241251100011
J	Di, A; Brown, ME; Deriy, LV; Li, CY; Szeto, FL; Chen, YM; Huang, P; Tong, JK; Naren, AP; Bindokas, V; Palfrey, HC; Nelson, DJ				Di, Anke; Brown, Mary E.; Deriy, Ludmila V.; Li, Chunying; Szeto, Frances L.; Chen, Yimei; Huang, Ping; Tong, Jiankun; Naren, Anjaparavanda P.; Bindokas, Vytautas; Palfrey, H. Clive; Nelson, Deborah J.			CFTR regulates phagosome acidification in macrophages and alters bactericidal activity	NATURE CELL BIOLOGY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; CHLORIDE CHANNELS; INTRACELLULAR ORGANELLES; HUMAN NEUTROPHILS; PH; PHAGOCYTOSIS; CELLS; ACTIVATION; MATURATION	Acidification of phagosomes has been proposed to have a key role in the microbicidal function of phagocytes. Here, we show that in alveolar macrophages the cystic fibrosis transmembrane conductance regulator Cl- channel (CFTR) participates in phagosomal pH control and has bacterial killing capacity. Alveolar macrophages from Cftr(-/-) mice retained the ability to phagocytose and generate an oxidative burst, but exhibited defective killing of internalized bacteria. Lysosomes from CFTR-null macrophages failed to acidify, although they retained normal fusogenic capacity with nascent phagosomes. We hypothesize that CFTR contributes to lysosomal acidification and that in its absence phagolysosomes acidify poorly, thus providing an environment conducive to bacterial replication.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Tennessee, Dept Physiol, Memphis, TN 38163 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago; University of Tennessee System; University of Tennessee Health Science Center; University of Chicago; University of Chicago	Nelson, DJ (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA.	nelson@uchicago.edu			NIDDK NIH HHS [DK42086] Funding Source: Medline; NIGMS NIH HHS [R01 GM36823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ALAWQATI Q, 1992, J EXP BIOL, V172, P245; Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARASCH J, 1993, J CELL SCI, P229; Barg S, 2001, J CELL SCI, V114, P2145; Belhoussine R, 1999, INT J CANCER, V81, P81, DOI 10.1002/(SICI)1097-0215(19990331)81:1<81::AID-IJC15>3.0.CO;2-P; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Chandy G, 2001, AM J PHYSIOL-CELL PH, V281, pC908, DOI 10.1152/ajpcell.2001.281.3.C908; DECOURSEY TE, 2004, SCI STKE; Di AK, 2001, J BIOL CHEM, V276, P37124, DOI 10.1074/jbc.M105038200; Fu J, 2001, J PHYSIOL-LONDON, V536, P459, DOI 10.1111/j.1469-7793.2001.0459c.xd; GADSBY DC, 1995, ANNU REV PHYSIOL, V57, P387; Gibson GA, 2000, AM J PHYSIOL-CELL PH, V279, pC1088, DOI 10.1152/ajpcell.2000.279.4.C1088; GRISHAM MB, 1985, J IMMUNOL METHODS, V82, P315, DOI 10.1016/0022-1759(85)90363-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamrick TS, 2000, INFECT IMMUN, V68, P125, DOI 10.1128/IAI.68.1.125-132.2000; Hara-Chikuma M, 2005, J BIOL CHEM, V280, P1241, DOI 10.1074/jbc.M407030200; Harrison RE, 2002, CURR BIOL, V12, pR357, DOI 10.1016/S0960-9822(02)00859-X; JENSEN MS, 1973, J CELL BIOL, V56, P379, DOI 10.1083/jcb.56.2.379; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; Kasper D, 2005, EMBO J, V24, P1079, DOI 10.1038/sj.emboj.7600576; Kobayashi T, 2000, HISTOCHEM CELL BIOL, V113, P251, DOI 10.1007/s004180000132; Lee WL, 2003, MICROBES INFECT, V5, P1299, DOI 10.1016/j.micinf.2003.09.014; Li CY, 2004, J BIOL CHEM, V279, P24673, DOI 10.1074/jbc.M400688200; Luckie DB, 2001, J MEMBRANE BIOL, V179, P275, DOI 10.1007/s002320010052; LUKACS GL, 1991, J BIOL CHEM, V266, P24540; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; Makranz C, 2006, GLIA, V53, P441, DOI 10.1002/glia.20303; McCarty NA, 2000, J EXP BIOL, V203, P1947; Moraes TJ, 2006, AM J RESP CELL MOL, V34, P364, DOI 10.1165/rcmb.2005-0146OC; Morris MR, 2005, CLIN EXP IMMUNOL, V142, P68, DOI [10.1111/j.1365-2249.2005.02893.x, 10.1111/j.1365-2249.2005.02893.X]; Naren AP, 1997, NATURE, V390, P302, DOI 10.1038/36882; Newman J, 2004, ACTA CRYSTALLOGR D, V60, P610, DOI 10.1107/S0907444903029640; Oh YK, 1996, INFECT IMMUN, V64, P319, DOI 10.1128/IAI.64.1.319-325.1996; Poschet J, 2002, TRENDS MOL MED, V8, P512, DOI 10.1016/S1471-4914(02)02414-0; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Roos D, 2002, SCIENCE, V296, P669, DOI 10.1126/science.1071271; Russell DG, 2001, NAT REV MOL CELL BIO, V2, P569, DOI 10.1038/35085034; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Scott CC, 2003, J MEMBRANE BIOL, V193, P137, DOI 10.1007/s00232-002-2008-2; Sonawane ND, 2003, J CELL BIOL, V160, P1129, DOI 10.1083/jcb.200211098; Sonawane ND, 2002, J BIOL CHEM, V277, P5506, DOI 10.1074/jbc.M110818200; STYRT B, 1982, FEBS LETT, V149, P113, DOI 10.1016/0014-5793(82)81083-1; Tesciuba AG, 2001, J IMMUNOL, V167, P1996, DOI 10.4049/jimmunol.167.4.1996; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691; Yates RM, 2005, IMMUNITY, V23, P409, DOI 10.1016/j.immuni.2005.09.007; Ydrenius L, 2000, J LEUKOCYTE BIOL, V67, P520, DOI 10.1002/jlb.67.4.520	49	366	375	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					933	U52		10.1038/ncb1456	http://dx.doi.org/10.1038/ncb1456			23	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16921366				2022-12-25	WOS:000240241700009
J	Kortlever, RM; Higgins, PJ; Bernards, R				Kortlever, Roderik M.; Higgins, Paul J.; Bernards, Rene			Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence	NATURE CELL BIOLOGY			English	Article							CELLULAR SENESCENCE; CANCER PROGRESSION; HUMAN FIBROBLASTS; ONCOGENIC RAS; G(1) CONTROL; HUMAN-CELLS; CYCLIN D1; EXPRESSION; GROWTH; GENE	p53 limits the proliferation of primary diploid fibroblasts by inducing a state of growth arrest named replicative senescence - a process which protects against oncogenic transformation and requires integrity of the p53 tumour suppressor pathway(1-3). However, little is known about the downstream target genes of p53 in this growth-limiting response. Here, we report that suppression of the p53 target gene encoding plasminogen activator inhibitor-1 ( PAI-1) by RNA interference ( RNAi) leads to escape from replicative senescence both in primary mouse embryo fibroblasts and primary human BJ fibroblasts. PAI-1 knockdown results in sustained activation of the PI( 3) K-PKB-GSK3 beta pathway and nuclear retention of cyclin D1, consistent with a role for PAI-1 in regulating growth factor signalling. In agreement with this, we find that the PI( 3) K-PKB-GSK3 beta-cyclin D1 pathway is also causally involved in cellular senescence. Conversely, ectopic expression of PAI-1 in proliferating p53-deficient murine or human fibroblasts induces a phenotype displaying all the hallmarks of replicative senescence. Our data indicate that PAI-1 is not merely a marker of senescence, but is both necessary and sufficient for the induction of replicative senescence downstream of p53.	Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Netherlands Cancer Institute; Netherlands Cancer Institute; Albany Medical College	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Kortlever, Roderik/AAY-9220-2020	Kortlever, Roderik/0000-0001-5558-2851; Bernards, Rene/0000-0001-8677-3423	NIGMS NIH HHS [GM57242, R01 GM057242-10, R01 GM057242] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almholt K, 2005, INT J CANCER, V113, P525, DOI 10.1002/ijc.20631; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bissell MJ, 1999, CANCER RES, V59, p1757S; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Choong PFM, 2003, CLIN ORTHOP RELAT R, pS46, DOI 10.1097/01.blo.0000093845.72468.bd; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Frandsen TL, 2001, CANCER RES, V61, P532; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Martens JWM, 2003, THROMB HAEMOSTASIS, V89, P393; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; MU XC, 1995, J CELL PHYSIOL, V165, P647, DOI 10.1002/jcp.1041650324; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Parfyonova YV, 2002, BIOCHEMISTRY-MOSCOW+, V67, P119, DOI 10.1023/A:1013964517211; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; QUELLE DE, 1995, ONCOGENE, V11, P635; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Usher PA, 2005, INT J CANCER, V113, P870, DOI 10.1002/ijc.20665; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; West MD, 1996, EXP GERONTOL, V31, P175, DOI 10.1016/0531-5565(95)02013-6; Yu JY, 2003, MOL THER, V7, P228, DOI 10.1016/S1525-0016(02)00037-0; Zhao RB, 2000, GENE DEV, V14, P981	41	411	420	3	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					877	U155		10.1038/ncb1448	http://dx.doi.org/10.1038/ncb1448			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16862142	Green Accepted, Green Published			2022-12-25	WOS:000239423000019
J	Matsuyama, A; Arai, R; Yashiroda, Y; Shirai, A; Kamata, A; Sekido, S; Kobayashi, Y; Hashimoto, A; Hamamoto, M; Hiraoka, Y; Horinouchi, S; Yoshida, M				Matsuyama, Akihisa; Arai, Ritsuko; Yashiroda, Yoko; Shirai, Atsuko; Kamata, Ayako; Sekido, Shigeko; Kobayashi, Yumiko; Hashimoto, Atsushi; Hamamoto, Makiko; Hiraoka, Yasushi; Horinouchi, Sueharu; Yoshida, Minoru			ORFeome cloning and global analysis of protein localization in the fission yeast Schizosaccharomyces pombe	NATURE BIOTECHNOLOGY			English	Article							NUCLEAR EXPORT SIGNAL; LEPTOMYCIN B; OXIDATIVE STRESS; COMPARTMENTS; INHIBITION; SELECTION; SEQUENCE; IMPORTIN; ELEMENT; BINDING	Cloning of the entire set of an organism's protein-coding open reading frames (ORFs), or 'ORFeome', is a means of connecting the genome to downstream 'omics' applications. Here we report a proteome-scale study of the fission yeast Schizosaccharomyces pombe based on cloning of the ORFeome. Taking advantage of a recombination-based cloning system, we obtained 4,910 ORFs in a form that is readily usable in various analyses. First, we evaluated ORF prediction in the fission yeast genome project by expressing each ORF tagged at the 3' terminus. Next, we determined the localization of 4,431 proteins, corresponding to similar to 90% of the fission yeast proteome, by tagging each ORF with the yellow fluorescent protein. Furthermore, using leptomycin B, an inhibitor of the nuclear export protein Crm1, we identified 285 proteins whose localization is regulated by Crm1.	RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan; JST, CREST, Res Project, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Natl Inst Informat & Commun Technol, Kansai Adv Res Ctr, Kobe, Hyogo 6512492, Japan	RIKEN; Japan Science & Technology Agency (JST); University of Tokyo; National Institute of Information & Communications Technology (NICT) - Japan	Yoshida, M (corresponding author), RIKEN, Chem Genet Lab, Wako, Saitama 3510198, Japan.	yoshidam@riken.jp	Yashiroda, Yoko/C-8769-2014; Hiraoka, Yasushi/B-5111-2009; Yoshida, Minoru/C-8049-2014; Matsuyama, Akihisa/P-7805-2016; shirai, atsuko/C-5406-2017	Hiraoka, Yasushi/0000-0001-9407-8228; Yoshida, Minoru/0000-0002-4376-5674; Matsuyama, Akihisa/0000-0002-6135-6276; shirai, atsuko/0000-0003-1344-4746				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Burgess DR, 2005, TRENDS CELL BIOL, V15, P156, DOI 10.1016/j.tcb.2005.01.006; Csank C, 2002, METHOD ENZYMOL, V350, P347, DOI 10.1016/S0076-6879(02)50973-3; D'Alessio C, 2003, J BIOL CHEM, V278, P22379, DOI 10.1074/jbc.M300892200; ELDER RT, 1983, P NATL ACAD SCI-BIOL, V80, P2432, DOI 10.1073/pnas.80.9.2432; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B; Matsuyama A, 2004, YEAST, V21, P1289, DOI 10.1002/yea.1181; Matsuyama A, 2000, GENETICS, V155, P539; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nguyen AN, 2002, MOL BIOL CELL, V13, P2651, DOI 10.1091/mbc.02-03-0043; Paoletti A, 2000, MOL BIOL CELL, V11, P2757, DOI 10.1091/mbc.11.8.2757; Paoletti A, 2003, MOL BIOL CELL, V14, P2793, DOI 10.1091/mbc.E02-10-0661; Poetz O, 2005, MECH AGEING DEV, V126, P161, DOI 10.1016/j.mad.2004.09.030; Qin J, 2003, MOL CELL BIOL, V23, P3253, DOI 10.1128/MCB.23.9.3253-3264.2003; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Sipiczki M, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-2-reviews1011, DOI 10.1186/GB-2000-1-2-REVIEWS1011]; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Umeda M, 2005, GENETICS, V171, P7, DOI 10.1534/genetics.105.042598; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020	30	445	2696	2	60	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					841	847		10.1038/nbt1222	http://dx.doi.org/10.1038/nbt1222			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16823372				2022-12-25	WOS:000239025100035
J	Schwartz, YB; Kahn, TG; Nix, DA; Li, XY; Bourgon, R; Biggin, M; Pirrotta, V				Schwartz, Yuri B.; Kahn, Tatyana G.; Nix, David A.; Li, Xiao-Yong; Bourgon, Richard; Biggin, Mark; Pirrotta, Vincenzo			Genome-wide analysis of Polycomb targets in Drosophila melanogaster	NATURE GENETICS			English	Article							HISTONE METHYLTRANSFERASE ACTIVITY; EMBRYONIC STEM-CELLS; BITHORAX COMPLEX; RESPONSE ELEMENT; BINDING-SITES; GENES; ZESTE; CHROMATIN; PROTEINS; ENHANCER	Polycomb group (PcG) complexes are multiprotein assemblages that bind to chromatin and establish chromatin states leading to epigenetic silencing(1,2). PcG proteins regulate homeotic genes in flies and vertebrates, but little is known about other PcG targets and the role of the PcG in development, differentiation and disease. Here, we determined the distribution of the PcG proteins PC, E(Z) and PSC and of trimethylation of histone H3 Lys27 (me3K27) in the D. melanogaster genome. At more than 200 PcG target genes, binding sites for the three PcG proteins colocalize to presumptive Polycomb response elements (PREs). In contrast, H3 me3K27 forms broad domains including the entire transcription unit and regulatory regions. PcG targets are highly enriched in genes encoding transcription factors, but they also include genes coding for receptors, signaling proteins, morphogens and regulators representing all major developmental pathways.	Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley Drosophila Transcript Network Project, Genom Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Stat, Berkeley, CA 94720 USA	Rutgers State University New Brunswick; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Pirrotta, V (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, 604 Allison Rd, Piscataway, NJ 08854 USA.	pirrotta@biology.rutgers.edu		Bourgon, Richard/0000-0002-5890-4374	NIGMS NIH HHS [GM704403] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barges S, 2000, DEVELOPMENT, V127, P779; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bloyer S, 2003, DEV BIOL, V261, P426, DOI 10.1016/S0012-1606(03)00314-2; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; Busturia A, 1997, DEVELOPMENT, V124, P4343; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHIANG A, 1995, DEVELOPMENT, V121, P1681; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Jagla K, 2001, BIOESSAYS, V23, P125, DOI 10.1002/1521-1878(200102)23:2<125::AID-BIES1019>3.3.CO;2-3; JONES RS, 1990, GENETICS, V126, P185; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Negre N, 2006, PLOS BIOL, V4, P917, DOI 10.1371/journal.pbio.0040170; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; PHILLIPS MD, 1990, GENETICS, V125, P91; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Reim I, 2003, DEVELOPMENT, V130, P3187, DOI 10.1242/dev.00548; Ringrose L, 2003, DEV CELL, V5, P759, DOI 10.1016/S1534-5807(03)00337-X; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sengupta AK, 2004, DEVELOPMENT, V131, P1959, DOI 10.1242/dev.01084; Shimell MJ, 2000, DEV BIOL, V218, P38, DOI 10.1006/dbio.1999.9576; Strutt H, 1997, MOL CELL BIOL, V17, P6773, DOI 10.1128/MCB.17.12.6773	30	464	490	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2006	38	6					700	705		10.1038/ng1817	http://dx.doi.org/10.1038/ng1817			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16732288	Green Submitted			2022-12-25	WOS:000237954800026
J	Okada, M; Cheeseman, IM; Hori, T; Okawa, K; McLeod, IX; Yates, JR; Desai, A; Fukagawa, T				Okada, M; Cheeseman, IM; Hori, T; Okawa, K; McLeod, IX; Yates, JR; Desai, A; Fukagawa, T			The CENP-H-I complex is required for the efficient incorporation of newly synthesized CENP-A into centromeres	NATURE CELL BIOLOGY			English	Article							BUDDING YEAST KINETOCHORE; VERTEBRATE CELLS; SACCHAROMYCES-CEREVISIAE; OUTER KINETOCHORE; FISSION YEAST; PROTEIN; COMPONENT; CORE; ARCHITECTURE; SEGREGATION	In vertebrates, centromeres lack defined sequences and are thought to be propagated by epigenetic mechanisms involving the incorporation of specialized nucleosomes containing the histone H3 variant centromere protein (CENP)-A. However, the precise mechanisms that target CENP-A to centromeres remain poorly understood. Here, we isolated a multi-subunit complex, which includes the established inner kinetochore components CENP-H and CENP-I, and nine other proteins, from both human and chicken cells. Our analysis of these proteins demonstrates that the CENP-H-I complex can be divided into three functional sub-complexes, each of which is required for faithful chromosome segregation. Interestingly, newly expressed CENP-A is not efficiently incorporated into centromeres in knockout mutants of a subclass of CENP-H-I complex proteins, indicating that the CENP-H-I complex may function, in part, as a marker directing CENP-A deposition to centromeres.	Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan; Grad Univ Adv Studies, Mishima, Shizuoka 4118540, Japan; Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Kyoto Univ, HMRO, Grad Sch Med, Sakyo Ku, Kyoto 6068501, Japan; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan; Ludwig Institute for Cancer Research; Kyoto University; Scripps Research Institute	Fukagawa, T (corresponding author), Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4118540, Japan.	tfukagaw@lab.nig.ac.jp	Fukagawa, Tatsuo/AAK-3922-2021	Cheeseman, Iain/0000-0002-3829-5612	NIGMS NIH HHS [R01GM074215-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ando S, 2002, MOL CELL BIOL, V22, P2229, DOI 10.1128/MCB.22.7.2229-2241.2002; Bierie B, 2004, GENE EXPR PATTERNS, V4, P389, DOI 10.1016/j.modgep.2004.01.008; Cheeseman I. M., 2005, SCI STKE, V266, ppl1; Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; Fukagawa T, 2004, EXP CELL RES, V296, P21, DOI 10.1016/j.yexcr.2004.03.004; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; Goshima G, 2003, J CELL BIOL, V160, P25, DOI 10.1083/jcb.200210005; Hayashi T, 2004, CELL, V118, P715, DOI 10.1016/j.cell.2004.09.002; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; Liu XK, 2005, EMBO J, V24, P2919, DOI 10.1038/sj.emboj.7600762; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; Mikami Y, 2005, MOL CELL BIOL, V25, P1958, DOI 10.1128/MCB.25.5.1958-1970.2005; Minoshima Y, 2005, MOL CELL BIOL, V25, P10315, DOI 10.1128/MCB.25.23.10315-10328.2005; Mythreye K, 2003, J CELL BIOL, V160, P833, DOI 10.1083/jcb.200211116; Nishihashi A, 2002, DEV CELL, V2, P463, DOI 10.1016/S1534-5807(02)00144-2; Obuse C, 2004, GENES CELLS, V9, P105, DOI 10.1111/j.1365-2443.2004.00705.x; Obuse C, 2004, NAT CELL BIOL, V6, P1135, DOI 10.1038/ncb1187; Oegema K, 2001, J CELL BIOL, V153, P1209, DOI 10.1083/jcb.153.6.1209; PALMER DK, 1987, J CELL BIOL, V104, P805, DOI 10.1083/jcb.104.4.805; Regnier V, 2005, MOL CELL BIOL, V25, P3967, DOI 10.1128/MCB.25.10.3967-3981.2005; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shelby RD, 2000, J CELL BIOL, V151, P1113, DOI 10.1083/jcb.151.5.1113; Takahashi K, 2000, SCIENCE, V288, P2215, DOI 10.1126/science.288.5474.2215; Westermann S, 2003, J CELL BIOL, V163, P215, DOI 10.1083/jcb.200305100; Yamashita A, 2000, FEBS LETT, V481, P147, DOI 10.1016/S0014-5793(00)01987-6	32	376	407	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					446	U61		10.1038/ncb1396	http://dx.doi.org/10.1038/ncb1396			41	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16622420				2022-12-25	WOS:000237299400008
J	Chen, YP; Shen, YY; Guo, X; Zhang, CS; Yang, WJ; Ma, ML; Liu, S; Zhang, MB; Wen, LP				Chen, YP; Shen, YY; Guo, X; Zhang, CS; Yang, WJ; Ma, ML; Liu, S; Zhang, MB; Wen, LP			Transdermal protein delivery by a coadministered peptide identified via phage display	NATURE BIOTECHNOLOGY			English	Article							DRUG-DELIVERY; PENETRATION ENHANCERS; SKIN PENETRATION; HAIR FOLLICLE	Efficient transdermal drug delivery of large hydrophilic drugs is challenging. Here we report that the short synthetic peptide, ACSSSPSKHCG, identified by in vivo phage display, facilitated efficient transdermal protein drug delivery through intact skin. Coadministration of the peptide and insulin to the abdominal skin of diabetic rats resulted in elevated systemic levels of insulin and suppressed serum glucose levels for at least 11 h. Significant systemic bioavailability of human growth hormone was also achieved when topically coadministered with the peptide. The transdermal-enhancing activity of the peptide was sequence specific and dose dependent, did not involve direct interaction with insulin and enabled penetration of insulin into hair follicles beyond a depth of 600 mu m. Time-lapse studies suggested that the peptide creates a transient opening in the skin barrier to enable macromolecular drugs to reach systemic circulation.	Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wen, LP (corresponding author), Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230027, Anhui, Peoples R China.	lpwen@ustc.edu.cn	liu, shu/G-7430-2014	Wen, Longping/0000-0003-0384-4578				Agarwal R, 2000, METHOD FIND EXP CLIN, V22, P129, DOI 10.1358/mf.2000.22.2.796082; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Duerr DM, 2004, J VIROL METHODS, V116, P177, DOI 10.1016/j.jviromet.2003.11.012; Frenkel D, 2002, P NATL ACAD SCI USA, V99, P5675, DOI 10.1073/pnas.072027199; Guy R. H., 2003, TRANSDERMAL DRUG DEL; Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Karande P, 2005, P NATL ACAD SCI USA, V102, P4688, DOI 10.1073/pnas.0501176102; Karande P, 2004, NAT BIOTECHNOL, V22, P192, DOI 10.1038/nbt928; LAUER AC, 1995, PHARM RES-DORDR, V12, P179, DOI 10.1023/A:1016250422596; Lavon A, 2004, DRUG DISCOV TODAY, V9, P670, DOI 10.1016/S1359-6446(04)03170-8; LI LN, 1995, NAT MED, V1, P705, DOI 10.1038/nm0795-705; Lopes LB, 2005, PHARM RES-DORDR, V22, P750, DOI 10.1007/s11095-005-2591-x; Meidan VM, 1998, PHARMACEUT RES, V15, P85, DOI 10.1023/A:1011956905388; Montagna W, 1956, STRUCTURE FUNCTION S; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Prausnitz MR, 2004, ADV DRUG DELIVER REV, V56, P581, DOI 10.1016/j.addr.2003.10.023; Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304; Purdon CH, 2004, CRIT REV THER DRUG, V21, P97, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i2.20; Rafii S, 2003, CANCER CELL, V4, P331, DOI 10.1016/S1535-6108(03)00278-2; ROLLAND A, 1993, PHARMACEUT RES, V10, P1738, DOI 10.1023/A:1018922114398; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; SCHEUPLEIN RJ, 1971, PHYSIOL REV, V51, P702, DOI 10.1152/physrev.1971.51.4.702; Schutze-Redelmeier MPM, 2004, VACCINE, V22, P1985, DOI 10.1016/j.vaccine.2003.10.028; Thomas BJ, 2004, DRUG DISCOV TODAY, V9, P697, DOI 10.1016/S1359-6446(04)03180-0; Uversky VN, 2003, J PHARM SCI, V92, P847, DOI 10.1002/jps.10355; Williams AC, 2004, ADV DRUG DELIVER REV, V56, P603, DOI 10.1016/j.addr.2003.10.025	30	160	190	10	98	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					455	460		10.1038/nbt1193	http://dx.doi.org/10.1038/nbt1193			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16565728				2022-12-25	WOS:000236766300030
J	Roberts, AE; Araki, T; Swanson, KD; Montgomery, KT; Schiripo, TA; Joshi, VA; Li, L; Yassin, Y; Tamburino, AM; Neel, BG; Kucherlapati, RS				Roberts, Amy E.; Araki, Toshiyuki; Swanson, Kenneth D.; Montgomery, Kate T.; Schiripo, Taryn A.; Joshi, Victoria A.; Li, Li; Yassin, Yosuf; Tamburino, Alex M.; Neel, Benjamin G.; Kucherlapati, Raju S.			Germline gain-of-function mutations in SOS1 cause Noonan syndrome	NATURE GENETICS			English	Article							RAS ACTIVATOR SON; FACIO-CUTANEOUS SYNDROME; SEVENLESS; MUTANTS; PATHWAY; DOMAIN; KRAS	Noonan syndrome, the most common single-gene cause of congenital heart disease, is characterized by short stature, characteristic facies, learning problems and leukemia predisposition(1). Gain-of-function mutations in PTPN11, encoding the tyrosine phosphatase SHP2, cause similar to 50% of Noonan syndrome cases. SHP2 is required for RAS-ERK MAP kinase (MAPK) cascade activation(2), and Noonan syndrome mutants enhance ERK activation ex vivo(3,4) and in mice(5). KRAS mutations account for < 5% of cases of Noonan syndrome(6), but the gene(s) responsible for the remainder are unknown. We identified missense mutations in SOS1, which encodes an essential RAS guanine nucleotide-exchange factor (RAS-GEF), in similar to 20% of cases of Noonan syndrome without PTPN11 mutation. The prevalence of specific cardiac defects differs in SOS1 mutation-associated Noonan syndrome. Noonan syndrome-associated SOS1 mutations are hypermorphs encoding products that enhance RAS and ERK activation. Our results identify SOS1 mutants as a major cause of Noonan syndrome, representing the first example of activating GEF mutations associated with human disease ;and providing new insights into RAS-GEF regulation.	Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA; Harvard Partners Ctr Genet & Genom, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Div Genet, Dept Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital	Neel, BG (corresponding author), Beth Israel Deaconess Med Ctr, Canc Biol Program, Div Hematol Oncol, Dept Med, Boston, MA 02115 USA.	bneel@bidmc.harvard.edu	Kucherlapati, Raju/ABC-8807-2021	Araki, Toshiyuki/0000-0002-1179-4534	NATIONAL CANCER INSTITUTE [R37CA049152] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE016140] Funding Source: NIH RePORTER; NCI NIH HHS [R37CA49152] Funding Source: Medline; NCRR NIH HHS [M01-RR02172] Funding Source: Medline; NIDCR NIH HHS [DE16140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Bentires-Alj M, 2006, NAT MED, V12, P283, DOI 10.1038/nm0306-283; BOS JL, 1989, CANCER RES, V49, P4682; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Godbey WT, 1999, GENE THER, V6, P1380, DOI 10.1038/sj.gt.3300976; Goi T, 1999, MOL CELL BIOL, V19, P1731; Hart TC, 2002, AM J HUM GENET, V70, P943, DOI 10.1086/339689; Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200; Kontaridis MI, 2006, J BIOL CHEM, V281, P6785, DOI 10.1074/jbc.M513068200; Lauchle JO, 2006, PEDIATR BLOOD CANCER, V46, P579, DOI 10.1002/pbc.20644; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Niihori T, 2006, NAT GENET, V38, P294, DOI 10.1038/ng1749; NIMNUAL A, 2002, SCI STKE, pPE36, DOI DOI 10.1126/STKE.2002.145; Rodriguez-Viciana P, 2006, SCIENCE, V311, P1287, DOI 10.1126/science.1124642; Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sondermann H, 2005, P NATL ACAD SCI USA, V102, P16632, DOI 10.1073/pnas.0508315102; Sondermann H, 2003, STRUCTURE, V11, P1583, DOI 10.1016/j.str.2003.10.015; Sondermann H, 2004, CELL, V119, P393, DOI 10.1016/j.cell.2004.10.005; Tartaglia M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI 10.1146/annurev.genom.6.080604.162305; VANDERBURGT I, 1994, AM J MED GENET, V53, P187, DOI 10.1002/ajmg.1320530213	23	415	438	4	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2007	39	1					70	74		10.1038/ng1926	http://dx.doi.org/10.1038/ng1926			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17143285				2022-12-25	WOS:000243136500019
J	Fukami, M; Wada, Y; Miyabayashi, K; Nishino, I; Hasegawa, T; Camerino, G; Kretz, C; Buj-Bello, A; Laporte, J; Yamada, G; Morohashi, K; Ogata, T				Fukami, Maki; Wada, Yuka; Miyabayashi, Kanako; Nishino, Ichizo; Hasegawa, Tomonobu; Camerino, Giovanna; Kretz, Christine; Buj-Bello, Anna; Laporte, Jocelyn; Yamada, Gen; Morohashi, Ken-ichirou; Ogata, Tsutomu			CXorf6 is a causative gene for hypospadias	NATURE GENETICS			English	Article							LINKED MYOTUBULAR MYOPATHY; MALE HYPOGENITALISM; XQ28; MUTATIONS; MTM1; DELETION	46,XY disorders of sex development (DSD) refer to a wide range of abnormal genitalia, including hypospadias, which affects similar to 0.5% of male newborns. We identified three different nonsense mutations of CXorf6 in individuals with hypospadias and found that its mouse homolog was specifically expressed in fetal Sertoli and Leydig cells around the critical period for sex development. These data imply that CXorf6 is a causative gene for hypospadias.	Natl Inst Basic Biol, Div Sex Differentiat, Okazaki, Aichi 4448787, Japan; Natl Inst Neurosci, Dept Neuromuscular Res, Kodaira, Tokyo 1878502, Japan; Keio Univ, Sch Med, Dept Pediat, Tokyo 1608582, Japan; Univ Pavia, Dipartimento Patol Umana & Ereditaria, Sezione Biol Gen & Genet Med, I-27100 Pavia, Italy; Inst Genet & Biol Mol & Cellulaire, Dept Mol Pathol, F-67404 Illkirch Graffenstaden, France; Kumamoto Univ, Sch Med, Ctr Anim Resources & Dev, Kumamoto 860, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); National Center for Neurology & Psychiatry - Japan; Keio University; University of Pavia; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Kumamoto University	Ogata, T (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Endocrinol & Metab, Tokyo 1578535, Japan.	tomogata@nch.go.jp	Fukami, Maki/ABE-4694-2020; BUJ-BELLO, Anna/J-7556-2013; Nishino, Ichizo/G-2676-2010; laporte, jocelyn/O-4888-2019; Hasegawa, Tomonobu/L-3331-2013; laporte, jocelyn/J-7008-2012; Laporte, Jocelyn/H-6801-2016	Fukami, Maki/0000-0001-9971-4035; Nishino, Ichizo/0000-0001-9452-112X; Ogata, Tsutomu/0000-0001-7178-9991; Nordenskjold, Agneta/0000-0001-6638-4631				Bartsch O, 1999, CYTOGENET CELL GENET, V85, P310, DOI 10.1159/000015284; Biancalana V, 2003, HUM GENET, V112, P135, DOI 10.1007/s00439-002-0869-1; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hu LJ, 1996, HUM MOL GENET, V5, P139, DOI 10.1093/hmg/5.1.139; Laporte J, 1997, GENOMICS, V41, P458, DOI 10.1006/geno.1997.4662; Laporte J, 1997, HUM MOL GENET, V6, P1505, DOI 10.1093/hmg/6.9.1505; Nomura M, 1998, J BIOCHEM, V124, P217, DOI 10.1093/oxfordjournals.jbchem.a022083; Tsai TC, 2005, NEUROMUSCULAR DISORD, V15, P245, DOI 10.1016/j.nmd.2004.12.005; WINTER JSD, 1976, J CLIN ENDOCR METAB, V42, P679, DOI 10.1210/jcem-42-4-679; [No title captured]	10	98	106	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2006	38	12					1369	1371		10.1038/ng1900	http://dx.doi.org/10.1038/ng1900			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17086185				2022-12-25	WOS:000242404200011
J	Berger, MF; Philippakis, AA; Qureshi, AM; He, FXS; Estep, PW; Bulyk, ML				Berger, Michael F.; Philippakis, Anthony A.; Qureshi, Aaron M.; He, Fangxue S.; Estep, Preston W., III; Bulyk, Martha L.			Compact, universal DNA microarrays to comprehensively determine transcription-factor binding site specificities	NATURE BIOTECHNOLOGY			English	Article							CAENORHABDITIS-ELEGANS; PROTEIN; SEQUENCE; RECOGNITION; AFFINITIES; EXPRESSION	Transcription factors ( TFs) interact with specific DNA regulatory sequences to control gene expression throughout myriad cellular processes. However, the DNA binding specificities of only a small fraction of TFs are sufficiently characterized to predict the sequences that they can and cannot bind. We present a maximally compact, synthetic DNA sequence design for protein binding microarray ( PBM) experiments(1) that represents all possible DNA sequence variants of a given length k ( that is, all 'k- mers') on a single, universal microarray. We constructed such all k- mer microarrays covering all 10 - base pair ( bp) binding sites by converting high- density single- stranded oligonucleotide arrays to double- stranded ( ds) DNA arrays. Using these microarrays we comprehensively determined the binding specificities over a full range of affinities for five TFs of different structural classes from yeast, worm, mouse and human. The unbiased coverage of all k-mers permits high- throughput interrogation of binding site preferences, including nucleotide interdependencies, at unprecedented resolution.	Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Grad Biophys Program, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol, Boston, MA 02115 USA; Univ Maryland, Dept Math, College Pk, MD 20742 USA; Longen Inc, Waltham, MA 02451 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard Medical School; University System of Maryland; University of Maryland College Park	Bulyk, ML (corresponding author), Harvard Univ, Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA.	mlbulyk@receptor.med.harvard.edu			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003420, R01HG003985] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG003985, R01 HG003420] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BERG OG, 1987, J MOL BIOL, V193, P723, DOI 10.1016/0022-2836(87)90354-8; Berger Michael F., 2006, V338, P245; BJERVE S, 1977, ANN STAT, V5, P357, DOI 10.1214/aos/1176343800; Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758; Braun P, 2002, P NATL ACAD SCI USA, V99, P2654, DOI 10.1073/pnas.042684199; Bulyk ML, 2002, NUCLEIC ACIDS RES, V30, P1255, DOI 10.1093/nar/30.5.1255; Bulyk ML, 2001, P NATL ACAD SCI USA, V98, P7158, DOI 10.1073/pnas.111163698; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; Dudley AM, 2002, P NATL ACAD SCI USA, V99, P7554, DOI 10.1073/pnas.112683499; Gaudet J, 2002, SCIENCE, V295, P821, DOI 10.1126/science.1065175; Golomb S.W., 1967, SHIFT REGISTER SEQUE; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Kwan AHY, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng124; Li MZ, 2005, NAT GENET, V37, P311, DOI 10.1038/ng1505; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Linnell J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh042; Liu JJ, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-176; Miller JC, 2001, J MOL BIOL, V313, P309, DOI 10.1006/jmbi.2001.4975; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Mukherjee S, 2004, NAT GENET, V36, P1331, DOI 10.1038/ng1473; OKKEMA PG, 1994, DEVELOPMENT, V120, P2175; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; Philippakis AA, 2006, PLOS COMPUT BIOL, V2, P439, DOI 10.1371/journal.pcbi.0020053; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Singh-Gasson S, 1999, NAT BIOTECHNOL, V17, P974, DOI 10.1038/13664; Tanay A, 2006, GENOME RES, V16, P962, DOI 10.1101/gr.5113606; Warren CL, 2006, P NATL ACAD SCI USA, V103, P867, DOI 10.1073/pnas.0509843102; WILMEN A, 1994, NUCLEIC ACIDS RES, V22, P2791, DOI 10.1093/nar/22.14.2791	30	477	491	0	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2006	24	11					1429	1435		10.1038/nbt1246	http://dx.doi.org/10.1038/nbt1246			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	106TP	16998473	Green Accepted			2022-12-25	WOS:000242124700040
J	Gavard, J; Gutkind, JS				Gavard, Julie; Gutkind, J. Silvio			VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin	NATURE CELL BIOLOGY			English	Article							COUPLED RECEPTOR TRAFFICKING; FOCAL ADHESION KINASE; VASCULAR-PERMEABILITY; TYROSINE PHOSPHORYLATION; ADRENERGIC-RECEPTOR; DOWN-REGULATION; SRC ACTIVITY; GROWTH; PROTEIN; ANGIOGENESIS	How vascular endothelial growth factor (VEGF) induces vascular permeability, its first described function, remains poorly understood. Here, we provide evidence of a novel signalling pathway by which VEGF stimulation promotes the rapid endocytosis of a key endothelial cell adhesion molecule, VE-cadherin, thereby disrupting the endothelial barrier function. This process is initiated by the activation of the small GTPase Rac by VEGFR-2 through the Src-dependent phosphorylation of Vav2, a guanine nucleotide-exchange factor. Rac activation, in turn, promotes the p21-activated kinase (PAK)-mediated phosphorylation of a highly conserved motif within the intracellular tail of VE-cadherin. Surprisingly, this results in the recruitment of beta-arrestin2 to serine-phosphorylated VE-cadherin, thereby promoting its internalization into clathrin-coated vesicles and the consequent disassembly of intercellular junctions. Ultimately, this novel biochemical route by which VEGF promotes endothelial permeability through the beta-arrestin2-dependent endocytosis of VE-cadherin may help identify new therapeutic targets for the treatment of many human diseases that are characterized by vascular leakage.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, DHHS, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gavard, Julie/I-5487-2012; Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Gavard, Julie/I-5487-2012	Gavard, Julie/0000-0002-7985-9007; Gutkind, J. Silvio/0000-0002-5150-4482; Gavard, Julie/0000-0003-3107-2026	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Ali J, 1997, MICROCIRCULATION-LON, V4, P267, DOI 10.3109/10739689709146790; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; Bruckner K, 2004, DEV CELL, V7, P73, DOI 10.1016/j.devcel.2004.06.007; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chen W, 2003, SCIENCE, V301, P1394, DOI 10.1126/science.1083195; Chen W, 2004, SCIENCE, V306, P2257, DOI 10.1126/science.1104135; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; Crosby CV, 2005, BLOOD, V105, P2771, DOI 10.1182/blood-2004-06-2244; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Dejana E, 2004, NAT REV MOL CELL BIO, V5, P261, DOI 10.1038/nrm1357; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Esser S, 1998, J CELL SCI, V111, P1853; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fukuhara S, 2005, MOL CELL BIOL, V25, P136, DOI 10.1128/MCB.25.1.136-146.2005; Gavard J, 2004, J CELL SCI, V117, P257, DOI 10.1242/jcs.00857; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Kooistra MRH, 2005, FEBS LETT, V579, P4966, DOI 10.1016/j.febslet.2005.07.080; Lamalice L, 2004, ONCOGENE, V23, P434, DOI 10.1038/sj.onc.1207034; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8; May C, 2005, BLOOD, V105, P4337, DOI 10.1182/blood-2005-01-0010; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Stockton RA, 2004, J BIOL CHEM, V279, P46621, DOI 10.1074/jbc.M408877200; Vincent L, 2005, J CLIN INVEST, V115, P2992, DOI 10.1172/JCI24586; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Weis S, 2004, J CLIN INVEST, V113, P885, DOI 10.1172/JCI200420702; Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987; Wong EYM, 2000, BIOCHEM J, V346, P209, DOI 10.1042/0264-6021:3460209; Wu JH, 2003, J BIOL CHEM, V278, P44238, DOI 10.1074/jbc.M309450200; Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200	49	745	793	0	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1223	U17		10.1038/ncb1486	http://dx.doi.org/10.1038/ncb1486			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17060906				2022-12-25	WOS:000241732400011
J	de Jong, MD; Simmons, CP; Thanh, TT; Hien, VM; Smith, GJD; Chau, TNB; Hoang, DM; Chau, NVV; Khanh, TH; Dong, VC; Qui, PT; Van Cam, B; Ha, DQ; Guan, Y; Peiris, JSM; Chinh, NT; Hien, TT; Farrar, J				de Jong, Menno D.; Simmons, Cameron P.; Thanh, Tran Tan; Hien, Vo Minh; Smith, Gavin J. D.; Chau, Tran Nguyen Bich; Hoang, Dang Minh; Chau, Nguyen Van Vinh; Khanh, Truong Huu; Dong, Vo Cong; Qui, Phan Tu; Van Cam, Bach; Ha, Do Quang; Guan, Yi; Peiris, J. S. Malik; Chinh, Nguyen Tran; Hien, Tran Tinh; Farrar, Jeremy			Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia	NATURE MEDICINE			English	Article							BRONCHIAL EPITHELIAL-CELLS; CYTOKINE RESPONSES; HIGH VIRULENCE; HUMAN-DISEASE; VIRUS; INFECTION; MICE; A/VIETNAM/1203/04; MACROPHAGES; ADAPTATION	Avian influenza A (H5N1) viruses cause severe disease in humans(1,2), but the basis for their virulence remains unclear. In vitro and animal studies indicate that high and disseminated viral replication is important for disease pathogenesis(3-5). Laboratory experiments suggest that virus-induced cytokine dysregulation may contribute to disease severity(6-9). To assess the relevance of these findings for human disease, we performed virological and immunological studies in 18 individuals with H5N1 and 8 individuals infected with human influenza virus subtypes. Influenza H5N1 infection in humans is characterized by high pharyngeal virus loads and frequent detection of viral RNA in rectum and blood. Viral RNA in blood was present only in fatal H5N1 cases and was associated with higher pharyngeal viral loads. We observed low peripheral blood T-lymphocyte counts and high chemokine and cytokine levels in H5N1-infected individuals, particularly in those who died, and these correlated with pharyngeal viral loads. Genetic characterization of H5N1 viruses revealed mutations in the viral polymerase complex associated with mammalian adaptation and virulence. Our observations indicate that high viral load, and the resulting intense inflammatory responses, are central to influenza H5N1 pathogenesis. The focus of clinical management should be on preventing this intense cytokine response, by early diagnosis and effective antiviral treatment.	Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam; Hosp Trop Dis, Ho Chi Minh City, Vietnam; Univ Hong Kong, State Key Lab Emerging Infect Dis, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Pediat Hosp 1, Ho Chi Minh City, Vietnam; Pediat Hosp 2, Ho Chi Minh City, Vietnam	University of Oxford; University of Hong Kong	de Jong, MD (corresponding author), Univ Oxford, Clin Res Unit, 190 Ben Ham Tu, Ho Chi Minh City, Vietnam.	dejongmd@gmail.com	Farrar, Jeremy J./HGA-7610-2022; Simmons, Cameron P/ABA-3896-2021; Peiris, Joseph Sriyal Malik/C-4380-2009	Simmons, Cameron P/0000-0002-9039-7392; Smith, Gavin JD/0000-0001-5031-468X; Guan, Yi/0000-0001-6057-9243; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Farrar, Jeremy/0000-0002-2700-623X; Tran Tan, Thanh/0000-0002-8096-7750	Wellcome Trust [074636] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Beigel H, 2005, NEW ENGL J MED, V353, P1374, DOI 10.1056/NEJMra052211; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; Chan MCW, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-135; CHEN H, 2006, P NATL ACAD SCI US; Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7; Chotpitayasunondh T, 2005, EMERG INFECT DIS, V11, P201, DOI 10.3201/eid1102.041061; Chutinimitkul S, 2006, EMERG INFECT DIS, V12, P1041, DOI 10.3201/eid1206.060227; de Jong MD, 2005, NEW ENGL J MED, V352, P686, DOI 10.1056/NEJMoa044307; de Jong MD, 2005, NEW ENGL J MED, V353, P2667, DOI 10.1056/NEJMoa054512; Gabriel G, 2005, P NATL ACAD SCI USA, V102, P18590, DOI 10.1073/pnas.0507415102; Govorkova EA, 2005, J VIROL, V79, P2191, DOI 10.1128/JVI.79.4.2191-2198.2005; Guan Y, 2002, P NATL ACAD SCI USA, V99, P8950, DOI 10.1073/pnas.132268999; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; JORENS PG, 1992, CYTOKINE, V4, P592, DOI 10.1016/1043-4666(92)90025-M; Lipatov AS, 2005, J GEN VIROL, V86, P1121, DOI 10.1099/vir.0.80663-0; Maines TR, 2005, J VIROL, V79, P11788, DOI 10.1128/JVI.79.18.11788-11800.2005; Obenauer JC, 2006, SCIENCE, V311, P1576, DOI 10.1126/science.1121586; Openshaw PJM, 2004, CLIN EXP IMMUNOL, V136, P11, DOI 10.1111/j.1365-2249.2004.02448.x; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Salomon R, 2006, J EXP MED, V203, P689, DOI 10.1084/jem.20051938; Sauty A, 1999, J IMMUNOL, V162, P3549; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Smith GJD, 2006, VIROLOGY, V350, P258, DOI 10.1016/j.virol.2006.03.048; SOUSA AR, 1994, AM J RESP CELL MOL, V10, P142, DOI 10.1165/ajrcmb.10.2.8110469; To KF, 2001, J MED VIROL, V63, P242, DOI 10.1002/1096-9071(200103)63:3&lt;242::AID-JMV1007&gt;3.0.CO;2-N; Tumpey TM, 2000, J VIROL, V74, P6105, DOI 10.1128/JVI.74.13.6105-6116.2000; Yen HL, 2005, J INFECT DIS, V192, P665, DOI 10.1086/432008; Zhou JF, 2006, J INFECT DIS, V193, P945, DOI 10.1086/500954	29	1403	1466	1	73	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1203	1207		10.1038/nm1477	http://dx.doi.org/10.1038/nm1477			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16964257	Green Published, Green Accepted			2022-12-25	WOS:000241102200039
J	Kubagawa, HM; Watts, JL; Corrigan, C; Edmonds, JW; Sztul, E; Browse, J; Miller, MA				Kubagawa, Homare M.; Watts, Jennifer L.; Corrigan, Chad; Edmonds, Johnathan W.; Sztul, Elizabeth; Browse, John; Miller, Michael A.			Oocyte signals derived from polyunsaturated fatty acids control sperm recruitment in vivo	NATURE CELL BIOLOGY			English	Article							T-CELL RECRUITMENT; CAENORHABDITIS-ELEGANS; MEIOTIC MATURATION; GERM-LINE; C-ELEGANS; ARACHIDONIC-ACID; LEUKOTRIENE B-4; GENE; PROSTAGLANDINS; IDENTIFICATION	A fundamental question in animal development is how motile cells find their correct target destinations. During mating in the nematode Caenorhabditis elegans, males inject sperm through the hermaphrodite vulva into the uterus. Amoeboid sperm crawl around fertilized eggs to the spermatheca - a convoluted tube where fertilization occurs(1,2). Here, we show that polyunsaturated fatty acids (PUFAs), the precursors of eicosanoid signalling molecules, function in oocytes to control directional sperm motility within the uterus. PUFAs are transported from the intestine, the site of fat metabolism, to the oocytes yolk, which is a lipoprotein complex. Loss of the RME-2 low-density lipoprotein (LDL) receptor, which mediates yolk endocytosis(3) and fatty acid transport into oocytes, causes severe defects in sperm targeting. We used an RNAi screen to identify lipid regulators required for directional sperm motility. Our results support the hypothesis that PUFAs function in oocytes as precursors of signals that control sperm recruitment to the spermatheca. A common property of PUFAs in mammals and C. elegans is that these fats control local recruitment of motile cells to their target tissues.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	University of Alabama System; University of Alabama Birmingham; Washington State University	Miller, MA (corresponding author), Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA.	mamiller@uab.edu	Watts, Jennifer/AAC-7425-2020	Browse, John/0000-0002-2554-2821; Watts, Jennifer/0000-0003-4349-0639; Miller, Michael/0000-0003-4872-7121	NIDDK NIH HHS [R01DK074114, R01 DK074114-01, R01 DK074114] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074114] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARTON MK, 1987, GENETICS, V115, P107; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; BRENNER S, 1974, GENETICS, V77, P71; Chandrasekharan NV, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-241; Dey I, 2003, P NATL ACAD SCI USA, V100, P13561, DOI 10.1073/pnas.1835863100; Eisenbach M, 2006, NAT REV MOL CELL BIO, V7, P276, DOI 10.1038/nrm1893; EPSTEIN HF, 1974, J MOL BIOL, V90, P291, DOI 10.1016/0022-2836(74)90374-X; FRANCIS R, 1995, GENETICS, V139, P579; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; GRAHAM PL, 1993, DEV GENET, V14, P471, DOI 10.1002/dvg.1020140608; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; HABENICHT AJR, 1990, NATURE, V345, P634, DOI 10.1038/345634a0; Hall DH, 1999, DEV BIOL, V212, P101, DOI 10.1006/dbio.1999.9356; Hill KL, 2001, DEV BIOL, V232, P105, DOI 10.1006/dbio.2000.0136; JANSSENTIMMEN U, 1994, ANN NY ACAD SCI, V733, P325, DOI 10.1111/j.1749-6632.1994.tb17282.x; Kahn-Kirby AH, 2004, CELL, V119, P889, DOI 10.1016/j.cell.2004.11.005; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kohara Y, 2001, Tanpakushitsu Kakusan Koso, V46, P2425; Koljak R, 1997, SCIENCE, V277, P1994, DOI 10.1126/science.277.5334.1994; Kosinski M, 2005, DEVELOPMENT, V132, P3357, DOI 10.1242/dev.01916; Kurzchalia TV, 2003, NAT CELL BIOL, V5, P684, DOI 10.1038/ncb0803-684; Luster AD, 2004, NAT REV IMMUNOL, V4, P711, DOI 10.1038/nri1438; McCarter J, 1999, DEV BIOL, V205, P111, DOI 10.1006/dbio.1998.9109; McKay RM, 2003, DEV CELL, V4, P131, DOI 10.1016/S1534-5807(02)00411-2; Merris M, 2003, J LIPID RES, V44, P172, DOI 10.1194/jlr.M200323-JLR200; Miller MA, 2001, SCIENCE, V291, P2144, DOI 10.1126/science.1057586; Reinke V, 2004, DEVELOPMENT, V131, P311, DOI 10.1242/dev.00914; Rowley AF, 2005, J EXP BIOL, V208, P3, DOI 10.1242/jeb.01275; SALBACH PB, 1992, P NATL ACAD SCI USA, V89, P2439, DOI 10.1073/pnas.89.6.2439; SHARROCK WJ, 1990, J BIOL CHEM, V265, P14422; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Singson A, 2001, DEV BIOL, V230, P101, DOI 10.1006/dbio.2000.0118; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; WARD S, 1979, DEV BIOL, V73, P304, DOI 10.1016/0012-1606(79)90069-1; Watts JL, 2003, GENETICS, V163, P581; Watts JL, 2002, P NATL ACAD SCI USA, V99, P5854, DOI 10.1073/pnas.092064799	39	110	150	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1143	U183		10.1038/ncb1476	http://dx.doi.org/10.1038/ncb1476			22	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16998478				2022-12-25	WOS:000241395300019
J	Mabb, AM; Wuerzberger-Davis, SM; Miyamoto, S				Mabb, Angela M.; Wuerzberger-Davis, Shelly M.; Miyamoto, Shigeki			PIASy mediates NEMO sumoylation and NF-kappa B activation in response to genotoxic stress	NATURE CELL BIOLOGY			English	Article							OXIDATIVE STRESS; DNA-DAMAGE; RADIATION; APOPTOSIS; LINKAGE; SUMO-1; CELLS; UBC9; ATM	Protein modification by SUMO (small ubiquitin-like modifier) is an important regulatory mechanism for multiple cellular processes(1,2). SUMO-1 modification of NEMO (NF-kappa B essential modulator), the I kappa B kinase (IKK) regulatory subunit, is critical for activation of NF-kappa B by genotoxic agents(3). However, the SUMO ligase, and the mechanisms involved in NEMO sumoylation, remain unknown. Here, we demonstrate that although small interfering RNAs (siRNAs) against PIASy (protein inhibitor of activated STATy) inhibit NEMO sumoylation and NF-kappa B activation in response to genotoxic agents, overexpression of PIASy enhances these events. PIASy preferentially stimulates site-selective modification of NEMO by SUMO-1, but not SUMO-2 and SUMO-3, in vitro. PIASy-NEMO interaction is increased by genotoxic stress and occurs in the nucleus in a manner mutually exclusive with IKK interaction. In addition, hydrogen peroxide (H2O2) also increases PIASy-NEMO interaction and NEMO sumoylation, whereas antioxidants prevent these events induced by DNA-damaging agents. Our findings demonstrate that PIASy is the first SUMO ligase for NEMO whose substrate specificity seems to be controlled by IKK interaction, subcellular targeting and oxidative stress conditions.	Univ Wisconsin, Dept Pharmacol, Program Mol & Cellular Pharmacol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Miyamoto, S (corresponding author), Univ Wisconsin, Dept Pharmacol, Program Mol & Cellular Pharmacol, Madison, WI 53706 USA.	smiyamot@wisc.edu		Mabb, Angela/0000-0002-3000-8690	NATIONAL CANCER INSTITUTE [R01CA077474, R01CA081065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA77474, R01CA81065, R01 CA077474] Funding Source: Medline; NIGMS NIH HHS [T32GM008688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Azuma Y, 2005, EMBO J, V24, P2172, DOI 10.1038/sj.emboj.7600700; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; England K, 2004, CELL DEATH DIFFER, V11, P252, DOI 10.1038/sj.cdd.4401338; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Jang HD, 2004, J BIOL CHEM, V279, P24873, DOI 10.1074/jbc.M313018200; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Liu B, 2005, MOL CELL BIOL, V25, P1113, DOI 10.1128/MCB.25.3.1113-1123.2005; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; O'Connor S, 2004, MOL CELL BIOL, V24, P4895, DOI 10.1128/MCB.24.11.4895-4908.2004; Pham NA, 2001, EXP CELL RES, V264, P345, DOI 10.1006/excr.2000.5148; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wuerzberger-Davis SM, 2005, MOL CANCER RES, V3, P345, DOI 10.1158/1541-7786.MCR-05-0028	26	176	187	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					986	U85		10.1038/ncb1458	http://dx.doi.org/10.1038/ncb1458			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16906147				2022-12-25	WOS:000240241700015
J	Miller, HI; Conko, G; Kershen, DL				Miller, Henry I.; Conko, Gregory; Kershen, Drew L.			Why spurning food biotech has become a liability	NATURE BIOTECHNOLOGY			English	Editorial Material							CORN		Competet Enterprise Inst, Washington, DC 20036 USA			miller@hoover.stanford.edu						Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Dowd PF, 2000, J ECON ENTOMOL, V93, P1669, DOI 10.1603/0022-0493-93.6.1669; Kershen DL., 2000, OKLA LAW REV, V53, P631; Kershen DL, 2006, FOOD DRUG LAW J, V61, P197; Munkvold GP, 1999, PLANT DIS, V83, P130, DOI 10.1094/PDIS.1999.83.2.130; Nickerson C., 2000, BOSTON GLOBE    0830, pA01; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; WEISE E, 2005, US TODAY        0202, pD8	8	7	7	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2006	24	9					1075	1077		10.1038/nbt0906-1075	http://dx.doi.org/10.1038/nbt0906-1075			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	083YK	16964211				2022-12-25	WOS:000240495200020
J	Watanabe, K; Hotta, K; Praseuth, AP; Koketsu, K; Migita, A; Boddy, CN; Wang, CCC; Oguri, H; Oikawa, H				Watanabe, Kenji; Hotta, Kinya; Praseuth, Alex P.; Koketsu, Kento; Migita, Akira; Boddy, Christopher N.; Wang, Clay C. C.; Oguri, Hiroki; Oikawa, Hideaki			Total biosynthesis of antitumor nonribosomal peptides in Escherichia coli	NATURE CHEMICAL BIOLOGY			English	Article							QUINOXALINE ANTIBIOTICS; HETEROLOGOUS HOST; DNA-BINDING; PROTEIN; ECHINOMYCIN; EXPRESSION; PRODUCTS; COMPLEX; GENES	Nonribosomal peptides (NRPs) are a class of microbial secondary metabolites that have a wide variety of medicinally important biological activities, such as antibiotic (vancomycin), immunosuppressive (cyclosporin A), antiviral (luzopeptin A) and antitumor (echinomycin and triostin A) activities(1,2). However, many microbes are not amenable to cultivation and require time-consuming empirical optimization of incubation conditions for mass production of desired secondary metabolites for clinical and commercial use(3). Therefore, a fast, simple system for heterologous production of natural products is much desired. Here we show the first example of the de novo total biosynthesis of biologically active forms of heterologous NRPs in Escherichia coli. Our system can serve not only as an effective and flexible platform for large-scale preparation of natural products from simple carbon and nitrogen sources, but also as a general tool for detailed characterizations and rapid engineering of biosynthetic pathways for microbial syntheses of novel compounds and their analogs.	Univ So Calif, Dept Pharmaceut Sci, Los Angeles, CA 90033 USA; Hokkaido Univ, Div Chem, Grad Sch Sci, Sapporo, Hokkaido 0600810, Japan; Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA; Univ So Calif, Dept Chem, Los Angeles, CA 90033 USA	University of Southern California; Hokkaido University; Syracuse University; University of Southern California	Watanabe, K (corresponding author), Univ So Calif, Dept Pharmaceut Sci, Los Angeles, CA 90033 USA.	kenjiwat@usc.edu; hoik@sci.hokudai.ac.jp	Oguri, Hiroki/AAV-2045-2020; Hotta, Kinya/A-2574-2009; Oguri, Hiroki/F-9541-2015; Watanabe, Kenji/N-2012-2015; Wang, Clay/ABG-9056-2021; Oikawa, Hideaki/F-9128-2012; Oguri, Hiroki/B-7366-2014; Boddy, Christopher N./H-8084-2019	Oguri, Hiroki/0000-0001-8007-1631; Hotta, Kinya/0000-0002-9427-0081; Oguri, Hiroki/0000-0001-8007-1631; Watanabe, Kenji/0000-0002-0463-4831; Oikawa, Hideaki/0000-0002-6947-3397; Boddy, Christopher/0000-0002-3259-3184; Wang, Clay/0000-0003-2955-7569	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075857] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 075857-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrett AGM, 1997, J AM CHEM SOC, V119, P8608, DOI 10.1021/ja9708326; BLAKE TJ, 1977, TETRAHEDRON LETT, P2621; Boger DL, 2001, J AM CHEM SOC, V123, P561, DOI 10.1021/ja003602r; Chen H, 2002, CHEM BIOL, V9, P103, DOI 10.1016/S1074-5521(02)00090-X; CHEUNG HT, 1978, J AM CHEM SOC, V100, P46, DOI 10.1021/ja00469a008; CIARDELLI TL, 1978, J AM CHEM SOC, V100, P7684, DOI 10.1021/ja00492a042; CORNISH A, 1983, J ANTIBIOT, V36, P1664, DOI 10.7164/antibiotics.36.1664; DELL A, 1975, J AM CHEM SOC, V97, P2497, DOI 10.1021/ja00842a029; Furuya K, 1998, FEMS MICROBIOL LETT, V168, P243, DOI 10.1111/j.1574-6968.1998.tb13280.x; Gruenewald S, 2004, APPL ENVIRON MICROB, V70, P3282, DOI 10.1128/AEM.70.6.3282-3291.2004; Kurnasov O, 2003, FEMS MICROBIOL LETT, V227, P219, DOI 10.1016/S0378-1097(03)00684-0; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Lau J, 2004, J BIOTECHNOL, V110, P95, DOI 10.1016/j.jbiotec.2004.02.001; McGinnis S, 2004, NUCLEIC ACIDS RES, V32, pW20, DOI 10.1093/nar/gkh435; NEIDLE S, 1987, BIOCHEM J, V243, P1; Peiru S, 2005, APPL ENVIRON MICROB, V71, P2539, DOI 10.1128/AEM.71.5.2539-2547.2005; Pfeifer BA, 2003, APPL ENVIRON MICROB, V69, P6698, DOI 10.1128/AEM.69.11.6698-6702.2003; RANCE MJ, 1989, J ANTIBIOT, V42, P206; REID DG, 1984, BIOCHIM BIOPHYS ACTA, V798, P111, DOI 10.1016/0304-4165(84)90017-5; Royo JL, 2005, J BIOTECHNOL, V116, P113, DOI 10.1016/j.jbiotec.2004.10.006; Schmoock G, 2005, J BIOL CHEM, V280, P4339, DOI 10.1074/jbc.M411026200; Schwarzer D, 2003, NAT PROD REP, V20, P275, DOI 10.1039/b111145k; SHULER ML, 1994, ANN NY ACAD SCI, V745, P455; Sorensen HP, 2005, J BIOTECHNOL, V115, P113, DOI 10.1016/j.jbiotec.2004.08.004; STEINBACH P, 1987, CLIN GENET, V32, P1; Takahashi K, 2001, J ANTIBIOT, V54, P622, DOI 10.7164/antibiotics.54.622; Trauger JW, 2000, NATURE, V407, P215, DOI 10.1038/35025116; Van Lanen SG, 2003, BIOCHEMISTRY-US, V42, P5312, DOI 10.1021/bi034197u; Watanabe K, 2003, J BIOL CHEM, V278, P42020, DOI 10.1074/jbc.M305339200; Watanabe K, 2003, P NATL ACAD SCI USA, V100, P9774, DOI 10.1073/pnas.1632167100	30	172	187	1	68	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2006	2	8					423	428		10.1038/nchembio803	http://dx.doi.org/10.1038/nchembio803			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065GD	16799553				2022-12-25	WOS:000239146800011
J	Randall, JB; Munsell, LY; Morris, JC; Swarm, R; Yarasheski, KE; Holtzman, DM				Bateman, Randall J.; Munsell, Ling Y.; Morris, John C.; Swarm, Robert; Yarasheski, Kevin E.; Holtzman, David M.			Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo	NATURE MEDICINE			English	Article							BLOOD-BRAIN-BARRIER; GAMMA-SECRETASE INHIBITOR; MUSCLE PROTEIN-METABOLISM; ALZHEIMERS-DISEASE; A-BETA; MOUSE MODEL; GENE; PLASMA; TRANSPORT; INSERTION	Certain disease states are characterized by disturbances in production, accumulation or clearance of protein. In Alzheimer disease, accumulation of amyloid-b (A beta) in the brain and disease-causing mutations in amyloid precursor protein or in enzymes that produce A beta indicate dysregulation of production or clearance of A beta. Whether dysregulation of A beta synthesis or clearance causes the most common form of Alzheimer disease (sporadic, > 99% of cases), however, is not known. Here, we describe a method to determine the production and clearance rates of proteins within the human central nervous system (CNS). We report the first measurements of the fractional production and clearance rates of A beta in vivo in the human CNS to be 7.6% per hour and 8.3% per hour, respectively. This method may be used to search for novel biomarkers of disease, to assess underlying differences in protein metabolism that contribute to disease and to evaluate treatments in terms of their pharmacodynamic effects on proposed disease-causing pathways.	Washington Univ, Sch Med, Dept Neurol, Alzheimer Dis Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Randall, JB (corresponding author), Washington Univ, Sch Med, Dept Neurol, Alzheimer Dis Res Ctr, 660 S Euclid Ave,Box 8111, St Louis, MO 63110 USA.	batemanr@neuro.wustl.edu	Yarasheski, Kevin/AAC-7450-2021; Morris, John C/A-1686-2012	Yarasheski, Kevin/0000-0001-5436-2451; Bateman, Randall/0000-0002-7729-1702	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005681, K08AG027091] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000036, P41 RR000954, M01 RR00036, RR000954] Funding Source: Medline; NIA NIH HHS [L30 AG024455, K08 AG027091-01, P50 AG05681, P50 AG005681, L30 AG024455-01, K08 AG027091] Funding Source: Medline; NIDDK NIH HHS [P30 DK056341-05S2, P30 DK056341-06, P30 DK056341, DK056341] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cirrito JR, 2003, J NEUROSCI, V23, P8844; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Elias N, 2000, ARTERIOSCL THROM VAS, V20, P1309, DOI 10.1161/01.ATV.20.5.1309; Fishman RA., 1992, CEREBROSPINAL FLUID; GARLICK PJ, 1980, BIOCHEM J, V192, P719, DOI 10.1042/bj1920719; Golde TE, 2000, BBA-MOL BASIS DIS, V1502, P172, DOI 10.1016/S0925-4439(00)00043-0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Lanz TA, 2004, J PHARMACOL EXP THER, V309, P49, DOI 10.1124/jpet.103.060715; Merchak A, 2000, J MASS SPECTROM, V35, P734, DOI 10.1002/1096-9888(200006)35:6<734::AID-JMS2>3.0.CO;2-H; OWEN F, 1989, LANCET, V1, P51; PODLISNY MB, 1987, SCIENCE, V238, P669, DOI 10.1126/science.2960019; Poduslo JF, 2001, NEUROBIOL DIS, V8, P555, DOI 10.1006/nbdi.2001.0402; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Saido TC, 2003, ABETA METABOLISM ALZ; SANPIETRO A, 1953, J BIOL CHEM, V201, P457; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Siemers E, 2005, CLIN NEUROPHARMACOL, V28, P126, DOI 10.1097/01.wnf.0000167360.27670.29; SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x; Williams MA, 2002, NEUROLOGY, V58, P1859, DOI 10.1212/WNL.58.12.1859; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; Wolfe RR, 2005, CURR OPIN CLIN NUTR, V8, P61, DOI 10.1097/00075197-200501000-00009; Wolfe RR., 2005, ISOTOPE TRACERS META, V2; Yarasheski KE, 1998, AM J PHYSIOL-ENDOC M, V275, pE577, DOI 10.1152/ajpendo.1998.275.4.E577; Yarasheski KE, 2003, J GERONTOL A-BIOL, V58, P918; YARASHESKI KE, 1992, BIOL MASS SPECTROM, V21, P486, DOI 10.1002/bms.1200211004; ZLOKOVIC BV, 1993, BIOCHEM BIOPH RES CO, V197, P1034, DOI 10.1006/bbrc.1993.2582	27	422	447	0	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					856	861		10.1038/nm1438	http://dx.doi.org/10.1038/nm1438			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16799555	Green Accepted			2022-12-25	WOS:000238862800076
J	Xiang, SL; Fruehauf, J; Li, CJ				Xiang, Shuanglin; Fruehauf, Johannes; Li, Chiang J.			Short hairpin RNA-expressing bacteria elicit RNA interference in mammals	NATURE BIOTECHNOLOGY			English	Article							ESCHERICHIA-COLI; CELLS; PROTEIN; INDUCTION; TRANSPORT; DELIVERY; INVASIN; GENE	RNA-interference (RNAi) is a potent mechanism, conserved from plants to humans for specific silencing of genes, which holds promise for functional genomics and gene-targeted therapies. Here we show that bacteria engineered to produce a short hairpin RNA (shRNA) targeting a mammalian gene induce trans-kingdom RNAi in vitro and in vivo. Nonpathogenic Escherichia coli were engineered to transcribe shRNAs from a plasmid containing the invasin gene Inv and the listeriolysin O gene HlyA, which encode two bacterial factors needed for successful transfer of the shRNAs into mammalian cells. Upon oral or intravenous administration, E. coli encoding shRNA against CTNNB1 (catenin beta-1) induce significant gene silencing in the intestinal epithelium and in human colon cancer xenografts in mice. These results provide an example of trans-kingdom RNAi in higher organisms and suggest the potential of bacteria-mediated RNAi for functional genomics, therapeutic target validation and development of clinically compatible RNAi-based therapies.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Li, CJ (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gastroenterol, 330 Brookline Ave, Boston, MA 02215 USA.	cli@BIDMC.harvard.edu						Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Battistoni A, 2000, INFECT IMMUN, V68, P30, DOI 10.1128/IAI.68.1.30-37.2000; Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; Darji A, 1997, CELL, V91, P765, DOI 10.1016/S0092-8674(00)80465-1; Feinberg EH, 2003, SCIENCE, V301, P1545, DOI 10.1126/science.1087117; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Grillot-Courvalin C, 1998, NAT BIOTECHNOL, V16, P862, DOI 10.1038/nbt0998-862; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kim SB, 2004, PERITON DIALYSIS INT, V24, P597; Mathew E, 2003, GENE THER, V10, P1105, DOI 10.1038/sj.gt.3301966; May RC, 2005, METHOD ENZYMOL, V392, P308, DOI 10.1016/S0076-6879(04)92018-6; MILIOTIS MD, 1991, J CLIN MICROBIOL, V29, P830, DOI 10.1128/JCM.29.4.830-831.1991; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Narayanan K, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng051; Pawelek JM, 2003, LANCET ONCOL, V4, P548, DOI 10.1016/S1470-2045(03)01194-X; Rembacken BJ, 1999, LANCET, V354, P635, DOI 10.1016/S0140-6736(98)06343-0; Roy D, 2004, SCIENCE, V304, P1515, DOI 10.1126/science.1098371; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Toso JF, 2002, J CLIN ONCOL, V20, P142, DOI 10.1200/JCO.20.1.142; Xiang R, 2005, CANCER RES, V65, P553; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197; Zhao M, 2005, P NATL ACAD SCI USA, V102, P755, DOI 10.1073/pnas.0408422102	27	193	224	2	41	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2006	24	6					697	702		10.1038/nbt1211	http://dx.doi.org/10.1038/nbt1211			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	051UQ	16699500				2022-12-25	WOS:000238187300032
J	Zhang, K; Martiny, AC; Reppas, NB; Barry, KW; Malek, J; Chisholm, SW; Church, GM				Zhang, Kun; Martiny, Adam C.; Reppas, Nikos B.; Barry, Kerrie W.; Malek, Joel; Chisholm, Sallie W.; Church, George M.			Sequencing genomes from single cells by polymerase cloning	NATURE BIOTECHNOLOGY			English	Article							MULTIPLE DISPLACEMENT AMPLIFICATION; DNA-POLYMERASE; PROCHLOROCOCCUS; METAGENOMICS; DIVERSITY; SEA	Genome sequencing currently requires DNA from pools of numerous nearly identical cells (clones), leaving the genome sequences of many difficult-to-culture microorganisms unattainable. We report a sequencing strategy that eliminates culturing of microorganisms by using real-time isothermal amplification to form polymerase clones (plones) from the DNA of single cells. Two Escherichia coli plones, analyzed by Affymetrix chip hybridization, demonstrate that plonal amplification is specific and the bias is randomly distributed. Whole-genome shotgun sequencing of Prochlorococcus MIT9312 plones showed 62% coverage of the genome from one plone at a sequencing depth of 3.5x, and 66% coverage from a second plone at a depth of 4.7x. Genomic regions not revealed in the initial round of sequencing are recovered by sequencing PCR amplicons derived from plonal DNA. The mutation rate in single-cell amplification is < 2 x 10(5), better than that of current genome sequencing standards. Polymerase cloning should provide a critical tool for systematic characterization of genome diversity in the biosphere.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; US DOE, Joint Genome Inst, Walnut Creek, CA 94598 USA; Agencourt Biosci, Beverly, MA 01915 USA	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI	Zhang, K (corresponding author), Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	kzhang@genetics.med.harvard.edu	Martiny, Adam/AAC-4459-2019; Zhang, Kun/ABE-6349-2020; Barry, Kerrie Whitelaw/AAA-5500-2020	Martiny, Adam/0000-0003-2829-4314; Zhang, Kun/0000-0002-7596-5224; Barry, Kerrie Whitelaw/0000-0002-8999-6785; Chisholm, Sallie/0000-0003-1480-2445; church, george/0000-0001-6232-9969				Acinas SG, 2004, NATURE, V430, P551, DOI 10.1038/nature02649; Beja O, 2002, APPL ENVIRON MICROB, V68, P335, DOI 10.1128/AEM.68.1.335-345.2002; CHISHOLM SW, 1988, NATURE, V334, P340, DOI 10.1038/334340a0; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; Dean FB, 2001, GENOME RES, V11, P1095, DOI 10.1101/gr.180501; DeLong EE, 2005, NAT REV MICROBIOL, V3, P459, DOI 10.1038/nrmicro1158; Detter JC, 2002, GENOMICS, V80, P691, DOI 10.1006/geno.2002.7020; Dietmaier W, 1999, AM J PATHOL, V154, P83, DOI 10.1016/S0002-9440(10)65254-6; Dufresne A, 2003, P NATL ACAD SCI USA, V100, P10020, DOI 10.1073/pnas.1733211100; Falkowski PG, 2004, SCIENCE, V304, P58, DOI 10.1126/science.1097146; GRAY JW, 1987, SCIENCE, V238, P323, DOI 10.1126/science.2443974; Hafner GJ, 2001, BIOTECHNIQUES, V30, P852, DOI 10.2144/01304rr03; Handyside AH, 2004, MOL HUM REPROD, V10, P767, DOI 10.1093/molehr/gah101; Hellani A, 2004, MOL HUM REPROD, V10, P847, DOI 10.1093/molehr/gah114; Hosono S, 2003, GENOME RES, V13, P954, DOI 10.1101/gr.816903; Hutchison CA, 2005, P NATL ACAD SCI USA, V102, P17332, DOI 10.1073/pnas.0508809102; Jiang Zhengwen, 2005, Nucleic Acids Res, V33, pe91, DOI 10.1093/nar/gni089; Kyrpides NC, 1999, BIOINFORMATICS, V15, P773, DOI 10.1093/bioinformatics/15.9.773; Lage JM, 2003, GENOME RES, V13, P294, DOI 10.1101/gr.377203; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Moreira D, 2002, TRENDS MICROBIOL, V10, P31, DOI 10.1016/S0966-842X(01)02257-0; Nelson JR, 2002, BIOTECHNIQUES, P44; Paez JG, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh069; Panelli S, 2005, BIOTECHNIQUES, V39, P174, DOI 10.2144/05392BM03; Partensky F, 1999, MICROBIOL MOL BIOL R, V63, P106, DOI 10.1128/MMBR.63.1.106-127.1999; Raghunathan A, 2005, APPL ENVIRON MICROB, V71, P3342, DOI 10.1128/AEM.71.6.3342-3347.2005; Riesenfeld CS, 2004, ANNU REV GENET, V38, P525, DOI 10.1146/annurev.genet.38.072902.091216; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Rodriguez-Valera F, 2004, FEMS MICROBIOL LETT, V231, P153, DOI 10.1016/S0378-1097(04)00006-0; Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Sorensen KJ, 2004, ANAL BIOCHEM, V324, P312, DOI 10.1016/j.ab.2003.10.020; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; Thompson JR, 2005, SCIENCE, V307, P1311, DOI 10.1126/science.1106028; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851; Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340; Urbach E, 1998, LIMNOL OCEANOGR, V43, P1615, DOI 10.4319/lo.1998.43.7.1615; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Yu DG, 2000, P NATL ACAD SCI USA, V97, P5978, DOI 10.1073/pnas.100127597; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	40	311	344	1	87	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2006	24	6					680	686		10.1038/nbt1214	http://dx.doi.org/10.1038/nbt1214			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	051UQ	16732271				2022-12-25	WOS:000238187300030
J	Ferby, I; Reschke, M; Kudlacek, O; Knyazev, P; Pante, G; Amann, K; Sommergruber, W; Kraut, N; Ullrich, A; Fassler, R; Klein, R				Ferby, Ingvar; Reschke, Markus; Kudlacek, Oliver; Knyazev, Pjotr; Pante, Guido; Amann, Kerstin; Sommergruber, Wolfgang; Kraut, Norbert; Ullrich, Axel; Faessler, Reinhard; Klein, R. diger			Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; ENDOGENOUS INHIBITOR; TARGETED DISRUPTION; TYROSINE KINASE; TRANSGENIC MICE; CELL-MIGRATION; FACTOR-ALPHA; EXPRESSION; GENE; DIFFERENTIATION	The growing number of recently identified negative feedback regulators of receptor tyrosine kinases (RTKs) highlights the importance of signal attenuation and modulation for correct signaling outcome. Mitogen-inducible gene 6 (Mig6 also known as RALT or Gene 33) is a multiadaptor protein thought to be involved in the regulation of RTK and stress signaling(1-3). Here, we show that deletion of the mouse gene encoding Mig6 (designated Errfi1, which stands for ERBB receptor feedback inhibitor 1) causes hyperactivation of endogenous epidermal growth factor receptor (EGFR) and sustained signaling through the mitogen-activated protein kinase (MAPK) pathway, resulting in overproliferation and impaired differentiation of epidermal keratinocytes. Furthermore, Errfi1(-/-) mice develop spontaneous tumors in various organs and are highly susceptible to chemically induced formation of skin tumors. A tumor-suppressive role for Mig6 is supported by our finding that MIG6 is downregulated in various human cancers. Inhibition of endogenous Egfr signaling with the Egfr inhibitor gefitinib (Iressa) or replacement of wild-type Egfr with the kinase-deficient protein encoded by the hypomorphic Egfr(wa 2) allele completely rescued skin defects in Erffi1(-/-) mice. Carcinogen-induced tumors displayed by Errfi1(-/-) mice were highly sensitive to gefitinib. These results indicate that Mig6 is a specific negative regulator of Egfr signaling in skin morphogenesis and is a novel tumor suppressor of Egfr-dependent carcinogenesis.	Max Planck Inst Neurobiol, Dept Mol Neurobiol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Biol Mol, D-82152 Martinsried, Germany; Max Planck Inst Biochem, Dept Mol Med, D-82152 Martinsried, Germany; Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany; Boehringer Ingelheim Austria GmbH, A-1121 Vienna, Austria	Max Planck Society; Max Planck Society; Max Planck Society; University of Erlangen Nuremberg; Boehringer Ingelheim	Klein, R (corresponding author), Max Planck Inst Neurobiol, Dept Mol Neurobiol, Klopferspitz 18, D-82152 Martinsried, Germany.	rklein@neuro.mpg.de	Klein, Ruediger/C-6147-2008; Ferby, Ingvar/B-7895-2008	Klein, Ruediger/0000-0002-3109-0163; Kudlacek, Oliver/0000-0002-3086-8551; Ferby, Ingvar/0000-0002-3435-1728	Worldwide Cancer Research [09-0228] Funding Source: Medline	Worldwide Cancer Research		Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Ballaro C, 2005, EMBO REP, V6, P755, DOI 10.1038/sj.embor.7400458; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; CHU DTW, 1988, J BIOL CHEM, V263, P13007; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Dlugosz AA, 1997, CANCER RES, V57, P3180; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; Hackel PO, 2001, BIOL CHEM, V382, P1649, DOI 10.1515/BC.2001.200; Koshikawa K, 2004, HEPATO-GASTROENTEROL, V51, P186; Krampert M, 2005, J BIOL CHEM, V280, P23844, DOI 10.1074/jbc.M412212200; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Ogunbiyi OA, 1997, GASTROENTEROLOGY, V113, P761, DOI 10.1016/S0016-5085(97)70169-0; Pante G, 2005, J CELL BIOL, V171, P337, DOI 10.1083/jcb.200502013; Savontaus M, 1996, AM J PATHOL, V149, P2169; Shen-Ong GL, 2003, CANCER RES, V63, P3296; Tseng RC, 2005, INT J CANCER, V117, P241, DOI 10.1002/ijc.21178; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271; Zhang YW, 2005, P NATL ACAD SCI USA, V102, P11740, DOI 10.1073/pnas.0505171102	30	196	206	2	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					568	573		10.1038/nm1401	http://dx.doi.org/10.1038/nm1401			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16648858				2022-12-25	WOS:000238149100041
J	Ropero, S; Fraga, MF; Ballestar, E; Hamelin, R; Yamamoto, H; Boix-Chornet, M; Caballero, R; Alaminos, M; Setien, F; Paz, MF; Herranz, M; Palacios, J; Arango, D; Orntoft, TF; Aaltonen, LA; Schwartz, S; Esteller, M				Ropero, S; Fraga, MF; Ballestar, E; Hamelin, R; Yamamoto, H; Boix-Chornet, M; Caballero, R; Alaminos, M; Setien, F; Paz, MF; Herranz, M; Palacios, J; Arango, D; Orntoft, TF; Aaltonen, LA; Schwartz, S; Esteller, M			A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition	NATURE GENETICS			English	Article							MICROSATELLITE INSTABILITY; CELLS; ACETYLATION	Disruption of histone acetylation patterns is a common feature of cancer cells, but very little is known about its genetic basis. We have identified truncating mutations in one of the primary human histone deacetylases, HDAC2, in sporadic carcinomas with microsatellite instability and in tumors arising in individuals with hereditary nonpolyposis colorectal cancer syndrome. The presence of the HDAC2 frameshift mutation causes a loss of HDAC2 protein expression and enzymatic activity and renders these cells more resistant to the usual antiproliferative and proapoptotic effects of histone deacetylase inhibitors. As such drugs may serve as therapeutic agents for cancer, our findings support the use of HDAC2 mutational status in future pharmacogenetic treatment of these individuals.	Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Madrid 28029, Spain; Ctr Etud Polymorphisme Humain, INSERM U434, F-75010 Paris, France; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Spanish Natl Canc Ctr CNIO, Lab Breast & Gynaecol Canc, Madrid 28029, Spain; Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol, Barcelona 08035, Spain; Aarhus Univ Hosp Skejby, Mol Diagnost Lab, Dept Clin Biochem, DK-8200 Aarhus N, Denmark; Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, Helsinki, Finland	Centro Nacional de Investigaciones Oncologicas (CNIO); Institut National de la Sante et de la Recherche Medicale (Inserm); Sapporo Medical University; Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitari Vall d'Hebron; Aarhus University; University of Helsinki	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Madrid 28029, Spain.	mesteller@cnio.es	Fraga, Mario F/H-7824-2017; Esteller, Manel/L-5956-2014; Arango, Diego/M-5667-2016; Ballestar, Esteban/ABG-8561-2020; Schwartz, Simo/H-7776-2012; Aaltonen, Lauri/A-5375-2010; Arango, Diego/AFW-0125-2022; ALAMINOS, MIGUEL/N-9960-2016	Fraga, Mario F/0000-0001-8450-2603; Esteller, Manel/0000-0003-4490-6093; Arango, Diego/0000-0003-2953-3284; Aaltonen, Lauri/0000-0001-6839-4286; Arango, Diego/0000-0003-2953-3284; ALAMINOS, MIGUEL/0000-0003-4876-2672; Schwartz, Simo/0000-0001-8297-7971; Ballestar, Esteban/0000-0002-1400-2440				Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bannister AJ, 2004, METHOD ENZYMOL, V376, P269; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Ionov Y, 2004, P NATL ACAD SCI USA, V101, P1273, DOI 10.1073/pnas.0307276101; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marks PA, 2005, CELL CYCLE, V4, P549, DOI 10.4161/cc.4.4.1564; Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; Wang DF, 2005, J MED CHEM, V48, P6936, DOI 10.1021/jm0505011	20	209	220	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					566	569		10.1038/ng1773	http://dx.doi.org/10.1038/ng1773			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16642021				2022-12-25	WOS:000237147500019
J	Stoetzel, C; Laurier, V; Davis, EE; Muller, J; Rix, S; Badano, JL; Leitch, CC; Salem, N; Chouery, E; Corbani, S; Jalk, N; Vicaire, S; Sarda, P; Hamel, C; Lacombe, D; Holder, M; Odent, S; Holder, S; Brooks, AS; Elcioglu, NH; Da Silva, E; Rossillion, B; Sigaudy, S; de Ravel, TJL; Lewis, RA; Leheup, B; Verloes, A; Amati-Bonneau, P; Megarbane, A; Poch, O; Bonneau, D; Beales, PL; Mandel, JL; Katsanis, N; Dollfus, H				Stoetzel, C; Laurier, V; Davis, EE; Muller, J; Rix, S; Badano, JL; Leitch, CC; Salem, N; Chouery, E; Corbani, S; Jalk, N; Vicaire, S; Sarda, P; Hamel, C; Lacombe, D; Holder, M; Odent, S; Holder, S; Brooks, AS; Elcioglu, NH; Da Silva, E; Rossillion, B; Sigaudy, S; de Ravel, TJL; Lewis, RA; Leheup, B; Verloes, A; Amati-Bonneau, P; Megarbane, A; Poch, O; Bonneau, D; Beales, PL; Mandel, JL; Katsanis, N; Dollfus, H			BBS10 encodes a vertebrate-specific chaperonin-like protein and is a major BBS locus	NATURE GENETICS			English	Article							BARDET-BIEDL-SYNDROME; GENE; DISORDER; GENOMICS	Bardet-Biedl syndrome (BBS) is a genetically heterogeneous ciliopathy. Although nine BBS genes have been cloned, they explain only 40-50% of the total mutational load. Here we report a major new BBS locus, BBS10, that encodes a previously unknown, rapidly evolving vertebrate-specific chaperonin-like protein. We found BBS10 to be mutated in about 20% of an unselected cohort of families of various ethnic origins, including some families with mutations in other BBS genes, consistent with oligogenic inheritance. In zebrafish, mild suppression of bbs10 exacerbated the phenotypes of other bbs morphants.	Univ Strasbourg 1, Fac Med Strasbourg, Med Genet Lab, EA 3949, F-67085 Strasbourg, France; Hop Univ Strasbourg, Serv Genet Med, F-67098 Strasbourg, France; Hop Univ Strasbourg, Ctr Reference Affect Genet Ophtalmol, F-67098 Strasbourg, France; Johns Hopkins Univ, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Univ Strasbourg 1, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, F-67404 Illkirch Graffenstaden, France; Communaute Urbaine Strasbourg, Strasbourg, France; Ctr Rech Publ Sante, Lab Biol Mol Anal Genet & Modelisat, L-1911 Luxembourg, Luxembourg; UCL, Mol Med Unit, Inst Child Hlth, London WC1N 1EH, England; Univ St Joseph, Fac Med, Unite Genet Med, Beirut 1000, Lebanon; CHU Montpellier, Hop Arnaud de Villeneuve, Serv Genet Med, F-34295 Montpellier, France; CHU Montpellier, Hop St Eloi, Inst Neurosci Montpellier, F-34295 Montpellier, France; CHU, Hop Pellegrin, Serv Genet Med, F-33076 Bordeaux, France; CHU Lille, Hop Jeanne de Flandres, Serv Genet Clin, F-59037 Lille, France; CHU Hop Sud, Unite Genet Med, F-35203 Rennes, France; Northwick Pk & St Marks NHS Trust, Kennedy Galton Ctr, Harrow HA1 3UJ, Middx, England; Erasmus MC, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands; Marmara Univ Hosp, Dept Pediat Genet, TR-34668 Istanbul, Turkey; Univ Hosp Coimbra, Dept Ophthalmol, P-3041853 Coimbra, Portugal; Univ Geneva, Hop Cantonal, Serv Ophtalmol, CH-1211 Geneva, Switzerland; CHU Timone, Serv Genet Med, F-13385 Marseille, France; Univ Hosp Gasthuisberg, Ctr Human Genet, B-3000 Louvain, Belgium; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; CHU Enfants Brabois, Serv Genet, F-54500 Vandoeuvre Les Nancy, France; Hop Robert Debre, Unite Genet Clin, F-75935 Paris, France; CHU Angers, Serv Genet, F-49933 Angers, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Luxembourg Institute of Health; University of London; University College London; Saint Joseph University Beirut; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; CHU Bordeaux; Universite de Lille - ISITE; CHU Lille; CHU Rennes; Imperial College London; Erasmus University Rotterdam; Erasmus MC; Marmara University; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); University of Geneva; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; KU Leuven; University Hospital Leuven; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; CHU de Nancy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Dollfus, H (corresponding author), Univ Strasbourg 1, Fac Med Strasbourg, Med Genet Lab, EA 3949, F-67085 Strasbourg, France.	helene.dollfus@medecine.u-strasbg.fr	Megarbane, Andre/ABD-5574-2021; Muller, Jean/L-7412-2018; Katsanis, Nicholas/E-1837-2012; /AAK-8500-2021; Beales, Philip L/C-7367-2009; Bonneau, Dominique/K-6110-2015; amati-bonneau, patrizia/K-6198-2015; Mandel, Jean Louis/Q-2668-2016; VERLOES, Alain/E-7287-2014	Muller, Jean/0000-0002-7682-559X; Davis, Erica/0000-0002-2412-8397; Mandel, Jean Louis/0000-0002-0535-6589; Dollfus, Helene/0000-0002-2249-895X; Katsanis, Nicholas/0000-0002-2480-0171; Badano, Jose/0000-0002-0706-8652; de Ravel, Thomy/0000-0002-3361-3781; VERLOES, Alain/0000-0003-4819-0264; Silva, Eduardo/0000-0002-2739-9854; Lacombe, Didier/0000-0002-8956-2207	Medical Research Council [G0801843] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Ansley SJ, 2003, NATURE, V425, P628, DOI 10.1038/nature02030; Badano JL, 2006, NATURE, V439, P326, DOI 10.1038/nature04370; Beales PL, 2005, CURR OPIN GENET DEV, V15, P315, DOI 10.1016/j.gde.2005.04.006; Blacque OE, 2004, GENE DEV, V18, P1630, DOI 10.1101/gad.1194004; Chiang AP, 2004, AM J HUM GENET, V75, P475, DOI 10.1086/423903; Ditzel L, 1998, CELL, V93, P125, DOI 10.1016/S0092-8674(00)81152-6; Fan YL, 2004, NAT GENET, V36, P989, DOI 10.1038/ng1414; Hichri H, 2005, EUR J HUM GENET, V13, P607, DOI 10.1038/sj.ejhg.5201372; Katsanis N, 2001, SCIENCE, V293, P2256, DOI 10.1126/science.1063525; Katsanis N, 2004, HUM MOL GENET, V13, pR65, DOI 10.1093/hmg/ddh092; Kim JC, 2005, J CELL SCI, V118, P1007, DOI 10.1242/jcs.01676; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; Li JB, 2004, CELL, V117, P541, DOI 10.1016/S0092-8674(04)00450-7; Nishimura DY, 2005, AM J HUM GENET, V77, P1021, DOI 10.1086/498323; Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644	15	206	212	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2006	38	5					521	524		10.1038/ng1771	http://dx.doi.org/10.1038/ng1771			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16582908				2022-12-25	WOS:000237147500011
J	Durand, CM; Betancur, C; Boeckers, TM; Bockmann, J; Chaste, P; Fauchereau, F; Nygren, G; Rastam, M; Gillberg, IC; Anckarsater, H; Sponheim, E; Goubran-Botros, H; Delorme, R; Chabane, N; Mouren-Simeoni, MC; de Mas, P; Bieth, E; Roge, B; Heron, D; Burglen, L; Gillberg, C; Leboyer, M; Bourgeron, T				Durand, Christelle M.; Betancur, Catalina; Boeckers, Tobias M.; Bockmann, Juergen; Chaste, Pauline; Fauchereau, Fabien; Nygren, Gudrun; Rastam, Maria; Gillberg, I. Carina; Anckarsater, Henrik; Sponheim, Eili; Goubran-Botros, Hany; Delorme, Richard; Chabane, Nadia; Mouren-Simeoni, Marie-Christine; de Mas, Philippe; Bieth, Eric; Roge, Bernadette; Heron, Delphine; Burglen, Lydie; Gillberg, Christopher; Leboyer, Marion; Bourgeron, Thomas			Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders	NATURE GENETICS			English	Article							POSTSYNAPTIC DENSITY; DELETION SYNDROME; IDENTIFICATION; SYNAPSES; COMPLEX; SPEECH; FAMILY	SHANK3 (also known as ProSAP2) regulates the structural organization of dendritic spines and is a binding partner of neuroligins; genes encoding neuroligins are mutated in autism and Asperger syndrome. Here, we report that a mutation of a single copy of SHANK3 on chromosome 22q13 can result in language and/or social communication disorders. These mutations concern only a small number of individuals, but they shed light on one gene dosage - sensitive synaptic pathway that is involved in autism spectrum disorders.	Inst Pasteur, Human Genet & Cognit Funct, Paris, France; Univ Paris 12, INSERM, U513, Creteil, France; Univ Ulm, Inst Anat & Cell Biol, Ulm, Germany; Univ Paris 07, Paris, France; Univ Gothenburg, Dept Child & Adolescent Psychiat, Gothenburg, Sweden; Univ Oslo, Ctr Child & Adolescent Psychiat, Oslo, Norway; Hop Robert Debre, Assistance Publ Hop Paris, Serv Psychopathol Enfant & Adolescent, F-75019 Paris, France; Purpan Hosp, Dept Med Genet, Toulouse, France; Univ Toulouse Le Mirail, Ctr Etud Rech & Psychopathp, Toulouse, France; Grp Hosp Pitie Salpetriere, Dept Genet, F-75634 Paris, France; Hop Trousseau, Assistance Publ Hop Paris, Serv Genet, F-75571 Paris, France; St Georges Hosp Med Sch, London, England; Grp Hosp Henri Mondor & Albert Chenevier, Assistance Publ Hop Paris, Dept Psychiat, Creteil, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Ulm University; UDICE-French Research Universities; Universite Paris Cite; University of Gothenburg; University of Oslo; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; CHU de Toulouse; Universite de Toulouse; Universite de Toulouse - Jean Jaures; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; St Georges University London; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Bourgeron, T (corresponding author), Inst Pasteur, Human Genet & Cognit Funct, Paris, France.	thomasb@pasteur.fr	Leboyer, Marion/AAW-3648-2021; Anckarsater, Henrik/C-2244-2009; Betancur, Catalina/K-3791-2017	Leboyer, Marion/0000-0001-5473-3697; Betancur, Catalina/0000-0002-3327-4804; Bourgeron, Thomas/0000-0001-8164-9220; Delorme, Richard/0000-0002-5614-3663				Baron MK, 2006, SCIENCE, V311, P531, DOI 10.1126/science.1118995; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Bonaglia MC, 2006, J MED GENET, V43, P822, DOI 10.1136/jmg.2005.038604; Bonaglia MC, 2001, AM J HUM GENET, V69, P261, DOI 10.1086/321293; Carlisle HJ, 2005, TRENDS NEUROSCI, V28, P182, DOI 10.1016/j.tins.2005.01.008; Folstein SE, 2001, NAT REV GENET, V2, P943, DOI 10.1038/35103559; Jamain S, 2003, NAT GENET, V34, P27, DOI 10.1038/ng1136; Lai CSL, 2001, NATURE, V413, P519, DOI 10.1038/35097076; Manning MA, 2004, PEDIATRICS, V114, P451, DOI 10.1542/peds.114.2.451; Meyer G, 2004, NEUROPHARMACOLOGY, V47, P724, DOI 10.1016/j.neuropharm.2004.06.023; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; Persico AM, 2006, TRENDS NEUROSCI, V29, P349, DOI 10.1016/j.tins.2006.05.010; Roussignol G, 2005, J NEUROSCI, V25, P3560, DOI 10.1523/JNEUROSCI.4354-04.2005; Somerville MJ, 2005, NEW ENGL J MED, V353, P1694, DOI 10.1056/NEJMoa051962; Vorstman JAS, 2006, MOL PSYCHIATR, V11, P18, DOI 10.1038/sj.mp.4001757	15	1069	1127	6	142	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2007	39	1					25	27		10.1038/ng1933	http://dx.doi.org/10.1038/ng1933			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17173049	Green Submitted, Green Accepted			2022-12-25	WOS:000243136500013
J	Disanza, A; Mantoani, S; Hertzog, M; Gerboth, S; Frittoli, E; Steffen, A; Berhoerster, K; Kreienkamp, HJ; Milanesi, F; Di Fiore, PP; Ciliberto, A; Stradal, TEB; Scita, G				Disanza, Andrea; Mantoani, Sara; Hertzog, Maud; Gerboth, Silke; Frittoli, Emanuela; Steffen, Anika; Berhoerster, Kerstin; Kreienkamp, Hans-Juergen; Milanesi, Francesca; Di Fiore, Pier Paolo; Ciliberto, Andrea; Stradal, Theresia E. B.; Scita, Giorgio			Regulation of cell shape by Cdc42 is mediated by the synergic actin-bundling activity of the Eps8-IRSp53 complex	NATURE CELL BIOLOGY			English	Article							RECEPTOR TYROSINE KINASE; ENA/VASP PROTEINS; N-WASP; FILOPODIUM FORMATION; FIBROBLAST MOTILITY; CROSS-LINKING; RAC; IRSP53; EPS8; REORGANIZATION	Actin-crosslinking proteins organize actin into highly dynamic and architecturally diverse subcellular scaffolds that orchestrate a variety of mechanical processes, including lamellipodial and filopodial protrusions in motile cells. How signalling pathways control and coordinate the activity of these crosslinkers is poorly defined. IRSp53, a multi-domain protein that can associate with the Rho-GTPases Rac and Cdc42, participates in these processes mainly through its amino-terminal IMD (IRSp53 and MIM domain). The isolated IMD has actin-bundling activity in vitro and is sufficient to induce filopodia in vivo. However, the manner of regulation of this activity in the full-length protein remains largely unknown. Eps8 is involved in actin dynamics through its actin barbed-ends capping activity and its ability to modulate Rac activity. Moreover, Eps8 binds to IRSp53. Here, we describe a novel actin crosslinking activity of Eps8. Additionally, Eps8 activates and synergizes with IRSp53 in mediating actin bundling in vitro, enhancing IRSp53-dependent membrane extensions in vivo. Cdc42 binds to and controls the cellular distribution of the IRSp53-Eps8 complex, supporting the existence of a Cdc42-IRSp53-Eps8 signalling pathway. Consistently, Cdc42-induced filopodia are inhibited following individual removal of either IRSp53 or Eps8. Collectively, these results support a model whereby the synergic bundling activity of the IRSp53-Eps8 complex, regulated by Cdc42, contributes to the generation of actin bundles, thus promoting filopodial protrusions.	IFOM, I-20139 Milan, Italy; Ist Europeo Oncol, Dept Expt Oncol, I-20141 Milan, Italy; German Res Ctr Biotechnol, Signalling & Motil Grp, D-38124 Braunschweig, Germany; Univ Hamburg, Hosp Eppendorf, Inst Human Genet, D-20246 Hamburg, Germany; Univ Milan, Dipartimento Med Chirurg & Odonoiatria, I-20122 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); Helmholtz Association; Helmholtz-Center for Infection Research; University of Hamburg; University of Milan	Scita, G (corresponding author), IFOM, Via Adamello 16, I-20139 Milan, Italy.	giorgio.scita@ifom-ieo-campus.it	Scita, Giorgio/J-9670-2012; Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950; Scita, Giorgio/0000-0001-7984-1889; Stradal, Theresia/0000-0002-0352-9474; Disanza, Andrea/0000-0001-5101-2907; Steffen, Anika/0000-0002-2933-0543				Auerbuch V, 2003, MOL MICROBIOL, V49, P1361, DOI 10.1046/j.1365-2958.2003.03639.x; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Bear JE, 2002, CELL, V109, P509, DOI 10.1016/S0092-8674(02)00731-6; Benesch S, 2005, J CELL SCI, V118, P3103, DOI 10.1242/jcs.02444; Choi J, 2005, J NEUROSCI, V25, P869, DOI 10.1523/JNEUROSCI.3212-04.2005; Connolly BA, 2005, MOL CELL BIOL, V25, P4602, DOI 10.1128/MCB.25.11.4602-4614.2005; Czuchra A, 2005, MOL BIOL CELL, V16, P4473, DOI 10.1091/mbc.E05-01-0061; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; Disanza A, 2005, CELL MOL LIFE SCI, V62, P955, DOI 10.1007/s00018-004-4472-6; Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Funato Y, 2004, CANCER RES, V64, P5237, DOI 10.1158/0008-5472.CAN-04-0327; Govind S, 2001, J CELL BIOL, V152, P579, DOI 10.1083/jcb.152.3.579; Innocenti M, 2005, NAT CELL BIOL, V7, P969, DOI 10.1038/ncb1304; Innocenti M, 2004, NAT CELL BIOL, V6, P319, DOI 10.1038/ncb1105; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Innocenti M, 2002, J CELL BIOL, V156, P125, DOI 10.1083/jcb.200108035; KOLESKO AJ, 2003, SCI STKE PE20; Kovar DR, 2006, CELL, V124, P423, DOI 10.1016/j.cell.2005.11.038; Krause M, 2002, J CELL SCI, V115, P4721, DOI 10.1242/jcs.00218; Kreis T., 1999, GUIDEBOOK CYTOSKELET, V2nd; Krugmann S, 2001, CURR BIOL, V11, P1645, DOI 10.1016/S0960-9822(01)00506-1; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; Mangan S, 2003, P NATL ACAD SCI USA, V100, P11980, DOI 10.1073/pnas.2133841100; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Miki H, 2002, BIOCHEM BIOPH RES CO, V293, P93, DOI 10.1016/S0006-291X(02)00218-8; Millard TH, 2005, EMBO J, V24, P240, DOI 10.1038/sj.emboj.7600535; Mogilner A, 2005, BIOPHYS J, V89, P782, DOI 10.1529/biophysj.104.056515; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Nakagawa H, 2003, J CELL SCI, V116, P2577, DOI 10.1242/jcs.00462; Offenhauser N, 2004, MOL BIOL CELL, V15, P91, DOI 10.1091/mbc.E03-06-0427; Pantaloni D, 2001, SCIENCE, V292, P1502, DOI 10.1126/science.1059975; Pollard TD, 2004, DEV CELL, V6, P312, DOI 10.1016/S1534-5807(04)00073-5; Pollard TD, 2003, NATURE, V422, P741, DOI 10.1038/nature01598; Revenu C, 2004, NAT REV MOL CELL BIO, V5, P635, DOI 10.1038/nrm1437; Romero S, 2004, CELL, V119, P419, DOI 10.1016/j.cell.2004.09.039; Rottner K, 1999, NAT CELL BIOL, V1, P321, DOI 10.1038/13040; Samarin S, 2003, J CELL BIOL, V163, P131, DOI 10.1083/jcb.200303191; Schirenbeck A, 2005, BIOCHEM SOC T, V33, P1256, DOI 10.1042/BST0331256; Schirenbeck A, 2006, P NATL ACAD SCI USA, V103, P7694, DOI 10.1073/pnas.0511243103; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Stradal T, 2001, CURR BIOL, V11, P891, DOI 10.1016/S0960-9822(01)00239-1; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Tilney LG, 2000, J CELL SCI, V113, P1255; Tilney LG, 1998, J CELL BIOL, V143, P121, DOI 10.1083/jcb.143.1.121; TILNEY LG, 1995, J CELL BIOL, V130, P629, DOI 10.1083/jcb.130.3.629; Tseng Y, 2005, BIOCHEM BIOPH RES CO, V334, P183, DOI 10.1016/j.bbrc.2005.05.205; Tseng Y, 2002, J BIOL CHEM, V277, P25609, DOI 10.1074/jbc.M202609200; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; Wu XW, 2006, GENE DEV, V20, P571, DOI 10.1101/gad.361406; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200; Yeh TC, 1996, J BIOL CHEM, V271, P2921, DOI 10.1074/jbc.271.6.2921	52	172	183	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1337	U15		10.1038/ncb1502	http://dx.doi.org/10.1038/ncb1502			19	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17115031				2022-12-25	WOS:000242419800009
J	Dorus, S; Busby, SA; Gerike, U; Shabanowitz, J; Hunt, DF; Karr, TL				Dorus, Steve; Busby, Scott A.; Gerike, Ursula; Shabanowitz, Jeffrey; Hunt, Donald F.; Karr, Timothy L.			Genomic and functional evolution of the Drosophila melanogaster sperm proteome	NATURE GENETICS			English	Article							REPRODUCTIVE PROTEINS; MOLECULAR EVOLUTION; GENES; EXPRESSION; SUBSTITUTION; CHROMOSOME; DATABASE; TESTIS; RATES	In addition to delivering a haploid genome to the egg, sperm have additional critical functions, including egg activation, origination of the zygote centrosome and delivery of paternal factors(1,2). Despite this, existing knowledge of the molecular basis of sperm form and function is limited. We used whole-sperm mass spectrometry to identify 381 proteins of the Drosophila melanogaster sperm proteome (DmSP). This approach identified mitochondrial, metabolic and cytoskeletal proteins, in addition to several new functional categories. We also observed nonrandom genomic clustering of sperm genes and underrepresentation on the X chromosome. Identification of widespread functional constraint on the proteome indicates that sexual selection has had a limited role in the overall evolution of D. melanogaster sperm. The relevance of the DmSP to the study of mammalian sperm function and fertilization mechanisms is demonstrated by the identification of substantial homology between the DmSP and proteins of the mouse axoneme accessory structure.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22904 USA	University of Bath; University of Virginia; University of Virginia	Karr, TL (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	T.L.Karr@bath.ac.uk	Hunt, Donald F/I-6936-2012; Karr, Timothy L/G-1693-2011	Hunt, Donald F/0000-0003-2815-6368; 	NIGMS NIH HHS [F32 GM076913] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boutanaev AM, 2002, NATURE, V420, P666, DOI 10.1038/nature01216; Cao WL, 2006, MOL CELL PROTEOMICS, V5, P801, DOI 10.1074/mcp.M500322-MCP200; Challapalli KK, 2004, ELECTROPHORESIS, V25, P3040, DOI 10.1002/elps.200405979; Clark NL, 2005, PLOS GENET, V1, P335, DOI 10.1371/journal.pgen.0010035; Duret L, 2000, MOL BIOL EVOL, V17, P68, DOI 10.1093/oxfordjournals.molbev.a026239; Fay JC, 2002, NATURE, V415, P1024, DOI 10.1038/4151024a; Fernandez D, 2002, PEPTIDES, V23, P461, DOI 10.1016/S0196-9781(01)00622-2; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; Jamieson B.G.M., 1999, INSECTS THEIR SPERMA; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; LI WH, 1993, J MOL EVOL, V36, P96, DOI 10.1007/BF02407308; Loppin B, 2005, CURR BIOL, V15, P87, DOI 10.1016/j.cub.2004.12.071; LOPPIN B, 2004, CO0MPREHENSIVE INSEC; Lu AQ, 2000, MECH DEVELOP, V94, P171, DOI 10.1016/S0925-4773(00)00262-8; Mitchell BF, 2005, MOL BIOL CELL, V16, P4509, DOI 10.1091/mbc.E05-04-0347; Mueller JL, 2005, GENETICS, V171, P131, DOI 10.1534/genetics.105.043844; Nurminsky DI, 1998, NATURE, V396, P572, DOI 10.1038/25126; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Parisi M, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-6-r40; Parisi M, 2003, SCIENCE, V299, P697, DOI 10.1126/science.1079190; Parsch J, 2001, MOL BIOL EVOL, V18, P801, DOI 10.1093/oxfordjournals.molbev.a003862; Perotti ME, 2001, MOL REPROD DEV, V60, P248, DOI 10.1002/mrd.1085; Sardiello M, 2003, NUCLEIC ACIDS RES, V31, P322, DOI 10.1093/nar/gkg123; Snook RR, 2000, GENETICS, V155, P167; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; Swanson WJ, 2001, P NATL ACAD SCI USA, V98, P7375, DOI 10.1073/pnas.131568198; Togo T, 2004, MOL REPROD DEV, V67, P465, DOI 10.1002/mrd.20037; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Yeh SD, 2002, J BIOL CHEM, V277, P6311, DOI 10.1074/jbc.M106941200; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G	30	208	208	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2006	38	12					1440	1445		10.1038/ng1915	http://dx.doi.org/10.1038/ng1915			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17099714				2022-12-25	WOS:000242404200023
J	Cai, ST; Lee, CC; Kohwi-Shigematsu, T				Cai, Shutao; Lee, Charles C.; Kohwi-Shigematsu, Terumi			SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes	NATURE GENETICS			English	Article							GLOBIN LOCUS REQUIRES; MAR-BINDING PROTEIN; HISTONE ACETYLATION; IN-VIVO; DIFFERENTIATION; CELLS; IDENTIFICATION; CONFORMATION; ORGANIZATION; SUFFICIENT	SATB1 (special AT-rich sequence binding protein 1) organizes cell type-specific nuclear architecture by anchoring specialized DNA sequences and recruiting chromatin remodeling factors to control gene transcription. We studied the role of SATB1 in regulating the coordinated expression of Il5, Il4 and Il13, located in the 200-kb T-helper 2 (T(H)2) cytokine locus on mouse chromosome 11. We show that on T(H)2 cell activation, SATB1 expression is rapidly induced to form a unique transcriptionally active chromatin structure at the cytokine locus. In this structure, chromatin is folded into numerous small loops, all anchored to SATB1 at their base. In addition, histone H3 is acetylated at Lys9 and Lys14, and the T(H)2-specific factors GATA3, STAT6 and c-Maf, the chromatin-remodeling enzyme Brg1 and RNA polymerase II are all bound across the 200-kb region. Before activation, the TH2 cytokine locus is already associated with GATA3 and STAT6, showing some looping, but these are insufficient to induce cytokine gene expression. Using RNA interference, we show that on cell activation, SATB1 is required not only for compacting chromatin into dense loops at the 200-kb cytokine locus but also for inducing Il4, Il5, Il13 and c-Maf expression. Thus, SATB1 is a necessary determinant for the hitherto unidentified higher-order, transcriptionally active chromatin structure that forms on TH2 cell activation.	Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kohwi-Shigematsu, T (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA.	terumiks@lbl.gov						Alvarez JD, 2000, GENE DEV, V14, P521; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Baguet A, 2004, P NATL ACAD SCI USA, V101, P11410, DOI 10.1073/pnas.0403334101; Britanova O, 2005, EUR J NEUROSCI, V21, P658, DOI 10.1111/j.1460-9568.2005.03897.x; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Cook PR, 2002, NAT GENET, V32, P347, DOI 10.1038/ng1102-347; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Dobreva G, 2006, CELL, V125, P971, DOI 10.1016/j.cell.2006.05.012; Drissen R, 2004, GENE DEV, V18, P2485, DOI 10.1101/gad.317004; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Fields PE, 2002, J IMMUNOL, V169, P647, DOI 10.4049/jimmunol.169.2.647; Glimcher LH, 2000, GENE DEV, V14, P1693; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hager GL, 2006, CHROMOSOME RES, V14, P107, DOI 10.1007/s10577-006-1030-0; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kohwi-Shigematsu T, 1998, METHOD CELL BIOL, V53, P323; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; Kosak ST, 2004, GENE DEV, V18, P1371, DOI 10.1101/gad.1209304; Kurata H, 1999, IMMUNITY, V11, P677, DOI 10.1016/S1074-7613(00)80142-9; Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103; Lee CC, 2003, PHOTOCH PHOTOBIO SCI, V2, P145, DOI 10.1039/b207598a; Lee CD, 2002, MRS INTERNET J N S R, V7; Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191; Liu Z, 2005, MOL CELL BIOL, V25, P3220, DOI 10.1128/MCB.25.8.3220-3231.2005; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Makar KW, 2003, NAT IMMUNOL, V4, P1183, DOI 10.1038/ni1004; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Paddison PJ, 2004, NAT METHODS, V1, P163, DOI 10.1038/nmeth1104-163; Palstra RJ, 2003, NAT GENET, V35, P190, DOI 10.1038/ng1244; Pavan KP, 2006, MOL CELL, V22, P231, DOI 10.1016/j.molcel.2006.03.010; Smale ST, 2002, ANNU REV IMMUNOL, V20, P427, DOI 10.1146/annurev.immunol.20.100301.064739; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Wen J, 2005, BLOOD, V105, P3330, DOI 10.1182/blood-2004-08-2988; Wilson CB, 2005, SEMIN IMMUNOL, V17, P105, DOI 10.1016/j.smim.2005.01.005; Wurtele H, 2006, CHROMOSOME RES, V14, P477, DOI 10.1007/s10577-006-1075-0; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu JF, 2001, J IMMUNOL, V166, P7276, DOI 10.4049/jimmunol.166.12.7276	50	425	447	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1278	1288		10.1038/ng1913	http://dx.doi.org/10.1038/ng1913			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17057718	Green Submitted			2022-12-25	WOS:000241592700016
J	Gouon-Evans, V; Boussemart, L; Gadue, P; Nierhoff, D; Koehler, CI; Kubo, A; Shafritz, DA; Keller, G				Gouon-Evans, Valerie; Boussemart, Lise; Gadue, Paul; Nierhoff, Dirk; Koehler, Christoph I.; Kubo, Atsushi; Shafritz, David A.; Keller, Gordon			BMP-4 is required for hepatic specification of mouse embryonic stem cell-derived definitive endoderm	NATURE BIOTECHNOLOGY			English	Article							LIVER DEVELOPMENT; RAT-LIVER; HEPATOCYTE DIFFERENTIATION; TRANSCRIPTION FACTOR; EXPRESSION PATTERNS; ALPHA-FETOPROTEIN; PROGENITOR CELLS; GUT ENDODERM; FETAL LIVER; IN-VITRO	When differentiated in the presence of activin A in serum-free conditions, mouse embryonic stem cells efficiently generate an endoderm progenitor population defined by the coexpression of either Brachyury, Foxa2 and c- Kit, or c- Kit and Cxcr4. Specification of these progenitors with bone morphogenetic protein- 4 in combination with basic fibroblast growth factor and activin A results in the development of hepatic populations highly enriched ( 45 - 70%) for cells that express the alpha- fetoprotein and albumin proteins. These cells also express transcripts of Afp, Alb1, Tat, Cps1, Cyp7a1 and Cyp3a11; they secrete albumin, store glycogen, show ultrastructural characteristics of mature hepatocytes, and are able to integrate into and proliferate in injured livers in vivo and mature into hepatocytes expressing dipeptidyl peptidase IV or fumarylacetoacetate hydrolase. Together, these findings establish a developmental pathway in embryonic stem cell differentiation cultures that leads to efficient generation of cells with an immature hepatocytic phenotype.	CUNY Mt Sinai Sch Med, Dept Gene & Cell Med, Black Family Stem Cell Inst, New York, NY 10029 USA; Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Univ Cologne, Dept Gastroenterol & Hepatol, D-5000 Cologne 41, Germany	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Yeshiva University; Albert Einstein College of Medicine; University of Cologne	Keller, G (corresponding author), CUNY Mt Sinai Sch Med, Dept Gene & Cell Med, Black Family Stem Cell Inst, 1425 Masidon Ave, New York, NY 10029 USA.	gordon.keller@mssm.edu		Keller, Gordon/0000-0001-9309-9297; Boussemart, Lise/0000-0003-0935-3358; Gouon-Evans, Valerie/0000-0001-5424-6573	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL076058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017609, K01DK068041, P30DK041296, U01DK072513] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL076058] Funding Source: Medline; NIDDK NIH HHS [U01 DK072513, R01-DK17609, P30-DK41296, K01DK068041-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asahina K, 2004, GENES CELLS, V9, P1297, DOI 10.1111/j.1365-2443.2004.00809.x; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133; Brennan J, 2001, NATURE, V411, P965, DOI 10.1038/35082103; CASCIO S, 1991, DEVELOPMENT, V113, P217; CONLON FL, 1994, DEVELOPMENT, V120, P1919; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; Dabeva MD, 2000, AM J PATHOL, V156, P2017, DOI 10.1016/S0002-9440(10)65074-2; DZIADEK MA, 1983, EMBO J, V2, P549, DOI 10.1002/j.1460-2075.1983.tb01461.x; GADUE P, IN PRESS P NATL ASS; GERMAIN L, 1988, CANCER RES, V48, P4909; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; Gu DQ, 2002, TRANSPLANTATION, V73, P1818, DOI 10.1097/00007890-200206150-00020; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; GUZ Y, 1995, DEVELOPMENT, V121, P11; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; KAESTNER KH, 1994, GENOMICS, V20, P377, DOI 10.1006/geno.1994.1191; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Kawashita Y, 2005, SURG TODAY, V35, P705, DOI 10.1007/s00595-005-3024-5; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; Laconi E, 1998, AM J PATHOL, V153, P319, DOI 10.1016/S0002-9440(10)65574-5; Lavon N, 2005, J CELL BIOCHEM, V96, P1193, DOI 10.1002/jcb.20590; Lemaigre F, 2004, CURR OPIN GENET DEV, V14, P582, DOI 10.1016/j.gde.2004.08.004; Lillie RD, 1976, HISTOPATHOLOGIC TECH, V4th; Lowe LA, 2001, DEVELOPMENT, V128, P1831; Martin CA, 2001, APPL IMMUNOHISTO M M, V9, P70, DOI 10.1097/00022744-200103000-00013; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Minguet S, 2003, J CLIN INVEST, V112, P1152, DOI 10.1172/JCI200317409; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; Neufeld D S, 1997, Methods Mol Biol, V75, P145; Nierhoff D, 2005, HEPATOLOGY, V42, P130, DOI 10.1002/hep.20735; Nitou M, 2002, EXP CELL RES, V279, P330, DOI 10.1006/excr.2002.5615; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; Reedy MV, 2003, GENE EXPR PATTERNS, V3, P53, DOI 10.1016/S1567-133X(02)00072-8; Rossi JM, 2001, GENE DEV, V15, P1998, DOI 10.1101/gad.904601; SHIOJIRI N, 1991, CANCER RES, V51, P2611; SIGAL SH, 1994, HEPATOLOGY, V19, P999; Suzuki A, 2000, HEPATOLOGY, V32, P1230, DOI 10.1053/jhep.2000.20349; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005; Vincent SD, 2003, GENE DEV, V17, P1646, DOI 10.1101/gad.1100503; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; Willenbring H, 2004, NAT MED, V10, P744, DOI 10.1038/nm1062; Yasunaga M, 2005, NAT BIOTECHNOL, V23, P1542, DOI 10.1038/nbt1167; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231; Zaret KS, 2001, CURR OPIN GENET DEV, V11, P568, DOI 10.1016/S0959-437X(00)00234-3	51	308	336	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2006	24	11					1402	1411		10.1038/nbt1258	http://dx.doi.org/10.1038/nbt1258			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	106TP	17086172				2022-12-25	WOS:000242124700037
J	Sung, LY; Gao, SR; Shen, HM; Yu, H; Song, YF; Smith, SL; Chang, CC; Inoue, K; Kuo, L; Lian, J; Li, A; Tian, XC; Tuck, DP; Weissman, SM; Yang, XZ; Cheng, T				Sung, Li-Ying; Gao, Shaorong; Shen, Hongmei; Yu, Hui; Song, Yifang; Smith, Sadie L.; Chang, Ching-Chien; Inoue, Kimiko; Kuo, Lynn; Lian, Jin; Li, Ao; Tian, X. Cindy; Tuck, David P.; Weissman, Sherman M.; Yang, Xiangzhong; Cheng, Tao			Differentiated cells are more efficient than adult stem cells for cloning by somatic cell nuclear transfer	NATURE GENETICS			English	Article							CLONED MICE; P21(CIP1/WAF1); P18(INK4C); GENOME; MOUSE	Since the creation of Dolly via somatic cell nuclear transfer (SCNT) 1, more than a dozen species of mammals have been cloned using this technology(2). One hypothesis for the limited success of cloning via SCNT (1%-5%) 3 is that the clones are likely to be derived from adult stem cells(4). Support for this hypothesis comes from the findings that the reproductive cloning efficiency for embryonic stem cells is five to ten times higher than that for somatic cells as donors(5,6) and that cloned pups cannot be produced directly from cloned embryos derived from differentiated B and T cells or neuronal cells(7-10). The question remains as to whether SCNT-derived animal clones can be derived from truly differentiated somatic cells. We tested this hypothesis with mouse hematopoietic cells at different differentiation stages: hematopoietic stem cells, progenitor cells and granulocytes. We found that cloning efficiency increases over the differentiation hierarchy, and terminally differentiated postmitotic granulocytes yield cloned pups with the greatest cloning efficiency.	Univ Pittsburgh, Inst Canc, Canc Stem Cell Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Radiat Oncol, Pittsburgh, PA 15213 USA; Univ Connecticut, Ctr Regenerat Biol, Storrs, CT 06269 USA; Univ Connecticut, Dept Anim Sci, Storrs, CT 06269 USA; Univ Connecticut, Dept Stat, Storrs, CT 06269 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Connecticut; University of Connecticut; University of Connecticut; Yale University; Yale University	Yang, XZ (corresponding author), Univ Pittsburgh, Inst Canc, Canc Stem Cell Program, Pittsburgh, PA 15213 USA.	xiangzhong.yang@uconn.edu; chengt@upmc.edu	Li, aoyu/GXV-4925-2022; Pillay, Nischalan/F-9536-2012; Li, Ao/GRR-5311-2022; Kuo, Lynn/AAQ-6409-2021	Kuo, Lynn/0000-0002-1903-4425; SUNG, LI-YING/0000-0003-1221-2476; Cheng, Tao/0000-0002-5925-2769; Marjani, Sadie/0000-0003-1241-8538	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI080424] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70561, R01 HL070561-05A2, R01 HL070561] Funding Source: Medline; NIAID NIH HHS [R01 AI080424] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blelloch R, 2006, STEM CELLS, V24, P2007, DOI 10.1634/stemcells.2006-0050; Campbell K H, 1999, Cloning, V1, P3, DOI 10.1089/15204559950020058; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Eggan E, 2004, NATURE, V428, P44, DOI 10.1038/nature02375; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Gao SR, 2003, CLONING STEM CELLS, V5, P287, DOI 10.1089/153623003772032790; Gao SR, 2003, BIOL REPROD, V68, P595, DOI 10.1095/biolreprod.102.005819; Hochedlinger K, 2002, NATURE, V415, P1035, DOI 10.1038/nature718; Hochedlinger K, 2002, CURR OPIN CELL BIOL, V14, P741, DOI 10.1016/S0955-0674(02)00380-0; Humpherys D, 2001, SCIENCE, V293, P95, DOI 10.1126/science.1061402; Inoue K, 2005, CURR BIOL, V15, P1114, DOI 10.1016/j.cub.2005.05.021; Inoue K, 2006, J CELL SCI, V119, P1985, DOI 10.1242/jcs.02913; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Li JS, 2005, CURR BIOL, V15, pR756, DOI 10.1016/j.cub.2005.09.010; Li JS, 2004, NATURE, V428, P393, DOI 10.1038/nature02433; Molofsky AV, 2004, CURR OPIN CELL BIOL, V16, P700, DOI 10.1016/j.ceb.2004.09.004; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Smith AL, 2005, J GERONTOL A-BIOL, V60, P448, DOI 10.1093/gerona/60.4.448; Smyth MJ, 2005, J EXP MED, V201, P1973, DOI 10.1084/jem.20042280; Takano H, 2004, J EXP MED, V199, P295, DOI 10.1084/jem.20030929; Tian X Cindy, 2003, Reprod Biol Endocrinol, V1, P98, DOI 10.1186/1477-7827-1-98; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Yanagimachi R, 2002, MOL CELL ENDOCRINOL, V187, P241, DOI 10.1016/S0303-7207(01)00697-9; Yu H, 2006, BLOOD, V107, P1200, DOI 10.1182/blood-2005-02-0685; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126	30	89	103	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1323	1328		10.1038/ng1895	http://dx.doi.org/10.1038/ng1895			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17013394				2022-12-25	WOS:000241592700022
J	Bergamaschi, D; Samuels, Y; Sullivan, A; Zvelebil, M; Breyssens, H; Bisso, A; Del Sal, G; Syed, N; Smith, P; Gasco, M; Crook, T; Lu, X				Bergamaschi, Daniele; Samuels, Yardena; Sullivan, Alexandra; Zvelebil, Marketa; Breyssens, Hilde; Bisso, Andrea; Del Sal, Giannino; Syed, Nelofer; Smith, Paul; Gasco, Milena; Crook, Tim; Lu, Xin			iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72 polymorphic p53	NATURE GENETICS			English	Article							TUMOR-SUPPRESSOR; MESSENGER-RNA; ETHNIC-GROUPS; CANCER RISK; EXPRESSION; DOMAIN; ASPP2; IDENTIFICATION; ASSOCIATION; HAPLOTYPES	iASPP is one of the most evolutionarily conserved inhibitors of p53, whereas ASPP1 and ASPP2 are activators of p53. We show here that, in addition to the DNA-binding domain, the ASPP family members also bind to the proline-rich region of p53, which contains the most common p53 polymorphism at codon 72. Furthermore, the ASPP family members, particularly iASPP, bind to and regulate the activity of p53Pro72 more efficiently than that of p53Arg72. Hence, escape from negative regulation by iASPP is a newly identified mechanism by which p53Arg72 activates apoptosis more efficiently than p53Pro72.	UCL, Ludwig Inst Canc Res, London W1W 7BS, England; Univ Trieste, LNCIB, I-34100 Trieste, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy; Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, Lab Canc Genet & Epigenet, Chester Beatty Labs, London SW3 6JB, England; S Croce & Carle Hosp, Dept Med Oncol, I-12100 Cuneo, Italy	Ludwig Institute for Cancer Research; University of London; University College London; University of Trieste; University of Trieste; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Lu, X (corresponding author), UCL, Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	x.lu@ludwig.ucl.ac.uk		Bisso, Andrea/0000-0002-7158-8740; DEL SAL, GIANNINO/0000-0003-2185-6003; Samuels, Yardena/0000-0002-3349-7266; Bergamaschi, Daniele/0000-0002-3955-1091; Zvelebil, Marketa/0000-0001-8018-5591; Lu, Xin/0000-0002-6587-1152	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Agirre X, 2006, ONCOGENE, V25, P1862, DOI 10.1038/sj.onc.1209236; Agorastos T, 2004, EUR J CANCER PREV, V13, P277, DOI 10.1097/01.cej.0000136717.95465.09; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Cenci M, 2003, ANTICANCER RES, V23, P1385; D'Erchia AM, 1999, GENOMICS, V58, P50, DOI 10.1006/geno.1999.5794; de Oliveira WRP, 2004, INT J DERMATOL, V43, P489, DOI 10.1111/j.1365-4632.2004.02289.x; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gostissa M, 2004, J BIOL CHEM, V279, P48013, DOI 10.1074/jbc.M310801200; Granja F, 2004, CANCER LETT, V210, P151, DOI 10.1016/j.canlet.2004.01.016; IWABUCHI K, 1993, ONCOGENE, V8, P1693; Liu ZJ, 2004, LEUKEMIA, V18, P880, DOI 10.1038/sj.leu.2403300; Lossos IS, 2002, LEUKEMIA LYMPHOMA, V43, P2309, DOI 10.1080/1042819021000040017; Matakidou A, 2003, MUTAGENESIS, V18, P377, DOI 10.1093/mutage/geg008; Noma C, 2004, CANCER LETT, V210, P197, DOI 10.1016/j.canlet.2004.03.031; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Siddique MM, 2005, CANCER EPIDEM BIOMAR, V14, P2245, DOI 10.1158/1055-9965.EPI-05-0153; Sjalander A, 1996, HUM HERED, V46, P41, DOI 10.1159/000154324; SJALANDER A, 1995, HUM HERED, V45, P144, DOI 10.1159/000154275; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; SLEE EA, 2004, ONCOGENE; Trigiante G, 2006, NAT REV CANCER, V6, P217, DOI 10.1038/nrc1818; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vives V, 2006, GENE DEV, V20, P1262, DOI 10.1101/gad.374006; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Zhang XW, 2005, LEUKEMIA RES, V29, P179, DOI 10.1016/j.leukres.2004.07.001; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	30	205	217	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1133	1141		10.1038/ng1879	http://dx.doi.org/10.1038/ng1879			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16964264				2022-12-25	WOS:000241251100012
J	Gutierrez-Marcos, JF; Costa, LM; Dal Pra, M; Scholten, S; Kranz, E; Perez, P; Dickinson, HG				Gutierrez-Marcos, Jose F.; Costa, Liliana M.; Dal Pra, Mauro; Scholten, Stefan; Kranz, Erhard; Perez, Pascual; Dickinson, Hugh G.			Epigenetic asymmetry of imprinted genes in plant gametes	NATURE GENETICS			English	Article							DNA METHYLATION; ARABIDOPSIS-THALIANA; POLYCOMB GENE; GLYCOSYLASE; ENDOSPERM; MEDEA; EXPRESSION; DEMETER; PROTEIN; GENOME	Plant imprinted genes show parent-of-origin expression in seed endosperm, but little is known about the nature of parental imprints in gametes before fertilization. We show here that single differentially methylated regions (DMRs) correlate with allele-specific expression of two maternally expressed genes in the seed and that one DMR is differentially methylated between gametes. Thus, plants seem to have developed similar strategies as mammals to epigenetically mark imprinted genes.	Univ Oxford, Dept Plant Sci, Oxford OX1 3RB, England; Univ Hamburg, Biozentrum Klein Flottbek, D-22609 Hamburg, Germany; Univ Hamburg, Bot Garten, D-22609 Hamburg, Germany; Biogemma, F-63170 Clermont Ferrand, France	University of Oxford; University of Hamburg; University of Hamburg	Gutierrez-Marcos, JF (corresponding author), Univ Oxford, Dept Plant Sci, S Parks Rd, Oxford OX1 3RB, England.	jose.gutierrez@plants.ox.ac.uk	Gutierrez-Marcos, Jose/AAE-2229-2020	Gutierrez-Marcos, Jose/0000-0002-5441-9080				Baroux U, 2006, GENE DEV, V20, P1081, DOI 10.1101/gad.378106; Chan SWL, 2005, NAT REV GENET, V6, P351, DOI 10.1038/nrg1601; Choi YH, 2002, CELL, V110, P33, DOI 10.1016/S0092-8674(02)00807-3; Danilevskaya ON, 2003, PLANT CELL, V15, P425, DOI 10.1105/tpc.006759; Gehring M, 2006, CELL, V124, P495, DOI 10.1016/j.cell.2005.12.034; Gutierrez-Marcos JF, 2003, PHILOS T ROY SOC B, V358, P1105, DOI 10.1098/rstb.2003.1292; Jullien PE, 2006, CURR BIOL, V16, P486, DOI 10.1016/j.cub.2006.01.020; JULLIEN PE, 2006, PLANT CELL; Kinoshita T, 2004, SCIENCE, V303, P521, DOI 10.1126/science.1089835; Kohler C, 2005, NAT GENET, V37, P28, DOI 10.1038/ng1495; Lewis A, 2004, NAT GENET, V36, P1291, DOI 10.1038/ng1468; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Saze H, 2003, NAT GENET, V34, P65, DOI 10.1038/ng1138; Xiao WY, 2003, DEV CELL, V5, P891, DOI 10.1016/S1534-5807(03)00361-7; Yadegari R, 2000, PLANT CELL, V12, P2367, DOI 10.1105/tpc.12.12.2367	15	121	133	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2006	38	8					876	878		10.1038/ng1828	http://dx.doi.org/10.1038/ng1828			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16823380				2022-12-25	WOS:000239325700015
J	Liu, PY; Wang, Y; Vikis, H; Maciag, A; Wang, DL; Lu, Y; Liu, Y; You, M				Liu, Pengyuan; Wang, Yian; Vikis, Haris; Maciag, Anna; Wang, Daolong; Lu, Yan; Liu, Yan; You, Ming			Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice	NATURE GENETICS			English	Article							PULMONARY ADENOMA; LABORATORY MICE; FAMILY HISTORY; CANCER; MOUSE; COMPLEXITY; GENETICS; LOCUS; LINES	We performed a whole-genome association analysis of lung tumor susceptibility using dense SNP maps (similar to 1 SNP per 20 kb) in inbred mice. We reproduced the pulmonary adenoma susceptibility 1 (Pas1) locus identified in previous linkage studies and further narrowed this quantitative trait locus (QTL) to a region of less than 0.5 Mb in which at least two genes, Kras2 (Kirsten rat sarcoma oncogene 2) and Casc1 (cancer susceptibility candidate 1; also known as Las1), are strong candidates. Casc1 knockout mouse tumor bioassays showed that Casc1-deficient mice were susceptible to chemical induction of lung tumors. We also found three more genetic loci for lung adenoma development. Analysis of one of these candidate loci identified a previously uncharacterized gene Lasc1, bearing a nonsynonymous substitution (D102E). We found that the Lasc1 Glu102 allele preferentially promotes lung tumor cell growth. Our findings demonstrate the prospects for using dense SNP maps in laboratory mice to refine previous QTL regions and identify genetic determinants of complex traits.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA099147, R01CA099187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012063, R01ES013340] Funding Source: NIH RePORTER; NCI NIH HHS [CA099147, CA099187] Funding Source: Medline; NIEHS NIH HHS [ES013340, ES012063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; CHURCHILL GA, 1994, GENETICS, V138, P963; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; Festing MFW, 1998, GENOMICS, V53, P129, DOI 10.1006/geno.1998.5450; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HEDRICK PW, 1987, GENETICS, V117, P331; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Jin YJ, 2003, J BIOL CHEM, V278, P51587, DOI 10.1074/jbc.M309165200; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; McDoniels-Silvers AL, 2001, EXP LUNG RES, V27, P297, DOI 10.1080/019021401300054064; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; SELLERS TA, 1992, CANCER, V69, P86, DOI 10.1002/1097-0142(19920101)69:1<86::AID-CNCR2820690116>3.0.CO;2-S; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SELLERS TA, 1991, GENET EPIDEMIOL, V8, P199, DOI 10.1002/gepi.1370080306; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; Wade CM, 2005, NAT GENET, V37, P1175, DOI 10.1038/ng1666; Wang M, 2003, CANCER RES, V63, P3317; Yalcin B, 2004, P NATL ACAD SCI USA, V101, P9734, DOI 10.1073/pnas.0401189101; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	25	63	63	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2006	38	8					888	895		10.1038/ng1849	http://dx.doi.org/10.1038/ng1849			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16862160				2022-12-25	WOS:000239325700017
J	Margolin, Y; Cloutier, JF; Shafirovich, V; Geacintov, NE; Dedon, PC				Margolin, Yelena; Cloutier, Jean-Francois; Shafirovich, Vladimir; Geacintov, Nicholas E.; Dedon, Peter C.			Paradoxical hotspots for guanine oxidation by a chemical mediator of inflammation	NATURE CHEMICAL BIOLOGY			English	Article							ONE-ELECTRON OXIDATION; DNA-DAMAGE; GENOMIC DNA	Guanine in DNA is a major oxidation target owing to its low ionization potential (IP), and there is often an inverse correlation between damage frequency and sequence-dependent variation in guanine IP. We report that the biological oxidant nitrosoperoxycarbonate (ONOOCO2-) paradoxically selects guanines with the highest IP in GC-containing contexts. Along with sequence-dependent variation in damage chemistry, this behavior points to factors other than charge migration as determinants of genomic DNA oxidation.	MIT, Biol Engn Div, Cambridge, MA 02139 USA; NYU, Dept Chem, New York, NY 10003 USA; NYU, Radiat & Solid State Lab, New York, NY 10003 USA	Massachusetts Institute of Technology (MIT); New York University; New York University	Dedon, PC (corresponding author), MIT, Biol Engn Div, Cambridge, MA 02139 USA.	pcdedon@mit.edu		Dedon, Peter/0000-0003-0011-3067	NCI NIH HHS [CA110261, CA026731] Funding Source: Medline; NIEHS NIH HHS [ES002109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA026731, R01CA110261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Cloutier JF, 2001, J MOL BIOL, V313, P539, DOI 10.1006/jmbi.2001.4997; Dedon PC, 2004, ARCH BIOCHEM BIOPHYS, V423, P12, DOI 10.1016/j.abb.2003.12.017; Dong M, 2006, MUTAT RES-FUND MOL M, V594, P120, DOI 10.1016/j.mrfmmm.2005.08.008; Douki T, 1996, FREE RADICAL RES, V24, P369, DOI 10.3109/10715769609088035; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; Joffe A, 2003, CHEM RES TOXICOL, V16, P1528, DOI 10.1021/tx034142t; Ly D, 1996, J AM CHEM SOC, V118, P8747, DOI 10.1021/ja9615785; Misiaszek R, 2005, J AM CHEM SOC, V127, P2191, DOI 10.1021/ja044390r; Ravanat JL, 2003, J AM CHEM SOC, V125, P2030, DOI 10.1021/ja028608q; Rodriguez H, 1999, BIOCHEMISTRY-US, V38, P16578, DOI 10.1021/bi9918994; Saito I, 1998, J AM CHEM SOC, V120, P12686, DOI 10.1021/ja981888i; Shafirovich V, 2001, J BIOL CHEM, V276, P24621, DOI 10.1074/jbc.M101131200; Spassky A, 1997, BIOCHEMISTRY-US, V36, P6571, DOI 10.1021/bi962761d; Tretyakova NY, 2000, MUTAT RES-FUND MOL M, V447, P287, DOI 10.1016/S0027-5107(99)00221-3	14	52	52	1	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2006	2	7					365	366		10.1038/nchembio796	http://dx.doi.org/10.1038/nchembio796			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	054KV	16751762				2022-12-25	WOS:000238376400009
J	Weirich, CS; Erzberger, JP; Flick, JS; Berger, JM; Thorner, J; Weis, K				Weirich, Christine S.; Erzberger, Jan P.; Flick, Jeffrey S.; Berger, James M.; Thorner, Jeremy; Weis, Karsten			Activation of the DExD/H-box protein Dbp5 by the nuclear-pore protein Gle1 and its coactivator InsP(6) is required for mRNA export	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; INOSITOL HEXAKISPHOSPHATE; CYTOPLASMIC FIBRILS; NUCLEOPORIN RIP1P; PHOSPHOLIPASE-C; TELOMERE LENGTH; POLY(A)(+) RNA; DNA-PK; YEAST	The DExD/H-box ATPase Dbp5 is essential for nuclear mRNA export, although its precise role in this process remains poorly understood. Here, we identify the nuclear pore protein Gle1 as a cellular activator of Dbp5. Dbp5 alone is unable to stably bind RNA or effectively hydrolyse ATP under physiological conditions, but addition of Gle1 dramatically stimulates these activities. A gle1 point mutant deficient for Dbp5 stimulation in vitro displays an mRNA export defect in vivo, indicating that activation of Dbp5 is an essential function of Gle1. Interestingly, Gle1 binds directly to inositol hexakisphosphate ( InsP(6)) and InsP(6) potentiates the Gle1-mediated stimulation of Dbp5. Dominant mutations in DBP5 and GLE1 that rescue mRNA export phenotypes associated with the lack of InsP(6) mimic the InsP(6) effects in vitro. Our results define specific functions for Gle1 and InsP(6) in mRNA export and suggest that local activation of Dbp5 at the nuclear pore is critical for mRNA export.	Univ Calif Berkeley, Div Cell & Dev Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Div Biochem & Mol Biol, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Vanderbilt University	Weis, K (corresponding author), Univ Calif Berkeley, Div Cell & Dev Biol, Berkeley, CA 94720 USA.	kweis@berkeley.edu	Weis, Karsten/F-5719-2011; THORNER, Jeremy/O-6132-2019	Weis, Karsten/0000-0001-7224-925X; THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R01GM071747, R37GM021841, R01GM058065] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM71747, GM58065, GM21841] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Ballut L, 2005, NAT STRUCT MOL BIOL, V12, P861, DOI 10.1038/nsmb990; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Estruch F, 2003, MOL BIOL CELL, V14, P1664, DOI 10.1091/mbc.E02-09-0602; Estruch F, 2005, J BIOL CHEM, V280, P9691, DOI 10.1074/jbc.M413025200; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Larsson C, 1997, J BACTERIOL, V179, P7243, DOI 10.1128/jb.179.23.7243-7250.1997; Lund MK, 2005, MOL CELL, V20, P645, DOI 10.1016/j.molcel.2005.10.005; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150; Maurer P, 2001, MOL BIOL CELL, V12, P539, DOI 10.1091/mbc.12.3.539; Miller AL, 2004, J BIOL CHEM, V279, P51022, DOI 10.1074/jbc.M409394200; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rogers GW, 2002, PROG NUCLEIC ACID RE, V72, P307, DOI 10.1016/S0079-6603(02)72073-4; Rollenhagen C, 2004, MOL CELL BIOL, V24, P4869, DOI 10.1128/MCB.24.11.4869-4879.2004; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Saiardi A, 2005, P NATL ACAD SCI USA, V102, P1911, DOI 10.1073/pnas.0409322102; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2002, P NATL ACAD SCI USA, V99, P14206, DOI 10.1073/pnas.212527899; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Segref A, 1997, EMBO J, V16, P3256, DOI 10.1093/emboj/16.11.3256; Shen XT, 2003, SCIENCE, V299, P112, DOI 10.1126/science.1078068; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; Takemura R, 2004, J CELL SCI, V117, P4189, DOI 10.1242/jcs.01296; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Vainberg IE, 2000, MOL CELL BIOL, V20, P3996, DOI 10.1128/MCB.20.11.3996-4005.2000; Weirich CS, 2004, MOL CELL, V16, P749, DOI 10.1016/j.molcel.2004.10.032; Yang QS, 2005, BIOCHEMISTRY-US, V44, P13591, DOI 10.1021/bi0508946; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200; Zeitler B, 2004, J CELL BIOL, V167, P583, DOI 10.1083/jcb.200407156; Zhao J, 2002, EMBO J, V21, P1177, DOI 10.1093/emboj/21.5.1177	49	206	213	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					668	U54		10.1038/ncb1424	http://dx.doi.org/10.1038/ncb1424			27	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16783364				2022-12-25	WOS:000238837800009
J	Kim, JH; Choi, HJ; Kim, B; Kim, MH; Lee, JM; Kim, IS; Lee, MH; Choi, SJ; Kim, KI; Kim, SI; Chung, CH; Baek, SH				Kim, Jung Hwa; Choi, Hee June; Kim, Bogyou; Kim, Mi Hyang; Lee, Ji Min; Kim, Ik Soo; Lee, Moon Hee; Choi, Soo Joon; Kim, Keun Il; Kim, Su-Il; Chung, Chin Ha; Baek, Sung Hee			Roles of sumoylation of a reptin chromatin-remodelling complex in cancer metastasis	NATURE CELL BIOLOGY			English	Article							NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATION; SUMO-1 MODIFICATION; GENE-TRANSCRIPTION; NUCLEAR RECEPTORS; PROSTATE-CANCER; SUPPRESSOR GENE; PROTEIN; EXPRESSION; TIP60	Defining the functional modules within transcriptional regulatory factors that govern switching between repression and activation events is a central issue in biology. Recently, we have reported the dynamic role of a beta-catenin-reptin chromatin remodelling complex in regulating a metastasis suppressor gene KAI1 (ref.1), which is capable of inhibiting the progression of tumour metastasis2-5. Here, we identify signalling factors that confer repressive function on reptin and hence repress the expression of KAI1. Biochemical purification of a reptin-containing complex has revealed the presence of specific desumoylating enzymes that reverse the sumoylation of reptin that underlies its function as a repressor. Desumoylation of reptin alters the repressive function of reptin and its association with HDAC1. Furthermore, the sumoylation status of reptin modulates the invasive activity of cancer cells with metastatic potential. These data clearly define a functional model and provide a novel link for SUMO modification in cancer metastasis.	Seoul Natl Univ, Dept Biol Sci, Res Ctr Funct Cellul, Seoul 151742, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea; Sookmyung Womens Univ, Dept Biol Sci, Seoul 140742, South Korea	Seoul National University (SNU); Seoul National University (SNU); Sookmyung Women's University	Baek, SH (corresponding author), Seoul Natl Univ, Dept Biol Sci, Res Ctr Funct Cellul, Seoul 151742, South Korea.	sbaek@snu.ac.kr	KIM, KEUN IL/D-2959-2011; Kim, Ik Soo/AAM-7787-2020					Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Bachant J, 2002, MOL CELL, V9, P1169, DOI 10.1016/S1097-2765(02)00543-9; Baek SH, 2004, BIOCHEM BIOPH RES CO, V319, P707, DOI 10.1016/j.bbrc.2004.04.169; Baek SH, 2003, P NATL ACAD SCI USA, V100, P3245, DOI 10.1073/pnas.0330217100; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feng Y, 2003, CANCER RES, V63, P8726; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Glass CK, 2000, GENE DEV, V14, P121; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Jonsson ZO, 2004, MOL CELL, V16, P465, DOI 10.1016/j.molcel.2004.09.033; Kanemaki M, 1999, J BIOL CHEM, V274, P22437, DOI 10.1074/jbc.274.32.22437; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kurihara I, 2005, J BIOL CHEM, V280, P6721, DOI 10.1074/jbc.M411820200; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; PETRYLAK DP, 1995, NAT MED, V1, P739, DOI 10.1038/nm0895-739; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Shevde LA, 2003, CANCER LETT, V198, P1, DOI 10.1016/S0304-3835(03)00304-5; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Zheng G, 2004, J BIOL CHEM, V279, P42410, DOI 10.1074/jbc.M407287200	35	125	129	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					631	639		10.1038/ncb1415	http://dx.doi.org/10.1038/ncb1415			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16699503				2022-12-25	WOS:000238029000017
J	Kollet, O; Dar, A; Shivtiel, S; Kalinkovich, A; Lapid, K; Sztainberg, Y; Tesio, M; Samstein, RM; Goichberg, P; Spiegel, A; Elson, A; Lapidot, T				Kollet, Orit; Dar, Ayelet; Shivtiel, Shoham; Kalinkovich, Alexander; Lapid, Kfir; Sztainberg, Yejezkel; Tesio, Melania; Samstein, Robert M.; Goichberg, Polina; Spiegel, Asaf; Elson, Ari; Lapidot, Tsvee			Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells	NATURE MEDICINE			English	Article							HEPATOCYTE GROWTH-FACTOR; COLONY-STIMULATING FACTOR; STEM-CELL; BONE-MARROW; MATRIX DEGRADATION; MESSENGER-RNA; IN-VITRO; RESORPTION; MMP-9; EXPRESSION	Here we investigated the potential role of bone-resorbing osteoclasts in homeostasis and stress-induced mobilization of hematopoietic progenitors. Different stress situations induced activity of osteoclasts ( OCLs) along the stem cell-rich endosteum region of bone, secretion of proteolytic enzymes and mobilization of progenitors. Specific stimulation of OCLs with RANKL recruited mainly immature progenitors to the circulation in a CXCR4- and MMP-9-dependent manner; however, RANKL did not induce mobilization in young female PTP epsilon-knockout mice with defective OCL bone adhesion and resorption. Inhibition of OCLs with calcitonin reduced progenitor egress in homeostasis, G-CSF mobilization and stress situations. RANKL-stimulated bone-resorbing OCLs also reduced the stem cell niche components SDF-1, stem cell factor ( SCF) and osteopontin along the endosteum, which was associated with progenitor mobilization. Finally, the major bone-resorbing proteinase, cathepsin K, also cleaved SDF-1 and SCF. Our findings indicate involvement of OCLs in selective progenitor recruitment as part of homeostasis and host defense, linking bone remodeling with regulation of hematopoiesis.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Lapidot, T (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	Tsvee.Lapidot@weizmann.ac.il	Lapid, Kfir/C-5265-2014; Lapidot, Tsvee/A-1812-2010; Kollet, Orit/A-6861-2008	Lapid, Kfir/0000-0002-8898-8695; TESIO, Melania/0000-0001-9291-0797; Elson, Ari/0000-0001-9808-9135; Samstein, Robert/0000-0001-6860-2401				AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Adams GB, 2006, NAT IMMUNOL, V7, P333, DOI 10.1038/ni1331; Adams GB, 2006, NATURE, V439, P599, DOI 10.1038/nature04247; Armbrust T, 2002, LIVER, V22, P486, DOI 10.1034/j.1600-0676.2002.01731.x; BLAVIER L, 1995, J CELL SCI, V108, P3649; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Chiusaroli R, 2004, MOL BIOL CELL, V15, P234, DOI 10.1091/mbc.e03-04-0207; Christopherson KW, 2003, BLOOD, V101, P4680, DOI 10.1182/blood-2002-12-3893; Cottler-Fox Michele H, 2003, Hematology Am Soc Hematol Educ Program, P419; Crestani B, 2002, LAB INVEST, V82, P1015, DOI 10.1097/01.LAB.0000024361.92500.19; Dar A, 2005, NAT IMMUNOL, V6, P1038, DOI 10.1038/ni1251; Fujii K, 2004, BRIT J HAEMATOL, V124, P190, DOI 10.1046/j.1365-2141.2003.04745.x; Goto T, 2003, J ELECTRON MICROSC, V52, P551, DOI 10.1093/jmicro/52.6.551; Gowen M, 1999, J BONE MINER RES, V14, P1654, DOI 10.1359/jbmr.1999.14.10.1654; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; Grassi F, 2004, J CELL PHYSIOL, V199, P244, DOI 10.1002/jcp.10445; Grassi F, 2003, HISTOCHEM CELL BIOL, V120, P391, DOI 10.1007/s00418-003-0587-3; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Janowska-Wieczorek ANNA, 2000, Hematology, V4, P515; JOHNELL O, 1977, CALC TISS RES, V23, P241, DOI 10.1007/BF02012792; Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524; Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041; Kiviranta R, 2005, BONE, V36, P159, DOI 10.1016/j.bone.2004.09.020; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Lee SK, 2006, BONE, V38, P678, DOI 10.1016/j.bone.2005.10.011; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Matsuda-Hashii Y, 2004, EXP HEMATOL, V32, P955, DOI 10.1016/j.exphem.2004.06.012; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; MERRY K, 1993, J CELL SCI, V104, P1013; MOLENDIJK WJ, 1986, CELL TISSUE KINET, V19, P407, DOI 10.1111/j.1365-2184.1986.tb00738.x; Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422; OKADA Y, 1995, LAB INVEST, V72, P311; Perez-Amodio S, 2004, J BONE MINER RES, V19, P1722, DOI 10.1359/JBMR.040509; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Pruijt JFM, 1999, P NATL ACAD SCI USA, V96, P10863, DOI 10.1073/pnas.96.19.10863; Rothe L, 1998, ENDOCRINOLOGY, V139, P4353, DOI 10.1210/en.139.10.4353; Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood-2004-01-0272; Shen HM, 2001, J IMMUNOL, V166, P5027, DOI 10.4049/jimmunol.166.8.5027; Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992; Takamatsu Y, 1998, BLOOD, V92, P3465, DOI 10.1182/blood.V92.9.3465.421k35_3465_3473; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Vaaraniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Watanabe T, 2003, INT J HEMATOL, V77, P75, DOI 10.1007/BF02982606; Wright LM, 2005, BONE, V36, P840, DOI 10.1016/j.bone.2005.01.021; Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404; Zaidi M, 2002, BONE, V30, P655, DOI 10.1016/S8756-3282(02)00688-9	50	565	592	2	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					657	664		10.1038/nm1417	http://dx.doi.org/10.1038/nm1417			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715089				2022-12-25	WOS:000238149200027
J	Smyth, DJ; Cooper, JD; Bailey, R; Field, S; Burren, O; Smink, LJ; Guja, C; Ionescu-Tirgoviste, C; Widmer, B; Dunger, DB; Savage, DA; Walker, NM; Clayton, DG; Todd, JA				Smyth, Deborah J.; Cooper, Jason D.; Bailey, Rebecca; Field, Sarah; Burren, Oliver; Smink, Luc J.; Guja, Cristian; Ionescu-Tirgoviste, Constantin; Widmer, Barry; Dunger, David B.; Savage, David A.; Walker, Neil M.; Clayton, David G.; Todd, John A.			A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region	NATURE GENETICS			English	Article							LYMPHOID TYROSINE PHOSPHATASE; GENE; DISEASE	In this study we report convincing statistical support for a sixth type 1 diabetes (T1D) locus in the innate immunity viral RNA receptor gene region IFIH1 (also known as mda-5 or Helicard) on chromosome 2q24.3. We found the association in an interim analysis of a genome-wide nonsynonymous SNP (nsSNP) scan, and we validated it in a case-control collection and replicated it in an independent family collection. In 4,253 cases, 5,842 controls and 2,134 parent-child trio genotypes, the risk ratio for the minor allele of the nsSNP rs1990760 A -> G (A946T) was 0.86 (95% confidence interval = 0.82-0.90) at P = 1.42 x 10(-10).	Addenbrookes Hosp, Cambridge Inst Med Res, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Cambridge CB2 2XY, England; Inst Diabet Nutr & Metab Dis N Paulescu, Clin Diabet, Bucharest 79811, Romania; Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2XY, England; Queens Univ Belfast, Dept Med Genet, Belfast BT9 7AB, Antrim, North Ireland	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Queens University Belfast	Todd, JA (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	john.todd@cimr.cam.ac.uk	Todd, John A/A-3542-2010; Guja, Cristian/K-2334-2019	Todd, John A/0000-0003-2740-8148; Walker, Neil/0000-0001-9796-7688; Burren, Oliver/0000-0002-3388-5760; Dunger, Professor David/0000-0002-2566-9304; smyth, deborah/0000-0002-6330-2669	Medical Research Council [G0000934] Funding Source: Medline; Wellcome Trust [068545/Z/02] Funding Source: Medline; MRC [G0000934] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Barratt BJ, 2004, DIABETES, V53, P1884, DOI 10.2337/diabetes.53.7.1884; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Clayton DG, 2005, NAT GENET, V37, P1243, DOI 10.1038/ng1653; Cucca F, 2001, HUM MOL GENET, V10, P2025, DOI 10.1093/hmg/10.19.2025; Hardenbol P, 2005, GENOME RES, V15, P269, DOI 10.1101/gr.3185605; Knip M, 2005, DIABETES, V54, pS125, DOI 10.2337/diabetes.54.suppl_2.S125; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Power C, 2006, INT J EPIDEMIOL, V35, P34, DOI 10.1093/ije/dyi183; Smyth D, 2004, DIABETES, V53, P3020, DOI 10.2337/diabetes.53.11.3020; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Vella A, 2005, AM J HUM GENET, V76, P773, DOI 10.1086/429843; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802	15	492	512	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					617	619		10.1038/ng1800	http://dx.doi.org/10.1038/ng1800			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16699517				2022-12-25	WOS:000237954800012
J	Baral, TN; Magez, S; Stijlemans, B; Conrath, K; Vanhollebeke, B; Pays, E; Muyldermans, S; De Baetselier, P				Baral, Toya Nath; Magez, Stefan; Stijlemans, Benoit; Conrath, Katja; Vanhollebeke, Benoit; Pays, Etienne; Muyldermans, Serge; De Baetselier, Patrick			Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor	NATURE MEDICINE			English	Article							VARIANT SURFACE GLYCOPROTEIN; SLEEPING-SICKNESS; BRUCEI-RHODESIENSE; HUMAN SERUM; APOLIPOPROTEIN L; ANTIGENIC VARIATION; LYTIC FACTOR; RESISTANCE; IDENTIFICATION; ANTIBODIES	High systemic drug toxicity and increasing prevalence of drug resistance hampers efficient treatment of human African trypanosomiasis (HAT). Hence, development of new highly specific trypanocidal drugs is necessary. Normal human serum (NHS) contains apolipoprotein L-I (apoL-I), which lyses African trypanosomes except resistant forms such as Trypanosoma brucei rhodesiense(1). T. b. rhodesiense expresses the apoL-I neutralizing serum resistance-associated (SRA) protein(2), endowing this parasite with the ability to infect humans and cause HAT. A truncated apoL-I (Tr-apoL-I) has been engineered by deleting its SRA-interacting domain, which makes it lytic for T. b. rhodesiense(1). Here, we conjugated Tr-apoL-I with a single-domain antibody (nanobody) that efficiently targets conserved cryptic epitopes of the variant surface glycoprotein (VSG) of trypanosomes(3) to generate a new manmade type of immunotoxin with potential for trypanosomiasis therapy. Treatment with this engineered conjugate resulted in clear curative and alleviating effects on acute and chronic infections of mice with both NHS-resistant and NHS-sensitive trypanosomes.	Vrije Univ Brussel VIB, Dept Cellular & Mol Interact, Lab Cellulaire Mol Immunol, B-1050 Brussels, Belgium; Univ Libre Bruxelles, IBMM, Mol Parasitol Lab, B-6041 Gosselies, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Universite Libre de Bruxelles	Baral, TN (corresponding author), Vrije Univ Brussel VIB, Dept Cellular & Mol Interact, Lab Cellulaire Mol Immunol, Pleinlaan 2, B-1050 Brussels, Belgium.	tbaral@vub.ac.be	Muyldermans, Serge/AAC-7374-2019; Magez, Stefan/AAC-5682-2021; Muyldermans, Serge V/C-6418-2016; De Baetselier, Patrick/D-3866-2014; Stijlemans, Benoit/AAD-9122-2021	Muyldermans, Serge/0000-0002-3678-3575; Magez, Stefan/0000-0003-3760-7968; Muyldermans, Serge V/0000-0002-3678-3575; Stijlemans, Benoit/0000-0003-0082-9751; Vanhollebeke, Benoit/0000-0002-0353-365X				BACCHI CJ, 1993, PARASITOL TODAY, V9, P190, DOI 10.1016/0169-4758(93)90145-6; Barrett MP, 2003, LANCET, V362, P1469, DOI 10.1016/S0140-6736(03)14694-6; Burri C, 2000, LANCET, V355, P1419, DOI 10.1016/S0140-6736(00)02141-3; Chisi J E, 2004, East Afr Med J, V81, P505; Conrath K, 2005, J MOL BIOL, V350, P112, DOI 10.1016/j.jmb.2005.04.050; Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; Cortez-Retamozo V, 2002, INT J CANCER, V98, P456, DOI 10.1002/ijc.10212; DEGREEF C, 1994, MOL BIOCHEM PARASIT, V68, P277, DOI 10.1016/0166-6851(94)90172-4; Duchateau PN, 2000, J LIPID RES, V41, P1231; Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576; Horn D, 2004, CURR MOL MED, V4, P563, DOI 10.2174/1566524043360078; Hutchinson OC, 2003, LANCET INFECT DIS, V3, P42, DOI 10.1016/S1473-3099(03)00488-2; Legros D, 2002, LANCET INFECT DIS, V2, P437, DOI 10.1016/S1473-3099(02)00321-3; Magez S, 1999, INFECT IMMUN, V67, P3128, DOI 10.1128/IAI.67.6.3128-3132.1999; Magez S, 2004, J INFECT DIS, V189, P527, DOI 10.1086/381151; Mehlert A, 2002, GLYCOBIOLOGY, V12, P607, DOI 10.1093/glycob/cwf079; Muyldermans S, 2001, J Biotechnol, V74, P277; Naessens J, 2005, CLIN EXP IMMUNOL, V139, P405, DOI 10.1111/j.1365-2249.2004.02717.x; Nguyen VK, 2001, ADV IMMUNOL, V79, P261, DOI 10.1016/S0065-2776(01)79006-2; Pays E, 2004, CURR OPIN MICROBIOL, V7, P369, DOI 10.1016/j.mib.2004.05.001; PEPIN J, 1994, ADV PARASIT, V33, P1, DOI 10.1016/S0065-308X(08)60410-8; Perez-Morga D, 2005, SCIENCE, V309, P469, DOI 10.1126/science.1114566; Stijlemans B, 2004, J BIOL CHEM, V279, P1256, DOI 10.1074/jbc.M307341200; Vanhamme L, 2004, INT J PARASITOL, V34, P887, DOI 10.1016/j.ijpara.2004.04.008; Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461; VANMEIRVENNE N, 1976, ANN SOC BELG MED TR, V56, P55; Welburn SC, 2001, TRENDS PARASITOL, V17, P19, DOI 10.1016/S1471-4922(00)01839-0; Welburn SC, 2001, LANCET, V358, P2017, DOI 10.1016/S0140-6736(01)07096-9; Xong HV, 1998, CELL, V95, P839, DOI 10.1016/S0092-8674(00)81706-7	30	124	155	1	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					580	584		10.1038/nm1395	http://dx.doi.org/10.1038/nm1395			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604085				2022-12-25	WOS:000238149100043
J	Liu, YW; Teige, I; Birnir, B; Issazadeh-Navikas, S				Liu, Yawei; Teige, Ingrid; Birnir, Bryndis; Issazadeh-Navikas, Shohreh			Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE	NATURE MEDICINE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GROWTH-FACTOR-BETA; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA EXPRESSION; MHC CLASS-I; TGF-BETA; ALLERGIC ENCEPHALOMYELITIS; NEUROTROPHIC FACTOR; NEGATIVE REGULATOR; LEUKOCYTE INTEGRIN	Neurons have been neglected as cells with a major immune-regulatory function because they do not express major histocompatibility complex class II. Our data show that neurons are highly immune regulatory, having a crucial role in governing T-cell response and central nervous system (CNS) inflammation. Neurons induce the proliferation of activated CD4+ T cells through B7-CD28 and transforming growth factor (TGF)-beta 1-TGF-beta receptor signaling pathways, resulting in amplification of T-cell receptor signaling through phosphorylated ZAP-70, interleukin (IL)-2 and IL- 9. The interaction between neurons and T cells results in the conversion of encephalitogenic T cells to CD25(+) TGF-beta 1(+)CTLA-4(+)FoxP3(+) T regulatory (T-reg) cells that suppress encephalitogenic T cells and inhibit experimental autoimmune encephalomyelitis. Suppression is dependent on cytotoxic T lymphocyte antigen (CTLA)-4 but not TGF-beta 1. Autocrine action of TGF-beta 1, however, is important for the proliferative arrest of T-reg cells. Blocking the B7 and TGF-beta pathways prevents the CNS-specific generation of Treg cells. These findings show that generation of neuron-dependent Treg cells in the CNS is instrumental in regulating CNS inflammation.	Lund Univ, Inst Expt Med Sci, Neuroinflammat Unit, S-22184 Lund, Sweden; Lund Univ, Clin Res Ctr, Dept Clin Sci, S-20502 Malmo, Sweden	Lund University; Lund University	Issazadeh-Navikas, S (corresponding author), Lund Univ, Inst Expt Med Sci, Neuroinflammat Unit, BMC,I13,, S-22184 Lund, Sweden.	shohreh.issazadeh@med.lu.se	Issazadeh-Navikas, Shohreh/AAI-7900-2021	Birnir, Bryndis/0000-0002-1763-0266				Campanella M, 2002, STROKE, V33, P586, DOI 10.1161/hs0202.103399; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chen Wanjun, 2002, Curr Dir Autoimmun, V5, P62; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Estevez AG, 1998, J NEUROSCI, V18, P3708; Flugel A, 2000, BRAIN PATHOL, V10, P353; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Hurwitz AA, 2002, P NATL ACAD SCI USA, V99, P3013, DOI 10.1073/pnas.042684699; Issazadeh S, 1998, J IMMUNOL, V161, P1104; Issazadeh S, 1999, J IMMUNOL, V162, P761; ISSAZADEH S, 1995, J NEUROSCI RES, V40, P579, DOI 10.1002/jnr.490400503; Issazadeh S, 1996, J NEUROIMMUNOL, V69, P103; Issazadeh S, 1997, EUR J IMMUNOL, V27, P1584, DOI 10.1002/eji.1830270640; Karandikar NJ, 1996, J EXP MED, V184, P783, DOI 10.1084/jem.184.2.783; KEARNEY ER, 1995, J IMMUNOL, V155, P1032; Kerschensteiner M, 2003, ANN NEUROL, V53, P292, DOI 10.1002/ana.10446; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Kullberg MC, 2005, EUR J IMMUNOL, V35, P2886, DOI 10.1002/eji.200526106; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MAEHLEN J, 1989, J NEUROIMMUNOL, V23, P125, DOI 10.1016/0165-5728(89)90031-3; Medana I, 2001, J IMMUNOL, V167, P674, DOI 10.4049/jimmunol.167.2.674; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; Mott RT, 2004, GLIA, V46, P369, DOI 10.1002/glia.20009; Nakada M, 1999, J ALLERGY CLIN IMMUN, V104, P222, DOI 10.1016/S0091-6749(99)70139-9; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; Neumann H, 1996, EUR J NEUROSCI, V8, P2582, DOI 10.1111/j.1460-9568.1996.tb01552.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; SANTAMBROGIO L, 1993, J IMMUNOL, V151, P1116; SCHMITT E, 1994, J IMMUNOL, V153, P3989; Teige A, 2004, J IMMUNOL, V172, P186, DOI 10.4049/jimmunol.172.1.186; Teige I, 2003, J IMMUNOL, V170, P4776, DOI 10.4049/jimmunol.170.9.4776; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; Thompson C, 2004, CURR OPIN PHARMACOL, V4, P408, DOI 10.1016/j.coph.2004.05.001; Tian L, 1997, J IMMUNOL, V158, P928; Tian L, 2000, EUR J IMMUNOL, V30, P810, DOI 10.1002/1521-4141(200003)30:3<810::AID-IMMU810>3.3.CO;2-O; Vahlenkamp TW, 2004, VET IMMUNOL IMMUNOP, V98, P203, DOI 10.1016/j.vetimm.2003.12.006; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WEKERLE H, 1987, J EXP BIOL, V132, P43; Zhang XS, 2005, J IMMUNOL, V175, P2931, DOI 10.4049/jimmunol.175.5.2931	45	231	238	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					518	525		10.1038/nm1402	http://dx.doi.org/10.1038/nm1402			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16633347				2022-12-25	WOS:000238149100035
J	Marques, JT; Devosse, T; Wang, D; Zamanian-Daryoush, M; Serbinowski, P; Hartmann, R; Fujita, T; Behlke, MA; Williams, BRG				Marques, JT; Devosse, T; Wang, D; Zamanian-Daryoush, M; Serbinowski, P; Hartmann, R; Fujita, T; Behlke, MA; Williams, BRG			A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells	NATURE BIOTECHNOLOGY			English	Article							INNATE IMMUNE-RESPONSE; ANTIVIRAL RESPONSE; INTERFERING RNAS; DEPENDENT STIMULATION; GENE-EXPRESSION; PROTEIN-KINASE; RIG-I; ACTIVATION; SIRNAS; INHIBITION	Nonspecific effects triggered by small interfering RNAs (siRNAs) complicate the use of RNA interference (RNAi) to specifically downregulate gene expression(1-5). To uncover the basis of these nonspecific activities, we analyzed the effect of chemically synthesized siRNAs on mammalian double-stranded RNA (dsRNA)-activated signaling pathways. siRNAs ranging from 21 to 27 nucleotides (nt) in length activated the interferon system when they lacked 2-nt 3' overhangs, a characteristic of Dicer products. We show that the recognition of siRNAs is mediated by the RNA helicase RIG-I and that the presence of 3' overhangs impairs its ability to unwind the dsRNA substrate and activate downstream signaling to the transcription factor IRF-3. These results suggest a structural basis for discrimination between microRNAs that are endogenous Dicer products, and nonself dsRNAs such as by-products of viral replication. These findings will enable the rational design of siRNAs that avoid nonspecific effects or, alternatively, that induce bystander effects to potentially increase the efficacy of siRNA-based treatments of viral infections or cancer.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus, Denmark; Kyoto Univ, Inst Virus Res, Genet Mol Lab, Kyoto 6068507, Japan; Integrated DNA Technol Inc, Coralville, Iwate 52241, Japan; Monash Univ, Monash Inst Med Res, Clayton, Vic 3168, Australia	Cleveland Clinic Foundation; Aarhus University; Kyoto University; Monash University	Williams, BRG (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	bryan.williams@med.monash.edu.au	Williams, Bryan R. G./A-5021-2009; Wang, Die/H-8860-2017; Marques, João/F-7683-2012	Williams, Bryan R. G./0000-0002-4969-1151; Wang, Die/0000-0001-7628-7309; Marques, João/0000-0002-3457-3320; Hartmann, Rune/0000-0003-1159-066X; Behlke, Mark/0000-0002-4218-857X	NCI NIH HHS [P01 CA 62220] Funding Source: Medline; NIAID NIH HHS [R01 AI34039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P2705, DOI 10.1093/nar/gkg393; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kim DH, 2004, NAT BIOTECHNOL, V22, P321, DOI 10.1038/nbt940; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Levy DE, 2004, NAT IMMUNOL, V5, P699, DOI 10.1038/ni0704-699; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; Marques JT, 2005, NAT BIOTECHNOL, V23, P1399, DOI 10.1038/nbt1161; Marques JT, 2005, J VIROL, V79, P11105, DOI 10.1128/JVI.79.17.11105-11114.2005; Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Rose SD, 2005, NUCLEIC ACIDS RES, V33, P4140, DOI 10.1093/nar/gki732; Siolas D, 2005, NAT BIOTECHNOL, V23, P227, DOI 10.1038/nbt1052; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zhang WD, 2005, NAT MED, V11, P56, DOI 10.1038/nm1174	28	295	358	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2006	24	5					559	565		10.1038/nbt1205	http://dx.doi.org/10.1038/nbt1205			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	039TX	16648842				2022-12-25	WOS:000237331300031
J	Park, D; Lapteva, N; Seethammagari, M; Slawin, KM; Spencer, DM				Park, Dongsu; Lapteva, Natalia; Seethammagari, Mamatha; Slawin, Kevin M.; Spencer, David M.			An essential role for Akt1 in dendritic cell function and tumor immunotherapy	NATURE BIOTECHNOLOGY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; NEGATIVE REGULATOR; IN-VIVO; CYTOKINE PRODUCTION; ENDOTHELIAL-CELLS; ACTIVATION; APOPTOSIS; SURVIVAL; EXPRESSION	Current dendritic cell (DC) vaccine preparations involving ex vivo differentiation and maturation produce short-lived, transiently active DCs that may curtail T-cell responses in vivo. We demonstrate that Akt1, downregulation of which decreases DC lifespan, is critical for proinflammatory signal-mediated DC survival and maturation. Lipopolysaccharide or CD40 signaling stabilizes Akt1, promoting both activation and Bcl-2-dependent survival of DCs. Expression of a potent allele encoding a lipid raft targeted Akt1, MF-Delta Akt, is sufficient for maturation and survival of murine bone marrow-derived DCs in vivo. MF-Delta Akt transduced DCs enhanced T-cell proliferation, activation and long- term memory responses, enabling eradication of large preestablished lymphomas and aggressive B16 melanomas. Human myeloid DCs expressing constitutively active MF-Delta hAkt also survived significantly longer and promoted antigen-specific T-cell responses. Thus, Akt1 is a critical regulator of DC lifespan, and its manipulation in DCs can improve the clinical efficacy of DC-based tumor vaccines.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Methodist Hosp, Scott Dept Urol, Houston, TX 77030 USA	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston	Spencer, DM (corresponding author), Baylor Coll Med, Dept Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.	dspencer@bcm.edu		Park, Dongsu/0000-0002-2570-3250				Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Bharti AC, 2004, APOPTOSIS, V9, P677, DOI 10.1023/B:APPT.0000045780.10463.c6; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chuang TH, 2004, NAT IMMUNOL, V5, P495, DOI 10.1038/ni1066; Contin C, 2003, J BIOL CHEM, V278, P32801, DOI 10.1074/jbc.M209993200; Del Prete A, 2004, EMBO J, V23, P3505, DOI 10.1038/sj.emboj.7600361; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Hanks BA, 2005, NAT MED, V11, P130, DOI 10.1038/nm1183; Hermans IF, 2000, J IMMUNOL, V164, P3095, DOI 10.4049/jimmunol.164.6.3095; Hou WS, 2004, NAT IMMUNOL, V5, P583, DOI 10.1038/ni1071; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Ishii KJ, 2002, J EXP MED, V196, P269, DOI 10.1084/jem.20020773; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495; Kanto T, 2001, J IMMUNOL, V167, P3773, DOI 10.4049/jimmunol.167.7.3773; Katome T, 2003, J BIOL CHEM, V278, P28312, DOI 10.1074/jbc.M302094200; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Li B, 2002, GENE THER, V9, P233, DOI 10.1038/sj.gt.3301641; Liu K, 2002, J EXP MED, V196, P1091, DOI 10.1084/jem.20021215; Lutgens E, 1999, NAT MED, V5, P1313, DOI 10.1038/15271; Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Miga AJ, 2001, EUR J IMMUNOL, V31, P959, DOI 10.1002/1521-4141(200103)31:3<959::AID-IMMU959>3.0.CO;2-A; Mochizuki T, 2002, J BIOL CHEM, V277, P2790, DOI 10.1074/jbc.M106361200; Mukherjee A, 2003, J BIOL CHEM, V278, P40806, DOI 10.1074/jbc.M306440200; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Napolitani G, 2003, EUR J IMMUNOL, V33, P2832, DOI 10.1002/eji.200324073; Nikitina EY, 2005, CANCER RES, V65, P4309, DOI 10.1158/0008-5472.CAN-04-3119; Nopora A, 2002, J IMMUNOL, V169, P3006, DOI 10.4049/jimmunol.169.6.3006; Okugawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC399, DOI 10.1152/ajpcell.00026.2003; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Park Y, 2002, J IMMUNOL, V168, P5, DOI 10.4049/jimmunol.168.1.5; Ridgway D, 2003, CANCER INVEST, V21, P873, DOI 10.1081/CNV-120025091; Riesterer O, 2004, ONCOGENE, V23, P4624, DOI 10.1038/sj.onc.1207596; Schuler G, 2003, CURR OPIN IMMUNOL, V15, P138, DOI 10.1016/S0952-7915(03)00015-3; Shen L, 2004, NAT BIOTECHNOL, V22, P1546, DOI 10.1038/nbt1035; Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; Vassiliou E, 2004, J IMMUNOL, V173, P6955, DOI 10.4049/jimmunol.173.11.6955; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood-2002-06-1688; Xu J, 2002, J BIOL CHEM, V277, P35561, DOI 10.1074/jbc.M203805200; Yu QG, 2004, J IMMUNOL, V172, P6047, DOI 10.4049/jimmunol.172.10.6047	50	85	107	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1581	1590		10.1038/nbt1262	http://dx.doi.org/10.1038/nbt1262			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17143278				2022-12-25	WOS:000242795800038
J	Putz, MM; Midgley, CM; Law, M; Smith, GL				Puetz, Mike M.; Midgley, Claire M.; Law, Mansun; Smith, Geoffrey L.			Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination	NATURE MEDICINE			English	Article							PROTECTION; IMMUNITY; PROTEIN; HUMANS; TARGET; MICE	Smallpox was eradicated without an adequate understanding of how vaccination induced protection. In response to possible bioterrorism with smallpox, the UK government vaccinated similar to 300 health care workers with vaccinia virus (VACV) strain Lister. Antibody responses were analyzed using ELISA for multiple surface antigens of the extracellular enveloped virus (EEV) and the intracellular mature virus (IMV), plaque reduction neutralization and a fluorescence-based flow cytometric neutralization assay. Antibody depletion experiments showed that the EEV surface protein B5 is the only target responsible for EEV neutralization in vaccinated humans, whereas multiple IMV surface proteins, including A27 and H3, are targets for IMV-neutralizing antibodies. These data suggest that it would be unwise to exclude the B5 protein from a future smallpox vaccine. Repeated vaccination provided significantly higher B5-specific and thus EEV-neutralizing antibody responses. These data provide a benchmark against which new, safer smallpox vaccines and residual immunity can be compared.	Univ London Imperial Coll Sci Technol & Med, Dept Virol, Fac Med, London W2 1PG, England	Imperial College London	Smith, GL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Virol, Fac Med, St Marys Campus, London W2 1PG, England.	glsmith@imperial.ac.uk	Smith, Geoffrey L/G-2894-2012; Law, Mansun/A-3899-2008	Smith, Geoffrey L/0000-0002-3730-9955; Law, Mansun/0000-0002-8934-9756	MRC [G0501257] Funding Source: UKRI; Medical Research Council [G0501257] Funding Source: Medline; NIAID NIH HHS [R41AI058365] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R41AI058365] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome Trust); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aldaz-Carroll L, 2005, VIROLOGY, V341, P59, DOI 10.1016/j.virol.2005.07.006; Auckland C, 2005, VACCINE, V23, P4185, DOI 10.1016/j.vaccine.2004.10.052; Bell E, 2004, VIROLOGY, V325, P425, DOI 10.1016/j.virol.2004.05.004; Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100; Boulter E A, 1973, Prog Med Virol, V16, P86; Carter GC, 2005, J GEN VIROL, V86, P1279, DOI 10.1099/vir.0.80831-0; Carter GC, 2003, J GEN VIROL, V84, P2443, DOI 10.1099/vir.0.19271-0; Crotty S, 2003, J IMMUNOL, V171, P4969, DOI 10.4049/jimmunol.171.10.4969; Davies DH, 2005, J VIROL, V79, P11724, DOI 10.1128/JVI.79.18.11724-11733.2005; Davies DH, 2005, P NATL ACAD SCI USA, V102, P547, DOI 10.1073/pnas.0408782102; Edghill-Smith Y, 2005, NAT MED, V11, P740, DOI 10.1038/nm1261; Fang M, 2005, J IMMUNOL, V175, P6829, DOI 10.4049/jimmunol.175.10.6829; Fenner F., 1988, SMALLPOX ITS ERADICA, P121; Fogg C, 2004, J VIROL, V78, P10230, DOI 10.1128/JVI.78.19.10230-10237.2004; Frey SE, 2003, JAMA-J AM MED ASSOC, V289, P3295, DOI 10.1001/jama.289.24.3295; Galmiche MC, 1999, VIROLOGY, V254, P71, DOI 10.1006/viro.1998.9516; Hammarlund E, 2003, NAT MED, V9, P1131, DOI 10.1038/nm917; Hooper JW, 2004, J VIROL, V78, P4433, DOI 10.1128/JVI.78.9.4433-4443.2004; Hooper JW, 2000, VIROLOGY, V266, P329, DOI 10.1006/viro.1999.0096; Kidokoro M, 2005, P NATL ACAD SCI USA, V102, P4152, DOI 10.1073/pnas.0406671102; Law M, 2006, P NATL ACAD SCI USA, V103, P5989, DOI 10.1073/pnas.0601025103; Law M, 2005, J GEN VIROL, V86, P991, DOI 10.1099/vir.0.80660-0; Law M, 2001, VIROLOGY, V280, P132, DOI 10.1006/viro.2000.0750; MCCARTHY K., 1958, JOUR HYGIENE, V56, P466; Pulford DJ, 2004, VACCINE, V22, P3358, DOI 10.1016/j.vaccine.2004.02.034; Putz MM, 2005, J GEN VIROL, V86, P2955, DOI 10.1099/vir.0.81265-0; Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915; Su HP, 2005, P NATL ACAD SCI USA, V102, P4240, DOI 10.1073/pnas.0501103102; Viner KM, 2005, MICROBES INFECT, V7, P579, DOI 10.1016/j.micinf.2005.02.004; Xu R, 2004, J IMMUNOL, V172, P6265, DOI 10.4049/jimmunol.172.10.6265	30	94	96	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2006	12	11					1310	1315		10.1038/nm1457	http://dx.doi.org/10.1038/nm1457			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17086190				2022-12-25	WOS:000241844900029
J	Seal, S; Thompson, D; Renwick, A; Elliott, A; Kelly, P; Barfoot, R; Chagtai, T; Jayatilake, H; Ahmed, M; Spanova, K; North, B; McGuffog, L; Evans, DG; Eccles, D; Easton, DF; Stratton, MR; Rahman, N				Seal, Sheila; Thompson, Deborah; Renwick, Anthony; Elliott, Anna; Kelly, Patrick; Barfoot, Rita; Chagtai, Tasnim; Jayatilake, Hiran; Ahmed, Munaza; Spanova, Katarina; North, Bernard; McGuffog, Lesley; Evans, D. Gareth; Eccles, Diana; Easton, Douglas F.; Stratton, Michael R.; Rahman, Nazneen		BCS Collaboration	Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles	NATURE GENETICS			English	Article							BRCA2 MUTATIONS; HELICASE BRIP1; BACH1; PROTEIN; PREDISPOSITION	We identified constitutional truncating mutations of the BRCA1-interacting helicase BRIP1 in 9/1,212 individuals with breast cancer from BRCA1/BRCA2 mutation-negative families but in only 2/2,081 controls (P = 0.0030), and we estimate that BRIP1 mutations confer a relative risk of breast cancer of 2.0 (95% confidence interval = 1.2-3.2, P = 0.012). Biallelic BRIP1 mutations were recently shown to cause Fanconi anemia complementation group J. Thus, inactivating truncating mutations of BRIP1, similar to those in BRCA2, cause Fanconi anemia in biallelic carriers and confer susceptibility to breast cancer in monoallelic carriers.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ Cambridge, Strangeways Res Labs, Canc Res UK Genet Epidemiol Unit, Cambridge CB1 8RN, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 6YA, Hants, England; Wellcome Trust Sanger Inst, Canc Genome Project, Hixton CB10 1SA, Cambs, England	University of London; Institute of Cancer Research - UK; Cancer Research UK; University of Cambridge; University of Manchester; Wellcome Trust Sanger Institute	Rahman, N (corresponding author), Inst Canc Res, Sect Canc Genet, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	nazneen.rahman@icr.ac.uk	Eccles, Diana/K-6327-2019; Evans, D Gareth/AAB-4308-2022; Rahman, Nazneen/B-8890-2012; Rahman, Nazneen/D-2802-2013	Eccles, Diana/0000-0002-9935-3169; Evans, D Gareth/0000-0002-8482-5784; Rahman, Nazneen/0000-0003-4376-0440	MRC [G0000934] Funding Source: UKRI; Medical Research Council [G0000934] Funding Source: Medline; Wellcome Trust [068545/Z/02] Funding Source: Medline; Breast Cancer Now [2003:592] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Breast Cancer Now		Antoniou AC, 2001, GENET EPIDEMIOL, V21, P1, DOI 10.1002/gepi.1014; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Cantor SB, 2006, CELL CYCLE, V5, P164, DOI 10.4161/cc.5.2.2338; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Peng M, 2006, ONCOGENE, V25, P2245, DOI 10.1038/sj.onc.1209257; Reid S, 2005, J MED GENET, V42, P147, DOI 10.1136/jmg.2004.022673; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; Seal S, 2003, CANCER RES, V63, P8596; SWIFT M, 1980, J NATL CANCER I, V65, P863; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240	15	527	542	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2006	38	11					1239	1241		10.1038/ng1902	http://dx.doi.org/10.1038/ng1902			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17033622				2022-12-25	WOS:000241592700009
J	Giraldes, JW; Akey, DL; Kittendorf, JD; Sherman, DH; Smith, JL; Fecik, RA				Giraldes, John W.; Akey, David L.; Kittendorf, Jeffrey D.; Sherman, David H.; Smith, Janet L.; Fecik, Robert A.			Structural and mechanistic insights into polyketide macrolactonization from polyketide-based affinity labels	NATURE CHEMICAL BIOLOGY			English	Article							TERMINAL THIOESTERASE DOMAIN; CRYSTAL-STRUCTURE; BIOSYNTHESIS; ARCHITECTURE; DERIVATIVES; INHIBITION; SURFACTIN; SYNTHASE; SERINE	Polyketides are a diverse class of natural products having important clinical properties, including antibiotic, immunosuppressive and anticancer activities. They are biosynthesized by polyketide synthases (PKSs), which are modular, multienzyme complexes that sequentially condense simple carboxylic acid derivatives(1). The final reaction in many PKSs involves thioesterase-catalyzed cyclization of linear chain elongation intermediates. As the substrate in PKSs is presented by a tethered acyl carrier protein, introduction of substrate by diffusion is problematic, and no substrate-bound type I PKS domain structure has been reported so far. We describe the chemical synthesis of polyketide- based affinity labels that covalently modify the active site serine of excised pikromycin thioesterase from Streptomyces venezuelae. Crystal structures reported here of the affinity label-pikromycin thioesterase adducts provide important mechanistic insights. These results suggest that affinity labels can be valuable tools for understanding the mechanisms of individual steps within multifunctional PKSs and for directing rational engineering of PKS domains for combinatorial biosynthesis.	Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Fecik, RA (corresponding author), Univ Minnesota, Dept Med Chem, 308 Harvard St SE,8-101 Weaver Densford Hall, Minneapolis, MN 55455 USA.	davidhs@umich.edu; janetsmith@umich.edu; fecik001@umn.edu			NIDDK NIH HHS [R37 DK042303, DK042303] Funding Source: Medline; NIGMS NIH HHS [F32 GM075641, GM076477] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076477, F32GM075641] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldrich CC, 2005, J AM CHEM SOC, V127, P8910, DOI 10.1021/ja0504340; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bellizzi JJ, 2000, P NATL ACAD SCI USA, V97, P4573, DOI 10.1073/pnas.080508097; Benning MM, 1998, J BIOL CHEM, V273, P33572, DOI 10.1074/jbc.273.50.33572; Bertrand JA, 1996, BIOCHEMISTRY-US, V35, P3147, DOI 10.1021/bi9520996; Bruner SD, 2002, STRUCTURE, V10, P301, DOI 10.1016/S0969-2126(02)00716-5; Chakravarty B, 2004, P NATL ACAD SCI USA, V101, P15567, DOI 10.1073/pnas.0406901101; Crimmins MT, 2001, J ORG CHEM, V66, P894, DOI 10.1021/jo001387r; Delano W.L, 2002, PYMOL USERS MANUAL; Devedjiev Y, 2000, STRUCTURE, V8, P1137, DOI 10.1016/S0969-2126(00)00529-3; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; He WG, 2006, BIOORG MED CHEM LETT, V16, P391, DOI 10.1016/j.bmcl.2005.09.077; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keatinge-Clay AT, 2006, STRUCTURE, V14, P737, DOI 10.1016/j.str.2006.01.009; Kim BS, 2002, J BIOL CHEM, V277, P48028, DOI 10.1074/jbc.M207770200; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; Li J, 2000, NAT STRUCT BIOL, V7, P555; Lu HX, 2002, BIOCHEMISTRY-US, V41, P12590, DOI 10.1021/bi026006d; OLEKSYSZYN J, 1989, BIOCHEM BIOPH RES CO, V161, P143, DOI 10.1016/0006-291X(89)91572-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v; RYCHNOVSKY SD, 1993, J ORG CHEM, V58, P3511, DOI 10.1021/jo00065a011; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Tang YY, 2006, P NATL ACAD SCI USA, V103, P11124, DOI 10.1073/pnas.0601924103; Tsai SC, 2001, P NATL ACAD SCI USA, V98, P14808, DOI 10.1073/pnas.011399198; Tsai SC, 2002, BIOCHEMISTRY-US, V41, P12598, DOI 10.1021/bi0260177; Tseng CC, 2002, BIOCHEMISTRY-US, V41, P13350, DOI 10.1021/bi026592a; Weissman KJ, 2005, NAT REV MICROBIOL, V3, P925, DOI 10.1038/nrmicro1287; Wu JQ, 2005, ANGEW CHEM INT EDIT, V44, P7557, DOI 10.1002/anie.200502246; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111	30	72	76	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2006	2	10					531	536		10.1038/nchembio822	http://dx.doi.org/10.1038/nchembio822			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	095IX	16969373				2022-12-25	WOS:000241302500010
J	Jin, LQ; Hope, KJ; Zhai, QL; Smadja-Joffe, F; Dick, JE				Jin, Liqing; Hope, Kristin J.; Zhai, Qiongli; Smadja-Joffe, Florence; Dick, John E.			Targeting of CD44 eradicates human acute myeloid leukemic stem cells	NATURE MEDICINE			English	Article							PRIMITIVE HEMATOPOIETIC-CELLS; BONE-MARROW; ADHESION MOLECULES; NOD/SCID MICE; SCID MICE; IN-VITRO; DIFFERENTIATION; TRANSPLANTATION; IDENTIFICATION; PROGENITORS	The long-term survival of patients with acute myeloid leukemia (AML) is dismally poor. A permanent cure of AML requires elimination of leukemic stem cells (LSCs), the only cell type capable of initiating and maintaining the leukemic clonal hierarchy. We report a therapeutic approach using an activating monoclonal antibody directed to the adhesion molecule CD44. In vivo administration of this antibody to nonobese diabetic-severe combined immune-deficient mice transplanted with human AML markedly reduced leukemic repopulation. Absence of leukemia in serially transplanted mice demonstrated that AML LSCs are directly targeted. Mechanisms underlying this eradication included interference with transport to stem cell-supportive microenvironmental niches and alteration of AML-LSC fate, identifying CD44 as a key regulator of AML LSCs. The finding that AML LSCs require interaction with a niche to maintain their stem cell properties provides a therapeutic strategy to eliminate quiescent AML LSCs and may be applicable to other types of cancer stem cells.	Univ Toronto, Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 1L7, Canada; Hop St Louis, INSERM, U718, F-75475 Paris, France	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Dick, JE (corresponding author), Univ Toronto, Hlth Network, Div Cell & Mol Biol, Toronto Med Discovery Tower,101 Coll St,Suite 8-3, Toronto, ON M5G 1L7, Canada.	jdick@uhnres.utoronto.ca		Hope, Kristin/0000-0003-1449-4948; Dick, John/0000-0002-9527-8317				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; Bendall LJ, 2000, LEUKEMIA, V14, P1239, DOI 10.1038/sj.leu.2401830; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cancelas JA, 2006, NAT MED, V12, P278, DOI 10.1038/nm0306-278; Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Gadhoum Z, 2004, BLOOD, V103, P1059, DOI 10.1182/blood-2003-04-1218; Guan Y, 2000, LEUKEMIA, V14, P2135, DOI 10.1038/sj.leu.2401975; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; KORTLEPEL K, 1993, LEUKEMIA, V7, P1174; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Legras S, 1998, BLOOD, V91, P3401, DOI 10.1182/blood.V91.9.3401.3401_3401_3413; LIESVELD JL, 1991, EXP HEMATOL, V19, P63; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Madlambayan GJ, 2005, EXP HEMATOL, V33, P1229, DOI 10.1016/j.exphem.2005.05.018; Mazurier F, 2003, NAT MED, V9, P959, DOI 10.1038/nm886; Mazurier F, 2004, BLOOD, V103, P545, DOI 10.1182/blood-2003-05-1558; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Nilsson SK, 2003, BLOOD, V101, P856, DOI 10.1182/blood-2002-05-1344; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; REUSSBORST MA, 1992, ANN HEMATOL, V65, P169, DOI 10.1007/BF01703110; SINGH S, 2003, CANCER RES, V63, P5281; Tallman Martin S, 2005, Hematology Am Soc Hematol Educ Program, P143; Tavor S, 2004, CANCER RES, V64, P2817, DOI 10.1158/0008-5472.CAN-03-3693; TILL JE, 1980, BIOCHIM BIOPHYS ACTA, V605, P431, DOI 10.1016/0304-419X(80)90009-8; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Woerner SM, 1995, CLIN CANCER RES, V1, P1125; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	37	913	1001	5	122	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1167	1174		10.1038/nm1483	http://dx.doi.org/10.1038/nm1483			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16998484				2022-12-25	WOS:000241102200033
J	Gassama-Diagne, A; Yu, W; ter Beest, M; Martin-Belmonte, F; Kierbel, A; Engel, J; Mostov, K				Gassama-Diagne, Ama; Yu, Wei; ter Beest, Martin; Martin-Belmonte, Fernando; Kierbel, Arlinet; Engel, Joanne; Mostov, Keith			Phosphatidylinositol-3,4,5-trisphosphate regulates the formation of the basolateral plasma membrane in epithelial cells	NATURE CELL BIOLOGY			English	Article							POLARITY; MORPHOGENESIS; LOCALIZATION; NEUTROPHILS; ISOFORMS; PATHWAY; COMPLEX	Polarity is a central feature of eukaryotic cells and phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) has a central role in the polarization of neurons and chemotaxing cells. In polarized epithelial cells, PtdIns(3,4,5)P-3 is stably localized at the basolateral plasma membrane, but excluded from the apical plasma membrane, as shown by localization of GFP fused to the PtdIns(3,4,5)P-3-binding pleckstrin-homology domain of Akt (GFP-PH-Akt), a fusion protein that indicates the location of PtdIns(3,4,5)P-3. Here, we ectopically inserted exogenous PtdIns(3,4,5)P-3 into the apical plasma membrane of polarized Madin-Darby canine kidney (MDCK) cells. Within 5 min many cells formed protrusions that extended above the apical surface. These protrusions contained basolateral plasma membrane proteins and excluded apical proteins, indicating that their plasma membrane was transformed from apical to basolateral. Addition of PtdIns(3,4,5)P-3 to the basolateral surface of MDCK cells grown as cysts caused basolateral protrusions. MDCK cells grown in the presence of a phosphatidylinositol 3-kinase inhibitor had abnormally short lateral surfaces, indicating that PtdIns(3,4,5)P-3 regulates the formation of the basolateral surface.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Hop Purpan, Inst Federatif Rech Claude Preval, INSERM Unite 563, IFR30,Dept Lipoprot & Mediateurs Lipid, F-31059 Toulouse, France; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gassama-Diagne, A (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	gassama@toulouse.inserm.fr	Martin-Belmonte, Fernando/J-8029-2014	Martin-Belmonte, Fernando/0000-0002-2564-4430; mostov, keith/0000-0002-8123-6247				Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Gibson MC, 2003, CURR OPIN CELL BIOL, V15, P747, DOI 10.1016/j.ceb.2003.10.008; Hansen SH, 2000, MOL CELL BIOL, V20, P9364, DOI 10.1128/MCB.20.24.9364-9375.2000; Huang YE, 2003, MOL BIOL CELL, V14, P1913, DOI 10.1091/mbc.E02-10-0703; Kierbel A, 2005, MOL BIOL CELL, V16, P2577, DOI 10.1091/mbc.E04-08-0717; LIPSHUTZ JH, 2001, CURRENT PROTOCOLS CE; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Macara AG, 2004, CURR BIOL, V14, pR160, DOI 10.1016/j.cub.2004.01.048; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Tian W, 2003, EMBO REP, V4, P982, DOI 10.1038/sj.embor.embor947; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5; Yu W, 2005, MOL BIOL CELL, V16, P433, DOI 10.1091/mbc.e04-05-0435; Yu W, 2003, MOL BIOL CELL, V14, P748, DOI 10.1091/mbc.E02-06-0350	29	226	231	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					963	U64		10.1038/ncb1461	http://dx.doi.org/10.1038/ncb1461			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16921364				2022-12-25	WOS:000240241700012
J	Norton, L; Massague, J				Norton, Larry; Massague, Joan			Is cancer a disease of self-seeding?	NATURE MEDICINE			English	Editorial Material							GENE-EXPRESSION SIGNATURE; STEM-CELLS; BREAST; TUMOR; BEVACIZUMAB; METASTASIS; SURVIVAL	The high cell density, rapid growth rate and large population size of cancer are conventionally attributed to a pathologically high ratio of cell production to cell death. Yet these features might also or instead result from inappropriate cell movement, already understood to underlie invasion and metastasis. This integrating concept could induce a broadening of our existing anticancer pharmacopoeia, which, with mitosis as its predominant target, is now seldom curative.	Cornell Univ, Weill Coll Med, New York, NY 10021 USA; Cornell Univ, Dept Med, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Norton, L (corresponding author), Cornell Univ, Weill Coll Med, New York, NY 10021 USA.	nortonpub@mskcc.org		Massague, Joan/0000-0001-9324-8408; Norton, Larry/0000-0003-3701-9250	NCI NIH HHS [P01-CA94060-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA094060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; DANG CT, 2003, CANC MED, P645; *E COOP ONC GROUP, 2004, CLIN LUNG CANC, V6, P276; Foekens JA, 2006, J CLIN ONCOL, V24, P1665, DOI 10.1200/JCO.2005.03.9115; Folkman J, 2003, CANC MED, P161; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3706, DOI 10.1200/JCO.2005.00.232; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; NORTON L, 1990, PROG CLIN BIOL RES, V354, P109; Norton L, 2001, ONCOLOGIST, V6, P30; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Rizki A, 2004, CANCER CELL, V6, P1, DOI 10.1016/j.ccr.2004.06.019; Schneider BS, 1996, P ROY SOC B-BIOL SCI, V263, P129, DOI 10.1098/rspb.1996.0020; Troester MA, 2004, CANCER RES, V64, P4218, DOI 10.1158/0008-5472.CAN-04-0107; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967	25	267	271	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2006	12	8					875	878		10.1038/nm0806-875	http://dx.doi.org/10.1038/nm0806-875			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	071TS	16892025				2022-12-25	WOS:000239626200011
J	Perkins, MD; Small, PM				Perkins, Mark D.; Small, Peter M.			Partnering for better microbial diagnostics	NATURE BIOTECHNOLOGY			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; INFECTION; SPECIMENS		FIND, CH-1216 Cointrin, Switzerland; Bill & Melinda Gates Fdn, Global Hlth Program, Seattle, WA 98102 USA	Bill & Melinda Gates Foundation	Perkins, MD (corresponding author), FIND, 71 Ave Louis Casai, CH-1216 Cointrin, Switzerland.	peter.small@gatesfoundation.org						Albert H, 2002, INT J TUBERC LUNG D, V6, P529; Amexo M, 2004, LANCET, V364, P1896, DOI 10.1016/S0140-6736(04)17446-1; Archibald LK, 1998, CLIN INFECT DIS, V26, P290, DOI 10.1086/516297; Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767; Gutierrez EB, 2002, PATHOL RES PRACT, V198, P339, DOI 10.1078/0344-0338-00264; Johansen IS, 2003, J CLIN MICROBIOL, V41, P4454, DOI 10.1128/JCM.41.9.4454-4456.2003; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Liam CK, 1997, INT J TUBERC LUNG D, V1, P326; Madebo T., 1999, MED GEN MED, pE6; Mori T, 2004, AM J RESP CRIT CARE, V170, P59, DOI 10.1164/rccm.200402-179OC; Pronyk PM, 2004, INT J TUBERC LUNG D, V8, P796; Small PM, 2000, LANCET, V356, P1048, DOI 10.1016/S0140-6736(00)02724-0; *WHO, 2004, GLOB TUB CONTR	13	17	17	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2006	24	8					919	921		10.1038/nbt0806-919	http://dx.doi.org/10.1038/nbt0806-919			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	072VY	16900130				2022-12-25	WOS:000239702300024
J	McLaurin, J; Kierstead, ME; Brown, ME; Hawkes, CA; Lambermon, MHL; Phinney, AL; Darabie, AA; Cousins, JE; French, JE; Lan, MF; Chen, FS; Wong, SSN; Mount, HTJ; Fraser, PE; Westaway, D; St George-Hyslop, P				McLaurin, JoAnne; Kierstead, Meredith E.; Brown, Mary E.; Hawkes, Cheryl A.; Lambermon, Mark H. L.; Phinney, Amie L.; Darabie, Audrey A.; Cousins, Julian E.; French, Janet E.; Lan, Melissa F.; Chen, Fusheng; Wong, Sydney S. N.; Mount, Howard T. J.; Fraser, Paul E.; Westaway, David; St George-Hyslop, Peter			Cyclohexanehexol inhibitors of A beta aggregation prevent and reverse Alzheimer phenotype in a mouse model	NATURE MEDICINE			English	Article							AMYLOID PEPTIDES; TRANSGENIC MICE; DISEASE; PROTEIN; INOSITOL; IMMUNIZATION; ANTIBODIES; MEMBRANES; PLAQUES; NEUROPATHOLOGY	When given orally to a transgenic mouse model of Alzheimer disease, cyclohexanehexol stereoisomers inhibit aggregation of amyloid b peptide ( Ab) into high-molecular-weight oligomers in the brain and ameliorate several Alzheimer disease-like phenotypes in these mice, including impaired cognition, altered synaptic physiology, cerebral Ab pathology and accelerated mortality. These therapeutic effects, which occur regardless of whether the compounds are given before or well after the onset of the Alzheimer disease-like phenotype, support the idea that the accumulation of Ab oligomers has a central role in the pathogenesis of Alzheimer disease.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 3H2, Canada; Univ Toronto, Univ Hlth Network, Toronto Western Hosp, Res Inst, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	McLaurin, J (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	j.mclaurin@utoronto.ca	Mount, Howard/B-4097-2013					Auton M, 2005, P NATL ACAD SCI USA, V102, P15065, DOI 10.1073/pnas.0507053102; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Chishti MA, 2001, J BIOL CHEM, V276, P21562, DOI 10.1074/jbc.M100710200; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; Fisher SK, 2002, J NEUROCHEM, V82, P736, DOI 10.1046/j.1471-4159.2002.01041.x; Frenkel D, 2000, P NATL ACAD SCI USA, V97, P11455, DOI 10.1073/pnas.97.21.11455; Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167; HACCOU P, 1995, STAT ANAL BEHAV DATA, P120; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hu L, 2003, NEUROSCIENCE, V121, P421, DOI 10.1016/S0306-4522(03)00394-4; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5; Koppaka V, 2000, BIOCHEMISTRY-US, V39, P10011, DOI 10.1021/bi000619d; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; McLaurin J, 1997, EUR J BIOCHEM, V245, P355, DOI 10.1111/j.1432-1033.1997.t01-2-00355.x; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; McLaurin J, 1998, J MOL BIOL, V278, P183, DOI 10.1006/jmbi.1998.1677; McLaurin J, 2000, J BIOL CHEM, V275, P18495, DOI 10.1074/jbc.M906994199; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mount HTJ, 2004, J NEUROCHEM, V88, P1449, DOI 10.1046/j.1471-4159.2003.02278.x; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Phinney AL, 1999, NEUROSCIENCE, V90, P1207, DOI 10.1016/S0306-4522(98)00645-9; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; SHETTY HU, 1994, BIOL MASS SPECTROM, V23, P440, DOI 10.1002/bms.1200230710; SPECTOR R, 1988, NEUROCHEM RES, V13, P785, DOI 10.1007/BF00971603; Tanaka M, 2004, NAT MED, V10, P148, DOI 10.1038/nm985; Uldry M, 2004, PFLUG ARCH EUR J PHY, V447, P480, DOI 10.1007/s00424-003-1085-0; Uldry M, 2001, EMBO J, V20, P4467, DOI 10.1093/emboj/20.16.4467; Vaucher E, 2002, EXP NEUROL, V175, P398, DOI 10.1006/exnr.2002.7915; Wiltfang J, 2002, J NEUROCHEM, V81, P481, DOI 10.1046/j.1471-4159.2002.00818.x; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062	35	293	321	1	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					801	808		10.1038/nm1423	http://dx.doi.org/10.1038/nm1423			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16767098				2022-12-25	WOS:000238862800067
J	Mount, C; Downton, C				Mount, Claire; Downton, Christian			Alzheimer disease: progress or profit?	NATURE MEDICINE			English	Article							CHOLINESTERASE-INHIBITORS; METAANALYSIS		Wood Mackenzie, London EC2N 1HN, England		Mount, C (corresponding author), Wood Mackenzie, London EC2N 1HN, England.	claire.mount@woodmac.com						*ALZH ASS FACT SHE, 2005, FDA APPR CHOL INH; *ALZH DIS INT, 1999, FACTSH 3 PREV DEM; *ALZH DIS RES, 2003, 108 C 1 SESS, pS566; Beckett L. A., 2001, ALZ DIS ASSOC DIS, V15, P169, DOI DOI 10.1097/00002093-200110000-00002; Birks J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005593; Farlow MR, 2002, INT J CLIN PRACT, P37; Filonenko V. S, 2003, SOL SYS RES, V37, P2; GEARING M, 1995, NEUROLOGY, V45, P461, DOI 10.1212/WNL.45.3.461; HODES, 2006, NAT MED, P770; Lanctot KL, 2003, CAN MED ASSOC J, V169, P557; *LEW GROUP, 2004, SAV LIV SAV MON DIV; Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110; NICOLL JA, 2003, NAT MED, V9, P389; Schechter LE, 2005, J PHARMACOL EXP THER, V314, P1274, DOI 10.1124/jpet.105.086363; TABET N, 2000, COCHRANE DB SYST REV, V4, P2854; Tariot PN, 2003, ALZ DIS ASSOC DIS, V17, pS105, DOI 10.1097/00002093-200307004-00005; Vas C.J., 2001, ALZHEIMERS DIS BRAIN	17	216	233	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					780	784		10.1038/nm0706-780	http://dx.doi.org/10.1038/nm0706-780			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829947				2022-12-25	WOS:000238862800063
J	Brown, BD; Venneri, MA; Zingale, A; Sergi, LS; Naldini, L				Brown, Brian D.; Venneri, Mary Anna; Zingale, Anna; Sergi, Lucia Sergi; Naldini, Luigi			Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer	NATURE MEDICINE			English	Article							IMMUNE-RESPONSE; THERAPEUTIC-EFFICACY; LENTIVIRAL VECTORS; HEMOPHILIA-A; FACTOR-IX; CELLS; MICE; IDENTIFICATION; TARGETS; ANTIGEN	MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression by repressing translation of target cellular transcripts. Increasing evidence indicates that miRNAs have distinct expression profiles and play crucial roles in numerous cellular processes, although the extent of miRNA regulation is not well known. By challenging mice with lentiviral vectors encoding target sequences of endogenous miRNAs, we show the efficiency of miRNAs in sharply segregating gene expression among different tissues. Transgene expression from vectors incorporating target sequences for mir-142-3p was effectively suppressed in intravascular and extravascular hematopoietic lineages, whereas expression was maintained in nonhemato-poietic cells. This expression profile, which could not be attained until now, enabled stable gene transfer in immunocompetent mice, thus overcoming a major hurdle to successful gene therapy. Our results provide novel in situ evidence of miRNA regulation and demonstrate a new paradigm in vector design with applications for genetic engineering and therapeutic gene transfer.	San Raffaele Telethon Inst Gene Therapy, HSR TIGET, I-20132 Milan, Italy; Vita Salute Raffaele Univ, San Raffaele Sci Inst, I-20132 Milan, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Naldini, L (corresponding author), San Raffaele Telethon Inst Gene Therapy, HSR TIGET, Via Olgettina 58, I-20132 Milan, Italy.	naldini.luigi@hsr.it	Naldini, Luigi/E-9083-2012	lucia, Sergi Sergi/0000-0002-8631-7433; VENNERI, MARY ANNA/0000-0002-0687-8135; NALDINI, Luigi/0000-0002-7835-527X	Telethon [TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Amendola M, 2005, NAT BIOTECHNOL, V23, P108, DOI 10.1038/nbt1049; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Brown BD, 2004, J THROMB HAEMOST, V2, P111, DOI 10.1111/j.1538-7836.2004.00552.x; Brown BD, 2004, BLOOD, V103, P804, DOI 10.1182/blood-2003-05-1426; Brown BD, 2002, BLOOD, V100, P1133, DOI 10.1182/blood-2001-11-0067; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; De Geest BR, 2003, BLOOD, V101, P2551, DOI 10.1182/blood-2002-07-2146; De Palma M, 2005, BLOOD, V105, P2307, DOI 10.1182/blood-2004-03-0798; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Follenzi A, 2004, BLOOD, V103, P3700, DOI 10.1182/blood-2003-09-3217; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; High K, 2005, J THROMB HAEMOST, V3, P1682, DOI 10.1111/j.1538-7836.2005.01460.x; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lois C, 2002, SCIENCE, V295, P868, DOI 10.1126/science.1067081; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Mingozzi F, 2003, J CLIN INVEST, V111, P1347, DOI 10.1172/JCI200316887; Onoe T, 2005, J IMMUNOL, V175, P139, DOI 10.4049/jimmunol.175.1.139; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Steiniger B, 2003, J HISTOCHEM CYTOCHEM, V51, P655, DOI 10.1177/002215540305100511; Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	30	382	464	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2006	12	5					585	591		10.1038/nm1398	http://dx.doi.org/10.1038/nm1398			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16633348				2022-12-25	WOS:000238149100044
J	Mason, JT; Xu, LX; Sheng, ZM; O'Leary, TJ				Mason, JT; Xu, LX; Sheng, ZM; O'Leary, TJ			A liposome-PCR assay for the ultrasensitive detection of biological toxins	NATURE BIOTECHNOLOGY			English	Article							BOTULINUM	We describe an ultrasensitive immunoassay for detecting biotoxins that uses liposomes with encapsulated DNA reporters, and ganglioside receptors embedded in the bilayer, as a detection reagent. After immobilization of the target biotoxin by a capture antibody and co-binding of the detection reagent, the liposomes are ruptured to release the reporters, which are quantified by real-time PCR. Assays for cholera and botulinum toxins are several orders of magnitude more sensitive than current detection methods.	Armed Forces Inst Pathol, Dept Biophys, Rockville, MD 20850 USA; Armed Forces Inst Pathol, Dept Mol Pathol, Rockville, MD 20850 USA; Vet Hlth Adm, Biomed Lab Res & Dev Serv, Washington, DC 20420 USA	United States Department of Defense; United States Department of Defense; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Mason, JT (corresponding author), Armed Forces Inst Pathol, Dept Biophys, 1413 Res Blvd, Rockville, MD 20850 USA.	mason@afip.osd.mil	Oleary, Timothy/AAE-5219-2021; Oleary, Timothy/AAF-2829-2021	O'LEARY, TIMOTHY/0000-0002-2435-9136				Adler M, 2003, BIOCHEM BIOPH RES CO, V300, P757, DOI 10.1016/S0006-291X(02)02912-1; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Chao HY, 2004, TOXICON, V43, P27, DOI 10.1016/j.toxicon.2003.10.013; SCHENGRUND CL, 1991, J NEUROCHEM, V57, P1024, DOI 10.1111/j.1471-4159.1991.tb08253.x; Singh AK, 2000, ANAL CHEM, V72, P6019, DOI 10.1021/ac000846l; Torchilin Vladimir P., 2003, P193	6	107	120	3	48	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2006	24	5					555	557		10.1038/nbt1201	http://dx.doi.org/10.1038/nbt1201			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	039TX	16617336				2022-12-25	WOS:000237331300030
J	Rousseaux, C; Thuru, X; Gelot, A; Barnich, N; Neut, C; Dubuquoy, L; Dubuquoy, C; Merour, E; Geboes, K; Chamaillard, M; Ouwehand, A; Leyer, G; Carcano, D; Colombel, JF; Ardid, D; Desreumaux, P				Rousseaux, Christel; Thuru, Xavier; Gelot, Agathe; Barnich, Nicolas; Neut, Christel; Dubuquoy, Laurent; Dubuquoy, Caroline; Merour, Emilie; Geboes, Karen; Chamaillard, Mathias; Ouwehand, Arthur; Leyer, Greg; Carcano, Didier; Colombel, Jean-Frederic; Ardid, Denis; Desreumaux, Pierre			Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors	NATURE MEDICINE			English	Article							IRRITABLE-BOWEL-SYNDROME; COLON; HYPERSENSITIVITY; EXPRESSION	Abdominal pain is common in the general population and, in patients with irritable bowel syndrome, is attributed to visceral hypersensitivity. We found that oral administration of specific Lactobacillus strains induced the expression of mu-opioid and cannabinoid receptors in intestinal epithelial cells, and mediated analgesic functions in the gut-similar to the effects of morphine. These results suggest that the microbiology of the intestinal tract influences our visceral perception, and suggest new approaches for the treament of abdominal pain and irritable bowel syndrome.	Hop Swynghedauw, INSERM, U795, F-59037 Lille, France; Univ Lille 2, Hop Swynghedauw, F-59037 Lille, France; Hop Huriez, Digest Tract Dis & Nutr Dept, F-59037 Lille, France; INSERM, U766, F-63001 Clermont Ferrand, France; Univ Clermont Ferrand 1, Lab Pharmacol Med, Unite Format & Rech Med, F-63001 Clermont Ferrand, France; Inst Univ & Technol Biol, F-63172 Aubiere, France; Fac Med & Pharm, Lab Pathogenie Bacterienne Intestinale, Ctr Biomed Rech & Valorisat, F-63001 Clermont Ferrand, France; Katholieke Univ Leuven, Dept Pathol & Gastroenterol, B-3000 Louvain, Belgium; Danisco Cultures Div, F-75017 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); KU Leuven	Desreumaux, P (corresponding author), Hop Swynghedauw, INSERM, U795, Rue A Verhaeghe, F-59037 Lille, France.	pdesreumaux@hotmail.com	ardid, denis/K-2234-2015; Neut, Christel/S-2521-2018; Thuru, Xavier/F-7695-2018; Dubuquoy, laurent/J-4978-2015; Dubuquoy, Laurent/N-1623-2019; GELOT, Agathe/K-5552-2015; Neut, Christel/AAA-5153-2021; Chamaillard, Mathias/L-6542-2013; Geboes, Karen P/E-1752-2018; Desreumaux, Pierre F/R-6877-2018	Neut, Christel/0000-0002-2036-6152; Thuru, Xavier/0000-0002-0998-4160; Dubuquoy, laurent/0000-0003-3596-5497; Chamaillard, Mathias/0000-0002-0243-9717; Geboes, Karen P/0000-0002-1003-666X; Desreumaux, Pierre F/0000-0002-6127-5281; Ouwehand, Arthur/0000-0001-8348-0633; Barnich, Nicolas/0000-0001-9465-7844				Altermann E, 2005, P NATL ACAD SCI USA, V102, P3906, DOI 10.1073/pnas.0409188102; Bourdu S, 2005, GASTROENTEROLOGY, V128, P1996, DOI 10.1053/j.gastro.2005.03.082; Cervero F, 1999, LANCET, V353, P2145, DOI 10.1016/S0140-6736(99)01306-9; D'Argenio G, 2006, FASEB J, V20, P568, DOI 10.1096/fj.05-4943fje; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Kajander K, 2005, ALIMENT PHARM THER, V22, P387, DOI 10.1111/j.1365-2036.2005.02579.x; Kamiya T, 2006, GUT, V55, P191, DOI 10.1136/gut.2005.070987; O'Mahony L, 2005, GASTROENTEROLOGY, V128, P541, DOI 10.1053/j.gastro.2004.11.050; Philippe D, 2006, GUT, V55, P815, DOI 10.1136/gut.2005.080887; Philippe D, 2003, J CLIN INVEST, V111, P1329, DOI 10.1172/JCI200316750; Sanders ME, 2001, J DAIRY SCI, V84, P319, DOI 10.3168/jds.S0022-0302(01)74481-5; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Verdu EF, 2006, GUT, V55, P182, DOI 10.1136/gut.2005.066100; Wright K, 2005, GASTROENTEROLOGY, V129, P437, DOI 10.1053/j.gastro.2005.05.026	15	526	569	2	69	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					35	37		10.1038/nm1521	http://dx.doi.org/10.1038/nm1521			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17159985				2022-12-25	WOS:000243301800033
J	Ni, YX; Zhao, XH; Bao, GB; Zou, L; Teng, L; Wang, Z; Song, M; Xiong, JX; Bai, Y; Pei, G				Ni, Yanxiang; Zhao, Xiaohui; Bao, Guobin; Zou, Lin; Teng, Lin; Wang, Zhu; Song, Min; Xiong, Jiaxiang; Bai, Yun; Pei, Gang			Activation of beta(2)-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation	NATURE MEDICINE			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; A-BETA; TRANSGENIC MICE; ENDOCYTIC PATHWAY; PRESENILIN; BRAIN; STRESS; OLIGOMERIZATION; TRAFFICKING	Amyloid plaque is the hallmark and primary cause of Alzheimer disease. Mutations of presenilin-1, the gamma-secretase catalytic subunit, can affect amyloid-beta (A beta) production and Alzheimer disease pathogenesis. However, it is largely unknown whether and how c-secretase activity and amyloid plaque formation are regulated by environmental factors such as stress, which is mediated by receptors including beta(2)-adrenergic receptor (beta(2)-AR). Here we report that activation of beta(2)-AR enhanced gamma-secretase activity and thus A beta production. This enhancement involved the association of beta(2)-AR with presenilin-1 and required agonist-induced endocytosis of beta(2)-AR and subsequent trafficking of gamma-secretase to late endosomes and lysosomes, where A beta production was elevated. Similar effects were observed after activation of delta-opioid receptor. Furthermore, chronic treatment with beta(2)-AR agonists increased cerebral amyloid plaques in an Alzheimer disease mouse model. Thus, beta(2)-AR activation can stimulate c-secretase activity and amyloid plaque formation, which suggests that abnormal activation of beta(2)-AR might contribute to A beta accumulation in Alzheimer disease pathogenesis.	Chinese Acad Sci, Shanghai Inst Biol Sci, Mol Cell Biol Lab, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Chinese Acad Sci, Grad Sch, Shanghai 200031, Peoples R China; Third Mil Med Univ, Dept Med Genet, Chongqing 400038, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Army Medical University	Pei, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Mol Cell Biol Lab, Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	gpei@sibs.ac.cn	Zhao, Xiaohui/G-7626-2012; Wang, Zhu/H-3844-2013					Bahadoran P, 2003, J BIOL CHEM, V278, P11386, DOI 10.1074/jbc.M211996200; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Cai DM, 2006, P NATL ACAD SCI USA, V103, P1941, DOI 10.1073/pnas.0510708103; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cataldo AM, 2000, AM J PATHOL, V157, P277, DOI 10.1016/S0002-9440(10)64538-5; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Farmery MR, 2003, J BIOL CHEM, V278, P24277, DOI 10.1074/jbc.M211992200; Ferry B, 1999, BIOL PSYCHIAT, V46, P1140, DOI 10.1016/S0006-3223(99)00157-2; FOLLESA P, 1993, MOL PHARMACOL, V43, P132; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gonzalez-Gaitan Marcos, 2003, Cell, V115, P513, DOI 10.1016/S0092-8674(03)00932-2; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; Guo DF, 2001, CELL RES, V11, P165, DOI 10.1038/sj.cr.7290083; Hall RA, 2002, CIRC RES, V91, P672, DOI 10.1161/01.RES.0000037000.74258.03; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Khachaturian AS, 2006, ARCH NEUROL-CHICAGO, V63, P686, DOI 10.1001/archneur.63.5.noc60013; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Langui D, 2004, AM J PATHOL, V165, P1465, DOI 10.1016/S0002-9440(10)63405-0; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Ramsden M, 2003, J NEUROCHEM, V87, P1052, DOI 10.1046/j.1471-4159.2003.02114.x; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; RussoNeustadt A, 1997, J NEUROSCI, V17, P5573; Saito T, 2005, NAT MED, V11, P434, DOI 10.1038/nm1206; Seachrist JL, 2003, LIFE SCI, V74, P225, DOI 10.1016/j.lfs.2003.09.009; Shenoy SK, 2006, J BIOL CHEM, V281, P1261, DOI 10.1074/jbc.M506576200; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Soeder KJ, 1999, J BIOL CHEM, V274, P12017, DOI 10.1074/jbc.274.17.12017; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tanzi RE, 2005, NAT NEUROSCI, V8, P977, DOI 10.1038/nn0805-977; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vetrivel KS, 2004, J BIOL CHEM, V279, P44945, DOI 10.1074/jbc.M407986200; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Walters MR, 2003, J CARDIOVASC PHARM, V42, P266, DOI 10.1097/00005344-200308000-00017; Wang YP, 2004, CELL RES, V14, P467, DOI 10.1038/sj.cr.7290249; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wilson RS, 2003, NEUROLOGY, V61, P1479, DOI 10.1212/01.WNL.0000096167.56734.59; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Yin DL, 2000, J EXP MED, V191, P1423, DOI 10.1084/jem.191.8.1423	49	173	191	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2006	12	12					1390	1396		10.1038/nm1485	http://dx.doi.org/10.1038/nm1485			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17115048				2022-12-25	WOS:000242618200019
J	Wolf, A; Keil, R; Gotzl, O; Mun, A; Schwarze, K; Lederer, M; Huttelmaier, S; Hatzfeld, M				Wolf, Annika; Keil, Rene; Goetzl, Oliver; Mun, Andrej; Schwarze, Katrin; Lederer, Marcell; Huettelmaier, Stefan; Hatzfeld, Mechthild			The armadillo protein p0071 regulates Rho signalling during cytokinesis	NATURE CELL BIOLOGY			English	Article							FAMILY GTPASES; LIVING CELLS; EXCHANGE FACTOR; ECT2; ADHESION; DOMAINS; ACTIN; VISUALIZATION; ACCUMULATION; MEMBRANE	Cytokinesis requires the spatio-temporal coordination of cell-cycle control and cytoskeletal reorganization. Members of the Rho-family of GTPases are crucial regulators of this process and assembly of the contractile ring depends on local activation of Rho signalling(1-4). Here, we show that the armadillo protein p0071, unlike its relative p120(ctn), is localized at the midbody during cytokinesis and is essential for cell division. Both knockdown and overexpression of p0071 interfered with normal cell growth and survival due to cytokinesis defects with formation of multinucleated cells and induction of apoptosis. This failure of cytokinesis seemingly correlated with the deregulation of Rho activity in response to altered p0071 expression. The function of p0071 in regulating Rho activity occurred through an association of p0071 with RhoA, as well as the physical and functional interaction of p0071 with Ect2, the one Rho guanine-nucleotide exchange factor (GEF) essential for cytokinesis. These findings support an essential role for p0071 in spatially regulating restricted Rho signalling during cytokinesis.	Univ Halle Wittenberg, Inst Pathophysiol, Div Pathobiochem, D-06114 Halle, Germany; Univ Halle Wittenberg, Jr Grp Posttranscript Gene Regulat, ZAMED, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg	Hatzfeld, M (corresponding author), Univ Halle Wittenberg, Inst Pathophysiol, Div Pathobiochem, Hollystr 1, D-06114 Halle, Germany.	mechthild.hatzfeld@medizin.uni-halle.de	Hüttelmaier, Stefan/AAQ-1203-2021					Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; BOSTOCK CJ, 1971, EXP CELL RES, V68, P163, DOI 10.1016/0014-4827(71)90599-4; Franz CM, 2004, J BIOL CHEM, V279, P6588, DOI 10.1074/jbc.M312812200; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Grosheva I, 2001, J CELL SCI, V114, P695; Hatzfeld M, 2005, EUR J CELL BIOL, V84, P205, DOI 10.1016/j.ejcb.2004.12.016; Hatzfeld M, 1996, J CELL SCI, V109, P2767; Hatzfeld M, 2003, J CELL SCI, V116, P1219, DOI 10.1242/jcs.00275; Hu CD, 2003, NAT BIOTECHNOL, V21, P539, DOI 10.1038/nbt816; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Kim JE, 2005, J BIOL CHEM, V280, P5733, DOI 10.1074/jbc.M409298200; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Murthy K, 2005, CURR BIOL, V15, P724, DOI 10.1016/j.cub.2005.02.055; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Pettitt J, 2003, J CELL BIOL, V162, P15, DOI 10.1083/jcb.200212136; Piekny A, 2005, TRENDS CELL BIOL, V15, P651, DOI 10.1016/j.tcb.2005.10.006; Rackham O, 2004, EMBO J, V23, P3346, DOI 10.1038/sj.emboj.7600341; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Schmidt A, 2005, EUR J CELL BIOL, V84, P189, DOI 10.1016/j.ejcb.2004.12.020; Skop AR, 2004, SCIENCE, V305, P61, DOI 10.1126/science.1097931; Skop AR, 2001, CURR BIOL, V11, P735, DOI 10.1016/S0960-9822(01)00231-7; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Yoshizaki H, 2004, J BIOL CHEM, V279, P44756, DOI 10.1074/jbc.M402292200; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049	29	53	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1432	U78		10.1038/ncb1504	http://dx.doi.org/10.1038/ncb1504			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17115030				2022-12-25	WOS:000242419800020
J	Cheng, T; Petraglia, AL; Li, Z; Thiyagarajan, M; Zhong, ZH; Wu, ZH; Liu, D; Maggirwar, SB; Deane, R; Fernandez, JA; LaRue, B; Griffin, JH; Chopp, M; Zlokovic, BV				Cheng, Tong; Petraglia, Anthony L.; Li, Zhang; Thiyagarajan, Meenakshisundaram; Zhong, Zhihui; Wu, Zhenhua; Liu, Dong; Maggirwar, Sanjay B.; Deane, Rashid; Fernandez, Jose A.; LaRue, Barbra; Griffin, John H.; Chopp, Michael; Zlokovic, Berislav V.			Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage	NATURE MEDICINE			English	Article							FOCAL CEREBRAL-ISCHEMIA; FACTOR-KAPPA-B; ENDOTHELIAL-CELLS; MATRIX METALLOPROTEINASES; NEURONAL DAMAGE; EMBOLIC STROKE; RAT MODEL; RECEPTOR; APOPTOSIS; BARRIER	Brain hemorrhage is a serious complication of tissue plasminogen activator (tPA) therapy for ischemic stroke. Here we report that activated protein C (APC), a plasma serine protease with systemic anticoagulant, anti- inflammatory and antiapoptotic activities, and direct vasculoprotective and neuroprotective activities, blocks tPA- mediated brain hemorrhage after transient brain ischemia and embolic stroke in rodents. We show that APC inhibits a pro- hemorrhagic tPA- induced, NF-kappa B-dependent matrix metalloproteinase-9 pathway in ischemic brain endothelium in vivo and in vitro by acting through protease-activated receptor 1. The present findings suggest that APC may improve thrombolytic therapy for stroke, in part, by reducing tPA- mediated hemorrhage.	Univ Rochester, Med Ctr, Frank P Smith Lab Neurosci & Neurosurg Res, Dept Neurosurg, Rochester, NY 14642 USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI 48202 USA; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	University of Rochester; Henry Ford Health System; Henry Ford Hospital; University of Rochester; Scripps Research Institute	Zlokovic, BV (corresponding author), Univ Rochester, Med Ctr, Frank P Smith Lab Neurosci & Neurosurg Res, Dept Neurosurg, 601 Elmwood Ave, Rochester, NY 14642 USA.	berislav_zlokovic@urmc.rochester.edu	Fernandez, Jose A/A-3211-2008	Fernandez, Jose A/0000-0002-0804-1865; Griffin, John/0000-0002-4302-2547	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063290] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63290] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Deane R, 2004, NEURON, V43, P333, DOI 10.1016/j.neuron.2004.07.017; Domotor E, 2003, BLOOD, V101, P4797, DOI 10.1182/blood-2002-12-3680; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Fernandez JA, 2003, BLOOD CELL MOL DIS, V30, P271, DOI 10.1016/S1079-9796(03)00034-2; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Junge CE, 2003, P NATL ACAD SCI USA, V100, P13019, DOI 10.1073/pnas.2235594100; Laderoute KR, 2005, SEMIN CELL DEV BIOL, V16, P502, DOI 10.1016/j.semcdb.2005.03.005; Lapchak PA, 2000, STROKE, V31, P3034, DOI 10.1161/01.STR.31.12.3034; Li YH, 2003, FEBS LETT, V555, P346, DOI 10.1016/S0014-5793(03)01272-9; Liu D, 2004, NAT MED, V10, P1379, DOI 10.1038/nm1122; Ludeman MJ, 2005, J BIOL CHEM, V280, P13122, DOI 10.1074/jbc.M410381200; Matys T, 2003, NAT MED, V9, P371, DOI 10.1038/nm0403-371; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Nurmi A, 2004, J NEUROCHEM, V91, P755, DOI 10.1111/j.1471-4159.2004.02756.x; Pfefferkorn T, 2003, STROKE, V34, P2025, DOI 10.1161/01.STR.0000083051.93319.28; Riewald M, 2005, J BIOL CHEM, V280, P19808, DOI 10.1074/jbc.M500747200; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Sumii T, 2002, STROKE, V33, P831, DOI 10.1161/hs0302.104542; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Wu ZH, 2003, J NEUROSCI METH, V130, P53, DOI 10.1016/S0165-0270(03)00206-1; Ye XF, 1999, BIOCHEM BIOPH RES CO, V259, P671, DOI 10.1006/bbrc.1999.0846; Zhang L, 2005, CIRCULATION, V112, P3486, DOI 10.1161/CIRCULATIONAHA.104.516757; Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5; Zhang ZG, 2002, CIRCULATION, V106, P740, DOI 10.1161/01.CIR.0000023942.10849.41; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; ZIVIN JA, 1985, SCIENCE, V230, P1289, DOI 10.1126/science.3934754; Zlokovic BV, 2006, NAT MED, V12, P390, DOI 10.1038/nm0406-390; Zlokovic BV, 2005, ANN NEUROL, V58, P474, DOI 10.1002/ana.20602	42	216	224	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1278	1285		10.1038/nm1498	http://dx.doi.org/10.1038/nm1498			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17072311				2022-12-25	WOS:000241844900025
J	Oishi, I; Kawakami, Y; Raya, A; Callol-Massot, C; Belmonte, JCI				Oishi, Isao; Kawakami, Yasuhiko; Raya, Angel; Callol-Massot, Carles; Belmonte, Juan Carlos Izpisua			Regulation of primary cilia formation and left-right patterning in zebrafish by a noncanonical Wnt signaling mediator, duboraya	NATURE GENETICS			English	Article							LEFT-RIGHT ASYMMETRY; PLANAR CELL POLARITY; KUPFFERS VESICLE; GASTRULATION; EMBRYO; ESTABLISHMENT; VERTEBRATES; FRIZZLED-2; ACTIVATION; MECHANISMS	Primary cilia are microtubule-based organelles that project from the surface of nearly every animal cell(1). Although important functions of primary cilia in morphogenesis and tissue homeostasis have been identified2,3, the mechanisms that control the formation of primary cilia are not understood. Here we characterize a zebrafish gene, termed duboraya ( dub), that is essential for ciliogenesis. Knockdown of dub in zebrafish embryos results in both defects in primary cilia formation in Kupffer's vesicle and randomization of left-right organ asymmetries. We show that, at the molecular level, the function of dub in ciliogenesis is regulated by phosphorylation, which in turn depends on Frizzled-2-mediated noncanonical Wnt signaling. We also provide evidence that, at the cellular level, dub function is essential for actin organization in the cells lining Kupffer's vesicle. Taken together, our findings identify a molecular factor that links noncanonical Wnt signaling with the control of left-right axis specification, and provide an entry point for analyzing the mechanisms that regulate primary cilia formation.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; ICREA, Barcelona 08003, Spain; Ctr Regenerat Med Barcelona, Barcelona 08003, Spain	Salk Institute; ICREA; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Centro de Medicina Regenerativa de Barcelona; University of Barcelona	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu	Oishi, Isao/L-8639-2018; Raya, Angel/E-6205-2010	Oishi, Isao/0000-0003-3682-5349; Raya, Angel/0000-0003-2189-9775; Kawakami, Yasuhiko/0000-0002-0043-9705	ICREA Funding Source: Custom	ICREA(ICREA)		Ahumada A, 2002, SCIENCE, V298, P2006, DOI 10.1126/science.1073776; Bisgrove BW, 2003, ANNU REV GENOM HUM G, V4, P1, DOI 10.1146/annurev.genom.4.070802.110428; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Essner JJ, 2005, DEVELOPMENT, V132, P1247, DOI 10.1242/dev.01663; Essner JJ, 2002, NATURE, V418, P37, DOI 10.1038/418037a; Eyers CE, 2005, BIOCHEM J, V389, P127, DOI 10.1042/BJ20050387; Germino GG, 2005, NAT GENET, V37, P455, DOI 10.1038/ng0505-455; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Huang CJ, 2003, DEV DYNAM, V228, P30, DOI 10.1002/dvdy.10356; Kawakami Y, 2005, NATURE, V435, P165, DOI 10.1038/nature03512; Kramer-Zucker AG, 2005, DEVELOPMENT, V132, P1907, DOI 10.1242/dev.01772; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Liu XX, 1999, P NATL ACAD SCI USA, V96, P14383, DOI 10.1073/pnas.96.25.14383; Matsui T, 2005, GENE DEV, V19, P164, DOI 10.1101/gad.1253605; Ng JK, 2002, DEVELOPMENT, V129, P5161; Park TJ, 2006, NAT GENET, V38, P303, DOI 10.1038/ng1753; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; Praetorius HA, 2005, ANNU REV PHYSIOL, V67, P515, DOI 10.1146/annurev.physiol.67.040403.101353; Raya A, 2006, NAT REV GENET, V7, P283, DOI 10.1038/nrg1830; Raya A, 2003, GENE DEV, V17, P1213, DOI 10.1101/gad.1084403; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Ross AJ, 2005, NAT GENET, V37, P1135, DOI 10.1038/ng1644; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Sumanas S, 2001, GENESIS, V30, P114, DOI 10.1002/gene.1043; Tada M, 2000, DEVELOPMENT, V127, P2227; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wheatley DN, 1995, PATHOBIOLOGY, V63, P222, DOI 10.1159/000163955	30	96	98	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	NOV	2006	38	11					1316	1322		10.1038/ng1892	http://dx.doi.org/10.1038/ng1892			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17013396				2022-12-25	WOS:000241592700021
J	Woelk, T; Oldrini, B; Maspero, E; Confalonieri, S; Cavallaro, E; Di Fiore, PP; Polo, S				Woelk, Tanja; Oldrini, Barbara; Maspero, Elena; Confalonieri, Stefano; Cavallaro, Elena; Di Fiore, Pier Paolo; Polo, Simona			Molecular mechanisms of coupled monoubiquitination	NATURE CELL BIOLOGY			English	Article							UBIQUITIN-INTERACTING MOTIFS; GROWTH-FACTOR RECEPTOR; FUNCTIONAL DIVERSITY; BINDING DOMAINS; NEDD4 FAMILY; PROTEIN; TARGET; IDENTIFICATION; UBIQUITYLATION; ENDOCYTOSIS	Many proteins contain ubiquitin-binding domains or motifs (UBDs), such as the UIM (ubiquitin-interacting motif) and are referred to as ubiquitin receptors. Ubiquitin receptors themselves are frequently monoubiquitinated by a process that requires the presence of a UBD and is referred to as coupled monoubiquitination. Using a UIM-containing protein, eps15, as a model, we show here that coupled monoubiquitination strictly depends on the ability of the UIM to bind to monoubiquitin (mUb). We found that the underlying molecular mechanism is based on interaction between the UIM and a ubiquitin ligase (E3), which has itself been modified by ubiquitination. Furthermore, we demonstrate that the in vivo ubiquitination of members of the Nedd4 family of E3 ligases correlates with their ability to monoubiquitinate eps15. Thus, our results clarify the mechanism of coupled monoubiquitination and identify the ubiquitination of E3 ligases as a critical determinant in this process.	FIRC Inst Mol Oncol, IFOM, I-20139 Milan, Italy; European Inst Oncol, I-20141 Milan, Italy; Univ Milan, I-20122 Milan, Italy	IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Milan	Di Fiore, PP (corresponding author), FIRC Inst Mol Oncol, IFOM, Via Adamello 16, I-20139 Milan, Italy.	pierpaolo.difiore@ifom-ieo-campus.it; simona.polo@ifom-ieo-campus.it	Polo, Simona/P-3509-2014; Confalonieri, Stefano/AAQ-6786-2020; Maspero, Elena/E-5735-2016; Di Fiore, Pier Paolo/K-2130-2012	Confalonieri, Stefano/0000-0001-6886-9851; Maspero, Elena/0000-0001-6468-4796; Di Fiore, Pier Paolo/0000-0002-2252-0950; Polo, Simona/0000-0001-5536-9399				Bienko M, 2005, SCIENCE, V310, P1821, DOI 10.1126/science.1120615; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Confalonieri S, 2000, J CELL BIOL, V150, P905, DOI 10.1083/jcb.150.4.905; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; Gao M, 2005, MOL CELL, V19, P581, DOI 10.1016/j.molcel.2005.08.017; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Harvey KF, 2002, J BIOL CHEM, V277, P9307, DOI 10.1074/jbc.M110443200; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Polo Simona, 2003, Sci STKE, V2003, pre17, DOI 10.1126/stke.2132003re17; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Shearwin-Whyatt LM, 2004, J CELL SCI, V117, P3679, DOI 10.1242/jcs.01212; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Stamenova SD, 2004, J BIOL CHEM, V279, P16017, DOI 10.1074/jbc.M313479200; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Tenno T, 2004, GENES CELLS, V9, P865, DOI 10.1111/j.1365-2443.2004.00780.x; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Wang M, 2006, EMBO J, V25, P1710, DOI 10.1038/sj.emboj.7601061; Xu HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200; Zhang Y, 2003, GENE DEV, V17, P2733, DOI 10.1101/gad.1156403	40	149	150	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1246	U23		10.1038/ncb1484	http://dx.doi.org/10.1038/ncb1484			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17013377				2022-12-25	WOS:000241732400013
J	Renwick, A; Thompson, D; Seal, S; Kelly, P; Chagtai, T; Ahmed, M; North, B; Jayatilake, H; Barfoot, R; Spanova, K; McGuffog, L; Evans, DG; Eccles, D; Easton, DF; Stratton, MR; Rahman, N				Renwick, Anthony; Thompson, Deborah; Seal, Sheila; Kelly, Patrick; Chagtai, Tasnim; Ahmed, Munaza; North, Bernard; Jayatilake, Hiran; Barfoot, Rita; Spanova, Katarina; McGuffog, Lesley; Evans, D. Gareth; Eccles, Diana; Easton, Douglas F.; Stratton, Michael R.; Rahman, Nazneen		Breast Cancer Susceptibility	ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles	NATURE GENETICS			English	Article							EARLY-ONSET; CHEK2-ASTERISK-1100DELC; FAMILIES; MISSENSE	We screened individuals from 443 familial breast cancer pedigrees and 521 controls for ATM sequence variants and identified 12 mutations in affected individuals and two in controls (P = 0.0047). The results demonstrate that ATM mutations that cause ataxia-telangiectasia in biallelic carriers are breast cancer susceptibility alleles in monoallelic carriers, with an estimated relative risk of 2.37 (95% confidence interval (c.i.) = 1.51 - 3.78, P = 0.0003). There was no evidence that other classes of ATM variant confer a risk of breast cancer.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ Cambridge, Canc Res UK, Genet Epidemiol Unit, Strangeways Res Labs, Cambridge CB1 8RN, England; St Marys Hosp, Dept Med Genet, Manchester M13 0JH, Lancs, England; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 6YA, Hants, England; Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge CB10 1SA, England	University of London; Institute of Cancer Research - UK; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Manchester; University of Cambridge; Wellcome Trust Sanger Institute	Rahman, N (corresponding author), Inst Canc Res, Sect Canc Genet, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	nazneen.rahman@icr.ac.uk	Evans, D Gareth/AAB-4308-2022; Eccles, Diana/K-6327-2019; Rahman, Nazneen/B-8890-2012; Rahman, Nazneen/D-2802-2013	Evans, D Gareth/0000-0002-8482-5784; Eccles, Diana/0000-0002-9935-3169; Rahman, Nazneen/0000-0003-4376-0440	Medical Research Council [G0000934] Funding Source: Medline; Wellcome Trust [068545/Z/02] Funding Source: Medline; Breast Cancer Now [2003:592] Funding Source: Medline; MRC [G0000934] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Breast Cancer Now; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Antoniou AC, 2003, GENET EPIDEMIOL, V25, P190, DOI 10.1002/gepi.10261; Becker-Catania SG, 2000, MOL GENET METAB, V70, P122, DOI 10.1006/mgme.2000.2998; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Olsen JH, 2005, BRIT J CANCER, V93, P260, DOI 10.1038/sj.bjc.6602658; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sommer SS, 2003, CANCER GENET CYTOGEN, V145, P115, DOI 10.1016/S0165-4608(03)00119-5; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141	13	519	529	0	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2006	38	8					873	875		10.1038/ng1837	http://dx.doi.org/10.1038/ng1837			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16832357				2022-12-25	WOS:000239325700014
J	Sauzeau, V; Sevilla, MA; Rivas-Elena, JV; de Alava, E; Montero, MJ; Lopez-Novoa, JM; Bustelo, XR				Sauzeau, Vincent; Sevilla, Maria A.; Rivas-Elena, Juan V.; de Alava, Enrique; Montero, Maria J.; Lopez-Novoa, Jose M.; Bustelo, Xose R.			Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction	NATURE MEDICINE			English	Article							ELEVATED HEART-RATE; HYPERTENSION; FAMILY; REQUIREMENT; PROTEINS	Although much is known about environmental factors that predispose individuals to hypertension and cardiovascular disease, little information is available regarding the genetic and signaling events involved(1-3). Indeed, few genes associated with the progression of these pathologies have been discovered despite intensive research in animal models and human populations(1-3). Here we identify Vav3, a GDP-GTP exchange factor that stimulates Rho and Rac GTPases(4), as an essential factor regulating the homeostasis of the cardiovascular system. Vav3-deficient mice exhibited tachycardia, systemic arterial hypertension and extensive cardiovascular remodeling. These mice also showed hyperactivity of sympathetic neurons from the time of birth. The high catecholamine levels associated with this condition led to the activation of the renin-angiotensin system, increased levels of kidney-related hormones and the progressive loss of cardiovascular and renal homeostasis. Pharmacological studies with drugs targeting sympathetic and renin-angiotensin responses confirmed the causative role and hierarchy of these events in the development of the Vav3-null mouse phenotype. These observations uncover the crucial role of Vav3 in the regulation of the sympathetic nervous system (SNS) and cardiovascular physiology, and reveal a signaling pathway that could be involved in the pathophysiology of human disease states involving tachycardia and sympathetic hyperactivity with unknown etiologies(2,5,6).	Univ Salamanca, Ctr Invest Canc, E-37007 Salamanca, Spain; Univ Salamanca, Inst Biol Mol & Celular Canc, E-37007 Salamanca, Spain; Univ Salamanca, Red Temat Cooperat, Ctr Canc, CSIC, E-37007 Salamanca, Spain; Univ Salamanca, Dept Fisiol & Farmacol, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Canc, Campus Unamuno, E-37007 Salamanca, Spain.	xbustelo@usal.es	IBIS, SARCOMAS/O-1893-2015; Montero, María José MJ/C-3084-2018; Lopez-Novoa, Jose M/A-3672-2008; Sevilla, M Angeles/J-8146-2017; Sauzeau, Vincent/D-3548-2015; de Alava, Enrique/GOH-0368-2022; Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010	Montero, María José MJ/0000-0003-2125-0378; Sevilla, M Angeles/0000-0003-2960-8514; de Alava, Enrique/0000-0001-8400-046X; Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Sauzeau, Vincent/0000-0002-6187-0312; Lopez-Novoa, Jose M./0000-0002-6211-7269	NCI NIH HHS [R01 CA073735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beevers G, 2001, BRIT MED J, V322, P912, DOI 10.1136/bmj.322.7291.912; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Carrasco GA, 2003, EUR J PHARMACOL, V463, P235, DOI 10.1016/S0014-2999(03)01285-8; CHEVILLARD C, 1988, EUR J PHARMACOL, V147, P23, DOI 10.1016/0014-2999(88)90629-2; DiBona GF, 2004, HYPERTENSION, V43, P147, DOI 10.1161/01.HYP.0000113047.47711.fa; Faccio R, 2005, NAT MED, V11, P284, DOI 10.1038/nm1194; Flores O, 1998, EXP NEPHROL, V6, P39; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; Intengan HD, 2001, HYPERTENSION, V38, P581, DOI 10.1161/hy09t1.096249; Jerkic M, 2004, FASEB J, V18, P609, DOI 10.1096/fj.03-0197fje; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Palatini P, 2006, DRUGS, V66, P133, DOI 10.2165/00003495-200666020-00001; Palatini P, 2004, CLIN EXP HYPERTENS, V26, P637, DOI 10.1081/CEH-200031959; Palatini P, 1999, AM J HYPERTENS, V12, p3S, DOI 10.1016/S0895-7061(98)00207-6; Palatini P, 1999, Curr Hypertens Rep, V1, P219, DOI 10.1007/s11906-999-0024-7; Remuzzi G, 2002, NAT REV DRUG DISCOV, V1, P986, DOI 10.1038/nrd962; Schmieder RE, 2000, J HUM HYPERTENS, V14, P597, DOI 10.1038/sj.jhh.1001044; Staessen JA, 2003, LANCET, V361, P1629, DOI 10.1016/S0140-6736(03)13302-8; Takahashi N, 1999, J AM SOC NEPHROL, V10, P1598; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Tybulewicz VLJ, 2003, IMMUNOL REV, V192, P42, DOI 10.1034/j.1600-065X.2003.00032.x; Valdivielso JM, 2001, AM J PHYSIOL-REG I, V280, pR771, DOI 10.1152/ajpregu.2001.280.3.R771	24	85	86	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					841	845		10.1038/nm1426	http://dx.doi.org/10.1038/nm1426			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16767097	Green Accepted, Green Submitted			2022-12-25	WOS:000238862800073
J	Choi, JM; Ahn, MH; Chae, WJ; Jung, YG; Park, JC; Song, HM; Kim, YE; Shin, JA; Park, CS; Park, JW; Park, TK; Lee, JH; Seo, BF; Kim, KD; Kim, ES; Lee, DH; Lee, SK; Lee, SK				Choi, Je-Min; Ahn, Mi-Hyun; Chae, Wook-Jin; Jung, Yung-Gook; Park, Jae-Chul; Song, Hyun-Mi; Kim, Young-Eun; Shin, Jung-Ah; Park, Choon-Sik; Park, Jung-Won; Park, Tae-Kwann; Lee, Jung-Hoon; Seo, Byung-Fhy; Kim, Kyun-Do; Kim, Eun-Sung; Lee, Dong-Ho; Lee, Seung-Kyou; Lee, Sang-Kyou			Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation	NATURE MEDICINE			English	Article							CD4(+) T-CELLS; AIRWAY HYPERRESPONSIVENESS; IN-VIVO; TYROSINE PHOSPHATASE; INHIBITORY RECEPTORS; MAMMALIAN-CELLS; ASTHMA; MOUSE; ACTIVATION; MODEL	CTLA-4 is a negative regulator of T-cell activation, and its inhibitory effects can be accomplished either by competition with CD28 or by transmitting negative signals through its intracellular domain. To utilize the cytoplasmic domain of CTLA-4 to suppress allergic inflammation, we fused it to a novel protein-transduction domain in the human transcriptional factor Hph-1. Transduction efficiency was verified in vitro and in vivo after ocular, intranasal and intradermal administration. After transduction into T cells, the Hph-1 ctCTLA-4 fusion protein inhibited the production of interleukin (IL)-2, and downregulated CD69 and CD25. Intranasal administration of Hph-1-ctCTLA-4 resulted in markedly reduced infiltration of inflammatory cells, secretion of T helper type 2 (T(H)2) cytokines, serum IgE levels and airway hyper-responsiveness in a mouse model of allergic airway inflammation. These results indicated that Hph-1-ctCTLA-4 constitutes an effective immunosuppressive protein drug for potential use in the treatment of allergic asthma, via nasal administration.	Yonsei Univ, Coll Engn, Dept Biotechnol, Seoul 120749, South Korea; Soonchunhyang Univ Hosp, Genome Res Ctr Allergy & Resp Dis, Puchon 420767, South Korea; Yonsei Univ, Sch Med, Dept Internal Med, Div Allergy & Immunol, Seoul 120749, South Korea; Soonchunhyang Univ Hosp, Dept Ophthalmol, Puchon 420767, South Korea; Chungnam Natl Univ Hosp, Dept Dermatol, Taejon 301721, South Korea; Amorepacific Co, R&D Ctr, Skin Res Inst, Yongin 449729, South Korea; ForHumanTech Co Ltd, Suwon, South Korea	Yonsei University; Soonchunhyang University; Soonchunhyang University Hospital; Yonsei University; Soonchunhyang University; Soonchunhyang University Hospital; Chungnam National University; Chungnam National University Hospital; Samsung	Lee, SK (corresponding author), Yonsei Univ, Coll Engn, Dept Biotechnol, Seoul 120749, South Korea.	sjrlee@yonsei.ac.kr		Park, Tae Kwann/0000-0001-9689-4384; Park, Jung-Won/0000-0003-0249-8749; Choi, Je-Min/0000-0002-9482-710X; Park, Choon-Sik/0000-0003-2977-0255				Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Busch R, 2004, J IMMUNOL METHODS, V286, P97, DOI 10.1016/j.jim.2003.12.012; Calvo CR, 1997, J EXP MED, V186, P1645, DOI 10.1084/jem.186.10.1645; Chikuma S, 2005, J IMMUNOL, V175, P177, DOI 10.4049/jimmunol.175.1.177; Guntermann C, 2002, J IMMUNOL, V168, P4420, DOI 10.4049/jimmunol.168.9.4420; Krautwald S, 2004, J BIOL CHEM, V279, P44005, DOI 10.1074/jbc.M401327200; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; Lee YC, 2002, J IMMUNOL, V168, P3595, DOI 10.4049/jimmunol.168.7.3595; Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298; Myou S, 2003, J IMMUNOL, V171, P4379, DOI 10.4049/jimmunol.171.8.4379; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374, DOI 10.1164/ajrccm/146.2.374; Oh SW, 2002, J IMMUNOL, V168, P1992, DOI 10.4049/jimmunol.168.4.1992; Park JW, 2004, AM J RESP CRIT CARE, V169, P726, DOI 10.1164/rccm.200307-1042OC; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Schneider H, 2000, BIOCHEM BIOPH RES CO, V269, P279, DOI 10.1006/bbrc.2000.2234; Schneider H, 2001, EUR J IMMUNOL, V31, P2042, DOI 10.1002/1521-4141(200107)31:7<2042::AID-IMMU2042>3.0.CO;2-D; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; TEFT WA, 2005, ANNU REV IMMUNOL; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Veldhoen M, 2005, EUR J IMMUNOL, V35, P207, DOI 10.1002/eji.200425542; Vijayakrishnan L, 2004, IMMUNITY, V20, P563, DOI 10.1016/S1074-7613(04)00110-4; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yi LA, 2004, INT IMMUNOL, V16, P539, DOI 10.1093/intimm/dxh055; Zhang JY, 1999, J IMMUNOL, V163, P3012	30	112	118	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2006	12	5					574	579		10.1038/nm1385	http://dx.doi.org/10.1038/nm1385			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604087				2022-12-25	WOS:000238149100042
J	Zilberman, D; Gehring, M; Tran, RK; Ballinger, T; Henikoff, S				Zilberman, Daniel; Gehring, Mary; Tran, Robert K.; Ballinger, Tracy; Henikoff, Steven			Genome-wide analysis of Arabidopsis thaliana DNA methylation uncovers an interdependence between methylation and transcription	NATURE GENETICS			English	Article							TRANSPOSABLE ELEMENTS; GENE-EXPRESSION; CHROMOSOME-WIDE; CG METHYLATION; POLYCOMB GENE; ELONGATION; CHROMATIN; INITIATION; SITES	Cytosine methylation, a common form of DNA modification that antagonizes transcription, is found at transposons and repeats in vertebrates, plants and fungi. Here we have mapped DNA methylation in the entire Arabidopsis thaliana genome at high resolution. DNA methylation covers transposons and is present within a large fraction of A. thaliana genes. Methylation within genes is conspicuously biased away from gene ends, suggesting a dependence on RNA polymerase transit. Genic methylation is strongly influenced by transcription: moderately transcribed genes are most likely to be methylated, whereas genes at either extreme are least likely. In turn, transcription is influenced by methylation: short methylated genes are poorly expressed, and loss of methylation in the body of a gene leads to enhanced transcription. Our results indicate that genic transcription and DNA methylation are closely interwoven processes.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Henikoff, S (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	steveh@fhcrc.org		Henikoff, Steven/0000-0002-7621-8685; Zilberman, Daniel/0000-0002-0123-8649				BARRY C, 1993, P NATL ACAD SCI USA, V90, P4557, DOI 10.1073/pnas.90.10.4557; Belotserkovskaya R, 2004, BBA-GENE STRUCT EXPR, V1677, P87, DOI 10.1016/j.bbaexp.2003.09.017; Berardini TZ, 2004, PLANT PHYSIOL, V135, P745, DOI 10.1104/pp.104.040071; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Chan SWL, 2005, NAT REV GENET, V6, P351, DOI 10.1038/nrg1601; Field LM, 2004, INSECT MOL BIOL, V13, P109, DOI 10.1111/j.0962-1075.2004.00470.x; Freitag M, 2005, CURR OPIN GENET DEV, V15, P191, DOI 10.1016/j.gde.2005.02.003; Gehring M, 2006, CELL, V124, P495, DOI 10.1016/j.cell.2005.12.034; Gilfillan GD, 2006, GENE DEV, V20, P858, DOI 10.1101/gad.1399406; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Hohn T, 1996, P NATL ACAD SCI USA, V93, P8334, DOI 10.1073/pnas.93.16.8334; Jacobsen SE, 2000, CURR BIOL, V10, P179, DOI 10.1016/S0960-9822(00)00324-9; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Jullien PE, 2006, PLANT CELL, V18, P1360, DOI 10.1105/tpc.106.041178; Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979; Kakutani T, 2004, COLD SPRING HARB SYM, V69, P139, DOI 10.1101/sqb.2004.69.139; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kato M, 2004, GENETICS, V168, P961, DOI 10.1534/genetics.104.029637; Kato M, 2003, CURR BIOL, V13, P421, DOI 10.1016/S0960-9822(03)00106-4; Kinoshita T, 2004, SCIENCE, V303, P521, DOI 10.1126/science.1089835; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Lippman Z, 2004, NATURE, V430, P471, DOI 10.1038/nature02651; Liu CL, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-19; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; Rountree MR, 1997, GENE DEV, V11, P2383, DOI 10.1101/gad.11.18.2383; Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543; Schwabish MA, 2006, MOL CELL, V22, P415, DOI 10.1016/j.molcel.2006.03.014; Selker EU, 2004, COLD SPRING HARB SYM, V69, P119, DOI 10.1101/sqb.2004.69.119; Simmen MW, 1999, SCIENCE, V283, P1164, DOI 10.1126/science.283.5405.1164; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; Soppe WJJ, 2000, MOL CELL, V6, P791, DOI 10.1016/S1097-2765(05)00090-0; Svejstrup JQ, 2003, SCIENCE, V301, P1053, DOI 10.1126/science.1088901; Thibaud-Nissen F, 2006, PLANT J, V47, P152, DOI 10.1111/j.1365-313X.2006.02770.x; Tran RK, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r90; Tran RK, 2005, CURR BIOL, V15, P154, DOI 10.1016/j.cub.2005.01.008; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Xiao WY, 2003, DEV CELL, V5, P891, DOI 10.1016/S1534-5807(03)00361-7; Zhang XY, 2006, CELL, V126, P1189, DOI 10.1016/j.cell.2006.08.003; Zilberman D, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-249	41	990	1067	8	167	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2007	39	1					61	69		10.1038/ng1929	http://dx.doi.org/10.1038/ng1929			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17128275				2022-12-25	WOS:000243136500018
J	Choi, SY; Huang, P; Jenkins, GM; Chan, DC; Schiller, J; Frohman, MA				Choi, Seok-Yong; Huang, Ping; Jenkins, Gary M.; Chan, David C.; Schiller, Juergen; Frohman, Michael A.			A common lipid links Mfn-mediated mitochondrial fusion and SNARE-regulated exocytosis	NATURE CELL BIOLOGY			English	Article							BIMOLECULAR FLUORESCENCE COMPLEMENTATION; PHOSPHOLIPASE-D DEFINES; RAT-LIVER MITOCHONDRIA; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; OUTER-MEMBRANE; CELLS; CARDIOLIPIN; PROTEIN; APOPTOSIS	Fusion of vesicles into target membranes during many types of regulated exocytosis requires both SNARE-complex proteins and fusogenic lipids, such as phosphatidic acid. Mitochondrial fusion is less well understood but distinct, as it is mediated instead by the protein Mitofusin (Mfn). Here, we identify an ancestral member of the phospholipase D (PLD) superfamily of lipid-modifying enzymes that is required for mitochondrial fusion. Mitochondrial PLD (MitoPLD) targets to the external face of mitochondria and promotes transmitochondrial membrane adherence in a Mfn-dependent manner by hydrolysing cardiolipin to generate phosphatidic acid. These findings reveal that although mitochondrial fusion and regulated exocytic fusion are mediated by distinct sets of protein machinery, the underlying processes are unexpectedly linked by the generation of a common fusogenic lipid. Moreover, our findings suggest a novel basis for the mitochondrial fragmentation observed during apoptosis.	SUNY Stony Brook, Grad Program Mol & Cellular Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol, Ctr Dev Genet, Stony Brook, NY 11794 USA; CALTECH, Beckman Inst, Div Biol, Pasadena, CA 91125 USA; Univ Leipzig, Fac Med, Inst Med Phys & Biophys, D-04107 Leipzig, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; California Institute of Technology; Leipzig University	Frohman, MA (corresponding author), SUNY Stony Brook, Grad Program Mol & Cellular Biol, Stony Brook, NY 11794 USA.	Michael@pharm.stonybrook.edu	Schiller, Jürgen/A-1500-2008	Schiller, Jürgen/0000-0002-4328-8652; Choi, Seok-Yong/0000-0001-7193-292X	PHS HHS [64166, 71520] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bektas M, 2005, J CELL BIOL, V169, P801, DOI 10.1083/jcb.200407123; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CABLE MB, 1978, P NATL ACAD SCI USA, V75, P1227, DOI 10.1073/pnas.75.3.1227; Cao JS, 2004, J BIOL CHEM, V279, P31727, DOI 10.1074/jbc.M402930200; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Di Paolo G, 2004, NATURE, V431, P415, DOI 10.1038/nature02896; Esposti MD, 2003, CELL DEATH DIFFER, V10, P1300, DOI 10.1038/sj.cdd.4401306; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HOVIUS R, 1993, FEBS LETT, V330, P71, DOI 10.1016/0014-5793(93)80922-H; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Huang P, 2005, MOL BIOL CELL, V16, P2614, DOI 10.1091/mbc.E04-12-1124; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kanaji S, 2000, J CELL BIOL, V151, P277, DOI 10.1083/jcb.151.2.277; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Kuhlenbaumer G, 2002, J NEUROL, V249, P1629, DOI 10.1007/s00415-002-0946-3; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; Leiros I, 2000, STRUCTURE, V8, P655, DOI 10.1016/S0969-2126(00)00150-7; Liu JH, 2003, MOL CANCER RES, V1, P892; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Malka F, 2005, EMBO REP, V6, P853, DOI 10.1038/sj.embor.7400488; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; Nakanishi H, 2006, J CELL SCI, V119, P1406, DOI 10.1242/jcs.02841; Nakanishi H, 2004, MOL BIOL CELL, V15, P1802, DOI 10.1091/mbc.e03-11-0798; Neutzner A, 2005, J BIOL CHEM, V280, P18598, DOI 10.1074/jbc.M500807200; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; Shyu YJ, 2006, BIOTECHNIQUES, V40, P61, DOI 10.2144/000112036; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; VICOGNE J, P NATL ACAD SCI USA, DOI DOI 10.1073/PNAS0606881103; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	40	322	332	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1255	U29		10.1038/ncb1487	http://dx.doi.org/10.1038/ncb1487			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17028579				2022-12-25	WOS:000241732400014
J	Kishimoto, H; Kojima, T; Watanabe, Y; Kagawa, S; Fujiwara, T; Uno, F; Teraishi, F; Kyo, S; Mizuguchi, H; Hashimoto, Y; Urata, Y; Tanaka, N; Fujiwara, T				Kishimoto, Hiroyuki; Kojima, Toru; Watanabe, Yuichi; Kagawa, Shunsuke; Fujiwara, Toshiya; Uno, Futoshi; Teraishi, Fuminori; Kyo, Satoru; Mizuguchi, Hiroyuki; Hashimoto, Yuuri; Urata, Yasuo; Tanaka, Noriaki; Fujiwara, Toshiyoshi			In vivo imaging of lymph node metastasis with telomerase-specific replication-selective adenovirus	NATURE MEDICINE			English	Article							GREEN FLUORESCENT PROTEIN; VISUALIZING GENE-EXPRESSION; FROZEN-SECTION ANALYSIS; CELL LUNG-CANCER; BREAST-CANCER; SENTINEL NODE; BIOPSY; MELANOMA; MICE; DELIVERY	Currently available methods for detection of tumors in vivo such as computed tomography and magnetic resonance imaging are not specific for tumors. Here we describe a new approach for visualizing tumors whose fluorescence can be detected using telomerase-specific replication-competent adenovirus expressing green fluorescent protein (GFP) (OBP-401). OBP-401 contains the replication cassette, in which the human telomerase reverse transcriptase (hTERT) promoter drives expression of E1 genes, and the GFP gene for monitoring viral replication. When OBP-401 was intratumorally injected into HT29 tumors orthotopically implanted into the rectum in BALB/c nu/nu mice, para-aortic lymph node metastasis could be visualized at laparotomy under a three-chip color cooled charged-coupled device camera. Our results indicate that OBP-401 causes viral spread into the regional lymphatic area and selectively replicates in neoplastic lesions, resulting in GFP expression in metastatic lymph nodes. This technology is adaptable to detect lymph node metastasis in vivo as a preclinical model of surgical navigation.	Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Div Surg Oncol, Dept Surg, Okayama 7008558, Japan; Okayama Univ Hosp, Ctr Gene & Cell Therapy, Okayama, Japan; Oncolys BioPharma, Minato Ku, Tokyo 1060032, Japan; Kanazawa Univ, Sch Med, Dept Obstet & Gynecol, Kanazawa, Ishikawa 9208641, Japan; Natl Inst Biomed Innovat, Lab Gene Transfer & Regulat, Ibaraki, Osaka 5670085, Japan	Okayama University; Okayama University; Oncolys BioPharma; Kanazawa University; National Institute of Health Sciences - Japan	Fujiwara, T (corresponding author), Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Div Surg Oncol, Dept Surg, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshi_f@md.okayama-u.ac.jp	Kagawa, Shunsuke/B-2189-2011	Mizuguchi, Hiroyuki/0000-0003-0594-8178; Kagawa, Shunsuke/0000-0002-3610-8211				Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Chao C, 2001, AM J SURG, V182, P609, DOI 10.1016/S0002-9610(01)00794-2; Coello Michael C, 2004, Clin Lung Cancer, V5, P214; Ehrhardt D, 2003, CURR OPIN PLANT BIOL, V6, P622, DOI 10.1016/j.pbi.2003.09.014; Fujiwara T, 2006, J CLIN ONCOL, V24, P1689, DOI 10.1200/JCO.2005.03.4116; Fujiwara T, 2006, INT J CANCER, V119, P432, DOI 10.1002/ijc.21846; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gulec SA, 2001, AM SURGEON, V67, P529; Hasegawa S, 2000, CANCER GENE THER, V7, P1336, DOI 10.1038/sj.cgt.0237; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Kelloff G, 2005, CLIN CANCER RES, V11, P2785, DOI 10.1158/1078-0432.CCR-04-2626; Koopal SA, 2000, CANCER, V89, P1720, DOI 10.1002/1097-0142(20001015)89:8<1720::AID-CNCR11>3.3.CO;2-6; Kuerer HM, 2005, J CLIN ONCOL, V23, P1698, DOI 10.1200/JCO.2005.09.047; MacDonald SLS, 2003, EUR J RADIOL, V45, P18, DOI 10.1016/S0720-048X(02)00300-5; Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3; McMasters KM, 2001, J CLIN ONCOL, V19, P2851, DOI 10.1200/JCO.2001.19.11.2851; Misteli T, 1997, NAT BIOTECHNOL, V15, P961, DOI 10.1038/nbt1097-961; Ohtani S, 2004, MOL CANCER THER, V3, P93; Taki M, 2005, ONCOGENE, V24, P3130, DOI 10.1038/sj.onc.1208460; Tanis PJ, 2001, ANN SURG ONCOL, V8, P222, DOI 10.1007/s10434-001-0222-2; Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037; Tsutsumi S, 2001, CANCER LETT, V169, P77, DOI 10.1016/S0304-3835(00)00622-4; Umeoka T, 2004, CANCER RES, V64, P6259, DOI 10.1158/0008-5472.CAN-04-1335; van Roessel P, 2002, NAT CELL BIOL, V4, pE15, DOI 10.1038/ncb0102-e15; Watanabe T, 2006, EXP CELL RES, V312, P256, DOI 10.1016/j.yexcr.2005.10.026; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; Yang M, 2005, BIOTECHNIQUES, V39, P170, DOI 10.2144/05392BM02	28	142	151	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1213	1219		10.1038/nm1404	http://dx.doi.org/10.1038/nm1404			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17013385	Green Submitted			2022-12-25	WOS:000241102200041
J	Pohlmann, A; Fricke, WF; Reinecke, F; Kusian, B; Liesegang, H; Cramm, R; Eitinger, T; Ewering, C; Potter, M; Schwartz, E; Strittmatter, A; Voss, I; Gottschalk, G; Steinbuchel, A; Friedrich, B; Bowien, B				Pohlmann, Anne; Fricke, Wolfgang Florian; Reinecke, Frank; Kusian, Bernhard; Liesegang, Heiko; Cramm, Rainer; Eitinger, Thomas; Ewering, Christian; Poetter, Markus; Schwartz, Edward; Strittmatter, Axel; Voss, Ingo; Gottschalk, Gerhard; Steinbuechel, Alexander; Friedrich, Baerbel; Bowien, Botho			Genome sequence of the bioplastic-producing "Knallgas" bacterium Ralstonia eutropha H16	NATURE BIOTECHNOLOGY			English	Article							NITRIC-OXIDE; GENE; IDENTIFICATION; BIOSYNTHESIS; REDUCTASE; COMPLEX; FORMATE; OPERON; ENZYME; ACID	sThe H-2-oxidizing lithoautotrophic bacterium Ralstonia eutropha H16 is a metabolically versatile organism capable of subsisting, in the absence of organic growth substrates, on H-2 and CO2 as its sole sources of energy and carbon. R. eutropha H16 first attracted biotechnological interest nearly 50 years ago with the realization that the organism's ability to produce and store large amounts of poly[R-(-)-3-hydroxybutyrate] and other polyesters could be harnessed to make biodegradable plastics. Here we report the complete genome sequence of the two chromosomes of R. eutropha H16. Together, chromosome 1 (4,052,032 base pairs (bp)) and chromosome 2 (2,912,490 bp) encode 6,116 putative genes. Analysis of the genome sequence offers the genetic basis for exploiting the biotechnological potential of this organism and provides insights into its remarkable metabolic versatility.	Humboldt Univ, Inst Biol Mikrobiol, D-10115 Berlin, Germany; Univ Gottingen, Lab Genomanal, D-37077 Gottingen, Germany; Univ Munster, Inst Mol Mikrobiol & Biotechnol, D-48149 Munster, Germany; Univ Gottingen, Inst Mikrobiol & Genet, D-37077 Gottingen, Germany	Humboldt University of Berlin; University of Gottingen; University of Munster; University of Gottingen	Friedrich, B (corresponding author), Humboldt Univ, Inst Biol Mikrobiol, Chausseestr 117, D-10115 Berlin, Germany.	baerbel.friedrich@rz.hu-berlin.de	; Eitinger, Thomas/C-3926-2019	Cramm, Rainer/0000-0002-3630-3885; Liesegang, Heiko/0000-0003-1792-2047; Eitinger, Thomas/0000-0003-1449-6433; Fricke, W. Florian/0000-0003-1586-0962				Antoine R, 2005, J MOL BIOL, V351, P799, DOI 10.1016/j.jmb.2005.05.071; Antoine R, 2003, J BACTERIOL, V185, P1470, DOI 10.1128/JB.185.4.1470-1474.2003; Aragno M., 1992, The prokaryotes: a handbook on the biology of bacteria: ecophysiology, isolation, identification, applications, vol. 1., P344; ARMSTRONG FA, 2006, Patent No. 2006030196; ASRAR J, 2002, BIOPOLYMERS, V4, P53; Bowen D, 1998, SCIENCE, V280, P2129, DOI 10.1126/science.280.5372.2129; Bowien B, 2002, ARCH MICROBIOL, V178, P85, DOI 10.1007/s00203-002-0441-3; Bramer CO, 2001, MICROBIOL-SGM, V147, P2203, DOI 10.1099/00221287-147-8-2203; Burgdorf T, 2001, J MOL MICROB BIOTECH, V3, P619; Cramm R, 1999, FEBS LETT, V460, P6, DOI 10.1016/S0014-5793(99)01315-0; FRIEDRICH CG, 1979, J GEN MICROBIOL, V115, P185, DOI 10.1099/00221287-115-1-185; Ghai R, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-198; GOTTSCHALK G, 1964, ARCH MIKROBIOL, V48, P95, DOI 10.1007/BF00406600; HEUMANN H, 2000, Patent No. 0012140; Holden MTG, 2004, P NATL ACAD SCI USA, V101, P14240, DOI 10.1073/pnas.0403302101; Ihara M, 2006, PHOTOCHEM PHOTOBIOL, V82, P676, DOI 10.1562/2006-01-16-RA-778; JOHNSON BF, 1971, J BACTERIOL, V107, P468, DOI 10.1128/JB.107.2.468-475.1971; KERSTERS K, 1984, BERGEYS MANUAL SYSTE, V1, P381; Kim DY, 2005, BIOMACROMOLECULES, V6, P897, DOI 10.1021/bm049334x; KUNG SS, 1992, J BACTERIOL, V174, P8023, DOI 10.1128/JB.174.24.8023-8029.1992; LEE SY, 2005, BIOTECHNOLOGY BIOPOL, P207; Lutke-Eversloh T, 2002, NAT MATER, V1, P236, DOI 10.1038/nmat773; Lutz BJ, 2005, ANAL CHEM, V77, P4969, DOI 10.1021/ac050313i; Nierman WC, 2004, P NATL ACAD SCI USA, V101, P14246, DOI 10.1073/pnas.0403306101; Oh JI, 1998, J BIOL CHEM, V273, P26349, DOI 10.1074/jbc.273.41.26349; Overbeek R, 2003, NUCLEIC ACIDS RES, V31, P164, DOI 10.1093/nar/gkg148; Overbeek R, 2005, NUCLEIC ACIDS RES, V33, P5691, DOI 10.1093/nar/gki866; PEMBERTON JM, 1979, PLASMIDS MED ENV COM, P287; Pohlmann A, 2000, MOL MICROBIOL, V38, P626, DOI 10.1046/j.1365-2958.2000.02157.x; Potter M, 2004, MICROBIOL-SGM, V150, P2301, DOI 10.1099/mic.0.26970-0; Ren QH, 2005, PLOS COMPUT BIOL, V1, P190, DOI 10.1371/journal.pcbi.0010027; Saegusa H, 2002, J BIOSCI BIOENG, V94, P106, DOI 10.1263/jbb.94.106; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; Schiex T, 2003, NUCLEIC ACIDS RES, V31, P3738, DOI 10.1093/nar/gkg610; SCHLEGEL HG, 1965, NATURE, V205, P308, DOI 10.1038/205308b0; SCHLEGEL HG, 1961, NATURE, V191, P463, DOI 10.1038/191463a0; Schwartz E, 2001, FEMS MICROBIOL LETT, V201, P213, DOI 10.1111/j.1574-6968.2001.tb10759.x; Schwartz E, 2003, J MOL BIOL, V332, P369, DOI 10.1016/S0022-2836(03)00894-5; SCHWARTZ E, 2003, PROKARYOTES EVOLVING; Siedow A, 1999, J BACTERIOL, V181, P4919, DOI 10.1128/JB.181.16.4919-4928.1999; Slater S, 1998, J BACTERIOL, V180, P1979, DOI 10.1128/JB.180.8.1979-1987.1998; Staden R, 1996, MOL BIOTECHNOL, V5, P233, DOI 10.1007/BF02900361; Steinbuchel A, 1998, TRENDS BIOTECHNOL, V16, P419, DOI 10.1016/S0167-7799(98)01194-9; STEINBUECHEL A, 1992, Current Opinion in Biotechnology, V3, P291, DOI 10.1016/0958-1669(92)90107-T; Tech Maike, 2003, In Silico Biology, V3, P441; Vincent KA, 2005, P NATL ACAD SCI USA, V102, P16951, DOI 10.1073/pnas.0504499102; WINDHOVEL U, 1991, MOL MICROBIOL, V5, P2695, DOI 10.1111/j.1365-2958.1991.tb01978.x; York GM, 2003, J BACTERIOL, V185, P3788, DOI 10.1128/JB.185.13.3788-3794.2003	48	416	886	2	111	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2006	24	10					1257	1262		10.1038/nbt1244	http://dx.doi.org/10.1038/nbt1244			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	093TG	16964242	Green Published, hybrid			2022-12-25	WOS:000241191700029
J	Yoshioka, M; Yuasa, S; Matsumura, K; Kimura, K; Shiomi, T; Kimura, N; Shukunami, C; Okada, Y; Mukai, M; Shin, H; Yozu, R; Sata, M; Ogawa, S; Hiraki, Y; Fukuda, K				Yoshioka, Masatoyo; Yuasa, Shinsuke; Matsumura, Keisuke; Kimura, Kensuke; Shiomi, Takayuki; Kimura, Naritaka; Shukunami, Chisa; Okada, Yasunori; Mukai, Makio; Shin, Hankei; Yozu, Ryohei; sata, Maka Sata; Ogawa, Satoshi; Hiraki, Yuji; Fukuda, Keiichi			Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis	NATURE MEDICINE			English	Article							AORTIC-VALVE CALCIFICATION; GROWTH-PLATE CHONDROCYTES; INTERSTITIAL-CELLS; ENDOTHELIAL-CELLS; MESSENGER-RNA; EXPRESSION; CARTILAGE; HEART; LOCALIZATION; INHIBITOR	The avascularity of cardiac valves is abrogated in several valvular heart diseases (VHDs). This study investigated the molecular mechanisms underlying valvular avascularity and its correlation with VHD. Chondromodulin-l, an antiangiogenic factor isolated from cartilage, is abundantly expressed in cardiac valves. Gene targeting of chondromodulin-l resulted in enhanced Vegf-A expression, angiogenesis, lipid deposition and calcification in the cardiac valves of aged mice. Echocardiography showed aortic valve thickening, calcification and turbulent flow, indicative of early changes in aortic stenosis. Conditioned medium obtained from cultured valvular interstitial cells strongly inhibited tube formation and mobilization of endothelial cells and induced their apoptosis; these effects were partially inhibited by chondromodulin-l small interfering RNA. In human VHD, including cases associated with infective endocarditis, rheumatic heart disease and atherosclerosis, VEGF-A expression, neovascularization and calcification were observed in areas of chondromodulin-l downregulation. These findings provide evidence that chondromodulin-l has a pivotal role in maintaining valvular normal function by preventing angiogenesis that may lead to VHD.	Keio Univ, Sch Med, Dept Regenerat Med & Adv Cardiac Therapeut, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Cardiopulm Div, Dept Internal Med,Shinjiku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Cardiovasc Surg, Shinjuku Ku, Tokyo 1608582, Japan; Kyoto Univ, Dept Cellular Differentiat, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Keio Univ, Sch Med, Div Diagnost Pathol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan	Keio University; Keio University; Keio University; Keio University; Kyoto University; Keio University; University of Tokyo	Fukuda, K (corresponding author), Keio Univ, Sch Med, Dept Regenerat Med & Adv Cardiac Therapeut, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kfukuda@sc.itc.keio.ac.jp	Okada, Yasunori/B-5550-2014; Shukunami, Chisa/G-2887-2019; Yuasa, Shinsuke/L-8310-2013; Shiomi, Takayuki/A-2228-2014; Fukuda, Keiichi/L-3777-2013	Okada, Yasunori/0000-0001-9208-4755; Shukunami, Chisa/0000-0001-5616-6761; Shiomi, Takayuki/0000-0002-4250-1204; Yuasa, Shinsuke/0000-0001-5593-7552				Agmon Y, 2001, J AM COLL CARDIOL, V38, P827, DOI 10.1016/S0735-1097(01)01422-X; Akiyama H, 2004, P NATL ACAD SCI USA, V101, P6502, DOI 10.1073/pnas.0401711101; Azizan A, 2001, J BIOL CHEM, V276, P23632, DOI 10.1074/jbc.M009967200; Camenisch TD, 2002, DEV BIOL, V248, P170, DOI 10.1006/dbio.2002.0731; Chalajour F, 2004, EXP CELL RES, V298, P455, DOI 10.1016/j.yexcr.2004.04.034; CHANTHOMAS PS, 1993, DEV DYNAM, V197, P203, DOI 10.1002/aja.1001970305; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dietz UH, 1999, DEV DYNAM, V216, P233, DOI 10.1002/(SICI)1097-0177(199911)216:3<233::AID-DVDY2>3.0.CO;2-G; Enomoto H, 2003, AM J PATHOL, V162, P171, DOI 10.1016/S0002-9440(10)63808-4; FILIP DA, 1986, CIRC RES, V59, P310, DOI 10.1161/01.RES.59.3.310; Fondard O, 2005, EUR HEART J, V26, P1333, DOI 10.1093/eurheartj/ehi248; Fujimoto N, 2000, METH MOL B, V151, P347, DOI 10.1385/1-59259-046-2:347; Funaki H, 2001, INVEST OPHTH VIS SCI, V42, P1193; Gotlieb AI, 2002, J THORAC CARDIOV SUR, V124, P591, DOI 10.1067/mtc.2002.123812; HAMMON JW, 1974, J THORAC CARDIOV SUR, V68, P352; Hiraki Y, 1997, FEBS LETT, V415, P321, DOI 10.1016/S0014-5793(97)01151-4; Hiraki Y, 1999, EUR J BIOCHEM, V260, P869, DOI 10.1046/j.1432-1327.1999.00227.x; Hiraki Y, 1991, Seikagaku, V63, P1449; Hiraki Y, 1997, J BIOL CHEM, V272, P32419, DOI 10.1074/jbc.272.51.32419; Ikeda T, 2004, ARTHRITIS RHEUM-US, V50, P3561, DOI 10.1002/art.20611; Inoue H, 1997, BIOCHEM BIOPH RES CO, V241, P395, DOI 10.1006/bbrc.1997.7820; Kyuwa S, 1997, EXP ANIM TOKYO, V46, P11, DOI 10.1538/expanim.46.11; LESTER W, 1988, LAB INVEST, V59, P710; LITWIN SE, 1994, CIRCULATION, V89, P345, DOI 10.1161/01.CIR.89.1.345; Mazzone A, 2004, J AM COLL CARDIOL, V43, P1670, DOI 10.1016/j.jacc.2003.12.041; Mohler ER, 2001, CIRCULATION, V103, P1522, DOI 10.1161/01.cir.103.11.1522; Moulton KS, 2003, P NATL ACAD SCI USA, V100, P4736, DOI 10.1073/pnas.0730843100; Nakamichi Y, 2003, MOL CELL BIOL, V23, P636, DOI 10.1128/MCB.23.2.636-644.2003; O'Brien KD, 2002, CIRCULATION, V106, P2224, DOI 10.1161/01.CIR.0000035655.45453.D2; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; OBrien KD, 1996, CIRCULATION, V93, P672, DOI 10.1161/01.CIR.93.4.672; Oshima Y, 2003, INVEST OPHTH VIS SCI, V44, P1814, DOI 10.1167/iovs.02-0664; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; Pohle K, 2004, MAYO CLIN PROC, V79, P1242, DOI 10.4065/79.10.1242; Rabkin E, 2001, CIRCULATION, V104, P2525, DOI 10.1161/hc4601.099489; Rajamannan NM, 2003, CIRCULATION, V107, P2181, DOI 10.1161/01.CIR.0000070591.21548.69; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Sachdev SW, 2001, MECH DEVELOP, V105, P157, DOI 10.1016/S0925-4773(01)00417-8; Shukunami C, 1999, INT J DEV BIOL, V43, P39; Shukunami C, 1998, BIOCHEM BIOPH RES CO, V249, P885, DOI 10.1006/bbrc.1998.9233; Shukunami C, 1999, FEBS LETT, V456, P165, DOI 10.1016/S0014-5793(99)00931-X; Shworak NW, 2004, CURR OPIN CARDIOL, V19, P140, DOI 10.1097/00001573-200403000-00013; Soini Y, 2003, HUM PATHOL, V34, P756, DOI 10.1016/S0046-8177(03)00245-4; Sugi Y, 2004, DEV BIOL, V269, P505, DOI 10.1016/j.ydbio.2004.01.045; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Tanaka K, 2005, J AM COLL CARDIOL, V46, P134, DOI 10.1016/j.jacc.2005.03.058; Yamauchi R, 2004, ARTERIOSCL THROM VAS, V24, P282, DOI 10.1161/01.ATV.0000114565.42679.c6; ZACKS S, 1991, ARCH PATHOL LAB MED, V115, P774	48	115	123	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1151	1159		10.1038/nm1476	http://dx.doi.org/10.1038/nm1476			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16980969				2022-12-25	WOS:000241102200031
J	Alcazar-Roman, AR; Tran, EJ; Guo, SL; Wente, SR				Alcazar-Roman, Abel R.; Tran, Elizabeth J.; Guo, Shuangli; Wente, Susan R.			Inositol hexakisphosphate and Gle1 activate the DEAD-box protein Dbp5 for nuclear mRNA export	NATURE CELL BIOLOGY			English	Article							PORE COMPLEX; CYTOPLASMIC FIBRILS; INTERACTS; RAT8P/DBP5P; HELICASE; IMPORT; DBP5P/RAT8P; NUP116P; KAP95P; KINASE	Regulation of nuclear mRNA export is critical for proper eukaryotic gene expression. A key step in this process is the directional translocation of mRNA-ribonucleoprotein particles ( mRNPs) through nuclear pore complexes ( NPCs) that are embedded in the nuclear envelope1. Our previous studies in Saccharomyces cerevisiae defined an in vivo role for inositol hexakisphosphate ( InsP(6)) and NPC-associated Gle1 in mRNA export(2). Here, we show that Gle1 and InsP(6) act together to stimulate the RNA-dependent ATPase activity of the essential DEAD-box protein Dbp5. Overexpression of DBP5 specifically suppressed mRNA export and growth defects of an ipk1 nup42 mutant defective in InsP(6) production and Gle1 localization. In vitro kinetic analysis showed that InsP(6) significantly increased Dbp5 ATPase activity in a Gle1-dependent manner and lowered the effective RNA concentration for half-maximal ATPase activity. Gle1 alone had minimal effects. Maximal InsP(6) binding required both Dbp5 and Gle1. It has been suggested that Dbp5 requires unidentified cofactors(3, 4). We now propose that Dbp5 activation at NPCs requires Gle1 and InsP(6). This would facilitate spatial control of the remodelling of mRNP protein composition during directional transport and provide energy to power transport cycles.	Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA	Vanderbilt University	Wente, SR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, U-3209 MRBIII,465 21st Ave S, Nashville, TN 37232 USA.	susan.wente@vanderbilt.edu	; Tran, Elizabeth/G-7818-2018	Alcazar-Roman, Abel R./0000-0003-1668-1886; Tran, Elizabeth/0000-0002-9541-004X	NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051219, F32GM075459] Funding Source: NIH RePORTER; NCI NIH HHS [5T32-CA009385] Funding Source: Medline; NIGMS NIH HHS [1F32-GM075459, R01-GM51219] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chaves SR, 2001, J BIOL CHEM, V276, P17712, DOI 10.1074/jbc.M010760200; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Estruch F, 2003, MOL BIOL CELL, V14, P1664, DOI 10.1091/mbc.E02-09-0602; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Hodge CA, 1999, EMBO J, V18, P5778, DOI 10.1093/emboj/18.20.5778; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Ives EB, 2000, J BIOL CHEM, V275, P36575, DOI 10.1074/jbc.M007586200; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Kendirgi F, 2003, J CELL BIOL, V160, P1029, DOI 10.1083/jcb.200211081; Kendirgi F, 2005, MOL BIOL CELL, V16, P4304, DOI 10.1091/mbc.E04-11-0998; Liang WQ, 1997, MOL CELL BIOL, V17, P4124, DOI 10.1128/MCB.17.7.4124; Lund MK, 2005, MOL CELL, V20, P645, DOI 10.1016/j.molcel.2005.10.005; Macbeth MR, 2005, SCIENCE, V309, P1534, DOI 10.1126/science.1113150; Miller AL, 2004, J BIOL CHEM, V279, P51022, DOI 10.1074/jbc.M409394200; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; NASMYTH KA, 1980, CELL, V19, P753, DOI 10.1016/S0092-8674(80)80051-1; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Rayala HJ, 2004, MOL CELL PROTEOMICS, V3, P145, DOI 10.1074/mcp.M300106-MCP200; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rodriguez MS, 2004, BIOL CELL, V96, P639, DOI 10.1016/j.biolcel.2004.04.014; Rollenhagen C, 2004, MOL CELL BIOL, V24, P4869, DOI 10.1128/MCB.24.11.4869-4879.2004; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; SHEARS SB, 1997, SIGNALING INOSITIDES, P134; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Steger DJ, 2003, SCIENCE, V299, P114, DOI 10.1126/science.1078062; Strahm Y, 1999, EMBO J, V18, P5761, DOI 10.1093/emboj/18.20.5761; Strawn LA, 2004, NAT CELL BIOL, V6, P197, DOI 10.1038/ncb1097; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Suntharalingam M, 2004, J BIOL CHEM, V279, P35384, DOI 10.1074/jbc.M402044200; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; Tseng-Rogenski SSI, 2003, NUCLEIC ACIDS RES, V31, P4995, DOI 10.1093/nar/gkg712; Weirich CS, 2004, MOL CELL, V16, P749, DOI 10.1016/j.molcel.2004.10.032; Windgassen M, 2004, MOL CELL BIOL, V24, P10479, DOI 10.1128/MCB.24.23.10479-10491.2004; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; York SJ, 2005, J BIOL CHEM, V280, P4264, DOI 10.1074/jbc.M412070200; Zhao J, 2002, EMBO J, V21, P1177, DOI 10.1093/emboj/21.5.1177	40	214	222	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					711	U131		10.1038/ncb1427	http://dx.doi.org/10.1038/ncb1427			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16783363				2022-12-25	WOS:000238837800013
J	Fahmy, RG; Waldman, A; Zhang, GS; Mitchell, A; Tedla, N; Cai, H; Geczy, CR; Chesterman, CN; Perry, M; Khachigian, LM				Fahmy, Roger G.; Waldman, Alla; Zhang, Guishui; Mitchell, Ainslie; Tedla, Nicodemus; Cai, Hong; Geczy, Carolyn R.; Chesterman, Colin N.; Perry, Michael; Khachigian, Levon M.			Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun	NATURE BIOTECHNOLOGY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PATHOLOGICAL ANGIOGENESIS; ADHESION MOLECULE-1; NEOINTIMA FORMATION; MESSENGER-RNA; NITRIC-OXIDE; INHIBITION; PROTEIN-1; ARTHRITIS	Conventional anti-inflammatory strategies induce multiple side effects, highlighting the need for novel targeted therapies. Here we show that knockdown of the basic-region leucine zipper protein, c-Jun, by a catalytic DNA molecule, Dz13, suppresses vascular permeability and transendothelial emigration of leukocytes in murine models of vascular permeability, inflammation, acute inflammation and rheumatoid arthritis. Treatment with Dz13 reduced vascular permeability due to cutaneous anaphylactic challenge or VEGF administration in mice. Dz13 also abrogated monocyte-endothelial cell adhesion in vitro and abolished leukocyte rolling, adhesion and extravasation in a rat model of inflammation. Dz13 suppressed neutrophil infiltration in the lungs of mice challenged with endotoxin, a model of acute inflammation. Finally, Dz13 reduced joint swelling, inflammatory cell infiltration and bone erosion in a mouse model of rheumatoid arthritis. Mechanistic studies showed that Dz13 blocks cytokine-inducible endothelial c-Jun, E-selectin, ICAM-1, VCAM-1 and VE-cadherin expression but has no effect on JAM-1, PECAM-1, p-JNK-1 or c-Fos. These findings implicate c-Jun as a useful target for anti-inflammatory therapies.	Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2031, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2031, Australia; Univ New S Wales, Cytokine Res Unit, Dept Pathol, Sydney, NSW 2052, Australia; Univ New S Wales, Dept Physiol & Pharmacol, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of New South Wales Sydney; University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2031, Australia.	l.khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164; Bolon B, 2004, VET PATHOL, V41, P30, DOI 10.1354/vp.41-1-30; Botting R, 2004, FRONT BIOSCI-LANDMRK, V9, P956, DOI 10.2741/1303; Breaker RR, 2004, NATURE, V432, P838, DOI 10.1038/nature03195; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chen JH, 2005, NAT MED, V11, P1188, DOI 10.1038/nm1307; Cirino G, 2003, TRENDS PHARMACOL SCI, V24, P91, DOI 10.1016/S0165-6147(02)00049-4; Davies NM, 1998, ALIMENT PHARM THER, V12, P303; Engelhardt B, 2004, EUR J IMMUNOL, V34, P2955, DOI 10.1002/eji.200425327; Fahmy RG, 2004, NUCLEIC ACIDS RES, V32, P2281, DOI 10.1093/nar/gkh543; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Gamble JR, 2000, CIRC RES, V87, P603, DOI 10.1161/01.RES.87.7.603; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Howard PA, 2004, J AM COLL CARDIOL, V43, P519, DOI 10.1016/j.jacc.2003.09.043; Ito Y, 2003, CANCER RES, V63, P6651; Kagari T, 2002, J IMMUNOL, V169, P1459, DOI 10.4049/jimmunol.169.3.1459; Khachigian LM, 2002, J BIOL CHEM, V277, P22985, DOI 10.1074/jbc.M200977200; Lowe HC, 2002, THROMB HAEMOSTASIS, V87, P134, DOI 10.1055/s-0037-1612956; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143; Min W, 1997, J IMMUNOL, V159, P3508; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Schuff KG, 2003, PRIMARY CARE, V30, P791, DOI 10.1016/S0095-4543(03)00088-5; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; STAINES NA, 1994, BRIT J RHEUMATOL, V33, P798; van Buul JD, 2004, ARTERIOSCL THROM VAS, V24, P824, DOI 10.1161/01.ATV.0000122854.76267.5c; Wang NP, 1999, ARTERIOSCL THROM VAS, V19, P2078, DOI 10.1161/01.ATV.19.9.2078; Zhang GC, 1996, PHYSIOL PLANTARUM, V96, P683, DOI 10.1111/j.1399-3054.1996.tb00243.x	33	94	100	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					856	863		10.1038/nbt1225	http://dx.doi.org/10.1038/nbt1225			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16823369				2022-12-25	WOS:000239025100038
J	Gregorevic, P; Allen, JM; Minami, E; Blankinship, MJ; Haraguchi, M; Meuse, L; Finn, E; Adams, ME; Froehner, SC; Murry, CE; Chamberlain, JS				Gregorevic, Paul; Allen, James M.; Minami, Elina; Blankinship, Michael J.; Haraguchi, Miki; Meuse, Leonard; Finn, Eric; Adams, Marvin E.; Froehner, Stanley C.; Murry, Charles E.; Chamberlain, Jeffrey S.			rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; DEFICIENT MICE; GENE-THERAPY; UTROPHIN; MOUSE; MDX; SARCOLEMMA; SKELETAL; COMPLEX; MODEL	Mice carrying mutations in both the dystrophin and utrophin genes die prematurely as a consequence of severe muscular dystrophy. Here, we show that intravascular administration of recombinant adeno-associated viral (rAAV) vectors carrying a microdystrophin gene restores expression of dystrophin in the respiratory, cardiac and limb musculature of these mice, considerably reducing skeletal muscle pathology and extending lifespan. These findings suggest rAAV vector-mediated systemic gene transfer may be useful for treatment of serious neuromuscular disorders such as Duchenne muscular dystrophy.	Univ Washington, Dept Neurol, Senator Paul D Wellstone Muscular Dystrophy Coope, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Ctr Cardiovasc Biol & Regenerat Med, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chamberlain, JS (corresponding author), Univ Washington, Dept Neurol, Senator Paul D Wellstone Muscular Dystrophy Coope, 1959 NE Pacific St, Seattle, WA 98195 USA.	jsc5@u.washington.edu	Gregorevic, Paul/AAH-6040-2021	Gregorevic, Paul/0000-0002-7418-8945; Chamberlain, Jeffrey/0000-0001-5299-0059	NIAMS NIH HHS [R37 AR040864] Funding Source: Medline; NINDS NIH HHS [P01 NS046788] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR040864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS046788] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Collins KA, 2003, PHYSIOL GENOMICS, V13, P227, DOI 10.1152/physiolgenomics.00005.2003; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Gozal D, 2000, PEDIATR PULM, V29, P141, DOI 10.1002/(SICI)1099-0496(200002)29:2<141::AID-PPUL9>3.0.CO;2-Y; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Greelish JP, 1999, NAT MED, V5, P439, DOI 10.1038/7439; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; Hawkins D, 1997, J BIOMECH, V30, P63, DOI 10.1016/S0021-9290(96)00094-2; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Yue YP, 2003, CIRCULATION, V108, P1626, DOI 10.1161/01.CIR.0000089371.11664.27	13	225	241	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					787	789		10.1038/nm1439	http://dx.doi.org/10.1038/nm1439			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16819550	Green Accepted			2022-12-25	WOS:000238862800064
J	Tanentzapf, G; Brown, NH				Tanentzapf, Guy; Brown, Nicholas H.			An interaction between integrin and the talin FERM domain mediates integrin activation but not linkage to the cytoskeleton	NATURE CELL BIOLOGY			English	Article							CYTOPLASMIC DOMAIN; DROSOPHILA; MEMBRANE; ADHESION; SUBUNIT; BINDING; REQUIREMENT; PROTEINS; DYNAMICS; TAILS	Transmembrane adhesion receptors, such as integrins, mediate cell adhesion by interacting with intracellular proteins that connect to the cytoskeleton. Talin, one such linker protein, is thought to have two roles: mediating inside-out activation of integrins, and connecting extracellular matrix (ECM)-bound integrins to the cytoskeleton(1). Talin's amino-terminal head, which consists of a FERM domain, binds an NPxY motif within the cytoplasmic tail of most integrin beta subunits(2). This is consistent with the role of FERM domains in recruiting other proteins to the plasma membrane(3). We tested the role of the talin-head-NPxY interaction in integrin function in Drosophila. We found that introduction of a mutation that perturbs this binding in vitro(2) into the isolated talin head disrupts its recruitment by integrins in vivo. Surprisingly, when engineered into the full-length talin, this mutation did not disrupt talin recruitment by integrins nor its ability to connect integrins to the cytoskeleton. However, it reduced the ability of talin to strengthen integrin adhesion to the ECM, indicating that the function of the talin-head-NPxY interaction is solely to regulate integrin adhesion.	Univ Cambridge, Gurdon Inst, Cambridge CB2 1QN, England; Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 1QN, England	University of Cambridge; University of Cambridge	Brown, NH (corresponding author), Univ Cambridge, Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	n.brown@gurdon.cam.ac.uk	Tanentzapf, Guy/C-8864-2012	Tanentzapf, Guy/0000-0002-2443-233X; Brown, Nicholas/0000-0002-8958-7017	Wellcome Trust [69943] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Becam IE, 2005, NAT CELL BIOL, V7, P510, DOI 10.1038/ncb1253; BOGAERT T, 1987, CELL, V51, P929, DOI 10.1016/0092-8674(87)90580-0; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; BROWER DL, 1984, P NATL ACAD SCI-BIOL, V81, P7485, DOI 10.1073/pnas.81.23.7485; BROWER DL, 1989, NATURE, V342, P285, DOI 10.1038/342285a0; Brown NH, 2002, DEV CELL, V3, P569, DOI 10.1016/S1534-5807(02)00290-3; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Carman CV, 2003, CURR OPIN CELL BIOL, V15, P547, DOI 10.1016/j.ceb.2003.08.003; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Chou TB, 1996, GENETICS, V144, P1673; Clark KA, 2003, DEVELOPMENT, V130, P2611, DOI 10.1242/dev.00492; Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FOGERTY FJ, 1994, DEVELOPMENT, V120, P1747; Garcia-Alvarez B, 2003, MOL CELL, V11, P49, DOI 10.1016/S1097-2765(02)00823-7; Grabbe C, 2004, DEVELOPMENT, V131, P5795, DOI 10.1242/dev.01462; GRINBLAT Y, 1994, DEVELOPMENT, V120, P91; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jannuzi AL, 2002, MOL BIOL CELL, V13, P1352, DOI 10.1091/mbc.01-08-0429; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; Martin-Bermudo MD, 1998, J CELL BIOL, V141, P1073, DOI 10.1083/jcb.141.4.1073; Nayal A, 2004, CURR OPIN CELL BIOL, V16, P94, DOI 10.1016/j.ceb.2003.11.007; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Prokop A, 1998, DEV BIOL, V196, P58, DOI 10.1006/dbio.1997.8830; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Tanentzapf G, 2006, J CELL SCI, V119, P1632, DOI 10.1242/jcs.02859; Tepass U, 1996, DEV BIOL, V177, P217, DOI 10.1006/dbio.1996.0157; Tremuth L, 2004, J BIOL CHEM, V279, P22258, DOI 10.1074/jbc.M400947200; Ulmer TS, 2003, BIOCHEMISTRY-US, V42, P8307, DOI 10.1021/bi034384s; Yagi R, 2001, EMBO REP, V2, P814, DOI 10.1093/embo-reports/kve178	30	103	104	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					601	606		10.1038/ncb1411	http://dx.doi.org/10.1038/ncb1411			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16648844				2022-12-25	WOS:000238029000013
J	Frigola, J; Song, J; Stirzaker, C; Hinshelwood, RA; Peinado, MA; Clark, SJ				Frigola, J; Song, J; Stirzaker, C; Hinshelwood, RA; Peinado, MA; Clark, SJ			Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band	NATURE GENETICS			English	Article							ALTERED METHYLATION PATTERNS; DNA METHYLATION; CPG ISLANDS; EXPRESSION; HYPERMETHYLATION; INACTIVATION; P21(WAF1); RECEPTORS; MECHANISM; PROTEINS	We report a new mechanism in carcinogenesis involving coordinate long-range epigenetic gene silencing. Epigenetic silencing in cancer has always been envisaged as a local event silencing discrete genes. However, in this study of silencing in colorectal cancer, we found common repression of the entire 4-Mb band of chromosome 2q.14.2, associated with global methylation of histone H3 Lys9. DNA hypermethylation within the repressed genomic neighborhood was localized to three separate enriched CpG island `suburbs', with the largest hypermethylated suburb spanning 1 Mb. These data change our understanding of epigenetic gene silencing in cancer cells: namely, epigenetic silencing can span large regions of the chromosome, and both DNA-methylated and neighboring unmethylated genes can be coordinately suppressed by global changes in histone modification. We propose that loss of gene expression can occur through long-range epigenetic silencing, with similar implications as loss of heterozygosity in cancer.	St Vincents Hosp, Garvan Inst Med Res, Canc Program, Darlinghurst, NSW 2010, Australia; Hosp Duran & Reynals, Inst Recerca Oncol, Inst Invest Biomed Bellvitge IDIBELL, Barcelona 08907, Spain	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals	Clark, SJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Program, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	s.clark@garvan.org.au	Frigola, Jordi/N-4602-2015; Clark, Susan J/U-7365-2019; Clark, Susan J/B-2272-2008; Peinado, Miguel A./A-5591-2008	Frigola, Jordi/0000-0002-7231-3853; Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030; Peinado, Miguel A./0000-0002-4090-793X; Stirzaker, Clare/0000-0001-5601-3140				Adamska M, 2004, DEV BIOL, V272, P134, DOI 10.1016/j.ydbio.2004.04.026; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brockdorff N, 2002, TRENDS GENET, V18, P352, DOI 10.1016/S0168-9525(02)02717-8; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Frigola J, 2005, HUM MOL GENET, V14, P319, DOI 10.1093/hmg/ddi028; Frigola J, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.7.e28; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Huschtscha LI, 1998, CANCER RES, V58, P3508; Jaffrey RG, 2000, CANCER RES, V60, P4349; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kangas M, 1999, GENOMICS, V58, P82, DOI 10.1006/geno.1999.5811; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Latham KE, 2005, TRENDS GENET, V21, P120, DOI 10.1016/j.tig.2004.12.003; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840; Lorincz MC, 2002, MOL CELL BIOL, V22, P7572, DOI 10.1128/MCB.22.21.7572-7580.2002; Melki JR, 1999, CANCER RES, V59, P3730; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Mylonas I, 2005, ONCOL REP, V13, P81; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Nie Y, 2001, CARCINOGENESIS, V22, P1615, DOI 10.1093/carcin/22.10.1615; O'Neill MJ, 2005, HUM MOL GENET, V14, pR113, DOI 10.1093/hmg/ddi108; Palmisano WA, 2003, CANCER RES, V63, P4620; Pang RTK, 2004, MOL ENDOCRINOL, V18, P471, DOI 10.1210/me.2003-0245; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; Reis FM, 2004, MOL CELL ENDOCRINOL, V225, P77, DOI 10.1016/j.mce.2004.02.016; Rush LJ, 2004, CANCER RES, V64, P2424, DOI 10.1158/0008-5472.CAN-03-2870; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Tang C, 1997, GUT, V40, P267, DOI 10.1136/gut.40.2.267; Tang CW, 1996, CARCINOGENESIS, V17, P2171, DOI 10.1093/carcin/17.10.2171; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; van Noesel MM, 2003, GENE CHROMOSOME CANC, V38, P226, DOI 10.1002/gcc.10278; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Zhu WG, 2004, J BIOL CHEM, V279, P15161, DOI 10.1074/jbc.M311703200	47	295	310	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					540	549		10.1038/ng1781	http://dx.doi.org/10.1038/ng1781			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16642018				2022-12-25	WOS:000237147500015
J	Snyder, EY; Hinman, LM; Kalichman, MW				Snyder, EY; Hinman, LM; Kalichman, MW			Can science resolve the ethical impasse in stem cell research? Commentary	NATURE BIOTECHNOLOGY			English	Editorial Material							EARLY MOUSE EMBRYO; NUCLEAR TRANSFER; EXPRESSION; POLARITY; GENE		Burnham Inst Med Res, Stem Cell & Regenerat Program, La Jolla, CA 92037 USA; Univ San Diego, Values Inst, San Diego, CA 92110 USA; Univ Calif San Diego, Res Eth Program, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of San Diego; University of California System; University of California San Diego	Snyder, EY (corresponding author), Burnham Inst Med Res, Stem Cell & Regenerat Program, La Jolla, CA 92037 USA.	esnyder@burnham.org; hinman@sandiego.edu; kalichman@ucsd.edu	Kalichman, Michael/AAX-3510-2020	Kalichman, Michael/0000-0002-4268-1188				Austriaco Nicanor Pier Giorgio, 2002, Natl Cathol Bioeth Q, V2, P659; BERG P, 2005, WASHINGTON POST 0719, pA21; Bertocchini F, 2004, DEVELOPMENT, V131, P3381, DOI 10.1242/dev.01178; CAMUS A, 2004, HDB STEM CELLS, V1, P129; Chung Y, 2006, NATURE, V439, P216, DOI 10.1038/nature04277; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Deb K, 2006, SCIENCE, V311, P992, DOI 10.1126/science.1120925; DEOBAGKAR DD, 1990, P NATL ACAD SCI USA, V87, P1691, DOI 10.1073/pnas.87.5.1691; Dobson AT, 2004, HUM MOL GENET, V13, P1461, DOI 10.1093/hmg/ddh157; Flax JD, 1998, NAT BIOTECHNOL, V16, P1033, DOI 10.1038/3473; Gong Y, 2004, NATURE, V430, P689, DOI 10.1038/nature02796; Guenin LM, 2004, MAYO CLIN PROC, V79, P801; Hori J, 2003, STEM CELLS, V21, P405, DOI 10.1634/stemcells.21-4-405; HURLBUT WB, 2004, DEC 2004 M PRES COUN; Imitola J, 2004, AM J PATHOL, V164, P1615, DOI 10.1016/S0002-9440(10)63720-0; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Landry DW, 2004, J CLIN INVEST, V114, P1184, DOI 10.1172/JCI200423065; LANZA R, 2002, SCIENCE, V295, P819; Meissner A, 2006, NATURE, V439, P212, DOI 10.1038/nature04257; Melton DA, 2004, NEW ENGL J MED, V351, P2791, DOI 10.1056/NEJMp048348; Park KI, 2002, GENE THER, V9, P613, DOI 10.1038/sj.gt.3301721; President's Council on Bioethics, 2005, ALT SOURC HUM PLUR S; Rossant J, 2004, SEMIN CELL DEV BIOL, V15, P573, DOI 10.1016/j.semcdb.2004.04.003; Rossant J, 2004, DEV CELL, V7, P155, DOI 10.1016/j.devcel.2004.07.012; Russell WMS, 1959, PRINCIPLES HUMANE AN; Sandel MJ, 2004, NEW ENGL J MED, V351, P207, DOI 10.1056/NEJMp048145; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Zernicka-Goetz M, 2004, SEMIN CELL DEV BIOL, V15, P563, DOI 10.1016/j.semcdb.2004.04.004; Zhang LX, 2004, SCIENCE, V306, P114, DOI 10.1126/science.1100569; ZUCKER HA, 2004, SESSION 6 SEEKING MO; 2004, C CONV SAN DEIG CTR	31	9	10	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					397	400		10.1038/nbt0406-397	http://dx.doi.org/10.1038/nbt0406-397			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16601717				2022-12-25	WOS:000236766300016
J	Nishio, M; Watanabe, KI; Sasaki, J; Taya, C; Takasuga, S; Iizuka, R; Balla, T; Yamazaki, M; Watanabe, H; Itoh, R; Kuroda, S; Horie, Y; Forster, I; Mak, TW; Yonekawa, H; Penninger, JM; Kanaho, Y; Suzuki, A; Sasaki, T				Nishio, Miki; Watanabe, Ken-ichi; Sasaki, Junko; Taya, Choji; Takasuga, Shunsuke; Iizuka, Ryota; Balla, Tamas; Yamazaki, Masakazu; Watanabe, Hiroshi; Itoh, Reietsu; Kuroda, Shoko; Horie, Yasuo; Forster, Irmgard; Mak, Tak W.; Yonekawa, Hiromichi; Penninger, Josef M.; Kanaho, Yasunori; Suzuki, Akira; Sasaki, Takehiko			Control of cell polarity and motility by the PtdIns(3,4,5)P-3 phosphatase SHIP1	NATURE CELL BIOLOGY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; GREEN FLUORESCENT PROTEIN; PHOSPHOINOSITIDE 3-KINASES; CHEMOATTRACTANT RECEPTOR; CHEMOTAXIS; ACTIVATION; ROLES; PTEN; PI3K-GAMMA; GAMMA	Proper neutrophil migration into inflammatory sites ensures host defense without tissue damage. Phosphoinositide 3-kinase (PI(3)K) and its lipid product phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) regulate cell migration, but the role of PtdIns(3,4,5)P-3-degrading enzymes in this process is poorly understood. Here, we show that Src homology 2 (SH2) domain-containing inositol-5-phosphatase 1 (SHIP1), a PtdIns(3,4,5)P-3 phosphatase, is a key regulator of neutrophil migration. Genetic inactivation of SHIP1 led to severe defects in neutrophil polarization and motility. In contrast, loss of the PtdIns(3,4,5)P-3 phosphatase PTEN had no impact on neutrophil chemotaxis. To study PtdIns(3,4,5)P-3 metabolism in living primary cells, we generated a novel transgenic mouse (AktPH-GFP Tg) expressing a bioprobe for PtdIns(3,4,5)P-3. Time-lapse footage showed rapid, localized binding of AktPH-GFP to the leading edge membrane of chemotaxing ship1(+/+)AktPH-GFP Tg neutrophils, but only diffuse localization in ship1(-/-)AktPH-GFP Tg neutrophils. By directing where PtdIns(3,4,5)P-3 accumulates, SHIP1 governs the formation of the leading edge and polarization required for chemotaxis.	Akita Univ, Sch Med, Dept Pathol & Immunol, Akita 0108543, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Akita Univ, Sch Med, Dept Mol Biol, Akita 0108543, Japan; Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, Tokyo 1138613, Japan; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; Akita Univ, Sch Med, Dept Gastroenterol, Akita 0108543, Japan; Univ Dusseldorf, Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany; Campbell Familly Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada; Austrian Acad Sci, Inst Mol & Biotechnol, A-1030 Vienna, Austria	Akita University; Japan Science & Technology Agency (JST); Akita University; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Akita University; Heinrich Heine University Dusseldorf; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Sasaki, T (corresponding author), Akita Univ, Sch Med, Dept Pathol & Immunol, 1-1-1 Hondo, Akita 0108543, Japan.	tsasaki@med.akita-u.ac.jp	Penninger, Josef M/I-6860-2013; Suzuki, Akira/GYD-6697-2022; Förster, Irmgard/P-8545-2016; Watanabe, Hiroshi/GOP-0177-2022	Penninger, Josef M/0000-0002-8194-3777; Suzuki, Akira/0000-0002-5950-8808; Förster, Irmgard/0000-0002-7644-5642; Watanabe, Hiroshi/0000-0001-8887-5407; Sasaki, Takehiko/0000-0003-1837-3748; Balla, Tamas/0000-0002-9077-3335	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000196] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000196] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Balla Tamas, 2002, Sci STKE, V2002, ppl3, DOI 10.1126/stke.2002.125.pl3; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Condliffe AM, 2005, BLOOD, V106, P1432, DOI 10.1182/blood-2005-03-0944; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; Fergus GJ, 2007, NAT CELL BIOL, V9, P86, DOI 10.1038/ncb1517; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Kanegasaki S, 2003, J IMMUNOL METHODS, V282, P1, DOI 10.1016/j.jim.2003.07.008; Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7; Lacalle RA, 2004, J CELL SCI, V117, P6207, DOI 10.1242/jcs.01545; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095; Niggli V, 2003, INT J BIOCHEM CELL B, V35, P1619, DOI 10.1016/S1357-2725(03)00144-4; Oikawa T, 2004, NAT CELL BIOL, V6, P420, DOI 10.1038/ncb1125; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Park HT, 2002, BIOESSAYS, V24, P821, DOI 10.1002/bies.10141; Patel DD, 2001, CURR DIRECT AUTOIMMU, V3, P133; Postma M, 2004, EMBO REP, V5, P35, DOI 10.1038/sj.embor.7400051; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 1999, MOL BIOL CELL, V10, P1163, DOI 10.1091/mbc.10.4.1163; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shitara H, 2001, FEBS LETT, V500, P7, DOI 10.1016/S0014-5793(01)02574-1; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Terashima Y, 2005, NAT IMMUNOL, V6, P827, DOI 10.1038/ni1222; Vedham V, 2005, MOL CELL BIOL, V25, P4211, DOI 10.1128/MCB.25.10.4211-4220.2005; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Ward SG, 2004, TRENDS IMMUNOL, V25, P67, DOI 10.1016/j.it.2003.12.003; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Xu JS, 2003, CELL, V114, P201, DOI 10.1016/S0092-8674(03)00555-5	49	222	229	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					36	U40		10.1038/ncb1515	http://dx.doi.org/10.1038/ncb1515			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17173042				2022-12-25	WOS:000243255100010
J	Cox, KM; Sterling, JD; Regan, JT; Gasdaska, JR; Frantz, KK; Peele, CG; Black, A; Passmore, D; Moldovan-Loomis, C; Srinivasan, M; Cuison, S; Cardarelli, PM; Dickey, LF				Cox, Kevin M.; Sterling, Jason D.; Regan, Jeffrey T.; Gasdaska, John R.; Frantz, Karen K.; Peele, Charles G.; Black, Amelia; Passmore, David; Moldovan-Loomis, Cristina; Srinivasan, Mohan; Cuison, Severino; Cardarelli, Pina M.; Dickey, Lynn F.			Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor	NATURE BIOTECHNOLOGY			English	Article							DEPENDENT CELLULAR CYTOTOXICITY; IMMUNOGLOBULIN-G; TRANSGENIC PLANTS; N-GLYCOSYLATION; FUCOSE; IGG; LYMPHOMA; POLYMORPHISM; GLYCOFORMS; GROWTH	N-glycosylation is critical to the function of monoclonal antibodies (mAbs) and distinguishes various systems used for their production. We expressed human mAbs in the small aquatic plant Lemna minor, which offers several advantages for manufacturing therapeutic proteins free of zoonotic pathogens(1). Glycosylation of a mAb against human CD30 was optimized by co-expressing the heavy and light chains of the mAb with an RNA interference construct targeting expression of the endogenous alpha-1,3-fucosyltransferase and beta-1,2-xylosyltransferase genes. The resultant mAbs contained a single major N-glycan species without detectable plant-specific N-glycans and had better antibody-dependent cell-mediated cytotoxicity and effector cell receptor binding activities than mAbs expressed in cultured Chinese hamster ovary (CHO) cells.	Biolex Therapeut, Pittsboro, NC 27312 USA; Medarex Inc, Milpitas, CA 95035 USA		Cox, KM (corresponding author), Biolex Therapeut, 158 Credle St, Pittsboro, NC 27312 USA.	kcox@biolex.com						Anumula KR, 1998, GLYCOBIOLOGY, V8, P685, DOI 10.1093/glycob/8.7.685; Bakker H, 2006, P NATL ACAD SCI USA, V103, P7577, DOI 10.1073/pnas.0600879103; Bardor M, 2003, PLANT BIOTECHNOL J, V1, P451, DOI 10.1046/j.1467-7652.2003.00041.x; Bencurova M, 2004, GLYCOBIOLOGY, V14, P457, DOI 10.1093/glycob/cwh058; Borchmann P, 2003, BLOOD, V102, P3737, DOI 10.1182/blood-2003-02-0515; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Elbers IJW, 2001, PLANT PHYSIOL, V126, P1314, DOI 10.1104/pp.126.3.1314; Fujiyama K, 2006, J BIOSCI BIOENG, V101, P212, DOI 10.1263/jbb.101.212; Gasdaska JR., 2003, BIOPROCESS J, V2, P49, DOI DOI 10.12665/J22.GASDASKA; Gomord W, 2005, TRENDS BIOTECHNOL, V23, P559, DOI 10.1016/j.tibtech.2005.09.003; HEPBURN AG, 1985, J GEN MICROBIOL, V131, P2961; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Kanda Y, 2006, BIOTECHNOL BIOENG, V94, P680, DOI 10.1002/bit.20880; Koprivova A, 2003, PLANT BIOLOGY, V5, P582, DOI 10.1055/s-2003-44721; Krapp S, 2003, J MOL BIOL, V325, P979, DOI 10.1016/S0022-2836(02)01250-0; Leiter H, 1999, J BIOL CHEM, V274, P21830, DOI 10.1074/jbc.274.31.21830; Ma JKC, 1998, NAT MED, V4, P601, DOI 10.1038/nm0598-601; Niwa R, 2004, CLIN CANCER RES, V10, P6248, DOI 10.1158/1078-0432.CCR-04-0850; PACKER N, 1998, GLYCOCONJ J, V49, P737; SCHENK RU, 1972, CAN J BOTANY, V50, P199, DOI 10.1139/b72-026; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Shinkawa T, 2003, J BIOL CHEM, V278, P3466, DOI 10.1074/jbc.M210665200; Triguero A, 2005, PLANT BIOTECHNOL J, V3, P449, DOI 10.1111/j.1467-7652.2005.00137.x; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; Weng WK, 2004, J CLIN ONCOL, V22, P4717, DOI 10.1200/JCO.2004.06.003; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7; Yamamoto YT, 2001, IN VITRO CELL DEV-PL, V37, P349; Zeitlin L, 1998, NAT BIOTECHNOL, V16, P1361, DOI 10.1038/4344; Zhu L, 2005, NAT BIOTECHNOL, V23, P1159, DOI 10.1038/nbt1132	30	322	408	1	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1591	1597		10.1038/nbt1260	http://dx.doi.org/10.1038/nbt1260			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17128273				2022-12-25	WOS:000242795800039
J	Hinkes, B; Wiggins, RC; Gbadegesin, R; Vlangos, CN; Seelow, D; Nurnberg, G; Garg, P; Verma, R; Chaib, H; Hoskins, BE; Ashraf, S; Becker, C; Hennies, HC; Goyal, M; Wharram, BL; Schachter, AD; Mudumana, S; Drummond, I; Kerjaschki, D; Waldherr, R; Dietrich, A; Ozaltin, F; Bakkaloglu, A; Cleper, R; Basel-Vanagaite, L; Pohl, M; Griebel, M; Tsygin, AN; Soylu, A; Muller, D; Sorli, CS; Bunney, TD; Katan, M; Liu, JH; Attanasio, M; O'Toole, JF; Hasselbacher, K; Mucha, B; Otto, EA; Airik, R; Kispert, A; Kelley, GG; Smrcka, AV; Gudermann, T; Holzman, LB; Nurnberg, P; Hildebrandt, F				Hinkes, Bernward; Wiggins, Roger C.; Gbadegesin, Rasheed; Vlangos, Christopher N.; Seelow, Dominik; Nuernberg, Gudrun; Garg, Puneet; Verma, Rakesh; Chaib, Hassan; Hoskins, Bethan E.; Ashraf, Shazia; Becker, Christian; Hennies, Hans Christian; Goyal, Meera; Wharram, Bryan L.; Schachter, Asher D.; Mudumana, Sudha; Drummond, Iain; Kerjaschki, Dontscho; Waldherr, Ruediger; Dietrich, Alexander; Ozaltin, Fatih; Bakkaloglu, Aysin; Cleper, Roxana; Basel-Vanagaite, Lina; Pohl, Martin; Griebel, Martin; Tsygin, Alexey N.; Soylu, Alper; Mueller, Dominik; Sorli, Caroline S.; Bunney, Tom D.; Katan, Matilda; Liu, Jinhong; Attanasio, Massimo; O'Toole, John F.; Hasselbacher, Katrin; Mucha, Bettina; Otto, Edgar A.; Airik, Rannar; Kispert, Andreas; Kelley, Grant G.; Smrcka, Alan V.; Gudermann, Thomas; Holzman, Lawrence B.; Nuernberg, Peter; Hildebrandt, Friedhelm			Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible	NATURE GENETICS			English	Article							PHOSPHOLIPASE-C-EPSILON; PODOCYTE DEPLETION; GLOMERULAR PROTEIN; DRASH-SYNDROME; NEPHRIN; GLOMERULOSCLEROSIS; PODOCALYXIN; EXPRESSION; IQGAP1; GENE	Nephrotic syndrome, a malfunction of the kidney glomerular filter, leads to proteinuria, edema and, in steroid-resistant nephrotic syndrome, end-stage kidney disease. Using positional cloning, we identified mutations in the phospholipase C epsilon gene (PLCE1) as causing early-onset nephrotic syndrome with end-stage kidney disease. Kidney histology of affected individuals showed diffuse mesangial sclerosis (DMS). Using immunofluorescence, we found PLC epsilon 1 expression in developing and mature glomerular podocytes and showed that DMS represents an arrest of normal glomerular development. We identified IQ motif-containing GTPase-activating protein 1 as a new interaction partner of PLC epsilon 1. Two siblings with a missense mutation in an exon encoding the PLCe1 catalytic domain showed histology characteristic of focal segmental glomerulosclerosis. Notably, two other affected individuals responded to therapy, making this the first report of a molecular cause of nephrotic syndrome that may resolve after therapy. These findings, together with the zebrafish model of human nephrotic syndrome generated by plce1 knockdown, open new inroads into pathophysiology and treatment mechanisms of nephrotic syndrome.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Cologne, Cologne Ctr Genom, Cologne, Germany; RZPD Deutsches Ressourcenzentrum Genomforsch GmbH, Berlin, Germany; Univ Cologne, Inst Genet, Cologne, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Childrens Hosp, Boston, MA 02129 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Renal Unit, Boston, MA 02129 USA; Univ Vienna, Clin Inst Pathol, A-1090 Vienna, Austria; Gerneinschaftspraxis Pathol, D-69115 Heidelberg, Germany; Univ Marburg, Dept Pharmacol & Toxicol, Marburg, Germany; Hacettepe Univ, Fac Med, Dept Pediat Nephrol, TR-06100 Ankara, Turkey; Schneider Childrens Med Ctr, Dept Med Genet, Petah Tiqwa, Israel; Rabin Med Ctr, Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Univ Freiburg, Dept Pediat, D-79106 Freiburg, Germany; Tech Univ Munich, Childrens Hosp, Schwabing, Germany; Sci Ctr Childrens Hlth, Moscow, Russia; Dokuz Eylul Univ, Dept Pediat, Izmir, Turkey; Charite Childrens Hosp, Dept Pediat Nephrol, Berlin, Germany; Inst Canc Res, Chester Beatty Labs, Ctr Cell & Mol Biol, Canc Res UK, London SW3 6JB, England; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany; SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA; Univ Rochester, Sch Med, Dept Pharmacol & Physiol, Rochester, NY 14642 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Cologne; University of Cologne; Harvard University; Boston Children's Hospital; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Vienna; Philipps University Marburg; Hacettepe University; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; University of Freiburg; Technical University of Munich; Dokuz Eylul University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Hannover Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Rochester; University of Michigan System; University of Michigan	Hildebrandt, F (corresponding author), Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.	fhilde@umich.edu	Airik, Rannar/AAS-7810-2021; Soylu, Alper/AAR-7694-2020; Dietrich, Alexander/G-8619-2013; Hennies, Hans C/G-9424-2014; Seelow, Dominik/HGB-3124-2022	Airik, Rannar/0000-0002-7055-6325; Soylu, Alper/0000-0002-5901-7398; Dietrich, Alexander/0000-0002-1168-8707; Hennies, Hans C/0000-0001-7210-2389; Seelow, Dominik/0000-0002-9746-4412; Otto, Edgar/0000-0002-2387-9973; Bunney, Tom/0000-0002-0281-8813; Mucha, Bettina/0000-0002-6410-7320; Wiggins, Roger/0000-0002-1166-2849; Alexey, Tsygin/0000-0001-6301-9313; Basel-Vanagaite, Vanagaite, Lina/0000-0002-9076-8157; Garg, Puneet/0000-0001-7439-459X; Attanasio, Massimo/0000-0002-1278-3650; Holzman, Lawrence/0000-0002-8961-234X	NIDDK NIH HHS [R01-DK56294, R01-DK53093, P50-DK039255, DK46073] Funding Source: Medline; NIGMS NIH HHS [R01-GM053536] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255, R01DK053093, R56DK046073, R01DK046073, R01DK056294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053536] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1981, KIDNEY INT, V20, P765; Antignac C, 2005, NEFROLOGIA, V25, P25; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; BRODEHL J, 1988, LANCET, V1, P380; Brown MD, 2006, TRENDS CELL BIOL, V16, P242, DOI 10.1016/j.tcb.2006.03.002; Habib R, 1993, Adv Nephrol Necker Hosp, V22, P43; HABIB R, 1993, PEDIATR NEPHROL, V7, P347, DOI 10.1007/BF00857534; HABIB R, 1985, CLIN NEPHROL, V24, P269; Hasselbacher K, 2006, KIDNEY INT, V70, P1008, DOI 10.1038/sj.ki.5001679; HOLMBERG C, 2004, PEDIAT NEPHROLOGY; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; KERSHAW DB, 1995, J BIOL CHEM, V270, P29439, DOI 10.1074/jbc.270.49.29439; KESTILA M, 1994, GENOMICS, V19, P570, DOI 10.1006/geno.1994.1109; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kim YH, 2001, KIDNEY INT, V60, P957, DOI 10.1046/j.1523-1755.2001.060003957.x; Kramer-Zucker AG, 2005, DEV BIOL, V285, P316, DOI 10.1016/j.ydbio.2005.06.038; Kriz W, 2002, MICROSC RES TECHNIQ, V57, P189, DOI 10.1002/jemt.10072; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Lehtonen S, 2005, P NATL ACAD SCI USA, V102, P9814, DOI 10.1073/pnas.0504166102; Liu XL, 2005, FEBS J, V272, P228, DOI 10.1111/j.1432-1033.2004.04408.x; Mucha B, 2006, PEDIATR RES, V59, P325, DOI 10.1203/01.pdr.0000196717.94518.f0; Ransom RF, 2004, CONTRIB NEPHROL, V141, P189; Reiser J, 2005, NAT GENET, V37, P739, DOI 10.1038/ng1592; Ruf RG, 2004, J AM SOC NEPHROL, V15, P722, DOI 10.1097/01.ASN.0000113552.59155.72; SCHNABEL E, 1989, EUR J CELL BIOL, V48, P313; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Sorli SC, 2005, ONCOGENE, V24, P90, DOI 10.1038/sj.onc.1208168; Strauch K, 2003, AM J HUM GENET, V73, P615; Tryggvason K, 2006, NEW ENGL J MED, V354, P1387, DOI 10.1056/NEJMra052131; Verma R, 2006, J CLIN INVEST, V116, P1346, DOI 10.1172/JCI27414; Wang H, 2005, CIRC RES, V97, P1305, DOI 10.1161/01.RES.0000196578.15385.bb; Westerfield M, 1994, ZEBRAFISH BOOK; Wharram BL, 2005, J AM SOC NEPHROL, V16, P2941, DOI 10.1681/ASN.2005010055; Wiggins JE, 2005, J AM SOC NEPHROL, V16, P2953, DOI 10.1681/ASN.2005050488; Wing Michele R, 2003, Mol Interv, V3, P273, DOI 10.1124/mi.3.5.273; Winn MP, 2005, SCIENCE, V308, P1801, DOI 10.1126/science.1106215; Yang YX, 1999, AM J PATHOL, V154, P181, DOI 10.1016/S0002-9440(10)65264-9; Zenker M, 2004, HUM MOL GENET, V13, P2625, DOI 10.1093/hmg/ddh284	41	382	425	0	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2006	38	12					1397	1405		10.1038/ng1918	http://dx.doi.org/10.1038/ng1918			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17086182				2022-12-25	WOS:000242404200016
J	Wang, SC; Nakajima, Y; Yu, YL; Xia, WY; Chen, CT; Yang, CC; McIntush, EW; Li, LY; Hawke, DH; Kobayashi, R; Hung, MC				Wang, Shao-Chun; Nakajima, Yusuke; Yu, Yung-Luen; Xia, Weiya; Chen, Chun-Te; Yang, Cheng-Chieh; McIntush, Eric W.; Li, Long-Yuan; Hawke, David H.; Kobayashi, Ryuji; Hung, Mien-Chie			Tyrosine phosphorylation controls PCNA function through protein stability	NATURE CELL BIOLOGY			English	Article							EPIDERMAL-GROWTH-FACTOR; CELL NUCLEAR ANTIGEN; FACTOR RECEPTOR; EGF RECEPTOR; DNA-REPAIR; BREAST; EXPRESSION; LOCALIZATION; CANCER; UBIQUITIN	The proliferating cell nuclear antigen (PCNA) is an essential protein for DNA replication and damage repair. How its function is controlled remains an important question. Here, we show that the chromatin-bound PCNA protein is phosphorylated on Tyr 211, which is required for maintaining its function on chromatin and is dependent on the tyrosine kinase activity of EGF receptor (EGFR) in the nucleus. Phosphorylation on Tyr 211 by EGFR stabilizes chromatin-bound PCNA protein and associated functions. Consistently, increased PCNA Tyr 211 phosphorylation coincides with pronounced cell proliferation, and is better correlated with poor survival of breast cancer patients, as well as nuclear EGFR in tumours, than is the total PCNA level. These results identify a novel nuclear mechanism linking tyrosine kinase receptor function with the regulation of the PCNA sliding clamp.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; Bethyl Labs Inc, Montgomery, TX 77356 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; China Med Univ Hosp, Ctr Mol Med, Taichung 404, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Wang, Shao-Chun/P-9904-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Shao-Chun/0000-0002-5477-1682; Hawke, David/0000-0002-6102-7843; Li, Long-Yuan/0000-0001-7472-8318	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; PHS HHS [P01 099031, R01 109311] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ammosova T, 2005, J BIOL CHEM, V280, P36364, DOI 10.1074/jbc.M503673200; Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Assy N, 1997, J HEPATOL, V26, P945, DOI 10.1016/S0168-8278(97)80266-8; Baselga J, 2002, ONCOLOGIST, V7, P2; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Bukholm IRK, 2003, J CLIN PATHOL, V56, P368, DOI 10.1136/jcp.56.5.368; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Frassoldati A, 1997, BREAST CANCER RES TR, V44, P185, DOI 10.1023/A:1005875002458; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Grossi F, 2003, EUR J CANCER, V39, P1242, DOI 10.1016/S0959-8049(03)00232-6; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Haracska L, 2004, MOL CELL BIOL, V24, P4267, DOI 10.1128/MCB.24.10.4267-4274.2004; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Heimann R, 1997, CANCER J, V3, P224; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Jeziorski A, 2000, J EXP CLIN CANC RES, V19, P61; JONSSON ZO, 1995, EMBO J, V14, P5745, DOI 10.1002/j.1460-2075.1995.tb00261.x; Kannouche PL, 2004, CELL CYCLE, V3, P1011; Kato, 1999, Breast Cancer, V6, P370, DOI 10.1007/BF02966456; Kato T, 2003, BRIT J CANCER, V88, P1900, DOI 10.1038/sj.bjc.6600921; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kiyokawa N, 1997, J BIOL CHEM, V272, P18656, DOI 10.1074/jbc.272.30.18656; Lee JS, 2001, ANAL QUANT CYTOL, V23, P161; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; MARTI U, 1995, J HEPATOL, V23, P318, DOI 10.1016/S0168-8278(95)80011-5; Marti U, 2001, THYROID, V11, P137, DOI 10.1089/105072501300042785; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; SHRESTHA P, 1992, VIRCHOWS ARCH A, V421, P193, DOI 10.1007/BF01611175; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Tao YG, 2005, EXP CELL RES, V303, P240, DOI 10.1016/j.yexcr.2004.09.030; Ulrich HD, 2004, CELL CYCLE, V3, P15; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wells A, 2002, NAT REV MOL CELL BIO, V3, P697, DOI 10.1038/nrm905; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	48	230	245	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1359	U24		10.1038/ncb1501	http://dx.doi.org/10.1038/ncb1501			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17115032				2022-12-25	WOS:000242419800011
J	Orme, MH; Alrubaie, S; Bradley, GL; Walker, CD; Leevers, SJ				Orme, Mariam H.; Alrubaie, Saif; Bradley, Gemma L.; Walker, Cherryl D.; Leevers, Sally J.			Input from Ras is required for maximal PI(3)K signalling in Drosophila	NATURE CELL BIOLOGY			English	Article							PHOSPHOINOSITIDE 3-KINASE; KINASE; GROWTH; ACTIVATION; INSULIN; COMPLEX; ADAPTER; DP110	Class I phosphoinositide 3-kinases (PI(3)Ks) are activated through associated adaptor molecules in response to G protein-coupled and tyrosine kinase receptor signalling(1). They contain Ras-binding domains (RBDs) and can also be activated through direct association with active GTP-bound Ras(2-10). The ability of Ras to activate PI(3)K has been established in vitro and by overexpression analysis, but its relevance for normal PI(3)K function in vivo is unknown. The Drosophila class I PI(3)K, Dp110, is activated by nutrient-responsive insulin signalling and modulates growth, oogenesis and metabolism(11-15). To investigate the importance of Ras-mediated PI(3)K activation for normal PI(3)K function, we replaced Dp110 with Dp110(RBD), which is unable to bind to Ras but otherwise biochemically normal. We found that Ras-mediated Dp110 regulation is dispensable for viability. However, egg production, which requires large amounts of growth, is dramatically lowered in Dp110(RBD) flies. Furthermore, insulin cannot maximally activate PI(3)K signalling in Dp110(RBD) imaginal discs and Dp110(RBD) flies are small. Thus, Dp110 integrates inputs from its phosphotyrosine-binding adaptor and Ras to achieve maximal PI(3)K signalling in specific biological situations.	Canc Res UK London Res Inst, Growth Regulat Lab, London WC2A 3PX, England	Cancer Research UK	Leevers, SJ (corresponding author), Canc Res UK London Res Inst, Growth Regulat Lab, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.	sally.leevers@cancer.org.uk						Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Drummond-Barbosa D, 2001, DEV BIOL, V231, P265, DOI 10.1006/dbio.2000.0135; Karim FD, 1998, DEVELOPMENT, V125, P1; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; LaFever L, 2005, SCIENCE, V309, P1071, DOI 10.1126/science.1111410; Leevers Sally J., 2004, VVolume 42, P167; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lizcano JM, 2003, BIOCHEM J, V374, P297, DOI 10.1042/BJ20030577; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Strutt H, 2003, CURR BIOL, V13, P1451, DOI 10.1016/S0960-9822(03)00545-1; Suire S, 2002, CURR BIOL, V12, P1068, DOI 10.1016/S0960-9822(02)00933-8; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Weinkove D, 1997, J BIOL CHEM, V272, P14606, DOI 10.1074/jbc.272.23.14606; Wu Q, 2006, ANNU REV ENTOMOL, V51, P1, DOI 10.1146/annurev.ento.51.110104.151011	26	51	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1298	U67		10.1038/ncb1493	http://dx.doi.org/10.1038/ncb1493			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17041587				2022-12-25	WOS:000241732400020
J	Gao, F; Cheng, JK; Shi, T; Yeh, ETH				Gao, Fei; Cheng, Jinke; Shi, Tong; Yeh, Edward T. H.			Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NF kappa B-dependent transcription	NATURE CELL BIOLOGY			English	Article							UBIQUITIN-LIKE PROTEIN; RBP-J; LIM PROTEIN; CYCLIN D1; NEDD8; IDENTIFICATION; CONJUGATION; CULLIN-2; BINDING; FAMILY	Neddylation has an important role in ubiquitin- mediated protein degradation through modification of cullins, which are the main substrates for NEDD8 modification. Here, we show that breast cancer-associated protein 3 (BCA3) is a NEDD8 substrate. BCA3 suppressed NF kappa B-dependent transcription through its ability to bind to p65 and the cyclin D1 promoter in a neddylation- dependent manner. Transcriptional suppression mediated by BCA3 may be attributed to the ability of neddylated BCA3 to recruit SIRT1, a class III histone deacetylase. Silencing of endogenous BCA3 in DU145 and MCF7 cells enhanced NF kappa B transcription and inhibited tumour necrosis factor (TNF) alpha-induced apoptosis. Conversely, BCA3 silencing could be reversed by over-expression of wild-type BCA3 and SENP8, a NEDD8-specific protease, but not by neddylation- deficient BCA3 or a SENP8 mutant. These results provide a crucial link between neddylation and transcriptional regulation by SIRT1, a NAD-dependent histone deacetylase that prolongs life span in yeast and worms.	Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Brown Fdn Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA; Shanghai Jiao Tong Univ, Sch Med, Dept Cell Biol, Minist Educ China,Key Lab Cell Differentiat & Apo, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Inst Digest Dis, Shanghai 200001, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Ministry of Education, China; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Yeh, ETH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Cardiol, 1515 Holocombe Blvd,Unit 449, Houston, TX 77030 USA.	etyeh@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA080089, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672, R01 CA 80089] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bouras T, 2005, J BIOL CHEM, V280, P10264, DOI 10.1074/jbc.M408748200; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Gan-Erdene T, 2003, J BIOL CHEM, V278, P28892, DOI 10.1074/jbc.M302890200; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kitching R, 2003, BBA-GENE STRUCT EXPR, V1625, P116, DOI 10.1016/S0167-4781(02)00562-6; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; McLaughlin F, 2004, BIOCHEM PHARMACOL, V68, P1139, DOI 10.1016/j.bcp.2004.05.034; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Oakley F, 2003, J BIOL CHEM, V278, P24359, DOI 10.1074/jbc.M211051200; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Qin HY, 2004, NUCLEIC ACIDS RES, V32, P1492, DOI 10.1093/nar/gkh295; Sastri M, 2005, P NATL ACAD SCI USA, V102, P349, DOI 10.1073/pnas.0408608102; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Westerhout EM, 2005, NUCLEIC ACIDS RES, V33, P796, DOI 10.1093/nar/gki220; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503	30	110	121	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1171	U236		10.1038/ncb1483	http://dx.doi.org/10.1038/ncb1483			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16998474				2022-12-25	WOS:000241395300023
J	Hanna, J; Goldman-Wohl, D; Hamani, Y; Avraham, I; Greenfield, C; Natanson-Yaron, S; Prus, D; Cohen-Daniel, L; Arnon, TI; Manaster, I; Gazit, R; Yutkin, V; Benharroch, D; Porgador, A; Keshet, E; Yagel, S; Mandelboim, O				Hanna, Jacob; Goldman-Wohl, Debra; Hamani, Yaron; Avraham, Inbal; Greenfield, Caryn; Natanson-Yaron, Shira; Prus, Diana; Cohen-Daniel, Leonor; Arnon, Tal I.; Manaster, Irit; Gazit, Roi; Yutkin, Vladimir; Benharroch, Daniel; Porgador, Angel; Keshet, Eli; Yagel, Simcha; Mandelboim, Ofer			Decidual NK cells regulate key developmental processes at the human fetal-maternal interface	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELLS; HLA-G EXPRESSION; ACTIVATING RECEPTOR; GENE-EXPRESSION; RECOGNITION; TROPHOBLASTS; DIFFERENTIATION; PREGNANCY; HEMAGGLUTININS; ENDOMETRIUM	Human CD56(bright) NK cells accumulate in the maternal decidua during pregnancy and are found in direct contact with fetal trophoblasts. Several mechanisms have been proposed to explain the inability of NK cells to kill the semiallogeneic fetal cells. However, the actual functions of decidual NK (dNK) cells during pregnancy are mostly unknown. Here we show that dNK cells, but not peripheral blood - derived NK subsets, regulate trophoblast invasion both in vitro and in vivo by production of the interleukin-8 and interferon-inducible protein - 10 chemokines. Furthermore, dNK cells are potent secretors of an array of angiogenic factors and induce vascular growth in the decidua. Notably, such functions are regulated by specific interactions between dNK-activating and dNK-inhibitory receptors and their ligands, uniquely expressed at the fetal-maternal interface. The overall results support a 'peaceful' model for reproductive immunology, in which elements of innate immunity have been incorporated in a constructive manner to support reproductive tissue development.	Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel; Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Pathol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Urol, IL-91120 Jerusalem, Israel; Ben Gurion Univ Negev, Dept Microbiol & Immunol, IL-92865 Beer Sheva, Israel; Ben Gurion Univ Negev, Dept Pathol, IL-92865 Beer Sheva, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Ben Gurion University; Ben Gurion University	Mandelboim, O (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel.	syagel@hadassah.org.il; oferman@md2.huji.ac.il	Hanna, Jacob/K-1339-2012; Gazit, Roi/J-3352-2017; Keshet, Eli/GQR-0445-2022	Hanna, Jacob/0000-0003-2042-9974; Mandelboim, Ofer/0000-0002-9354-1855; Gazit, Roi/0000-0002-0548-2147; Porgador, Angel/0000-0003-1540-4449				Arnon TI, 2005, NAT IMMUNOL, V6, P515, DOI 10.1038/ni1190; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Ashkar AA, 2001, SEMIN IMMUNOL, V13, P235, DOI 10.1006/smim.2000.0319; Ashkar AA, 2000, J EXP MED, V192, P259, DOI 10.1084/jem.192.2.259; Bulmer JN, 2005, MOL IMMUNOL, V42, P511, DOI 10.1016/j.molimm.2004.07.035; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Corthay A, 2005, IMMUNITY, V22, P371, DOI 10.1016/j.immuni.2005.02.003; Coudert JD, 2005, BLOOD, V106, P1711, DOI 10.1182/blood-2005-03-0918; Drake PM, 2001, J EXP MED, V193, P1199, DOI 10.1084/jem.193.10.1199; Faust Z, 1999, AM J REPROD IMMUNOL, V42, P71; Fehniger TA, 2003, BLOOD, V101, P3052, DOI 10.1182/blood-2002-09-2876; Fisher Susan J, 2004, Reprod Biol Endocrinol, V2, P53, DOI 10.1186/1477-7827-2-53; Goldman-Wohl DS, 2000, MOL HUM REPROD, V6, P535, DOI 10.1093/molehr/6.6.535; Gonen-Gross T, 2003, J IMMUNOL, V171, P1343, DOI 10.4049/jimmunol.171.3.1343; Guimond MJ, 1997, BIOL REPROD, V56, P169, DOI 10.1095/biolreprod56.1.169; Hanna J, 2004, J CLIN INVEST, V114, P1612, DOI 10.1172/JCI200422787; Hanna J, 2004, J IMMUNOL, V173, P6547, DOI 10.4049/jimmunol.173.11.6547; Hanna J, 2003, BLOOD, V102, P1569, DOI 10.1182/blood-2003-02-0517; Henderson TA, 2003, J CLIN ENDOCR METAB, V88, P440, DOI 10.1210/jc.2002-021174; Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214; Katz G, 2004, J IMMUNOL, V173, P1819, DOI 10.4049/jimmunol.173.3.1819; Katz G, 2001, J IMMUNOL, V166, P7260, DOI 10.4049/jimmunol.166.12.7260; King A, 1996, AM J REPROD IMMUNOL, V35, P258; Kitaya K, 2000, BIOL REPROD, V63, P683, DOI 10.1095/biolreprod63.3.683; Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305; Kopcow HD, 2005, P NATL ACAD SCI USA, V102, P15563, DOI 10.1073/pnas.0507835102; Langer N, 1999, AM J REPROD IMMUNOL, V42, P263; Lanier LL, 2005, ADV EXP MED BIOL, V560, P51; Leonard S, 2006, PLACENTA, V27, pS40, DOI 10.1016/j.placenta.2005.11.007; Li XF, 2001, J CLIN ENDOCR METAB, V86, P1823, DOI 10.1210/jc.86.4.1823; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; MCMASTER MT, 1995, J IMMUNOL, V154, P3771; Moffett A, 2004, PLACENTA, V25, P1, DOI 10.1016/S0143-4004(03)00167-X; Monk JM, 2005, PLACENTA, V26, P835, DOI 10.1016/j.placenta.2004.10.016; Moretta A, 2002, NAT IMMUNOL, V3, P6, DOI 10.1038/ni0102-6; Parham P, 2004, IMMUNOL LETT, V92, P11, DOI 10.1016/j.imlet.2003.11.016; Parham P, 2004, J EXP MED, V200, P951, DOI 10.1084/jem.20041783; Pazmany L, 1999, J REPROD IMMUNOL, V43, P127, DOI 10.1016/S0165-0378(99)00028-5; Rajagopalan S, 2006, PLOS BIOL, V4, P70, DOI 10.1371/journal.pbio.0040009; Red-Horse K, 2004, J CLIN INVEST, V114, P744, DOI 10.1172/JCI200422991; Shiroishi M, 2003, P NATL ACAD SCI USA, V100, P8856, DOI 10.1073/pnas.1431057100; Tabiasco J, 2006, PLACENTA, V27, pS34, DOI 10.1016/j.placenta.2006.01.009; Tayade C, 2006, J IMMUNOL, V176, P148, DOI 10.4049/jimmunol.176.1.148; Tjwa M, 2003, CELL TISSUE RES, V314, P5, DOI 10.1007/s00441-003-0776-3; Trundley A, 2004, TISSUE ANTIGENS, V63, P1, DOI 10.1111/j.1399-0039.2004.00170.x; Verma S, 2000, BIOL REPROD, V62, P959, DOI 10.1095/biolreprod62.4.959; Zhang LL, 2000, CANCER RES, V60, P3655; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387; Zhou Y, 1998, J REPROD IMMUNOL, V39, P197, DOI 10.1016/S0165-0378(98)00022-9	49	1158	1203	4	83	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1065	1074		10.1038/nm1452	http://dx.doi.org/10.1038/nm1452			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16892062				2022-12-25	WOS:000240373900031
J	McNamara, JO; Andrechek, ER; Wang, Y; D Viles, K; Rempel, RE; Gilboa, E; Sullenger, BA; Giangrande, PH				McNamara, James O.; Andrechek, Eran R.; Wang, Yong; D Viles, Kristi; Rempel, Rachel E.; Gilboa, Eli; Sullenger, Bruce A.; Giangrande, Paloma H.			Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras	NATURE BIOTECHNOLOGY			English	Article							SMALL INTERFERING RNA; POLO-LIKE KINASES; IN-VIVO; INTRATUMORAL INFUSION; MEMBRANE ANTIGEN; MAMMALIAN-CELLS; CANCER-CELLS; GENE; DICER; SUPPRESSION	Technologies that mediate targeted delivery of small interfering RNAs (siRNAs) are needed to improve their therapeutic efficacy and safety. Therefore, we have developed aptamer-siRNA chimeric RNAs capable of cell type-specific binding and delivery of functional siRNAs into cells. The aptamer portion of the chimeras mediates binding to PSMA, a cell-surface receptor overexpressed in prostate cancer cells and tumor vascular endothelium, whereas the siRNA portion targets the expression of survival genes. When applied to cells expressing PSMA, these RNAs are internalized and processed by Dicer, resulting in depletion of the siRNA target proteins and cell death. In contrast, the chimeras do not bind to or function in cells that do not express PSMA. These reagents also specifically inhibit tumor growth and mediate tumor regression in a xenograft model of prostate cancer. These studies demonstrate an approach for targeted delivery of siRNAs with numerous potential applications, including cancer therapeutics.	Duke Univ, Med Ctr, Duke Ctr Translat Res, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University; Duke University	Sullenger, BA (corresponding author), Duke Univ, Med Ctr, Duke Ctr Translat Res, Dept Surg, Durham, NC 27710 USA.	b.sullenger@cgct.duke.edu	Dong, Ping/H-4011-2016; Wang, Yong/D-9271-2012; Wang, Yong/J-7241-2015	McNamara, James/0000-0003-4091-618X; Andrechek, Eran/0000-0002-8680-3423	NCI NIH HHS [1U54 CA 119313, 5T32 CA 00911-28] Funding Source: Medline; NIGMS NIH HHS [2P01 GM 059299] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA119313, K04CA000911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM059299] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allerson CR, 2005, J MED CHEM, V48, P901, DOI 10.1021/jm049167j; Anderson J, 2003, AIDS RES HUM RETROV, V19, P699, DOI 10.1089/088922203322280928; Cory S, 2005, CANCER CELL, V8, P5, DOI 10.1016/j.ccr.2005.06.012; Cui Y, 2004, J MEMBRANE BIOL, V202, P137, DOI 10.1007/s00232-004-0725-4; Devroe E, 2004, EXPERT OPIN BIOL TH, V4, P319, DOI 10.1517/eobt.4.3.319.27320; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fountaine TM, 2005, CURR GENE THER, V5, P399, DOI 10.2174/1566523054546206; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; ISRAELI RS, 1994, CANCER RES, V54, P1807; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Lewis DL, 2005, METHOD ENZYMOL, V392, P336, DOI 10.1016/S0076-6879(04)92020-4; Lorenz C, 2004, BIOORG MED CHEM LETT, V14, P4975, DOI 10.1016/j.bmcl.2004.07.018; Lupold SE, 2002, CANCER RES, V62, P4029; Matyal R, 2005, INT ANESTHESIOL CLIN, V43, P135, DOI 10.1097/01.aia.0000157499.41843.a3; McGuire S, 2001, AM J PHYSIOL-HEART C, V281, pH715, DOI 10.1152/ajpheart.2001.281.2.H715; Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915; Padilla R, 1999, NUCLEIC ACIDS RES, V27, P1561, DOI 10.1093/nar/27.6.1561; Pestourie C, 2005, BIOCHIMIE, V87, P921, DOI 10.1016/j.biochi.2005.04.013; Reagan-Shaw S, 2005, FASEB J, V19, P611, DOI 10.1096/fj.04-2910fje; Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140; Shepherd GM, 2003, MT SINAI J MED, V70, P113; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102; Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425; Wang Y, 2006, MOL CANCER THER, V5, P362, DOI 10.1158/1535-7163.MCT-05-0266; Yano J, 2004, CLIN CANCER RES, V10, P7721, DOI 10.1158/1078-0432.CCR-04-1049	37	779	898	10	220	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2006	24	8					1005	1015		10.1038/nbt1223	http://dx.doi.org/10.1038/nbt1223			11	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	072VY	16823371				2022-12-25	WOS:000239702300041
J	Todd, JA				Todd, JA			Statistical false positive or true disease pathway?	NATURE GENETICS			English	Editorial Material							GENOME-WIDE ASSOCIATION; TYPE-1 DIABETES LOCUS; PARKINSON-DISEASE; GENE; VARIANT; RISK; SUSCEPTIBILITY; POLYMORPHISM; PROBABILITY; HAPLOTYPE		Univ Cambridge, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab,Addenbrooke, Cambridge Inst Med Res,Wellcome Trust Med Res Cou, Cambridge CB2 2XY, England	University of Cambridge	Todd, JA (corresponding author), Univ Cambridge, Juvenile Diabet Res Fdn, Wellcome Trust Diabet & Inflammat Lab,Addenbrooke, Cambridge Inst Med Res,Wellcome Trust Med Res Cou, Cambridge CB2 2XY, England.	john.todd@cimr.cam.ac.uk	Todd, John A/A-3542-2010	Todd, John A/0000-0003-2740-8148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amundadottir LT, 2006, NAT GENET, V38, P652, DOI 10.1038/ng1808; Anjos S, 2002, J BIOL CHEM, V277, P46478, DOI 10.1074/jbc.M206894200; BRASSAT D, 2006, GENES IMMUN; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Clarimon J, 2006, AM J HUM GENET, V78, P1082, DOI 10.1086/504727; Clayton DG, 2005, NAT GENET, V37, P1243, DOI 10.1038/ng1653; Dahlman I, 2002, NAT GENET, V30, P149, DOI 10.1038/ng825; Graham RR, 2006, NAT GENET, V38, P550, DOI 10.1038/ng1782; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; GROVES CJ, IN PRESS DIABETES; Herbert A, 2006, SCIENCE, V312, P279, DOI 10.1126/science.1124779; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Lowe CE, 2004, GENES IMMUN, V5, P301, DOI 10.1038/sj.gene.6364064; Manly KF, 2004, GENOME RES, V14, P997, DOI 10.1101/gr.2156804; Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902; Moskvina V, 2006, HUM HERED, V61, P55, DOI 10.1159/000092553; Raymond CK, 2005, GENOMICS, V86, P759, DOI 10.1016/j.ygeno.2005.08.013; Service RF, 2006, SCIENCE, V311, P1544, DOI 10.1126/science.311.5767.1544; Smyth DJ, 2006, NAT GENET, V38, P617, DOI 10.1038/ng1800; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Vella A, 2005, AM J HUM GENET, V76, P773, DOI 10.1086/429843; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Wong MY, 2003, INT J EPIDEMIOL, V32, P51, DOI 10.1093/ije/dyg002; 1999, NAT GENET, V22, P1; 2005, NAT GENET, V37, P1153	26	123	131	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2006	38	7					731	733		10.1038/ng0706-731	http://dx.doi.org/10.1038/ng0706-731			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16804532				2022-12-25	WOS:000238669300002
J	Hayes, MJ; Kimata, Y; Wattam, SL; Lindon, C; Mao, GJ; Yamano, H; Fry, AM				Hayes, Michelle J.; Kimata, Yuu; Wattam, Samantha L.; Lindon, Catherine; Mao, Guojie; Yamano, Hiroyuki; Fry, Andrew M.			Early mitotic degradation of Nek2A depends on Cdc20-indedpenent interaction with the APC/C	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; DESTRUCTION BOX; CELL-CYCLE; SUBSTRATE RECOGNITION; PROTEIN-KINASE; KEN BOX; CDC20; CDH1; PROTEOLYSIS; CHECKPOINT	The temporal control of mitotic protein degradation remains incompletely understood. In particular, it is unclear why the mitotic checkpoint prevents the anaphase-promoting complex/cyclosome (APC/C)-mediated degradation of cyclin B and securin in early mitosis, but not cyclin A(1-3). Here, we show that another APC/C substrate, NIMA-related kinase 2A (Nek2A), is also destroyed in pro-metaphase in a checkpoint-independent manner and that this depends on an exposed carboxy-terminal methionine-arginine (MR) dipeptide tail. Truncation of the Nek2A C terminus delays its degradation until late mitosis, whereas Nek2A C-terminal peptides interfere with APC/C activity in an MR-dependent manner. Most importantly, we show that Nek2A binds directly to the APC/C, also in an MR-dependent manner, even in the absence of the adaptor protein Cdc20. As similar C-terminal dipeptide tails promote direct association of Cdc20, Cdh1 and Apc10-Doc1 with core APC/C subunits, we propose that this sequence also allows a substrate, Nek2A, to directly bind the APC/C. Thus, although Cdc20 is required for the degradation of Nek2A, it is not required for its recruitment and this renders its degradation insensitive to the mitotic checkpoint.	Univ Leicester, Dept Biochem, Leicester, Leics, England; Marie Curie Res Inst, Surrey RH8 0TL, England; Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England	University of Leicester; University of Cambridge; University of Cambridge	Fry, AM (corresponding author), Univ Leicester, Dept Biochem, Leicester, Leics, England.	amf5@le.ac.uk	Kimata, Yuu/U-2311-2017; Hayes, Michelle/HCI-5829-2022	Kimata, Yuu/0000-0001-6223-1320; Lindon, Catherine/0000-0003-3554-2574	MRC [G120/892] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C000013/1] Funding Source: Medline; Medical Research Council [G120/892] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Carroll CW, 2005, CURR BIOL, V15, P11, DOI 10.1016/j.cub.2004.12.066; Castro A, 2005, ONCOGENE, V24, P314, DOI 10.1038/sj.onc.1207973; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Faragher AJ, 2003, MOL BIOL CELL, V14, P2876, DOI 10.1091/mbc.E03-02-0108; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Gabellini D, 2003, EMBO J, V22, P3715, DOI 10.1093/emboj/cdg340; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Grosskortenhaus R, 2002, DEV CELL, V2, P29, DOI 10.1016/S1534-5807(01)00104-6; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hames RS, 2005, MOL BIOL CELL, V16, P1711, DOI 10.1091/mbc.E04-08-0688; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Passmore LA, 2003, EMBO J, V22, P786, DOI 10.1093/emboj/cdg084; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Schmidt A, 2005, GENE DEV, V19, P502, DOI 10.1101/gad.320705; Uto K, 2000, EMBO J, V19, P1816, DOI 10.1093/emboj/19.8.1816; Vodermaier HC, 2003, CURR BIOL, V13, P1459, DOI 10.1016/S0960-9822(03)00581-5; Wendt KS, 2001, NAT STRUCT BIOL, V8, P784, DOI 10.1038/nsb0901-784; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Zur A, 2002, EMBO J, V21, P4500, DOI 10.1093/emboj/cdf452	35	126	129	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					607	614		10.1038/ncb1410	http://dx.doi.org/10.1038/ncb1410			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16648845				2022-12-25	WOS:000238029000014
J	Roscioli, T; Cliffe, ST; Bloch, DB; Bell, CG; Mullan, G; Taylor, PJ; Sarris, M; Wang, J; Donald, JA; Kirk, EP; Ziegler, JB; Salzer, U; McDonald, GB; Wong, M; Lindeman, R; Buckley, MF				Roscioli, Tony; Cliffe, Simon T.; Bloch, Donald B.; Bell, Christopher G.; Mullan, Glenda; Taylor, Peter J.; Sarris, Maria; Wang, Joanne; Donald, Jennifer A.; Kirk, Edwin P.; Ziegler, John B.; Salzer, Ulrich; McDonald, George B.; Wong, Melanie; Lindeman, Robert; Buckley, Michael F.			Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeficiency and hepatic veno-occlusive disease	NATURE GENETICS			English	Article							COMMON VARIABLE IMMUNODEFICIENCY; RECEPTOR; HUMANS	We describe mutations in the PML nuclear body protein Sp110 in the syndrome veno-occlusive disease with immunodeficiency, an autosomal recessive disorder of severe hypogammaglobulinemia, combined T and B cell immunodeficiency, absent lymph node germinal centers, absent tissue plasma cells and hepatic veno-occlusive disease. This is the first report of the involvement of a nuclear body protein in a human primary immunodeficiency and of high-penetrance genetic mutations in hepatic veno-occlusive disease.	Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol & Genet, Mol & Cytogenet Unit, Sydney, NSW 2031, Australia; Univ Sydney, Royal Prince Alfred Hosp, Dept Mol & Clin Genet, Sydney, NSW 2050, Australia; Harvard Univ, Sch Med, Dept Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02129 USA; Univ New S Wales, Sch Med Sci, Sydney, NSW 2052, Australia; Univ Washington, Sch Med, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Sch Pharm, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Macquarie Univ, Dept Biol Sci, Sydney, NSW 2109, Australia; Sydney Childrens Hosp, Dept Med Genet, Sydney, NSW 2031, Australia; Univ New S Wales, Sch Womens & Childrens Hosp, Sydney, NSW 2052, Australia; Sydney Childrens Hosp, Dept Immunol & Infect Dis, Sydney, NSW 2031, Australia; Univ Hosp, Div Rheumatol & Clin Immunol, Ctr Med, D-79106 Freiberg, Germany; Childrens Hosp, Dept Immunol & Allergy, Westmead, NSW 2145, Australia	University of New South Wales Sydney; University of Sydney; Harvard University; Harvard Medical School; University of New South Wales Sydney; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Macquarie University; University of Sydney; University of New South Wales Sydney; University of Sydney; University of Sydney	Roscioli, T (corresponding author), Univ New S Wales, Ctr Vasc Res, Sydney, NSW 2052, Australia.	tony.roscioli@email.cs.nsw.gov.au	Bell, Christopher/C-1585-2008	Bell, Christopher/0000-0003-4601-1242; Donald, Jennifer/0000-0002-2732-1379; Kirk, Edwin/0000-0002-4662-0024; buckley, michael/0000-0002-8298-8758; Sarris, Maria/0000-0001-6961-5829; Bloch, Donald/0000-0002-6828-4754				Bairoch A, 2005, NUCLEIC ACIDS RES, V33, pD154, DOI 10.1093/nar/gki070; Bloch DB, 2000, MOL CELL BIOL, V20, P6138, DOI 10.1128/MCB.20.16.6138-6146.2000; Elder ME, 2001, J IMMUNOL, V166, P656, DOI 10.4049/jimmunol.166.1.656; Everett RD, 2005, J VIROL, V79, P5078, DOI 10.1128/JVI.79.8.5078-5089.2005; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Grimbacher B, 2003, NAT IMMUNOL, V4, P261, DOI 10.1038/ni902; KADEREIT S, 1993, J BIOL CHEM, V268, P24432; KINGSTON HM, 1983, LANCET, V2, P1200; McDonald GB, 2003, BLOOD, V101, P2043, DOI 10.1182/blood-2002-06-1860; MELLIS C, 1976, J PEDIATR-US, V88, P236, DOI 10.1016/S0022-3476(76)80988-2; Pan H, 2005, NATURE, V434, P767, DOI 10.1038/nature03419; PARK WJ, 1995, HUM MOL GENET, V4, P1229, DOI 10.1093/hmg/4.7.1229; Salzer U, 2005, NAT GENET, V37, P820, DOI 10.1038/ng1600; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Watashi K, 2003, MOL CELL BIOL, V23, P7498, DOI 10.1128/MCB.23.21.7498-7509.2003	15	63	65	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					620	622		10.1038/ng1780	http://dx.doi.org/10.1038/ng1780			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16648851	Green Accepted			2022-12-25	WOS:000237954800013
J	Weiss, Y; Shulman, A; Ben Shir, I; Keinan, E; Wolf, S				Weiss, Yael; Shulman, Avidor; Ben Shir, Irina; Keinan, Ehud; Wolf, Shmuel			Herbicide-resistance conferred by expression of a catalytic antibody in Arabidopsis thaliana	NATURE BIOTECHNOLOGY			English	Article							ALDOLASE ANTIBODIES; IN-VITRO; ACTIVATION; TOLERANCE; THERAPY	Engineering herbicide resistance in crops facilitates control of weed species, particularly those that are closely related to the crop, and may be useful in selecting lines that have undergone multiple transformation events. Here we show that herbicide-resistant plants can be engineered by designing a herbicide and expressing a catalytic antibody that destroys the herbicide in planta. First, we developed a carbamate herbicide that can be catalytically destroyed by the aldolase antibody 38C2. This compound has herbicidal activity on all three plant species tested. Second, the light chain and half of the heavy chain (Fab) of the catalytic antibody were targeted to the endoplasmic reticulum in two classes of Arabidopsis thaliana transformants. Third, the two transgenic plants were crossed to produce a herbicide-resistant F1 hybrid. The in vitro catalytic activity of the protein from F1 hybrids corroborates that catalytic antibodies can be constitutively expressed in transgenic plants, and that they can confer a unique trait.	Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Plant Sci & Genet Agr, Rehovot, Israel; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Otto Warburg Minerva Ctr Agr Biotechnol, Rehovot, Israel; Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Scripps Research Institute; Scripps Research Institute	Keinan, E (corresponding author), Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel.	keinan@tx.technion.ac.il						Amir R., 2005, CATALYTIC ANTIBODIES, P284; ANDERSON PC, 1986, PUBLICATION, V41; Artsaenko O, 1998, MOL BREEDING, V4, P313, DOI 10.1023/A:1009676832273; BOWDISH K, 1991, J BIOL CHEM, V266, P11901; BRIK A, 2005, CATALYTIC ANTIBODIES, P132; CHALEFF RS, 1984, SCIENCE, V75, P5104; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DARMENCY H, 1985, WEED RES, V25, P175, DOI 10.1111/j.1365-3180.1985.tb00633.x; EASTIN EF, 1981, P S WEED SCI SOC, V34, P263; GRESSEL J, 1989, SOC EXPT BIOL SEMINA, V38, P239; HIATT A, 1989, NATURE, V342, P76, DOI 10.1038/342076a0; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Keinan E, 2021, ASIACHEM, V2, P96; LINDNER AB, 2005, CATALYTIC ANTIBODIES, P418; List B, 1998, P NATL ACAD SCI USA, V95, P15351, DOI 10.1073/pnas.95.26.15351; Ma JKC, 1995, TRENDS BIOTECHNOL, V13, P522, DOI 10.1016/S0167-7799(00)89016-2; Miyashita M, 1997, TETRAHEDRON, V53, P12469, DOI 10.1016/S0040-4020(97)00781-3; Ostler EL, 2002, J IMMUNOL METHODS, V269, P111, DOI 10.1016/S0022-1759(02)00228-4; Rader C, 2003, J MOL BIOL, V332, P889, DOI 10.1016/S0022-2836(03)00992-6; SEBASTIAN SA, 1987, CROP SCI, V27, P948, DOI 10.2135/cropsci1987.0011183X002700050025x; Shabat D, 1999, P NATL ACAD SCI USA, V96, P6925, DOI 10.1073/pnas.96.12.6925; Shulman A, 2002, CHEM-EUR J, V8, P229, DOI 10.1002/1521-3765(20020104)8:1<229::AID-CHEM229>3.0.CO;2-P; SHULMAN A, 2000, THESIS ISRAEL I TECH; Strachan G, 1998, BIOSENS BIOELECTRON, V13, P665, DOI 10.1016/S0956-5663(98)00022-0; Tanaka F, 2004, J MOL BIOL, V335, P1007, DOI 10.1016/j.jmb.2003.11.014; Tanaka F, 2000, J AM CHEM SOC, V122, P4835, DOI 10.1021/ja0005441; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; TAVLADORAKI P, 1993, NATURE, V366, P469, DOI 10.1038/366469a0; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; Wang J, 2002, BIOCHEM BIOPH RES CO, V291, P605, DOI 10.1006/bbrc.2002.6484; Wang J, 2001, BIOCHEM J, V360, P151, DOI 10.1042/0264-6021:3600151; Wentworth P, 1996, P NATL ACAD SCI USA, V93, P799, DOI 10.1073/pnas.93.2.799; Windsor B, 2003, NAT BIOTECHNOL, V21, P428, DOI 10.1038/nbt809; YIN J, 2005, CATALYTIC ANTIBODIES, P1	34	8	8	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2006	24	6					713	717		10.1038/nbt1213	http://dx.doi.org/10.1038/nbt1213			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	051UQ	16751769				2022-12-25	WOS:000238187300035
J	Lee, CS; Kim, IS; Park, JB; Lee, MN; Lee, HY; Suh, PG; Ryu, SH				Lee, CS; Kim, IS; Park, JB; Lee, MN; Lee, HY; Suh, PG; Ryu, SH			The phox homology domain of phospholipase D activates dynamin GTPase activity and accelerates EGFR endocytosis	NATURE CELL BIOLOGY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; PX DOMAIN; BINDING; PHOSPHORYLATION; LOCALIZES; INDUCTION; MEMBRANE	Dynamin is a large GTP-binding protein that mediates endocytosis by hydrolyzing GTP(1,2,3). Previously, we reported that phospholipase D2 (PLD2) interacts with dynamin in a GTP-dependent manner(4). This implies that PLD may regulate the GTPase cycle of dynamin. Here, we show that PLD functions as a GTPase activating protein (GAP) through its phox homology domain (PX), which directly activates the GTPase domain of dynamin, and that the arginine residues in the PLD-PX are vital for this GAP function. Moreover, wild-type PLD-PX, but not mutated PLD-PXs defective for GAP function in vitro, increased epidermal growth factor receptor (EGFR) endocytosis at physiological EGF concentrations. In addition, the silencing of PLDs was shown to retard EGFR endocytosis and the addition of wild-type PLDs or lipase-inactive PLDs, but not PLD1 mutants with defective GAP activity for dynamin in vitro, resulted in the recovery of EGFR endocytosis. These findings suggest that PLD, functioning as an intermolecular GAP for dynamin, accelerates EGFR endocytosis. Moreover, we determined that the phox homology domain itself had GAP activity - a novel function in addition to its role as a binding motif for proteins or lipids.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Ryu, SH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.	sungho@postech.ac.kr	Lee, Mi Nam/A-2357-2012; Suh, Pann-Ghill/F-3610-2010	Ryu, Sung Ho/0000-0003-0913-3048				Barylko B, 1998, J BIOL CHEM, V273, P3791, DOI 10.1074/jbc.273.6.3791; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Du GW, 2004, MOL BIOL CELL, V15, P1024, DOI 10.1091/mbc.E03-09-0673; Ellson CD, 2002, J CELL SCI, V115, P1099; Exton JH, 2002, FEBS LETT, V531, P58, DOI 10.1016/S0014-5793(02)03405-1; Freyberg Z, 2003, TRENDS CELL BIOL, V13, P540, DOI 10.1016/j.tcb.2003.08.004; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Jang IH, 2003, J BIOL CHEM, V278, P18184, DOI 10.1074/jbc.M208438200; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kim JH, 2005, MOL CELL BIOL, V25, P3194, DOI 10.1128/MCB.25.8.3194-3208.2005; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; LEMBACH KJ, 1976, P NATL ACAD SCI USA, V73, P183, DOI 10.1073/pnas.73.1.183; Li GL, 2005, ENDOCRINOLOGY, V146, P4690, DOI 10.1210/en.2005-0505; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Park JB, 2004, ADV ENZYME REGUL, V44, P249, DOI 10.1016/j.advenzreg.2003.11.021; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Song BD, 2003, BIOCHEMISTRY-US, V42, P1369, DOI 10.1021/bi027062h; TUMA PL, 1993, J BIOL CHEM, V268, P17240; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Warnock Dale E., 1996, Bioessays, V18, P885, DOI 10.1002/bies.950181107	30	104	109	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					477	U101		10.1038/ncb1401	http://dx.doi.org/10.1038/ncb1401			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16622417				2022-12-25	WOS:000237299400011
J	Kiepiela, P; Ngumbela, K; Thobakgale, C; Ramduth, D; Honeyborne, I; Moodley, E; Reddy, S; de Pierres, C; Mncube, Z; Mkhwanazi, N; Bishop, K; van der Stok, M; Nair, K; Khan, N; Crawford, H; Payne, R; Leslie, A; Prado, J; Prendergast, A; Frater, J; McCarthy, N; Brander, C; Learn, GH; Nickle, D; Rousseau, C; Coovadia, H; Mullins, JI; Heckerman, D; Walker, BD; Goulder, P				Kiepiela, Photini; Ngumbela, Kholiswa; Thobakgale, Christina; Ramduth, Dhanwanthie; Honeyborne, Isobella; Moodley, Eshia; Reddy, Shabashini; de Pierres, Chantal; Mncube, Zenele; Mkhwanazi, Nompumelelo; Bishop, Karen; van der Stok, Mary; Nair, Kriebashnie; Khan, Nasreen; Crawford, Hayley; Payne, Rebecca; Leslie, Alasdair; Prado, Julia; Prendergast, Andrew; Frater, John; McCarthy, Noel; Brander, Christian; Learn, Gerald H.; Nickle, David; Rousseau, Christine; Coovadia, Hoosen; Mullins, James I.; Heckerman, David; Walker, Bruce D.; Goulder, Philip			CD8(+) T-cell responses to different HIV proteins have discordant associations with viral load	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PRIMARY INFECTION; ESCAPE VARIANTS; LYMPHOCYTE RESPONSES; ACUTE SEROCONVERSION; IMMUNE-RESPONSES; TYPE-1 INFECTION; AUTOLOGOUS VIRUS; SIV REPLICATION; VACCINE DESIGN	Selection of T-cell vaccine antigens for chronic persistent viral infections has been largely empirical. To define the relationship, at the population level, between the specificity of the cellular immune response and viral control for a relevant human pathogen, we performed a comprehensive analysis of the 160 dominant CD8(+) T-cell responses in 578 untreated HIV-infected individuals from KwaZulu-Natal, South Africa. Of the HIV proteins targeted, only Gag-specific responses were associated with lowering viremia. Env-specific and Accessory/Regulatory protein-specific responses were associated with higher viremia. Increasing breadth of Gag-specific responses was associated with decreasing viremia and increasing Env breadth with increasing viremia. Association of the specific CD8(+) T-cell response with low viremia was independent of HLA type and unrelated to epitope sequence conservation. These population-based data, suggesting the existence of both effective immune responses and responses lacking demonstrable biological impact in chronic HIV infection, are of relevance to HIV vaccine design and evaluation.	Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Congella, South Africa; Nuffield Dept Med, Dept Paediat, Oxford OX1 3SY, England; Dept Zool, Oxford OX1 3SY, England; Massachusetts Gen Hosp, Partners AIDS Res Ctr, Boston, MA 02129 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Microsoft Res, Redmond, WA 98052 USA; Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	University of Kwazulu Natal; University of Oxford; Harvard University; Massachusetts General Hospital; University of Washington; University of Washington Seattle; Microsoft; Howard Hughes Medical Institute	Goulder, P (corresponding author), Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, ZA-4013 Congella, South Africa.	philip.goulder@paediatrics.ox.ac.uk	Learn, Gerald H/B-6934-2011; Prado, Julia Garcia/R-7177-2019; Bishop, Karen/G-7073-2015; McCarthy, Noel D/K-3314-2012; Payne, Rebecca/AAC-4783-2022; Learn, Jerry/E-3356-2012; Nickle, David/ABF-2727-2020	Learn, Gerald H/0000-0003-0434-7733; Prado, Julia Garcia/0000-0002-5439-4645; Bishop, Karen/0000-0003-4935-7708; Payne, Rebecca/0000-0002-9037-7367; Brander, Christian/0000-0002-0548-5778; Thobakgale-Tshabalala, Christina/0000-0001-5619-8894; Prendergast, Andrew/0000-0001-7904-7992; leslie, alasdair/0000-0003-2538-6467; McCarthy, Noel/0000-0003-1113-1017; Frater, John/0000-0001-7163-7277	Medical Research Council [G0500384, G108/626] Funding Source: Medline; NIAID NIH HHS [2R01AI46995-06, R01AI067073, P30 AI027757] Funding Source: Medline; PHS HHS [N01-A1-15422] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G108/626, G0500384] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI067073, P30AI027757, R01AI046995] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Addo MM, 2003, J VIROL, V77, P2081, DOI 10.1128/JVI.77.3.2081-2092.2003; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Casimiro DR, 2005, J VIROL, V79, P15547, DOI 10.1128/JVI.79.24.15547-15555.2005; Draenert R, 2004, J VIROL, V78, P630, DOI 10.1128/JVI.78.2.630-641.2004; Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002; Feeney ME, 2004, J VIROL, V78, P8927, DOI 10.1128/JVI.78.16.8927-8930.2004; Fernandez CS, 2005, J VIROL, V79, P5721, DOI 10.1128/JVI.79.9.5721-5731.2005; Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; GALLIMORE A, 1995, NAT MED, V1, P1167, DOI 10.1038/nm1195-1167; Goulder PJR, 2004, NAT REV IMMUNOL, V4, P630, DOI 10.1038/nri1417; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 2001, J VIROL, V75, P1339, DOI 10.1128/JVI.75.3.1339-1347.2001; Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Kobayashi M, 2005, J VIROL, V79, P11529, DOI 10.1128/JVI.79.17.11529-11532.2005; Leslie A, 2005, J EXP MED, V201, P891, DOI 10.1084/jem.20041455; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; MADDISON WP, 1989, FOLIA PRIMATOL, V53, P190, DOI 10.1159/000156416; Martinez-Picado J, 2006, J VIROL, V80, P3617, DOI 10.1128/JVI.80.7.3617-3623.2006; Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004; Matano T, 2004, J EXP MED, V199, P1709, DOI 10.1084/jem.20040432; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Migueles SA, 2003, J VIROL, V77, P6889, DOI 10.1128/JVI.77.12.6889-6898.2003; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Novitsky V, 2003, J VIROL, V77, P882, DOI 10.1128/JVI.77.2.882-890.2003; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; Ramduth D, 2005, J INFECT DIS, V192, P1588, DOI 10.1086/496894; Reimann KA, 2005, J VIROL, V79, P8878, DOI 10.1128/JVI.79.14.8878-8885.2005; RIVIERE Y, 1995, AIDS RES HUM RETROV, V11, P903, DOI 10.1089/aid.1995.11.903; Rousseau CM, 2006, J VIROL METHODS, V136, P118, DOI 10.1016/j.jviromet.2006.04.009; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SAFRIT JT, 1994, J IMMUNOL, V153, P3822; Staprans SI, 2004, P NATL ACAD SCI USA, V101, P13026, DOI 10.1073/pnas.0404739101; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wilson JDK, 2000, AIDS, V14, P225, DOI 10.1097/00002030-200002180-00003; Wilson NA, 2006, J VIROL, V80, P5875, DOI 10.1128/JVI.00171-06; Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006	48	818	851	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2007	13	1					46	53		10.1038/nm1520	http://dx.doi.org/10.1038/nm1520			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17173051				2022-12-25	WOS:000243301800035
J	Liu, TX; Becker, MW; Jelinek, J; Wu, WS; Deng, M; Mikhalkevich, N; Hsu, K; Bloomfield, CD; Stone, RM; DeAngelo, DJ; Galinsky, IA; Issa, JP; Clarke, MF; Look, AT				Liu, Ting Xi; Becker, Michael W.; Jelinek, Jaroslav; Wu, Wen-Shu; Deng, Min; Mikhalkevich, Natallia; Hsu, Karl; Bloomfield, Clara D.; Stone, Richard M.; DeAngelo, Daniel J.; Galinsky, Ilene A.; Issa, Jean-Pierre; Clarke, Michael F.; Look, A. Thomas			Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation	NATURE MEDICINE			English	Article							MOLECULAR DELINEATION; TUMOR-SUPPRESSOR; REGION; LEUKEMIA; IDENTIFICATION; LINE; DIVISION; DISEASES; DNA	m Interstitial loss of all or part of the long arm of chromosome 5, or del(5q), is a frequent clonal chromosomal abnormality in human myelodysplastic syndrome (MDS, a preleukemic disorder) and acute myeloid leukemia (AML)(1), and is thought to contribute to the pathogenesis of these diseases by deleting one or more tumor-suppressor genes(2). Although a major commonly deleted region (CDR) has been delineated on chromosome band 5q31.1 (refs.3-7), attempts to identify tumor suppressors within this band have been unsuccessful. We focused our analysis of gene expression on RNA from primitive leukemia-initiating cells, which harbor 5q deletions(8,9), and analyzed 12 genes within the CDR that are expressed by normal hematopoietic stem cells. Here we show that the gene encoding alpha-catenin (CTNNA1) is expressed at a much lower level in leukemia-initiating stem cells from individuals with AML or MDS with a 5q deletion than in individuals with MDS or AML lacking a 5q deletion or in normal hematopoietic stem cells. Analysis of HL-60 cells, a myeloid leukemia line with deletion of the 5q31 region(10,11), showed that the CTNNA1 promoter of the retained allele is suppressed by both methylation and histone deacetylation. Restoration of CTNNA1 expression in HL-60 cells resulted in reduced proliferation and apoptotic cell death. Thus, loss of expression of the alpha-catenin tumor suppressor in hematopoietic stem cells may provide a growth advantage that contributes to human MDS or AML with del(5q).	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Lab Dev & Dis, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China; Univ Rochester, Div Hematol Oncol, Rochester, NY 14642 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Chicago, Canc & Leukemia Grp, Chicago, IL 60606 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Stanford Univ, Inst Stem Cell & Regenerat Med, Palo Alto, CA 94304 USA; Stanford Univ, Div Hematol Oncol, Palo Alto, CA 94304 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; University of Rochester; University of Texas System; UTMD Anderson Cancer Center; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Chicago; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Stanford University; Stanford University	Look, AT (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	thomas_look@dfci.harvard.edu	Jelinek, Jaroslav/O-6876-2019; Jelinek, Jaroslav/A-8476-2008; Wu, Wen-Shu/I-1258-2014; Jelinek, Jaroslav/D-2282-2012	Wu, Wen-Shu/0000-0002-0225-2522; Jelinek, Jaroslav/0000-0002-2533-0220; Becker, Michael/0000-0001-9890-8815; Issa, Jean-Pierre/0000-0003-2258-5030	NCI NIH HHS [CA101140, CA104987, CA108631] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA108631, R01CA104987, U10CA101140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dick JE, 2003, NATURE, V423, P231, DOI 10.1038/423231a; FAIRMAN J, 1995, P NATL ACAD SCI USA, V92, P7406, DOI 10.1073/pnas.92.16.7406; Horrigan SK, 2000, BLOOD, V95, P2372, DOI 10.1182/blood.V95.7.2372.007k20_2372_2377; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Lai F, 2001, GENOMICS, V71, P235, DOI 10.1006/geno.2000.6414; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Lee JY, 2002, CANCER GENET CYTOGEN, V137, P124, DOI 10.1016/S0165-4608(02)00565-4; Liang JC, 1999, CANCER GENET CYTOGEN, V113, P105, DOI 10.1016/S0165-4608(99)00030-8; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; Mrozek K, 2003, GENE CHROMOSOME CANC, V38, P249, DOI 10.1002/gcc.10274; Nilsson L, 2000, BLOOD, V96, P2012, DOI 10.1182/blood.V96.6.2012.h8002012a_2012_2021; NIMER SD, 1987, BLOOD, V70, P1705; Shipley J, 1996, GENE CHROMOSOME CANC, V15, P182, DOI 10.1002/(SICI)1098-2264(199603)15:3<182::AID-GCC7>3.0.CO;2-Z; Shu JM, 2006, CANCER RES, V66, P5077, DOI 10.1158/0008-5472.CAN-05-2629; Ulger C, 2003, CANCER GENET CYTOGEN, V147, P28, DOI 10.1016/S0165-4608(03)00155-9; VandenBerghe H, 1997, CANCER GENET CYTOGEN, V94, P1, DOI 10.1016/S0165-4608(96)00350-0; Vanpoucke G, 2002, BBA-GENE STRUCT EXPR, V1574, P262, DOI 10.1016/S0167-4781(01)00378-5; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Yamashita YM, 2003, SCIENCE, V301, P1547, DOI 10.1126/science.1087795; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhao ND, 1997, P NATL ACAD SCI USA, V94, P6948, DOI 10.1073/pnas.94.13.6948	27	155	161	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					78	83		10.1038/nm1512	http://dx.doi.org/10.1038/nm1512			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17159988				2022-12-25	WOS:000243301800039
J	Cowan, CR; Hyman, AA				Cowan, Carrie R.; Hyman, Anthony A.			Cyclin E-Cdk2 temporally regulates centrosome assembly and establishment of polarity in Caenorhabditis elegans embryos	NATURE CELL BIOLOGY			English	Article							ASYMMETRIC CELL-DIVISION; C-ELEGANS; PAR PROTEINS; S-PHASE; POLARIZATION; DUPLICATION; PROGRESSION; ZYGOTE; INTERFERENCE; CYTOSKELETON	Establishment of polarity in C. elegans embryos is dependent on the centrosome(1). The sperm contributes a pair of centrioles to the egg and these centrioles remain incapable of polarizing the cortex while the egg completes meiosis. Coincident with the establishment of polarity, the centrioles recruit centrosomal proteins(1), several of which are required for polarity(1-3), suggesting that the temporal regulation of centrosome assembly may control the initiation of polarization. We found that cyclin E-Cdk2 is required for the establishment of polarity. Cyclin E-Cdk2 controls the recruitment of centrosomal proteins specifically at the time of polarity establishment. Cyclin E is required for several examples of asymmetric cell division and fate determination in C. elegans and Drosophila(4-6). Here, we suggest a possible mechanism for cyclin E-Cdk2-dependent differentiation: the establishment of cortical polarity by the centrosome.	Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Max Planck Society	Cowan, CR (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	cowan@mpi-cbg.de	Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Cowan, Carrie/0000-0002-2867-1733				Balczon R, 2002, CELL MOTIL CYTOSKEL, V52, P183, DOI 10.1002/cm.10043; Berger C, 2005, NAT CELL BIOL, V7, P56, DOI 10.1038/ncb1203; Bhat KM, 2004, DEVELOPMENT, V131, P1123, DOI 10.1242/dev.01014; Brauchle M, 2003, CURR BIOL, V13, P819, DOI 10.1016/S0960-9822(03)00295-1; Brodigan TM, 2003, DEV BIOL, V254, P102, DOI 10.1016/S0012-1606(02)00032-5; Cowan CR, 2004, NATURE, V431, P92, DOI 10.1038/nature02825; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Cuenca AA, 2003, DEVELOPMENT, V130, P1255, DOI 10.1242/dev.00284; EDGAR LG, 1994, DEVELOPMENT, V120, P443; Encalada SE, 2000, DEV BIOL, V228, P225, DOI 10.1006/dbio.2000.9965; Fay DS, 2000, DEVELOPMENT, V127, P4049; Fay DS, 2005, SEMIN CELL DEV BIOL, V16, P397, DOI 10.1016/j.semcdb.2005.02.002; Gunsalus KC, 2004, NUCLEIC ACIDS RES, V32, pD406, DOI 10.1093/nar/gkh110; Hamill DR, 2002, DEV CELL, V3, P673, DOI 10.1016/S1534-5807(02)00327-1; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hinchcliffe EH, 2001, SCIENCE, V291, P1547, DOI 10.1126/science.1056866; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Hird S, 1996, J CELL SCI, V109, P525; Kamath R.S., 2001, GENOME BIOL, V2; Kirkham M, 2003, CELL, V112, P575, DOI 10.1016/S0092-8674(03)00117-X; Koreth J, 2005, ONCOGENE, V24, P2756, DOI 10.1038/sj.onc.1208607; Leidel S, 2003, DEV CELL, V4, P431, DOI 10.1016/S1534-5807(03)00062-5; Liu J, 2000, MOL BIOL EVOL, V17, P1061, DOI 10.1093/oxfordjournals.molbev.a026387; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; Moroy T, 2004, INT J BIOCHEM CELL B, V36, P1424, DOI 10.1016/S1357-2725(03)00432-1; Munro E, 2004, DEV CELL, V7, P413, DOI 10.1016/j.devcel.2004.08.001; Munro EM, 2006, CURR OPIN CELL BIOL, V18, P86, DOI 10.1016/j.ceb.2005.12.007; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Nance J, 2005, BIOESSAYS, V27, P126, DOI 10.1002/bies.20175; O'Connell KF, 2000, DEV BIOL, V222, P55, DOI 10.1006/dbio.2000.9714; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SEYDOUX G, 1993, DEV BIOL, V157, P423, DOI 10.1006/dbio.1993.1146; Sonneville R, 2004, DEVELOPMENT, V131, P3527, DOI 10.1242/dev.01244; Sonnichsen B, 2005, NATURE, V434, P462, DOI 10.1038/nature03353; Tilmann C, 2005, DEV CELL, V9, P489, DOI 10.1016/j.devcel.2005.09.004; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Wallenfang MR, 2000, NATURE, V408, P89, DOI 10.1038/35040562; Zipperlen P, 2001, EMBO J, V20, P3984, DOI 10.1093/emboj/20.15.3984	42	54	74	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1441	U82		10.1038/ncb1511	http://dx.doi.org/10.1038/ncb1511			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17115027				2022-12-25	WOS:000242419800021
J	Di Marcotullio, L; Ferretti, E; Greco, A; De Smaele, E; Po, A; Sico, MA; Alimandi, M; Giannini, G; Maroder, M; Screpanti, I; Gulino, A				Di Marcotullio, Lucia; Ferretti, Elisabetta; Greco, Azzura; De Smaele, Enrico; Po, Agnese; Sico, Maria Anna; Alimandi, Maurizio; Giannini, Giuseppe; Maroder, Marella; Screpanti, Isabella; Gulino, Alberto			Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch- dependent ubiquitination	NATURE CELL BIOLOGY			English	Article							PROGENITOR-CELL MAINTENANCE; SONIC HEDGEHOG; ASYMMETRIC DIVISION; MOUSE MODEL; STEM-CELLS; PROTEIN; PROLIFERATION; NOTCH; EXPRESSION; DIFFERENTIATION	The developmental protein Numb is a major determinant of binary cell fates(1-3). It is also required for the differentiation of cerebellar granule cell progenitors (GCPs)(4) at a stage of development responsive to the morphogenic glycoprotein Hedehog(5,6). Hedgehog signalling is crucial for the physiological maintenance and self-renewal of neural stem cells and its deregulation is responsible for their progression towards tumorigenesis(5,7-11). The mechanisms that inhibit this pathway during the differentiation stage are poorly understood. Here, we identify Numb as a Hedgehog-pathway inhibitor that is downregulated in early GCPs and GCP-derived cancer cells. We demonstrate that the Hedgehog transcription factor Gli1 is targeted by Numb for Itch-dependent ubiquitination, which suppresses Hedgehog signals, thus arresting growth and promoting cell differentiation. This novel Numb-dependent regulatory loop may limit the extent and duration of Hedgehog signalling during neural-progenitor differentiation, and its subversion may be a relevant event in brain tumorigenesis.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Univ Roma La Sapienza, Inst Pasteur, Cenci Bolognetti Fdn, I-00161 Rome, Italy; Neuromed Inst, I-86077 Pozzilli, Italy	Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; IRCCS Neuromed	Gulino, A (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, 324 Viale Regina Elena, I-00161 Rome, Italy.	alberto.gulino@uniroma1.it	Po, Agnese/G-8754-2015; Alimandi, Maurizio/AAG-9246-2019; 高, 雨莉/HGU-8187-2022; De Smaele, Enrico/C-1124-2013; Giannini, Giuseppe/B-5672-2013; Po, Agnese/AEQ-0192-2022; Ferretti, Elisabetta/G-5413-2013	Po, Agnese/0000-0002-9346-8782; Alimandi, Maurizio/0000-0002-1409-6803; De Smaele, Enrico/0000-0003-4524-4423; Giannini, Giuseppe/0000-0003-0299-4056; Po, Agnese/0000-0002-9346-8782; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178; Ferretti, Elisabetta/0000-0001-7265-6429	Telethon [GGP04168] Funding Source: Medline	Telethon(Fondazione Telethon)		Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Ahn S, 2005, NATURE, V437, P894, DOI 10.1038/nature03994; Ali-Seyed M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-54; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Angers A, 2004, J BIOL CHEM, V279, P11471, DOI 10.1074/jbc.M309934200; Argenti B, 2005, J NEUROSCI, V25, P8338, DOI 10.1523/JNEUROSCI.2438-05.2005; Barnes EA, 2005, ONCOGENE, V24, P902, DOI 10.1038/sj.onc.1208240; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Cayouette M, 2002, NAT NEUROSCI, V5, P1265, DOI 10.1038/nn1202-1265; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Ferretti E, 2005, TRENDS MOL MED, V11, P537, DOI 10.1016/j.molmed.2005.10.005; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Incardona JP, 2000, P NATL ACAD SCI USA, V97, P12044, DOI 10.1073/pnas.220251997; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Klein AL, 2004, DEV BIOL, V266, P161, DOI 10.1016/j.ydbio.2003.10.017; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Li HS, 2003, NEURON, V40, P1105, DOI 10.1016/S0896-6273(03)00755-4; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Palma V, 2005, DEVELOPMENT, V132, P335, DOI 10.1242/dev.01567; Palma V, 2004, DEVELOPMENT, V131, P337, DOI 10.1242/dev.00930; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Petersen PH, 2002, NATURE, V419, P929, DOI 10.1038/nature01124; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Shen Q, 2002, DEVELOPMENT, V129, P4843; Verdi JM, 1999, P NATL ACAD SCI USA, V96, P10472, DOI 10.1073/pnas.96.18.10472; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	43	225	230	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1415	U68		10.1038/ncb1510	http://dx.doi.org/10.1038/ncb1510			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17115028				2022-12-25	WOS:000242419800018
J	Zuo, XF; Zhang, J; Zhang, Y; Hsu, SC; Zhou, DG; Guo, W				Zuo, Xiaofeng; Zhang, Jian; Zhang, Ying; Hsu, Shu-Chan; Zhou, Daoguo; Guo, Wei			Exo70 interacts with the Arp2/3 complex and regulates cell migration	NATURE CELL BIOLOGY			English	Article							EXOCYST COMPLEX; ACTIN; PROTEIN; LAMELLIPODIA; CYTOSKELETON; MEMBRANE; REGIONS; RHO	The exocyst is a multiprotein complex essential for tethering secretory vesicles to specific domains of the plasma membrane for exocytosis(1-3). Here, we report that the exocyst component Exo70 interacts with the Arp2/3 complex, a key regulator of actin polymerization(4,5). We further show that the exocyst Arp2/3 interaction is regulated by epidermal growth factor (EGF) signalling. Inhibition of Exo70 by RNA interference (RNAi) or antibody microinjection blocks the formation of actin-based membrane protrusions and affects various aspects of cell motility. We propose that Exo70, in addition to functioning in exocytosis, also regulates actin at the leading edges of migrating cells, therefore coordinating cytoskeleton and membrane traffic during cell migration.	Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA	University of Pennsylvania; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Rutgers State University New Brunswick	Guo, W (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	guowei@sas.upenn.edu						Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; Hsu SC, 2004, INT REV CYTOL, V233, P243, DOI 10.1016/S0074-7696(04)33006-8; Inoue M, 2003, NATURE, V422, P629, DOI 10.1038/nature01533; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Machesky LM, 1997, BIOCHEM J, V328, P105; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Novick P, 2002, TRENDS CELL BIOL, V12, P247, DOI 10.1016/S0962-8924(02)02293-6; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Takaya A, 2004, MOL BIOL CELL, V15, P2549, DOI 10.1091/mbc.E03-11-0857; Wang S, 2004, J BIOL CHEM, V279, P35958, DOI 10.1074/jbc.M313778200; Welch MD, 1997, J CELL BIOL, V138, P375, DOI 10.1083/jcb.138.2.375; Xu KF, 2005, P NATL ACAD SCI USA, V102, P2784, DOI 10.1073/pnas.0409871102	17	138	143	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1383	U38		10.1038/ncb1505	http://dx.doi.org/10.1038/ncb1505			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17086175				2022-12-25	WOS:000242419800014
J	Sasano, T; McDonald, AD; Kikuchi, K; Donahue, JK				Sasano, Tetsuo; McDonald, Amy D.; Kikuchi, Kan; Donahue, J. Kevin			Molecular ablation of ventricular tachycardia after myocardial infarction	NATURE MEDICINE			English	Article							ACTION-POTENTIAL DURATION; GENE-TRANSFER; BIOLOGICAL PACEMAKER; EXPRESSION; VECTORS; HEART; MICE	Ventricular tachycardia is a common and lethal complication after myocardial infarction. Here we show that focal transfer of a gene encoding a dominant-negative version of the KCNH2 potassium channel ( KCNH2-G628S) to the infarct scar border eliminated all ventricular arrhythmias in a porcine model. No proarrhythmia or other negative effects were discernable. Our results demonstrate the potential viability of gene therapy for ablation of ventricular arrhythmias.	Case Western Reserve Univ, Heart & Vasc Res Ctr, Metrohlth Hosp, Sch Med, Cleveland, OH 44109 USA; Kyushu Kosei Nenkin Hosp, Div Cardiol, Kitakyushu, Fukuoka 8078555, Japan	Case Western Reserve University; MetroHealth System	Kikuchi, K (corresponding author), Johns Hopkins Univ, Sch Med, Div Cardiol, Baltimore, MD 21205 USA.	kdonahue@metrohealth.org			NHLBI NIH HHS [R01 HL067148] Funding Source: Medline; NIBIB NIH HHS [R01 EB002846] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		*AM HEART ASS, 2002, 2001 HEART STROK STA; Brunner M, 2003, AM J PHYSIOL-HEART C, V285, pH194, DOI 10.1152/ajpheart.00971.2002; Donahue JK, 2000, NAT MED, V6, P1395; Gould PA, 2006, JAMA-J AM MED ASSOC, V295, P1907, DOI 10.1001/jama.295.16.1907; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; LESH MD, 1989, CIRC RES, V65, P1426, DOI 10.1161/01.RES.65.5.1426; Maisel WH, 2006, JAMA-J AM MED ASSOC, V295, P1901, DOI 10.1001/jama.295.16.1901; Miake J, 2002, NATURE, V419, P132, DOI 10.1038/419132b; Qu JH, 2003, CIRCULATION, V107, P1106, DOI 10.1161/01.CIR.0000059939.97249.2C; Quinones MJ, 1996, CIRCULATION, V94, P1394, DOI 10.1161/01.CIR.94.6.1394; Rothman SA, 1997, CIRCULATION, V96, P3499; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270	13	87	96	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1256	1258		10.1038/nm1503	http://dx.doi.org/10.1038/nm1503			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17072309	Green Accepted			2022-12-25	WOS:000241844900022
J	Gutierrez, GJ; Vogtlin, A; Castro, A; Ferby, I; Salvagiotto, G; Ronai, Z; Lorca, T; Nebreda, AR				Gutierrez, Gustavo J.; Voegtlin, Andrea; Castro, Ana; Ferby, Ingvar; Salvagiotto, Giorgia; Ronai, Ze'ev; Lorca, Thierry; Nebreda, Angel R.			Meiotic regulation of the CDK activator RINGO/Speedy by ubiquitin-proteasome-mediated processing and degradation	NATURE CELL BIOLOGY			English	Article							NF-KAPPA-B1 PRECURSOR PROTEIN; CELL-CYCLE REGULATOR; SOMATIC WEE1; XENOPUS; KINASE; PHOSPHORYLATION; TRANSLATION; PROTEOLYSIS; PROGRESSION; EXPRESSION	Xenopus RINGO/Speedy (XRINGO) is a potent inducer of oocyte meiotic maturation that can directly activate Cdk1 and Cdk2. Here, we show that endogenous XRINGO protein accumulates transiently during meiosis I entry and then is downregulated. This tight regulation of XRINGO expression is the consequence of two interconnected mechanisms: processing and degradation. XRINGO processing involves recognition of at least three distinct phosphorylated recognition motifs by the SCF beta TrCP ubiquitin ligase, followed by proteasome-mediated limited degradation, resulting in an amino-terminal XRINGO fragment. XRINGO processing is directly stimulated by several kinases, including protein kinase A and glycogen synthase kinase-3 beta, and may contribute to the maintenance of G2 arrest. On the other hand, XRINGO degradation after meiosis I is mediated by the ubiquitin ligase Siah-2, which probably requires phosphorylation of XRINGO on Ser 243 and may be important for the omission of S phase at the meiosis-I-meiosis-II transition in Xenopus oocytes.	EMBL, D-69117 Heidelberg, Germany; BIMR, La Jolla, CA 92037 USA; Univ Zurich, Fac Vet Med, Inst Virol, CH-8057 Zurich, Switzerland; CNRS, CRBM, F-34096 Montpellier, France; Max Planck Inst Neurobiol, D-82152 Martinsried, Germany; Inst Mol Pathol, A-1030 Vienna, Austria; Spanish Natl Canc Ctr, CNIO, E-28029 Madrid, Spain	European Molecular Biology Laboratory (EMBL); University of Zurich; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Max Planck Society; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Centro Nacional de Investigaciones Oncologicas (CNIO)	Nebreda, AR (corresponding author), EMBL, Meyerhofstr 1, D-69117 Heidelberg, Germany.	gustavo@burnham.org; anebreda@cnio.es	Gutierrez, Gustavo/AAO-9957-2021; Ferby, Ingvar/B-7895-2008; Nebreda, Angel Rodriguez/R-9594-2019; CASTRO, ANNA/F-4350-2010; Gutierrez, Gustavo/B-6771-2013	Gutierrez, Gustavo/0000-0001-8652-972X; CASTRO, ANNA/0000-0002-3655-1352; Gutierrez, Gustavo/0000-0003-4133-5002; Lorca, Thierry/0000-0003-2007-8924; Ferby, Ingvar/0000-0002-3435-1728; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA111515, R01CA078419] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bogdan S, 2001, MECH DEVELOP, V103, P61, DOI 10.1016/S0925-4773(01)00332-X; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Castro A, 2001, MOL BIOL CELL, V12, P2660, DOI 10.1091/mbc.12.9.2660; Cheng Aiyang, 2005, BMC Biochemistry, V6, DOI 10.1186/1471-2091-6-19; Ciechanover A, 2001, BIOCHIMIE, V83, P341, DOI 10.1016/S0300-9084(01)01239-1; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DELLA NG, 1995, CELL TISSUE RES, V279, P411, DOI 10.1007/s004410050298; Dinarina A, 2005, BIOCHEM J, V386, P349, DOI 10.1042/BJ20041779; Ferby I, 1999, GENE DEV, V13, P2177, DOI 10.1101/gad.13.16.2177; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gutierrez GJ, 2006, TRENDS BIOCHEM SCI, V31, P324, DOI 10.1016/j.tibs.2006.04.001; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochegger H, 2001, DEVELOPMENT, V128, P3795; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kanemori Y, 2005, P NATL ACAD SCI USA, V102, P6279, DOI 10.1073/pnas.0501873102; Karaiskou A, 2001, J BIOL CHEM, V276, P36028, DOI 10.1074/jbc.M104722200; Lenormand JL, 1999, EMBO J, V18, P1869, DOI 10.1093/emboj/18.7.1869; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; MACKETT M, 1990, NUCLEIC ACIDS RES, V18, P1082, DOI 10.1093/nar/18.4.1082; Mendez R, 2002, EMBO J, V21, P1833, DOI 10.1093/emboj/21.7.1833; Moore JD, 2003, SCIENCE, V300, P987, DOI 10.1126/science.1081418; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Nebreda AR, 2006, CURR OPIN CELL BIOL, V18, P192, DOI 10.1016/j.ceb.2006.01.001; NEWPORT JW, 1984, CELL, V37, P731, DOI 10.1016/0092-8674(84)90409-4; Padmanabhan K, 2006, GENE DEV, V20, P199, DOI 10.1101/gad.1383106; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Perez LH, 2002, NAT CELL BIOL, V4, P737, DOI 10.1038/ncb850; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Porter LA, 2002, J CELL BIOL, V157, P357, DOI 10.1083/jcb.200109045; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Rape M, 2002, NAT CELL BIOL, V4, pE113, DOI 10.1038/ncb0502-e113; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Schmitt A, 2002, P NATL ACAD SCI USA, V99, P4361, DOI 10.1073/pnas.022056399; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; Suzuki H, 2000, J BIOL CHEM, V275, P2877, DOI 10.1074/jbc.275.4.2877; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102	42	39	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1084	U75		10.1038/ncb1472	http://dx.doi.org/10.1038/ncb1472			22	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16964245				2022-12-25	WOS:000241395300012
J	Miharada, K; Hiroyama, T; Sudo, K; Nagasawa, T; Nakamura, Y				Miharada, Kenichi; Hiroyama, Takashi; Sudo, Kazuhiro; Nagasawa, Toshiro; Nakamura, Yukio			Efficient enucleation of erythroblasts differentiated in vitro from hematopoietic stem and progenitor cells	NATURE BIOTECHNOLOGY			English	Article							RED-BLOOD-CELLS; ERYTHROPOIESIS; PROTEIN	Erythroblast enucleation is thought to be largely dependent on signals mediated by other cells, such as macrophages. In an attempt to improve the in vitro production of red blood cells (RBCs) from immature hematopoietic progenitor cells, we have developed a method to produce enucleated RBCs efficiently in the absence of feeder cells. Our method may represent an efficient way to produce transfusable RBCs on a large scale from hematopoietic progenitors.	RIKEN, BioResource Ctr, Cell Engn Div, Tsukuba, Ibaraki 3050074, Japan; Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 3058577, Japan	RIKEN; University of Tsukuba	Nakamura, Y (corresponding author), RIKEN, BioResource Ctr, Cell Engn Div, Koyadai 3-1-1, Tsukuba, Ibaraki 3050074, Japan.	yukionak@brc.riken.jp	Nakamura, Yukio/A-5263-2016; Miharada, Kenichi/C-1397-2014	Nakamura, Yukio/0000-0001-8056-4946; Miharada, Kenichi/0000-0001-8073-4001				Gerber HP, 2003, J MOL MED, V81, P20, DOI 10.1007/s00109-002-0397-4; Giarratana MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047; Hanspal M, 1998, BLOOD, V92, P2940, DOI 10.1182/blood.V92.8.2940.420k31_2940_2950; Hess JR, 2002, TRANSFUS MED REV, V16, P283, DOI 10.1053/tmrv.2002.35212; Hiroyama T, 2006, EXP HEMATOL, V34, P760, DOI 10.1016/j.exphem.2006.03.004; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; Kingsley PD, 2004, BLOOD, V104, P19, DOI 10.1182/blood-2003-12-4162; Kolbus A, 2003, BLOOD, V102, P3136, DOI 10.1182/blood-2003-03-0923; Lee JCM, 2004, BLOOD, V103, P1912, DOI 10.1182/blood-2003-03-0928; Neildez-Nguyen TMA, 2002, NAT BIOTECHNOL, V20, P467, DOI 10.1038/nbt0502-467; Ohneda O, 1997, BRIT J HAEMATOL, V98, P798, DOI 10.1046/j.1365-2141.1997.3163133.x; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Yanai Nobuaki, 1997, Leukemia (Basingstoke), V11, P484; Yoshida H, 2005, NATURE, V437, P754, DOI 10.1038/nature03964; Zhang CC, 2004, BLOOD, V103, P2513, DOI 10.1182/blood-2003-08-2955	15	139	166	2	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2006	24	10					1255	1256		10.1038/nbt1245	http://dx.doi.org/10.1038/nbt1245			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	093TG	16980975				2022-12-25	WOS:000241191700028
J	King, CG; Kobayashi, T; Cejas, PJ; Kim, T; Yoon, K; Kim, GK; Chiffoleau, E; Hickman, SP; Walsh, PT; Turka, LA; Choi, Y				King, Carolyn G.; Kobayashi, Takashi; Cejas, Pedro J.; Kim, Taesoo; Yoon, Kwiyeom; Kim, Gregory K.; Chiffoleau, Elise; Hickman, Somia P.; Walsh, Patrick T.; Turka, Laurence A.; Choi, Yongwon			TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis	NATURE MEDICINE			English	Article							INTESTINAL INFLAMMATION; INTERLEUKIN-1; AUTOIMMUNITY; DEFICIENCY; ACTIVATION; MATURATION; PATHWAYS; CTLA-4; FOXP3; CD28	TRAF6 has a key role in the regulation of innate immune responses by mediating signals from both TNF receptor and interleukin-1 receptor/Toll-like receptor superfamilies. Here we show that T cell - specific deletion of TRAF6 unexpectedly results in multiorgan inflammatory disease. TRAF6-deficient T cells exhibit hyperactivation of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway compared with wild-type T cells and, as a result, become resistant to suppression by CD4(+)CD25(+) regulatory T cells. These data identify a previously unrecognized role for TRAF6 in the maintenance of peripheral tolerance, and suggest the presence of a T cell - intrinsic control mechanism to render responder T cells susceptible to tolerizing signals.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Choi, Y (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Dept Pathol & Lab Med, 421 Curie Blvd, Philadelphia, PA 19104 USA.	ychoi3@mail.med.upenn.edu	Chiffoleau, Elise/N-2982-2018; Walsh, Patrick/I-7909-2014	Chiffoleau, Elise/0000-0001-6167-682X; Walsh, Patrick/0000-0002-0130-8766; King, Carolyn G./0000-0001-6059-323X				Akiyama T, 2005, SCIENCE, V308, P248, DOI 10.1126/science.1105677; Alegre ML, 2001, NAT REV IMMUNOL, V1, P220, DOI 10.1038/35105024; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chiffoleau E, 2003, J IMMUNOL, V171, P5751, DOI 10.4049/jimmunol.171.11.5751; Chung JY, 2002, J CELL SCI, V115, P679; Dempsey PW, 2003, CYTOKINE GROWTH F R, V14, P193, DOI 10.1016/S1359-6101(03)00021-2; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Hennet T, 1995, P NATL ACAD SCI USA, V92, P12070, DOI 10.1073/pnas.92.26.12070; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kobayashi T, 2003, IMMUNITY, V19, P353, DOI 10.1016/S1074-7613(03)00230-9; Liu YC, 2004, ANNU REV IMMUNOL, V22, P81, DOI 10.1146/annurev.immunol.22.012703.104813; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Mackey MF, 2003, EUR J IMMUNOL, V33, P779, DOI 10.1002/eji.200323729; Parsons MJ, 2001, J IMMUNOL, V167, P42, DOI 10.4049/jimmunol.167.1.42; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Rudd CE, 2003, NAT REV IMMUNOL, V3, P544, DOI 10.1038/nri1131; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Singh B, 2001, IMMUNOL REV, V182, P190, DOI 10.1034/j.1600-065X.2001.1820115.x; Thornton AM, 2004, J IMMUNOL, V172, P6519, DOI 10.4049/jimmunol.172.11.6519; Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	25	169	178	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1088	1092		10.1038/nm1449	http://dx.doi.org/10.1038/nm1449			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16921377				2022-12-25	WOS:000240373900034
J	Knight, CG; Zitzmann, N; Prabhakar, S; Antrobus, R; Dwek, R; Hebestreit, H; Rainey, PB				Knight, Christopher G.; Zitzmann, Nicole; Prabhakar, Sripadi; Antrobus, Robin; Dwek, Raymond; Hebestreit, Holger; Rainey, Paul B.			Unraveling adaptive evolution: how a single point mutation affects the protein coregulation network	NATURE GENETICS			English	Article							CATABOLITE REPRESSION CONTROL; PSEUDOMONAS-FLUORESCENS; LIFE-HISTORY; EXPERIMENTAL POPULATIONS; NATURAL VARIATION; EXPRESSION; PLEIOTROPY; GENES; CRC; PHOSPHORYLATION	Understanding the mechanisms of evolution requires identification of the molecular basis of the multiple ( pleiotropic) effects of specific adaptive mutations. We have characterized the pleiotropic effects on protein levels of an adaptive single-base pair substitution in the coding sequence of a signaling pathway gene in the bacterium Pseudomonas fluorescens SBW25. We find 52 proteomic changes, corresponding to 46 identified proteins. None of these proteins is required for the adaptive phenotype. Instead, many are found within specific metabolic pathways associated with fitness-reducing ( that is, antagonistic) effects of the mutation. The affected proteins fall within a single coregulatory network. The mutation `rewires' this network by drawing particular proteins into tighter coregulating relationships. Although these changes are specific to the mutation studied, the quantitatively altered proteins are also affected in a coordinated way in other examples of evolution to the same niche.	Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England; Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Dept Plant Sci, Oxford OX1 3RB, England	University of Oxford; University of Auckland	Knight, CG (corresponding author), Univ Manchester, Manchester Interdisciplinary Bioctr, 131 Princess St, Manchester M1 7DN, Lancs, England.	chris.knight@manchester.ac.uk	Knight, Chris/AAM-3228-2020; Rainey, Paul/A-3207-2008	Knight, Chris/0000-0001-9815-4267; Rainey, Paul/0000-0003-0879-5795				BARTON NH, 1990, GENETICS, V124, P773; BARTON NH, 1989, ANNU REV GENET, V23, P337, DOI 10.1146/annurev.ge.23.120189.002005; Batagelj V, 2004, MATH VIS, P77; BEAUMONT HJE, 2006, PROKARYOTIC DIVERSIT, P91; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bochdanovits Z, 2004, P ROY SOC B-BIOL SCI, V271, pS75, DOI 10.1098/rsbl.2003.0091; CASPARI E, 1952, EVOLUTION, V6, P1, DOI 10.2307/2405500; Davies AG, 2004, NEURON, V42, P731, DOI 10.1016/j.neuron.2004.05.004; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; Ehrich TH, 2003, J EXP ZOOL PART B, V296B, P58, DOI 10.1002/jez.b.00009; Estes S, 2005, GENETICS, V170, P645, DOI 10.1534/genetics.104.040022; Foster KR, 2004, NATURE, V431, P693, DOI 10.1038/nature02894; Garcia A, 2004, BLOOD, V103, P2088, DOI 10.1182/blood-2003-07-2392; Goymer P, 2006, GENETICS, V173, P515, DOI 10.1534/genetics.106.055863; Hester KL, 2000, J BACTERIOL, V182, P1150, DOI 10.1128/JB.182.4.1150-1153.2000; Jenkins NL, 2004, P ROY SOC B-BIOL SCI, V271, P2523, DOI 10.1098/rspb.2004.2897; Karp NA, 2005, PROTEOMICS, V5, P3105, DOI 10.1002/pmic.200500083; Knight CG, 2001, EVOLUTION, V55, P1795, DOI 10.1111/j.0014-3820.2001.tb00828.x; LANDE R, 1980, GENETICS, V94, P203; Leroi AM, 2005, MECH AGEING DEV, V126, P421, DOI 10.1016/j.mad.2004.07.012; Leroi AM, 2001, TRENDS ECOL EVOL, V16, P24, DOI 10.1016/S0169-5347(00)02032-2; LUPAS A, 1989, J BIOL CHEM, V264, P17337; MacLean RC, 2004, P NATL ACAD SCI USA, V101, P8072, DOI 10.1073/pnas.0307195101; Marden JH, 2003, P NATL ACAD SCI USA, V100, P3369, DOI 10.1073/pnas.0634985100; McAdams HH, 2004, NAT REV GENET, V5, P169, DOI 10.1038/nrg1292; Morales G, 2004, J BACTERIOL, V186, P1337, DOI 10.1128/JB.186.5.1337-1344.2004; Nishijyo T, 2001, MOL MICROBIOL, V40, P917, DOI 10.1046/j.1365-2958.2001.02435.x; O'Neill EE, 2002, PROTEOMICS, V2, P288, DOI 10.1002/1615-9861(200203)2:3<288::AID-PROT288>3.0.CO;2-0; O'Toole GA, 2000, J BACTERIOL, V182, P425, DOI 10.1128/JB.182.2.425-431.2000; Patel MN, 2002, P NATL ACAD SCI USA, V99, P769, DOI 10.1073/pnas.012511099; Pinheiro J, 2001, MIXED EFFECTS MODELS; Promislow DEL, 2004, P ROY SOC B-BIOL SCI, V271, P1225, DOI 10.1098/rspb.2004.2732; R Development Core Team, 2005, R LANG ENV STAT COMP; Rainey PB, 2000, TRENDS ECOL EVOL, V15, P243, DOI 10.1016/S0169-5347(00)01871-1; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Rainey PB, 2004, RES MICROBIOL, V155, P370, DOI 10.1016/j.resmic.2004.01.011; Rainey PB, 2003, NATURE, V425, P72, DOI 10.1038/nature01906; Rietsch A, 2004, INFECT IMMUN, V72, P1383, DOI 10.1128/IAI.72.3.1383-1390.2004; Spiers AJ, 2002, GENETICS, V161, P33; Spiers AJ, 2003, MOL MICROBIOL, V50, P15, DOI 10.1046/j.1365-2958.2003.03670.x; Spiers AJ, 2005, MICROBIOL-SGM, V151, P2829, DOI 10.1099/mic.0.27984-0; Steams S. C., 1992, EVOLUTION LIFE HIST; Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447; Weckwerth W, 2004, P NATL ACAD SCI USA, V101, P7809, DOI 10.1073/pnas.0303415101; Welch JJ, 2003, EVOLUTION, V57, P1723, DOI 10.1554/02-673; WOLFF JA, 1991, J BACTERIOL, V173, P4700, DOI 10.1128/jb.173.15.4700-4706.1991; Wright S., 1968, GENETIC BIOMETRIC FD; ZAHN CT, 1971, IEEE T COMPUT, VC 20, P68, DOI 10.1109/T-C.1971.223083; [No title captured]	49	59	60	2	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2006	38	9					1015	1022		10.1038/ng1867	http://dx.doi.org/10.1038/ng1867			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	078OC	16921374				2022-12-25	WOS:000240112100018
J	Morris, CE; Sands, DC				Morris, Cindy E.; Sands, David C.			The breeder's dilemma - yield or nutrition?	NATURE BIOTECHNOLOGY			English	Editorial Material							AMYLOPECTIN STARCH; INSULIN-RESISTANCE; OMEGA-3-FATTY-ACIDS; CONSUMPTION; TRYPTOPHAN		INRA, Unite Pathol Vegetale, F-84140 Montfavet, France; Montana State Univ, Dept Plant Soil & Plant Pathol, Bozeman, MT 59717 USA	INRAE; Montana State University System; Montana State University Bozeman	Morris, CE (corresponding author), INRA, Unite Pathol Vegetale, F-84140 Montfavet, France.	dsands@montana.edu						Aharoni A, 2004, PLANT CELL, V16, P3110, DOI 10.1105/tpc.104.023895; BEHALL KM, 1995, AM J CLIN NUTR, V61, P334, DOI 10.1093/ajcn/61.2.334; BREOTON BP, 1994, NUTR ANTHR, V22, P2; BYRNES SE, 1995, J NUTR, V125, P1430; Douglas AE, 1998, ANNU REV ENTOMOL, V43, P17, DOI 10.1146/annurev.ento.43.1.17; Douglas AE, 2001, J EXP BIOL, V204, P349; Goff SA, 2006, SCIENCE, V311, P815, DOI 10.1126/science.1112614; HEINE W, 1995, AMINO ACIDS, V9, P191, DOI 10.1007/BF00805951; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Huang SS, 2004, J AGR FOOD CHEM, V52, P1958, DOI 10.1021/jf0342223; Jobling SA, 2003, NAT BIOTECHNOL, V21, P77, DOI 10.1038/nbt772; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; Potrykus I, 2001, PLANT PHYSIOL, V125, P1157, DOI 10.1104/pp.125.3.1157; Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248; Young SN, 2002, PHARMACOL BIOCHEM BE, V71, P857, DOI 10.1016/S0091-3057(01)00670-0	15	84	86	3	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2006	24	9					1078	1080		10.1038/nbt0906-1078	http://dx.doi.org/10.1038/nbt0906-1078			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	083YK	16964212				2022-12-25	WOS:000240495200021
J	Okada, Y; Jiang, Q; Lemieux, M; Jeannotte, L; Su, LS; Zhang, Y				Okada, Yuki; Jiang, Qi; Lemieux, Margot; Jeannotte, Lucie; Su, Lishan; Zhang, Yi			Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L	NATURE CELL BIOLOGY			English	Article							ACUTE MYELOID-LEUKEMIA; U937 CELL-LINE; HEMATOPOIETIC PROGENITORS; LEUCINE-ZIPPER; MLL; EXPRESSION; AF10; GENE; LEUKEMOGENESIS; CLATHRIN	Chromosomal translocation is a common cause of leukaemia(1) and the most common chromosome translocations found in leukaemia patients involve the mixed lineage leukaemia (MLL) gene(2,3). AF10 is one of more than 30 MLL fusion partners in leukaemia(4). We have recently demonstrated that the H3K79 methyltransferase hDOT1L contributes to MLL-AF10-mediated leukaemogenesis through its interaction with AF10 (ref. 5). In addition to MLL, AF10 has also been reported to fuse to CALM (clathrin-assembly protein-like lymphoid-myeloid) in patients with T-cell acute lymphoblastic leukaemia (T-ALL) and acute myeloid leukaemia (AML)(6,7). Here, we analysed the molecular mechanism of leukaemogenesis by CALM-AF10. We demonstrate that CALM-AF10 fusion is both necessary and sufficient for leukaemic transformation. Additionally, we provide evidence that hDOT1L has an important role in the transformation process. hDOT1L contributes to CALM-AF10-mediated leukaemic transformation by preventing nuclear export of CALM-AF10 and by upregulating the Hoxa5 gene through H3K79 methylation. Thus, our study establishes CALM-AF10 fusion as a cause of leukaemia and reveals that mistargeting of hDOT1L and upregulation of Hoxa5 through H3K79 methylation is the underlying mechanism behind leukaemia caused by CALM-AF10 fusion.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Ctr Rechg Hotel Dieu Quebec, Quebec City, PQ G1R 2J6, Canada; Univ N Carolina, Howard Hughes Med Inst, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Laval University; Howard Hughes Medical Institute; University of North Carolina; University of North Carolina Chapel Hill	Zhang, Y (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	yi_zhang@med.unc.edu		Jeannotte, Lucie/0000-0001-5578-420X; Zhang, Yi/0000-0002-2789-0811	NHLBI NIH HHS [R21 HL072240, HL72240] Funding Source: Medline; NIAID NIH HHS [R01 AI080432, AI48407, R01 AI048407, R01 AI077454, R56 AI048407] Funding Source: Medline; NIGMS NIH HHS [GM68804, R01 GM068804] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL072240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI077454, R56AI048407, R01AI080432, R01AI048407] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068804] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Carlson KM, 2000, LEUKEMIA, V14, P100, DOI 10.1038/sj.leu.2401629; CHAPLIN T, 1995, BLOOD, V86, P2073, DOI 10.1182/blood.V86.6.2073.bloodjournal8662073; Crooks GM, 1999, BLOOD, V94, P519, DOI 10.1182/blood.V94.2.519.414k20_519_528; Daser A, 2004, GENE DEV, V18, P965, DOI 10.1101/gad.1195504; Dik WA, 2005, LEUKEMIA, V19, P1948, DOI 10.1038/sj.leu.2403891; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Dreyling MH, 1998, BLOOD, V91, P4662; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; Kobayashi H, 1997, GENE CHROMOSOME CANC, V20, P253, DOI 10.1002/(SICI)1098-2264(199711)20:3<253::AID-GCC5>3.0.CO;2-1; KOBAYASHI H, 1995, GENE CHROMOSOME CANC, V13, P217, DOI 10.1002/gcc.2870130312; Meyerholz A, 2005, TRAFFIC, V6, P1225, DOI 10.1111/j.1600-0854.2005.00355.x; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Quentmeier H, 2004, LEUKEMIA LYMPHOMA, V45, P567, DOI 10.1080/10428190310001609942; So CW, 2004, BLOOD, V103, P3192, DOI 10.1182/blood-2003-10-3722; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004	24	150	153	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					1017	U105		10.1038/ncb1464	http://dx.doi.org/10.1038/ncb1464			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16921363	Green Accepted, Green Published			2022-12-25	WOS:000240241700019
J	Wunder, C; Churin, Y; Winau, F; Warnecke, D; Vieth, M; Lindner, B; Zahringer, U; Mollenkopf, HJ; Heinz, E; Meyer, TF				Wunder, Christian; Churin, Yuri; Winau, Florian; Warnecke, Dirk; Vieth, Michael; Lindner, Buko; Zaehringer, Ulrich; Mollenkopf, Hans-Joachim; Heinz, Ernst; Meyer, Thomas F.			Cholesterol glucosylation promotes immune evasion by Helicobacter pylori	NATURE MEDICINE			English	Article							CAG PATHOGENICITY ISLAND; LIPID RAFTS; STEROL BIOSYNTHESIS; PROFILES; PHAGOCYTOSIS; GLUCOSIDES; STRAINS; GROWTH; MICE	Helicobacter pylori infection causes gastric pathology such as ulcer and carcinoma. Because H. pylori is auxotrophic for cholesterol, we have explored the assimilation of cholesterol by H. pylori in infection. Here we show that H. pylori follows a cholesterol gradient and extracts the lipid from plasma membranes of epithelial cells for subsequent glucosylation. Excessive cholesterol promotes phagocytosis of H. pylori by antigen-presenting cells, such as macrophages and dendritic cells, and enhances antigen-specific T cell responses. A cholesterol-rich diet during bacterial challenge leads to T cell-dependent reduction of the H. pylori burden in the stomach. Intrinsic alpha-glucosylation of cholesterol abrogates phagocytosis of H. pylori and subsequent T cell activation. We identify the gene hp0421 as encoding the enzyme cholesterol-alpha-glucosyltransferase responsible for cholesterol glucosylation. Generation of knockout mutants lacking hp0421 corroborates the importance of cholesteryl glucosides for escaping phagocytosis, T cell activation and bacterial clearance in vivo. Thus, we propose a mechanism regulating the host - pathogen interaction whereby glucosylation of a lipid tips the scales towards immune evasion or response.	Max Planck Inst Infect Biol, Dept Immunol, D-10117 Berlin, Germany; Univ Hamburg, Biozentrum Klein Flottbeck, D-22609 Hamburg, Germany; Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany; Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany; Max Planck Inst Infect Biol, Core Facil Microarray, D-10117 Berlin, Germany; Max Planck Inst Infect Biol, Dept Biol Mol, D-10117 Berlin, Germany	Max Planck Society; University of Hamburg; Otto von Guericke University; Forschungszentrum Borstel; Max Planck Society; Max Planck Society	Wunder, C (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	wunderc@mail.nih.gov; meyer@mpiib-berlin.mpg.de	Meyer, Thomas F. F/J-2485-2013; Mollenkopf, Hans-Joachim/AAH-2500-2019; Wunder, Christian/K-8542-2017; Lindner, Buko/G-9731-2014	Meyer, Thomas F. F/0000-0002-6120-8679; Wunder, Christian/0000-0001-9091-0080; Mollenkopf, Hans-Joachim/0000-0003-1167-4783				Allen LAH, 2000, J EXP MED, V191, P115, DOI 10.1084/jem.191.1.115; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; Ben-Menachem G, 2003, P NATL ACAD SCI USA, V100, P7913, DOI 10.1073/pnas.1232451100; Burger K, 2000, CELL MOL LIFE SCI, V57, P1577, DOI 10.1007/PL00000643; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Dixon MF, 1997, HELICOBACTER, V2, pS17; Falush D, 2003, SCIENCE, V299, P1582, DOI 10.1126/science.1080857; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Gomez-Duarte OG, 1998, VACCINE, V16, P460, DOI 10.1016/S0264-410X(97)00247-8; Guillemin K, 2002, P NATL ACAD SCI USA, V99, P15136, DOI 10.1073/pnas.182558799; HAQUE M, 1995, ACTA MED OKAYAMA, V49, P205; HAQUE M, 1995, J BACTERIOL, V177, P5334, DOI 10.1128/jb.177.18.5334-5337.1995; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Heuermann D, 1998, MOL GEN GENET, V257, P519, DOI 10.1007/s004380050677; HIRAI Y, 1995, J BACTERIOL, V177, P5327, DOI 10.1128/jb.177.18.5327-5333.1995; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kawakubo M, 2004, SCIENCE, V305, P1003, DOI 10.1126/science.1099250; LEBRUN AH, 2006, J BIOL CHEM; Legler DF, 2004, FASEB J, V18, P73, DOI 10.1096/fj.03-1338fje; Li JW, 2005, CELL CYCLE, V4, P1599, DOI 10.4161/cc.4.11.2117; LIVERMORE BP, 1978, INFECT IMMUN, V20, P215, DOI 10.1128/IAI.20.1.215-220.1978; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MAYBERRY WR, 1983, BIOCHIM BIOPHYS ACTA, V752, P434, DOI 10.1016/0005-2760(83)90273-4; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Montecucco C, 2001, NAT REV MOL CELL BIO, V2, P457, DOI 10.1038/35073084; Odenbreit S, 2001, CELL MICROBIOL, V3, P21, DOI 10.1046/j.1462-5822.2001.00088.x; Oku M, 2003, EMBO J, V22, P3231, DOI 10.1093/emboj/cdg331; OTOOLE PW, 1994, MOL MICROBIOL, V14, P691, DOI 10.1111/j.1365-2958.1994.tb01307.x; PARKS LW, 1995, ANNU REV MICROBIOL, V49, P95, DOI 10.1146/annurev.mi.49.100195.000523; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; Raggers RJ, 2000, TRAFFIC, V1, P226, DOI 10.1034/j.1600-0854.2000.010305.x; Schaible UE, 1999, J CELL SCI, V112, P681; Schaller H, 2004, PLANT PHYSIOL BIOCH, V42, P465, DOI 10.1016/j.plaphy.2004.05.012; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Shimomura H, 2004, FEMS MICROBIOL LETT, V237, P407, DOI 10.1016/j.femsle.2004.07.004; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Slonczewski JL, 2000, HELICOBACTER, V5, P240, DOI 10.1046/j.1523-5378.2000.00037.x; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMITH PF, 1971, J BACTERIOL, V108, P986, DOI 10.1128/JB.108.3.986-991.1971; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tannaes T, 2005, FEMS MICROBIOL LETT, V244, P117, DOI 10.1016/j.femsle.2005.01.030; Testerman TL, 2001, J CLIN MICROBIOL, V39, P3842, DOI 10.1128/JCM.39.11.3842-3850.2001; Wang YZ, 2000, TRAFFIC, V1, P952, DOI 10.1034/j.1600-0854.2000.011205.x	47	208	212	2	36	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1030	1038		10.1038/nm1480	http://dx.doi.org/10.1038/nm1480			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16951684				2022-12-25	WOS:000240373900027
J	Gauss, R; Jarosch, E; Sommer, T; Hirsch, C				Gauss, Robert; Jarosch, Ernst; Sommer, Thomas; Hirsch, Christian			A complex of Yos9p and the HRD ligase integrates endoplasmic reticulum quality control into the degradation machinery	NATURE CELL BIOLOGY			English	Article							ER-ASSOCIATED DEGRADATION; MANNOSIDASE-LIKE PROTEIN; MISFOLDED GLYCOPROTEINS; SACCHAROMYCES-CEREVISIAE; YEAST GENES; TRANSPORT; VERSATILE; GLYCANS; MODULES; LECTIN	quality-control system surveys the lumen of the endoplasmic reticulum for terminally misfolded proteins. Polypeptides singled out by this system are ultimately degraded by the cytosolic ubiquitin-proteasome pathway. Key components of both the endoplasmic reticulum quality-control system and the degradation machinery have been identified, but a connection between the two systems has remained elusive. Here, we report an association between the endoplasmic reticulum quality-control lectin Yos9p and Hrd3p, a component of the ubiquitin-proteasome system that links these pathways. We identify designated regions in the luminal domain of Hrd3p that interact with Yos9p and the ubiquitin ligase Hrd1p. Binding of misfolded proteins occurs through Hrd3p, suggesting that Hrd3p recognises proteins that deviate from their native conformation, whereas Yos9p ensures that only terminally misfolded polypeptides are degraded.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Sommer, T (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13125 Berlin, Germany.	tsommer@mdc-berlin.de		Jarosch, Ernst/0000-0002-5897-3492				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; Friedmann E, 2002, J BIOL CHEM, V277, P35274, DOI 10.1074/jbc.M201044200; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Gauss R, 2005, YEAST, V22, P1, DOI 10.1002/yea.1187; Gauss R, 2006, EMBO J, V25, P1827, DOI 10.1038/sj.emboj.7601088; Gemmill TR, 1999, BBA-GEN SUBJECTS, V1426, P227, DOI 10.1016/S0304-4165(98)00126-3; GUELMAN R, 2002, BONE, V30, P23; Hebert DN, 2005, TRENDS CELL BIOL, V15, P364, DOI 10.1016/j.tcb.2005.05.007; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hitt R, 2004, FEMS YEAST RES, V4, P815, DOI 10.1016/j.femsyr.2004.04.002; Jakob CA, 2001, EMBO REP, V2, P423; Janke C, 2004, YEAST, V21, P947, DOI 10.1002/yea.1142; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Kostova Z, 2005, J CELL SCI, V118, P1485, DOI 10.1242/jcs.01740; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Meusser B, 2004, MOL CELL, V14, P247, DOI 10.1016/S1097-2765(04)00212-6; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Plemper RK, 1999, J CELL SCI, V112, P4123; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Spear ED, 2005, J CELL BIOL, V169, P73, DOI 10.1083/jcb.200411136; Szathmary R, 2005, MOL CELL, V19, P765, DOI 10.1016/j.molcel.2005.08.015	28	181	184	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					849	U102		10.1038/ncb1445	http://dx.doi.org/10.1038/ncb1445			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16845381				2022-12-25	WOS:000239423000015
J	Lei, EP; Corces, VG				Lei, Elissa P.; Corces, Victor G.			RNA interference machinery influences the nuclear organization of a chromatin insulator	NATURE GENETICS			English	Article							POSITION-EFFECT VARIEGATION; GYPSY TRANSPOSABLE ELEMENT; GERMLINE STEM-CELLS; DROSOPHILA-MELANOGASTER; INTERALLELIC COMPLEMENTATION; PROTEIN; GENE; LOCALIZATION; CHROMOSOME; COMPONENTS	RNA interference (RNAi) is a conserved silencing mechanism that can act through alteration of chromatin structure. Chromatin insulators promote higher-order nuclear organization, thereby establishing DNA domains subject to distinct transcriptional controls. We present evidence for a functional relationship between RNAi and the gypsy insulator of D. melanogaster. Insulator activity is decreased when Argonaute genes required for RNAi are mutated, and insulator function is improved when the levels of the Rm62 helicase, involved in double-stranded RNA (dsRNA)-mediated silencing and heterochromatin formation, are reduced. Rm62 interacts physically with the DNA-binding insulator protein CP190 in an RNA-dependent manner. Finally, reduction of Rm62 levels results in marked nuclear reorganization of a compromised insulator. These results suggest that the RNAi machinery acts as a modulator of nuclear architecture capable of effecting global changes in gene expression.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Corces, VG (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.	corces@jhu.edu		Corces, Victor/0000-0001-5140-4337	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015601, ZIADK015601] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMERO SA, 1991, GENE DEV, V5, P188, DOI 10.1101/gad.5.2.188; Buszczak M, 2006, GENE DEV, V20, P977, DOI 10.1101/gad.1396306; Byrd K, 2003, J CELL BIOL, V162, P565, DOI 10.1083/jcb.200305013; Capelson M, 2005, MOL CELL, V20, P105, DOI 10.1016/j.molcel.2005.08.031; Cox DN, 2000, DEVELOPMENT, V127, P503; CSINK AK, 1994, GENETICS, V138, P153; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; Grimaud C, 2006, CELL, V124, P957, DOI 10.1016/j.cell.2006.01.036; Hall IM, 2003, P NATL ACAD SCI USA, V100, P193, DOI 10.1073/pnas.232688099; Harlow E., 1988, ANTIBODIES LAB MANUA; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; JACK JW, 1985, CELL, V42, P869, DOI 10.1016/0092-8674(85)90283-1; Lin HF, 1997, DEVELOPMENT, V124, P2463; Malceva NI, 1997, DEV GENET, V20, P163, DOI 10.1002/(SICI)1520-6408(1997)20:2<163::AID-DVG9>3.0.CO;2-5; Mongelard F, 2002, GENETICS, V160, P1481; Noma K, 2004, NAT GENET, V36, P1174, DOI 10.1038/ng1452; Pai CY, 2004, MOL CELL, V16, P737, DOI 10.1016/j.molcel.2004.11.004; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Pal-Bhadra M, 2002, MOL CELL, V9, P315, DOI 10.1016/S1097-2765(02)00440-9; PARKHURST SM, 1988, GENE DEV, V2, P1205, DOI 10.1101/gad.2.10.1205; PARKHURST SM, 1986, MOL CELL BIOL, V6, P47, DOI 10.1128/MCB.6.1.47; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; SCHUPBACH T, 1991, GENETICS, V129, P1119; SHAFFER CD, 1994, METHODS CELL BIOL; Tsai SF, 1997, P NATL ACAD SCI USA, V94, P3837, DOI 10.1073/pnas.94.8.3837; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Yusufzai TM, 2004, P NATL ACAD SCI USA, V101, P8620, DOI 10.1073/pnas.0402938101	30	112	123	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2006	38	8					936	941		10.1038/ng1850	http://dx.doi.org/10.1038/ng1850			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16862159				2022-12-25	WOS:000239325700025
J	Pfleger, BF; Pitera, DJ; D Smolke, C; Keasling, JD				Pfleger, Brian F.; Pitera, Douglas J.; D Smolke, Christina; Keasling, Jay D.			Combinatorial engineering of intergenic regions in operons tunes expression of multiple genes	NATURE BIOTECHNOLOGY			English	Article							SMALL RNA REGULATORS; ESCHERICHIA-COLI; MESSENGER-RNA; SECONDARY STRUCTURES; TRANSLATION; SITES; DECAY	Many applications of synthetic biology require the balanced expression of multiple genes. Although operons facilitate coordinated expression of multiple genes in prokaryotes and eukaryotes, coordinating the many post-transcriptional processes that determine the relative levels of gene expression in operons by a priori design remains a challenge. We describe a method for tuning the expression of multiple genes within operons by generating libraries of tunable intergenic regions (TIGRs), recombining various post-transcriptional control elements and screening for the desired relative expression levels. TIGRs can vary the relative expression of two reporter genes over a 100-fold range and balance expression of three genes in an operon that encodes a heterologous mevalonate biosynthetic pathway, resulting in a sevenfold increase in mevalonate production. This technology should be useful for optimizing the expression of multiple genes in synthetic operons, both in prokaryotes and eukaryotes.	Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Synthet Biol Dept, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Keasling, JD (corresponding author), Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA.	keasling@berkeley.edu	Keasling, Jay D/J-9162-2012; Pfleger, Brian Frederick/AAA-2559-2022	Keasling, Jay D/0000-0003-4170-6088; Pfleger, Brian Frederick/0000-0002-9232-9959				Arraiano Cecilia Maria, 2003, Molecular Microbiology, V49, P267, DOI 10.1046/j.1365-2958.2003.03545.x; BAGA M, 1988, CELL, V52, P197, DOI 10.1016/0092-8674(88)90508-9; Burke Emily, 2003, Methods Mol Biol, V226, P525; Chappell SA, 2003, J BIOL CHEM, V278, P33793, DOI 10.1074/jbc.M303495200; Deana A, 2005, GENE DEV, V19, P2526, DOI 10.1101/gad.1348805; DESMIT MH, 1994, J MOL BIOL, V244, P144, DOI 10.1006/jmbi.1994.1714; Endy D, 2005, NATURE, V438, P449, DOI 10.1038/nature04342; Fernandez-Miragall O, 2006, RNA, V12, P223, DOI 10.1261/rna.2153206; Gottesman S, 2004, ANNU REV MICROBIOL, V58, P303, DOI 10.1146/annurev.micro.58.030603.123841; Isaacs FJ, 2004, NAT BIOTECHNOL, V22, P841, DOI 10.1038/nbt986; Kaberdin VR, 2003, NUCLEIC ACIDS RES, V31, P4710, DOI 10.1093/nar/gkg690; Khosla C, 2003, NAT REV DRUG DISCOV, V2, P1019, DOI 10.1038/nrd1256; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Kushner SR, 2004, IUBMB LIFE, V56, P585, DOI 10.1080/15216540400022441; Majdalani N, 2005, CRIT REV BIOCHEM MOL, V40, P93, DOI 10.1080/10409230590918702; Mandal M, 2004, NAT REV MOL CELL BIO, V5, P451, DOI 10.1038/nrm1403; Martin P, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472-6750-6-4; Martin VJJ, 2003, NAT BIOTECHNOL, V21, P796, DOI 10.1038/nbt833; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Naureckiene S, 1996, MOL MICROBIOL, V21, P55, DOI 10.1046/j.1365-2958.1996.6121101.x; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Pfleger BF, 2005, BIOTECHNOL BIOENG, V92, P553, DOI 10.1002/bit.20630; Rodwell VW, 2000, METHOD ENZYMOL, V324, P259; Sambrook J., 2002, MOL CLONING LAB MANU; Smolke CD, 2002, BIOTECHNOL BIOENG, V80, P762, DOI 10.1002/bit.10434; Smolke CD, 2000, APPL ENVIRON MICROB, V66, P5399, DOI 10.1128/AEM.66.12.5399-5405.2000; Spickler C, 2000, J BACTERIOL, V182, P2422, DOI 10.1128/JB.182.9.2422-2427.2000; White MM, 2006, MOL PHARMACOL, V69, P407, DOI 10.1124/mol.105.020727; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	29	374	427	5	182	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2006	24	8					1027	1032		10.1038/nbt1226	http://dx.doi.org/10.1038/nbt1226			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	072VY	16845378				2022-12-25	WOS:000239702300044
J	Freund, P; Schmidlin, E; Wannier, T; Bloch, J; Mir, A; Schwab, ME; Rouiller, EM				Freund, Patrick; Schmidlin, Eric; Wannier, Thierry; Bloch, Jocelyne; Mir, Anis; Schwab, Martin E.; Rouiller, Eric M.			Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates	NATURE MEDICINE			English	Article							SPINAL-CORD; UNILATERAL SECTION; HAND REPRESENTATION; CORTICOSPINAL TRACT; MACAQUE MONKEY; REGENERATION; INHIBITORS; LEVEL	In rodents, after spinal lesion, neutralizing the neurite growth inhibitor Nogo-A promotes axonal sprouting and functional recovery. To evaluate this treatment in primates, 12 monkeys were subjected to cervical lesion. Recovery of manual dexterity and sprouting of corticospinal axons were enhanced in monkeys treated with Nogo-A-specific antibody as compared to monkeys treated with control antibody.	Univ Fribourg, Fac Sci, Dept Med, Univ Physiol, CH-1700 Fribourg, Switzerland; Univ Fribourg, Fac Sci, Dept Med, Program Neurosci, CH-1700 Fribourg, Switzerland; Univ Zurich, ETH Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Univ Lausanne Hosp, Neurosurg Clin, Dept Neurosurg, CH-1011 Lausanne, Switzerland; Novartis Inst BioMed Res, Neurosci Res, CH-4002 Basel, Switzerland	University of Fribourg; University of Fribourg; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Novartis	Rouiller, EM (corresponding author), Univ Fribourg, Fac Sci, Dept Med, Univ Physiol, CH-1700 Fribourg, Switzerland.	Eric.Rouiller@unifr.ch	Schwab, Martin E/B-6818-2016; Bloch, Jocelyne/A-9668-2017; Freund, Patrick/D-4193-2013	Bloch, Jocelyne/0000-0002-6405-1590; Freund, Patrick/0000-0002-4851-2246; Rouiller, Eric/0000-0003-1355-6019				BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fouad K, 2004, EUR J NEUROSCI, V20, P2479, DOI 10.1111/j.1460-9568.2004.03716.x; Galea MP, 1997, J COMP NEUROL, V381, P282; Galea MP, 1997, J COMP NEUROL, V381, P307; JENNY AB, 1983, J NEUROSCI, V3, P567; LAWRENCE DG, 1976, BRAIN, V99, P235, DOI 10.1093/brain/99.2.235; LEMON RN, 1993, EXP PHYSIOL, V78, P263, DOI 10.1113/expphysiol.1993.sp003686; Liebscher T, 2005, ANN NEUROL, V58, P706, DOI 10.1002/ana.20627; NUDO RJ, 2006, EVOLUTION NERVOUS SY, V4; PORTER R, 1990, ELECTROEN CLIN NEURO, V76, P282, DOI 10.1016/0013-4694(90)90029-J; Sasaki S, 2004, J NEUROPHYSIOL, V92, P3142, DOI 10.1152/jn.00342.2004; Schmidlin E, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-56; Schmidlin E, 2004, BRAIN RES, V1017, P172, DOI 10.1016/j.brainres.2004.05.036; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004	15	244	250	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					790	792		10.1038/nm1436	http://dx.doi.org/10.1038/nm1436			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16819551	Green Submitted			2022-12-25	WOS:000238862800065
J	Iwatsubo, T; Ihara, Y; Kanazawa, I				Iwatsubo, Takeshi; Ihara, Yasuo; Kanazawa, Ichiro			Alzheimer disease research in Japan: public funding	NATURE MEDICINE			English	Editorial Material									Natl Ctr Neurol & Psychiat, Kodaira, Tokyo 1878551, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan	National Center for Neurology & Psychiatry - Japan; University of Tokyo; University of Tokyo	Kanazawa, I (corresponding author), Natl Ctr Neurol & Psychiat, 4-1-1 Ogawa Higashimachi, Kodaira, Tokyo 1878551, Japan.	ichiro@ncnp.go.jp							0	3	3	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					778	779		10.1038/nm0706-778	http://dx.doi.org/10.1038/nm0706-778			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829946				2022-12-25	WOS:000238862800062
J	Vithana, EN; Morgan, P; Sundaresan, P; D Ebenezer, N; Tan, DTH; Mohamed, MD; Anand, S; Khine, KO; Venkataraman, D; Yong, VHK; Salto-Tellez, M; Venkatraman, A; Guo, K; Hemadevi, B; Srinivasan, M; Prajna, V; Khine, M; Casey, JR; Inglehearn, CF; Aung, T				Vithana, Eranga N.; Morgan, Patricio; Sundaresan, Periasamy; D Ebenezer, Neil; Tan, Donald T. H.; Mohamed, Moin D.; Anand, Seema; Khine, Khin O.; Venkataraman, Divya; Yong, Victor H. K.; Salto-Tellez, Manuel; Venkatraman, Anandalakshmi; Guo, Ke; Hemadevi, Boomiraj; Srinivasan, Muthiah; Prajna, Venkatesh; Khine, Myint; Casey, Joseph R.; Inglehearn, Chris F.; Aung, Tin			Mutations in sodium-borate cotransporter SLC4A11 cause recessive congenital hereditary endothelial dystrophy (CHED2)	NATURE GENETICS			English	Article							GENE; CHROMOSOME-20; FAMILY	Congenital hereditary endothelial dystrophy ( CHED) is a heritable, bilateral corneal dystrophy characterized by corneal opacification and nystagmus. We describe seven different mutations in the SLC4A11 gene in ten families with autosomal recessive CHED. Mutations in SLC4A11, which encodes a membrane-bound sodium-borate cotransporter, cause loss of function of the protein either by blocking its membrane targeting or nonsense-mediated decay.	Singapore Eye Res Inst, Singapore 168751, Singapore; Natl Univ Singapore, Dept Ophthalmol, Yong Soo Lin Sch Med, Singapore 117597, Singapore; Aravind Med Res Fdn, Madurai 625020, Tamil Nadu, India; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2H7, Canada; UCL, Inst Ophthalmol, London EC1V 9EL, England; Singapore Natl Eye Ctr, Singapore 168751, Singapore; St James Univ Hosp, Sect Ophthalmol & Neurosci, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Eye Dept, Leeds Teaching Hosp NHS Trust, Leeds LS9 7TF, W Yorkshire, England; Natl Univ Singapore, Dept Pathol, Singapore 117597, Singapore; Yangon Eye Hosp, Yangon, Myanmar; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Inst Mol & Cell Biol, Singapore 138673, Singapore	National University of Singapore; Singapore National Eye Center; National University of Singapore; University of Alberta; University of London; University College London; Singapore National Eye Center; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; University of Leeds; National University of Singapore; University of Alberta; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Vithana, EN (corresponding author), Singapore Eye Res Inst, 11 3rd Hosp Ave, Singapore 168751, Singapore.	evithana@yahoo.co.uk	.P, Sundaresan/AAR-8426-2021; Khine, M/AAP-1881-2021; Inglehearn, Chris/GYD-9783-2022; Casey, Joseph/A-8888-2013	Khine, M/0000-0003-2582-7306; Casey, Joseph/0000-0002-9890-5056; Salto-Tellez, Manuel/0000-0001-8586-282X; Namperumalsamy, Venkatesh Prajna/0000-0003-2019-4044				Alper SL, 2002, J NEPHROL, V15, pS41; Chan C. C., 1982, CORNEA, V1, P155; Gottsch JD, 2003, INVEST OPHTH VIS SCI, V44, P594, DOI 10.1167/iovs.02-0300; Hand CK, 1999, GENOMICS, V61, P1, DOI 10.1006/geno.1999.5920; KIRKNESS CM, 1987, BRIT J OPHTHALMOL, V71, P130, DOI 10.1136/bjo.71.2.130; Mohamed MD, 2001, BRIT J OPHTHALMOL, V85, P758; Park M, 2004, MOL CELL, V16, P331, DOI 10.1016/j.molcel.2004.09.030; Parker MD, 2001, BIOCHEM BIOPH RES CO, V282, P1103, DOI 10.1006/bbrc.2001.4692; Romero MF, 2004, PFLUG ARCH EUR J PHY, V447, P495, DOI 10.1007/s00424-003-1180-2; TOMA NMG, 1995, HUM MOL GENET, V4, P2395, DOI 10.1093/hmg/4.12.2395; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025	11	181	186	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2006	38	7					755	757		10.1038/ng1824	http://dx.doi.org/10.1038/ng1824			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16767101				2022-12-25	WOS:000238669300010
J	Arumugam, TV; Chan, SL; Jo, DG; Yilmaz, G; Tang, SC; Cheng, AW; Gleichmann, M; Okun, E; Dixit, VD; Chigurupati, S; Mughal, MR; Ouyang, X; Miele, L; Magnus, T; Poosala, S; Granger, DN; Mattson, MP				Arumugam, TV; Chan, SL; Jo, DG; Yilmaz, G; Tang, SC; Cheng, AW; Gleichmann, M; Okun, E; Dixit, VD; Chigurupati, S; Mughal, MR; Ouyang, X; Miele, L; Magnus, T; Poosala, S; Granger, DN; Mattson, MP			Gamma secretase-mediated notch signaling worsens brain damage and functional outcome in ischemic stroke	NATURE MEDICINE			English	Article							ACTIVATION; DISEASE		NIA, Neurosci Lab, Intramural Res Program, Baltimore, MD 21224 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA; Natl Taiwan Univ Hosp, Dept Neurol, Stroke Ctr, Taipei, Taiwan; NIA, Immunol Lab, Intramural Res Program, Baltimore, MD 21224 USA; NIA, Res Resources Branch, Intramural Res Program, Baltimore, MD 21224 USA; Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA; Univ Illinois, Ctr Canc, Chicago, IL 60612 USA; Johns Hopkins Med Inst, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; National Taiwan University; National Taiwan University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Johns Hopkins University; Johns Hopkins Medicine	Mattson, MP (corresponding author), NIA, Neurosci Lab, Intramural Res Program, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	mattsonm@grc.nia.nih.gov	okun, eitan/AAC-9571-2019; Mattson, Mark P/F-6038-2012; Jo, Dong-Gyu/AAN-9278-2021; Arumugam, Thiruma Valavan/B-4898-2011; Arumugam, Thiruma/C-7969-2009; Arumugam, Thiruma/AAG-6958-2019	okun, eitan/0000-0001-8474-1487; Jo, Dong-Gyu/0000-0003-2271-1076; Miele, Lucio/0000-0002-5853-7287; Arumugam, Thiruma/0000-0002-3377-0939; Tang, Sung-Chun/0000-0003-3731-5973	NATIONAL INSTITUTE ON AGING [Z01AG000314, ZIAAG000317, Z01AG000317, Z01AG000313, ZIAAG000313, ZIAAG000314] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Ciofani M, 2005, NAT IMMUNOL, V6, P881, DOI 10.1038/ni1234; Costa RM, 2005, TRENDS NEUROSCI, V28, P429, DOI 10.1016/j.tins.2005.05.003; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Eagar TN, 2004, IMMUNITY, V20, P407, DOI 10.1016/S1074-7613(04)00081-0; Frijns CJM, 2002, STROKE, V33, P2115, DOI 10.1161/01.STR.0000021902.33129.69; Ishikura N, 2005, P NATL ACAD SCI USA, V102, P886, DOI 10.1073/pnas.0408612101; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Pollack Scott J, 2005, Curr Opin Investig Drugs, V6, P35; Prunell GF, 2005, CNS NEUROL DISORD-DR, V4, P51, DOI 10.2174/1568007053005082; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Sugawara Taku, 2004, NeuroRx, V1, P17, DOI 10.1602/neurorx.1.1.17; Wang Y, 2004, P NATL ACAD SCI USA, V101, P9458, DOI 10.1073/pnas.0308126101; Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475	15	207	230	1	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2006	12	6					621	623		10.1038/nm1403	http://dx.doi.org/10.1038/nm1403			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16680150				2022-12-25	WOS:000238149200021
J	Sayer, JA; Otto, EA; O'Toole, JF; Nurnberg, G; Kennedy, MA; Becker, C; Hennies, HC; Helou, J; Attanasio, M; Fausett, BV; Utsch, B; Khanna, H; Liu, Y; Drummond, I; Kawakami, I; Kusakabe, T; Tsuda, M; Ma, L; Lee, H; Larson, RG; Allen, SJ; Wilkinson, CJ; Nigg, EA; Shou, CC; Lillo, C; Williams, DS; Hoppe, B; Kemper, MJ; Neuhaus, T; Parisi, MA; Glass, IA; Petry, M; Kispert, A; Gloy, J; Ganner, A; Walz, G; Zhu, XL; Goldman, D; Nurnberg, P; Swaroop, A; Leroux, MR; Hildebrandt, F				Sayer, John A.; Otto, Edgar A.; O'Toole, John F.; Nurnberg, Gudrun; Kennedy, Michael A.; Becker, Christian; Hennies, Hans Christian; Helou, Juliana; Attanasio, Massimo; Fausett, Blake V.; Utsch, Boris; Khanna, Hemant; Liu, Yan; Drummond, Iain; Kawakami, Isao; Kusakabe, Takehiro; Tsuda, Motoyuki; Ma, Li; Lee, Hwankyu; Larson, Ronald G.; Allen, Susan J.; Wilkinson, Christopher J.; Nigg, Erich A.; Shou, Chengchao; Lillo, Concepcion; Williams, David S.; Hoppe, Bernd; Kemper, Markus J.; Neuhaus, Thomas; Parisi, Melissa A.; Glass, Ian A.; Petry, Marianne; Kispert, Andreas; Gloy, Joachim; Ganner, Athina; Walz, Gerd; Zhu, Xueliang; Goldman, Daniel; Nurnberg, Peter; Swaroop, Anand; Leroux, Michel R.; Hildebrandt, Friedhelm			The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4	NATURE GENETICS			English	Article							PRIMARY CILIA; RETINITIS-PIGMENTOSA; DOMAIN PROTEIN; NEPHRONOPHTHISIS; GENE; INVERSIN; MUTATIONS; INTERACTS; ENCODES; DISEASE	The molecular basis of nephronophthisis(1), the most frequent genetic cause of renal failure in children and young adults, and its association with retinal degeneration and cerebellar vermis aplasia in Joubert syndrome(2) are poorly understood. Using positional cloning, we here identify mutations in the gene CEP290 as causing nephronophthisis. It encodes a protein with several domains also present in CENPF, a protein involved in chromosome segregation. CEP290 ( also known as NPHP6) interacts with and modulates the activity of ATF4, a transcription factor implicated in cAMP-dependent renal cyst formation. NPHP6 is found at centrosomes and in the nucleus of renal epithelial cells in a cell cycle-dependent manner and in connecting cilia of photoreceptors. Abrogation of its function in zebrafish recapitulates the renal, retinal and cerebellar phenotypes of Joubert syndrome. Our findings help establish the link between centrosome function, tissue architecture and transcriptional control in the pathogenesis of cystic kidney disease, retinal degeneration, and central nervous system development.	Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Newcastle Univ, Sch Clin Med Sci, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; Univ Cologne, Cologne Ctr Genom, D-5000 Cologne 41, Germany; RZPD Deutsch Ressourcectr Genomforsch, Berlin, Germany; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Univ Michigan, Inst Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Ophthalmol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Renal Unit, Charlestown, MA 02129 USA; Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Max Planck Inst Biochem, Dept Cell Biol, D-82152 Martinsried, Germany; Peking Univ, Sch Oncol, Beijing Inst Canc Res, Dept Biochem & Mol Biol, Beijing 100036, Peoples R China; Univ Calif San Diego, Sch Med, Dept Pharmacol & Neurosci, La Jolla, CA 92093 USA; Univ Cologne, Dept Pediat, D-5000 Cologne 41, Germany; Univ Zurich, Dept Pediat, CH-8006 Zurich, Switzerland; Univ Washington, Dept Pediat, Seattle, WA 98105 USA; Hannover Med Sch, Inst Mol Biol, D-30625 Hannover, Germany; Univ Cologne, Inst Genet, D-5000 Cologne 41, Germany; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Newcastle University - UK; University of Cologne; Simon Fraser University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Harvard University; Massachusetts General Hospital; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Max Planck Society; Peking University; University of California System; University of California San Diego; University of Cologne; University of Zurich; University of Washington; University of Washington Seattle; Hannover Medical School; University of Cologne; University of Michigan System; University of Michigan	Hildebrandt, F (corresponding author), Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.	fhilde@umich.edu	Hennies, Hans C/G-9424-2014; Sayer, John A./AAN-2729-2020; Lillo, Concepcion/A-6321-2009; Kusakabe, Takehiro/H-7178-2012	Hennies, Hans C/0000-0001-7210-2389; Sayer, John A./0000-0003-1881-3782; Lillo, Concepcion/0000-0001-5814-9826; Kusakabe, Takehiro/0000-0002-8325-3665; Wilkinson, Christopher/0000-0002-7448-0938; Lee, Hwankyu/0000-0002-2036-1490; Otto, Edgar/0000-0002-2387-9973; Utsch, Boris/0000-0003-4623-581X; nigg, erich/0000-0003-4835-5719; Swaroop, Anand/0000-0002-1975-1141; Attanasio, Massimo/0000-0002-1278-3650	NATIONAL EYE INSTITUTE [R29EY007961, R01EY007042, R01EY013408, R01EY007961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053093, R01DK064614] Funding Source: NIH RePORTER; NEI NIH HHS [EY13408, EY07003, R01 EY007042, EY07961, R01 EY007042-20] Funding Source: Medline; NIDDK NIH HHS [DK1068306, DK1069274, DK53093, DK064614] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Barthel LK, 2000, METHOD ENZYMOL, V316, P579; Chen DH, 2001, BIOCHEM BIOPH RES CO, V280, P99, DOI 10.1006/bbrc.2000.4087; Germino GG, 2005, NAT GENET, V37, P455, DOI 10.1038/ng0505-455; Hildebrandt F, 2005, NAT REV GENET, V6, P928, DOI 10.1038/nrg1727; Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149; HILDEBRANDT F, 2001, DIS KIDNEY URINARY T; Khanna H, 2005, J BIOL CHEM, V280, P33580, DOI 10.1074/jbc.M505827200; KHANNA H, IN PRESS HUM MOL GEN; Kim JC, 2005, J CELL SCI, V118, P1007, DOI 10.1242/jcs.01676; Kramer-Zucker AG, 2005, DEVELOPMENT, V132, P1907, DOI 10.1242/dev.01772; Mazet F, 2005, DEV BIOL, V282, P494, DOI 10.1016/j.ydbio.2005.02.021; Mollet G, 2005, HUM MOL GENET, V14, P645, DOI 10.1093/hmg/ddi061; Mollet G, 2002, NAT GENET, V32, P300, DOI 10.1038/ng996; Morgan D, 2002, HUM MOL GENET, V11, P3345, DOI 10.1093/hmg/11.26.3345; Nakashima Y, 2003, J COMP NEUROL, V460, P180, DOI 10.1002/cne.10645; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; Olbrich H, 2003, NAT GENET, V34, P455, DOI 10.1038/ng1216; Otto E, 2002, AM J HUM GENET, V71, P1161, DOI 10.1086/344395; Otto EA, 2005, NAT GENET, V37, P282, DOI 10.1038/ng1520; Otto EA, 2003, NAT GENET, V34, P413, DOI 10.1038/ng1217; Pazour GJ, 2003, CURR OPIN CELL BIOL, V15, P105, DOI 10.1016/S0955-0674(02)00012-1; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; SARAIVA JM, 1992, AM J MED GENET, V43, P726, DOI 10.1002/ajmg.1320430415; Simons M, 2005, NAT GENET, V37, P537, DOI 10.1038/ng1552; Utsch B, 2006, PEDIATR NEPHROL, V21, P32, DOI 10.1007/s00467-005-2054-y; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Watnick T, 2003, NAT GENET, V34, P355, DOI 10.1038/ng0803-355; WESTERFIELD M, 1995, ZEBRAFISH BOOK; Zhou XB, 2005, J BIOL CHEM, V280, P13973, DOI 10.1074/jbc.M414310200	30	411	424	0	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					674	681		10.1038/ng1786	http://dx.doi.org/10.1038/ng1786			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16682973				2022-12-25	WOS:000237954800022
J	Asanuma, K; Yanagida-Asanuma, E; Faul, C; Tomino, Y; Kim, K; Mundel, P				Asanuma, K; Yanagida-Asanuma, E; Faul, C; Tomino, Y; Kim, K; Mundel, P			Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling	NATURE CELL BIOLOGY			English	Article							BIOLOGY; PROTEIN; GTPASES; DEGRADATION; PLASTICITY; PODOCYTES; POLARITY	The Rho family of small GTPases (RhoA, Rac1 and Cdc42) controls signal-transduction pathways that influence many aspects of cell behaviour, including cytoskeletal dynamics(1-3). At the leading edge, Rac1 and Cdc42 promote cell motility through the formation of lamellipodia and filopodia, respectively. On the contrary, RhoA promotes the formation of contractile actin-myosin-containing stress fibres in the cell body and at the rear(1,2,4). Here, we identify synaptopodin, an actin-associated protein, as a novel regulator of RhoA signalling and cell migration in kidney podocytes. We show that synaptopodin induces stress fibres by competitive blocking of Smurf1-mediated ubiquitination of RhoA, thereby preventing the targeting of RhoA for proteasomal degradation. Gene silencing of synaptopodin in kidney podocytes causes the loss of stress fibres and the formation of aberrant non-polarized filopodia and impairment of cell migration. Together, these data show that synaptopodin is essential for the integrity of the podocyte actin cytoskeleton and for the regulation of podocyte cell migration.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Juntendo Univ, Sch Med, Dept Internal Med, Tokyo 1138421, Japan	Icahn School of Medicine at Mount Sinai; Juntendo University	Mundel, P (corresponding author), Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.	peter.mundel@mssm.edu	Faul, Christian/D-1549-2011		NIDA NIH HHS [DA18886] Funding Source: Medline; NIDDK NIH HHS [DK57683, DK064236] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK064236, R01DK057683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA018886] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Asanuma K, 2005, J CLIN INVEST, V115, P1188, DOI 10.1172/JCI200523371; Deller T, 2003, P NATL ACAD SCI USA, V100, P10494, DOI 10.1073/pnas.1832384100; DRENCKHAHN D, 1988, LAB INVEST, V59, P673; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faul C, 2005, J CELL BIOL, V169, P415, DOI 10.1083/jcb.200411169; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Jaffe AB, 2003, SCIENCE, V302, P1690, DOI 10.1126/science.1092874; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Mundel P, 1997, J CELL BIOL, V139, P193, DOI 10.1083/jcb.139.1.193; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; MUNDEL P, 1995, ANAT EMBRYOL, V192, P387; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772	16	309	343	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					485	U109		10.1038/ncb1400	http://dx.doi.org/10.1038/ncb1400			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16622418				2022-12-25	WOS:000237299400012
J	Azuara, V; Perry, P; Sauer, S; Spivakov, M; Jorgensen, HF; John, RM; Gouti, M; Casanova, M; Warnes, G; Merkenschlager, M; Fisher, AG				Azuara, V; Perry, P; Sauer, S; Spivakov, M; Jorgensen, HF; John, RM; Gouti, M; Casanova, M; Warnes, G; Merkenschlager, M; Fisher, AG			Chromatin signatures of pluripotent cell lines	NATURE CELL BIOLOGY			English	Article							STEM-CELLS; SELF-RENEWAL; REPLICATION; DIFFERENTIATION; METHYLATION; GENOME; GENES; ESTABLISHMENT; TRANSCRIPTION	Epigenetic genome modifications are thought to be important for specifying the lineage and developmental stage of cells within a multicellular organism. Here, we show that the epigenetic profile of pluripotent embryonic stem cells (ES) is distinct from that of embryonic carcinoma cells, haematopoietic stem cells (HSC) and their differentiated progeny. Silent, lineage-specific genes replicated earlier in pluripotent cells than in tissue-specific stem cells or differentiated cells and had unexpectedly high levels of acetylated H3K9 and methylated H3K4. Unusually, in ES cells these markers of open chromatin were also combined with H3K27 trimethylation at some non-expressed genes. Thus, pluripotency of ES cells is characterized by a specific epigenetic profile where lineage-specific genes may be accessible but, if so, carry repressive H3K27 trimethylation modifications. H3K27 methylation is functionally important for preventing expression of these genes in ES cells as premature expression occurs in embryonic ectoderm development (Eed)-deficient ES cells. Our data suggest that lineage-specific genes are primed for expression in ES cells but are held in check by opposing chromatin modifications.	Imperial Coll Sch Med, Hammersmith Hosp, MRC Clin Sci Ctr, Lymphocyte Dev Grp, London W12 0NN, England; Imperial Coll Sch Med, Hammersmith Hosp, MRC Clin Sci Ctr, Dev Epigenet Grp, London W12 0NN, England; Canc Res UK, FACS Lab, London WC2A 3PX, England	Imperial College London; Imperial College London; Cancer Research UK	Azuara, V (corresponding author), Imperial Coll Sch Med, Hammersmith Hosp, MRC Clin Sci Ctr, Lymphocyte Dev Grp, London W12 0NN, England.	v.azuara@imperial.ac.uk; amanda.fisher@csc.mrc.ac.uk	Gouti, Mina/D-3235-2018; John, Rosalind M/A-4491-2010; John, Ros/AAF-4229-2022; Warnes, Gary/I-1110-2019; John, Ros/AFI-8619-2022; John, Rosalind/AAQ-8221-2021	Gouti, Mina/0000-0001-7422-1605; John, Rosalind M/0000-0002-3827-7617; John, Ros/0000-0002-3827-7617; Warnes, Gary/0000-0001-7614-6266; John, Ros/0000-0002-3827-7617; Jorgensen, Helle/0000-0002-7909-2977; Merkenschlager, Matthias/0000-0003-2889-3288; Spivakov, Mikhail/0000-0002-0383-3943; Azuara, Veronique/0000-0003-4608-3713; Casanova, Miguel/0000-0001-8622-6550	Medical Research Council [MC_U120027516] Funding Source: Medline; Parkinson&apos;s UK [G-4045] Funding Source: Medline; MRC [MC_U120027516] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Parkinson&apos;s UK(Parkinson&apos;s UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Azuara V, 2003, NAT CELL BIOL, V5, P668, DOI 10.1038/ncb1006; Ballas N, 2005, CURR OPIN NEUROBIOL, V15, P500, DOI 10.1016/j.conb.2005.08.015; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Evans M, 2002, CR BIOL, V325, P1003, DOI 10.1016/S1631-0691(02)01527-5; Evsikov AV, 2003, SCIENCE, V302; Faust C, 1998, DEVELOPMENT, V125, P4495; Fortunel NO, 2003, SCIENCE, V302, P393; Gilbert DM, 2004, NAT REV MOL CELL BIO, V5, P848, DOI 10.1038/nrm1495; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; Gomez M, 2004, P NATL ACAD SCI USA, V101, P6923, DOI 10.1073/pnas.0401854101; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; Hiratani I, 2004, P NATL ACAD SCI USA, V101, P16861, DOI 10.1073/pnas.0406687101; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; Lin CM, 2003, CURR BIOL, V13, P1019, DOI 10.1016/S0960-9822(03)00382-8; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Morin-Kensicki Elizabeth M., 2001, Genesis The Journal of Genetics and Development, V31, P142, DOI 10.1002/gene.10017; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; Perry P, 2004, CELL CYCLE, V3, P1645; Peters AHFM, 2005, CURR OPIN CELL BIOL, V17, P230, DOI 10.1016/j.ceb.2005.02.006; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rugg-Gunn PJ, 2005, NAT GENET, V37, P585, DOI 10.1038/ng1556; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Schubeler D, 2002, NAT GENET, V32, P438, DOI 10.1038/ng1005; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vogel G, 2003, SCIENCE, V302, P371; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; Williams RRE, 2006, J CELL SCI, V119, P132, DOI 10.1242/jcs.02727; Woodfine K, 2004, HUM MOL GENET, V13, P191, DOI 10.1093/hmg/ddh016; Zhang JM, 2002, NATURE, V420, P198, DOI 10.1038/nature01150	37	1003	1037	0	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					532	U189		10.1038/ncb1403	http://dx.doi.org/10.1038/ncb1403			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16570078				2022-12-25	WOS:000237299400018
J	Foltz, DR; Jansen, LET; Black, BE; Bailey, AO; Yates, JR; Cleveland, DW				Foltz, DR; Jansen, LET; Black, BE; Bailey, AO; Yates, JR; Cleveland, DW			The human CENP-A centromeric nucleosome-associated complex	NATURE CELL BIOLOGY			English	Article							CHROMOSOME SEGREGATION; MICROTUBULE CAPTURE; BUDDING YEAST; PROTEIN; CHROMATIN; KINETOCHORE; DNA; COMPONENT; CELLS; TRANSCRIPTION	The basic element for chromosome inheritance, the centromere, is epigenetically determined in mammals. The prime candidate for specifying centromere identity is the array of nucleosomes assembled with CENP-A, the centromere-specific histone H3 variant. Here, we show that CENP-A nucleosomes directly recruit a proximal CENP-A nucleosome associated complex (NAC) comprised of three new human centromere proteins (CENP-M, CENP-N and CENP-T), along with CENP-U(50), CENPC and CENP-H. Assembly of the CENP-A NAC at centromeres is dependent on CENP-M, CENP-N and CENP-T. Facilitates chromatin transcription (FACT) and nucleophosmin-1 (previously implicated in transcriptional chromatin remodelling and as a multifunctional nuclear chaperone, respectively) are absent from histone H3-containing nucleosomes, but are stably recruited to CENP-A nucleosomes independent of CENP-A NAC. Seven new CENP-A-nucleosome distal (CAD) centromere components (CENP-K, CENP-L, CENP-O, CENP-P, CENP-Q, CENP-R and CENP-S) are identified as assembling on the CENP-A NAC. The CENP-A NAC is essential, as disruption of the complex causes errors of chromosome alignment and segregation that preclude cell survival despite continued centromere-derived mitotic checkpoint signalling.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Cleveland, DW (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.	dcleveland@ucsd.edu	Bailey, Aaron/ABB-8522-2021; Cleveland, Don/AAN-9783-2021	Bailey, Aaron/0000-0001-8063-3032; Cleveland, Don/0000-0002-1934-3682; Jansen, Lars/0000-0002-2158-0345	NCRR NIH HHS [RR11823] Funding Source: Medline; NIGMS NIH HHS [GM 29513] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029513, R37GM029513] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amor DJ, 2004, TRENDS CELL BIOL, V14, P359, DOI 10.1016/j.tcb.2004.05.009; Amor DJ, 2002, AM J HUM GENET, V71, P695, DOI 10.1086/342730; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bierie B, 2004, GENE EXPR PATTERNS, V4, P389, DOI 10.1016/j.modgep.2004.01.008; Black BE, 2004, NATURE, V430, P578, DOI 10.1038/nature02766; Blower MD, 2002, DEV CELL, V2, P319, DOI 10.1016/S1534-5807(02)00135-1; Bomont P, 2005, EMBO J, V24, P3927, DOI 10.1038/sj.emboj.7600848; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cheeseman IM, 2001, J CELL BIOL, V155, P1137, DOI 10.1083/jcb.200109063; Cheeseman IM, 2002, J CELL BIOL, V157, P199, DOI 10.1083/jcb.200201052; CHEESEMAN IM, 2005, SCI STKE; Chen RH, 1998, J CELL BIOL, V143, P283, DOI 10.1083/jcb.143.2.283; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; Fukagawa T, 1999, EMBO J, V18, P4196, DOI 10.1093/emboj/18.15.4196; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; Goshima G, 1999, GENE DEV, V13, P1664, DOI 10.1101/gad.13.13.1664; Goshima G, 2003, J CELL BIOL, V160, P25, DOI 10.1083/jcb.200210005; Hanissian SH, 2004, ONCOGENE, V23, P3700, DOI 10.1038/sj.onc.1207448; Hayashi T, 2004, CELL, V118, P715, DOI 10.1016/j.cell.2004.09.002; Henikoff S, 2005, ANNU REV CELL DEV BI, V21, P133, DOI 10.1146/annurev.cellbio.21.012704.133518; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; Liu ST, 2003, NAT CELL BIOL, V5, P341, DOI 10.1038/ncb953; MacCoss MJ, 2002, P NATL ACAD SCI USA, V99, P7900, DOI 10.1073/pnas.122231399; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Mao YH, 2005, J CELL BIOL, V170, P873, DOI 10.1083/jcb.200505040; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Minoshima Y, 2005, MOL CELL BIOL, V25, P10315, DOI 10.1128/MCB.25.23.10315-10328.2005; Nishihashi A, 2002, DEV CELL, V2, P463, DOI 10.1016/S1534-5807(02)00144-2; Obuse C, 2004, GENES CELLS, V9, P105, DOI 10.1111/j.1365-2443.2004.00705.x; Okuda M, 2002, ONCOGENE, V21, P6170, DOI 10.1038/sj.onc.1205708; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Regnier V, 2005, MOL CELL BIOL, V25, P3967, DOI 10.1128/MCB.25.10.3967-3981.2005; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Sarma K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; SMITH S, 1991, EMBO J, V10, P971, DOI 10.1002/j.1460-2075.1991.tb08031.x; Sugata N, 1999, J BIOL CHEM, V274, P27343, DOI 10.1074/jbc.274.39.27343; Sullivan BA, 2001, NAT REV GENET, V2, P584, DOI 10.1038/35084512; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Yoda K, 2004, METHOD ENZYMOL, V375, P253; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	49	521	559	0	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					458	U77		10.1038/ncb1397	http://dx.doi.org/10.1038/ncb1397			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16622419				2022-12-25	WOS:000237299400009
J	Peng, JC; Karpen, GH				Peng, Jamy C.; Karpen, Gary H.			H3K9 methylation and RNA interference regulate nucleolar organization and repeated DNA stability	NATURE CELL BIOLOGY			English	Article							POSITION-EFFECT VARIEGATION; DROSOPHILA-MELANOGASTER; EPIGENETIC CONTROL; GENE; HETEROCHROMATIN; REPLICATION; RECOMBINATION; TRANSCRIPTION; FAMILY; IDENTIFICATION	Investigations aimed at identifying regulators of nuclear architecture in Drosophila demonstrated that cells lacking H3K9 methylation and RNA interference (RNAi) pathway components displayed disorganized nucleoli, ribosomal DNA (rDNA) and satellite DNAs. The levels of H3K9 dimethylation (H3K9me2) in chromatin associated with repeated DNAs decreased dramatically in Su(var)3-9 and dcr-2 (dicer-2) mutant tissues compared with wild type. We also observed a substantial increase in extrachromosomal circular (ecc) repeated DNAs in mutant tissues. The disorganized nucleolus phenotype depends on the presence of Ligase 4 and ecc DNA formation is not induced by removal of cohesin. We conclude that the structural integrity and organization of repeated DNAs and nucleoli are regulated by the H3K9 methylation and RNAi pathways, and other regulators of heterochromatin-mediated silencing. In addition, repeated DNA stability involves suppression of non-homologous end joining (NHEJ) or other recombination pathways. These results suggest a mechanism for how local chromatin structure can regulate genome stability, and the organization of chromosomal elements and nuclear organelles.	Lawrence Berkeley Natl Lab, Dept Genom & Bioinformat, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Karpen, GH (corresponding author), Lawrence Berkeley Natl Lab, Dept Genom & Bioinformat, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	karpen@fruitfly.org	Peng, Jamy/N-1134-2018	Peng, Jamy/0000-0002-4043-8475	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066272, R01GM061169] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM061169, R01 GM066272, R01 GM061169-04, R01 GM061169] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Astrom SU, 2003, GENETICS, V163, P931; Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Cam HP, 2005, NAT GENET, V37, P809, DOI 10.1038/ng1602; Cartwright IL, 1999, METHOD ENZYMOL, V304, P462; Cohen S, 2003, GENOME RES, V13, P1133, DOI 10.1101/gr.907603; Cohen Z, 2006, ONCOGENE, V25, P4515, DOI 10.1038/sj.onc.1209485; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dernburg AF, 1996, CELL, V86, P135, DOI 10.1016/S0092-8674(00)80084-7; Donaldson KM, 2002, GENETICS, V160, P995; Dorsett D, 2005, DEVELOPMENT, V132, P4743, DOI 10.1242/dev.02064; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; GILLESPIE DE, 1995, GENE DEV, V9, P2495, DOI 10.1101/gad.9.20.2495; GINDHART JG, 1995, GENETICS, V139, P797; GLASER RL, 1992, CHROMOSOMA, V102, P15, DOI 10.1007/BF00352285; Gonzalez-Reyes A, 1997, DEVELOPMENT, V124, P4927; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; HAWLEY RS, 1989, ANNU REV GENET, V23, P87, DOI 10.1146/annurev.genet.23.1.87; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Hodgson JW, 1997, MECH DEVELOP, V66, P69, DOI 10.1016/S0925-4773(97)00091-9; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; John B, 1988, HETEROCHROMATIN MOL, P1; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KARPEN GH, 1988, GENE DEV, V2, P1745, DOI 10.1101/gad.2.12b.1745; Karpen GH, 1996, SCIENCE, V273, P118, DOI 10.1126/science.273.5271.118; Kobayashi T, 2005, SCIENCE, V309, P1581, DOI 10.1126/science.1116102; Kuschak TI, 2001, BIOTECHNIQUES, V30, P1064, DOI 10.2144/01305rr05; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lin HF, 1997, DEVELOPMENT, V124, P2463; LIN YH, 1991, GENETICS, V127, P31; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Osipovich O, 2004, NAT IMMUNOL, V5, P309, DOI 10.1038/ni1042; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pikaard CS, 2000, TRENDS GENET, V16, P495, DOI 10.1016/S0168-9525(00)02113-2; PONT G, 1987, J MOL BIOL, V195, P447, DOI 10.1016/0022-2836(87)90665-6; ROMEIJN R, 2004, LIGASE4 MUTATIONS; Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schotta G, 2003, SEMIN CELL DEV BIOL, V14, P67, DOI 10.1016/S1084-9521(02)00138-6; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; SPRADLING A, 1987, ANNU REV GENET, V21, P373, DOI 10.1146/annurev.ge.21.120187.002105; Sullivan BA, 2004, NAT STRUCT MOL BIOL, V11, P1076, DOI 10.1038/nsmb845; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Westphal T, 2002, GENETICS, V160, P609; Wilson JE, 1996, DEV GENET, V19, P199, DOI 10.1002/(SICI)1520-6408(1996)19:3<199::AID-DVG3>3.0.CO;2-4; Xu KY, 2004, CURR BIOL, V14, P1025, DOI 10.1016/j.cub.2004.05.055	59	283	299	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					25	U24		10.1038/ncb1514	http://dx.doi.org/10.1038/ncb1514			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17159999	Green Accepted			2022-12-25	WOS:000243255100009
J	Shima, N; Alcaraz, A; Liachko, I; Buske, TR; Andrews, CA; Munroe, RJ; Hartford, SA; Tye, BK; Schimenti, JC				Shima, Naoko; Alcaraz, Ana; Liachko, Ivan; Buske, Tavanna R.; Andrews, Catherine A.; Munroe, Robert J.; Hartford, Suzanne A.; Tye, Bik K.; Schimenti, John C.			A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice	NATURE GENETICS			English	Article							DNA-REPLICATION; GENOMIC INSTABILITY; MINICHROMOSOME MAINTENANCE; PROTEINS; MUTANTS; COMPLEX; CEREVISIAE; ACTIVATION; CHECKPOINT; CANDIDATE	Mcm4 (minichromosome maintenance-deficient 4 homolog) encodes a subunit of the MCM2-7 complex (also known as MCM2-MCM7), the replication licensing factor and presumptive replicative helicase. Here, we report that the mouse chromosome instability mutation Chaos3 (chromosome aberrations occurring spontaneously 3), isolated in a forward genetic screen, is a viable allele of Mcm4. Mcm4(Chaos3) encodes a change in an evolutionarily invariant amino acid (F345I), producing an apparently destabilized MCM4. Saccharomyces cerevisiae strains that we engineered to contain a corresponding allele (resulting in an F391I change) showed a classical minichromosome loss phenotype. Whereas homozygosity for a disrupted Mcm4 allele (Mcm4(-)) caused preimplantation lethality, Mcm(Chaos3/-) embryos died late in gestation, indicating that Mcm4Chaos3 is hypomorphic. Mutant embryonic fibroblasts were highly susceptible to chromosome breaks induced by the DNA replication inhibitor aphidicolin. Most notably, > 80% of Mcm4(Chaos3/Chaos3) females succumbed to mammary adenocarcinomas with a mean latency of 12 months. These findings suggest that hypomorphic alleles of the genes encoding the subunits of the MCM2-7 complex may increase breast cancer risk.	Univ Minnesota, Coll Biol Sci, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA; Jackson Lab, Bar Harbor, ME 04609 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	University of Minnesota System; University of Minnesota Twin Cities; Cornell University; Jackson Laboratory; Cornell University	Shima, N (corresponding author), Univ Minnesota, Coll Biol Sci, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.	shima023@umn.edu; jcs92@cornell.edu		Hartford, Suzanne/0000-0001-8816-8585; Shima, Naoko/0000-0001-5927-8451	NIGMS NIH HHS [R01 GM45415] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045415] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; DARZYNKIEWICZ Z, 1997, ANAL DNA CONTENT BRD; Dertinger SD, 1996, MUTAT RES-GENET TOX, V371, P283, DOI 10.1016/S0165-1218(96)90117-2; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Glover TW, 2005, HUM MOL GENET, V14, pR197, DOI 10.1093/hmg/ddi265; Gonzalez MA, 2005, NAT REV CANCER, V5, P135, DOI 10.1038/nrc1548; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Keays DA, 2006, MAMM GENOME, V17, P230, DOI 10.1007/s00335-005-0101-4; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lei M, 2005, CURR CANCER DRUG TAR, V5, P365, DOI 10.2174/1568009054629654; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lengronne A, 2002, MOL CELL, V9, P1067, DOI 10.1016/S1097-2765(02)00513-0; Liang DT, 1999, J CELL SCI, V112, P559; MAINE GT, 1984, GENETICS, V106, P365; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Moyer SE, 2006, P NATL ACAD SCI USA, V103, P10236, DOI 10.1073/pnas.0602400103; Reinholdt Laura, 2004, Methods Mol Biol, V262, P87; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Shetty A, 2005, BRIT J CANCER, V93, P1295, DOI 10.1038/sj.bjc.6602829; Shima N, 2003, GENETICS, V163, P1031; Sidorova JM, 2003, MUTAT RES-FUND MOL M, V532, P5, DOI 10.1016/j.mrfmmm.2003.08.006; Snyder M, 2005, P NATL ACAD SCI USA, V102, P14539, DOI 10.1073/pnas.0507479102; Stoeber K, 2001, J CELL SCI, V114, P2027; Tye BK, 1999, METHODS, V18, P329, DOI 10.1006/meth.1999.0793; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Woodward AM, 2006, J CELL BIOL, V173, P673, DOI 10.1083/jcb.200602108	30	227	230	2	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2007	39	1					93	98		10.1038/ng1936	http://dx.doi.org/10.1038/ng1936			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17143284				2022-12-25	WOS:000243136500023
J	Bettegowda, C; Huang, X; Lin, J; Cheong, I; Kohli, M; Szabo, SA; Zhang, XS; Diaz, LA; Velculescu, VE; Parmigiani, G; Kinzler, KW; Vogelstein, B; Zhou, S				Bettegowda, Chetan; Huang, Xin; Lin, Jimmy; Cheong, Ian; Kohli, Manu; Szabo, Stephen A.; Zhang, Xiaosong; Diaz, Luis A., Jr.; Velculescu, Victor E.; Parmigiani, Giovanni; Kinzler, Kenneth W.; Vogelstein, Bert; Zhou, Shibin			The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT	NATURE BIOTECHNOLOGY			English	Article							BACTERIOLYTIC THERAPY; GENE-EXPRESSION; SEQUENCE; SPORES; SPORULATION; BACTERIUM; PERFRINGENS; OXIDATION; ACIDS	Bacteriolytic anti-cancer therapies employ attenuated bacterial strains that selectively proliferate within tumors. Clostridium novyi-NT spores represent one of the most promising of these agents, as they generate potent anti-tumor effects in experimental animals. We have determined the 2.55-Mb genomic sequence of C. novyi-NT, identifying a new type of transposition and 139 genes that do not have homologs in other bacteria. The genomic sequence was used to facilitate the detection of transcripts expressed at various stages of the life cycle of this bacterium in vitro as well as in infections of tumors in vivo. Through this analysis, we found that C. novyi-NT spores contained mRNA and that the spore transcripts were distinct from those in vegetative forms of the bacterium.	Johns Hopkins Med Inst, Howard Hughes Med Inst, Ludwig Ctr Canc Genet & Therapeut, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Dept Pharmacol & Mol Sci, Baltimore, MD 21231 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Biostat, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Zhou, S (corresponding author), Johns Hopkins Med Inst, Howard Hughes Med Inst, Ludwig Ctr Canc Genet & Therapeut, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St, Baltimore, MD 21231 USA.	sbzhou@jhmi.edu	Velculescu, Victor/ABF-4846-2020; Diaz, Luis A/A-6018-2008	Velculescu, Victor/0000-0003-1195-438X; Diaz, Luis/0000-0002-7079-8914; Cheong, Ian/0000-0002-3062-6878	NCI NIH HHS [P50 CA062924, CA062924] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA062924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal N, 2004, P NATL ACAD SCI USA, V101, P15172, DOI 10.1073/pnas.0406242101; Alsaker KV, 2005, J BACTERIOL, V187, P7103, DOI 10.1128/JB.187.20.7103-7118.2005; Arthur JR, 2000, CELL MOL LIFE SCI, V57, P1825; Barbe S, 2006, J APPL MICROBIOL, V101, P571, DOI 10.1111/j.1365-2672.2006.02886.x; Bettegowda C, 2003, P NATL ACAD SCI USA, V100, P15083, DOI 10.1073/pnas.2036598100; Bruggemann H, 2003, P NATL ACAD SCI USA, V100, P1316, DOI 10.1073/pnas.0335853100; CANO RJ, 1995, SCIENCE, V268, P1060, DOI 10.1126/science.7538699; Carraro DM, 2003, BIOTECHNIQUES, V34, P626, DOI 10.2144/03343dd05; Cerar A, 2004, PATHOL RES PRACT, V200, P657, DOI 10.1016/j.prp.2004.06.010; CHAMBON P, 1968, J BIOL CHEM, V243, P5110; CHEONG I, 2006, IN PRESS SCIENCE; Coenye T, 2005, FEMS MICROBIOL REV, V29, P147, DOI 10.1016/j.femsre.2004.11.004; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698; Dang LH, 2004, CANCER BIOL THER, V3, P326, DOI 10.4161/cbt.3.3.704; Diaz LA, 2005, TOXICOL SCI, V88, P562, DOI 10.1093/toxsci/kfi316; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evguenieva-Hackenberg E, 2005, MOL MICROBIOL, V57, P318, DOI 10.1111/j.1365-2958.2005.04662.x; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Fawcett P, 2000, P NATL ACAD SCI USA, V97, P8063, DOI 10.1073/pnas.140209597; FORSDAHL K, 1995, J MOL CELL CARDIOL, V27, P893, DOI 10.1016/0022-2828(95)90039-X; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; Jain RK, 2001, P NATL ACAD SCI USA, V98, P14748, DOI 10.1073/pnas.261606598; JENG YH, 1974, J BACTERIOL, V119, P514, DOI 10.1128/JB.119.2.514-521.1974; Kunau WH, 1995, PROG LIPID RES, V34, P267, DOI 10.1016/0163-7827(95)00011-9; Liu HB, 2004, J BACTERIOL, V186, P164, DOI 10.1128/JB.186.1.164-178.2004; Minton NP, 2003, NAT REV MICROBIOL, V1, P237, DOI 10.1038/nrmicro777; Moore TDE, 1996, J BACTERIOL, V178, P4301, DOI 10.1128/jb.178.14.4301-4305.1996; Moriya S, 1999, PLASMID, V41, P17, DOI 10.1006/plas.1998.1381; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; Nuwaysir EF, 2002, GENOME RES, V12, P1749, DOI 10.1101/gr.362402; Parmigiani G., 2003, ANAL GENE EXPRESSION; Pawelek JM, 2003, LANCET ONCOL, V4, P548, DOI 10.1016/S1470-2045(03)01194-X; Ryan RM, 2006, BIOESSAYS, V28, P84, DOI 10.1002/bies.20336; SCHARPF R, IN PRESS BIOSTATISTI; Sebaihia M, 2006, NAT GENET, V38, P779, DOI 10.1038/ng1830; Segall AM, 2005, MOL CELL, V19, P433, DOI 10.1016/j.molcel.2005.08.003; Seshadri R, 2005, SCIENCE, V307, P105, DOI 10.1126/science.1102226; Setlow P, 2003, CURR OPIN MICROBIOL, V6, P550, DOI 10.1016/j.mib.2003.10.001; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Songer JG, 1997, TRENDS MICROBIOL, V5, P156, DOI 10.1016/S0966-842X(97)01005-6; Subramanian G, 2001, MOL DIAGN, V6, P243, DOI 10.1054/modi.2001.28062; Theys J., 2003, Current Gene Therapy, V3, P207, DOI 10.2174/1566523034578357; Titball RV, 1999, ANAEROBE, V5, P51, DOI 10.1006/anae.1999.0191; Vreeland RH, 2000, NATURE, V407, P897, DOI 10.1038/35038060; Wang ST, 2006, J MOL BIOL, V358, P16, DOI 10.1016/j.jmb.2006.01.059; Ward N, 2005, CURR OPIN MICROBIOL, V8, P564, DOI 10.1016/j.mib.2005.08.011; WEEKS G, 1969, J BACTERIOL, V97, P827, DOI 10.1128/JB.97.2.827-836.1969	51	101	415	0	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0733-222X	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1573	1580		10.1038/nbt1256	http://dx.doi.org/10.1038/nbt1256			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17115055	Green Accepted			2022-12-25	WOS:000242795800037
J	Chen, K; Rajewsky, N				Chen, Kevin; Rajewsky, Nikolaus			Natural selection on human microRNA binding sites inferred from SNP data	NATURE GENETICS			English	Article							POLYMORPHISM; RNA; IMPACT	A fundamental problem in biology is understanding how natural selection has shaped the evolution of gene regulation. Here we use SNP genotype data and techniques from population genetics to study an entire layer of short, cis-regulatory sites in the human genome. MicroRNAs (miRNAs) are a class of small noncoding RNAs that post-transcriptionally repress mRNA through cis-regulatory sites in 3 ' UTRs. We show that negative selection in humans is stronger on computationally predicted conserved miRNA binding sites than on other conserved sequence motifs in 3 ' UTRs, thus providing independent support for the target prediction model and explicitly demonstrating the contribution of miRNAs to darwinian fitness. Our techniques extend to nonconserved miRNA binding sites, and we estimate that 30%-50% of these are functional when the mRNA and miRNA are endogenously coexpressed. As we show that polymorphisms in predicted miRNA binding sites are likely to be deleterious, they are candidates for causal variants of human disease. We believe that our approach can be extended to studying other classes of cis-regulatory sites.	NYU, Dept Biol, Ctr Comparat Funct Genom, New York, NY 10003 USA; Max Delbruck Ctr Mol Med, Berlin, Germany	New York University; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Rajewsky, N (corresponding author), NYU, Dept Biol, Ctr Comparat Funct Genom, New York, NY 10003 USA.	rajewsky@mdc-berlin.de		Rajewsky, Nikolaus/0000-0002-4785-4332				Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502; Akashi H, 1999, GENETICS, V151, P221; Allen E, 2005, NATURE, V438, P224, DOI 10.1038/nature04256; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Clark AG, 2005, GENOME RES, V15, P1496, DOI 10.1101/gr.4107905; Clop A, 2006, NAT GENET, V38, P813, DOI 10.1038/ng1810; Drake JA, 2006, NAT GENET, V38, P223, DOI 10.1038/ng1710; Fairbrother WG, 2004, PLOS BIOL, V2, P1388, DOI 10.1371/journal.pbio.0020268; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Gottwein E, 2006, J VIROL, V80, P5321, DOI 10.1128/JVI.02734-05; Griffiths-Jones S, 2005, NUCLEIC ACIDS RES, V33, pD121, DOI 10.1093/nar/gki081; Hartl :D. L, 2000, PRIMER POPULATION GE; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Iwai N, 2005, BIOCHEM BIOPH RES CO, V331, P1439, DOI 10.1016/j.bbrc.2005.04.051; Jin P, 2004, NAT CELL BIOL, V6, P1048, DOI 10.1038/ncb1104-1048; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lu R, 2004, P NATL ACAD SCI USA, V101, P15201, DOI 10.1073/pnas.0404995101; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Rockman MV, 2005, PLOS BIOL, V3, P2208, DOI 10.1371/journal.pbio.0030387; Sabeti PC, 2006, SCIENCE, V312, P1614, DOI 10.1126/science.1124309; SAWYER SA, 1992, GENETICS, V132, P1161; Sood P, 2006, P NATL ACAD SCI USA, V103, P2746, DOI 10.1073/pnas.0511045103; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI [10.2307/2408641, 10.1111/j.1558-5646.1984.tb05657.x]	30	350	378	0	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2006	38	12					1452	1456		10.1038/ng1910	http://dx.doi.org/10.1038/ng1910			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17072316				2022-12-25	WOS:000242404200025
J	Hiratsuka, S; Watanabe, A; Aburatani, H; Maru, Y				Hiratsuka, Sachie; Watanabe, Akira; Aburatani, Hiroyuki; Maru, Yoshiro			Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis	NATURE CELL BIOLOGY			English	Article							MIGRATION; INFLAMMATION; EXPRESSION; CANCER; DOMAIN; TWIST	Primary tumours influence the environment in the lungs before metastasis(1,2). However, the mechanism of metastasis is not well understood. Here, we show that the inflammatory chemoattractants S100A8 and S100A9, whose expression is induced by distant primary tumours, attract Mac 1 (macrophage antigen 1)(+)-myeloid cells in the premetastatic lung. In addition, tumour cells use this mechanism, through activation of the mitogen-activated protein kinase (MAPK) p38, to acquire migration activity with pseudopodia for invasion (invadopodia). The expression of S100A8 and S100A9 was eliminated in lung Mac 1(+)-myeloid cells and endothelial cells deprived of soluble factors, such as vascular endothelial growth factor A (VEGF-A), tumour necrosis factor a (TNF alpha) and transforming growth factor beta (TGF beta) both in vitro and in vivo. Neutralizing anti-S100A8 and anti-S100A9 antibodies blocked the morphological changes and migration of tumour cells and Mac 1+-myeloid cells. Thus, the S100A8 and S100A9 pathway may be common to both myeloid cell recruitment and tumour-cell invasion.	Tokyo Womens Med Univ, Sch Med, Dept Pharmacol, Shinjyuku Ku, Tokyo 1628666, Japan; Univ Tokyo, Genome Sci Div, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan	Tokyo Women's Medical University; University of Tokyo	Maru, Y (corresponding author), Tokyo Womens Med Univ, Sch Med, Dept Pharmacol, Shinjyuku Ku, Tokyo 1628666, Japan.	ymaru@research.twmu.ac.jp						Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Chen S, 2005, IMMUNOLOGY, V114, P565, DOI 10.1111/j.1365-2567.2004.02110.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Couzin J, 2003, SCIENCE, V299, P1002, DOI 10.1126/science.299.5609.1002; DEVERY JM, 1994, J IMMUNOL, V152, P1888; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Folkman J, 1992, Semin Cancer Biol, V3, P65; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Hobbs JAR, 2003, MOL CELL BIOL, V23, P2564, DOI 10.1128/MCB.23.7.2564-2576.2003; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; LACKMANN M, 1993, J IMMUNOL, V150, P2981; Marx J, 2004, SCIENCE, V306, P966, DOI 10.1126/science.306.5698.966; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Ohira S, 2006, AM J PATHOL, V168, P1155, DOI 10.2353/ajpath.2006.050204; Roth J, 2003, J IMMUNOL, V171, P5651, DOI 10.4049/jimmunol.171.11.5651; TODA KI, 1990, CANCER RES, V50, P5526; Watanabe T, 2004, AM J PHYSIOL-GASTR L, V287, pG919, DOI 10.1152/ajpgi.00372.2003; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	25	770	813	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1369	U31		10.1038/ncb1507	http://dx.doi.org/10.1038/ncb1507			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17128264				2022-12-25	WOS:000242419800012
J	Loser, K; Mehling, A; Loeser, S; Apelt, J; Kuhn, A; Grabbe, S; Schwarz, T; Penninger, JM; Beissert, S				Loser, Karin; Mehling, Annette; Loeser, Stefanie; Apelt, Jenny; Kuhn, Annegret; Grabbe, Stephan; Schwarz, Thomas; Penninger, Josef M.; Beissert, Stefan			Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells	NATURE MEDICINE			English	Article							IMMUNOLOGICAL SELF-TOLERANCE; CONTACT HYPERSENSITIVITY; SYSTEMIC AUTOIMMUNITY; LYMPH-NODE; INTESTINAL INFLAMMATION; TUMOR-IMMUNITY; CD25(+); INDUCTION; LIGAND; MICE	Regulatory CD4(+)CD25(+) T cells are important in suppressing immune responses. The requirements for the maintenance of peripheral CD4(+)CD25(+) T cells remain incompletely understood. Receptor activator of NF-kappa B ( RANK) and its ligand (RANKL; also known as CD254, OPGL and TRANCE) are key regulators of bone remodeling, mammary gland formation, lymph node development and T-cell/dendritic cell communication. Here we report that RANKL is expressed in keratinocytes of the inflamed skin. RANKL overexpression in keratinocytes resulted in functional alterations of epidermal dendritic cells and systemic increases of regulatory CD4(+)CD25(+) T cells. Thus, epidermal RANKL expression can change dendritic cell functions to maintain the number of peripheral CD4(+)CD25(+) regulatory T cells. Epidermal RANKL mediated ultraviolet-induced immunosuppression and overexpression of epidermal RANKL suppressed allergic contact hypersensitivity responses and the development of systemic autoimmunity. Therefore, environmental stimuli at the skin can rewire the local and systemic immune system by means of RANKL.	Univ Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany; Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria; German Canc Res Ctr, Tumor Immunol Program, Div Immunogenet, D-69120 Heidelberg, Germany; Univ Essen Gesamthsch, Dept Dermatol, D-45122 Essen, Germany; Univ Kiel, Dept Dermatol, D-24105 Kiel, Germany	University of Munster; University of Munster; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Helmholtz Association; German Cancer Research Center (DKFZ); University of Duisburg Essen; University of Kiel	Beissert, S (corresponding author), Univ Munster, Dept Dermatol, Von Esmarch Str 56, D-48149 Munster, Germany.	beisser@uni-muenster.de	Penninger, Josef M/I-6860-2013; Grabe, Stephan/AAJ-4578-2021; Schwarz, Thomas/A-9148-2010	Penninger, Josef M/0000-0002-8194-3777; Grabe, Stephan/0000-0002-6863-8719; 				ALUFER TM, 2006, NATURE, V383, P81; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ashcroft AJ, 2003, IMMUNITY, V19, P849, DOI 10.1016/S1074-7613(03)00326-1; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bruder D, 2004, EUR J IMMUNOL, V34, P623, DOI 10.1002/eji.200324799; Bynoe MS, 2003, IMMUNITY, V19, P317, DOI 10.1016/S1074-7613(03)00239-5; Cavani A, 2003, J IMMUNOL, V171, P5760, DOI 10.4049/jimmunol.171.11.5760; Cremer I, 2002, BLOOD, V100, P3646, DOI 10.1182/blood-2002-01-0312; Dombrecht EJ, 2006, CLIN EXP RHEUMATOL, V24, P31; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Geissmann F, 2002, J EXP MED, V196, P417, DOI 10.1084/jem.20020018; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Green EA, 2002, IMMUNITY, V16, P183, DOI 10.1016/S1074-7613(02)00279-0; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Itoh M, 1999, J IMMUNOL, V162, P5317; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; KRAGBALLE K, 1992, J CELL BIOCHEM, V49, P46, DOI 10.1002/jcb.240490109; Kuhn A, 2001, J AM ACAD DERMATOL, V45, P86, DOI 10.1067/mjd.2001.114589; Labeur MS, 1999, J IMMUNOL, V162, P168; Lehmann J, 2002, P NATL ACAD SCI USA, V99, P13031, DOI 10.1073/pnas.192162899; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Loser K, 2005, GENE THER, V12, P1294, DOI 10.1038/sj.gt.3302567; Loser K, 2004, EUR J IMMUNOL, V34, P2022, DOI 10.1002/eji.200324785; Loser K, 2006, J INVEST DERMATOL, V126, P1307, DOI 10.1038/sj.jid.5700185; Mahnke K, 2003, BLOOD, V101, P4862, DOI 10.1182/blood-2002-10-3229; Malek TR, 2002, IMMUNITY, V17, P167, DOI 10.1016/S1074-7613(02)00367-9; Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615; Papiernik M, 1998, INT IMMUNOL, V10, P371, DOI 10.1093/intimm/10.4.371; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Salomon B, 2001, J EXP MED, V194, P677, DOI 10.1084/jem.194.5.677; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; Schwarz A, 2004, J IMMUNOL, V172, P1036, DOI 10.4049/jimmunol.172.2.1036; Setoguchi R, 2005, J EXP MED, V201, P723, DOI 10.1084/jem.20041982; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1084/jem.20030422	46	307	324	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2006	12	12					1372	1379		10.1038/nm1518	http://dx.doi.org/10.1038/nm1518			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17143276				2022-12-25	WOS:000242618200017
J	Caulfield, T; Cook-Deegan, RM; Kieff, FS; Walsh, JP				Caulfield, Timothy; Cook-Deegan, Robert M.; Kieff, F. Scott; Walsh, John P.			Evidence and anecdotes: an analysis of human gene patenting controversies	NATURE BIOTECHNOLOGY			English	Editorial Material							INTELLECTUAL PROPERTY; DNA PATENTS; SCIENCE; ECONOMICS; CONFLICTS; SECRECY; LAW		Univ Alberta, Hlth Law Inst, Edmonton, AB T6G 2M7, Canada; Duke Univ, Sch Med, Durham, NC USA; IGSP, Ctr Genome Eth Law & Policy, Sanford Inst Publ Policy, Durham, NC USA; Stanford Univ, Hoover Inst, Stanford, CA 94305 USA; Univ Washington, Sch Law, Stanford, CA USA; Georgia Inst Technol, Sch Publ Policy, Atlanta, GA 30332 USA	University of Alberta; Duke University; Stanford University; University System of Georgia; Georgia Institute of Technology	Caulfield, T (corresponding author), Univ Alberta, Hlth Law Inst, Edmonton, AB T6G 2M7, Canada.	tcaulfld@law.ualberta.ca		Cook-Deegan, Robert/0000-0002-8251-4237	NHGRI NIH HHS [P50 HG003391, P50 HG003391-030001] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG003391] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Agrawal A, 2002, MANAGE SCI, V48, P44, DOI 10.1287/mnsc.48.1.44.14279; *AUSTR GOV ADV COM, 2005, PAT EXPT US; *AUSTR LAW REF COM, 2003, 99 AUSTR LAW REV; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Benzie R., 2001, NATL POST A, VA15; Blumenthal D, 2006, ACAD MED, V81, P137, DOI 10.1097/00001888-200602000-00008; Campbell EG, 2002, JAMA-J AM MED ASSOC, V287, P473, DOI 10.1001/jama.287.4.473; Canadian Biotechnology Advisory Committee, 2006, HUM GEN MAT INT PROP; Canadian Biotechnology Advisory Committee, 2002, PAT HIGH LIF FORMS R; Canadian Biotechnology Advisory Committee, 2005, HUM GEN MAT MAK CAN; Caulfield T, 2005, COMMUNITY GENET, V8, P223, DOI 10.1159/000087959; CHO M, 1998, AM ASS CLIN CHEM NEW, P47; Cho MK, 2003, J MOL DIAGN, V5, P3, DOI 10.1016/S1525-1578(10)60444-8; Cohen J, 1999, SCIENCE, V285, P26, DOI 10.1126/science.285.5424.26; COHEN W, 1994, U IND RES CTR US; *DAN COUNC ETH, 2004, PAT HUM GEN STEM CEL; DASGUPTA P, 1987, ECON J, V97, P581, DOI 10.2307/2232925; David PA, 2004, J INST THEOR ECON, V160, P9, DOI 10.1628/093245604773861069; Eisenberg RS, 2003, SCIENCE, V299, P1018, DOI 10.1126/science.1081790; Federal Trade Commission, 2003, PROM INN PROP BAL CO; Grimm D, 2006, SCIENCE, V312, P1862, DOI 10.1126/science.312.5782.1862; Grushcow JM, 2004, J LEGAL STUD, V33, P59, DOI 10.1086/381288; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Jensen K, 2005, SCIENCE, V310, P239, DOI 10.1126/science.1120014; Kevles D J, 2001, Brooklyn Law Rev, V67, P233; Kieff FS, 2001, NORTHWEST U LAW REV, V95, P691; MERGES RP, 1990, COLUMBIA LAW REV, V90, P839, DOI 10.2307/1122920; Merz JF, 2002, NATURE, V415, P577, DOI 10.1038/415577a; NAGAOKA S, 2006, OECD C RES U PAT INV; *NAT AC SCI, 2005, REAP BEN GEN PROT RE; *NAT RES COUNC COM, 2005, REAP BEN GEN PROT RE; NAT'L ACAD. OF SCI, 2004, PAT SYST 21 CENT; Nelson RR, 2004, RES POLICY, V33, P455, DOI 10.1016/j.respol.2003.09.008; NICOL D, 2003, 6 CTR LAW GEN; *NUFF COUNC BIOET, 2002, ETH PAT DNA DISC PAP; *ONT MIN HLTH, 2002, GEN TEST GEN PAT CHA; Organisation for Economic Co-operation and Development, 2002, GEN INV INT PROP RIG; Pressman L, 2006, NAT BIOTECHNOL, V24, P31, DOI 10.1038/nbt0106-31; Public Health Genetics Unit, 2003, INT PROP RIGHTS GEN; Ravetz J.R., 1973, SCI KNOWLEDGE ITS SO; Resnik DB, 2001, J LAW MED ETHICS, V29, P152, DOI 10.1111/j.1748-720X.2001.tb00335.x; ROHRBAUGH MI, 2005, FED REGISTER, V70, P18413; SCOTCHMER S, 1991, J ECON PERSPECT, V5, P29, DOI 10.1257/jep.5.1.29; STERN S, 2005, NBER; STRAUS J, 2002, BMBF OECD WORKSH GEN; The Royal Society, 2003, KEEP SCI OP EFF INT; VANOVERWALLE G, 2006, CHIZAIKEN FORUM, V64, P42; Vogeli C, 2006, ACAD MED, V81, P128, DOI 10.1097/00001888-200602000-00007; Walsh J. P., 2003, PATENTS KNOWLEDGE BA; Walsh JP, 2005, SCIENCE, V309, P2002, DOI 10.1126/science.1115813; Walsh JP, 2003, NATURE, V422, P801, DOI 10.1038/422801c; Walsh JP, 2003, SCIENCE, V299, P1021, DOI 10.1126/science.299.5609.1021; *WHO, 2005, GEN GEN PAT DNA REV; WHO, 2006, PUBL HLTH INN INT PR; Williams-Jones Bryn, 2002, Health Law J, V10, P123	55	95	97	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2006	24	9					1091	1094		10.1038/nbt0906-1091	http://dx.doi.org/10.1038/nbt0906-1091			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biotechnology & Applied Microbiology	083YK	16964215	Green Accepted			2022-12-25	WOS:000240495200024
J	Gorr, IH; Reis, A; Boos, D; Wuhr, M; Madgwick, S; Jones, KT; Stemmann, O				Gorr, Ingo H.; Reis, Alexandra; Boos, Dominik; Wuehr, Martin; Madgwick, Suzanne; Jones, Keith T.; Stemmann, Olaf			Essential CDK1-inhibitory role for separase during meiosis I in vertebrate oocytes	NATURE CELL BIOLOGY			English	Article							MOUSE EGGS; XENOPUS OOCYTES; METAPHASE; MATURATION; INHIBITION; ANAPHASE; SECURIN; COHESIN; ARREST; CDC14	Separase not only triggers anaphase of meiosis I by proteolytic cleavage of cohesin on chromosome arms, but in vitro vertebrate separase also acts as a direct inhibitor of cyclin-dependent kinase 1 (Cdk1) on liberation from the inhibitory protein, securin. Blocking separase-Cdk1 complex formation by microinjection of anti-separase antibodies prevents polarbody extrusion in vertebrate oocytes. Importantly, proper meiotic maturation is rescued by chemical inhibition of Cdk1 or expression of Cdk1-binding separase fragments lacking cohesin-cleaving activity.	Univ Newcastle Upon Tyne, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Newcastle University - UK; Max Planck Society	Jones, KT (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	k.t.jones@newcastle.ac.uk; stemann@biochem.mpg.de	Holt, Janet E/B-2415-2013; Wühr, Martin/A-2447-2009; Jones, Keith/C-9821-2013; Jones, Keith/AAA-3479-2021	Wühr, Martin/0000-0002-0244-8947; Jones, Keith/0000-0002-0294-0851; Jones, Keith/0000-0002-0294-0851; Boos, Dominik/0000-0003-0018-4375; Stemmann, Olaf/0000-0003-3044-2515	Wellcome Trust [075744] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Buonomo SBC, 2003, DEV CELL, V4, P727, DOI 10.1016/S1534-5807(03)00129-1; DONAHUE RP, 1968, J EXP ZOOL, V169, P237, DOI 10.1002/jez.1401690210; Fan HY, 2006, CELL CYCLE, V5, P198, DOI 10.4161/cc.5.2.2321; Gorr IH, 2005, MOL CELL, V19, P135, DOI 10.1016/j.molcel.2005.05.022; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; HAMPL A, 1995, DEVELOPMENT, V121, P925; Huang XX, 2005, MOL BIOL CELL, V16, P4725, DOI 10.1091/mbc.E05-03-0190; Ivanov D, 2005, CELL, V122, P849, DOI 10.1016/j.cell.2005.07.018; Madgwick S, 2004, DEV BIOL, V275, P68, DOI 10.1016/j.ydbio.2004.07.024; Marston AL, 2003, DEV CELL, V4, P711, DOI 10.1016/S1534-5807(03)00130-8; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nixon VL, 2002, CURR BIOL, V12, P746, DOI 10.1016/S0960-9822(02)00811-4; OHSUMI K, 1994, J CELL SCI, V107, P3005; SORENSEN RA, 1976, DEV BIOL, V50, P531, DOI 10.1016/0012-1606(76)90172-X; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; TARKOWSKI AK, 1966, CYTOGENETICS, V5, P394, DOI 10.1159/000129914; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6	17	48	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					1035	U120		10.1038/ncb1467	http://dx.doi.org/10.1038/ncb1467			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16906143	Green Accepted			2022-12-25	WOS:000240241700022
J	Motegi, F; Sugimoto, A				Motegi, Fumio; Sugimoto, Asako			Sequential functioning of the ECT-2 RhoGEF, RHO-1 and CDC-42 establishes cell polarity in Caenorhabditis elegans embryos	NATURE CELL BIOLOGY			English	Article							ANTERIOR-POSTERIOR POLARITY; C-ELEGANS; CENTROSOME MATURATION; PAR PROTEINS; CYTOKINESIS; LOCALIZATION; MYOSIN; POLARIZATION; MAINTENANCE; COMPLEX	During development, the establishment of cell polarity is important for cells to undergo asymmetric cell divisions that give rise to diverse cell types. In C. elegans embryos, cues from the centrosome trigger the cortical flow of an actomyosin network, leading to the formation of anterior-posterior polarity(1). However, its precise mechanism is poorly understood. Here, we show that small GTPases have sequential and crucial functions in this process. ECT-2, a potential guanine nucleotide-exchange factor (GEF)(2) for RHO-1, was uniformly distributed at the cortex before polarization, but was excluded from the posterior cortex by the polarity cue from the centrosomes. This local exclusion of ECT-2 led to an asymmetric RHO-1 distribution, which generated a cortical flow of the actomyosin that translocated PAR proteins(3) and CDC-42 (refs 4, 5) to the anterior cortex. Polarized CDC-42 was, in turn, involved in maintaining the established anterior-cortical domains. Our results suggest that a local change in the function of ECT-2 and RHO-1 links the centrosomal polarity cue with the polarization of the cell cortex.	RIKEN, Ctr Dev Biol, Lab Dev Genom, Chuo Ku, Kobe, Hyogo 6500047, Japan	RIKEN	Sugimoto, A (corresponding author), RIKEN, Ctr Dev Biol, Lab Dev Genom, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	sugimoto@cdb.riken.jp	Sugimoto, Asako/U-3707-2019; Sugimoto, Asako/I-7239-2015	Sugimoto, Asako/0000-0001-6001-4293; Sugimoto, Asako/0000-0001-6001-4293				Audhya A, 2005, J CELL BIOL, V171, P267, DOI 10.1083/jcb.200506124; Cowan CR, 2004, NATURE, V431, P92, DOI 10.1038/nature02825; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Cuenca AA, 2003, DEVELOPMENT, V130, P1255, DOI 10.1242/dev.00284; Dechant R, 2003, DEV CELL, V4, P333, DOI 10.1016/S1534-5807(03)00057-1; EDGER LG, 1995, METHOD CELL BIOL, V48, P303; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Gotta M, 2001, CURR BIOL, V11, P482, DOI 10.1016/S0960-9822(01)00142-7; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamill DR, 2002, DEV CELL, V3, P673, DOI 10.1016/S1534-5807(02)00327-1; HILL DP, 1988, DEV BIOL, V125, P75, DOI 10.1016/0012-1606(88)90060-7; HIRD SN, 1993, J CELL BIOL, V121, P1343, DOI 10.1083/jcb.121.6.1343; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kay AJ, 2001, CURR BIOL, V11, P474, DOI 10.1016/S0960-9822(01)00141-5; Kemphues K, 2000, CELL, V101, P345, DOI 10.1016/S0092-8674(00)80844-2; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Morita K, 2005, EMBO REP, V6, P1163, DOI 10.1038/sj.embor.7400533; Motegi F, 2006, DEV CELL, V10, P509, DOI 10.1016/j.devcel.2006.03.001; Munro E, 2004, DEV CELL, V7, P413, DOI 10.1016/j.devcel.2004.08.001; Nance J, 2003, DEVELOPMENT, V130, P5339, DOI 10.1242/dev.00735; Nishimura Y, 2006, J CELL SCI, V119, P104, DOI 10.1242/jcs.02737; Praitis V, 2001, GENETICS, V157, P1217; Severson AF, 2003, J CELL BIOL, V161, P21, DOI 10.1083/jcb.200210171; Shelton CA, 1999, J CELL BIOL, V146, P439, DOI 10.1083/jcb.146.2.439; Sumiyoshi E, 2002, J CELL SCI, V115, P1403; Wallenfang MR, 2000, NATURE, V408, P89, DOI 10.1038/35040562; Yonemura S, 2004, EXP CELL RES, V295, P300, DOI 10.1016/j.yexcr.2004.01.005; Yuce O, 2005, J CELL BIOL, V170, P571, DOI 10.1083/jcb.200501097	30	125	138	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					978	U80		10.1038/ncb1459	http://dx.doi.org/10.1038/ncb1459			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16921365				2022-12-25	WOS:000240241700014
J	Murata, T; Delprato, A; Ingmundson, A; Toomre, DK; Lambright, DG; Roy, CR				Murata, Takahiro; Delprato, Anna; Ingmundson, Alyssa; Toomre, Derek K.; Lambright, David G.; Roy, Craig R.			The Legionella pneumophila effector protein DrrA is a Rab1 guanine nucleotide-exchange factor	NATURE CELL BIOLOGY			English	Article							GTP-BINDING PROTEINS; INTRACELLULAR GROWTH; TRANSLOCATED SUBSTRATE; PHAGOSOME TRAFFICKING; ENDOPLASMIC-RETICULUM; DOTA PROTEIN; SYSTEM; CELLS; ORGANELLE; FUSION	The intracellular pathogen Legionella pneumophila avoids fusion with lysosomes and subverts membrane transport from the endoplasmic reticulum to create an organelle that supports bacterial replication(1,2). Transport of endoplasmic reticulum-derived vesicles to the Legionella-containing vacuole ( LCV) requires bacterial proteins that are translocated into host cells by a type IV secretion apparatus called Dot/Icm(3-7). Recent observations have revealed recruitment of the host GTPase Rab1 to the LCV by a process requiring the Dot/Icm system(8,9). Here, a visual screen was used to identify L. pneumophila mutants with defects in Rab1 recruitment. One of the factors identified in this screen was DrrA, a new Dot/Icm substrate protein translocated into host cells. We show that DrrA is a potent and highly specific Rab1 guanine nucleotide-exchange factor ( GEF). DrrA can disrupt Rab1-mediated secretory transport to the Golgi apparatus by competing with endogenous exchange factors to recruit and activate Rab1 on plasma membrane-derived organelles. These data establish that intracellular pathogens have the capacity to directly modulate the activation state of a specific member of the Rab family of GTPases and thus further our understanding of the mechanisms used by bacterial pathogens to manipulate host vesicular transport.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA; Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cell Biol, New Haven, CT 06536 USA	Yale University; University of Massachusetts System; University of Massachusetts Worcester; Yale University	Roy, CR (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, 295 Congress Ave, New Haven, CT 06536 USA.	craig.roy@yale.edu		Delprato, Anna/0000-0002-6134-2560; Roy, Craig/0000-0003-4490-440X	NIAID NIH HHS [R01 AI041699, AI41699, R01 AI041699-10] Funding Source: Medline; NIGMS NIH HHS [GM56324] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041699, R37AI041699, R01AI041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056324] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amor JC, 2005, J BIOL CHEM, V280, P1392, DOI 10.1074/jbc.M410820200; BERGER KH, 1993, MOL MICROBIOL, V7, P7, DOI 10.1111/j.1365-2958.1993.tb01092.x; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; Chen J, 2004, SCIENCE, V303, P1358, DOI 10.1126/science.1094226; Coers J, 2000, MOL MICROBIOL, V38, P719, DOI 10.1046/j.1365-2958.2000.02176.x; Conover GM, 2003, MOL MICROBIOL, V48, P305, DOI 10.1046/j.1365-2958.2003.03400.x; Delprato A, 2004, CELL, V118, P607, DOI 10.1016/j.cell.2004.08.009; Derre I, 2005, INFECT IMMUN, V73, P4370, DOI 10.1128/IAI.73.7.4370-4380.2005; Derre I, 2004, INFECT IMMUN, V72, P3048, DOI 10.1128/IAI.72.5.3048-3053.2004; Dorer MS, 2006, PLOS PATHOG, V2, P315, DOI 10.1371/journal.ppat.0020034; HORWITZ MA, 1983, J EXP MED, V158, P2108, DOI 10.1084/jem.158.6.2108; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; Kagan JC, 2004, J EXP MED, V199, P1201, DOI 10.1084/jem.20031706; Kagan JC, 2002, NAT CELL BIOL, V4, P945, DOI 10.1038/ncb883; Luo ZQ, 2004, P NATL ACAD SCI USA, V101, P841, DOI 10.1073/pnas.0304916101; Machner MP, 2006, DEV CELL, V11, P47, DOI 10.1016/j.devcel.2006.05.013; Merriam JJ, 1997, INFECT IMMUN, V65, P2497, DOI 10.1128/IAI.65.6.2497-2501.1997; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; Nagai H, 2005, P NATL ACAD SCI USA, V102, P826, DOI 10.1073/pnas.0406239101; Nagai H, 2002, SCIENCE, V295, P679, DOI 10.1126/science.1067025; Nagai H, 2001, EMBO J, V20, P5962, DOI 10.1093/emboj/20.21.5962; OHMORI H, 1995, J BACTERIOL, V177, P156, DOI 10.1128/jb.177.1.156-165.1995; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Robinson CG, 2006, CELL MICROBIOL, V8, P793, DOI 10.1111/j.1462-5822.2005.00666.x; Roy CR, 1998, MOL MICROBIOL, V28, P663, DOI 10.1046/j.1365-2958.1998.00841.x; Roy CR, 1997, INFECT IMMUN, V65, P571, DOI 10.1128/IAI.65.2.571-578.1997; Rubin EJ, 1999, P NATL ACAD SCI USA, V96, P1645, DOI 10.1073/pnas.96.4.1645; Satoh A, 2003, TRAFFIC, V4, P153, DOI 10.1034/j.1600-0854.2003.00103.x; Segal G, 1998, P NATL ACAD SCI USA, V95, P1669, DOI 10.1073/pnas.95.4.1669; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873; YU H, 1993, GENE, V132, P273, DOI 10.1016/0378-1119(93)90207-J; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; ZHU AX, 1994, BIOCHEM BIOPH RES CO, V205, P1875, DOI 10.1006/bbrc.1994.2889; Zuckman DM, 1999, MOL MICROBIOL, V32, P990, DOI 10.1046/j.1365-2958.1999.01410.x	37	272	284	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					971	U76		10.1038/ncb1463	http://dx.doi.org/10.1038/ncb1463			19	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16906144				2022-12-25	WOS:000240241700013
J	Moutaftsi, M; Peters, B; Pasquetto, V; Tscharke, DC; Sidney, J; Bui, HH; Grey, H; Sette, A				Moutaftsi, Magdalini; Peters, Bjoern; Pasquetto, Valerie; Tscharke, David C.; Sidney, John; Bui, Huynh-Hoa; Grey, Howard; Sette, Alessandro			A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus	NATURE BIOTECHNOLOGY			English	Article							T-CELL RESPONSES; TYPE-1 INFECTION; SMALLPOX; DETERMINANTS; RECOGNIZE; ESCAPE; DESIGN; GENOME; MICE	The value of predictive algorithms for identifying CD8+ T (TCD8+)-cell epitopes has not been adequately tested experimentally. Here we demonstrate that conventional bioinformatic methods predict the vast majority of TCD8+-cell epitopes derived from vaccinia virus WR strain (VACV-WR) in the H-2(b) mouse model. This approach reveals the breadth of T-cell responses to vaccinia, a widely studied murine viral infection model, and may provide a tool for developing comprehensive antigenic maps of any complex pathogen.	La Jolla Inst Allergy & Immunol, San Diego, CA 92109 USA; Queensland Inst Med Res, Div Infect Dis & Immunol, Herston, Qld 4006, Australia	La Jolla Institute for Immunology; QIMR Berghofer Medical Research Institute	Sette, A (corresponding author), La Jolla Inst Allergy & Immunol, 3030 Bunker Hill St,Suite 326, San Diego, CA 92109 USA.	alex@liai.org	Sette, Alessandro/AFO-8916-2022; Tscharke, David/C-9133-2009	Tscharke, David/0000-0001-6825-9172	NIAID NIH HHS [R01-AI-53268] Funding Source: Medline; PHS HHS [HHSN266200400024C] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allen TM, 2005, J VIROL, V79, P12952, DOI 10.1128/JVI.79.20.12952-12960.2005; Bowen DG, 2005, J EXP MED, V201, P1709, DOI 10.1084/jem.20050808; Bray M, 2004, CLIN INFECT DIS, V38, P882, DOI 10.1086/381976; De Groot AS, 2004, METHODS, V34, P425, DOI 10.1016/j.ymeth.2004.06.004; Jing LC, 2005, J IMMUNOL, V175, P7550, DOI 10.4049/jimmunol.175.11.7550; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; Klenerman P, 1998, NATURE, V394, P482, DOI 10.1038/28860; McCraith S, 2000, P NATL ACAD SCI USA, V97, P4879, DOI 10.1073/pnas.080078197; Oseroff C, 2005, P NATL ACAD SCI USA, V102, P13980, DOI 10.1073/pnas.0506768102; Pasquetto V, 2005, J IMMUNOL, V175, P5504, DOI 10.4049/jimmunol.175.8.5504; Smith CL, 2005, J IMMUNOL, V175, P8431, DOI 10.4049/jimmunol.175.12.8431; Terajima M, 2003, J EXP MED, V197, P927, DOI 10.1084/jem.20022222; Tscharke DC, 2005, J EXP MED, V201, P95, DOI 10.1084/jem.20041912; Wallace ME, 1999, J VIROL, V73, P7619, DOI 10.1128/JVI.73.9.7619-7626.1999	14	374	388	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					817	819		10.1038/nbt1215	http://dx.doi.org/10.1038/nbt1215			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16767078	Green Published			2022-12-25	WOS:000239025100031
J	Consonni, C; Humphry, ME; Hartmann, HA; Livaja, M; Durner, J; Westphal, L; Vogel, J; Lipka, V; Kemmerling, B; Schulze-Lefert, P; Somerville, SC; Panstruga, R				Consonni, Chiara; Humphry, Matthew E.; Hartmann, H. Andreas; Livaja, Maren; Durner, Jorg; Westphal, Lore; Vogel, John; Lipka, Volker; Kemmerling, Birgit; Schulze-Lefert, Paul; Somerville, Shauna C.; Panstruga, Ralph			Conserved requirement for a plant host cell protein in powdery mildew pathogenesis	NATURE GENETICS			English	Article							NONHOST RESISTANCE; DISEASE RESISTANCE; MLO RESISTANCE; SALICYLIC-ACID; BARLEY; ARABIDOPSIS; DEFENSE; GENE; SUSCEPTIBILITY; PENETRATION	In the fungal phylum Ascomycota, the ability to cause disease in plants and animals has been gained and lost repeatedly during phylogenesis(1). In monocotyledonous barley, loss-of-function mlo alleles result in effective immunity against the Ascomycete Blumeria graminis f. sp. hordei, the causal agent of powdery mildew disease(2,3). However, mlo-based disease resistance has been considered a barley-specific phenomenon to date. Here, we demonstrate a conserved requirement for MLO proteins in powdery mildew pathogenesis in the dicotyledonous plant species Arabidopsis thaliana. Epistasis analysis showed that mlo resistance in A. thaliana does not involve the signaling molecules ethylene, jasmonic acid or salicylic acid, but requires a syntaxin, glycosyl hydrolase and ABC transporter(4-6). These findings imply that a common host cell entry mechanism of powdery mildew fungi evolved once and at least 200 million years ago, suggesting that within the Erysiphales ( powdery mildews) the ability to cause disease has been a stable trait throughout phylogenesis.	Max Planck Inst Plant Breeding Res, Dept Plant Microbe Interact, D-50829 Cologne, Germany; Carnegie Inst Washington, Dept Plant Biol, Stanford, CA 94305 USA; GSF, Natl Res Ctr Environm & Hlth, Inst Biochem Plant Pathol, Dept Plant Immun, D-85754 Oberschleissheim, Germany; Inst Plant Biochem, Dept Stress & Dev Biol, D-06120 Halle, Germany; USDA, Genom & Gene Discovery Unit, Albany, CA 94710 USA; Univ Tubingen, Dept Plant Biochem, D-72076 Tubingen, Germany	Max Planck Society; Carnegie Institution for Science; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Leibniz Institut fur Pflanzenbiochemie; United States Department of Agriculture (USDA); Eberhard Karls University of Tubingen	Panstruga, R (corresponding author), Max Planck Inst Plant Breeding Res, Dept Plant Microbe Interact, Carl von Linne Weg 10, D-50829 Cologne, Germany.	panstrug@mpiz-koeln.mpg.de	Lipka, Volker/C-5874-2009; Schulze-Lefert, Paul/B-6707-2011; Vogel, John P/B-3176-2009; Schulze-Lefert, Paul/A-7746-2008; Humphry, Matt/E-8072-2010; Panstruga, Ralph/F-3340-2011; Humphry, Matthew/A-8136-2008; Bruening, Stefan/B-8505-2011	Panstruga, Ralph/0000-0002-3756-8957; Vogel, John/0000-0003-1786-2689; Kemmerling, Birgit/0000-0003-1174-0189	PHS HHS [FG32 GN19499-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Berbee ML, 2001, PHYSIOL MOL PLANT P, V59, P165, DOI 10.1006/pmpp.2001.0355; Bhat RA, 2005, P NATL ACAD SCI USA, V102, P3135, DOI 10.1073/pnas.0500012102; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; Collins NC, 2003, NATURE, V425, P973, DOI 10.1038/nature02076; Devoto A, 2003, J MOL EVOL, V56, P77, DOI 10.1007/s00239-002-2382-5; Dong XN, 1998, CURR OPIN PLANT BIOL, V1, P316, DOI 10.1016/1369-5266(88)80053-0; Freialdenhoven A, 1996, PLANT CELL, V8, P5, DOI 10.1105/tpc.8.1.5; Galagan JE, 2005, NATURE, V438, P1105, DOI 10.1038/nature04341; Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1; Jarosch B, 1999, MOL PLANT MICROBE IN, V12, P508, DOI 10.1094/MPMI.1999.12.6.508; JORGENSEN JH, 1992, EUPHYTICA, V63, P141, DOI 10.1007/BF00023919; Kumar J, 2001, PHYTOPATHOLOGY, V91, P127, DOI 10.1094/PHYTO.2001.91.2.127; Lipka V, 2005, SCIENCE, V310, P1180, DOI 10.1126/science.1119409; Mori Yasuhiro, 2000, Mycoscience, V41, P437, DOI 10.1007/BF02461662; Morris K, 2000, PLANT J, V23, P677, DOI 10.1046/j.1365-313x.2000.00836.x; Panstruga R, 2005, PLANT MOL BIOL, V59, P485, DOI 10.1007/s11103-005-0353-0; Panstruga R, 2005, BIOCHEM SOC T, V33, P389, DOI 10.1042/BST0330389; Peterhansel C, 1997, PLANT CELL, V9, P1397, DOI 10.1105/tpc.9.8.1397; Piffanelli P, 2004, NATURE, V430, P887, DOI 10.1038/nature02781; Piffanelli P, 2002, PLANT PHYSIOL, V129, P1076, DOI 10.1104/pp.010954; Stein M, 2006, PLANT CELL, V18, P731, DOI 10.1105/tpc.105.038372; van Wees SCM, 2003, PLANT J, V33, P733, DOI 10.1046/j.1365-313X.2003.01665.x; Vogel J, 2000, P NATL ACAD SCI USA, V97, P1897, DOI 10.1073/pnas.030531997; Vogel JP, 2004, PLANT J, V40, P968, DOI 10.1111/j.1365-313X.2004.02264.x; Vogel JP, 2002, PLANT CELL, V14, P2095, DOI 10.1105/tpc.003509; WOLFE KH, 1989, P NATL ACAD SCI USA, V86, P6201, DOI 10.1073/pnas.86.16.6201; WOLTER M, 1993, MOL GEN GENET, V239, P122, DOI 10.1007/BF00281610; Xu ZW, 2004, PLANT MOL BIOL, V55, P343, DOI 10.1007/s11103-004-0790-1	28	341	380	8	122	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					716	720		10.1038/ng1806	http://dx.doi.org/10.1038/ng1806			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16732289	Green Published			2022-12-25	WOS:000237954800029
J	Kitamura, T; Feng, Y; Kitamura, YI; Chua, SC; Xu, AW; Barsh, GS; Rossetti, L; Accili, D				Kitamura, Tadahiro; Feng, Yun; Kitamura, Yukari Ido; Chua, Streamson C., Jr.; Xu, Allison W.; Barsh, Gregory S.; Rossetti, Luciano; Accili, Domenico			Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR FOXO1; PROOPIOMELANOCORTIN MESSENGER-RNA; CENTRAL-NERVOUS-SYSTEM; BETA-CELL FUNCTION; HYPOTHALAMIC NEURONS; INSULIN SENSITIVITY; GLUCOSE-PRODUCTION; SIGNAL TRANSDUCER; INDUCED ANOREXIA; GENE-EXPRESSION	Leptin controls food intake by regulating the transcription of key neuropeptides in the hypothalamus. The mechanism by which leptin regulates gene expression is unclear, however. Here we show that delivery of adenovirus encoding a constitutively nuclear mutant FoxO1, a transcription factor known to control liver metabolism and pancreatic beta-cell function, to the hypothalamic arcuate nucleus of rodents results in a loss of the ability of leptin to curtail food intake and suppress expression of Agrp. Conversely, a transactivation-deficient FoxO1 mutant prevents induction of Agrp by fasting. We also find that FoxO1 and the transcription factor Stat3 exert opposing actions on the expression of Agrp and Pomc through transcriptional squelching. FoxO1 promotes opposite patterns of coactivator-corepressor exchange at the Pomc and Agrp promoters, resulting in activation of Agrp and inhibition of Pomc. Thus, FoxO1 represents a shared component of pathways integrating food intake and peripheral metabolism.	Columbia Univ, Ctr Med, Dept Med, New York, NY 10032 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Diabet Res & Training Ctr, Bronx, NY 10461 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA	Columbia University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Stanford University; Stanford University	Accili, D (corresponding author), Columbia Univ, Ctr Med, Dept Med, 1150 St Nicholas Ave, New York, NY 10032 USA.	da230@columbia.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, R01DK048321, R01DK057539, P30DK063608, R37DK048321, P30DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG021654] Funding Source: NIH RePORTER; NIA NIH HHS [AG 21654] Funding Source: Medline; NIDDK NIH HHS [DK20541, DK48321, DK63608, DK57539] Funding Source: Medline; PHS HHS [AK45024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Barsh GS, 2002, NAT REV GENET, V3, P589, DOI [10.1038/nrn902, 10.1038/nrg862]; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bousquet C, 2000, J CLIN INVEST, V106, P1417, DOI 10.1172/JCI11182; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Choudhury AI, 2005, J CLIN INVEST, V115, P940; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Figlewicz DP, 2003, BRAIN RES, V964, P107, DOI 10.1016/S0006-8993(02)04087-8; Frescas D, 2005, J BIOL CHEM, V280, P20589, DOI 10.1074/jbc.M412357200; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Gropp E, 2005, NAT NEUROSCI, V8, P1289, DOI 10.1038/nn1548; HAVRANKOVA J, 1978, NATURE, V272, P827, DOI 10.1038/272827a0; He W, 2006, NAT NEUROSCI, V9, P227, DOI 10.1038/nn1626; Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101; Kaelin CB, 2004, ENDOCRINOLOGY, V145, P5798, DOI 10.1210/en.2004-0956; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; Kitamura YI, 2005, CELL METAB, V2, P153, DOI 10.1016/j.cmet.2005.08.004; Kortylewski M, 2003, J BIOL CHEM, V278, P5242, DOI 10.1074/jbc.M205403200; Lam TKT, 2005, SCIENCE, V309, P943, DOI 10.1126/science.1112085; Luquet S, 2005, SCIENCE, V310, P683, DOI 10.1126/science.1115524; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Mizuno TM, 1998, DIABETES, V47, P294, DOI 10.2337/diabetes.47.2.294; Morton GJ, 2005, CELL METAB, V2, P411, DOI 10.1016/j.cmet.2005.10.009; Munzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Obici S, 2002, NAT NEUROSCI, V5, P566, DOI 10.1038/nn861; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Pocai A, 2005, NATURE, V434, P1026, DOI 10.1038/nature03439; Schwartz MW, 2003, DIABETES, V52, P232, DOI 10.2337/diabetes.52.2.232; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Schwartz MW, 1997, DIABETES, V46, P2119, DOI 10.2337/diabetes.46.12.2119; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; Xu AW, 2005, J CLIN INVEST, V115, P951, DOI 10.1172/JCI200524301	40	329	345	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					534	540		10.1038/nm1392	http://dx.doi.org/10.1038/nm1392			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604086				2022-12-25	WOS:000238149100037
J	Lai, LX; Kang, JX; Li, RF; Wang, JD; Witt, WT; Yong, HY; Hao, YH; Wax, DM; Murphy, CN; Rieke, A; Samuel, M; Linville, ML; Korte, SW; Evans, RW; Starzl, TE; Prather, RS; Dai, YF				Lai, LX; Kang, JX; Li, RF; Wang, JD; Witt, WT; Yong, HY; Hao, YH; Wax, DM; Murphy, CN; Rieke, A; Samuel, M; Linville, ML; Korte, SW; Evans, RW; Starzl, TE; Prather, RS; Dai, YF			Generation of cloned transgenic pigs rich in omega-3 fatty acids	NATURE BIOTECHNOLOGY			English	Article								Meat products are generally low in omega-3 (n-3) fatty acids, which are beneficial to human health. We describe the generation of cloned pigs that express a humanized Caenorhabditis elegans gene, fat-1, encoding an n-3 fatty acid desaturase. The hfat-1 transgenic pigs produce high levels of n-3 fatty acids from n-6 analogs, and their tissues have a significantly reduced ratio of n-6/n-3 fatty acids (P < 0.001).	Univ Pittsburgh, Dept Surg, Thomas Starzl Transplantat Inst, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Epidemiol, GSPH, Pittsburgh, PA 15261 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA; Univ Missouri, Div Anim Sci, Columbia, MO 65211 USA; Univ Missouri, Natl Swine Resource & Res Ctr, Columbia, MO 65211 USA; Univ Missouri, Off Anim Resources, Columbia, MO 65211 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Dai, YF (corresponding author), Univ Pittsburgh, Dept Surg, Thomas Starzl Transplantat Inst, Pittsburgh, PA 15261 USA.	pratherr@missouri.edu; daiy@upmc.edu	Prather, Randall S/B-4528-2012; Lai, Liangxue/H-4545-2011	Dai, Yifan/0000-0003-2872-8442; Prather, Randall/0000-0002-6012-4035	NCI NIH HHS [CA79553] Funding Source: Medline; NCRR NIH HHS [R01 RR013438, U42 RR018877] Funding Source: Medline; NIDDK NIH HHS [P30 DK040561, P30 DK040561-11, R01 DK064207, R01DK64207, R01 DK064207-01] Funding Source: Medline; NIH HHS [T32 OD011126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079553] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR013438, U42RR018877] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040561, R01DK064207] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [T32OD011126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Dai YF, 2002, NAT BIOTECHNOL, V20, P251, DOI 10.1038/nbt0302-251; Howe PRC, 1998, WORLD REV NUTR DIET, V83, P132; Kang JX, 2004, NATURE, V427, P504, DOI 10.1038/427504a; Lai LX, 2002, SCIENCE, V295, P1089, DOI 10.1126/science.1068228; Simopoulos AP, 2003, WORLD REV NUTR DIET, V92, P1; SIMOPOULOS AP, 1998, WORLD REV NUTR DIET, V83; Spychalla JP, 1997, P NATL ACAD SCI USA, V94, P1142, DOI 10.1073/pnas.94.4.1142	7	244	320	0	63	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0733-222X	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					435	436		10.1038/nbt1198	http://dx.doi.org/10.1038/nbt1198			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16565727	Green Accepted			2022-12-25	WOS:000236766300026
J	Fischer, J; Lefevre, C; Morava, E; Mussini, JM; Laforet, P; Negre-Salvayre, A; Lathrop, M; Salvayre, R				Fischer, Judith; Lefevre, Caroline; Morava, Eva; Mussini, Jean-Marie; Laforet, Pascal; Negre-Salvayre, Anne; Lathrop, Mark; Salvayre, Robert			The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy	NATURE GENETICS			English	Article							CHANARIN-DORFMAN-SYNDROME; FAMILY-MEMBERS; LIPOLYSIS; METABOLISM; EXPRESSION; PROTEIN; CGI-58	Neutral lipid storage disease comprises a heterogeneous group of autosomal recessive disorders characterized by systemic accumulation of triglycerides in cytoplasmic droplets. Here we report a neutral lipid storage disease subgroup characterized by mild myopathy, absence of ichthyosis and mutations in both alleles of adipose triglyceride lipase (PNPLA2, also known as ATGL). Three of these mutations are predicted to lead to a truncated ATGL protein with an intact patatin domain containing the active site, but with defects in the hydrophobic domain. The block in triglyceride degradation was mimicked by short interfering RNA directed against ATGL. NLSDM is distinct from Chanarin-Dorfman syndrome, which is characterized by neutral lipid storage disease with ichthyosis, mild myopathy and hepatomegaly due to mutations in ABHD5 (also known as CGI-58).	Ctr Natl Genotypage, F-91057 Evry, France; Radboud Univ Nijmegen, Ctr Med, Dept Pediat, NL-6500 HB Nijmegen, Netherlands; Univ Nantes, Ctr Hosp, Dept Internal Med, F-44093 Nantes, France; Grp Hosp Pitie Salpetriere, AP HP, Inst Myol, Ctr Ref Pathol Neuromusc, F-75651 Paris 13, France; CHU Rangueil, IFR 31, F-31432 Toulouse 04, France; Univ Toulouse 3, INSERM, U446, F-31432 Toulouse 04, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Radboud University Nijmegen; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Fischer, J (corresponding author), Ctr Natl Genotypage, F-91057 Evry, France.	fischer@cng.fr; salvayre@toulouse.inserm.fr	Morava, E./L-4529-2015; Fischer, Judith/E-6327-2016	Fischer, Judith/0000-0002-8580-8118; Negre-Salvayre, Anne/0000-0003-2136-5706				CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553; DORFMAN ML, 1974, ARCH DERMATOL, V110, P261, DOI 10.1001/archderm.110.2.261; Gronke S, 2005, CELL METAB, V1, P323, DOI 10.1016/j.cmet.2005.04.003; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; JORDANS GHW, 1953, ACTA MED SCAND, V145, P419; Kurat CF, 2006, J BIOL CHEM, V281, P491, DOI 10.1074/jbc.M508414200; Lake AC, 2005, J LIPID RES, V46, P2477, DOI 10.1194/jlr.M500290-JLR200; Lass A, 2006, CELL METAB, V3, P309, DOI 10.1016/j.cmet.2006.03.005; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; RADOM J, 1987, EUR J BIOCHEM, V164, P703, DOI 10.1111/j.1432-1033.1987.tb11183.x; Smirnova E, 2006, EMBO REP, V7, P106, DOI 10.1038/sj.embor.7400559; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	15	332	353	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2007	39	1					28	30		10.1038/ng1951	http://dx.doi.org/10.1038/ng1951			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17187067				2022-12-25	WOS:000243136500014
J	Gros-Louis, F; Dupre, N; Dion, P; Fox, MA; Laurent, S; Verreault, S; Sanes, JR; Bouchard, JP; Rouleau, GA				Gros-Louis, Francois; Dupre, Nicolas; Dion, Patrick; Fox, Michael A.; Laurent, Sandra; Verreault, Steve; Sanes, Joshua R.; Bouchard, Jean-Pierre; Rouleau, Guy A.			Mutations in SYNE1 lead to a newly discovered form of autosomal recessive cerebellar ataxia	NATURE GENETICS			English	Article							NEUROMUSCULAR-JUNCTION; PROTEIN; GENE; NUCLEI; MSP-300; REPEAT; MUTANT	The past decade has seen great advances in unraveling the biological basis of hereditary ataxias. Molecular studies of spinocerebellar ataxias (SCA) have extended our understanding of dominant ataxias(1). Causative genes have been identified for a few autosomal recessive ataxias: Friedreich's ataxia(2), ataxia with vitamin E deficiency(3), ataxia telangiectasia(4), recessive spastic ataxia of Charlevoix-Saguenay(5) and ataxia with oculomotor apraxia type 1 (refs. 6,7) and type 2 (ref. 8). Nonetheless, genes remain unidentified for most recessive ataxias. Additionally, pure cerebellar ataxias, which represent up to 20% of all ataxias, remain poorly studied with only two causative dominant genes being described: CACNA1A (ref. 9) and SPTBN2 (ref. 10). Here, we report a newly discovered form of recessive ataxia in a French-Canadian cohort and show that SYNE1 mutations are causative in all of our kindreds, making SYNE1 the first identified gene responsible for a recessively inherited pure cerebellar ataxia.	Univ Montreal, Cent Hosp, Ctr Study Brain Dis, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Cent Hosp Univ Ste Justine, Montreal, PQ H2L 4M1, Canada; Univ Quebec, Hop Enfants Jesus, Fac Med, Laval Univ,Dept Neurol Sci, Quebec City, PQ G1J 1Z4, Canada; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Universite de Montreal; Universite de Montreal; Laval University; University of Quebec; Harvard University	Rouleau, GA (corresponding author), Univ Montreal, Cent Hosp, Ctr Study Brain Dis, Montreal, PQ H2L 4M1, Canada.	guy.rouleau@umontreal.ca	Dupre, Nicolas/Y-1828-2019	Fox, Michael/0000-0002-1649-7782				Apel ED, 2000, J BIOL CHEM, V275, P31986, DOI 10.1074/jbc.M004775200; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cottrell JR, 2004, NEURON, V44, P677, DOI 10.1016/j.neuron.2004.10.025; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; Engert JC, 2000, NAT GENET, V24, P120, DOI 10.1038/72769; Grady RM, 2005, P NATL ACAD SCI USA, V102, P4359, DOI 10.1073/pnas.0500711102; HOLMES A, 1908, BRAIN, V30, P466; Ikeda Y, 2006, NAT GENET, V38, P184, DOI 10.1038/ng1728; Ishikawa K, 2005, AM J HUM GENET, V77, P280, DOI 10.1086/432518; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Moreira MC, 2004, NAT GENET, V36, P225, DOI 10.1038/ng1303; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Parkinson NJ, 2001, NAT GENET, V29, P61, DOI 10.1038/ng710; RosenbergHasson Y, 1996, MECH DEVELOP, V60, P83, DOI 10.1016/S0925-4773(96)00602-8; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Schols L, 2004, LANCET NEUROL, V3, P291, DOI 10.1016/S1474-4422(04)00737-9; Starr DA, 2002, SCIENCE, V298, P406, DOI 10.1126/science.1075119; Zhang QP, 2002, GENOMICS, V80, P473, DOI 10.1006/geno.2002.6859; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	22	221	228	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2007	39	1					80	85		10.1038/ng1927	http://dx.doi.org/10.1038/ng1927			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17159980				2022-12-25	WOS:000243136500021
J	Parsa, AT; Waldron, JS; Panner, A; Crane, CA; Parney, IF; Barry, JJ; Cachola, KE; Murray, JC; Tihan, T; Jensen, MC; Mischel, PS; Stokoe, D; Pieper, RO				Parsa, Andrew T.; Waldron, James S.; Panner, Amith; Crane, Courtney A.; Parney, Ian F.; Barry, Jeffrey J.; Cachola, Kristine E.; Murray, Joseph C.; Tihan, Tarik; Jensen, Michael C.; Mischel, Paul S.; Stokoe, David; Pieper, Russell O.			Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma	NATURE MEDICINE			English	Article							RENAL-CELL CARCINOMA; T-CELLS; IMMUNE EVASION; GLIOBLASTOMA-MULTIFORME; POTENTIAL MECHANISM; CANCER; BLOCKADE; IMMUNOTHERAPY; PATHWAY; PD-L1	Cancer immunoresistance and immune escape(1-3) may play important roles in tumor progression and pose obstacles for immunotherapy. Expression of the immunosuppressive protein B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PD-L1), is increased in many pathological conditions, including cancer(4-10). Here we show that expression of the gene encoding B7-H1 increases post transcriptionally in human glioma after loss of phosphatase and tensin homolog (PTEN) and activation of the phosphatidylinositol-3-OH kinase (PI(3) K) pathway. Tumor specimens from individuals with glioblastoma multiforme (GBM) had levels of B7-H1 protein that correlated with PTEN loss, and tumor-specific T cells lysed human glioma targets expressing wild-type PTEN more effectively than those expressing mutant PTEN. These data identify a previously unrecognized mechanism linking loss of the tumor suppressor PTEN with immunoresistance, mediated in part by B7-H1.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Canc Immunotherapeut & Tumor Immunol, Duarte, CA 91010 USA; Univ Calif Los Angeles, David Geffen Sch Med, Henry E Singleton Brain Canc Res Program, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	University of California System; University of California San Francisco; City of Hope; Beckman Research Institute of City of Hope; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Parsa, AT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M-779, San Francisco, CA 94143 USA.	parsaa@neurosurg.ucsf.edu	Murray, Joseph C/J-8916-2014; Tihan, Tarik/AAU-6371-2021	Murray, Joseph C/0000-0001-6159-7814; Tihan, Tarik/0000-0003-4551-2555; Parney, Ian/0000-0002-9702-8047				Blank C, 2006, INT J CANCER, V119, P317, DOI 10.1002/ijc.21775; Blank C, 2005, CANCER IMMUNOL IMMUN, V54, P307, DOI 10.1007/s00262-004-0593-x; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Dong HD, 2003, J CLIN INVEST, V111, P363, DOI 10.1172/JCI200316015; Dong HD, 2003, J MOL MED, V81, P281, DOI 10.1007/s00109-003-0430-2; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hirano F, 2005, CANCER RES, V65, P1089; Iwai Y, 2005, INT IMMUNOL, V17, P133, DOI 10.1093/intimm/dxh194; Kahlon KS, 2004, CANCER RES, V64, P9160, DOI 10.1158/0008-5472.CAN-04-0454; Kaur S, 2005, J INTERF CYTOK RES, V25, P780, DOI 10.1089/jir.2005.25.780; Latchman YE, 2004, P NATL ACAD SCI USA, V101, P10691, DOI 10.1073/pnas.0307252101; Mischel PS, 2004, NAT REV NEUROSCI, V5, P782, DOI 10.1038/nrn1518; Mischel PS, 2003, ONCOGENE, V22, P2361, DOI 10.1038/sj.onc.1206344; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pardoll D, 2004, NAT MED, V10, P887, DOI 10.1038/nm0904-887; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rich JN, 2004, NAT REV DRUG DISCOV, V3, P430, DOI 10.1038/nrd1380; Saudemont A, 2004, BLOOD, V104, P2124, DOI 10.1182/blood-2004-01-0064; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Thompson RH, 2005, UROLOGY, V66, P10, DOI 10.1016/j.urology.2005.06.010; Thompson RH, 2004, P NATL ACAD SCI USA, V101, P17174, DOI 10.1073/pnas.0406351101; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wilmotte R, 2005, NEUROREPORT, V16, P1081, DOI 10.1097/00001756-200507130-00010; Wintterle S, 2003, CANCER RES, V63, P7462	30	1013	1086	5	111	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JAN	2007	13	1					84	88		10.1038/nm1517	http://dx.doi.org/10.1038/nm1517			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17159987				2022-12-25	WOS:000243301800040
J	Kim, H; Rafiuddin-Shah, M; Tu, HC; Jeffers, JR; Zambetti, GP; Hsieh, JJD; Cheng, EHY				Kim, Hyungjin; Rafiuddin-Shah, Mubina; Tu, Ho-Chou; Jeffers, John R.; Zambetti, Gerard P.; Hsieh, James J-D.; Cheng, Emily H-Y.			Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies	NATURE CELL BIOLOGY			English	Article							CYTOCHROME-C RELEASE; BH3-ONLY PROTEINS; FAMILY-MEMBER; X-L; CELL-DEATH; DEFICIENT MICE; BH3 DOMAINS; BAX; PUMA; BIM	'inactivator' BH3-only molecules including BAD, NOXA, BMF, BIK/BLK and HRK/DP5. BAD displaces tBID, BIM or PUMA from BCL-2-BCL-X-L to activate BAX-BAK, whereas NOXA specifically antagonizes MCL-1. Coexpression of BAD and NOXA killed wild-type but not Bax, Bak doubly deficient cells or Puma deficient cells with Bim knockdown, indicating that activator BH3-only molecules function downstream of inactivator BH3-only molecules to activate BAX-BAK. Our data establish a hierarchical regulation of mitochondrion-dependent apoptosis by various BCL-2 subfamilies.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; St Jude Childrens Hosp, Memphis, TN 38105 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); St Jude Children's Research Hospital	Cheng, EHY (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.	echeng@im.wustl.edu	Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007	NCI NIH HHS [CA63230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; BAK, 2000, MOL CELL, V6, P1389; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Coultas L, 2004, MOL CELL BIOL, V24, P1570, DOI 10.1128/MCB.24.4.1570-1581.2004; Cuconati A, 2003, GENE DEV, V17, P2922, DOI 10.1101/gad.1156903; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Horvitz HR, 2003, CHEMBIOCHEM, V4, P697, DOI 10.1002/cbic.200300614; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Imaizumi K, 2004, J NEUROSCI, V24, P3721, DOI 10.1523/JNEUROSCI.5101-03.2004; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Morrison DJ, 2005, CANCER RES, V65, P8174, DOI 10.1158/0008-5472.CAN-04-3657; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	50	674	701	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1348	U19		10.1038/ncb1499	http://dx.doi.org/10.1038/ncb1499			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17115033				2022-12-25	WOS:000242419800010
J	Rhind, N				Rhind, Nicholas			DNA replication timing: random thoughts about origin firing	NATURE CELL BIOLOGY			English	Article							XENOPUS EGG EXTRACTS; DIHYDROFOLATE-REDUCTASE ORIGIN; S-PHASE; FISSION YEAST; ARS ELEMENTS; HUMAN GENOME; ATR; CHROMOSOME; CHROMATIN; LAEVIS	Regions of metazoan genomes replicate at defined times within S phase. This observation suggests that replication origins fire with a defined timing pattern that remains the same from cycle to cycle. However, an alterative model based on the stochastic firing of origins may also explain replication timing. This model assumes varying origin efficiency instead of a strict origin-timing programme. Here, we discuss the evidence for both models.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Rhind, N (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, 364 Plantat St,LRB904, Worcester, MA 01605 USA.	nick.rhind@umassmed.edu		Rhind, Nicholas/0000-0003-1758-7736	NIGMS NIH HHS [R01 GM069957-03, R01 GM069957] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069957] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; DePamphilis ML, 1999, BIOESSAYS, V21, P5, DOI 10.1002/(SICI)1521-1878(199901)21:1<5::AID-BIES2>3.0.CO;2-6; Diaz-Martinez L, 2003, CELL CYCLE, V2, P576, DOI 10.4161/cc.2.6.596; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; DIJKWEL PA, 1995, MOL CELL BIOL, V15, P3023; Dijkwel PA, 2002, MOL CELL BIOL, V22, P3053, DOI 10.1128/MCB.22.9.3053-3065.2002; Donaldson AD, 2005, TRENDS GENET, V21, P444, DOI 10.1016/j.tig.2005.05.012; DROUIN R, 1990, CHROMOSOMA, V99, P273, DOI 10.1007/BF01731703; DUBEY DD, 1994, EMBO J, V13, P3638, DOI 10.1002/j.1460-2075.1994.tb06671.x; Edwards MC, 2002, J BIOL CHEM, V277, P33049, DOI 10.1074/jbc.M204438200; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; Herrick J, 2000, J MOL BIOL, V300, P1133, DOI 10.1006/jmbi.2000.3930; Herrick J, 2002, J MOL BIOL, V320, P741, DOI 10.1016/S0022-2836(02)00522-3; Hyrien O, 2003, BIOESSAYS, V25, P116, DOI 10.1002/bies.10208; JACOB F, 1963, CR HEBD ACAD SCI, V256, P298; Jun S, 2004, CELL CYCLE, V3, P223; LASKEY RA, 1985, J EMBRYOL EXP MORPH, V89, P285; Lucas I, 2000, J MOL BIOL, V296, P769, DOI 10.1006/jmbi.2000.3500; MacAlpine DM, 2004, GENE DEV, V18, P3094, DOI 10.1101/gad.1246404; Marheineke K, 2004, J BIOL CHEM, V279, P28071, DOI 10.1074/jbc.M401574200; Marheineke K, 2001, J BIOL CHEM, V276, P17092, DOI 10.1074/jbc.M100271200; Miao H, 2003, J BIOL CHEM, V278, P4295, DOI 10.1074/jbc.M204264200; NEWLON CS, 1991, GENETICS, V129, P343; Patel PK, 2006, MOL BIOL CELL, V17, P308, DOI 10.1091/mbc.E05-07-0657; Raghuraman MK, 2001, SCIENCE, V294, P115, DOI 10.1126/science.294.5540.115; Sadoni N, 2004, J CELL SCI, V117, P5353, DOI 10.1242/jcs.01412; Shechter D, 2005, CELL CYCLE, V4, P235; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sorensen CS, 2004, CELL CYCLE, V3, P941; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; TALJANIDISZ J, 1989, MOL CELL BIOL, V9, P2881, DOI 10.1128/MCB.9.7.2881; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Woodfine K, 2005, CELL CYCLE, V4, P172, DOI 10.4161/cc.4.1.1350; Woodfine K, 2004, HUM MOL GENET, V13, P191, DOI 10.1093/hmg/ddh016	40	91	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1313	1316		10.1038/ncb1206-1313	http://dx.doi.org/10.1038/ncb1206-1313			4	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17139278	Green Accepted			2022-12-25	WOS:000242419800002
J	Krause, A; Ramakumar, A; Bartels, D; Battistoni, F; Bekel, T; Boch, J; Bohm, M; Friedrich, F; Hurek, T; Krause, L; Linke, B; McHardy, AC; Sarkar, A; Schneiker, S; Syed, AA; Thauer, R; Vorholter, FJ; Weidner, S; Puhler, A; Reinhold-Hurek, B; Kaiser, O; Goesmann, A				Krause, Andrea; Ramakumar, Adarsh; Bartels, Daniela; Battistoni, Federico; Bekel, Thomas; Boch, Jens; Boehm, Melanie; Friedrich, Frauke; Hurek, Thomas; Krause, Lutz; Linke, Burkhard; McHardy, Alice C.; Sarkar, Abhijit; Schneiker, Susanne; Syed, Arshad Ali; Thauer, Rudolf; Vorhoelter, Frank-Joerg; Weidner, Stefan; Puehler, Alfred; Reinhold-Hurek, Barbara; Kaiser, Olaf; Goesmann, Alexander			Complete genome of the mutualistic, N-2-fixing grass endophyte Azoarcus sp strain BH72	NATURE BIOTECHNOLOGY			English	Article							KALLAR GRASS; PROTEIN SECRETION; DIAZOTROPHIC RODS; IV SECRETION; RICE ROOTS; PLANT; SEQUENCE; COLONIZATION; NITROGEN; BACTERIA	Azoarcus sp. strain BH72, a mutualistic endophyte of rice and other grasses, is of agrobiotechnological interest because it supplies biologically fixed nitrogen to its host and colonizes plants in remarkably high numbers without eliciting disease symptoms. The complete genome sequence is 4,376,040- bp long and contains 3,992 predicted protein- coding sequences. Genome comparison with the Azoarcus- related soil bacterium strain EbN1 revealed a surprisingly low degree of synteny. Coding sequences involved in the synthesis of surface components potentially important for plant- microbe interactions were more closely related to those of plant- associated bacteria. Strain BH72 appears to be 'disarmed' compared to plant pathogens, having only a few enzymes that degrade plant cell walls; it lacks type III and IV secretion systems, related toxins and an N- acyl homoserine lactones - based communication system. The genome contains remarkably few mobile elements, indicating a low rate of recent gene transfer that is presumably due to adaptation to a stable, low- stress microenvironment.	Univ Bremen, Lab Gen Microbiol, D-28334 Bremen, Germany; Univ Bielefeld, CeBiTec, D-33501 Bielefeld, Germany; Univ Halle Wittenberg, Genet Inst, D-06120 Halle, Germany; Univ Bielefeld, Lehrstuhl Genet, D-33501 Bielefeld, Germany; Max Planck Inst Terr Microbiol, D-35043 Marburg, Germany	University of Bremen; University of Bielefeld; Martin Luther University Halle Wittenberg; University of Bielefeld; Max Planck Society	Reinhold-Hurek, B (corresponding author), Univ Bremen, Lab Gen Microbiol, POB 330440, D-28334 Bremen, Germany.	breinhold@uni-bremen.de	McHardy, Alice C/K-9377-2018; McHardy, Alice/ABF-2322-2020; Böhm, Michael/C-3638-2011; Krause, Lutz/G-6283-2013; Krause, Lutz/M-7305-2015	McHardy, Alice C/0000-0003-2370-3430; McHardy, Alice/0000-0003-2370-3430; Krause, Lutz/0000-0003-3806-0845; Krause, Lutz/0000-0003-3806-0845; Puhler, Alfred/0000-0003-4723-2960; Goesmann, Alexander/0000-0002-7086-2568; Krause, Andrea/0000-0002-2411-1077; Battistoni, Federico/0000-0002-5648-1304				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Barac T, 2004, NAT BIOTECHNOL, V22, P583, DOI 10.1038/nbt960; Bartels D, 2005, BIOINFORMATICS, V21, P853, DOI 10.1093/bioinformatics/bti091; Battistoni F, 2005, FEMS MICROBIOL LETT, V249, P233, DOI 10.1016/j.femsle.2005.06.015; Camilli A, 2006, SCIENCE, V311, P1113, DOI 10.1126/science.1121357; Christie PJ, 2004, BBA-MOL CELL RES, V1694, P219, DOI 10.1016/j.bbamcr.2004.02.013; Crosa JH, 2002, MICROBIOL MOL BIOL R, V66, P223, DOI 10.1128/MMBR.66.2.223-249.2002; CROWLEY DE, 1991, PLANT SOIL, V130, P179, DOI 10.1007/BF00011873; Dorr J, 1998, MOL MICROBIOL, V30, P7, DOI 10.1046/j.1365-2958.1998.01010.x; Egener T, 1999, MOL PLANT MICROBE IN, V12, P813, DOI 10.1094/MPMI.1999.12.9.813; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Filloux A, 2004, BBA-MOL CELL RES, V1694, P163, DOI 10.1016/j.bbamcr.2004.05.003; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401; He SY, 2004, BBA-MOL CELL RES, V1694, P181, DOI 10.1016/j.bbamcr.2004.03.011; Hubber A, 2004, MOL MICROBIOL, V54, P561, DOI 10.1111/j.1365-2958.2004.04292.x; Hurek T, 2003, J BIOTECHNOL, V106, P169, DOI 10.1016/j.jbiotec.2003.07.010; Hurek T, 2002, MOL PLANT MICROBE IN, V15, P233, DOI 10.1094/MPMI.2002.15.3.233; HUREK T, 1987, APPL ENVIRON MICROB, V53, P163, DOI 10.1128/AEM.53.1.163-169.1987; HUREK T, 1994, J BACTERIOL, V176, P1913, DOI 10.1128/jb.176.7.1913-1923.1994; James EK, 1998, CRIT REV PLANT SCI, V17, P77, DOI 10.1016/S0735-2689(98)00357-8; Kaiser O, 2003, J BIOTECHNOL, V106, P121, DOI 10.1016/j.jbiotec.2003.08.008; Katzen F, 1998, J BACTERIOL, V180, P1607, DOI 10.1128/JB.180.7.1607-1617.1998; Koebnik R, 2005, TRENDS MICROBIOL, V13, P343, DOI 10.1016/j.tim.2005.06.005; Krause A, 2002, MOL PLANT MICROBE IN, V15, P1228, DOI 10.1094/MPMI.2002.15.12.1228; McHardy AC, 2004, BIOINFORMATICS, V20, P1622, DOI 10.1093/bioinformatics/bth137; Meyer F, 2003, NUCLEIC ACIDS RES, V31, P2187, DOI 10.1093/nar/gkg312; Miche L, 2006, MOL PLANT MICROBE IN, V19, P502, DOI 10.1094/MPMI-19-0502; Paulsen IT, 2005, NAT BIOTECHNOL, V23, P873, DOI 10.1038/nbt1110; Rabus R, 2005, ARCH MICROBIOL, V183, P27, DOI 10.1007/s00203-004-0742-9; REINHOLD B, 1986, APPL ENVIRON MICROB, V52, P520, DOI 10.1128/AEM.52.3.520-526.1986; Reinhold-Hurek B, 2006, MOL PLANT MICROBE IN, V19, P181, DOI 10.1094/MPMI-19-0181; Reinhold-Hurek B, 1998, TRENDS MICROBIOL, V6, P139, DOI 10.1016/S0966-842X(98)01229-3; Reinhold-Hurek B., 2005, BERGEYS MANUAL SYSTE, V2, P890; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; REINHOLDHUREK B, 1993, INT J SYST BACTERIOL, V43, P574, DOI 10.1099/00207713-43-3-574; REINHOLDHUREK B, 1993, J BACTERIOL, V175, P7056, DOI 10.1128/jb.175.21.7056-7065.1993; Sevilla M, 2001, MOL PLANT MICROBE IN, V14, P358, DOI 10.1094/MPMI.2001.14.3.358; Thieme F, 2005, J BACTERIOL, V187, P7254, DOI 10.1128/JB.187.21.7254-7266.2005; Tu Q, 2003, FEMS MICROBIOL LETT, V221, P269, DOI 10.1016/S0378-1097(03)00204-0; Yurgel SN, 2004, FEMS MICROBIOL REV, V28, P489, DOI 10.1016/j.femsre.2004.04.002	42	184	568	5	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2006	24	11					1385	1391		10.1038/nbt1243	http://dx.doi.org/10.1038/nbt1243			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	106TP	17057704	hybrid			2022-12-25	WOS:000242124700035
J	Schubert, W; Bonnekoh, B; Pommer, AJ; Philipsen, L; Bockelmann, R; Malykh, Y; Gollnick, H; Friedenberger, M; Bode, M; Dress, AWM				Schubert, Walter; Bonnekoh, Bernd; Pommer, Ansgar J.; Philipsen, Lars; Boeckelmann, Raik; Malykh, Yanina; Gollnick, Harald; Friedenberger, Manuela; Bode, Marcus; Dress, Andreas W. M.			Analyzing proteome topology and function by automated multidimensional fluorescence microscopy	NATURE BIOTECHNOLOGY			English	Article							RESONANCE ENERGY-TRANSFER	Temporal and spatial regulation of proteins contributes to function. We describe a multidimensional microscopic robot technology for high-throughput protein colocalization studies that runs cycles of fluorescence tagging, imaging and bleaching in situ. This technology combines three advances: a fluorescence technique capable of mapping hundreds of different proteins in one tissue section or cell sample; a method selecting the most prominent combinatorial molecular patterns by representing the data as binary vectors; and a system for imaging the distribution of these protein clusters in a so-called toponome map. By analyzing many cell and tissue types, we show that this approach reveals rules of hierarchical protein network organization, in which the frequency distribution of different protein clusters obeys Zipf's law, and state-specific lead proteins appear to control protein network topology and function. The technology may facilitate the development of diagnostics and targeted therapies.	Univ Magdeburg, Inst Med Neurobiol, MPRR Grp, D-39120 Magdeburg, Germany; Univ Magdeburg, Clin Dermatol & Venereol, D-39120 Magdeburg, Germany; SIBS, CAS MPG Partner Inst Computat Biol, PICB, CN-200031 Shanghai, Peoples R China; MPI Math Sci, D-04103 Leipzig, Germany	Otto von Guericke University; Otto von Guericke University; Max Planck Society; Max Planck Society	Schubert, W (corresponding author), Univ Magdeburg, Inst Med Neurobiol, MPRR Grp, D-39120 Magdeburg, Germany.	walter.schubert@medizin.uni-magdeburg.de	Böckelmann, Raik/G-1825-2013	Schubert, Walter/0000-0002-3395-7154				BENNETT GJ, 1988, PAIN, V33, P87, DOI 10.1016/0304-3959(88)90209-6; Bockelmann R, 2001, AM J PATHOL, V158, P367, DOI 10.1016/S0002-9440(10)63978-8; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V117, pS475, DOI 10.1016/j.jaci.2005.10.018; Bray D, 2003, SCIENCE, V301, P1864, DOI 10.1126/science.1089118; Cancho RFI, 2003, P NATL ACAD SCI USA, V100, P788, DOI 10.1073/pnas.0335980100; Chen HX, 1999, BIOORG MED CHEM LETT, V9, P1511; Chen X, 2005, J BIOMED BIOTECHNOL, P87, DOI 10.1155/JBB.2005.87; Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626; Conchello JA, 1996, P SOC PHOTO-OPT INS, V2655, P199, DOI 10.1117/12.237477; Conrad C, 2004, GENOME RES, V14, P1130, DOI 10.1101/gr.2383804; DRESS AWM, 2004, ANN COMB, V8, P475; Ganesan S, 2006, P NATL ACAD SCI USA, V103, P4089, DOI 10.1073/pnas.0509922103; Garry EM, 2003, CURR BIOL, V13, P321, DOI 10.1016/S0960-9822(03)00084-8; Gottlieb AB, 2005, J IMMUNOL, V175, P2721, DOI 10.4049/jimmunol.175.4.2721; Han JDJ, 2004, NATURE, V430, P88, DOI 10.1038/nature02555; Herman Brian, 2004, Methods Mol Biol, V261, P351; Hoyle DC, 2002, BIOINFORMATICS, V18, P576, DOI 10.1093/bioinformatics/18.4.576; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kehlen A, 2003, CANCER RES, V63, P8500; Koonin EV, 2002, NATURE, V420, P218, DOI 10.1038/nature01256; Mohamed HA, 2002, J NEUROSCI RES, V69, P110, DOI 10.1002/jnr.10271; Newman MEJ, 2005, CONTEMP PHYS, V46, P323, DOI 10.1080/00107510500052444; Pacholski ML, 1999, CHEM REV, V99, P2977, DOI 10.1021/cr980137w; Perfetto SP, 2004, NAT REV IMMUNOL, V4, P648, DOI 10.1038/nri1416; Schubert W, 2003, ADV BIOCHEM ENG BIOT, V83, P189; SCHUBERT W, 1999, Patent No. 6638506; SCHUBERT W, 1999, Patent No. 9929731; Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Zipf G. K., 1949, HUMAN BEHAV PRINCIPL	32	317	343	2	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2006	24	10					1270	1278		10.1038/nbt1250	http://dx.doi.org/10.1038/nbt1250			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	093TG	17013374				2022-12-25	WOS:000241191700031
J	Strunker, T; Weyand, I; Bonigk, W; Van, Q; Loogen, A; Brown, JE; Kashikar, N; Hagen, V; Krause, E; Kaupp, UB				Struenker, Timo; Weyand, Ingo; Boenigk, Wolfgang; Van, Qui; Loogen, Astrid; Brown, Joel E.; Kashikar, Nachiket; Hagen, Volker; Krause, Eberhard; Kaupp, U. Benjamin			A K+-selective cGMP-gated ion channel controls chemosensation of sperm	NATURE CELL BIOLOGY			English	Article							CA2+; IDENTIFICATION; CHEMOTAXIS; ACTIVATION; SEQUENCE; CAMP	Eggs attract sperm by chemical factors, a process called chemotaxis. Sperm from marine invertebrates use cGMP signalling to transduce incident chemoattractants into changes in the Ca2+ concentration in the flagellum, which control the swimming behaviour during chemotaxis(1-3). The signalling pathway downstream of the synthesis of cGMP by a guanylyl cyclase is ill-defined. In particular, the ion channels that are involved in Ca2+ influx and their mechanisms of gating are not known(4). Using rapid voltage-sensitive dyes and kinetic techniques, we record the voltage response that is evoked by the chemoattractant in sperm from the sea urchin Arbacia punctulata. We show that the chemoattractant evokes a brief hyperpolarization followed by a sustained depolarization. The hyperpolarization is caused by the opening of K+-selective cyclic-nucleotide-gated ( CNG) channels in the flagellum. Ca2+ influx commences at the onset of recovery from hyperpolarization. The voltage threshold of Ca2+ entry indicates the involvement of low-voltage-activated Ca-v channels. These results establish a model of chemosensory transduction in sperm whereby a cGMP-induced hyperpolarization opens Ca-v channels by a 'recovery-from-inactivation' mechanism and unveil an evolutionary kinship between transduction mechanisms in sperm and photoreceptors.	Forschyngszentrum Julich, Inst Neurowissensch & Biophys, Abt Zellulare Signalverarbeitung, INB1, D-52425 Julich, Germany; Marine Biol Lab, Woods Hole, MA 02543 USA; Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany	Marine Biological Laboratory - Woods Hole	Kaupp, UB (corresponding author), Forschyngszentrum Julich, Inst Neurowissensch & Biophys, Abt Zellulare Signalverarbeitung, INB1, D-52425 Julich, Germany.	a.eckert@fz-juelich.de	Strünker, Timo/AAE-4722-2020	Kashikar, Nachiket/0000-0002-4466-7486				Beltran C, 1996, BIOCHEMISTRY-US, V35, P7591, DOI 10.1021/bi952806v; Bohmer M, 2005, EMBO J, V24, P2741, DOI 10.1038/sj.emboj.7600744; Bullen A, 1999, BIOPHYS J, V76, P2272, DOI 10.1016/S0006-3495(99)77383-2; COOK SP, 1993, J BIOL CHEM, V268, P22408; Darszon A, 2005, INT REV CYTOL, V243, P79, DOI 10.1016/S0074-7696(05)43002-8; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; Darszon A, 2001, DEV BIOL, V240, P1, DOI 10.1006/dbio.2001.0387; FAIN GL, 1981, PROG BIOPHYS MOL BIO, V37, P91, DOI 10.1016/0079-6107(82)90021-9; FLUHLER E, 1985, BIOCHEMISTRY-US, V24, P5749, DOI 10.1021/bi00342a010; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; GOMEZ MD, 1995, NEURON, V15, P607, DOI 10.1016/0896-6273(95)90149-3; Granados-Gonzalez G, 2005, FEBS LETT, V579, P6667, DOI 10.1016/j.febslet.2005.10.035; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; Hagen V, 2001, ANGEW CHEM INT EDIT, V40, P1046; Hagen V, 2005, DYNAMIC STUDIES IN BIOLOGY: PHOTOTRIGGERS, PHOTOSWITCHES AND CAGED BIOMOLECULES, P155, DOI 10.1002/3527605592.ch4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; KAUER JS, 1987, BRAIN RES, V418, P255, DOI 10.1016/0006-8993(87)90093-X; Kaupp UB, 2006, J CELL PHYSIOL, V208, P487, DOI 10.1002/jcp.20669; Kaupp UB, 2003, NAT CELL BIOL, V5, P109, DOI 10.1038/ncb915; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; Matsumoto M, 2003, DEV BIOL, V260, P314, DOI 10.1016/S0012-1606(03)00236-7; Mengerink Kathryn J, 2004, Methods Mol Biol, V253, P141; Nimigean CM, 2004, J GEN PHYSIOL, V124, P203, DOI 10.1085/jgp.200409133; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PONGS O, 1988, EMBO J, V7, P1087, DOI 10.1002/j.1460-2075.1988.tb02917.x; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Solzin J, 2004, J GEN PHYSIOL, V124, P115, DOI 10.1085/jgp.200409030; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; Wood CD, 2005, J CELL BIOL, V169, P725, DOI 10.1083/jcb.200411001; Yu X, 2004, P NATL ACAD SCI USA, V101, P1051, DOI 10.1073/pnas.0305167101	36	95	98	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1149	U198		10.1038/ncb1473	http://dx.doi.org/10.1038/ncb1473			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16964244				2022-12-25	WOS:000241395300020
J	Yuan, J; Fowler, WU; Kimball, E; Lu, WY; Rabinowitz, JD				Yuan, Jie; Fowler, William U.; Kimball, Elizabeth; Lu, Wenyun; Rabinowitz, Joshua D.			Kinetic flux profiling of nitrogen assimilation in Escherichia coli	NATURE CHEMICAL BIOLOGY			English	Article							METABOLIC-FLUX; PERFORMANCE	We present a new method for probing cellular metabolic fluxes that is based on the kinetics of assimilation of isotope-labeled nutrient into a diversity of downstream metabolites. In the case of nitrogen assimilation, half-maximal labeling of most metabolites occurs in 10-300 s. Fluxes measured on the basis of the kinetics of nitrogen assimilation in exponentially growing E. coli agree well with those fluxes predicted to allow optimal biomass production.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA	Princeton University; Princeton University	Rabinowitz, JD (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.	joshr@princeton.edu	Rabinowitz, Joshua/GPP-4019-2022	Rabinowitz, Joshua/0000-0002-1247-4727				CHATHAM JC, 1995, J BIOL CHEM, V270, P7999, DOI 10.1074/jbc.270.14.7999; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Fischer E, 2005, NAT GENET, V37, P636, DOI 10.1038/ng1555; Helling RB, 2002, J BACTERIOL, V184, P1041, DOI 10.1128/jb.184.4.1041-1045.2002; Ibarra RU, 2002, NATURE, V420, P186, DOI 10.1038/nature01149; Ikeda TP, 1996, J MOL BIOL, V259, P589, DOI 10.1006/jmbi.1996.0342; Lu WY, 2006, J AM SOC MASS SPECTR, V17, P37, DOI 10.1016/j.jasms.2005.09.001; Reitzer L, 2003, ANNU REV MICROBIOL, V57, P155, DOI 10.1146/annurev.micro.57.030502.090820; Schilling CH, 1998, P NATL ACAD SCI USA, V95, P4193, DOI 10.1073/pnas.95.8.4193; Segre D, 2002, P NATL ACAD SCI USA, V99, P15112, DOI 10.1073/pnas.232349399; Stephanopoulos G, 1999, METAB ENG, V1, P1, DOI 10.1006/mben.1998.0101; SZYPERSKI T, 1995, EUR J BIOCHEM, V232, P433, DOI 10.1111/j.1432-1033.1995.433zz.x; van Winden WA, 2005, FEMS YEAST RES, V5, P559, DOI 10.1016/j.femsyr.2004.10.007	14	102	104	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2006	2	10					529	530		10.1038/nchembio816	http://dx.doi.org/10.1038/nchembio816			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	095IX	16936719				2022-12-25	WOS:000241302500009
J	Zhang, JQ; Tam, WL; Tong, GQ; Wu, Q; Chan, HY; Soh, BS; Lou, YF; Yang, JC; Ma, YP; Chai, L; Ng, HH; Lufkin, T; Robson, P; Lim, B				Zhang, Jinqiu; Tam, Wai-Leong; Tong, Guo Qing; Wu, Qiang; Chan, Hsiao-Yun; Soh, Boon-Seng; Lou, Yuefei; Yang, Jianchang; Ma, Yupo; Chai, Li; Ng, Huck-Hui; Lufkin, Thomas; Robson, Paul; Lim, Bing			Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1	NATURE CELL BIOLOGY			English	Article							OKIHIRO-SYNDROME; OCT4 EXPRESSION; MURINE HOMOLOG; NANOG; FATE; GENE; DIFFERENTIATION; PROLIFERATION; LINES	Embryonic stem (ES) cells are pluripotent cells that can self-renew or differentiate into many cell types. A unique network of transcription factors and signalling molecules are essential for maintaining this capability. Here, we report that a spalt family member, Sall4, is required for the pluripotency of ES cells. Similarly to Oct4, a reduction in Sall4 levels in mouse ES cells results in respecification, under the appropriate culture conditions, of ES cells to the trophoblast lineage. Sall4 regulates transcription of Pou5f1 which encodes Oct4. Sall4 binds to the highly conserved regulatory region of the Pou5f1 distal enhancer and activates Pou5f1 expression in vivo and in vitro. Microinjection of Sall4 small interfering (si) RNA into mouse zygotes resulted in reduction of Sall4 and Oct4 mRNAs in preimplantation embryos and significant expansion of Cdx2 expression into the inner cell mass. These results demonstrate that Sall4 is a transcriptional activator of Pou5f1 and has a critical role in the maintenance of ES cell pluripotency by modulating Oct4 expression. The data also indicates that Sall4 is important for early embryonic cell-fate decisions.	Genome Inst Singapore, Singapore 138672, Singapore; Natl Univ Singapore, Grad Sch IntegratSci & Engn, Singapore 117456, Singapore; Genome Inst Singapore, Gene Regulat Lab, Singapore 138672, Singapore; Nevada Canc Inst, Div Lab Med, Las Vegas, NV 89135 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); University of California System; University of California San Diego; Harvard University; Brigham & Women's Hospital; Harvard Medical School; National University of Singapore; Harvard University; Harvard Medical School	Lim, B (corresponding author), Genome Inst Singapore, 60 Biopolis St, Singapore 138672, Singapore.	limb1@gis.a-star.edu.sg	Lufkin, Thomas/AAG-7476-2019; Robson, Paul/A-3464-2009; Lufkin, Thomas/B-5352-2011; Ng, Huck Hui/A-1135-2009; Tam, Wai Leong/P-1497-2019	Lufkin, Thomas/0000-0002-7902-4771; Robson, Paul/0000-0002-0191-3958; Lufkin, Thomas/0000-0002-7902-4771; Tam, Wai Leong/0000-0003-2365-5264; Chan, Hsiao Yun/0000-0001-7939-4134; Wu, Qiang/0000-0003-2049-1639; Chai, Li/0000-0003-1937-4750; NG, HUCK HUI/0000-0001-6352-8417	NCI NIH HHS [K08 CA097185] Funding Source: Medline; NCRR NIH HHS [P20 RR016464] Funding Source: Medline; NIAID NIH HHS [AI54973] Funding Source: Medline; NIDDK NIH HHS [K08 DK063220, DK04763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA097185] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK063220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Elstob PR, 2001, DEVELOPMENT, V128, P723; Fuhrmann G, 2001, DEV CELL, V1, P377, DOI 10.1016/S1534-5807(01)00038-7; Gu PL, 2005, MOL CELL BIOL, V25, P3492, DOI 10.1128/MCB.25.9.3492-3505.2005; Hamatani T, 2004, DEV CELL, V6, P117, DOI 10.1016/S1534-5807(03)00373-3; Kohlhase J, 2002, HUM MOL GENET, V11, P2979, DOI 10.1093/hmg/11.23.2979; Kohlhase J, 2002, CYTOGENET GENOME RES, V98, P274, DOI 10.1159/000071048; Koshiba-Takeuchi K, 2006, NAT GENET, V38, P175, DOI 10.1038/ng1707; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; MA Y, 2006, BLOOD, DOI DOI 10.1182/BLOOD-2006-02-001594V1; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Nordhoff V, 2001, MAMM GENOME, V12, P309, DOI 10.1007/s003350010279; Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Rubio CA, 2003, EUR J CLIN INVEST, V33, P406, DOI 10.1046/j.1365-2362.2003.01151.x; Saburi S, 1997, DIFFERENTIATION, V62, P1, DOI 10.1046/j.1432-0436.1997.6210001.x; Sakaki-Yumoto M, 2006, DEVELOPMENT, V133, P3005, DOI 10.1242/dev.02457; Shimada H, 1999, MOL REPROD DEV, V52, P376, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;376::AID-MRD6&gt;3.0.CO;2-U; Strumpf D, 2005, DEVELOPMENT, V132, P2093, DOI 10.1242/dev.01801; Tanaka S, 1998, SCIENCE, V282, P2072, DOI 10.1126/science.282.5396.2072; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yeom YI, 1996, DEVELOPMENT, V122, P881; Yin YJ, 2004, ARTERIOSCL THROM VAS, V24, P691, DOI 10.1161/01.ATV.0000120375.51196.73; Yoshikawa T, 2006, GENE EXPR PATTERNS, V6, P213, DOI 10.1016/j.modgep.2005.06.003	27	416	449	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1114	U125		10.1038/ncb1481	http://dx.doi.org/10.1038/ncb1481			21	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16980957				2022-12-25	WOS:000241395300016
J	Chong, CR; Chen, XC; Shi, LR; O Liu, J; Sullivan, DJ				Chong, Curtis R.; Chen, Xiaochun; Shi, Lirong; O Liu, Jun; Sullivan, David J., Jr.			A clinical drug library screen identifies astemizole as an antimalarial agent	NATURE CHEMICAL BIOLOGY			English	Article							INHIBITION; ANTIHISTAMINE	The high cost and protracted time line of new drug discovery are major roadblocks to creating therapies for neglected diseases. To accelerate drug discovery we created a library of 2,687 existing drugs and screened for inhibitors of the human malaria parasite Plasmodium falciparum. The antihistamine astemizole and its principal human metabolite are promising new inhibitors of chloroquine-sensitive and multidrug-resistant parasites, and they show efficacy in two mouse models of malaria.	Johns Hopkins Univ, Sch Med, Johns Hopkins Clin Compound Screening Initiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Med Sci Training Program, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Malaria Res Inst, W Harry Feinstone Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Sullivan, DJ (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Clin Compound Screening Initiat, Baltimore, MD 21205 USA.	dsulliva@jhsph.edu			NCRR NIH HHS [RR0052] Funding Source: Medline; PHS HHS [R01 A145774] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Cavalli A, 2002, J MED CHEM, V45, P3844, DOI 10.1021/jm0208875; Gottlieb S, 1999, BRIT MED J, V319, P7, DOI 10.1136/bmj.319.7201.7a; JANSSENS F, 1986, DRUG DEVELOP RES, V8, P27, DOI 10.1002/ddr.430080105; JANSSENS MML, 1993, CLIN REV ALLERG, V11, P35; Lindquist M, 1997, LANCET, V349, P1322, DOI 10.1016/S0140-6736(97)26018-6; RICHARDS DM, 1984, DRUGS, V28, P38, DOI 10.2165/00003495-198428010-00003; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; Traebert M, 2004, EUR J PHARMACOL, V484, P41, DOI 10.1016/j.ejphar.2003.11.003; Zhou SF, 2005, CLIN PHARMACOKINET, V44, P279, DOI 10.2165/00003088-200544030-00005	10	209	218	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	AUG	2006	2	8					415	416		10.1038/nchembio806	http://dx.doi.org/10.1038/nchembio806			2	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	065GD	16816845				2022-12-25	WOS:000239146800009
J	Fluhrer, R; Grammer, G; Israel, L; Condron, MM; Haffner, C; Friedmann, E; Bohland, C; Imhof, A; Martoglio, B; Teplow, DB; Haass, C				Fluhrer, Regina; Grammer, Gudula; Israel, Lars; Condron, Margaret M.; Haffner, Christof; Friedmann, Elena; Boehland, Claudia; Imhof, Axel; Martoglio, Bruno; Teplow, David B.; Haass, Christian			A gamma-secretase-like intramembrane cleavage of TNF alpha by the GxGD aspartyl protease SPPL2b	NATURE CELL BIOLOGY			English	Article							SIGNAL PEPTIDE PEPTIDASE; IDENTIFICATION; NICASTRIN; ENZYME	secretase and signal peptide peptidase ( SPP) are unusual GxGD aspartyl proteases, which mediate intramembrane proteolysis. In addition to SPP, a family of SPP-like proteins ( SPPLs) of unknown function has been identified. We demonstrate that SPPL2b utilizes multiple intramembrane cleavages to liberate the intracellular domain of tumor necrosis factor alpha ( TNF alpha) into the cytosol and the carboxy-terminal counterpart into the extracellular space. These findings suggest common principles for regulated intramembrane proteolysis by GxGD aspartyl proteases.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany; Univ Munich, Adolf Butenandt Inst, Prot Anal Unit, D-80336 Munich, Germany; Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90095 USA; ETH Honggerberg, Swiss Fed Inst Technol, CH-8092 Zurich, Switzerland	University of Munich; University of Munich; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Swiss Federal Institutes of Technology Domain; ETH Zurich	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers & Parkinsons Dis Res, D-80336 Munich, Germany.	chaass@med.uni-muenchen.de	Haffner, Christof/AAG-6676-2020; Fluhrer, Regina/F-2642-2011; Imhof, Axel/AAU-5313-2021	Imhof, Axel/0000-0003-2993-8249	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018921] Funding Source: NIH RePORTER; NIA NIH HHS [AG18921] Funding Source: Medline; NINDS NIH HHS [NS38328, NS4414] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Krawitz P, 2005, J BIOL CHEM, V280, P39515, DOI 10.1074/jbc.M501645200; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Nyborg AC, 2004, J BIOL CHEM, V279, P15153, DOI 10.1074/jbc.M309305200; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Schroeter EH, 2003, P NATL ACAD SCI USA, V100, P13075, DOI 10.1073/pnas.1735338100; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Zhao GJ, 2005, J BIOL CHEM, V280, P37689, DOI 10.1074/jbc.M507993200	14	110	116	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					894	U175		10.1038/ncb1450	http://dx.doi.org/10.1038/ncb1450			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16829951	Green Submitted			2022-12-25	WOS:000239423000022
J	Carninci, P; Sandelin, A; Lenhard, B; Katayama, S; Shimokawa, K; Ponjavic, J; Semple, CAM; Taylor, MS; Engstrom, PG; Frith, MC; Forrest, ARR; Alkema, WB; Tan, SL; Plessy, C; Kodzius, R; Ravasi, T; Kasukawa, T; Fukuda, S; Kanamori-Katayama, M; Kitazume, Y; Kawaji, H; Kai, C; Nakamura, M; Konno, H; Nakano, K; Mottagui-Tabar, S; Arner, P; Chesi, A; Gustincich, S; Persichetti, F; Suzuki, H; Grimmond, SM; Wells, CA; Orlando, V; Wahlestedt, C; Liu, ET; Harbers, M; Kawai, J; Bajic, VB; Hume, DA; Hayashizaki, Y				Carninci, Piero; Sandelin, Albin; Lenhard, Boris; Katayama, Shintaro; Shimokawa, Kazuro; Ponjavic, Jasmina; Semple, Colin A. M.; Taylor, Martin S.; Engstrom, Par G.; Frith, Martin C.; Forrest, Alistair R. R.; Alkema, Wynand B.; Tan, Sin Lam; Plessy, Charles; Kodzius, Rimantas; Ravasi, Timothy; Kasukawa, Takeya; Fukuda, Shiro; Kanamori-Katayama, Mutsumi; Kitazume, Yayoi; Kawaji, Hideya; Kai, Chikatoshi; Nakamura, Mari; Konno, Hideaki; Nakano, Kenji; Mottagui-Tabar, Salim; Arner, Peter; Chesi, Alessandra; Gustincich, Stefano; Persichetti, Francesca; Suzuki, Harukazu; Grimmond, Sean M.; Wells, Christine A.; Orlando, Valerio; Wahlestedt, Claes; Liu, Edison T.; Harbers, Matthias; Kawai, Jun; Bajic, Vladimir B.; Hume, David A.; Hayashizaki, Yoshihide			Genome-wide analysis of mammalian promoter architecture and evolution	NATURE GENETICS			English	Article							RNA-POLYMERASE-II; CORE PROMOTER; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; CAP ANALYSIS; ELEMENTS; DATABASE; IDENTIFICATION; CONSTRUCTION; ENCYCLOPEDIA	Mammalian promoters can be separated into two classes, conserved TATA box-enriched promoters, which initiate at a welldefined site, and more plastic, broad and evolvable CpG-rich promoters. We have sequenced tags corresponding to several hundred thousand transcription start sites (TSSs) in the mouse and human genomes, allowing precise analysis of the sequence architecture and evolution of distinct promoter classes. Different tissues and families of genes differentially use distinct types of promoters. Our tagging methods allow quantitative analysis of promoter usage in different tissues and show that differentially regulated alternative TSSs are a common feature in protein-coding genes and commonly generate alternative N termini. Among the TSSs, we identified new start sites associated with the majority of exons and with 3' UTRs. These data permit genome-scale identification of tissue-specific promoters and analysis of the cis-acting elements associated with them.	RIKEN Yokohma Inst, GSC, Genome Explorat Res Grp, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; RIKEN Wako Inst, Discovery Res Inst, Genome Sci Lab, Wako, Saitama 3510198, Japan; Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden; Western Gen Hosp, Human Genome Unit, UK Med Res Council, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Oxford, Oxford OX3 7BN, England; Univ Queensland, Inst Mol Biosci, ARC, Special Res Ctr Funct & Appl Genome, Brisbane, Qld 4072, Australia; Inst Infocomm Res, Knowledge Extract Lab, Singapore 119613, Singapore; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA; NTT Software Corp, Network Serv Solut Business Grp, Broadband Commun Serv Business Unit, Naka Ku, Yokohama, Kanagawa 2318551, Japan; Huddinge Univ Hosp, Karolinska Inst, Dept Med, S-14186 Huddinge, Sweden; ISAS SISSA, Sector Neurobiol, Giovanni Armenise Harvard Fdn Lab, I-34012 Trieste, Italy; Epigenet & Genome Reprogramming Lab, IGB CNR, Dulbecco Telethon Inst, I-80131 Naples, Italy; Genome Inst Singapore, Singapore 138672, Singapore; Kabushiki Kaisha Dnaform, Minato Ku, Tokyo 1080073, Japan; Univ Western Cape, S African Natl Bioinformat Inst, Bellville, South Africa; Yokohama City Univ, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan; Griffith Univ, Eskitis Inst Cell & Mol Therapies, Nathan, Qld 4111, Australia	RIKEN; RIKEN; Karolinska Institutet; University of Edinburgh; University of Oxford; University of Queensland; Agency for Science Technology & Research (A*STAR); A*STAR - Institute for Infocomm Research (I2R); University of California System; University of California San Diego; Karolinska Institutet; International School for Advanced Studies (SISSA); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Fondazione Telethon; Dulbecco Telethon Institute (DTI); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); South African National Biodiversity Institute; University of the Western Cape; Yokohama City University; University of Tsukuba; Griffith University	Hume, DA (corresponding author), RIKEN Yokohma Inst, GSC, Genome Explorat Res Grp, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	d.hume@imb.uq.edu.au; yosihide@gsc.riken.jp	Plessy, Charles/N-5054-2015; Wahlestedt, Claes/A-7039-2009; Chesi, Alessandra/AAT-8248-2020; Forrest, Alistair/A-6597-2008; Hume, David A/C-7695-2013; Carninci, Piero/K-1568-2014; Alkema, Wynand/G-5826-2018; Semple, Colin A M/A-5613-2009; Wells, Christine A/A-5071-2010; Hayashizaki, Yoshihide/N-6590-2015; Katayama, Shintaro/F-2958-2010; K, Rimantas/H-4512-2019; Kawaji, Hideya/N-5116-2015; Kasukawa, Takeya/N-5070-2015; Taylor, Martin S/C-3825-2009; Sandelin, Albin/G-2881-2011; Konno, Hideaki/A-9191-2012; Kawai, Jun/A-6451-2016; Grimmond, Sean M/J-5304-2016; Konno, Hideaki/N-4366-2014; Tomic, Nevena/AAA-2135-2021; Suzuki, Harukazu/N-9553-2015; Ravasi, Timothy/B-8777-2008; Liu, Edison/C-4141-2008; Grimmond, Sean/K-3246-2019; Bajic, Vladimir/D-2810-2009; Chesi, Alessandra/N-7693-2017	Plessy, Charles/0000-0001-7410-6295; Forrest, Alistair/0000-0003-4543-1675; Carninci, Piero/0000-0001-7202-7243; Alkema, Wynand/0000-0002-5523-9217; Semple, Colin A M/0000-0003-1765-4118; Wells, Christine A/0000-0003-3133-3628; Katayama, Shintaro/0000-0001-7581-5157; K, Rimantas/0000-0001-9417-8894; Kawaji, Hideya/0000-0002-0575-0308; Kasukawa, Takeya/0000-0001-5085-0802; Taylor, Martin S/0000-0001-7656-330X; Sandelin, Albin/0000-0002-7109-7378; Grimmond, Sean M/0000-0002-8102-7998; Konno, Hideaki/0000-0002-8470-4835; Suzuki, Harukazu/0000-0002-8087-0836; Grimmond, Sean/0000-0002-8102-7998; Harbers, Matthias/0000-0002-5613-7220; Engstrom, Par/0000-0001-5265-2121; Arner, Peter/0000-0002-6208-6220; Lenhard, Boris/0000-0002-1114-1509; Persichetti, Francesca/0000-0002-9804-644X; Fukuda, Shiro/0000-0002-0065-662X; Frith, Martin/0000-0003-0998-2859; Ravasi, Timothy/0000-0002-9950-465X; Gustincich, Stefano/0000-0002-2749-2514; Bajic, Vladimir/0000-0001-5435-4750; Hume, David/0000-0002-2615-1478; Chesi, Alessandra/0000-0002-0954-7446	Biotechnology and Biological Sciences Research Council [BB/H531586/1, S17961] Funding Source: Medline; Telethon [TCP00094] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Telethon(Fondazione Telethon)		Bajic VB, 2004, NAT BIOTECHNOL, V22, P1467, DOI 10.1038/nbt1032; Bentley DL, 2005, CURR OPIN CELL BIOL, V17, P251, DOI 10.1016/j.ceb.2005.04.006; Bluthgen N, 2005, NUCLEIC ACIDS RES, V33, P272, DOI 10.1093/nar/gki167; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Brodsky AS, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-r64; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Carninci P, 2003, GENOME RES, V13, P1273, DOI 10.1101/gr.1119703; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Imamura T, 2004, BIOCHEM BIOPH RES CO, V322, P593, DOI 10.1016/j.bbrc.2004.07.159; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; Kadonaga JT, 2002, EXP MOL MED, V34, P259, DOI 10.1038/emm.2002.36; Kapranov P, 2005, GENOME RES, V15, P987, DOI 10.1101/gr.3455305; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Keightley PD, 2003, P NATL ACAD SCI USA, V100, P13402, DOI 10.1073/pnas.2233252100; Kodzius R, 2006, NAT METHODS, V3, P211, DOI 10.1038/nmeth0306-211; Kodzius R, 2004, FEBS LETT, V559, P22, DOI 10.1016/S0014-5793(04)00018-3; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Lenhard Boris, 2003, J Biol, V2, P13, DOI 10.1186/1475-4924-2-13; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Patton J, 2006, GENE, V369, P35, DOI 10.1016/j.gene.2005.10.009; Prescott EM, 2002, P NATL ACAD SCI USA, V99, P8796, DOI 10.1073/pnas.132270899; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; Sandelin A, 2004, J MOL BIOL, V338, P207, DOI 10.1016/j.jmb.2004.02.048; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Schug J, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-4-r33; Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100; Siepel A, 2004, J COMPUT BIOL, V11, P413, DOI 10.1089/1066527041410472; Smale ST, 2003, ANNU REV BIOCHEM, V72, P449, DOI 10.1146/annurev.biochem.72.121801.161520; Suzuki Y, 2001, GENOME RES, V11, P677, DOI 10.1101/gr.GR-1640R; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804; Wu YC, 2005, GENOMICS, V86, P329, DOI 10.1016/j.ygeno.2005.05.011; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441	40	944	978	1	91	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					626	635		10.1038/ng1789	http://dx.doi.org/10.1038/ng1789			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16645617				2022-12-25	WOS:000237954800015
J	Guo, YY; Weller, P; Farrell, E; Cheung, P; Fitch, B; Clark, D; Wu, SY; Wang, JM; Liao, GC; Zhang, ZM; Allard, J; Cheng, J; Nguyen, A; Jiang, S; Shafer, S; Usuka, J; Masjedizadeh, M; Peltz, G				Guo, YY; Weller, P; Farrell, E; Cheung, P; Fitch, B; Clark, D; Wu, SY; Wang, JM; Liao, GC; Zhang, ZM; Allard, J; Cheng, J; Nguyen, A; Jiang, S; Shafer, S; Usuka, J; Masjedizadeh, M; Peltz, G			In silico pharmacogenetics of warfarin metabolism	NATURE BIOTECHNOLOGY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; SOLID-PHASE EXTRACTION; LIQUID-CHROMATOGRAPHY; LIVER-MICROSOMES; VITAMIN-K; IDENTIFICATION; EXPRESSION; ENZYMES; ACID; PHENPROCOUMON	Pharmacogenetic approaches can be instrumental for predicting individual differences in response to a therapeutic intervention. Here we used a recently developed murine haplotype-based computational method to identify a genetic factor regulating the metabolism of warfarin, a commonly prescribed anticoagulant with a narrow therapeutic index and a large variation in individual dosing. After quantification of warfarin and nine of its metabolites in plasma from 13 inbred mouse strains, we correlated strain-specific differences in 7-hydroxywarfarin accumulation with genetic variation within a chromosomal region encoding cytochrome P450 2C (Cyp2c) enzymes. This computational prediction was experimentally confirmed by showing that the rate-limiting step in biotransformation of warfarin to its 7-hydroxylated metabolite was inhibited by tolbutamide, a Cyp2c isoform-specific substrate, and that this transformation was mediated by expressed recombinant Cyp2c29. We show that genetic variants responsible for interindividual pharmacokinetic differences in drug metabolism can be identified by computational genetic analysis in mice.	Roche Palo Alto, Dept Genet & Genom, Palo Alto, CA 94304 USA; Roche Palo Alto, Dept Drug Metab & Pharmacokinet, Palo Alto, CA 94304 USA; Roche Palo Alto, Dept Chem Serv, Palo Alto, CA 94304 USA; Stanford Univ, Dept Anesthesiol, Stanford, CA 94305 USA	Roche Holding; Roche Holding; Roche Holding; Stanford University	Peltz, G (corresponding author), Roche Palo Alto, Dept Genet & Genom, S3-1,3431 Hillview Ave, Palo Alto, CA 94304 USA.	gary.peltz@roche.com	Shafer, Steven/AAH-4514-2021	Shafer, Steven/0000-0002-0289-7793	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068885] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 R01 GM068885-01A1, R01 GM068885] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTERS JTM, 1995, DRUG METAB DISPOS, V23, P696; Crespi CL, 1999, PHARMACOL THERAPEUT, V84, P121, DOI 10.1016/S0163-7258(99)00028-5; Daly AK, 2003, PHARMACOGENETICS, V13, P247, DOI 10.1097/00008571-200305000-00002; EDELBROEK PM, 1990, J CHROMATOGR-BIOMED, V530, P347, DOI 10.1016/S0378-4347(00)82337-3; Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487; Fitch WL, 2004, DRUG METAB DISPOS, V32, P1482, DOI 10.1124/dmd.104.000471; HALLAK HO, 1993, BRIT J CLIN PHARMACO, V35, P327, DOI 10.1111/j.1365-2125.1993.tb05703.x; JAMES AH, 1992, J CLIN PATHOL, V45, P704, DOI 10.1136/jcp.45.8.704; JANSING RL, 1992, MOL PHARMACOL, V41, P209; Kaminsky LS, 1997, PHARMACOL THERAPEUT, V73, P67, DOI 10.1016/S0163-7258(96)00140-4; Liao GC, 2004, SCIENCE, V306, P690, DOI 10.1126/science.1100636; Luo G, 1998, ARCH BIOCHEM BIOPHYS, V357, P45, DOI 10.1006/abbi.1998.0806; Meyer RP, 2001, BIOCHEM BIOPH RES CO, V285, P32, DOI 10.1006/bbrc.2001.5111; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; OMURA T, 1964, J BIOL CHEM, V239, P2370; Patten CJ, 1996, ARCH BIOCHEM BIOPHYS, V333, P127, DOI 10.1006/abbi.1996.0373; Phillips KA, 2001, JAMA-J AM MED ASSOC, V286, P2270, DOI 10.1001/jama.286.18.2270; RETTIE AE, 1994, PHARMACOGENETICS, V4, P39, DOI 10.1097/00008571-199402000-00005; Rieder MJ, 2005, NEW ENGL J MED, V352, P2285, DOI 10.1056/NEJMoa044503; RILEY RJ, 1993, BIOCHEM PHARMACOL, V45, P1065, DOI 10.1016/0006-2952(93)90251-Q; Rossi DT, 2002, MASS SPECTROMETRY IN DRUG DISCOVERY, P171; Rowland M., 1995, CLIN PHARMACOKINET, P367; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; Suttie J W, 1987, Adv Exp Med Biol, V214, P3; Ufer M, 2004, J CHROMATOGR B, V809, P217, DOI 10.1016/j.jchromb.2004.06.023; Wang CT, 2005, J HEALTH SCI, V51, P70, DOI 10.1248/jhs.51.70; Wang JM, 2005, COMPUTATIONAL GENETICS AND GENOMICS: TOOLS FOR UNDERSTANDING DISEASE, P71, DOI 10.1007/978-1-59259-930-1_4; Wang JM, 2005, TRENDS GENET, V21, P526, DOI 10.1016/j.tig.2005.06.010; Zhang Z, 1995, DRUG METAB DISPOS, V23, P1339; Zhang ZY, 2001, ANAL BIOCHEM, V298, P40, DOI 10.1006/abio.2001.5383	30	51	55	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2006	24	5					531	536		10.1038/nbt1195	http://dx.doi.org/10.1038/nbt1195			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	039TX	16680137	Green Accepted			2022-12-25	WOS:000237331300027
J	Mao, XM; Kikani, CK; Riojas, RA; Langlais, P; Wang, LX; Ramos, FJ; Fang, QC; Christ-Roberts, CY; Hong, JY; Kim, RY; Liu, F; Dong, LQ				Mao, XM; Kikani, CK; Riojas, RA; Langlais, P; Wang, LX; Ramos, FJ; Fang, QC; Christ-Roberts, CY; Hong, JY; Kim, RY; Liu, F; Dong, LQ			APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function	NATURE CELL BIOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; INSULIN-RESISTANCE; GLUT4 TRANSLOCATION; GLUCOSE-UPTAKE; MUSCLE-CELLS; RAB5; FAT; ACRP30/ADIPONECTIN; PHOSPHORYLATION; INHIBITION	Adiponectin, also known as Acrp30, is an adipose tissue-derived hormone with anti-atherogenic, anti-diabetic and insulin sensitizing properties(1-3). Two seven-transmembrane domain-containing proteins, AdipoR1 and AdipoR2, have recently been identified as adiponectin receptors(4), yet signalling events downstream of these receptors remain poorly defined. By using the cytoplasmic domain of AdipoR1 as bait, we screened a yeast two-hybrid cDNA library derived from human fetal brain. This screening led to the identification of a phosphotyrosine binding domain and a pleckstrin homology domain-containing adaptor protein, APPL1 (adaptor protein containing pleckstrin homology domain, phosphotyrosine binding (PTB) domain and leucine zipper motif). APPL1 interacts with adiponectin receptors in mammalian cells and the interaction is stimulated by adiponectin. Overexpression of APPL1 increases, and suppression of APPL1 level reduces, adiponectin signalling and adiponectin-mediated downstream events (such as lipid oxidation, glucose uptake and the membrane translocation of glucose transport 4 (GLUT4)). Adiponectin stimulates the interaction between APPL1 and Rab5 (a small GTPase) interaction, leading to increased GLUT4 membrane translocation. APPL1 also acts as a critical regulator of the crosstalk between adiponectin signalling and insulin signalling pathways. These results demonstrate a key function for APPL1 in adiponectin signalling and provide a molecular mechanism for the insulin sensitizing function of adiponectin.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78229 USA; Shanghai Jiao Tong Univ, Affiliated Hosp 6, Shanghai Diabet Inst, Shanghai 200233, Peoples R China	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Shanghai Jiao Tong University	Dong, LQ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	dongq@uthscsa.edu		Kikani, Chintan/0000-0003-1140-0192	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069930, R01DK052933, F31DK068874] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG021890] Funding Source: NIH RePORTER; NIA NIH HHS [T32 AG021890] Funding Source: Medline; NIDDK NIH HHS [R01 DK52933, F31DK068874, R01 DK69930, R01 DK069930] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arai M, 2004, NUCLEIC ACIDS RES, V32, pW390, DOI 10.1093/nar/gkh380; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Ceddia RB, 2005, DIABETOLOGIA, V48, P132, DOI 10.1007/s00125-004-1609-y; Chen XM, 2001, EMBO REP, V2, P842, DOI 10.1093/embo-reports/kve179; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Hotta K, 2000, ARTERIOSCL THROM VAS, V20, P1595, DOI 10.1161/01.ATV.20.6.1595; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Huang J, 2001, P NATL ACAD SCI USA, V98, P13084, DOI 10.1073/pnas.241368698; Kadowaki T, 2005, ENDOCR REV, V26, P439, DOI 10.1210/er.2005-0005; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Langlais P, 2004, MOL ENDOCRINOL, V18, P350, DOI 10.1210/me.2003-0117; Liu J, 2002, J BIOL CHEM, V277, P26281, DOI 10.1074/jbc.M204679200; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Miaczynska M, 2004, CELL, V116, P445, DOI 10.1016/S0092-8674(04)00117-5; Mitsuuchi Y, 1999, ONCOGENE, V18, P4891, DOI 10.1038/sj.onc.1203080; Nechamen CA, 2004, BIOL REPROD, V71, P629, DOI 10.1095/biolreprod.103.025833; Rother KI, 1998, J BIOL CHEM, V273, P17491, DOI 10.1074/jbc.273.28.17491; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Statnick M A, 2000, Int J Exp Diabetes Res, V1, P81, DOI 10.1155/EDR.2000.81; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tsao TS, 2002, EUR J PHARMACOL, V440, P213, DOI 10.1016/S0014-2999(02)01430-9; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Wong GW, 2004, P NATL ACAD SCI USA, V101, P10302, DOI 10.1073/pnas.0403760101; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984	27	501	546	3	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					516	U165		10.1038/ncb1404	http://dx.doi.org/10.1038/ncb1404			21	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16622416				2022-12-25	WOS:000237299400016
J	Musio, A; Selicorni, A; Focarelli, ML; Gervasini, C; Milani, D; Russo, S; Vezzoni, P; Larizza, L				Musio, A; Selicorni, A; Focarelli, ML; Gervasini, C; Milani, D; Russo, S; Vezzoni, P; Larizza, L			X-linked Cornelia de Lange syndrome owing to SMC1L1 mutations	NATURE GENETICS			English	Article							SISTER-CHROMATID COHESION; NIPPED-B; ROBERTS-SYNDROME; HUMAN HOMOLOG; CUT GENE; DROSOPHILA; PHENOTYPE; PROTEINS; NIPBL; EXPRESSION	Cornelia de Lange syndrome is a multisystem developmental disorder characterized by facial dysmorphisms, upper limb abnormalities, growth delay and cognitive retardation. Mutations in the NIPBL gene, a component of the cohesin complex, account for approximately half of the affected individuals. We report here that mutations in SMC1L1 (also known as SMC1), which encodes a different subunit of the cohesin complex, are responsible for CdLS in three male members of an affected family and in one sporadic case.	CNR, Inst Biomed Technol, Human Genome Dept, I-20090 Segrate, Italy; Univ Milan, Fdn Policlin, Clin Pediat 1, I-20122 Milan, Italy; Univ Milan, San Paolo Sch Med, Div Med Genet, I-20142 Milan, Italy; Ist Auxol Italiano, Mol Genet Lab, I-20095 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Milan; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); IRCCS Istituto Auxologico Italiano	Musio, A (corresponding author), CNR, Inst Biomed Technol, Human Genome Dept, Via Fratelli Cervi,93, I-20090 Segrate, Italy.	antonio.musio@itb.cnr.it	Musio, Antonio/GRO-1712-2022; Vezzoni, Paolo/R-3416-2019; Gervasini, Cristina/A-5728-2014; Milani, Donatella/AAC-8430-2019; Vezzoni, Paolo/K-3197-2018	Gervasini, Cristina/0000-0002-1165-7935; Milani, Donatella/0000-0002-3087-8514; Russo, Silvia/0000-0002-5893-0193; MUSIO, ANTONIO/0000-0001-7701-6543; Vezzoni, Paolo/0000-0002-6382-3923				BROWN CJ, 1995, HUM MOL GENET, V4, P251, DOI 10.1093/hmg/4.2.251; Dorsett D, 2005, DEVELOPMENT, V132, P4743, DOI 10.1242/dev.02064; Egemen A, 2005, GENET COUNSEL, V16, P27; Gillis LA, 2004, AM J HUM GENET, V75, P610, DOI 10.1086/424698; Gruber S, 2003, CELL, V112, P765, DOI 10.1016/S0092-8674(03)00162-4; Krantz ID, 2004, NAT GENET, V36, P631, DOI 10.1038/ng1364; Losada A, 2005, GENE DEV, V19, P1269, DOI 10.1101/gad.1320505; Musio A, 2005, HUM MOL GENET, V14, P525, DOI 10.1093/hmg/ddi049; Rollins RA, 2004, MOL CELL BIOL, V24, P3100, DOI 10.1128/MCB.24.8.3100-3111.2004; Schule B, 2005, AM J HUM GENET, V77, P1117, DOI 10.1086/498695; SELICORNI A, 1993, AM J MED GENET, V47, P977, DOI 10.1002/ajmg.1320470708; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Tonkin ET, 2004, NAT GENET, V36, P636, DOI 10.1038/ng1363; Vega H, 2005, NAT GENET, V37, P468, DOI 10.1038/ng1548	14	330	345	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2006	38	5					528	530		10.1038/ng1779	http://dx.doi.org/10.1038/ng1779			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16604071				2022-12-25	WOS:000237147500013
J	Poland, H				Poland, H			Integrating genomics against infectious disease	NATURE GENETICS			English	Editorial Material							DIAGNOSTICS	The most recent National Academies Keck Futures Initiative Conference, entitled `The Genomics Revolution: Implications for Treatment and Control of Infectious Disease', was held at the Arnold and Mabel Beckman Center in Irvine, California. It provided strategies and opportunities for interdisciplinary collaboration and incentives to innovate.	Univ So Calif, Annenberg Sch Commun, Los Angeles, CA 90089 USA	University of Southern California	Poland, H (corresponding author), Univ So Calif, Annenberg Sch Commun, 3502 Watt Ways, Los Angeles, CA 90089 USA.	hpoland@usc.edu						Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Brenner S, 2000, NAT BIOTECHNOL, V18, P630, DOI 10.1038/76469; Fortina P, 2005, TRENDS BIOTECHNOL, V23, P168, DOI 10.1016/j.tibtech.2005.02.007; Galan JE, 2005, CURR OPIN MICROBIOL, V8, P1, DOI 10.1016/j.mib.2004.12.015; Jain KK, 2005, CLIN CHIM ACTA, V358, P37, DOI 10.1016/j.cccn.2005.03.014; Lagally ET, 2004, ANAL CHEM, V76, P3162, DOI 10.1021/ac035310p; Levene MJ, 2003, SCIENCE, V299, P682, DOI 10.1126/science.1079700; Mabey D, 2004, NAT REV MICROBIOL, V2, P231, DOI 10.1038/nrmicro841; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Nabel GJ, 2005, SCIENCE, V308, P1878, DOI 10.1126/science.1114854; Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325; Shendure J, 2005, SCIENCE, V309, P1728, DOI 10.1126/science.1117389; Ziegler C, 2004, ANAL BIOANAL CHEM, V379, P946, DOI 10.1007/s00216-004-2694-y	13	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2006	38	5					513	514		10.1038/ng0506-513	http://dx.doi.org/10.1038/ng0506-513			2	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16642016				2022-12-25	WOS:000237147500008
J	Garcia-Rodriguez, C; Levy, R; Arndt, JW; Forsyth, CM; Razai, A; Lou, JL; Geren, I; Stevens, RC; Marks, JD				Garcia-Rodriguez, Consuelo; Levy, Raphael; Arndt, Joseph W.; Forsyth, Charles M.; Razai, Ali; Lou, Jianlong; Geren, Isin; Stevens, Raymond C.; Marks, James D.			Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin	NATURE BIOTECHNOLOGY			English	Article							YEAST SURFACE DISPLAY; STRUCTURAL REPERTOIRE; AFFINITY MATURATION; BINDING; SPECIFICITY; SEQUENCE; MUTAGENESIS; REGIONS; IMMUNE; TOXIN	Broadening antibody specificity without compromising affinity should facilitate detection and neutralization of toxin and viral subtypes. We used yeast display and a co-selection strategy to increase cross-reactivity of a single chain (sc) Fv antibody to botulinum neurotoxin type A (BoNT/A). Starting with a scFv that binds the BoNT/A1 subtype with high affinity (136 pM) and the BoNT/A2 subtype with low affinity (109 nM), we increased its affinity for BoNT/A2 1,250-fold, to 87 pM, while maintaining high-affinity binding to BoNT/A1 (115 pM). To find the molecular basis for improved cross-reactivity, we determined the X-ray co-crystal structures of wild-type and cross-reactive antibodies complexed to BoNT/A1 at resolutions up to 2.6 angstrom, and measured the thermodynamic contribution of BoNT/A1 and A2 amino acids to wild-type and cross-reactive antibody binding. The results show how an antibody can be engineered to bind two different antigens despite structural differences in the antigen-antibody interface and may provide a general strategy for tuning antibody specificity and cross-reactivity.	Univ Calif San Francisco, Dept Anesthesia & Pharmaceut Chem, San Francisco Gen Hosp, San Francisco, CA 94110 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Scripps Research Institute	Marks, JD (corresponding author), Univ Calif San Francisco, Dept Anesthesia & Pharmaceut Chem, San Francisco Gen Hosp, Room 3C-38,1001 Potrero Ave, San Francisco, CA 94110 USA.	marks@anesthesia.ucsf.edu	Stevens, Raymond/K-7272-2015; Geren, Isin/AAG-7281-2019; Pacific-Southwest, RCE/B-6155-2009	Stevens, Raymond/0000-0002-4522-8725; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI053389, U01AI056493, U54AI065359] Funding Source: NIH RePORTER; NIAID NIH HHS [U54 AI065359, R21 AI53389-01, U01 AI056493] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amersdorfer P, 2002, VACCINE, V20, P1640, DOI 10.1016/S0264-410X(01)00482-0; [Anonymous], 1998, HDB EP CLIN LAB WORK; Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BETZ AG, 1993, P NATL ACAD SCI USA, V90, P2385, DOI 10.1073/pnas.90.6.2385; BLACK RE, 1980, AM J MED, V69, P567, DOI 10.1016/0002-9343(80)90469-6; Blake RC, 1999, ANAL BIOCHEM, V272, P123, DOI 10.1006/abio.1999.4176; Boder ET, 2000, P NATL ACAD SCI USA, V97, P10701, DOI 10.1073/pnas.170297297; Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553; Bozheyeva G., 1999, FORMER SOVIET BIOL W; Byrne MP, 1998, INFECT IMMUN, V66, P4817, DOI 10.1128/IAI.66.10.4817-4822.1998; CHOTHIA C, 1992, J MOL BIOL, V227, P799, DOI 10.1016/0022-2836(92)90224-8; CLAYTON MA, 1995, INFECT IMMUN, V63, P2738, DOI 10.1128/IAI.63.7.2738-2742.1995; Coleman PF, 2006, EMERG INFECT DIS, V12, P198, DOI 10.3201/eid1203.050038; Cumbers SJ, 2002, NAT BIOTECHNOL, V20, P1129, DOI 10.1038/nbt752; Davis IW, 2004, NUCLEIC ACIDS RES, V32, pW615, DOI 10.1093/nar/gkh398; Drake AW, 2004, ANAL BIOCHEM, V328, P35, DOI 10.1016/j.ab.2003.12.025; Dubreuil O, 2005, J BIOL CHEM, V280, P24880, DOI 10.1074/jbc.M500048200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ewert S, 2004, METHODS, V34, P184, DOI 10.1016/j.ymeth.2004.04.007; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; FRANZ DR, 1993, BOTULINUM AND TETANUS NEUROTOXINS, P473; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; Korpimaki T, 2004, J AGR FOOD CHEM, V52, P40, DOI 10.1021/jf034951i; Krykbaev RA, 2002, PROTEIN SCI, V11, P2899, DOI 10.1110/ps.0223402; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Miyazaki C, 1999, PROTEIN ENG, V12, P407, DOI 10.1093/protein/12.5.407; Nowakowski A, 2002, P NATL ACAD SCI USA, V99, P11346, DOI 10.1073/pnas.172229899; ORRWEAVER TL, 1983, P NATL ACAD SCI-BIOL, V80, P4417, DOI 10.1073/pnas.80.14.4417; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Poul MA, 2000, J MOL BIOL, V301, P1149, DOI 10.1006/jmbi.2000.4026; Razai A, 2005, J MOL BIOL, V351, P158, DOI 10.1016/j.jmb.2005.06.003; Schier R, 1996, GENE, V169, P147, DOI 10.1016/0378-1119(95)00821-7; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Sethi DK, 2006, IMMUNITY, V24, P429, DOI 10.1016/j.immuni.2006.02.010; Smith TJ, 2005, INFECT IMMUN, V73, P5450, DOI 10.1128/IAI.73.9.5450-5457.2005; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOMLINSON IM, 1995, EMBO J, V14, P4628, DOI 10.1002/j.1460-2075.1995.tb00142.x; *US SEC COUNC, 1995, 10 REP EX COMM SPEC; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VanAntwerp JJ, 2000, BIOTECHNOL PROGR, V16, P31, DOI 10.1021/bp990133s; WAGNER SD, 1995, NATURE, V376, P732, DOI 10.1038/376732a0; Werther WA, 1996, J IMMUNOL, V157, P4986; WILLEMS A, 1993, RES MICROBIOL, V144, P547, DOI 10.1016/0923-2508(93)90004-L; WU TT, 1970, J EXP MED, V132, P211, DOI 10.1084/jem.132.2.211; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626	50	135	153	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2007	25	1					107	116		10.1038/nbt1269	http://dx.doi.org/10.1038/nbt1269			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126CY	17173035	Bronze			2022-12-25	WOS:000243491000036
J	Christoffersen, RE				Christoffersen, Ralph E.			Antibiotics - an investment worth making?	NATURE BIOTECHNOLOGY			English	Editorial Material									Morgenthaler Ventures, Boulder, CO 80303 USA		Christoffersen, RE (corresponding author), Morgenthaler Ventures, 4430 Arapahoe Ave,Suite 220, Boulder, CO 80303 USA.	rchris@morgenthaler.com						2006, NAT REV DRUG DISCOVE, V5, P446	1	28	29	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1512	1514		10.1038/nbt1206-1512	http://dx.doi.org/10.1038/nbt1206-1512			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17160052				2022-12-25	WOS:000242795800026
J	Lewis, K; Ausubel, FM				Lewis, Kim; Ausubel, Frederick M.			Prospects for plant-derived antibacterials	NATURE BIOTECHNOLOGY			English	Editorial Material							MULTIDRUG PUMP; ANTIBIOTIC-ACTIVITY; BERBERINE; RESISTANCE; IDENTIFICATION; INHIBITORS; METABOLITES; POTENTIATE; AGENTS		Northeastern Univ, Antimicrobial Discovery Ctr, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Harvard Univ, Dept Genet, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Biol Mol, Boston, MA 02114 USA	Northeastern University; Northeastern University; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Lewis, K (corresponding author), Northeastern Univ, Antimicrobial Discovery Ctr, Boston, MA 02115 USA.	k.lewis@neu.edu; ausubel@molbio.mgh.harvard.edu			NIAID NIH HHS [AI064332, AI059483] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI064332, R21AI059483] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adonizio AL, 2006, J ETHNOPHARMACOL, V105, P427, DOI 10.1016/j.jep.2005.11.025; AMIN AH, 1969, CAN J MICROBIOL, V15, P1067, DOI 10.1139/m69-190; Ball AR, 2006, ACS CHEM BIOL, V1, P594, DOI 10.1021/cb600238x; Bauer G, 2004, J ANTIMICROB CHEMOTH, V53, P592, DOI 10.1093/jac/dkh125; Bauer WD, 2004, CURR OPIN PLANT BIOL, V7, P429, DOI 10.1016/j.pbi.2004.05.008; Belofsky G, 2006, J NAT PROD, V69, P261, DOI 10.1021/np058057s; Belofsky G, 2004, J NAT PROD, V67, P481, DOI 10.1021/np030409c; Bryskier A, 2005, ANTIMICROBIAL AGENTS: ANTIBACTERIALS AND ANTIFUNGALS, P1; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Gibbons S, 2004, NAT PROD REP, V21, P263, DOI 10.1039/b212695h; Hammerschmidt R, 1999, ANNU REV PHYTOPATHOL, V37, P285, DOI 10.1146/annurev.phyto.37.1.285; HAN GY, 1981, ACTA CHIM SINICA, V39, P433; Hsieh PC, 1998, P NATL ACAD SCI USA, V95, P6602, DOI 10.1073/pnas.95.12.6602; Hung DT, 2005, SCIENCE, V310, P670, DOI 10.1126/science.1116739; Lewis K, 2001, J MOL MICROB BIOTECH, V3, P247; Lomovskaya O, 2001, ANTIMICROB AGENTS CH, V45, P105, DOI 10.1128/AAC.45.1.105-116.2001; LOMOVSKAYA O, 1992, P NATL ACAD SCI USA, V89, P8938, DOI 10.1073/pnas.89.19.8938; Morel C, 2003, J AGR FOOD CHEM, V51, P5677, DOI 10.1021/jf0302714; Moy TI, 2006, P NATL ACAD SCI USA, V103, P10414, DOI 10.1073/pnas.0604055103; Nikaido H, 1998, CURR OPIN MICROBIOL, V1, P516, DOI 10.1016/S1369-5274(98)80083-0; Pankey GA, 2005, J ANTIMICROB CHEMOTH, V56, P470, DOI 10.1093/jac/dki248; Severina II, 2001, IUBMB LIFE, V52, P321, DOI 10.1080/152165401317291183; Silver LL, 2006, IDRUGS, V9, P394; Stermitz FR, 2000, P NATL ACAD SCI USA, V97, P1433, DOI 10.1073/pnas.030540597; Stermitz FR, 2002, PLANTA MED, V68, P1140, DOI 10.1055/s-2002-36347; Stermitz FR, 2003, BIOORG MED CHEM LETT, V13, P1915, DOI 10.1016/S0960-894X(03)00316-0; Tegos G, 2002, ANTIMICROB AGENTS CH, V46, P3133, DOI 10.1128/AAC.46.10.3133-3141.2002; Teplitski M, 2000, MOL PLANT MICROBE IN, V13, P637, DOI 10.1094/MPMI.2000.13.6.637	28	268	280	0	53	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1504	1507		10.1038/nbt1206-1504	http://dx.doi.org/10.1038/nbt1206-1504			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17160050				2022-12-25	WOS:000242795800024
J	D'Amour, KA; Bang, AG; Eliazer, S; Kelly, OG; Agulnick, AD; Smart, NG; Moorman, MA; Kroon, E; Carpenter, MK; Baetge, EE				D'Amour, Kevin A.; Bang, Anne G.; Eliazer, Susan; Kelly, Olivia G.; Agulnick, Alan D.; Smart, Nora G.; Moorman, Mark A.; Kroon, Evert; Carpenter, Melissa K.; Baetge, Emmanuel E.			Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells	NATURE BIOTECHNOLOGY			English	Article							INSULIN-PRODUCING CELLS; BETA-CELLS; HUMAN FETAL; MOUSE EMBRYO; DIFFERENTIAL EXPRESSION; EPITHELIAL-CELLS; PROGENITOR CELLS; DORSAL PANCREAS; MUTANT MICE; ENDODERM	Of paramount importance for the development of cell therapies to treat diabetes is the production of sufficient numbers of pancreatic endocrine cells that function similarly to primary islets. We have developed a differentiation process that converts human embryonic stem ( hES) cells to endocrine cells capable of synthesizing the pancreatic hormones insulin, glucagon, somatostatin, pancreatic polypeptide and ghrelin. This process mimics in vivo pancreatic organogenesis by directing cells through stages resembling definitive endoderm, gut-tube endoderm, pancreatic endoderm and endocrine precursor - en route to cells that express endocrine hormones. The hES cell - derived insulin- expressing cells have an insulin content approaching that of adult islets. Similar to fetal beta- cells, they release C- peptide in response to multiple secretory stimuli, but only minimally to glucose. Production of these hES cell - derived endocrine cells may represent a critical step in the development of a renewable source of cells for diabetes cell therapy.	Novocell Inc, San Diego, CA 92121 USA		Baetge, EE (corresponding author), Novocell Inc, 3550 Gen Atom Ct, San Diego, CA 92121 USA.	ebaetge@novocell.com		KROON, EVERT/0000-0002-4069-3644				Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Baharvand H, 2006, DEV GROWTH DIFFER, V48, P323, DOI 10.1111/j.1440-169x.2006.00867.x; Barbacci E, 1999, DEVELOPMENT, V126, P4795; BEATTIE GM, 1994, CELL TRANSPLANT, V3, P421, DOI 10.1177/096368979400300509; Bhushan A, 2001, DEVELOPMENT, V128, P5109; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; Bonner-Weir S, 2005, NAT BIOTECHNOL, V23, P857, DOI 10.1038/nbt1115; Chen YL, 2004, DEV BIOL, V271, P144, DOI 10.1016/j.ydbio.2004.03.030; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; DEKRIJGER RR, 1992, DEV BIOL, V153, P368, DOI 10.1016/0012-1606(92)90121-V; Demeterco C, 2000, J CLIN ENDOCR METAB, V85, P3892, DOI 10.1210/jc.85.10.3892; Do Kwon Y, 2005, MOL THER, V12, P28, DOI 10.1016/y.ymthe.2005.03.01; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Frederickson Christopher, 2003, Sci STKE, V2003, ppe18, DOI 10.1126/stke.2003.182.pe18; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; Gu GQ, 2002, DEVELOPMENT, V129, P2447; Hansson M, 2004, DIABETES, V53, P2603, DOI 10.2337/diabetes.53.10.2603; Harrison KA, 1999, NAT GENET, V23, P71, DOI 10.1038/12674; Hart A, 2003, DEV DYNAM, V228, P185, DOI 10.1002/dvdy.10368; Hayek A, 1997, J CLIN ENDOCR METAB, V82, P2471, DOI 10.1210/jc.82.8.2471; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Herrera PL, 2002, ENDOCRINE, V19, P267, DOI 10.1385/ENDO:19:3:267; Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102; Hori Y, 2005, PLOS MED, V2, P347, DOI 10.1371/journal.pmed.0020103; Jacquemin P, 2006, DEV BIOL, V290, P189, DOI 10.1016/j.ydbio.2005.11.023; Jacquemin P, 2003, DEV BIOL, V258, P105, DOI 10.1016/S0012-1606(03)00115-5; Jensen J, 2004, DEV DYNAM, V229, P176, DOI 10.1002/dvdy.10460; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kanai Y, 1996, J CELL BIOL, V133, P667, DOI 10.1083/jcb.133.3.667; Kanai-Azuma M, 2002, DEVELOPMENT, V129, P2367; Klimstra DS, 1997, HISTOLOGY PATHOLOGIS, V2, P613; LATIF ZA, 1988, TRANSPLANTATION, V45, P827; Lau J, 2006, CELL MOL LIFE SCI, V63, P642, DOI 10.1007/s00018-005-5357-z; Li H, 1999, NAT GENET, V23, P67; Liew CG, 2005, ANN MED, V37, P521, DOI 10.1080/07853890500379463; Madsen OD, 2005, APMIS, V113, P858, DOI 10.1111/j.1600-0463.2005.apm_418.x; Martin M, 2005, DEV BIOL, V284, P399, DOI 10.1016/j.ydbio.2005.05.035; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; MCLEAN AB, IN PRESS STEM CELLS; MISLER S, 1992, DIABETES, V41, P662, DOI 10.2337/diabetes.41.6.662; Molotkov A, 2005, DEV DYNAM, V232, P950, DOI 10.1002/dvdy.20256; Murtaugh LC, 2003, ANNU REV CELL DEV BI, V19, P71, DOI 10.1146/annurev.cellbio.19.111301.144752; Nishimura W, 2006, DEV BIOL, V293, P526, DOI 10.1016/j.ydbio.2006.02.028; PICTET R, 1972, HDB PHYSL ENDOCRINOL, V7, P25; Polak M, 2000, DIABETES, V49, P225, DOI 10.2337/diabetes.49.2.225; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; Pyne NJ, 2003, DIABETOLOGIA, V46, P1179, DOI 10.1007/s00125-003-1176-7; Rajagopal J, 2003, SCIENCE, V299, P363; Rindi G, 2004, ANN NY ACAD SCI, V1014, P1, DOI 10.1196/annals.1294.001; Roche E, 2005, FASEB J, V19, P1341, DOI 10.1096/fj.04-3024fje; SASAKI H, 1993, DEVELOPMENT, V118, P47; Schisler JC, 2005, P NATL ACAD SCI USA, V102, P7297, DOI 10.1073/pnas.0502168102; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Segev H, 2004, STEM CELLS, V22, P265, DOI 10.1634/stemcells.22-3-265; Sipione S, 2004, DIABETOLOGIA, V47, P499, DOI 10.1007/s00125-004-1349-z; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Stafford D, 2004, DEV GENES EVOL, V214, P432, DOI 10.1007/s00427-004-0420-6; Stafford D, 2002, CURR BIOL, V12, P1215, DOI 10.1016/S0960-9822(02)00929-6; STURGESS NC, 1985, LANCET, V2, P474; Sun ZX, 2001, GENE DEV, V15, P3217, DOI 10.1101/gad946701; TAM PPL, 1993, MICROSC RES TECHNIQ, V26, P301, DOI 10.1002/jemt.1070260405; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; Tomita T, 2002, PATHOL INT, V52, P425, DOI 10.1046/j.1440-1827.2002.01368.x; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; Xu XF, 2006, CLONING STEM CELLS, V8, P96, DOI 10.1089/clo.2006.8.96; Yamaguchi TP, 2001, CURR BIOL, V11, pR713, DOI 10.1016/S0960-9822(01)00417-1; Yasunaga M, 2005, NAT BIOTECHNOL, V23, P1542, DOI 10.1038/nbt1167; Ye F, 2005, DIABETOLOGIA, V48, P277, DOI 10.1007/s00125-004-1638-6	70	1400	1603	5	210	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2006	24	11					1392	1401		10.1038/nbt1259	http://dx.doi.org/10.1038/nbt1259			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	106TP	17053790				2022-12-25	WOS:000242124700036
J	Takahashi, A; Ohtani, N; Yamakoshi, K; Iida, SI; Tahara, H; Nakayama, K; Nakayama, KI; Ide, T; Saya, H; Hara, E				Takahashi, Akiko; Ohtani, Naoko; Yamakoshi, Kimi; Iida, Shin-ichi; Tahara, Hidetoshi; Nakayama, Keiko; Nakayama, Keiichi I.; Ide, Toshinori; Saya, Hideyuki; Hara, Eiji			Mitogenic signalling and the p16(INK4a)-Rb pathway cooperate to enforce irreversible cellular senescence	NATURE CELL BIOLOGY			English	Article							PROTEIN-KINASE-C; HUMAN FIBROBLASTS; CANCER-CELLS; DELTA; P53; EXPRESSION; ARREST; PHOSPHORYLATION; SUPPRESSION; ACTIVATION	The p16(INK4a) cyclin-dependent kinase inhibitor has a key role in establishing stable G1 cell-cycle arrest through activating the retinoblastoma (Rb) tumour suppressor protein pRb(1-5) in cellular senescence. Here, we show that the p16(INK4a)/Rb-pathway also cooperates with mitogenic signals to induce elevated intracellular levels of reactive oxygen species (ROS), thereby activating protein kinase C delta (PKC delta) in human senescent cells. Importantly, once activated by ROS, PKC delta promotes further generation of ROS, thus establishing a positive feedback loop to sustain ROS-PKC delta signalling(6-8). Sustained activation of ROS-PKC delta signalling irreversibly blocks cytokinesis, at least partly through reducing the level of WARTS (also known as LATS1), a mitotic exit network (MEN) kinase required for cytokinesis(9--11), in human senescent cells. This irreversible cytokinetic block is likely to act as a second barrier to cellular immortalization ensuring stable cell-cycle arrest in human senescent cells. These results uncover an unexpected role for the p16(INK4a)-Rb pathway and provide a new insight into how senescent cell-cycle arrest is enforced in human cells.	Univ Tokushima, Inst Genome Res, Tokushima 7708503, Japan; Kumamoto Univ, Grad Sch Med Sci, Kumamoto 8608556, Japan; Hiroshima Univ, Sch Med, Hiroshima 7348551, Japan; Tohoku Univ, Grad Sch Med, Sendai, Miyagi 9808575, Japan; Kyushu Univ, Med Inst Bioregulat, Fukuoka 8128582, Japan; Hiroshima Int Univ, Fac Pharmaceut Sci, Kure 7370112, Japan	Tokushima University; Kumamoto University; Hiroshima University; Tohoku University; Kyushu University	Hara, E (corresponding author), Univ Tokushima, Inst Genome Res, Tokushima 7708503, Japan.	hara@genome.tokushima-u.ac.jp	Ohtani, Naoko/AAB-1891-2021; Saya, Hideyuki/J-4325-2013	Ohtani, Naoko/0000-0001-8934-0797; Takahashi, Akiko/0000-0003-1904-7645				Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Behrend L, 2005, MOL CELL BIOL, V25, P7758, DOI 10.1128/MCB.25.17.7758-7769.2005; Bey EA, 2004, J IMMUNOL, V173, P5730, DOI 10.4049/jimmunol.173.9.5730; Bothos J, 2005, CANCER RES, V65, P6568, DOI 10.1158/0008-5472.CAN-05-0862; Chen JH, 2004, J BIOL CHEM, V279, P49439, DOI 10.1074/jbc.M409153200; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; Dirac AMG, 2003, J BIOL CHEM, V278, P11731, DOI 10.1074/jbc.C300023200; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; ELIOR I, 2005, AM J PHYSIOL-ENDOC M, V288, pE405; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; Herbig U, 2006, MECH AGEING DEV, V127, P16, DOI 10.1016/j.mad.2005.09.002; Iida S, 2004, ONCOGENE, V23, P5266, DOI 10.1038/sj.onc.1207623; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lloyd AC, 2002, NAT CELL BIOL, V4, pE25, DOI 10.1038/ncb0202-e25; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Maehara K, 2005, J CELL BIOL, V168, P553, DOI 10.1083/jcb.200411093; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Satyanarayana A, 2004, MOL CELL BIOL, V24, P5459, DOI 10.1128/MCB.24.12.5459-5474.2004; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; TAHARA H, 1995, ONCOGENE, V10, P835; Voorhoeve PM, 2003, CANCER CELL, V4, P311, DOI 10.1016/S1535-6108(03)00223-X; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wheaton K, 2004, MOL CELL BIOL, V24, P7298, DOI 10.1128/MCB.24.16.7298-7311.2004; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140	31	361	381	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1291	U63		10.1038/ncb1491	http://dx.doi.org/10.1038/ncb1491			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17028578				2022-12-25	WOS:000241732400019
J	Samoilov, MS; Arkin, AP				Samoilov, Michael S.; Arkin, Adam P.			Deviant effects in molecular reaction pathways	NATURE BIOTECHNOLOGY			English	Article							EUKARYOTIC GENE-EXPRESSION; STOCHASTIC SIMULATION; CHEMICAL-KINETICS; MASTER EQUATION; SYSTEMS; NOISE; OSCILLATIONS; ACTIVATION; FLUCTUATIONS; MODULE	In biological networks, any manifestations of behaviors substantially 'deviant' from the predictions of continuous-deterministic classical chemical kinetics (CCK) are typically ascribed to systems with complex dynamics and/or a small number of molecules. Here we show that in certain cases such restrictions are not obligatory for CCK to be largely incorrect. By systematically identifying properties that may cause significant divergences between CCK and the more accurate discrete-stochastic chemical master equation (CME) system descriptions, we comprehensively characterize potential CCK failure patterns in biological settings, including consequences of the assertion that CCK is closer to the 'mode' rather than the 'average' of stochastic reaction dynamics, as generally perceived. We demonstrate that mechanisms underlying such nonclassical effects can be very simple, are common in cellular networks and result in often unintuitive system behaviors. This highlights the importance of deviant effects in biotechnologically or biomedically relevant applications, and suggests some approaches to diagnosing them in situ.	Univ Calif Berkeley, Lawrence Berkeley Lab, Howard Hughes Med Inst, Dept Bioengn,Ctr Synthet Biol,Phys Biosci Div, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Samoilov, MS (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Howard Hughes Med Inst, Dept Bioengn,Ctr Synthet Biol,Phys Biosci Div, 1 Cyclotron Rd,MS 977-257, Berkeley, CA 94720 USA.	mssamoilov@lbl.gov; aparkin@lbl.gov	Arkin, Adam/M-9941-2019; Arkin, Adam P/A-6751-2008	Arkin, Adam/0000-0002-4999-2931; Arkin, Adam P/0000-0002-4999-2931; Samoilov, Michael/0000-0003-3559-5326				Arkin A, 1998, GENETICS, V149, P1633; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; Berry R. S., 2000, PHYS CHEM; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Cao Y, 2004, J CHEM PHYS, V121, P12169, DOI 10.1063/1.1823412; Cao Y, 2004, J CHEM PHYS, V121, P4059, DOI 10.1063/1.1778376; Clardy J, 2004, NATURE, V432, P829, DOI 10.1038/nature03194; Davis KL, 2006, FEBS J, V273, P84, DOI 10.1111/j.1742-4658.2005.05043.x; DYKMAN MI, 1994, J CHEM PHYS, V100, P5735, DOI 10.1063/1.467139; Endy D, 1997, BIOTECHNOL BIOENG, V55, P375, DOI 10.1002/(SICI)1097-0290(19970720)55:2<375::AID-BIT15>3.0.CO;2-G; English BP, 2006, NAT CHEM BIOL, V2, P87, DOI 10.1038/nchembio759; Gillespie D. T., 2005, HDB MAT MODELING, P1735; Gillespie DT, 2000, J CHEM PHYS, V113, P297, DOI 10.1063/1.481811; GILLESPIE DT, 1981, J CHEM PHYS, V75, P704, DOI 10.1063/1.442111; GILLESPIE DT, 1992, PHYSICA A, V188, P404, DOI 10.1016/0378-4371(92)90283-V; GILLESPIE DT, 1992, MARKOV PROCESSES; Giraldo R, 2004, PLASMID, V52, P69, DOI 10.1016/j.plasmid.2004.06.002; GITTERMAN M, 1991, PHYSICA A, V170, P503, DOI 10.1016/0378-4371(91)90004-V; Guido NJ, 2006, NATURE, V439, P856, DOI 10.1038/nature04473; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Kitahara K., 1975, ADV CHEM PHYS, V29, P85; Kubo R., 1973, J STAT PHYS, V9, P51, DOI DOI 10.1007/BF01016797; KURTZ TG, 1972, J CHEM PHYS, V57, P2976, DOI 10.1063/1.1678692; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Marhl M, 2005, FEBS LETT, V579, P5461, DOI 10.1016/j.febslet.2005.09.007; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; MCQUARRIE DA, 1964, J CHEM PHYS, V40, P2914, DOI 10.1063/1.1724926; Newman JRS, 2006, NATURE, V441, P840, DOI 10.1038/nature04785; Paulsson J, 2000, P NATL ACAD SCI USA, V97, P7148, DOI 10.1073/pnas.110057697; Pedraza JM, 2005, SCIENCE, V307, P1965, DOI 10.1126/science.1109090; Qian H, 2002, P NATL ACAD SCI USA, V99, P10376, DOI 10.1073/pnas.152007599; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; Rosenfeld N, 2005, SCIENCE, V307, P1962, DOI 10.1126/science.1106914; Salyers A, 2002, BACTERIAL PATHOGENES; Samoilov M, 2005, P NATL ACAD SCI USA, V102, P2310, DOI 10.1073/pnas.0406841102; Samoilov M, 2002, J PHYS CHEM A, V106, P10205, DOI 10.1021/jp025846z; SAMOILOV M, 1995, J CHEM PHYS, V102, P7983, DOI 10.1063/1.468996; Simpson ML, 2004, P IEEE, V92, P848, DOI 10.1109/JPROC.2004.826600; Srivastava R, 2002, J THEOR BIOL, V218, P309, DOI 10.1006/jtbi.2002.3078; Stelling J, 2004, CELL, V118, P675, DOI 10.1016/j.cell.2004.09.008; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; Ting AY, 2002, SCIENCE, V298, P1189, DOI 10.1126/science.1079331; Van Kampen NG., 1976, ADV CHEM PHYS, V34, P245, DOI DOI 10.1002/9780470142530.CH5); Van Kampen NG, 1992, STOCHASTIC PROCESSES; Voet D, 1999, FUNDAMENTALS BIOCH; Wolf DM, 2005, J THEOR BIOL, V234, P227, DOI 10.1016/j.jtbi.2004.11.020; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yamaoka K, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-253; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; ZHENG Q, 1991, J CHEM PHYS, V94, P3644, DOI 10.1063/1.459735	50	91	91	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2006	24	10					1235	1240		10.1038/nbt1253	http://dx.doi.org/10.1038/nbt1253			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	093TG	17033664				2022-12-25	WOS:000241191700025
J	Huang, GN; Zeng, WZ; Kim, JY; Yuan, JP; Han, LH; Muallem, S; Worley, PF				Huang, Guo N.; Zeng, Weizhong; Kim, Joo Young; Yuan, Joseph P.; Han, Linhuang; Muallem, Shmuel; Worley, Paul F.			STIM1 carboxyl-terminus activates native SOC, I-crac and TRPC1 channels	NATURE CELL BIOLOGY			English	Article							PLASMA-MEMBRANE; CA2+ SENSOR; PROTEINS; STORE; FAMILY; CELLS; COMPONENTS; RECEPTORS	Receptor- evoked Ca2+ signalling involves Ca2+ release from the endoplasmic reticulum, followed by Ca2+ influx across the plasma membrane(1). Ca2+ influx is essential for many cellular functions, from secretion to transcription, and is mediated by Ca2+- release activated Ca2+ (I-crac) channels and store- operated calcium entry ( SOC) channels(2). Although the molecular identity and regulation of I-crac and SOC channels have not been precisely determined(1), notable recent findings are the identification of STIM1, which has been indicated to regulate SOC and I-crac channels by functioning as an endoplasmic reticulum Ca2+ sensor(3-6), and ORAI1 ( ref. 7) or CRACM1 ( ref. 8) - both of which may function as I-crac channels or as an I-crac subunit. How STIM1 activates the Ca2+ influx channels and whether STIM1 contributes to the channel pore remains unknown. Here, we identify the structural features that are essential for STIM1- dependent activation of SOC and I-crac channels, and demonstrate that they are identical to those involved in the binding and activation of TRPC1. Notably, the cytosolic carboxyl terminus of STIM1 is sufficient to activate SOC, I-crac and TRPC1 channels even when native STIM1 is depleted by small interfering RNA. Activity of STIM1 requires an ERM domain, which mediates the selective binding of STIM1 to TRPC1, 2 and 4, but not to TRPC3, 6 or 7, and a cationic lysine- rich region, which is essential for gating of TRPC1. Deletion of either region in the constitutively active STIM1(D76A) yields dominant- negative mutants that block native SOC channels, expressed TRPC1 in HEK293 cells and I-crac in Jurkat cells. These observations implicate STIM1 as a key regulator of activity rather than a channel component, and reveal similar regulation of SOC, I(cra)c and TRPC channel activation by STIM1.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Program Biochem Cellular & Mol Biol, Baltimore, MD 21205 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University	Muallem, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	shumuel.muallem@utsouthwestern.edu; pworley@jhmi.edu	Kim, Joo Young/X-7562-2019	Kim, Joo Young/0000-0003-2623-1491; Huang, Guo/0000-0002-4335-9123	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010309, R37DA010309, P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00266, DA10309] Funding Source: Medline; NIMH NIH HHS [MH068830] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Freichel M, 2005, J PHYSIOL-LONDON, V567, P59, DOI 10.1113/jphysiol.2005.092999; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Tsai RYL, 1997, BIOTECHNIQUES, V23, P794, DOI 10.2144/97235bm06; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Williams RT, 2001, BIOCHEM J, V357, P673, DOI 10.1042/0264-6021:3570673; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7; Yuan JP, 2003, CELL, V114, P777, DOI 10.1016/S0092-8674(03)00716-5; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	19	521	544	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					1003	U96		10.1038/ncb1454	http://dx.doi.org/10.1038/ncb1454			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16906149				2022-12-25	WOS:000240241700017
J	Crow, YJ; Hayward, BE; Parmar, R; Robins, P; Leitch, A; Ali, M; Black, DN; van Bokhoven, H; Brunner, HG; Hamel, BC; Corry, PC; Cowan, FM; Frints, SG; Klepper, J; Livingston, JH; Lynch, SA; Massey, RF; Meritet, JF; Michaud, JL; Ponsot, G; Voit, T; Lebon, P; Bonthron, DT; Jackson, AP; Barnes, DE; Lindahl, T				Crow, Yanick J.; Hayward, Bruce E.; Parmar, Rekha; Robins, Peter; Leitch, Andrea; Ali, Manir; Black, Deborah N.; van Bokhoven, Hans; Brunner, Han G.; Hamel, Ben C.; Corry, Peter C.; Cowan, Frances M.; Frints, Suzanne G.; Klepper, Joerg; Livingston, John H.; Lynch, Sally Ann; Massey, Roger F.; Meritet, Jean Francois; Michaud, Jacques L.; Ponsot, Gerard; Voit, Thomas; Lebon, Pierre; Bonthron, David T.; Jackson, Andrew P.; Barnes, Deborah E.; Lindahl, Tomas			Mutations in the gene encoding the 3 '-5 ' DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus	NATURE GENETICS			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; PROGRESSIVE FAMILIAL ENCEPHALOPATHY; INTERFERON-ALPHA; INTRATHECAL SYNTHESIS; MICE; ENCEPHALITIS; INDUCTION; INFECTION; SERUM	Aicardi-Goutieres syndrome (AGS) presents as a severe neurological brain disease and is a genetic mimic of the sequelae of transplacentally acquired viral infection(1,2). Evidence exists for a perturbation of innate immunity as a primary pathogenic event in the disease phenotype(3). Here, we show that TREX1, encoding the major mammalian 3'-> 5' DNA exonuclease(4), is the AGS1 gene, and AGS-causing mutations result in abrogation of TREX1 enzyme activity. Similar loss of function in the Trex1(-/-) mouse leads to an inflammatory phenotype(5). Our findings suggest an unanticipated role for TREX1 in processing or clearing anomalous DNA structures, failure of which results in the triggering of an abnormal innate immune response.	Univ Leeds, St Jamess Univ Hosp, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England; St Lukes Hosp, Dept Paediat, Bradford BD5 0NA, W Yorkshire, England; London Res Inst, Canc Res UK, S Mimms EN6 3LD, Herts, England; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; McGill Univ, Montreal Neurol Inst, Dept Neurogenet, Montreal, PQ, Canada; Radboud Univ Nijmegen, Med Ctr, Dept Human Genet 417, NL-6525 GA Nijmegen, Netherlands; St Lukes Hosp, Bradford Child Dev Ctr, Bradford BD5 0NA, W Yorkshire, England; Hammersmith Hosp, Imperial Coll, Dept Paediat, London W12 0HS, England; Univ Hosp AzM Maastricht, Dept Clin Genet, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Essen, Dept Pediat & Pediat Neurol, D-45122 Essen, Germany; Gen Infirm, Dept Paediat Neurol, Leeds LS1 3EX, W Yorkshire, England; Our Ladys Hosp Sick Children, Natl Ctr Med Genet, Dublin 12, Ireland; Hull Royal Infirm, Dept Paediat, Kingston Upon Hull HU3 2JZ, N Humberside, England; Hop Cochin, Serv Virol, F-75674 Paris, France; Univ Paris 05, F-75674 Paris, France; Hop St Justine, Res Ctr, Montreal, PQ H3T 1C5, Canada; Hop Cochin, Serv Neuropediat, F-75674 Paris, France	Saint James's University Hospital; University of Leeds; Cancer Research UK; University of Edinburgh; McGill University; Radboud University Nijmegen; Imperial College London; Maastricht University; Maastricht University Medical Centre (MUMC); University of Duisburg Essen; Leeds General Infirmary; Our Ladys Children Hospital Crumlin; University of Hull; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Montreal; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Crow, YJ (corresponding author), Univ Leeds, St Jamess Univ Hosp, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England.	yanickcrow@mac.com	Ali, Manir/ABE-5251-2020; Brunner, Han/C-9928-2013; Crow, Yanick J/N-6120-2014; van Bokhoven, Hans/D-8764-2012; Jackson, Andrew P/D-3442-2009; Bokhoven, J.H.L.M. van van/H-8015-2014	Ali, Manir/0000-0003-3204-3788; Crow, Yanick J/0000-0001-7211-7564; Jackson, Andrew P/0000-0002-8739-2646; Bokhoven, J.H.L.M. van van/0000-0002-2153-9254; Bonthron, David/0000-0001-8132-8179; Frints, Suzanna G.M./0000-0002-5027-8364; Lynch, Sally Ann/0000-0003-3540-1333	Medical Research Council [MC_U127580972] Funding Source: Medline; MRC [MC_U127580972] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AICARDI J, 1984, ANN NEUROL, V15, P49, DOI 10.1002/ana.410150109; Aicardi J, 2000, NEUROPEDIATRICS, V31, P113, DOI 10.1055/s-2000-7533; Akwa Y, 1998, J IMMUNOL, V161, P5016; Ali M, 2006, J MED GENET, V43, P444, DOI 10.1136/jmg.2005.031880; Batteux F, 1999, EUR CYTOKINE NETW, V10, P509; BLACK DN, 1988, ANN NEUROL, V24, P483, DOI 10.1002/ana.410240402; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; Crow YJ, 2000, AM J HUM GENET, V67, P213, DOI 10.1086/302955; Crow YJ, 2003, J MED GENET, V40, P183, DOI 10.1136/jmg.40.3.183; Dale RC, 2000, NEUROPEDIATRICS, V31, P155, DOI 10.1055/s-2000-7492; De Laet C, 2005, NEUROPEDIATRICS, V36, P399, DOI 10.1055/s-2005-873058; DUSSAIX E, 1985, ACTA NEUROL SCAND, V71, P504; Goutieres F, 1998, ANN NEUROL, V44, P900, DOI 10.1002/ana.410440608; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Ishii KJ, 2005, INT J CANCER, V117, P517, DOI 10.1002/ijc.21402; Kawane K, 2003, NAT IMMUNOL, V4, P138, DOI 10.1038/ni881; LEBON P, 1988, J NEUROL SCI, V84, P201, DOI 10.1016/0022-510X(88)90125-6; LEBON P, 1983, BRIT MED J, V287, P1165, DOI 10.1136/bmj.287.6400.1165; LINDAHL T, 1969, J BIOL CHEM, V244, P5014; Mazur DJ, 2001, J BIOL CHEM, V276, P14718, DOI 10.1074/jbc.M010051200; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Perrino FW, 2005, J BIOL CHEM, V280, P15212, DOI 10.1074/jbc.M500108200; PREBLE OT, 1982, SCIENCE, V216, P429, DOI 10.1126/science.6176024; Prokunina L, 2004, HUM MOL GENET, V13, pR143, DOI 10.1093/hmg/ddh076; Raymond AA, 1996, LUPUS, V5, P123, DOI 10.1177/096120339600500207; RICH SA, 1986, ARTHRITIS RHEUM, V29, P501, DOI 10.1002/art.1780290407; Sanchis A, 2005, J PEDIATR-US, V146, P701, DOI 10.1016/j.jpeds.2005.01.033; STEPHENSON J, 2002, EUR J PEDIAT NEUR SA, V6, P67; Yasutomo K, 2001, NAT GENET, V28, P313, DOI 10.1038/91070	30	610	638	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2006	38	8					917	920		10.1038/ng1845	http://dx.doi.org/10.1038/ng1845			4	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16845398				2022-12-25	WOS:000239325700021
J	Friedmann, E; Hauben, E; Maylandt, K; Schleeger, S; Vreugde, S; Lichtenthaler, SF; Kuhn, PH; Stauffer, D; Rovelli, G; Martoglio, B				Friedmann, Elena; Hauben, Ehud; Maylandt, Kerstin; Schleeger, Simone; Vreugde, Sarah; Lichtenthaler, Stefan F.; Kuhn, Peer-Hendrik; Stauffer, Daniela; Rovelli, Giorgio; Martoglio, Bruno			SPPL2a and SPPL2b promote intramembrane proteolysis of TNF alpha in activated dendritic cells to trigger IL-12 production	NATURE CELL BIOLOGY			English	Article							SIGNAL PEPTIDE PEPTIDASE; TUMOR-NECROSIS-FACTOR; GAMMA-SECRETASE; ASPARTIC PROTEASES; TRANSMEMBRANE FORM; FACTOR RECEPTOR; IDENTIFICATION; PRESENILIN-1; SUPERFAMILY; MACROPHAGES	Homologues of signal peptide peptidase ( SPPLs) are putative aspartic proteases that may catalyse regulated intramembrane proteolysis of type II membrane-anchored signalling factors. Here, we show that four human SPPLs are each sorted to a different compartment of the secretory pathway. We demonstrate that SPPL2a and SPPL2b, which are sorted to endosomes and the plasma membrane, respectively, are functional proteases that catalyse intramembrane cleavage of tumour necrosis factor alpha ( TNF alpha). The two proteases promoted the release of the TNFa intracellular domain, which in turn triggers expression of the pro-inflammatory cytokine interleukin-12 by activated human dendritic cells. Our study reveals a critical function for SPPL2a and SPPL2b in the regulation of innate and adaptive immunity.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland; San Raffaele Telethon Inst Gene Therapy, HSR, TIGET, I-20132 Milan, Italy; Novartis Pharma AG, Expertise Platform Proteases, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland; DIBIT, Mol Histol & Cell Growth Unit, I-20132 Milan, Italy; Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Novartis; University of Munich	Martoglio, B (corresponding author), Novartis Pharma AG, Expertise Platform Proteases, Novartis Inst Biomed Res, CH-4002 Basel, Switzerland.	bruno.martoglio@novartis.com	Lichtenthaler, Stefan F/B-6587-2016; Hauben, Ehud/R-8692-2019	Lichtenthaler, Stefan F/0000-0003-2211-2575; Hauben, Ehud/0000-0002-6062-411X; Kuhn, Peer-Hendrik/0000-0001-7891-5102; Vreugde, Sarah/0000-0003-4719-9785				Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brunkan AL, 2005, J NEUROCHEM, V93, P769, DOI 10.1111/j.1471-4159.2005.03099.x; CARTSTEA ED, 2005, IDRUGS, V8, P642; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Domonkos A, 2001, EUR CYTOKINE NETW, V12, P411; Eissner G, 2000, J IMMUNOL, V164, P6193, DOI 10.4049/jimmunol.164.12.6193; Eissner G, 2004, CYTOKINE GROWTH F R, V15, P353, DOI 10.1016/j.cytogfr.2004.03.011; Friedmann E, 2004, J BIOL CHEM, V279, P50790, DOI 10.1074/jbc.M407898200; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hauben E, 2005, TRENDS IMMUNOL, V26, P248, DOI 10.1016/j.it.2005.03.004; Krawitz P, 2005, J BIOL CHEM, V280, P39515, DOI 10.1074/jbc.M501645200; Laudon H, 2005, J BIOL CHEM, V280, P35352, DOI 10.1074/jbc.M507217200; Lemberg MK, 2002, MOL CELL, V10, P735, DOI 10.1016/S1097-2765(02)00655-X; Ma XJ, 2001, MICROBES INFECT, V3, P121, DOI 10.1016/S1286-4579(00)01359-9; Martoglio B, 2003, HUM MOL GENET, V12, pR201, DOI 10.1093/hmg/ddg303; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; PECK R, 1989, CELL IMMUNOL, V122, P1, DOI 10.1016/0008-8749(89)90143-3; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Rawson RB, 2002, ESSAYS BIOCHEM, V38, P155, DOI 10.1042/bse0380155; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Trinchieri G, 2003, IMMUNITY, V19, P641, DOI 10.1016/S1074-7613(03)00296-6; Watts AD, 1999, J LEUKOCYTE BIOL, V66, P1005, DOI 10.1002/jlb.66.6.1005; Weihofen A, 2003, J BIOL CHEM, V278, P16528, DOI 10.1074/jbc.M301372200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7	34	158	168	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					843	U95		10.1038/ncb1440	http://dx.doi.org/10.1038/ncb1440			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16829952				2022-12-25	WOS:000239423000014
J	Avila, J				Avila, Jesus			The Spanish experience	NATURE MEDICINE			English	Editorial Material													Avila, Jesus/I-2610-2015	Avila, Jesus/0000-0002-6288-0571					0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					776	776						1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16829945				2022-12-25	WOS:000238862800058
J	Lim, MH; Xu, D; Lippard, SJ				Lim, Mi Hee; Xu, Dong; Lippard, Stephen J.			Visualization of nitric oxide in living cells by a copper-based fluorescent probe	NATURE CHEMICAL BIOLOGY			English	Article							NITROSATION; CATALYSIS	Nitric oxide (NO) serves as a messenger for cellular signaling. To visualize NO in living cells, we synthesized a turn-on fluorescent probe for use in combination with microscopy. Unlike existing fluorescent sensors, the construct-a Cu(II) complex of a fluorescein modified with an appended metal-chelating ligand (FL)-directly and immediately images NO rather than a derivative reactive nitrogen species. Using spectroscopic and mass spectrometric methods, we established that the mechanism of the reaction responsible for the NO-induced fluorescence involves reduction of the complex to Cu(I) with release of the nitrosated ligand, which occurs irreversibly. We detected NO produced by both constitutive and inducible NO synthases (cNOS and iNOS, respectively) in live neurons and macrophages in a concentration- and time-dependent manner by using the Cu(II)based imaging agent. Both the sensitivity to nanomolar concentrations of NO and the spatiotemporal information provided by this complex demonstrate its value for numerous biological applications.	MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	lippard@mit.edu	Lim, Mi Hee/D-1913-2018		NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013886] Funding Source: NIH RePORTER; NCRR NIH HHS [1S10RR13886-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bonnett R., 1975, J CHEM SOC P1, V22, P2261; Conner Elaine M., 1995, Methods (Orlando), V7, P3, DOI 10.1006/meth.1995.1002; Ford PC, 2002, CHEM REV, V102, P993, DOI 10.1021/cr0000271; Furchgott RF, 1999, ANGEW CHEM INT EDIT, V38, P1870, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1870::AID-ANIE1870>3.0.CO;2-8; Hampl V., 1996, METHODS NITRIC OXIDE, P309; HILDERBRAND SA, 2005, TOPICS FLUORESCENCE, P163; Ignarro LJ, 1999, ANGEW CHEM INT EDIT, V38, P1882, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1882::AID-ANIE1882>3.0.CO;2-V; JI XB, 1988, APPL ENVIRON MICROB, V54, P1791, DOI 10.1128/AEM.54.7.1791-1794.1988; Karaghiosoff K, 2006, J ORG CHEM, V71, P1295, DOI 10.1021/jo0513820; Koppenol WH, 1996, METHOD ENZYMOL, V268, P7; Lee J, 2002, CHEM REV, V102, P1019, DOI 10.1021/cr0000731; Lijinsky W., 1992, CHEM BIOL N NITROSO; Lim MH, 2005, J AM CHEM SOC, V127, P12170, DOI 10.1021/ja053150o; Lozinsky EM, 2004, ANAL BIOCHEM, V326, P139, DOI 10.1016/j.ab.2003.12.004; Malinski T, 1996, METHOD ENZYMOL, V268, P58; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; Miles Allen M., 1995, Methods (Orlando), V7, P40, DOI 10.1006/meth.1995.1006; MIWA M, 1987, CARCINOGENESIS, V8, P955, DOI 10.1093/carcin/8.7.955; MONCADA S, 1991, PHARMACOL REV, V43, P109; Murad F, 1999, ANGEW CHEM INT EDIT, V38, P1857, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1856::AID-ANIE1856>3.0.CO;2-D; Nagano T, 2002, CHEM REV, V102, P1235, DOI 10.1021/cr010152s; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Nolan EM, 2004, INORG CHEM, V43, P2624, DOI 10.1021/ic035158+; PACKER L, 1996, METHODS ENZYMOLOGY B; RALT D, 1988, J BACTERIOL, V170, P359, DOI 10.1128/jb.170.1.359-364.1988; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Sasaki E, 2005, J AM CHEM SOC, V127, P3684, DOI 10.1021/ja042967z; Sato M, 2005, P NATL ACAD SCI USA, V102, P14515, DOI 10.1073/pnas.0505136102; SJOBACK R, 1995, SPECTROCHIM ACTA A, V51, pL7, DOI 10.1016/0584-8539(95)01421-P; Smith RC, 2005, ORG LETT, V7, P3573, DOI 10.1021/ol0513903; Tsuge K, 2004, J AM CHEM SOC, V126, P6564, DOI 10.1021/ja049444b; Wang D, 2004, J BIOL CHEM, V279, P20622, DOI 10.1074/jbc.M402547200; Wink DA, 1996, METHOD ENZYMOL, V268, P12; Xia Y, 2004, ENDOCRINOLOGY, V145, P4550, DOI 10.1210/en.2004-0327	34	311	326	7	119	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUL	2006	2	7					375	380		10.1038/nchembio794	http://dx.doi.org/10.1038/nchembio794			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	054KV	16732295				2022-12-25	WOS:000238376400012
J	Peinelt, C; Vig, M; Koomoa, DL; Beck, A; Nadler, MJS; Koblan-Huberson, M; Lis, A; Fleig, A; Penner, R; Kinet, JP				Peinelt, Christine; Vig, Monika; Koomoa, Dana L.; Beck, Andreas; Nadler, Monica J. S.; Koblan-Huberson, Murielle; Lis, Annette; Fleig, Andrea; Penner, Reinhold; Kinet, Jean-Pierre			Amplification of CRAC current by STIM1 and CRACM1 (Orai1)	NATURE CELL BIOLOGY			English	Article							OPERATED CALCIUM-CHANNELS; PLASMA-MEMBRANE; CA2+ CHANNELS; T-LYMPHOCYTES; MAST-CELLS; STORE; DEPLETION; POTENTIATION; INFLUX; SENSOR	Depletion of intracellular calcium stores activates store-operated calcium entry across the plasma membrane in many cells. STIM1, the putative calcium sensor in the endoplasmic reticulum, and the calcium release-activated calcium ( CRAC) modulator CRACM1 ( also known as Orai1) in the plasma membrane have recently been shown to be essential for controlling the store-operated CRAC current ( I-CRAC)(1-4). However, individual overexpression of either protein fails to significantly amplify I-CRAC. Here, we show that STIM1 and CRACM1 interact functionally. Overexpression of both proteins greatly potentiates I-CRAC, suggesting that STIM1 and CRACM1 mutually limit store-operated currents and that CRACM1 may be the long-sought CRAC channel.	Univ Hawaii, Ctr Biomed Res, Queens Med Ctr, Honolulu, HI 96813 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96813 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	The Queen's Medical Center; University of Hawaii System; University of Hawaii System; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Penner, R (corresponding author), Univ Hawaii, Ctr Biomed Res, Queens Med Ctr, Honolulu, HI 96813 USA.	rpenner@hawaii.edu; jkinet@bidmc.harvard.edu	Peinelt, Christine/ABH-5292-2020	Fleig, Andrea/0000-0001-8396-7249; Peinelt, Christine/0000-0002-3474-6893; Vig, Monika/0000-0002-4770-8853; Penner, Reinhold/0000-0002-5366-1537	NIAID NIH HHS [R01-AI050200, R01 AI050200] Funding Source: Medline; NIGMS NIH HHS [R37 GM053950, R01 GM065360, R01-GM065360, 5-R37-GM053950] Funding Source: Medline; NINDS NIH HHS [R01-NS040927, R01 NS040927] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053950, R01GM065360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040927] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; VIG M, 2006, SCIENCE; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; Zweifach A, 1996, J GEN PHYSIOL, V107, P597, DOI 10.1085/jgp.107.5.597; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	15	464	496	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					771	U231		10.1038/ncb1435	http://dx.doi.org/10.1038/ncb1435			6	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16733527	Green Accepted			2022-12-25	WOS:000238837800021
J	Siragam, V; Crow, AR; Brinc, D; Song, S; Freedman, J; Lazarus, AH				Siragam, Vinayakumar; Crow, Andrew R.; Brinc, Davor; Song, Seng; Freedman, John; Lazarus, Alan H.			Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells	NATURE MEDICINE			English	Article							IDIOPATHIC THROMBOCYTOPENIC PURPURA; RETICULOENDOTHELIAL SYSTEM FUNCTION; IMMUNE THROMBOCYTOPENIA; AUTOIMMUNE-DISEASE; MURINE ITP; ANTI-D; IVIG; IGG; MACROPHAGES; ANTIBODIES	Despite a more than 20-year experience of therapeutic benefit, the relevant molecular and cellular targets of intravenous immunoglobulin ( IVIg) in autoimmune disease remain unclear. Contrary to the prevailing theories of IVIg action in autoimmunity, we show that IVIg drives signaling through activating Fc gamma receptors ( Fc gamma R) in the amelioration of mouse immune thrombocytopenic purpura ( ITP). The actual administration of IVIg was unnecessary because as few as 105 IVIg-treated cells could, upon adoptive transfer, ameliorate ITP. IVIg did not interact with the inhibitory Fc gamma RIIB on the initiator cell, although Fc gamma RIIB does have a role in the late phase of IVIg action. Notably, only IVIg-treated CD11c(+) dendritic cells could mediate these effects. We hypothesize that IVIg forms soluble immune complexes in vivo that prime dendritic-cell regulatory activity. In conclusion, the clinical effects of IVIg in ameliorating ITP seem to involve the acute interaction of IVIg with activating Fc gamma R on dendritic cells.	Canadian Blood Serv, Ottawa, ON K1G 4J5, Canada; St Michaels Hosp, Dept Lab Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2C4, Canada; Toronto Platelet Immunobiol Grp, Toronto, ON, Canada	Canadian Blood Services; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Lazarus, AH (corresponding author), Canadian Blood Serv, 1800 Alta Vista Dr, Ottawa, ON K1G 4J5, Canada.	lazarusa@smh.toronto.on.ca	Brinc, Davor/AAF-1771-2021	Crow, Andrew R/0000-0001-6978-4999; Brinc, Davor/0000-0003-4471-8965; Lazarus, Alan/0000-0002-5051-6916				Arnal C, 2002, J RHEUMATOL, V29, P75; Boruchov AM, 2005, J CLIN INVEST, V115, P2914, DOI 10.1172/JCI24772; Braun-Moscovici Y, 2003, CURR OPIN RHEUMATOL, V15, P237, DOI 10.1097/00002281-200305000-00010; Bruhns P, 2003, IMMUNITY, V18, P573, DOI 10.1016/S1074-7613(03)00080-3; Bussel JB, 2000, SEMIN HEMATOL, V37, P261, DOI 10.1053/shem.2000.8957; Cao XH, 2004, J IMMUNOL, V172, P4851, DOI 10.4049/jimmunol.172.8.4851; Crow AR, 2003, BLOOD, V102, P558, DOI 10.1182/blood-2003-01-0023; Crow AR, 2001, BRIT J HAEMATOL, V115, P679, DOI 10.1046/j.1365-2141.2001.03136.x; DEANDRES B, 1991, J IMMUNOL, V146, P1566; FEHR J, 1982, NEW ENGL J MED, V306, P1254, DOI 10.1056/NEJM198205273062102; Jolles S, 2005, CLIN EXP IMMUNOL, V142, P1, DOI 10.1111/j.1365-2249.2005.02834.X; Knezevic-Maramica I, 2003, TRANSFUSION, V43, P1460, DOI 10.1046/j.1537-2995.2003.00519.x; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; LATOUR S, 1992, J IMMUNOL, V149, P2155; Lazarus AH, 2003, TRANSFUS APHER SCI, V28, P249, DOI 10.1016/S1473-0502(03)00043-0; MCMILLAN R, 1974, NEW ENGL J MED, V291, P812, DOI 10.1056/NEJM197410172911602; SALAMA A, 1984, BLUT, V49, P29, DOI 10.1007/BF00320381; SALAMA A, 1983, LANCET, V2, P193; SALEH MN, 1989, BLOOD, V74, P1328; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Semple JW, 2002, BLOOD REV, V16, P9, DOI 10.1054/blre.2001.0172; Siragam V, 2005, J CLIN INVEST, V115, P155, DOI 10.1172/JCI200522753; Song S, 2005, BLOOD, V105, P1546, DOI 10.1182/blood-2004-05-1886; Song S, 2003, BLOOD, V101, P3708, DOI 10.1182/blood-2002-10-3078; Spisek R, 2006, TRANSFUSION, V46, P55, DOI 10.1111/j.1537-2995.2005.00670.x; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838	27	199	204	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					688	692		10.1038/nm1416	http://dx.doi.org/10.1038/nm1416			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715090				2022-12-25	WOS:000238149200032
J	Tolhuis, B; Muijrers, I; de Wit, E; Teunissen, H; Talhout, W; van Steensel, B; van Lohuizen, M				Tolhuis, Bas; Muijrers, Inhua; de Wit, Elzo; Teunissen, Hans; Talhout, Wendy; van Steensel, Bas; van Lohuizen, Maarten			Genome-wide profiling of PRC1 and PRC2 polycomb chromatin binding in Drosophila melanogaster	NATURE GENETICS			English	Article							CELLULAR MEMORY; TRITHORAX GROUP; EXPRESSION; PROTEINS; GENE; IDENTIFICATION; TARGET; CANCER; CELLS; BMI1	Polycomb group (PcG) proteins maintain transcriptional repression of developmentally important genes(1) and have been implicated in cell proliferation and stem cell self-renewal2. We used a genome-wide approach(3) to map binding patterns of PcG proteins (Pc, esc and Sce) in Drosophila melanogaster Kc cells. We found that Pc associates with large genomic regions of up to similar to 150 kb in size, hereafter referred to as 'Pc domains'. Sce and esc accompany Pc in most of these domains. PcG-bound chromatin is trimethylated at histone H3 Lys27 and is generally transcriptionally silent. Furthermore, PcG proteins preferentially bind to developmental genes. Many of these encode transcriptional regulators and key components of signal transduction pathways, including Wingless, Hedgehog, Notch and Delta. We also identify several new putative functions of PcG proteins, such as in steroid hormone biosynthesis. These results highlight the extensive involvement of PcG proteins in the coordination of development through the formation of large repressive chromatin domains.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	m.v.lohuizen@nki.nl		de Wit, Elzo/0000-0003-2883-1415				Baehrecke EH, 2000, CELL DEATH DIFFER, V7, P1057, DOI 10.1038/sj.cdd.4400753; Baldi P, 2001, BIOINFORMATICS, V17, P509, DOI 10.1093/bioinformatics/17.6.509; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Breiling A, 2004, EMBO REP, V5, P976, DOI 10.1038/sj.embor.7400260; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Dejardin J, 2005, NATURE, V434, P533, DOI 10.1038/nature03386; Ficz G, 2005, DEVELOPMENT, V132, P3963, DOI 10.1242/dev.01950; Greil F, 2003, GENE DEV, V17, P2825, DOI 10.1101/gad.281503; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Henikoff S, 2000, P NATL ACAD SCI USA, V97, P716, DOI 10.1073/pnas.97.2.716; Hernandez-Munoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Klebes A, 2005, DEVELOPMENT, V132, P3753, DOI 10.1242/dev.01927; Lascaris R, 2003, GENOME BIOL, V4; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Maurange C, 2002, GENE DEV, V16, P2672, DOI 10.1101/gad.242702; Negre N, 2006, PLOS BIOL, V4, P917, DOI 10.1371/journal.pbio.0040170; Paul SM, 2003, DEVELOPMENT, V130, P4963, DOI 10.1242/dev.00691; Rietveld LEG, 2002, EMBO J, V21, P1389, DOI 10.1093/emboj/21.6.1389; Ringrose L, 2003, DEV CELL, V5, P759, DOI 10.1016/S1534-5807(03)00337-X; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Schubeler D, 2002, NAT GENET, V32, P438, DOI 10.1038/ng1005; Stolc V, 2004, SCIENCE, V306, P655, DOI 10.1126/science.1101312; Sun LV, 2003, P NATL ACAD SCI USA, V100, P9428, DOI 10.1073/pnas.1533393100; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van Steensel B, 2000, NAT BIOTECHNOL, V18, P424, DOI 10.1038/74487; van Steensel B, 2003, P NATL ACAD SCI USA, V100, P2580, DOI 10.1073/pnas.0438000100; van Steensel B, 2001, NAT GENET, V27, P304, DOI 10.1038/85871; Warren JT, 2002, P NATL ACAD SCI USA, V99, P11043, DOI 10.1073/pnas.162375799	30	289	301	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					694	699		10.1038/ng1792	http://dx.doi.org/10.1038/ng1792			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16628213				2022-12-25	WOS:000237954800025
J	Uno, T; Takeda, K; Kojima, Y; Yoshizawa, H; Akiba, H; Mittler, RS; Gejyo, F; Okumura, K; Yagita, H; Smyth, MJ				Uno, Tomoyasu; Takeda, Kazuyoshi; Kojima, Yuko; Yoshizawa, Hirohisa; Akiba, Hisaya; Mittler, Robert S.; Gejyo, Fumitake; Okumura, Ko; Yagita, Hideo; Smyth, Mark J.			Eradication of established tumors in mice by a combination antibody-based therapy	NATURE MEDICINE			English	Article							APOPTOSIS-INDUCING LIGAND; T-CELL IMMUNITY; MONOCLONAL-ANTIBODIES; CANCER-IMMUNOTHERAPY; TUMORICIDAL ACTIVITY; IN-VIVO; INDUCTION; FAMILY; INTERLEUKIN-12; CHEMOTHERAPY	Tumor-cell apoptosis is the basis of many cancer therapies(1-3), and tumor-specific T cells are the principal effectors of successful antitumor immunotherapies(4-7). Here we show that induction of tumor-cell apoptosis by an agonistic monoclonal antibody to DR5, the apoptosis-inducing receptor for TNF-related apoptosis-inducing ligand ( TRAIL), combined with T-cell activation by agonistic monoclonal antibodies to the costimulatory molecules CD40 and CD137, potently and rapidly stimulated tumor-specific effector CD8(+) T cells capable of eradicating preestablished tumors. Primary fibrosarcomas initiated with the carcinogen 3-methylcholanthrene ( MCA), multiorgan metastases and a primary tumor containing as many as 90% tumor cells resistant to DR5-specific monoclonal antibody were rejected without apparent toxicity or induction of autoimmunity. This combination therapy of three monoclonal antibodies ( trimAb) rapidly induced tumor-specific CD8+ T cells producing interferon ( IFN)-gamma in the tumor-draining lymph node, consistent with a crucial requirement for CD8+ T cells and IFN-gamma in the tumor rejection process. These results in mice indicate that a rational monoclonal antibody-based therapy that both causes tumor-cell apoptosis through DR5 and activates T cells may be an effective strategy for cancer immunotherapy in humans.	Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Homeostat Regulat & Dev, Div Resp Med, Niigata 9518510, Japan; Peter MacCallum Canc Inst, Canc Immunol Program, Melbourne, Vic 3002, Australia; Juntendo Univ, Sch Med, Biomed Res Ctr, Div Biomed Imaging Res,Bunkyo Ku, Tokyo 1138421, Japan; Niigata Univ, Med & Dent Hosp, Biosci Med Res Ctr, Niigata 9518510, Japan; Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30329 USA; Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30329 USA	Juntendo University; Niigata University; Peter Maccallum Cancer Center; Juntendo University; Niigata University; Emory University; Emory University	Takeda, K (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.	ktakeda@med.juntendo.ac.jp	Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; BASOMBRIO MA, 1970, CANCER RES, V30, P2458; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; Dhodapkar KM, 2002, J EXP MED, V195, P125, DOI 10.1084/jem.20011097; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; HAMANN U, 1983, J IMMUNOL, V130, P7; Hayakawa Y, 2003, P NATL ACAD SCI USA, V100, P9464, DOI 10.1073/pnas.1630663100; Hixon JA, 2002, BIOL BLOOD MARROW TR, V8, P316, DOI 10.1053/bbmt.2002.v8.pm12108917; Hurwitz AA, 1998, P NATL ACAD SCI USA, V95, P10067, DOI 10.1073/pnas.95.17.10067; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Melero I, 1997, NAT MED, V3, P682, DOI 10.1038/nm0697-682; Noguchi Y, 1996, P NATL ACAD SCI USA, V93, P11798, DOI 10.1073/pnas.93.21.11798; Pardoll D, 2004, NAT MED, V10, P887, DOI 10.1038/nm0904-887; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100; Selenko N, 2001, LEUKEMIA, V15, P1619, DOI 10.1038/sj.leu.2402226; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586; zum Buschenfelde CM, 2002, CANCER RES, V62, P2244	30	206	231	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					693	698		10.1038/nm1405	http://dx.doi.org/10.1038/nm1405			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16680149				2022-12-25	WOS:000238149200033
J	Munoz, R; Moreno, M; Oliva, C; Orbenes, C; Larrain, J				Munoz, R; Moreno, M; Oliva, C; Orbenes, C; Larrain, J			Syndecan-4 regulates non-canonical Wnt signalling and is essential for convergent and extension movements in Xenopus embryos	NATURE CELL BIOLOGY			English	Article							CONTROLS CELL POLARITY; GASTRULATION MOVEMENTS; FRIZZLED-7; ADHESION; INTEGRIN; REPAIR	Early shaping of Xenopus laevis embryos occurs through convergent and extension movements, a process that is driven by intercalation of polarized dorsal mesodermal cells and regulated by non-canonical Wnt signalling(1-3). Here, we have identified Xenopus syndecan-4 (xSyn4), a cell-surface transmembrane heparan sulphate proteoglycan. At the gastrula stage, xSyn4 is expressed in the involuting dorsal mesoderm and the anterior neuroectoderm. Later, it is found in the pronephros, branchial arches, brain and tailbud. Both gain- and loss-of-function of xSyn4 impaired convergent extension movements in Xenopus embryos and in activin-treated ectodermal explants. xSyn4 interacts functionally and biochemically with the Wnt receptor Frizzled7 (xFz7) and its signal transducer Dishevelled (xDsh). Furthermore, xSyn4 is necessary and sufficient for translocation of xDsh to the plasma membrane - a landmark in the activation of non-canonical Wnt signalling(1-3). Our results suggest that the ability of xSyn4 to translocate xDsh is regulated by fibronectin, a component of the extracellular matrix required for proper convergent extension movements(4-6). We propose a model where xSyn4 and fibronectin cooperate with xFz7 and Wnt in the specific activation of the non-canonical Wnt pathway.	Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Cell & Mol Biol, Ctr Cell Regulat & Pathol, Santiago, Chile	Pontificia Universidad Catolica de Chile	Larrain, J (corresponding author), Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Cell & Mol Biol, Ctr Cell Regulat & Pathol, Alameda 340, Santiago, Chile.	jlarrain@bio.puc.cl	Oliva, Carlos/AAS-1194-2020	Oliva, Carlos/0000-0002-9551-149X; Munoz Videla, Rosana/0000-0003-1957-4103				Djiane A, 2000, DEVELOPMENT, V127, P3091; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Goto T, 2005, CURR BIOL, V15, P787, DOI 10.1016/j.cub.2005.03.040; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Marsden M, 2003, CURR BIOL, V13, P1182, DOI 10.1016/S0960-9822(03)00433-0; Marsden M, 2001, DEVELOPMENT, V128, P3635; Martin P, 2004, DEVELOPMENT, V131, P3021, DOI 10.1242/dev.01253; Medina A, 2000, MECH DEVELOP, V92, P227, DOI 10.1016/S0925-4773(00)00240-9; Moreno M, 2005, EMBO J, V24, P1397, DOI 10.1038/sj.emboj.7600615; Ohkawara B, 2003, DEVELOPMENT, V130, P2129, DOI 10.1242/dev.00435; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Solnica-Krezel L, 2005, CURR BIOL, V15, pR213, DOI 10.1016/j.cub.2005.03.016; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sumanas S, 2001, GENESIS, V30, P119, DOI 10.1002/gene.1044; Tada M, 2000, DEVELOPMENT, V127, P2227; Topczewski J, 2001, DEV CELL, V1, P251, DOI 10.1016/S1534-5807(01)00005-3; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Wallingford JB, 2001, DEVELOPMENT, V128, P2581; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wilcox-Adelman SA, 2002, GLYCOCONJUGATE J, V19, P305, DOI 10.1023/A:1025304602057; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1	27	114	123	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					492	U123		10.1038/ncb1399	http://dx.doi.org/10.1038/ncb1399			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16604063				2022-12-25	WOS:000237299400013
J	Fischer, W; Perkins, S; Theiler, J; Bhattacharya, T; Yusim, K; Funkhouser, R; Kuiken, C; Haynes, B; Letvin, NL; Walker, BD; Hahn, BH; Korber, BT				Fischer, Will; Perkins, Simon; Theiler, James; Bhattacharya, Tanmoy; Yusim, Karina; Funkhouser, Robert; Kuiken, Carla; Haynes, Barton; Letvin, Norman L.; Walker, Bruce D.; Hahn, Beatrice H.; Korber, Bette T.			Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants	NATURE MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RHESUS-MONKEYS; LYMPHOCYTE ESCAPE; VIRAL ESCAPE; TYPE-1; RESPONSES; INFECTION; IMMUNOGENICITY; ENVELOPE; AIDS	HIV-1/AIDS vaccines must address the extreme diversity of HIV-1. We have designed new polyvalent vaccine antigens comprised of sets of 'mosaic' proteins, assembled from fragments of natural sequences via a computational optimization method. Mosaic proteins resemble natural proteins, and a mosaic set maximizes the coverage of potential T-cell epitopes (peptides of nine amino acids) for a viral population. We found that coverage of viral diversity using mosaics was greatly increased compared to coverage by natural-sequence vaccine candidates, for both variable and conserved proteins; for conserved HIV-1 proteins, global coverage may be feasible. For example, four mosaic proteins perfectly matched 74% of 9-amino-acid potential epitopes in global Gag sequences; 87% of potential epitopes matched at least 8 of 9 positions. In contrast, a single natural Gag protein covered only 37% (9 of 9) and 67% (8 of 9). Mosaics provide diversity coverage comparable to that afforded by thousands of separate peptides, but, because the fragments of natural proteins are compressed into a small number of native-like proteins, they are tractable for vaccines.	Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Duke Univ, Dept Med, Durham, NC 27710 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA; Univ Alabama, Birmingham, AL 35294 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; The Santa Fe Institute; Duke University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; University of Alabama System; University of Alabama Birmingham	Korber, BT (corresponding author), Los Alamos Natl Lab, POB 1663, Los Alamos, NM 87545 USA.	btk@lanl.gov	Bhattacharya, Tanmoy/J-8956-2013; Fischer, Will/B-1323-2013; Fischer, Will/AAD-2807-2019	Bhattacharya, Tanmoy/0000-0002-1060-652X; Fischer, Will/0000-0003-4579-4062; Fischer, Will/0000-0003-4579-4062; Korber, Bette/0000-0002-2026-5757; Hahn, Beatrice/0000-0002-9400-9887	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI055421, P01AI061734] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI055421-01-A1, P01 AI061734-01] Funding Source: Medline; PHS HHS [N01-15442] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allen TM, 2005, J VIROL, V79, P12952, DOI 10.1128/JVI.79.20.12952-12960.2005; Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Altfeld M, 2003, J VIROL, V77, P7330, DOI 10.1128/JVI.77.13.7330-7340.2003; Ammaranond P, 2005, AIDS RES HUM RETROV, V21, P395, DOI 10.1089/aid.2005.21.395; Bansal A, 2005, AIDS, V19, P241; Barouch DH, 2003, J VIROL, V77, P7367, DOI 10.1128/JVI.77.13.7367-7375.2003; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Doria-Rose NA, 2005, J VIROL, V79, P11214, DOI 10.1128/JVI.79.17.11214-11224.2005; Feeney ME, 2005, J IMMUNOL, V174, P7524, DOI 10.4049/jimmunol.174.12.7524; Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004; Gao F, 2005, J VIROL, V79, P1154, DOI 10.1128/JVI.79.2.1154-1163.2005; Gaschen B, 2002, SCIENCE, V296, P2354, DOI 10.1126/science.1070441; Hanke T, 1998, VACCINE, V16, P426, DOI 10.1016/S0264-410X(97)00296-X; Hel Z, 2006, J IMMUNOL, V176, P85, DOI 10.4049/jimmunol.176.1.85; Holland JH, 1992, ADAPTATION NATURAL A, DOI DOI 10.7551/MITPRESS/1090.001.0001; Jones NA, 2004, J EXP MED, V200, P1243, DOI 10.1084/jem.20040511; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Killian MS, 2005, AIDS, V19, P887, DOI 10.1097/01.aids.0000171402.00372.c2; Kong WP, 2003, J VIROL, V77, P12764, DOI 10.1128/JVI.77.23.12764-12772.2003; Korber B, 2001, BRIT MED BULL, V58, P19, DOI 10.1093/bmb/58.1.19; Lichterfeld M, 2004, AIDS, V18, P1383, DOI 10.1097/01.aids.0000131329.51633.a3; Masemola A, 2004, J VIROL, V78, P3233, DOI 10.1128/JVI.78.7.3233-3243.2004; Milicic A, 2005, J IMMUNOL, V175, P4618, DOI 10.4049/jimmunol.175.7.4618; Moore JP, 2004, NAT MED, V10, P769, DOI 10.1038/nm0804-769; Nabel GJ, 2002, VACCINE, V20, P1945, DOI 10.1016/S0264-410X(02)00074-9; Oxenius A, 2004, J INFECT DIS, V189, P1199, DOI 10.1086/382028; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Seaman MS, 2005, J VIROL, V79, P2956, DOI 10.1128/JVI.79.5.2956-2963.2005; Singh RAK, 2002, J IMMUNOL, V169, P6779, DOI 10.4049/jimmunol.169.12.6779; Weaver EA, 2006, J VIROL, V80, P6745, DOI 10.1128/JVI.02484-05; Williamson C, 2003, AIDS RES HUM RETROV, V19, P133, DOI 10.1089/088922203762688649	32	328	364	1	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JAN	2007	13	1					100	106		10.1038/nm1461	http://dx.doi.org/10.1038/nm1461			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	123NE	17187074				2022-12-25	WOS:000243301800043
J	Tomlins, SA; Mehra, R; Rhodes, DR; Cao, XH; Wang, L; Dhanasekaran, SM; Kalyana-Sundaram, S; Wei, JT; Rubin, MA; Pienta, KJ; Shah, RB; Chinnaiyan, AM				Tomlins, Scott A.; Mehra, Rohit; Rhodes, Daniel R.; Cao, Xuhong; Wang, Lei; Dhanasekaran, Saravana M.; Kalyana-Sundaram, Shanker; Wei, John T.; Rubin, Mark A.; Pienta, Kenneth J.; Shah, Rajal B.; Chinnaiyan, Arul M.			Integrative molecular concept modeling of prostate cancer progression	NATURE GENETICS			English	Article							GENE-EXPRESSION; HIGH-GRADE; INTRAEPITHELIAL NEOPLASIA; CARCINOMA; TRANSCRIPTOME; PROFILES; MARKERS; CARCINOGENESIS; ADENOCARCINOMA; TMPRSS2	Despite efforts to profile prostate cancer, the genetic alterations and biological processes that correlate with the observed histological progression are unclear. Using laser-capture microdissection to isolate 101 cell populations, we have profiled prostate cancer progression from benign epithelium to metastatic disease. By analyzing expression signatures in the context of over 14,000 'molecular concepts', or sets of biologically connected genes, we generated an integrative model of progression. Molecular concepts that demarcate critical transitions in progression include protein biosynthesis, E26 transformation-specific (ETS) family transcriptional targets, androgen signaling and cell proliferation. Of note, relative to low-grade prostate cancer (Gleason pattern 3), high-grade cancer (Gleason pattern 4) shows an attenuated androgen signaling signature, similar to metastatic prostate cancer, which may reflect dedifferentiation and explain the clinical association of grade with prognosis. Taken together, these data show that analyzing gene expression signatures in the context of a compendium of molecular concepts is useful in understanding cancer biology.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Bioinformat Program, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; University of Michigan System; University of Michigan	Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	arul@umich.edu	Kalyana-Sundaram, Shanker/F-6860-2012; Wei, John T/E-8967-2012; Pienta, Kenneth/E-7679-2015	Rubin, Mark/0000-0002-8321-9950; Tomlins, Scott/0000-0001-8661-9821; Dhanasekaran, saravana mohan/0000-0002-0489-2224; Kalyana-Sundaram, Shanker/0000-0002-7309-3848; Pienta, Kenneth/0000-0002-4138-2186	NCI NIH HHS [UO1 CA111275-01, P50CA69568, R01 CA102872, 5P30 CA46592] Funding Source: Medline; NIDA NIH HHS [U54 DA021519-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA069568, P30CA046592, U01CA111275, R01CA102872] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [U54DA021519] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Ashida S, 2004, CANCER RES, V64, P5963, DOI 10.1158/0008-5472.CAN-04-0020; Best CJM, 2003, DIAGN MOL PATHOL, V12, P63, DOI 10.1097/00019606-200306000-00001; Bostwick DG, 2004, MODERN PATHOL, V17, P360, DOI 10.1038/modpathol.3800053; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; De Marzo AM, 2004, J CELL BIOCHEM, V91, P459, DOI 10.1002/jcb.10747; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; DeMarzo AM, 2003, LANCET, V361, P955, DOI 10.1016/S0140-6736(03)12779-1; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fischer AH, 2004, J CELL BIOCHEM, V91, P170, DOI 10.1002/jcb.10735; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Humphrey PA, 2004, MODERN PATHOL, V17, P292, DOI 10.1038/modpathol.3800054; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Konishi N, 2005, PATHOL INT, V55, P531, DOI 10.1111/j.1440-1827.2005.01865.x; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; Kristiansen G, 2005, J PATHOL, V205, P359, DOI 10.1002/path.1676; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lin BY, 1999, CANCER RES, V59, P4180; Moore S, 2005, INT J CANCER, V114, P563, DOI 10.1002/ijc.20773; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nelson Peter S, 2004, J Urol, V172, pS28, DOI 10.1097/01.ju.0000142067.17181.68; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Paris PL, 2004, HUM MOL GENET, V13, P1303, DOI 10.1093/hmg/ddh155; Quinn DI, 2005, EUR J CANCER, V41, P858, DOI 10.1016/j.ejca.2004.12.035; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rhodes DR, 2005, NAT GENET, V37, pS31, DOI 10.1038/ng1570; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sato K, 1999, JNCI-J NATL CANCER I, V91, P1574, DOI 10.1093/jnci/91.18.1574; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Stuart RO, 2004, P NATL ACAD SCI USA, V101, P615, DOI 10.1073/pnas.2536479100; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sumitomo M, 2004, CANCER CELL, V5, P67, DOI 10.1016/S1535-6108(03)00331-3; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2006, ANNU REV PATHOL-MECH, V1, P243, DOI 10.1146/annurev.pathol.1.110304.100047; Tomlins SA, 2006, NEOPLASIA, V8, P153, DOI 10.1593/neo.05754; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; True L, 2006, P NATL ACAD SCI USA, V103, P10991, DOI 10.1073/pnas.0603678103; Vaillancourt L, 1996, AM J SURG PATHOL, V20, P86, DOI 10.1097/00000478-199601000-00010; Vanaja DK, 2003, CANCER RES, V63, P3877; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Welsh JB, 2001, CANCER RES, V61, P5974	50	687	731	1	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2007	39	1					41	51		10.1038/ng1935	http://dx.doi.org/10.1038/ng1935			11	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17173048				2022-12-25	WOS:000243136500016
J	Brenchley, JM; Price, DA; Schacker, TW; Asher, TE; Silvestri, G; Rao, S; Kazzaz, Z; Bornstein, E; Lambotte, O; Altmann, D; Blazar, BR; Rodriguez, B; Teixeira-Johnson, L; Landay, A; Martin, JN; Hecht, FM; Picker, LJ; Lederman, MM; Deeks, SG; Douek, DC				Brenchley, Jason M.; Price, David A.; Schacker, Timothy W.; Asher, Tedi E.; Silvestri, Guido; Rao, Srinivas; Kazzaz, Zachary; Bornstein, Ethan; Lambotte, Olivier; Altmann, Daniel; Blazar, Bruce R.; Rodriguez, Benigno; Teixeira-Johnson, Leia; Landay, Alan; Martin, Jeffrey N.; Hecht, Frederick M.; Picker, Louis J.; Lederman, Michael M.; Deeks, Steven G.; Douek, Daniel C.			Microbial translocation is a cause of systemic immune activation in chronic HIV infection	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; T-CELL DEPLETION; COMBINATION ANTIRETROVIRAL THERAPY; INFLAMMATORY-BOWEL-DISEASE; VERSUS-HOST-DISEASE; TOLL-LIKE RECEPTORS; GASTROINTESTINAL-TRACT; TYPE-1 INFECTION; SIV INFECTION; INTESTINAL PERMEABILITY	Chronic activation of the immune system is a hallmark of progressive HIV infection and better predicts disease outcome than plasma viral load, yet its etiology remains obscure. Here we show that circulating microbial products, probably derived from the gastrointestinal tract, are a cause of HIV-related systemic immune activation. Circulating lipopolysaccharide, which we used as an indicator of microbial translocation, was significantly increased in chronically HIV-infected individuals and in simian immunodeficiency virus (SIV)-infected rhesus macaques (P <= 0.002). We show that increased lipopolysaccharide is bioactive in vivo and correlates with measures of innate and adaptive immune activation. Effective antiretroviral therapy seemed to reduce microbial translocation partially. Furthermore, in nonpathogenic SIV infection of sooty mangabeys, microbial translocation did not seem to occur. These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection.	NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; NIAID, Lab Anim Med, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Infect Dis, London W12 0NN, England; Univ Minnesota, Dept Pediat, Div Hematol Oncol & Blood & Marrow Transplantat, Minneapolis, MN 55455 USA; Case Western Reserve Univ, Cleveland, OH 44016 USA; Univ Hosp Cleveland, Cleveland, OH 44016 USA; Rush Med Coll, Dept Immunol & Microbiol, Chicago, IL 60612 USA; Univ Calif San Francisco, San Francisco, CA 90210 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97006 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Minnesota System; University of Minnesota Twin Cities; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Imperial College London; University of Minnesota System; University of Minnesota Twin Cities; Case Western Reserve University; University Hospitals of Cleveland; Rush University; University of California System; University of California San Francisco; Oregon Health & Science University	Douek, DC (corresponding author), NIAID, Human Immunol Sect, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.	ddouek@mail.nih.gov	Eckhardt, Erik/G-1567-2010; Brenchley, Jason/AAC-5085-2019; Lambotte, Olivier/GRT-0160-2022; Price, David A/C-7876-2013; Rodriguez, Benigno/C-3365-2009	Price, David A/0000-0001-9416-2737; Rodriguez, Benigno/0000-0001-9736-7957; Brenchley, Jason/0000-0001-8357-2984; Altmann, Daniel/0000-0002-2436-6192; Hecht, Frederick/0000-0002-5782-1171	MRC [G108/441] Funding Source: UKRI; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083, P51RR000165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052755, Z01AI005034, R01AI066998, R37AI066998, P30AI027763, U01AI041531, U01AI025879, U01AI038858, P30AI036219, R01AI052745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062246] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; Medical Research Council [G108/441] Funding Source: Medline; NCRR NIH HHS [M01-RR0083-37, RR-00165] Funding Source: Medline; NIAID NIH HHS [R0I AI052755, P30 AI27763, AI052745, AI066998, AI 36219, AI41531, AI 25879, AI 38858] Funding Source: Medline; NIMH NIH HHS [P30 MH62246] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aziz N, 1999, J INFECT DIS, V179, P843, DOI 10.1086/314673; Bafica A, 2004, J IMMUNOL, V172, P7229, DOI 10.4049/jimmunol.172.12.7229; Barclay G R, 1995, Prog Clin Biol Res, V392, P263; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Caradonna L, 2000, J ENDOTOXIN RES, V6, P205, DOI 10.1177/09680519000060030101; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; COHEN IR, 1966, SCIENCE, V152, P1257, DOI 10.1126/science.152.3726.1257; Cooke KR, 2002, J ENDOTOXIN RES, V8, P441, DOI 10.1179/096805102125001046; Emu B, 2005, J VIROL, V79, P14169, DOI 10.1128/JVI.79.22.14169-14178.2005; Fort MM, 2005, J IMMUNOL, V174, P6416, DOI 10.4049/jimmunol.174.10.6416; George MD, 2005, J VIROL, V79, P2709, DOI 10.1128/JVI.79.5.2709-2719.2005; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Grossman Z, 2006, NAT MED, V12, P289, DOI 10.1038/nm1380; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Haas DW, 1998, J INFECT DIS, V177, P1746, DOI 10.1086/517437; Hazenberg MD, 2000, BLOOD, V95, P249, DOI 10.1182/blood.V95.1.249.001k40_249_255; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; Hill GR, 1999, J CLIN INVEST, V104, P459, DOI 10.1172/JCI6896; Holmes CL, 2003, CHEST, V124, P1103, DOI 10.1378/chest.124.3.1103; Ito T, 2006, BLOOD, V107, P2423, DOI 10.1182/blood-2005-07-2709; Kitchens RL, 2005, J ENDOTOXIN RES, V11, P225, DOI 10.1179/096805105X46565; Kotler DP, 2005, AIDS, V19, P107, DOI 10.1097/00002030-200501280-00002; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; Lederman MM, 1998, J INFECT DIS, V178, P70, DOI 10.1086/515591; Lien E, 1998, BLOOD, V92, P2084, DOI 10.1182/blood.V92.6.2084.418k26_2084_2092; MacArthur RD, 2000, J INFECT DIS, V181, P1486, DOI 10.1086/315370; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Morris L, 1998, J EXP MED, V188, P233, DOI 10.1084/jem.188.2.233; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049; Sankaran S, 2005, P NATL ACAD SCI USA, V102, P9860, DOI 10.1073/pnas.0503463102; Schietroma M, 2006, ANN SURG, V243, P359, DOI 10.1097/01.sla.0000201455.89037.f6; Schietroma Mario, 2006, Chir Ital, V58, P171; Sharpstone D, 1999, GUT, V45, P70, DOI 10.1136/gut.45.1.70; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; Skoner DP, 1999, J INFECT DIS, V180, P10, DOI 10.1086/314823; Strutz F, 1999, INTENS CARE MED, V25, P435, DOI 10.1007/s001340050877; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Titanji K, 2006, BLOOD, V108, P1580, DOI 10.1182/blood-2005-11-013383; Valdez H, 1997, AIDS Clin Rev, P187; Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; WELLMANN W, 1986, GUT, V27, P814, DOI 10.1136/gut.27.7.814; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H; Zaunders JJ, 2001, J INFECT DIS, V183, P736, DOI 10.1086/318827	50	2518	2613	1	180	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2006	12	12					1365	1371		10.1038/nm1511	http://dx.doi.org/10.1038/nm1511			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17115046	Green Published			2022-12-25	WOS:000242618200016
J	Brenner, R; Ellis-Grosse, EJ; Echols, R				Brenner, Randall; Ellis-Grosse, Evelyn J.; Echols, Roger			Moving goalposts - regulatory oversight of antibacterial drugs	NATURE BIOTECHNOLOGY			English	Editorial Material							ANTIMICROBIAL DRUGS; NEED		Wyeth Pharmaceut, Collegeville, PA 19426 USA; E2g Biopharmaceut Counseling, Downingtown, PA 19335 USA	Pfizer	Brenner, R (corresponding author), Wyeth Pharmaceut, 500 Arcolo Rd, Collegeville, PA 19426 USA.	brenner1@wyeth.com; evelyn@e2gconsulting.com						BAKHLE D, 2003, BUSINESS BRIEFING PH; BLASER MJ, 2006, COMMUNICATION   0928; Bradley JS, 2003, PEDIATR INFECT DIS J, V22, P982, DOI 10.1097/01.inf.0000094940.81959.14; *EUR MED AG COMM P, 2004, NOT GUID EV MED PROD; GETZ KA, 2005, APPL CLIN TRIAL 1201; *INT C HARM, 2000, ICH HARM TRIP GUID E; International Conference of Harmonization (ICH), 1998, ETHN FACT ACC FOR CL; International Conference on Harmonization, 2003, ICH HARM TRIP GUID E; *JAP FARM MED SAF, 1998, GUID CLIN EV ANT DRU; Livermore DM, 2004, CLIN MICROBIOL INFEC, V10, P1, DOI 10.1111/j.1465-0691.2004.1004.x; Metlay JP, 2006, EMERG INFECT DIS, V12, P183; Nordberg P, 2005, ANTIBACTERIAL RESIST; Norrby SR, 2005, LANCET INFECT DIS, V5, P115, DOI 10.1016/S1473-3099(05)01283-1; Powers JH, 2004, CLIN MICROBIOL INFEC, V10, P23, DOI 10.1111/j.1465-0691.2004.1007.x; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Spellberg B, 2004, CLIN INFECT DIS, V38, P1279, DOI 10.1086/420937; Talbot GH, 2006, CLIN INFECT DIS, V42, P657, DOI 10.1086/499819; *TASK FORC ANT AV, 2004, BAD BUGS DRUGS ANT R; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; U.S. Food and Drug Administration, 1977, GUID CLIN EV ANT DRU, P77; *US FDA, 1992, FDA POINTS CONS CLIN; *US FDA, 2004, ANT RES DRUG DEV FDA; *US FDA, 1998, GUID IND DEV ANT DRU; *US FDA, 2004, GEN PRINCIPLES EMEA; *US FDA CTR DRUG E, 1998, GUID IND E9 STAT PRI; US Food and Drug Administration, 1999, GUID IND POP PHARM; Weber JT, 2005, EMERG INFECT DIS, V11, P791, DOI 10.3201/eid1106.050471; World Health Organization, 2001, WHO GLOB STRAT CONT	28	4	4	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2006	24	12					1515	1519		10.1038/nbt1206-1515	http://dx.doi.org/10.1038/nbt1206-1515			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	116IL	17160053				2022-12-25	WOS:000242795800027
J	De la Fuente, R; Baumann, C; Fan, T; Schmidtmann, A; Dobrinski, I; Muegge, K				De La Fuente, Rabindranath; Baumann, Claudia; Fan, Tao; Schmidtmann, Anja; Dobrinski, Ina; Muegge, Kathrin			Lsh is required for meiotic chromosome synapsis and retrotransposon silencing in female germ cells	NATURE CELL BIOLOGY			English	Article							SNF2 FAMILY; MOUSE; HETEROCHROMATIN; OOCYTES; GENE; MICE; LOCALIZATION; METHYLATION; MEMBER	Lymphoid specific helicase (Lsh) is a major epigenetic regulator that is essential for DNA methylation and transcriptional silencing of parasitic elements in the mammalian genome(1,2). However, whether Lsh is involved in the regulation of chromatin-mediated processes during meiosis is not known. Here, we show that Lsh is essential for the completion of meiosis and transcriptional repression of repetitive elements in the female gonad. Oocytes from Lsh knockout mice exhibit demethylation of transposable elements and tandem repeats at pericentric heterochromatin, as well as incomplete chromosome synapsis associated with persistent RAD51 foci and gamma H2AX phosphorylation. Failure to load crossover-associated foci results in the generation of non-exchange chromosomes. The severe oocyte loss observed and lack of ovarian follicle formation, together with the patterns of Lsh nuclear compartmentalization in the germ line, demonstrate that Lsh has a critical and previously unidentified role in epigenetic gene silencing and maintenance of genomic stability during female meiosis.	Univ Penn, Sch Vet Med, Female Germ Cell Biol Grp, Dept Clin Studies,Ctr Anim Transgenesis & Germ Ce, Kennett Sq, PA 19348 USA; NCI, Mol Immunoregulat Lab, SAIC Basic Res Program, Frederick, MD 21701 USA	University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	De la Fuente, R (corresponding author), Univ Penn, Sch Vet Med, Female Germ Cell Biol Grp, Dept Clin Studies,Ctr Anim Transgenesis & Germ Ce, 382 W St Rd,Kennett Sq, Kennett Sq, PA 19348 USA.	rfuente@vet.upenn.edu	Dobrinski, Ina/A-1095-2007	Baumann, Claudia/0000-0002-4647-0839	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042740] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR017359] Funding Source: NIH RePORTER; NCRR NIH HHS [RR17359] Funding Source: Medline; NICHD NIH HHS [HD042740] Funding Source: Medline; PHS HHS [N01-C0-12400] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Bourc'his D, 2004, NATURE, V431, P96, DOI 10.1038/nature02886; De La Fuente R, 2004, DEV BIOL, V275, P447, DOI 10.1016/j.ydbio.2004.08.028; Dennis K, 2001, GENE DEV, V15, P2940, DOI 10.1101/gad.929101; Di Giacomo M, 2005, P NATL ACAD SCI USA, V102, P737, DOI 10.1073/pnas.0406212102; Fan T, 2005, DEVELOPMENT, V132, P635, DOI 10.1242/dev.01612; Geiman TM, 1998, GENOMICS, V54, P477, DOI 10.1006/geno.1998.5557; Geiman TM, 2001, BBA-GEN SUBJECTS, V1526, P211, DOI 10.1016/S0304-4165(01)00129-5; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Hayashi K, 2005, NATURE, V438, P374, DOI 10.1038/nature04112; Huang JQ, 2004, NUCLEIC ACIDS RES, V32, P5019, DOI 10.1093/nar/gkh821; Jarvis CD, 1996, GENE, V169, P203, DOI 10.1016/0378-1119(95)00843-8; Johnson J, 2004, NATURE, V428, P145, DOI 10.1038/nature02316; Kneitz B, 2000, GENE DEV, V14, P1085; LAMMERS JHM, 1994, MOL CELL BIOL, V14, P1137, DOI 10.1128/MCB.14.2.1137; Libby BJ, 2002, DEV BIOL, V242, P174, DOI 10.1006/dbio.2001.0535; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Muegge K, 2005, BIOCHEM CELL BIOL, V83, P548, DOI 10.1139/O05-119; Obata Y, 2002, NATURE, V418, P497, DOI 10.1038/418497a; Page SL, 2003, SCIENCE, V301, P785, DOI 10.1126/science.1086605; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Petukhova GV, 2003, DEV CELL, V5, P927, DOI 10.1016/S1534-5807(03)00369-1; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Sun LQ, 2004, GENE DEV, V18, P1035, DOI 10.1101/gad.1176104; Turner JMA, 2005, NAT GENET, V37, P41, DOI 10.1038/ng1484; Webster KE, 2005, P NATL ACAD SCI USA, V102, P4068, DOI 10.1073/pnas.0500702102; Yan QS, 2003, EMBO J, V22, P5154, DOI 10.1093/emboj/cdg493; Yuan L, 2002, SCIENCE, V296, P1115, DOI 10.1126/science.1070594; Zhu HM, 2006, EMBO J, V25, P335, DOI 10.1038/sj.emboj.7600925	30	99	102	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1448	U85		10.1038/ncb1513	http://dx.doi.org/10.1038/ncb1513			10	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17115026				2022-12-25	WOS:000242419800022
J	Ulmer, JB; Valley, U; Rappuoli, R				Ulmer, Jeffrey B.; Valley, Ulrich; Rappuoli, Rino			Vaccine manufacturing: challenges and solutions	NATURE BIOTECHNOLOGY			English	Article							A H3N2 VIRUSES; HEALTHY-ADULTS; HEPATITIS-B; DNA VACCINE; PROTECTIVE ANTIGEN; BACILLUS-ANTHRACIS; INFLUENZA VACCINE; REVERSE GENETICS; FOLLOW-UP; RECOMBINANT	The recent influenza vaccine shortages have provided a timely reminder of the tenuous nature of the world's vaccine supply and the potential for manufacturing issues to severely disrupt vital access to important vaccines. The application of new technologies to the discovery, assessment, development and production of vaccines has the potential to prevent such occurrences and enable the introduction of new vaccines. Gene- based vaccines, virus- like particles, plant- derived vaccines and novel adjuvants and delivery systems represent promising approaches to creating safer, more potent vaccines. As a consequence, more people will have faster access to more effective vaccines against a broader spectrum of infectious diseases. However, the increased cost of producing new vaccines and regulatory uncertainty remain challenges for vaccine manufacturers.	Novartis Vaccines & Diagnost, Emeryville, CA 94608 USA; GMBH & Co KG, Novartis Vaccines & Diagnost, D-35041 Marburg, Germany; Novartis Vaccines & Diagnost SRL, I-53100 Siena, Italy	Novartis; Novartis; Novartis	Ulmer, JB (corresponding author), Novartis Vaccines & Diagnost, 4560 Horton St,Mailtop 4-3, Emeryville, CA 94608 USA.	jeffrey_ulmer@chiron.com						Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6; Belshe Robert, 2004, Expert Rev Vaccines, V3, P643, DOI 10.1586/14760584.3.6.643; Buonagurio DA, 2006, VACCINE, V24, P2151, DOI 10.1016/j.vaccine.2005.11.007; Cooper CL, 2004, J CLIN IMMUNOL, V24, P693, DOI 10.1007/s10875-004-6244-3; Cooper MR, 2002, SOUTHERN MED J, V95, P1113, DOI 10.1097/00007611-200210000-00002; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Farchaus JW, 1998, APPL ENVIRON MICROB, V64, P982; Germann TC, 2006, P NATL ACAD SCI USA, V103, P5935, DOI 10.1073/pnas.0601266103; Greco M, 2001, VACCINE, V19, P1606, DOI 10.1016/S0264-410X(00)00359-5; Halperin SA, 2002, VACCINE, V20, P1240, DOI 10.1016/S0264-410X(01)00428-5; HARDY CT, 1995, VIROLOGY, V211, P302, DOI 10.1006/viro.1995.1405; Harper DM, 2006, LANCET, V367, P1247, DOI 10.1016/S0140-6736(06)68439-0; Hoare M, 2005, BIOTECHNOL PROGR, V21, P1577, DOI 10.1021/bp050190n; Holst J, 2003, VACCINE, V21, P734, DOI 10.1016/S0264-410X(02)00591-1; KATZ JM, 1992, J GEN VIROL, V73, P1159, DOI 10.1099/0022-1317-73-5-1159; Kazzaz J, 2006, J CONTROL RELEASE, V110, P566, DOI 10.1016/j.jconrel.2005.10.010; Langermans JAM, 2005, VACCINE, V23, P2740, DOI 10.1016/j.vaccine.2004.11.051; Martineau Bill, 2004, Mater Manag Health Care, V13, P42; McConkey SJ, 2003, NAT MED, V9, P729, DOI 10.1038/nm881; McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128; Neumann G, 2005, P NATL ACAD SCI USA, V102, P16825, DOI 10.1073/pnas.0505587102; Nicolson C, 2005, VACCINE, V23, P2943, DOI 10.1016/j.vaccine.2004.08.054; Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Rappuoli R, 2002, SCIENCE, V297, P937, DOI 10.1126/science.1075173; Ribot WJ, 2006, VACCINE, V24, P3469, DOI 10.1016/j.vaccine.2006.02.013; Rottinghaus ST, 2003, VACCINE, V21, P4604, DOI 10.1016/S0264-410X(03)00447-X; Sheridan C, 2005, NAT BIOTECHNOL, V23, P1359, DOI 10.1038/nbt1105-1359; Tacket CO, 2005, VACCINE, V23, P1866, DOI 10.1016/j.vaccine.2004.11.019; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Thanavala Y, 2005, P NATL ACAD SCI USA, V102, P3378, DOI 10.1073/pnas.0409899102; Ulmer JB, 2006, TRENDS MOL MED, V12, P216, DOI 10.1016/j.molmed.2006.03.007; Vandepapeliere P, 2005, VACCINE, V23, P2591, DOI 10.1016/j.vaccine.2004.11.034; Vidal D, 2006, MINI-REV MED CHEM, V6, P499, DOI 10.2174/138955706776876131; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476; Wille-Reece U, 2005, J IMMUNOL, V174, P7676, DOI 10.4049/jimmunol.174.12.7676	36	232	249	2	59	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2006	24	11					1377	1383		10.1038/nbt1261	http://dx.doi.org/10.1038/nbt1261			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	106TP	17093488	Bronze			2022-12-25	WOS:000242124700034
J	Lang, MR; Lapierre, LA; Frotscher, M; Goldenring, JR; Knapik, EW				Lang, Michael R.; Lapierre, Lynne A.; Frotscher, Michael; Goldenring, James R.; Knapik, Ela W.			Secretory COPII coat component Sec23a is essential for craniofacial chondrocyte maturation	NATURE GENETICS			English	Article							TO-GOLGI TRANSPORT; II COLLAGEN GENE; ENDOPLASMIC-RETICULUM; VESICLE FORMATION; LIVING CELLS; ZEBRAFISH; EXPRESSION; MUTATIONS; REVEALS; PATHWAY	An increasing number of human disorders have been linked to mutations in genes of the secretory pathway. The chemically induced zebrafish crusher variant results in malformed craniofacial skeleton, kinked pectoral fins and a short body length. By positional cloning, we identified a nonsense mutation converting leucine to a stop codon (L402X) in the sec23a gene, an integral component of the COPII complex, which is critical for anterograde protein trafficking between endoplasmic reticulum and Golgi apparatus. Zebrafish crusher mutants develop normally until the onset of craniofacial chondrogenesis. crusher chondrocytes accumulate proteins in a distended endoplasmic reticulum, resulting in severe reduction of cartilage extracellular matrix (ECM) deposits, including type II collagen. We demonstrate that the paralogous gene sec23b is also an essential component of the ECM secretory pathway in chondrocytes. In contrast, knockdown of the COPI complex does not hinder craniofacial morphogenesis. As SEC23A lesions cause the cranio-lenticulo-sutural dysplasia syndrome, crusher provides the first vertebrate model system that links the biology of endoplasmic reticulum to Golgi trafficking with a clinically relevant dysmorphology.	Vanderbilt Univ, Med Ctr, Dept Med, Div Med Genet, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Univ Freiburg, Inst Biol 1, Dept Biol, D-79104 Freiburg, Germany; Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA; Univ Freiburg, Inst Anat & Cell Biol, D-79104 Freiburg, Germany; Nashville Vet Adm Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; University of Freiburg; Vanderbilt University; University of Freiburg	Knapik, EW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Med Genet, Nashville, TN 37232 USA.	ela.knapik@vanderbilt.edu	Knapik, Ela W./J-6172-2014	Knapik, Ela W./0000-0002-2977-3619				Bandoh N, 2005, TISSUE ANTIGENS, V66, P185, DOI 10.1111/j.1399-0039.2005.00462.x; Barrallo-Gimeno A, 2004, DEVELOPMENT, V131, P1463, DOI 10.1242/dev.01033; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi XP, 2002, NATURE, V419, P271, DOI 10.1038/nature01040; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Boyadjiev SA, 2003, HUM GENET, V113, P1, DOI 10.1007/s00439-003-0932-6; Boyadjiev SA, 2006, NAT GENET, V38, P1192, DOI 10.1038/ng1876; Chiang EFL, 2001, DEV BIOL, V231, P149, DOI 10.1006/dbio.2000.0129; Coutinho P, 2004, DEV CELL, V7, P547, DOI 10.1016/j.devcel.2004.07.020; Gebe JA, 2002, TISSUE ANTIGENS, V59, P78, DOI 10.1034/j.1399-0039.2002.590202.x; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; Jones B, 2003, NAT GENET, V34, P29, DOI 10.1038/ng1145; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; Ma YJ, 2004, J CHEM NEUROANAT, V28, P51, DOI 10.1016/j.jchemneu.2003.08.007; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Mironov AA, 2003, DEV CELL, V5, P583, DOI 10.1016/S1534-5807(03)00294-6; Neuhauss SCF, 1996, DEVELOPMENT, V123, P357; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Paccaud JP, 1996, MOL BIOL CELL, V7, P1535, DOI 10.1091/mbc.7.10.1535; Pearson J, 1996, JUVENILE FAM COURT J, V47, P15, DOI 10.1111/j.1755-6988.1996.tb00751.x; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; Stagg SM, 2006, NATURE, V439, P234, DOI 10.1038/nature04339; Stephens DJ, 2002, J CELL SCI, V115, P1149; YAN YL, 1995, DEV DYNAM, V203, P363, DOI 10.1002/aja.1002030308; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	30	144	147	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1198	1203		10.1038/ng1880	http://dx.doi.org/10.1038/ng1880			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16980978				2022-12-25	WOS:000241251100021
J	Vagnarelli, P; Hudson, DF; Ribeiro, SA; Trinkle-Mulcahy, L; Spence, JM; Lai, F; Farr, CJ; Lamond, AI; Earnshaw, WC				Vagnarelli, Paola; Hudson, Damien F.; Ribeiro, Susana A.; Trinkle-Mulcahy, Laura; Spence, Jennifer M.; Lai, Fan; Farr, Christine J.; Lamond, Angus I.; Earnshaw, William C.			Condensin and Repo-Man-PP1 co-operate in the regulation of chromosome architecture during mitosis	NATURE CELL BIOLOGY			English	Article							STRUCTURAL INTEGRITY; SISTER CHROMATIDS; TOPOISOMERASE-II; ESSENTIAL ROLES; AURORA-B; CENP-C; PROTEIN; SEGREGATION; RESOLUTION; FAMILY	The reversible condensation of chromosomes during cell division remains a classic problem in cell biology. Condensation requires the condensin complex(1) in certain experimental systems(2-8), but not in many others(9-15). Anaphase chromosome segregation almost always fails in condensin-depleted cells, leading to the formation of prominent chromatin bridges and cytokinesis failure(4,9-17). Here, live-cell analysis of chicken DT40 cells bearing a conditional knockout of condensin subunit SMC2 revealed that condensin-depleted chromosomes abruptly lose their compact architecture during anaphase and form massive chromatin bridges. The compact chromosome structure can be preserved and anaphase chromosome segregation rescued by preventing the targeting subunit Repo-Man from recruiting protein phosphatase 1 (PP1) to chromatin at anaphase onset. This study identifies an activity critical for mitotic chromosome structure that is inactivated by Repo-Man-PP1 during anaphase. This activity, provisionally termed 'regulator of chromosome architecture' (RCA), cooperates with condensin to preserve the characteristic chromosome architecture during mitosis.	Univ Edinburgh, Inst Cell Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; IPATIMUP, P-4050465 Oporto, Portugal; Univ Dundee, Dundee DD1 5EH, Scotland; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Edinburgh; University of Dundee; University of Cambridge	Earnshaw, WC (corresponding author), Univ Edinburgh, Inst Cell Biol, Wellcome Trust Ctr Cell Biol, Swann Bldg,Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.	Bill.Earnshaw@ed.ac.uk	Fukagawa, Tatsuo/AAK-3922-2021; lai, fan/A-9732-2011; Earnshaw, William/AAY-7438-2020; Trinkle-Mulcahy, Laura/E-2197-2013; Lai, Fan/ABD-2862-2021; Vagnarelli, Paola/AAI-1996-2020	Vagnarelli, Paola/0000-0002-0000-2271; Earnshaw, William/0000-0002-7191-0621; Farr, Christine/0000-0002-5357-5962; Lamond, Angus/0000-0001-6204-6045; Lai, Fan/0000-0002-0568-2616	Wellcome Trust [073915, 073980] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adams RR, 2001, J CELL BIOL, V153, P865, DOI 10.1083/jcb.153.4.865; Aono N, 2002, NATURE, V417, P197, DOI 10.1038/417197a; Belmont AS, 1998, TRENDS CELL BIOL, V8, P121, DOI 10.1016/S0962-8924(97)01211-7; Bhalla N, 2002, MOL BIOL CELL, V13, P632, DOI 10.1091/mbc.01-05-0264; Coelho PA, 2003, J CELL SCI, V116, P4763, DOI 10.1242/jcs.00799; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; Eckley DM, 1997, J CELL BIOL, V136, P1169, DOI 10.1083/jcb.136.6.1169; Fukagawa T, 2001, EMBO J, V20, P4603, DOI 10.1093/emboj/20.16.4603; Gerlich D, 2006, CURR BIOL, V16, P333, DOI 10.1016/j.cub.2005.12.040; Hagstrom KA, 2002, GENE DEV, V16, P729, DOI 10.1101/gad.968302; Hirano T, 2005, CURR BIOL, V15, pR265, DOI 10.1016/j.cub.2005.03.037; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Hirota T, 2004, J CELL SCI, V117, P6435, DOI 10.1242/jcs.01604; Hudson DF, 2003, DEV CELL, V5, P323, DOI 10.1016/S1534-5807(03)00199-0; Kaitna S, 2002, CURR BIOL, V12, P798, DOI 10.1016/S0960-9822(02)00820-5; Lavoie BD, 2000, MOL BIOL CELL, V11, P1293, DOI 10.1091/mbc.11.4.1293; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Oliveira RA, 2005, MOL CELL BIOL, V25, P8971, DOI 10.1128/MCB.25.20.8971-8984.2005; Ono T, 2003, CELL, V115, P109, DOI 10.1016/S0092-8674(03)00724-4; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Savvidou E, 2005, J CELL SCI, V118, P2529, DOI 10.1242/jcs.02392; Spence JM, 2002, EMBO J, V21, P5269, DOI 10.1093/emboj/cdf511; Steffensen S, 2001, CURR BIOL, V11, P295, DOI 10.1016/S0960-9822(01)00096-3; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sutani T, 1999, GENE DEV, V13, P2271, DOI 10.1101/gad.13.17.2271; Trinkle-Mulcahy L, 2006, J CELL BIOL, V172, P679, DOI 10.1083/jcb.200508154	30	174	179	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1133	U161		10.1038/ncb1475	http://dx.doi.org/10.1038/ncb1475			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16998479	Green Accepted			2022-12-25	WOS:000241395300018
J	Clarke, MCH; Figg, N; Maguire, JJ; Davenport, AP; Goddard, M; Littlewood, TD; Bennett, MR				Clarke, Murray C. H.; Figg, Nichola; Maguire, Janet J.; Davenport, Anthony P.; Goddard, Martin; Littlewood, Trevor D.; Bennett, Martin R.			Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis	NATURE MEDICINE			English	Article							DIPHTHERIA-TOXIN; CELLULAR PROLIFERATION; ARTERIAL INJURY; TRANSGENIC MICE; FAS LIGAND; DEATH; EXPRESSION; RECEPTOR; MACROPHAGES; DEPLETION	Vascular smooth muscle cell (VSMC) apoptosis occurs in many arterial diseases, including aneurysm formation, angioplasty restenosis and atherosclerosis. Although VSMC apoptosis promotes vessel remodeling, coagulation and inflammation, its precise contribution to these diseases is unknown, given that apoptosis frequently accompanies vessel injury or alterations to flow. To study the direct consequences of VSMC apoptosis, we generated transgenic mice expressing the human diphtheria toxin receptor (hDTR, encoded by HBEGF) from a minimal Tagln (also known as SM22 alpha) promoter. Despite apoptosis inducing loss of 50 - 70% of VSMCs, normal arteries showed no inflammation, reactive proliferation, thrombosis, remodeling or aneurysm formation. In contrast, VSMC apoptosis in atherosclerotic plaques of SM22 alpha-hDTR Apoe(-/-) mice induced marked thinning of fibrous cap, loss of collagen and matrix, accumulation of cell debris and intense intimal inflammation. We conclude that VSMC apoptosis is 'silent' in normal arteries, which have a large capacity to withstand cell loss. In contrast, VSMC apoptosis alone is sufficient to induce features of plaque vulnerability in atherosclerosis. SM22 alpha-hDTR Apoe(-/-) mice may represent an important new model to test agents proposed to stabilize atherosclerotic plaques.	Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, ACCI, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Pharmacol, ACCI, Cambridge CB2 2QQ, England; Papworth Hosp, Dept Pathol, Cambridge CB3 8RE, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; GlaxoSmithKline; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; GlaxoSmithKline; University of Cambridge; Papworth Hospital	Bennett, MR (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Cardiovasc Med, ACCI, Box 110, Cambridge CB2 2QQ, England.	mrb@mole.bio.cam.ac.uk	Davenport, Anthony P./A-5773-2008; Maguire, Janet J/Z-2180-2019	Davenport, Anthony P./0000-0002-2096-3117; Maguire, Janet J/0000-0002-9254-7040; Bennett, Martin/0000-0002-2565-1825; Clarke, Murray/0000-0002-8215-8885				Bauriedel G, 1999, CARDIOVASC RES, V41, P480, DOI 10.1016/S0008-6363(98)00318-6; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; CHO A, 1995, CIRC RES, V76, P168, DOI 10.1161/01.RES.76.2.168; Cho A, 1997, CIRC RES, V81, P328, DOI 10.1161/01.RES.81.3.328; CHUNG DW, 1977, BIOCHIM BIOPHYS ACTA, V483, P248, DOI 10.1016/0005-2744(77)90053-5; CLOWES AW, 1983, LAB INVEST, V49, P327; CLOWES AW, 1986, LAB INVEST, V54, P295; CLOWES AW, 1985, CIRC RES, V56, P139, DOI 10.1161/01.RES.56.1.139; DAVIES MJ, 1993, BRIT HEART J, V69, P377; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; GENG YJ, 1995, AM J PATHOL, V147, P251; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; KEEN JH, 1982, P NATL ACAD SCI-BIOL, V79, P2912, DOI 10.1073/pnas.79.9.2912; Kolodgie FD, 2000, AM J PATHOL, V157, P1259, DOI 10.1016/S0002-9440(10)64641-X; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Littlewood TD, 2003, CURR OPIN LIPIDOL, V14, P469, DOI 10.1097/00041433-200310000-00007; LopezCandales A, 1997, AM J PATHOL, V150, P993; Lutgens E, 1999, CARDIOVASC RES, V41, P473, DOI 10.1016/S0008-6363(98)00311-3; Malik N, 1998, CIRCULATION, V98, P1657, DOI 10.1161/01.CIR.98.16.1657; Mitamura T, 1997, J BIOL CHEM, V272, P27084, DOI 10.1074/jbc.272.43.27084; NAGLICH JG, 1992, P NATL ACAD SCI USA, V89, P2170, DOI 10.1073/pnas.89.6.2170; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Saito M, 2001, NAT BIOTECHNOL, V19, P746, DOI 10.1038/90795; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Schaub FJ, 2003, CIRC RES, V93, P515, DOI 10.1161/01.RES.0000093205.42313.7C; Schneider DB, 2000, ARTERIOSCL THROM VAS, V20, P298, DOI 10.1161/01.ATV.20.2.298; XU W, 1996, BLOOD	30	508	529	2	54	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1075	1080		10.1038/nm1459	http://dx.doi.org/10.1038/nm1459			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16892061				2022-12-25	WOS:000240373900032
J	Ziv, Y; Bielopolski, D; Galanty, Y; Lukas, C; Taya, Y; Schultz, DC; Lukas, J; Bekker-Jensen, S; Bartek, J; Shiloh, Y				Ziv, Yael; Bielopolski, Dana; Galanty, Yaron; Lukas, Claudia; Taya, Yoichi; Schultz, David C.; Lukas, Jiri; Bekker-Jensen, Simon; Bartek, Jiri; Shiloh, Yosef			Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM and KAP-1 dependent pathway	NATURE CELL BIOLOGY			English	Article							ZINC-FINGER PROTEINS; CELLULAR-RESPONSE; REPRESSOR DOMAIN; IN-VIVO; DAMAGE; TRANSCRIPTION; COREPRESSOR; GENOME; REPAIR; CELLS	The cellular DNA-damage response is a signaling network that is vigorously activated by cytotoxic DNA lesions, such as double-strand breaks ( DSBs) 1. The DSB response is mobilized by the nuclear protein kinase ATM, which modulates this process by phosphorylating key players in these pathways(2). A long-standing question in this field is whether DSB formation affects chromatin condensation. Here, we show that DSB formation is followed by ATM-dependent chromatin relaxation. ATM's effector in this pathway is the protein KRAB-associated protein ( KAP-1, also known as TIF1 beta, KRIP-1 or TRIM28), previously known as a corepressor of gene transcription(3,4). In response to DSB induction, KAP-1 is phosphorylated in an ATM-dependent manner on Ser 824. KAP-1 is phosphorylated exclusively at the damage sites, from which phosphorylated KAP-1 spreads rapidly throughout the chromatin. Ablation of the phosphorylation site of KAP- 1 leads to loss of DSB-induced chromatin decondensation and renders the cells hypersensitive to DSB-inducing agents. Knocking down KAP-1, or mimicking a constitutive phosphorylation of this protein, leads to constitutive chromatin relaxation. These results suggest that chromatin relaxation is a fundamental pathway in the DNA-damage response and identify its primary mediators.	Tel Aviv Univ, Sackler Sch Med, David & Inez Myers Lab Genet Res, Dept Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; Ctr Genotox Stress Res, DK-2100 Copenhagen, Denmark; Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Tel Aviv University; Sackler Faculty of Medicine; Danish Cancer Society; National Cancer Center - Japan; Case Western Reserve University	Ziv, Y (corresponding author), Tel Aviv Univ, Sackler Sch Med, David & Inez Myers Lab Genet Res, Dept Mol Genet & Biochem, IL-69978 Tel Aviv, Israel.	yaelz@post.tau.ac.il; yossih@post.tau.ac.il	Bartek, Jiri/G-5870-2014	Lukas, Claudia/0000-0001-7169-6883; Bekker-Jensen, Simon/0000-0002-7308-4597; Bielopolski, Dana/0000-0001-9476-0032; Lukas, Jiri/0000-0001-9087-506X; Galanty, Yaron/0000-0001-7167-9004	NINDS NIH HHS [NS31763] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Bhoumik A, 2005, MOL CELL, V18, P577, DOI 10.1016/j.molcel.2005.04.015; Birger Y, 2003, EMBO J, V22, P1665, DOI 10.1093/emboj/cdg142; Biton S, 2006, J BIOL CHEM, V281, P17482, DOI 10.1074/jbc.M601895200; Cammas F, 2000, DEVELOPMENT, V127, P2955; Carpenter AE, 2005, MOL CELL BIOL, V25, P958, DOI 10.1128/MCB.25.3.958-968.2005; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Essers J, 2002, EMBO J, V21, P2030, DOI 10.1093/emboj/21.8.2030; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gontijo AMDC, 2003, BIOCHIMIE, V85, P1133, DOI 10.1016/j.biochi.2003.10.018; JABERABOANSARI A, 1989, RADIAT RES, V119, P57, DOI 10.2307/3577367; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kruhlak MJ, 2006, J CELL BIOL, V172, P823, DOI 10.1083/jcb.200510015; LE DB, 1996, EMBO J, V15, P6701; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Lu Qianjin, 2004, Methods Mol Biol, V287, P77; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Muller WG, 2001, J CELL BIOL, V154, P33, DOI 10.1083/jcb.200011069; Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002; Phair RD, 2004, METHOD ENZYMOL, V375, P393; Phair RD, 2004, MOL CELL BIOL, V24, P6393, DOI 10.1128/MCB.24.14.6393-6402.2004; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SHILOH Y, 2006, TRENDS BIOCH SCI; Shinozaki T, 2003, ONCOGENE, V22, P8870, DOI 10.1038/sj.onc.1207176; TAKAHASHI K, 1985, INT J RADIAT BIOL, V48, P389, DOI 10.1080/09553008514551391; TELFORD DJ, 1989, INT J BIOCHEM, V21, P127, DOI 10.1016/0020-711X(89)90100-6; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Verger A, 2004, CELL MOL LIFE SCI, V61, P2154, DOI 10.1007/s00018-004-4176-y; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	39	540	556	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					870	U142		10.1038/ncb1446	http://dx.doi.org/10.1038/ncb1446			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16862143				2022-12-25	WOS:000239423000018
J	Almeida, AM; Murakami, Y; Layton, DM; Hillmen, P; Sellick, GS; Maeda, Y; Richards, S; Patterson, S; Kotsianidis, I; Mollica, L; Crawford, DH; Baker, A; Ferguson, M; Roberts, I; Houlston, R; Kinoshita, T; Karadimitris, A				Almeida, Antonio M.; Murakami, Yoshiko; Layton, D. Mark; Hillmen, Peter; Sellick, Gabrielle S.; Maeda, Yusuke; Richards, Stephen; Patterson, Scott; Kotsianidis, Ioannis; Mollica, Luigina; Crawford, Dorothy H.; Baker, Alastair; Ferguson, Michael; Roberts, Irene; Houlston, Richard; Kinoshita, Taroh; Karadimitris, Anastasios			Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency	NATURE MEDICINE			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GPI-ANCHOR; MEMBRANE-PROTEIN; 3RD MANNOSE; GLYCOSYLATION; CELLS; BIOSYNTHESIS; PATHOGENESIS; SURFACE; LYSIS	Attachment to the plasma membrane by linkage to a glycosylphosphatidylinositol (GPI) anchor(1) is a mode of protein expression highly conserved from protozoa to mammals(2). As a clinical entity, deficiency of GPI has been recognized as paroxysmal nocturnal hemoglobinuria, an acquired clonal disorder associated with somatic mutations of the X-linked PIGA gene in hematopoietic cells(3,4). We have identified a novel disease characterized by a propensity to venous thrombosis and seizures in which deficiency of GPI is inherited in an autosomal recessive manner. In two unrelated kindreds, a point mutation (c -> g) at position -270 from the start codon of PIGM, a mannosyltransferase-encoding gene, disrupts binding of the transcription factor Sp1 to its cognate promoter motif. This mutation substantially reduces transcription of PIGM and blocks mannosylation of GPI, leading to partial but severe deficiency of GPI. These findings indicate that biosynthesis of GPI is essential to maintain homeostasis of blood coagulation and neurological function.	Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, London W12 0NN, England; Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, Suita, Osaka 565, Japan; Gen Infirm, Haematol Malignancy Diagnost Serv Lab, Leeds Teaching Hosp NHS Trust, Leeds LS1 3EX, W Yorkshire, England; Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; Univ Edinburgh, Clin & Basic Virol Lab, Sch Biomed Sci, Edinburgh EH9 1HQ, Midlothian, Scotland; Kings Coll Hosp London, Paediat Liver Ctr, London SE5 9RS, England; Univ Dundee, Div Biol Chem & Mol Microbiol, Dundee DD1 4HN, Scotland	Imperial College London; Osaka University; Leeds General Infirmary; University of Leeds; University of London; Institute of Cancer Research - UK; University of Edinburgh; King's College Hospital NHS Foundation Trust; King's College Hospital; University of Dundee	Karadimitris, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Hammersmith Hosp, Du Cane Rd, London W12 0NN, England.	a.karadimitris@imperial.ac.uk	Kotsianidis, Ioannis/AGH-1791-2022; KOTSIANIDIS, IOANNIS/ABH-1436-2021; KARADIMITRIS, ANASTASIOS/B-4353-2009; Kinoshita, Taroh/C-7353-2009; Ferguson, Michael A. J./F-7829-2010	KOTSIANIDIS, IOANNIS/0000-0001-7668-0186; Ferguson, Michael A. J./0000-0003-1321-8714; Richards, Stephen/0000-0002-8421-5353; Karadimitris, Anastasios/0000-0002-9566-9780; Houlston, Richard/0000-0002-5268-0242; Almeida, Antonio/0000-0003-4361-0928				Ashida H, 2005, MOL BIOL CELL, V16, P1439, DOI 10.1091/mbc.E04-09-0802; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Brodsky RA, 2000, AM J CLIN PATHOL, V114, P459, DOI 10.1093/ajcp/114.3.459; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HILLMEN P, 1993, P NATL ACAD SCI USA, V90, P5272, DOI 10.1073/pnas.90.11.5272; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; Hong Y, 2000, J BIOL CHEM, V275, P20911, DOI 10.1074/jbc.M001913200; Hugel B, 1999, BLOOD, V93, P3451, DOI 10.1182/blood.V93.10.3451.410k27_3451_3456; Imbach T, 2000, J CLIN INVEST, V105, P233, DOI 10.1172/JCI8691; Jaeken J, 2001, METABOLIC MOL BASES, P1601; Karadimitris A, 2001, LEUKEMIA, V15, P1148, DOI 10.1038/sj.leu.2402180; Karadimitris A, 2000, BRIT J HAEMATOL, V111, P1158, DOI 10.1046/j.1365-2141.2000.02494.x; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; LANDER ES, 1987, SCIENCE, V236, P1567, DOI 10.1126/science.2884728; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Luzzatto L, 1997, CELL, V88, P1, DOI 10.1016/S0092-8674(00)81850-4; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; Nozaki M, 1999, LAB INVEST, V79, P293; Orlean P, 2000, J CLIN INVEST, V105, P131, DOI 10.1172/JCI9157; Parker C, 2005, BLOOD, V106, P3699, DOI 10.1182/blood-2005-04-1717; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; Sellick GS, 2005, HUM GENET, V117, P207, DOI 10.1007/s00439-005-1301-4; Takahashi M, 1996, EMBO J, V15, P4254, DOI 10.1002/j.1460-2075.1996.tb00800.x; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; THOMAS LJ, 1992, J CLIN INVEST, V89, P1172, DOI 10.1172/JCI115700; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; Zhang J, 2003, CIRCULATION, V108, P623, DOI 10.1161/01.CIR.0000078642.45127.7B	30	160	162	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					846	851		10.1038/nm1410	http://dx.doi.org/10.1038/nm1410			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16767100				2022-12-25	WOS:000238862800074
J	Hollanda, LM; Lima, CSP; Cunha, AF; Albuquerque, DM; Vassallo, J; Ozelo, MC; Joazeiro, PP; Saad, STO; Costa, FF				Hollanda, Luciana M.; Lima, Carmen S. P.; Cunha, Anderson F.; Albuquerque, Dulcineia M.; Vassallo, Jose; Ozelo, Margareth C.; Joazeiro, Paulo P.; Saad, Sara T. O.; Costa, Fernando F.			An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis	NATURE GENETICS			English	Article							TRANSIENT MYELOPROLIFERATIVE DISORDER; ACUTE MEGAKARYOBLASTIC LEUKEMIA; X-LINKED THROMBOCYTOPENIA; ACQUIRED MUTATIONS; DOWN-SYNDROME; MACROTHROMBOCYTOPENIA; DIAGNOSIS; CHILDREN; ANEMIA; GENE	Acquired somatic mutations(1-6) in exon 2 of the hematopoietic transcription factor GATA-1 have been found in individuals with Down syndrome with both transient myeloproliferative disorder(2-10) and acute megakaryoblastic leukemia(1-4,6,8-10). These mutations prevent the synthesis of the full-length protein but allow the synthesis of its short isoform, GATA-1s. Experiments in mice(11) suggest that GATA-1s supports normal adult megakaryopoiesis, platelet formation and erythropoiesis. Here we report a mutation, 332G -> C, in exon 2 of GATA1, leading to the synthesis of only the short isoform in seven affected males from two generations of a family. Hematological profiles of affected males demonstrate macrocytic anemia, normal platelet counts and neutropenia in most cases. Altogether, data suggest that GATA-1s alone, produced in low or normal levels, is not sufficient to support normal erythropoiesis. Moreover, this is the first study to indicate that a germline splicing mutation does not lead to leukemia in the absence of other cooperating events, such as Down syndrome.	Univ Estadual Campinas, Sch Med Sci, Hemoctr, Dept Internal Med, BR-13083970 Campinas, SP, Brazil; Univ Estadual Campinas, Sch Med Sci, Dept Anat Pathol, BR-13083970 Campinas, SP, Brazil; Univ Estadual Campinas, Inst Biol, Dept Histol, BR-13083970 Campinas, SP, Brazil	Universidade Estadual de Campinas; Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade Estadual de Campinas	Costa, FF (corresponding author), Univ Estadual Campinas, Sch Med Sci, Hemoctr, Dept Internal Med, BR-13083970 Campinas, SP, Brazil.	ferreira@unicamp.br	da Cunha, Anderson Ferreira/B-7931-2012; da Cunha, Anderson Ferreira/M-9038-2019; Costa, Fernando F/D-1566-2012; de Albuquerque, Dulcineia Martins/U-8601-2019; HOLLANDA, LUCIANA MARIA DE/F-7893-2011; Ozelo, Margareth C/K-5819-2012; JOAZEIRO, PAULO/C-6733-2014; VASSALLO, JOSE/AAP-4600-2021; Lima, Carmen Silvia Passos/K-4775-2013	da Cunha, Anderson Ferreira/0000-0003-3485-5659; Costa, Fernando F/0000-0002-4632-572X; HOLLANDA, LUCIANA MARIA DE/0000-0002-6047-4043; Ozelo, Margareth C/0000-0001-5938-0675; VASSALLO, JOSE/0000-0002-2192-4865; 				Ahmed M, 2004, BLOOD, V103, P2480, DOI 10.1182/blood-2003-10-3383; Balduini CL, 2004, THROMB HAEMOSTASIS, V91, P129, DOI 10.1160/TH03-05-0290; Budde U, 2002, SEMIN THROMB HEMOST, V28, P173, DOI 10.1055/s-2002-27820; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; Centurione L, 2004, BLOOD, V104, P3573, DOI 10.1182/blood-2004-01-0193; Conran N, 2004, AM J HEMATOL, V76, P343, DOI 10.1002/ajh.20129; Crispino JD, 2005, PEDIATR BLOOD CANCER, V44, P40, DOI 10.1002/pbc.20066; dos Santos CO, 2004, EXP HEMATOL, V32, P157, DOI 10.1016/j.exphem.2003.11.002; Freson K, 2002, HUM MOL GENET, V11, P147, DOI 10.1093/hmg/11.2.147; Freson K, 2001, BLOOD, V98, P85, DOI 10.1182/blood.V98.1.85; Gao DY, 1999, CRYOBIOLOGY, V38, P225, DOI 10.1006/cryo.1999.2162; GAWAZ MP, 1991, KIDNEY INT, V40, P257, DOI 10.1038/ki.1991.208; Groet J, 2003, LANCET, V361, P1617, DOI 10.1016/S0140-6736(03)13266-7; Gurbuxani S, 2004, BLOOD, V103, P399, DOI 10.1182/blood-2003-05-1556; Hitzler JK, 2003, BLOOD, V101, P4301, DOI 10.1182/blood-2003-01-0013; Hitzler JK, 2005, NAT REV CANCER, V5, P11, DOI 10.1038/nrc1525; Li Z, 2005, NAT GENET, V37, P613, DOI 10.1038/ng1566; Mehaffey MG, 2001, BLOOD, V98, P2681, DOI 10.1182/blood.V98.9.2681; Mundschau G, 2003, BLOOD, V101, P4298, DOI 10.1182/blood-2002-12-3904; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Pedrazzoli P, 2000, BRIT J HAEMATOL, V108, P653, DOI 10.1046/j.1365-2141.2000.01860.x; Rainis L, 2003, BLOOD, V102, P981, DOI 10.1182/blood-2002-11-3599; Rhodes J, 2005, DEV CELL, V8, P97, DOI 10.1016/j.devcel.2004.11.014; Shimada A, 2004, BLOOD, V103, P366, DOI 10.1182/blood-2003-09-3219; Shimizu R, 2001, EMBO J, V20, P5250, DOI 10.1093/emboj/20.18.5250; Stenberg PE, 1998, BLOOD, V91, P1599, DOI 10.1182/blood.V91.5.1599.1599_1599_1608; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; Xu G, 2003, BLOOD, V102, P2960, DOI 10.1182/blood-2003-02-0390; Yu CN, 2002, BLOOD, V100, P2040, DOI 10.1182/blood-2002-02-0387	30	144	148	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					807	812		10.1038/ng1825	http://dx.doi.org/10.1038/ng1825			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16783379				2022-12-25	WOS:000238669300017
J	Moseley, ML; Zu, T; Ikeda, Y; Gao, WC; Mosemiller, AK; Daughters, RS; Chen, G; Weatherspoon, MR; Clark, HB; Ebner, TJ; Day, JW; Ranum, LPW				Moseley, Melinda L.; Zu, Tao; Ikeda, Yoshio; Gao, Wangcai; Mosemiller, Anne K.; Daughters, Randy S.; Chen, Gang; Weatherspoon, Marcy R.; Clark, H. Brent; Ebner, Timothy J.; Day, John W.; Ranum, Laura P. W.			Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8	NATURE GENETICS			English	Article							SCA8 REPEAT EXPANSION; CEREBELLAR CORTEX; MYOTONIC-DYSTROPHY; TRANSGENIC MICE; ANTISENSE TRANSCRIPTION; BINDING PROTEIN; PARALLEL FIBER; CTG EXPANSION; LOCUS; RNA	We previously reported that a (CTG)(n) expansion causes spinocerebellar ataxia type 8 (SCA8), a slowly progressive ataxia with reduced penetrance. We now report a transgenic mouse model in which the full-length human SCA8 mutation is transcribed using its endogenous promoter. (CTG)(116) expansion, but not (CTG)(11) control lines, develop a progressive neurological phenotype with in vivo imaging showing reduced cerebellar-cortical inhibition. 1C2-positive intranuclear inclusions in cerebellar Purkinje and brainstem neurons in SCA8 expansion mice and human SCA8 autopsy tissue result from translation of a polyglutamine protein, encoded on a previously unidentified antiparallel transcript (ataxin 8, ATXN8) spanning the repeat in the CAG direction. The neurological phenotype in SCA8 BAC expansion but not BAC control lines demonstrates the pathogenicity of the (CTG-CAG)(n) expansion. Moreover, the expression of noncoding (CUG)(n) expansion transcripts (ataxin 8 opposite strand, ATXN8OS) and the discovery of intranuclear polyglutamine inclusions suggests SCA8 pathogenesis involves toxic gain-of-function mechanisms at both the protein and RNA levels.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Ranum, LPW (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA.	ranum001@umn.edu			NINDS NIH HHS [R01 NS040389, R01 NS40389] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040389] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benzow KA, 2002, MAMM GENOME, V13, P134, DOI 10.1007/s0033501-2105-2; Brusco A, 2002, J NEUROL, V249, P923, DOI 10.1007/s00415-002-0760-y; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; Carter AG, 2002, NAT NEUROSCI, V5, P1309, DOI 10.1038/nn970; Cho DH, 2005, MOL CELL, V20, P483, DOI 10.1016/j.molcel.2005.09.002; Day JW, 2000, NEUROLOGY, V55, P649, DOI 10.1212/WNL.55.5.649; Dorsman JC, 2002, HUM MOL GENET, V11, P1487, DOI 10.1093/hmg/11.13.1487; Dunbar RL, 2004, NEUROSCIENCE, V126, P213, DOI 10.1016/j.neuroscience.2004.02.020; Ebner TJ, 2005, PROG BRAIN RES, V148, P125, DOI 10.1016/S0079-6123(04)48011-X; Gao WC, 2003, J NEUROSCI, V23, P1859; Hanson CL, 2000, NEUROSCIENCE, V96, P317, DOI 10.1016/S0306-4522(99)00470-4; Hausser M, 1997, NEURON, V19, P665, DOI 10.1016/S0896-6273(00)80379-7; Ikeda Y, 2000, NEUROLOGY, V54, P950, DOI 10.1212/WNL.54.4.950; Ikeda Y, 2004, AM J HUM GENET, V75, P3, DOI 10.1086/422014; Ikeda Y, 2000, J NEUROL SCI, V182, P76, DOI 10.1016/S0022-510X(00)00446-9; Izumi Y, 2003, AM J HUM GENET, V72, P704, DOI 10.1086/367775; Juvonen V, 2000, ANN NEUROL, V48, P354, DOI 10.1002/1531-8249(200009)48:3<354::AID-ANA10>3.0.CO;2-A; Kanadia RN, 2003, SCIENCE, V302, P1978, DOI 10.1126/science.1088583; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Koob MD, 1999, NAT GENET, V21, P379, DOI 10.1038/7710; Koob MD, 1998, NAT GENET, V18, P72, DOI 10.1038/ng0198-72; Liquori CL, 2001, SCIENCE, V293, P864, DOI 10.1126/science.1062125; LLANO I, 1993, J PHYSIOL-LONDON, V468, P177, DOI 10.1113/jphysiol.1993.sp019766; Mankodi A, 2000, SCIENCE, V289, P1769, DOI 10.1126/science.289.5485.1769; Margolis RL, 2004, ANN NEUROL, V56, P670, DOI 10.1002/ana.20248; Marsh JL, 2000, HUM MOL GENET, V9, P13, DOI 10.1093/hmg/9.1.13; Martins S, 2005, AM J MED GENET B, V139B, P109, DOI 10.1002/ajmg.b.30235; Mittmann W, 2005, J PHYSIOL-LONDON, V563, P369, DOI 10.1113/jphysiol.2004.075028; Moseley ML, 2000, HUM MOL GENET, V9, P2125, DOI 10.1093/hmg/9.14.2125; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Nemes JP, 2000, HUM MOL GENET, V9, P1543, DOI 10.1093/hmg/9.10.1543; Orr HT, 2001, GENE DEV, V15, P925, DOI 10.1101/gad.888401; Orr HT, 2000, NEUROBIOL DIS, V7, P129, DOI 10.1006/nbdi.2000.0305; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Ranum LPW, 2004, TRENDS GENET, V20, P506, DOI 10.1016/j.tig.2004.08.004; Ranum LPW, 2004, AM J HUM GENET, V74, P793, DOI 10.1086/383590; Reinert KC, 2004, J NEUROPHYSIOL, V92, P199, DOI 10.1152/jn.01275.2003; Schols L, 2003, ANN NEUROL, V54, P110, DOI 10.1002/ana.10608; Shakkottai VG, 2004, J CLIN INVEST, V113, P582, DOI 10.1172/JCI200420216; Silveira I, 2000, AM J HUM GENET, V66, P830, DOI 10.1086/302827; Sobrido MJ, 2001, NEUROLOGY, V57, P1310, DOI 10.1212/WNL.57.7.1310; Stevanin G, 2000, NAT GENET, V24, P213, DOI 10.1038/73408; Sulek A, 2003, AM J HUM GENET, V73, P972, DOI 10.1086/378524; Suter KJ, 2004, NEUROSCIENCE, V124, P305, DOI 10.1016/j.neuroscience.2003.11.015; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; Vincent JB, 2000, AM J HUM GENET, V66, P819, DOI 10.1086/302803; Worth PF, 2000, NAT GENET, V24, P214, DOI 10.1038/73411; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217; Zoghbi HY, 1999, CURR OPIN NEUROBIOL, V9, P566, DOI 10.1016/S0959-4388(99)00013-6	50	317	330	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					758	769		10.1038/ng1827	http://dx.doi.org/10.1038/ng1827			12	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16804541				2022-12-25	WOS:000238669300011
J	Wu, XY; Yoo, YD; Okuhama, NN; Tucker, PW; Liu, G; Guan, JL				Wu, Xiaoyang; Yoo, Youngdong; Okuhama, Nataly N.; Tucker, Philip W.; Liu, Gang; Guan, Jun-Lin			Regulation of RNA-polymerase-II-dependent transcription by N-WASP and its nuclear-binding partners	NATURE CELL BIOLOGY			English	Article							ACTIN-FILAMENTS; ARP2/3 COMPLEX; BETA-ACTIN; PROTEINS; PSF; REARRANGEMENT; P54(NRB)/NONO; LOCALIZATION; HOMOLOG; SIGNALS	The presence of actin in the nucleus has been well established, and several studies have implicated nuclear actin in transcriptional regulation(1-3). Neuronal Wiskott-Aldrich syndrome protein ( N-WASP) is a member of the WASP family of proteins; these proteins function in the cytoplasm as key regulators of cortical actin filament(4-6). Interestingly, N-WASP has also been observed in the nucleus(7-11). However, a potential nuclear function for N-WASP has not been established. Here, we report the identification of nuclear N-WASP within a large nuclear-protein complex containing PSF-NonO ( polypyrimidine-tract-binding-protein-associated splicing factor-non-Pou-domain octamer-binding protein/p54nrb), nuclear actin and RNA polymerase II. The PSF-NonO complex is involved in the regulation of many cellular processes(12), such as transcription, RNA processing, DNA unwinding and repair. We demonstrate that the interaction of N-WASP with the PSF-NonO complex can couple N-WASP with RNA polymerase II to regulate transcription. We also provide evidence that the potential function of N-WASP in promoting polymerization of nuclear actins has an important role in this process. Based on these results, we propose a nuclear function for N-WASP in transcriptional regulation.	Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78705 USA	Cornell University; Albany Medical College; University of Texas System; University of Texas Austin	Guan, JL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14853 USA.	jg19@cornell.edu			NHLBI NIH HHS [HL73394] Funding Source: Medline; NIGMS NIH HHS [GM48050] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073394] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bear JE, 2001, CURR OPIN CELL BIOL, V13, P158, DOI 10.1016/S0955-0674(00)00193-9; Bettinger BT, 2004, NAT REV MOL CELL BIO, V5, P410, DOI 10.1038/nrm1370; Blessing CA, 2004, TRENDS CELL BIOL, V14, P435, DOI 10.1016/j.tcb.2004.07.009; Emili A, 2002, RNA, V8, P1102, DOI 10.1017/S1355838202025037; Hofmann WA, 2004, NAT CELL BIOL, V6, P1094, DOI 10.1038/ncb1182; Hu P, 2004, GENE DEV, V18, P3010, DOI 10.1101/gad.1250804; Kameoka S, 2004, EMBO J, V23, P1782, DOI 10.1038/sj.emboj.7600187; Kiseleva E, 2004, J CELL SCI, V117, P2481, DOI 10.1242/jcs.01098; Kukalev A, 2005, NAT STRUCT MOL BIOL, V12, P238, DOI 10.1038/nsmb904; LEE KAW, 1990, METHOD ENZYMOL, V181, P20; McDonald D, 2006, J CELL BIOL, V172, P541, DOI 10.1083/jcb.200507101; Miki H, 1998, BIOCHEM BIOPH RES CO, V243, P73, DOI 10.1006/bbrc.1997.8064; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Millard TH, 2004, BIOCHEM J, V380, P1, DOI 10.1042/BJ20040176; Naar AM, 2002, GENE DEV, V16, P1339, DOI 10.1101/gad.987602; Pederson T, 2002, J STRUCT BIOL, V140, P3, DOI 10.1016/S1047-8477(02)00528-2; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Peng R, 2002, RNA, V8, P1334, DOI 10.1017/S1355838202022070; Percipalle P, 2003, P NATL ACAD SCI USA, V100, P6475, DOI 10.1073/pnas.1131933100; Philimonenko VV, 2004, NAT CELL BIOL, V6, P1165, DOI 10.1038/ncb1190; REDMOND T, 1994, J BIOL CHEM, V269, P21657; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SCHEER U, 1984, CELL, V39, P111, DOI 10.1016/0092-8674(84)90196-X; Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6; Suetsugu S, 2003, J BIOL CHEM, V278, P42515, DOI 10.1074/jbc.M302177200; Takenawa T, 2001, J CELL SCI, V114, P1801; Vetterkind S, 2002, J BIOL CHEM, V277, P87, DOI 10.1074/jbc.M104555200; Wu XY, 2004, J BIOL CHEM, V279, P9565, DOI 10.1074/jbc.M310739200; Yang YS, 1997, NUCLEIC ACIDS RES, V25, P2284, DOI 10.1093/nar/25.12.2284; YANG YS, 1993, MOL CELL BIOL, V13, P5593, DOI 10.1128/MCB.13.9.5593; ZHANG WW, 1993, BIOCHEM J, V290, P267, DOI 10.1042/bj2900267	31	127	129	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					756	U215		10.1038/ncb1433	http://dx.doi.org/10.1038/ncb1433			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16767080				2022-12-25	WOS:000238837800019
J	Love, JC; Ronan, JL; Grotenbreg, GM; van der Veen, AG; Ploegh, HL				Love, J. Christopher; Ronan, Jehnna L.; Grotenbreg, Gijsbert M.; van der Veen, Annemarthe G.; Ploegh, Hidde L.			A microengraving method for rapid selection of single cells producing antigen-specific antibodies	NATURE BIOTECHNOLOGY			English	Article							MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; ARRAYS; COMPATIBILITY; HYBRIDOMAS; MICROWELLS; CLONING	Monoclonal antibodies that recognize specific antigens of interest are used as therapeutic agents and as tools for biomedical research(1). Discovering a single monoclonal antibody requires retrieval of an individual hybridoma from polyclonal mixtures of cells producing antibodies with a variety of specificities. The time required to isolate hybridomas by a limiting serial-dilution, however, has restricted the diversity and breadth of available antibodies. Here we present a soft lithographic method based on intaglio printing to generate microarrays comprising the secreted products of single cells. These engraved arrays enable a rapid (< 12 h) and high-throughput (> 100,000 individual cells) system for identification, recovery and clonal expansion of cells producing antigen-specific antibodies. This method can be adapted, in principle, to detect any secreted product in a multiplexed manner.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; CBR Inst Biomed Res, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)	Love, JC (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	love@cbrinstitute.org; ploegh@wi.mit.edu						Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Barry R, 2004, PROTEOMICS, V4, P3717, DOI 10.1002/pmic.200300877; Brekke OH, 2003, NAT REV DRUG DISCOV, V2, P52, DOI 10.1038/nrd984; Carroll S, 2004, EXPERT OPIN BIOL TH, V4, P1821, DOI 10.1517/14712598.4.11.1821; DAVIS JM, 1982, J IMMUNOL METHODS, V50, P161, DOI 10.1016/0022-1759(82)90222-8; De Masi F, 2005, PROTEOMICS, V5, P4070, DOI 10.1002/pmic.200401279; FULLER SA, 2003, CURRENT PROTOCOLS MO, P2; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Harlow E., 1988, ANTIBODIES LAB MANUA; He MY, 2005, ANAL CHEM, V77, P1539, DOI 10.1021/ac0480850; Hendershot L. M. S., 2003, MOL BIOL B CELLS; Herzenberg LA, 2002, CLIN CHEM, V48, P1819; KANG IK, 1988, BIOMATERIALS, V9, P349, DOI 10.1016/0142-9612(88)90032-4; Khademhosseini A, 2005, LAB CHIP, V5, P1380, DOI 10.1039/b508096g; Kim H, 2004, BIOMACROMOLECULES, V5, P822, DOI 10.1021/bm034341r; Lee JN, 2003, ANAL CHEM, V75, P6544, DOI 10.1021/ac0346712; Lee JN, 2004, LANGMUIR, V20, P11684, DOI 10.1021/la048562+; LJUNGGREN HG, 1990, IMMUNOGENETICS, V32, P440; Ostuni E, 2001, LANGMUIR, V17, P2828, DOI 10.1021/la001372o; Pasqualini R, 2004, P NATL ACAD SCI USA, V101, P257, DOI 10.1073/pnas.0305834101; RUEDA AZ, 1988, J IMMUNOL METHODS, V114, P213, DOI 10.1016/0022-1759(88)90176-7; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080; Yamamura S, 2005, ANAL CHEM, V77, P8050, DOI 10.1021/ac0515632; Yokoyama W.M., 1995, CURRENT PROTOCOLS IM	25	324	436	7	115	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2006	24	6					703	707		10.1038/nbt1210	http://dx.doi.org/10.1038/nbt1210			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	051UQ	16699501				2022-12-25	WOS:000238187300033
J	Babitt, JL; Huang, FW; Wrighting, DM; Xia, Y; Sidis, Y; Samad, TA; Campagna, JA; Chung, RT; Schneyer, AL; Woolf, CJ; Andrews, NC; Lin, HY				Babitt, JL; Huang, FW; Wrighting, DM; Xia, Y; Sidis, Y; Samad, TA; Campagna, JA; Chung, RT; Schneyer, AL; Woolf, CJ; Andrews, NC; Lin, HY			Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression	NATURE GENETICS			English	Article							REPULSIVE GUIDANCE MOLECULE; 1Q-LINKED JUVENILE HEMOCHROMATOSIS; ANTIMICROBIAL PEPTIDE HEPCIDIN; GROWTH-FACTOR-BETA; IRON OVERLOAD; GENE-EXPRESSION; LIVER-CELLS; I RECEPTOR; MOUSE; INFLAMMATION	Hepcidin is a key regulator of systemic iron homeostasis. Hepcidin deficiency induces iron overload, whereas hepcidin excess induces anemia. Mutations in the gene encoding hemojuvelin (HFE2, also known as HJV) cause severe iron overload and correlate with low hepcidin levels, suggesting that hemojuvelin positively regulates hepcidin expression. Hemojuvelin is a member of the repulsive guidance molecule (RGM) family, which also includes the bone morphogenetic protein (BMP) coreceptors RGMA and DRAGON (RGMB). Here, we report that hemojuvelin is a BMP coreceptor and that hemojuvelin mutants associated with hemochromatosis have impaired BMP signaling ability. Furthermore, BMP upregulates hepatocyte hepcidin expression, a process enhanced by hemojuvelin and blunted in Hfe2(-/-) hepatocytes. Our data suggest a mechanism by which HFE2 mutations cause hemochromatosis: hemojuvelin dysfunction decreases BMP signaling, thereby lowering hepcidin expression.	Harvard Univ, Sch Med, Program Membrane Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Div Nephrol, Massachusetts Gen Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neural Plast Res Grp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute	Lin, HY (corresponding author), Harvard Univ, Sch Med, Program Membrane Biol, Boston, MA 02115 USA.	hlin@partners.org	Woolf, Clifford/A-9784-2010; Xia, Yin/M-5440-2018	Xia, Yin/0000-0003-0315-7532; Andrews, Nancy/0000-0003-0243-4462	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066373, K08DK075846, F32DK068997, R01DK069533, R01DK071837] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07623] Funding Source: Medline; NIDDK NIH HHS [R01 DK066373, F32 DK-068997, K08 DK075846, DK-69533, R01 DK066373-03, DK-71837, F32 DK068997-02, K08 DK075846-01, F32 DK068997] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ALPINI G, 1994, HEPATOLOGY, V20, P494, DOI 10.1002/hep.1840200231; Babitt JL, 2005, J BIOL CHEM, V280, P29820, DOI 10.1074/jbc.M503511200; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; Courselaud B, 2002, J BIOL CHEM, V277, P41163, DOI 10.1074/jbc.M202653200; DeBleser PJ, 1997, J HEPATOL, V26, P886, DOI 10.1016/S0168-8278(97)80257-7; del Re E, 2004, J BIOL CHEM, V279, P22765, DOI 10.1074/jbc.M401350200; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Huang FW, 2005, J CLIN INVEST, V115, P2187, DOI 10.1172/JCI25049; Huang FW, 2004, BLOOD, V104, P2176, DOI 10.1182/blood-2004-01-0400; Kanzler S, 2001, ONCOGENE, V20, P5015, DOI 10.1038/sj.onc.1204544; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Knittel T, 1997, EXP CELL RES, V232, P263, DOI 10.1006/excr.1997.3504; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Krijt J, 2004, BLOOD, V104, P4308, DOI 10.1182/blood-2004-06-2422; Lanzara C, 2004, BLOOD, V103, P4317, DOI 10.1182/blood-2004-01-0192; Lee P, 2005, P NATL ACAD SCI USA, V102, P1906, DOI 10.1073/pnas.0409808102; Lee PL, 2004, BLOOD, V103, P4669, DOI 10.1182/blood-2004-01-0072; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; Lin L, 2005, BLOOD, V106, P2884, DOI 10.1182/blood-2005-05-1845; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Martinez AR, 2004, HAEMATOLOGICA, V89, P1441; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Miller SI, 2000, AM J ADDICTION, V9, P275; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; Nemeth E, 2003, BLOOD, V101, P2461, DOI 10.1182/blood-2002-10-3235; Nemeth E, 2004, SCIENCE, V306, P2090, DOI 10.1126/science.1104742; Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945; Nicolas G, 2002, J CLIN INVEST, V110, P1037, DOI 10.1172/JCI200215686; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Niederkofler V, 2005, J CLIN INVEST, V115, P2180, DOI 10.1172/JCI25683; Papanikolaou G, 2004, NAT GENET, V36, P77, DOI 10.1038/ng1274; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Piscione TD, 2001, AM J PHYSIOL-RENAL, V280, pF19, DOI 10.1152/ajprenal.2001.280.1.F19; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; Samad TA, 2005, J BIOL CHEM, V280, P14122, DOI 10.1074/jbc.M410034200; Samad TA, 2004, J NEUROSCI, V24, P2027, DOI 10.1523/JNEUROSCI.4115-03.2004; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Wang RH, 2005, CELL METAB, V2, P399, DOI 10.1016/j.cmet.2005.10.010; Zhang AS, 2005, J BIOL CHEM, V280, P33885, DOI 10.1074/jbc.M506207200; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	50	790	858	3	52	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					531	539		10.1038/ng1777	http://dx.doi.org/10.1038/ng1777			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16604073				2022-12-25	WOS:000237147500014
J	Sheng, GQ; Chang, GQ; Lin, JY; Yu, ZX; Fang, ZH; Rong, J; Lipton, SA; Li, SH; Tong, G; Leibowitz, SF; Li, XJ				Sheng, Guoqing; Chang, Guo-Qing; Lin, John Y.; Yu, Zhao-Xue; Fang, Zhi-Hui; Rong, Juan; Lipton, Stuart A.; Li, Shi-Hua; Tong, Gang; Leibowitz, Sarah F.; Li, Xiao-Jiang			Hypothalamic huntingtin-associated protein 1 as a mediator of feeding behavior	NATURE MEDICINE			English	Article							GAMMA-AMINOBUTYRIC-ACID; BODY-WEIGHT; INTRACELLULAR TRAFFICKING; GENETICALLY-OBESE; GABA(A) RECEPTORS; ZUCKER RATS; INSULIN; DISEASE; HAP1; BRAIN	The hypothalamus responds to circulating leptin and insulin in the control of food intake and body weight. A number of neurotransmitters in the hypothalamus, including gamma-aminobutyric acid ( GABA), also have key roles in feeding. Huntingtin-associated protein 1 (Hap1) is expressed more abundantly in the hypothalamus than in other brain regions, and lack of Hap1 in mice leads to early postnatal death. Hap1 is also involved in intracellular trafficking of the GABA(A) receptor. Here, we report that fasting upregulates the expression of Hap1 in the rodent hypothalamus, whereas intracerebroventricular administration of insulin downregulates Hap1 by increasing its degradation through ubiquitination. Decreasing the expression of mouse hypothalamic Hap1 by siRNA reduces the level and activity of hypothalamic GABAA receptors and causes a decrease in food intake and body weight. These findings provide evidence linking hypothalamic Hap1 to GABA in the stimulation of feeding and suggest that this mechanism is involved in the feeding-inhibitory actions of insulin in the brain.	Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; Rockefeller Univ, Lab Behav Neurobiol, New York, NY 10021 USA; Burnham Inst Med Res, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Emory University; Rockefeller University; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu		Lin, John/0000-0002-1723-4597; Lipton, Stuart/0000-0002-3490-1259	NIA NIH HHS [AG00975, AG19206] Funding Source: Medline; NICHD NIH HHS [P01 HD29587] Funding Source: Medline; NIMH NIH HHS [MH43422] Funding Source: Medline; NINDS NIH HHS [NS36232, NS045016] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD029587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036232, R01NS045016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019206] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benoit SC, 2004, RECENT PROG HORM RES, V59, P267, DOI 10.1210/rp.59.1.267; Carvalheira JBC, 2003, DIABETOLOGIA, V46, P1629, DOI 10.1007/s00125-003-1246-x; Chan EYW, 2002, HUM MOL GENET, V11, P945, DOI 10.1093/hmg/11.8.945; Chang GQ, 2005, MOL BRAIN RES, V135, P69, DOI 10.1016/j.molbrainres.2004.12.017; COSCINA DV, 1992, INT J OBESITY, V16, P425; DECAVEL C, 1990, J COMP NEUROL, V302, P1019, DOI 10.1002/cne.903020423; Dragatsis I, 2004, HUM MOL GENET, V13, P3115, DOI 10.1093/hmg/ddh328; Emmerson PJ, 1999, J PHYSIOL-LONDON, V517, P431, DOI 10.1111/j.1469-7793.1999.0431t.x; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Fujinaga R, 2004, J COMP NEUROL, V478, P88, DOI 10.1002/cne.20277; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gutekunst CA, 1998, J NEUROSCI, V18, P7674, DOI 10.1523/jneurosci.18-19-07674.1998; Herring D, 2003, J BIOL CHEM, V278, P24046, DOI 10.1074/jbc.M301420200; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kittler JT, 2004, P NATL ACAD SCI USA, V101, P12736, DOI 10.1073/pnas.0401860101; KREMER HPH, 1990, J NEUROPATH EXP NEUR, V49, P371, DOI 10.1097/00005072-199007000-00002; Leibowitz SF, 2004, PEPTIDES, V25, P473, DOI 10.1016/j.peptides.2004.02.006; Li SH, 2003, J NEUROSCI, V23, P6956; Li SH, 2000, MOL CELL NEUROSCI, V16, P168, DOI 10.1006/mcne.2000.0858; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Li XJ, 1996, P NATL ACAD SCI USA, V93, P4839, DOI 10.1073/pnas.93.10.4839; Li XJ, 2005, TRENDS PHARMACOL SCI, V26, P1, DOI 10.1016/j.tips.2004.11.001; MacDonald PE, 2004, ENDOCRINOLOGY, V145, P4078, DOI 10.1210/en.2004-0028; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; McBain CJ, 2001, NAT REV NEUROSCI, V2, P11, DOI 10.1038/35049047; McGuire JR, 2006, J BIOL CHEM, V281, P3552, DOI 10.1074/jbc.M509806200; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OLGIATI VR, 1980, PSYCHOPHARMACOLOGY, V68, P163, DOI 10.1007/BF00432135; Page KJ, 1998, EUR J NEUROSCI, V10, P1835, DOI 10.1046/j.1460-9568.1998.00185.x; Petersen A, 2005, HUM MOL GENET, V14, P39, DOI 10.1093/hmg/ddi004; Pratley RE, 2000, ANN NEUROL, V47, P64, DOI 10.1002/1531-8249(200001)47:1<64::AID-ANA11>3.3.CO;2-J; Pu SY, 1999, ENDOCRINOLOGY, V140, P933, DOI 10.1210/en.140.2.933; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Samson SLA, 2002, J MOL ENDOCRINOL, V29, P265, DOI 10.1677/jme.0.0290265; SANBERG PR, 1981, MED J AUSTRALIA, V1, P407, DOI 10.5694/j.1326-5377.1981.tb135681.x; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; Stratford TR, 1997, J NEUROSCI, V17, P4434; TSUJII S, 1991, BRAIN RES, V540, P48, DOI 10.1016/0006-8993(91)90491-D; van den Pol AN, 2003, NEURON, V40, P1059, DOI 10.1016/S0896-6273(03)00809-2; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; Yang XJ, 1999, DIABETES, V48, P1763, DOI 10.2337/diabetes.48.9.1763	45	75	81	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					526	533		10.1038/nm1382	http://dx.doi.org/10.1038/nm1382			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16604089				2022-12-25	WOS:000238149100036
J	Kumar, P; Bischof, O; Purbey, PK; Notani, D; Urlaub, H; Dejean, A; Galande, S				Kumar, Pavan P.; Bischof, Oliver; Purbey, Prabhat Kumar; Notani, Dimple; Urlaub, Henning; Dejean, Anne; Galande, Sanjeev			Functional interaction between PML and SATB1 regulates chromatin-loop architecture and transcription of the MHC class I locus	NATURE CELL BIOLOGY			English	Article							NUCLEAR-BODIES; SPATIAL-ORGANIZATION; BINDING PROTEIN; GENE; ATTACHMENT; EXPRESSION; REGIONS; PROTOONCOGENE; INTERFERON; ASSOCIATE	The function of the subnuclear structure the promyelocytic leukaemia (PML) body is unclear largely because of the functional heterogeneity of its constituents. Here, we provide the evidence for a direct link between PML, higher-order chromatin organization and gene regulation. We show that PML physically and functionally interacts with the matrix attachment region (MAR)-binding protein, special AT-rich sequence binding protein 1 (SATB1) to organize the major histocompatibility complex (MHC) class I locus into distinct higher-order chromatin-loop structures. Interferon gamma (IFN gamma) treatment and silencing of either SATB1 or PML dynamically alter chromatin architecture, thus affecting the expression profile of a subset of MHC class I genes. Our studies identify PML and SATB1 as a regulatory complex that governs transcription by orchestrating dynamic chromatin-loop architecture.	Natl Ctr Cell Sci, Pune 411007, Maharashtra, India; Inst Pasteur, INSERM, U579, Unite Org Nucl & Oncogenese, F-75724 Paris 15, France; Max Planck Inst Biophys Chem, Bioanalyt Mass Spectrometry Grp, D-37077 Gottingen, Germany	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Max Planck Society	Galande, S (corresponding author), Natl Ctr Cell Sci, Ganeshkhind, Pune 411007, Maharashtra, India.	sanjeev@nccs.res.in	Dejean, Anne/L-5145-2018; Bischof, Oliver/K-1548-2019	Puvvula, Pavan Kumar/0000-0002-1326-6954; Notani, Dimple/0000-0002-9460-8070; Purbey, Prabhat/0000-0001-6373-6283	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bischof O, 2005, MOL CELL BIOL, V25, P1013, DOI 10.1128/MCB.25.3.1013-1024.2005; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bruno S, 2003, BLOOD, V101, P3514, DOI 10.1182/blood-2002-11-3335; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; de Laat W, 2003, CHROMOSOME RES, V11, P447, DOI 10.1023/A:1024922626726; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Dickinson LA, 1997, J BIOL CHEM, V272, P11463; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Galande S, 2001, MOL CELL BIOL, V21, P5591, DOI 10.1128/MCB.21.16.5591-5604.2001; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; Hawkins SM, 2001, J BIOL CHEM, V276, P44472, DOI 10.1074/jbc.M104193200; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kiesslich A, 2002, J STRUCT BIOL, V140, P167, DOI 10.1016/S1047-8477(02)00571-3; Kohwi-Shigematsu T, 1998, METHOD CELL BIOL, V53, P323; KohwiShigematsu T, 1997, BIOCHEMISTRY-US, V36, P12005, DOI 10.1021/bi971444j; Kumanovics A, 2003, ANNU REV IMMUNOL, V21, P629, DOI 10.1146/annurev.immunol.21.090501.080116; Kumar PP, 2005, MOL CELL BIOL, V25, P1620, DOI 10.1128/MCB.25.5.1620-1633.2005; Larghero J, 1999, LEUKEMIA, V13, P1295, DOI 10.1038/sj.leu.2401464; LAVAU C, 1995, ONCOGENE, V11, P871; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Pavan KP, 2006, MOL CELL, V22, P231, DOI 10.1016/j.molcel.2006.03.010; Platani M, 2004, PROG MOL SUBCELL BIO, V35, P1; Rampalli S, 2003, NUCLEIC ACIDS RES, V31, P3248, DOI 10.1093/nar/gkg410; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Seo J, 2005, J BIOL CHEM, V280, P24600, DOI 10.1074/jbc.M414076200; Shiels C, 2001, J CELL SCI, V114, P3705; Singh GB, 1997, NUCLEIC ACIDS RES, V25, P1419, DOI 10.1093/nar/25.7.1419; Spector DL, 2003, ANNU REV BIOCHEM, V72, P573, DOI 10.1146/annurev.biochem.72.121801.161724; Spilianakis CG, 2004, NAT IMMUNOL, V5, P1017, DOI 10.1038/ni1115; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Volpi EV, 2000, J CELL SCI, V113, P1565; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wiesmeijer K, 2002, J STRUCT BIOL, V140, P180, DOI 10.1016/S1047-8477(02)00529-4; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	45	181	190	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					45	U57		10.1038/ncb1516	http://dx.doi.org/10.1038/ncb1516			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17173041	Green Published			2022-12-25	WOS:000243255100011
J	Liu, F; Thirumangalathu, S; Gallant, NM; Yang, SH; Stoick-Cooper, CL; Reddy, ST; Andl, T; Taketo, MM; Dlugosz, AA; Moon, RT; Barlow, LA; Millar, SE				Liu, Fei; Thirumangalathu, Shoba; Gallant, Natalie M.; Yang, Steven H.; Stoick-Cooper, Cristi L.; Reddy, Seshamma T.; Andl, Thomas; Taketo, Makoto M.; Dlugosz, Andrzej A.; Moon, Randall T.; Barlow, Linda A.; Millar, Sarah E.			Wnt-beta-catenin signaling initiates taste papilla development	NATURE GENETICS			English	Article							HAIR FOLLICLE MORPHOGENESIS; BUD DEVELOPMENT; RECEPTOR-CELLS; DIFFERENTIATION; EXPRESSION; PATTERN; GENE; MICE; COMPLEXES; MOUSE	Fungiform taste papillae form a regular array on the dorsal tongue. Taste buds arise from papilla epithelium(1) and, unusually for epithelial derivatives, synapse with neurons, release neurotransmitters and generate receptor and action potentials(2,3). Despite the importance of taste as one of our five senses, genetic analyses of taste papilla and bud development are lacking. We demonstrate that Wnt-beta-catenin signaling is activated in developing fungiform placodes and taste bud cells. A dominant stabilizing mutation of epithelial beta-catenin causes massive overproduction of enlarged fungiform papillae and taste buds. Likewise, genetic deletion of epithelial beta-catenin or inhibition of Wnt-beta-catenin signaling by ectopic dickkopf1 (Dkk1)(4-6) blocks initiation of fungiform papilla morphogenesis. Ectopic papillae are innervated in the stabilizing beta-catenin mutant, whereas ectopic Dkk1 causes absence of lingual epithelial innervation. Thus, Wnt-beta-catenin signaling is critical for fungiform papilla and taste bud development. Altered regulation of this pathway may underlie evolutionary changes in taste papilla patterning.	Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; Univ Colorado, Hlth Sci Ctr, Dept Cell & Dev Biol, Aurora, CO 80045 USA; Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA; Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan	University of Pennsylvania; University of Pennsylvania; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Kyoto University	Barlow, LA (corresponding author), Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA.	Linda.Barlow@uchsc.edu; millars@mail.med.upenn.edu	Moon, Randall/M-5605-2019; Moon, Randall T/B-1743-2014	Moon, Randall/0000-0002-9352-1408; Moon, Randall T/0000-0002-9352-1408; Andl, Thomas/0000-0002-5555-468X; Liu, Fei/0000-0002-7398-2274	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045973, T32AR007465, R01AR047709] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003947] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL007312] Funding Source: Medline; NIAMS NIH HHS [R01 AR045973, R01-AR47709, R01 AR045973-08, R01-AR45973, T32-AR007465] Funding Source: Medline; NICHD NIH HHS [T32-HD007505] Funding Source: Medline; NIDCD NIH HHS [R01-DC003947] Funding Source: Medline; NIDCR NIH HHS [R01-DE015342] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andl T, 2004, DEVELOPMENT, V131, P2257, DOI 10.1242/dev.01125; Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Barlow LA, 1997, DEVELOPMENT, V124, P949; Brault V, 2001, DEVELOPMENT, V128, P1253; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Fritzsch B, 1997, INT J DEV NEUROSCI, V15, P563, DOI 10.1016/S0736-5748(96)00111-6; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Hall JM, 1999, J COMP NEUROL, V406, P143, DOI 10.1002/(SICI)1096-9861(19990405)406:2<143::AID-CNE1>3.0.CO;2-X; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Jiang TX, 2004, INT J DEV BIOL, V48, P117, DOI 10.1387/ijdb.15272377; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Mbiene JP, 1997, ACTA ANAT, V160, P139; MISTRETTA CM, 1991, TASTE SMELL HLTH DIS, P35; Miura H, 2003, GENE EXPR PATTERNS, V3, P427, DOI 10.1016/S1567-133X(03)00081-4; Noramly S, 1999, DEVELOPMENT, V126, P3509; Northcutt RG, 1998, TRENDS NEUROSCI, V21, P38, DOI 10.1016/S0166-2236(97)01146-6; Okubo T, 2006, GENE DEV, V20, P2654, DOI 10.1101/gad.1457106; Parker MA, 2004, DEV DYNAM, V230, P630, DOI 10.1002/dvdy.20086; ROPER S, 1983, SCIENCE, V220, P1311, DOI 10.1126/science.6857254; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; STONE LM, 1995, P NATL ACAD SCI USA, V92, P1916, DOI 10.1073/pnas.92.6.1916; SUGIMOTO K, 1990, J GEN PHYSIOL, V96, P809, DOI 10.1085/jgp.96.4.809; Zhang GH, 2006, ANAT EMBRYOL, V211, P625, DOI 10.1007/s00429-006-0112-2; Zhou YQ, 2006, DEV BIOL, V297, P198, DOI 10.1016/j.ydbio.2006.05.022; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8	30	116	120	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2007	39	1					106	112		10.1038/ng1932	http://dx.doi.org/10.1038/ng1932			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17128274				2022-12-25	WOS:000243136500025
J	Woodbury, EL; Morgan, DO				Woodbury, Erika L.; Morgan, David O.			Cdk and APC activities limit the spindle-stabilizing function of Fin1 to anaphase	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; MITOTIC CYCLINS; BUDDING YEAST; DESTRUCTION; DYNAMICS; COMPLEX; CDC14; EXIT	The fidelity of chromosome segregation depends on proper regulation of mitotic spindle behaviour. In anaphase, spindle stability is promoted by the dephosphorylation of cyclin-dependent kinase (Cdk) substrates, which results from Cdk inactivation and phosphatase activation(1-4). Few of the critical Cdk targets have been identified(3,5,6). Here, we identify the budding-yeast protein Fin1 (ref. 7) as a spindle-stabilizing protein whose activity is strictly limited to anaphase by changes in its phosphorylation state and rate of degradation. Phosphorylation of Fin1 from S phase to metaphase, by the cyclin-dependent kinase Clb5-Cdk1, inhibits Fin1 association with the spindle. In anaphase, when Clb5-Cdk1 is inactivated, Fin1 is dephosphorylated by the phosphatase Cdc14. Fin1 dephosphorylation targets it to the poles and microtubules of the elongating spindle, where it contributes to spindle integrity. A non-phosphorylatable Fin1 mutant localizes to the spindle before anaphase and impairs efficient chromosome segregation. As cells complete mitosis and disassemble the spindle, the ubiqutin ligase APC(Cdh1) targets Fin1 for destruction. Our studies illustrate how phosphorylation-dependent changes in the behaviour of Cdk1 substrates influence complex mitotic processes.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Morgan, DO (corresponding author), Univ Calif San Francisco, Dept Physiol, UCSF Mail Code 2200,Genetech Hall Room N312B,600, San Francisco, CA 94158 USA.	David.Morgan@ucsf.edu		Morgan, David/0000-0001-8753-4416	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069901, R01GM050684] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50684, R01 GM069901] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayscough KR, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P477; Carroll CW, 2005, METHOD ENZYMOL, V398, P219, DOI 10.1016/S0076-6879(05)98018-X; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; D'Amours D, 2004, GENE DEV, V18, P2581, DOI 10.1101/gad.1247304; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; Higuchi T, 2005, NATURE, V433, P171, DOI 10.1038/nature03240; Jaspersen SL, 2000, CURR BIOL, V10, P615, DOI 10.1016/S0960-9822(00)00491-7; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Loog M, 2005, NATURE, V434, P104, DOI 10.1038/nature03329; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Parry DH, 2003, CURR BIOL, V13, P647, DOI 10.1016/S0960-9822(03)00242-2; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; Pereira G, 2003, SCIENCE, V302, P2120, DOI 10.1126/science.1091936; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Schuyler SC, 2003, J CELL BIOL, V160, P517, DOI 10.1083/jcb.200210021; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; van Hemert MJ, 2002, P NATL ACAD SCI USA, V99, P5390, DOI 10.1073/pnas.072556099; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Zhu CJ, 2006, P NATL ACAD SCI USA, V103, P6196, DOI 10.1073/pnas.0506926103	24	102	103	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					106	U138		10.1038/ncb1523	http://dx.doi.org/10.1038/ncb1523			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17173039				2022-12-25	WOS:000243255100019
J	Lee, MH; Lee, SW; Lee, EJ; Choi, SJ; Chung, SS; Lee, JI; Cho, JM; Seol, JH; Baek, SH; Kim, KI; Chiba, T; Tanaka, K; Bang, OS; Chung, CH				Lee, Moon Hee; Lee, Sung Won; Lee, Eun Joo; Choi, Soo Joon; Chung, Sung Soo; Lee, Jae Il; Cho, Joong Myung; Seol, Jae Hong; Baek, Sung Hee; Kim, Keun Il; Chiba, Tomoki; Tanaka, Keiji; Bang, Ok Sun; Chung, Chin Ha			SUMO-specific protease SUSP4 positively regulates p53 by promoting Mdm2 self-ubiquitination	NATURE CELL BIOLOGY			English	Article							TUMOR-SUPPRESSOR; E3 LIGASE; C-JUN; SUMOYLATION; TRANSCRIPTION; FAMILY; YEAST	The p53 tumour suppressor has a key role in the control of cell growth and differentiation, and in the maintenance of genome integrity(1,2). p53 is kept labile under normal conditions, but in response to stresses, such as DNA damage, it accumulates in the nucleus for induction of cell-cycle arrest, DNA repair or apoptosis. Mdm2 is an ubiquitin ligase that promotes p53 ubiquitination and degradation(3-5). Mdm2 is also self-ubiquitinated and degraded. Here, we identified a novel cascade for the increase in p53 level in response to DNA damage. A new SUMO-specific protease, SUSP4, removed SUMO-1 from Mdm2 and this desumoylation led to promotion of Mdm2 self-ubiquitination, resulting in p53 stabilization. Moreover, SUSP4 competed with p53 for binding to Mdm2, also resulting in p53 stabilization. Overexpression of SUSP4 inhibited cell growth, whereas knockdown of susp4 by RNA interference (RNAi) promoted of cell growth. UV damage induced SUSP4 expression, leading to an increase in p53 levels in parallel with a decrease in Mdm2 levels. These findings establish a new mechanism for the elevation of cellular p53 levels in response to UV damage.	Seoul Natl Univ, Sch Biol Sci, NRL Prot Biochem, Seoul 151742, South Korea; Crystalgenom Inc, Seoul 138736, South Korea; Sookmyung Womans Univ, Dept Biol Sci, Seoul 140742, South Korea; Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan	Seoul National University (SNU); Sookmyung Women's University; Tokyo Metropolitan Institute of Medical Science	Chung, CH (corresponding author), Seoul Natl Univ, Sch Biol Sci, NRL Prot Biochem, Seoul 151742, South Korea.	osbang@snu.ac.kr; chchung@snu.ac.kr	KIM, KEUN IL/D-2959-2011					Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Boggio R, 2004, MOL CELL, V16, P549, DOI 10.1016/j.molcel.2004.11.007; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851; Gong L, 2006, J BIOL CHEM, V281, P15869, DOI 10.1074/jbc.M511658200; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	31	60	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1424	U72		10.1038/ncb1512	http://dx.doi.org/10.1038/ncb1512			11	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17086174				2022-12-25	WOS:000242419800019
J	Sacher, M; Pfander, B; Hoege, C; Jentsch, S				Sacher, Meik; Pfander, Boris; Hoege, Carsten; Jentsch, Stefan			Control of Rad52 recombination activity by double-strand break-induced SUMO modification	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; S-PHASE; MITOTIC RECOMBINATION; MEIOTIC RECOMBINATION; PACHYTENE CHECKPOINT; UBIQUITIN; SRS2; HELICASE; YEAST	Homologous recombination is essential for genetic exchange, meiosis and error-free repair of double-strand breaks(1). Central to this process is Rad52, a conserved homo-oligomeric ring-shaped protein, which mediates the exchange of the early recombination factor RPA by Rad51 and promotes strand annealing(2,3). Here, we report that Rad52 of Saccharomyces cerevisiae is modified by the ubiquitin-like protein SUMO, primarily at two sites that flank the conserved Rad52 domain. Sumoylation is induced on DNA damage and triggered by Mre11-Rad50-Xrs2 (MRX) complex-governed double-strand breaks (DSBs). Although sumoylation-defective Rad52 is largely recombination proficient, mutant analysis revealed that the SUMO modification sustains Rad52 activity and concomitantly shelters the protein from accelerated proteasomal degradation. Furthermore, our data indicate that sumoylation becomes particularly relevant for those Rad52 molecules that are engaged in recombination.	Max Planck Inst Biochem, Dept Mol Cell Biol, D-82152 Martinsried, Germany	Max Planck Society	Jentsch, S (corresponding author), Max Planck Inst Biochem, Dept Mol Cell Biol, Klopferspitz 18A, D-82152 Martinsried, Germany.	Jentsch@biochem.mpg.de	Pfander, Boris/A-8703-2013	Pfander, Boris/0000-0003-2180-5054				AGUILERA A, 1988, GENETICS, V119, P779; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Bartke T, 2004, MOL CELL, V14, P801, DOI 10.1016/j.molcel.2004.05.018; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Gangloff S, 2000, NAT GENET, V25, P192, DOI 10.1038/76055; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Ho JCY, 2001, NUCLEIC ACIDS RES, V29, P4179, DOI 10.1093/nar/29.20.4179; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hong EJE, 2002, GENE DEV, V16, P363, DOI 10.1101/gad.938102; Huang LS, 2005, P NATL ACAD SCI USA, V102, P12431, DOI 10.1073/pnas.0502324102; Ira G, 2003, CELL, V115, P401, DOI 10.1016/S0092-8674(03)00886-9; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kagawa W, 2002, MOL CELL, V10, P359, DOI 10.1016/S1097-2765(02)00587-7; Klenk C, 2006, J BIOL CHEM, V281, P8357, DOI 10.1074/jbc.M513703200; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; Krogh BO, 2004, ANNU REV GENET, V38, P233, DOI 10.1146/annurev.genet.38.072902.091500; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Pfander B, 2005, NATURE, V436, P428, DOI 10.1038/nature03665; Ramotar D, 2003, CURR GENET, V43, P213, DOI 10.1007/s00294-003-0396-1; RATTRAY AJ, 1994, GENETICS, V138, P587; Roeder GS, 2000, TRENDS GENET, V16, P395, DOI 10.1016/S0168-9525(00)02080-1; Sacher M, 2005, METHOD ENZYMOL, V399, P392, DOI 10.1016/S0076-6879(05)99027-7; San-Segundo PA, 1999, CELL, V97, P313, DOI 10.1016/S0092-8674(00)80741-2; SCHIESTL RH, 1990, GENETICS, V124, P817; Schmidt KH, 2004, MOL CELL BIOL, V24, P3213, DOI 10.1128/MCB.24.8.3213-3226.2004; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Sugawara N, 2000, MOL CELL BIOL, V20, P5300, DOI 10.1128/MCB.20.14.5300-5309.2000; Symington LS, 2002, MICROBIOL MOL BIOL R, V66, P630, DOI 10.1128/MMBR.66.4.630-670.2002; Torres JZ, 2004, MOL CELL BIOL, V24, P3198, DOI 10.1128/MCB.24.8.3198-3212.2004; Torres JZ, 2004, GENE DEV, V18, P498, DOI 10.1101/gad.1154704; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Zhao XL, 2005, P NATL ACAD SCI USA, V102, P4777, DOI 10.1073/pnas.0500537102	38	149	152	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1284	U59		10.1038/ncb1488	http://dx.doi.org/10.1038/ncb1488			18	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17013376				2022-12-25	WOS:000241732400018
J	Tarpey, P; Thomas, S; Sarvananthan, N; Mallya, U; Lisgo, S; Talbot, CJ; Roberts, EO; Awan, M; Surendran, M; McLean, RJ; Reinecke, RD; Langmann, A; Lindner, S; Koch, M; Jain, S; Woodruff, G; Gale, RP; Degg, C; Droutsas, K; Asproudis, I; Zubcov, AA; Pieh, C; Veal, CD; Machado, RD; Backhouse, OC; Baumber, L; Constantinescu, CS; Brodsky, MC; Hunter, DG; Hertle, RW; Read, RJ; Edkins, S; O'Meara, S; Parker, A; Stevens, C; Teague, J; Wooster, R; Futreal, PA; Trembath, RC; Stratton, MR; Raymond, FL; Gottlob, I				Tarpey, Patrick; Thomas, Shery; Sarvananthan, Nagini; Mallya, Uma; Lisgo, Steven; Talbot, Chris J.; Roberts, Eryl O.; Awan, Musarat; Surendran, Mylvaganam; McLean, Rebecca J.; Reinecke, Robert D.; Langmann, Andrea; Lindner, Susanne; Koch, Martina; Jain, Sunila; Woodruff, Geoffrey; Gale, Richard P.; Degg, Chris; Droutsas, Konstantinos; Asproudis, Ioannis; Zubcov, Alina A.; Pieh, Christina; Veal, Colin D.; Machado, Rajiv D.; Backhouse, Oliver C.; Baumber, Laura; Constantinescu, Cris S.; Brodsky, Michael C.; Hunter, David G.; Hertle, Richard W.; Read, Randy J.; Edkins, Sarah; O'Meara, Sarah; Parker, Adrian; Stevens, Claire; Teague, Jon; Wooster, Richard; Futreal, P. Andrew; Trembath, Richard C.; Stratton, Michael R.; Raymond, F. Lucy; Gottlob, Irene			Mutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmus	NATURE GENETICS			English	Article							MOTOR NYSTAGMUS; MODEL; GENE	Idiopathic congenital nystagmus is characterized by involuntary, periodic, predominantly horizontal oscillations of both eyes. We identified 22 mutations in FRMD7 in 26 families with X-linked idiopathic congenital nystagmus. Screening of 42 singleton cases of idiopathic congenital nystagmus (28 male, 14 females) yielded three mutations (7%). We found restricted expression of FRMD7 in human embryonic brain and developing neural retina, suggesting a specific role in the control of eye movement and gaze stability.	Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Leicester, Sch Med, Ophthalmol Grp, Leicester LE2 7LX, Leics, England; Univ Newcastle Upon Tyne, Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England; Wills Eye Hosp & Res Inst, Foerderer Eye Movement Ctr Children, Philadelphia, PA 19107 USA; Med Univ Graz, Dept Ophthalmol, A-8036 Graz, Austria; Royal Preston Hosp, Preston PR2 9HT, Lancs, England; Leeds Gen Infirm, Dept Ophthalmol, Leeds LS2 9NS, W Yorkshire, England; Univ Hosp Leicester, Dept Med Phys, Leicester LE1 5WW, Leics, England; Univ Giessen, Dept Ophthalmol, D-35392 Giessen, Germany; Univ Hosp Ioannina, Fac Med, Dept Ophthalmol, GR-45110 Ioannina, Greece; Univ Frankfurt, Hosp Eye, D-60590 Frankfurt, Germany; Univ Freiburg, Dept Ophthalmol, Freiburg, Germany; Kings Coll London, Div Med & Mol Genet, London SE1 9RT, England; Univ Nottingham, Sch Med & Surg Sci, Div Clin Neurol, Nottingham NG7 2UH, England; Univ Arkansas Med Sci, Dept Ophthalmol, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72202 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Div Paediat Ophthalmol, Pittsburgh, PA 15213 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Wellcome Trust Sanger Institute; University of Leicester; Newcastle University - UK; University of Leicester; Jefferson University; Medical University of Graz; Royal Preston Hospital; Leeds General Infirmary; University of Leeds; University Hospitals of Leicester NHS Trust; University of Leicester; Justus Liebig University Giessen; University Hospital Ioannina; Goethe University Frankfurt; University of Freiburg; University of London; King's College London; University of Nottingham; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Harvard University; Boston Children's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Read, RJ (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Cambridge CB2 2XY, England.	flr24@cam.ac.uk; ig15@leicester.ac.uk	Machado, Rajiv D./AAD-7813-2019; Read, Randy J/L-1418-2013; Southgate, Laura/H-7924-2019	Machado, Rajiv D./0000-0001-9247-0744; Read, Randy J/0000-0001-8273-0047; Southgate, Laura/0000-0002-2090-1450; Lisgo, Steven/0000-0001-5186-3971; Hunter, David/0000-0002-4587-4794; Trembath, Richard/0000-0003-0550-3400; Thomas, Shery/0000-0002-4722-9182; Talbot, Christopher/0000-0001-7406-8962; Constantinescu, Cris/0000-0003-2066-7585; Veal, Colin/0000-0002-9840-2512	Medical Research Council [G9900837, G9826762] Funding Source: Medline; Wellcome Trust [050211] Funding Source: Medline; MRC [G9826762, G9900837] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980; Cabot A, 1999, AM J HUM GENET, V64, P1141, DOI 10.1086/302324; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gottlob I, 2001, CURR OPIN OPHTHALMOL, V12, P378, DOI 10.1097/00055735-200110000-00010; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Jacobs JB, 2004, J VISION, V4, P604, DOI 10.1167/4.7.7; Kerrison J B, 2001, Ophthalmic Genet, V22, P241, DOI 10.1076/opge.22.4.241.2216; Kerrison JB, 1999, AM J HUM GENET, V64, P600, DOI 10.1086/302244; Kubo T, 2002, J NEUROSCI, V22, P8504; Pilling RF, 2005, BRIT J OPHTHALMOL, V89, P1278, DOI 10.1136/bjo.2005.070045; STAYTE M, 1993, BRIT J OPHTHALMOL, V77, P228, DOI 10.1136/bjo.77.4.228; Tarpey P, 2004, AM J HUM GENET, V75, P318, DOI 10.1086/422703; Toyofuku T, 2005, NAT NEUROSCI, V8, P1712, DOI 10.1038/nn1596; Zhang BR, 2005, HUM GENET, V116, P128, DOI 10.1007/s00439-004-1188-5	14	130	145	0	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1242	1244		10.1038/ng1893	http://dx.doi.org/10.1038/ng1893			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17013395	Green Accepted, Green Published			2022-12-25	WOS:000241592700010
J	Zhao, Z; Tavoosidana, G; Sjolinder, M; Gondor, A; Mariano, P; Wang, S; Kanduri, C; Lezcano, M; Sandhu, KS; Singh, U; Pant, V; Tiwari, V; Kurukuti, S; Ohlsson, R				Zhao, Zhihu; Tavoosidana, Gholamreza; Sjolinder, Mikael; Gondor, Anita; Mariano, Piero; Wang, Sha; Kanduri, Chandrasekhar; Lezcano, Magda; Sandhu, Kuljeet Singh; Singh, Umashankar; Pant, Vinod; Tiwari, Vijay; Kurukuti, Sreenivasulu; Ohlsson, Rolf			Circular chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra- and interchromosomal interactions	NATURE GENETICS			English	Article							GENES; IGF2; CTCF; H19; COLOCALIZATION; INACTIVATION; ASSOCIATION; METHYLATION; EXPRESSION; PARENT	Accumulating evidence converges on the possibility that chromosomes interact with each other to regulate transcription in trans. To systematically explore the epigenetic dimension of such interactions, we devised a strategy termed circular chromosome conformation capture (4C). This approach involves a circularization step that enables high-throughput screening of physical interactions between chromosomes without a preconceived idea of the interacting partners. Here we identify 114 unique sequences from all autosomes, several of which interact primarily with the maternally inherited H19 imprinting control region. Imprinted domains were strongly overrepresented in the library of 4C sequences, further highlighting the epigenetic nature of these interactions. Moreover, we found that the direct interaction between differentially methylated regions was linked to epigenetic regulation of transcription in trans. Finally, the patterns of interactions specific to the maternal H19 imprinting control region underwent reprogramming during in vitro maturation of embryonic stem cells. These observations shed new light on development, cancer epigenetics and the evolution of imprinting.	Uppsala Univ, Dept Genet & Dev, Evolut Biol Ctr, SE-75136 Uppsala, Sweden	Uppsala University	Ohlsson, R (corresponding author), Uppsala Univ, Dept Genet & Dev, Evolut Biol Ctr, SE-75136 Uppsala, Sweden.	rolf.ohlsson@ebc.uu.se	kurukuti, sreenivasulu/AAI-5663-2020; Singh, Umashankar/ABE-3830-2020; Mariano, Pier Nilsson/AAP-5562-2021; Tavoosidana, Gholamreza/AAV-3893-2020	Singh, Umashankar/0000-0001-8578-8201; Tavoosidana, Gholamreza/0000-0002-1079-7434; Sandhu, Kuljeet/0000-0001-7632-6339; Kanduri, Chandrasekhar/0000-0001-6271-9078; Pant, Vinod/0000-0002-3286-1804; Gondor, Anita/0000-0002-1523-4411; Tiwari, Vijay/0000-0003-0292-6635				Bacher CP, 2006, NAT CELL BIOL, V8, P293, DOI 10.1038/ncb1365; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Dean W, 1998, DEVELOPMENT, V125, P2273; Dekker J, 2006, NAT METHODS, V3, P17, DOI 10.1038/NMETH823; Horike S, 2005, NAT GENET, V37, P31, DOI 10.1038/ng1491; Kono T, 2004, NATURE, V428, P860, DOI 10.1038/nature02402; Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103; Ling JQ, 2006, SCIENCE, V312, P269, DOI 10.1126/science.1123191; Luedi PP, 2005, GENOME RES, V15, P875, DOI 10.1101/gr.3303505; Massey JB, 2006, CURR OPIN LIPIDOL, V17, P296, DOI 10.1097/01.mol.0000226123.17629.ab; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Ohlsson R, 2001, TRENDS GENET, V17, P136, DOI 10.1016/S0168-9525(00)02211-3; Okamura K, 2004, DNA RES, V11, P381, DOI 10.1093/dnares/11.6.381; Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423; Pant V, 2003, GENE DEV, V17, P586, DOI 10.1101/gad.254903; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Spilianakis CG, 2005, NATURE, V435, P637, DOI 10.1038/nature03574; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Wurtele H, 2006, CHROMOSOME RES, V14, P477, DOI 10.1007/s10577-006-1075-0	19	612	652	0	81	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1341	1347		10.1038/ng1891	http://dx.doi.org/10.1038/ng1891			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17033624				2022-12-25	WOS:000241592700025
J	Lee, H; Zahra, D; Vogelzang, A; Newton, R; Thatcher, J; Quan, A; So, T; Zwirner, J; Koentgen, F; Padkjaer, SB; Mackay, F; Whitfeld, PL; Mackay, CR				Lee, Hyun; Zahra, David; Vogelzang, Alexis; Newton, Rebecca; Thatcher, Jenny; Quan, Annie; So, Trina; Zwirner, Joerg; Koentgen, Frank; Padkjaer, Soren B.; Mackay, Fabienne; Whitfeld, Peter L.; Mackay, Charles R.			Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies	NATURE BIOTECHNOLOGY			English	Article							PROTEIN-COUPLED RECEPTORS; ANAPHYLATOXIN RECEPTOR; LYMPHOID-CELLS; CHEMOKINE; ARTHRITIS; BINDING; MIGRATION; RESPONSES; DISEASE; DOMAIN	Complement component C5a binds C5a receptor (C5aR) and facilitates leukocyte chemotaxis and release of inflammatory mediators. We used neutrophils from human C5aR knock-in mice, in which the mouse C5aR coding region was replaced with that of human C5aR, to immunize wild-type mice and to generate high-affinity antagonist monoclonal antibodies (mAbs) to human C5aR. These mAbs blocked neutrophil migration to C5a in vitro and, at low doses, both prevented and reversed inflammatory arthritis in the murine K/BxN model. Of similar to 40 mAbs generated to C5aR, all potent inhibitors recognized a small region of the second extracellular loop that seems to be critical for regulation of receptor activity. Human C5aR knock-in mice not only facilitated production of high-affinity mAbs against an important human therapeutic target but were also useful in preclinical validation of the potency of these antagonists. This strategy should be applicable to other important mAb therapeutics.	Gavan Inst Med Res, Immunol & Inflammat Dept, Darlinghurst, NSW 2010, Australia; G2 Inflammat Pty Ltd, Darlinghurst, NSW 2010, Australia; Univ Gottingen, Dept Immunol, D-37075 Gottingen, Germany; Ozgene Pty Ltd, Bentley, WA 6983, Australia; Novo Nordisk AS, DK-2760 Malov, Denmark	University of Gottingen; Novo Nordisk	Mackay, CR (corresponding author), Gavan Inst Med Res, Immunol & Inflammat Dept, 384 Victoria St, Darlinghurst, NSW 2010, Australia.	c.mackay@garvan.org.au	Mackay, Charles R/A-9673-2008; Vogelzang, Alexis/C-5440-2017; Mackay, Fabienne/B-7440-2008	Mackay, Charles R/0000-0002-6338-7340; Mackay, Fabienne/0000-0002-6074-2693; Vogelzang, Alexis/0000-0002-2921-1755				Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Carter PJ, 2006, NAT REV IMMUNOL, V6, P343, DOI 10.1038/nri1837; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; GERARD C, 1992, J IMMUNOL, V149, P2600; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; Gerard NP, 2005, J BIOL CHEM, V280, P39677, DOI 10.1074/jbc.C500287200; Grant EP, 2002, J EXP MED, V196, P1461, DOI 10.1084/jem.20020205; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hopkin M, 2006, NATURE, V440, P855, DOI 10.1038/440855a; Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074-7613(02)00275-3; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; OPPERMANN M, 1993, J IMMUNOL, V151, P3785; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Shevchuk NA, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh014; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Soruri A, 2003, IMMUNOL LETT, V88, P47, DOI 10.1016/S0165-2478(03)00052-X; Sumichika Hiroshi, 2004, Curr Opin Investig Drugs, V5, P505; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8955, DOI 10.1073/pnas.92.19.8955; Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373	30	49	77	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2006	24	10					1279	1284		10.1038/nbt1248	http://dx.doi.org/10.1038/nbt1248			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	093TG	16980974				2022-12-25	WOS:000241191700032
J	Chang, AH; T Stephan, M; Sadelain, M				Chang, Alex H.; T Stephan, Matthias; Sadelain, Michel			Stem cell-derived erythroid cells mediate long-term systemic protein delivery	NATURE BIOTECHNOLOGY			English	Article							COAGULATION-FACTOR-IX; FACTOR-VIII GENE; HEMOPHILIA-A; MOUSE MODEL; PHENOTYPIC CORRECTION; TRANSGENE EXPRESSION; THERAPY; TOLERANCE; MICE; TRANSDUCTION	We demonstrate here the capacity of erythroid cells to mediate long-term, systemic and therapeutic protein delivery in vivo. By targeting human factor IX (hFIX) expression to late-stage erythropoiesis, we achieve long-term hFIX secretion at levels significantly higher (> tenfold) than those obtained with an archetypal ubiquitous promoter in a mouse model of hemophilia B. Erythroid cell-derived hFIX is biologically active, resulting in phenotypic correction of the bleeding disorder. In addition to achieving high expression levels and resistance to transcriptional silencing, red cell-mediated protein delivery offers multiple advantages including immune tolerance induction, reduction of the risk of insertional oncogenesis and relative ease of application by either engrafting transduced hematopoietic stem cells or transfusing ex vivo-generated, stem cell-derived erythroid cells.	Mem Sloan Kettering Canc Ctr, Lab Gene Transfer & Gene Express, New York, NY 10021 USA; Cornell Univ, Grad Program Immunol, Weill Grad Sch Med Sci, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Gene Transfer & Somat Cell Engn Facil, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Gene Transfer & Gene Express, 1275 York Ave, New York, NY 10021 USA.	m-sadelain@ski.mskcc.org	CHANG, ALEX/A-8284-2011	Stephan, Matthias/0000-0001-8310-0100	NATIONAL CANCER INSTITUTE [P01CA059350, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066952, R01HL057612] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08748, CA 59350] Funding Source: Medline; NHLBI NIH HHS [HL 66952, HL 57612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AXELROD JH, 1990, P NATL ACAD SCI USA, V87, P5173, DOI 10.1073/pnas.87.13.5173; Bagley J, 2002, FRONT BIOSCI, V7, pD1331, DOI 10.2741/bagley; BENNETT B, 1992, J IMMUNOL METHODS, V153, P31, DOI 10.1016/0022-1759(92)90302-A; Bigger BW, 2006, GENE THER, V13, P117, DOI 10.1038/sj.gt.3302638; CHALLITA PM, 1994, P NATL ACAD SCI USA, V91, P2567, DOI 10.1073/pnas.91.7.2567; Evans GL, 1998, P NATL ACAD SCI USA, V95, P5734, DOI 10.1073/pnas.95.10.5734; Ganong W. F., 2001, GANONGS REV MED PHYS; Giarratana MC, 2005, NAT BIOTECHNOL, V23, P69, DOI 10.1038/nbt1047; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Heim DA, 2000, IMMUNOL REV, V178, P29, DOI 10.1034/j.1600-065X.2000.17802.x; Herzog RW, 1997, P NATL ACAD SCI USA, V94, P5804, DOI 10.1073/pnas.94.11.5804; HOEBEN RC, 1992, THROMB HAEMOSTASIS, V67, P341; Kikuchi J, 2004, J GENE MED, V6, P1049, DOI 10.1002/jgm.609; Kohn DB, 2003, NAT REV CANCER, V3, P477, DOI 10.1038/nrc1122; Kootstra NA, 2003, MOL THER, V7, P623, DOI 10.1016/S1525-0016(03)00073-X; KURACHI S, 1995, J BIOL CHEM, V270, P5276, DOI 10.1074/jbc.270.10.5276; Li QL, 2002, BLOOD, V100, P3077, DOI 10.1182/blood-2002-04-1104; Liu Y, 1996, BIOCHEM BIOPH RES CO, V224, P549, DOI 10.1006/bbrc.1996.1063; Mannucci PM, 2001, NEW ENGL J MED, V344, P1773, DOI 10.1056/NEJM200106073442307; Margaritis P, 2004, J CLIN INVEST, V113, P1025, DOI 10.1172/JCI200420106; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; Moayeri M, 2005, MOL THER, V12, P1034, DOI 10.1016/j.ymthe.2005.09.007; Ng ES, 2005, BLOOD, V106, P1601, DOI 10.1182/blood-2005-03-0987; Rodriguez MH, 2002, THROMB HAEMOSTASIS, V87, P366, DOI 10.1055/s-0037-1613013; Sadelain M, 2004, GENE THER, V11, P569, DOI 10.1038/sj.gt.3302243; Samakoglu S, 2006, NAT BIOTECHNOL, V24, P89, DOI 10.1038/nbt1176; Tiede A, 2003, GENE THER, V10, P1917, DOI 10.1038/sj.gt.3302093; von Kalle C, 2004, J CLIN INVEST, V114, P889, DOI 10.1172/JCI200423132; Wang LL, 1997, P NATL ACAD SCI USA, V94, P11563, DOI 10.1073/pnas.94.21.11563; Woods NB, 2001, J INTERN MED, V249, P339, DOI 10.1046/j.1365-2796.2001.00806.x	30	64	74	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2006	24	8					1017	1021		10.1038/nbt1227	http://dx.doi.org/10.1038/nbt1227			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	072VY	16845377				2022-12-25	WOS:000239702300042
J	Cleard, F; Moshkin, Y; Karch, F; Maeda, RK				Cleard, Fabienne; Moshkin, Yuri; Karch, Francois; Maeda, Robert K.			Probing long-distance regulatory interactions in the Drosophila melanogaster bithorax complex using Dam identification	NATURE GENETICS			English	Article							CHROMATIN DOMAIN BOUNDARY; ABDOMINAL-B; INSULATOR ACTIVITY; MCP ELEMENT; PROMOTER; FAB-7; GENE; METHYLTRANSFERASE; DNA; TRANSVECTION	A cis-regulatory region of nearly 300 kb controls the expression of the three bithorax complex (BX-C) homeotic genes: Ubx, abd-A and Abd-B-1,B-2. Interspersed between the numerous enhancers and silencers within the complex are elements called domain boundaries. Recently, many pieces of evidence have suggested that boundaries function to create autonomous domains by interacting among themselves and forming chromatin loops(3-6). In order to test this hypothesis, we used Dam identification to probe for interactions between the Fab-7 boundary and other regions in the BX-C7. We were surprised to find that the targeting of Dam methyltransferase (Dam) to the Fab-7 boundary results in a strong methylation signal at the Abd-Bm promoter, similar to 35 kb away. Moreover, this methylation pattern is found primarily in the tissues where Abd-B is not expressed and requires an intact Fab-7 boundary. Overall, our work provides the first documented example of a dynamic, long-distance physical interaction between distal regulatory elements within a living, multicellular organism.	Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva, Switzerland; Univ Geneva, Natl Res Ctr Frontiers Genet, CH-1211 Geneva, Switzerland; Erasmus Univ, Med Ctr, Dept Biochem, NL-3015 Rotterdam, Netherlands	University of Geneva; University of Geneva; Erasmus University Rotterdam; Erasmus MC	Karch, F (corresponding author), Univ Geneva, Dept Zool & Anim Biol, 30 Quai E Ansermet, CH-1211 Geneva, Switzerland.	francois.karch@zoo.unige.ch	Moshkin, Yuri/ABA-3435-2021; Moshkin, Yuri M./M-3093-2016	Moshkin, Yuri/0000-0003-2964-8823; Moshkin, Yuri M./0000-0003-2964-8823; Cleard, Fabienne/0000-0003-0694-4822				Bantignies F, 2003, GENE DEV, V17, P2406, DOI 10.1101/gad.269503; Barges S, 2000, DEVELOPMENT, V127, P779; Bender W, 2000, DEVELOPMENT, V127, P3981; Cai HN, 2001, SCIENCE, V291, P493, DOI 10.1126/science.291.5503.493; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Chen Q, 2005, DEV BIOL, V286, P629, DOI 10.1016/j.ydbio.2005.08.025; GALLONI M, 1993, EMBO J, V12, P1087, DOI 10.1002/j.1460-2075.1993.tb05750.x; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; Gruzdeva N, 2005, MOL CELL BIOL, V25, P3682, DOI 10.1128/MCB.25.9.3682-3689.2005; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; Hogga I, 2001, MOL CELL, V8, P1145, DOI 10.1016/S1097-2765(01)00377-X; Lebrun E, 2003, MOL CELL BIOL, V23, P1498, DOI 10.1128/MCB.23.5.1498-1508.2003; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Maeda RK, 2006, DEVELOPMENT, V133, P1413, DOI 10.1242/dev.02323; MARTIN CH, 1995, P NATL ACAD SCI USA, V92, P8398, DOI 10.1073/pnas.92.18.8398; MCCALL K, 1994, GENETICS, V138, P387; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Mihaly J, 1998, CELL MOL LIFE SCI, V54, P60, DOI 10.1007/s000180050125; Muller M, 1999, GENETICS, V153, P1333; Muravyova E, 2001, SCIENCE, V291, P495, DOI 10.1126/science.291.5503.495; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Siegal ML, 1996, GENETICS, V144, P715; Sipos L, 1998, GENETICS, V149, P1031; TREMML G, 1989, EMBO J, V8, P2677, DOI 10.1002/j.1460-2075.1989.tb08408.x; van Steensel B, 2000, NAT BIOTECHNOL, V18, P424, DOI 10.1038/74487; van Steensel B, 2001, NAT GENET, V27, P304, DOI 10.1038/85871; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195; Zhou JM, 1999, DEVELOPMENT, V126, P3057; Zhou JM, 1999, CELL, V99, P567, DOI 10.1016/S0092-8674(00)81546-9	30	102	105	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	AUG	2006	38	8					931	935		10.1038/ng1833	http://dx.doi.org/10.1038/ng1833			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16823379				2022-12-25	WOS:000239325700024
J	Doxey, AC; Yaish, MW; Griffith, M; McConkey, BJ				Doxey, Andrew C.; Yaish, Mahmoud W.; Griffith, Marilyn; McConkey, Brendan J.			Ordered surface carbons distinguish antifreeze proteins and their ice-binding regions	NATURE BIOTECHNOLOGY			English	Article							SWISS-MODEL; IDENTIFICATION; CRYOPROTECTIN; CABBAGE; GROWTH; LEAVES; SERVER; PLANTS	Antifreeze proteins (AFPs) are found in cold-adapted organisms and have the unusual ability to bind to and inhibit the growth of ice crystals. However, the underlying molecular basis of their ice-binding activity is unclear because of the difficulty of studying the AFP-ice interaction directly and the lack of a common motif, domain or fold among different AFPs. We have formulated a generic ice-binding model and incorporated it into a physicochemical pattern-recognition algorithm. It successfully recognizes ice-binding surfaces for a diverse range of AFPs, and clearly discriminates AFPs from other structures in the Protein Data Bank(1). The algorithm was used to identify a novel AFP from winter rye, and the antifreeze activity of this protein was subsequently confirmed. The presence of a common and distinct physicochemical pattern provides a structural basis for unifying AFPs from fish, insects and plants.	Univ Waterloo, Dept Biol, Waterloo, ON N2L 3G1, Canada	University of Waterloo	McConkey, BJ (corresponding author), Univ Waterloo, Dept Biol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	mcconkey@uwaterloo.ca	Yaish, Mahmoud W/F-7168-2014	Yaish, Mahmoud W/0000-0002-5171-3014; Doxey, Andrew/0000-0003-2015-099X				Antson AA, 2001, J MOL BIOL, V305, P875, DOI 10.1006/jmbi.2000.4336; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bravo LA, 2005, J EXP BOT, V56, P1189, DOI 10.1093/jxb/eri112; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; DeLuca CI, 1998, J MOL BIOL, V275, P515, DOI 10.1006/jmbi.1997.1482; DEVRIES AL, 1986, METHOD ENZYMOL, V127, P293; DUMAN JG, 1974, NATURE, V247, P237, DOI 10.1038/247237a0; Fernandez-Recio J, 2005, PROTEINS, V58, P134, DOI 10.1002/prot.20285; Gallagher KR, 2003, BIOPHYS CHEM, V105, P195, DOI 10.1016/S0301-4622(03)00087-5; Gauthier SY, 1998, EUR J BIOCHEM, V258, P445, DOI 10.1046/j.1432-1327.1998.2580445.x; Graether SP, 1999, J BIOL CHEM, V274, P11842, DOI 10.1074/jbc.274.17.11842; Graether SP, 2004, EUR J BIOCHEM, V271, P3285, DOI 10.1111/j.1432-1033.2004.04256.x; Griffith M, 2004, TRENDS PLANT SCI, V9, P399, DOI 10.1016/j.tplants.2004.06.007; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harding MM, 1999, EUR J BIOCHEM, V264, P653, DOI 10.1046/j.1432-1327.1999.00617.x; Hincha DK, 2001, PLANT PHYSIOL, V125, P835, DOI 10.1104/pp.125.2.835; HON WC, 1994, PLANT PHYSIOL, V104, P971, DOI 10.1104/pp.104.3.971; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; Jia ZC, 2002, TRENDS BIOCHEM SCI, V27, P101, DOI 10.1016/S0968-0004(01)02028-X; Jorov A, 2004, PROTEIN SCI, V13, P1524, DOI 10.1110/ps.04641104; Kelley LA, 1997, PROTEIN SCI, V6, P2628; Knight CA, 2000, NATURE, V406, P249, DOI 10.1038/35018671; Madura JD, 2000, J MOL RECOGNIT, V13, P101, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<101::AID-JMR493>3.0.CO;2-9; McConkey BJ, 2002, BIOINFORMATICS, V18, P1365, DOI 10.1093/bioinformatics/18.10.1365; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Sieg F, 1996, PLANT PHYSIOL, V111, P215, DOI 10.1104/pp.111.1.215; Snider CS, 2000, PHYTOPATHOLOGY, V90, P354, DOI 10.1094/PHYTO.2000.90.4.354; Wang GL, 2003, BIOINFORMATICS, V19, P1589, DOI 10.1093/bioinformatics/btg224; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8	30	59	65	1	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					852	855		10.1038/nbt1224	http://dx.doi.org/10.1038/nbt1224			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16823370				2022-12-25	WOS:000239025100037
J	Herrera, S				Herrera, Stephan			Bonkers about biofuels	NATURE BIOTECHNOLOGY			English	Editorial Material							ETHANOL; ENERGY											Farrell AE, 2006, SCIENCE, V311, P506, DOI 10.1126/science.1121416; GREENE N, 2005, BRING BIOFUELS PUMP; HERRERA S, 2006, IND BIOTECHNOL, V2, P101; LUGAR RG, 2005, WALL STREET J   0213, pA17; PEPLOW M, 2005, NEWS NATURE     0701; PEPLOW M, 2006, NEWS NATURE     0126; Pimentel D., 2005, NAT RESOUR RES, V14, P65, DOI [DOI 10.1007/S11053-005-4679-8, 10.1007/s11053-005-4679-8]; Ragauskas AJ, 2006, SCIENCE, V311, P484, DOI 10.1126/science.1114736; Shapouri H, 2003, T ASAE, V46, P959, DOI 10.13031/2013.13951; SHAPOURI H, 1995, 721 USDA; WANG M, ANLESDTM163; Zhang YHP, 2005, P NATL ACAD SCI USA, V102, P7321, DOI 10.1073/pnas.0408734102	12	86	99	0	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					755	760		10.1038/nbt0706-755	http://dx.doi.org/10.1038/nbt0706-755			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16841053				2022-12-25	WOS:000239025100017
J	Levine, AD				Levine, Aaron D.			Research policy and the mobility of US stem cell scientists	NATURE BIOTECHNOLOGY			English	Editorial Material									Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Program Sci Technol & Environm Policy, Princeton, NJ 08544 USA	Princeton University	Levine, AD (corresponding author), Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Program Sci Technol & Environm Policy, Princeton, NJ 08544 USA.	adlevine@princeton.edu	Levine, Aaron/E-6495-2010					Holden C, 2004, SCIENCE, V306, P1111, DOI 10.1126/science.306.5699.1111; Knowles LP, 2004, NAT BIOTECHNOL, V22, P157, DOI 10.1038/nbt0204-157; Levine A, 2005, POLIT LIFE SCI, V23, P40; Noll R., 2006, STATES STEM CELLS PO; Normile D, 2005, SCIENCE, V307, P660, DOI 10.1126/science.307.5710.660; Smith JO, 2006, NAT BIOTECHNOL, V24, P391, DOI 10.1038/nbt0406-391; SOMERS T, 2005, SAN DIEGO UNION 1210, pA1; Walters L, 2004, KENNEDY INST ETHIC J, V14, P3, DOI 10.1353/ken.2004.0019; WEISS R, 2006, WASHINGTON POST 0302, pA12	9	19	19	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					865	866		10.1038/nbt0706-865	http://dx.doi.org/10.1038/nbt0706-865			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16841069				2022-12-25	WOS:000239025100039
J	Petreaca, RC; Chiu, HC; Eckelhoefer, HA; Chuang, C; Xu, L; Nugent, CI				Petreaca, Ruben C.; Chiu, Huan-Chih; Eckelhoefer, Holly A.; Chuang, Charles; Xu, Ling; Nugent, Constance I.			Chromosome end protection plasticity revealed by Stn1p and Ten1p bypass of Cdc13p	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE TELOMERASE; DNA-POLYMERASE-ALPHA; BINDING PROTEIN; LENGTH REGULATION; YEAST; REPAIR; REPLICATION; MAINTENANCE; CHECKPOINT; SUBUNIT	Genome stability necessitates a mechanism to protect the termini of linear chromosomes from inappropriate degradation or recombination1,2. In many species this protection depends on 'capping' proteins that bind telomeric DNA(3,4). The budding yeast Cdc13p binds single-stranded telomeric sequences(5,6), prevents lethal degradation of chromosome ends(7,8) and regulates telomere extension by telomerase(5,9). Two Cdc13-interacting proteins, Stn1p and Ten1p, are also required for viability and telomere length regulation(10,11). It has been proposed that Cdc13p DNA binding directs a Cdc13p-Stn1p-Ten1p complex to telomeres to mediate end protection(12). However, the functional significance of these protein interactions, and their respective roles in maintaining telomere integrity, remain undefined. Here, we show that co-overexpressing TEN1 with a truncated form of STN1 efficiently bypasses the essential role of CDC13. We further show that this truncated Stn1p binds directly to Pol12p, a polymerase alpha-primase regulatory subunit, and that Pol12 activity is required for CDC13 bypass. Thus, Stn1p and Ten1p control a Cdc13p-independent telomere capping mechanism that is coupled to the conventional DNA replication machinery.	Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; Univ Calif Riverside, Grad Program Cell Mol & Dev Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Nugent, CI (corresponding author), Univ Calif Riverside, Dept Cell Biol & Neurosci, 5429 Boyce Hall, Riverside, CA 92521 USA.	connie.nugent@ucr.edu						Bai C, 1996, METHOD ENZYMOL, V273, P331; Bertuch AA, 2003, MOL CELL BIOL, V23, P8202, DOI 10.1128/MCB.23.22.8202-8215.2003; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Chandra A, 2001, GENE DEV, V15, P404, DOI 10.1101/gad.861001; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; Evans SK, 2002, GENETICS, V162, P1101; Ferreira MG, 2004, MOL CELL, V13, P7, DOI 10.1016/S1097-2765(03)00531-8; Fisher TS, 2004, NAT STRUCT MOL BIOL, V11, P1198, DOI 10.1038/nsmb854; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; Grandin N, 2001, EMBO J, V20, P1173, DOI 10.1093/emboj/20.5.1173; Grossi S, 2004, GENE DEV, V18, P992, DOI 10.1101/gad.300004; James P, 1996, GENETICS, V144, P1425; Kaina B, 2004, CYTOGENET GENOME RES, V104, P77, DOI 10.1159/000077469; Koc A, 2004, J BIOL CHEM, V279, P223, DOI 10.1074/jbc.M303952200; Le S, 1999, GENETICS, V152, P143; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; McClintock B, 1941, GENETICS, V26, P234; Miller KM, 2003, MOL CELL, V11, P303, DOI 10.1016/S1097-2765(03)00041-8; Muller H.J., 1938, COLLECTING NET, V13, P181; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Qi HY, 2000, GENE DEV, V14, P1777; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049; Taggart AKP, 2002, SCIENCE, V297, P1023, DOI 10.1126/science.1074968; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Theobald DL, 2003, STRUCTURE, V11, P1049, DOI 10.1016/S0969-2126(03)00183-7	33	58	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					748	U202		10.1038/ncb1430	http://dx.doi.org/10.1038/ncb1430			15	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16767082				2022-12-25	WOS:000238837800018
J	Schuchmann, S; Schmitz, D; Rivera, C; Vanhatalo, S; Salmen, B; Mackie, K; Sipila, ST; Voipio, J; Kaila, K				Schuchmann, Sebastian; Schmitz, Dietmar; Rivera, Claudio; Vanhatalo, Sampsa; Salmen, Benedikt; Mackie, Ken; Sipila, Sampsa T.; Voipio, Juha; Kaila, Kai			Experimental febrile seizures are precipitated by a hyperthermia-induced respiratory alkalosis	NATURE MEDICINE			English	Article							TEMPORAL-LOBE EPILEPSY; IMMATURE RAT MODEL; LONG-TERM; VENTILATORY RESPONSES; AMBIENT-TEMPERATURE; HIPPOCAMPAL SLICES; CARBON-DIOXIDE; NEWBORN RATS; PH; CHILDREN	Febrile seizures are frequent during early childhood, and prolonged ( complex) febrile seizures are associated with an increased susceptibility to temporal lobe epilepsy. The pathophysiological consequences of febrile seizures have been extensively studied in rat pups exposed to hyperthermia. The mechanisms that trigger these seizures are unknown, however. A rise in brain pH is known to enhance neuronal excitability. Here we show that hyperthermia causes respiratory alkalosis in the immature brain, with a threshold of 0.2-0.3 pH units for seizure induction. Suppressing alkalosis with 5% ambient CO2 abolished seizures within 20 s. CO2 also prevented two long-term effects of hyperthermic seizures in the hippocampus: the upregulation of the I-h current and the upregulation of CB1 receptor expression. The effects of hyperthermia were closely mimicked by intraperitoneal injection of bicarbonate. Our work indicates a mechanism for triggering hyperthermic seizures and suggests new strategies in the research and therapy of fever-related epileptic syndromes.	Univ Helsinki, Dept Biol & Environm Sci, FIN-00014 Helsinki, Finland; Univ Med Berlin, Neurosci Res Ctr, Charite, D-10119 Berlin, Germany; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Clin Neurophysiol, Childrens Hosp, Helsinki 00029, Finland; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Helsinki, Ctr Neurosci, FIN-00014 Helsinki, Finland	University of Helsinki; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Washington; University of Washington Seattle; University of Helsinki	Kaila, K (corresponding author), Univ Helsinki, Dept Biol & Environm Sci, Viikinkaari 1 POB 65, FIN-00014 Helsinki, Finland.	kai.kaila@helsinki.fi	Vanhatalo, Sampsa/B-1393-2013; Rivera, Claudio/ABE-2499-2021; Mackie, Kenneth P/B-7358-2011; Mackie, Ken/E-3715-2013; Kaila, Kai K/R-8528-2016	Rivera, Claudio/0000-0003-2462-6561; Mackie, Ken/0000-0001-8501-6199; Kaila, Kai K/0000-0003-0668-5955; Voipio, Juha/0000-0001-7096-1286; Schmitz, Dietmar/0000-0003-2741-5241	NIDA NIH HHS [K02 DA000286, R01 DA011322] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011322, K02DA000286] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARAM JA, 1987, NEUROSCI LETT, V83, P345, DOI 10.1016/0304-3940(87)90112-1; BALESTRINO M, 1988, J PHYSIOL-LONDON, V396, P247, DOI 10.1113/jphysiol.1988.sp016961; Banke TG, 2005, J NEUROSCI, V25, P42, DOI 10.1523/JNEUROSCI.3154-04.2005; Baram TZ, 1997, DEV BRAIN RES, V98, P265, DOI 10.1016/S0165-3806(96)00190-3; Baulac S, 2004, LANCET NEUROL, V3, P421, DOI 10.1016/S1474-4422(04)00808-7; Bender RA, 2004, ADV EXP MED BIOL, V548, P213; Berg AT, 1996, EPILEPSIA, V37, P126, DOI 10.1111/j.1528-1157.1996.tb00003.x; Brewster A, 2002, J NEUROSCI, V22, P4591, DOI 10.1523/JNEUROSCI.22-11-04591.2002; Cameron YL, 2000, PEDIATR RES, V47, P813, DOI 10.1203/00006450-200006000-00022; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; Chen K, 2003, NEURON, V39, P599, DOI 10.1016/S0896-6273(03)00499-9; Chesler M, 2003, PHYSIOL REV, V83, P1183, DOI 10.1152/physrev.00010.2003; CURTIS M, 1998, J NEUROSCI, V178, P7543; Dube C, 2006, BRAIN, V129, P911, DOI 10.1093/brain/awl018; Dube C, 2000, ANN NEUROL, V47, P336, DOI 10.1002/1531-8249(200003)47:3<336::AID-ANA9>3.0.CO;2-W; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; GADOMSKI AM, 1994, J CLIN EPIDEMIOL, V47, P1043, DOI 10.1016/0895-4356(94)90120-1; Hajos N, 2000, EUR J NEUROSCI, V12, P3239, DOI 10.1046/j.1460-9568.2000.00217.x; HAUSER WA, 1994, EPILEPSIA, V35, pS1, DOI 10.1111/j.1528-1157.1994.tb05932.x; Haut SR, 2004, LANCET NEUROL, V3, P608, DOI 10.1016/S1474-4422(04)00881-6; HOLTZMAN D, 1981, SCIENCE, V213, P1034, DOI 10.1126/science.7268407; JAROLIMEK W, 1989, BRAIN RES, V505, P225, DOI 10.1016/0006-8993(89)91447-9; KAILA K, 1998, PH BRAIN FUNCTION, P1; Kang JQ, 2006, J NEUROSCI, V26, P2590, DOI 10.1523/JNEUROSCI.4243-05.2006; Lahtinen H, 2002, J NEUROPHYSIOL, V88, P1469, DOI 10.1152/jn.2002.88.3.1469; Lee J, 1996, BRAIN RES, V706, P210, DOI 10.1016/0006-8993(95)01214-1; Mantegazza M, 2005, P NATL ACAD SCI USA, V102, P18177, DOI 10.1073/pnas.0506818102; Mariak Z, 1999, J APPL PHYSIOL, V87, P1609, DOI 10.1152/jappl.1999.87.5.1609; Mortola JP, 2000, ANNU REV PHYSIOL, V62, P847, DOI 10.1146/annurev.physiol.62.1.847; Mulley JC, 2005, HUM MOL GENET, V14, pR243, DOI 10.1093/hmg/ddi355; ODEMPSEY TJD, 1993, ARCH DIS CHILD, V68, P492, DOI 10.1136/adc.68.4.492; Prole DL, 2003, J GEN PHYSIOL, V122, P775, DOI 10.1085/jgp.200308897; Putnam RW, 2005, RESP PHYSIOL NEUROBI, V149, P165, DOI 10.1016/j.resp.2005.03.004; Putnam RW, 2004, AM J PHYSIOL-CELL PH, V287, pC1493, DOI 10.1152/ajpcell.00282.2004; Richerson GB, 2004, NAT REV NEUROSCI, V5, P449, DOI 10.1038/nrn1409; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; Saiki C, 1996, J PHYSIOL-LONDON, V491, P261, DOI 10.1113/jphysiol.1996.sp021213; Schmitz D, 2003, NAT NEUROSCI, V6, P1058, DOI 10.1038/nn1116; Singh R, 1999, ANN NEUROL, V45, P75, DOI 10.1002/1531-8249(199901)45:1<75::AID-ART13>3.0.CO;2-W; TAYLOR JA, 1995, ARCH PEDIAT ADOL MED, V149, P283, DOI 10.1001/archpedi.1995.02170150063011; Toth Z, 1998, J NEUROSCI, V18, P4285; TSUBOI T, 1984, NEUROLOGY, V34, P175, DOI 10.1212/WNL.34.2.175; Vanhatalo S, 2005, CLIN EEG NEUROSCI, V36, P311, DOI 10.1177/155005940503600411; VAUGHANJONES RD, 1986, PFLUG ARCH EUR J PHY, V406, P641, DOI 10.1007/BF00584033; Voipio J, 2003, J NEUROPHYSIOL, V89, P2208, DOI 10.1152/jn.00915.2002; VOIPIO J, 1993, PFLUG ARCH EUR J PHY, V423, P193, DOI 10.1007/BF00374394; Wirrell EC, 1996, EPILEPSIA, V37, P459, DOI 10.1111/j.1528-1157.1996.tb00592.x; Xiong ZQ, 2000, J NEUROSCI, V20, P1290; Yi DK, 1996, DEV PSYCHOBIOL, V29, P497, DOI 10.1002/(SICI)1098-2302(199609)29:6<497::AID-DEV2>3.0.CO;2-H	50	193	203	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					817	823		10.1038/nm1422	http://dx.doi.org/10.1038/nm1422			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16819552	Green Accepted			2022-12-25	WOS:000238862800069
J	Izumi, Y; Ohta, N; Hisata, K; Raabe, T; Matsuzaki, F				Izumi, Yasushi; Ohta, Nao; Hisata, Kanako; Raabe, Thomas; Matsuzaki, Fumio			Drosophila Pins-binding protein Mud regulates spindle-polarity coupling and centrosome organization	NATURE CELL BIOLOGY			English	Article							HETEROTRIMERIC G-PROTEINS; NEUROBLAST ASYMMETRIC DIVISIONS; CAENORHABDITIS-ELEGANS EMBRYOS; MUSHROOM-BODY-DEFECT; CELL-DIVISION; G-ALPHA; CYTOPLASMIC DYNEIN; DISTINCT ROLES; C-ELEGANS; COMPLEX	The orientation of the mitotic spindle relative to the cell axis determines whether polarized cells undergo symmetric or asymmetric divisions. Drosophila epithelial cells and neuroblasts provide an ideal pair of cells to study the regulatory mechanisms involved. Epithelial cells divide symmetrically, perpendicular to the apical-basal axis. In the asymmetric divisions of neuroblasts, by contrast, the spindle reorients parallel to that axis, leading to the unequal distribution of cell-fate determinants to one daughter cell(1). Receptor-independent G-protein signalling involving the GoLoco protein Pins is essential for spindle orientation in both cell types(2). Here, we identify Mushroom body defect ( Mud) 3 as a downstream effector in this pathway. Mud directly associates and colocalizes with Pins at the cell cortex overlying the spindle pole(s) in both neuroblasts and epithelial cells. The cortical Mud protein is essential for proper spindle orientation in the two different division modes. Moreover, Mud localizes to centrosomes during mitosis independently of Pins to regulate centrosomal organization. We propose that Drosophila Mud, vertebrate NuMA(4) and Caenorhabditis elegans Lin-5 (refs 5, 6) have conserved roles in the mechanism by which G-proteins regulate the mitotic spindle.	RIKEN, Ctr Dev Biol, Lab Cell Asymmetry, Chuo Ku, Kobe, Hyogo 6500047, Japan; Univ Wurzburg, Inst Med Res & Cell Res, D-97078 Wurzburg, Germany; Japan Sci & Technol Corp, CREST, Chuo Ku, Kobe, Hyogo 6500047, Japan	RIKEN; University of Wurzburg; Japan Science & Technology Agency (JST)	Izumi, Y (corresponding author), RIKEN, Ctr Dev Biol, Lab Cell Asymmetry, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan.	izumi@cdb.riken.jp; fumio@cdb.riken.jp						Ahringer J, 2003, CURR OPIN CELL BIOL, V15, P73, DOI 10.1016/S0955-0674(02)00018-2; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Bellaiche Y, 2005, CURR OPIN CELL BIOL, V17, P658, DOI 10.1016/j.ceb.2005.10.002; Berrueta L, 1999, CURR BIOL, V9, P425, DOI 10.1016/S0960-9822(99)80190-0; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; Cai Y, 2003, CELL, V112, P51, DOI 10.1016/S0092-8674(02)01170-4; CHOU TB, 1992, GENETICS, V131, P643; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Guan ZH, 2000, P NATL ACAD SCI USA, V97, P8122, DOI 10.1073/pnas.97.14.8122; Izumi Y, 2004, J CELL BIOL, V164, P729, DOI 10.1083/jcb.200309162; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lu BW, 2001, NATURE, V409, P522, DOI 10.1038/35054077; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; PROKOP A, 1994, DEV BIOL, V161, P321, DOI 10.1006/dbio.1994.1034; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Siegrist SE, 2005, CELL, V123, P1323, DOI 10.1016/j.cell.2005.09.043; Siller KH, 2005, MOL BIOL CELL, V16, P5127, DOI 10.1091/mbc.E05-04-0338; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Wilkie TM, 2005, CURR BIOL, V15, pR843, DOI 10.1016/j.cub.2005.10.008; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Yu FW, 2005, GENE DEV, V19, P1341, DOI 10.1101/gad.1295505; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174	31	196	197	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					586	593		10.1038/ncb1409	http://dx.doi.org/10.1038/ncb1409			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16648846				2022-12-25	WOS:000238029000011
J	MacDonald, ML; Lamerdin, J; Owens, S; Keon, BH; Bilter, GK; Shang, ZD; Huang, ZP; Yu, H; Dias, J; Minami, T; Michnick, SW; Westwick, JK				MacDonald, Marnie L.; Lamerdin, Jane; Owens, Stephen; Keon, Brigitte H.; Bilter, Graham K.; Shang, Zhidi; Huang, Zhengping; Yu, Helen; Dias, Jennifer; Minami, Tomoe; Michnick, Stephen W.; Westwick, John K.			Identifying off-target effects and hidden phenotypes of drugs in human cells	NATURE CHEMICAL BIOLOGY			English	Article							FRAGMENT COMPLEMENTATION ASSAYS; PROTEIN-PROTEIN INTERACTIONS; IN-VIVO; FLUORESCENT PROTEIN; LIVING CELLS; BIOCHEMICAL NETWORKS; MAMMALIAN-CELLS; VITRO; PROLIFERATION; VISUALIZATION	We present a strategy for identifying off-target effects and hidden phenotypes of drugs by directly probing biochemical pathways that underlie therapeutic or toxic mechanisms in intact, living cells. High-content protein-fragment complementation assays (PCAs) were constructed with synthetic fragments of a mutant fluorescent protein ('Venus', EYFP or both), allowing us to measure spatial and temporal changes in protein complexes in response to drugs that activate or inhibit particular pathways. One hundred and seven different drugs from six therapeutic areas were screened against 49 different PCA reporters for ten cellular processes. This strategy reproduced known structure-function relationships and also predicted 'hidden,' potent antiproliferative activities for four drugs with novel mechanisms of action, including disruption of mitochondrial membrane potential. A simple algorithm identified a 25-assay panel that was highly predictive of antiproliferative activity, and the predictive power of this approach was confirmed with cross-validation tests. This study suggests a strategy for therapeutic discovery that identifies novel, unpredicted mechanisms of drug action and thereby enhances the productivity of drug-discovery research.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Odyssey Thera Inc, San Ramon, CA 94583 USA	Universite de Montreal	Michnick, SW (corresponding author), Univ Montreal, Dept Biochim, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	stephen.michnick@umontreal.ca						Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Benton R, 2006, PLOS BIOL, V4, P240, DOI 10.1371/journal.pbio.0040020; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; BURGHARDT RC, 1992, TOXICOL APPL PHARM, V112, P235, DOI 10.1016/0041-008X(92)90193-V; Fang DY, 2004, P NATL ACAD SCI USA, V101, P14782, DOI 10.1073/pnas.0404445101; Fotsis T, 1997, CANCER RES, V57, P2916; Froyland L, 1997, J LIPID RES, V38, P1851; Galarneau A, 2002, NAT BIOTECHNOL, V20, P619, DOI 10.1038/nbt0602-619; Ghosh I, 2000, J AM CHEM SOC, V122, P5658, DOI 10.1021/ja994421w; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Keblys M, 2004, MYCOPATHOLOGIA, V158, P317, DOI 10.1007/s11046-005-5523-8; Leveson-Gower DB, 2004, BIOCHEMISTRY-US, V43, P14257, DOI 10.1021/bi0491245; Lin FT, 2002, BIOCHEMISTRY-US, V41, P10692, DOI 10.1021/bi025705n; Maki CG, 1996, CANCER RES, V56, P2649; Michnick SW, 2000, METHOD ENZYMOL, V328, P208, DOI 10.1016/S0076-6879(00)28399-7; Miklos GLG, 2004, NAT BIOTECHNOL, V22, P615, DOI 10.1038/nbt965; Minnich A, 2001, AM J PHYSIOL-ENDOC M, V280, pE270, DOI 10.1152/ajpendo.2001.280.2.E270; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Nyfeler B, 2005, P NATL ACAD SCI USA, V102, P6350, DOI 10.1073/pnas.0501976102; Parsonnet J, 1996, AM J GASTROENTEROL, V91, P847; Pelletier JN, 1998, P NATL ACAD SCI USA, V95, P12141, DOI 10.1073/pnas.95.21.12141; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Remy I, 2004, METHODS, V32, P381, DOI 10.1016/j.ymeth.2003.10.011; Remy I, 2004, MOL CELL BIOL, V24, P1493, DOI 10.1128/MCB.24.4.1493-1504.2004; Remy I, 2001, P NATL ACAD SCI USA, V98, P7678, DOI 10.1073/pnas.131216098; Remy Ingrid, 2004, Methods Mol Biol, V261, P411; SEIGLEMURANDI F, 1992, PHARMAZIE, V47, P288; Stoughton RB, 2005, NAT REV DRUG DISCOV, V4, P345, DOI 10.1038/nrd1696; Subramaniam R, 2001, NAT BIOTECHNOL, V19, P769, DOI 10.1038/90831; Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; WALD N, 1989, BRIT J OBSTET GYNAEC, V96, P389, DOI 10.1111/j.1471-0528.1989.tb02411.x; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; WEINBACH EC, 1969, NATURE, V221, P1016, DOI 10.1038/2211016a0; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Yu H, 2003, ASSAY DRUG DEV TECHN, V1, P811, DOI 10.1089/154065803772613444; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zhou SY, 1999, TOXICOL SCI, V48, P82, DOI 10.1093/toxsci/48.1.82	47	243	252	2	28	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2006	2	6					329	337		10.1038/nchembio790	http://dx.doi.org/10.1038/nchembio790			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	045OH	16680159				2022-12-25	WOS:000237750900015
J	Witt, H; Sahin-Toth, M; Landt, O; Chen, JM; Kahne, T; Drenth, JPH; Kukor, Z; Szepessy, E; Halangk, W; Dahm, S; Rohde, K; Schulz, HU; Le Marechal, C; Akar, N; Ammann, RW; Truninger, K; Bargetzi, M; Bhatia, E; Castellani, C; Cavestro, GM; Cerny, M; Destro-Bisol, G; Spedini, G; Eiberg, H; Jansen, JBMJ; Koudova, M; Rausova, E; Macek, M; Malats, N; Real, FX; Menzel, HJ; Moral, P; Galavotti, R; Pignatti, PF; Rickards, O; Spicak, J; Zarnescu, NO; Bock, W; Gress, TM; Friess, H; Ockenga, J; Schmidt, H; Pfutzer, R; Lohr, M; Simon, P; Weiss, FU; Lerch, MM; Teich, N; Keim, V; Berg, T; Wiedenmann, B; Luck, W; Groneberg, DA; Becker, M; Keil, T; Kage, A; Bernardova, J; Braun, M; Guldner, C; Halangk, J; Rosendahl, J; Witt, U; Treiber, M; Nickel, R; Ferec, C				Witt, Heiko; Sahin-Toth, Miklos; Landt, Olfert; Chen, Jian-Min; Kaehne, Thilo; Drenth, Joost P. H.; Kukor, Zoltan; Szepessy, Edit; Halangk, Walter; Dahm, Stefan; Rohde, Klaus; Schulz, Hans-Ulrich; Le Marechal, Cedric; Akar, Nejat; Ammann, Rudolf W.; Truninger, Kaspar; Bargetzi, Mario; Bhatia, Eesh; Castellani, Carlo; Cavestro, Giulia Martina; Cerny, Milos; Destro-Bisol, Giovanni; Spedini, Gabriella; Eiberg, Hans; Jansen, Jan B. M. J.; Koudova, Monika; Rausova, Eva; Macek, Milan, Jr.; Malats, Nuria; Real, Francisco X.; Menzel, Hans-Jurgen; Moral, Pedro; Galavotti, Roberta; Pignatti, Pier Franco; Rickards, Olga; Spicak, Julius; Zarnescu, Narcis Octavian; Bock, Wolfgang; Gress, Thomas M.; Friess, Helmut; Ockenga, Johann; Schmidt, Hartmut; Pfutzer, Roland; Lohr, Matthias; Simon, Peter; Weiss, Frank Ulrich; Lerch, Markus M.; Teich, Niels; Keim, Volker; Berg, Thomas; Wiedenmann, Bertram; Luck, Werner; Groneberg, David Alexander; Becker, Michael; Keil, Thomas; Kage, Andreas; Bernardova, Jana; Braun, Markus; Gueldner, Claudia; Halangk, Juliane; Rosendahl, Jonas; Witt, Ulrike; Treiber, Matthias; Nickel, Renate; Ferec, Claude			A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis	NATURE GENETICS			English	Article							HUMAN CATIONIC TRYPSINOGEN; HEREDITARY PANCREATITIS; ACTIVATION; GENE; MUTATIONS	Chronic pancreatitis is a common inflammatory disease of the pancreas. Mutations in the genes encoding cationic trypsinogen (PRSS1) 1 and the pancreatic secretory trypsin inhibitor (SPINK1) 2 are associated with chronic pancreatitis. Because increased proteolytic activity owing to mutated PRSS1 enhances the risk for chronic pancreatitis, mutations in the gene encoding anionic trypsinogen (PRSS2) may also predispose to disease. Here we analyzed PRSS2 in individuals with chronic pancreatitis and controls and found, to our surprise, that a variant of codon 191 (G191R) is overrepresented in control subjects: G191R was present in 220/6,459 (3.4%) controls but in only 32/2,466 (1.3%) affected individuals (odds ratio 0.37; P = 1.1 x 10(-8)). Upon activation by enterokinase or trypsin, purified recombinant G191R protein showed a complete loss of trypsin activity owing to the introduction of a new tryptic cleavage site that renders the enzyme hypersensitive to autocatalytic proteolysis. In conclusion, the G191R variant of PRSS2 mitigates intrapancreatic trypsin activity and thereby protects against chronic pancreatitis.	Univ Hosp Berlin, Charite, Dept Gastroenterol & Hepatol, D-13353 Berlin, Germany; Univ Hosp Berlin, Charite, Dept Pediat, D-13353 Berlin, Germany; Boston Univ, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; TIB MOLBIOL, D-12103 Berlin, Germany; INSERM, U613, F-29220 Brest, France; Univ Bretagne Occidentale, Fac Med Brest & Sci Sante, F-29238 Brest, France; Etablissement Francais Sang Bretagne, Brest, France; CHRU, Brest, France; Hop Morvan, Lab Genet Mol & Histocompatibil, F-29220 Brest, France; Otto Von Guericke Univ, Inst Expt Internal Med, D-39120 Magdeburg, Germany; Univ Nijmegen, Radboud Med Ctr, Dept Med, Div Gastroenterol & Hepatol, NL-6500 HB Nijmegen, Netherlands; Otto Von Guericke Univ, Dept Surg, D-39120 Magdeburg, Germany; Max Delbruck Ctr Mol Med, Dept Bioinformat, D-13092 Berlin, Germany; Ankara Univ, Sch Med, Dept Pediat Mol Genet, TR-06530 Ankara, Turkey; Univ Zurich Hosp, Div Gastroenterol, Dept Med, CH-8092 Zurich, Switzerland; Kantonsspital, Div Gastroenterol, Dept Med, CH-5001 Aarau, Switzerland; Kantonsspital, Ctr Oncol Hematol, Dept Med, CH-5001 Aarau, Switzerland; Sanjay Gandhi Postgrad Inst Med Sci, Dept Endocrinol, Lucknow 226014, Uttar Pradesh, India; Osped Civile, Cyst Fibrosis Ctr, I-37126 Verona, Italy; Univ Parma, Dept Clin Sci, Gastroenterol Sect, I-43100 Parma, Italy; Univ Hosp Motol, Dept Neonatol, Clin Obstet & Gynecol, Prague 103 5, Czech Republic; Charles Univ Prague, Sch Med 2, Prague 103 5, Czech Republic; Univ Roma La Sapienza, Dept Human & Anim Biol, Sect Anthropol, I-00133 Rome, Italy; Univ Copenhagen, Panum Inst, Dept Med Biochem & Genet, DK-2200 Copenhagen, Denmark; Univ Hosp Motol, Cyst Fibrosis Ctr, Inst Biol & Med Genet, CZ-15006 Prague, Czech Republic; Charles Univ Prague, Sch Med 2, CZ-15006 Prague, Czech Republic; Univ Pompeu Fabra, Inst Municipal Invest Med, Barcelona 08003, Spain; Univ Innsbruck, Inst Med Biol & Human Genet, A-6020 Innsbruck, Austria; Univ Barcelona, Dept Anim Biol, Unitat Antropol, E-08028 Barcelona, Spain; Univ Verona, Sect Biol & Genet, DMIBG, I-37134 Verona, Italy; Univ Roma Tor Vergata, Dept Biol, I-00185 Rome, Italy; IKEM, Inst Clin & Expt Med, Clin Hepatogastroenterol, Prague 14021 4, Czech Republic; Univ Bucharest, Emergency Hsop, Dept Surg 2, Bucharest 72435, Romania; Univ Hosp Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Heidelberg, Dept Gen Surg, D-69120 Heidelberg, Germany; Univ Hosp Berlin, Charite, Dept Gastroenterol Hepatol & Gastroenterol, D-10008 Berlin, Germany; Univ Hosp Munster, D-48149 Munster, Germany; Univ Heidelberg, Med Fac Mannheim, Dept Med 2, D-68167 Mannheim, Germany; Ernst Moritz Arndt Univ Greifswald, Dept Gastroenterol Endocrinol & Nutr, D-17487 Greifswald, Germany; Univ Leipzig, Dept Gastroenterol & Hepatol, D-04103 Leipzig, Germany; Deutsch Rote Kreuz Klin Westend, Dept Pediat Gastroenterol, D-14050 Berlin, Germany; Univ Hosp Berlin, Charite, Inst Social Med & Epidemiol, D-10008 Berlin, Germany; Univ Hosp Berlin, Charite, Dept Surg, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Boston University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale; Universite de Bretagne Occidentale; CHU Brest; Universite de Bretagne Occidentale; CHU Brest; Universite de Bretagne Occidentale; Otto von Guericke University; Radboud University Nijmegen; Otto von Guericke University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ankara University; University of Zurich; University Zurich Hospital; Kantonsspital Aarau AG (KSA); Kantonsspital Aarau AG (KSA); Sanjay Gandhi Postgraduate Institute of Medical Sciences; University of Parma; Motol University Hospital; Charles University Prague; Sapienza University Rome; University of Copenhagen; Motol University Hospital; Charles University Prague; Pompeu Fabra University; University of Innsbruck; University of Barcelona; University of Verona; University of Rome Tor Vergata; Institute for Clinical & Experimental Medicine (IKEM); University of Bucharest; Ulm University; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster; Ruprecht Karls University Heidelberg; Ernst Moritz Arndt Universitat Greifswald; Leipzig University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Witt, H (corresponding author), Univ Hosp Berlin, Charite, Dept Gastroenterol & Hepatol, Augustenburg Pl 1, D-13353 Berlin, Germany.	heiko.witt@charite.de	Weiss, Frank Ulrich/A-6386-2009; Groneberg, David/A-5132-2018; Cavestro, Giulia Martina/AAA-9252-2019; Zarnescu, Narcis/J-4196-2015; Drenth, Joost/V-7436-2019; Rickards, Olga/L-7878-2015; Drenth, J.P.H./H-8025-2014; Teich, Niels/AAF-5104-2019; Löhr, Matthias/A-3692-2012; Akar, Nejat/H-2949-2019; Lerch, Markus M./E-2206-2016; Arribas, Francisco X Real/H-5275-2015; Kaehne, Thilo/E-4858-2012; Ferec, Claude/ABG-9699-2020; Castellani, Carlo/AAB-3847-2019; Malats, Nuria/H-7041-2015; Moral, Pedro/K-9587-2014	Weiss, Frank Ulrich/0000-0003-3369-6369; Groneberg, David/0000-0001-8551-6556; Cavestro, Giulia Martina/0000-0003-1947-9368; Zarnescu, Narcis/0000-0003-3973-6309; Rickards, Olga/0000-0003-2880-7466; Löhr, Matthias/0000-0002-7647-198X; Lerch, Markus M./0000-0002-9643-8263; Arribas, Francisco X Real/0000-0001-9501-498X; Ferec, Claude/0000-0002-2325-0710; Chen, Jian-Min/0000-0002-2424-3969; Gress, Thomas/0000-0002-9333-5461; Berg, Thomas/0000-0003-0003-6241; Malats, Nuria/0000-0003-2538-3784; Moral, Pedro/0000-0001-5072-5892; Sahin-Toth, Miklos/0000-0003-4513-9922; Wiedenmann, Bertram/0000-0002-7890-2552; Destro Bisol, Giovanni/0000-0002-4232-9715	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058088] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK058088-06, R01 DK058088-05A1, R01 DK058088-04, R01 DK058088-03, DK058088, R01 DK058088, R01 DK058088-04S1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; CHEN JM, 2004, HDB PROTEOLYTIC ENZY, P1489; COLOMB E, 1978, BIOCHIM BIOPHYS ACTA, V525, P186, DOI 10.1016/0005-2744(78)90213-9; COLOMB E, 1979, BIOCHIM BIOPHYS ACTA, V571, P343, DOI 10.1016/0005-2744(79)90104-9; Gaboriaud C, 1996, J MOL BIOL, V259, P995, DOI 10.1006/jmbi.1996.0376; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Kenesi E, 2003, BIOCHEM BIOPH RES CO, V309, P749, DOI 10.1016/j.bbrc.2003.08.064; Kukor Z, 2003, EUR J BIOCHEM, V270, P2047, DOI 10.1046/j.1432-1033.2003.03581.x; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Sahin-Toth M, 2000, BIOCHEM BIOPH RES CO, V278, P286, DOI 10.1006/bbrc.2000.3797; Sahin-Toth M, 2000, J BIOL CHEM, V275, P22750, DOI 10.1074/jbc.M002943200; SCHEELE G, 1981, GASTROENTEROLOGY, V80, P461; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Witt H, 2000, NAT GENET, V25, P213, DOI 10.1038/76088; Witt H, 1999, GASTROENTEROLOGY, V117, P7, DOI 10.1016/S0016-5085(99)70543-3	15	164	173	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2006	38	6					668	673		10.1038/ng1797	http://dx.doi.org/10.1038/ng1797			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16699518	Green Accepted			2022-12-25	WOS:000237954800021
J	Yaniv, K; Isogai, S; Castranova, D; Dye, L; Hitomi, J; Weinstein, BM				Yaniv, Karina; Isogai, Sumio; Castranova, Daniel; Dye, Louis; Hitomi, Jiro; Weinstein, Brant M.			Live imaging of lymphatic development in the zebrafish	NATURE MEDICINE			English	Article							ENDOTHELIAL-GROWTH-FACTOR; EMBRYONIC VASCULAR DEVELOPMENT; TRANSGENIC ZEBRAFISH; MOUSE EMBRYOS; FACTOR-C; IN-VIVO; EXPRESSION; SYSTEM; PROX1; GENE	The lymphatic system has become the subject of great interest in recent years because of its important role in normal and pathological processes. Progress in understanding the origins and early development of this system, however, has been hampered by difficulties in observing lymphatic cells in vivo and in performing defined genetic and experimental manipulation of the lymphatic system in currently available model organisms. Here, we show that the optically clear developing zebrafish provides a useful model for imaging and studying lymphatic development, with a lymphatic system that shares many of the morphological, molecular and functional characteristics of the lymphatic vessels found in other vertebrates. Using two-photon time-lapse imaging of transgenic zebrafish, we trace the migration and lineage of individual cells incorporating into the lymphatic endothelium. Our results show lymphatic endothelial cells of the thoracic duct arise from primitive veins through a novel and unexpected pathway.	NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA; Iwate Med Univ, Sch Med, Dept Anat, Morioka, Iwate 0208505, Japan; NICHHD, Microscopy & Imaging Core, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Iwate Medical University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Weinstein, BM (corresponding author), NICHHD, Mol Genet Lab, NIH, 6B-309,6 Ctr Dr, Bethesda, MD 20892 USA.	bw96w@nih.gov			Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008808, ZIAHD001011] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008808, Z01HD001011] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bovenkamp DE, 2004, GENE EXPR PATTERNS, V4, P361, DOI 10.1016/j.modgep.2004.01.014; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Glasgow E, 1998, MECH DEVELOP, V76, P175, DOI 10.1016/S0925-4773(98)00121-X; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Huntington GS, 1910, AM J ANAT, V10, P177, DOI 10.1002/aja.1000100108; Isogai S, 2003, DEVELOPMENT, V130, P5281, DOI 10.1242/dev.00733; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Kampmeier O.F, 1969, EVOLUTION COMP MORPH; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karkkainen MJ, 2004, NAT IMMUNOL, V5, P74, DOI 10.1038/ni1013; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lawson ND, 2003, GENE DEV, V17, P1346, DOI 10.1101/gad.1072203; Lawson ND, 2002, DEV BIOL, V248, P307, DOI 10.1006/dbio.2002.0711; Liu YW, 2003, MOL CELL BIOL, V23, P7243, DOI 10.1128/MCB.23.20.7243-7255.2003; Long QM, 1997, DEVELOPMENT, V124, P4105; Martyn U, 2004, DEV DYNAM, V231, P33, DOI 10.1002/dvdy.20048; Ny A, 2005, NAT MED, V11, P998, DOI 10.1038/nm1285; Ober EA, 2004, EMBO REP, V5, P78, DOI 10.1038/sj.embor.7400047; Oliver G, 2005, ANNU REV CELL DEV BI, V21, P457, DOI 10.1146/annurev.cellbio.21.012704.132338; Pepper MS, 2003, J CELL BIOL, V163, P209, DOI 10.1083/jcb.200308082; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Sabin FR, 1902, AM J ANAT, V1, P367, DOI 10.1002/aja.1000010310; TILNEY NL, 1971, J ANAT, V109, P369; van der Putte S C, 1975, Adv Anat Embryol Cell Biol, V51, P3; VANDERPUTTE SCJ, 1975, ACTA MORPHOL NEER SC, V13, P245; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Wigle JT, 2002, EMBO J, V21, P1505, DOI 10.1093/emboj/21.7.1505; Wilting J, 2006, DEV BIOL, V292, P165, DOI 10.1016/j.ydbio.2005.12.043; Yu HH, 2004, GENE EXPR PATTERNS, V4, P371, DOI 10.1016/j.modgep.2004.01.011; Yuan L, 2002, DEVELOPMENT, V129, P4797	31	340	347	1	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					711	716		10.1038/nm1427	http://dx.doi.org/10.1038/nm1427			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16732279				2022-12-25	WOS:000238149200036
J	Calvo, S; Jain, M; Xie, XH; Sheth, SA; Chang, B; Goldberger, OA; Spinazzola, A; Zeviani, M; Carr, SA; Mootha, VK				Calvo, S; Jain, M; Xie, XH; Sheth, SA; Chang, B; Goldberger, OA; Spinazzola, A; Zeviani, M; Carr, SA; Mootha, VK			Systematic identification of human mitochondrial disease genes through integrative genomics	NATURE GENETICS			English	Article							RESPIRATORY-CHAIN DISORDERS; HETEROGENEITY; PROTEINS; SEQUENCE; LOCUS; PROTEOME; DATABASE; MUSCLE; MOUSE	The majority of inherited mitochondrial disorders are due to mutations not in the mitochondrial genome ( mtDNA) but rather in the nuclear genes encoding proteins targeted to this organelle. Elucidation of the molecular basis for these disorders is limited because only half(1,2) of the estimated 1,500 mitochondrial proteins(3) have been identified. To systematically expand this catalog, we experimentally and computationally generated eight genome-scale data sets, each designed to provide clues as to mitochondrial localization: targeting sequence prediction, protein domain enrichment, presence of cis-regulatory motifs, yeast homology, ancestry, tandem-mass spectrometry, coexpression and transcriptional induction during mitochondrial biogenesis. Through an integrated analysis we expand the collection to 1,080 genes, which includes 368 novel predictions with a 10% estimated false prediction rate. By combining this expanded inventory with genetic intervals linked to disease, we have identified candidate genes for eight mitochondrial disorders, leading to the discovery of mutations in MPV17 that result in hepatic mtDNA depletion syndrome(4). The integrative approach promises to better define the role of mitochondria in both rare and common human diseases.	MIT, Broad Inst, Cambridge, MA 02142 USA; Harvard Univ, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02446 USA; Natl Neurol Inst C Besta, Unite Mol Neurogenet, I-20126 Milan, Italy	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; IRCCS Istituto Neurologico Besta	Mootha, VK (corresponding author), MIT, Broad Inst, 77 Massachusetts Ave, Cambridge, MA 02142 USA.	vamsi@hms.harvard.edu	Spinazzola, Antonella/P-5298-2017; Carr, Steven A./AAH-8366-2019; Zeviani, Massimo/AAU-2632-2021; Zeviani, Massimo/K-2891-2014; Spinazzola, Antonella/P-5791-2019	Spinazzola, Antonella/0000-0003-4242-8091; Zeviani, Massimo/0000-0002-9067-5508; Spinazzola, Antonella/0000-0003-4242-8091; Xie, Xiaohui/0000-0002-5479-6345				Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Andreoli C, 2004, NUCLEIC ACIDS RES, V32, pD459, DOI 10.1093/nar/gkh137; Basel-Vanagaite L, 2004, NEUROLOGY, V62, P87, DOI 10.1212/01.WNL.0000101680.49036.69; Christodoulou K, 2001, NEUROGENETICS, V3, P127, DOI 10.1007/s100480100112; Cotter D, 2004, NUCLEIC ACIDS RES, V32, pD463, DOI 10.1093/nar/gkh048; El-Shanti H, 2000, AM J HUM GENET, V66, P1229, DOI 10.1086/302858; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x; Guda C, 2004, BIOINFORMATICS, V20, P1785, DOI 10.1093/bioinformatics/bth171; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Kerrison JB, 1999, ARCH OPHTHALMOL-CHIC, V117, P805; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; MARIMAN ECM, 1995, HUM GENET, V95, P56, DOI 10.1007/BF00225075; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mootha VK, 2003, CELL, V115, P629, DOI 10.1016/S0092-8674(03)00926-7; Prokisch H, 2004, PLOS BIOL, V2, P795, DOI 10.1371/journal.pbio.0020160; Rotig A, 2003, J AM SOC NEPHROL, V14, P2995, DOI 10.1097/01.ASN.0000095481.24091.C9; Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718; Seyda A, 2001, AM J HUM GENET, V68, P386, DOI 10.1086/318196; Shoubridge EA, 2001, SEMIN NEUROL, V21, P261, DOI 10.1055/s-2001-17943; Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765; Steinmuller R, 1998, EUR J HUM GENET, V6, P201, DOI 10.1038/sj.ejhg.5200180; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55; Zeviani Massimo, 2004, Suppl Clin Neurophysiol, V57, P304; ZWACKA RM, 1994, EMBO J, V13, P5129, DOI 10.1002/j.1460-2075.1994.tb06842.x	30	261	269	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					576	582		10.1038/ng1776	http://dx.doi.org/10.1038/ng1776			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16582907				2022-12-25	WOS:000237147500021
J	Scortti, M; Lacharme-Lora, L; Wagner, M; Chico-Calero, I; Losito, P; Vazquez-Boland, JA				Scortti, Mariela; Lacharme-Lora, Lizeth; Wagner, Martin; Chico-Calero, Isabel; Losito, Patrizia; Vazquez-Boland, Jose Ava			Coexpression of virulence and fosfomycin susceptibility in Listeria: molecular basis of an antimicrobial in vitro-in vivo paradox	NATURE MEDICINE			English	Article							MONOCYTOGENES; PENETRATION; PRFA	Discrepancies between resistance in vitro and therapeutic efficacy in vivo are generally attributed to failure of laboratory susceptibility tests to reflect an antibiotic's pharmacokinetic or pharmacodynamic properties. We show here that this phenomenon can result from differential in vitro-in vivo expression of bacterial determinants of antibiotic susceptibility. We found that an in vivo-induced virulence factor, Hpt, also mediates uptake of fosfomycin in Listeria monocytogenes. These bacteria therefore seem resistant to fosfomycin in vitro, although they are in fact susceptible to the antibiotic during infection.	Univ Bristol, Bacterial Mol Pathogenesis Grp, Fac Med & Vet Sci, Langford BS40 5DU, England; Univ Complutense Madrid, Fac Vet, Grp Patogenesis Mol Bacteriana, E-28040 Madrid, Spain; Univ Leon, Grp Patogenesis Mol & Genom Bacteriana, Fac Vet, E-24071 Leon, Spain	University of Bristol; Complutense University of Madrid; Universidad de Leon	Vazquez-Boland, JA (corresponding author), Univ Bristol, Bacterial Mol Pathogenesis Grp, Fac Med & Vet Sci, Langford BS40 5DU, England.	v.boland@bristol.ac.uk		Vazquez-Boland, Jose A/0000-0003-4521-5972	Wellcome Trust [074020] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bishai W, 2002, J ANTIMICROB CHEMOTH, V49, P433, DOI 10.1093/jac/49.3.433; Chico-Calero I, 2002, P NATL ACAD SCI USA, V99, P431, DOI 10.1073/pnas.012363899; Ermolaeva S, 2004, MOL MICROBIOL, V52, P601, DOI 10.1111/j.1365-2958.2004.04003.x; Freitag NE, 1999, INFECT IMMUN, V67, P1844; Gobernado M, 2003, Rev Esp Quimioter, V16, P15; Hof H, 1997, CLIN MICROBIOL REV, V10, P345, DOI 10.1128/CMR.10.2.345; Joukhadar C, 2003, J ANTIMICROB CHEMOTH, V51, P1247, DOI 10.1093/jac/dkg187; KADNER RJ, 1983, J BACTERIOL, V155, P1052, DOI 10.1128/JB.155.3.1052-1061.1983; MICHELET C, 1994, ANTIMICROB AGENTS CH, V38, P438, DOI 10.1128/AAC.38.3.438; Ripio MT, 1997, J BACTERIOL, V179, P7174, DOI 10.1128/jb.179.22.7174-7180.1997; Sauermann R, 2005, ANTIMICROB AGENTS CH, V49, P4448, DOI 10.1128/AAC.49.11.4448-4454.2005; Troxler R, 2000, CLIN MICROBIOL INFEC, V6, P525, DOI 10.1046/j.1469-0691.2000.00168.x; Varaldo PE, 2002, J ANTIMICROB CHEMOTH, V50, P1, DOI 10.1093/jac/dkf093; Vazquez-Boland JA, 2001, CLIN MICROBIOL REV, V14, P584, DOI 10.1128/CMR.14.3.584-640.2001; Vega Y, 2004, MOL MICROBIOL, V52, P1553, DOI 10.1111/j.1365-2958.2004.04052.x	15	54	61	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					515	517		10.1038/nm1396	http://dx.doi.org/10.1038/nm1396			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16633349				2022-12-25	WOS:000238149100034
J	Asselin-Labat, ML; Sutherland, KD; Barker, H; Thomas, R; Shackleton, M; Forrest, NC; Hartley, L; Robb, L; Grosveld, FG; van der Wees, J; Lindeman, GJ; Visvader, JE				Asselin-Labat, Marie-Liesse; Sutherland, Kate D.; Barker, Holly; Thomas, Richard; Shackleton, Mark; Forrest, Natasha C.; Hartley, Lynne; Robb, Lorraine; Grosveld, Frank G.; van der Wees, Jacqueline; Lindeman, Geoffrey J.; Visvader, Jane E.			Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation	NATURE CELL BIOLOGY			English	Article							TRANSCRIPTION FACTOR GATA-3; HUMAN BREAST-TUMORS; NERVOUS-SYSTEM; STEM-CELLS; GENE; EXPRESSION; CANCER; INITIATION; LINEAGE; THYMUS	The transcription factor Gata-3 is a defining marker of the 'luminal' subtypes of breast cancer(1-4). To gain insight into the role of Gata-3 in breast epithelial development and oncogenesis, we have explored its normal function within the mammary gland by conditionally deleting Gata-3 at different stages of development. We report that Gata-3 has essential roles in the morphogenesis of the mammary gland in both the embryo and adult. Through the discovery of a novel marker (beta(3)-integrin) of luminal progenitor cells and their purification, we demonstrate that Gata-3 deficiency leads to an expansion of luminal progenitors and a concomitant block in differentiation. Remarkably, introduction of Gata-3 into a stem cell-enriched population induced maturation along the alveolar luminal lineage. These studies provide evidence for the existence of an epithelial hierarchy within the mammary gland and establish Gata-3 as a critical regulator of luminal differentiation.	Walter & Eliza Hall Inst Med Res, BCRC Lab, Parkville, Vic 3050, Australia; Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia; Walter & Eliza Hall Inst Med Res, Canc & Haematol Div, Parkville, Vic 3050, Australia; Erasmus MC, Dept Cell Biol, NL-3000 DR Rotterdam, Netherlands; Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute; University of Melbourne; Walter & Eliza Hall Institute; Erasmus University Rotterdam; Erasmus MC; Royal Melbourne Hospital	Visvader, JE (corresponding author), Walter & Eliza Hall Inst Med Res, BCRC Lab, Parkville, Vic 3050, Australia.	lindeman@wehi.edu.au; visvader@wehi.edu.au		Lindeman, Geoffrey/0000-0001-9386-2416; Barker, Holly/0000-0002-9350-5520; Sutherland, Kate/0000-0002-7453-3366				Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Asselin-Labat ML, 2006, J NATL CANCER I, V98, P1011, DOI 10.1093/jnci/djj267; Grote D, 2006, DEVELOPMENT, V133, P53, DOI 10.1242/dev.02184; Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.3.CO;2-4; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Kurek D, 2007, DEVELOPMENT, V134, P261, DOI 10.1242/dev.02721; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Pai SY, 2003, IMMUNITY, V19, P863, DOI 10.1016/S1074-7613(03)00328-5; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Sum EYM, 2005, ONCOGENE, V24, P4820, DOI 10.1038/sj.onc.1208638; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; van der Wees J, 2004, NEUROBIOL DIS, V16, P169, DOI 10.1016/j.nbd.2004.02.004; van Doorninck J H, 1999, J Neurosci, V19, pRC12; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wilkinson DG, 1992, SITU HYBRIDIZATION P	33	612	632	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	FEB	2007	9	2					201	U103		10.1038/ncb1530	http://dx.doi.org/10.1038/ncb1530			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	131WR	17187062				2022-12-25	WOS:000243903000013
J	Yasuhara, N; Shibazaki, N; Tanaka, S; Nagai, M; Kamikawa, Y; Oe, S; Asally, M; Kamachi, Y; Kondoh, H; Yoneda, Y				Yasuhara, Noriko; Shibazaki, Noriko; Tanaka, Shinya; Nagai, Masahiro; Kamikawa, Yasunao; Oe, Souichi; Asally, Munehiro; Kamachi, Yusuke; Kondoh, Hisato; Yoneda, Yoshihiro			Triggering neural differentiation of ES cells by subtype switching of importin-alpha	NATURE CELL BIOLOGY			English	Article							NUCLEAR-LOCALIZATION SIGNAL; TRANSCRIPTIONAL REGULATION; PROTEIN IMPORT; IDENTIFICATION; GENE; SOX2; EXPRESSION; REQUIRES; OCT-3/4; NANOG	Nuclear proteins are selectively imported into the nucleus by transport factors such as importin-alpha and importin-beta(1,2). Here, we show that the expression of importin-alpha subtypes is strictly regulated during neural differentiation of mouse embryonic stem (ES) cells, and that the switching of importin-alpha subtype expression is critical for neural differentiation. Moreover, reproducing the switching of importin-alpha subtype expression in undifferentiated ES cells induced neural differentiation in the presence of leukaemia inhibitory factor (LIF) and serum, coordinated with the regulated expression of Oct3/4, Brn2 and SOX2, which are involved in ES-neural identity determination. These transcription factors were selectively imported into the nucleus by specific subtypes of importin-alpha. Thus, importin-alpha subtype switching has a major impact on cell differentiation through the regulated nuclear import of a specific set of transcription factors. This is the first study to propose that transport factors should be considered as major players in cell-fate determination.	Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dev Biol Grp, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Biomol Dynam Grp, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Yoneda, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yyoneda@anat3.med.osaka-u.ac.jp	Kamachi, Yusuke/C-9029-2009; Asally, Munehiro/AAZ-3693-2020; Kamachi, Yusuke/AAB-6710-2022	Asally, Munehiro/0000-0002-8273-7617; Kamachi, Yusuke/0000-0001-5018-1119				ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Argentaro A, 2003, J BIOL CHEM, V278, P33839, DOI 10.1074/jbc.M302078200; Baranek C, 2005, NUCLEIC ACIDS RES, V33, P6277, DOI 10.1093/nar/gki947; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Ilia M, 2003, EXP NEUROL, V181, P159, DOI 10.1016/S0014-4886(03)00047-5; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamikubo Y, 2004, HYBRIDOMA HYBRIDOM, V23, P301, DOI 10.1089/hyb.2004.23.301; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kuroda T, 2005, MOL CELL BIOL, V25, P2475, DOI 10.1128/MCB.25.6.2475-2485.2005; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Okumura-Nakanishi S, 2005, J BIOL CHEM, V280, P5307, DOI 10.1074/jbc.m410015200; Pan GJ, 2004, J BIOL CHEM, V279, P37013, DOI 10.1074/jbc.M405117200; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SAKAGUCHI T, 2003, HYBRIDOMA HYBRIDOM, V6, P397; Sock E, 1996, J BIOL CHEM, V271, P17512, DOI 10.1074/jbc.271.29.17512; Tanaka S, 2004, MOL CELL BIOL, V24, P8834, DOI 10.1128/MCB.24.20.8834-8846.2004; Tomioka M, 2002, NUCLEIC ACIDS RES, V30, P3202, DOI 10.1093/nar/gkf435; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	27	180	184	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					72	U93		10.1038/ncb1521	http://dx.doi.org/10.1038/ncb1521			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17159997				2022-12-25	WOS:000243255100014
J	Bhangale, TR; Stephens, M; Nickerson, DA				Bhangale, Tushar R.; Stephens, Matthew; Nickerson, Deborah A.			Automating resequencing-based detection of insertion-deletion polymorphisms	NATURE GENETICS			English	Article							HUMAN GENOME; LINKAGE-DISEQUILIBRIUM; STRUCTURAL VARIATION; SEQUENCE VARIATION; SNPS; RISK; GENE; TOOL; IDENTIFICATION; PROMOTER	Structural and insertion-deletion (indel) variants have received considerable recent attention, partly because of their phenotypic consequences. Among these variants, the most common are small indels (similar to 1-30 bp). Identifying and genotyping indels using sequence traces obtained from diploid samples requires extensive manual review, which makes large-scale studies inconvenient. We report a new algorithm, implemented in available software (PolyPhred version 6.0), to help automate detection and genotyping of indels from sequence traces. The algorithm identifies heterozygous individuals, which permits the discovery of low-frequency indels. It finds 80% of all indel polymorphisms with almost no false positives and finds 97% with a false discovery rate of 10%. Additionally, genotyping accuracy exceeds 99%, and it correctly infers indel length in 96% of the cases. Using this approach, we identify indels in the HapMap ENCODE regions, providing the first report of these polymorphisms in this data set.	Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Stat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Bhangale, TR (corresponding author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.	tushar@u.washington.edu; debnick@u.washington.edu			NHGRI NIH HHS [HG/LM02585] Funding Source: Medline; NHLBI NIH HHS [HL66682] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066682] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG002585] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; ALBERTINI AM, 1982, CELL, V29, P319, DOI 10.1016/0092-8674(82)90148-9; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Bhangale TR, 2005, HUM MOL GENET, V14, P59, DOI 10.1093/hmg/ddi006; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Conrad DF, 2006, NAT GENET, V38, P75, DOI 10.1038/ng1697; de Sanctis L, 2004, J CLIN ENDOCR METAB, V89, P5669, DOI 10.1210/jc.2004-0398; Eichler EE, 2006, NAT GENET, V38, P9, DOI 10.1038/ng0106-9; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Hinds DA, 2006, NAT GENET, V38, P82, DOI 10.1038/ng1695; Karban AS, 2004, HUM MOL GENET, V13, P35, DOI 10.1093/hmg/ddh008; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lin SC, 2004, J ORAL PATHOL MED, V33, P323, DOI 10.1111/j.1600-0714.2004.00214.x; Livingston RJ, 2004, GENOME RES, V14, P1821, DOI 10.1101/gr.2730004; Locke DP, 2006, AM J HUM GENET, V79, P275, DOI 10.1086/505653; Manaster C, 2005, HUM MUTAT, V26, P11, DOI 10.1002/humu.20188; McCarroll SA, 2006, NAT GENET, V38, P86, DOI 10.1038/ng1696; Mills RE, 2006, GENOME RES, V16, P1182, DOI 10.1101/gr.4565806; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Newman TL, 2006, HUM MOL GENET, V15, P1159, DOI 10.1093/hmg/ddl031; Nickerson DA, 1997, NUCLEIC ACIDS RES, V25, P2745, DOI 10.1093/nar/25.14.2745; Othman M, 2005, BLOOD, V105, P4330, DOI 10.1182/blood-2002-09-2942; Rockman MV, 2004, CURR BIOL, V14, P1531, DOI 10.1016/j.cub.2004.08.051; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212; Stephens M, 2006, NAT GENET, V38, P375, DOI 10.1038/ng1746; Tuzun E, 2005, NAT GENET, V37, P727, DOI 10.1038/ng1562; Weber JL, 2002, AM J HUM GENET, V71, P854, DOI 10.1086/342727; Weckx S, 2005, GENOME RES, V15, P436, DOI 10.1101/gr.2754005	32	71	76	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	DEC	2006	38	12					1457	1462		10.1038/ng1925	http://dx.doi.org/10.1038/ng1925			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17115056				2022-12-25	WOS:000242404200026
J	Bhandari, V; Choo-Wing, R; Lee, CG; Zhu, Z; Nedrelow, JH; Chupp, GL; Zhang, XC; Matthay, MA; Ware, LB; Homer, RJ; Lee, PJ; Geick, A; de Fougerolles, AR; Elias, JA				Bhandari, Vineet; Choo-Wing, Rayman; Lee, Chun G.; Zhu, Zhou; Nedrelow, Jonathan H.; Chupp, Geoffrey L.; Zhang, Xucher; Matthay, Michael A.; Ware, Lorraine B.; Homer, Robert J.; Lee, Patty J.; Geick, Anke; de Fougerolles, Antonin R.; Elias, Jack A.			Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TIE-2; EXPRESSION; NECROSIS; ANGIOGENESIS; APOPTOSIS; OXYGEN; VEGF; PATHOPHYSIOLOGY; PATHOGENESIS	The angiogenic growth factor angiopoietin 2 (Ang2) destabilizes blood vessels, enhances vascular leak and induces vascular regression and endothelial cell apoptosis. We considered that Ang2 might be important in hyperoxic acute lung injury (ALI). Here we have characterized the responses in lungs induced by hyperoxia in wild-type and Ang2(-/-) mice or those given either recombinant Ang2 or short interfering RNA (siRNA) targeted to Ang2. During hyperoxia Ang2 expression is induced in lung epithelial cells, while hyperoxia-induced oxidant injury, cell death, inflammation, permeability alterations and mortality are ameliorated in Ang2(-/-) and siRNA-treated mice. Hyperoxia induces and activates the extrinsic and mitochondrial cell death pathways and activates initiator and effector caspases through Ang2-dependent pathways in vivo. Ang2 increases inflammation and cell death during hyperoxia in vivo and stimulates epithelial necrosis in hyperoxia in vitro. Ang2 in plasma and alveolar edema fluid is increased in adults with ALI and pulmonary edema. Tracheal Ang2 is also increased in neonates that develop bronchopulmonary dysplasia. Ang2 is thus a mediator of epithelial necrosis with an important role in hyperoxic ALI and pulmonary edema.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Div Perinatal Med, Dept Pediat, New Haven, CT 06520 USA; Univ Calif San Francisco, Sch Med, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; Vanderbilt Univ, Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; VACT Hlth Care Syst, Pathol & Lab Med Serv, West Haven, CT 06516 USA; Alnylam Pharmaceut, Cambridge, MA 02142 USA	Yale University; Yale University; University of California System; University of California San Francisco; Vanderbilt University; Yale University	Elias, JA (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, 333 Cedar St, New Haven, CT 06520 USA.	jack.elias@yale.edu	Bhandari, Vineet/AAS-3365-2020; Ware, Lorraine/AAJ-9307-2021; homer, robert/P-3884-2019; Lee, Chun Geun/AAC-2838-2021	Ware, Lorraine/0000-0002-9429-4702; homer, robert/0000-0002-2055-5885; Lee, Chun Geun/0000-0002-9514-3658	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056389, P01HL056389, R01HL061904, K08HL074195, R01HL064242, R37HL051856] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-64242, HL-61904, HL-56389, HL-74195, P50 HL056389, R01 HL064242, P01 HL056389, R37 HL051856, K08 HL074195, R37 HL051856-14] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anandarajah AP, 2004, CURR OPIN RHEUMATOL, V16, P338, DOI 10.1097/01.bor.0000129718.13939.81<; Barazzone C, 2000, AM J RESP CELL MOL, V22, P517, DOI 10.1165/ajrcmb.22.5.f180; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; Beck H, 2000, AM J PATHOL, V157, P1473, DOI 10.1016/S0002-9440(10)64786-4; Bhandari A, 2003, FRONT BIOSCI-LANDMRK, V8, pE370, DOI 10.2741/1060; Bloch W, 2000, FASEB J, V14, P2373; Brat DJ, 2004, LAB INVEST, V84, P397, DOI 10.1038/labinvest.3700070; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; Fearon U, 2003, J RHEUMATOL, V30, P260; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; He CH, 2005, J CLIN INVEST, V115, P1039, DOI 10.1172/JCI200523004; Horowitz S, 1999, CHEST, V116, p64S, DOI 10.1378/chest.116.suppl_1.64S; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Joza N, 2002, TRENDS GENET, V18, P142, DOI 10.1016/S0168-9525(01)02618-X; Karmpaliotis D, 2002, AM J PHYSIOL-LUNG C, V283, pL585, DOI 10.1152/ajplung.00048.2002; Kim I, 2001, CARDIOVASC RES, V49, P872, DOI 10.1016/S0008-6363(00)00295-9; Kimura H, 2004, HEPATOL RES, V29, P51, DOI 10.1016/j.hepres.2004.02.004; Koga K, 2001, CANCER RES, V61, P6248; LIN EY, 1993, J IMMUNOL, V151, P1979; Lip PL, 2004, BRIT J OPHTHALMOL, V88, P1543, DOI 10.1136/bjo.2004.048587; Lobov IB, 2002, P NATL ACAD SCI USA, V99, P11205, DOI 10.1073/pnas.172161899; Mantell LL, 1999, ANN NY ACAD SCI, V887, P171, DOI 10.1111/j.1749-6632.1999.tb07931.x; McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39, DOI 10.1164/ajrccm.164.supplement_2.2106065; Mitsutake N, 2002, THYROID, V12, P95, DOI 10.1089/105072502753522310; Nakayama T, 2004, HISTOPATHOLOGY, V44, P232, DOI 10.1111/j.0309-0167.2004.01817.x; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; O'Reilly MA, 1998, AM J RESP CELL MOL, V19, P777, DOI 10.1165/ajrcmb.19.5.3200; O'Reilly MA, 2001, AM J PHYSIOL-LUNG C, V281, pL291, DOI 10.1152/ajplung.2001.281.2.L291; O'Reilly MA, 2000, LAB INVEST, V80, P1845, DOI 10.1038/labinvest.3780195; Ohashi H, 2004, MOL VIS, V10, P608; Oshima Y, 2004, J CELL PHYSIOL, V199, P412, DOI 10.1002/jcp.10442; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; Raffray M, 1997, PHARMACOL THERAPEUT, V75, P153, DOI 10.1016/S0163-7258(97)00037-5; Richard C, 2002, PROSTATE, V50, P83; Sandhu R, 2004, CARDIOVASC RES, V64, P115, DOI 10.1016/j.cardiores.2004.05.013; Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Tsigkos S, 2003, EXPERT OPIN INV DRUG, V12, P933, DOI 10.1517/eoid.12.6.933.21790; Wang X, 2003, J BIOL CHEM, V278, P29184, DOI 10.1074/jbc.M301624200; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; Ware LB, 2001, AM J RESP CRIT CARE, V163, P1376, DOI 10.1164/ajrccm.163.6.2004035; Waxman AB, 1998, J CLIN INVEST, V101, P1970, DOI 10.1172/JCI1337; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Wurmbach JH, 2000, ANTICANCER RES, V20, P5217; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zagzag D, 2000, LAB INVEST, V80, P837, DOI 10.1038/labinvest.3780088; Zhu S, 2001, AM J RESP CRIT CARE, V163, P166, DOI 10.1164/ajrccm.163.1.2005068	50	261	277	2	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2006	12	11					1286	1293		10.1038/nm1494	http://dx.doi.org/10.1038/nm1494			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17086189	Green Accepted			2022-12-25	WOS:000241844900026
J	Choi, M; Moschetta, A; Bookout, AL; Peng, L; Umetani, M; Holmstrom, SR; Suino-Powell, K; Xu, HE; Richardson, JA; Gerard, RD; Mangelsdorf, DJ; Kliewer, SA				Choi, Mihwa; Moschetta, Antonio; Bookout, Angie L.; Peng, Li; Umetani, Michihisa; Holmstrom, Sam R.; Suino-Powell, Kelly; Xu, H. Eric; Richardson, James A.; Gerard, Robert D.; Mangelsdorf, David J.; Kliewer, Steven A.			Identification of a hormonal basis for gallbladder filling	NATURE MEDICINE			English	Article							MOTOR FUNCTION; CYCLIC-AMP; PATHOGENESIS; GALLSTONES; ARTICLE	The cycle of gallbladder filling and emptying controls the flow of bile into the intestine for digestion. Here we show that fibroblast growth factor-15, a hormone made by the distal small intestine in response to bile acids, is required for gallbladder filling. These studies demonstrate that gallbladder filling is actively regulated by an endocrine pathway and suggest a postprandial timing mechanism that controls gallbladder motility.	Univ Texas, SW Med Ctr, Dept Biol Mol, Dallas, TX 75390 USA; Consorzio Mario Negri Sud, I-66030 Chieti, Italy; Univ Bari, Clin Med Murri, Policlin Bari, I-70124 Bari, Italy; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Van Andel Res Inst, Lab Struct Sci, Grand Rapids, MI 49503 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Consorzio Mario Negri Sud; Universita degli Studi di Bari Aldo Moro; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Van Andel Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kliewer, SA (corresponding author), Univ Texas, SW Med Ctr, Dept Biol Mol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	steven.kliewer@utsouthwestern.edu	Umetani, Michi/AAP-3964-2020; Moschetta, Antonio/K-6211-2016; Moschetta, Antonio/AAC-5295-2022; Xu, H. Eric/ABD-7487-2021	Umetani, Michi/0000-0001-8474-7088; Mangelsdorf, David/0000-0002-4355-0796; Xu, H. Eric/0000-0002-6829-8144; Moschetta, Antonio/0000-0003-2123-6074	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U19DK062434, R01DK067158] Funding Source: NIH RePORTER; NIDDK NIH HHS [U19DK62434, DK067158] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON KE, 1972, ACTA PHYSIOL SCAND, V85, P511; CAREY MC, 1993, AM J SURG, V165, P410, DOI 10.1016/S0002-9610(05)80932-8; GOMEZ G, 1988, GASTROENTEROLOGY, V94, P1036, DOI 10.1016/0016-5085(88)90564-1; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Kline LW, 1997, J EXP BIOL, V200, P2669; LAMORTE WW, 1981, SURG CLIN N AM, V61, P765; Li JL, 2005, J BIOL CHEM, V280, P7427, DOI 10.1074/jbc.M411473200; MALAGELADA JR, 1973, J CLIN INVEST, V52, P2160, DOI 10.1172/JCI107400; MASCLEE AA, 2003, DIG LIVER DIS S3, V35, P35; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pauletzki J, 2000, ALIMENT PHARM THERAP, V14, P32, DOI 10.1046/j.1365-2036.2000.014s2032.x; Pozo MJ, 2004, CURR MED CHEM, V11, P1801, DOI 10.2174/0929867043364955; Shaffer EA, 2000, ALIMENT PHARM THER, V14, P2, DOI 10.1046/j.1365-2036.2000.014s2002.x; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482; Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200	15	222	229	3	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2006	12	11					1253	1255		10.1038/nm1501	http://dx.doi.org/10.1038/nm1501			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	102WU	17072310				2022-12-25	WOS:000241844900021
J	Lorenz-Depiereux, B; Bastepe, M; Benet-Pages, A; Amyere, M; Wagenstaller, J; Muller-Barth, U; Badenhoop, K; Kaiser, SM; Rittmaster, RS; Shlossberg, AH; Olivares, JL; Loris, C; Ramos, FJ; Glorieux, F; Vikkula, M; Juppner, H; Strom, TM				Lorenz-Depiereux, Bettina; Bastepe, Murat; Benet-Pages, Anna; Amyere, Mustapha; Wagenstaller, Janine; Mueller-Barth, Ursula; Badenhoop, Klaus; Kaiser, Stephanie M.; Rittmaster, Roger S.; Shlossberg, Alan H.; Olivares, Jose L.; Loris, Cesar; Ramos, Feliciano J.; Glorieux, Francis; Vikkula, Miikka; Juppner, Harald; Strom, Tim M.			DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis	NATURE GENETICS			English	Article							PHEX; MINERALIZATION; IDENTIFICATION; ROLES; GENE	Hypophosphatemia is a genetically heterogeneous disease. Here, we mapped an autosomal recessive form (designated ARHP) to chromosome 4q21 and identified homozygous mutations in DMP1 (dentin matrix protein 1), which encodes a non-collagenous bone matrix protein expressed in osteoblasts and osteocytes. Intact plasma levels of the phosphaturic protein FGF23 were clearly elevated in two of four affected individuals, providing a possible explanation for the phosphaturia and inappropriately normal 1,25(OH) 2D levels and suggesting that DMP1 may regulate FGF23 expression.	GSF, Inst Human Genet, Natl Res Ctr Environm & Hlth, D-85764 Neuherberg, Germany; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Catholic Univ Louvain, B-1200 Brussels, Belgium; Christian Duve Inst, B-1200 Brussels, Belgium; Med Genet, D-63450 Hanau, Germany; Univ Hosp, Div Endocrinol Diabet & Metab, D-60590 Frankfurt, Germany; Queen Elizabeth 2 Hlth Sci Ctr, Div Endocrinol & Metab, Halifax, NS, Canada; Univ Zaragoza, Fac Med, Univ Hosp Lozano Blesa, Dept Pediat, E-50009 Zaragoza, Spain; Univ Zaragoza, Childrens Hosp Miguel Servet, Serv Nephrol, E-50009 Zaragoza, Spain; Shriners Hosp Children, Genet Unit, Montreal, PQ, Canada; Massachusetts Gen Hosp, Pediat Nephrol Unit, Boston, MA 02114 USA; Tech Univ Munich, Klinikum Rechts Isar, Inst Human Genet, D-81675 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Universite Catholique Louvain; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Queen Elizabeth II Health Sciences Centre; Lozano Blesa University Clinical Hospital; University of Zaragoza; Miguel Servet University Hospital; University of Zaragoza; McGill University; Harvard University; Massachusetts General Hospital; Technical University of Munich	Juppner, H (corresponding author), GSF, Inst Human Genet, Natl Res Ctr Environm & Hlth, D-85764 Neuherberg, Germany.	jueppner@helix.mgh.harvard.edu; TimStrom@gsf.de	Bastepe, Murat/GQQ-3389-2022; Ramos, Feliciano J./ABH-8920-2020; Vikkula, Miikka/Q-1038-2018	Ramos, Feliciano J./0000-0002-5732-2209; Vikkula, Miikka/0000-0002-6236-338X; Bastepe, Murat/0000-0002-2643-3504	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK075856, R37DK046718, P30DK040561] Funding Source: NIH RePORTER; NIDDK NIH HHS [R21 DK075856, R21 DK075856-01, R37 DK046718, P30 DK040561, P30 DK040561-11, R01 DK046718] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boileau G, 2001, BIOCHEM J, V355, P707, DOI 10.1042/bj3550707; Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Ling YF, 2005, J BONE MINER RES, V20, P2169, DOI 10.1359/JBMR.050815; Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200; Qin C, 2004, CRIT REV ORAL BIOL M, V15, P126, DOI 10.1177/154411130401500302; Qin CL, 2003, J BIOL CHEM, V278, P34700, DOI 10.1074/jbc.M305315200; Rowe PSN, 2005, BONE, V36, P33, DOI 10.1016/j.bone.2004.09.015; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Steiglitz BM, 2004, J BIOL CHEM, V279, P980, DOI 10.1074/jbc.M310179200; White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497; White KE, 2001, KIDNEY INT, V60, P2079, DOI 10.1046/j.1523-1755.2001.00064.x; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Ye L, 2005, J BIOL CHEM, V280, P6197, DOI 10.1074/jbc.M412911200	15	388	402	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1248	1250		10.1038/ng1868	http://dx.doi.org/10.1038/ng1868			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17033625	Green Accepted			2022-12-25	WOS:000241592700012
J	Morozova, N; Liang, YH; Tokarev, AA; Chen, SH; Cox, R; Andrejic, J; Lipatova, Z; Sciorra, VA; Emr, SD; Segev, N				Morozova, Nadya; Liang, Yongheng; Tokarev, Andrei A.; Chen, Shu H.; Cox, Randal; Andrejic, Jelena; Lipatova, Zhanna; Sciorra, Vicki A.; Emr, Scott D.; Segev, Nava			TRAPPII subunits are required for the specificity switch of a Ypt-Rab GEF	NATURE CELL BIOLOGY			English	Article							GENETIC INTERACTIONS; NUCLEOTIDE EXCHANGE; PROTEIN; YEAST; GTPASES; GOLGI; COMPLEX; IDENTIFICATION; LOCALIZATION; EFFECTOR	Ypt-Rab GTPases are key regulators of the various steps of intracellular trafficking. Guanine nucleotide-exchange factors (GEFs) regulate the conversion of Ypt-Rabs to the GTP-bound state, in which they interact with effectors that mediate all the known aspects of vesicular transport(1-3). An interesting possibility is that Ypt-Rabs coordinate separate steps of the transport pathways(4). The conserved modular complex TRAPP is a GEF for the Golgi gatekeepers Ypt1 and Ypt31/32 (refs 5-7). However, it is not known how Golgi entry and exit are coordinated. TRAPP comes in two configurations: the seven-subunit TRAPPI is required for endoplasmic reticulum-to-Golgi transport, whereas the ten-subunit TRAPPII functions in late Golgi(8-10). The two essential TRAPPII-specific subunits Trs120 and Trs130 have been identified as Ypt31/32 genetic interactors(11-13). Here, we show that they are required for switching the GEF specificity of TRAPP from Ypt1 to Ypt31. Moreover, a trs 130ts mutation confers opposite effects on the intracellular localization of these GTPases. We suggest that the Trs120-Trs130 subcomplex joins TRAPP in the late Golgi to switch its GEF activity from Ypt1 to Ypt31/32. Such a 'switchable' GEF could ensure sequential activation of these Ypts, thereby coordinating Golgi entry and exit.	Univ Illinois, Dept Biol Sci, Mol Biol Lab, Chicago, IL 60607 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California San Diego	Segev, N (corresponding author), Univ Illinois, Dept Biol Sci, Mol Biol Lab, Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.	nava@uic.edu	Liang, Yongheng/B-2024-2009; Liang, Yongheng/F-9972-2011	Liang, Yongheng/0000-0002-5430-2042	NIGMS NIH HHS [GM-45444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045444] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bensen ES, 2001, MOL BIOL CELL, V12, P13, DOI 10.1091/mbc.12.1.13; Chen SH, 2005, MOL BIOL CELL, V16, P178, DOI 10.1091/mbc.E04-03-0258; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Hu WH, 2005, J BIOL CHEM, V280, P29233, DOI 10.1074/jbc.M501670200; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; James P, 1996, GENETICS, V144, P1425; JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; Jones S, 1998, MOL BIOL CELL, V9, P2819, DOI 10.1091/mbc.9.10.2819; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; Jones S, 1999, GENETICS, V152, P1543; Jones S, 2000, MOL BIOL CELL, V11, P4403, DOI 10.1091/mbc.11.12.4403; Lafreniere RG, 1997, GENE, V198, P313, DOI 10.1016/S0378-1119(97)00333-8; Losev E, 2006, NATURE, V441, P1002, DOI 10.1038/nature04717; Matsuura-Tokita K, 2006, NATURE, V441, P1007, DOI 10.1038/nature04737; Nagamine K, 1997, BIOCHEM BIOPH RES CO, V235, P185, DOI 10.1006/bbrc.1997.6758; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; ROSE M, 1988, METHODS YEAST GENETI, P146; ROSSI G, 1995, MOL BIOL CELL, V6, P1769, DOI 10.1091/mbc.6.12.1769; Sacher M, 2000, EUR J CELL BIOL, V79, P71, DOI 10.1078/S0171-9335(04)70009-6; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Sciorra VA, 2005, MOL BIOL CELL, V16, P776, DOI 10.1091/mbc.e04-08-0700; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Segev N, 2001, SCI STKE, pre11, DOI DOI 10.1126/STKE.2001.100.RE11; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; Wang W, 2002, MOL BIOL CELL, V13, P3336, DOI 10.1091/mbc.01-12-0577; YAMAKAWA K, 1995, HUM MOL GENET, V4, P709, DOI 10.1093/hmg/4.4.709; Yamamoto K, 2002, CURR GENET, V42, P85, DOI 10.1007/s00294-002-0336-5; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang CJ, 2002, YEAST, V19, P1075, DOI 10.1002/yea.903	34	117	124	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1263	U44		10.1038/ncb1489	http://dx.doi.org/10.1038/ncb1489			22	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17041589				2022-12-25	WOS:000241732400015
J	Minetti, GC; Colussi, C; Adami, R; Serra, C; Mozzetta, C; Parente, V; Fortuni, S; Straino, S; Sampaolesi, M; Di Padova, M; Illi, B; Gallinari, P; Steinkuhler, C; Capogrossi, MC; Sartorelli, V; Bottinelli, R; Gaetano, C; Puri, PL				Minetti, G. C.; Colussi, C.; Adami, R.; Serra, C.; Mozzetta, C.; Parente, V.; Fortuni, S.; Straino, S.; Sampaolesi, M.; Di Padova, M.; Illi, B.; Gallinari, P.; Steinkuehler, C.; Capogrossi, M. C.; Sartorelli, V.; Bottinelli, R.; Gaetano, C.; Puri, P. L.			Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors	NATURE MEDICINE			English	Article							MUSCULAR-DYSTROPHY; SKELETAL MYOGENESIS; MYOSTATIN BLOCKADE; DEFICIENT MICE; MDX MICE; EXPRESSION; SEVERITY	Pharmacological interventions that increase myofiber size counter the functional decline of dystrophic muscles(1,2). We show that deacetylase inhibitors increase the size of myofibers in dystrophin-deficient (MDX) and alpha-sarcoglycan (alpha-SG)-deficient mice by inducing the expression of the myostatin antagonist follistatin(3) in satellite cells. Deacetylase inhibitor treatment conferred on dystrophic muscles resistance to contraction-coupled degeneration and alleviated both morphological and functional consequences of the primary genetic defect. These results provide a rationale for using deacetylase inhibitors in the pharmacological therapy of muscular dystrophies.	Fdn A Cesalpino, Dulbecco Telethon Inst, Inst Cell Biol & Tissue Engn, San Raffaele Biomed Sci Pk Rome, I-00128 Rome, Italy; IRCCS, Ist Dermatopat Immacolata, Lab Vasc Pathol, I-00167 Rome, Italy; Univ Pavia, Dept Expt Med, Human Physiol Unit, I-27100 Pavia, Italy; Univ Pavia, Interuniv Inst Mycol, I-27100 Pavia, Italy; Burnham Inst, La Jolla, CA 92037 USA; Hosp San Raffaele, Stem Cell Res Inst, I-20132 Milan, Italy; NIAMSD, Muscle Gene Express Grp, Muscle Biol Lab, NIH, Bethesda, MD 20892 USA; IRCCS, Lab Vasc Biol & Gene Therapy, Ctr Cardiol Monzino, I-20138 Milan, Italy; Ist Ric Biol Mol P Angeletti, I-00040 Rome, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Pavia; University of Pavia; Sanford Burnham Prebys Medical Discovery Institute; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); IRCCS Centro Cardiologico Monzino; Merck & Company	Puri, PL (corresponding author), Fdn A Cesalpino, Dulbecco Telethon Inst, Inst Cell Biol & Tissue Engn, San Raffaele Biomed Sci Pk Rome, Via Castel Romano 100, I-00128 Rome, Italy.	plpuri@dti.telethon.it	Mozzetta, Chiara/Q-2786-2019; Bottinelli, Roberto/AAC-1904-2020; Gaetano, Carlo/P-9997-2019; Gallinari, Paola/ABE-8238-2021; Mozzetta, Chiara/K-9947-2018; Parente, Valeria/H-7817-2016; Sampaolesi, Maurilio/H-6509-2013; Illi, Barbara/AAY-8650-2020; canepari, Monica MC/D-7677-2015; Colussi, Claudia/H-8609-2019	Mozzetta, Chiara/0000-0002-7147-7266; Bottinelli, Roberto/0000-0002-4960-7490; Gaetano, Carlo/0000-0002-5238-1832; Mozzetta, Chiara/0000-0002-7147-7266; Parente, Valeria/0000-0001-6559-9817; Sampaolesi, Maurilio/0000-0002-2422-3757; Puri, Pier Lorenzo/0000-0003-4964-0095; Adami, Raffaella/0000-0001-9656-3219; Sartorelli, Vittorio/0000-0002-9284-3675; Colussi, Claudia/0000-0002-7727-8911; DI PADOVA, Monica/0000-0003-3808-7159	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041126, Z01AR041126] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; Telethon [GGP02284] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Telethon(Fondazione Telethon)		Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Duclos F, 1998, J CELL BIOL, V142, P1461, DOI 10.1083/jcb.142.6.1461; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Engvall E, 2003, FASEB J, V17, P1579, DOI 10.1096/fj.02-1215rev; Iezzi S, 2004, DEV CELL, V6, P673, DOI 10.1016/S1534-5807(04)00107-8; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Parsons SA, 2006, AM J PATHOL, V168, P1975, DOI 10.2353/ajpath.2006.051316; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Zammit PS, 2002, NAT MED, V8, P1355, DOI 10.1038/nm1202-1355	15	239	250	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1147	1150		10.1038/nm1479	http://dx.doi.org/10.1038/nm1479			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16980968	Green Published			2022-12-25	WOS:000241102200030
J	Gupta, ML; Carvalho, P; Roof, DM; Pellman, D				Gupta, Mohan L., Jr.; Carvalho, Pedro; Roof, David M.; Pellman, David			Plus end-specific depolymerase activity of Kip3, a kinesin-8 protein, explains its role in positioning the yeast mitotic spindle	NATURE CELL BIOLOGY			English	Article							REGULATE MICROTUBULE DYNAMICS; MOTOR PROTEINS; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; FISSION YEAST; NUCLEAR MIGRATION; CELL CORTEX; ANAPHASE; MICROSCOPY; MECHANISM	The budding yeast protein Kip3p is a member of the conserved kinesin-8 family of microtubule motors, which are required for microtubule -cortical interactions, normal spindle assembly and kinetochore dynamics. Here, we demonstrate that Kip3p is both a plus end-directed motor and a plus end-specific depolymerase - a unique combination of activities not found in other kinesins. The ATPase activity of Kip3p was activated by both microtubules and unpolymerized tubulin. Furthermore, Kip3p in the ATP-bound state formed a complex with unpolymerized tubulin. Thus, motile kinesin-8s may depolymerize microtubules by a mechanism that is similar to that used by non-motile kinesin-13 proteins. Fluorescent speckle analysis established that, in vivo, Kip3p moved toward and accumulated on the plus ends of growing microtubules, suggesting that motor activity brings Kip3p to its site of action. Globally, and more dramatically on cortical contact, Kip3p promoted catastrophes and pausing, and inhibited microtubule growth. These findings explain the role of Kip3p in positioning the mitotic spindle in budding yeast and potentially other processes controlled by kinesin-8 family members.	Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Penn, Dept Biol Anim, Program Cell & Mol Biol, Philadelphia, PA 19104 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Pennsylvania	Pellman, D (corresponding author), Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	david_pellman@dfci.harvard.edu	Carvalho, Pedro/HHN-1424-2022	Carvalho, Pedro/0000-0002-9691-5277	NIGMS NIH HHS [R01 GM61345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adames NR, 2000, J CELL BIOL, V149, P863, DOI 10.1083/jcb.149.4.863; Akhmanova A, 2005, CURR OPIN CELL BIOL, V17, P47, DOI 10.1016/j.ceb.2004.11.001; ALGAIER J, 1988, BIOCHIM BIOPHYS ACTA, V954, P235, DOI 10.1016/0167-4838(88)90078-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bringmann H, 2004, SCIENCE, V303, P1519, DOI 10.1126/science.1094838; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Busch KE, 2004, DEV CELL, V6, P831, DOI 10.1016/j.devcel.2004.05.008; Carvalho P, 2004, DEV CELL, V6, P815, DOI 10.1016/j.devcel.2004.05.001; Cottingham FR, 1999, J CELL BIOL, V147, P335, DOI 10.1083/jcb.147.2.335; Cottingham FR, 1997, J CELL BIOL, V138, P1041, DOI 10.1083/jcb.138.5.1041; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; DeZwaan TM, 1997, J CELL BIOL, V138, P1023, DOI 10.1083/jcb.138.5.1023; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; Garcia MA, 2002, CURR BIOL, V12, P610, DOI 10.1016/S0960-9822(02)00761-3; Gatt MK, 2005, J CELL SCI, V118, P2671, DOI 10.1242/jcs.02410; Goshima G, 2005, CURR BIOL, V15, P1979, DOI 10.1016/j.cub.2005.09.054; Goshima G, 2003, J CELL BIOL, V162, P1003, DOI 10.1083/jcb.200303022; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Hunter AW, 2003, MOL CELL, V11, P445, DOI 10.1016/S1097-2765(03)00049-2; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; Kline-Smith SL, 2002, MOL BIOL CELL, V13, P2718, DOI 10.1091/mbc.E01-12-0143; Komarova YA, 2002, J CELL SCI, V115, P3527; Labbe JC, 2003, CURR BIOL, V13, P707, DOI 10.1016/S0960-9822(03)00251-3; Liakopoulos D, 2003, CELL, V112, P561, DOI 10.1016/S0092-8674(03)00119-3; Maddox PS, 2003, CURR BIOL, V13, P1423, DOI 10.1016/S0960-9822(03)00547-5; Mennella V, 2005, NAT CELL BIOL, V7, P235, DOI 10.1038/ncb1222; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; Miller RK, 1998, MOL BIOL CELL, V9, P2051, DOI 10.1091/mbc.9.8.2051; Moore A, 2004, TRENDS CELL BIOL, V14, P537, DOI 10.1016/j.tcb.2004.09.001; Moore AT, 2005, J CELL BIOL, V169, P391, DOI 10.1083/jcb.200411089; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; Ogawa T, 2004, CELL, V116, P591, DOI 10.1016/S0092-8674(04)00129-1; PASCHAL BM, 1993, METHOD CELL BIOL, V39, P65, DOI 10.1016/S0091-679X(08)60161-2; Pearson CG, 2004, NAT REV MOL CELL BIO, V5, P481, DOI 10.1038/nrm1402; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; Rischitor PE, 2004, EUKARYOT CELL, V3, P632, DOI 10.1128/EC.3.3.632-645.2004; Rose MD., 1990, METHODS YEAST GENETI; Severin F, 2001, J CELL BIOL, V153, P435, DOI 10.1083/jcb.153.2.435; Sharp DJ, 2000, BBA-MOL CELL RES, V1496, P128, DOI 10.1016/S0167-4889(00)00014-8; Shipley K, 2004, EMBO J, V23, P1422, DOI 10.1038/sj.emboj.7600165; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; Sproul LR, 2005, CURR BIOL, V15, P1420, DOI 10.1016/j.cub.2005.06.066; Straight AF, 1998, J CELL BIOL, V143, P687, DOI 10.1083/jcb.143.3.687; Tirnauer JS, 1999, J CELL BIOL, V145, P993, DOI 10.1083/jcb.145.5.993; TIWARI SC, 1993, ANAL BIOCHEM, V215, P96, DOI 10.1006/abio.1993.1560; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Tytell JD, 2006, J CELL BIOL, V172, P861, DOI 10.1083/jcb.200509101; Wadsworth P, 1999, CELL MOTIL CYTOSKEL, V42, P48, DOI 10.1002/(SICI)1097-0169(1999)42:1<48::AID-CM5>3.3.CO;2-#; Waterman-Storer CM, 1998, CURR BIOL, V8, P1227, DOI 10.1016/S0960-9822(07)00515-5; West RR, 2001, MOL BIOL CELL, V12, P3919, DOI 10.1091/mbc.12.12.3919; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082; Zhu CJ, 2005, MOL BIOL CELL, V16, P3187, DOI 10.1091/mbc.E05-02-0167	54	239	241	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					913	U33		10.1038/ncb1457	http://dx.doi.org/10.1038/ncb1457			22	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16906148				2022-12-25	WOS:000240241700007
J	von Kriegsheim, A; Pitt, A; Grindlay, GJ; Kolch, W; Dhillon, AS				von Kriegsheim, Alex; Pitt, Andrew; Grindlay, G. Joan; Kolch, Walter; Dhillon, Amardeep S.			Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5	NATURE CELL BIOLOGY			English	Article							PROTEIN PHOSPHATASE 2A; KINASE ACTIVATION; PHOSPHORYLATION; P21-ACTIVATED-KINASE-1; DEPHOSPHORYLATION; SPECIFICITY	The Raf-MEK-ERK pathway couples growth factor, mitogenic and extracellular matrix signals to cell fate decisions such as growth, proliferation, migration, differentiation and survival(1,2). Raf-1 is a direct effector of the Ras GTPase and is the initiating kinase in this signalling cascade. Although Raf-1 activation is well studied, little is known about how Raf-1 is inactivated. Here, we used a proteomic approach to identify molecules that may inactivate Raf-1 signalling. Protein phosphatase 5 (PP5) was identified as an inactivator that associates with Raf-1 on growth factor stimulation and selectively dephosphorylates an essential activating site, Ser 338. The PP5-mediated dephosphorylation of Ser 338 inhibited Raf-1 activity and downstream signalling to MEK, an effect that was prevented by phosphomimetic substitution of Ser 338, or by ablation of PP5 catalytic function. Furthermore, depletion of endogenous PP5 increased cellular phospho-Ser 338 levels. Our results suggest that PP5 is a physiological regulator of Raf-1 signalling pathways.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Sir Henry Wellcome Funct Genom Facil, Glasgow G12 8QQ, Lanark, Scotland	Beatson Institute; University of Glasgow	Dhillon, AS (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	wkolch@beatson.gla.ac.uk; A.Dhillon@beatson.gla.ac.uk	von Kriegsheim, Alex/C-2371-2016; RASOR, Scotland/A-3274-2011; Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022; Pitt, Andrew R/E-9083-2010	von Kriegsheim, Alex/0000-0002-4952-8573; Dhillon, Amardeep/0000-0002-6065-663X; Pitt, Andrew R/0000-0003-3619-6503; Kolch, Walter/0000-0001-5777-5016	Biotechnology and Biological Sciences Research Council [BB/C511572/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Gong CX, 2004, J NEUROCHEM, V88, P298, DOI 10.1046/j.1471-4159.2003.02147.x; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jin SH, 2005, J BIOL CHEM, V280, P24698, DOI 10.1074/jbc.M413374200; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; O'Neill E, 2004, BRIT J CANCER, V90, P283, DOI 10.1038/sj.bjc.6601488; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; Wechsler T, 2004, P NATL ACAD SCI USA, V101, P1247, DOI 10.1073/pnas.0307765100; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Xiang XQ, 2002, J BIOL CHEM, V277, P44996, DOI 10.1074/jbc.M203953200; Yang J, 2005, EMBO J, V24, P1, DOI 10.1038/sj.emboj.7600496	25	100	105	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					1011	U102		10.1038/ncb1465	http://dx.doi.org/10.1038/ncb1465			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16892053				2022-12-25	WOS:000240241700018
J	Miller, DG; Wang, PR; Petek, LM; Hirata, RK; Sands, MS; Russell, DW				Miller, Daniel G.; Wang, Pei-Rong; Petek, Lisa M.; Hirata, Roli K.; Sands, Mark S.; Russell, David W.			Gene targeting in vivo by adeno-associated virus vectors	NATURE BIOTECHNOLOGY			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; BETA-GLUCURONIDASE; VIRAL VECTORS; INTRAVENOUS-INJECTION; TRANSGENIC MOUSE; MUTATIONS; EXPRESSION; REPAIR; MICE; DNA	Therapeutic gene delivery typically involves the addition of a transgene expression cassette to mutant cells. This approach is complicated by transgene silencing, aberrant transcriptional regulation and insertional mutagenesis. An alternative strategy is to correct mutations through homologous recombination, allowing for normal regulation of gene expression from the endogenous locus. Adeno-associated virus (AAV) vectors containing single-stranded DNA efficiently transduce cells in vivo and have been shown to target homologous chromosomal sequences in cultured cells(1). To determine whether AAV-mediated gene targeting can occur in vivo, we developed a mouse model that contains a mutant, nuclear-localized lacZ gene inserted at the ubiquitously expressed ROSA26 locus. Foci of beta-galactosidase-positive hepatocytes were observed in these mice after injection with an AAV vector containing a lacZ gene fragment, and precise correction of the 4-bp deletion was demonstrated by gene sequencing. We also used AAV gene-targeting vectors to correct the naturally occurring GusB gene mutation responsible for murine mucopolysaccharidosis type VII2.	Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Div Genet & Dev Med, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Washington Univ, Dept Med, Div Genet, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Washington University (WUSTL)	Russell, DW (corresponding author), Univ Washington, Dept Med, Div Hematol, 1705 NE Pacific St, Seattle, WA 98195 USA.	drussell@u.washington.edu	Wilson, Matthew H/K-3193-2013	Sands, Mark/0000-0002-5559-0832; Miller, Daniel/0000-0002-5700-3048	NIDDK NIH HHS [K08 DK062100] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK062100] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albuquerque-Silva J, 2001, NAT BIOTECHNOL, V19, P1011, DOI 10.1038/nbt1101-1011a; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; Gillett PM, 2001, J PEDIATR GASTR NUTR, V33, P216, DOI 10.1097/00005176-200108000-00025; GOSSEN JA, 1993, BIOTECHNIQUES, V14, P624; GOSSEN JA, 1988, NUCLEIC ACIDS RES, V16, P9343, DOI 10.1093/nar/16.19.9343; Graham IR, 2001, NAT BIOTECHNOL, V19, P507, DOI 10.1038/89209; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Grimm D, 2003, BLOOD, V102, P2412, DOI 10.1182/blood-2003-02-0495; Hendrie PC, 2005, MOL THER, V12, P9, DOI 10.1016/j.ymthe.2005.04.006; Hirata R, 2002, NAT BIOTECHNOL, V20, P735, DOI 10.1038/nbt0702-735; Inoue N, 1999, J VIROL, V73, P7376, DOI 10.1128/JVI.73.9.7376-7380.1999; Koeberl DD, 1997, P NATL ACAD SCI USA, V94, P1426, DOI 10.1073/pnas.94.4.1426; Kren BT, 1999, P NATL ACAD SCI USA, V96, P10349, DOI 10.1073/pnas.96.18.10349; Liu XM, 2004, J VIROL, V78, P4165, DOI 10.1128/JVI.78.8.4165-4175.2004; Miller DG, 2003, MOL CELL BIOL, V23, P3550, DOI 10.1128/MCB.23.10.3550-3557.2003; Nickerson HD, 2004, GENE THER, V11, P1351, DOI 10.1038/sj.gt.3302311; Russell DW, 1998, NAT GENET, V18, P325, DOI 10.1038/ng0498-325; Sands MS, 1999, LAB ANIM SCI, V49, P328; SANDS MS, 1993, P NATL ACAD SCI USA, V90, P6567, DOI 10.1073/pnas.90.14.6567; SANDS MS, 1993, LAB INVEST, V68, P676; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Trobridge G, 2005, HUM GENE THER, V16, P522, DOI 10.1089/hum.2005.16.522; van der Steege G, 2001, NAT BIOTECHNOL, V19, P305, DOI 10.1038/86664; Vasquez KM, 2000, SCIENCE, V290, P530, DOI 10.1126/science.290.5491.530; Vijg J, 1997, MECH AGEING DEV, V99, P257; Ware CB, 2003, TRANSGENIC RES, V12, P743, DOI 10.1023/B:TRAG.0000005246.35812.c8; WOLFE JH, 1995, GENE THER, V2, P70; WOLFE JH, 1992, NATURE, V360, P749, DOI 10.1038/360749a0; Zolotukhin S, 1999, GENE THER, V6, P973, DOI 10.1038/sj.gt.3300938	30	87	96	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2006	24	8					1022	1026		10.1038/nbt1231	http://dx.doi.org/10.1038/nbt1231			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	072VY	16878127				2022-12-25	WOS:000239702300043
J	Alderton, GK; Galbiati, L; Griffith, E; Surinya, KH; Neitzel, H; Jackson, AP; Jeggo, PA; O'Driscoll, M				Alderton, Gemma K.; Galbiati, Laura; Griffith, Elen; Surinya, Katharina H.; Neitzel, Heidemarie; Jackson, Andrew P.; Jeggo, Penny A.; O'Driscoll, Mark			Regulation of mitotic entry by microcephalin and its overlap with ATR signalling	NATURE CELL BIOLOGY			English	Article							DNA-DAMAGE; SECKEL-SYNDROME; CHECKPOINT; REPLICATION; CHK1; PATHWAY; PROTEIN; CDC25A; INACTIVATION; IRRADIATION	Ataxia-telangiectasia mutated and Rad3 related ( ATR)-Seckel syndrome and autosomal recessive primary microcephaly ( MCPH) syndrome share clinical features. RNA interference ( RNAi) of MCPH1 have implicated the protein it encodes as a DNA-damage response protein that regulates the transcription of Chk1 and BRCA1, two genes involved in the response to DNA damage(1,2). Here, we report that truncating mutations observed in MCPH-syndrome patients do not impact on Chk1 or BRCA1 expression or early ATR-dependent damage-induced phosphorylation events. However, like ATR-Seckel syndrome cells, MCPH1-mutant cell lines show defective G2-M checkpoint arrest and nuclear fragmentation after DNA damage, and contain supernumerary mitotic centrosomes. MCPH1-mutant and ATR-Seckel cells also show impaired degradation of Cdc25A and fail to inhibit Cdc45 loading onto chromatin after replication arrest. Additionally, microcephalin interacts with Chk1. We conclude that MCPH1 has a function downstream of Chk1 in the ATR-signalling pathway. In contrast with ATR-Seckel syndrome cells, MCPH1-mutant cells have low levels of Tyr 15-phosphorylated Cdk1 ( pY15-Cdk1) in S and G2 phases, which correlates with an elevated frequency of G2-like cells displaying premature chromosome condensation ( PCC)(3,4). Thus, MCPH1 also has an ATR-independent role in maintaining inhibitory Cdk1 phosphorylation, which prevents premature entry into mitosis.	Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Univ Leeds, Mol Med Unit, Leeds LS2 9JT, W Yorkshire, England; Charite Univ Med, Inst Human Genet, Berlin, Germany; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Sussex; University of Leeds; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Edinburgh	Jeggo, PA (corresponding author), Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England.	p.a.jeggo@sussex.ac.uk; M.O-Driscoll@sussex.ac.uk	Jackson, Andrew P/D-3442-2009	Jackson, Andrew P/0000-0002-8739-2646; Surinya, Kathy/0000-0003-0507-2962; O'Driscoll, Mark/0000-0003-2765-316X; Alderton, Gemma/0000-0003-3041-8451	Medical Research Council [G0300428, G108/461] Funding Source: Medline; MRC [G108/461, G0300428] Funding Source: UKRI; Medical Research Council [G0300662B] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Beier H, 2001, NUCLEIC ACIDS RES, V29, P4767, DOI 10.1093/nar/29.23.4767; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; FENECH M, 1986, MUTAT RES, V161, P193, DOI 10.1016/0027-5107(86)90010-2; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Jackson AP, 2002, AM J HUM GENET, V71, P136, DOI 10.1086/341283; Lin SY, 2005, P NATL ACAD SCI USA, V102, P15105, DOI 10.1073/pnas.0507722102; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Sengupta S, 2004, J CELL BIOL, V166, P801, DOI 10.1083/jcb.200405128; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sorensen CS, 2004, CELL CYCLE, V3, P941; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Trimborn M, 2004, AM J HUM GENET, V75, P261, DOI 10.1086/422855; Uto K, 2004, EMBO J, V23, P3386, DOI 10.1038/sj.emboj.7600328; Woods CG, 2005, AM J HUM GENET, V76, P717, DOI 10.1086/429930; Xu XZ, 2004, J BIOL CHEM, V279, P34091, DOI 10.1074/jbc.C400139200; Zachos G, 2005, MOL CELL BIOL, V25, P563, DOI 10.1128/MCB.25.2.563-574.2005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	30	133	141	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					725	U157		10.1038/ncb1431	http://dx.doi.org/10.1038/ncb1431			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16783362				2022-12-25	WOS:000238837800015
J	Horvath, A; Boikos, S; Giatzakis, C; Robinson-White, A; Groussin, L; Griffin, KJ; Stein, E; Levine, E; Delimpasi, G; Hsiao, HP; Keil, M; Heyerdahl, S; Matyakhina, L; Libe, R; Fratticci, A; Kirschner, LS; Cramer, K; Gaillard, RC; Bertagna, X; Carney, JA; Bertherat, J; Bossis, I; Stratakis, CA				Horvath, Anelia; Boikos, Sosipatros; Giatzakis, Christoforos; Robinson-White, Audrey; Groussin, Lionel; Griffin, Kurt J.; Stein, Erica; Levine, Elizabeth; Delimpasi, Georgia; Hsiao, Hui Pin; Keil, Meg; Heyerdahl, Sarah; Matyakhina, Ludmila; Libe, Rossella; Fratticci, Amato; Kirschner, Lawrence S.; Cramer, Kevin; Gaillard, Rolf C.; Bertagna, Xavier; Carney, J. Aidan; Bertherat, Jerome; Bossis, Ioannis; Stratakis, Constantine A.			A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia	NATURE GENETICS			English	Article							SPLICE VARIANTS; PRKAR1A GENE; EXPRESSION; SUBUNIT; DISEASE; PROTEIN; ORGANIZATION; COMPLEX; CLONING	Phosphodiesterases (PDEs) regulate cyclic nucleotide levels. Increased cyclic AMP (cAMP) signaling has been associated with PRKAR1A or GNAS mutations and leads to adrenocortical tumors and Cushing syndrome1-7. We investigated the genetic source of Cushing syndrome in individuals with adrenocortical hyperplasia that was not caused by known defects. We performed genome-wide SNP genotyping, including the adrenocortical tumor DNA. The region with the highest probability to harbor a susceptibility gene by loss of heterozygosity (LOH) and other analyses was 2q31-2q35. We identified mutations disrupting the expression of the PDE11A isoform-4 gene (PDE11A) in three kindreds. Tumor tissues showed 2q31-2q35 LOH, decreased protein expression and high cyclic nucleotide levels and cAMP-responsive element binding protein (CREB) phosphorylation. PDE11A codes for a dual-specificity PDE that is expressed in adrenal cortex and is partially inhibited by tadalafil and other PDE inhibitors(8,9); its germline inactivation is associated with adrenocortical hyperplasia, suggesting another means by which dysregulation of cAMP signaling causes endocrine tumors.	US Natl Inst Child Hlth & Human Dev, Sect Endocrinol & Genet, US Natl Inst Hlth, Bethesda, MD 20892 USA; US Natl Inst Child Hlth & Human Dev, Pediat Endocrinol Training Program, US Natl Inst Hlth, Dev Endocrinol Branch, Bethesda, MD 20892 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Univ Paris 05, Hop Cochin, INSERM, U567,Inst Cochin,Dept Endocrinol Metab & Canc, F-75679 Paris, France; Univ Paris 05, Hosp Cochin, CNRS, UMR 8104,CNRS, F-75679 Paris, France; Univ Paris 05, Hosp Cochin, Ctr Reference Malad Rare Surrenale, Serv Endocrinol, F-75679 Paris, France; Ohio State Univ, Div Endocrinol, Columbus, OH 43210 USA; Ohio State Univ, Div Human Canc Genet, Columbus, OH 43210 USA; Sapio Sci LLC, York, PA 17402 USA; CHU Vaudois, Div Endocrinol Diabetol & Metab, CH-1011 Lausanne, Switzerland	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; Mayo Clinic; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Stratakis, CA (corresponding author), US Natl Inst Child Hlth & Human Dev, Sect Endocrinol & Genet, US Natl Inst Hlth, Bethesda, MD 20892 USA.	stratakc@mail.nih.gov	Stratakis, Constantine/AAP-4745-2020	BERTHERAT, Jerome/0000-0003-2551-3008; libe, rossella/0000-0003-2881-6362; Stein, Erica/0000-0001-8778-8846; Groussin, Lionel/0000-0003-1476-475X	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000642, Z01HD000642] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bertherat J, 2003, CANCER RES, V63, P5308; Bourdeau I, 2002, ANN NY ACAD SCI, V968, P240, DOI 10.1111/j.1749-6632.2002.tb04339.x; D'Andrea MR, 2005, J HISTOCHEM CYTOCHEM, V53, P895, DOI 10.1369/jhc.5A6625.2005; de Tejada IS, 2002, INT J IMPOT RES, V14, pS6, DOI 10.1038/sj/ijir/3900790; Fawcett L, 2000, P NATL ACAD SCI USA, V97, P3702, DOI 10.1073/pnas.050585197; Francis SH, 2005, INT J IMPOT RES, V17, P467, DOI 10.1038/sj.ijir.3901377; GAL A, 1994, NAT GENET, V7, P64, DOI 10.1038/ng0594-64; Gbekor E, 2002, J UROLOGY, V167, P246; Groussin L, 2002, J CLIN ENDOCR METAB, V87, P4324, DOI 10.1210/jc.2002-020592; Gunther DF, 2004, J CLIN ENDOCR METAB, V89, P3173, DOI 10.1210/jc.2003-032247; Hetman JM, 2000, P NATL ACAD SCI USA, V97, P12891, DOI 10.1073/pnas.200355397; HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Kawamura M, 2002, PHARMACOL TOXICOL, V90, P106, DOI 10.1034/j.1600-0773.2002.900209.x; Kirschner LS, 2000, HUM MOL GENET, V9, P3037, DOI 10.1093/hmg/9.20.3037; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Lehnart SE, 2005, CELL, V123, P25, DOI 10.1016/j.cell.2005.07.030; Loughney K, 2005, INT J IMPOT RES, V17, P320, DOI 10.1038/sj.ijir.3901317; Masciarelli S, 2004, J CLIN INVEST, V114, P196, DOI 10.1172/JCI2004210804; Michibata H, 2001, BBA-GENE STRUCT EXPR, V1517, P278, DOI 10.1016/S0167-4781(00)00293-1; Millar JK, 2005, SCIENCE, V310, P1187, DOI 10.1126/science.1112915; Persani L, 2000, J CLIN ENDOCR METAB, V85, P2872, DOI 10.1210/jc.85.8.2872; Stratakis CA, 2001, J CLIN ENDOCR METAB, V86, P4041, DOI 10.1210/jc.86.9.4041; Stratakis CA, 1998, HORM METAB RES, V30, P456, DOI 10.1055/s-2007-978914; Ting JC, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-25; Wayman C, 2005, INT J IMPOT RES, V17, P216, DOI 10.1038/sj.ijir.3901307; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Yuasa K, 2000, J BIOL CHEM, V275, P31469, DOI 10.1074/jbc.M003041200; Yuasa K, 2001, EUR J BIOCHEM, V268, P4440, DOI 10.1046/j.1432-1327.2001.02366.x; Yuasa K, 2001, EUR J BIOCHEM, V268, P168, DOI 10.1046/j.1432-1327.2001.01866.x	30	231	245	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					794	800		10.1038/ng1809	http://dx.doi.org/10.1038/ng1809			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16767104				2022-12-25	WOS:000238669300015
J	Liang, C; Feng, P; Ku, B; Dotan, I; Canaani, D; Oh, BH; Jung, JU				Liang, Chengyu; Feng, Pinghui; Ku, Bonsu; Dotan, Iris; Canaani, Dan; Oh, Byung-Ha; Jung, Jae U.			Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG	NATURE CELL BIOLOGY			English	Article							CELL-DEATH; IN-VIVO; INDUCED APOPTOSIS; COLON-CANCER; VIRAL BCL-2; GENE; BECLIN-1; INHIBITION; IDENTIFICATION; MACROAUTOPHAGY	Autophagy, the degradation of cytoplasmic components, is an evolutionarily conserved homeostatic process involved in environmental adaptation, lifespan determination and tumour development. The tumor suppressor Beclin1 is part of the PI( 3) kinase class III ( PI( 3) KC3) lipid-kinase complex that induces autophagy. The autophagic activity of the Beclin1-PI( 3) KC3 complex, however, is suppressed by Bcl-2. Here, we report the identification of a novel coiled-coil UV irradiation resistance-associated gene ( UVRAG) as a positive regulator of the Beclin1-PI( 3) KC3 complex. UVRAG, a tumour suppressor candidate that is monoallelically mutated at high frequency in human colon cancers, associates with the Beclin1-Bcl-2-PI( 3) KC3 multiprotein complex, where UVRAG and Beclin1 interdependently induce autophagy. UVRAG-mediated activation of the Beclin1-PI( 3) KC3 complex promotes autophagy and also suppresses the proliferation and tumorigenicity of human colon cancer cells. These results identify UVRAG as an essential component of the Beclin1-PI( 3) KC3 lipid kinase complex that is an important signalling checkpoint for autophagy and tumour-cell growth.	Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, Southborough, MA 01772 USA; Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Div Tumor Virol, Southborough, MA 01772 USA; Pohang Univ Sci & Technol, Ctr Biomol Recognit, Dept Life Sci, Pohang 790784, South Korea; Tel Aviv Univ, Dept Biochem, IL-69978 Tel Aviv, Israel	Harvard University; Harvard University; Pohang University of Science & Technology (POSTECH); Tel Aviv University	Jung, JU (corresponding author), Harvard Univ, New England Reg Primate Res Ctr, Sch Med, Dept Microbiol & Mol Genet, 1 Pine Hill Dr, Southborough, MA 01772 USA.	jae_jung@hms.harvard.edu	Oh, Byung-Ha/C-2061-2011	LIANG, CHENGYU/0000-0001-6082-2143; Ku, Bonsu/0000-0003-1784-8975	NATIONAL CANCER INSTITUTE [R01CA082057, R01CA106156, R01CA091819, R01CA031363] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000168] Funding Source: NIH RePORTER; NCI NIH HHS [CA31363, CA106156, CA91819, CA82057] Funding Source: Medline; NCRR NIH HHS [RR00168] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; de Lima BD, 2005, J GEN VIROL, V86, P31, DOI 10.1099/vir.0.80480-0; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Gangappa S, 2002, J EXP MED, V195, P931, DOI 10.1084/jem.20011825; Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Iida A, 2000, HUM GENET, V106, P277, DOI 10.1007/s004390051038; Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178; Jia L, 1997, BRIT J HAEMATOL, V98, P673, DOI 10.1046/j.1365-2141.1997.2623081.x; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620; Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Loh J, 2005, PLOS PATHOG, V1, P80, DOI 10.1371/journal.ppat.0010010; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Perelman B, 1997, GENOMICS, V41, P397, DOI 10.1006/geno.1997.4623; Polster BM, 2004, BBA-MOL CELL RES, V1644, P211, DOI 10.1016/j.bbamcr.2003.11.001; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Roy DJ, 2000, ARCH VIROL, V145, P2411, DOI 10.1007/s007050070030; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; Wang GH, 1999, J GEN VIROL, V80, P2737, DOI 10.1099/0022-1317-80-10-2737; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	39	790	839	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					688	U94		10.1038/ncb1426	http://dx.doi.org/10.1038/ncb1426			25	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16799551				2022-12-25	WOS:000238837800011
J	Okada, S; Nakamura, M; Katoh, H; Miyao, T; Shimazaki, T; Ishii, K; Yamane, J; Yoshimura, A; Iwamoto, Y; Toyama, Y; Okano, H				Okada, Seiji; Nakamura, Masaya; Katoh, Hiroyuki; Miyao, Tamaki; Shimazaki, Takuya; Ishii, Ken; Yamane, Junichi; Yoshimura, Akihiko; Iwamoto, Yukihide; Toyama, Yoshiaki; Okano, Hideyuki			Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury	NATURE MEDICINE			English	Article							FIBRILLARY ACIDIC PROTEIN; MEDIATED RECOMBINATION; DEFICIENT MICE; GLIAL SCAR; ACTIVATION; CNS; INDUCTION; CELLS; INFILTRATION; EXPRESSION	In the injured central nervous system (CNS), reactive astrocytes form a glial scar and are considered to be detrimental for axonal regeneration, but their function remains elusive. Here we show that reactive astrocytes have a crucial role in wound healing and functional recovery by using mice with a selective deletion of the protein signal transducer and activator of transcription 3 (Stat3) or the protein suppressor of cytokine signaling 3 (Socs3) under the control of the Nes promoter-enhancer (Nes-Stat3(-/-), Nes-Socs3(-/-)). Reactive astrocytes in Nes-Stat(3-/-) mice showed limited migration and resulted in markedly widespread infiltration of inflammatory cells, neural disruption and demyelination with severe motor deficits after contusive spinal cord injury (SCI). On the contrary, we observed rapid migration of reactive astrocytes to seclude inflammatory cells, enhanced contraction of lesion area and notable improvement in functional recovery in Nes-Socs3(-/-) mice. These results suggest that Stat3 is a key regulator of reactive astrocytes in the healing process after SCI, providing a potential target for intervention in the treatment of CNS injury.	Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo 1608582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol, Core Res Evoluat Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjuku Ku, Tokyo 1608562, Japan; Kyushu Univ, Grad Sch Med Sci, Div Mol & Cellular Immunol, Med Inst Bioregulat,Higashi Ku, Fukuoka 8128582, Japan	Keio University; Kyushu University; Japan Science & Technology Agency (JST); Keio University; Kyushu University	Okano, H (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hidokano@sc.itc.keio.ac.jp	Shimazaki, Takuya/L-1159-2013; Nakamura, Masaya/K-4111-2013; Yoshimura, Akihiko/K-5515-2013; Ishii, Ken J/B-1685-2012; Okano, Hideyuki/I-7584-2019; Toyama, Yoshiaki/K-5743-2013	Shimazaki, Takuya/0000-0002-3936-2098; Ishii, Ken J/0000-0002-6728-3872; Okada, Seiji/0000-0002-5107-8209; ISHII, KEN/0000-0003-0094-7918				Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Betz UAK, 1996, CURR BIOL, V6, P1307, DOI 10.1016/S0960-9822(02)70717-3; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Gao Q, 2004, P NATL ACAD SCI USA, V101, P4661, DOI 10.1073/pnas.0303992101; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Johansson CB, 2002, J NEUROSCI RES, V69, P784, DOI 10.1002/jnr.10376; Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7; Kerr BJ, 2004, EXP NEUROL, V188, P391, DOI 10.1016/j.expneurol.2004.04.012; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lacroix S, 2002, J COMP NEUROL, V454, P213, DOI 10.1002/cne.10407; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Okano HJ, 1997, J NEUROSCI, V17, P3024; Ozawa Y, 2004, MOL CELL NEUROSCI, V26, P258, DOI 10.1016/j.mcn.2004.02.001; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Penkowa M, 1999, J NEUROSCI, V19, P2535; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sriram K, 2004, J BIOL CHEM, V279, P19936, DOI 10.1074/jbc.M309304200; Takeda K, 1998, J IMMUNOL, V161, P4652; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Xia XG, 2002, MOL CELL NEUROSCI, V21, P379, DOI 10.1006/mcne.2002.1180; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545	30	680	706	0	55	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					829	834		10.1038/nm1425	http://dx.doi.org/10.1038/nm1425			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16783372				2022-12-25	WOS:000238862800071
J	Sebaihia, M; Wren, BW; Mullany, P; Fairweather, NF; Minton, N; Stabler, R; Thomson, NR; Roberts, AP; Cerdeno-Tarrraga, AM; Wang, HW; Holden, MTG; Wright, A; Churcher, C; Quail, MA; Baker, S; Bason, N; Brooks, K; Chillingworth, T; Cronin, A; Davis, P; Dowd, L; Fraser, A; Feltwell, T; Hance, Z; Holroyd, S; Jagels, K; Moule, S; Mungall, K; Price, C; Rabbinowitsch, E; Sharp, S; Simmonds, M; Stevens, K; Unwin, L; Whithead, S; Dupuy, B; Dougan, G; Barrell, B; Parkhill, J				Sebaihia, Mohammed; Wren, Brendan W.; Mullany, Peter; Fairweather, Neil F.; Minton, Nigel; Stabler, Richard; Thomson, Nicholas R.; Roberts, Adam P.; Cerdeno-Tarrraga, Ana M.; Wang, Hongmei; Holden, Matthew T. G.; Wright, Anne; Churcher, Carol; Quail, Michael A.; Baker, Stephen; Bason, Nathalie; Brooks, Karen; Chillingworth, Tracey; Cronin, Ann; Davis, Paul; Dowd, Linda; Fraser, Audrey; Feltwell, Theresa; Hance, Zahra; Holroyd, Simon; Jagels, Kay; Moule, Sharon; Mungall, Karen; Price, Claire; Rabbinowitsch, Ester; Sharp, Sarah; Simmonds, Mark; Stevens, Kim; Unwin, Louise; Whithead, Sally; Dupuy, Bruno; Dougan, Gordon; Barrell, Bart; Parkhill, Julian			The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome	NATURE GENETICS			English	Article							STAPHYLOCOCCUS-AUREUS; ENTEROCOCCUS-FAECALIS; CONJUGAL TRANSFER; SURFACE PROTEIN; VIRULENCE; SEQUENCE; GENE; ELEMENT; IDENTIFICATION; PERFRINGENS	We determined the complete genome sequence of Clostridium difficile strain 630, a virulent and multidrug-resistant strain. Our analysis indicates that a large proportion (11%) of the genome consists of mobile genetic elements, mainly in the form of conjugative transposons. These mobile elements are putatively responsible for the acquisition by C. difficile of an extensive array of genes involved in antimicrobial resistance, virulence, host interaction and the production of surface structures. The metabolic capabilities encoded in the genome show multiple adaptations for survival and growth within the gut environment. The extreme genome variability was confirmed by whole-genome microarray analysis; it may reflect the organism's niche in the gut and should provide information on the evolution of virulence in this organism.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; London Sch Hyg & Trop Med, Dept Infect & Trop Med, London WC1E 7HT, England; UCL, Eastman Dent Inst Oral Hlth Care Sci, London WC1X 8LD, England; Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, London SW7 2AZ, England; Univ Nottingham, Inst Infect Immun & Inflammat, Ctr Biomol Sci, Nottingham NG7 2RD, England; Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France	Wellcome Trust Sanger Institute; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; Imperial College London; University of Nottingham; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Parkhill, J (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Gen Campus, Cambridge CB10 1SA, England.	parkhill@sanger.ac.uk	Holden, Matthew TG/K-6449-2014; Quail, michael/ABE-6131-2020; Sebaihia, Mohammed/AAF-6589-2019; Parkhill, Julian/G-4703-2011; Roberts, Adam/AAU-5493-2021; Roberts, Adam P/C-1787-2008; Thomson, Nicholas/P-5988-2014	Holden, Matthew TG/0000-0002-4958-2166; Sebaihia, Mohammed/0000-0002-3324-3346; Parkhill, Julian/0000-0002-7069-5958; Roberts, Adam/0000-0002-0760-3088; Roberts, Adam P/0000-0002-0760-3088; Stabler, Richard/0000-0002-2402-6630; Baker, Stephen/0000-0003-1308-5755; Thomson, Nicholas/0000-0002-4432-8505; Minton, Nigel/0000-0002-9277-1261; Cerdeno-Tarraga, Ana M./0000-0001-6635-3237; Davis, Paul/0000-0001-5545-0824	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTHUR M, 1995, GENE, V154, P87, DOI 10.1016/0378-1119(94)00851-I; Begley M, 2005, FEMS MICROBIOL REV, V29, P625, DOI 10.1016/j.femsre.2004.09.003; Bell KS, 2004, P NATL ACAD SCI USA, V101, P11105, DOI 10.1073/pnas.0402424101; BORRIELLO SP, 1988, J MED MICROBIOL, V25, P191, DOI 10.1099/00222615-25-3-191; Braun V, 2000, MOL MICROBIOL, V36, P1447, DOI 10.1046/j.1365-2958.2000.01965.x; Broussolle V, 2002, ANAEROBE, V8, P89, DOI 10.1006/anae.2002.0424; Bruggemann H, 2003, P NATL ACAD SCI USA, V100, P1316, DOI 10.1073/pnas.0335853100; Burrus V, 2002, MOL MICROBIOL, V46, P601, DOI 10.1046/j.1365-2958.2002.03191.x; Calabi E, 2001, MOL MICROBIOL, V40, P1187, DOI 10.1046/j.1365-2958.2001.02461.x; Carter GP, 2005, J MED MICROBIOL, V54, P119, DOI 10.1099/jmm.0.45817-0; Carver TJ, 2005, BIOINFORMATICS, V21, P3422, DOI 10.1093/bioinformatics/bti553; Champion OL, 2005, P NATL ACAD SCI USA, V102, P16043, DOI 10.1073/pnas.0503252102; DAVIES HA, 1990, MICROB PATHOGENESIS, V9, P141, DOI 10.1016/0882-4010(90)90088-8; de Vries YP, 2005, FEMS MICROBIOL LETT, V252, P169, DOI 10.1016/j.femsle.2005.08.042; Depardieu F, 2003, MOL MICROBIOL, V50, P931, DOI 10.1046/j.1365-2958.2003.03737.x; Dramsi S, 2005, RES MICROBIOL, V156, P289, DOI 10.1016/j.resmic.2004.10.011; ELSDEN SR, 1976, ARCH MICROBIOL, V107, P283, DOI 10.1007/BF00425340; Farrow KA, 2001, MICROBIOL-SGM, V147, P2717, DOI 10.1099/00221287-147-10-2717; FRANKE AE, 1981, J BACTERIOL, V145, P494, DOI 10.1128/JB.145.1.494-502.1981; Garnier F, 2000, MICROBIOL-UK, V146, P1481, DOI 10.1099/00221287-146-6-1481; Haraldsen JD, 2003, MOL MICROBIOL, V48, P811, DOI 10.1046/j.1365-2958.2003.03471.x; Hennequin C, 2003, MICROBIOL-SGM, V149, P2779, DOI 10.1099/mic.0.26145-0; Jansen R, 2002, MOL MICROBIOL, V43, P1565, DOI 10.1046/j.1365-2958.2002.02839.x; Lee ASY, 2005, BIOCHEM BIOPH RES CO, V335, P659, DOI 10.1016/j.bbrc.2005.07.131; Loo VG, 2005, NEW ENGL J MED, V353, P2442, DOI 10.1056/NEJMoa051639; Lyon GJ, 2004, PEPTIDES, V25, P1389, DOI 10.1016/j.peptides.2003.11.026; Makarova KS, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-7; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; McDonald LC, 2005, NEW ENGL J MED, V353, P2433, DOI 10.1056/NEJMoa051590; Moir A, 2002, CELL MOL LIFE SCI, V59, P403, DOI 10.1007/s00018-002-8432-8; Mojica FJM, 2005, J MOL EVOL, V60, P174, DOI 10.1007/s00239-004-0046-3; MULLANY P, 1990, J GEN MICROBIOL, V136, P1343, DOI 10.1099/00221287-136-7-1343; Nolling J, 2001, J BACTERIOL, V183, P4823, DOI 10.1128/JB.183.16.4823-4838.2001; Ohtani K, 2002, MOL MICROBIOL, V44, P171, DOI 10.1046/j.1365-2958.2002.02863.x; Paredes CJ, 2005, NAT REV MICROBIOL, V3, P969, DOI 10.1038/nrmicro1288; Poilane I, 1998, CAN J MICROBIOL, V44, P157, DOI 10.1139/cjm-44-2-157; Roberts AP, 2001, MICROBIOL-SGM, V147, P1243, DOI 10.1099/00221287-147-5-1243; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Savariau-Lacomme MP, 2003, J BACTERIOL, V185, P4461, DOI 10.1128/JB.185.15.4461-4470.2003; Selmer T, 2001, EUR J BIOCHEM, V268, P1363, DOI 10.1046/j.1432-1327.2001.02001.x; Shimizu T, 2002, P NATL ACAD SCI USA, V99, P996, DOI 10.1073/pnas.022493799; Sleator RD, 2005, MOL MICROBIOL, V55, P1183, DOI 10.1111/j.1365-2958.2004.04454.x; van Schaik W, 2005, CURR OPIN BIOTECH, V16, P218, DOI 10.1016/j.copbio.2005.01.008; Voth DE, 2005, CLIN MICROBIOL REV, V18, P247, DOI 10.1128/CMR.18.2.247-263.2005; Waligora AJ, 2001, INFECT IMMUN, V69, P2144, DOI 10.1128/IAI.69.4.2144-2153.2001; Wang HM, 2000, J BACTERIOL, V182, P6577, DOI 10.1128/JB.182.23.6577-6583.2000; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; WILSON KH, 1983, J CLIN MICROBIOL, V18, P1017, DOI 10.1128/JCM.18.4.1017-1019.1983; Wright A, 2005, PROTEOMICS, V5, P2443, DOI 10.1002/pmic.200401179; WUST J, 1982, J CLIN MICROBIOL, V16, P1096	50	641	980	3	114	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					779	786		10.1038/ng1830	http://dx.doi.org/10.1038/ng1830			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16804543				2022-12-25	WOS:000238669300013
J	Teixeira-Clerc, F; Julien, B; Grenard, P; Van Nhieu, JT; Deveaux, V; Li, LY; Serriere-Lanneau, V; Ledent, C; Mallat, A; Lotersztajn, S				Teixeira-Clerc, Fatima; Julien, Boris; Grenard, Pascale; Van Nhieu, Jeanne Tran; Deveaux, Vanessa; Li, Liying; Serriere-Lanneau, Valerie; Ledent, Catherine; Mallat, Ariane; Lotersztajn, Sophie			CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis	NATURE MEDICINE			English	Article							HUMAN HEPATIC MYOFIBROBLASTS; SPHINGOSINE 1-PHOSPHATE; ENDOCANNABINOID SYSTEM; ANTIFIBROGENIC PROTEIN; MOLECULAR-MECHANISMS; OVERWEIGHT PATIENTS; STELLATE CELLS; RISK-FACTORS; MICE; CIRRHOSIS	Hepatic fibrosis, the common response associated with chronic liver diseases, ultimately leads to cirrhosis, a major public health problem worldwide(1). We recently showed that activation of hepatic cannabinoid CB2 receptors limits progression of experimental liver fibrosis(2). We also found that during the course of chronic hepatitis C, daily cannabis use is an independent predictor of fibrosis progression(3). Overall, these results suggest that endocannabinoids may drive both CB2-mediated antifibrogenic effects and CB2-independent profibrogenic effects. Here we investigated whether activation of cannabinoid CB1 receptors ( encoded by Cnr1) promotes progression of fibrosis. CB1 receptors were highly induced in human cirrhotic samples and in liver fibrogenic cells. Treatment with the CB1 receptor antagonist SR141716A decreased the wound-healing response to acute liver injury and inhibited progression of fibrosis in three models of chronic liver injury. We saw similar changes in Cnr1(-/-) mice as compared to wildtype mice. Genetic or pharmacological inactivation of CB1 receptors decreased fibrogenesis by lowering hepatic transforming growth factor ( TGF)-beta 1 and reducing accumulation of fibrogenic cells in the liver after apoptosis and growth inhibition of hepatic myofibroblasts. In conclusion, our study shows that CB1 receptor antagonists hold promise for the treatment of liver fibrosis.	Hop Henri Mondor, INSERM, U581, F-94000 Creteil, France; Univ Paris 12, Fac Med, F-94000 Creteil, France; Grp Hosp Henri Mondor Albert Chenevier, AP HP, Serv Hepatol & Gastroenterol, F-94000 Creteil, France; Grp Hosp Henri Mondor Albert Chenevier, AP HP, Dept Pathol, F-94000 Creteil, France; Univ Libre Bruxelles, IRIBHN, Brussels, Belgium	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Libre de Bruxelles	Lotersztajn, S (corresponding author), Hop Henri Mondor, INSERM, U581, F-94000 Creteil, France.	sophie.lotersztajn@creteil.inserm.fr	Teixeira-Clerc, Fatima/AAB-5499-2021; Teixeira-Clerc, Fatima/C-9884-2009; Julien, Boris/E-2374-2012; VAN NHIEU, Jeanne TRAN/R-5235-2018; Lotersztajn, Sophie/K-9160-2017	Teixeira-Clerc, Fatima/0000-0003-1098-9222; lotersztajn, Sophie/0000-0002-0053-7807				Batkai S, 2001, NAT MED, V7, P827, DOI 10.1038/89953; Biecker E, 2004, EUR J CLIN INVEST, V34, P283, DOI 10.1111/j.1365-2362.2004.01331.x; Bilkei-Gorzo A, 2005, P NATL ACAD SCI USA, V102, P15670, DOI 10.1073/pnas.0504640102; Bouaboula M, 1997, J BIOL CHEM, V272, P22330, DOI 10.1074/jbc.272.35.22330; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Davaille J, 2002, J BIOL CHEM, V277, P37323, DOI 10.1074/jbc.M202798200; Despres JP, 2005, NEW ENGL J MED, V353, P2121, DOI 10.1056/NEJMoa044537; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188; Hezode C, 2005, HEPATOLOGY, V42, P63, DOI 10.1002/hep.20733; Julien B, 2005, GASTROENTEROLOGY, V128, P742, DOI 10.1053/j.gastro.2004.12.050; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Li LY, 2004, J HEPATOL, V41, P407, DOI 10.1016/j.jhep.2004.05.016; Li LY, 2003, GASTROENTEROLOGY, V125, P460, DOI 10.1016/S0016-5085(03)00906-5; Li LY, 2001, J BIOL CHEM, V276, P38152; Li XN, 2002, J HEPATOL, V36, P488, DOI 10.1016/S0168-8278(02)00011-9; Lotersztajn S, 2005, ANNU REV PHARMACOL, V45, P605, DOI 10.1146/annurev.pharmtox.45.120403.095906; MALLAT A, IN PRESS J ENDOCRINO; Milligan G, 2003, MOL PHARMACOL, V64, P1271, DOI 10.1124/mol.64.6.1271; Osei-Hyiaman D, 2005, J CLIN INVEST, V115, P1298, DOI 10.1172/JCI200523057; Pertwee RG, 1999, CURR MED CHEM, V6, P635; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Rinaldi-Carmona M, 1998, J PHARMACOL EXP THER, V284, P644; RinaldiCarmona M, 1996, LIFE SCI, V58, P1239, DOI 10.1016/0024-3205(96)00085-9; Ros J, 2002, GASTROENTEROLOGY, V122, P85, DOI 10.1053/gast.2002.30305; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Tao JC, 1999, J BIOL CHEM, V274, P23761, DOI 10.1074/jbc.274.34.23761; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; Vrochides D, 1996, HEPATOLOGY, V23, P1650, DOI 10.1053/jhep.1996.v23.pm0008675189; Wang L, 2003, P NATL ACAD SCI USA, V100, P1393, DOI 10.1073/pnas.0336351100	32	399	430	0	37	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUN	2006	12	6					671	676		10.1038/nm1421	http://dx.doi.org/10.1038/nm1421			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715087				2022-12-25	WOS:000238149200029
J	Lieberman, RL; Wustman, BA; Huertas, P; Powe, AC; Pine, CW; Khanna, R; Schlossmacher, MG; Ringe, D; Petsko, GA				Lieberman, Raquel L.; Wustman, Brandon A.; Huertas, Pedro; Powe, Allan C., Jr.; Pine, Corey W.; Khanna, Richie; Schlossmacher, Michael G.; Ringe, Dagmar; Petsko, Gregory A.			Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease	NATURE CHEMICAL BIOLOGY			English	Article							LYSOSOMAL STORAGE DISORDERS; X-RAY-STRUCTURE; SAPOSIN-C; PROTEIN; GLUCOCEREBROSIDASE; INHIBITORS; MUTATIONS; MIGLUSTAT; ENZYME; CELLS	Gaucher disease results from mutations in the lysosomal enzyme acid beta-glucosidase ( GCase)(1). Although enzyme replacement therapy has improved the health of some affected individuals, such as those with the prevalent N370S mutation, oral treatment with pharmacological chaperones may be therapeutic in a wider range of tissue compartments by restoring sufficient activity of endogenous mutant GCase(2). Here we demonstrate that isofagomine ( IFG, 1) binds to the GCase active site, and both increases GCase activity in cell lysates and restores lysosomal trafficking in cells containing N370S mutant GCase. We also compare the crystal structures of IFG-bound GCase at low pH with those of glycerol-bound GCase at low pH and apo-GCase at neutral pH. Our data indicate that IFG induces active GCase, which is secured by interactions with Asn370. The design of small molecules that stabilize substrate-bound conformations of mutant proteins may be a general therapeutic strategy for diseases caused by protein misfolding and mistrafficking.	Brigham & Womens Hosp, Struct Neurol Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Brandeis Univ, Rosenstiel Ctr Basic Biomed Sci, Waltham, MA 02454 USA; Amicus Therapeut, Cranbury, NJ 08512 USA; MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Brandeis University; Harvard University; Massachusetts Institute of Technology (MIT)	Petsko, GA (corresponding author), Brigham & Womens Hosp, Struct Neurol Lab, 75 Francis St, Boston, MA 02115 USA.	petsko@brandeis.edu	Petsko, Gregory/AAO-7962-2020	Schlossmacher, Michael/0000-0002-0394-0300				Alfonso P, 2005, BLOOD CELL MOL DIS, V35, P268, DOI 10.1016/j.bcmd.2005.05.007; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; Beutler E, 1996, HUM MUTAT, V8, P207, DOI 10.1002/(SICI)1098-1004(1996)8:3<207::AID-HUMU2>3.0.CO;2-6; Butters TD, 2005, GLYCOBIOLOGY, V15, pR43, DOI 10.1093/glycob/cwi076; Dvir H, 2003, EMBO REP, V4, P704, DOI 10.1038/sj.embor.embor873; Elstein D, 2004, J INHERIT METAB DIS, V27, P757, DOI 10.1023/B:BOLI.0000045756.54006.17; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fan JQ, 2003, TRENDS PHARMACOL SCI, V24, P355, DOI 10.1016/S0165-6147(03)00158-5; Goker-Alpan O, 2006, NEUROLOGY, V67, P908, DOI 10.1212/01.wnl.0000230215.41296.18; GRACE ME, 1994, J BIOL CHEM, V269, P2283; Kolter T, 2003, CHEMBIOCHEM, V4, P260, DOI 10.1002/cbic.200390045; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lin H, 2004, BBA-MOL BASIS DIS, V1689, P219, DOI 10.1016/j.bbadis.2004.03.007; Liou B, 2006, J BIOL CHEM, V281, P4242, DOI 10.1074/jbc.M511110200; Mellor HR, 2003, BIOCHEM J, V374, P307, DOI 10.1042/BJ20030348; MIAO SC, 1994, J BIOL CHEM, V269, P10975; OSIECKINEWMAN K, 1987, BIOCHIM BIOPHYS ACTA, V915, P87, DOI 10.1016/0167-4838(87)90128-2; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pastores GM, 2005, CLIN THER, V27, P1215, DOI 10.1016/j.clinthera.2005.08.004; Premkumar L, 2005, J BIOL CHEM, V280, P23815, DOI 10.1074/jbc.M502799200; Qi XY, 1998, BIOCHEMISTRY-US, V37, P11544, DOI 10.1021/bi980785+; Salvioli R, 2005, BIOCHEM J, V390, P95, DOI 10.1042/BJ20050325; Sawkar AR, 2006, CELL MOL LIFE SCI, V63, P1179, DOI 10.1007/s00018-005-5437-0; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Steet RA, 2006, P NATL ACAD SCI USA, V103, P13813, DOI 10.1073/pnas.0605928103; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Wong KD, 2004, MOL GENET METAB, V82, P192, DOI 10.1016/j.ymgme.2004.04.011; Zimmer KP, 1999, J PATHOL, V188, P407; Zwart PH, 2004, ACTA CRYSTALLOGR D, V60, P2230, DOI 10.1107/S0907444904012995	30	183	193	2	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	FEB	2007	3	2					101	107		10.1038/nchembio850	http://dx.doi.org/10.1038/nchembio850			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	128UZ	17187079				2022-12-25	WOS:000243685800013
J	Schmahl, J; Raymond, CS; Soriano, P				Schmahl, Jennifer; Raymond, Christopher S.; Soriano, Philippe			PDGF signaling specificity is mediated through multiple immediate early genes	NATURE GENETICS			English	Article							CELL-DEVELOPMENT; RECEPTOR; IDENTIFICATION; EXPRESSION; ALPHA; PATHWAYS; CLONING; ROLES; MOUSE; MICE	Growth factor signaling leads to the induction or repression of immediate early genes, but how these genes act collectively as effectors of downstream processes remains unresolved. We have used gene trap-coupled microarray analysis to identify and mutate multiple platelet-derived growth factor (PDGF) intermediate early genes in mice. Mutations in these genes lead to a high frequency of phenotypes that affect the same cell types and processes as those controlled by the PDGF pathway. We conclude that these genes form a network that controls specific processes downstream of PDGF signaling.	Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Soriano, P (corresponding author), Fred Hutchinson Canc Res Ctr, Program Dev Biol, 1100 Fairview Ave N, Seattle, WA 98109 USA.	psoriano@fhcrc.org	Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X; Raymond, Christopher/0000-0003-1128-8524	NCI NIH HHS [CA09657] Funding Source: Medline; NICHD NIH HHS [HD24875, R01 HD024875, R37 HD025326] Funding Source: Medline; NIGMS NIH HHS [GM071158] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM071158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bertotti A, 2003, TRENDS BIOCHEM SCI, V28, P527, DOI 10.1016/j.tibs.2003.09.001; Betsholtz C, 2001, BIOESSAYS, V23, P494, DOI 10.1002/bies.1069; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Chen WSV, 2004, NAT GENET, V36, P304, DOI 10.1038/ng1306; El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Goutebroze L, 2000, MOL CELL BIOL, V20, P1699, DOI 10.1128/MCB.20.5.1699-1712.2000; GRUNEBERG H, 1960, GENET RES, V1, P69, DOI 10.1017/S0016672300000094; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hoch RV, 2006, DEVELOPMENT, V133, P663, DOI 10.1242/dev.02242; Hoch RV, 2003, DEVELOPMENT, V130, P4769, DOI 10.1242/dev.00721; Ishiguro H, 2001, ONCOGENE, V20, P5062, DOI 10.1038/sj.onc.1204603; Klinghoffer RA, 2002, DEV CELL, V2, P103, DOI 10.1016/S1534-5807(01)00103-4; Klinghoffer RA, 2001, MOL CELL, V7, P343, DOI 10.1016/S1097-2765(01)00182-4; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Socolovsky M, 1998, BLOOD, V92, P1491, DOI 10.1182/blood.V92.5.1491.417k40_1491_1496; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Takemoto M, 2006, EMBO J, V25, P1160, DOI 10.1038/sj.emboj.7601014; Tallquist MD, 2003, DEVELOPMENT, V130, P507, DOI 10.1242/dev.00241; Zhou JH, 1998, BIOCHEM BIOPH RES CO, V242, P502, DOI 10.1006/bbrc.1997.7993	32	144	154	2	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JAN	2007	39	1					52	60		10.1038/ng1922	http://dx.doi.org/10.1038/ng1922			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17143286				2022-12-25	WOS:000243136500017
J	Fenical, W; Jensen, PR				Fenical, William; Jensen, Paul R.			Developing a new resource for drug discovery: marine actinomycete bacteria	NATURE CHEMICAL BIOLOGY			English	Article							SALINOSPORAMIDE-A; PROTEASOME INHIBITOR; SALINISPORA-TROPICA; NATURAL-PRODUCTS; GEN. NOV.; CHLORINE SUBSTITUENTS; ANTITUMOR-ANTIBIOTICS; OCEAN SEDIMENTS; METABOLITES; ACTINOBACTERIA	Natural products are both a fundamental source of new chemical diversity and an integral component of today's pharmaceutical compendium. Yet interest in natural-product drug discovery has waned, in part owing to diminishing returns from traditional resources such as soil bacteria. The oceans cover 70% of the Earth's surface and harbor most of the planet's biodiversity. Although marine plants and invertebrates have received considerable attention as a resource for natural-product discovery, the microbiological component of this diversity remains relatively unexplored. Recent studies have revealed that select groups of marine actinomycetes are a robust source of new natural products. Members of the genus Salinispora have proven to be a particularly rich source of new chemical structures, including the potent proteasome inhibitor salinosporamide A, and other distinct groups are yielding new classes of terpenoids, amino acid-derived metabolites and polyene macrolides. The continued development of improved cultivation methods and technologies for accessing deep-sea environments promises to provide access to this significant new source of chemical diversity.	Univ Calif San Diego, Ctr Marine Biotechnol & Biomed, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Fenical, W (corresponding author), Univ Calif San Diego, Ctr Marine Biotechnol & Biomed, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	wfenical@ucsd.edu	Jansen, Nils/G-1835-2011	Fenical, William/0000-0002-8955-1735; jensen, paul/0000-0003-2349-1888	NCI NIH HHS [CA 052955, CA 44848, CA 048112] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044848, P01CA048112, U19CA052955, R37CA044848, U01CA052955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Berdy J, 2005, J ANTIBIOT, V58, P1, DOI 10.1038/ja.2005.1; Bernan V. S, 2004, Current Medicinal Chemistry - Anti-Infective Agents, V3, P181, DOI 10.2174/1568012043353883; Bister B, 2004, ANGEW CHEM INT EDIT, V43, P2574, DOI 10.1002/anie.200353160; Buchanan GO, 2005, ORG LETT, V7, P2731, DOI 10.1021/ol050901i; Carter-Franklin JN, 2003, J AM CHEM SOC, V125, P3688, DOI 10.1021/ja029271v; Challis GL, 2000, FEMS MICROBIOL LETT, V187, P111, DOI 10.1111/j.1574-6968.2000.tb09145.x; Charan RD, 2004, J NAT PROD, V67, P1431, DOI 10.1021/np040042r; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Clardy J, 2004, NATURE, V432, P829, DOI 10.1038/nature03194; Endo A, 2005, J AM CHEM SOC, V127, P8298, DOI 10.1021/ja0522783; Feling RH, 2003, ANGEW CHEM INT EDIT, V42, P355, DOI 10.1002/anie.200390115; Fiedler HP, 2005, ANTON LEEUW INT J G, V87, P37, DOI 10.1007/s10482-004-6538-8; Goodfellow M, 1984, BIOL BIOCH BIOMEDICA, P453; Gribble GW, 2003, HANDB ENVIRON CHEM, V3, P1; Groll M, 2006, J AM CHEM SOC, V128, P5136, DOI 10.1021/ja058320b; Han SK, 2003, INT J SYST EVOL MICR, V53, P2061, DOI 10.1099/ijs.0.02627-0; HARRIS CM, 1985, J AM CHEM SOC, V107, P6652, DOI 10.1021/ja00309a038; He HY, 2001, J AM CHEM SOC, V123, P5362, DOI 10.1021/ja010129o; HELMKE E, 1984, INT J SYST BACTERIOL, V34, P127, DOI 10.1099/00207713-34-2-127; Janssen PH, 2002, APPL ENVIRON MICROB, V68, P2391, DOI 10.1128/AEM.68.5.2391-2396.2002; Jensen PR, 2006, ENVIRON MICROBIOL, V8, P1881, DOI 10.1111/j.1462-2920.2006.01093.x; JENSEN PR, 1991, APPL ENVIRON MICROB, V57, P1102, DOI 10.1128/AEM.57.4.1102-1108.1991; Kim TK, 2006, APPL ENVIRON MICROB, V72, P2118, DOI 10.1128/AEM.72.3.2118-2125.2006; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; Kwon HC, 2006, J AM CHEM SOC, V128, P1622, DOI 10.1021/ja0558948; Lam KS, 2006, CURR OPIN MICROBIOL, V9, P245, DOI 10.1016/j.mib.2006.03.004; Larsen TO, 2005, NAT PROD REP, V22, P672, DOI 10.1039/b404943h; Liu W, 2003, P NATL ACAD SCI USA, V100, P11959, DOI 10.1073/pnas.2034291100; Macherla VR, 2005, J MED CHEM, V48, P3684, DOI 10.1021/jm048995+; Magarvey NA, 2004, APPL ENVIRON MICROB, V70, P7520, DOI 10.1128/AEM.70.12.7520-7529.2004; Maldonado LA, 2005, INT J SYST EVOL MICR, V55, P1759, DOI 10.1099/ijs.0.63625-0; Mincer TJ, 2002, APPL ENVIRON MICROB, V68, P5005, DOI 10.1128/AEM.68.10.5005-5011.2002; Mulholland NP, 2006, ORG BIOMOL CHEM, V4, P2845, DOI 10.1039/b607109k; Naumann K, 1999, J PRAK CHEM-CHEM ZTG, V341, P417; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Newman DJ, 2004, J NAT PROD, V67, P1216, DOI 10.1021/np040031y; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; Oh DC, 2006, ORG LETT, V8, P1021, DOI 10.1021/ol052686b; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PATHIRANA C, 1992, TETRAHEDRON LETT, V33, P7663, DOI 10.1016/0040-4039(93)88010-G; Pathom-aree W, 2006, EXTREMOPHILES, V10, P181, DOI 10.1007/s00792-005-0482-z; Pfeifer BA, 2001, MICROBIOL MOL BIOL R, V65, P106, DOI 10.1128/MMBR.65.1.106-118.2001; Reddy LR, 2004, J AM CHEM SOC, V126, P6230, DOI 10.1021/ja048613p; Renner MK, 1999, J AM CHEM SOC, V121, P11273, DOI 10.1021/ja992482o; RYCHNOVSKY SD, 1995, J AM CHEM SOC, V117, P197, DOI 10.1021/ja00106a024; SCHLEGEL R, 1981, J ANTIBIOT, V34, P122, DOI 10.7164/antibiotics.34.122; Soria-Mercado IE, 2005, J NAT PROD, V68, P904, DOI 10.1021/np058011z; Stach JEM, 2003, APPL ENVIRON MICROB, V69, P6189, DOI 10.1128/AEM.69.10.6189-6200.2003; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727; Walsh CT, 2002, CHEMBIOCHEM, V3, P125; Ward AC, 2006, CURR OPIN MICROBIOL, V9, P279, DOI 10.1016/j.mib.2006.04.004; WEYLAND H, 1969, NATURE, V223, P858, DOI 10.1038/223858a0; Williams PG, 2005, J ORG CHEM, V70, P6196, DOI 10.1021/jo050511+; Yi H, 2004, INT J SYST EVOL MICR, V54, P1585, DOI 10.1099/ijs.0.03036-0; ZoBell C., 1946, MARINE MICROBIOLOGY	57	618	668	4	212	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	DEC	2006	2	12					666	673		10.1038/nchembio841	http://dx.doi.org/10.1038/nchembio841			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	107KC	17108984				2022-12-25	WOS:000242168800010
J	Richardson, RJ; Dixon, J; Malhotra, S; Hardman, MJ; Knowles, L; Boot-Handford, RP; Shore, P; Whitmarsh, A; Dixon, MJ				Richardson, Rebecca J.; Dixon, Jill; Malhotra, Saimon; Hardman, Matthew J.; Knowles, Lynnette; Boot-Handford, Ray P.; Shore, Paul; Whitmarsh, Alan; Dixon, Michael J.			Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch	NATURE GENETICS			English	Article							POPLITEAL PTERYGIUM SYNDROME; REPEATED-EPILATION; EPIDERMAL MORPHOGENESIS; MICE LACKING; IKK-ALPHA; SKIN; P63; 14-3-3-SIGMA; MUTATION; KINASE	The epidermis is a highly organized structure, the integrity of which is central to the protection of an organism(1). Development and subsequent maintenance of this tissue depends critically on the intricate balance between proliferation and differentiation of a resident stem cell population(1,2); however, the signals controlling the proliferation-differentiation switch in vivo remain elusive(3). Here, we show that mice carrying a homozygous missense mutation in interferon regulatory factor 6 (Irf6), the homolog of the gene mutated in the human congenital disorders Van der Woude syndrome and popliteal pterygium syndrome, have a hyperproliferative epidermis that fails to undergo terminal differentiation, resulting in soft tissue fusions. We further demonstrate that mice that are compound heterozygotes for mutations in Irf6 and the gene encoding the cell cycle regulator protein stratifin (Sfn; also known as 14-3-3 sigma) show similar defects of keratinizing epithelia. Our results indicate that Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch and that Irf6 and Sfn interact genetically in this process.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Dent, Manchester M13 9PT, Lancs, England	University of Manchester; University of Manchester	Dixon, MJ (corresponding author), Univ Manchester, Fac Life Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.	mike.dixon@manchester.ac.uk	Hardman, Matthew/ABE-4936-2020; Richardson, Rebecca/L-5198-2019	Richardson, Rebecca/0000-0002-4701-8713; Hardman, Matthew/0000-0002-6423-5074; Shore, Paul/0000-0002-1832-5976; Whitmarsh, Alan/0000-0003-1184-6610; Boot-Handford, Raymond/0000-0002-6167-8419	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016215] Funding Source: NIH RePORTER; MRC [G0400264] Funding Source: UKRI; Medical Research Council [G0400264] Funding Source: Medline; NIDCR NIH HHS [P50-DE016215] Funding Source: Medline; Wellcome Trust [066173, 064732] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Wellcome Trust(Wellcome Trust)		Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Dixon J, 2006, P NATL ACAD SCI USA, V103, P13403, DOI 10.1073/pnas.0603730103; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; Fuchs E, 2002, NAT REV GENET, V3, P199, DOI 10.1038/nrg758; Ghassibe M, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.009274; GUENET JL, 1979, J HERED, V70, P90, DOI 10.1093/oxfordjournals.jhered.a109223; Hardman MJ, 1998, DEVELOPMENT, V125, P1541; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Herron BJ, 2005, NAT GENET, V37, P1210, DOI 10.1038/ng1652; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; INGRAHAM CR, 2006, ABNORMAL SKIN LIMB C, DOI DOI 10.1038/NG1903; Inman CK, 2005, MOL CELL BIOL, V25, P3182, DOI 10.1128/MCB.25.8.3182-3193.2005; Kondo S, 2002, NAT GENET, V32, P285, DOI 10.1038/ng985; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Lees MM, 1999, J MED GENET, V36, P888; Li QT, 2005, P NATL ACAD SCI USA, V102, P15977, DOI 10.1073/pnas.0508310102; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; WALLIN J, 1994, DEVELOPMENT, V120, P1109; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	28	232	240	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	NOV	2006	38	11					1329	1334		10.1038/ng1894	http://dx.doi.org/10.1038/ng1894			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	099KH	17041603				2022-12-25	WOS:000241592700023
J	Denoyelle, C; Abou-Rjaily, G; Bezrookove, V; Verhaegen, M; Johnson, TM; Fullen, DR; Pointer, JN; Gruber, SB; Su, LD; Nikiforov, MA; Kaufman, RJ; Bastian, BC; Soengas, MS				Denoyelle, Christophe; Abou-Rjaily, George; Bezrookove, Vladimir; Verhaegen, Monique; Johnson, Timothy M.; Fullen, Douglas R.; Pointer, Jenny N.; Gruber, Stephen B.; Su, Lyndon D.; Nikiforov, Mikhail A.; Kaufman, Randal J.; Bastian, Boris C.; Soengas, Maria S.			Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway	NATURE CELL BIOLOGY			English	Article							UNFOLDED PROTEIN RESPONSE; CELL-CYCLE ARREST; INDUCED SENESCENCE; TUMOR SUPPRESSION; MELANOCYTIC LESIONS; HUMAN FIBROBLASTS; STRESS INDUCTION; MAMMALIAN-CELLS; SPITZ NEVI; BRAF GENE	Dysfunction of the endoplasmic reticulum (ER) has been reported in a variety of human pathologies, including cancer. However, the contribution of the ER to the early stages of normal cell transformation is largely unknown. Using primary human melanocytes and biopsies of human naevi (moles), we show that the extent of ER stress induced by cellular oncogenes may define the mechanism of activation of premature senescence. Specifically, we found that oncogenic forms of HRAS (HRAS(G12V)) but not its downstream target BRAF (BRAF(V600E)), engaged a rapid cell-cycle arrest that was associated with massive vacuolization and expansion of the ER. However, neither p53, p16(INK4a) nor classical senescence markers - such as foci of heterochromatin or DNA damage - were able to account for the specific response of melanocytes to HRAS(G12V). Instead, HRAS(G12V)-driven senescence was mediated by the ER-associated unfolded protein response (UPR). The impact of HRAS on the UPR was selective, as it was poorly induced by activated NRAS (more frequently mutated in melanoma than HRAS). These results argue against premature senescence as a converging mechanism of response to activating oncogenes and support a direct role of the ER as a gatekeeper of tumour control.	Univ Michigan, Dept Dermatol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet & Epidemiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Soengas, MS (corresponding author), Univ Michigan, Dept Dermatol, 1500E Med Ctr Dr,4217 CCGC, Ann Arbor, MI 48109 USA.	soengas@umich.edu	Soengas, Maria S/H-6455-2015; DENOYELLE, Christophe CD/K-6205-2015	Soengas, Maria S/0000-0003-0612-6299; DENOYELLE, Christophe CD/0000-0001-7153-8826; Poynter, Jenny/0000-0002-8460-3938; Bastian, Boris/0000-0003-1836-6062	NCI NIH HHS [CA107237, R33 CA95300, U01CA83180] Funding Source: Medline; NIAID NIH HHS [AI12243] Funding Source: Medline; NIDDK NIH HHS [DK42394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R33CA095300, U01CA083180, R01CA107237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042394, R37DK042394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Back SH, 2006, J BIOL CHEM, V281, P18691, DOI 10.1074/jbc.M602030200; Barnhill RL, 1999, HUM PATHOL, V30, P513, DOI 10.1016/S0046-8177(99)90193-4; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bauer Jurgen, 2005, Adv Dermatol, V21, P81, DOI 10.1016/j.yadr.2005.04.002; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, CELL CYCLE, V4, P1722, DOI 10.4161/cc.4.12.2260; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Federovitch CM, 2005, CURR OPIN CELL BIOL, V17, P409, DOI 10.1016/j.ceb.2005.06.010; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Hamanaka RB, 2005, MOL BIOL CELL, V16, P5493, DOI 10.1091/mbc.E05-03-0268; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Li WQ, 2004, J BIOL CHEM, V279, P37398, DOI 10.1074/jbc.M405730200; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505; Maldonado JL, 2004, AM J PATHOL, V164, P1783, DOI 10.1016/S0002-9440(10)63736-4; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Narita M, 2005, NAT MED, V11, P920, DOI 10.1038/nm0905-920; Papp T, 1999, J MED GENET, V36, P610; Philips MR, 2005, BIOCHEM SOC T, V33, P657, DOI 10.1042/BST0330657; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Ron D, 2004, J CELL BIOL, V167, P23, DOI 10.1083/jcb.200408117; Saldanha G, 2004, INT J CANCER, V111, P705, DOI 10.1002/ijc.20325; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sriburi R, 2004, J CELL BIOL, V167, P35, DOI 10.1083/jcb.200406136; Strungs I, 2004, PATHOLOGY, V36, P396, DOI 10.1080/00313020412331283888; te Poele RH, 2002, CANCER RES, V62, P1876; Turner DJ, 2005, J CUTAN PATHOL, V32, P334, DOI 10.1111/j.0303-6987.2005.00338.x; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Wang Y, 2000, J BIOL CHEM, V275, P27013; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x	56	258	264	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1053	U24		10.1038/ncb1471	http://dx.doi.org/10.1038/ncb1471			18	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16964246				2022-12-25	WOS:000241395300009
J	Krause, DS; Lazarides, K; von Andrian, UH; Van Etten, RA				Krause, Daniela S.; Lazarides, Katherine; von Andrian, Ulrich H.; Van Etten, Richard A.			Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells	NATURE MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; BONE-MARROW; HEMATOPOIETIC PROGENITORS; ADHESION MOLECULES; SELECTIN LIGAND; MICE; BCR/ABL; TRANSPLANTATION; PROLIFERATION; INHIBITION	In individuals with chronic myeloid leukemia (CML) treated by autologous hematopoietic stem cell (HSC) transplantation, malignant progenitors in the graft contribute to leukemic relapse(1), but the mechanisms of homing and engraftment of leukemic CML stem cells are unknown. Here we show that CD44 expression is increased on mouse stem-progenitor cells expressing BCR-ABL and that CD44 contributes functional E-selectin ligands. In a mouse retroviral transplantation model of CML, BCR-ABL1-transduced progenitors from CD44-mutant donors are defective in homing to recipient marrow, resulting in decreased engraftment and impaired induction of CML-like myeloproliferative disease. By contrast, CD44-deficient stem cells transduced with empty retrovirus engraft as efficiently as do wild-type HSCs. CD44 is dispensable for induction of acute B-lymphoblastic leukemia by BCR-ABL, indicating that CD44 is specifically required on leukemic cells that initiate CML. The requirement for donor CD44 is bypassed by direct intrafemoral injection of BCR-ABL1-transduced CD44-deficient stem cells or by coexpression of human CD44. Antibody to CD44 attenuates induction of CML-like leukemia in recipients. These results show that BCR-ABL-expressing leukemic stem cells depend to a greater extent on CD44 for homing and engraftment than do normal HSCs, and argue that CD44 blockade may be beneficial in autologous transplantation in CML.	Tufts Univ New England Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA	Tufts Medical Center; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Van Etten, RA (corresponding author), Tufts Univ New England Med Ctr, Mol Oncol Res Inst, 750 Washington St, Boston, MA 02111 USA.	rvanetten@tufts-nemc.org	von Andrian, Ulrich H/A-5775-2008		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56949, P01 HL056949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; BARNETT MJ, 1994, BLOOD, V84, P724; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; DEISSEROTH AB, 1994, BLOOD, V83, P3068, DOI 10.1182/blood.V83.10.3068.3068; Dimitroff CJ, 2000, P NATL ACAD SCI USA, V97, P13841, DOI 10.1073/pnas.250484797; GHAFFARI S, 1995, BLOOD, V86, P2976; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Katayama Y, 2005, J EXP MED, V201, P1183, DOI 10.1084/jem.20042014; Khaldoyanidi S, 1996, J LEUKOCYTE BIOL, V60, P579, DOI 10.1002/jlb.60.5.579; Krause DS, 2005, BLOOD, V106, p206A; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; Luger SM, 2002, BLOOD, V99, P1150, DOI 10.1182/blood.V99.4.1150; Mazo IB, 1998, J EXP MED, V188, P465, DOI 10.1084/jem.188.3.465; Mazurier F, 2003, NAT MED, V9, P959, DOI 10.1038/nm886; Oostendorp RAJ, 2000, BONE MARROW TRANSPL, V26, P559, DOI 10.1038/sj.bmt.1702536; Papayannopoulou T, 2001, BLOOD, V98, P2403, DOI 10.1182/blood.V98.8.2403; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Protin U, 1999, J IMMUNOL, V163, P4917; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; Salgia R, 1999, BLOOD, V94, P4233; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Verfaillie CM, 1996, BLOOD, V87, P4770, DOI 10.1182/blood.V87.11.4770.bloodjournal87114770; Vermeulen M, 1998, BLOOD, V92, P894, DOI 10.1182/blood.V92.3.894.415k22_894_900; Wang JCY, 2005, TRENDS CELL BIOL, V15, P494, DOI 10.1016/j.tcb.2005.07.004; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953	30	322	336	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1175	1180		10.1038/nm1489	http://dx.doi.org/10.1038/nm1489			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16998483	Green Published			2022-12-25	WOS:000241102200034
J	Yousefi, S; Perozzo, R; Schmid, I; Ziemiecki, A; Schaffner, T; Scapozza, L; Brunner, T; Simon, HU				Yousefi, Shida; Perozzo, Remo; Schmid, Ines; Ziemiecki, Andrew; Schaffner, Thomas; Scapozza, Leonardo; Brunner, Thomas; Simon, Hans-Uwe			Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis	NATURE CELL BIOLOGY			English	Article							CYTOCHROME-C RELEASE; CELL-DEATH; EMBRYONIC-DEVELOPMENT; NEUTROPHIL APOPTOSIS; TUMOR-SUPPRESSOR; PROTEIN; GENE; P53; MITOCHONDRIA; DISRUPTION	Autophagy-related gene (Atg) 5 is a gene product required for the formation of autophagosomes. Here, we report that Atg5, in addition to the promotion of autophagy, enhances susceptibility towards apoptotic stimuli. Enforced expression of Atg5-sensitized tumour cells to anticancer drug treatment both in vitro and in vivo. In contrast, silencing the Atg5 gene with short interfering RNA (siRNA) resulted in partial resistance to chemotherapy. Apoptosis was associated with calpain-mediated Atg5 cleavage, resulting in an amino-terminal cleavage product with a relative molecular mass of 24,000 (M-r 24K). Atg5 cleavage was observed independent of the cell type and the apoptotic stimulus, suggesting that calpain activation and Atg5 cleavage are general phenomena in apoptotic cells. Truncated Atg5 translocated from the cytosol to mitochondria, associated with the anti-apoptotic molecule Bwcl-x(L) and triggered cytochrome c release and caspase activation. Taken together, calpain-mediated Atg5 cleavage provokes apoptotic cell death, therefore, represents a molecular link between autophagy and apoptosis - a finding with potential importance for clinical anticancer therapies.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Geneva, Sch Pharmaceut Sci, EPGL, Pharmaceut Biochem Grp, CH-1211 Geneva 4, Switzerland; Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; Univ Bern, Dept Pathol, CH-3010 Bern, Switzerland	University of Bern; University of Geneva; University of Bern; University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Simon, Hans-Uwe/AAU-5079-2020; Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-7410-2020; Yousefi, Shida/AAU-7986-2020	Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736; Yousefi, Shida/0000-0002-9855-4305; Scapozza, Leonardo/0000-0003-1079-648X				Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Altznauer F, 2004, J BIOL CHEM, V279, P5947, DOI 10.1074/jbc.M308576200; Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Bovia F, 2003, BLOOD, V101, P1727, DOI 10.1182/blood-2001-12-0249; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Gao G, 2000, J CELL BIOCHEM, V80, P53; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Martinelli S, 2004, J BIOL CHEM, V279, P44123, DOI 10.1074/jbc.M405883200; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Simon HU, 2000, J IMMUNOL, V165, P4069, DOI 10.4049/jimmunol.165.7.4069; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Takeuchi H, 2004, BRIT J CANCER, V90, P1069, DOI 10.1038/sj.bjc.6601605; Uren RT, 2005, J BIOL CHEM, V280, P2266, DOI 10.1074/jbc.M411106200; von Gunten S, 2005, BLOOD, V106, P1423, DOI 10.1182/blood-2004-10-4112; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	35	1009	1055	5	148	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1124	U146		10.1038/ncb1482	http://dx.doi.org/10.1038/ncb1482			21	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16998475	Green Submitted			2022-12-25	WOS:000241395300017
J	Shi, S; Calhoun, HC; Xia, F; Li, JH; Le, L; Li, WX				Shi, Song; Calhoun, Healani C.; Xia, Fan; Li, Jinghong; Le, Long; Li, Willis X.			JAK signaling globally counteracts heterochromatic gene silencing	NATURE GENETICS			English	Article							HEMATOPOIETIC ONCOGENE; JAK/STAT PATHWAY; DROSOPHILA; GENOME; ACTIVATION; COMPONENTS; KINASE; CANCER; STATS; IDENTIFICATION	The JAK/STAT pathway has pleiotropic roles in animal development, and its aberrant activation is implicated in multiple human cancers(1-3). JAK/ STAT signaling effects have been attributed largely to direct transcriptional regulation by STAT of specific target genes that promote tumor cell proliferation or survival. We show here in a Drosophila melanogaster hematopoietic tumor model, however, that JAK overactivation globally disrupts heterochromatic gene silencing, an epigenetic tumor suppressive mechanism(4). This disruption allows derepression of genes that are not direct targets of STAT, as evidenced by suppression of heterochromatin-mediated position effect variegation. Moreover, mutations in the genes encoding heterochromatin components heterochromatin protein 1 (HP1) and Su(var)3-9 enhance tumorigenesis induced by an oncogenic JAK kinase without affecting JAK/ STAT signaling. Consistently, JAK loss of function enhances heterochromatic gene silencing, whereas overexpressing HP1 suppresses oncogenic JAK-induced tumors. These results demonstrate that the JAK/ STAT pathway regulates cellular epigenetic status and that globally disrupting heterochromatin-mediated tumor suppression is essential for tumorigenesis induced by JAK overactivation.	Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA	University of Rochester	Li, WX (corresponding author), Univ Rochester, Med Ctr, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.	willis_li@urmc.rochester.edu	Li, Willis X/AAL-7212-2020; Li, Willis/ABC-5695-2020	Li, Willis X/0000-0001-9041-7341; Li, Willis/0000-0001-9041-7341; Li, Jinghong/0000-0003-2497-9295	NATIONAL CANCER INSTITUTE [R01CA131326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065774, R01GM077046] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA131326, R01 CA131326-01A2] Funding Source: Medline; NIGMS NIH HHS [R01GM077046, R01 GM077046-03, R01 GM065774-04, R01 GM065774, R01 GM077046, R01GM65774] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agaisse Herve, 2004, Immunol Rev, V198, P72, DOI 10.1111/j.0105-2896.2004.0133.x; Bach EA, 2003, GENETICS, V165, P1149; Badenhorst P, 2002, GENE DEV, V16, P3186, DOI 10.1101/gad.1032202; Baeg GH, 2005, GENE DEV, V19, P1861, DOI 10.1101/gad.1320705; Betz A, 2001, P NATL ACAD SCI USA, V98, P9563, DOI 10.1073/pnas.171302098; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; DORER DR, 1994, CELL, V77, P993, DOI 10.1016/0092-8674(94)90439-1; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Gilbert MM, 2005, MECH DEVELOP, V122, P939, DOI 10.1016/j.mod.2005.03.004; Grewal SIS, 2002, CURR OPIN GENET DEV, V12, P178, DOI 10.1016/S0959-437X(02)00284-8; Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; Hou SX, 2002, DEV CELL, V3, P765, DOI 10.1016/S1534-5807(02)00376-3; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Lebestky T, 2003, GENE DEV, V17, P348, DOI 10.1101/gad.1052803; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li JH, 2003, DEV CELL, V5, P787, DOI 10.1016/S1534-5807(03)00328-9; Li YH, 2003, DEVELOPMENT, V130, P1817, DOI 10.1242/dev.00405; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Muller P, 2005, NATURE, V436, P871, DOI 10.1038/nature03869; Ronsseray S, 2001, GENETICS, V159, P1631; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; ZINYK DL, 1993, NAT GENET, V4, P195, DOI 10.1038/ng0693-195	28	123	128	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	SEP	2006	38	9					1071	1076		10.1038/ng1860	http://dx.doi.org/10.1038/ng1860			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	078OC	16892059	Green Accepted			2022-12-25	WOS:000240112100027
J	Zakrzewski, JL; Kochman, AA; Lu, SX; Terwey, TH; Kim, TD; Hubbard, VM; Muriglan, SJ; Suh, D; Smith, OM; Grubin, J; Patel, N; Chow, A; Cabrera-Perez, J; Radhakrishnan, R; Diab, A; Perales, MA; Rizzuto, G; Menet, E; Pamer, EG; Heller, G; Zuniga-Pflucker, JC; Alpdogan, O; van den Brink, MRM				Zakrzewski, Johannes L.; Kochman, Adam A.; Lu, Sydney X.; Terwey, Theis H.; Kim, Theo D.; Hubbard, Vanessa M.; Muriglan, Stephanie J.; Suh, David; Smith, Odette M.; Grubin, Jeremy; Patel, Neel; Chow, Andrew; Cabrera-Perez, Javier; Radhakrishnan, Radhika; Diab, Adi; Perales, Miguel-Angel; Rizzuto, Gabrielle; Menet, Ewa; Pamer, Eric G.; Heller, Glen; Zuniga-Pflucker, Juan Carlos; Alpdogan, Onder; van den Brink, Marcel R. M.			Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation	NATURE MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; VERSUS-HOST-DISEASE; KERATINOCYTE GROWTH-FACTOR; DELTA-LIKE-1 IN-VITRO; NOTCH LIGAND DELTA1; IMMUNE RECONSTITUTION; LYMPHOID PROGENITORS; UNRELATED DONORS; THYMUS; LEUKEMIA	Immunoincompetence after allogeneic hematopoietic stem cell transplantation (HSCT) affects in particular the T-cell lineage and is associated with an increased risk for infections, graft failure and malignant relapse. To generate large numbers of T-cell precursors for adoptive therapy, we cultured mouse hematopoietic stem cells (HSCs) in vitro on OP9 mouse stromal cells expressing the Notch-1 ligand Delta-like-1 (OP9-DL1). We infused these cells, together with T-cell-depleted mouse bone marrow or purified HSCs, into lethally irradiated allogeneic recipients and determined their effect on T-cell reconstitution after transplantation. Recipients of OP9-DL1-derived T-cell precursors showed increased thymic cellularity and substantially improved donor T-cell chimerism (versus recipients of bone marrow or HSCs only). OP9-DL1-derived T-cell precursors gave rise to host-tolerant CD4(+) and CD8(+) populations with normal T-cell antigen receptor repertoires, cytokine secretion and proliferative responses to antigen. Administration of OP9-DL1-derived T-cell precursors increased resistance to infection with Listeria monocytogenes and mediated significant graft-versustumor (GVT) activity but not graft-versus-host disease (GVHD). We conclude that the adoptive transfer of OP9-DL1-derived T-cell precursors markedly enhances T-cell reconstitution after transplantation, resulting in GVT activity without GVHD.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Immunol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA; Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Immunol, Toronto, ON M4N 3M5, Canada	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	van den Brink, MRM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Zuckerman Res Ctr 1404,Mailbox 111, New York, NY 10021 USA.	m-van-den-brink@ski.mskcc.org	Rizzuto, Gabrielle/GWR-2224-2022; Zuniga-Pflucker, Juan C/H-1295-2012; van den Brink, Marcel R. M./HGB-9434-2022	Lu, Sydney/0000-0002-2217-1674; Chow, Andrew/0000-0003-1151-2450; PERALES, MIGUEL-ANGEL/0000-0002-5910-4571; Rizzuto, Gabrielle/0000-0003-3052-0253; Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178	NCI NIH HHS [CA33049, P20-CA103694, CA107096, P30 CA008748] Funding Source: Medline; NHLBI NIH HHS [HL69929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P20CA103694, R01CA107096, P01CA033049, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alpdogan O, 2006, BLOOD, V107, P2453, DOI 10.1182/blood-2005-07-2831; Arber C, 2003, BLOOD, V102, P421, DOI 10.1182/blood-2002-12-3834; Balciunaite G, 2005, EUR J IMMUNOL, V35, P1292, DOI 10.1002/eji.200425822; BitMansour A, 2002, BLOOD, V100, P4660, DOI 10.1182/blood-2002-05-1552; Chen BJ, 2004, BLOOD, V103, P4344, DOI 10.1182/blood-2003-07-2534; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Dallas MH, 2005, J EXP MED, V201, P1361, DOI 10.1084/jem.20042450; Danilenko DM, 1999, TOXICOL PATHOL, V27, P64, DOI 10.1177/019262339902700113; DANILENKO DM, 1996, FASEB J, V10, P1148; De Smedt M, 2004, BLOOD CELL MOL DIS, V33, P227, DOI 10.1016/j.bcmd.2004.08.007; Delaney C, 2005, BLOOD, V106, P2693, DOI 10.1182/blood-2005-03-1131; Foss DL, 2001, J EXP MED, V193, P365, DOI 10.1084/jem.193.3.365; Guy-Grand D, 2003, J EXP MED, V197, P333, DOI 10.1084/jem.20021639; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; Harman BC, 2003, SEMIN IMMUNOL, V15, P91, DOI 10.1016/S1044-5323(03)00005-8; Hongeng S, 1997, LANCET, V350, P767, DOI 10.1016/S0140-6736(97)03098-5; Huang JX, 2005, J IMMUNOL, V175, P4858, DOI 10.4049/jimmunol.175.8.4858; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; KEEVER CA, 1989, BLOOD, V73, P1340; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; La Motte-Mohs RN, 2005, BLOOD, V105, P1431, DOI 10.1182/blood-2004-04-1293; Lambolez F, 2006, NAT IMMUNOL, V7, P76, DOI 10.1038/ni1293; Min DL, 2002, BLOOD, V99, P4592, DOI 10.1182/blood.V99.12.4592; OCHS L, 1995, BLOOD, V86, P3979, DOI 10.1182/blood.V86.10.3979.bloodjournal86103979; PERALES MA, IN PRESS J IMMUNOL; Petrovic A, 2004, BLOOD, V103, P1542, DOI 10.1182/blood-2003-03-0957; Porter DL, 1999, ANNU REV MED, V50, P369; Prockop SE, 2004, J IMMUNOL, V173, P1604, DOI 10.4049/jimmunol.173.3.1604; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; Rossi S, 2002, BLOOD, V100, P682, DOI 10.1182/blood.V100.2.682; Schmaltz C, 2001, BLOOD, V97, P2886, DOI 10.1182/blood.V97.9.2886; Schmitt TM, 2004, NAT IMMUNOL, V5, P410, DOI 10.1038/ni1055; Schmitt TM, 2004, J EXP MED, V200, P469, DOI 10.1084/jem.20040394; Schmitt TM, 2002, IMMUNITY, V17, P749, DOI 10.1016/S1074-7613(02)00474-0; Small TN, 1999, BLOOD, V93, P467, DOI 10.1182/blood.V93.2.467.402k22_467_480; STOREK J, 1995, BONE MARROW TRANSPL, V16, P413; Terszowski G, 2006, SCIENCE, V312, P284, DOI 10.1126/science.1123497; Terwey TH, 2005, BLOOD, V106, P3322, DOI 10.1182/blood-2005-05-1860; van den Brink MRM, 2004, NAT REV IMMUNOL, V4, P856, DOI 10.1038/nri1484; Yang YG, 2002, BLOOD, V99, P4207, DOI 10.1182/blood.V99.11.4207; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	41	137	148	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1039	1047		10.1038/nm1463	http://dx.doi.org/10.1038/nm1463			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16936725				2022-12-25	WOS:000240373900028
J	Manning, K; Tor, M; Poole, M; Hong, Y; Thompson, AJ; King, GJ; Giovannoni, JJ; Seymour, GB				Manning, Kenneth; Tor, Mahmut; Poole, Mervin; Hong, Yiguo; Thompson, Andrew J.; King, Graham J.; Giovannoni, James J.; Seymour, Graham B.			A naturally occurring epigenetic mutation in a gene encoding an SBP-box transcription factor inhibits tomato fruit ripening	NATURE GENETICS			English	Article							DNA METHYLATION; ARABIDOPSIS; CNR; INHERITANCE	A major component in the regulatory network controlling fruit ripening is likely to be the gene at the tomato Colorless nonripening (Cnr) locus(1,2). The Cnr mutation results in colorless fruits with a substantial loss of cell-to-cell adhesion. The nature of the mutation and the identity of the Cnr gene were previously unknown. Using positional cloning and virus-induced gene silencing, here we demonstrate that an SBP-box (SQUAMOSA promoter binding protein-like) gene resides at the Cnr locus. Furthermore, the Cnr phenotype results from a spontaneous epigenetic change in the SBP-box promoter. The discovery that Cnr is an epimutation was unexpected, as very few spontaneous epimutations have been described in plants(3,4). This study demonstrates that an SBP-box gene is critical for normal ripening and highlights the likely importance of epialleles in plant development and the generation of natural variation.	Univ Nottingham, Sch Biosci, Plant Sci Div, Loughborough LE12 5RD, Leics, England; Univ Warwick, Warwick Hort Res Int, Warwick CV35 9EF, England; Rothamsted Res, Harpenden AL5 2JQ, Herts, England; Cornell Univ, Boyce Thompson Inst Plant Sci Res, Ithaca, NY 14853 USA; USDA ARS, Ithaca, NY 14853 USA	University of Nottingham; University of Warwick; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Cornell University; Boyce Thompson Institute for Plant Research; United States Department of Agriculture (USDA)	Seymour, GB (corresponding author), Univ Nottingham, Sch Biosci, Plant Sci Div, Sutton Bonington Campus, Loughborough LE12 5RD, Leics, England.	Graham.Seymour@nottingham.ac.uk	Thompson, Andrew J./AAF-3017-2020; Seymour, Graham B/N-4539-2014; Poole, Mervin C/A-5639-2009; Tor, Mahmut/AAF-6449-2020; King, Graham J/AAW-3368-2020; Tor, Mahmut/AAU-4624-2020; tor, mahmut/C-1132-2009; Hong, Yiguo/AAI-2303-2020	Thompson, Andrew J./0000-0002-7419-3402; Poole, Mervin C/0000-0001-8624-5022; Tor, Mahmut/0000-0002-4416-5048; King, Graham J/0000-0002-5975-6051; Seymour, Graham/0000-0001-8365-4947	Biotechnology and Biological Sciences Research Council [D20300/2, D20300] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alexander L, 2002, J EXP BOT, V53, P2039, DOI 10.1093/jxb/erf072; Cardon GH, 1997, PLANT J, V12, P367, DOI 10.1046/j.1365-313X.1997.12020367.x; Chang S. J., 1993, Plant Molecular Biology Reporter, V11, P113, DOI 10.1007/BF02670468; Cubas P, 1999, NATURE, V401, P157, DOI 10.1038/43657; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Eriksson EM, 2004, PLANT PHYSIOL, V136, P4184, DOI 10.1104/pp.104.045765; Fraser PD, 2001, PHYTOCHEMISTRY, V58, P75, DOI 10.1016/S0031-9422(01)00175-3; Giovannoni JJ, 2004, PLANT CELL, V16, pS170, DOI 10.1105/tpc.019158; Jacobsen SE, 1997, SCIENCE, V277, P1100, DOI 10.1126/science.277.5329.1100; Kalisz S, 2004, TRENDS ECOL EVOL, V19, P309, DOI 10.1016/j.tree.2004.03.034; Kinoshita T, 2004, SCIENCE, V303, P521, DOI 10.1126/science.1089835; Klein J, 1996, MOL GEN GENET, V250, P7, DOI 10.1007/s004380050046; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liljegren SJ, 2004, CELL, V116, P843, DOI 10.1016/S0092-8674(04)00217-X; Lindroth AM, 2001, SCIENCE, V292, P2077, DOI 10.1126/science.1059745; Martienssen RA, 2001, SCIENCE, V293, P1070, DOI 10.1126/science.293.5532.1070; MESSEGUER R, 1991, PLANT MOL BIOL, V16, P753, DOI 10.1007/BF00015069; Orfila C, 2002, PLANTA, V215, P440, DOI 10.1007/s00425-002-0753-1; Orfila C, 2001, PLANT PHYSIOL, V126, P210, DOI 10.1104/pp.126.1.210; Rapp RA, 2005, NEW PHYTOL, V168, P81, DOI 10.1111/j.1469-8137.2005.01491.x; Stone JM, 2005, PLANT J, V41, P744, DOI 10.1111/j.1365-313X.2005.02334.x; TANKSLEY SD, 1992, GENETICS, V132, P1141; Thompson AJ, 1999, PLANT PHYSIOL, V120, P383, DOI 10.1104/pp.120.2.383; Tor M, 2002, THEOR APPL GENET, V104, P165, DOI 10.1007/s001220100760; Unte US, 2003, PLANT CELL, V15, P1009, DOI 10.1105/tpc.010678; van Wezel R, 2001, MOL PLANT MICROBE IN, V14, P1125, DOI 10.1094/MPMI.2001.14.9.1125; Vrebalov J, 2002, SCIENCE, V296, P343, DOI 10.1126/science.1068181; Wang H, 2005, NATURE, V436, P714, DOI 10.1038/nature03863; Zhang Z, 2000, GENE, V253, P145, DOI 10.1016/S0378-1119(00)00289-4; Zou NX, 2003, BIOTECHNIQUES, V35, P758, DOI 10.2144/03354st06	30	850	943	19	252	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2006	38	8					948	952		10.1038/ng1841	http://dx.doi.org/10.1038/ng1841			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16832354				2022-12-25	WOS:000239325700027
J	Clop, A; Marcq, F; Takeda, H; Pirottin, D; Tordoir, X; Bibe, B; Bouix, J; Caiment, F; Elsen, JM; Eychenne, F; Larzul, C; Laville, E; Meish, F; Milenkovic, D; Tobin, J; Charlier, C; Georges, M				Clop, Alex; Marcq, Fabienne; Takeda, Haruko; Pirottin, Dimitri; Tordoir, Xavier; Bibe, Bernard; Bouix, Jacques; Caiment, Florian; Elsen, Jean-Michel; Eychenne, Francis; Larzul, Catherine; Laville, Elisabeth; Meish, Francoise; Milenkovic, Dragan; Tobin, James; Charlier, Carole; Georges, Michel			A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep	NATURE GENETICS			English	Article							QUANTITATIVE TRAIT LOCI; MUSCLE HYPERTROPHY; TEXEL SHEEP; SERUM; MASS	Texel sheep are renowned for their exceptional meatiness. To identify the genes underlying this economically important feature, we performed a whole-genome scan in a Romanov x Texel F2 population. We mapped a quantitative trait locus with a major effect on muscle mass to chromosome 2 and subsequently fine-mapped it to a chromosome interval encompassing the myostatin (GDF8) gene. We herein demonstrate that the GDF8 allele of Texel sheep is characterized by a G to A transition in the 3' UTR that creates a target site for mir1 and mir206, microRNAs (miRNAs) that are highly expressed in skeletal muscle. This causes translational inhibition of the myostatin gene and hence contributes to the muscular hypertrophy of Texel sheep. Analysis of SNP databases for humans and mice demonstrates that mutations creating or destroying putative miRNA target sites are abundant and might be important effectors of phenotypic variation.	Univ Liege, Fac Vet Med, Dept Anim Prod, Unit Anim Genom, B-4000 Liege, Belgium; Univ Liege, Ctr Biomed Integrat Genoprote, B-4000 Liege, Belgium; INRA, SAGA, Stn Ameliorat Genet Anim, F-31326 Castanet Tolosan, France; INRA, Rech Viande Stn, F-63122 St Genes Champanelle, France; Univ Limoges, Fac Sci, INRA, F-87060 Limoges, France; Wyeth Ayerst Res, Cardiovasc & Metab Dis, Cambridge, MA 02140 USA	University of Liege; University of Liege; INRAE; INRAE; INRAE; Universite de Limoges; Pfizer	Georges, M (corresponding author), Univ Liege, Fac Vet Med, Dept Anim Prod, Unit Anim Genom, B43,20 Blvd Colonster, B-4000 Liege, Belgium.	michel.georges@ulg.ac.be	Larzul, Catherine/AAN-6884-2021; Clop, Alex/D-1519-2009; Larzul, Catherine/AAX-8677-2020; caiment, florian/N-7623-2015; Clop, Alex/AAH-9231-2021	Clop, Alex/0000-0001-9238-2728; Larzul, Catherine/0000-0002-0533-331X; Clop, Alex/0000-0001-9238-2728; Caiment, Florian/0000-0002-3325-0466; Georges, Michel/0000-0003-4124-2375; Milenkovic, Dragan/0000-0001-6353-0912; Charlier, Carole/0000-0002-9694-094X				Abelson JF, 2005, SCIENCE, V310, P317, DOI 10.1126/science.1116502; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Davis E, 2005, CURR BIOL, V15, P743, DOI 10.1016/j.cub.2005.02.060; HALEY CS, 1994, GENETICS, V136, P1195; Hill JJ, 2002, J BIOL CHEM, V277, P40735, DOI 10.1074/jbc.M206379200; HOFACKER IL, 1994, MONATSH CHEM, V125, P167, DOI 10.1007/BF00818163; Johnson PL, 2005, J ANIM SCI, V83, P1988; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; Laville E, 2004, J ANIM SCI, V82, P3128; Lee SJ, 1999, CURR OPIN GENET DEV, V9, P604, DOI 10.1016/S0959-437X(99)00004-0; MARCQ F, 2002, P 7 WORLD C GEN APPL, P323; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Seaton G, 2002, BIOINFORMATICS, V18, P339, DOI 10.1093/bioinformatics/18.2.339; TERWILLIGER JD, 1995, AM J HUM GENET, V56, P777; Tobin JF, 2005, CURR OPIN PHARMACOL, V5, P328, DOI 10.1016/j.coph.2005.01.011; Ueijma H, 2000, NAT GENET, V25, P375, DOI 10.1038/78040; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	20	946	1054	0	114	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					813	818		10.1038/ng1810	http://dx.doi.org/10.1038/ng1810			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16751773				2022-12-25	WOS:000238669300018
J	Kirkpatrick, DS; Hathaway, NA; Hanna, J; Elsasser, S; Rush, J; Finley, D; King, RW; Gygi, SP				Kirkpatrick, Donald S.; Hathaway, Nathaniel A.; Hanna, John; Elsasser, Suzanne; Rush, John; Finley, Daniel; King, Randall W.; Gygi, Steven P.			Quantitative analysis of in vitro ubiquitinated cyclin B1 reveals complex chain topology	NATURE CELL BIOLOGY			English	Article							ANAPHASE-PROMOTING COMPLEX; POLYUBIQUITIN CHAINS; MULTIUBIQUITIN CHAIN; DNA-REPAIR; CONJUGATING ENZYMES; MITOTIC CYCLIN; 26S PROTEASOME; PROTEIN; DEGRADATION; PROTEOLYSIS	Protein ubiquitination regulates many cellular processes, including protein degradation, signal transduction, DNA repair and cell division. In the classical model, a uniform polyubiquitin chain that is linked through Lys 48 is required for recognition and degradation by the 26S proteasome. Here, we used a reconstituted system and quantitative mass spectrometry to demonstrate that cyclin B1 is modified by ubiquitin chains of complex topology, rather than by homogeneous Lys 48-linked chains. The anaphase-promoting complex was found to attach monoubiquitin to multiple lysine residues on cyclin B1, followed by polyubiquitin chain extensions linked through multiple lysine residues of ubiquitin ( Lys 63, Lys 11 and Lys 48). These heterogeneous ubiquitin chains were sufficient for binding to ubiquitin receptors, as well as for degradation by the 26S proteasome, even when they were synthesized with mutant ubiquitin that lacked Lys 48. Together, our observations expand the context of what can be considered to be a sufficient degradation signal and provide unique insights into the mechanisms of substrate ubiquitination.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Cell Signaling Technol Inc, Beverly, MA 01915 USA; Harvard Univ, Sch Med, Taplin Biol Mass Spectrometry Facil, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	King, RW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	randy_king@hms.harvard.edu; steven_gygi@hms.harvard.edu		Kirkpatrick, Donald/0000-0003-3091-2804; King, Randall/0000-0001-7882-8180	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066492, R01GM065592, R01GM067945, R56GM066492] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG3456] Funding Source: Medline; NIGMS NIH HHS [GM66492, GM67945, GM065592] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Carroll CW, 2002, NAT CELL BIOL, V4, P880, DOI 10.1038/ncb871; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Flick K, 2004, NAT CELL BIOL, V6, P634, DOI 10.1038/ncb1143; Flick K, 2006, NAT CELL BIOL, V8, P509, DOI 10.1038/ncb1402; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Guterman A, 2004, J BIOL CHEM, V279, P1729, DOI 10.1074/jbc.M307050200; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kirkpatrick DS, 2005, NAT CELL BIOL, V7, P750, DOI 10.1038/ncb0805-750; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Mastrandrea LD, 1999, J BIOL CHEM, V274, P27299, DOI 10.1074/jbc.274.38.27299; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Passmore LA, 2005, MOL CELL, V20, P855, DOI 10.1016/j.molcel.2005.11.003; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Rape M, 2006, CELL, V124, P89, DOI 10.1016/j.cell.2005.10.032; Rape M, 2004, NATURE, V432, P588, DOI 10.1038/nature03023; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Seino H, 2003, MOL CELL BIOL, V23, P3497, DOI 10.1128/MCB.23.10.3497-3505.2003; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Townsley FM, 1998, YEAST, V14, P747, DOI 10.1002/(SICI)1097-0061(19980615)14:8<747::AID-YEA271>3.0.CO;2-T; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4	40	333	350	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					700	U121		10.1038/ncb1436	http://dx.doi.org/10.1038/ncb1436			27	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16799550				2022-12-25	WOS:000238837800012
J	Rollmann, SM; Magwire, MM; Morgan, TJ; Ozsoy, ED; Yamamoto, A; Mackay, TFC; Anholt, RRH				Rollmann, Stephanie M.; Magwire, Michael M.; Morgan, Theodore J.; Ozsoy, Ergi D.; Yamamoto, Akihiko; Mackay, Trudy F. C.; Anholt, Robert R. H.			Pleiotropic fitness effects of the Tre1-Gr5a region in Drosophila melanogaster	NATURE GENETICS			English	Article							LIFE-SPAN; GENETIC ARCHITECTURE; RECEPTOR; INSULIN; LONGEVITY; TREHALOSE; SENSITIVITY; EVOLUTION; HOMOLOG; MUTANT	The abundance of transposable elements and DNA repeat sequences in mammalian genomes raises the question of whether such insertions represent passive evolutionary baggage or may influence the expression of complex traits. We addressed this question in Drosophila melanogaster, in which the effects of single transposable elements on complex traits can be assessed in genetically identical individuals reared in controlled environments(1). Here we demonstrate that single P-element insertions in the intergenic region between the gustatory receptor 5a (Gr5a, also known as Tre)(2-4) and trapped in endoderm 1 (Tre1)(5), which encodes an orphan receptor, exert complex pleiotropic effects on fitness traits, including selective nutrient intake, life span, and resistance to starvation and heat stress. Mutations in this region interact epistatically with downstream components of the insulin signaling pathway. Transposon-induced sex-specific and sex-antagonistic effects further accentuate the complex influences that intergenic transposable elements can contribute to quantitative trait phenotypes.	N Carolina State Univ, Dept Zool, Raleigh, NC 27695 USA; N Carolina State Univ, WM Keck Ctr Behav Biol, Raleigh, NC 27695 USA; N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA; Hacettepe Univ, Dept Biol, TR-06800 Beytepe, Turkey	University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University; Hacettepe University	Anholt, RRH (corresponding author), N Carolina State Univ, Dept Zool, Raleigh, NC 27695 USA.	anholt@ncsu.edu	Anholt, Robert/S-5977-2019	Morgan, Theodore/0000-0003-4535-2061				Alcedo J, 2004, NEURON, V41, P45, DOI 10.1016/S0896-6273(03)00816-X; Andolfatto P, 2005, NATURE, V437, P1149, DOI 10.1038/nature04107; Anholt RRH, 2003, NAT GENET, V35, P180, DOI 10.1038/ng1240; Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427; Carroll SB, 2005, PLOS BIOL, V3, P1159, DOI 10.1371/journal.pbio.0030245; *CHIMP SEQ AN CONS, 2005, NATURE, V1, P69; Chyb S, 2003, P NATL ACAD SCI USA, V100, P14526, DOI 10.1073/pnas.2135339100; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Dahanukar A, 2001, NAT NEUROSCI, V4, P1182, DOI 10.1038/nn765; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Harbison ST, 2004, GENETICS, V166, P1807, DOI 10.1534/genetics.166.4.1807; Holzenberger M, 2004, EXP GERONTOL, V39, P1761, DOI 10.1016/j.exger.2004.08.017; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Kunwar PS, 2003, PLOS BIOL, V1, P372, DOI 10.1371/journal.pbio.0000080; LARSEN PL, 1995, GENETICS, V139, P1567; Liang HY, 2003, EXP GERONTOL, V38, P1353, DOI 10.1016/j.exger.2003.10.019; Lukacsovich T, 2001, GENETICS, V157, P727; Mackay TFC, 2001, ANNU REV GENET, V35, P303, DOI 10.1146/annurev.genet.35.102401.090633; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Partridge L, 2005, CELL, V120, P461, DOI 10.1016/j.cell.2005.01.026; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; TANIMURA T, 1982, J COMP PHYSIOL, V147, P433, DOI 10.1007/BF00612007; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Ueno K, 2001, CURR BIOL, V11, P1451, DOI 10.1016/S0960-9822(01)00450-X	27	26	26	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					824	829		10.1038/ng1823	http://dx.doi.org/10.1038/ng1823			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16783380				2022-12-25	WOS:000238669300020
J	Zubko, MK; Lydall, D				Zubko, Mikhajlo K.; Lydall, David			Linear chromosome maintenance in the absence of essential telomere-capping proteins	NATURE CELL BIOLOGY			English	Article							SINGLE-STRANDED-DNA; SACCHAROMYCES-CEREVISIAE; END-PROTECTION; BUDDING YEAST; BINDING PROTEIN; CDC13; CHECKPOINT; MUTANTS; DAMAGE; EXO1	Telomeres were defined by their ability to cap chromosome ends(1,2). Proteins with high affinity for the structure at chromosome ends, binding the G-rich, 3' single-stranded overhang at telomeres include Pot1 in humans and fission yeast, TEBP in Oxytricha nova and Cdc13 in budding yeast(3-5). Cdc13 is considered essential for telomere capping because budding yeast that lack Cdc13 rapidly accumulate excessive single-stranded DNA ( ssDNA) at telomeres, arrest cell division and die(6-8). Cdc13 has a separate, critical role in telomerase recruitment to telomeres(9,10). Here, we show that neither Cdc13 nor its partner Stn1 are necessary for telomere capping if nuclease activities that are active at uncapped telomeres are attenuated. Recombination-dependent and -independent mechanisms permit maintenance of chromosomes without Cdc13. Our results indicate that the structure of the eukaryotic telomere cap is remarkably flexible and that changes in the DNA damage response allow alternative strategies for telomere capping to evolve.	Univ Newcastle Upon Tyne, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Newcastle Upon Tyne, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Newcastle Upon Tyne, Ctr Integrated Syst Biol Ageing & Nutr, Henry Wellcome Lab Biogerontol Res, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Lydall, D (corresponding author), Univ Newcastle Upon Tyne, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	d.a.lydall@ncl.ac.uk			Wellcome Trust [075294, 054371] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abad JP, 2004, MOL BIOL EVOL, V21, P1613, DOI 10.1093/molbev/msh174; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bertuch AA, 2004, GENETICS, V166, P1651, DOI 10.1534/genetics.166.4.1651; di Fagagna FD, 2004, GENE DEV, V18, P1781, DOI 10.1101/gad.1214504; Downey M, 2006, CELL, V124, P1155, DOI 10.1016/j.cell.2005.12.044; Evans SK, 1999, SCIENCE, V286, P117, DOI 10.1126/science.286.5437.117; Ferreira MG, 2004, MOL CELL, V13, P7, DOI 10.1016/S1097-2765(03)00531-8; Gardner RG, 2005, CELL, V120, P803, DOI 10.1016/j.cell.2005.01.016; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Grandin N, 2001, EMBO J, V20, P6127, DOI 10.1093/emboj/20.21.6127; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lin J, 2004, MOL BIOL CELL, V15, P1623, DOI 10.1091/mbc.E03-10-0740; Liti G, 2003, MOL CELL, V11, P1373, DOI 10.1016/S1097-2765(03)00177-1; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; Maringele L, 2002, GENE DEV, V16, P1919, DOI 10.1101/gad.225102; Maringele L, 2005, CELL CYCLE, V4, P747, DOI 10.4161/cc.4.6.1741; Maringele L, 2004, GENE DEV, V18, P2663, DOI 10.1101/gad.316504; Maringele L, 2004, GENETICS, V166, P1641, DOI 10.1534/genetics.166.4.1641; MARINGELE L, 2006, YEAST PROTOCOLS METH, P65; McClintock B, 1941, GENETICS, V26, P234; Mitton-Fry RM, 2004, J MOL BIOL, V338, P241, DOI 10.1016/j.jmb.2004.01.063; Muller H, 1938, COLLECTING NET, V13, P181; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Reddel RR, 2003, CANCER LETT, V194, P155, DOI 10.1016/S0304-3835(02)00702-4; Teng SC, 1999, MOL CELL BIOL, V19, P8083; Theobald DL, 2003, STRUCTURE, V11, P1049, DOI 10.1016/S0969-2126(03)00183-7; Zubko MK, 2004, GENETICS, V168, P103, DOI 10.1534/genetics.104.027904	30	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					734	740		10.1038/ncb1428	http://dx.doi.org/10.1038/ncb1428			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16767084				2022-12-25	WOS:000238837800016
J	Amundadottir, LT; Sulem, P; Gudmundsson, J; Helgason, A; Baker, A; Agnarsson, BA; Sigurdsson, A; Benediktsdottir, KR; Cazier, JB; Sainz, J; Jakobsdottir, M; Kostic, J; Magnusdottir, DN; Ghosh, S; Agnarsson, K; Birgisdottir, B; Le Roux, L; Olafsdottir, A; Blondal, T; Andresdottir, M; Gretarsdottir, OS; Bergthorsson, JT; Gudbjartsson, D; Gylfason, A; Thorleifsson, G; Manolescu, A; Kristjansson, K; Geirsson, G; Isaksson, H; Douglas, J; Johansson, JE; Balter, K; Wiklund, F; Montie, JE; Yu, XY; Suarez, BK; Ober, C; Cooney, KA; Gronberg, H; Catalona, WJ; Einarsson, GV; Barkardottir, RB; Gulcher, JR; Kong, A; Thorsteinsdottir, U; Stefansson, K				Amundadottir, Laufey T.; Sulem, Patrick; Gudmundsson, Julius; Helgason, Agnar; Baker, Adam; Agnarsson, Bjarni A.; Sigurdsson, Asgeir; Benediktsdottir, Kristrun R.; Cazier, Jean-Baptiste; Sainz, Jesus; Jakobsdottir, Margret; Kostic, Jelena; Magnusdottir, Droplaug N.; Ghosh, Shyamali; Agnarsson, Kari; Birgisdottir, Birgitta; Le Roux, Louise; Olafsdottir, Adalheidur; Blondal, Thorarinn; Andresdottir, Margret; Gretarsdottir, Olafia Svandis; Bergthorsson, Jon T.; Gudbjartsson, Daniel; Gylfason, Arnaldur; Thorleifsson, Gudmar; Manolescu, Andrei; Kristjansson, Kristleifur; Geirsson, Gudmundur; Isaksson, Helgi; Douglas, Julie; Johansson, Jan-Erik; Balter, Katarina; Wiklund, Fredrik; Montie, James E.; Yu, Xiaoying; Suarez, Brian K.; Ober, Carole; Cooney, Kathleen A.; Gronberg, Henrik; Catalona, William J.; Einarsson, Gudmundur V.; Barkardottir, Rosa B.; Gulcher, Jeffrey R.; Kong, Augustine; Thorsteinsdottir, Unnur; Stefansson, Kari			A common variant associated with prostate cancer in European and African populations	NATURE GENETICS			English	Article							CONFERS RISK; GENE; INFERENCE; POLYMORPHISMS	With the increasing incidence of prostate cancer, identifying common genetic variants that confer risk of the disease is important. Here we report such a variant on chromosome 8q24, a region initially identified through a study of Icelandic families. Allele -8 of the microsatellite DG8S737 was associated with prostate cancer in three case-control series of European ancestry from Iceland, Sweden and the US. The estimated odds ratio ( OR) of the allele is 1.62 (P = 2.7 x 10(-11)). About 19% of affected men and 13% of the general population carry at least one copy, yielding a population attributable risk ( PAR) of similar to 8%. The association was also replicated in an African American case-control group with a similar OR, in which 41% of affected individuals and 30% of the population are carriers. This leads to a greater estimated PAR (16%) that may contribute to higher incidence of prostate cancer in African American men than in men of European ancestry.	DeCODE Genet, IS-101 Reykjavik, Iceland; Univ Iceland, Landspitali Hosp, Dept Pathol, IS-101 Reykjavik, Iceland; Univ Iceland, Landspitali Hosp, Dept Urol, IS-101 Reykjavik, Iceland; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; Orebro Univ Hosp, Dept Urol & Clin Med, Orebro, Sweden; Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden; Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Landspitali National University Hospital; University of Iceland; Landspitali National University Hospital; University of Iceland; University of Michigan System; University of Michigan; Orebro University; Karolinska Institutet; University of Michigan System; University of Michigan; Northwestern University; Feinberg School of Medicine; Washington University (WUSTL); University of Chicago; University of Michigan System; University of Michigan	Thorsteinsdottir, U (corresponding author), DeCODE Genet, Sturlugata 8, IS-101 Reykjavik, Iceland.	unnur.thorsteinsdottir@decode.is; kstefans@decode.is	Helgason, Agnar/K-1522-2015; Manolescu, Andrei/G-4565-2014; Amundadottir, Laufey T/L-7656-2016; Cazier, Jean-Baptiste/F-2369-2010; Cazier, Jean-Baptiste/GLR-2949-2022; Stefansson, Kari/AAE-7187-2019	Manolescu, Andrei/0000-0002-0713-4664; Amundadottir, Laufey T/0000-0003-1859-8971; Cazier, Jean-Baptiste/0000-0001-7581-9051; Cazier, Jean-Baptiste/0000-0001-7581-9051; Gudbjartsson, Daniel/0000-0002-5222-9857; Yu, Xiaoying/0000-0003-1659-2365; Kong, Augustine/0000-0001-8193-5438; Ober, Carole/0000-0003-4626-9809; Cooney, Kathleen/0000-0003-3831-6943; Bergthorsson, Jon Thor/0000-0002-0560-2639; le Roux, Louise/0000-0002-9491-9653; Helgason, Agnar/0000-0002-8545-3767	NATIONAL CANCER INSTITUTE [R01CA105055] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA105055-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundadottir LT, 2004, PLOS MED, V1, P229, DOI 10.1371/journal.pmed.0010065; Baudis M, 2001, BIOINFORMATICS, V17, P1228, DOI 10.1093/bioinformatics/17.12.1228; Beebe-Dimmer JL, 2006, PROSTATE CANCER P D, V9, P50, DOI 10.1038/sj.pcan.4500840; Boehnke M, 1997, AM J HUM GENET, V61, P423, DOI 10.1086/514862; Crawford ED, 2003, UROLOGY, V62, P3, DOI 10.1016/j.urology.2003.10.013; Douglas JA, 2005, CANCER EPIDEM BIOMAR, V14, P2035, DOI 10.1158/1055-9965.EPI-05-0170; El Gedaily A, 2001, PROSTATE, V46, P184; Epstein MP, 2000, AM J HUM GENET, V67, P1219, DOI 10.1016/S0002-9297(07)62952-8; FALK CT, 1987, ANN HUM GENET, V51, P227, DOI 10.1111/j.1469-1809.1987.tb00875.x; Grant SFA, 2006, NAT GENET, V38, P320, DOI 10.1038/ng1732; Gretarsdottir S, 2003, NAT GENET, V35, P131, DOI 10.1038/ng1245; Gretarsdottir S, 2002, AM J HUM GENET, V70, P593, DOI 10.1086/339252; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514; Gulcher J, 2001, CANCER J, V7, P61; Gulcher JR, 2000, EUR J HUM GENET, V8, P739, DOI 10.1038/sj.ejhg.5200530; Helgadottir A, 2006, NAT GENET, V38, P68, DOI 10.1038/ng1692; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lindmark F, 2004, JNCI-J NATL CANCER I, V96, P1248, DOI 10.1093/jnci/djh227; MANTEL N, 1959, J NATL CANCER I, V22, P719; *NIH, 1999, NIH PUB, V99; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pritchard JK, 2000, AM J HUM GENET, V67, P170, DOI 10.1086/302959; Pritchard JK, 2000, GENETICS, V155, P945; Schaid DJ, 2004, HUM MOL GENET, V13, pR103, DOI 10.1093/hmg/ddh072	28	589	637	0	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					652	658		10.1038/ng1808	http://dx.doi.org/10.1038/ng1808			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16682969				2022-12-25	WOS:000237954800018
J	Montini, E; Cesana, D; Schmidt, M; Sanvito, F; Ponzoni, M; Bartholomae, C; Sergi, LS; Benedicenti, F; Ambrosi, A; Di Serio, C; Doglioni, C; von Kalle, C; Naldini, L				Montini, Eugenio; Cesana, Daniela; Schmidt, Manfred; Sanvito, Francesca; Ponzoni, Maurilio; Bartholomae, Cynthia; Sergi, Lucia Sergi; Benedicenti, Fabrizio; Ambrosi, Alessandro; Di Serio, Clelia; Doglioni, Claudio; von Kalle, Christof; Naldini, Luigi			Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration	NATURE BIOTECHNOLOGY			English	Article							INSERTIONAL MUTAGENESIS; ACTIVE GENES; HUMAN GENOME; THERAPY; CANCER; TRANSPLANTATION; IDENTIFICATION; TRANSDUCTION; ACTIVATION; EXPRESSION	Insertional mutagenesis represents a major hurdle to gene therapy and necessitates sensitive preclinical genotoxicity assays. Cdkn2a(-/-) mice are susceptible to a broad range of cancer-triggering genetic lesions. We exploited hematopoietic stem cells from these tumor-prone mice to assess the oncogenicity of prototypical retroviral and lentiviral vectors. We transduced hematopoietic stem cells in matched clinically relevant conditions, and compared integration site selection and tumor development in transplanted mice. Retroviral vectors triggered dose-dependent acceleration of tumor onset contingent on long terminal repeat activity. Insertions at oncogenes and cell-cycle genes were enriched in early-onset tumors, indicating cooperation in tumorigenesis. In contrast, tumorigenesis was unaffected by lentiviral vectors and did not enrich for specific integrants, despite the higher integration load and robust expression of lentiviral vectors in all hematopoietic lineages. Our results validate a much-needed platform to assess vector safety and provide direct evidence that prototypical lentiviral vectors have low oncogenic potential, highlighting a major rationale for application to gene therapy.	San Raffaele Telethon Inst Gene Therapy, I-20132 Milan, Italy; Univ Vita Salute San Raffaele, Univ Ctr Stat Biomed Sci, I-20132 Milan, Italy; Univ Hosp, Dept Internal Med 1, D-79106 Freiburg, Germany; Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany; Hosp San Raffaele, Dept Pathol, I-20132 Milan, Italy; Cincinnati Childrens Res Fdn, Mol & Gene Therapy Program, Cincinnati, OH 45229 USA	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Naldini, L (corresponding author), San Raffaele Telethon Inst Gene Therapy, Via Olgettina 58, I-20132 Milan, Italy.	naldini.luigi@hsr.it	Naldini, Luigi/E-9083-2012; Di Serio, Clelia/AAO-5494-2020; Montini, Eugenio/L-1152-2016; ambrosi, alessandro/H-4424-2011	Montini, Eugenio/0000-0003-1771-6067; ambrosi, alessandro/0000-0003-1976-5663; lucia, Sergi Sergi/0000-0002-8631-7433; DI SERIO, Mariaclelia Stefania/0000-0001-6385-6058; Cesana, Daniela/0000-0001-6366-4224; NALDINI, Luigi/0000-0002-7835-527X; DOGLIONI, Claudio/0000-0002-4969-5216	NHLBI NIH HHS [2 P01 HL053750-11] Funding Source: Medline; Telethon [TGT06S01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053750] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ailles L, 2002, MOL THER, V6, P615, DOI 10.1006/mthe.2002.0720; Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126/science.1070104; Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Baum C, 2004, MOL THER, V9, P5, DOI 10.1016/j.ymthe.2003.10.013; Biffi A, 2004, J CLIN INVEST, V113, P1118, DOI 10.1172/JCI200419205; Bordignon C, 2002, NAT IMMUNOL, V3, P318, DOI 10.1038/ni0402-318; Cavazzana-Calvo Marina, 2005, Annu Rev Med, V56, P585, DOI 10.1146/annurev.med.56.090203.104142; COFFIN J, 2000, RETROVIRUSES; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; De Palma M, 2005, BLOOD, V105, P2307, DOI 10.1182/blood-2004-03-0798; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gaspar HB, 2004, LANCET, V364, P2181, DOI 10.1016/S0140-6736(04)17590-9; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hematti P, 2004, PLOS BIOL, V2, P2183, DOI 10.1371/journal.pbio.0020423; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hwang HC, 2002, P NATL ACAD SCI USA, V99, P11293, DOI 10.1073/pnas.162356099; Imren S, 2004, J CLIN INVEST, V114, P953, DOI 10.1172/JCI200421838; Johnson C, 2005, J VIROL, V79, P57, DOI 10.1128/JVI.79.1.57-66.2005; Kay MA, 2001, NAT MED, V7, P33, DOI 10.1038/83324; Klug CA, 2000, BLOOD, V96, P894, DOI 10.1182/blood.V96.3.894.015k35_894_901; Kohn DB, 1998, NAT MED, V4, P775, DOI 10.1038/nm0798-775; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Malech HL, 1997, P NATL ACAD SCI USA, V94, P12133, DOI 10.1073/pnas.94.22.12133; May C, 2002, BLOOD, V99, P1902, DOI 10.1182/blood.V99.6.1902; Mikkers H, 2003, ADV CANCER RES, V88, P53, DOI 10.1016/S0065-230X(03)88304-5; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; Modlich U, 2005, BLOOD, V105, P4235, DOI 10.1182/blood-2004-11-4535; Nakai H, 2003, NAT GENET, V34, P297, DOI 10.1038/ng1179; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Nielsen AA, 2005, J VIROL, V79, P67, DOI 10.1128/JVI.79.1.67-78.2005; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Pawliuk R, 2001, SCIENCE, V294, P2368, DOI 10.1126/science.1065806; Roberts MR, 1998, J IMMUNOL, V161, P375; Schmidt M, 2002, BLOOD, V100, P2737, DOI 10.1182/blood-2002-02-0407; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637; Wu XL, 2006, VIROLOGY, V344, P292, DOI 10.1016/j.virol.2005.08.047; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Zentilin L, 2000, GENE THER, V7, P153, DOI 10.1038/sj.gt.3301057	49	540	569	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2006	24	6					687	696		10.1038/nbt1216	http://dx.doi.org/10.1038/nbt1216			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	051UQ	16732270				2022-12-25	WOS:000238187300031
J	Taymor, KS; Scott, CT; Greely, HT				Taymor, KS; Scott, CT; Greely, HT			The paths around stem cell intellectual property	NATURE BIOTECHNOLOGY			English	Editorial Material							NUCLEAR TRANSFER; ES CELLS; BLASTOCYSTS		Stanford Univ, Program Stem Cells Soc, Palo Alto, CA 94304 USA	Stanford University	Taymor, KS (corresponding author), Stanford Univ, Program Stem Cells Soc, 701 Welch Rd, Palo Alto, CA 94304 USA.	ktaymor@stanford.edu						Brambrink T, 2006, P NATL ACAD SCI USA, V103, P933, DOI 10.1073/pnas.0510485103; Chung Y, 2006, NATURE, V439, P216, DOI 10.1038/nature04277; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397; Jaenisch R, 2004, NEW ENGL J MED, V351, P2787, DOI 10.1056/NEJMp048304; Kiessling Ann A, 2004, Conn Law Rev, V36, P1051; Kuliev A, 2005, AM J MED GENET A, V134A, P105, DOI 10.1002/ajmg.a.30635; Meissner A, 2006, NATURE, V439, P212, DOI 10.1038/nature04257; Melton DA, 2004, NEW ENGL J MED, V351, P2791, DOI 10.1056/NEJMp048348; NIH, 2001, STEM CELLS SCI PROGR; Rabin S, 2005, NAT BIOTECHNOL, V23, P817, DOI 10.1038/nbt0705-817; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; THOMSON JA, 1998, Patent No. 5843780; TOMOHIRO K, 2004, NATURE, V428, P860; Vrana KE, 2003, P NATL ACAD SCI USA, V100, P11911, DOI 10.1073/pnas.2034195100; *WICELL RES I PUBL, 2001, MEM UND; Wilmut I, 1997, NATURE, V386, P200, DOI 10.1038/386200a0; Wisconsin Alumni Research Foundation, 2001, [No title captured], Patent No. [US6200806, 6200806]; 2000, Patent No. 6147276; 2005, Patent No. 20050158854	20	15	17	3	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					411	414		10.1038/nbt0406-411	http://dx.doi.org/10.1038/nbt0406-411			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16601720				2022-12-25	WOS:000236766300019
J	Fulga, TA; Elson-Schwab, I; Khurana, V; Steinhilb, ML; Spires, TL; Hyman, BT; Feany, MB				Fulga, Tudor A.; Elson-Schwab, Ilan; Khurana, Vikram; Steinhilb, Michelle L.; Spires, Tara L.; Hyman, Bradley T.; Feany, Mel B.			Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo	NATURE CELL BIOLOGY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; HIRANO BODIES; MOUSE MODEL; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY PATHOLOGY; ALZHEIMERS-DISEASE; CELL-DEATH; DROSOPHILA; TAUOPATHY; FILAMENTS	Hyperphosphorylated forms of the microtubule-associated protein (MAP) tau accumulate in Alzheimer's disease and related tauopathies and are thought to have an important role in neurodegeneration. However, the mechanisms through which phosphorylated tau induces neurodegeneration have remained elusive. Here, we show that tau-induced neurodegeneration is associated with accumulation of filamentous actin (F-actin) and the formation of actin-rich rods in Drosophila and mouse models of tauopathy. Importantly, modulating F-actin levels genetically leads to dramatic modification of tau-induced neurodegeneration. The ability of tau to interact with F-actin in vivo and in vitro provides a molecular mechanism for the observed phenotypes. Finally, we show that the Alzheimer's disease-linked human beta-amyloid protein (A beta) synergistically enhances the ability of wild-type tau to promote alterations in the actin cytoskeleton and neurodegeneration. These findings raise the possibility that a direct interaction between tau and actin may be a critical mediator of tau-induced neurotoxicity in Alzheimer's disease and related disorders.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Fulga, TA (corresponding author), Brigham & Womens Hosp, Dept Pathol, Harvard New Res Bldg Room 652,77 Loius Pasteur Av, Boston, MA 02115 USA.	Tudor_Fulga@hms.harvard.edu	Spires-Jones, Tara/AAR-7697-2020	Spires-Jones, Tara/0000-0003-2530-0598; Khurana, Vikram/0000-0002-4018-5527; Fulga, Tudor/0000-0002-1056-0082; Feany, Mel/0000-0003-0315-7970	NATIONAL INSTITUTE ON AGING [R01AG019790] Funding Source: NIH RePORTER; NIA NIH HHS [AG19790, AG5134] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andorfer C, 2005, J NEUROSCI, V25, P5446, DOI 10.1523/JNEUROSCI.4637-04.2005; Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; CORREAS I, 1990, BIOCHEM J, V269, P61, DOI 10.1042/bj2690061; CROSS D, 1993, J CELL SCI, V105, P51; Cunningham CC, 1997, J CELL BIOL, V136, P845, DOI 10.1083/jcb.136.4.845; Dias-Santagata D, 2007, J CLIN INVEST, V117, P236, DOI 10.1172/JCI28769; DITELLA M, 1994, CELL MOTIL CYTOSKEL, V29, P117, DOI 10.1002/cm.970290204; Farias GA, 2002, J CELL BIOCHEM, V85, P315, DOI 10.1002/jcb.10133; Finelli A, 2004, MOL CELL NEUROSCI, V26, P365, DOI 10.1016/j.mcn.2004.03.001; GALLOWAY PG, 1987, BRAIN RES, V403, P337, DOI 10.1016/0006-8993(87)90071-0; GALLOWAY PG, 1987, J NEUROPATH EXP NEUR, V46, P185, DOI 10.1097/00005072-198703000-00006; Ghosh S, 2004, HUM MOL GENET, V13, P2011, DOI 10.1093/hmg/ddh214; GOLDMAN JE, 1983, J NEUROPATH EXP NEUR, V42, P146, DOI 10.1097/00005072-198303000-00004; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9143; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harms C, 2004, MOL CELL NEUROSCI, V25, P69, DOI 10.1016/j.mcn.2003.09.012; HENRIQUEZ JP, 1995, CELL BIOCHEM FUNCT, V13, P239, DOI 10.1002/cbf.290130404; HIRANO A, 1994, NEUROPATH APPL NEURO, V20, P3, DOI 10.1111/j.1365-2990.1994.tb00951.x; Jackson GR, 2002, NEURON, V34, P509, DOI 10.1016/S0896-6273(02)00706-7; Karsten SL, 2006, NEURON, V51, P549, DOI 10.1016/j.neuron.2006.07.019; Kempf M, 1996, J NEUROSCI, V16, P5583; Khurana V, 2006, CURR BIOL, V16, P230, DOI 10.1016/j.cub.2005.12.042; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; MACIVER SK, 1995, NEUROREPORT, V6, P1985, DOI 10.1097/00001756-199510010-00008; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MORAGA DM, 1993, J NEUROCHEM, V61, P979, DOI 10.1111/j.1471-4159.1993.tb03611.x; Muqit MMK, 2002, NAT REV NEUROSCI, V3, P237, DOI 10.1038/nrn751; Nishimura I, 2004, CELL, V116, P671, DOI 10.1016/S0092-8674(04)00170-9; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Ramsden M, 2005, J NEUROSCI, V25, P10637, DOI 10.1523/JNEUROSCI.3279-05.2005; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Roger B, 2004, CURR BIOL, V14, P363, DOI 10.1016/j.cub.2004.01.058; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; SCHOCHET SS, 1968, ACTA NEUROPATHOL, V11, P330, DOI 10.1007/BF00686729; Shulman JM, 2003, GENETICS, V165, P1233; Spires TL, 2006, AM J PATHOL, V168, P1598, DOI 10.2353/ajpath.2006.050840; Wagner CR, 2002, P NATL ACAD SCI USA, V99, P8037, DOI 10.1073/pnas.082235499; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Wittmann CW, 2001, SCIENCE, V293, P711, DOI 10.1126/science.1062382; Zhu XW, 2004, BRAIN RES, V1000, P32, DOI 10.1016/j.brainres.2004.01.012; Zmuda JF, 2000, J CELL SCI, V113, P2797	49	327	342	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	FEB	2007	9	2					139	U17		10.1038/ncb1528	http://dx.doi.org/10.1038/ncb1528			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	131WR	17187063				2022-12-25	WOS:000243903000006
J	Sato, K; Suematsu, A; Nakashima, T; Takemoto-Kimura, S; Aoki, K; Morishita, Y; Asahara, H; Ohya, K; Yamaguchi, A; Takai, T; Kodama, T; Chatila, TA; Bito, H; Takayanagi, H				Sato, Kojiro; Suematsu, Ayako; Nakashima, Tomoki; Takemoto-Kimura, Sayaka; Aoki, Kazuhiro; Morishita, Yasuyuki; Asahara, Hiroshi; Ohya, Keiichi; Yamaguchi, Akira; Takai, Toshiyuki; Kodama, Tatsuhiko; Chatila, Talal A.; Bito, Haruhiko; Takayanagi, Hiroshi			Regulation of osteoclast differentiation and function by the CaMK-CREB pathway	NATURE MEDICINE			English	Article							PROTEIN-KINASE-IV; T-CELLS; C-FOS; BONE HOMEOSTASIS; NUCLEAR FACTOR; TRANSCRIPTION; CALMODULIN; RANKL; EXPRESSION; INHIBITOR	Calcium (Ca2+) signaling is essential for a variety of cellular responses and higher biological functions. Ca2+/calmodulin-dependent kinases (CaMKs) and the phosphatase calcineurin activate distinct downstream pathways that are mediated by the transcription factors cAMP response element (CRE)-binding protein ( CREB) and nuclear factor of activated T cells ( NFAT), respectively(1). The importance of the calcineurin-NFAT pathway in bone metabolism has been demonstrated in osteoclasts, osteoblasts and chondrocytes(2-5). However, the contribution of the CaMK-CREB pathway is poorly understood, partly because of the difficulty of dissecting the functions of homologous family members(6-8). Here we show that the CaMKIV-CREB pathway is crucial for osteoclast differentiation and function. Pharmacological inhibition of CaMKs as well as the genetic ablation of Camk4 reduced CREB phosphorylation and downregulated the expression of c-Fos, which is required for the induction of NFATc1 ( the master transcription factor for osteoclastogenesis(2,3)) that is activated by receptor activator of NF-kappa B ligand ( RANKL). Furthermore, CREB together with NFATc1 induced the expression of specific genes expressed by differentiated osteoclasts. Thus, the CaMK-CREB pathway biphasically functions to regulate the transcriptional program of osteoclastic bone resorption, by not only enhancing induction of NFATc1 but also facilitating NFATc1-dependent gene regulation once its expression is induced. This provides a molecular basis for a new therapeutic strategy for bone diseases.	Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan; Ctr Excellence Program Frontier Res Mol Destruct, Tokyo 1138549, Japan; Univ Tokyo, Grad Sch Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Pharmacol Sect, Grad Sch,Bunkyo Ku, Tokyo 1138549, Japan; Univ Tokyo, Grad Sch Med, Dept Human Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Natl Ctr Child Hlth & Dev, Dept Innovat Surg, Setagaya Ku, Tokyo 1578535, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Oral Pathol, Bunkyo Ku, Tokyo 1138549, Japan; Tohoku Univ, Dept Expt Immunol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan; Univ Tokyo, Dept Mol Biol & Med, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Div Rheumatol Allergy & Immunol, Los Angeles, CA 90095 USA; Japan Sci & Technol Agcy JST, SORST, Kawaguchi, Saitama 3320012, Japan	Tokyo Medical & Dental University (TMDU); University of Tokyo; Tokyo Medical & Dental University (TMDU); University of Tokyo; National Center for Child Health & Development - Japan; Tokyo Medical & Dental University (TMDU); Tohoku University; University of Tokyo; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Japan Science & Technology Agency (JST)	Takayanagi, H (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Cell Signaling, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138549, Japan.	taka.csi@tmd.ac.jp	AOKI, Kazuhiro/GRO-6475-2022; Bito, Haruhiko/A-8635-2008; Yamaguchi, Akira/AAX-9286-2020	AOKI, Kazuhiro/0000-0001-6643-6315; Sato, Kojiro/0000-0003-4105-3726; Bito, Haruhiko/0000-0001-6315-9594; Chatila, Talal/0000-0001-7439-2762				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Anderson KA, 2002, MOL CELL BIOL, V22, P23, DOI 10.1128/MCB.22.1.23-29.2002; Aoki K, 2006, J CLIN INVEST, V116, P1525, DOI 10.1172/JCI22513; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Garcia-Rodriguez C, 1998, J EXP MED, V187, P2031, DOI 10.1084/jem.187.12.2031; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kim Y, 2005, J BIOL CHEM, V280, P32905, DOI 10.1074/jbc.M505820200; Kitsos CM, 2005, J BIOL CHEM, V280, P33101, DOI 10.1074/jbc.M505208200; Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Long FX, 2001, DEVELOPMENT, V128, P541; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Seales EC, 2006, J CELL BIOCHEM, V97, P45, DOI 10.1002/jcb.20659; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Tokumitsu H, 2004, J BIOL CHEM, V279, P40296, DOI 10.1074/jbc.M406534200; Tokumitsu H, 2002, J BIOL CHEM, V277, P15813, DOI 10.1074/jbc.M201075200; Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200	30	264	282	7	49	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2006	12	12					1410	1416		10.1038/nm1515	http://dx.doi.org/10.1038/nm1515			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17128269				2022-12-25	WOS:000242618200022
J	Sidhu, SS; Fellouse, FA				Sidhu, Sachdev S.; Fellouse, Frederic A.			Synthetic therapeutic antibodies	NATURE CHEMICAL BIOLOGY			English	Article							AFFINITY HUMAN-ANTIBODIES; PHAGE DISPLAY LIBRARY; SINGLE-FRAMEWORK SCAFFOLD; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; SELECTION SYSTEM; SURFACE DISPLAY; LIGHT-CHAINS; DOMAIN; REPERTOIRES	Advances in selection technologies have sped up the process of generating antibodies with exquisitely tailored characteristics. In particular, synthetic antibody libraries, in which the antigen-binding sites are entirely man-made, have come of age and now rival or even exceed the potential of natural immune repertoires. Control over both library design and selection conditions enables unprecedented precision in antibody engineering. Synthetic libraries have been used to gain insights into the mechanisms of antibody structure and function, to tackle particularly difficult therapeutic challenges and to expand the utility of antibodies to novel areas of research.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Roche Holding; Genentech; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Sidhu, SS (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	sidhu@gene.com						Almagro JC, 2004, J MOL RECOGNIT, V17, P132, DOI 10.1002/jmr.659; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BARBAS CF, 1993, GENE, V137, P57, DOI 10.1016/0378-1119(93)90251-W; Bradbury A, 2003, TRENDS BIOTECHNOL, V21, P312, DOI 10.1016/S0167-7799(03)00117-3; Bradbury A, 2003, TRENDS BIOTECHNOL, V21, P275, DOI 10.1016/S0167-7799(03)00112-4; Bradbury ARM, 2004, J IMMUNOL METHODS, V290, P29, DOI 10.1016/j.jim.2004.04.007; Brekke OH, 2003, CURR OPIN PHARMACOL, V3, P544, DOI 10.1016/j.coph.2003.05.002; Chambers RS, 2005, CURR OPIN CHEM BIOL, V9, P46, DOI 10.1016/j.cbpa.2004.10.011; Collis AVJ, 2003, J MOL BIOL, V325, P337, DOI 10.1016/S0022-2836(02)01222-6; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Desiderio A, 2001, J MOL BIOL, V310, P603, DOI 10.1006/jmbi.2001.4756; DOBSON CL, 2005, PHAGE DISPLAY BIOTEC, V3, P659; Feldhaus MJ, 2003, NAT BIOTECHNOL, V21, P163, DOI 10.1038/nbt785; Fellouse FA, 2006, J MOL BIOL, V357, P100, DOI 10.1016/j.jmb.2005.11.092; Fellouse FA, 2005, J MOL BIOL, V348, P1153, DOI 10.1016/j.jmb.2005.03.041; Fellouse FA, 2004, P NATL ACAD SCI USA, V101, P12467, DOI 10.1073/pnas.0401786101; FELLOUSE FA, 2005, PHAGE DISPLAY BIOTEC, V3, P709; Fuh G, 2006, J BIOL CHEM, V281, P6625, DOI 10.1074/jbc.M507783200; Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Harvey BR, 2004, P NATL ACAD SCI USA, V101, P9193, DOI 10.1073/pnas.0400187101; Hoet RM, 2005, NAT BIOTECHNOL, V23, P344, DOI 10.1038/nbt1067; Hoogenboom Hennie R, 2002, Methods Mol Biol, V178, P1; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; Hoogenboom HR, 2005, NAT BIOTECHNOL, V23, P1105, DOI 10.1038/nbt1126; Hudson PJ, 1999, CURR OPIN IMMUNOL, V11, P548, DOI 10.1016/S0952-7915(99)00013-8; Jespers L, 2004, J MOL BIOL, V337, P893, DOI 10.1016/j.jmb.2004.02.013; Johnson G, 2000, NUCLEIC ACIDS RES, V28, P214, DOI 10.1093/nar/28.1.214; Jung D, 2006, ANNU REV IMMUNOL, V24, P541, DOI 10.1146/annurev.immunol.23.021704.115830; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; Koch H, 2006, J MOL BIOL, V357, P427, DOI 10.1016/j.jmb.2005.12.043; Lee CV, 2004, J MOL BIOL, V340, P1073, DOI 10.1016/j.jmb.2004.05.051; LEE CV, IN PRESS NAT BIOTECH; Li B, 2006, J MOL BIOL, V361, P522, DOI 10.1016/j.jmb.2006.06.042; Liang WC, 2006, J BIOL CHEM, V281, P951, DOI 10.1074/jbc.M508199200; Lipovsek D, 2004, J IMMUNOL METHODS, V290, P51, DOI 10.1016/j.jim.2004.04.008; MacCallum RM, 1996, J MOL BIOL, V262, P732, DOI 10.1006/jmbi.1996.0548; Maur AAD, 2002, J BIOL CHEM, V277, P45075, DOI 10.1074/jbc.M205264200; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; MUYLDERMANS S, 1994, PROTEIN ENG, V7, P1129, DOI 10.1093/protein/7.9.1129; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Persson H, 2006, J MOL BIOL, V357, P607, DOI 10.1016/j.jmb.2006.01.004; Rader C, 1997, CURR OPIN BIOTECH, V8, P503, DOI 10.1016/S0958-1669(97)80075-4; Reiersen H, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni010; Reiter Y, 1999, J MOL BIOL, V290, P685, DOI 10.1006/jmbi.1999.2923; Riechmann L, 1996, J MOL BIOL, V259, P957, DOI 10.1006/jmbi.1996.0373; Sanz L, 2004, TRENDS IMMUNOL, V25, P85, DOI 10.1016/j.it.2003.12.001; Schaedel O, 2006, CURR PHARM DESIGN, V12, P363, DOI 10.2174/138161206775201983; Sidhu SS, 2004, J MOL BIOL, V338, P299, DOI 10.1016/j.jmb.2004.02.050; Silacci M, 2005, PROTEOMICS, V5, P2340, DOI 10.1002/pmic.200401273; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Trikha M, 2002, CURR OPIN BIOTECH, V13, P609, DOI 10.1016/S0958-1669(02)00348-8; Urban JH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni033; Urech DM, 2003, BBA-GEN SUBJECTS, V1622, P117, DOI 10.1016/S0304-4165(03)00133-8; van Wyngaardt W, 2004, BMC BIOTECHNOL, V4, DOI 10.1186/1472-6750-4-6; Visintin M, 2004, J IMMUNOL METHODS, V290, P135, DOI 10.1016/j.jim.2004.04.014; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; Wittrup KD, 2001, CURR OPIN BIOTECH, V12, P395, DOI 10.1016/S0958-1669(00)00233-0	62	106	121	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	DEC	2006	2	12					682	688		10.1038/nchembio843	http://dx.doi.org/10.1038/nchembio843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	107KC	17108986				2022-12-25	WOS:000242168800012
J	Akey, DL; Kittendorf, JD; Giraldes, JW; Fecik, RA; Sherman, DH; Smith, JL				Akey, David L.; Kittendorf, Jeffrey D.; Giraldes, John W.; Fecik, Robert A.; Sherman, David H.; Smith, Janet L.			Structural basis for macrolactonization by the pikromycin thioesterase	NATURE CHEMICAL BIOLOGY			English	Article							PICROMYCIN/METHYMYCIN POLYKETIDE SYNTHASE; STREPTOMYCES-VENEZUELAE; CRYSTAL-STRUCTURE; CHAIN ELONGATION; BIOSYNTHESIS; 10-DEOXYMETHYNOLIDE; ARCHITECTURE; EXPRESSION; CHANNEL; DOMAIN	Polyketides are a class of biologically active microbial and plant-derived metabolites that possess a high degree of structural and functional diversity and include many human therapeutics, among them anti-infective and anti-cancer drugs, growth promoters and anti-parasitic agents(1). The macrolide antibiotics, characterized by a glycoside-linked macrolactone, constitute an important class of polyketides, including erythromycin and the natural ketolide anti- infective agent pikromycin. Here we describe new mechanistic details of macrolactone ring formation catalyzed by the pikromycin polyketide synthase thioesterase domain from Streptomyces venezuelae. A pentaketide phosphonate mimic of the final pikromycin linear chain-elongation intermediate was synthesized and shown to be an active site affinity label. The crystal structures of the affinity-labeled enzyme and of a 12-membered-ring macrolactone product complex suggest a mechanism for cyclization in which a hydrophilic barrier in the enzyme and structural restraints of the substrate induce a curled conformation to direct macrolactone ring formation.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities	Smith, JL (corresponding author), Univ Michigan, Inst Life Sci, 210 Washtenaw Ave, Ann Arbor, MI 48109 USA.	fecik001@umn.edu; davidhs@umich.edu; JanetSmith@umich.edu			NIDDK NIH HHS [DK042303, R37 DK042303] Funding Source: Medline; NIGMS NIH HHS [GM076477, GM075641] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076477, F32GM075641] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aldrich CC, 2005, J AM CHEM SOC, V127, P8910, DOI 10.1021/ja0504340; Aldrich CC, 2005, J AM CHEM SOC, V127, P8441, DOI 10.1021/ja042592h; Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fortman JL, 2005, CHEMBIOCHEM, V6, P960, DOI 10.1002/cbic.200400428; GIRALDES JW, IN PRESS NAT CHEM BI; He WG, 2006, BIOORG MED CHEM LETT, V16, P391, DOI 10.1016/j.bmcl.2005.09.077; Heathcole ML, 2001, CHEM BIOL, V8, P207, DOI 10.1016/S1074-5521(01)00002-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kao CL, 2006, J AM CHEM SOC, V128, P5606, DOI 10.1021/ja058433v; Kim BS, 2002, J BIOL CHEM, V277, P48028, DOI 10.1074/jbc.M207770200; Lu HX, 2002, BIOCHEMISTRY-US, V41, P12590, DOI 10.1021/bi026006d; Muchmore CRA, 1998, PROTEIN SCI, V7, P39, DOI 10.1002/pro.5560070104; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Tsai SC, 2001, P NATL ACAD SCI USA, V98, P14808, DOI 10.1073/pnas.011399198; Tsai SC, 2002, BIOCHEMISTRY-US, V41, P12598, DOI 10.1021/bi0260177; Wu JQ, 2005, ANGEW CHEM INT EDIT, V44, P7557, DOI 10.1002/anie.200502246; Xue YQ, 2000, NATURE, V403, P571, DOI 10.1038/35000624; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111; Xue YQ, 2001, METAB ENG, V3, P15, DOI 10.1006/mben.2000.0167	21	95	100	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	OCT	2006	2	10					537	542		10.1038/nchembio824	http://dx.doi.org/10.1038/nchembio824			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	095IX	16969372				2022-12-25	WOS:000241302500011
J	Manak, JR; Dike, S; Sementchenko, V; Kapranov, P; Biemar, F; Long, J; Cheng, J; Bell, I; Ghosh, S; Piccolboni, A; Gingeras, TR				Manak, J. Robert; Dike, Sujit; Sementchenko, Victor; Kapranov, Philipp; Biemar, Frederic; Long, Jeff; Cheng, Jill; Bell, Ian; Ghosh, Srinka; Piccolboni, Antonio; Gingeras, Thomas R.			Biological function of unannotated transcription during the early development of Drosophila melanogaster	NATURE GENETICS			English	Article							GENE-EXPRESSION; SERIAL ANALYSIS; GENOME; IDENTIFICATION	Many animal and plant genomes are transcribed much more extensively than current annotations predict. However, the biological function of these unannotated transcribed regions is largely unknown. Approximately 7% and 23% of the detected transcribed nucleotides during D. melanogaster embryogenesis map to unannotated intergenic and intronic regions, respectively. Based on computational analysis of coordinated transcription, we conservatively estimate that 29% of all unannotated transcribed sequences function as missed or alternative exons of well-characterized protein-coding genes. We estimate that 15.6% of intergenic transcribed regions function as missed or alternative transcription start sites (TSS) used by 11.4% of the expressed protein-coding genes. Identification of P element mutations within or near newly identified 5' exons provides a strategy for mapping previously uncharacterized mutations to their respective genes. Collectively, these data indicate that at least 85% of the fly genome is transcribed and processed into mature transcripts representing at least 30% of the fly genome.	Affymetrix Inc, Santa Clara, CA 95051 USA; Univ Calif Berkeley, Ctr Integrat Genom, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Affymetrix; University of California System; University of California Berkeley	Manak, JR (corresponding author), Affymetrix Inc, Santa Clara, CA 95051 USA.	John_Manak@affymetrix.com		Manak, John/0000-0002-6562-7694; Gingeras, Thomas/0000-0001-9106-3573; Kapranov, Philipp/0000-0003-2647-4856	NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NHGRI NIH HHS [U01 HG003147] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U01HG003147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; Celniker SE, 2002, GENOME BIOL, V3, DOI DOI 10.1186/GB-2002-3-12-RESEARCH0079; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; Denholm B, 2005, DEVELOPMENT, V132, P2389, DOI 10.1242/dev.01829; FOE VE, 1989, DEVELOPMENT, V107, P1; Hild M, 2004, GENOME BIOL, V5; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42; MISRA S, 2002, GENOME BIOL, V3, P83, DOI [DOI 10.1186/GB-2002-3-12-RESEARCH0083, 10.1186/gb-2002-3-12-research0083]; Ng P, 2005, NAT METHODS, V2, P105, DOI 10.1038/NMETH733; Shamloula HK, 2002, GENETICS, V161, P693; Shiraki T, 2003, P NATL ACAD SCI USA, V100, P15776, DOI 10.1073/pnas.2136655100; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Stolc V, 2004, SCIENCE, V306, P655, DOI 10.1126/science.1101312; Strapps WR, 2001, DEVELOPMENT, V128, P4829; Su YH, 2004, J NEUROSCI, V24, P3627, DOI 10.1523/JNEUROSCI.4644-03.2004; Tadros W, 2005, DEV DYNAM, V232, P593, DOI 10.1002/dvdy.20297; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Thibault ST, 2004, NAT GENET, V36, P283, DOI 10.1038/ng1314; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wei CL, 2004, P NATL ACAD SCI USA, V101, P11701, DOI 10.1073/pnas.0403514101	26	148	154	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1151	1158		10.1038/ng1875	http://dx.doi.org/10.1038/ng1875			8	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16951679				2022-12-25	WOS:000241251100014
J	De Piccoli, G; Cortes-Ledesma, F; Ira, G; Torres-Rosell, J; Uhle, S; Farmer, S; Hwang, JY; Machin, F; Ceschia, A; McAleenan, A; Cordon-Preciado, V; Clemente-Blanco, A; Vilella-Mitjana, F; Ullal, P; Jarmuz, A; Leitao, B; Bressan, D; Dotiwala, F; Papusha, A; Zhao, XL; Myung, K; Haber, JE; Aguilera, A; Aragon, L				De Piccoli, Giacomo; Cortes-Ledesma, Felipe; Ira, Gregory; Torres-Rosell, Jordi; Uhle, Stefan; Farmer, Sarah; Hwang, Ji-Young; Machin, Felix; Ceschia, Audrey; McAleenan, Alexandra; Cordon-Preciado, Violeta; Clemente-Blanco, Andres; Vilella-Mitjana, Felip; Ullal, Pranav; Jarmuz, Adam; Leitao, Beatriz; Bressan, Debra; Dotiwala, Farokh; Papusha, Alma; Zhao, Xiaolan; Myung, Kyungjae; Haber, James E.; Aguilera, Andres; Aragon, Luis			Smc5-Smc6 mediate DNA double-strand-break repair by promoting sister-chromatid recombination	NATURE CELL BIOLOGY			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; COHESIN; REGIONS; GENES	DNA double-strand breaks (DSB) can arise during DNA replication, or after exposure to DNA-damaging agents, and their correct repair is fundamental for cell survival and genomic stability. Here, we show that the Smc5-Smc6 complex is recruited to DSBs de novo to support their repair by homologous recombination between sister chromatids. In addition, we demonstrate that Smc5-Smc6 is necessary to suppress gross chromosomal rearrangements. Our findings show that the Smc5-Smc6 complex is essential for genome stability as it promotes repair of DSBs by error-free sisterchromatid recombination (SCR), thereby suppressing inappropriate non-sister recombination events.	Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Cell Cycle Grp, London W12 0NN, England; Univ Sevilla, Fac Biol, Dept Genet, E-41012 Seville, Spain; Brandeis Univ, Rosenstiel Ctr, Waltham, MA 02454 USA; Baylor Coll Med, Dept Human & Mol Genet, Houston, TX 77030 USA; Natl Human Genome Res Inst, Genome Instabil Sect, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Mem Sloan Kettering Canc Ctr, Mol Biol Program, New York, NY 10021 USA	Imperial College London; University of Sevilla; Brandeis University; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Memorial Sloan Kettering Cancer Center	Haber, JE (corresponding author), Univ London Imperial Coll Sci Technol & Med, MRC Clin Sci Ctr, Cell Cycle Grp, Du Cane Rd, London W12 0NN, England.	haber@brandeis.edu; aguilo@us.es; luis.aragon@csc.mrc.ac.uk	Dotiwala, Farokh/C-7068-2009; Blanco, Andrés Clemente/D-4255-2014; Hwang, Ji-Young/J-6460-2016; Dotiwala, Farokh/S-5367-2019; Ledesma, Felipe Cortés/F-4803-2014; Aguilera, Andres/L-1825-2014; Machín, Félix/K-6569-2017; Ira, Grzegorz/B-7912-2010; Torres-Rosell, Jordi/A-4213-2010; Vilella, Felipe/C-2970-2018	Blanco, Andrés Clemente/0000-0002-3674-0671; Hwang, Ji-Young/0000-0001-8044-1989; Dotiwala, Farokh/0000-0002-7387-2219; Ledesma, Felipe Cortés/0000-0002-0440-6783; Aguilera, Andres/0000-0003-4782-1714; Machín, Félix/0000-0003-4559-7798; Torres-Rosell, Jordi/0000-0003-1308-6926; Haber, James/0000-0002-1878-0610; Zhao, Xiaolan/0000-0002-8302-6905; Vilella, Felipe/0000-0002-0039-9846	MRC [MC_U120074328] Funding Source: UKRI; Medical Research Council [MC_U120074328] Funding Source: Medline; NIGMS NIH HHS [R01 GM020056, GM20056, R01 GM080600, R37 GM020056] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020056, R01GM080600, R37GM020056] Funding Source: NIH RePORTER	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Daley JM, 2005, ANNU REV GENET, V39, P431, DOI 10.1146/annurev.genet.39.073003.113340; Gonzalez-Barrera S, 2003, MOL CELL, V11, P1661, DOI 10.1016/S1097-2765(03)00183-7; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang J, 2003, GENE DEV, V17, P2162, DOI 10.1101/gad.1108403; KADYK LC, 1992, GENETICS, V132, P387; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; LEHMANN AR, 1995, MOL CELL BIOL, V15, P7067; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; Myung K, 2001, NAT GENET, V27, P113, DOI 10.1038/83673; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; Strom L, 2004, MOL CELL, V16, P1003, DOI 10.1016/j.molcel.2004.11.026; Torres-Rosell J, 2005, NAT CELL BIOL, V7, P412, DOI 10.1038/ncb1239; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Valencia M, 2001, NATURE, V414, P666, DOI 10.1038/414666a	18	147	147	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					1032	U118		10.1038/ncb1466	http://dx.doi.org/10.1038/ncb1466			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16892052	Green Accepted			2022-12-25	WOS:000240241700021
J	Noren, NK; Foos, G; Hauser, CA; Pasquale, EB				Noren, Nicole K.; Foos, Gabriele; Hauser, Craig A.; Pasquale, Elena B.			The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway	NATURE CELL BIOLOGY			English	Article							TYROSINE KINASE; C-ABL; COLORECTAL-CANCER; FAMILY KINASES; GROWTH-FACTOR; BIOLOGICAL SIGNIFICANCE; EPITHELIAL-CELLS; UP-REGULATION; TUMOR-GROWTH; EXPRESSION	Recent evidence supports a role for EphB receptor tyrosine kinases as tumour suppressors in colorectal and prostate cancer. However, it is unclear how these receptors inhibit cancer cell tumorigenicity - an activity that is highly unusual for a family of receptor tyrosine kinases. Here, we report that the EphB4 receptor can behave as a tumour suppressor in a mouse xenograft model of breast cancer when stimulated by its ligand, ephrin-B2. In breast cancer cells, EphB4 activates an antioncogenic pathway involving Abl family tyrosine kinases and the Crk adaptor protein. This Abl - Crk pathway inhibits breast cancer cell viability and proliferation in addition to motility and invasion, and also downregulates the pro-invasive matrix metalloprotease, MMP-2. Consistent with these effects, EphB4 and the Abl - Crk pathway are constitutively active in non-transformed mammary epithelial cells. These findings identify a novel Eph receptor signalling pathway with tumour-suppressor activity and predict that therapeutic intervention to activate EphB4 signalling will inhibit tumour progression.	Burnham Inst Med Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Pasquale, EB (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92093 USA.	elenap@burnham.org	Noren Hooten, Nicole/J-5498-2019	Noren Hooten, Nicole/0000-0002-1683-3838				Barrios A, 2003, CURR BIOL, V13, P1571, DOI 10.1016/j.cub.2003.08.030; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Berclaz G, 1996, BIOCHEM BIOPH RES CO, V226, P869, DOI 10.1006/bbrc.1996.1442; Chodniewicz D, 2004, BBA-MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006; Depaepe V, 2005, NATURE, V435, P1244, DOI 10.1038/nature03651; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guo DL, 2006, CARCINOGENESIS, V27, P454, DOI 10.1093/carcin/bgi259; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Harbott LK, 2005, MOL CELL NEUROSCI, V30, P1, DOI 10.1016/j.mcn.2005.05.002; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Jubb AM, 2005, CLIN CANCER RES, V11, P5181, DOI 10.1158/1078-0432.CCR-05-0143; Kain KH, 2003, ONCOGENE, V22, P6071, DOI 10.1038/sj.onc.1206930; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655; Koolpe M, 2005, J BIOL CHEM, V280, P17301, DOI 10.1074/jbc.M500363200; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Liu W, 2004, BRIT J CANCER, V90, P1620, DOI 10.1038/sj.bjc.6601723; Liu WB, 2002, CANCER, V94, P934, DOI 10.1002/cncr.10122; Miao H, 2003, J CELL BIOL, V162, P1281, DOI 10.1083/jcb.200304018; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Moresco EMY, 2005, J NEUROSCI, V25, P6105, DOI 10.1523/JNEUROSCI.1432-05.2005; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Nikolova Z, 1998, J CELL SCI, V111, P2741; Noblitt LW, 2004, CANCER GENE THER, V11, P757, DOI 10.1038/sj.cgt.7700761; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, CELL CYCLE, V2, P273, DOI 10.4161/cc.2.4.409; Sellappan S, 2004, CANCER RES, V64, P3479, DOI 10.1158/0008-5472.CAN-3299-2; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Sini P, 2004, NAT CELL BIOL, V6, P268, DOI 10.1038/ncb1096; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Takino T, 2003, J CELL SCI, V116, P3145, DOI 10.1242/jcs.00632; Truong T, 2003, P NATL ACAD SCI USA, V100, P10281, DOI 10.1073/pnas.1635435100; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Wu QH, 2004, PATHOL ONCOL RES, V10, P26, DOI 10.1007/BF02893405; Xia GB, 2005, CLIN CANCER RES, V11, P4305, DOI 10.1158/1078-0432.CCR-04-2109; Xia GB, 2005, CANCER RES, V65, P4623, DOI 10.1158/0008-5472.CAN-04-2667; Yang CF, 2005, J BIOL CHEM, V280, P24363, DOI 10.1074/jbc.M411629200; Yu HH, 2001, ONCOGENE, V20, P3995, DOI 10.1038/sj.onc.1204524; Zelinski DP, 2001, CANCER RES, V61, P2301; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	50	237	250	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					815	U53		10.1038/ncb1438	http://dx.doi.org/10.1038/ncb1438			18	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16862147				2022-12-25	WOS:000239423000011
J	Ozaki, K; Sato, H; Iida, A; Mizuno, H; Nakamura, T; Miyamoto, Y; Takahashi, A; Tsunoda, T; Ikegawa, S; Kamatani, N; Hori, M; Nakamura, Y; Tanaka, T				Ozaki, Kouichi; Sato, Hiroshi; Iida, Aritoshi; Mizuno, Hiroya; Nakamura, Takahiro; Miyamoto, Yoshinari; Takahashi, Atsushi; Tsunoda, Tatsuhiko; Ikegawa, Shiro; Kamatani, Naoyuki; Hori, Masatsugu; Nakamura, Yusuke; Tanaka, Toshihiro			A functional SNP in PSMA6 confers risk of myocardial infarction in the Japanese population	NATURE GENETICS			English	Article							CORONARY-ARTERY-DISEASE; NF-KAPPA-B; LINKAGE ANALYSIS; HUMAN GENOME; PROTEASOME INHIBITION; GENE; ATHEROSCLEROSIS; STRATIFICATION; SUSCEPTIBILITY; CHROMOSOME-2	Inflammation is now considered critical in the pathogenesis of myocardial infarction. One of the mechanisms regulating the inflammatory process is the ubiquitin-proteasome system. We investigated whether variants of the 20S proteasome are associated with susceptibility to myocardial infarction and found a common SNP (minor allele frequency of 0.35) in the proteasome subunit a type 6 gene (PSMA6) conferring risk of myocardial infarction in the Japanese population (chi(2) = 21.1, P = 0.0000044, 2,592 affected individuals versus 2,851 controls). We replicated this association in another panel of myocardial infarction and control subjects, although its relevance to other ethnic groups remains to be clarified. The SNP, located in the 5' untranslated region of exon 1 in this gene, enhanced the transcription of PSMA6. Moreover, suppression of PSMA6 expression using short interfering RNA in cultured cells reduced activation of the transcription factor NF-kappa B by stabilizing phosphorylated I kappa B. Our results implicate this PSMA6 SNP as a previously unknown genetic risk factor for myocardial infarction.	RIKEN, Inst Phys & Chem Res, Lab Cardiovasc Dis, SNP Res Ctr,Minato Ku, Tokyo 1088639, Japan; Osaka Univ, Grad Sch Med, Dept Cardiovasc Med, Suita, Osaka 5650871, Japan; RIKEN, Inst Phys & Chem Res, Lab Bone & Joint Dis, SNP Res Ctr,Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, SNP Res Ctr, Lab Med Informat,Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	RIKEN; Osaka University; RIKEN; RIKEN	Tanaka, T (corresponding author), RIKEN, Inst Phys & Chem Res, Lab Cardiovasc Dis, SNP Res Ctr,Minato Ku, 4-6-1,Shirokanedai, Tokyo 1088639, Japan.	toshitan@ims.u-tokyo.ac.jp	Ikegawa, Shiro/N-6895-2015; Iida, Aritoshi/CAA-1373-2022; Tsunoda, Tatsuhiko/K-2061-2014; Tanaka, Toshihiro/J-9310-2014	Ikegawa, Shiro/0000-0003-0316-2147; Iida, Aritoshi/0000-0001-7538-1651; Tsunoda, Tatsuhiko/0000-0002-5439-7918; Tanaka, Toshihiro/0000-0001-6201-9784; Ozaki, Kouichi/0000-0003-0028-1570				Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Broeckel U, 2002, NAT GENET, V30, P210, DOI 10.1038/ng827; Cipollone F, 2004, JAMA-J AM MED ASSOC, V291, P2221, DOI 10.1001/jama.291.18.2221; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; den Dunnen JT, 2000, HUM MUTAT, V15, P7; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Elliott PJ, 2003, J MOL MED, V81, P235, DOI 10.1007/s00109-003-0422-2; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; Haga H, 2002, J HUM GENET, V47, P605, DOI 10.1007/s100380200092; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Harrap SB, 2002, ARTERIOSCL THROM VAS, V22, P874, DOI 10.1161/01.ATV.0000016258.40568.F1; Hauser ER, 2004, AM J HUM GENET, V75, P436, DOI 10.1086/423900; Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311; Herrmann J, 2004, CARDIOVASC RES, V61, P11, DOI 10.1016/j.cardiores.2003.09.033; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Maki CG, 1996, CANCER RES, V56, P2649; Meiners S, 2002, CIRCULATION, V105, P483, DOI 10.1161/hc0402.102951; Ozaki K, 2004, NATURE, V429, P72, DOI 10.1038/nature02502; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Pajukanta P, 2000, AM J HUM GENET, V67, P1481, DOI 10.1086/316902; Pritchard JK, 1999, AM J HUM GENET, V65, P220, DOI 10.1086/302449; Pye J, 2003, AM J PHYSIOL-HEART C, V284, pH919, DOI 10.1152/ajpheart.00851.2002; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Samani NJ, 2005, AM J HUM GENET, V77, P1011; Wang LJ, 2003, SCIENCE, V302, P1578, DOI 10.1126/science.1088477; Wang Q, 2004, AM J HUM GENET, V74, P262, DOI 10.1086/381560; Yamada Y, 2002, NEW ENGL J MED, V347, P1916, DOI 10.1056/NEJMoa021445	30	72	81	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2006	38	8					921	925		10.1038/ng1846	http://dx.doi.org/10.1038/ng1846			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16845397				2022-12-25	WOS:000239325700022
J	Valdar, W; Solberg, LC; Gauguier, D; Burnett, S; Klenerman, P; O Cookson, W; Taylor, MS; Rawlins, JNP; Mott, R; Flint, J				Valdar, William; Solberg, Leah C.; Gauguier, Dominique; Burnett, Stephanie; Klenerman, Paul; O Cookson, William; Taylor, Martin S.; Rawlins, J. Nicholas P.; Mott, Richard; Flint, Jonathan			Genome-wide genetic association of complex traits in heterogeneous stock mice	NATURE GENETICS			English	Article							AIRWAY HYPERRESPONSIVENESS; MODEL SELECTION; LOCUS ANALYSIS; QTL; RESOLUTION; C57BL/6J; DISSECTION; IDENTIFY; STRAINS; ANXIETY	Difficulties in fine-mapping quantitative trait loci (QTLs) are a major impediment to progress in the molecular dissection of complex traits in mice. Here we show that genome-wide high-resolution mapping of multiple phenotypes can be achieved using a stock of genetically heterogeneous mice. We developed a conservative and robust bootstrap analysis to map 843 QTLs with an average 95% confidence interval of 2.8 Mb. The QTLs contribute to variation in 97 traits, including models of human disease (asthma, type 2 diabetes mellitus, obesity and anxiety) as well as immunological, biochemical and hematological phenotypes. The genetic architecture of almost all phenotypes was complex, with many loci each contributing a small proportion to the total variance. Our data set, freely available at http://gscan.well.ox.ac.uk, provides an entry point to the functional characterization of genes involved in many complex traits.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Nuffield Dept Med, Oxford OX1 3SY, England; Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford	Flint, J (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	rmott@well.ox.ac.uk; jf@well.ox.ac.uk	Gauguier, Dominique/G-2190-2016; Taylor, Martin S/C-3825-2009; Valdar, William/AAE-4354-2019	Gauguier, Dominique/0000-0001-6156-9530; Taylor, Martin S/0000-0001-7656-330X; Mott, Richard/0000-0002-1022-9330; klenerman, paul/0000-0003-4307-9161; Flint, Jonathan/0000-0002-9427-4429				Ackerman KG, 2005, PHYSIOL GENOMICS, V21, P105, DOI 10.1152/physiolgenomics.00267.2004; Balding DJ, 2002, J R STAT SOC B, V64, P737; Ball RD, 2001, GENETICS, V159, P1351; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Broman KW, 2002, J R STAT SOC B, V64, P641, DOI 10.1111/1467-9868.00354; Caldarone B, 1997, NAT GENET, V17, P335, DOI 10.1038/ng1197-335; Cervino AC, 2005, GENOMICS, V86, P505, DOI 10.1016/j.ygeno.2005.07.010; Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518; Cohen RM, 2001, MAMM GENOME, V12, P501, DOI 10.1007/s00335-001-2047-5; Darvasi A, 1998, NAT GENET, V18, P19, DOI 10.1038/ng0198-19; Demarest K, 2001, BEHAV GENET, V31, P79, DOI 10.1023/A:1010261909853; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Deutschbauer AM, 2005, NAT GENET, V37, P1333, DOI 10.1038/ng1674; DiPetrillo K, 2005, TRENDS GENET, V21, P683, DOI 10.1016/j.tig.2005.09.008; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537, DOI 10.1165/ajrcmb.23.4.4199; Flint J, 2005, NAT REV GENET, V6, P271, DOI 10.1038/nrg1576; Foreman JE, 2005, PHYSIOL GENOMICS, V23, P295, DOI 10.1152/physiolgenomics.00062.2005; Gershenfeld HK, 1997, BEHAV GENET, V27, P201, DOI 10.1023/A:1025653812535; Hackett CA, 2001, GENET RES, V77, P95, DOI 10.1017/S0016672300004869; Henderson ND, 2004, BEHAV GENET, V34, P267, DOI 10.1023/B:BEGE.0000017872.25069.44; Mackay TFC, 2004, CURR OPIN GENET DEV, V14, P253, DOI 10.1016/j.gde.2004.04.003; Morris KH, 1999, MAMM GENOME, V10, P225, DOI 10.1007/s003359900977; Mott R, 2000, P NATL ACAD SCI USA, V97, P12649, DOI 10.1073/pnas.230304397; Mott R, 2002, GENETICS, V160, P1609; Petkov PM, 2005, PLOS GENET, V1, P312, DOI 10.1371/journal.pgen.0010033; *R DEV COR TEAM, 2004, LANG ENV STAT COMP; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Sillanpaa MJ, 2002, TRENDS GENET, V18, P301, DOI 10.1016/S0168-9525(02)02688-4; Singer JB, 2005, GENETICS, V169, P855, DOI 10.1534/genetics.104.031492; Singer JB, 2004, SCIENCE, V304, P445, DOI 10.1126/science.1093139; Solberg LC, 2006, MAMM GENOME, V17, P129, DOI 10.1007/s00335-005-0112-1; Steinberger D, 2003, J NEUROSCI, V23, P2426; Talbot CJ, 2003, MAMM GENOME, V14, P223, DOI 10.1007/s00335-002-3059-5; Talbot CJ, 1999, NAT GENET, V21, P305, DOI 10.1038/6825; Taylor BA, 1997, GENOMICS, V43, P249, DOI 10.1006/geno.1997.4835; Toye AA, 2005, DIABETOLOGIA, V48, P675, DOI 10.1007/s00125-005-1680-z; Valdar W, 2006, GENETICS, V172, P1783, DOI 10.1534/genetics.104.039313; VALDAR W, IN PRESS GENETICS; Visscher PM, 1996, THEOR APPL GENET, V93, P691, DOI 10.1007/BF00224064; Visscher PM, 1996, GENETICS, V143, P1013; Wang XS, 2005, CIRC RES, V96, P27, DOI 10.1161/01.RES.0000151332.39871.13; Wang XS, 2004, GENOME RES, V14, P1767, DOI 10.1101/gr.2668204; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; Wehner JM, 1997, NAT GENET, V17, P331, DOI 10.1038/ng1197-331; Wiltshire T, 2003, P NATL ACAD SCI USA, V100, P3380, DOI 10.1073/pnas.0130101100; Yalcin B, 2005, GENETICS, V171, P673, DOI 10.1534/genetics.104.028902; Yalcin B, 2004, NAT GENET, V36, P1197, DOI 10.1038/ng1450	48	406	410	2	33	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2006	38	8					879	887		10.1038/ng1840	http://dx.doi.org/10.1038/ng1840			9	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	067TO	16832355				2022-12-25	WOS:000239325700016
J	Ching, YP; Chan, SF; Jeang, KT; Jin, DY				Ching, Yick-Pang; Chan, Shing-Fai; Jeang, Kuan-Teh; Jin, Dong-Yan			The retroviral oncoprotein Tax targets the coiled-coil centrosomal protein TAX1BP2 to induce centrosome overduplication	NATURE CELL BIOLOGY			English	Article							GENETIC INSTABILITY; TYPE-1 TAX; CELL-CYCLE; CENTRIOLE; DUPLICATION; SUPPRESSOR; AMPLIFICATION; ABERRATIONS; ACTIVATION; ROOTLETIN	Emerging evidence suggests that supernumerary centrosomes drive genome instability and oncogenesis(1-3). Human T-cell leukaemia virus type I ( HTLV-I) is etiologically associated with adult T-cell leukaemia ( ATL) 4. ATL cells are aneuploid, but the causes of aneuploidy are incompletely understood(5,6). Here, we show that centrosome amplification is frequent in HTLV-I-transformed cells and that this phenotype is caused by the viral Tax oncoprotein. We also show that the fraction of Tax protein that localizes to centrosomes interacts with TAX1BP2, a novel centrosomal protein composed almost entirely of coiled-coil domains. Overexpression of TAX1BP2 inhibited centrosome duplication, whereas depletion of TAX1BP2 by RNAi resulted in centrosome hyperamplification. Our findings suggest that the HTLV-I Tax oncoprotein targets TAX1BP2 causing genomic instability and aneuploidy.	Univ Hong Kong, Dept Biochem, Pokfulam, Hong Kong, Peoples R China; NIAID, Mol Microbiol Lab, Bethesda, MD 20892 USA	University of Hong Kong; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jin, DY (corresponding author), Univ Hong Kong, Dept Biochem, 21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	dyjin@hkucc.hku.hk	Jeang, Kuan-Teh/A-2424-2008; Ching, Yick Pang/C-4244-2009	CHING, Yick Pang/0000-0002-6461-8358	FIC NIH HHS [R01 TW06186-01] Funding Source: Medline; Intramural NIH HHS Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R01TW006186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI001023, Z01AI000547] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bahe S, 2005, J CELL BIOL, V171, P27, DOI 10.1083/jcb.200504107; Chin KT, 2005, NUCLEIC ACIDS RES, V33, P1859, DOI 10.1093/nar/gki332; Ching Yick-Pang, 2004, Retrovirology, V1, P18, DOI 10.1186/1742-4690-1-18; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Ching YP, 2002, J BIOL CHEM, V277, P15237, DOI 10.1074/jbc.C200032200; Chun ACS, 2000, AIDS RES HUM RETROV, V16, P1689, DOI 10.1089/08892220050193155; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Doxsey S, 2005, ANNU REV CELL DEV BI, V21, P411, DOI 10.1146/annurev.cellbio.21.122303.120418; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Forgues M, 2003, MOL CELL BIOL, V23, P5282, DOI 10.1128/MCB.23.15.5282-5292.2003; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Gallo RC, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-17; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; Gromley A, 2003, J CELL BIOL, V161, P535, DOI 10.1083/jcb.200301105; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Jin DY, 1997, J BIOL CHEM, V272, P25816, DOI 10.1074/jbc.272.41.25816; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Khodjakov A, 1999, J CELL BIOL, V146, P585, DOI 10.1083/jcb.146.3.585; Kramer A, 2005, LEUKEMIA, V19, P1142, DOI 10.1038/sj.leu.2403780; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsuoka M, 2005, CANCER RES, V65, P4467, DOI 10.1158/0008-5472.CAN-05-0559; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ou YY, 2002, J CELL SCI, V115, P1825; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Pihan GA, 1998, CANCER RES, V58, P3974; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Yang J, 2005, MOL CELL BIOL, V25, P4129, DOI 10.1128/MCB.25.10.4129-4137.2005; Yang J, 2002, J CELL BIOL, V159, P431, DOI 10.1083/jcb.200207153; Zou CZ, 2005, J CELL BIOL, V171, P437, DOI 10.1083/jcb.200506185	36	61	64	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2006	8	7					717	U143		10.1038/ncb1432	http://dx.doi.org/10.1038/ncb1432			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	060YJ	16767081				2022-12-25	WOS:000238837800014
J	Kirschenlohr, HL; Griffin, JL; Clarke, SC; Rhydwen, R; Grace, AA; Schofield, PM; Brindle, KM; Metcalfe, JC				Kirschenlohr, Heide L.; Griffin, Julian L.; Clarke, Sarah C.; Rhydwen, Ranyl; Grace, Andrew A.; Schofield, Peter M.; Brindle, Kevin M.; Metcalfe, James C.			Proton NMR analysis of plasma is a weak predictor of coronary artery disease	NATURE MEDICINE			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; CARDIOVASCULAR RISK-FACTORS; HEART-DISEASE; PRIOR KNOWLEDGE; H-1-NMR; WOMEN; ATHEROSCLEROSIS; QUANTIFICATION; LIPOPROTEINS; INVESTIGATE	Multivariate analysis of H-1-NMR spectra of blood sera was reported previously to predict angiographically defined advanced coronary artery disease ( CAD) with > 90% accuracy and specificity. The analysis depended mainly on the major lipid regions of the spectra, but many variables, including gender and drug treatment, affect lipid composition and are potential confounders. We have determined the predictive power of the same methodology for angiographically defined CAD using plasma samples from groups of male patients, classified by statin treatment, who had normal coronary arteries ( NCAs) or CAD. Predictions for NCA and CAD groups were only 80.3% correct for patients not treated with statins and 61.3% for treated patients, compared with random correct predictions of 50%. A confidence limit of > 99% was achieved for 36.2% of predictions for untreated groups and 6.2% for treated groups. Detection of CAD by H-1-NMR with > 99% confidence was therefore very weak compared with angiography.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Papworth Hosp, NHS Trust, Dept Cardiol, Cambridge CB3 8RE, England	University of Cambridge; Papworth Hospital	Metcalfe, JC (corresponding author), Univ Cambridge, Dept Biochem, Bldg O,Downing Site,Tennis Court Rd, Cambridge CB2 1QW, England.	jcm@mole.bio.cam.ac.uk			Biotechnology and Biological Sciences Research Council [E17880] Funding Source: Medline; Medical Research Council [G0100186] Funding Source: Medline; MRC [G0100186] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ANTHONY ML, 1994, MOL PHARMACOL, V46, P199; BELL JD, 1987, FEBS LETT, V219, P239, DOI 10.1016/0014-5793(87)81224-3; Bittner V, 2002, AM J CARDIOL, V90, p77I, DOI 10.1016/S0002-9149(02)02637-1; Blake GJ, 2002, CIRCULATION, V106, P1930, DOI 10.1161/01.CIR.0000033222.75187.B9; Brindle JT, 2002, NAT MED, V8, P1439, DOI 10.1038/nm802; Brindle JT, 2003, ANALYST, V128, P32, DOI 10.1039/b209155k; Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x; Clarke SC, 2001, CIRCULATION, V103, P1497; CRAIG WY, 1992, CLIN CHEM, V38, P550; Eriksson L, 2001, MULTI MEGAVARIATE DA, P43; Freedman DS, 2004, CLIN CHEM, V50, P1189, DOI 10.1373/clinchem.2004.032763; Gavaghan CL, 2000, FEBS LETT, V484, P169, DOI 10.1016/S0014-5793(00)02147-5; Jousilahti P, 1999, CIRCULATION, V99, P1165, DOI 10.1161/01.cir.99.9.1165; Le Moyec L, 2005, NMR BIOMED, V18, P421, DOI 10.1002/nbm.974; Legato MJ, 2000, AM J CARDIOL, V86, p15L; LIM HM, 1991, YALE J BIOL MED, V64, P63; LOUNILA J, 1994, PHYS REV LETT, V72, P4049, DOI 10.1103/PhysRevLett.72.4049; Mierisova S, 2001, NMR BIOMED, V14, P247, DOI 10.1002/nbm.697; PEDERSEN TR, 1994, LANCET, V344, P1383; Ransohoff DF, 2004, NAT REV CANCER, V4, P309, DOI 10.1038/nrc1322; Ransohoff DF, 2005, NAT REV CANCER, V5, P142, DOI 10.1038/nrc1550; VANDERVEEN JWC, 1988, MAGNET RESON MED, V6, P92, DOI 10.1002/mrm.1910060111; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244	23	137	147	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					705	710		10.1038/nm1432	http://dx.doi.org/10.1038/nm1432			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16732278				2022-12-25	WOS:000238149200035
J	Takegahara, N; Takamatsu, H; Toyofuku, T; Tsujimura, T; Okuno, T; Yukawa, K; Mizui, M; Yamamoto, M; Prasad, DVR; Suzuki, K; Ishii, M; Terai, K; Moriya, M; Nakatsuji, Y; Sakoda, S; Sato, S; Akira, S; Takeda, K; Inui, M; Takai, T; Ikawa, M; Okabe, M; Kumanogoh, A; Kikutani, H				Takegahara, Noriko; Takamatsu, Hyota; Toyofuku, Toshihiko; Tsujimura, Tohru; Okuno, Tatsusada; Yukawa, Kazunori; Mizui, Masayuki; Yamamoto, Midori; Prasad, Durbaka V. R.; Suzuki, Kazuhiro; Ishii, Masaru; Terai, Kenta; Moriya, Masayuki; Nakatsuji, Yuji; Sakoda, Saburo; Sato, Shintaro; Akira, Shizuo; Takeda, Kiyoshi; Inui, Masanori; Takai, Toshiyuki; Ikawa, Masahito; Okabe, Masaru; Kumanogoh, Atsushi; Kikutani, Hitoshi			Plexin-A1 and its interaction with DAP12 in immune responses and bone homeostasis	NATURE CELL BIOLOGY			English	Article							IV SEMAPHORIN CD100; T-CELL ACTIVATION; DAP12-DEFICIENT MICE; NONREDUNDANT ROLES; B-CELL; RECEPTOR; GUIDANCE; SYSTEM; EXPRESSION; MUTATIONS	Semaphorins and their receptors have diverse functions in axon guidance, organogenesis, vascularization and/or angiogenesis, oncogenesis and regulation of immune responses(1-11). The primary receptors for semaphorins are members of the plexin family(2,12-14). In particular, plexin-A1, together with ligand-binding neuropilins, transduces repulsive axon guidance signals for soluble class III semaphorins(15), whereas plexin-A1 has multiple functions in chick cardiogenesis as a receptor for the transmembrane semaphorin, Sema6D, independent of neuropilins(16). Additionally, plexin-A1 has been implicated in dendritic cell function in the immune system(17). However, the role of plexin-A1 in vivo, and the mechanisms underlying its pleiotropic functions, remain unclear. Here, we generated plexin-A1-deficient (plexin-A1(-/-)) mice and identified its important roles, not only in immune responses, but also in bone homeostasis. Furthermore, we show that plexin-A1 associates with the triggering receptor expressed on myeloid cells-2 (Trem2), linking semaphorin-signalling to the immuno-receptor tyrosine-based activation motif (ITAM)-bearing adaptor protein, DAP12. These findings reveal an unexpected role for plexin-A1 and present a novel signalling mechanism for exerting the pleiotropic functions of semaphorins.	Osaka Univ, Dept Mol Immunol, Suita, Osaka 5650871, Japan; Osaka Univ, CREST, Program JST, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Neurol, Suita, Osaka 5650871, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan; Osaka Univ, Genome Informat Res Ctr, Suita, Osaka 5650871, Japan; Wakayama Med Coll, Dept Physiol 2, Wakayama 6410012, Japan; Natl Osaka Med Ctr, Dept Clin Res, Osaka 5868521, Japan; ERATO, Japan Sci & Technol Agcy, Suita, Osaka 5650871, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Higashi Ku, Fukuoka 8128582, Japan; Tohoku Univ, Int Dev Aging & Canc, Dept Expt Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan; CREST, Program JST, Kawaguchi, Saitama 3320012, Japan	Osaka University; Japan Science & Technology Agency (JST); Osaka University; Osaka University; Osaka University; Osaka University; Osaka University; Wakayama Medical University; Japan Science & Technology Agency (JST); Kyushu University; Tohoku University; Japan Science & Technology Agency (JST)	Kumanogoh, A (corresponding author), Osaka Univ, Dept Mol Immunol, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	kumanogo@ragtime.biken.osaka-u.ac.jp; kikutani@ragtime.biken.osaka-u.ac.jp	Ishii, Masaru/D-2361-2009; Kumanogoh, Atsushi/C-7354-2009; Takegahara, Noriko/AAP-1694-2021; Akira, Shizuo/C-3134-2009; 寺井, 健太/AFQ-7663-2022; Mizui, Masayuki/AAD-1432-2019; Takeda, Kiyoshi/C-9331-2009; Kikutani, Hitoshi/C-9525-2009; Suzuki, Kazuhiro/B-3886-2012; ikawa, masahito/A-5315-2009; Okabe, Masaru/B-6917-2015	寺井, 健太/0000-0001-7638-3720; Mizui, Masayuki/0000-0003-2543-8108; ikawa, masahito/0000-0001-9859-6217; Okabe, Masaru/0000-0002-0803-9044; Suzuki, Kazuhiro/0000-0002-9081-538X; Takeda, Kiyoshi/0000-0002-1778-6332; Sato, Shintaro/0000-0001-5156-3354				Bakker ABH, 2000, IMMUNITY, V13, P345, DOI 10.1016/S1074-7613(00)00034-0; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106; Elhabazi A, 2003, CRIT REV IMMUNOL, V23, P65, DOI 10.1615/CritRevImmunol.v23.i12.40; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Granziero L, 2003, BLOOD, V101, P1962, DOI 10.1182/blood-2002-05-1339; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; Kaifu T, 2003, J CLIN INVEST, V111, P323, DOI 10.1172/JCI200316923; Kikutani H, 2003, NAT REV IMMUNOL, V3, P159, DOI 10.1038/nri1003; Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444; Kumanogoh A, 2005, IMMUNITY, V22, P305, DOI 10.1016/j.immuni.2005.01.014; Kumanogoh A, 2002, NATURE, V419, P629, DOI 10.1038/nature01037; Kumanogoh A, 2000, IMMUNITY, V13, P621, DOI 10.1016/S1074-7613(00)00062-5; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lanier LL, 2000, IMMUNOL TODAY, V21, P611, DOI 10.1016/S0167-5699(00)01745-X; Paloneva J, 2002, AM J HUM GENET, V71, P656, DOI 10.1086/342259; Paloneva J, 2000, NAT GENET, V25, P357, DOI 10.1038/77153; Pasterkamp RJ, 2003, CURR OPIN NEUROBIOL, V13, P79, DOI 10.1016/S0959-4388(03)00003-5; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Shi W, 2000, IMMUNITY, V13, P633, DOI 10.1016/S1074-7613(00)00063-7; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Toyofuku T, 2004, NAT CELL BIOL, V6, P1204, DOI 10.1038/ncb1193; Toyofuku T, 2004, GENE DEV, V18, P435, DOI 10.1101/gad.1167304; Turner LJ, 2004, J BIOL CHEM, V279, P33199, DOI 10.1074/jbc.M402943200; Walzer T, 2005, J IMMUNOL, V174, P51, DOI 10.4049/jimmunol.174.1.51; Wong AW, 2003, NAT IMMUNOL, V4, P891, DOI 10.1038/ni960	30	193	202	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					615	622		10.1038/ncb1416	http://dx.doi.org/10.1038/ncb1416			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16715077				2022-12-25	WOS:000238029000015
J	Fu, HQ; Wang, LX; Lin, CM; Singhania, S; Bouhassira, EE; Aladjem, MI				Fu, HQ; Wang, LX; Lin, CM; Singhania, S; Bouhassira, EE; Aladjem, MI			Preventing gene silencing with human replicators	NATURE BIOTECHNOLOGY			English	Article							BETA-GLOBIN LOCUS; DNA-REPLICATION; CONTROL REGION; ORIGIN; INITIATION; METHYLATION; EXPRESSION; CHROMATIN; CELLS; INACTIVATION	Transcriptional silencing, one of the major impediments to gene therapy in humans, is often accompanied by replication during late S-phase. We report that transcriptional silencing and late replication were prevented by DNA sequences that can initiate DNA replication (replicators). When replicators were included in silencing-prone transgenes, they did not undergo transcriptional silencing, replicated early and maintained histone acetylation patterns characteristic of euchromatin. A mutant replicator, which could not initiate replication, could not prevent gene silencing and replicated late when included in identical transgenes and inserted at identical locations. These observations suggest that replicators introduce epigenetic chromatin changes that facilitate initiation of DNA replication and affect gene silencing. Inclusion of functional replicators in gene therapy vectors may provide a tool for stabilizing gene expression patterns.	NCI, Mol Pharmacol Lab, Bethesda, MD 20892 USA; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Yeshiva University; Albert Einstein College of Medicine	Aladjem, MI (corresponding author), NCI, Mol Pharmacol Lab, Bethesda, MD 20892 USA.	aladjemm@mail.nih.gov	Aladjem, Mirit/G-2169-2010; Bouhassira, Eric/AAZ-4184-2021	Aladjem, Mirit/0000-0002-1875-3110; Fu, Haiqing/0000-0003-4764-1422	NATIONAL CANCER INSTITUTE [Z01BC010411] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056845] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [P01 HL55435] Funding Source: Medline; NIDDK NIH HHS [R01 DK56845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aggarwal BD, 2004, NATURE, V430, P372, DOI 10.1038/nature02694; Aladjem MI, 1998, SCIENCE, V281, P1005, DOI 10.1126/science.281.5379.1005; Aladjem MI, 2004, EMBO REP, V5, P686, DOI 10.1038/sj.embor.7400185; Aladjem MI, 2002, MOL CELL BIOL, V22, P442, DOI 10.1128/MCB.22.2.442-452.2002; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Azuara V, 2003, NAT CELL BIOL, V5, P668, DOI 10.1038/ncb1006; Bestor TH, 2000, J CLIN INVEST, V105, P409, DOI 10.1172/JCI9459; Bielinsky AK, 1998, SCIENCE, V279, P95, DOI 10.1126/science.279.5347.95; Danis E, 2004, NAT CELL BIOL, V6, P721, DOI 10.1038/ncb1149; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; Ellis J, 2005, HUM GENE THER, V16, P1241, DOI 10.1089/hum.2005.16.1241; Ellis J, 2001, CLIN GENET, V59, P17, DOI 10.1034/j.1399-0004.2001.590103.x; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; Ermakova OV, 1999, MOL CELL, V3, P321, DOI 10.1016/S1097-2765(00)80459-1; Feng YQ, 2001, MOL CELL BIOL, V21, P298, DOI 10.1128/MCB.21.1.298-309.2001; Feng YQ, 2005, MOL CELL BIOL, V25, P3864, DOI 10.1128/MCB.25.10.3864-3874.2005; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Ghosh M, 2004, MOL CELL BIOL, V24, P10193, DOI 10.1128/MCB.24.23.10193-10207.2004; Gilbert DM, 2002, CURR OPIN CELL BIOL, V14, P377, DOI 10.1016/S0955-0674(02)00326-5; Kalejta RF, 1998, MOL CELL, V2, P797, DOI 10.1016/S1097-2765(00)80294-4; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KITSBERG D, 1993, NATURE, V366, P588, DOI 10.1038/366588a0; Kobayashi T, 1998, MOL CELL BIOL, V18, P3266, DOI 10.1128/MCB.18.6.3266; Lin CM, 2003, CURR BIOL, V13, P1019, DOI 10.1016/S0960-9822(03)00382-8; Lorincz MC, 2002, MOL CELL BIOL, V22, P7572, DOI 10.1128/MCB.22.21.7572-7580.2002; Lorincz MC, 2001, MOL CELL BIOL, V21, P7913, DOI 10.1128/MCB.21.23.7913-7922.2001; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Mutskov V, 2004, EMBO J, V23, P138, DOI 10.1038/sj.emboj.7600013; Paixao S, 2004, MOL CELL BIOL, V24, P2958, DOI 10.1128/MCB.24.7.2958-2967.2004; Saha S, 2004, GENE DEV, V18, P397, DOI 10.1101/gad.1171404; Simon I, 2001, EMBO J, V20, P6150, DOI 10.1093/emboj/20.21.6150; Wang LX, 2004, MOL CELL BIOL, V24, P3373, DOI 10.1128/MCB.24.8.3373-3386.2004; Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8; Yao SY, 2004, MOL THER, V10, P27, DOI 10.1016/j.ymthe.2004.04.007; Zhou J, 2002, P NATL ACAD SCI USA, V99, P13693, DOI 10.1073/pnas.212392399	35	34	35	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2006	24	5					572	576		10.1038/nbt1202	http://dx.doi.org/10.1038/nbt1202			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	039TX	16604060				2022-12-25	WOS:000237331300033
J	Funato, Y; Michiue, T; Asashima, M; Miki, H				Funato, Y; Michiue, T; Asashima, M; Miki, H			The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled	NATURE CELL BIOLOGY			English	Article							AXIS FORMATION; CYCLIN D1; KINASE; ACCUMULATION; DOWNSTREAM; CLONING; TARGET; GENE	Dishevelled (Dvl) transduces signals from the Wnt receptor, Frizzled, to downstream components, leading to the stabilization of beta-catenin and subsequent activation of the transcription factor T cell factor (TCF) and/or lymphoid enchancer factor (LEF)(1-3). However, the mechanism of Dvl action remains unclear. Here, we report that nucleoredoxin (NRX)(4), a thioredoxin (TRX) family protein, interacts with Dvl. Overexpression of NRX selectively suppresses the Wnt-beta-catenin pathway and ablation of NRX by RNA-interference (RNAi) results in activation of TCF, accelerated cell proliferation and enhancement of oncogenicity through cooperation with mitogen-activated extracellular signal regulated kinase kinase (MEK) or Ras. We find that cells respond to H2O2 stimulation by activating TCF. Redox-dependent activation of the Wnt-beta-catenin pathway occurs independently of extracellular Wnts and is impaired by RNAi of NRX. In addition, association between Dvl and NRX is inhibited by H2O2 treatment. These data suggest a relationship between the Wnt-beta-catenin pathway and redox signalling through redox-sensitive association of NRX with Dvl.	Univ Tokyo, Inst Med Sci, Div Canc Genom, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Div Biochem, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci Biol, Meguro Ku, Tokyo 1538902, Japan; JST, ICORP, Tokyo 1538902, Japan; PRESTO, JST, Kawaguchi, Saitama 3320012, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Miki, H (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Genom, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	miki@ims.u-tokyo.ac.jp						Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Fujita M, 2001, CANCER RES, V61, P7722; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Kiecker C, 2001, DEVELOPMENT, V128, P4189; Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; LAURENT TC, 1964, J BIOL CHEM, V239, P3436; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Michiue T, 2004, DEV DYNAM, V230, P79, DOI 10.1002/dvdy.20037; Miki H, 1999, J BIOL CHEM, V274, P27605, DOI 10.1074/jbc.274.39.27605; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rhee SG, 2005, CURR OPIN CELL BIOL, V17, P183, DOI 10.1016/j.ceb.2005.02.004; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	30	285	298	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					501	U135		10.1038/ncb1405	http://dx.doi.org/10.1038/ncb1405			12	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16604061				2022-12-25	WOS:000237299400014
J	Fergus, GJ; Milne, L; Kulkarni, S; Sasaki, T; Walker, S; Andrews, S; Crabbe, T; Finan, P; Jones, G; Jackson, S; Camps, M; Rommel, C; Wymann, M; Hirsch, E; Hawkins, P; Stephens, L				Fergus, G. John; Milne, Laura; Kulkarni, Suhasini; Sasaki, Takehiko; Walker, Simon; Andrews, Simon; Crabbe, Tom; Finan, Peter; Jones, Gareth; Jackson, Shaun; Camps, Montserrat; Rommel, Christian; Wymann, Matthias; Hirsch, Emilio; Hawkins, Phillip; Stephens, Len			PI(3)K gamma has an important context-dependent role in neutrophil chemokinesis	NATURE CELL BIOLOGY			English	Article							3-KINASE; ACTIVATION; PI3K-GAMMA; DICTYOSTELIUM; CHEMOTAXIS; KINASE; ACTIN; GAMMA	The directional movement of cells in a gradient of external stimulus is termed chemotaxis and is important in many aspects of development and differentiated cell function. Phophoinositide 3-kinases (PI(3)Ks) are thought to have critical roles within the gradient-sensing machinery of a variety of highly motile cells(1,2), such as mammalian phagocytes(3), allowing these cells to respond quickly and efficiently to shallow gradients of soluble stimuli. Our analysis of mammalian neutrophil migration towards ligands such as fMLP shows that, although PtdIns(3,4)P-2 and PtdIns(3,4,5)P-3 accumulate in a PI(3)K gamma-dependent fashion at the up-gradient leading-edge, this signal is not required for efficient gradient-sensing and gradient-biased movement. PI(3)K gamma activity is however, a critical determinant of the proportion of cells that can move, that is, respond chemokinetically, in reaction to fMLP. Furthermore, this dependence of chemokinesis on PI(3)K gamma activity is context dependent, both with respect to the state of priming of the neutrophils and the type of surface on which they are migrating. We propose this effect of PI(3)K gamma is through roles in the regulation of some aspects of neutrophil polarization that are relevant to movement, such as integrin-based adhesion and the accumulation of polymerized (F)-actin at the leading-edge.	Babraham Inst, Cambridge CB22 3AT, England; Akita Univ, Akita 010, Japan; UCB, Slough SL1 4EN, Berks, England; Novartis, Cambridge, MA USA; Kings Coll London, London SE1 1UL, England; Monash Univ, Melbourne, Vic 3004, Australia; Serono Res Inst, CH-1211 Geneva, Switzerland; DKBW Univ, CH-4508 Basel, Switzerland; Univ Turin, I-10126 Turin, Italy	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Akita University; UCB Pharma SA; Novartis; University of London; King's College London; Monash University; University of Turin	Stephens, L (corresponding author), Babraham Inst, Cambridge CB22 3AT, England.	len.stephens@bbsrc.ac.uk	Jones, Gareth E/H-2282-2012; Wymann, Matthias P/C-3227-2008; Hirsch, Emilio/F-4848-2013	Jones, Gareth E/0000-0001-5879-3048; Wymann, Matthias P/0000-0003-3349-4281; Hirsch, Emilio/0000-0002-9073-6024; Sasaki, Takehiko/0000-0003-1837-3748; Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487; Camps, Montserrat/0000-0002-9849-8657; Jackson, Shaun/0000-0002-4750-1991; Walker, Simon/0000-0001-9185-4922				Coffer PJ, 1998, BIOCHEM J, V329, P121; Condliffe AM, 2005, BLOOD, V106, P1432, DOI 10.1182/blood-2005-03-0944; Dormann D, 2002, CELL MOTIL CYTOSKEL, V52, P221, DOI 10.1002/cm.10048; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Hannigan M, 2002, P NATL ACAD SCI USA, V99, P3603, DOI 10.1073/pnas.052010699; HASLETT C, 1985, AM J PATHOL, V119, P101; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Kanegasaki S, 2003, J IMMUNOL METHODS, V282, P1, DOI 10.1016/j.jim.2003.07.008; KELLER H, 1995, EUR J CELL BIOL, V66, P157; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Loovers HM, 2006, MOL BIOL CELL, V17, P1503, DOI 10.1091/mbc.E05-09-0825; Manahan CL, 2004, ANNU REV CELL DEV BI, V20, P223, DOI 10.1146/annurev.cellbio.20.011303.132633; Niggli V, 2000, FEBS LETT, V473, P217, DOI 10.1016/S0014-5793(00)01534-9; Niggli V, 1997, EUR J PHARMACOL, V335, P43, DOI 10.1016/S0014-2999(97)01169-2; NISHIO M, 2006, NATURE CELL BIOL, V8, DOI DOI 10.1028/NCB1515; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Sasaki Atsuo T, 2005, Novartis Found Symp, V269, P73; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SMITH DF, 2006, J LEUKOCYTE BIOL, DOI DOI 10.1189/JIB.0306227; Suire S, 2006, NAT CELL BIOL, V8, P1303, DOI 10.1038/ncb1494; Ward SG, 2004, TRENDS IMMUNOL, V25, P67, DOI 10.1016/j.it.2003.12.003; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Wells Claire M., 2004, V294, P31; Zicha D, 1997, Methods Mol Biol, V75, P449	29	202	208	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					86	U109		10.1038/ncb1517	http://dx.doi.org/10.1038/ncb1517			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17173040				2022-12-25	WOS:000243255100016
J	Liu, T; Ramesh, A; Ma, Z; Ward, SK; Zhang, LM; George, GN; Talaat, AM; Sacchettini, JC; Giedroc, DP				Liu, Tong; Ramesh, Arati; Ma, Zhen; Ward, Sarah K.; Zhang, Limei; George, Graham N.; Talaat, Adel M.; Sacchettini, James C.; Giedroc, David P.			CsoR is a novel Mycobacterium tuberculosis copper-sensing transcriptional regulator	NATURE CHEMICAL BIOLOGY			English	Article							CU,ZN SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; MERR FAMILY; PROTEIN; HOMEOSTASIS; EXPRESSION; REPRESSOR; REVEALS; BINDING; OPERON	Copper is an essential element that becomes highly cytotoxic when concentrations exceed the capacity of cells to sequester the ion. Here, we identify a new copper-specific repressor (CsoR) of a copper-sensitive operon (cso) in Mycobacterium tuberculosis (Mtb) that is representative of a large, previously uncharacterized family of proteins (DUF156). Electronic and X-ray absorption spectroscopies reveal that CsoR binds a single-monomer mole equivalent of Cu(I) to form a trigonally coordinated (S2N) Cu(I) complex. The 2.6-angstrom crystal structure of copper-loaded CsoR shows a homodimeric antiparallel four-helix bundle architecture that represents a novel DNA-binding fold. The Cu(I) is coordinated by Cys36, Cys65' and His61' in a subunit bridging site. Cu(I) binding negatively regulates the binding of CsoR to a DNA fragment encompassing the operator-promoter region of the Mtb cso operon; this results in derepression of the operon in Mtb and the heterologous host Mycobacterium smegmatis. Substitution of Cys36 or His61 with alanine abolishes Cu(I)- and CsoR-dependent regulation in vivo and in vitro. Potential roles of CsoR in Mtb pathogenesis are discussed.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Ctr Struct Biol, College Stn, TX 77843 USA; Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA; Univ Saskatchewan, Dept Geol Sci, Saskatoon, SK S7N 5C2, Canada	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; University of Wisconsin System; University of Wisconsin Madison; University of Saskatchewan	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	sacchett@tamu.edu; giedroc@tamu.edu	George, Graham N/E-3290-2013; Ma, Zhen/A-7151-2012; Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620; Ramesh, Arati/0000-0001-8655-0051; George, Graham/0000-0002-0420-7493	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI068135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215, R01GM042569, R01GM057375, R29GM042569] Funding Source: NIH RePORTER; NIAID NIH HHS [AI068135] Funding Source: Medline; NIGMS NIH HHS [GM057375, GM042569, T32 GM007215] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agranoff D, 2004, FRONT BIOSCI-LANDMRK, V9, P2996, DOI 10.2741/1454; Battistoni A, 2003, BIOCHEM SOC T, V31, P1326; Beaudoin J, 2003, J BIOL CHEM, V278, P14565, DOI 10.1074/jbc.M300861200; Bocharova OV, 2005, BIOCHEMISTRY-US, V44, P6776, DOI 10.1021/bi050251q; Brown KR, 2002, BIOCHEMISTRY-US, V41, P6469, DOI 10.1021/bi0160664; Brown NL, 2003, FEMS MICROBIOL REV, V27, P145, DOI 10.1016/S0168-6445(03)00051-2; Cavet JS, 2003, J BIOL CHEM, V278, P44560, DOI 10.1074/jbc.M307877200; Changela A, 2003, SCIENCE, V301, P1383, DOI 10.1126/science.1085950; Chao JA, 2005, NAT STRUCT MOL BIOL, V12, P952, DOI 10.1038/nsmb1005; Chen K, 2003, J AM CHEM SOC, V125, P12088, DOI 10.1021/ja036070y; COOPER JB, 1995, J MOL BIOL, V246, P531, DOI 10.1006/jmbi.1994.0105; D'Orazio M, 2001, BIOCHEM J, V359, P17, DOI 10.1042/0264-6021:3590017; Domenech P, 2002, FEMS MICROBIOL LETT, V207, P81, DOI 10.1016/S0378-1097(01)00552-3; Dong J, 2003, BIOCHEMISTRY-US, V42, P2768, DOI 10.1021/bi0272151; Eakin CM, 2006, NAT STRUCT MOL BIOL, V13, P202, DOI 10.1038/nsmb1068; Egli D, 2003, EMBO J, V22, P100, DOI 10.1093/emboj/cdg012; Francis MS, 1997, MICROB PATHOGENESIS, V22, P67, DOI 10.1006/mpat.1996.0092; Gaballa A, 2003, MICROBIOL-SGM, V149, P3413, DOI 10.1099/mic.0.26225-0; Graden JA, 1996, BIOCHEMISTRY-US, V35, P14583, DOI 10.1021/bi961642v; Graham JE, 1999, P NATL ACAD SCI USA, V96, P11554, DOI 10.1073/pnas.96.20.11554; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; Herring CD, 2004, J BACTERIOL, V186, P6714, DOI 10.1128/JB.186.20.6714-6720.2004; Iwig JS, 2006, MOL MICROBIOL, V62, P252, DOI 10.1111/j.1365-2958.2006.05369.x; Liu T, 2005, BIOCHEMISTRY-US, V44, P8673, DOI 10.1021/bi050450+; Liu T, 2004, J BIOL CHEM, V279, P17810, DOI 10.1074/jbc.M310560200; Mitrakul K, 2004, ORAL MICROBIOL IMMUN, V19, P395, DOI 10.1111/j.1399-302x.2004.00176.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; Palmgren MG, 1998, BBA-BIOENERGETICS, V1365, P37, DOI 10.1016/S0005-2728(98)00041-3; Pennella MA, 2005, BIOMETALS, V18, P413, DOI 10.1007/s10534-005-3716-8; Petris MJ, 2003, J BIOL CHEM, V278, P9639, DOI 10.1074/jbc.M209455200; Portmann R, 2006, BIOMETALS, V19, P61, DOI 10.1007/s10534-005-5381-3; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rasia RM, 2005, P NATL ACAD SCI USA, V102, P4294, DOI 10.1073/pnas.0407881102; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Rensing C, 2003, FEMS MICROBIOL REV, V27, P197, DOI 10.1016/S0168-6445(03)00049-4; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Schumacher MA, 2002, EMBO J, V21, P1210, DOI 10.1093/emboj/21.5.1210; Skaar EP, 2004, SCIENCE, V305, P1626, DOI 10.1126/science.1099930; Solioz M, 2003, FEMS MICROBIOL REV, V27, P183, DOI 10.1016/S0168-6445(03)00053-6; Spagnolo L, 2004, J BIOL CHEM, V279, P33447, DOI 10.1074/jbc.M404699200; Stoyanov JV, 2001, MOL MICROBIOL, V39, P502, DOI 10.1046/j.1365-2958.2001.02264.x; Strausak D, 1997, J BIOL CHEM, V272, P8932; Talaat AM, 2004, P NATL ACAD SCI USA, V101, P4602, DOI 10.1073/pnas.0306023101; Talaat AM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf103; Taylor AB, 2005, P NATL ACAD SCI USA, V102, P15459, DOI 10.1073/pnas.0506227102; TIMM JL, 1994, J BACTERIOL, V176, P6749, DOI 10.1128/JB.176.21.6749-6753.1994; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Wagner D, 2005, MICROBIOL-SGM, V151, P323, DOI 10.1099/mic.0.27213-0; Wheeler DL, 2000, NUCLEIC ACIDS RES, V28, P10, DOI 10.1093/nar/28.1.10; Xiao ZG, 2004, J AM CHEM SOC, V126, P3081, DOI 10.1021/ja0390350	52	248	254	2	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JAN	2007	3	1					60	68		10.1038/nchembio844	http://dx.doi.org/10.1038/nchembio844			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	118QE	17143269				2022-12-25	WOS:000242956000016
J	Poueymirou, WT; Auerbach, W; Frendewey, D; Hickey, JF; Escaravage, JM; Esau, L; Dore, A; Stevens, S; Adams, NC; Dominguez, MG; Gale, NW; Yancopoulos, GD; DeChiara, TM; Valenzuela, DM				Poueymirou, William T.; Auerbach, Wojtek; Frendewey, David; Hickey, Joseph F.; Escaravage, Jennifer M.; Esau, Lakeisha; Dore, Anthony T.; Stevens, Sean; Adams, Niels C.; Dominguez, Melissa G.; Gale, Nicholas W.; Yancopoulos, Geore D.; DeChiara, Thomas M.; Valenzuela, David M.			FO generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses	NATURE BIOTECHNOLOGY			English	Article							LYMPHOID DEVELOPMENT; ES CELLS; MUTAGENESIS; EXPRESSION; LINE	A useful approach for exploring gene function involves generating mutant mice from genetically modified embryonic stem (ES) cells. Recent advances in genetic engineering of ES cells have shifted the bottleneck in this process to the generation of mice. Conventional injections of ES cells into blastocyst hosts produce F0 generation chimeras that are only partially derived from ES cells, requiring additional breeding to obtain mutant mice that can be phenotyped. The tetraploid complementation approach directly yields mice that are almost entirely derived from ES cells, but it is inefficient, works only with certain hybrid ES cell lines and suffers from nonspecific lethality and abnormalities, complicating phenotypic analyses. Here we show that laser-assisted injection of either inbred or hybrid ES cells into eight cell-stage embryos efficiently yields F0 generation mice that are fully ES cell-derived and healthy, exhibit 100% germline transmission and allow immediate phenotypic analysis, greatly accelerating gene function assignment.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Wellcome Trust Sanger Institute; Regeneron	Valenzuela, DM (corresponding author), Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.	velocigene@regeneron.com		Frendewey, David/0000-0003-2305-3490				Adams NC, 2006, PRIN PRACT, P131; Auerbach W, 2000, BIOTECHNIQUES, V29, P1024, DOI 10.2144/00295st04; Austin CP, 2004, NAT GENET, V36, P921, DOI 10.1038/ng0904-921; Auwerx J, 2004, NAT GENET, V36, P925, DOI 10.1038/ng0904-925; CAO XQ, 1995, IMMUNITY, V2, P223, DOI 10.1016/1074-7613(95)90047-0; Capecchi MR, 2001, NAT MED, V7, P1086, DOI 10.1038/nm1001-1086; Cecconi F, 2002, Methods Mol Biol, V185, P335; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; Chen WSV, 2003, METHOD ENZYMOL, V365, P367; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004; EAKIN GS, 2005, DEV BIOL; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Evans MJ, 2001, NAT MED, V7, P1081, DOI 10.1038/nm1001-1081; Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101; Goldstein JL, 2001, NAT MED, V7, P1079, DOI 10.1038/nm1001-1079; McLaren A., 1984, Chimeras in developmental biology., P381; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nagy A., 2003, MANIPULATING MOUSE E; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PAPAIOANNOU VE, 1999, GENE TARGETING PRACT, P177; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Skarnes WC, 2004, NAT GENET, V36, P543, DOI 10.1038/ng0604-543; Smithies O, 2001, NAT MED, V7, P1083, DOI 10.1038/nm1001-1083; STEVENS S, 1980, SELECTED METHODS CEL; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561; Valenzuela DM, 2003, NAT BIOTECHNOL, V21, P652, DOI 10.1038/nbt822; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293	29	164	257	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	2007	25	1					91	99		10.1038/nbt1263	http://dx.doi.org/10.1038/nbt1263			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	126CY	17187059	hybrid			2022-12-25	WOS:000243491000034
J	Buck, MJ; Lieb, JD				Buck, Michael J.; Lieb, Jason D.			A chromatin-mediated mechanism for specification of conditional transcription factor targets	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; GENOME-WIDE; DNA-BINDING; HDA1 DEACETYLASE; OSMOTIC-STRESS; REPRESSION; YEAST; COMPLEX; GENES; IDENTIFICATION	Organisms respond to changes in their environment, and many such responses are initiated at the level of gene transcription. Here, we provide evidence for a previously undiscovered mechanism for directing transcriptional regulators to new binding targets in response to an environmental change. We show that repressor-activator protein 1 (Rap1), a master regulator of yeast metabolism, binds to an expanded target set after glucose depletion despite decreasing protein levels and no evidence of posttranslational modification. Computational analysis predicts that proteins capable of recruiting the chromatin regulator Tup1 act to restrict the binding distribution of Rap1 in the presence of glucose. Deletion of the gene(s) encoding Tup1, recruiters of Tup1 or chromatin regulators recruited by Tup1 cause Rap1 to bind specifically and inappropriately to low-glucose targets. These data, combined with whole-genome measurements of nucleosome occupancy and Tup1 distribution, provide evidence for a mechanism of dynamic target specification that coordinates the genome-wide distribution of intermediate-affinity DNA sequence motifs with chromatin-mediated regulation of accessibility to those sites.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Genome Sci, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Lieb, JD (corresponding author), Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA.	jlieb@bio.unc.edu		Lieb, Jason/0000-0001-7601-8061	NHGRI NIH HHS [HG0029989] Funding Source: Medline; NIGMS NIH HHS [R01 GM072518-01A1, R01 GM072518-02, GM072518, R01 GM072518] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072518] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Buck MJ, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r97; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Davie JK, 2003, J BIOL CHEM, V278, P50158, DOI 10.1074/jbc.M309753200; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Green SR, 2004, MOL BIOL CELL, V15, P4191, DOI 10.1091/mbc.E04-05-0412; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Haverty PM, 2004, NUCLEIC ACIDS RES, V32, P179, DOI 10.1093/nar/gkh183; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Liu XS, 2002, NAT BIOTECHNOL, V20, P835, DOI 10.1038/nbt717; Mukherjee S, 2004, NAT GENET, V36, P1331, DOI 10.1038/ng1473; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Park SH, 1999, MOL CELL BIOL, V19, P2044; Proft M, 2005, EUKARYOT CELL, V4, P1343, DOI 10.1128/EC.4.8.1343-1352.2005; Proft M, 1999, MOL CELL BIOL, V19, P537; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Rao B, 2005, MOL CELL BIOL, V25, P9447, DOI 10.1128/MCB.25.21.9447-9459.2005; Regnacq M, 2001, MOL MICROBIOL, V40, P1085, DOI 10.1046/j.1365-2958.2001.02450.x; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; Smith RL, 2000, TRENDS BIOCHEM SCI, V25, P325, DOI 10.1016/S0968-0004(00)01592-9; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5; Zhang Z, 2004, EMBO J, V23, P2246, DOI 10.1038/sj.emboj.7600227; Zhu H, 2000, NAT GENET, V26, P283, DOI 10.1038/81576; ZUBAY G, 1970, P NATL ACAD SCI USA, V66, P104, DOI 10.1073/pnas.66.1.104	30	74	75	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2006	38	12					1446	1451		10.1038/ng1917	http://dx.doi.org/10.1038/ng1917			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17099712	Green Submitted, Green Accepted			2022-12-25	WOS:000242404200024
J	Soto-Gutierrez, A; Kobayashi, N; Rivas-Carrillo, JD; Navarro-Alvarez, N; Zhao, DB; Okitsu, T; Noguchi, H; Basma, H; Tabata, Y; Chen, Y; Tanaka, K; Narushima, M; Miki, A; Ueda, T; Jun, HS; Yoon, JW; Lebkowski, J; Tanaka, N; Fox, IJ				Soto-Gutierrez, Alejandro; Kobayashi, Naoya; Rivas-Carrillo, Jorge David; Navarro-Alvarez, Nalu; Zhao, Debaio; Okitsu, Teru; Noguchi, Hirofumi; Basma, Hesham; Tabata, Yashuhiko; Chen, Yong; Tanaka, Kimiaki; Narushima, Michiki; Miki, Atsushi; Ueda, Tadayoshi; Jun, Hee-Sook; Yoon, Ji-Won; Lebkowski, Jane; Tanaka, Noriaki; Fox, Ira J.			Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes	NATURE BIOTECHNOLOGY			English	Article							EMBRYONIC STEM-CELLS; BIOARTIFICIAL LIVER; DEFINITIVE ENDODERM; TERATOMA FORMATION; IN-VITRO; DIFFERENTIATION; RATS; LINE; ESTABLISHMENT; GROWTH	Severe acute liver failure, even when transient, must be treated by transplantation and lifelong immune suppression. Treatment could be improved by bioartificial liver ( BAL) support, but this approach is hindered by a shortage of human hepatocytes. To generate an alternative source of cells for BAL support, we differentiated mouse embryonic stem (ES) cells into hepatocytes by coculture with a combination of human liver nonparenchymal cell lines and fibroblast growth factor- 2, human activin A and hepatocyte growth factor. Functional hepatocytes were isolated using albumin promoter - based cell sorting. ES cell - derived hepatocytes expressed liver- specific genes, secreted albumin and metabolized ammonia, lidocaine and diazepam. Treatment of 90% hepatectomized mice with a subcutaneously implanted BAL seeded with ES cell - derived hepatocytes or primary hepatocytes improved liver function and prolonged survival, whereas treatment with a BAL seeded with control cells did not. After functioning in the BAL, ES cell - derived hepatocytes developed characteristics nearly identical to those of primary hepatocytes.	Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68198 USA; Okayama Univ, Grad Sch Med & Dent, Dept Surg, Okayama 7008558, Japan; Roslin Inst, Roslin EH10 4AN, Midlothian, Scotland; Kyoto Univ Hosp, Dept Transplantat, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan; Dainippon Pharmaceut Co Ltd, Div Lab Prod, Osaka, Japan; Finch Univ Hlth Sci Chicago Med Sch, Rosalilnd Franklin Comprehens Diabet Ctr, N Chicago, IL 60064 USA; Chosun Univ, Sch Med, Dept Biochem, Kwangju 501759, South Korea; Geron Corp, Menlo Pk, CA 94025 USA	University of Nebraska System; University of Nebraska Medical Center; Okayama University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Kyoto University; Kyoto University; Dainippon Sumitomo Pharmaceutical Company; Chicago Medical School; Rosalind Franklin University Medical & Science; Chosun University; Geron Corporation	Fox, IJ (corresponding author), Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68198 USA.	immortal@md.okayama-u.ac.jp; ijfox@unmc.edu	Navarro, Nalu/AAI-1034-2019	Navarro, Nalu/0000-0003-0118-4676; Noguchi, Hirofumi/0000-0002-0880-6805; Jun, Hee-Sook/0000-0002-1166-4932	NIDDK NIH HHS [DK48794] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048794] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe T, 2004, THER APHER DIAL, V8, P180, DOI 10.1111/j.1526-0968.2004.00149.x; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Block GD, 1996, J CELL BIOL, V132, P1133, DOI 10.1083/jcb.132.6.1133; Chen SC, 1997, ANN NY ACAD SCI, V831, P350; Chen Y, 2005, TRANSPLANTATION, V79, P1378, DOI 10.1097/01.TP.0000160813.37515.97; Chinzei R, 2002, HEPATOLOGY, V36, P22, DOI 10.1053/jhep.2002.34136; D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163; Demetriou AA, 2004, ANN SURG, V239, P660, DOI 10.1097/01.sla.0000124298.74199.e5; Fujikawa T, 2005, AM J PATHOL, V166, P1781, DOI 10.1016/S0002-9440(10)62488-1; Gomez N, 1997, TRANSPLANTATION, V63, P1718, DOI 10.1097/00007890-199706270-00003; IKEDA H, 2006, IN PRESS TISSUE ENG; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kobayashi N, 2000, SCIENCE, V287, P1258, DOI 10.1126/science.287.5456.1258; Kobayashi N, 2000, HEPATOLOGY, V31, P851, DOI 10.1053/he.2000.5636; Kubo A, 2004, DEVELOPMENT, V131, P1651, DOI 10.1242/dev.01044; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lavon N, 2004, DIFFERENTIATION, V72, P230, DOI 10.1111/j.1432-0436.2004.07205002.x; LEE WM, 1993, NEW ENGL J MED, V329, P1862, DOI 10.1056/NEJM199312163292508; Maruyama M, 2004, TRANSPLANTATION, V77, P446, DOI 10.1097/01.TP.0000110292.73873.25; Matsumura T, 2004, TRANSPLANTATION, V77, P1357, DOI 10.1097/01.TP.0000124286.82961.7E; Nagata H, 2003, GASTROENTEROLOGY, V124, P422, DOI 10.1053/gast.2003.50065; Narushima M, 2005, NAT BIOTECHNOL, V23, P1274, DOI 10.1038/nbt1145; Noguchi H, 2002, HUM GENE THER, V13, P321, DOI 10.1089/10430340252769833; Oh SH, 2000, BIOCHEM BIOPH RES CO, V279, P500, DOI 10.1006/bbrc.2000.3985; Platt JL, 1997, NAT MED, V3, P26, DOI 10.1038/nm0197-26; Rafael E, 2000, CELL TRANSPLANT, V9, P107, DOI 10.1177/096368970000900113; Rambhatla L, 2003, CELL TRANSPLANT, V12, P1, DOI 10.3727/000000003783985179; Rifai K, 2003, J HEPATOL, V39, P984, DOI 10.1016/S0168-8278(03)00468-9; Roger V, 1998, ANN SURG, V228, P1, DOI 10.1097/00000658-199807000-00001; Schwartz RE, 2002, J CLIN INVEST, V109, P1291, DOI 10.1172/JCI200215182; Sen S, 2004, LIVER TRANSPLANT, V10, P1109, DOI 10.1002/lt.20236; SERRA R, 1993, J CELL PHYSIOL, V154, P543, DOI 10.1002/jcp.1041540313; Soto-Gutierrez A, 2006, CELL TRANSPLANT, V15, P335, DOI 10.3727/000000006783981945; Teramoto K, 2005, TRANSPL P, V37, P285, DOI 10.1016/j.transproceed.2004.12.120; Teratani T, 2005, HEPATOLOGY, V41, P836, DOI 10.1002/hep.20629; van de Kerkhove MP, 2005, J HEPATOL, V42, P541, DOI 10.1016/j.jhep.2004.11.041; Wang WJ, 2002, TRANSPLANTATION, V73, P122, DOI 10.1097/00007890-200201150-00023; Watanabe T, 2003, TRANSPLANTATION, V75, P1873, DOI 10.1097/01.TP.0000064621.50907.A6; WILLIAMS DE, 1994, PUBLIC RELAT REV, V20, P5, DOI 10.1016/0363-8111(94)90110-4; Yamada T, 2002, STEM CELLS, V20, P146, DOI 10.1634/stemcells.20-2-146; Yamamoto H, 2003, HEPATOLOGY, V37, P983, DOI 10.1053/jhep.2003.50202; Yasunaga M, 2005, NAT BIOTECHNOL, V23, P1542, DOI 10.1038/nbt1167	43	169	187	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2006	24	11					1412	1419		10.1038/nbt1257	http://dx.doi.org/10.1038/nbt1257			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	106TP	17086173	Green Submitted			2022-12-25	WOS:000242124700038
J	Suire, S; Condliffe, AM; Ferguson, GJ; Ellson, CD; Guillou, H; Davidson, K; Welch, H; Coadwell, J; Turner, M; Chilvers, ER; Hawkins, PT; Stephens, L				Suire, Sabine; Condliffe, Alison M.; Ferguson, G. John; Ellson, Chris D.; Guillou, Herve; Davidson, Keith; Welch, Heidi; Coadwell, John; Turner, Martin; Chilvers, Edwin R.; Hawkins, Phillip T.; Stephens, Len			G beta gamma s and the Ras binding domain of p110 gamma are both important regulators of PI(3)K gamma signalling in neutrophils	NATURE CELL BIOLOGY			English	Article							PHOSPHOINOSITIDE 3-KINASE; CELL POLARITY; ACTIVATION; PI3K-GAMMA; ROLES; PI3K; IB; RECRUITMENT; KINASE	Through their ability to regulate production of the key lipid messenger PtdIns(3,4,5)P-3, the class I phosphatidylinositol-3-OH kinases (PI(3)Ks) support many critical cell responses(1,2). They, in turn, can be regulated by cell-surface receptors through signals acting on either their adaptor subunits (for example, through phosphotyrosine or G beta gamma s) or their catalytic subunits (for example, through GTP-Ras). The relative significance of these controlling inputs is undefined in vivo. Here, we have studied the roles of G beta gamma s, the adaptor p101, Ras and the Ras binding domain (RBD) in the control of the class I PI(3)K, PI(3)K gamma, in mouse neutrophils. Loss of p101 leads to major reductions in the accumulation of PtdIns(3,4,5)P-3, activation of protein kinase B (PKB) and in migration towards G-protein activating ligands in vitro, and to an aseptically inflamed peritoneum in vivo. Loss of sensitivity of PI(3)K gamma to Ras unexpectedly caused similar reductions, but additionally caused a substantial loss in production of reactive oxygen species (ROS). We conclude that G beta gamma s, p101 and the Ras-RBD interaction all have important roles in the regulation of PI(3)K gamma in vivo and that they can simultaneously, but differentially, control distinct PI(3)K gamma effectors.	Babraham Inst, Babraham CB22 3AT, Cambs, England; Univ Cambridge, Addenbrookes Hosp, Resp Med Div, Sch Clin Med, Cambridge CB2 2QQ, England; Univ Cambridge, Sch Clin Med, Resp Med Div, Papworth Hosp, Cambridge, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Papworth Hospital; University of Cambridge	Stephens, L (corresponding author), Babraham Inst, Babraham CB22 3AT, Cambs, England.	len.stephens@bbsrc.ac.uk	Turner, Martin/N-9976-2014; Guillou, Herve/AAG-2826-2020; Guillou, Hervé/AGL-0750-2022	Turner, Martin/0000-0002-3801-9896; Guillou, Herve/0000-0002-5363-9081; Guillou, Hervé/0000-0002-5363-9081; Welch, Heidi/0000-0001-7865-7000; Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487; suire, sabine/0000-0002-2773-2215; condliffe, alison/0000-0002-6697-8648; Chilvers, Edwin/0000-0002-4230-9677	BBSRC [BB/D013593/1] Funding Source: UKRI; MRC [G120/825, G117/424] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/E/B/0000M090, BB/D013593/1, C20177, C19943] Funding Source: Medline; Medical Research Council [G120/825, G117/424] Funding Source: Medline; Wellcome Trust Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Brock C, 2003, J CELL BIOL, V160, P89, DOI 10.1083/jcb.200210115; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Coffer PJ, 1998, BIOCHEM J, V329, P121; Condliffe AM, 2005, BLOOD, V106, P1432, DOI 10.1182/blood-2005-03-0944; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; Krugmann S, 2002, BIOCHEM J, V362, P725, DOI 10.1042/0264-6021:3620725; Krugmann S, 1997, BIOCHEM SOC T, V25, pS604, DOI 10.1042/bst025s604; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Puri KD, 2005, BLOOD, V106, P150, DOI 10.1182/blood-2005-01-0023; Rickert P, 2000, TRENDS CELL BIOL, V10, P466, DOI 10.1016/S0962-8924(00)01841-9; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sasaki AT, 2004, J CELL BIOL, V167, P505, DOI 10.1083/jcb.200406177; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Sheppard FR, 2005, J LEUKOCYTE BIOL, V78, P1025, DOI 10.1189/jlb.0804442; Simon SI, 2005, ANNU REV BIOMED ENG, V7, P151, DOI 10.1146/annurev.bioeng.7.060804.100423; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Suire S, 2005, CURR BIOL, V15, P566, DOI 10.1016/j.cub.2005.02.020; Suire S, 2002, CURR BIOL, V12, P1068, DOI 10.1016/S0960-9822(02)00933-8; Thomas MJ, 2005, EUR J IMMUNOL, V35, P1283, DOI 10.1002/eji.200425634; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Voigt P, 2006, J BIOL CHEM, V281, P9977, DOI 10.1074/jbc.M512502200; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Welch HCE, 2005, CURR BIOL, V15, P1867, DOI 10.1016/j.cub.2005.09.050; Wymann MP, 2005, CURR OPIN CELL BIOL, V17, P141, DOI 10.1016/j.ceb.2005.02.011; Zheng LM, 1997, J BIOL CHEM, V272, P23448, DOI 10.1074/jbc.272.37.23448	32	134	138	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1303	1309		10.1038/ncb1494	http://dx.doi.org/10.1038/ncb1494			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17041586				2022-12-25	WOS:000241732400021
J	Dagia, NM; Gadhoum, SZ; Knoblauch, CA; Spencer, JA; Zamiri, P; Lin, CP; Sackstein, R				Dagia, Nilesh M.; Gadhoum, Samah Z.; Knoblauch, Christine A.; Spencer, Joel A.; Zamiri, Parisa; Lin, Charles P.; Sackstein, Robert			G-CSF induces E-selectin ligand expression on human myeloid cells	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; GRANULOCYTE-COLONY; IN-VIVO; RHEUMATOID-ARTHRITIS; ENDOTHELIAL-CELLS; HUMAN NEUTROPHILS; BONE-MARROW; ADHESION; PSGL-1; BLOOD	Clinical use of G-CSF can result in vascular and inflammatory complications(1-7). To investigate the molecular basis of these effects, we analyzed the adherence of G-CSF-mobilized human peripheral blood leukocytes (ML) to inflamed (TNF-alpha - stimulated) vascular endothelium. Studies using parallel plate assays under physiologic flow conditions and intravital microscopy in a mouse inflammation model each showed that ML take part in heightened adhesive interactions with endothelium compared to unmobilized (native) blood leukocytes, mediated by markedly increased E-selectin receptor-ligand interactions. Biochemical studies showed that ML express the potent E-selectin ligand HCELL (ref. 8) and another, previously unrecognized similar to 65-kDa E-selectin ligand, and possess enhanced levels of transcripts encoding glycosyltransferases (ST3GaIIIV, FucT-IV and FucT-VII) conferring glycan modifications associated with E-selectin ligand activity. Enzymatic treatments and physiologic binding assays showed that HCELL and the similar to 65-kDa E-selectin ligand contribute prominently to the observed G-CSF-induced myeloid cell adhesion to inflamed endothelium. Treatment of normal human bone marrow cells with a pharmacokinetically relevant concentration of G-CSF in vitro(9,10) resulted in increased expression of these two molecules, coincident with increased transcripts encoding pertinent glycosyltransferases and heightened E-selectin binding. These findings provide direct evidence for a role of G-CSF in the induction of E-selectin ligands on myeloid cells, thus providing mechanistic insight into the pathobiology of G-CSF complications.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Harvard Skin Dis Res Ctr, Boston, MA 02115 USA; Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute	Sackstein, R (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Dermatol, 77 Ave Louis Pasteur,Room 671, Boston, MA 02115 USA.	rsackstein@rics.bwh.harvard.edu	Spencer, Joel/GLT-9687-2022; Spencer, Joel/A-4590-2013	Spencer, Joel/0000-0002-4013-8763; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073714, R01HL060528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000664] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL060528, R01 HL073714] Funding Source: Medline; NIBIB NIH HHS [R01 EB000664] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Adler BK, 2001, BLOOD, V97, P3313, DOI 10.1182/blood.V97.10.3313; ALBERT RK, 1995, THORAX, V50, pS49, DOI 10.1136/thx.50.Suppl_1.S49; Arimura Kosei, 2005, Haematologica, V90, pECR10; BUSSOLINO F, 1989, NATURE, V337, P471, DOI 10.1038/337471a0; Cowland JB, 1999, J IMMUNOL METHODS, V232, P191, DOI 10.1016/S0022-1759(99)00176-3; Dereure O, 2004, BRIT J DERMATOL, V150, P1228, DOI 10.1111/j.1365-2133.2004.06007.x; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; Elfenbein GJ, 2004, EXP HEMATOL, V32, P327, DOI 10.1016/j.exphem.2004.01.010; Faulkner LB, 1998, BONE MARROW TRANSPL, V21, P1091, DOI 10.1038/sj.bmt.1701241; Fuhlbrigge RC, 2002, J IMMUNOL, V168, P5645, DOI 10.4049/jimmunol.168.11.5645; Fukumoto Y, 1997, BRIT J HAEMATOL, V97, P666, DOI 10.1046/j.1365-2141.1997.842724.x; Fuste B, 2004, HAEMATOLOGICA, V89, P578; Glass LF, 1996, J AM ACAD DERMATOL, V34, P455, DOI 10.1016/S0190-9622(96)90439-9; Hakansson L, 1997, BRIT J HAEMATOL, V98, P603, DOI 10.1046/j.1365-2141.1997.2723093.x; Hill JM, 2005, J AM COLL CARDIOL, V46, P1643, DOI 10.1016/j.jacc.2005.01.067; Jilma B, 2002, TRANSFUSION, V42, P328, DOI 10.1046/j.1537-2995.2002.00045.x; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kieffer JD, 2001, BIOCHEM BIOPH RES CO, V285, P577, DOI 10.1006/bbrc.2001.5230; KRIEGSMANN J, 1995, ARTHRITIS RHEUM, V38, P750, DOI 10.1002/art.1780380606; LINDEMANN A, 1993, EUR J CANCER, V29A, P2338, DOI 10.1016/0959-8049(93)90236-9; OHSAKA A, 1993, BRIT J HAEMATOL, V84, P574, DOI 10.1111/j.1365-2141.1993.tb03130.x; Sackstein R, 2005, CURR OPIN HEMATOL, V12, P444, DOI 10.1097/01.moh.0000177827.78280.79; Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703; Smith ML, 2004, J EXP MED, V200, P935, DOI 10.1084/jem.20040424; Stricker RB, 1996, AM J MED, V100, P665; van der Auwera P, 2001, AM J HEMATOL, V66, P245, DOI 10.1002/ajh.1052; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; Xia LJ, 2002, J CLIN INVEST, V109, P939; Zollner O, 1997, J CELL BIOL, V136, P707, DOI 10.1083/jcb.136.3.707; Zou XY, 2005, AM J PHYSIOL-CELL PH, V289, pC415, DOI 10.1152/ajpcell.00289.2004	30	44	52	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1185	1190		10.1038/nm1470	http://dx.doi.org/10.1038/nm1470			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	16980970				2022-12-25	WOS:000241102200036
J	Ding, M; Cui, SY; Li, CJ; Jothy, S; Haase, V; Steer, BM; Marsden, PA; Pippin, J; Shankland, S; Rastaldi, MP; Cohen, CD; Kretzler, M; Quaggin, SE				Ding, Mei; Cui, Shiying; Li, Chengjin; Jothy, Serge; Haase, Volker; Steer, Brent M.; Marsden, Philip A.; Pippin, Jeffrey; Shankland, Stuart; Rastaldi, Maria Pia; Cohen, Clemens D.; Kretzler, Matthias; Quaggin, Susan E.			Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice	NATURE MEDICINE			English	Article							RENAL-CELL-CARCINOMA; CRESCENTIC GLOMERULONEPHRITIS; EXPRESSION; PROTEIN; EXCISION; RECEPTOR; KIDNEY; CANCER; VEGF	Rapidly progressive glomerulonephritis (RPGN) is a clinical syndrome characterized by loss of renal function within days to weeks and by glomerular crescents on biopsy. The pathogenesis of this disease is unclear, but circulating factors are believed to have a major role(1,2). Here, we show that deletion of the Von Hippel - Lindau gene (Vhlh) from intrinsic glomerular cells of mice is sufficient to initiate a necrotizing crescentic glomerulonephritis and the clinical features that accompany RPGN. Loss of Vhlh leads to stabilization of hypoxia-inducible factor alpha subunits (HIFs). Using gene expression profiling, we identified de novo expression of the HIF target gene Cxcr4 (ref. 3) in glomeruli from both mice and humans with RPGN. The course of RPGN is markedly improved in mice treated with a blocking antibody to Cxcr4, whereas overexpression of Cxcr4 alone in podocytes of transgenic mice is sufficient to cause glomerular disease. Collectively, these results indicate an alternative mechanism for the pathogenesis of RPGN and glomerular disease in an animal model and suggest novel molecular pathways for intervention in this disease.	Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Univ Toronto, St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada; Univ Penn, Dept Med, Program Cell Growth & Canc, Philadelphia, PA 19104 USA; Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1W8, Canada; Univ Washington, Div Nephrol, Seattle, WA 98195 USA; San Carlo Hosp, Fdn Damico Ric Malattie Renali, Renal Immunopathol Lab, I-20153 Milan, Italy; Univ Munich, Med Poliklin, Nephrol Zentrum, D-80336 Munich, Germany	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Pennsylvania; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Washington; University of Washington Seattle; San Carlo Borromeo Hospital; University of Munich	Quaggin, SE (corresponding author), Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	quaggin@mshri.on.ca	Cui, Steve W./D-4909-2013; Marsden, Philip A/B-1441-2012; Haase, Volker Hans/AAJ-5061-2021; Haase, Volker Hans/A-6758-2013	Cui, Steve W./0000-0001-5864-4544; Haase, Volker Hans/0000-0002-7051-8994	NCI NIH HHS [R01 CA100787] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100787] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Cohen CD, 2002, KIDNEY INT, V61, P133, DOI 10.1046/j.1523-1755.2002.00113.x; Cui SY, 2005, J AM SOC NEPHROL, V16, P3247, DOI 10.1681/ASN.2005030278; DAVIES DJ, 1982, BMJ-BRIT MED J, V285, P606, DOI 10.1136/bmj.285.6342.606; Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423; Eremina V, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133788; FALK RJ, 1990, P NATL ACAD SCI USA, V87, P4115, DOI 10.1073/pnas.87.11.4115; Galban S, 2003, MOL CELL BIOL, V23, P2316, DOI 10.1128/MCB.23.7.2316-2328.2003; Grone HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134957; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hedger N, 2000, NEPHROL DIAL TRANSPL, V15, P1593, DOI 10.1093/ndt/15.10.1593; KAGAN A, 1993, NEPHRON, V65, P642, DOI 10.1159/000187581; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Li CG, 1998, BRIT J RHEUMATOL, V37, P1303; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Moeller MJ, 2004, J AM SOC NEPHROL, V15, P61, DOI 10.1097/01.ASN.0000102468.37809.C6; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; Sommer M, 1998, NEPHROL DIAL TRANSPL, V13, P2107, DOI 10.1093/ndt/13.8.2107; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Timoshanko JR, 2003, J AM SOC NEPHROL, V14, P1785, DOI 10.1097/01.ASN.0000073902.38428.33; Wada T, 2005, KIDNEY INT, V68, P1618, DOI 10.1111/j.1523-1755.2005.00574.x; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200	26	166	173	0	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2006	12	9					1081	1087		10.1038/nm1460	http://dx.doi.org/10.1038/nm1460			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16906157				2022-12-25	WOS:000240373900033
J	Schneiker, S; dos Santos, VAPM; Bartels, D; Bekel, T; Brecht, M; Buhrmester, J; Chernikova, TN; Denaro, R; Ferrer, M; Gertler, C; Goesmann, A; Golyshina, OV; Kaminski, F; Khachane, AN; Lang, S; Linke, B; McHardy, AC; Meyer, F; Nechitaylo, T; Puhler, A; Regenhardt, D; Rupp, O; Sabirova, JS; Selbitschka, W; Yakimov, MM; Timmis, KN; Vorholter, FJ; Weidner, S; Kaiser, O; Golyshin, PN				Schneiker, Susanne; dos Santos, Vitor A. P. Martins; Bartels, Daniela; Bekel, Thomas; Brecht, Martina; Buhrmester, Jens; Chernikova, Tatyana N.; Denaro, Renata; Ferrer, Manuel; Gertler, Christoph; Goesmann, Alexander; Golyshina, Olga V.; Kaminski, Filip; Khachane, Amit N.; Lang, Siegmund; Linke, Burkhard; McHardy, Alice C.; Meyer, Folker; Nechitaylo, Taras; Puehler, Alfred; Regenhardt, Daniela; Rupp, Oliver; Sabirova, Julia S.; Selbitschka, Werner; Yakimov, Michail M.; Timmis, Kenneth N.; Vorhoelter, Frank-Jorg; Weidner, Stefan; Kaiser, Olaf; Golyshin, Peter N.			Genome sequence of the ubiquitous hydrocarbon-degrading marine bacterium Alcanivorax borkumensis	NATURE BIOTECHNOLOGY			English	Article							FUNCTIONAL-ANALYSIS; ALKANE; GENES; BIODEGRADATION; IDENTIFICATION; DEGRADATION; STRATEGIES; DIVERSITY; DATABASE; SYSTEMS	Alcanivorax borkumensis is a cosmopolitan marine bacterium that uses oil hydrocarbons as its exclusive source of carbon and energy. Although barely detectable in unpolluted environments, A. borkumensis becomes the dominant microbe in oil-polluted waters. A. borkumensis SK2 has a streamlined genome with a paucity of mobile genetic elements and energy generation related genes, but with a plethora of genes accounting for its wide hydrocarbon substrate range and efficient oil-degradation capabilities. The genome further specifies systems for scavenging of nutrients, particularly organic and inorganic nitrogen and oligo-elements, biofilm formation at the oil-water interface, biosurfactant production and niche-specific stress responses. The unique combination of these features provides A. borkumensis SK2 with a competitive edge in oil-polluted environments. This genome sequence provides the basis for the future design of strategies to mitigate the ecological damage caused by oil spills.	German Res Ctr Biotechnol, Div Microbiol, D-38124 Braunschweig, Germany; Univ Bielefeld, Fac Biol, Lehrstuhl Genet, D-33594 Bielefeld, Germany; Univ Bielefeld, Ctr Biotechnol, D-33594 Bielefeld, Germany; Tech Univ Carolo Wilhelmina Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany; CNR, Ist Ambiente Marino Costiero, I-98122 Messina, Italy; Tech Univ Carolo Wilhelmina Braunschweig, Inst Biochem & Biotechnol, D-38106 Braunschweig, Germany	Helmholtz Association; Helmholtz-Center for Infection Research; University of Bielefeld; University of Bielefeld; Braunschweig University of Technology; Consiglio Nazionale delle Ricerche (CNR); L'Istituto per l'Ambiente Marino Costiero (IAMC-CNR); Braunschweig University of Technology	dos Santos, VAPM (corresponding author), German Res Ctr Biotechnol, Div Microbiol, D-38124 Braunschweig, Germany.	vds@gbf.de	Denaro, Renata/AAY-1494-2020; McHardy, Alice C/K-9377-2018; denaro, Renata/AFT-9627-2022; McHardy, Alice/ABF-2322-2020; Ferrer, Manuel/K-4535-2014; Yakimov, Michail/H-1829-2016	McHardy, Alice C/0000-0003-2370-3430; McHardy, Alice/0000-0003-2370-3430; Golyshin, Peter/0000-0002-5433-0350; Rupp, Oliver/0000-0003-2755-6458; Ferrer, Manuel/0000-0003-4962-4714; Goesmann, Alexander/0000-0002-7086-2568; Meyer, Folker/0000-0003-1112-2284; Puhler, Alfred/0000-0003-4723-2960; Chernikova, Tatyana/0000-0001-6684-9099; Golyshina, Olga/0000-0001-5132-6850; Yakimov, Michail/0000-0003-1418-363X				Abraham WR, 1998, BBA-LIPID LIPID MET, V1393, P57, DOI 10.1016/S0005-2760(98)00058-7; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Averhoff B, 2003, ARCH MICROBIOL, V180, P385, DOI 10.1007/s00203-003-0616-6; Bartels D, 2005, BIOINFORMATICS, V21, P853, DOI 10.1093/bioinformatics/bti091; Berman T, 2003, AQUAT MICROB ECOL, V31, P279, DOI 10.3354/ame031279; Danot O, 2001, P NATL ACAD SCI USA, V98, P435, DOI 10.1073/pnas.98.2.435; Dutta TK, 2001, APPL ENVIRON MICROB, V67, P1970, DOI 10.1128/AEM.67.4.1970-1974.2001; DYKSTERHOUSE SE, 1995, INT J SYST BACTERIOL, V45, P116, DOI 10.1099/00207713-45-1-116; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Golyshin PN, 2003, J BIOTECHNOL, V106, P215, DOI 10.1016/j.jbiotec.2003.07.013; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gordon D, 2001, GENOME RES, V11, P614, DOI 10.1101/gr.171401; Hara A, 2004, ENVIRON MICROBIOL, V6, P191, DOI 10.1046/j.1462-2920.2003.00550.x; Hara A, 2003, ENVIRON MICROBIOL, V5, P746, DOI 10.1046/j.1468-2920.2003.00468.x; Harayama Shigeaki, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P63; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; Head IM, 2006, NAT REV MICROBIOL, V4, P173, DOI 10.1038/nrmicro1348; Hou SB, 2004, P NATL ACAD SCI USA, V101, P18036, DOI 10.1073/pnas.0407638102; Kaiser O, 2003, J BIOTECHNOL, V106, P121, DOI 10.1016/j.jbiotec.2003.08.008; Kasai Y, 2001, ENVIRON MICROBIOL, V3, P246, DOI 10.1046/j.1462-2920.2001.00185.x; KOK M, 1989, J BIOL CHEM, V264, P5435; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Maier T, 2001, BIOCHEM BIOPH RES CO, V286, P652, DOI 10.1006/bbrc.2001.5449; McHardy AC, 2004, BIOINFORMATICS, V20, P1622, DOI 10.1093/bioinformatics/bth137; Medina-Bellver JI, 2005, ENVIRON MICROBIOL, V7, P773, DOI 10.1111/j.1462-2920.2005.00742.x; Meyer F, 2003, NUCLEIC ACIDS RES, V31, P2187, DOI 10.1093/nar/gkg312; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; OCHSNER UA, 1994, J BIOL CHEM, V269, P19787; PASSERI A, 1992, APPL MICROBIOL BIOT, V37, P281, DOI 10.1007/BF00210978; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Roling WFM, 2004, APPL ENVIRON MICROB, V70, P2603, DOI 10.1128/AEM.70.5.2603-2613.2004; Ron EZ, 2001, ENVIRON MICROBIOL, V3, P229, DOI 10.1046/j.1462-2920.2001.00190.x; Sabirova JS, 2006, J BACTERIOL, V188, P3763, DOI 10.1128/JB.00072-06; Smits THM, 2002, J BACTERIOL, V184, P1733, DOI 10.1128/JB.184.6.1733-1742.2002; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; Suzek BE, 2001, BIOINFORMATICS, V17, P1123, DOI 10.1093/bioinformatics/17.12.1123; Syutsubo K, 2001, ENVIRON MICROBIOL, V3, P371, DOI 10.1046/j.1462-2920.2001.00204.x; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Tauch A, 2002, J BIOTECHNOL, V95, P25, DOI 10.1016/S0168-1656(01)00443-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toren A, 2002, J BACTERIOL, V184, P165, DOI 10.1128/JB.184.1.165-170.2002; van Beilen JB, 2005, J BACTERIOL, V187, P85, DOI 10.1128/JB.187.1.85-91.2005; van Beilen JB, 2004, ENVIRON MICROBIOL, V6, P264, DOI 10.1111/j.1462-2920.2004.00567.x; van Beilen JB, 2003, OIL GAS SCI TECHNOL, V58, P427, DOI 10.2516/ogst:2003026; van Beilen JB, 2001, MICROBIOL-SGM, V147, P1621, DOI 10.1099/00221287-147-6-1621; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Yakimov MM, 1998, INT J SYST BACTERIOL, V48, P339, DOI 10.1099/00207713-48-2-339; Yakimov MM, 2005, ENVIRON MICROBIOL, V7, P1426, DOI 10.1111/j.1462-5822.2005.00829.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	51	304	703	2	218	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2006	24	8					997	1004		10.1038/nbt1232	http://dx.doi.org/10.1038/nbt1232			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	072VY	16878126	hybrid, Green Published			2022-12-25	WOS:000239702300040
J	Tam, BYY; Wei, K; Rudge, JS; Hoffman, J; Holash, J; Park, SK; Yuan, J; Hefner, C; Chartier, C; Lee, JS; Jiang, S; Niyak, NR; Kuypers, FA; Ma, L; Sundram, U; Wu, G; Garcia, JA; Schrier, SL; Maher, JJ; Johnson, RS; Yancopoulos, GD; Mulligan, RC; Kuo, CJ				Tam, Betty Y. Y.; Wei, Kevin; Rudge, John S.; Hoffman, Jana; Holash, Joceyln; Park, Sang-ki; Yuan, Jenny; Hefner, Colleen; Chartier, Cecile; Lee, Jeng-Shin; Jiang, Shelly; Niyak, Nihar R.; Kuypers, Frans A.; Ma, Lisa; Sundram, Uma; Wu, Grace; Garcia, Joseph A.; Schrier, Stanley L.; Maher, Jacquelyn J.; Johnson, Randall S.; Yancopoulos, George D.; Mulligan, Richard C.; Kuo, Calvin J.			VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis	NATURE MEDICINE			English	Article							ENDOTHELIAL GROWTH-FACTOR; LIVER; RECEPTOR; CELLS; HIF-1-ALPHA; HYPOXIA; HIF-2-ALPHA; EXPRESSION; SURVIVAL; GENE	Vascular endothelial growth factor ( VEGF) exerts crucial functions during pathological angiogenesis and normal physiology. We observed increased hematocrit (60-75%) after high-grade inhibition of VEGF by diverse methods, including adenoviral expression of soluble VEGF receptor ( VEGFR) ectodomains, recombinant VEGF Trap protein and the VEGFR2-selective antibody DC101. Increased production of red blood cells ( erythrocytosis) occurred in both mouse and primate models, and was associated with near-complete neutralization of VEGF corneal micropocket angiogenesis. High-grade inhibition of VEGF induced hepatic synthesis of erythropoietin ( Epo, encoded by Epo) > 40-fold through a HIF-1 alpha-independent mechanism, in parallel with suppression of renal Epo mRNA. Studies using hepatocyte-specific deletion of the Vegfa gene and hepatocyte-endothelial cell cocultures indicated that blockade of VEGF induced hepatic Epo by interfering with homeostatic VEGFR2-dependent paracrine signaling involving interactions between hepatocytes and endothelial cells. These data indicate that VEGF is a previously unsuspected negative regulator of hepatic Epo synthesis and erythropoiesis and suggest that levels of Epo and erythrocytosis could represent noninvasive surrogate markers for stringent blockade of VEGF in vivo.	Stanford Univ, Div Hematol, Sch Med, Stanford, CA 94305 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Calif San Diego, Mol Biol Sect, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Harvard Univ, Childrens Hosp, Dept Genet, Sch Med,Div Mol Med, Boston, MA 02115 USA; Stanford Univ, Div Obstet & Gynecol, Sch Med, Stanford, CA 94305 USA; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Stanford Univ, Div Pathol, Sch Med, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Div Cardiol, Dallas, TX USA	Stanford University; Regeneron; University of California System; University of California San Diego; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Boston Children's Hospital; Harvard Medical School; Stanford University; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kuo, CJ (corresponding author), Stanford Univ, Div Hematol, Sch Med, 269 Campus Dr,CCSR 1155, Stanford, CA 94305 USA.	cjkuo@stanford.edu	Johnson, Randall/AAM-1189-2021	Johnson, Randall/0000-0002-4084-6639; Garcia, Joseph/0000-0002-5621-7538; Kuo, Calvin/0000-0002-7427-5985	NCI NIH HHS [1 R01 CA95654-01] Funding Source: Medline; NHLBI NIH HHS [K08 HL067154, 1 R01 HL074267-01] Funding Source: Medline; NIDDK NIH HHS [P30 DK026743, P30 DK26743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095654] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067154, R01HL074267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Ebert BL, 1999, BLOOD, V94, P1864; Eremina V, 2003, J CLIN INVEST, V111, P707, DOI 10.1172/JCI200317423; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fiedler W, 2003, BLOOD, V102, P2763, DOI 10.1182/blood-2002-10-2998; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hegenbarth S, 2000, HUM GENE THER, V11, P481, DOI 10.1089/10430340050015941; Hennequin LF, 1999, J MED CHEM, V42, P5369, DOI 10.1021/jm990345w; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; IRVING MG, 1984, GASTROENTEROLOGY, V87, P1233; Jacobi J, 2004, GENE THER, V11, P302, DOI 10.1038/sj.gt.3302162; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KONNER J, 2004, CLIN COLORECTAL CANC, V2, pS81; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; KUO CJ, 2002, GENE THERAPY CANC; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lau SC, 2005, CURR OPIN MOL THER, V7, P493; Laughlin KM, 1996, J PHARMACOL EXP THER, V277, P1049; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834; Mahasreshti PJ, 2003, CLIN CANCER RES, V9, P2701; Malik AK, 2006, BLOOD, V107, P550, DOI 10.1182/blood-2005-05-2047; Matsumoto K, 2001, SCIENCE, V294, P559, DOI 10.1126/science.1063889; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Prewett M, 1999, CANCER RES, V59, P5209; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Richard S, 2002, BLOOD, V99, P3851, DOI 10.1182/blood.V99.10.3851; Rinaudo D, 2000, BIOTECHNIQUES, V29, P218, DOI 10.2144/00292bm03; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schipani E, 2001, GENE DEV, V15, P2865; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stec DE, 1999, J BIOL CHEM, V274, P21285, DOI 10.1074/jbc.274.30.21285; Tao NJ, 2001, MOL THER, V3, P28, DOI 10.1006/mthe.2000.0227; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wedge SR, 2000, CANCER RES, V60, P970; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; YAMANE A, 1994, ONCOGENE, V9, P2683; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zelzer E, 2004, DEVELOPMENT, V131, P2161, DOI 10.1242/dev.01053; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	49	135	143	1	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2006	12	7					793	800		10.1038/nm1428	http://dx.doi.org/10.1038/nm1428			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16799557				2022-12-25	WOS:000238862800066
J	Thomas, RK; Nickerson, E; Simons, JF; Janne, PA; Tengs, T; Yuza, Y; Garraway, LA; LaFramboise, T; Lee, JC; Shah, K; O'Neill, K; Sasaki, H; Lindeman, N; Wong, KK; Borras, AM; Gutmann, EJ; Dragnev, KH; DeBiasi, R; Chen, TH; Glatt, KA; Greulich, H; Desany, B; Lubeski, CK; Brockman, W; Alvarez, P; Hutchison, SK; Leamon, JH; Ronan, MT; Turenchalk, GS; Egholm, M; Sellers, WR; Rothberg, JM; Meyerson, M				Thomas, Roman K.; Nickerson, Elizabeth; Simons, Jan F.; Janne, Pasi A.; Tengs, Torstein; Yuza, Yuki; Garraway, Levi A.; LaFramboise, Thomas; Lee, Jeffrey C.; Shah, Kinjal; O'Neill, Keith; Sasaki, Hidefumi; Lindeman, Neal; Wong, Kwok-Kin; Borras, Ana M.; Gutmann, Edward J.; Dragnev, Konstantin H.; DeBiasi, Ralph; Chen, Tzu-Hsiu; Glatt, Karen A.; Greulich, Heidi; Desany, Brian; Lubeski, Christine K.; Brockman, William; Alvarez, Pablo; Hutchison, Stephen K.; Leamon, J. H.; Ronan, Michael T.; Turenchalk, Gregory S.; Egholm, Michael; Sellers, William R.; Rothberg, Jonathan M.; Meyerson, Matthew			Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing	NATURE MEDICINE			English	Article							CELL LUNG-CANCER; ACTIVATING MUTATIONS; ACQUIRED-RESISTANCE; KINASE INHIBITOR; EGF RECEPTOR; GEFITINIB; ERLOTINIB; THERAPY; DOMAIN	The sensitivity of conventional DNA sequencing in tumor biopsies is limited by stromal contamination and by genetic heterogeneity within the cancer. Here, we show that microreactor-based pyrosequencing can detect rare cancer-associated sequence variations by independent and parallel sampling of multiple representatives of a given DNA fragment. This technology can thereby facilitate accurate molecular diagnosis of heterogeneous cancer specimens and enable patient selection for targeted cancer therapies.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; MIT, Broad Inst, Cambridge, MA 02142 USA; Harvard Univ, Cambridge Ctr 7, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Melanoma Program Med Oncol, Boston, MA 02115 USA; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Translat Res Lab, Boston, MA 02115 USA; Dartmouth Hitchcock Med Ctr, Dept Pathol, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Dept Med, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Dana-Farber Cancer Institute; Nagoya City University; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Meyerson, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	matthew_meyerson@dfci.harvard.edu	Meyerson, Matthew L/E-7123-2012	wong, kwok kin/0000-0001-6323-235X	NCI NIH HHS [T32 CA009172, R01CA098185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009172, R01CA098185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Cortes-Funes H, 2005, ANN ONCOL, V16, P1081, DOI 10.1093/annonc/mdi221; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190; Janne PA, 2006, CLIN CANCER RES, V12, P751, DOI 10.1158/1078-0432.CCR-05-2047; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Ronaghi M, 1998, SCIENCE, V281, P363, DOI 10.1126/science.281.5375.363; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; VANOMMEN GJ, 1999, LANCET S1, V354, pS15	19	274	303	0	35	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2006	12	7					852	855		10.1038/nm1437	http://dx.doi.org/10.1038/nm1437			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	061HS	16799556				2022-12-25	WOS:000238862800075
J	Vertes, AA; Inui, M; Yukawa, H				Vertes, Alain A.; Inui, Masayuki; Yukawa, Hideaki			Implementing biofuels on a global scale	NATURE BIOTECHNOLOGY			English	Editorial Material									Res Inst Innovat Technol Earth, Kyoto 6190292, Japan	Research Institute of Innovative Technology for the Earth	Vertes, AA (corresponding author), Res Inst Innovat Technol Earth, 9-2 Kizugawadai, Kyoto 6190292, Japan.	mmg-lab@rite.or.jp		Inui, Masayuki/0000-0001-5953-7740; VERTES, Alain/0000-0003-0903-4082				Anastas P. T., 1998, GREEN CHEM THEORY PR; BOZBAS K, IN PRESS RENEW SUST; Chapman C., 2004, International Journal of Project Management, V22, P619, DOI 10.1016/j.ijproman.2004.05.001; Chornet E, 2002, NATURE, V418, P928, DOI 10.1038/418928a; DEFFEYES KS, 2001, IMPENDING OIL SHORTA; DEUTCH J, 2005, 23 MIT GLOB CHANG FO; EVANS ND, 2003, INNOVATION DISRUPTIV; Folley JA, 2005, SCIENCE, V310, P627, DOI 10.1126/science.1120104; Geroski PA, 2000, RES POLICY, V29, P603, DOI 10.1016/S0048-7333(99)00092-X; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; Hileman B, 2005, CHEM ENG NEWS, V83, P13, DOI 10.1021/cen-v083n036.p013a; JACKSON T, 1996, MAT CONCERNS; JORDAN JL, 2001, EC COMMENTARY; Kamm B, 2004, APPL MICROBIOL BIOT, V64, P137, DOI 10.1007/s00253-003-1537-7; Keller JB, 1999, APPL BIOCHEM BIOTECH, V77-9, P641; Kim S, 2005, BIOMASS BIOENERG, V29, P426, DOI 10.1016/j.biombioe.2005.06.004; Lovins AB, 1999, HARVARD BUS REV, V77, P145; Lynd LR, 1999, BIOTECHNOL PROGR, V15, P777, DOI 10.1021/bp990109e; Marris E, 2005, NATURE, V437, P11, DOI 10.1038/437011a; ONEILL PK, 2000, HARV BUS REV     JUL, P129; Penner SS, 2006, ENERGY, V31, P33, DOI 10.1016/j.energy.2004.04.060; Porter M.E., 1980, U ILLINOIS URBANA CH; RYAN L, IN PRESS ENERGY POLI; Sandford A, 2003, RESPIROLOGY, V8, P7, DOI 10.1046/j.1440-1843.2003.00436.x; SOLOW RM, 1956, Q J ECON, V70, P65, DOI 10.2307/1884513; Stern D.I., 2004, ENCY ENERGY, V2, P35, DOI [10.1016/B0-12-176480-X/00147-9, DOI 10.1016/B0-12-176480-X/00147-9]; VONBREMEN L, 1986, TRENDS BIOTECHN  JAN; Watkins MD, 2003, HARVARD BUS REV, V81, P72; Wiser R. H., 1998, Renewable & Sustainable Energy Reviews, V2, P361, DOI 10.1016/S1364-0321(98)00007-0; Wuebbles DJ, 2001, FUEL PROCESS TECHNOL, V71, P99, DOI 10.1016/S0378-3820(01)00139-4; Wyman CE, 1999, ANNU REV ENERG ENV, V24, P189, DOI 10.1146/annurev.energy.24.1.189; Yoshida A, 2005, APPL ENVIRON MICROB, V71, P6762, DOI 10.1128/AEM.71.11.6762-6768.2005; 2005, NATURE, V435, P713	33	23	26	0	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					761	764		10.1038/nbt0706-761	http://dx.doi.org/10.1038/nbt0706-761			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biotechnology & Applied Microbiology	063NJ	16841054				2022-12-25	WOS:000239025100018
J	Ancelin, K; Lange, UC; Hajkova, P; Schneider, R; Bannister, AJ; Kouzarides, T; Surani, MA				Ancelin, Katia; Lange, Ulrike C.; Hajkova, Petra; Schneider, Robert; Bannister, Andrew J.; Kouzarides, Tony; Surani, M. Azim			Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells	NATURE CELL BIOLOGY			English	Article							SPECIFICATION; H3; EXPRESSION; REPRESSION; PRDI-BF1; PROGRAM; GENE; G9A; H4	Blimp1, a transcriptional repressor, has a crucial role in the specification of primordial germ cells (PGCs) in mice at embryonic day 7.5 (E7.5)(1,2). This SET-PR domain protein can form complexes with various chromatin modifiers in a context-dependent manner(3,4). Here, we show that Blimp1 has a novel interaction with Prmt5, an arginine-specific histone methyltransferase, which mediates symmetrical dimethylation of arginine 3 on histone H2A and/or H4 tails (H2A/H4R3me2s). Prmt5 has been shown to associate with Tudor, a component of germ plasm in Drosophila melanogaster5. Blimp1-Prmt5 colocalization results in high levels of H2A/H4 R3 methylation in PGCs at E8.5. However, at E11.5, Blimp1-Prmt5 translocates from the nucleus to the cytoplasm, resulting in the loss of H2A/H4 R3 methylation at the time of extensive epigenetic reprogramming of germ cells(6). Subsequently, Dhx38, a putative target of the Blimp1-Prmt5 complex, is upregulated. Interestingly, expression of Dhx38 is also seen in pluripotent embryonic germ cells that are derived from PGCs when Blimp1 expression is lost. Our study demonstrates that Blimp1 is involved in a novel transcriptional regulatory complex in the mouse germ-cell lineage.	Univ Cambridge, Gurdon Inst Canc & Dev Biol, Wellcome Trust Canc Res UK, Cambridge CB2 1QN, England; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	Cancer Research UK; University of Cambridge; Max Planck Society	Surani, MA (corresponding author), Univ Cambridge, Gurdon Inst Canc & Dev Biol, Wellcome Trust Canc Res UK, Tennis Court Rd, Cambridge CB2 1QN, England.	as10021@mole.bio.cam.ac.uk	Ancelin, Katia/R-1719-2019	Ancelin, Katia/0000-0002-2117-9754; Bannister, Andrew/0000-0002-6312-4436; Surani, Azim/0000-0002-8640-4318; Kouzarides, Tony/0000-0002-8918-4162; Hajkova, Petra/0000-0003-4145-1468	Wellcome Trust Funding Source: Medline; Medical Research Council [G0300723B] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Anne J, 2005, DEVELOPMENT, V132, P2167, DOI 10.1242/dev.01809; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003; COTE J, 2005, J BIOL CHEM, V13, P13; Erhardt S, 2003, DEVELOPMENT, V130, P4235, DOI 10.1242/dev.00625; Fabbrizio E, 2002, EMBO REP, V3, P641, DOI 10.1093/embo-reports/kvf136; GINSBURG M, 1990, DEVELOPMENT, V110, P521; GRAHAM PL, 1993, GENETICS, V133, P919; Gyory I, 2004, NAT IMMUNOL, V5, P299, DOI 10.1038/ni1046; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Kuo TC, 2004, J IMMUNOL, V173, P5556, DOI 10.4049/jimmunol.173.9.5556; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Oberley MJ, 2003, J BIOL CHEM, V278, P42466, DOI 10.1074/jbc.M307733200; Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813; Pal S, 2004, MOL CELL BIOL, V24, P9630, DOI 10.1128/MCB.24.21.9630-9645.2004; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Saitou M, 2002, NATURE, V418, P293, DOI 10.1038/nature00927; Sarmento OF, 2004, J CELL SCI, V117, P4449, DOI 10.1242/jcs.01328; Seki Y, 2005, DEV BIOL, V278, P440, DOI 10.1016/j.ydbio.2004.11.025; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Surani MA, 2004, COLD SPRING HARB SYM, V69, P1, DOI 10.1101/sqb.2004.69.40; Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402; Vincent SD, 2005, DEVELOPMENT, V132, P1315, DOI 10.1242/dev.01711; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000	30	354	397	0	41	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					623	630		10.1038/ncb1413	http://dx.doi.org/10.1038/ncb1413			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16699504				2022-12-25	WOS:000238029000016
J	Senee, V; Chelala, C; Duchatelet, S; Feng, DR; Blanc, H; Cossec, JC; Charon, C; Nicolino, M; Boileau, P; Cavener, DR; Bougneres, P; Taha, D; Julier, C				Senee, Valerie; Chelala, Claude; Duchatelet, Sabine; Feng, Daorong; Blanc, Herve; Cossec, Jack-Christophe; Charon, Celine; Nicolino, Marc; Boileau, Pascal; Cavener, Douglas R.; Bougneres, Pierre; Taha, Doris; Julier, Cecile			Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism	NATURE GENETICS			English	Article							GLUTAMATE TRANSPORTER; REPRESSOR FUNCTIONS; GLAUCOMA; AGENESIS; MICE; TRANSACTIVATION; DELETION; PROTEIN; PATHWAY; DISEASE	We recently described a new neonatal diabetes syndrome associated with congenital hypothyroidism, congenital glaucoma, hepatic fibrosis and polycystic kidneys(1). Here, we show that this syndrome results from mutations in GLIS3, encoding GLI similar 3, a recently identified transcription factor(2). In the original family, we identified a frameshift mutation predicted to result in a truncated protein. In two other families with an incomplete syndrome, we found that affected individuals harbor deletions affecting the 11 or 12 5'-most exons of the gene. The absence of a major transcript in the pancreas and thyroid ( deletions from both families) and an eye-specific transcript ( deletion from one family), together with residual expression of some GLIS3 transcripts, seems to explain the incomplete clinical manifestations in these individuals. GLIS3 is expressed in the pancreas from early developmental stages, with greater expression in beta cells than in other pancreatic tissues. These results demonstrate a major role for GLIS3 in the development of pancreatic b cells and the thyroid, eye, liver and kidney.	Inst Pasteur, F-75015 Paris, France; INSERM, U730, F-75015 Paris, France; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Hop Debrousse, Dept Endocrinol Pediat, F-69005 Lyon, France; Ctr Natl Genotypage, F-91054 Evry, France; Hop Cochin St Vincent de Paul, Dept Endocrinol Pediat, F-75014 Paris, France; INSERM, U561, F-75014 Paris, France; King Faisal Specialist Hosp & Res Ctr, Div Pediat Endocrinol, Jeddah 21499, Saudi Arabia	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; CHU Lyon; CEA; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); King Faisal Specialist Hospital & Research Center	Julier, C (corresponding author), Inst Pasteur, F-75015 Paris, France.	cjulier@pasteur.fr	Boileau, Pascal/H-7508-2015; DUCHATELET, Sabine/V-2605-2019; JULIER, Cécile/M-9824-2017; Boileau, Pascal/AAG-9683-2021; Senée, Valérie/M-9854-2017; Cavener, Douglas R/E-3524-2010	Boileau, Pascal/0000-0001-9755-6467; JULIER, Cécile/0000-0002-1538-0240; Boileau, Pascal/0000-0001-9755-6467; Senée, Valérie/0000-0001-7012-3944; chelala, claude/0000-0002-2488-0669; Cossec, Jack-Christophe/0000-0002-0836-1009	PHS HHS [NIDDK62049] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Cohn Amy C, 2005, Ophthalmic Genet, V26, P45, DOI 10.1080/13816810590918398; Hara M, 2003, AM J PHYSIOL-ENDOC M, V284, pE177, DOI 10.1152/ajpendo.00321.2002; Haumaitre C, 2005, P NATL ACAD SCI USA, V102, P1490, DOI 10.1073/pnas.0405776102; Hebrok M, 2003, MECH DEVELOP, V120, P45, DOI 10.1016/S0925-4773(02)00331-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KATSUSHIMA H, 1987, ARCH OPHTHALMOL-CHIC, V105, P323; Kim YS, 2003, NUCLEIC ACIDS RES, V31, P5513, DOI 10.1093/nar/gkg776; Kim YS, 2002, J BIOL CHEM, V277, P30901, DOI 10.1074/jbc.M203563200; Lees C, 2005, GASTROENTEROLOGY, V129, P1696, DOI 10.1053/j.gastro.2005.05.010; Park SM, 2005, J MED GENET, V42, P379, DOI 10.1136/jmg.2004.024158; Peghini P, 1997, EMBO J, V16, P3822, DOI 10.1093/emboj/16.13.3822; Raeder H, 2006, NAT GENET, V38, P54, DOI 10.1038/ng1708; Sellick GS, 2004, NAT GENET, V36, P1301, DOI 10.1038/ng1475; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Taha D, 2003, AM J MED GENET A, V122A, P269, DOI 10.1002/ajmg.a.20267; Takahashi Masazumi, 2003, J Bioinform Comput Biol, V1, P253, DOI 10.1142/S021972000300006X; VERBRAAK FD, 1992, OPHTHALMIC PAED GEN, V13, P165, DOI 10.3109/13816819209046485; Villavicencio EH, 2000, AM J HUM GENET, V67, P1047, DOI 10.1016/S0002-9297(07)62934-6; Zhang F, 2002, J BIOL CHEM, V277, P10139, DOI 10.1074/jbc.M108062200	19	243	256	1	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					682	687		10.1038/ng1802	http://dx.doi.org/10.1038/ng1802			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16715098				2022-12-25	WOS:000237954800023
J	Wille, G; Meyer, D; Steinmetz, A; Hinze, E; Golbik, R; Tittmann, K				Wille, Georg; Meyer, Danilo; Steinmetz, Andrea; Hinze, Erik; Golbik, Ralph; Tittmann, Kai			The catalytic cycle of a thiamin diphosphate enzyme examined by cryocrystallography	NATURE CHEMICAL BIOLOGY			English	Article							CRYSTAL-STRUCTURE; DEPENDENT ENZYME; PYRUVATE OXIDASE; INTERMEDIATE; TRANSKETOLASE; ACCELERATION	Enzymes that use the cofactor thiamin diphosphate (ThDP, 1), the biologically active form of vitamin B-1, are involved in numerous metabolic pathways in all organisms. Although a theory of the cofactor's underlying reaction mechanism has been established over the last five decades(1,2), the three-dimensional structures of most major reaction intermediates of ThDP enzymes have remained elusive. Here, we report the X-ray structures of key intermediates in the oxidative decarboxylation of pyruvate, a central reaction in carbon metabolism catalyzed by the ThDP-and flavin-dependent enzyme pyruvate oxidase ( POX) 3 from Lactobacillus plantarum. The structures of 2-lactyl-ThDP (LThDP, 2) and its stable phosphonate analog, of 2-hydroxyethyl- ThDP (HEThDP, 3) enamine and of 2-acetyl-ThDP (AcThDP, 4; all shown bound to the enzyme's active site) provide profound insights into the chemical mechanisms and the stereochemical course of thiamin catalysis. These snapshots also suggest a mechanism for a phosphate-linked acyl transfer coupled to electron transfer in a radical reaction of pyruvate oxidase.	Univ Halle Wittenberg, Inst Biochem, D-06120 Halle, Saale, Germany	Martin Luther University Halle Wittenberg	Wille, G (corresponding author), Univ Halle Wittenberg, Inst Biochem, Kurt Mothes Str 3, D-06120 Halle, Saale, Germany.	georg.wille@biochemtech.uni-halle.de; kai.tittmann@biochemtech.uni-halle.de		Wille, Georg/0000-0002-8948-611X				Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; ARJUNAN P, 2006, IN PRESS J BIOL CHEM; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Chabriere E, 2001, SCIENCE, V294, P2559, DOI 10.1126/science.1066198; DUNATHAN HC, 1971, ADV ENZYMOL RAMB, V35, P79; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; GRUYS KJ, 1987, BIOCHEMISTRY-US, V26, P7575, DOI 10.1021/bi00398a007; Jordan F, 2005, BIOORG CHEM, V33, P190, DOI 10.1016/j.bioorg.2005.02.001; Jordan F, 1999, BIOCHEMISTRY-US, V38, P6369, DOI 10.1021/bi990373g; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; KLUGER R, 1987, CHEM REV, V87, P863, DOI 10.1021/cr00081a001; KLUGER R, 1981, J AM CHEM SOC, V103, P884, DOI 10.1021/ja00394a027; KLUGER R, 1977, J AM CHEM SOC, V99, P4504, DOI 10.1021/ja00455a052; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; Nemeria N, 2004, BIOCHEMISTRY-US, V43, P6565, DOI 10.1021/bi049549r; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schowen RL, 1998, COMPREHENSIVE BIOL C, V2, P217; Tittmann K, 2003, BIOCHEMISTRY-US, V42, P7885, DOI 10.1021/bi034465o; Tittmann K, 2005, BIOCHEMISTRY-US, V44, P13291, DOI 10.1021/bi051058z; Wille G, 2005, BIOCHEMISTRY-US, V44, P5086, DOI 10.1021/bi047337o; Zhang S, 2005, BIOCHEMISTRY-US, V44, P2237, DOI 10.1021/bi047696j	24	101	101	0	44	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2006	2	6					324	328		10.1038/nchembio788	http://dx.doi.org/10.1038/nchembio788			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	045OH	16680160				2022-12-25	WOS:000237750900014
J	Flick, K; Raasi, S; Zhang, HW; Yen, JL; Kaiser, P				Flick, K; Raasi, S; Zhang, HW; Yen, JL; Kaiser, P			A ubiquitin-interacting motif protects polyubiquitinated Met4 from degradation by the 26S proteasome	NATURE CELL BIOLOGY			English	Article							TRANSCRIPTIONAL ACTIVATOR MET4; SACCHAROMYCES-CEREVISIAE; BINDING PROTEINS; CELL-CYCLE; PROTEOLYSIS; INHIBITION; DOMAINS; METABOLISM; COMPLEX; LYSINE	Covalent attachment of ubiquitin to proteins regulates a host of cellular events by proteolysis dependent and independent mechanisms. A variety of protein domains that bind noncovalently to ubiquitin have been described and functionally linked to diverse cellular processes(1). Overall, however, the understanding and knowledge of the mechanisms by which ubiquitin-binding domains (UBDs) regulate these processes is limited. Here, we describe identification of a UBD in the yeast transcription factor Met4. Met4 activity, but not its stability, is regulated by polyubiquitination(2-4). We found that the UBD restricts the length of the polyubiquitin chain that is assembled on Met4, and prevents proteasomal recognition and degradation of polyubiquitinated Met4. Inactivation of the UBD allowed synthesis of longer ubiquitin chains on Met4 and transformed the normally stable polyubiquitinated Met4 into a short-lived protein. Our results demonstrate a function for UBDs in ubiquitin-chain synthesis and regulation of protein degradation.	Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; Johns Hopkins Univ, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	University of California System; University of California Irvine; Johns Hopkins University	Kaiser, P (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, 240D Med Sci I, Irvine, CA 92697 USA.	pkaiser@uci.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066164, R56GM066164] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46984] Funding Source: Medline; NIGMS NIH HHS [GM66164] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbey R, 2005, EMBO J, V24, P521, DOI 10.1038/sj.emboj.7600556; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Flick K, 2004, NAT CELL BIOL, V6, P634, DOI 10.1038/ncb1143; Heessen S, 2005, MOL CELL, V18, P225, DOI 10.1016/j.molcel.2005.03.015; Hicke L, 2005, NAT REV MOL CELL BIO, V6, P610, DOI 10.1038/nrm1701; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; McClellan AJ, 2005, NAT CELL BIOL, V7, P736, DOI 10.1038/ncb0805-736; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; Patton EE, 2000, EMBO J, V19, P1613, DOI 10.1093/emboj/19.7.1613; Raasi S, 2005, NAT STRUCT MOL BIOL, V12, P708, DOI 10.1038/nsmb962; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Rouillon A, 2000, EMBO J, V19, P282, DOI 10.1093/emboj/19.2.282; Su NY, 2005, MOL CELL BIOL, V25, P3875, DOI 10.1128/MCB.25.10.3875-3885.2005; Swanson KA, 2003, EMBO J, V22, P4597, DOI 10.1093/emboj/cdg471; Thomas D, 1997, MICROBIOL MOL BIOL R, V61, P503, DOI 10.1128/.61.4.503-532.1997; THOMAS D, 1992, MOL CELL BIOL, V12, P1719, DOI 10.1128/MCB.12.4.1719; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Yen JL, 2005, MOL BIOL CELL, V16, P1872, DOI 10.1091/mbc.E04-12-1130; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	29	70	73	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					509	U144		10.1038/ncb1402	http://dx.doi.org/10.1038/ncb1402			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16604062				2022-12-25	WOS:000237299400015
J	Graham, RR; Kozyrev, SV; Baechler, EC; Reddy, MPL; Plenge, RM; Bauer, JW; Ortmann, WA; Koeuth, T; Escribano, MF; Pons-Estel, B; Petri, M; Daly, M; Gregersen, PK; Martin, J; Altshuler, D; Behrens, TW; Alarcon-Riquelme, ME				Graham, RR; Kozyrev, SV; Baechler, EC; Reddy, MPL; Plenge, RM; Bauer, JW; Ortmann, WA; Koeuth, T; Escribano, MF; Pons-Estel, B; Petri, M; Daly, M; Gregersen, PK; Martin, J; Altshuler, D; Behrens, TW; Alarcon-Riquelme, ME		Argentine Collaborative Grp; Spanish Collaborative Grp	A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus	NATURE GENETICS			English	Article							HUMAN GENE-EXPRESSION; INDUCTION; ALPHA; GENOME; DISEQUILIBRIUM; ACTIVATION; LINKAGE; BLOOD; CELLS	Systemic lupus erythematosus (SLE) is a complex autoimmune disease(1) characterized by activation of the type I interferon (IFN) pathway(2-4). Here we convincingly replicate association of the IFN regulatory factor 5 (IRF5) rs2004640 T allele with SLE5 in four independent case-control cohorts (P = 4.4 x 10(-16)) and by family-based transmission disequilibrium test analysis (P = 0.0006). The rs2004640 T allele creates a 5' donor splice site in an alternate exon 1 of IRF5, allowing expression of several unique IRF5 isoforms. We also identify an independent cis-acting variant associated with elevated expression of IRF5 and linked to the exon 1B splice site. Haplotypes carrying the variant associated with elevated expression and lacking the exon 1B donor site do not confer risk of SLE. Thus, a common IRF5 haplotype driving elevated expression of multiple unique isoforms of IRF5 is an important genetic risk factor for SLE, establishing a causal role for type I IFN pathway genes in human autoimmunity.	Uppsala Univ, Rudbcek Lab, Unit Med Genet, Dept Genet & Pathol, S-75185 Uppsala, Sweden; MIT, Cambridge, MA 02142 USA; Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA; Massachusetts Gen Hosp, Ctr Human Genet Res & Mol Biol, Boston, MA 02114 USA; Univ Minnesota, Sch Med, Ctr Immunol, Minneapolis, MN 55455 USA; Hosp Virgen del Rocio, Serv Inmunol, Seville 41013, Spain; Sanatorio Parque, RA-2000 Rosario, Santa Fe, Argentina; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; N Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY 11030 USA; CSIC, Inst Biomed Lopez Neyra, Granada 18100, Spain	Uppsala University; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; University of Minnesota System; University of Minnesota Twin Cities; Virgen del Rocio University Hospital; Johns Hopkins University; Northwell Health; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Alarcon-Riquelme, ME (corresponding author), Uppsala Univ, Rudbcek Lab, Unit Med Genet, Dept Genet & Pathol, S-75185 Uppsala, Sweden.	behre001@umn.edu; marta.alarcon@genpat.uu.se	Daly, Mark J/B-2453-2017; REDDY, M.V. PRASAD LINGA/H-6330-2012; Alarcón-Riquelme, Marta E./ABF-8163-2020; Martin, Javier/B-8141-2008; Martín, María/HDL-9512-2022; Gillespie, Emily/N-1265-2013; González-Escribano, María Francisca/X-5554-2019; Martín, Javier/AAV-5209-2021; Altshuler, David M/A-4476-2009	Daly, Mark J/0000-0002-0949-8752; Alarcón-Riquelme, Marta E./0000-0002-7632-4154; Martin, Javier/0000-0002-2202-0622; Gillespie, Emily/0000-0001-5261-3931; Altshuler, David M/0000-0002-7250-4107; Kozyrev, Sergey/0000-0001-6209-4100; Pons-Estel, Bernardo/0000-0003-2518-0266	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043727, R55AR043727] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-00052] Funding Source: Medline; NIAMS NIH HHS [AR 43727] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alarcon-Segovia D, 2005, ARTHRITIS RHEUM-US, V52, P1138, DOI 10.1002/art.20999; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Barnes BJ, 2004, J BIOL CHEM, V279, P45194, DOI 10.1074/jbc.M400726200; Barnes BJ, 2003, J BIOL CHEM, V278, P16630, DOI 10.1074/jbc.M212609200; Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890; Cheung VG, 2005, NATURE, V437, P1365, DOI 10.1038/nature04244; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; Honda K, 2005, INT IMMUNOL, V17, P1367, DOI 10.1093/intimm/dxh318; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; Kirou KA, 2004, ARTHRITIS RHEUM, V50, P3958, DOI 10.1002/art.20798; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Mancl ME, 2005, J BIOL CHEM, V280, P21078, DOI 10.1074/jbc.M500543200; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; Mitchell MK, 2004, J URBAN HEALTH, V81, P301, DOI 10.1093/jurban/jth116; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Ronnblom L, 2001, J EXP MED, V194, pF59, DOI 10.1084/jem.194.12.f59; Sigurdsson S, 2005, AM J HUM GENET, V76, P528, DOI 10.1086/428480; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Woolson R F, 1982, Stat Med, V1, P37, DOI 10.1002/sim.4780010106	24	520	536	0	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					550	555		10.1038/ng1782	http://dx.doi.org/10.1038/ng1782			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16642019				2022-12-25	WOS:000237147500016
J	Kraytsberg, Y; Kudryavtseva, E; Mckee, AC; Geula, C; Kowall, NW; Khrapko, K				Kraytsberg, Y; Kudryavtseva, E; Mckee, AC; Geula, C; Kowall, NW; Khrapko, K			Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons	NATURE GENETICS			English	Article							PARKINSONIAN SIGNS; HUMAN BRAIN; MUTATIONS	Using a novel single-molecule PCR approach to quantify the total burden of mitochondrial DNA (mtDNA) molecules with deletions, we show that a high proportion of individual pigmented neurons in the aged human substantia nigra contain very high levels of mtDNA deletions. Molecules with deletions are largely clonal within each neuron; that is, they originate from a single deleted mtDNA molecule that has expanded clonally. The fraction of mtDNA deletions is significantly higher in cytochrome c oxidase (COX)- deficient neurons than in COX-positive neurons, suggesting that mtDNA deletions may be directly responsible for impaired cellular respiration.	Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bedford, MA 01730 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Khrapko, K (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	khrapko@hms.harvard.edu	Kowall, Neil/M-5378-2019; Khrapko, Konstantin/A-3244-2009	Kowall, Neil/0000-0002-6624-0213; 	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013846, R01AG019787] Funding Source: NIH RePORTER; NIA NIH HHS [AG19787, AG13846] Funding Source: Medline; NIEHS NIH HHS [ES11343] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769; Bennett DA, 1996, NEW ENGL J MED, V334, P71, DOI 10.1056/NEJM199601113340202; CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; Itoh K, 1996, NEUROBIOL AGING, V17, P843, DOI 10.1016/S0197-4580(96)00168-6; Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x; Khrapko K, 2005, REJUV RES, V8, P6, DOI 10.1089/rej.2005.8.6; Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434; KHRAPKO K, IN PRESS AGING CELL; Kraytsberg Y, 2005, EXPERT REV MOL DIAGN, V5, P809, DOI 10.1586/14737159.5.5.809; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; Nekhaeva E, 2002, MECH AGEING DEV, V123, P891, DOI 10.1016/S0047-6374(02)00026-X; Ross GW, 2004, ANN NEUROL, V56, P532, DOI 10.1002/ana.20226; Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594; SOONG NW, 1992, NAT GENET, V2, P318	15	661	682	0	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	MAY	2006	38	5					518	520		10.1038/ng1778	http://dx.doi.org/10.1038/ng1778			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	037LE	16604072				2022-12-25	WOS:000237147500010
J	Lyubimov, AY; Lario, PI; Moustafa, I; Vrielink, A				Lyubimov, AY; Lario, PI; Moustafa, I; Vrielink, A			Atomic resolution crystallography reveals how changes in pH shape the protein microenvironment	NATURE CHEMICAL BIOLOGY			English	Article							TOTALLY OPTIMIZED GEOMETRIES; CRYSTAL-STRUCTURE; CHOLESTEROL OXIDASE; SERINE-PROTEASE; STABILITY; TITRATION; FLAVINS	Hydrogen atoms are a vital component of enzyme structure and function(1-4). In recent years, atomic resolution crystallography (>= 1.2 angstrom) has been successfully used to investigate the role of the hydrogen atom in enzymatic catalysis(5-9). Here, atomic resolution crystallography was used to study the effect of pH on cholesterol oxidase from Streptomyces sp., a flavoenzyme oxidoreductase. Crystallographic observations of the anionic oxidized flavin cofactor at basic pH are consistent with the UV-visible absorption profile of the enzyme and readily explain the reversible pH-dependent loss of oxidation activity. Furthermore, a hydrogen atom, positioned at an unusually short distance from the main chain carbonyl oxygen of Met122 at high pH, was observed, suggesting a previously unknown mechanism of cofactor stabilization. This study shows how a redox active site responds to changes in the enzyme's environment and how these changes are able to influence the mechanism of enzymatic catalysis.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Vrielink, A (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, 1156 High St, Santa Cruz, CA 95064 USA.	vrielink@chemistry.ucsc.edu	Vrielink, Alice/D-3652-2013; Lario, Paula I/I-4842-2017	Vrielink, Alice/0000-0001-8197-3725; 				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berisio R, 1999, J MOL BIOL, V292, P845, DOI 10.1006/jmbi.1999.3093; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRUICE TC, 1958, J AM CHEM SOC, V80, P148, DOI 10.1021/ja01534a040; Cleland WW, 2000, ARCH BIOCHEM BIOPHYS, V382, P1, DOI 10.1006/abbi.2000.2011; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dunlop KV, 2005, ACTA CRYSTALLOGR D, V61, P80, DOI [10.1107/S0907444904027179, 10.1107/S090444904027179]; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HALL LH, 1987, INT J QUANTUM CHEM, V31, P195, DOI 10.1002/qua.560310203; HALL LH, 1987, INT J QUANTUM CHEM, V31, P217, DOI 10.1002/qua.560310204; HALL LH, 1987, BIOCHEMISTRY-US, V26, P7401, DOI 10.1021/bi00397a031; Kass IJ, 1998, BIOCHEMISTRY-US, V37, P17990, DOI 10.1021/bi982115+; Katona G, 2002, J BIOL CHEM, V277, P21962, DOI 10.1074/jbc.M200676200; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; Ko JJ, 2005, PROTEINS, V59, P183, DOI 10.1002/prot.20418; Kuhn P, 1998, BIOCHEMISTRY-US, V37, P13446, DOI 10.1021/bi9813983; Lario PI, 2003, J MOL BIOL, V326, P1635, DOI 10.1016/S0022-2836(03)00054-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li H, 2005, PROTEINS, V61, P704, DOI 10.1002/prot.20660; Longhi S, 1997, J MOL BIOL, V268, P779, DOI 10.1006/jmbi.1997.1000; MASSEY V, 1965, BIOCHEMISTRY-US, V4, P1161, DOI 10.1021/bi00882a027; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mirsky AE, 1936, P NATL ACAD SCI USA, V22, P439, DOI 10.1073/pnas.22.7.439; Ondrechen MJ, 2001, P NATL ACAD SCI USA, V98, P12473, DOI 10.1073/pnas.211436698; Pace CN, 1996, FASEB J, V10, P75, DOI 10.1096/fasebj.10.1.8566551; Pace CN, 2001, BIOCHEMISTRY-US, V40, P310, DOI 10.1021/bi001574j; Sampson NS, 2003, ACCOUNTS CHEM RES, V36, P713, DOI 10.1021/ar9800587; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; YIN Y, 2002, THESIS STATE U NEW Y; Yue QK, 1999, BIOCHEMISTRY-US, V38, P4277, DOI 10.1021/bi982497j	32	35	36	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAY	2006	2	5					259	264		10.1038/nchembio784	http://dx.doi.org/10.1038/nchembio784			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	034VE	16604066				2022-12-25	WOS:000236957900011
J	Mziaut, H; Trajkovski, M; Kersting, S; Ehninger, A; Altkruger, A; Lemaitre, RP; Schmidt, D; Saeger, HD; Lee, MS; Drechsel, DN; Muller, S; Solimena, M				Mziaut, H; Trajkovski, M; Kersting, S; Ehninger, A; Altkruger, A; Lemaitre, RP; Schmidt, D; Saeger, HD; Lee, MS; Drechsel, DN; Muller, S; Solimena, M			Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5	NATURE CELL BIOLOGY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; PANCREATIC BETA-CELLS; INSULIN GENE-TRANSCRIPTION; PROINSULIN BIOSYNTHESIS; SUMO-1 CONJUGATION; IA-2; IDENTIFICATION; ACTIVATION; EXOCYTOSIS; EXPRESSION	Nutrients and growth hormones promote insulin production and the proliferation of pancreatic beta-cells. An imbalance between ever-increasing metabolic demands and insulin output causes diabetes. Recent evidence indicates that beta-cells enhance insulin gene expression depending on their secretory activity. This signalling pathway involves a catalytically inactive receptor tyrosine phosphatase, ICA512, whose cytoplasmic tail is cleaved on glucose-stimulated exocytosis of insulin secretory granules and then moves into the nucleus, where it upregulates insulin transcription. Here, we show that the cleaved cytosolic fragment of ICA512 enhances the transcription of secretory granule genes ( including its own gene) by binding to tyrosine phosphorylated signal transducers and activators of transcription ( STAT) 5 and preventing its dephosphorylation. Sumoylation of ICA512 by the E3 SUMO ligase PIASy, in turn, may reverse this process by decreasing the binding of ICA512 to STAT5. These findings illustrate how the exocytosis of secretory granules, through a retrograde pathway that sustains STAT activity, converges with growth hormone signalling to induce adaptive changes in beta-cells in response to metabolic demands.	Dresden Univ Technol, Sch Med, Dept Surg, D-01307 Dresden, Germany; Dresden Univ Technol, Sch Med, Med Clin 3, D-01307 Dresden, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea	Technische Universitat Dresden; Technische Universitat Dresden; Max Planck Society; Max Planck Society; Sungkyunkwan University (SKKU); Samsung Medical Center	Solimena, M (corresponding author), Dresden Univ Technol, Sch Med, Dept Surg, D-01307 Dresden, Germany.	michele.solimena@mailbox.tu-dresden.de	Kersting, Stephan/ABG-2973-2020; Solimena, Michele/E-1275-2011; Lee, Myung Shik/C-9606-2011; Kersting, Stephan/C-5137-2009; Kersting, Stephan/AAQ-1889-2020; Solimena, Michele/GVS-5990-2022	Kersting, Stephan/0000-0002-2124-3103; Trajkovski, Mirko/0000-0002-3152-9551; Muller, Stefan/0000-0002-8792-7700				Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Berg KL, 1999, J BIOL CHEM, V274, P35855, DOI 10.1074/jbc.274.50.35855; Brelje TC, 2004, ENDOCRINOLOGY, V145, P4162, DOI 10.1210/en.2004-0201; Chen Y, 2003, J BIOL CHEM, V278, P16520, DOI 10.1074/jbc.M210572200; Cox NJ, 2004, DIABETES, V53, pS19, DOI 10.2337/diabetes.53.2007.S19; Drake PG, 2003, BIOCHEM J, V373, P393, DOI 10.1042/BJ20021851; Drucker DJ, 2003, MOL ENDOCRINOL, V17, P161, DOI 10.1210/me.2002-0306; Felberg J, 2004, J BIOL CHEM, V279, P3455, DOI 10.1074/jbc.M309537200; Friedrichsen BN, 2003, MOL ENDOCRINOL, V17, P945, DOI 10.1210/me.2002-0356; Galsgaard ED, 1996, MOL ENDOCRINOL, V10, P652, DOI 10.1210/me.10.6.652; Goodge KA, 2000, SEMIN CELL DEV BIOL, V11, P235, DOI 10.1006/scdb.2000.0172; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; Gu F, 2003, MOL CELL BIOL, V23, P3753, DOI 10.1128/MCB.23.11.3753-3762.2003; Harashima S, 2005, P NATL ACAD SCI USA, V102, P8704, DOI 10.1073/pnas.0408887102; Hermel JM, 1999, EUR J NEUROSCI, V11, P2609, DOI 10.1046/j.1460-9568.1999.00677.x; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kennedy HJ, 1999, BIOCHEM J, V342, P275, DOI 10.1042/0264-6021:3420275; Kishi A, 2003, AM J PHYSIOL-ENDOC M, V284, pE830, DOI 10.1152/ajpendo.00390.2002; Knoch KP, 2006, CELL METAB, V3, P123, DOI 10.1016/j.cmet.2005.12.008; Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Magistrelli G, 1996, BIOCHEM BIOPH RES CO, V227, P581, DOI 10.1006/bbrc.1996.1549; Marshall C, 2005, MOL ENDOCRINOL, V19, P213, DOI 10.1210/me.2004-0064; Matsuoka T, 2001, J BIOL CHEM, V276, P22071, DOI 10.1074/jbc.M010321200; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; Nielsen JH, 2001, DIABETES, V50, pS25, DOI 10.2337/diabetes.50.2007.S25; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; Ort T, 2000, EUR J CELL BIOL, V79, P621, DOI 10.1078/0171-9335-00095; Otani K, 2004, AM J PHYSIOL-ENDOC M, V286, pE41, DOI 10.1152/ajpendo.00533.2001; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saeki K, 2002, DIABETES, V51, P1842, DOI 10.2337/diabetes.51.6.1842; Sarmiento M, 1998, J BIOL CHEM, V273, P26368, DOI 10.1074/jbc.273.41.26368; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; SOLIMENA M, 1996, EMBO J, V15, P21002; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; Trajkovski M, 2004, J CELL BIOL, V167, P1063, DOI 10.1083/jcb.200408172; Uchimura Y, 2004, ANAL BIOCHEM, V331, P204, DOI 10.1016/j.ab.2004.04.034; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Weinhaus AJ, 1996, ENDOCRINOLOGY, V137, P1640, DOI 10.1210/en.137.5.1640; WELSH M, 1985, J BIOL CHEM, V260, P3590; Wicksteed B, 2003, J BIOL CHEM, V278, P42080, DOI 10.1074/jbc.M303509200; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Zahn TR, 2001, J COMP NEUROL, V429, P127, DOI 10.1002/1096-9861(20000101)429:1&lt;127::AID-CNE10&gt;3.0.CO;2-H; Zhou YP, 2003, METABOLISM, V52, P528, DOI 10.1053/meta.2003.50091	50	66	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	MAY	2006	8	5					435	U20		10.1038/ncb1395	http://dx.doi.org/10.1038/ncb1395			17	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	039IO	16622421				2022-12-25	WOS:000237299400007
J	D'haeseleer, P				D'haeseleer, P			What are DNA sequence motifs?	NATURE BIOTECHNOLOGY			English	Article							DISCOVERY; DATABASE; LOGOS	Sequence motifs are becoming increasingly important in the analysis of gene regulation. How do we define sequence motifs, and why should we use sequence logos instead of consensus sequences to represent them? Do they have any relation with binding affinity? How do we search for new instances of a motif in this sea of DNA?	Lawrence Livermore Natl Lab, Microbial Syst Div, Biosci Directorate, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	D'haeseleer, P (corresponding author), Lawrence Livermore Natl Lab, Microbial Syst Div, Biosci Directorate, POB 808,L-448, Livermore, CA 94551 USA.	patrikd@llnl.gov		D'haeseleer, Patrik/0000-0003-0007-8150				Djordjevic M, 2003, GENOME RES, V13, P2381, DOI 10.1101/gr.1271603; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Munch R, 2003, NUCLEIC ACIDS RES, V31, P266, DOI 10.1093/nar/gkg037; Salgado H, 2006, NUCLEIC ACIDS RES, V34, pD394, DOI 10.1093/nar/gkj156; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; Teixeira MC, 2006, NUCLEIC ACIDS RES, V34, pD446, DOI 10.1093/nar/gkj013; Vlieghe D, 2006, NUCLEIC ACIDS RES, V34, pD95, DOI 10.1093/nar/gkj115; Workman CT, 2005, NUCLEIC ACIDS RES, V33, pW389, DOI 10.1093/nar/gki439; Zhu J, 1999, BIOINFORMATICS, V15, P607, DOI 10.1093/bioinformatics/15.7.607	10	169	173	0	13	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	2006	24	4					423	425		10.1038/nbt0406-423	http://dx.doi.org/10.1038/nbt0406-423			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	032HU	16601727				2022-12-25	WOS:000236766300024
J	Klein, C; Grudzien, M; Appaswamy, G; Germeshausen, M; Sandrock, I; Schaffer, AA; Rathinam, C; Boztug, K; Schwinzer, B; Rezaei, N; Bohn, G; Melin, M; Carlsson, G; Fadeel, B; Dahl, N; Palmblad, J; Henter, JI; Zeidler, C; Grimbacher, B; Welte, K				Klein, Christoph; Grudzien, Magda; Appaswamy, Giridharan; Germeshausen, Manuela; Sandrock, Inga; Schaffer, Alejandro A.; Rathinam, Chozhavendan; Boztug, Kaan; Schwinzer, Beate; Rezaei, Nima; Bohn, Georg; Melin, Malin; Carlsson, Goran; Fadeel, Bengt; Dahl, Niklas; Palmblad, Jan; Henter, Jan-Inge; Zeidler, Cornelia; Grimbacher, Bodo; Welte, Karl			HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease)	NATURE GENETICS			English	Article							COLONY-STIMULATING-FACTOR; MYELOID PROGENITOR CELLS; PROTEIN HAX-1; MITOCHONDRIA; APOPTOSIS; DEATH; NEUTROPHILS; MUTATIONS; INTERACTS; LEUKEMIA	Autosomal recessive severe congenital neutropenia (SCN)(1) constitutes a primary immunodeficiency syndrome associated with increased apoptosis in myeloid cells(2,3), yet the underlying genetic defect remains unknown. Using a positional cloning approach and candidate gene evaluation, we identified a recurrent homozygous germline mutation in HAX1 in three pedigrees. After further molecular screening of individuals with SCN, we identified 19 additional affected individuals with homozygous HAX1 mutations, including three belonging to the original pedigree described by Kostmann(1). HAX1 encodes the mitochondrial protein HAX1, which has been assigned functions in signal transduction(4) and cytoskeletal control(5,6). Here, we show that HAX1 is critical for maintaining the inner mitochondrial membrane potential and protecting against apoptosis in myeloid cells. Our findings suggest that HAX1 is a major regulator of myeloid homeostasis and underline the significance of genetic control of apoptosis in neutrophil development.	Hannover Med Sch, Dept Pediat Hematol Oncol, D-30625 Hannover, Germany; Freiburg Univ Hosp, Med Ctr, Div Rheumatol & Clin Immunol, D-79106 Freiburg, Germany; NIH, Computat Biol Branch, Natl Ctr Biotechnol Informat, Dept Hlth & Human Serv, Bethesda, MD 20894 USA; Univ Tehran Med Sci, Immunol Asthma & Allergy Res Inst, Tehran, Iran; Univ Childrens Hosp, Dept Genet & Pathol, S-75185 Uppsala, Sweden; Karolinska Univ Hosp, Karolinska Inst, Dept Woman & Child Hlth, Childhood Canc Res Unit, S-17176 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Div Biochem & Toxicol, S-17177 Stockholm, Sweden; Karolinska Univ, Huddinge Hosp, Karolinska Inst, Dept Med, S-14186 Stockholm, Sweden	Hannover Medical School; University of Freiburg; National Institutes of Health (NIH) - USA; Immunology Asthma & Allergy Research Institute - Iran; Tehran University of Medical Sciences; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Klein, C (corresponding author), Hannover Med Sch, Dept Pediat Hematol Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	klein.christoph@mh-hannover.de	Boztug, Kaan/AAM-4161-2021; Rezaei, Nima/B-4245-2008; Schaffer, Alejandro/N-1222-2019; Schaffer, Alejandro A/F-2902-2012	Boztug, Kaan/0000-0001-8387-9185; Rezaei, Nima/0000-0002-3836-1827; Henter, Jan-Inge/0000-0002-0629-2126	NATIONAL LIBRARY OF MEDICINE [Z01LM000097, ZIALM000097] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Cario G, 2005, BRIT J HAEMATOL, V129, P275, DOI 10.1111/j.1365-2141.2005.05428.x; Carlsson G, 2004, BLOOD, V103, P3355, DOI 10.1182/blood-2003-04-1011; Carlsson G, 2001, ACTA PAEDIATR, V90, P757, DOI 10.1080/080352501750315663; Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; DONG F, 1995, NEW ENGL J MED, V333, P487, DOI 10.1056/NEJM199508243330804; Dufva M, 2001, J GEN VIROL, V82, P1581, DOI 10.1099/0022-1317-82-7-1581; ELSNER J, 1993, EXP HEMATOL, V21, P38; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; GILMAN PA, 1970, BLOOD-J HEMATOL, V36, P576, DOI 10.1182/blood.V36.5.576.576; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Kawaguchi Y, 2000, J VIROL, V74, P10104, DOI 10.1128/JVI.74.21.10104-10111.2000; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084/jem.191.10.1699; KOSTMANN R, 1956, Acta Paediatr Suppl, V45, P1; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Maianski NA, 2004, CELL DEATH DIFFER, V11, P143, DOI 10.1038/sj.cdd.4401320; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Radhika V, 2004, J BIOL CHEM, V279, P49406, DOI 10.1074/jbc.M408836200; Rosenberg PS, 2006, BLOOD, V107, P4628, DOI 10.1182/blood-2005-11-4370; SCHAFFER AA, 1994, HUM HERED, V44, P225, DOI 10.1159/000154222; Sharp TV, 2002, J VIROL, V76, P802, DOI 10.1128/JVI.76.2.802-816.2002; Suzuki Y, 1997, J IMMUNOL, V158, P2736; WETTE K, 2006, SEMIN HEMATOL, V43, P189; Yedavalli VSRK, 2005, J VIROL, V79, P13735, DOI 10.1128/JVI.79.21.13735-13746.2005	30	345	361	0	19	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JAN	2007	39	1					86	92		10.1038/ng1940	http://dx.doi.org/10.1038/ng1940			7	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	121CU	17187068				2022-12-25	WOS:000243136500022
J	Chang, MCY; Keasling, JD				Chang, Michelle C. Y.; Keasling, Jay D.			Production of isoprenoid pharmaceuticals by engineered microbes	NATURE CHEMICAL BIOLOGY			English	Article							ALCALIGENES-EUTROPHUS H16; ESCHERICHIA-COLI; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; TAXOL BIOSYNTHESIS; ARTEMISIA-ANNUA; NATURAL-PRODUCTS; AMORPHA-4,11-DIENE SYNTHASE; HETEROLOGOUS EXPRESSION; POLYKETIDE BIOSYNTHESIS	Throughout human history, natural products have been the foundation for the discovery and development of therapeutics used to treat diseases ranging from cardiovascular disease to cancer. Their chemical diversity and complexity have provided structural scaffolds for small-molecule drugs and have consistently served as inspiration for medicinal design. However, the chemical complexity of natural products also presents one of the main roadblocks for production of these pharmaceuticals on an industrial scale. Chemical synthesis of natural products is often difficult and expensive, and isolation from their natural sources is also typically low yielding. Synthetic biology and metabolic engineering offer an alternative approach that is becoming more accessible as the tools for engineering microbes are further developed. By reconstructing heterologous metabolic pathways in genetically tractable host organisms, complex natural products can be produced from inexpensive sugar starting materials through large-scale fermentation processes. In this Perspective, we discuss ongoing research aimed toward the production of terpenoid natural products in genetically engineered Escherichia coli and Saccharomyces cerevisiae.	Univ Calif Berkeley, Calif Inst Quantitat Biomed Res, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem Engn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; Lawrence Berkeley Natl Lab, Phys Biosci Div, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Chang, MCY (corresponding author), Univ Calif Berkeley, Calif Inst Quantitat Biomed Res, Berkeley, CA 94720 USA.	keasling@berkeley.edu	Keasling, Jay D/J-9162-2012	Keasling, Jay D/0000-0003-4170-6088				Albrecht M, 1999, BIOTECHNOL LETT, V21, P791, DOI 10.1023/A:1005547827380; Alper H, 2005, METAB ENG, V7, P155, DOI 10.1016/j.ymben.2004.12.003; Alper H, 2005, NAT BIOTECHNOL, V23, P612, DOI 10.1038/nbt1083; ARISTIDOU AA, 1994, BIOTECHNOL BIOENG, V44, P944, DOI 10.1002/bit.260440810; Bayer TS, 2005, NAT BIOTECHNOL, V23, P337, DOI 10.1038/nbt1069; BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; Bertea CM, 2005, PLANTA MED, V71, P40, DOI 10.1055/s-2005-837749; Causey TB, 2003, P NATL ACAD SCI USA, V100, P825, DOI 10.1073/pnas.0337684100; Causey TB, 2004, P NATL ACAD SCI USA, V101, P2235, DOI 10.1073/pnas.0308171100; Chang YJ, 2000, ARCH BIOCHEM BIOPHYS, V383, P178, DOI 10.1006/abbi.2000.2061; Chau M, 2004, ARCH BIOCHEM BIOPHYS, V427, P48, DOI 10.1016/j.abb.2004.04.016; Chau M, 2004, CHEM BIOL, V11, P663, DOI 10.1016/j.chembiol.2004.02.025; Cirino PC, 2002, CURR OPIN CHEM BIOL, V6, P130, DOI 10.1016/S1367-5931(02)00305-8; Conolly JD, 1991, DICT TERPENOIDS; DeJong JM, 2006, BIOTECHNOL BIOENG, V93, P212, DOI 10.1002/bit.20694; Dhingra V, 2001, BIOCHEM BIOPH RES CO, V281, P558, DOI 10.1006/bbrc.2000.4197; Donald KAG, 1997, APPL ENVIRON MICROB, V63, P3341, DOI 10.1128/AEM.63.9.3341-3344.1997; Duport C, 1998, NAT BIOTECHNOL, V16, P186, DOI 10.1038/nbt0298-186; ENSLEY BD, 1983, SCIENCE, V222, P167, DOI 10.1126/science.6353574; Farmer WR, 2000, NAT BIOTECHNOL, V18, P533, DOI 10.1038/75398; Farmer WR, 2001, BIOTECHNOL PROGR, V17, P57, DOI 10.1021/bp000137t; Fischer E, 2003, EUR J BIOCHEM, V270, P880, DOI 10.1046/j.1432-1033.2003.03448.x; Glazer AN., 2007, MICROBIOTECHNOL FUND, DOI [10.1017/CBO9780511811227, DOI 10.1017/CBO9780511811227]; HARBORNE JB, 1991, ECOLOGICAL CHEM BIOC, P399; Hefner J, 1998, ARCH BIOCHEM BIOPHYS, V360, P62, DOI 10.1006/abbi.1998.0926; Hemmi H, 1998, J BIOCHEM-TOKYO, V123, P1088; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; HORWITZ SB, 1994, NATURE, V367, P593, DOI 10.1038/367593a0; Huang QL, 2001, BIOORGAN MED CHEM, V9, P2237, DOI 10.1016/S0968-0896(01)00072-4; Jackson BE, 2003, ORG LETT, V5, P1629, DOI 10.1021/ol034231x; Jennewein S, 2004, P NATL ACAD SCI USA, V101, P9149, DOI 10.1073/pnas.0403009101; Jennewein S, 2004, CHEM BIOL, V11, P379, DOI 10.1016/j.chembiol.2004.02.022; Jennewein S, 2001, P NATL ACAD SCI USA, V98, P13595, DOI 10.1073/pnas.251539398; Kajiwara S, 1997, BIOCHEM J, V324, P421, DOI 10.1042/bj3240421; Kakinuma K, 2001, J AM CHEM SOC, V123, P1238, DOI 10.1021/ja003390y; Kealey JT, 1998, P NATL ACAD SCI USA, V95, P505, DOI 10.1073/pnas.95.2.505; Khosla C, 2003, NAT REV DRUG DISCOV, V2, P1019, DOI 10.1038/nrd1256; Kim SW, 2001, BIOTECHNOL BIOENG, V72, P408, DOI 10.1002/1097-0290(20000220)72:4<408::AID-BIT1003>3.0.CO;2-H; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; Korenromp E, 2005, WORLD MALARIA REPORT; Lange BM, 2000, P NATL ACAD SCI USA, V97, P13172, DOI 10.1073/pnas.240454797; Lau J, 2004, J BIOTECHNOL, V110, P95, DOI 10.1016/j.jbiotec.2004.02.001; Martin VJJ, 2003, NAT BIOTECHNOL, V21, P796, DOI 10.1038/nbt833; Martin VJJ, 2001, BIOTECHNOL BIOENG, V75, P497, DOI 10.1002/bit.10037; Matthews PD, 2000, APPL MICROBIOL BIOT, V53, P396, DOI 10.1007/s002530051632; McCaskill D, 1997, Adv Biochem Eng Biotechnol, V55, P107; MCNEIL DGJ, 2004, NY TIMES        1114; Menzella HG, 2005, NAT BIOTECHNOL, V23, P1171, DOI 10.1038/nbt1128; Mercke P, 2000, ARCH BIOCHEM BIOPHYS, V381, P173, DOI 10.1006/abbi.2000.1962; MERMOD N, 1986, BIO-TECHNOL, V4, P321, DOI 10.1038/nbt0486-321; Mutka SC, 2006, FEMS YEAST RES, V6, P40, DOI 10.1111/j.1567-1356.2005.00001.x; Nakamura CE, 2003, CURR OPIN BIOTECH, V14, P454, DOI 10.1016/j.copbio.2003.08.005; Neudert U, 1998, BBA-LIPID LIPID MET, V1392, P51, DOI 10.1016/S0005-2760(98)00017-4; Newman DJ, 2000, NAT PROD REP, V17, P215, DOI 10.1039/a902202c; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; Newman JD, 2006, BIOTECHNOL BIOENG, V95, P684, DOI 10.1002/bit.21017; PEOPLES OP, 1989, J BIOL CHEM, V264, P15298; Pfeifer BA, 2001, MICROBIOL MOL BIOL R, V65, P106, DOI 10.1128/MMBR.65.1.106-118.2001; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; Pfleger BF, 2006, NAT BIOTECHNOL, V24, P1027, DOI 10.1038/nbt1226; PITERA DJ, UNPUB METAB ENG; Polakowski T, 1998, APPL MICROBIOL BIOT, V49, P66, DOI 10.1007/s002530051138; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; Rohdich F, 2003, PURE APPL CHEM, V75, P393, DOI 10.1351/pac200375020393; Rohdich F, 2002, P NATL ACAD SCI USA, V99, P1158, DOI 10.1073/pnas.032658999; ROHMER M, 1993, BIOCHEM J, V295, P517, DOI 10.1042/bj2950517; ROTH RJ, 1989, J NAT PROD, V52, P1183, DOI 10.1021/np50065a050; Sauer U, 2004, CURR OPIN BIOTECH, V15, P58, DOI 10.1016/j.copbio.2003.11.001; Schoendorf A, 2001, P NATL ACAD SCI USA, V98, P1501, DOI 10.1073/pnas.98.4.1501; SCHUBERT P, 1988, J BACTERIOL, V170, P5837, DOI 10.1128/jb.170.12.5837-5847.1988; Schuler MA, 2003, ANNU REV PLANT BIOL, V54, P629, DOI 10.1146/annurev.arplant.54.031902.134840; Shimada H, 1998, APPL ENVIRON MICROB, V64, P2676; SLATER SC, 1988, J BACTERIOL, V170, P4431, DOI 10.1128/jb.170.10.4431-4436.1988; Sowden RJ, 2005, ORG BIOMOL CHEM, V3, P57, DOI 10.1039/b413068e; Spurgeon S, 1981, BIOSYNTHESIS ISOPREN; STANZAK R, 1986, BIO-TECHNOL, V4, P229, DOI 10.1038/nbt0386-229; Stephanopoulos G., 1998, METAB ENG; Stephanopoulos G, 1999, METAB ENG, V1, P1, DOI 10.1006/mben.1998.0101; Szczebara FM, 2003, NAT BIOTECHNOL, V21, P143, DOI 10.1038/nbt775; Szkopinska A, 2000, BIOCHEM BIOPH RES CO, V267, P473, DOI 10.1006/bbrc.1999.1981; Tang L, 2000, SCIENCE, V287, P640, DOI 10.1126/science.287.5453.640; Teoh KH, 2006, FEBS LETT, V580, P1411, DOI 10.1016/j.febslet.2006.01.065; VARMA A, 1994, BIO-TECHNOL, V12, P994, DOI 10.1038/nbt1094-994; Walker K, 2000, P NATL ACAD SCI USA, V97, P583, DOI 10.1073/pnas.97.2.583; Walker K, 2000, ARCH BIOCHEM BIOPHYS, V374, P371, DOI 10.1006/abbi.1999.1609; Walker K, 2002, P NATL ACAD SCI USA, V99, P9166, DOI 10.1073/pnas.082115799; Walker K, 2000, P NATL ACAD SCI USA, V97, P13591, DOI 10.1073/pnas.250491997; Walker KD, 2004, J BIOL CHEM, V279, P53947, DOI 10.1074/jbc.M411215200; Wallaart TE, 1999, J NAT PROD, V62, P430, DOI 10.1021/np980370p; Wang CW, 1999, BIOTECHNOL BIOENG, V62, P235, DOI 10.1002/(SICI)1097-0290(19990120)62:2<235::AID-BIT14>3.0.CO;2-U; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201; Yoshikuni Y, 2006, NATURE, V440, P1078, DOI 10.1038/nature04607; Yoshikuni Y, 2006, CHEM BIOL, V13, P91, DOI 10.1016/j.chembiol.2005.10.016; Yuan LZ, 2006, METAB ENG, V8, P79, DOI 10.1016/j.ymben.2005.08.005	95	274	305	4	133	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	DEC	2006	2	12					674	681		10.1038/nchembio836	http://dx.doi.org/10.1038/nchembio836			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	107KC	17108985				2022-12-25	WOS:000242168800011
J	Li, JH; Li, WX				Li, Jinghong; Li, Willis X.			A novel function of Drosophila eIF4A as a negative regulator of Dpp/BMP signalling that mediates SMAD degradation	NATURE CELL BIOLOGY			English	Article							WINGLESS; MUTATION; DOMINANT; HEDGEHOG	Signalling by the TGF-beta superfamily member and BMP orthologue Decapentaplegic (Dpp) is crucial for multiple developmental programmes and has to be tightly regulated. Here, we demonstrate that the Drosophila Dpp pathway is negatively regulated by eukaryotic translation initiation factor 4A (elF4A), which mediates activation-dependent degradation of the Dpp signalling components Mad and Medea. elF4A mutants exhibit increased Dpp signalling and accumulation of Mad and phospho-Mad. Overexpression of elF4A decreases Dpp signalling and causes loss of Mad and phospho-Mad. Furthermore, elF4A physically associates with Mad and Medea, and promotes their degradation following activation of Dpp signalling in a translation-independent manner. Finally, we show that elF4A acts synergistically with, but independently of, the ubiquitin ligase DSmurf, indicating that a dual system controls SMAD degradation. Thus, in addition to being an obligatory component of the cap-dependent translation initiation complex, elF4A has a novel function as a specific inhibitor of Dpp signalling that mediates the degradation of SMAD homologues.	Univ Rochester, Med Ctr, Dept Biomed Genet, Rochester, NY 14642 USA	University of Rochester	Li, WX (corresponding author), Univ Rochester, Med Ctr, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.	willis_li@urmc.rochester.edu	Li, Willis X/AAL-7212-2020; Li, Willis/ABC-5695-2020	Li, Willis X/0000-0001-9041-7341; Li, Willis/0000-0001-9041-7341; Li, Jinghong/0000-0003-2497-9295	NIGMS NIH HHS [R01GM077046, R01 GM077046-04, R01 GM077046, R01 GM065774, R01GM65774, R01 GM065774-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077046, R01GM065774] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunner E, 1999, DEV BIOL, V206, P178, DOI 10.1006/dbio.1998.9136; Kopp A, 1997, DEVELOPMENT, V124, P3703; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Neumann CJ, 1996, GENETICS, V142, P1147	4	24	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1407	U62		10.1038/ncb1506	http://dx.doi.org/10.1038/ncb1506			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17115029	Green Accepted			2022-12-25	WOS:000242419800017
J	Shirangi, TR; Taylor, BJ; McKeown, M				Shirangi, Troy R.; Taylor, Barbara J.; McKeown, Michael			A double-switch system regulates male courtship behavior in male and female Drosophila melanogaster	NATURE GENETICS			English	Article							DETERMINATION GENE FRUITLESS; SEXUAL-DIFFERENTIATION; EXPRESSION; MUSCLE; INTERSEX; INNERVATION; ORIENTATION; REPRESSION; MUTATIONS; NEURONS	Current models describe male-specific fruitless (fruM) as a genetic 'switch' regulating sexual behavior in Drosophila melanogaster, and they postulate that female (F) and male (M) doublesex (dsx) products control body sexual morphology. In contradiction to this simple model, we show that dsx, as well as fruM and non-sex-specific retained (retn), affect both male and female sexual behaviors. In females, both retn and dsxF contribute to female receptivity, and both genes act to repress male-like courtship activity in the presence or absence of fruM. In males, consistent with the opposing functions of dsxM and dsxF, dsxM acts as a positive factor for male courtship. retn also acts counter to fruM in the development of the male-specific muscle of Lawrence. Molecularly, retn seems to regulate sexual behavior via a previously described complex that represses zerknullt. Thus, we show that fru and dsx together act as a 'switch' system regulating behavior in the context of other developmental genes, such as retn.	Brown Univ, Mol Biol Cell Biol & Biochem Dept, Providence, RI 02912 USA; Oregon State Univ, Dept Zool, Corvallis, OR 97331 USA	Brown University; Oregon State University	McKeown, M (corresponding author), Brown Univ, Mol Biol Cell Biol & Biochem Dept, 69 Brown St, Providence, RI 02912 USA.	Michael_McKeown@Brown.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033352] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM007601] Funding Source: Medline; NINDS NIH HHS [NS33352] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Anand A, 2001, GENETICS, V158, P1569; Baker BS, 2001, CELL, V105, P13, DOI 10.1016/S0092-8674(01)00293-8; Billeter JC, 2004, J COMP NEUROL, V475, P270, DOI 10.1002/cne.20177; Billeter JC, 2006, CURR BIOL, V16, P1063, DOI 10.1016/j.cub.2006.04.039; CHASE BA, 1995, GENETICS, V139, P1649; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Christiansen AE, 2002, TRENDS GENET, V18, P510, DOI 10.1016/S0168-9525(02)02769-5; CURRIE DA, 1995, DEVELOPMENT, V121, P2549; Demir E, 2005, CELL, V121, P785, DOI 10.1016/j.cell.2005.04.027; Ditch LM, 2005, DEVELOPMENT, V132, P155, DOI 10.1242/dev.01568; Finley KD, 1997, P NATL ACAD SCI USA, V94, P913, DOI 10.1073/pnas.94.3.913; GAILEY DA, 1991, DEVELOPMENT, V113, P879; Garrett-Engele CM, 2002, DEVELOPMENT, V129, P4661; Gregory SL, 1996, MOL CELL BIOL, V16, P792; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; LAWRENCE PA, 1986, CELL, V45, P505, DOI 10.1016/0092-8674(86)90282-5; Lee G, 2000, J NEUROBIOL, V43, P404, DOI 10.1002/1097-4695(20000615)43:4<404::AID-NEU8>3.0.CO;2-D; Manoli DS, 2005, NATURE, V436, P395, DOI 10.1038/nature03859; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Stockinger P, 2005, CELL, V121, P795, DOI 10.1016/j.cell.2005.04.026; TAYLOR BJ, 1994, DEV GENET, V15, P275, DOI 10.1002/dvg.1020150309; Usui-Aoki K, 2000, NAT CELL BIOL, V2, P500, DOI 10.1038/35019537; Valentine SA, 1998, MOL CELL BIOL, V18, P6584, DOI 10.1128/MCB.18.11.6584; Villella A, 1996, GENETICS, V143, P331; Villella A, 1997, GENETICS, V147, P1107; Waterbury JA, 1999, GENETICS, V152, P1653; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	29	41	43	0	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2006	38	12					1435	1439		10.1038/ng1908	http://dx.doi.org/10.1038/ng1908			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17086183				2022-12-25	WOS:000242404200022
J	Higa, LA; Wu, M; Ye, T; Kobayashi, R; Sun, H; Zhang, H				Higa, Leigh Ann; Wu, Min; Ye, Tao; Kobayashi, Ryuji; Sun, Hong; Zhang, Hui			CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation	NATURE CELL BIOLOGY			English	Article							DNA-BINDING-PROTEIN; WD-REPEAT PROTEINS; MOLECULAR RECOGNITION; H3; COMPLEXES; CDT1; METHYLTRANSFERASE; CHROMATIN; DAMAGE; HETEROCHROMATIN	The CUL4-DDB1-ROC1 ubiquitin E3 ligase regulates cell-cycle progression, replication and DNA damage response(1-4). However, the substrate-specific adaptors of this ligase remain uncharacterized. Here, we show that CUL4-DDB1 complexes interact with multiple WD40-repeat proteins (WDRs) including TLE1-3, WDR5, L2DTL (also known as CDT2) and the Polycomb-group protein EED (also known as ESC). WDR5 and EED are core components of histone methylation complexes that are essential for histone H3 methylation and epigenetic control at K4 or K9 and K27, respectively(5-7), whereas L2DTL regulates CDT1 proteolysis after DNA damage through CUL4-DDB1 (ref. 8). We found that CUL4A-DDB1 interacts with H3 methylated mononucleosomes and peptides. Inactivation of either CUL4 or DDB1 impairs these histone modifications. However, loss of WDR5 specifically affects histone H3 methylation at K4 but not CDT1 degradation, whereas inactivation of L2DTL prevents CDT1 degradation but not histone methylation. Our studies suggest that CUL4-DDB1 ligases use WDR proteins as molecular adaptors for substrate recognition, and modulate multiple biological processes through ubiquitin-dependent proteolysis.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Peking Univ, Lab Chem Genom, Grad Sch, Shenzhen 518055, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	Yale University; Peking University; Hong Kong Polytechnic University; University of Texas System; UTMD Anderson Cancer Center	Zhang, H (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06520 USA.	hui.zhang@yale.edu	Wu, Min/AAE-5066-2021; Ye，PhD，FRSC, Tao/ABB-8698-2020	Wu, Min/0000-0003-1372-4764; Ye，PhD，FRSC, Tao/0000-0002-2780-9761; Higa, Leigh Ann/0000-0003-0117-0397	NATIONAL CANCER INSTITUTE [R01CA077695, R01CA098955, R01CA072878] Funding Source: NIH RePORTER; NCI NIH HHS [CA77695, CA98955, CA72878] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angers S, 2006, NATURE, V443, P590, DOI 10.1038/nature05175; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Couture JF, 2006, NAT STRUCT MOL BIOL, V13, P698, DOI 10.1038/nsmb1116; Craig JM, 2005, BIOESSAYS, V27, P17, DOI 10.1002/bies.20145; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Groisman R, 2006, GENE DEV, V20, P1429, DOI 10.1101/gad.378206; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Higa LAA, 2003, NAT CELL BIOL, V5, P1008, DOI 10.1038/ncb1061; Higa LA, 2006, CELL CYCLE, V5, P1675, DOI 10.4161/cc.5.15.3149; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Jennings BH, 2006, MOL CELL, V22, P645, DOI 10.1016/j.molcel.2006.04.024; Jia ST, 2005, NAT CELL BIOL, V7, P1007, DOI 10.1038/ncb1300; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Liu C, 2005, EMBO J, V24, P3940, DOI 10.1038/sj.emboj.7600854; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Ruthenburg AJ, 2006, NAT STRUCT MOL BIOL, V13, P704, DOI 10.1038/nsmb1119; Scacheri PC, 2006, PLOS GENET, V2, P406, DOI 10.1371/journal.pgen.0020051; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Tie F, 2003, MOL CELL BIOL, V23, P3352, DOI 10.1128/MCB.23.9.3352-3362.2003; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	32	329	363	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	NOV	2006	8	11					1277	U48		10.1038/ncb1490	http://dx.doi.org/10.1038/ncb1490			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	101HR	17041588				2022-12-25	WOS:000241732400017
J	Ioshikhes, IP; Albert, I; Zanton, SJ; Pugh, BF				Ioshikhes, Ilya P.; Albert, Istvan; Zanton, Sara J.; Pugh, B. Franklin			Nucleosome positions predicted through comparative genomics	NATURE GENETICS			English	Article							SACCHAROMYCES-CEREVISIAE; MULTIPLE ALIGNMENT; PROMOTER REGIONS; DNA PATTERN; YEAST; IDENTIFICATION; SEQUENCES; GENES; SITES; CORE	DNA sequence has long been recognized as an important contributor to nucleosome positioning, which has the potential to regulate access to genes. The extent to which the nucleosomal architecture at promoters is delineated by the underlying sequence is now being worked out. Here we use comparative genomics to report a genome-wide map of nucleosome positioning sequences (NPSs) located in the vicinity of all Saccharomyces cerevisiae genes. We find that the underlying DNA sequence provides a very good predictor of nucleosome locations that have been experimentally mapped to a small fraction of the genome. Notably, distinct classes of genes possess characteristic arrangements of NPSs that may be important for their regulation. In particular, genes that have a relatively compact NPS arrangement over the promoter region tend to have a TATA box buried in an NPS and tend to be highly regulated by chromatin modifying and remodeling factors.	Penn State Univ, Ctr Gene Regulat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA; Penn State Univ, Huck Inst Life Sci, Bioinformat Consulting Ctr, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Pugh, BF (corresponding author), Penn State Univ, Ctr Gene Regulat, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	bfp2@psu.edu	Albert, Istvan/J-3734-2015	Albert, Istvan/0000-0001-8366-984X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059055] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059055, GM59055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basehoar AD, 2004, CELL, V116, P699, DOI 10.1016/S0092-8674(04)00205-3; Bolshoy A, 1996, COMPUT APPL BIOSCI, V12, P383; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Cohanim AB, 2005, J BIOMOL STRUCT DYN, V22, P687, DOI 10.1080/07391102.2005.10507035; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Ioshikhes I, 1996, J MOL BIOL, V262, P129, DOI 10.1006/jmbi.1996.0503; Ioshikhes I, 1999, P NATL ACAD SCI USA, V96, P2891, DOI 10.1073/pnas.96.6.2891; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Lowary PT, 1997, P NATL ACAD SCI USA, V94, P1183, DOI 10.1073/pnas.94.4.1183; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Sabet N, 2004, MOL CELL BIOL, V24, P8823, DOI 10.1128/MCB.24.20.8823-8833.2004; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Sekinger EA, 2005, MOL CELL, V18, P735, DOI 10.1016/j.molcel.2005.05.003; Widom J, 1996, J MOL BIOL, V259, P579, DOI 10.1006/jmbi.1996.0341; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178; Zanton SJ, 2006, GENE DEV, V20, P2250, DOI 10.1101/gad.1437506; Zhang ZH, 2005, NUCLEIC ACIDS RES, V33, P2838, DOI 10.1093/nar/gki583	21	255	263	1	16	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1210	1215		10.1038/ng1878	http://dx.doi.org/10.1038/ng1878			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16964265				2022-12-25	WOS:000241251100023
J	Austin, MB; Saito, T; Bowman, ME; Haydock, S; Kato, A; Moore, BS; Kay, RR; Noel, JP				Austin, Michael B.; Saito, Tamao; Bowman, Marianne E.; Haydock, Stephen; Kato, Atsushi; Moore, Bradley S.; Kay, Robert R.; Noel, Joseph P.			Biosynthesis of Dictyostelium discoideum differentiation-inducing factor by a hybrid type I fatty acid - type III polyketide synthase	NATURE CHEMICAL BIOLOGY			English	Article							SLIME-MOLD DICTYOSTELIUM; CHALCONE SYNTHASE; CELL-DIFFERENTIATION; CRYSTAL-STRUCTURE; SPECIFICITY; IDENTIFICATION; ORGANIZATION; SUPERFAMILY; DIF-1	Differentiation-inducing factors (DIFs) are well known to modulate formation of distinct communal cell types from identical Dictyostelium discoideum amoebas, but DIF biosynthesis remains obscure. We report complimentary in vivo and in vitro experiments identifying one of two similar to 3,000-residue D. discoideum proteins, termed ` steely', as responsible for biosynthesis of the DIF acylphloroglucinol scaffold. Steely proteins possess six catalytic domains homologous to metazoan type I fatty acid synthases (FASs) but feature an iterative type III polyketide synthase (PKS) in place of the expected FAS C-terminal thioesterase used to off load fatty acid products. This new domain arrangement likely facilitates covalent transfer of steely N-terminal acyl products directly to the C-terminal type III PKS active sites, which catalyze both iterative polyketide extension and cyclization. The crystal structure of a steely C-terminal domain confirms conservation of the homodimeric type III PKS fold. These findings suggest new bioengineering strategies for expanding the scope of fatty acid and polyketide biosynthesis.	Salk Inst Biol Studies, Howard Hughes Med Inst, Jack H Skirball Ctr Chem Biol & Proteom, La Jolla, CA 92037 USA; Hokuriku Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92037 USA; Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92037 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Howard Hughes Medical Institute; Salk Institute; Hokuriku University; University of Cambridge; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of California System; University of California San Diego; MRC Laboratory Molecular Biology	Kay, RR (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Jack H Skirball Ctr Chem Biol & Proteom, La Jolla, CA 92037 USA.	rrk@mrc-lmb.cam.ac.uk; noel@salk.edu	Noel, Joseph P/A-9459-2009	Moore, Bradley/0000-0002-4652-1253; Kay, Robert R/0000-0001-9836-7967	Howard Hughes Medical Institute Funding Source: Medline; Medical Research Council [MC_U105115237] Funding Source: Medline; NIAID NIH HHS [R01 AI052443, AI52443] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052443] Funding Source: NIH RePORTER; MRC [MC_U105115237] Funding Source: UKRI	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abe I, 2005, J AM CHEM SOC, V127, P1362, DOI 10.1021/ja0431206; Abe I, 2004, PHYTOCHEMISTRY, V65, P2447, DOI 10.1016/j.phytochem.2004.08.005; Abe I, 2004, FEBS LETT, V562, P171, DOI 10.1016/S0014-5793(04)00230-3; Abe T, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng095; Asturias FJ, 2005, NAT STRUCT MOL BIOL, V12, P225, DOI 10.1038/nsmb899; Austin MB, 2004, J BIOL CHEM, V279, P45162, DOI 10.1074/jbc.M406567200; Austin MB, 2004, CHEM BIOL, V11, P1179, DOI 10.1016/j.chembiol.2004.05.024; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; BROOKMAN JJ, 1982, DEV BIOL, V91, P191, DOI 10.1016/0012-1606(82)90022-7; Chirala SS, 2004, LIPIDS, V39, P1045, DOI 10.1007/s11745-004-1329-9; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; Eichinger L, 2005, NATURE, V435, P43, DOI 10.1038/nature03481; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; Funa N, 2002, J BIOL CHEM, V277, P4628, DOI 10.1074/jbc.M110357200; Gokan N, 2005, BIOCHEM PHARMACOL, V70, P676, DOI 10.1016/j.bcp.2005.06.002; Jez JM, 2000, CHEM BIOL, V7, P919, DOI 10.1016/S1074-5521(00)00041-7; Jez JM, 2001, BIOCHEMISTRY-US, V40, P14829, DOI 10.1021/bi015621z; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; KAY RR, 1987, METHOD CELL BIOL, V28, P433; Kay RR, 1998, J BIOL CHEM, V273, P2669, DOI 10.1074/jbc.273.5.2669; KESSIN RH, 2001, DICTYOSTELIUM; Khosla C, 1999, ANNU REV BIOCHEM, V68, P219, DOI 10.1146/annurev.biochem.68.1.219; Maier T, 2006, SCIENCE, V311, P1258, DOI 10.1126/science.1123248; MASENTO MS, 1988, BIOCHEM J, V256, P23, DOI 10.1042/bj2560023; Menzella HG, 2005, NAT BIOTECHNOL, V23, P1171, DOI 10.1038/nbt1128; MORANDINI P, 1995, BIOCHEM J, V306, P735, DOI 10.1042/bj3060735; MORRIS HR, 1988, BIOCHEM J, V249, P903, DOI 10.1042/bj2490903; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; Saito T, 1999, EUR J BIOCHEM, V265, P809, DOI 10.1046/j.1432-1327.1999.00789.x; Sankaranarayanan R, 2004, NAT STRUCT MOL BIOL, V11, P894, DOI 10.1038/nsmb809; Schroder J, 2000, RECENT ADV PHYTOCHEM, V34, P55, DOI 10.1016/S0079-9920(00)80004-0; Serafimidis I, 2005, DEV BIOL, V282, P432, DOI 10.1016/j.ydbio.2005.03.023; Seshime Y, 2005, BIOCHEM BIOPH RES CO, V331, P253, DOI 10.1016/j.bbrc.2005.03.160; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Takaya Y, 2000, J ORG CHEM, V65, P985, DOI 10.1021/jo991338i; Thompson CRL, 2000, MOL CELL, V6, P1509, DOI 10.1016/S1097-2765(00)00147-7; Tillett D, 2000, CHEM BIOL, V7, P753, DOI 10.1016/S1074-5521(00)00021-1; Tsai SC, 2001, P NATL ACAD SCI USA, V98, P14808, DOI 10.1073/pnas.011399198; Witkowski A, 2004, CHEM BIOL, V11, P1667, DOI 10.1016/j.chembiol.2004.09.016	40	93	97	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2006	2	9					494	502		10.1038/nchembio811	http://dx.doi.org/10.1038/nchembio811			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	075XO	16906151	Green Accepted			2022-12-25	WOS:000239920900013
J	Kwok, BH; Kapitein, LC; Kim, JH; Peterman, EJG; Schmidt, CF; Kapoor, TM				Kwok, Benjamin H.; Kapitein, Lukas C.; Kim, Jeffrey H.; Peterman, Erwin J. G.; Schmidt, Christoph F.; Kapoor, Tarun M.			Allosteric inhibition of kinesin-5 modulates its processive directional motility	NATURE CHEMICAL BIOLOGY			English	Article							GREEN FLUORESCENT PROTEIN; MONASTROL INHIBITION; SINGLE MOLECULES; BIPOLAR KINESIN; MOTOR PROTEIN; CROSS-LINKS; IN-VITRO; EG5; MICROTUBULES; DISCOVERY	Small-molecule inhibitors of kinesin-5 (refs. 1-3), a protein essential for eukaryotic cell division(4), represent alternatives to antimitotic agents that target tubulin(5,6). While tubulin is needed for multiple intracellular processes, the known functions of kinesin-5 are limited to dividing cells, making it likely that kinesin-5 inhibitors would have fewer side effects than do tubulin-targeting drugs. Kinesin-5 inhibitors, such as monastrol(1), act through poorly understood allosteric mechanisms, not competing with ATP binding(7,8). Moreover, the microscopic mechanism of full-length kinesin-5 motility is not known. Here we characterize the motile properties and allosteric inhibition of Eg5, a vertebrate kinesin-5, using a GFP fusion protein in single-molecule fluorescence assays(9). We find that Eg5 is a processive kinesin whose motility includes, in addition to ATP-dependent directional motion, a diffusive component not requiring ATP hydrolysis. Monastrol suppresses the directional processive motility of microtubule-bound Eg5. These data on Eg5' s allosteric inhibition will impact these inhibitors' use as probes and development as chemotherapeutic agents.	Vrije Univ Amsterdam, Dept Phys & Astron, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Ctr Laser, NL-1081 HV Amsterdam, Netherlands; Rockefeller Univ, Lab Chem & Cell Biol, New York, NY 10021 USA; Univ Gottingen, Inst Phys 3, Fak Phys, D-37077 Gottingen, Germany	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Rockefeller University; University of Gottingen	Peterman, EJG (corresponding author), Vrije Univ Amsterdam, Dept Phys & Astron, Boelelaan 1081, NL-1081 HV Amsterdam, Netherlands.	erwinp@nat.vu.nl; kapoor@mail.rockefeller.edu	Peterman, Erwin/G-5529-2010; Schmidt, Christoph F/G-3787-2011; Kapitein, Lukas C/J-4776-2016	Peterman, Erwin/0000-0003-1058-249X; Schmidt, Christoph F/0000-0003-2864-6973; Kapitein, Lukas C/0000-0001-9418-6739	NIGMS NIH HHS [GM65933] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065933] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergnes G, 2005, CURR TOP MED CHEM, V5, P127, DOI 10.2174/1568026053507697; Cochran JC, 2005, J BIOL CHEM, V280, P12658, DOI 10.1074/jbc.M413140200; Cox CD, 2005, BIOORG MED CHEM LETT, V15, P2041, DOI 10.1016/j.bmcl.2005.02.055; Crevel IMTC, 2004, CURR BIOL, V14, pR411, DOI 10.1016/j.cub.2004.05.030; DeBonis S, 2004, MOL CANCER THER, V3, P1079; Desai A, 1999, METHOD CELL BIOL, V61, P385; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Helenius J, 2006, NATURE, V441, P115, DOI 10.1038/nature04736; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kapoor TM, 2001, J CELL BIOL, V154, P1125, DOI 10.1083/jcb.200106011; Kashina AS, 1996, NATURE, V379, P270, DOI 10.1038/379270a0; Krzysiak TC, 2006, EMBO J, V25, P2263, DOI 10.1038/sj.emboj.7601108; Kwok BH, 2004, CURR BIOL, V14, P1783, DOI 10.1016/j.cub.2004.09.052; Maliga Z, 2002, CHEM BIOL, V9, P989, DOI 10.1016/S1074-5521(02)00212-0; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Okada Y, 1999, SCIENCE, V283, P1152, DOI 10.1126/science.283.5405.1152; Peterman EJG, 1999, J PHYS CHEM A, V103, P10553, DOI 10.1021/jp991968o; Peterman EJG, 2004, ANNU REV PHYS CHEM, V55, P79, DOI 10.1146/annurev.physchem.55.091602.094340; Qian H, 1991, BIOPHYS J, V60, P910, DOI 10.1016/S0006-3495(91)82125-7; SAWIN KE, 1992, NATURE, V359, P540, DOI 10.1038/359540a0; Saxton MJ, 1997, BIOPHYS J, V72, P1744, DOI 10.1016/S0006-3495(97)78820-9; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; Sharp DJ, 1999, J CELL BIOL, V144, P125, DOI 10.1083/jcb.144.1.125; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; Turner J, 2001, J BIOL CHEM, V276, P25496, DOI 10.1074/jbc.M100395200; Yan YW, 2004, J MOL BIOL, V335, P547, DOI 10.1016/j.jmb.2003.10.074	28	91	92	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2006	2	9					480	485		10.1038/nchembio812	http://dx.doi.org/10.1038/nchembio812			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	075XO	16892050				2022-12-25	WOS:000239920900011
J	Morgan, NV; Westaway, SK; Morton, JEV; Gregory, A; Gissen, P; Sonek, S; Cangul, H; Coryell, J; Canham, N; Nardocci, N; Zorzi, G; Pasha, S; Rodriguez, D; Desguerre, I; Mubaidin, A; Bertini, E; Trembath, RC; Simonati, A; Schanen, C; Johnson, CA; Levinson, B; Woods, CG; Wilmot, B; Kramer, P; Gitschier, J; Maher, ER; Hayflick, SJ				Morgan, Neil V.; Westaway, Shawn K.; Morton, Jenny E. V.; Gregory, Allison; Gissen, Paul; Sonek, Scott; Cangul, Hakan; Coryell, Jason; Canham, Natalie; Nardocci, Nardo; Zorzi, Giovanna; Pasha, Shanaz; Rodriguez, Diana; Desguerre, Isabelle; Mubaidin, Amar; Bertini, Enrico; Trembath, Richard C.; Simonati, Alessandro; Schanen, Carolyn; Johnson, Colin A.; Levinson, Barbara; Woods, C. Geoffrey; Wilmot, Beth; Kramer, Patricia; Gitschier, Jane; Maher, Eamonn R.; Hayflick, Susan J.			PLA2G6, encoding a phospholipase A(2), is mutated in neurodegenerative disorders with high brain iron	NATURE GENETICS			English	Article							INFANTILE NEUROAXONAL DYSTROPHY; HALLERVORDEN-SPATZ-SYNDROME; INVOLVEMENT	Neurodegenerative disorders with high brain iron include Parkinson disease, Alzheimer disease and several childhood genetic disorders categorized as neuroaxonal dystrophies. We mapped a locus for infantile neuroaxonal dystrophy ( INAD) and neurodegeneration with brain iron accumulation (NBIA) to chromosome 22q12-q13 and identified mutations in PLA2G6, encoding a calcium-independent group VI phospholipase A(2), in NBIA, INAD and the related Karak syndrome. This discovery implicates phospholipases in the pathogenesis of neurodegenerative disorders with iron dyshomeostasis.	Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA; Univ Birmingham, Sch Med, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Birmingham Womens Hosp, W Midlands Reg Genet Serv, Birmingham B15 2TG, W Midlands, England; Uludag Univ, Sch Med, Dept Med Genet, TR-16036 Bursa, Turkey; Ist Nazl Neurol Carlo Besta, Dept Child Neurol, I-20133 Milan, Italy; Hop Armand Trousseau, Dept Pediat Neurol, F-75571 Paris, France; Hop Necker Enfants Malad, Dept Pediat Neurol, F-75270 Paris, France; Bambino Gesu Pediat Hosp, Mol Med Unit, I-00165 Rome, Italy; King Hussein Med Ctr, Dept Neurol, Amman, Jordan; Univ London Kings Coll, Div Genet & Mol Med, Sch Med, Guys Hosp, London SE1 9RT, England; Univ Verona, Sch Med, Dept Neurol & Visual Sci, I-37129 Verona, Italy; AI DuPont Hosp Children, Nemours Res Programs, Wilmington, DE 19899 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 1TN, England; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97239 USA; Oregon Hlth Sci Univ, Dept Pediat, Portland, OR 97239 USA; Howard Hughes Med Inst, Coconut Grove, FL 33133 USA	Oregon Health & Science University; University of Birmingham; Birmingham Women's Hospital; Uludag University; IRCCS Istituto Neurologico Besta; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; IRCCS Bambino Gesu; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Verona; Nemours Alfred I. duPont Hospital for Children; University of California System; University of California San Francisco; University of Cambridge; Oregon Health & Science University; Oregon Health & Science University; Howard Hughes Medical Institute	Hayflick, SJ (corresponding author), Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.	hayflick@ohsu.edu	woods, christopher g/A-1361-2010; MAHER, EAMONN R/A-9507-2008; Morgan, Neil V/A-5475-2009; Nardocci, Nardo/AAB-9903-2019; Bertini, Enrico/A-2284-2014; Bertini, Enrico/ABG-1278-2020; Zorzi, Giovanna/AAM-4138-2021; Gissen, Paul/A-4352-2010	MAHER, EAMONN R/0000-0002-6226-6918; Morgan, Neil V/0000-0001-6433-5692; Nardocci, Nardo/0000-0001-5863-5592; Bertini, Enrico/0000-0001-9276-4590; Zorzi, Giovanna/0000-0001-7041-5365; Gissen, Paul/0000-0002-9712-6122; Trembath, Richard/0000-0003-0550-3400	NCRR NIH HHS [M01 RR000334] Funding Source: Medline; NEI NIH HHS [R01 EY012353, R01 EY012353-07] Funding Source: Medline; NHGRI NIH HHS [N01HG65403] Funding Source: Medline; NIA NIH HHS [P30 AG008017] Funding Source: Medline; NICHD NIH HHS [R01 HD050832-01A1, R01 HD050832] Funding Source: Medline; Telethon [GTF04002] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD050832] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000334] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY012353] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [N01HG065403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG008017] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Telethon(Fondazione Telethon); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balsinde J, 2005, CELL SIGNAL, V17, P1052, DOI 10.1016/j.cellsig.2005.03.002; Farina L, 1999, NEURORADIOLOGY, V41, P376, DOI 10.1007/s002340050768; Farooqui AA, 2004, NEUROCHEM RES, V29, P1961, DOI 10.1007/s11064-004-6871-3; Hayflick SJ, 2003, NEW ENGL J MED, V348, P33, DOI 10.1056/NEJMoa020817; Larsson PKA, 1998, J BIOL CHEM, V273, P207, DOI 10.1074/jbc.273.1.207; Mubaidin A, 2003, J MED GENET, V40, P543, DOI 10.1136/jmg.40.7.543; Nardocci N, 1999, NEUROLOGY, V52, P1472, DOI 10.1212/WNL.52.7.1472; Simonati A, 1999, NEUROPEDIATRICS, V30, P151, DOI 10.1055/s-2007-973482; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572	11	365	388	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUL	2006	38	7					752	754		10.1038/ng1826	http://dx.doi.org/10.1038/ng1826			3	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16783378	Green Accepted			2022-12-25	WOS:000238669300009
J	Clee, SM; Yandell, BS; Schueler, KM; Rabaglia, ME; Richards, OC; Raines, SM; Kabara, EA; Klass, DM; Mui, ETK; Stapleton, DS; Gray-Keller, MP; Young, MB; Stoehr, JP; Lan, H; Boronenkov, I; Raess, PW; Flowers, MT; Attie, AD				Clee, Susanne M.; Yandell, Brian S.; Schueler, Kathryn M.; Rabaglia, Mary E.; Richards, Oliver C.; Raines, Summer M.; Kabara, Edward A.; Klass, Daniel M.; Mui, Eric T-K; Stapleton, Donald S.; Gray-Keller, Mark P.; Young, Matthew B.; Stoehr, Jonathan P.; Lan, Hong; Boronenkov, Igor; Raess, Philipp W.; Flowers, Matthew T.; Attie, Alan D.			Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus	NATURE GENETICS			English	Article							GENETIC-ANALYSIS; PROPEPTIDE CLEAVAGE; PANCREATIC-ISLETS; MELLITUS; INSULIN; RECEPTOR; CELLS; CROSSES; OBESITY; DOMAIN	We previously mapped the type 2 diabetes mellitus-2 locus (T2dm2), which affects fasting insulin levels, to distal chromosome 19 in a leptin-deficient obese F-2 intercross derived from C57BL/6 (B6) and BTBR T+ tf/J (BTBR) mice(1). Introgression of a 7-Mb segment of the B6 chromosome 19 into the BTBR background (strain 1339A) replicated the reduced insulin linked to T2dm2. The 1339A mice have markedly impaired insulin secretion in vivo and disrupted islet morphology. We used subcongenic strains derived from 1339A to localize the T2dm2 quantitative trait locus (QTL) to a 242-kb segment comprising the promoter, first exon and most of the first intron of the Sorcs1 gene. This was the only gene in the 1339A strain for which we detected amino acid substitutions and expression level differences between mice carrying B6 and BTBR alleles of this insert, thereby identifying variation within the Sorcs1 gene as underlying the phenotype associated with the T2dm2 locus. SorCS1 binds platelet-derived growth factor, a growth factor crucial for pericyte recruitment to the microvasculature, and may thus have a role in expanding or maintaining the islet vasculature. Our identification of the Sorcs1 gene provides insight into the pathway underlying the pathophysiology of obesity-induced type 2 diabetes mellitus.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA; Univ Wisconsin, Dept Stat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Attie, AD (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	attie@biochem.wisc.edu	Clee, Susanne/AAC-4278-2020; Clee, Susanne/F-7312-2010	Clee, Susanne/0000-0001-7946-688X; Raess, Philipp/0000-0002-6841-4993	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008692] Funding Source: NIH RePORTER; PHS HHS [58037, 66369] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Barroso I, 2003, PLOS BIOL, V1, P41, DOI 10.1371/journal.pbio.0000020; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Brissova M, 2004, DIABETES, V53, P1318, DOI 10.2337/diabetes.53.5.1318; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; CHURCHILL GA, 1994, GENETICS, V138, P963; Clee Susanne M, 2005, Am J Ther, V12, P491, DOI 10.1097/01.mjt.0000178781.89789.25; Duggirala R, 1999, AM J HUM GENET, V64, P1127, DOI 10.1086/302316; Florez JC, 2003, ANNU REV GENOM HUM G, V4, P257, DOI 10.1146/annurev.genom.4.070802.110436; Galli J, 1996, NAT GENET, V12, P31, DOI 10.1038/ng0196-31; Hampe W, 2001, HUM GENET, V108, P529, DOI 10.1007/s004390100504; Hermey G, 2006, BIOCHEM J, V395, P285, DOI 10.1042/BJ20051364; Hermey G, 2003, J BIOL CHEM, V278, P7390, DOI 10.1074/jbc.M210851200; Jacobsen L, 2001, J BIOL CHEM, V276, P22788, DOI 10.1074/jbc.M100857200; Kim JH, 2001, GENOMICS, V74, P273, DOI 10.1006/geno.2001.6569; Kluge R, 2000, DIABETOLOGIA, V43, P1565, DOI 10.1007/s001250051570; Lammert E, 2003, CURR BIOL, V13, P1070, DOI 10.1016/S0960-9822(03)00378-6; Liu YF, 2000, GENET RES, V75, P345, DOI 10.1017/S0016672300004493; Parikh H, 2004, REV ENDOCR METAB DIS, V5, P151, DOI 10.1023/B:REMD.0000021437.46773.26; Permutt MA, 2005, J CLIN INVEST, V115, P1431, DOI 10.1172/JCI24758; Petersen CM, 1999, EMBO J, V18, P595, DOI 10.1093/emboj/18.3.595; Rabaglia ME, 2005, AM J PHYSIOL-ENDOC M, V289, pE218, DOI 10.1152/ajpendo.00573.2004; Rhodes CJ, 2005, SCIENCE, V307, P380, DOI 10.1126/science.1104345; Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288; Stoehr JP, 2000, DIABETES, V49, P1946, DOI 10.2337/diabetes.49.11.1946; Wei SW, 1999, MAMM GENOME, V10, P249, DOI 10.1007/s003359900982; Westergaard UB, 2004, J BIOL CHEM, V279, P50221, DOI 10.1074/jbc.M408873200; Westergaard UB, 2005, FEBS LETT, V579, P1172, DOI 10.1016/j.febslet.2004.12.088; Wiltshire S, 2001, AM J HUM GENET, V69, P553, DOI 10.1086/323249; Zou F, 2001, GENETICS, V158, P1339	30	125	145	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUN	2006	38	6					688	693		10.1038/ng1796	http://dx.doi.org/10.1038/ng1796			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16682971				2022-12-25	WOS:000237954800024
J	Collins, CH; Leadbetter, JR; Arnold, FH				Collins, Cynthia H.; Leadbetter, Jared R.; Arnold, Frances H.			Dual selection enhances the signaling specificity of a variant of the quorum-sensing transcriptional activator LuxR	NATURE BIOTECHNOLOGY			English	Article							VIBRIO-FISCHERI; DIRECTED EVOLUTION; FLUORESCENT PROTEIN; BETA-GALACTOSIDASE; SYSTEM; COMMUNICATION; NETWORKS; PROMOTER; BACTERIA	The transcription factor LuxR activates gene expression in response to binding the signaling molecule 3-oxo-hexanoyl-homoserine lactone (3OC6HSL), an acyl-HSL with a carbonyl substituent at the third carbon of the acyl chain. We previously described a LuxR variant, LuxR-G2E, that activates gene expression by binding a broader range of acyl-HSLs, including straight-chain acyl-HSLs to which LuxR does not respond(1). Here, we use a dual positive-negative selection system to identify a variant of LuxR-G2E that retains the response to straight-chain acyl-HSLs, but no longer responds to 3OC6HSL. A single mutation, R67M,reduces LuxR-G2E's response to acyl-HSLs having a carbonyl substituent at the third carbon of the acyl chain. This specificity-enhancing mutation would not have been identified by positive selection alone. The dual selection system provides a rapid and reliable method for identifying LuxR variants that have or lack the desired response to a given set of acyl-HSL signals. LuxR variants with altered signaling specificities might become useful components for constructing artificial cell-cell communication systems that program population level behaviors.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.	frances@cheme.caltech.edu		Leadbetter, Jared/0000-0002-7033-0844; Collins, Cynthia/0000-0003-1647-860X; Arnold, Frances H./0000-0002-4027-364X	NIGMS NIH HHS [1 R01 GM074712-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074712] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Basu S, 2005, NATURE, V434, P1130, DOI 10.1038/nature03461; Basu S, 2004, P NATL ACAD SCI USA, V101, P6355, DOI 10.1073/pnas.0307571101; Bloom JD, 2005, CURR OPIN STRUC BIOL, V15, P447, DOI 10.1016/j.sbi.2005.06.004; Cirino Patrick C, 2003, Methods Mol Biol, V231, P3; Collins CH, 2005, MOL MICROBIOL, V55, P712, DOI 10.1111/j.1365-2958.2004.04437.x; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Egland KA, 1999, MOL MICROBIOL, V31, P1197, DOI 10.1046/j.1365-2958.1999.01261.x; Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907; Gould SM, 2005, BIOCHEMISTRY-US, V44, P5444, DOI 10.1021/bi0475471; GRAY KM, 1994, J BACTERIOL, V176, P3076, DOI 10.1128/JB.176.10.3076-3080.1994; Havranek JJ, 2003, NAT STRUCT BIOL, V10, P45, DOI 10.1038/nsb877; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Karig D, 2005, BIOTECHNOL BIOENG, V89, P709, DOI 10.1002/bit.20371; Kobayashi H, 2004, P NATL ACAD SCI USA, V101, P8414, DOI 10.1073/pnas.0402940101; Matsumura I, 2001, J MOL BIOL, V305, P331, DOI 10.1006/jmbi.2000.4259; Parikh MR, 2005, J MOL BIOL, V352, P621, DOI 10.1016/j.jmb.2005.07.020; Schaefer AL, 1996, P NATL ACAD SCI USA, V93, P9505, DOI 10.1073/pnas.93.18.9505; Schaefer AL, 1996, J BACTERIOL, V178, P2897, DOI 10.1128/jb.178.10.2897-2901.1996; Schaefer AL, 2002, J BACTERIOL, V184, P6515, DOI 10.1128/JB.184.23.6515-6521.2002; SHADEL GS, 1990, J BACTERIOL, V172, P3980, DOI 10.1128/jb.172.7.3980-3987.1990; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Taga ME, 2003, P NATL ACAD SCI USA, V100, P14549, DOI 10.1073/pnas.1934514100; Urbanowski AL, 2004, J BACTERIOL, V186, P631, DOI 10.1128/JB.186.3.631-637.2004; Voziyanov Y, 2002, NUCLEIC ACIDS RES, V30, P1656, DOI 10.1093/nar/30.7.1656; WEISS R, 2001, DNA COMP 6 INT WORKS; WEISS R, 2004, BRIDGE, V32, P39; Whitehead NA, 2001, FEMS MICROBIOL REV, V25, P365, DOI 10.1111/j.1574-6976.2001.tb00583.x; Yokobayashi Yohei, 2005, Natural Computing, V4, P245, DOI 10.1007/s11047-004-7442-x; You LC, 2004, NATURE, V428, P868, DOI 10.1038/nature02491	30	142	145	0	34	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2006	24	6					708	712		10.1038/nbt1209	http://dx.doi.org/10.1038/nbt1209			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	051UQ	16715074				2022-12-25	WOS:000238187300034
J	Kokel, D; Li, YH; Qin, J; Xue, D				Kokel, David; Li, Yehua; Qin, Jun; Xue, Ding			The nongenotoxic carcinogens naphthalene and para-dichlorobenzene suppress apoptosis in Caenorhabditis elegans	NATURE CHEMICAL BIOLOGY			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; CANCER GENETICS; TUMOR PROMOTERS; PROTEIN; NEMATODE; CED-3; PHAGOCYTOSIS; MECHANISMS; EGL-1	Naphthalene (1) and para-dichlorobenzene (PDCB, 2), which are widely used as moth repellents and air fresheners, cause cancer in rodents and are potential human carcinogens. However, their mechanisms of action remain unclear. Here we describe a novel method for delivering and screening hydrophobic chemicals in C. elegans and apply this technique to investigate the ways in which naphthalene and PDCB may promote tumorigenesis in mammals. We show that naphthalene and PDCB inhibit apoptosis in C. elegans, a result that suggests a cellular mechanism by which these chemicals may promote the survival and proliferation of latent tumor cells. In addition, we find that a naphthalene metabolite directly inactivates caspases by oxidizing the active site cysteine residue; this suggests a molecular mechanism by which these chemicals suppress apoptosis. Naphthalene and PDCB are the first small-molecule apoptosis inhibitors identified in C. elegans. The power of C. elegans molecular genetics, in combination with the possibility of carrying out large-scale chemical screens in this organism, makes C. elegans an attractive and economic animal model for both toxicological studies and drug screens.	Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA	University of Colorado System; University of Colorado Boulder; Baylor College of Medicine	Xue, D (corresponding author), Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.	ding.xue@colorado.edu		kokel, david/0000-0002-1981-1511; XUE, DING/0000-0002-8429-8136	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059083, R01GM066262] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aballay A, 2001, P NATL ACAD SCI USA, V98, P2735, DOI 10.1073/pnas.041613098; [Anonymous], 1990, IARC Sci Publ, P1; Ashby J, 1992, IARC Sci Publ, P135; *ATSDR, TOX PROF NAPHTH; Balmain A, 2001, NAT REV CANCER, V1, P77, DOI 10.1038/35094086; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; BAYLY AC, 1994, J CELL BIOL, V125, P197, DOI 10.1083/jcb.125.1.197; Bisswanger H, 2002, ENZYME KINETICS PRIN; BRENNER S, 1974, GENETICS, V77, P71; CERNIGLIA CE, 1977, APPL ENVIRON MICROB, V34, P363, DOI 10.1128/AEM.34.4.363-370.1977; Conradt B, 1999, CELL, V98, P317, DOI 10.1016/S0092-8674(00)81961-3; DORIT A, 2004, Patent No. 2004198716; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; Gu T, 1998, MOL CELL BIOL, V18, P4556, DOI 10.1128/MCB.18.8.4556; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Horvitz HR, 2003, CHEMBIOCHEM, V4, P697, DOI 10.1002/cbic.200300614; IARC, 2002, IARC MON EV CARC RIS, V82, P171, DOI DOI 10.1016/J.CHEMOSPHERE.2009.12.012; Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lackner MR, 2005, CANCER CELL, V7, P325, DOI 10.1016/j.ccr.2005.03.024; Lima BS, 2000, REGUL TOXICOL PHARM, V32, P135; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MILLER MG, 1986, BIOCHEM PHARMACOL, V35, P1177, DOI 10.1016/0006-2952(86)90157-7; Parrish J, 2000, P NATL ACAD SCI USA, V97, P11916, DOI 10.1073/pnas.210391597; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Perera FP, 1997, SCIENCE, V278, P1068, DOI 10.1126/science.278.5340.1068; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Schrenk D, 2004, TOXICOL LETT, V149, P43, DOI 10.1016/j.toxlet.2003.12.019; Stanfield GM, 2000, MOL CELL, V5, P423, DOI 10.1016/S1097-2765(00)80437-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Worner W, 1996, CANCER RES, V56, P1272; Wu YC, 2000, GENE DEV, V14, P536; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yan N, 2005, NATURE, V437, P831, DOI 10.1038/nature04002; Yan NG, 2004, MOL CELL, V15, P999, DOI 10.1016/j.molcel.2004.08.022; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	47	28	40	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2006	2	6					338	345		10.1038/nchembio791	http://dx.doi.org/10.1038/nchembio791			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	045OH	16699520				2022-12-25	WOS:000237750900016
J	Kaneko, S; Iwanami, A; Nakamura, M; Kishino, A; Kikuchi, K; Shibata, S; Okano, HJ; Ikegami, T; Moriya, A; Konishi, O; Nakayama, C; Kumagai, K; Kimura, T; Sato, Y; Goshima, Y; Taniguchi, M; Ito, M; He, ZG; Toyama, Y; Okano, H				Kaneko, Shinjiro; Iwanami, Akio; Nakamura, Masaya; Kishino, Akiyoshi; Kikuchi, Kaoru; Shibata, Shinsuke; Okano, Hirotaka J.; Ikegami, Takeshi; Moriya, Ayako; Konishi, Osamu; Nakayama, Chikao; Kumagai, Kazuo; Kimura, Toru; Sato, Yasufumi; Goshima, Yoshio; Taniguchi, Masahiko; Ito, Mamoru; He, Zhigang; Toyama, Yoshiaki; Okano, Hideyuki			A selective Sema3A inhibitor enhances regenerative responses and functional recovery of the injured spinal cord	NATURE MEDICINE			English	Article							OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; CHEMOREPELLENT SEMAPHORIN-III; PERIPHERAL-NERVE PROJECTION; IN-VIVO; NEURITE OUTGROWTH; AXON REGENERATION; CELL-MIGRATION; SENSORY AFFERENTS; NOGO RECEPTOR; GROWTH	Axons in the adult mammalian central nervous system (CNS) exhibit little regeneration after injury. It has been suggested that several axonal growth inhibitors prevent CNS axonal regeneration. Recent research has demonstrated that semaphorin3A (Sema3A) is one of the major inhibitors of axonal regeneration. We identified a strong and selective inhibitor of Sema3A, SM-216289, from the fermentation broth of a fungal strain. To examine the effect of SM-216289 in vivo, we transected the spinal cord of adult rats and administered SM-216289 into the lesion site for 4 weeks. Rats treated with SM-216289 showed substantially enhanced regeneration and/or preservation of injured axons, robust Schwann cell-mediated myelination and axonal regeneration in the lesion site, appreciable decreases in apoptotic cell number and marked enhancement of angiogenesis, resulting in considerably better functional recovery. Thus, Sema3A is essential for the inhibition of axonal regeneration and other regenerative responses after spinal cord injury (SCI). These results support the possibility of using Sema3A inhibitors in the treatment of human SCI.	Keio Univ, Sch Med, Dept Physiol, Shinjyuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Orthopaed Surg, Shinjyuku Ku, Tokyo 1608582, Japan; Harvard Univ, Sch Med, Childrens Hosp Boston, Div Neurosci, Boston, MA 02115 USA; Natl Hosp Org, Clin Res Ctr, Murayama Med Ctr, Tokyo 2080011, Japan; Dainippon Sumitomo Pharma Co Ltd, Konohana Ku, Osaka 5540022, Japan; Yokohama City Univ, Sch Med, Dept Mol Pharmacol & Neurobiol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Univ Tokyo, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Cent Inst Expt Anim, Kawasaki, Kanagawa 2160001, Japan	Keio University; Keio University; Harvard University; Boston Children's Hospital; Harvard Medical School; Dainippon Sumitomo Pharmaceutical Company; Yokohama City University; University of Tokyo	Okano, H (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjyuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hidokano@sc.itc.keio.ac.jp	Okano, Hideyuki/I-7584-2019; Nakamura, Masaya/K-4111-2013; Toyama, Yoshiaki/K-5743-2013; Shibata, Shinsuke/AAM-6620-2020; Kumagai, Kazuo/D-7676-2016	Kumagai, Kazuo/0000-0003-2312-5765; Okano, Hirotaka James/0000-0003-4611-7098				ARCHELOS JJ, 1993, J NEUROSCI RES, V35, P46, DOI 10.1002/jnr.490350107; Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Bagri A, 2002, ADV EXP MED BIOL, V515, P13; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BREGMAN BS, 1987, DEV BRAIN RES, V34, P265, DOI 10.1016/0165-3806(87)90214-8; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Christensen MD, 1997, EXP NEUROL, V147, P463, DOI 10.1006/exnr.1997.6608; De Winter F, 2002, EXP NEUROL, V175, P61, DOI 10.1006/exnr.2002.7884; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GUTHRIE S, 1994, NEUROPROTOCOLS, V4, P116; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Ikegami T, 2005, EUR J NEUROSCI, V22, P3036, DOI 10.1111/j.1460-9568.2005.04492.x; Kikuchi K, 2003, J BIOL CHEM, V278, P42985, DOI 10.1074/jbc.M302395200; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kumagai K, 2003, J ANTIBIOT, V56, P610, DOI 10.7164/antibiotics.56.610; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; Mikami Y, 2002, J NEUROSURG, V97, P142, DOI 10.3171/spi.2002.97.1.0142; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Olson L, 2002, NATURE, V416, P589, DOI 10.1038/416589a; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 2001, EUR J NEUROSCI, V13, P457, DOI 10.1046/j.0953-816X.2000.01398.x; Romero MI, 2001, J NEUROSCI, V21, P8408, DOI 10.1523/JNEUROSCI.21-21-08408.2001; Romero MI, 2000, J NEUROSCI, V20, P4435, DOI 10.1523/JNEUROSCI.20-12-04435.2000; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; Thomaidou D, 2001, J NEUROCHEM, V78, P767, DOI 10.1046/j.1471-4159.2001.00454.x; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Yaron A, 2005, NEURON, V45, P513, DOI 10.1016/j.neuron.2005.01.013; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3	50	297	311	1	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2006	12	12					1380	1389		10.1038/nm1505	http://dx.doi.org/10.1038/nm1505			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	113SS	17099709				2022-12-25	WOS:000242618200018
J	Tsuji, K; Bandyopadhyay, A; Harfe, BD; Cox, K; Kakar, S; Gerstenfeld, L; Einhorn, T; Tabin, CJ; Rosen, V				Tsuji, Kunikazu; Bandyopadhyay, Amitabha; Harfe, Brian D.; Cox, Karen; Kakar, Sanjeev; Gerstenfeld, Louis; Einhorn, Thomas; Tabin, Clifford J.; Rosen, Vicki			BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing	NATURE GENETICS			English	Article							SKELETAL OVEREXPRESSION; BETA FAMILY; EXPRESSION; MICE; PROTEIN; OSTEOPENIA; CARTILAGE; COLLAGEN; DEFECTS; REVEALS	Adult bones have a notable regenerative capacity. Over 40 years ago, an intrinsic activity capable of initiating this reparative response was found to reside within bone itself, and the term bone morphogenetic protein(1) (BMP) was coined to describe the molecules responsible for it. A family of BMP proteins was subsequently identified(2-4), but no individual BMP has been shown to be the initiator of the endogenous bone repair response. Here we demonstrate that BMP2 is a necessary component of the signaling cascade that governs fracture repair. Mice lacking the ability to produce BMP2 in their limb bones have spontaneous fractures that do not resolve with time. In fact, in bones lacking BMP2, the earliest steps of fracture healing seem to be blocked. Although other osteogenic stimuli are still present in the limb skeleton of BMP2-deficient mice, they cannot compensate for the absence of BMP2. Collectively, our results identify BMP2 as an endogenous mediator necessary for fracture repair.	Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Boston Univ, Sch Med, Dept Orthoped, Boston, MA 02118 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard Medical School; State University System of Florida; University of Florida; Boston University	Rosen, V (corresponding author), Harvard Univ, Sch Dent Med, Dept Dev Biol, 188 Longwood Ave, Boston, MA 02115 USA.	vicki_rosen@hsdm.harvard.edu	Bandyopadhyay, Amitabha/B-9735-2008; Tsuji, Kunikazu/HDM-9242-2022	Tsuji, Kunikazu/0000-0002-1013-8359; Einhorn, Thomas/0000-0002-5075-4885; Bandyopadhyay, Amitabha/0000-0002-0429-438X; /0000-0002-0477-1211				BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; Bertone AL, 2004, J ORTHOP RES, V22, P1261, DOI 10.1016/j.orthres.2004.03.014; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Brent AE, 2003, CELL, V113, P235, DOI 10.1016/S0092-8674(03)00268-X; CELESTE AJ, 1990, P NATL ACAD SCI USA, V87, P9843, DOI 10.1073/pnas.87.24.9843; Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513; COOK SD, 1994, CLIN ORTHOP RELAT R, P302; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Devlin RD, 2003, ENDOCRINOLOGY, V144, P1972, DOI 10.1210/en.2002-220918; Gazzerro E, 2005, ENDOCRINOLOGY, V146, P655, DOI 10.1210/en.2004-0766; Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623-200212000-00001; Katagiri T, 1998, DEV GENET, V22, P340, DOI 10.1002/(SICI)1520-6408(1998)22:4<340::AID-DVG4>3.0.CO;2-6; KOHNO K, 1984, J BIOL CHEM, V259, P3668; Lanske B, 1998, ENDOCRINOLOGY, V139, P5194, DOI 10.1210/en.139.12.5194; Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Murnaghan M, 2005, J ORTHOP RES, V23, P625, DOI 10.1016/j.orthres.2004.12.008; Niikura T, 2006, J ORTHOP RES, V24, P1463, DOI 10.1002/jor.20182; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OZKAYNAK E, 1990, EMBO J, V9, P2085, DOI 10.1002/j.1460-2075.1990.tb07376.x; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; Rountree RB, 2004, PLOS BIOL, V2, P1815, DOI 10.1371/journal.pbio.0020355; Sipe JB, 2004, BONE, V35, P1316, DOI 10.1016/j.bone.2004.08.020; Solloway MJ, 1998, DEV GENET, V22, P321, DOI 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.3.CO;2-7; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wu XB, 2003, J CLIN INVEST, V112, P924, DOI 10.1172/JCI200315543; YASKO AW, 1992, J BONE JOINT SURG AM, V74A, P659, DOI 10.2106/00004623-199274050-00005; Zhang HB, 1996, DEVELOPMENT, V122, P2977	30	610	640	1	61	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	DEC	2006	38	12					1424	1429		10.1038/ng1916	http://dx.doi.org/10.1038/ng1916			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	110TR	17099713				2022-12-25	WOS:000242404200020
J	Schlee, S; Carmillo, P; Whitty, A				Schlee, Sandra; Carmillo, Paul; Whitty, Adrian			Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret	NATURE CHEMICAL BIOLOGY			English	Article							NEUROTROPHIC FACTOR; TYROSINE KINASE; LIPID RAFTS; GDNF-FAMILY; CYTOKINE; BINDING; ARTEMIN; DIMERIZATION; AFFINITY; HORMONE	Cytokines and growth factors signal by modulating the interactions between multiple receptor components to form an activated receptor complex. The quantitative details of the activation mechanisms of this important class of receptors are not well understood. Using receptor phosphorylation measurements in live cells, as well as mathematical modeling and data fitting, we have characterized the multistep mechanism by which the GDNF-family neurotrophin artemin (ART), together with its co-receptor GDNF-family receptor alpha 3 (GFR alpha 3), brings about activation of the Ret receptor tyrosine kinase through formation of a pentameric signaling complex: ART-(GFR alpha(3))(2)-(Ret)(2). By systematically varying the concentrations of ART and cell-surface GFR alpha 3, we establish both the sequence of steps by which the signaling complex forms and the affinities of all the steps, including the two-dimensional affinities of the steps involving protein-protein interactions between membrane-bound species. Our results reveal the ways in which the individual binary interactions involved in the activation of a multicomponent receptor govern the receptor's functional properties.	Biogen Idec Inc, Cambridge, MA 02142 USA	Biogen	Whitty, A (corresponding author), Biogen Idec Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA.	adrian.whitty@biogenidec.com						Andres R, 2001, DEVELOPMENT, V128, P3685; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; Carmillo P, 2005, BIOCHEMISTRY-US, V44, P2545, DOI 10.1021/bi049247p; Coulpier M, 2002, J BIOL CHEM, V277, P1991, DOI 10.1074/jbc.M107992200; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Eigenbrot C, 1997, NAT STRUCT BIOL, V4, P435, DOI 10.1038/nsb0697-435; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; Gardell LR, 2003, NAT MED, V9, P1383, DOI 10.1038/nm944; Gavutis M, 2006, BIOPHYS J, V90, P3345, DOI 10.1529/biophysj.105.072546; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Hendriks BS, 2005, J BIOL CHEM, V280, P6157, DOI 10.1074/jbc.M410491200; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lapchak PA, 1996, REV NEUROSCIENCE, V7, P165; Lindsay RM, 1996, NEURON, V17, P571, DOI 10.1016/S0896-6273(00)80189-0; Masure S, 1999, EUR J BIOCHEM, V266, P892, DOI 10.1046/j.1432-1327.1999.00925.x; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Orozco OE, 2001, EUR J NEUROSCI, V13, P2177, DOI 10.1046/j.0953-816x.2001.01596.x; Paratcha G, 2002, CURR OPIN NEUROBIOL, V12, P542, DOI 10.1016/S0959-4388(02)00363-X; Pearce KH, 1999, BIOCHEMISTRY-US, V38, P81, DOI 10.1021/bi9817008; Rosenblad C, 2000, MOL CELL NEUROSCI, V15, P199, DOI 10.1006/mcne.1999.0817; Sadick MD, 1999, J PHARMACEUT BIOMED, V19, P883, DOI 10.1016/S0731-7085(98)00144-7; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Sarkar CA, 2003, BIOTECHNOL PROGR, V19, P955, DOI 10.1021/bp020017g; Silvian L, 2006, BIOCHEMISTRY-US, V45, P6801, DOI 10.1021/bi060035x; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Unsicker K, 1996, CELL TISSUE RES, V286, P175, DOI 10.1007/s004410050686; Vega QC, 1996, P NATL ACAD SCI USA, V93, P10657, DOI 10.1073/pnas.93.20.10657; Whitty A, 1998, P NATL ACAD SCI USA, V95, P13165, DOI 10.1073/pnas.95.22.13165; Whitty A, 1999, CHEM BIOL, V6, pR107, DOI 10.1016/S1074-5521(99)80034-9; Wilkinson JC, 2001, BIOCHEMISTRY-US, V40, P10230, DOI 10.1021/bi010705t; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	43	42	44	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2006	2	11					636	644		10.1038/nchembio823	http://dx.doi.org/10.1038/nchembio823			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	098BC	17013378				2022-12-25	WOS:000241494000016
J	Beadling, C; Slifka, MK				Beadling, Carol; Slifka, Mark K.			Quantifying viable virus-specific T cells without a priori knowledge of fine epitope specificity	NATURE MEDICINE			English	Article							ANTIGEN-PRESENTING CELLS; MHC CLASS-II; INTERCELLULAR TRANSFER; CYTOKINE RESPONSES; VIRAL-INFECTIONS; CUTTING EDGE; PEPTIDE; COMPLEXES; CD4(+); ACQUISITION	Identification of pathogen-specific T cells has been greatly facilitated by the advent of synthetic peptide-major histocompatibility complex (MHC) tetramers. In many cases, however, specific epitopes have not been defined, necessitating detection methods that function independently of exact peptide-MHC specificity. Lymphocytes acquire surface proteins from antigen-presenting cells (APCs), and we have exploited this phenomenon to develop the T-cell recognition of APCs by protein transfer (TRAP) assay. This method is based on biotinylation and streptavidin-fluorochrome labeling of APCs, followed by subsequent acquisition of this label by antigen-specific T cells. The TRAP procedure detects MHC class l-restricted T cells regardless of their cytokine profiles or peptide-MHC affinities, and provides a versatile tool for monitoring the phenomenon of APC membrane acquisition by antigen-specific T cells.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA	Oregon Health & Science University	Slifka, MK (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW 185th Ave, Beaverton, OR 97006 USA.	slifkam@ohsu.edu			NCRR NIH HHS [RR000163, P51 RR000163] Funding Source: Medline; NIAID NIH HHS [AI054458, R01 AI054458] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI054458] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Arnold PY, 1997, EUR J IMMUNOL, V27, P3198, DOI 10.1002/eji.1830271217; Beadling C, 2005, BLOOD, V105, P1179, DOI 10.1182/blood-2004-07-2833; Becker C, 2001, NAT MED, V7, P1159, DOI 10.1038/nm1001-1159; Belz GT, 2001, J IMMUNOL, V166, P4627, DOI 10.4049/jimmunol.166.7.4627; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.3.CO;2-3; Chang J, 2002, NAT MED, V8, P54, DOI 10.1038/nm0102-54; Chattopadhyay PK, 2005, NAT MED, V11, P1113, DOI 10.1038/nm1293; De Rosa SC, 2004, J IMMUNOL, V173, P5372, DOI 10.4049/jimmunol.173.9.5372; Harrington LE, 2002, J VIROL, V76, P3329, DOI 10.1128/JVI.76.7.3329-3337.2002; Hogan RJ, 2001, J IMMUNOL, V166, P1813, DOI 10.4049/jimmunol.166.3.1813; Huang JF, 1999, SCIENCE, V286, P952, DOI 10.1126/science.286.5441.952; Hudrisier D, 2001, J IMMUNOL, V166, P3645, DOI 10.4049/jimmunol.166.6.3645; Hudrisier D, 2002, FASEB J, V16, P477, DOI 10.1096/fj.01-0933rev; Hwang I, 2000, J EXP MED, V191, P1137, DOI 10.1084/jem.191.7.1137; Johnson AJ, 1999, J VIROL, V73, P3702, DOI 10.1128/JVI.73.5.3702-3708.1999; Joly E, 2003, NAT IMMUNOL, V4, P815, DOI 10.1038/ni0903-815; Liu F, 2005, J IMMUNOL, V174, P5936, DOI 10.4049/jimmunol.174.10.5936; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Marten NW, 2003, J VIROL, V77, P2775, DOI 10.1128/JVI.77.4.2775-2778.2003; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; NEPOM JT, 1981, J IMMUNOL, V127, P888; Patel DM, 1999, J IMMUNOL, V163, P5201; Raue HP, 2004, J IMMUNOL, V173, P6873, DOI 10.4049/jimmunol.173.11.6873; Slifka MK, 1999, NATURE, V401, P76, DOI 10.1038/43454; Tomaru U, 2003, NAT MED, V9, P469, DOI 10.1038/nm845; Tsang JYS, 2003, BLOOD, V101, P2704, DOI 10.1182/blood-2002-04-1230; Wetzel SA, 2005, J IMMUNOL, V174, P80, DOI 10.4049/jimmunol.174.1.80; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003	30	28	30	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2006	12	10					1208	1212		10.1038/nm1413	http://dx.doi.org/10.1038/nm1413			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	092MW	17013384				2022-12-25	WOS:000241102200040
J	Carazo-Salas, RE; Nurse, P				Carazo-Salas, Rafael E.; Nurse, Paul			Self-organization of interphase microtubule arrays in fission yeast	NATURE CELL BIOLOGY			English	Article							SPINDLE POLE BODY; ORGANIZING CENTERS; NUCLEAR-ENVELOPE; CELL-DIVISION; DYNAMICS; MITOSIS; ROLES	Microtubule organization is key to eukaryotic cell structure and function. In most animal cells, interphase microtubules organize around the centrosome, the major microtubule organizing centre (MTOC). Interphase microtubules can also become organized independently of a centrosome, but how acentrosomal microtubules arrays form and whether they are functionally equivalent to centrosomal arrays remains poorly understood 1,2. Here, we show that the interphase microtubule arrays of fission yeast cells can persist independently of nuclear-associated MTOCs, including the spindle pole body (SPB) - the centrosomal equivalent. By artificially enucleating cells, we show that arrays can form de novo (self-organize) without nuclear-associated MTOCs, but require the microtubule nucleator mod20-mbo1-mto1 (refs 3 - 5), the bundling factor ase1 (refs 6,7), and the kinesin klp2 (refs 8,9). Microtubule arrays in enucleated and nucleated cells are morphologically indistinguishable and similarly locate to the cellular axis and centre. By simultaneously tracking nuclear-independent and SPB-associated microtubule arrays within individual nucleated cells, we show that both define the cell centre with comparable precision. We propose that in fission yeast, nuclear-independent, self- organized, acentrosomal microtubule arrays are structurally and functionally equivalent to centrosomal arrays.	London Res Inst, Canc Res UK, Cell Cycle Lab, London WC2A 1PX, England; Rockefeller Univ, Lab Yeast Genet & Cell Biol, New York, NY 10021 USA	Cancer Research UK; Rockefeller University	Carazo-Salas, RE (corresponding author), London Res Inst, Canc Res UK, Cell Cycle Lab, 44 Lincolns Inn Fields, London WC2A 1PX, England.	rafael.carazo-salas@cancer.org.uk		Carazo-Salas, Rafael E/0000-0002-5943-3981				Behrens R, 2002, J CELL BIOL, V157, P783, DOI 10.1083/jcb.200112027; Brunner D, 2000, CELL, V102, P695, DOI 10.1016/S0092-8674(00)00091-X; Carazo-Salas RE, 2005, SCIENCE, V309, P297, DOI 10.1126/science.1113465; Daga RR, 2005, P NATL ACAD SCI USA, V102, P8228, DOI 10.1073/pnas.0409021102; Dammermann A, 2003, CURR BIOL, V13, pR614, DOI 10.1016/S0960-9822(03)00530-X; Ding R, 1997, MOL BIOL CELL, V8, P1461, DOI 10.1091/mbc.8.8.1461; Drummond DR, 2000, CURR BIOL, V10, P766, DOI 10.1016/S0960-9822(00)00570-4; Hayles J, 2001, NAT REV MOL CELL BIO, V2, P647, DOI 10.1038/35089520; Janson ME, 2005, J CELL BIOL, V169, P297, DOI 10.1083/jcb.200410119; Keating TJ, 1999, BIOL CELL, V91, P321, DOI 10.1016/S0248-4900(99)80093-8; Loiodice I, 2005, MOL BIOL CELL, V16, P1756, DOI 10.1091/mbc.E04-10-0899; Mahoney NM, 2006, CURR BIOL, V16, P564, DOI 10.1016/j.cub.2006.01.053; Malikov V, 2005, NAT CELL BIOL, V7, P1213, DOI 10.1038/ncb1332; Reilein A, 2005, J CELL BIOL, V171, P845, DOI 10.1083/jcb.200505071; Sagolla MJ, 2003, J CELL SCI, V116, P4891, DOI 10.1242/jcs.00796; Samejima I, 2005, MOL BIOL CELL, V16, P3040, DOI 10.1091/mbc.e04-11-1003; Sawin KE, 2004, CURR BIOL, V14, P763, DOI 10.1016/j.cub.2004.03.042; Tran PT, 2001, J CELL BIOL, V153, P397, DOI 10.1083/jcb.153.2.397; Troxell CL, 2001, MOL BIOL CELL, V12, P3476, DOI 10.1091/mbc.12.11.3476; Venkatram S, 2004, MOL BIOL CELL, V15, P2287, DOI 10.1091/mbc.E03-10-0728; West RR, 1998, MOL BIOL CELL, V9, P2839, DOI 10.1091/mbc.9.10.2839; Yamamoto A, 1999, J CELL BIOL, V145, P1233, DOI 10.1083/jcb.145.6.1233; Yamashita A, 2005, MOL BIOL CELL, V16, P1378, DOI 10.1091/mbc.e04-10-0859; Zheng LF, 2006, MOL BIOL CELL, V17, P2212, DOI 10.1091/mbc.E05-08-0811	24	57	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	OCT	2006	8	10					1102	U94		10.1038/ncb1479	http://dx.doi.org/10.1038/ncb1479			8	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	096RU	16998477				2022-12-25	WOS:000241395300014
J	Hughes, AE; Orr, N; Esfandiary, H; Diaz-Torres, M; Goodship, T; Chakravarthy, U				Hughes, Anne E.; Orr, Nick; Esfandiary, Hossein; Diaz-Torres, Martha; Goodship, Timothy; Chakravarthy, Usha			A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration	NATURE GENETICS			English	Article							COMPLEMENT FACTOR-H; SUSCEPTIBILITY; POLYMORPHISM; MACULOPATHY; VARIANT; GENE	Age-related macular degeneration (AMD; OMIM #603075) is the most frequent cause of visual impairment in the elderly population, with severe disease affecting nearly 10% of individuals of European descent over the age of 75 years. It is a complex disease in which genetic and environmental factors contribute to susceptibility. Complement factor H (CFH) has recently been identified as a major AMD susceptibility gene, and the Y402H polymorphism has been proposed as the likely causative factor. We genotyped polymorphisms spanning the cluster of CFH and five CFH-related genes on chromosome 1q23 in 173 individuals with severe neovascular AMD and 170 elderly controls with no signs of AMD. Detailed analysis showed a common haplotype associated with decreased risk of AMD that was present on 20% of chromosomes of controls and 8% of chromosomes of individuals with AMD. We found that this haplotype carried a deletion of CFHR1 and CFHR3, and the proteins encoded by these genes were absent in serum of homozygotes. The protective effect of the deletion haplotype cannot be attributed to linkage disequilibrium with Y402H and was replicated in an independent sample.	Queens Univ Belfast, Dept Med Genet, Belfast BT12 6BL, Antrim, North Ireland; Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; Queens Univ Belfast, Ctr Vis Sci & Vasc Biol, Belfast BT12 6BL, Antrim, North Ireland	Queens University Belfast; Newcastle University - UK; Queens University Belfast	Hughes, AE (corresponding author), Queens Univ Belfast, Dept Med Genet, Belfast BT12 6BL, Antrim, North Ireland.	A.Hughes@qub.ac.uk	Hughes, Anne/A-1307-2012	Chakravarthy, Usha/0000-0002-2606-3734				Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X; DISCIPIO RG, 1992, J IMMUNOL, V149, P2592; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; Heinen Stefan, 2006, Hum Mutat, V27, P292, DOI 10.1002/humu.9408; Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437; Jozsi M, 2005, EUR J HUM GENET, V13, P321, DOI 10.1038/sj.ejhg.5201324; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519; Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426	16	359	383	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1173	1177		10.1038/ng1890	http://dx.doi.org/10.1038/ng1890			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16998489				2022-12-25	WOS:000241251100017
J	Lee, K; Jeong, J; Kwak, I; Yu, CT; Lanske, B; Soegiarto, DW; Toftgard, R; Tsai, MJ; Tsai, S; Lydon, JP; DeMayo, FJ				Lee, Kevin; Jeong, JaeWook; Kwak, Inseok; Yu, Cheng-Tai; Lanske, Beate; Soegiarto, Desi W.; Toftgard, Rune; Tsai, Ming-Jer; Tsai, Sophia; Lydon, John P.; DeMayo, Francesco J.			Indian hedgehog is a major mediator of progesterone signaling in the mouse uterus	NATURE GENETICS			English	Article							GROWTH-FACTOR RECEPTOR; CANCER-CELLS; GENE; ANGIOGENESIS; ENDOMETRIUM; EXPRESSION; MICE	The hedgehog family of morphogens are regulators of cell proliferation, differentiation and cell-cell communication. These morphogens have been shown to have important roles in organogenesis, spermatogenesis, stem cell maintenance and oncogenesis(1-9). Indian hedgehog (encoded by Ihh) has been shown to be expressed in the uterine epithelium under the control of the steroid hormone, progesterone(10,11). Although in vivo and in vitro studies have shown that progesterone achieves its effects on uterine function through epithelial-stromal cross-talk, molecular mediator(s) for this cellular communication pathway have not been elucidated(12,13). Using new experimental approaches that ablate Ihh specifically in Pgr-positive uterine cells of the mouse, we demonstrate that Ihh is an essential mediator of Pgr action in the uterus, and expression of this factor is critical in mediating the communication between the uterine epithelium and stroma required for embryo implantation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Harvard Univ, Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Karolinska Inst, Ctr Nutr & Toxicol, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Baylor College of Medicine; Harvard University; Harvard School of Dental Medicine; Max Planck Society; Karolinska Institutet	DeMayo, FJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	fdemayo@bcm.tmc.edu	DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336; Lee, Kevin/0000-0002-1528-7417; Lanske, Beate/0000-0003-4638-804X	NCI NIH HHS [R01-CA77530] Funding Source: Medline; NICHD NIH HHS [5 T32 HD07165, U01HD042311] Funding Source: Medline; NIDDK NIH HHS [R01-DK55636, R01 DK45641] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007165] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD042311] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA077530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045641, R01DK055636] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIGSBY RM, 1993, STROMAL EPITHELIAL I, P71; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; COOKE PS, 1986, P NATL ACAD SCI USA, V83, P2109, DOI 10.1073/pnas.83.7.2109; DEY SK, 2003, MANIPULATING MOUSE E; FINN CA, 1972, BIOL REPROD, V7, P82, DOI 10.1093/biolreprod/7.1.82; FINN CA, 1964, J REPROD FERTIL, V53, P331; Hebrok M, 2000, DEVELOPMENT, V127, P4905; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lewis MT, 1999, DEVELOPMENT, V126, P5181; Lydon JP, 1999, CANCER RES, V59, P4276; MARTIN L, 1973, J ENDOCRINOL, V56, P303, DOI 10.1677/joe.0.0560303; Matsumoto H, 2002, DEV BIOL, V245, P280, DOI 10.1006/dbio.2002.0645; Mimeault M, 2006, INT J CANCER, V118, P1022, DOI 10.1002/ijc.21440; Mimeault M, 2005, PANCREAS, V31, P301, DOI 10.1097/01.mpa.0000175893.04660.1b; Niemann C, 2003, P NATL ACAD SCI USA, V100, P11873, DOI 10.1073/pnas.1834202100; Palma V, 2004, DEVELOPMENT, V131, P337, DOI 10.1242/dev.00930; Pereira FA, 1999, GENE DEV, V13, P1037, DOI 10.1101/gad.13.8.1037; Perron M, 2003, DEVELOPMENT, V130, P1565, DOI 10.1242/dev.00391; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Razzaque MS, 2005, J PATHOL, V207, P453, DOI 10.1002/path.1870; Soyal SM, 2005, GENESIS, V41, P58, DOI 10.1002/gene.20098; Sui GP, 2006, J SURG RES, V134, P1, DOI 10.1016/j.jss.2005.12.029; SURVEYOR GA, 1995, ENDOCRINOLOGY, V136, P3639, DOI 10.1210/en.136.8.3639; Takamoto N, 2002, MOL ENDOCRINOL, V16, P2338, DOI 10.1210/me.2001-0154; Talbi S, 2006, ENDOCRINOLOGY, V147, P1097, DOI 10.1210/en.2005-1076; Walter LM, 2005, REPRODUCTION, V129, P765, DOI 10.1530/rep.1.00625; Wijgerde M, 2005, ENDOCRINOLOGY, V146, P3558, DOI 10.1210/en.2005-0311	29	196	206	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	OCT	2006	38	10					1204	1209		10.1038/ng1874	http://dx.doi.org/10.1038/ng1874			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16951680				2022-12-25	WOS:000241251100022
J	Ramsey, SA; Smith, JJ; Orrell, D; Marelli, M; Petersen, TW; de Atauri, P; Bolouri, H; Aitchison, JD				Ramsey, Stephen A.; Smith, Jennifer J.; Orrell, David; Marelli, Marcello; Petersen, Timothy W.; de Atauri, Pedro; Bolouri, Hamid; Aitchison, John D.			Dual feedback loops in the GAL regulon suppress cellular heterogeneity in yeast	NATURE GENETICS			English	Article							EUKARYOTIC GENE-EXPRESSION; GREEN FLUORESCENT PROTEIN; SACCHAROMYCES-CEREVISIAE; QUANTITATIVE-ANALYSIS; REGULATORY PROTEINS; NOISE; AUTOREGULATION; GALACTOSE; NETWORKS; SWITCH	Transcriptional noise is known to be an important cause of cellular heterogeneity and phenotypic variation. The extent to which molecular interaction networks may have evolved to either filter or exploit transcriptional noise is a much debated question. The yeast genetic network regulating galactose metabolism involves two proteins, Gal3p and Gal80p, that feed back positively and negatively, respectively, on GAL gene expression. Using kinetic modeling and experimental validation, we demonstrate that these feedback interactions together are important for (i) controlling the cell-to-cell variability of GAL gene expression and (ii) ensuring that cells rapidly switch to an induced state for galactose uptake.	Inst Syst Biol, Seattle, WA 98103 USA	Institute for Systems Biology (ISB)	Bolouri, H (corresponding author), Inst Syst Biol, 1441 N 34th St, Seattle, WA 98103 USA.	hbolouri@systemsbiology.org; jaitchison@systemsbiology.org	de Atauri, Pedro Ramón/R-3957-2019; de Atauri, Pedro/AAG-2384-2020	de Atauri, Pedro Ramón/0000-0002-7754-7851; Marelli, Marcello/0000-0001-7095-8263	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067228, P50GM076547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067228, GM076547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acar M, 2005, NATURE, V435, P228, DOI 10.1038/nature03524; Becskei A, 2000, NATURE, V405, P590, DOI 10.1038/35014651; Biggar SR, 2001, EMBO J, V20, P3167, DOI 10.1093/emboj/20.12.3167; Blake WJ, 2003, NATURE, V422, P633, DOI 10.1038/nature01546; Brachmann CB, 1998, YEAST, V14, P115; Brandman O, 2005, SCIENCE, V310, P496, DOI 10.1126/science.1113834; de Atauri P., 2004, Systems Biology, V1, P28, DOI 10.1049/sb:20045013; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; Hasty J, 2000, P NATL ACAD SCI USA, V97, P2075, DOI 10.1073/pnas.040411297; Kaern M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; Melcher K, 1997, YEAST SUGAR METABOLI, P235; Orrell D, 2004, J THEOR BIOL, V230, P301, DOI 10.1016/j.jtbi.2004.05.013; Orrell D, 2006, PHYSICA D, V217, P64, DOI 10.1016/j.physd.2006.03.010; Ostergaard S, 2000, MICROBIOL MOL BIOL R, V64, P34, DOI 10.1128/MMBR.64.1.34-50.2000; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Pedelacq JD, 2006, NAT BIOTECHNOL, V24, P79, DOI 10.1038/nbt1172; Peng G, 2002, P NATL ACAD SCI USA, V99, P8548, DOI 10.1073/pnas.142100099; Platt A, 1998, EMBO J, V17, P4086, DOI 10.1093/emboj/17.14.4086; Ramsey Stephen, 2005, J Bioinform Comput Biol, V3, P437, DOI 10.1142/S0219720005001144; Rao CV, 2003, J CHEM PHYS, V118, P4999, DOI 10.1063/1.1545446; Raser JM, 2004, SCIENCE, V304, P1811, DOI 10.1126/science.1098641; Rosenfeld N, 2002, J MOL BIOL, V323, P785, DOI 10.1016/S0022-2836(02)00994-4; Ruhela A, 2004, FEBS LETT, V576, P119, DOI 10.1016/j.febslet.2004.09.001; Scholz O, 2000, EUR J BIOCHEM, V267, P1565, DOI 10.1046/j.1432-1327.2000.01170.x; Verma M, 2004, EUR J BIOCHEM, V271, P4064, DOI 10.1111/j.1432-1033.2004.04344.x; Verma M, 2003, J BIOL CHEM, V278, P48764, DOI 10.1074/jbc.M303526200; Volfson D, 2006, NATURE, V439, P861, DOI 10.1038/nature04281	30	69	72	2	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	SEP	2006	38	9					1082	1087		10.1038/ng1869	http://dx.doi.org/10.1038/ng1869			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	078OC	16936734				2022-12-25	WOS:000240112100029
J	Jacobs, T				Jacobs, Tom			The return of the biotech scorecard	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					768	768		10.1038/nbt0706-768	http://dx.doi.org/10.1038/nbt0706-768			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16841056				2022-12-25	WOS:000239025100020
J	Huber-Lang, M; Sarma, JV; Zetoune, FS; Rittirsch, D; Neff, TA; McGuire, SR; Lambris, JD; Warner, RL; Flierl, MA; Hoesel, LM; Gebhard, F; Younger, JG; Drouin, SM; Wetsel, RA; Ward, PA				Huber-Lang, Markus; Sarma, J. Vidya; Zetoune, Firas S.; Rittirsch, Daniel; Neff, Thomas A.; McGuire, Stephanie R.; Lambris, John D.; Warner, Roscoe L.; Flierl, Michael A.; Hoesel, Laszlo M.; Gebhard, Florian; Younger, John G.; Drouin, Scott M.; Wetsel, Rick A.; Ward, Peter A.			Generation of C5a in the absence of C3: a new complement activation pathway	NATURE MEDICINE			English	Article							REVERSE ARTHUS REACTION; DEFICIENT MICE; INFLAMMATORY RESPONSES; RECEPTOR ANTAGONIST; PULMONARY RESPONSE; REPERFUSION INJURY; COMPONENT C5; IN-VIVO; EXPRESSION; NEUTROPHILS	Complement-mediated tissue injury in humans occurs upon deposition of immune complexes, such as in autoimmune diseases and acute respiratory distress syndrome. Acute lung inflammatory injury in wild-type and C3(-/-) mice after deposition of IgG immune complexes was of equivalent intensity and was C5a dependent, but injury was greatly attenuated in Hc(-/-) mice ( Hc encodes C5). Injury in lungs of C3(-/-) mice and C5a levels in bronchoalveolar lavage ( BAL) fluids from these mice were greatly reduced in the presence of antithrombin III ( ATIII) or hirudin but were not reduced in similarly treated C3(+/+) mice. Plasma from C3(-/-) mice contained threefold higher levels of thrombin activity compared to plasma from C3(+/+) mice. There were higher levels of F2 mRNA ( encoding prothrombin) as well as prothrombin and thrombin protein in liver of C3(-/-) mice compared to C3(+/+) mice. A potent solid- phase C5 convertase was generated using plasma from either C3(+/+) or C3(-/-) mice. Human C5 incubated with thrombin generated C5a that was biologically active. These data suggest that, in the genetic absence of C3, thrombin substitutes for the C3-dependent C5 convertase. This linkage between the complement and coagulation pathways may represent a new pathway of complement activation.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Ulm, Sch Med, Dept Traumatol Hand & Reconstruct Surg, D-89075 Ulm, Germany; Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI 48109 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med, Houston, TX 77030 USA	University of Michigan System; University of Michigan; Ulm University; University of Pennsylvania; University of Michigan System; University of Michigan; University of Texas System; University of Texas Health Science Center Houston	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Lambris, John/Q-5633-2018; Huber-Lang, Markus/AAJ-2209-2020	Lambris, John/0000-0002-9370-5776; Younger, John/0000-0002-0820-0635; Rittirsch, Daniel/0000-0002-1185-2431	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031963] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069438, R01GM029507, R37GM029507, R24GM069736] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-31963] Funding Source: Medline; NIAID NIH HHS [AI-30040] Funding Source: Medline; NIDDK NIH HHS [DK-59422] Funding Source: Medline; NIGMS NIH HHS [GM-069438, GM-069736, GM-29507] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBAS AK, 1999, ROBBINS PATHOLOGIC B, P188; Ames RS, 2001, J IMMUNOL, V166, P6341, DOI 10.4049/jimmunol.166.10.6341; BARTON PA, 1993, INFECT IMMUN, V61, P1474, DOI 10.1128/IAI.61.4.1474-1481.1993; Baumann U, 2000, J IMMUNOL, V164, P1065, DOI 10.4049/jimmunol.164.2.1065; Baumann U, 2001, J IMMUNOL, V167, P1022, DOI 10.4049/jimmunol.167.2.1022; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Czermak BJ, 1999, J IMMUNOL, V162, P2321; Drouin SM, 2002, J IMMUNOL, V169, P5926, DOI 10.4049/jimmunol.169.10.5926; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Heller T, 1999, J IMMUNOL, V163, P985; Hopken UE, 1997, J EXP MED, V186, P749, DOI 10.1084/jem.186.5.749; Huber-Lang M, 2002, AM J PATHOL, V161, P1849, DOI 10.1016/S0002-9440(10)64461-6; HUGLI TE, 1977, CHEM BIOL THROMBIN, P345; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Kohl J, 1999, MOL IMMUNOL, V36, P893, DOI 10.1016/S0161-5890(99)00111-X; Kyriakides C, 1999, J APPL PHYSIOL, V87, P2357, DOI 10.1152/jappl.1999.87.6.2357; LARSEN GL, 1981, AM REV RESPIR DIS, V123, P434; LARSEN GL, 1982, AM REV RESPIR DIS, V126, P306; Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818; POLLEY MJ, 1978, J EXP MED, V147, P1713, DOI 10.1084/jem.147.6.1713; Rawal N, 2003, J BIOL CHEM, V278, P38476, DOI 10.1074/jbc.M307017200; Strachan AJ, 2001, BRIT J PHARMACOL, V134, P1778, DOI 10.1038/sj.bjp.0704417; Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385; Walters DM, 2002, AM J RESP CELL MOL, V27, P413, DOI 10.1165/rcmb.4844; Wang Y, 1996, P NATL ACAD SCI USA, V93, P8563, DOI 10.1073/pnas.93.16.8563; WARD PA, 1970, J IMMUNOL, V104, P535; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; WETSEL RA, 1983, J EXP MED, V157, P2029, DOI 10.1084/jem.157.6.2029; Wills-Karp M, 2004, NAT REV GENET, V5, P376, DOI 10.1038/nrg1326	30	707	752	3	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2006	12	6					682	687		10.1038/nm1419	http://dx.doi.org/10.1038/nm1419			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GI	16715088				2022-12-25	WOS:000238149200031
J	Dubois, MJ; Bergeron, S; Kim, HJ; Dombrowski, L; Perreault, M; Fournes, B; Faure, R; Olivier, M; Beauchemin, N; Shulman, GI; Siminovitch, KA; Kim, JK; Marette, A				Dubois, Marie-Julie; Bergeron, Sebastien; Kim, Hyo-Jeong; Dombrowski, Luce; Perreault, Mylene; Fournes, Benedicte; Faure, Robert; Olivier, Martin; Beauchemin, Nicole; Shulman, Gerald I.; Siminovitch, Katherine A.; Kim, Jason K.; Marette, Andre			The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RECEPTOR; SH2 DOMAIN; REGULATORY SUBUNIT; EPITHELIAL-CELLS; TRANSGENIC MICE; IN-VIVO; PHOSPHORYLATION; ACTIVATION	The protein tyrosine phosphatase SHP-1 is a well-known inhibitor of activation-promoting signaling cascades in hematopoietic cells but its potential role in insulin target tissues is unknown. Here we show that Ptpn6(me-v/me-v) (also known as viable motheaten) mice bearing a functionally deficient SHP-1 protein are markedly glucose tolerant and insulin sensitive as compared to wild-type littermates, as a result of enhanced insulin receptor signaling to IRS-PI3K-Akt in liver and muscle. Downregulation of SHP-1 activity in liver of normal mice by adenoviral expression of a catalytically inert mutant of SHP-1, or after small hairpin RNA mediated SHP-1 silencing, further confirmed this phenotype. Tyrosine phosphorylation of CEACAM1, a modulator of hepatic insulin clearance, and clearance of serum [I-125]-insulin were markedly increased in SHP-1-deficient mice or SHP-1-deficient hepatic cells in vitro. These findings show a novel role for SHP-1 in the regulation of glucose homeostasis through modulation of insulin signaling in liver and muscle as well as hepatic insulin clearance.	Univ Laval Hosp, Res Ctr, Dept Anat Physiol, Quebec City, PQ G1V 4G2, Canada; Univ Laval Hosp, Res Ctr, Lipid Res Unit, Quebec City, PQ G1V 4G2, Canada; Yale Univ, Sch Med, Yale Mouse Metabol Phenotyping Ctr, Dept Internal Med,Sect Endocrinol & Metab, New Haven, CT 06520 USA; Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Univ Laval Hosp, Res Ctr, Dept Pediat, Quebec City, PQ G1V 4G2, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Immunol, Toronto, ON M5G 1X5, Canada	Laval University; Laval University; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; McGill University; Laval University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Marette, A (corresponding author), Univ Laval Hosp, Res Ctr, Dept Anat Physiol, 2705 Laurier Blvd, Quebec City, PQ G1V 4G2, Canada.	andre.marette@crchul.ulaval.ca	Marette, Andre/E-9342-2013; Shulman, Gerald I./P-7176-2019; Siminovitch, Katherine/K-1475-2013	Shulman, Gerald I./0000-0003-1529-5668; Marette, Andre/0000-0003-3950-5973; Kim, Jason/0000-0002-7185-042X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059635, R01DK040936] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936, U24 DK-59635] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad F, 1997, J BIOL CHEM, V272, P448; Asante-Appiah E, 2003, AM J PHYSIOL-ENDOC M, V284, pE663, DOI 10.1152/ajpendo.00462.2002; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; Boulton IC, 2002, NAT IMMUNOL, V3, P229, DOI 10.1038/ni769; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Choice CV, 1998, J BIOL CHEM, V273, P22194, DOI 10.1074/jbc.273.35.22194; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dai T, 2004, J BIOL CHEM, V279, P45155, DOI 10.1074/jbc.M404764200; Duchesne C, 2003, J BIOL CHEM, V278, P14274, DOI 10.1074/jbc.M300425200; Dustin LB, 1999, J IMMUNOL, V162, P2717; Elchebly M, 2000, J MOL MED-JMM, V78, P473, DOI 10.1007/s001090000141; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Forget G, 2001, EUR J IMMUNOL, V31, P3185, DOI 10.1002/1521-4141(200111)31:11&lt;3185::AID-IMMU3185&gt;3.0.CO;2-J; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; Furnari FB, 1998, CANCER RES, V58, P5002; Goldstein BJ, 2002, J CLIN ENDOCR METAB, V87, P2474, DOI 10.1210/jc.87.6.2474; HAYASHI H, 1991, BIOCHEM J, V280, P769, DOI 10.1042/bj2800769; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; Kim HJ, 2004, DIABETES, V53, P1060, DOI 10.2337/diabetes.53.4.1060; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LEVY JR, 1987, ENDOCRINOLOGY, V121, P2075, DOI 10.1210/endo-121-6-2075; LiCalzi S, 1997, AM J PHYSIOL-ENDOC M, V273, pE801, DOI 10.1152/ajpendo.1997.273.4.E801; Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200; Maegawa H, 1999, J BIOL CHEM, V274, P30236, DOI 10.1074/jbc.274.42.30236; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Najjar SM, 2005, CELL METAB, V2, P43, DOI 10.1016/j.cmet.2005.06.001; Najjar SM, 1998, J BIOL CHEM, V273, P12923, DOI 10.1074/jbc.273.21.12923; Nakajima A, 2002, J IMMUNOL, V168, P1028, DOI 10.4049/jimmunol.168.3.1028; Norris K, 1997, FEBS LETT, V415, P243, DOI 10.1016/S0014-5793(97)01133-2; Perreault M, 2001, NAT MED, V7, P1138, DOI 10.1038/nm1001-1138; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Poy MN, 2002, NAT GENET, V30, P270, DOI 10.1038/ng840; Shayakhmetov DM, 2004, J VIROL, V78, P5368, DOI 10.1128/JVI.78.10.5368-5381.2004; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; Ueki K, 2000, MOL CELL BIOL, V20, P8035, DOI 10.1128/MCB.20.21.8035-8046.2000; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Zabolotny JM, 2004, J BIOL CHEM, V279, P24844, DOI 10.1074/jbc.M310688200; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	50	104	107	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					549	556		10.1038/nm1397	http://dx.doi.org/10.1038/nm1397			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16617349				2022-12-25	WOS:000238149100039
J	Jin, DK; Shido, K; Kopp, HG; Petit, I; Shmelkov, SV; Young, LM; Hooper, AT; Amano, H; Avecilla, ST; Heissig, B; Hattori, K; Zhang, F; Hicklin, DJ; Wu, Y; Zhu, ZP; Dunn, A; Salari, H; Werb, Z; Hackett, NR; Crystal, RG; Lyden, D; Rafii, S				Jin, David K.; Shido, Koji; Kopp, Hans-Georg; Petit, Isabelle; Shmelkov, Sergey V.; Young, Lauren M.; Hooper, Andrea T.; Amano, Hideki; Avecilla, Scott T.; Heissig, Beate; Hattori, Koichi; Zhang, Fan; Hicklin, Daniel J.; Wu, Yan; Zhu, Zhenping; Dunn, Ashley; Salari, Hassan; Werb, Zena; Hackett, Neil R.; Crystal, Ronald G.; Lyden, David; Rafii, Shahin			Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4(+) hemangiocytes	NATURE MEDICINE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; STEM-CELLS; TUMOR ANGIOGENESIS; GROWTH-FACTOR; FACTOR-I; ISCHEMIC TISSUES; CHEMOKINE SDF-1; DEFICIENT MICE; KIT-LIGAND; VEGF-A	The mechanisms through which hematopoietic cytokines accelerate revascularization are unknown. Here, we show that the magnitude of cytokine-mediated release of SDF-1 from platelets and the recruitment of nonendothelial CXCR4(+)VEGFR1(+) hematopoietic progenitors, 'hemangiocytes,' constitute the major determinant of revascularization. Soluble Kit-ligand (sKitL), thrombopoietin (TPO, encoded by Thpo) and, to a lesser extent, erythropoietin (EPO) and granulocyte-macrophage colony-stimulating factor (GM-CSF) induced the release of SDF-1 from platelets, enhancing neovascularization through mobilization of CXCR4(+)VEGFR1(+) hemangiocytes. Although revascularization of ischemic hindlimbs was partially diminished in mice deficient in both GM-CSF and G-CSF (Csf2(-/-)Csf3(-/-)), profound impairment in neovascularization was detected in sKitL-deficient Mmp9(-/-) as well as thrombocytopenic Thpo(-/-) and TPO receptor-deficient (Mpl(-/-)) mice. SDF-1-mediated mobilization and incorporation of hemangiocytes into ischemic limbs were impaired in Thpo(-/-), Mpl(-/-) and Mmp9(-/-) mice. Transplantation of CXCR4(+)VEGFR1(+) hemangiocytes into Mmp9(-/-) mice restored revascularization, whereas inhibition of CXCR4 abrogated cytokine- and VEGF-A-mediated mobilization of CXCR4(+)VEGFR1(+) cells and suppressed angiogenesis. In conclusion, hematopoietic cytokines, through graded deployment of SDF-1 from platelets, support mobilization and recruitment of CXCR4(+)VEGFR1(+) hemangiocytes, whereas VEGFR1 is essential for their angiogenic competency for augmenting revascularization. Delivery of SDF- 1 may be effective in restoring angiogenesis in individuals with vasculopathies.	Cornell Univ, Weill Med Coll, Dept Med Genet, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol Med Oncol, New York, NY 10021 USA; ImClone Syst Inc, New York, NY 10014 USA; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne Tumor Biol Branch, Melbourne, Vic 3050, Australia; Chemokine Therapeut Corp, Vancouver, BC V6T 1Z3, Canada; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Cornell Univ, Weill Med Coll, Howard Hughes Med Inst, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pediat, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Childrens Blood Fdn Labs, New York, NY 10021 USA	Cornell University; Cornell University; Eli Lilly; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of California System; University of California San Francisco; Cornell University; Howard Hughes Medical Institute; Cornell University; Cornell University	Rafii, S (corresponding author), Cornell Univ, Weill Med Coll, Dept Med Genet, 1300 York Ave, New York, NY 10021 USA.	srafii@med.cornell.edu	Hattori, Koichi/AAF-6862-2021; Petit, isabelle/AAF-5620-2020; Heissig, Beate/AAF-6771-2021; Avecilla, Scott/AAR-5873-2021	Petit, isabelle/0000-0002-9782-0683; Heissig, Beate/0000-0002-0348-5934; Avecilla, Scott/0000-0003-0661-9704; Kopp, Hans-Georg/0000-0002-0825-8888	Howard Hughes Medical Institute Funding Source: Medline; NCI NIH HHS [U01 CA105379-04, U01 CA105379] Funding Source: Medline; NHLBI NIH HHS [R01 HL075234-04, P01 HL067839-020004, R01 HL061849, P01 HL067839-050004, R01 HL061849-04, R01 HL058707-04, HL67839, P01 HL067839, R01 HL058707-03, R01 HL061849-03S1, R01 HL061849-05, HL59312, P01 HL067839-010004, P01 HL067839-02, R01 HL061849-02, P01 HL067839-030004, HL66592, R01-HL075234, P01 HL067839-040004, P01 HL059312, R01 HL061849-03, R01 HL075234, P01 HL059312-10] Funding Source: Medline; NIA NIH HHS [R01 AG023218, R01 AG023218-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA105379] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059312, P01HL067839, R01HL058707, R01HL061849, P50HL059312, R01HL075234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG023218] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aicher A, 2003, NAT MED, V9, P1370, DOI 10.1038/nm948; Avecilla ST, 2004, NAT MED, V10, P64, DOI 10.1038/nm973; AVRAHAM H, 1992, BLOOD, V79, P365; Basu S, 2000, BLOOD, V95, P3725; Brizzi MF, 1999, CIRC RES, V84, P785; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Bunting S, 1997, BLOOD, V90, P3423, DOI 10.1182/blood.V90.9.3423; Butler JM, 2005, J CLIN INVEST, V115, P86, DOI 10.1172/JCI200522869; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465; Dar A, 2005, NAT IMMUNOL, V6, P1038, DOI 10.1038/ni1251; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Forster R, 1998, J IMMUNOL, V160, P1522; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; Hattori K, 2003, LEUKEMIA LYMPHOMA, V44, P575, DOI 10.1080/1042819021000037985; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; Heeschen C, 2003, BLOOD, V102, P1340, DOI 10.1182/blood-2003-01-0223; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Henke M, 2003, LANCET, V362, P1255, DOI 10.1016/S0140-6736(03)14567-9; Johnson C, 2004, CIRC RES, V94, P262, DOI 10.1161/01.RES.0000111527.42357.62; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kertesz N, 2004, DEV BIOL, V276, P101, DOI 10.1016/j.ydbio.2004.08.025; Kirito K, 2005, CELL CYCLE, V4, P1729, DOI 10.4161/cc.4.12.2197; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Li JJ, 2001, THROMB HAEMOSTASIS, V85, P204, DOI 10.1055/s-0037-1615677; Liles WC, 2003, BLOOD, V102, P2728, DOI 10.1182/blood-2003-02-0663; Losordo DW, 2004, CIRCULATION, V109, P2692, DOI 10.1161/01.CIR.0000128596.49339.05; Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Matsui J, 2004, J BIOL CHEM, V279, P18600, DOI 10.1074/jbc.M311643200; Mohle R, 1997, P NATL ACAD SCI USA, V94, P663, DOI 10.1073/pnas.94.2.663; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Papayannopoulou T, 2004, BLOOD, V103, P1580, DOI 10.1182/blood-2003-05-1595; Pelus LM, 2005, EXP HEMATOL, V33, P295, DOI 10.1016/j.exphem.2004.11.008; Perez LE, 2004, EXP HEMATOL, V32, P300, DOI 10.1016/j.exphem.2003.12.005; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Selheim F, 2002, FEBS LETT, V512, P107, DOI 10.1016/S0014-5793(02)02232-9; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Takakura N, 2000, CELL, V102, P199, DOI 10.1016/S0092-8674(00)00025-8; Walter DH, 2005, CIRC RES, V97, P1142, DOI 10.1161/01.RES.0000193596.94936.2c; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	50	535	561	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2006	12	5					557	567		10.1038/nm1400	http://dx.doi.org/10.1038/nm1400			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	051GH	16648859	Green Published, Green Accepted			2022-12-25	WOS:000238149100040
J	Manjon, C; Sanchez-Herrero, E; Suzanne, M				Manjon, Cristina; Sanchez-Herrero, Ernesto; Suzanne, Magali			Sharp boundaries of Dpp signalling trigger local cell death required for Drosophila leg morphogenesis	NATURE CELL BIOLOGY			English	Article							GRADIENT FORMATION; GENETIC-CONTROL; EXPRESSION; SEGMENTATION; APOPTOSIS; NOTCH; PATHWAY; GROWTH; FATES	Morphogens are secreted signalling molecules that govern many developmental processes(1). In the Drosophila wing disc, the transforming growth factor beta (TGF beta) homologue Decapentaplegic (Dpp) forms a smooth gradient and specifies cell fate by conferring a defined value of morphogen activity. Thus, neighbouring cells have similar amounts of Dpp protein, and if a sharp discontinuity in Dpp activity is generated between these cells, Jun kinase (JNK)-dependent apoptosis is triggered to restore graded positional information(2,3). To date, it has been assumed that this apoptotic process is only activated when normal signalling is distorted. However, we now show that a similar process occurs during normal development: rupture in Dpp activity occurs during normal segmentation of the distal legs of Drosophila. This sharp boundary of Dpp signalling, independently of the absolute level of Dpp activity, induces a JNK-reaper-dependent apoptosis required for the morphogenesis of a particular structure of the leg, the joint. Our results show that Dpp could induce a developmental programme not only in a concentration dependent manner, but also by the creation of a sharp boundary of Dpp activity. Furthermore, the same process could be used either to restore a normal pattern in response to artificial disturbance or to direct a morphogenetic process.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Suzanne, M (corresponding author), Univ Nice, CNRS, UMR 6543, Inst Signalling Dev Biol & Canc, Parc Valrose, F-06108 Nice, France.	suzanne@unice.fr	Sánchez-Herrero, Ernesto/ABE-3595-2020					Adachi-Yamada T, 2002, DEV BIOL, V251, P74, DOI 10.1006/dbio.2002.0821; Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; Belenkaya TY, 2004, CELL, V119, P231, DOI 10.1016/j.cell.2004.09.031; Bishop SA, 1999, DEVELOPMENT, V126, P2993; BRAND AH, 1993, DEVELOPMENT, V118, P401; Campbell G, 2002, NATURE, V418, P781, DOI 10.1038/nature00971; Casares F, 2001, SCIENCE, V293, P1477, DOI 10.1126/science.1062542; Cashio P, 2005, SEMIN CELL DEV BIOL, V16, P225, DOI 10.1016/j.semcdb.2005.01.002; de Celis JF, 1998, DEVELOPMENT, V125, P4617; Drysdale RA, 2005, NUCLEIC ACIDS RES, V33, pD390, DOI 10.1093/nar/gki046; Edwards CJ, 2001, SEMIN ARTHRITIS RHEU, V31, P33, DOI 10.1053/sarh.2001.24875; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; Galindo MI, 2002, SCIENCE, V297, P256, DOI 10.1126/science.1072311; Haerry TE, 1998, DEVELOPMENT, V125, P3977; HAY BA, 1994, DEVELOPMENT, V120, P2121; Hayashi S, 2002, GENESIS, V34, P58, DOI 10.1002/gene.10137; Jiang CA, 2000, MOL CELL, V5, P445, DOI 10.1016/S1097-2765(00)80439-6; Jockusch EL, 2000, DEVELOPMENT, V127, P1617; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; McGuire SE, 2003, SCIENCE, V302, P1765, DOI 10.1126/science.1089035; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Nellesen DT, 1999, DEV BIOL, V213, P33, DOI 10.1006/dbio.1999.9324; Niwa N, 2000, DEVELOPMENT, V127, P4373; Perez-Garijo A, 2004, DEVELOPMENT, V131, P5591, DOI 10.1242/dev.01432; Rauskolb C, 1999, DEV BIOL, V210, P339, DOI 10.1006/dbio.1999.9273; Rauskolb C, 2001, DEVELOPMENT, V128, P4511; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Teleman AA, 2000, CELL, V103, P971, DOI 10.1016/S0092-8674(00)00199-9; Teleman AA, 2001, CELL, V105, P559, DOI 10.1016/S0092-8674(01)00377-4; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Yu SY, 2002, DEVELOPMENT, V129, P3269	33	85	87	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JAN	2007	9	1					57	U66		10.1038/ncb1518	http://dx.doi.org/10.1038/ncb1518			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	122VL	17143268	Green Submitted			2022-12-25	WOS:000243255100012
J	Lee, J; Mo, JH; Katakura, K; Alkalay, I; Rucker, AN; Liu, YT; Lee, HK; Shen, C; Cojocaru, G; Shenouda, S; Kagnoff, M; Eckmann, L; Ben-Neriah, Y; Raz, E				Lee, Jongdae; Mo, Ji-Hun; Katakura, Kyoko; Alkalay, Irit; Rucker, Adam N.; Liu, Yu-Tsueng; Lee, Hyun-Ku; Shen, Carol; Cojocaru, Gady; Shenouda, Steve; Kagnoff, Martin; Eckmann, Lars; Ben-Neriah, Yinon; Raz, Eyal			Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells	NATURE CELL BIOLOGY			English	Article						g	TOLL-LIKE RECEPTOR-9; NF-KAPPA-B; MURINE COLITIS; BACTERIAL FLAGELLIN; MOLECULAR-PATTERNS; NF-KAPPA-B1 P105; GENE-EXPRESSION; KINASE; DNA; LIPOPOLYSACCHARIDE	The mechanisms by which commensal bacteria suppress inflammatory signalling in the gut are still unclear. Here, we present a cellular mechanism whereby the polarity of intestinal epithelial cells (IECs) has a major role in colonic homeostasis. TLR9 activation through apical and basolateral surface domains have distinct transcriptional responses, evident by NF-kappa B activation and cDNA microarray analysis. Whereas basolateral TLR9 signals I kappa B alpha degradation and activation of the NF-kappa B pathway, apical TLR9 stimulation invokes a unique response in which ubiquitinated I kappa Ba accumulates in the cytoplasm preventing NF-kappa B activation. Furthermore, apical TLR9 stimulation confers intracellular tolerance to subsequent TLR challenges. IECs in TLR9-deficient mice, when compared with wild-type and TLR2-deficient mice, display a lower NF-kappa B activation threshold and these mice are highly susceptible to experimental colitis. Our data provide a case for organ-specific innate immunity in which TLR expression in polarized IECs has uniquely evolved to maintain colonic homeostasis and regulate tolerance and inflammation.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol, IL-91120 Jerusalem, Israel; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Hebrew University of Jerusalem; Scripps Research Institute	Raz, E (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.	j142133@ucsd.edu; yinon@cc.huji.ac.il; eraz@ucsd.edu	Ben-Neriah, Yinon/L-6285-2019; Mo, Ji-Hun/E-5586-2011	Mo, Ji-Hun/0000-0003-1331-364X; Lee, Jongdae/0000-0002-6270-4658	NATIONAL CENTER FOR RESEARCH RESOURCES [K26RR017030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056075, R01AI057709, P01AI040682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047101] Funding Source: NIH RePORTER; NCRR NIH HHS [RR17030] Funding Source: Medline; NIAID NIH HHS [AI57709, AI40682, AI56075] Funding Source: Medline; NIDDK NIH HHS [DK35108] Funding Source: Medline; NINDS NIH HHS [P30 NS047101] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje; Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Bantel H, 2002, FASEB J, V16, P1832, DOI 10.1096/fj.02-0223fje; Barczak A, 2003, GENOME RES, V13, P1775, DOI 10.1101/gr.1048803; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Blitzer JT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-28; BONEV MN, 1990, INT J RADIAT BIOL, V57, P993, DOI 10.1080/09553009014551111; Bozdech Z, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r9; CAMPBELL A, 1994, ANNU REV MICROBIOL, V48, P193, DOI 10.1146/annurev.micro.48.1.193; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; Cohen S, 2004, MOL CELL BIOL, V24, P475, DOI 10.1128/MCB.24.1.475-486.2004; COOPER HS, 1993, LAB INVEST, V69, P238; Dwinell MB, 1999, GASTROENTEROLOGY, V117, P359, DOI 10.1053/gast.1999.0029900359; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Katakura K, 2005, J CLIN INVEST, V115, P695, DOI 10.1172/JCI200522996; KATZ KD, 1989, GASTROENTEROLOGY, V97, P927, DOI 10.1016/0016-5085(89)91499-6; Kazmierczak BI, 2001, ANNU REV MICROBIOL, V55, P407, DOI 10.1146/annurev.micro.55.1.407; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lee J, 2003, P NATL ACAD SCI USA, V100, P6646, DOI 10.1073/pnas.0631696100; Lee J, 2000, J LEUKOCYTE BIOL, V68, P909; Leifer CA, 2004, J IMMUNOL, V173, P1179, DOI 10.4049/jimmunol.173.2.1179; Marrero JA, 2000, AM J PHYSIOL-GASTR L, V278, pG797, DOI 10.1152/ajpgi.2000.278.5.G797; Naidu AS, 1999, CRIT REV FOOD SCI, V39, P13, DOI 10.1080/10408699991279187; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; O'Neil DA, 1999, J IMMUNOL, V163, P6718; Okabe Y, 2005, J EXP MED, V202, P1333, DOI 10.1084/jem.20051654; Ortega-Cava CF, 2003, J IMMUNOL, V170, P3977, DOI 10.4049/jimmunol.170.8.3977; Otte JM, 2004, GASTROENTEROLOGY, V126, P1054, DOI 10.1053/j.gastro.2004.01.007; PARMA DH, 1992, GENE DEV, V6, P497, DOI 10.1101/gad.6.3.497; Pedersen G, 2005, CLIN EXP IMMUNOL, V141, P298, DOI 10.1111/j.1365-2249.2005.02848.x; Rachmilewitz D, 2004, GASTROENTEROLOGY, V126, P520, DOI 10.1053/j.gastro.2003.11.019; Rachmilewitz D, 2002, GASTROENTEROLOGY, V122, P1428, DOI 10.1053/gast.2002.32994; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rhee SH, 2005, P NATL ACAD SCI USA, V102, P13610, DOI 10.1073/pnas.0502174102; SANDLE GI, 1990, GASTROENTEROLOGY, V99, P97, DOI 10.1016/0016-5085(90)91235-X; Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x; Shang F, 2005, J BIOL CHEM, V280, P20365, DOI 10.1074/jbc.M414356200; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; VAN ISC, 2000, J CELL PHYSL, V184, P151; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4	46	453	475	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1327	U7		10.1038/ncb1500	http://dx.doi.org/10.1038/ncb1500			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17128265				2022-12-25	WOS:000242419800008
J	Yook, JI; Li, XY; Ota, I; Hu, C; Kim, HS; Kim, NH; Cha, SY; Ryu, JK; Choi, YJ; Kim, J; Fearon, ER; Weiss, SJ				Yook, Jong In; Li, Xiao-Yan; Ota, Ichiro; Hu, Casey; Kim, Hyun Sil; Kim, Nam Hee; Cha, So Young; Ryu, Joo Kyung; Choi, Yoon Jung; Kim, Jin; Fearon, Eric R.; Weiss, Stephen J.			A Wnt-Axin2-GSK3 beta cascade regulates Snail1 activity in breast cancer cells	NATURE CELL BIOLOGY			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOGEN-SYNTHASE KINASE-3-BETA; BETA-CATENIN; MAMMARY DEVELOPMENT; PROGENITOR CELLS; REPRESSOR SNAIL; AXIN; PATHWAY; PHOSPHORYLATION; MORPHOGENESIS	Accumulating evidence indicates that hyperactive Wnt signalling occurs in association with the development and progression of human breast cancer. As a consequence of engaging the canonical Wnt pathway, a beta-catenin-T-cell factor (TCF) transcriptional complex is generated, which has been postulated to trigger the epithelial - mesenchymal transition (EMT) that characterizes the tissue-invasive phenotype. However, the molecular mechanisms by which the beta-catenin-TCF complex induces EMT-like programmes remain undefined. Here, we demonstrate that canonical Wnt signalling engages tumour cell dedifferentiation and tissue-invasive activity through an Axin2-dependent pathway that stabilizes the Snail1 zinc-transcription factor, a key regulator of normal and neoplastic EMT programmes. Axin2 regulates EMT by acting as a nucleocytoplasmic chaperone for GSK3 beta, the dominant kinase responsible for controlling Snail1 protein turnover and activity. As dysregulated Wnt signalling marks a diverse array of cancerous tissue types, the identification of a beta-catenin-TCF-regulated Axin2 -GSK3 beta-Snail1 axis provides new mechanistic insights into cancer-associated EMT programmes.	Univ Michigan, Ctr Comprehens Canc, Div Med & Mol Genet, Dept Internal Med,Life Sci Inst, Ann Arbor, MI 48109 USA; Yonsei Univ, Coll Dent, Oral Canc Res Inst, Dept Oral Pathol, Seoul 120752, South Korea; Ilsan Hosp, Natl Hlth Insurance Corp, Dept Pathol, Kyungki 419719, South Korea; Univ Michigan, Dept Internal Med Human Genet & Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Yonsei University; Yonsei University Health System; NHIS Ilsan Hospital; University of Michigan System; University of Michigan	Weiss, SJ (corresponding author), Univ Michigan, Ctr Comprehens Canc, Div Med & Mol Genet, Dept Internal Med,Life Sci Inst, Ann Arbor, MI 48109 USA.	sjweiss@umich.edu		Ota, Ichiro/0000-0003-3815-8877; Kim, Hyun Sil/0000-0003-3614-1764; Yook, Jong In/0000-0002-7318-6112; Kim, Nam Hee/0000-0002-3087-5276	NATIONAL CANCER INSTITUTE [R01CA071699] Funding Source: NIH RePORTER; NCI NIH HHS [5 R01 CA71699] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Chia IV, 2005, MOL CELL BIOL, V25, P4371, DOI 10.1128/MCB.25.11.4371-4376.2005; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; Cong F, 2004, P NATL ACAD SCI USA, V101, P2882, DOI 10.1073/pnas.0307344101; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Jamora C, 2005, PLOS BIOL, V3, P131, DOI 10.1371/journal.pbio.0030011; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Kemler R, 2004, DEVELOPMENT, V131, P5817, DOI 10.1242/dev.01458; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rowlands TM, 2003, P NATL ACAD SCI USA, V100, P11400, DOI 10.1073/pnas.1534601100; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Stoothof WH, 2002, J NEUROCHEM, V83, P904, DOI 10.1046/j.1471-4159.2002.01197.x; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Wiechens N, 2004, J BIOL CHEM, V279, P5263, DOI 10.1074/jbc.M307253200; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yu HMI, 2005, DEVELOPMENT, V132, P1995, DOI 10.1242/dev.01786; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	30	501	517	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	DEC	2006	8	12					1398	U57		10.1038/ncb1508	http://dx.doi.org/10.1038/ncb1508			13	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	110ZJ	17072303				2022-12-25	WOS:000242419800016
J	Martin, HG; Ivanova, N; Kunin, V; Warnecke, F; Barry, KW; McHardy, AC; Yeates, C; He, SM; Salamov, AA; Szeto, E; Dalin, E; Putnam, NH; Shapiro, HJ; Pangilinan, JL; Rigoutsos, I; Kyrpides, NC; Blackall, LL; McMahon, KD; Hugenholtz, P				Martin, Hector Garcia; Ivanova, Natalia; Kunin, Victor; Warnecke, Falk; Barry, Kerrie W.; McHardy, Alice C.; Yeates, Christine; He, Shaomei; Salamov, Asaf A.; Szeto, Ernest; Dalin, Eileen; Putnam, Nik H.; Shapiro, Harris J.; Pangilinan, Jasmyn L.; Rigoutsos, Isidore; Kyrpides, Nikos C.; Blackall, Linda Louise; McMahon, Katherine D.; Hugenholtz, Philip			Metagenomic analysis of two enhanced biological phosphorus removal (EBPR) sludge communities	NATURE BIOTECHNOLOGY			English	Article							ACTIVATED-SLUDGE; ACCUMULATING ORGANISMS; PHOSPHATE REMOVAL; WASTE-WATER; METABOLISM; MICROBIOLOGY; BACTERIA; GENOME; IDENTIFICATION; ACINETOBACTER	Enhanced biological phosphorus removal (EBPR) is one of the best-studied microbially mediated industrial processes because of its ecological and economic relevance. Despite this, it is not well understood at the metabolic level. Here we present a metagenomic analysis of two lab-scale EBPR sludges dominated by the uncultured bacterium, "Candidatus Accumulibacter phosphatis.'' The analysis sheds light on several controversies in EBPR metabolic models and provides hypotheses explaining the dominance of A. phosphatis in this habitat, its lifestyle outside EBPR and probable cultivation requirements. Comparison of the same species from different EBPR sludges highlights recent evolutionary dynamics in the A. phosphatis genome that could be linked to mechanisms for environmental adaptation. In spite of an apparent lack of phylogenetic overlap in the flanking communities of the two sludges studied, common functional themes were found, at least one of them complementary to the inferred metabolism of the dominant organism. The present study provides a much needed blueprint for a systems-level understanding of EBPR and illustrates that metagenomics enables detailed, often novel, insights into even well-studied biological systems.	US DOE, Joint Genome Inst, Walnut Creek, CA 94598 USA; Univ Queensland, Adv Wastewater Management Ctr, St Lucia, Qld 4072, Australia; Univ Wisconsin, Dept Civil & Environm Engn, Madison, WI 53706 USA; IBM Corp, Div Res, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA	United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI; University of Queensland; University of Wisconsin System; University of Wisconsin Madison; International Business Machines (IBM)	Hugenholtz, P (corresponding author), US DOE, Joint Genome Inst, 2800 Mitchell Dr, Walnut Creek, CA 94598 USA.	phugenholtz@lbl.gov	Blackall, Linda Louise/AAC-4312-2020; Hugenholtz, Philip/AAD-9138-2019; McHardy, Alice/ABF-2322-2020; Kyrpides, Nikos C./A-6305-2014; Rigoutsos, Isidore/C-5381-2012; Blackall, Linda L/H-1947-2013; Putnam, Nicholas/B-9968-2008; McHardy, Alice C/K-9377-2018; Barry, Kerrie Whitelaw/AAA-5500-2020; Martin, Hector Garcia/B-5357-2009; McMahon, Katherine D/I-3651-2012	Blackall, Linda Louise/0000-0002-8848-7698; Hugenholtz, Philip/0000-0001-5386-7925; McHardy, Alice/0000-0003-2370-3430; Kyrpides, Nikos C./0000-0002-6131-0462; Blackall, Linda L/0000-0002-8848-7698; Putnam, Nicholas/0000-0002-1315-782X; McHardy, Alice C/0000-0003-2370-3430; Barry, Kerrie Whitelaw/0000-0002-8999-6785; Martin, Hector Garcia/0000-0002-4556-9685; Ivanova, Natalia/0000-0002-5802-9485; Kunin, Victor/0000-0002-8741-7866; Rigoutsos, Isidore/0000-0003-1529-8631; McMahon, Katherine D./0000-0002-7038-026X				Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Blackall LL, 2002, ANTON LEEUW INT J G, V81, P681, DOI 10.1023/A:1020538429009; BURNS DJW, 1979, J BACTERIOL, V139, P195, DOI 10.1128/JB.139.1.195-204.1979; *CEEP, 2001, 2 INT C REC PHOSPH S; Crocetti GR, 2000, APPL ENVIRON MICROB, V66, P1175, DOI 10.1128/AEM.66.3.1175-1182.2000; DEINEMA MH, 1985, WATER SCI TECHNOL, V17, P119, DOI 10.2166/wst.1985.0226; Elbehti A, 2000, J BACTERIOL, V182, P3602, DOI 10.1128/JB.182.12.3602-3606.2000; FARMER AM, 1999, SCOPE NEWSLETER; Fuhs GW, 1975, MICROB ECOL, V2, P119, DOI 10.1007/BF02010434; Harper, 1991, EUTROPHICATION FRESH; He S, 2006, WATER SCI TECHNOL, V54, P111, DOI 10.2166/wst.2006.378; Hesselmann RPX, 2000, WATER RES, V34, P3487, DOI 10.1016/S0043-1354(00)00092-0; Hesselmann RPX, 1999, SYST APPL MICROBIOL, V22, P454, DOI 10.1016/S0723-2020(99)80055-1; Korotkova N, 2005, J BACTERIOL, V187, P1523, DOI 10.1128/JB.187.4.1523-1526.2005; Kortstee GJJ, 2000, BIOCHEMISTRY-MOSCOW+, V65, P332; Lemos PC, 2003, APPL ENVIRON MICROB, V69, P241, DOI 10.1128/AEM.69.1.241-251.2003; Louie TM, 2000, WATER RES, V34, P1507, DOI 10.1016/S0043-1354(99)00302-4; Maurer M, 1997, WATER RES, V31, P907, DOI 10.1016/S0043-1354(96)00369-7; McMahon KD, 2002, APPL ENVIRON MICROB, V68, P4971, DOI 10.1128/AEM.68.10.4971-4978.2002; Mino T, 1998, WATER RES, V32, P3193, DOI 10.1016/S0043-1354(98)00129-8; Oehmen A, 2006, J BIOTECHNOL, V123, P22, DOI 10.1016/j.jbiotec.2005.10.009; Pereira H, 1996, WATER RES, V30, P2128, DOI 10.1016/0043-1354(96)00035-8; Schuler AJ, 2003, WATER ENVIRON RES, V75, P512, DOI 10.2175/106143003X141303; Schuler AJ, 2003, WATER ENVIRON RES, V75, P485, DOI 10.2175/106143003X141286; Seviour RJ, 2003, FEMS MICROBIOL REV, V27, P99, DOI 10.1016/S0168-6445(03)00021-4; STREICHAN M, 1990, FEMS MICROBIOL ECOL, V73, P113, DOI 10.1111/j.1574-6968.1990.tb03931.x; TCHOBANOGLOUS G, 1991, WASTEWATER ENG TREAT; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851; Tyson GW, 2005, APPL ENVIRON MICROB, V71, P6319, DOI 10.1128/AEM.71.10.6319-6324.2005; Tyson GW, 2004, NATURE, V428, P37, DOI 10.1038/nature02340; *US EPA OFF WAT, 1996, US EPA OW CLEAN WAT; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; WAGNER M, 1994, APPL ENVIRON MICROB, V60, P792, DOI 10.1128/AEM.60.3.792-800.1994; White D., 2012, PHYSL BIOCH PROKARYO; Wilen BM, 2003, WATER SCI TECHNOL, V47, P95, DOI 10.2166/wst.2003.0633; Zeng RJ, 2003, BIOTECHNOL BIOENG, V84, P170, DOI 10.1002/bit.10744	36	518	571	19	390	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	2006	24	10					1263	1269		10.1038/nbt1247	http://dx.doi.org/10.1038/nbt1247			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	093TG	16998472	Green Submitted			2022-12-25	WOS:000241191700030
J	Padiath, QS; Saigoh, K; Schiffmann, R; Asahara, H; Yamada, T; Koeppen, A; Hogan, K; Ptacek, LJ; Fu, YH				Padiath, Quasar S.; Saigoh, Kazumasa; Schiffmann, Raphael; Asahara, Hideaki; Yamada, Takeshi; Koeppen, Anulf; Hogan, Kirk; Ptacek, Louis J.; Fu, Ying-Hui			Lamin B1 duplications cause autosomal dominant leukodystrophy	NATURE GENETICS			English	Article							PROGRESSIVE MULTIPLE-SCLEROSIS; DREIFUSS MUSCULAR-DYSTROPHY; PELIZAEUS-MERZBACHER-DISEASE; NUCLEAR LAMINS; PARTIAL LIPODYSTROPHY; GENE-EXPRESSION; DNA-SEQUENCES; HUMAN TISSUES; DROSOPHILA; PROTEIN	Adult-onset autosomal dominant leukodystrophy (ADLD) is a slowly progressive neurological disorder characterized by symmetrical widespread myelin loss in the central nervous system, with a phenotype similar to chronic progressive multiple sclerosis. In this study, we identify a genomic duplication that causes ADLD. Affected individuals carry an extra copy of the gene for the nuclear laminar protein lamin B1, resulting in increased gene dosage in brain tissue from individuals with ADLD. Increased expression of lamin B1 in Drosophila melanogaster resulted in a degenerative phenotype. In addition, an abnormal nuclear morphology was apparent when cultured cells overexpressed this protein. This is the first human disease attributable to mutations in the gene encoding lamin B1. Antibodies to lamin B are found in individuals with autoimmune diseases, and it is also an antigen recognized by a monoclonal antibody raised against plaques from brains of individuals with multiple sclerosis. This raises the possibility that lamin B may be a link to the autoimmune attack that occurs in multiple sclerosis.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA; Kyushu Univ, Fac Med, Dept Neurol, Fukuoka 812, Japan; Iizuka Hosp, Dept Neurol, Iizuka, Fukuoka, Japan; Albany Med Coll, Vet Adm Med Ctr, Albany, NY 12208 USA; Albany Med Coll, Dept Neurol, Albany, NY 12208 USA; Univ Wisconsin, Dept Anesthesiol, Madison, WI 53792 USA; Howard Hughes Med Inst, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Kyushu University; Albany Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Albany Medical College; University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute	Fu, YH (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA.	yhf@neugenes.org	saigoh, Kazumasa/AAG-4678-2022; saigoh, Kazumasa/AFK-6417-2022; Saigoh, Kazumasa/AAG-2956-2020	Saigoh, Kazumasa/0000-0002-0905-5935	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002984, R01NS041331] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41331] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aarskog NK, 2000, HUM GENET, V107, P494, DOI 10.1007/s004390000399; Asahara H, 1996, Rinsho Shinkeigaku, V36, P968; Ausubel F., 1999, CURRENT PROTOCOLS MO; Bainton RJ, 2005, CELL, V123, P145, DOI 10.1016/j.cell.2005.07.029; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Bilen J, 2005, ANNU REV GENET, V39, P153, DOI 10.1146/annurev.genet.39.110304.095804; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Boor PKI, 2005, J NEUROPATH EXP NEUR, V64, P412; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; Coffeen CM, 2000, HUM MOL GENET, V9, P787, DOI 10.1093/hmg/9.5.787; De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274; ELDRIDGE R, 1984, NEW ENGL J MED, V311, P948, DOI 10.1056/NEJM198410113111504; ELLIS MC, 1993, DEVELOPMENT, V119, P855; Favreau C, 2003, EXP CELL RES, V282, P14, DOI 10.1006/excr.2002.5669; Garcia DM, 2003, BRAIN RES, V976, P9, DOI 10.1016/S0006-8993(03)02597-6; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; Glatt CE, 2001, NAT GENET, V27, P435, DOI 10.1038/86948; Gruenbaum Y, 2005, NAT REV MOL CELL BIO, V6, P21, DOI 10.1038/nrm1550; Guillemin K, 2001, NAT CELL BIOL, V3, P848, DOI 10.1038/ncb0901-848; Haithcock E, 2005, P NATL ACAD SCI USA, V102, P16690, DOI 10.1073/pnas.0506755102; Hegele RA, 2006, AM J HUM GENET, V79, P383, DOI 10.1086/505885; Inoue K, 2002, AM J HUM GENET, V71, P838, DOI 10.1086/342728; Inoue K, 2005, NEUROGENETICS, V6, P1, DOI 10.1007/s10048-004-0207-y; Lin F, 1997, EXP CELL RES, V236, P378, DOI 10.1006/excr.1997.3735; LIN F, 1995, GENOMICS, V27, P230, DOI 10.1006/geno.1995.1036; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lupski JR, 2005, PLOS GENET, V1, P627, DOI 10.1371/journal.pgen.0010049; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; Mignot C, 2004, CELL MOL LIFE SCI, V61, P369, DOI 10.1007/s00018-003-3143-3; Moisan E, 2006, J LEUKOCYTE BIOL, V79, P489, DOI 10.1189/jlb.0405190; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Schiffmann R, 2004, CURR OPIN NEUROL, V17, P187, DOI 10.1097/00019052-200404000-00017; Schuelke M, 2000, NAT BIOTECHNOL, V18, P233, DOI 10.1038/72708; SCHWANKHAUS JD, 1994, ARCH NEUROL-CHICAGO, V51, P757, DOI 10.1001/archneur.1994.00540200033013; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; SEBOUN E, 1997, MOL GENETIC BASIS NE, P631; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Somech R, 2005, PEDIATR RES, V57, p8R, DOI 10.1203/01.PDR.0000159566.54287.6C; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Super HG, 1997, GENE CHROMOSOME CANC, V20, P185, DOI 10.1002/(SICI)1098-2264(199710)20:2<185::AID-GCC9>3.0.CO;2-#; TAN EM, 1988, ANN INTERN MED, V108, P897, DOI 10.7326/0003-4819-108-6-897; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; Woodward KJ, 2005, AM J HUM GENET, V77, P966, DOI 10.1086/498048; Worman HJ, 2005, INT REV CYTOL, V246, P231, DOI 10.1016/S0074-7696(05)46006-4; XIONG WC, 1994, GENE DEV, V8, P981, DOI 10.1101/gad.8.8.981	50	282	295	0	12	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	OCT	2006	38	10					1114	1123		10.1038/ng1872	http://dx.doi.org/10.1038/ng1872			10	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	094PJ	16951681				2022-12-25	WOS:000241251100010
J	Gama, CI; Tully, SE; Sotogaku, N; Clark, PM; Rawat, M; Vaidehi, N; Goddard, WA; Nishi, A; Hsieh-Wilson, LC				Gama, Cristal I.; Tully, Sarah E.; Sotogaku, Naoki; Clark, Peter M.; Rawat, Manish; Vaidehi, Nagarajan; Goddard, William A., III; Nishi, Akinori; Hsieh-Wilson, Linda C.			Sulfation patterns of glycosaminoglycans encode molecular recognition and activity	NATURE CHEMICAL BIOLOGY			English	Article							HEPARAN-SULFATE; CHONDROITIN; PROTEIN; PROTEOGLYCANS; DISACCHARIDE; MICROARRAYS; DYNAMICS; LIGANDS; MIDKINE; CHAINS	Although glycosaminoglycans contribute to diverse physiological processes(1-4), an understanding of their molecular mechanisms has been hampered by the inability to access homogeneous glycosaminoglycan structures. Here, we assembled well-defined chondroitin sulfate oligosaccharides using a convergent, synthetic approach that permits installation of sulfate groups at precise positions along the carbohydrate backbone. Using these defined structures, we demonstrate that specific sulfation motifs function as molecular recognition elements for growth factors and modulate neuronal growth. These results provide both fundamental insights into the role of sulfation and direct evidence for a `sulfation code' whereby glycosaminoglycans encode functional information in a sequence-specific manner analogous to that of DNA, RNA and proteins.	CALTECH, Dept Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Kurume Univ, Sch Med, Dept Pharmacol, Kurume, Fukuoka 8300011, Japan; CALTECH, Mat & Proc Simulat Ctr, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; Kurume University; California Institute of Technology	Hsieh-Wilson, LC (corresponding author), CALTECH, Dept Chem & Chem Engn, Pasadena, CA 91125 USA.	lhw@caltech.edu			NINDS NIH HHS [R01 NS045061] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045061] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BICKNESE AR, 1994, J NEUROSCI, V14, P3500; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Brickman YG, 1998, J BIOL CHEM, V273, P4350, DOI 10.1074/jbc.273.8.4350; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; de Paz JL, 2006, J AM CHEM SOC, V128, P2766, DOI 10.1021/ja057584v; Deepa SS, 2004, J BIOL CHEM, V279, P37368, DOI 10.1074/jbc.M403031200; Feizi T, 2003, CURR OPIN STRUC BIOL, V13, P637, DOI 10.1016/j.sbi.2003.09.002; FernaudEspinosa I, 1996, J NEUROBIOL, V30, P410, DOI 10.1002/(SICI)1097-4695(199607)30:3<410::AID-NEU9>3.0.CO;2-7; GREELEY BH, 1994, J CHEM PHYS, V101, P4028, DOI 10.1063/1.467520; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Herndon ME, 1999, GLYCOBIOLOGY, V9, P143, DOI 10.1093/glycob/9.2.143; Holt CE, 2005, NEURON, V46, P169, DOI 10.1016/j.neuron.2005.03.021; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Jacquinet JC, 1998, CARBOHYD RES, V314, P283, DOI 10.1016/S0008-6215(98)00298-5; Jiang B, 2003, J NEUROSCI, V23, P3761; Kantor DB, 2004, NEURON, V44, P961, DOI 10.1016/j.neuron.2004.12.002; Karst NA, 2003, CURR MED CHEM, V10, P1993, DOI 10.2174/0929867033456891; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Lim KT, 1997, J COMPUT CHEM, V18, P501, DOI 10.1002/(SICI)1096-987X(199703)18:4<501::AID-JCC5>3.0.CO;2-X; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Nandini CD, 2004, J BIOL CHEM, V279, P50799, DOI 10.1074/jbc.M404746200; Park S, 2004, J AM CHEM SOC, V126, P4812, DOI 10.1021/ja0391661; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; RAPPE AK, 1991, J PHYS CHEM-US, V95, P3358, DOI 10.1021/j100161a070; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Seil FJ, 2000, J NEUROSCI, V20, P5367, DOI 10.1523/JNEUROSCI.20-14-05367.2000; Shuo T, 2003, GLYCOCONJUGATE J, V20, P267, DOI 10.1023/B:GLYC.0000025821.22618.33; Skoff AM, 2006, EXP NEUROL, V197, P430, DOI 10.1016/j.expneurol.2005.10.006; Tsuchida K, 2001, J BIOL CHEM, V276, P37155, DOI 10.1074/jbc.M105818200; Tully SE, 2004, J AM CHEM SOC, V126, P7736, DOI 10.1021/ja0484045; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200	33	411	428	2	87	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	SEP	2006	2	9					467	473		10.1038/nchembio810	http://dx.doi.org/10.1038/nchembio810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	075XO	16878128				2022-12-25	WOS:000239920900009
J	Pei, LM; Waki, H; Vaitheesvaran, B; Wilpitz, DC; Kurland, IJ; Tontonoz, P				Pei, Liming; Waki, Hironori; Vaitheesvaran, Bhavapriya; Wilpitz, Damien C.; Kurland, Irwin J.; Tontonoz, Peter			NR4A orphan nuclear receptors are transcriptional regulators of hepatic glucose metabolism	NATURE MEDICINE			English	Article							MASS ISOTOPOMER ANALYSIS; INSULIN-RESISTANCE; PPAR-GAMMA; NGFI-B; GLUCONEOGENESIS; INDUCTION; LIVER; GENE; IDENTIFICATION; REQUIREMENT	Hepatic glucose production is crucial for glucose homeostasis, and its dysregulation contributes to the pathogenesis of diabetes. Here, we show that members of the NR4A family of ligand-independent orphan nuclear receptors are downstream mediators of cAMP action in the hormonal control of gluconeogenesis. Hepatic expression of Nur77, Nurr1 and NOR1 is induced by the cAMP axis in response to glucagon and fasting in vivo and is increased in diabetic mice that exhibit elevated gluconeogenesis. Adenoviral expression of Nur77 induces genes involved in gluconeogenesis, stimulates glucose production both in vitro and in vivo, and raises blood glucose levels. Conversely, expression of an inhibitory mutant Nur77 receptor antagonizes gluconeogenic gene expression and lowers blood glucose levels in db/db mice. These results outline a previously unrecognized role for orphan nuclear receptors in the transcriptional control of glucose homeostasis.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Tontonoz, P (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, 675 Charles E Young Dr S, Los Angeles, CA 90095 USA.	ptontonoz@mednet.ucla.edu	Waki, Hironori/AAE-3942-2020	Waki, Hironori/0000-0002-5302-9793; Pei, Liming/0000-0002-1924-0333	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK058132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568] Funding Source: Medline; NIDDK NIH HHS [DK58132, R01 DK058132-06, P30 DK041301] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Erion MD, 2005, P NATL ACAD SCI USA, V102, P7970, DOI 10.1073/pnas.0502983102; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; KATZ J, 1989, J BIOL CHEM, V264, P12994; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Kovalovsky D, 2002, MOL ENDOCRINOL, V16, P1638, DOI 10.1210/me.16.7.1638; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; LAW SW, 1992, MOL ENDOCRINOL, V6, P2129, DOI 10.1210/me.6.12.2129; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Lin JD, 2004, CELL, V119, P121, DOI 10.1016/j.cell.2004.09.013; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Maxwell MA, 2005, J BIOL CHEM, V280, P12573, DOI 10.1074/jbc.M409580200; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; Montminy M, 2004, ANN ENDOCRINOL-PARIS, V65, P73, DOI 10.1016/S0003-4266(04)95634-X; Murphy EP, 1997, MOL ENDOCRINOL, V11, P39, DOI 10.1210/me.11.1.39; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; Ordentlich P, 2003, J BIOL CHEM, V278, P24791, DOI 10.1074/jbc.M302167200; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Rhee J, 2003, P NATL ACAD SCI USA, V100, P4012, DOI 10.1073/pnas.0730870100; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; SZAFRANECK J, 1974, CARBOHYD RES, V38, P97, DOI 10.1016/S0008-6215(00)82341-1; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Xu J, 2002, J BIOL CHEM, V277, P50237, DOI 10.1074/jbc.M201208200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang LP, 2005, CELL METAB, V2, P141, DOI 10.1016/j.cmet.2005.07.002	49	251	258	1	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2006	12	9					1048	1055		10.1038/nm1471	http://dx.doi.org/10.1038/nm1471			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	082GE	16906154				2022-12-25	WOS:000240373900029
J	Yao, TT; Song, L; Xu, W; DeMartino, GN; Florens, L; Swanson, SK; Washburn, MP; Conaway, RC; Conaway, JW; Cohen, RE				Yao, Tingting; Song, Ling; Xu, Wei; DeMartino, George N.; Florens, Laurence; Swanson, Selene K.; Washburn, Michael P.; Conaway, Ronald C.; Conaway, Joan Weliky; Cohen, Robert E.			Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1	NATURE CELL BIOLOGY			English	Article							GASTRIC-CARCINOMA CELLS; UBIQUITIN HYDROLASE; REGULATORY COMPLEX; STRUCTURAL BASIS; IDENTIFICATION; PROTEIN; SPECIFICITY; ISOPEPTIDASE; ASSOCIATION; CLONING	Uch37 is one of the three principal deubiquitinating enzymes (DUBs), and the only ubiquitin carboxy-terminal hydrolase (UCH)-family protease, that is associated with mammalian proteasomes. We show that Uch37 is responsible for the ubiquitin isopeptidase activity in the PA700 (19S) proteasome regulatory complex(1). PA700 isopeptidase disassembles Lys 48-linked polyubiquitin specifically from the distal end of the chain, a property that may be used to clear poorly ubiquitinated or unproductively bound substrates from the proteasome. To better understand Uch37 function and the mechanism responsible for its specificity, we investigated how Uch37 is recruited to proteasomes. Uch37 binds through Adrm1, a previously unrecognized orthologue of Saccharomyces cerevisiae Rpn13p, which in turn is bound to the S1 (also known as Rpn2) subunit of the 19S complex. Adrm1 (human Rpn13, hRpn13) binds the carboxy-terminal tail of Uch37, a region that is distinct from the UCH catalytic domain, which we show inhibits Uch37 activity. Following binding, Adrm1 relieves Uch37 autoinhibition, accelerating the hydrolysis of ubiquitin-7-amido-4-methylcoumarin (ubiquitin-AMC). However, neither Uch37 alone nor the Uch37-Adrm1 or Uch37-Adrm1-S1 complexes can hydrolyse di-ubiquitin efficiently; rather, incorporation into the 19S complex is required to enable processing of polyubiquitin chains.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Univ Iowa, Carver Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA	Stowers Institute for Medical Research; University of Iowa; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Kansas; University of Kansas Medical Center	Cohen, RE (corresponding author), Stowers Inst Med Res, Kansas City, MO 64110 USA.	rcohen@jhsph.edu	Song, Ling/HGA-5011-2022	Florens, Laurence/0000-0002-9310-6650; Washburn, Michael/0000-0001-7568-2585; Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM037666] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM37666, R37 GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Das C, 2006, P NATL ACAD SCI USA, V103, P4675, DOI 10.1073/pnas.0510403103; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Holzl H, 2000, J CELL BIOL, V150, P119, DOI 10.1083/jcb.150.1.119; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; James P, 1996, GENETICS, V144, P1425; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; Lam YA, 1997, J BIOL CHEM, V272, P28438, DOI 10.1074/jbc.272.45.28438; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lamerant N, 2005, FEBS J, V272, P1833, DOI 10.1111/j.1742-4658.2005.04613.x; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Lee KK, 2005, MOL CELL BIOL, V25, P1173, DOI 10.1128/MCB.25.3.1173-1182.2005; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Li TW, 2000, BIOCHEM BIOPH RES CO, V272, P270, DOI 10.1006/bbrc.2000.2767; Li TW, 2001, FEBS LETT, V488, P201, DOI 10.1016/S0014-5793(00)02436-4; Misaghi S, 2005, J BIOL CHEM, V280, P1512, DOI 10.1074/jbc.M410770200; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; SHIMADA S, 1994, CANCER RES, V54, P3831; SHIMADA S, 1991, CANCER RES, V51, P5694; Simins AB, 1999, CLIN EXP METASTAS, V17, P641, DOI 10.1023/A:1006790912877; Sumegi M, 2003, BIOCHEM BIOPH RES CO, V312, P1284, DOI 10.1016/j.bbrc.2003.11.074; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071	30	253	267	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2006	8	9					994	U92		10.1038/ncb1460	http://dx.doi.org/10.1038/ncb1460			16	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	080IS	16906146				2022-12-25	WOS:000240241700016
J	Magidson, V; Chang, F; Khodjakov, A				Magidson, Valentin; Chang, Fred; Khodjakov, Alexey			Regulation of cytokinesis by spindle-pole bodies	NATURE CELL BIOLOGY			English	Article							FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; PROTEIN; KINASE; CELL; SIN; SEGREGATION; ANAPHASE	In the fission yeast Schizosaccharomyces pombe, cytokinesis is thought to be controlled by the daughter spindle-pole body ( SPB) through a regulatory pathway named the septation initiation network ( SIN). Here, we demonstrate that laser ablation of both, but not a single SPB, results in failure of cytokinesis. Ablation of only the daughter SPB often leads to activation of the SIN on the mother SPB and successful cytokinesis. Thus, either SPB can drive cytokinesis.	Wadsworth Ctr, Albany, NY 12201 USA; Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Marine Biol Lab, Woods Hole, MA 02543 USA	Wadsworth Center; Columbia University; Marine Biological Laboratory - Woods Hole	Khodjakov, A (corresponding author), Wadsworth Ctr, Albany, NY 12201 USA.	khodj@wadsworth.org		Magidson, Valentin/0000-0002-0780-9123	NIGMS NIH HHS [R01 GM059363-08, R01 GM059363] Funding Source: Medline; PHS HHS [GMS 69670, GMS 59363] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059363] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cerutti L, 1999, J CELL SCI, V112, P2313; Daga RR, 2005, EMBO J, V24, P2436, DOI 10.1038/sj.emboj.7600705; Grallert A, 2004, GENE DEV, V18, P1007, DOI 10.1101/gad.296204; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; Khodjakov A, 2004, CURR BIOL, V14, P1330, DOI 10.1016/j.cub.2004.07.028; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Krapp A, 2004, CURR BIOL, V14, pR722, DOI 10.1016/j.cub.2004.08.049; Le Goff X, 2000, J CELL SCI, V113, P4157; Mishra M, 2004, J CELL SCI, V117, P3897, DOI 10.1242/jcs.01244; Morrell JL, 2004, CURR BIOL, V14, P579, DOI 10.1016/j.cub.2004.03.036; Sohrmann M, 1998, GENE DEV, V12, P84, DOI 10.1101/gad.12.1.84; Sparks CA, 1999, J CELL BIOL, V146, P777, DOI 10.1083/jcb.146.4.777; Wu JQ, 2003, DEV CELL, V5, P723, DOI 10.1016/S1534-5807(03)00324-1; Wu JQ, 2005, SCIENCE, V310, P310, DOI 10.1126/science.1113230	14	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	AUG	2006	8	8					891	U169		10.1038/ncb1449	http://dx.doi.org/10.1038/ncb1449			7	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	069CO	16845379	Green Submitted			2022-12-25	WOS:000239423000021
J	Rees, MI; Harvey, K; Pearce, BR; Chung, SK; Duguid, IC; Thomas, P; Beatty, S; Graham, GE; Armstrong, L; Shiang, R; Abbott, KJ; Zuberi, SM; Stephenson, JBP; Owen, MJ; Tijssen, MAJ; van den Maagdenberg, AMJM; Smart, TG; Supplisson, S; Harvey, RJ				Rees, Mark I.; Harvey, Kirsten; Pearce, Brian R.; Chung, Seo-Kyung; Duguid, Ian C.; Thomas, Philip; Beatty, Sarah; Graham, Gail E.; Armstrong, Linlea; Shiang, Rita; Abbott, Kim J.; Zuberi, Sameer M.; Stephenson, John B. P.; Owen, Michael J.; Tijssen, Marina A. J.; van den Maagdenberg, Arn M. J. M.; Smart, Trevor G.; Supplisson, Stephane; Harvey, Robert J.			Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease	NATURE GENETICS			English	Article							INHIBITORY GLYCINE RECEPTOR; GABA TRANSPORTER; DIFFERENT STOICHIOMETRIES; XENOPUS OOCYTES; HYPEREKPLEXIA; EXPRESSION; PROTEIN; LOCALIZATION; PHENOTYPE; INTERACTS	Hyperekplexia is a human neurological disorder characterized by an excessive startle response and is typically caused by missense and nonsense mutations in the gene encoding the inhibitory glycine receptor (GlyR) alpha 1 subunit (GLRA1)(1-3). Genetic heterogeneity has been confirmed in rare sporadic cases, with mutations affecting other postsynaptic glycinergic proteins including the GlyR beta subunit (GLRB) 4, gephyrin (GPHN)(5) and RhoGEF collybistin (ARHGEF9)(6). However, many individuals diagnosed with sporadic hyperekplexia do not carry mutations in these genes(2-7). Here we show that missense, nonsense and frameshift mutations in SLC6A5 (ref. 8), encoding the presynaptic glycine transporter 2 (GlyT2), also cause hyperekplexia. Individuals with mutations in SLC6A5 present with hypertonia, an exaggerated startle response to tactile or acoustic stimuli, and life-threatening neonatal apnea episodes. SLC6A5 mutations result in defective subcellular GlyT2 localization, decreased glycine uptake or both, with selected mutations affecting predicted glycine and Na(+) binding sites.	Sch Pharm, Dept Pharmacol, London WC1N 1AX, England; Univ Coll Swansea, Sch Med, Swansea SA2 8PP, W Glam, Wales; Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med, Auckland 1, New Zealand; UCL, Dept Pharmacol, London WC1E 6BT, England; Childrens & Womens Hlth Ctr British, Dept Med Genet, Vancouver, BC V6H 3N1, Canada; Virginia Commonwealth Univ, Med Ctr, Dept Human Genet, Richmond, VA 23298 USA; Womens & Childrens Hosp, Adelaide, SA, Australia; Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow G3 8SJ, Lanark, Scotland; Univ Wales Coll Cardiff, Coll Med, Cardiff CF14 4XN, Wales; Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DD Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human Genet, NL-2300 RC Leiden, Netherlands; Ecole Normale Super, CNRS, Neurobiol Lab, UMR8544, F-75005 Paris, France	University of London; University College London; University of London School of Pharmacy; Swansea University; University of Auckland; University of London; University College London; Virginia Commonwealth University; Womens & Childrens Hospital Australia; University of Glasgow; Cardiff University; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Harvey, RJ (corresponding author), Sch Pharm, Dept Pharmacol, 29-39 Brunswick Sq, London WC1N 1AX, England.	m.i.rees@swansea.ac.uk; robert.harvey@pharmacy.ac.uk	Chung, Seo-Kyung/I-3329-2017; Chung, Seo-Kyung/AAT-4693-2021; Rees, Mark I/J-3129-2012; van den Maagdenberg, Arn M.J.M./AAE-9052-2019; SUPPLISSON, Stéphane/L-6658-2017; Harvey, Robert/D-3994-2016; SUPPLISSON, Stéphane/AAD-7482-2019	Chung, Seo-Kyung/0000-0002-5008-8384; Chung, Seo-Kyung/0000-0002-5008-8384; Rees, Mark I/0000-0003-3570-5986; SUPPLISSON, Stéphane/0000-0002-0062-9752; Harvey, Robert/0000-0001-5956-6664; SUPPLISSON, Stéphane/0000-0002-0062-9752; Armstrong, Linlea/0000-0002-8191-6429; Duguid, Ian/0000-0001-6966-2641	Medical Research Council [G0400869, G9810900, G0601585(79887), G9603438, G0601585] Funding Source: Medline; MRC [G0400869, G9810900, G9603438] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barker Eric L., 1995, P321; Eulenburg V, 2005, TRENDS BIOCHEM SCI, V30, P325, DOI 10.1016/j.tibs.2005.04.004; Gabernet L, 2005, NEUROSCI LETT, V373, P79, DOI 10.1016/j.neulet.2004.09.064; Gomeza J, 2003, NEURON, V40, P785, DOI 10.1016/S0896-6273(03)00672-X; Gomeza J, 2003, NEURON, V40, P797, DOI 10.1016/S0896-6273(03)00673-1; Hahn KA, 2002, AM J HUM GENET, V70, P1349, DOI 10.1086/340092; Hahn M. K., 2002, Pharmacogenomics Journal, V2, P217, DOI 10.1038/sj.tpj.6500106; Hahn MK, 2005, MOL PHARMACOL, V68, P457, DOI 10.1124/mol.105.011270; Harvey K, 2004, J NEUROSCI, V24, P5816, DOI 10.1523/JNEUROSCI.1184-04.2004; Horiuchi M, 2005, J NEUROCHEM, V94, P307, DOI 10.1111/j.1471-4159.2005.03198.x; Horiuchi M, 2001, P NATL ACAD SCI USA, V98, P1448, DOI 10.1073/pnas.041329498; Krogsgaard-Larsen P, 2000, CURR PHARM DESIGN, V6, P1193, DOI 10.2174/1381612003399608; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Morrow JA, 1998, FEBS LETT, V439, P334, DOI 10.1016/S0014-5793(98)01390-8; Ohno K, 2004, MOL CELL NEUROSCI, V26, P518, DOI 10.1016/j.mcn.2004.04.007; Rees MI, 2003, J BIOL CHEM, V278, P24688, DOI 10.1074/jbc.M301070200; Rees MI, 2002, HUM MOL GENET, V11, P853, DOI 10.1093/hmg/11.7.853; Rees MI, 2001, HUM GENET, V109, P267, DOI 10.1007/s004390100569; Richerson GB, 2004, ADV EXP MED BIOL, V548, P76; Rosen GM, 2005, SLEEP MED, V6, P75, DOI 10.1016/j.sleep.2004.08.010; Roux MJ, 2000, NEURON, V25, P373, DOI 10.1016/S0896-6273(00)80901-0; Roux MJ, 2001, J BIOL CHEM, V276, P17699, DOI 10.1074/jbc.M009196200; SHIANG R, 1995, ANN NEUROL, V38, P85, DOI 10.1002/ana.410380115; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; Supplisson S, 2002, FEBS LETT, V529, P93, DOI 10.1016/S0014-5793(02)03251-9; Tsai G, 2004, P NATL ACAD SCI USA, V101, P8485, DOI 10.1073/pnas.0402662101; Tunnicliff G, 2003, J BIOMED SCI, V10, P30, DOI 10.1159/000068084; Vergouwe MN, 1997, CLIN NEUROL NEUROSUR, V99, P172, DOI 10.1016/S0303-8467(97)00022-X; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978	30	163	173	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036			NAT GENET	Nature Genet.	JUL	2006	38	7					801	806		10.1038/ng1814	http://dx.doi.org/10.1038/ng1814			6	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	058MO	16751771	Green Accepted			2022-12-25	WOS:000238669300016
J	Steiner, D; Forrer, P; Stumpp, MT; Pluckthun, A				Steiner, Daniel; Forrer, Patrik; Stumpp, Michael T.; Pluckthun, Andreas			Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display	NATURE BIOTECHNOLOGY			English	Article							HELPER PHAGE; COMBINATORIAL LIBRARIES; QUALITY-CONTROL; SELECTION; BINDING; THIOREDOXIN; EFFICIENT; FRAGMENT; IDENTIFICATION; EXPRESSION	Even proteins that fold well in bacteria are frequently displayed poorly on filamentous phages. Low protein presentation on phage might be caused by premature cytoplasmic folding, leading to inefficient translocation into the periplasm. As translocation is an intermediate step in phage assembly, we tested the display levels of a range of proteins using different translocation pathways by employing different signal sequences. Directing proteins to the cotranslational signal recognition particle (SRP) translocation pathway resulted in much higher display levels than directing them to the conventional post-translational Sec translocation pathway. For example, the display levels of designed ankyrin-repeat proteins (DARPins) were improved up to 700-fold by simply exchanging Sec- for SRP-dependent signal sequences. In model experiments this exchange of signal sequences improved phage display from tenfold enrichment to > 1,000-fold enrichment per phage display selection round. We named this method 'SRP phage display' and envision broad applicability, especially when displaying cDNA libraries or very stable and fast-folding proteins from libraries of alternative scaffolds.	Univ Zurich, Dept Biochem, Mol Partners AG, CH-8057 Zurich, Switzerland	University of Zurich	Pluckthun, A (corresponding author), Univ Zurich, Dept Biochem, Mol Partners AG, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	plueckthun@bioc.unizh.ch	Plückthun, Andreas/C-2746-2009	Plückthun, Andreas/0000-0003-4191-5306; Forrer, Patrik/0000-0002-9717-0991				Amstutz P, 2005, J BIOL CHEM, V280, P24715, DOI 10.1074/jbc.M501746200; [Anonymous], 2004, PHAGE DISPLAY PRACTI; Baek H, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.5.e18; Barbas C. F., 2001, PHAGE DISPLAY LAB MA; Binz HK, 2004, NAT BIOTECHNOL, V22, P575, DOI 10.1038/nbt962; Binz HK, 2003, J MOL BIOL, V332, P489, DOI 10.1016/S0022-2836(03)00896-9; Bothmann H, 2000, J BIOL CHEM, V275, P17100, DOI 10.1074/jbc.M910233199; Bothmann H, 1998, NAT BIOTECHNOL, V16, P376, DOI 10.1038/nbt0498-376; Bradbury ARM, 2004, J IMMUNOL METHODS, V290, P29, DOI 10.1016/j.jim.2004.04.007; BRINKMANN U, 1995, J IMMUNOL METHODS, V182, P41, DOI 10.1016/0022-1759(95)00016-4; Crameri R, 1996, ADV EXP MED BIOL, V409, P103; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; DeLisa MP, 2003, P NATL ACAD SCI USA, V100, P6115, DOI 10.1073/pnas.0937838100; DENG SJ, 1994, J BIOL CHEM, V269, P9533; Ewert S, 2003, J MOL BIOL, V325, P531, DOI 10.1016/S0022-2836(02)01237-8; Fekkes P, 1999, MICROBIOL MOL BIOL R, V63, P161, DOI 10.1128/MMBR.63.1.161-173.1999; Fisher AC, 2004, J BACTERIOL, V186, P7467, DOI 10.1128/JB.186.22.7467-7473.2004; Forrer P, 2004, J MOL BIOL, V344, P179, DOI 10.1016/j.jmb.2004.09.030; Forrer P, 2003, FEBS LETT, V539, P2, DOI 10.1016/S0014-5793(03)00177-7; GAILUS V, 1994, EUR J BIOCHEM, V222, P927, DOI 10.1111/j.1432-1033.1994.tb18941.x; Georgescu RE, 1998, BIOCHEMISTRY-US, V37, P10286, DOI 10.1021/bi9805083; Huber D, 2005, P NATL ACAD SCI USA, V102, P18872, DOI 10.1073/pnas.0509583102; Huber D, 2005, J BACTERIOL, V187, P2983, DOI 10.1128/JB.187.9.2983-2991.2005; Jager M, 2001, J MOL BIOL, V305, P1111, DOI 10.1006/jmbi.2000.4342; Jestin JL, 2001, RES MICROBIOL, V152, P187, DOI 10.1016/S0923-2508(01)01191-3; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Jung S, 1997, PROTEIN ENG, V10, P959, DOI 10.1093/protein/10.8.959; Koch HG, 2003, REV PHYSIOL BIOCH P, V146, P55, DOI 10.1007/s10254-002-0002-9; Kramer RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng058; Krebber A, 1996, GENE, V178, P71, DOI 10.1016/0378-1119(96)00337-X; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; LOHNING C, 2001, Patent No. 00105950; Luirink J, 2004, BBA-MOL CELL RES, V1694, P17, DOI 10.1016/j.bbamcr.2004.03.013; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Paschke M, 2005, GENE, V350, P79, DOI 10.1016/j.gene.2005.02.005; Pluckthun A, 1996, ANTIBODY ENG PRACTIC, P203; Rakonjac J, 1999, J MOL BIOL, V289, P1253, DOI 10.1006/jmbi.1999.2851; RAPOZA MP, 1993, J BACTERIOL, V175, P1856, DOI 10.1128/JB.175.6.1856-1859.1993; Robinson C, 2004, BBA-MOL CELL RES, V1694, P135, DOI 10.1016/j.bbamcr.2004.03.010; Rodi DJ, 2002, J MOL BIOL, V322, P1039, DOI 10.1016/S0022-2836(02)00844-6; Rondot S, 2001, NAT BIOTECHNOL, V19, P75, DOI 10.1038/83567; Russel M., 2004, PHAGE DISPLAY PRACTI, P1; Sambrook J, 2001, MOL CLONING LAB MANU; Schierle CF, 2003, J BACTERIOL, V185, P5706, DOI 10.1128/JB.185.19.5706-5713.2003; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Slootstra JW, 1997, MOL DIVERS, V2, P156, DOI 10.1007/BF01682203; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; Valent QA, 2001, ANTON LEEUW INT J G, V79, P17, DOI 10.1023/A:1010256109582; Wilson DR, 1998, CAN J MICROBIOL, V44, P313, DOI 10.1139/cjm-44-4-313; Yang F, 2000, NAT STRUCT BIOL, V7, P230	50	155	166	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2006	24	7					823	831		10.1038/nbt1218	http://dx.doi.org/10.1038/nbt1218			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	063NJ	16823375				2022-12-25	WOS:000239025100033
J	Joglekar, AP; Bouck, DC; Molk, JN; Bloom, KS; Salmon, ED				Joglekar, Ajit P.; Bouck, David C.; Molk, Jeffrey N.; Bloom, Kerry S.; Salmon, Edward D.			Molecular architecture of a kinetochore-microtubule attachment site	NATURE CELL BIOLOGY			English	Article							BUDDING YEAST KINETOCHORE; SACCHAROMYCES-CEREVISIAE; PROTEIN INTERACTIONS; VERTEBRATE CELLS; CENTROMERE; COMPLEX; CORE; COMPONENT; DYNAMICS; CSE4P	Kinetochore attachment to spindle microtubule plus-ends is necessary for accurate chromosome segregation during cell division in all eukaryotes. The centromeric DNA of each chromosome is linked to microtubule plus-ends by eight structural-protein complexes(1-9). Knowing the copy number of each of these complexes at one kinetochore-microtubule attachment site is necessary to understand the molecular architecture of the complex, and to elucidate the mechanisms underlying kinetochore function. We have counted, with molecular accuracy, the number of structural protein complexes in a single kinetochore-microtubule attachment using quantitative fluorescence microscopy of GFP-tagged kinetochore proteins in the budding yeast Saccharomyces cerevisiae. We find that relative to the two Cse4p molecules in the centromeric histone(1), the copy number ranges from one or two for inner kinetochore proteins such as Mif2p(2), to 16 for the DAM DASH complex(8.9) at the kinetochore-microtubule interface. These counts allow us to visualize the overall arrangement of a kinetochore-microtubule attachment. As most of the budding yeast kinetochore proteins have homologues in higher eukaryotes, including humans, this molecular arrangement is likely to be replicated in more complex kinetochores that have multiple microtubule attachments.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Salmon, ED (corresponding author), Univ N Carolina, Dept Biol, 607 Fordham Hall,CB 3280, Chapel Hill, NC 27599 USA.	tsalmon@email.unc.edu		Joglekar, Ajit/0000-0002-0607-5332; Bloom, Kerry/0000-0002-3457-004X; Bouck, David/0000-0002-6281-2544	NIGMS NIH HHS [GM60678, R37 GM032238, R37 GM024364, R01 GM032238-18, GM32238, R01 GM060678, R01 GM032238, GM24364, R01 GM024364] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060678, R37GM024364, R37GM032238, R01GM032238, R01GM024364] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chan GK, 2005, TRENDS CELL BIOL, V15, P589, DOI 10.1016/j.tcb.2005.09.010; Chen YH, 2000, MOL CELL BIOL, V20, P7037, DOI 10.1128/MCB.20.18.7037-7048.2000; Ciferri C, 2005, J BIOL CHEM, V280, P29088, DOI 10.1074/jbc.M504070200; Collins KA, 2004, CURR BIOL, V14, P1968, DOI 10.1016/j.cub.2004.10.024; De Wulf P, 2003, GENE DEV, V17, P2902, DOI 10.1101/gad.1144403; DeLuca JG, 2005, MOL BIOL CELL, V16, P519, DOI 10.1091/mbc.E04-09-0852; Espelin CW, 1997, J CELL BIOL, V139, P1383, DOI 10.1083/jcb.139.6.1383; Espelin CW, 2003, MOL BIOL CELL, V14, P4557, DOI 10.1091/mbc.E02-08-0533; Euskirchen GM, 2002, EUKARYOT CELL, V1, P229, DOI 10.1128/EC.1.2.229-240.2002; Hori T, 2003, J CELL SCI, V116, P3347, DOI 10.1242/jcs.00645; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Maddox PS, 2000, NAT CELL BIOL, V2, P36, DOI 10.1038/71357; McAinsh AD, 2003, ANNU REV CELL DEV BI, V19, P519, DOI 10.1146/annurev.cellbio.19.111301.155607; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Meluh PB, 1998, CELL, V94, P607, DOI 10.1016/S0092-8674(00)81602-5; Miranda JJL, 2005, NAT STRUCT MOL BIOL, V12, P138, DOI 10.1038/nsmb896; Nekrasov VS, 2003, MOL BIOL CELL, V14, P4931, DOI 10.1091/mbc.E03-06-0419; Nishihashi A, 2002, DEV CELL, V2, P463, DOI 10.1016/S1534-5807(02)00144-2; Ortiz J, 1999, GENE DEV, V13, P1140, DOI 10.1101/gad.13.9.1140; Pearson CG, 2004, CURR BIOL, V14, P1962, DOI 10.1016/j.cub.2004.09.086; Pearson CG, 2001, J CELL BIOL, V152, P1255, DOI 10.1083/jcb.152.6.1255; Roumanie O, 2005, J CELL BIOL, V170, P583, DOI 10.1083/jcb.200504108; Russell ID, 1999, J CELL BIOL, V145, P933, DOI 10.1083/jcb.145.5.933; Shang C, 2003, MOL BIOL CELL, V14, P3342, DOI 10.1091/mbc.E02-11-0765; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wei RR, 2005, P NATL ACAD SCI USA, V102, P5363, DOI 10.1073/pnas.0501168102; Westermann S, 2006, NATURE, V440, P565, DOI 10.1038/nature04409; Wu JQ, 2005, SCIENCE, V310, P310, DOI 10.1126/science.1113230; Yang SS, 1997, J CELL BIOL, V136, P345, DOI 10.1083/jcb.136.2.345; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	30	217	235	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392			NAT CELL BIOL	Nat. Cell Biol.	JUN	2006	8	6					581	585		10.1038/ncb1414	http://dx.doi.org/10.1038/ncb1414			5	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	049PR	16715078	Green Accepted, Green Published			2022-12-25	WOS:000238029000010
J	Pe'er, I; de Bakker, PIW; Maller, J; Yelensky, R; Altshuler, D; Daly, MJ				Pe'er, Itsik; de Bakker, Paul I. W.; Maller, Julian; Yelensky, Roman; Altshuler, David; Daly, Mark J.			Evaluating and improving power in whole-genome association studies using fixed marker sets	NATURE GENETICS			English	Article							LINKAGE-DISEQUILIBRIUM; WIDE ASSOCIATION; COMPLEX TRAITS; TAGGING SNPS; DISEASE; POLYMORPHISM; MODELS; FUTURE; GENES; TESTS	Emerging technologies make it possible for the first time to genotype hundreds of thousands of SNPs simultaneously, enabling whole-genome association studies. Using empirical genotype data from the International HapMap Project, we evaluate the extent to which the sets of SNPs contained on three whole-genome genotyping arrays capture common SNPs across the genome, and we find that the majority of common SNPs are well captured by these products either directly or through linkage disequilibrium. We explore analytical strategies that use HapMap data to improve power of association studies conducted with these fixed sets of markers and show that limited inclusion of specific haplotype tests in association analysis can increase the fraction of common variants captured by 25-100%. Finally, we introduce a Bayesian approach to association analysis by weighting the likelihood of each statistical test to reflect the number of putative causal alleles to which it is correlated.	Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; MIT, Broad Inst, Cambridge, MA 02142 USA; Harvard Univ, Cambridge, MA 02142 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University	Daly, MJ (corresponding author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.	altshul@broad.mit.edu; mjdaly@chgr.mgh.harvard.edu	de Bakker, Paul IW/B-8730-2009; maller, julian B/A-9323-2009; Altshuler, David M/A-4476-2009; Daly, Mark J/B-2453-2017	de Bakker, Paul IW/0000-0001-7735-7858; Altshuler, David M/0000-0002-7250-4107; Daly, Mark J/0000-0002-0949-8752; Maller, Julian/0000-0002-1565-9559				Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Chapman JM, 2003, HUM HERED, V56, P18, DOI 10.1159/000073729; Clark AG, 2005, GENOME RES, V15, P1496, DOI 10.1101/gr.4107905; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; Cohen JC, 2004, SCIENCE, V305, P869, DOI 10.1126/science.1099870; Collins FS, 1998, GENOME RES, V8, P1229, DOI 10.1101/gr.8.12.1229; Crawford DC, 2004, AM J HUM GENET, V74, P610, DOI 10.1086/382227; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Gunderson KL, 2005, NAT GENET, V37, P549, DOI 10.1038/ng1547; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Kruglyak L, 2005, NAT GENET, V37, P1299, DOI 10.1038/ng1205-1299; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lin S, 2004, NAT GENET, V36, P1181, DOI 10.1038/ng1457; Matsuzaki H, 2004, NAT METHODS, V1, P109, DOI 10.1038/nmeth718; Pe'er I, 2006, AM J HUM GENET, V78, P588, DOI 10.1086/502803; Pritchard JK, 2002, HUM MOL GENET, V11, P2417, DOI 10.1093/hmg/11.20.2417; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Roeder K, 2006, AM J HUM GENET, V78, P243, DOI 10.1086/500026; Sham PC, 2000, AM J HUM GENET, V66, P1616, DOI 10.1086/302891; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098; Wheeler DL, 2006, NUCLEIC ACIDS RES, V34, pD173, DOI 10.1093/nar/gkj158	30	220	247	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	JUN	2006	38	6					663	667		10.1038/ng1816	http://dx.doi.org/10.1038/ng1816			5	Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Genetics & Heredity	048NW	16715096				2022-12-25	WOS:000237954800020
J	Kelly, JW; Balch, WE				Kelly, JW; Balch, WE			The integration of cell and chemical biology in protein folding	NATURE CHEMICAL BIOLOGY			English	Editorial Material							ENDOPLASMIC-RETICULUM; DISEASE	Eukaryotic cells are specialized, interdependent functional units of complex tissues that are composed of metabolically integrated systems defined by chemically distinct organelles that operate as reaction vessels. It is now clear that the small-molecule and polymer-based composition of these organelles plays a crucial role in generating and maintaining protein folds and functions through the systems chemistry of the local environments.	Scripps Res Inst, Dept Chem, La Jolla, CA 92130 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92130 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92130 USA; Scripps Res Inst, Inst Childhood & Neglected Dis, La Jolla, CA 92130 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Kelly, JW (corresponding author), Scripps Res Inst, Dept Chem, 1055 N Torrey Pines Rd, La Jolla, CA 92130 USA.	jkelly@scripps.edu; webalch@scripps.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK046335, R01DK046335, R29DK046335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018917] Funding Source: NIH RePORTER; NIA NIH HHS [AG18917] Funding Source: Medline; NIDDK NIH HHS [DK46335] Funding Source: Medline; NIGMS NIH HHS [GM42336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanese V, 2006, CELL, V124, P75, DOI 10.1016/j.cell.2005.11.039; Allan RB, 1999, SCIENCE, V285, P63, DOI 10.1126/science.285.5424.63; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Brady RO, 2006, ANNU REV MED, V57, P283, DOI 10.1146/annurev.med.57.110104.115650; Buxbaum JN, 2000, ANNU REV MED, V51, P543, DOI 10.1146/annurev.med.51.1.543; COHEN E, 2006, IN PRESS SCIENCE; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006; Gadsby DC, 2006, NATURE, V440, P477, DOI 10.1038/nature04712; Gidalevitz T, 2006, SCIENCE, V311, P1471, DOI 10.1126/science.1124514; Hammarstrom P, 2003, SCIENCE, V299, P713, DOI 10.1126/science.1079589; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hill SJ, 2006, BRIT J PHARMACOL, V147, pS27, DOI 10.1038/sj.bjp.0706455; Hla T, 2005, PROSTAG OTH LIPID M, V77, P197, DOI 10.1016/j.prostaglandins.2005.06.008; Huff ME, 2003, J MOL BIOL, V334, P119, DOI 10.1016/j.jmb.2003.09.029; Kaeser PS, 2005, BIOCHEM SOC T, V33, P1345, DOI 10.1042/BST0331345; Lomas DA, 2005, BIOCHEM SOC T, V33, P321, DOI 10.1042/BST0330321; Lundbaek JA, 2003, BIOPHYS J, V84, P2080, DOI 10.1016/S0006-3495(03)75015-2; Molinete M, 2000, SEMIN CELL DEV BIOL, V11, P243, DOI 10.1006/scdb.2000.0173; Morley JF, 2004, MOL BIOL CELL, V15, P657, DOI 10.1091/mbc.E03-07-0532; Moyer B D, 2001, Expert Opin Ther Targets, V5, P165, DOI 10.1517/14728222.5.2.165; Onuchic JN, 2004, CURR OPIN STRUC BIOL, V14, P70, DOI 10.1016/j.sbi.2004.01.009; Pedemonte N, 2005, J CLIN INVEST, V115, P2564, DOI 10.1172/JCI24898; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Saghatelian A, 2005, CURR OPIN CHEM BIOL, V9, P62, DOI 10.1016/j.cbpa.2004.12.004; Sawkar AR, 2005, CHEM BIOL, V12, P1235, DOI 10.1016/j.chembiol.2005.09.007; Sawkar AR, 2002, P NATL ACAD SCI USA, V99, P15428, DOI 10.1073/pnas.192582899; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Sekijima Y, 2005, CELL, V121, P73, DOI 10.1016/j.cell.2005.01.018; Spiess C, 2004, TRENDS CELL BIOL, V14, P598, DOI 10.1016/j.tcb.2004.09.015; Storrie B, 2005, INT REV CYTOL, V244, P69, DOI 10.1016/S0074-7696(05)44002-4; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; VANGOOR F, 2006, AM J PHYSL LUNG CELL; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009	36	28	29	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAY	2006	2	5					224	227		10.1038/nchembio0506-224	http://dx.doi.org/10.1038/nchembio0506-224			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	034VE	16619016				2022-12-25	WOS:000236957900002
